,nct_id,primaryOutcomes,secondaryOutcomes,otherOutcomes,startDate,status,study_type,phases
0,NCT03646721,Adverse event,HbA1c,Assessment of key metabolite(s) of DA-1241,2018-08-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1,NCT00115570,Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint,Change from Baseline in basal insulin dose,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2,NCT02331147,proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks,Mean time to healing,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
3,NCT02682121,The primary outcome will be gene expression levels of mitofusin 2 and uncoupling protein 2,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4,NCT03747978,24-hour blood pressure,night blood pressure dip,,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5,NCT01814735,"Changes in fasting blood glucose, lipids, and blood pressure",Feasibility and cultural appropriateness,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6,NCT03386097,Cholesterol level in skin biopsies,,,2018-01-10,COMPLETED,OBSERVATIONAL,['NA']
7,NCT00295633,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8,NCT06281301,Number of participants that showed Macrosomia knowledge greater than 50 percent as assessed by the score on a survey,,,2024-01-30,RECRUITING,INTERVENTIONAL,['NA']
9,NCT00004266,,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10,NCT01271231,Glycated hemoglobin,Probing depth,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
11,NCT04729985,Emergency room visit and rehospitalization,Patient satisfaction,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12,NCT02058160,Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13,NCT05755555,HbA1C(%),,,2022-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14,NCT01140542,Mean change in HbA1c [percent] from baseline to the last study visit (Vlast),"Time to event (study withdrawal, time to study withdrawal due to an adverse event (AE) and time to lack of efficacy (LOE)",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15,NCT01275820,Glucose blood level,Dosage of Insulin,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
16,NCT03878758,Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available Comparators,Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Force),Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time),2019-02-07,COMPLETED,INTERVENTIONAL,['NA']
17,NCT00948168,Improvement in HbA1c,"Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
18,NCT02157480,Mean CGM glucose from a 6-day CGM recording,HbA1c,cardiometabolic stress test,2014-09,COMPLETED,INTERVENTIONAL,['NA']
19,NCT03660384,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
20,NCT04841720,Tmax,AE/serious AE,,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
21,NCT00527254,HBA1c Glycosylated hemoglobin,"Blood glucose, Total Cholesterol, HDL Cholesterol,LDL Cholesterol, Triglycerides, BMI, systolic and diastolic blood pressure and system adherence",,2003-10,COMPLETED,INTERVENTIONAL,['NA']
22,NCT04734158,corneal epithelial thickness,,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
23,NCT04407819,prevalence of sarcopenia in patients with T2D and in the control group,fat mass,,2018-03-20,COMPLETED,OBSERVATIONAL,['NA']
24,NCT00520065,Positive area under the curve (AUC) for plasma glucose and mean glucose level,Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
25,NCT03378635,Time to Plasma Glucose Recovery,Time to First Rescue Infusion of IV Glucose,,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
26,NCT03662997,% of Participants With No Strike-through After 7 Days Wear Time at Day 7 and 21,Mean Difference in Score in SF12 Health-Related Quality-of-Life Questionnaire,,2019-03-19,COMPLETED,INTERVENTIONAL,['NA']
27,NCT02158078,Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12,Change in measures of PROs from baseline at Week 12,,2014-06,TERMINATED,OBSERVATIONAL,['NA']
28,NCT00526513,Glycosylated Haemoglobin (HbA1c),Control of Post-Prandial Glycemia (PPBG),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
29,NCT04742023,Average Daily Glucose,Total Insulin Use,,2020-04-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
30,NCT03741660,change in systolic blood pressure,change in apoB:ApoA-1,,1991-01,COMPLETED,INTERVENTIONAL,['PHASE2']
31,NCT05919667,Change in blood glucose level,Change in plasma amino acid concentrations,,2022-02-28,COMPLETED,INTERVENTIONAL,['NA']
32,NCT01302327,beta cell function,,,2011-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
33,NCT05123963,Change in glucose control.,Change in plasma cytokine levels,,2021-09-15,RECRUITING,INTERVENTIONAL,['NA']
34,NCT03878706,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.,Comparison of liver steatosis level between treatment groups,,2017-11-03,RECRUITING,OBSERVATIONAL,['NA']
35,NCT01053728,- Pharmacodynamics (Glucose infusion rate) time-action profile,- anti-insulin antibody production,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
36,NCT00657800,Quality of Life (QoL),Emergency Room visits; admissions,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
37,NCT02802644,Neointimal coverage assessed by optical coherence tomography,Biomarkers,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
38,NCT00849576,Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.,"The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.",,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
39,NCT03761446,Mitochondrial Respiration,Physical function,,2019-03-18,RECRUITING,INTERVENTIONAL,['NA']
40,NCT00973830,Diabetes knowledge,Change in HbA1c reading,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
41,NCT03544541,Carotid Intima-Media Thickness,,,2018-01-05,COMPLETED,OBSERVATIONAL,['NA']
42,NCT03219411,Fasting plasma glucose at 12 weeks,Area under the curve-glucose during OGTT (oral glucose tolerance test),,2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE2']
43,NCT05668325,Home Based Mini Trampoline Exercise Tracking Form,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
44,NCT01027871,Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles,Glycemic Variability in Fasting Blood Glucose at Baseline and Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
45,NCT00734383,"Perioperative Plasma 15 f2t isoprostane, a biologically active marker of oxidative stress","Perioperative (includes coronary sinus levels) plasma antioxidant concentration; ET-1, TNF alpha, Troponin I, peroxynitrite; gene and protein expression of eNOS and iNOS; hemodynamics",,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
46,NCT02644590,"blood pressure monitoring , pre and post treatment with melatonin",,,2016-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
47,NCT00456300,"Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone",,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
48,NCT05746975,Peripheral DR lesions characterization,Correlate and analysed DR findings in each imaging technique with disease severity,,2023-04-03,RECRUITING,OBSERVATIONAL,['NA']
49,NCT02225379,Positive Predictive Value of the hypo-Sense,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
50,NCT01044017,Effect on postprandial plasma glucose concentration,"Safety and tolerability: AEs, laboratory parameters",,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
51,NCT00240019,The amount of protein in the urine after 8 weeks of treatment.,The estimated glomerular filtration rate after 8 weeks of treatment.,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
52,NCT01784289,Measure of blood Interleukin 7,Count of blood lymphocytes T,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
53,NCT02589730,change in glycated hemoglobin levels,change in scores measured by MKT,change in scores measured by self anxiety scale,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
54,NCT00566319,2-hour glucose,"Pedometer counts, Fasting glucose, total cholesterol, HDL-cholesterol, LDL- cholesterol, TNFα, IL-6, CRP, systolic and diastolic blood pressure, body mass, waist circumference, BMI, physical activity, psychological determinants",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
55,NCT04853537,gestational diabetes,any associated comorbidities questionnaires,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
56,NCT04181307,Number of Participants Who Are CW-Compliant and CW-Noncompliant,Number of Total Prescription Encounters,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
57,NCT00769275,"Overall cardiac event rate (cardiac death, myocardial infarction) was 3.0%, not different in screened and not screened cohort",,,2000-08,COMPLETED,OBSERVATIONAL,['NA']
58,NCT00733577,"Safety measures including: AEs daily; laboratory testing: day -1,2,5,7 and follow up; ECG: day -1, 2, 5, 6, 7 and follow-up; vital signs: daily; PK parameters day -1,5, and 6.",Subject reports of hunger and craving as reported on the Hunger and Craving questionnaire,,2008-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
59,NCT06073756,Neutrophil-to-lymphocyte ratio and platelets to lymphocytes ratio,HbA1c with good glycemic control and have HBA1C lower than 7and poor glycemic control and have HBA1C higher than 7with prescence or abscence of vascular complications,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
60,NCT00361153,"To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.","To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
61,NCT01293318,Association between copeptin level and severity of pancreatitis (according to Atlanta classification),"Determine whether change in copeptin level from day 0 to 2 is associated with organ failure, necrosis and/or superinfection",,2011-03,COMPLETED,OBSERVATIONAL,['NA']
62,NCT04019938,Serum Cystatin C,Bone mineral density,,2019-07-04,UNKNOWN,OBSERVATIONAL,['NA']
63,NCT02653599,Change in HbA1c from baseline at 12 weeks,Pulse,Change in glucagon-like peptide-1 levels from baseline at 12 weeks,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
64,NCT02220296,Incidence of adverse events,"t1/2, the terminal half-life of insulin 338",,2014-08-20,COMPLETED,INTERVENTIONAL,['PHASE1']
65,NCT03291834,Occurence of hypoglycemia or hyperglycemia,Measures taken to prevent hypoglycemia or hyperglycemia,,2017-08-15,COMPLETED,OBSERVATIONAL,['NA']
66,NCT03714646,Plasma acetate concentrations (microM),"Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)",,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
67,NCT00166803,"Vulnerable plaque analyses by PET: Define plaque location and activity at baseline, and compare with the follow-up scans site by site.","2.Biomarkers:hs-CRP, MMP-1, MCP-1.",,2005-06,SUSPENDED,INTERVENTIONAL,['NA']
68,NCT04812262,Number of participants with clinically significant abnormalities in 12-lead ECGs,Number of participants with antidrug antibodies (ADAs),,2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE1']
69,NCT02862431,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline for Glucagon,,2016-07-12,TERMINATED,INTERVENTIONAL,['PHASE1']
70,NCT00674986,Change From Baseline in Hemoglobin A1c (HbA1c) at Month 12,Glycemic Variability Pre and Post-Prandial Excursions at Each Meal,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
71,NCT06020664,Proportion of subjects with complete wound closure during the 12 weeks of the Treatment Phase,Changes in Wound-Q Health-Related Quality of Life outcome during the 12 weeks of the Treatment Phase as measured by changes in the subject response to the Wound-Q Health-Related Quality of Life scale,,2023-08-16,SUSPENDED,INTERVENTIONAL,['PHASE1']
72,NCT03859193,Change in nutritional knowledge,Patient Satisfaction with Care,,2019-09-27,COMPLETED,INTERVENTIONAL,['NA']
73,NCT00553020,To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes,"To evaluate the effect of insulin glargine (LantusT) and NPH-insulin (ProtaphanT) on suppression of endogenous glucose production, endogenous insulin secretion, and lipolysis",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
74,NCT01642394,Change in Glycated hemoglobin,Change in the diet composition,,2011-10-01,COMPLETED,INTERVENTIONAL,['NA']
75,NCT01789190,We aimed to study the influence of regular physical activity on the prolongation of the honeymoon period in type 1 diabetic patients by determining circulating parameters.,To study the influence of regular physical activity on the control of the inflammation process associated to type 1 diabetes.,,2011-01,TERMINATED,OBSERVATIONAL,['NA']
76,NCT02512068,Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet,Number of Participants With Markedly Abnormal Values of Clinical Laboratory Parameters Before the Start of Study Drug Administration in Treatment Period II,,2015-08-07,COMPLETED,INTERVENTIONAL,['PHASE3']
77,NCT00069615,Feasibility of collecting data from home computers,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
78,NCT02471404,Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52,Number of Patients Rescued,,2015-09-21,COMPLETED,INTERVENTIONAL,['PHASE4']
79,NCT06171412,Mean hours per week CGM worn,Mean count Barriers to Device Use,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
80,NCT02518022,• Number of hypoglycaemic events <70 mg/dl per arm from begin of consumption until lunch next day (12:00 am),• Max. alcohol in expiratory breath,,2015-09,WITHDRAWN,INTERVENTIONAL,['NA']
81,NCT03117543,Percentage of hOGTT venous plasma equivalent glucose (hOGTT-VPEqG) results within ±10% of paired venous plasma glucose measured on a YSI analyser (VPG-YSI) (reference standard).,Specificity of HbA1c for screening for GDM versus gold standard of 75g OGTT and VPG-YSI measurement (IADPSG 2010 criteria).,Serum insulin concentration at 60 min after 75g oral glucose in pregnant women of Black (Black African and Black Caribbean) compared to White European ethnicity.,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
82,NCT06282055,Identify different trajectories of insulin sensitivity throughout the menstrual cycle,Correlations between insulin sensitivity trajectories and confounders,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
83,NCT05574023,Less time spent in hypoglycaemia using Predictive Alarm vs Alarm on Threshold,Better glycemic metrics using Predictive Alarm vs Alarm on Threshold,,2021-05-10,COMPLETED,INTERVENTIONAL,['NA']
84,NCT01676116,"Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)",Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).,,2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
85,NCT02631148,Change in Systemic Renin-aldosterone-angiotensin System (RAAS) Activity,Change in Central Blood Pressure,,2016-01,TERMINATED,INTERVENTIONAL,['PHASE2']
86,NCT01932866,Change in abdominal circumference,Change in diabetes risk score,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
87,NCT01883804,The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.,The Change in Insulin Use From Baseline to Study Completion.,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
88,NCT01059812,Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment,Change in Body Weight,,2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
89,NCT00512538,Time to complete wound healing (full epithelialization with no drainage),Incidence of complete healing,,2000-10,TERMINATED,INTERVENTIONAL,['PHASE3']
90,NCT00119041,A1c,Patient Satisfaction,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
91,NCT01754337,Percentage of time of plasma glucose levels spent in target range.,Percentage of overnight time of plasma glucose levels spent in the high range,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
92,NCT02115711,Absolute reduction in average number of cigarettes/bidis smoked per day amongst smokers,"Absolute mean reduction in weight and waist circumference, for those who are overweight or have increased waist size at baseline, at the end of 2 years.",,2014-04,COMPLETED,INTERVENTIONAL,['NA']
93,NCT00213109,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
94,NCT02812030,Change in Best-Corrected Visual Acuity (BCVA),Non-ocular adverse events,,2016-09,WITHDRAWN,OBSERVATIONAL,['NA']
95,NCT01889706,Body fat content and anthropometric parameters,Insulin requirement,Assessment of skin AGE,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
96,NCT01741467,Differences in blood glucose,Changes in medication use,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
97,NCT02562326,Pharmacokinetics: AUClis 0-30min,Local tolerability,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
98,NCT06280729,Primary Endpoint,Exploratory Objectives,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
99,NCT01051102,Area under the Glucose Infusion Rate curve after a single dose,Area under the insulin aspart concentration-time curve after a single dose,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
100,NCT05616026,Change in HbA1c,Appointment Adherence,,2023-02-07,RECRUITING,INTERVENTIONAL,['NA']
101,NCT05922280,Douleur Neuropathique 4 Questionnaire DN4,,,2023-02-15,COMPLETED,INTERVENTIONAL,['NA']
102,NCT01742208,Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period),Change From Day 1 in 3-hour Urinary Glucose Excretion Following a Mixed Meal Tolerance Test (MMTT) to Day 29: Expansion Groups,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
103,NCT05124457,Prolonged neonatal hypoglycemia,5 Minute APGAR,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
104,NCT05110092,blood sugar control-HbA1c,,,2016-12-14,UNKNOWN,INTERVENTIONAL,['NA']
105,NCT00666718,Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24,Number of Injections of Insulin at Week 24,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
106,NCT02579148,Improvements in IIEF scores,Safety and Tolerability assessed by Adverse Events,,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE1']
107,NCT00889668,Clarke Error Grid,User Satisfaction,,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
108,NCT00707031,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Quality of Life: Change From Baseline in Patient's Satisfaction to Treatment (PAGI-QOL) at Week 24,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
109,NCT03939000,International normalized ratio,,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
110,NCT06234332,Numbers and morbidity of participants with adverse pregnancy outcomes,Incidence of depression in adolescents,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
111,NCT05762471,"Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM",Identification of GSBR-1290 metabolites following oral administration of multiple doses in plasma,,2023-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
112,NCT00877929,Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8,Change From Baseline in Urine Albumin:Creatinine Ratio (UACR),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
113,NCT03685253,Thigh Intraepidermal Nerve Fiber Density,Distal lower limb intraepidermal nerve fiber density,Cardiac Autonomic Neuropathy,2019-01-24,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
114,NCT00287456,,,,2006-02-02,WITHDRAWN,INTERVENTIONAL,['NA']
115,NCT06035367,Value of absolute photoacoustic signal on the participant arm,assess the tolerability of the investigational device by a usability questionnaire,,2023-07-06,RECRUITING,INTERVENTIONAL,['NA']
116,NCT02180334,Area under the curve (AUC) of plasma total GLP-1 levels,Area under the curve (AUC) of plasma active GLP-1 levels,The time to peak concentration of plasma paracetamol,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
117,NCT05013229,Change in HbA1c,Weekly insulin dose (total),,2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE3']
118,NCT05118061,Analytical verification of StatStrip glucose/ketone meter system - ketone comparison,,,2022-05-25,COMPLETED,OBSERVATIONAL,['NA']
119,NCT05399446,Change in Eating Disorder Symptoms,Change over time in Diabetes-Related Quality of Life,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
120,NCT05414409,Changes in the gut microbial metabolites in obese youth with type 1 in response to metformin,Changes in measures of beta cell function using a timed mixed meal tolerance test,,2022-09-30,RECRUITING,INTERVENTIONAL,['PHASE2']
121,NCT03526536,Change in blood glucose level,,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
122,NCT02739906,BG1h,Local tolerability (Number of injection site reactions),,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
123,NCT00171717,% of patients whose diabetes resolves 6 months after the conversion (fasting glucose < 1.26 g/L without hypoglycemic treatment).,Incidence of acute and chronic rejection treated at 6 months and at 1 year.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
124,NCT05849714,"proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)","Proportion of participants who experienced: episode of hypoglycemia <3 and < 4 mmol/L, episode of hyperglycemia >10, > 15 and >20 mmol/L, episode of ketoacidosis. (Part 2 of study)",,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
125,NCT00862875,Changes in total fat mass (in kg),"Epicardial fat, trunk fat, total fat free mass, weight & waist circumference, HbA1c, fasting glucose, RMR, TEF,PAEE & TEE, energy intake.",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
126,NCT01337440,the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA),change from baseline in autonomic nerve function,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
127,NCT02492763,Change From Baseline in Heart Rate at Week 12,Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12,,2015-07-27,TERMINATED,INTERVENTIONAL,['PHASE2']
128,NCT05671679,Percentage of time with sensor glucose in the target range,Percentage of postprandial time with sensor glucose in hypoglycaemia,,2023-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
129,NCT02002221,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups,"Number of Participants With Adverse Events, Serious Adverse Events and Death",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
130,NCT02585778,Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs),Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis,,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
131,NCT01213784,Left ventricular function,Muscle strength and mass,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
132,NCT05317585,Large for Gestational Age Infant,Maternal Patient Satisfaction Survey with Glucose Monitoring,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
133,NCT02747680,Brain activation during hypoglycemia (low blood sugar) using functional MRI,,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
134,NCT02693392,Glycosylated hemoglobin (HbA1c),Post-prandial Blood Glucose,,2016-01-17,COMPLETED,INTERVENTIONAL,['NA']
135,NCT02804620,Change in HbA1c%,ApoB,Weight,2014-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
136,NCT05313529,Change of cognitive function,Change of general cognitive function,,2022-10-08,RECRUITING,INTERVENTIONAL,['NA']
137,NCT03474601,Treatment outcome of pituitary diseases,Complications of pituitary disease,,2015-03-15,RECRUITING,OBSERVATIONAL,['NA']
138,NCT05872009,Number of neonates with adverse neonatal outcome,Percentage of participants with pathological placenta histology findings in case and control groups,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
139,NCT04527107,"Mean change in best-corrected visual acuity (BCVA) ETDRS letter score from Baseline, in subjects in Part B of the study",Incidence of systemic and ocular adverse events (AEs) and serious adverse events (SAEs),,2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2']
140,NCT05125185,Change of VCAM-1,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
141,NCT01030601,Central Retinal Thickness,Best corrected visual acuity and incidence of laser treatments,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
142,NCT05647083,Means of diabetic foot risk score,,,2022-09-09,RECRUITING,INTERVENTIONAL,['NA']
143,NCT02729441,24 Hour Ambulatory Blood Pressure Monitoring,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
144,NCT06063759,Accuracy of the Vital USA VitalDetectTM for assessment of microcirculation (in AU),,,2023-09-25,SUSPENDED,INTERVENTIONAL,['NA']
145,NCT01237119,Liver Histological improvement,NAFLD Activity Score,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
146,NCT01730534,Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.,Subjects Included in the Endpoint of All-cause Mortality.,,2013-04-25,COMPLETED,INTERVENTIONAL,['PHASE3']
147,NCT02848833,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,,2016-08-10,COMPLETED,OBSERVATIONAL,['NA']
148,NCT01032395,Differences in the Seroconversion Rates or Significant Increase by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant),,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
149,NCT04728620,User Experience,Order Completion,,2021-05-06,COMPLETED,INTERVENTIONAL,['NA']
150,NCT05395442,Collection of Post-Test Data,,,2022-06-03,COMPLETED,INTERVENTIONAL,['NA']
151,NCT01633762,changes in postprandial GLP-1 secretion,changes in metabolomic profile,,2012-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
152,NCT04306848,Blood glucose profile,participant survey,,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
153,NCT02829593,Change in Euglycemic GABA level in hypothalamus using MRI,,,2019-10-31,COMPLETED,INTERVENTIONAL,['NA']
154,NCT04615910,Pancreatic 68Ga-exendin uptake,relative 68Ga-exendin uptake,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
155,NCT05391984,SPADI for pain and disability,,,2022-06-07,RECRUITING,INTERVENTIONAL,['NA']
156,NCT00851201,"BMI percentile for age and sex, biomarkers e.g, glucose, insulin, lipids","dietary intake, and physical activity measures",,2009-08,COMPLETED,INTERVENTIONAL,['NA']
157,NCT01606904,change in weight,change in incretins,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
158,NCT03449199,Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12,Changes in Exploratory Renal Biomarkers (Creatinine-Corrected N-acetyl-beta-D-glucosaminidase),,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2']
159,NCT02834715,Glycaemic profile in response to mixed meal test,Liver enzymes,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
160,NCT04064996,Pain assessment With Visual Analog Scale,Albumin levels,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
161,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes,,2018-01-19,RECRUITING,OBSERVATIONAL,['NA']
162,NCT05473767,Change in postpartum weight retention,Change in physical activity,,2022-11-18,RECRUITING,INTERVENTIONAL,['NA']
163,NCT04974333,HbA1C,Waist circumference,,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
164,NCT04316429,Change in Endothelial Function (EF) Assessment:,Change in Physical Activity,,2020-06-09,COMPLETED,INTERVENTIONAL,['NA']
165,NCT00203632,The primary end-point of the study is the percent change in forearm blood flow to acetylcholine in patients randomized to rosiglitazone compared with placebo.,"Secondary end-points include (i) the percent change in forearm blood flow to verapamil and the absolute change to both acetylcholine and verapamil and (ii) the relationship between HOMA-IR, CRP and endothelial function.",,2003-09,TERMINATED,INTERVENTIONAL,['PHASE3']
166,NCT03552991,Quantitative insulin sensitivity check index (QUICKI),Lipopolysaccharide (LPS),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
167,NCT02081989,glucose uptake into peripheral skeletal muscle,,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
168,NCT04152915,"Cmax,sema,1mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period","t½,sema,1mg: terminal elimination half-life of semaglutide after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period",,2019-11-25,COMPLETED,INTERVENTIONAL,['PHASE1']
169,NCT06269419,Urinary creatinine ACR,,,2024-02-25,RECRUITING,OBSERVATIONAL,['NA']
170,NCT02627287,Injection success (full dose delivered s.c.) (yes/no),"Grading of bleeding, redness, bruising and swelling at the site of injection",,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
171,NCT02542774,First occurrence of cardiovascular disease,All cause mortality,,2015-08,UNKNOWN,OBSERVATIONAL,['NA']
172,NCT03205865,Diagnosis of Type 1 Diabetes,Detection of Islet Autoantibodies,Detection of Transglutaminase Antibodies,1993-12-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
173,NCT02774876,Area under the curve of sensor glucose levels,Coefficient of variation of glucose levels,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
174,NCT03985098,Adherence Measure,,,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
175,NCT04155996,Data collection - Sleep hours,Data collection - Medical treatment information,,2019-01-20,TERMINATED,OBSERVATIONAL,['NA']
176,NCT01980264,To noninvasively provide real-time imaging of cutaneous histopathology and molecular changes.,To provide a diagnostic tool for diseases.,,2009-08-05,RECRUITING,INTERVENTIONAL,['NA']
177,NCT03635671,Perfusion density,Retinal layer thickness,,2018-09-01,TERMINATED,OBSERVATIONAL,['NA']
178,NCT00696995,"The number of serious adverse drug reactions, including major hypoglycaemic events",Fasting plasma glucose at visits,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
179,NCT02482610,Vascular Endothelial Function,Oxidative Stress Biomarker (Malondialdehyde; MDA),,2016-06,COMPLETED,INTERVENTIONAL,['NA']
180,NCT01401751,To evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Safety Evaluation,,2011-07-01,COMPLETED,INTERVENTIONAL,['NA']
181,NCT05194592,Change (%) in LV mass index,Change (%) in mean 24hr ambulatory systolic and diastolic blood pressure,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE4']
182,NCT00738088,HbA1c reduction,insulin secretory response to glucose and tolbutamide,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4']
183,NCT05941468,Plaque Control Record (PCR),Oral Health Related Quality of Life(OHRQoL),,2023-03-28,RECRUITING,INTERVENTIONAL,['NA']
184,NCT04075110,Visceral Adiposity Index,leukotriene B4,,2019-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
185,NCT04072523,Prevalence of Left Ventricular dysfunction,Correlation of Left ventricular dysfunction and heart failure,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
186,NCT03085251,System accuracy criteria,,,2017-03-16,COMPLETED,INTERVENTIONAL,['NA']
187,NCT02093702,Mean Change in Diastolic Blood Pressure,Mean Change in Adherence to the Canadian Diabetes Association's Clinical Practice Guidelines Resistance Exercise Recommendations,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
188,NCT01689142,Change from baseline in HbA1c,Number of patients with various types of hypoglycemia events,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
189,NCT03237455,Inflammatory changes in the spine and/or sacroiliac joints,,,2018-08-01,RECRUITING,INTERVENTIONAL,['NA']
190,NCT03686436,measuring visual acuity by snellen chart,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
191,NCT06111664,"Prevalence of hypophosphatemia, DPi and SSL at the population level.",,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
192,NCT01809431,weight (body mass index),breastfeeding,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
193,NCT04275479,Share data with the current SBDS Registry,,,2020-01-10,RECRUITING,OBSERVATIONAL,['NA']
194,NCT05764850,Cluster analysis to decipher underlying mechanisms of type 1 diabetes,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
195,NCT03901248,"Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages",Change in HbA1c,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
196,NCT00425269,"Plasma Glucose, 2-h, Post-test","Intake of Fish, Post Test",,2006-04,COMPLETED,INTERVENTIONAL,['NA']
197,NCT00395148,Metabolic parameters,,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
198,NCT01765894,"Glucose homeostasis in controls, type 2 diabetics without medication and type 2 diabetics in metformin treatment.",IL-6 and incretins,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
199,NCT05260931,Ventricular sphericity indices,,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
200,NCT03251079,Safety Endpoint,,,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
201,NCT05618756,Postprandial Triglyceridaemia,Postprandial Insulinaemia,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
202,NCT02661165,The self-management Interviews to identify if and how patients' spirituality influences their diet and exercise.,,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
203,NCT05629806,Blood glucose fluctuation,,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE3']
204,NCT03736668,Measurement of left ventricular ejection fraction,Comparing the volume of the left atrium in Simpson biplane and in 3D,,2018-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
205,NCT01263132,Mean Neuropathic Pain Score at Visit 6 (Week 4),Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
206,NCT04291703,Progression to Stage 3 T1D,,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
207,NCT02470403,"Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death",The Apparent Volume of Distribution of LIK066 During the Terminal Elimination Phase Following Extra Vascular Administration (Vz/F) in Part 2 of the Study,,2015-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
208,NCT05166122,Referral adherence,Assess AI performance,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
209,NCT03802877,Recruitment,Completion of evaluation procedures,Breastfeeding,2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
210,NCT01881958,efficacy will be measured by comparing Hemoglobin A1c,Safety will be evaluated calculating number of Adverse Events.,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
211,NCT04358263,Percentage of time in hypoglycemic ranges,Changes in glycated haemoglobin (HbA1c),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
212,NCT00226330,Body weight,Patient reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36),,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
213,NCT04587336,"Aim1: Differences in Diabetes Distress Scale score by HbA1c level (HbA1c < 9 and HbA1c 9) and by medication regimen (no insulin, insulin).",,,2020-08-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
214,NCT00704652,Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients,"Changes in blood count, chemistry, Astrup and blood clotting following darbepoetin alpha therapy compared to control patients.",,2008-05,TERMINATED,OBSERVATIONAL,['NA']
215,NCT03406897,MMTT (Mixed Meal Tolerance Test),Incidence of Adverse Events (AE),,2018-07-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
216,NCT05755360,Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]),Absolute change in diabetes distress survey (DDS) scores (points),,2023-02-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
217,NCT00206349,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
218,NCT02068638,Amount of exogenous glucose required to maintain glycemia within a range between 7-10mM,Heart rate variability,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
219,NCT06081231,proportion of time spent in the target glucose range,concentration of HbA1c,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
220,NCT01169090,Change in HbA1c from baseline to Week 16.,Change from baseline in Fasting Plasma Glucose (FPG),,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
221,NCT00359775,Impact on Family measured by the Impact of Family Scale.,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
222,NCT05036343,Glucose,Change in Self-Efficacy for Managing Chronic Conditions - Managing Medications and Treatment Score,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
223,NCT00001985,,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
224,NCT02449850,Food allergy to any intervention allergen,Rhinitis/Allergic rhinitis,Any other allergic disease,2014-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
225,NCT05611944,SSI rate,patient satisfaction,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
226,NCT01217073,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period,Change From Baseline in FPG Levels at Week 78,,2010-10-08,COMPLETED,INTERVENTIONAL,['PHASE2']
227,NCT00168857,Change from baseline after one year of treatment in proteinuria (ratio of protein to creatinine as measure in spot urine sample).,Change from baseline after one year of treatment in the following: glomerular filtration rate; serum creatinine; macroalbuminuria; sodium excretion; high sensitive C-reactive protein; serum aldosterone; and other renal and cardiovascular measures.,,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE4']
228,NCT01667185,System Performance Effectiveness,System Performance at Alternate Wear Site,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
229,NCT02332434,"production and clearance rates of intestinal and hepatic TRL, in 2 groups of obese patients (15 patients per surgery procedure), before and 6 months after the surgery.",,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
230,NCT00499707,Change from baseline in hemoglobin A1c (HbA1c) at week 32.,"Key Secondary Measures: Change in FPG HbA1c and FPG responders Change in insulin, C-peptide, free fatty acids, lipids, insulin sensitivity and beta cell function Adverse Events Vital Signs Weight 32 weeks",,2003-10-08,COMPLETED,INTERVENTIONAL,['PHASE3']
231,NCT01039896,"Css,max and AUCinf","AUCtau, AUCt, Tmax",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
232,NCT00859755,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Assess the excretion of the study drug and metabolites in urine following dosing.,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
233,NCT05801614,non diabetic HbA1c,Changes in Insulin secretion,,2022-02-28,RECRUITING,INTERVENTIONAL,['NA']
234,NCT02130284,Rescue Events During In-clinic Procedues,,Device Metric/Performance - All Device Deficiencies,2014-10,COMPLETED,INTERVENTIONAL,['NA']
235,NCT04104711,Costs via frequency of complication-related hospital admissions,,Sociodemographic and disease-related characteristics of patients with diabetes,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
236,NCT05766774,Change in fasted plasma Eh[CySS] from baseline,Change in fasted plasma Eh[GSSG],,2023-06-28,RECRUITING,INTERVENTIONAL,['NA']
237,NCT03253562,benefit of improving the condition of elevated blood pressure in patients through neovascularization,comparing the anti-hyperglycemic effect of each drug for diabetic hypertensive patients,,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
238,NCT01244152,Weight change,Hemoglobin A1C,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
239,NCT02607007,Subjective Appetite,Food Intake,,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
240,NCT05394532,HbA1c,self management,,2020-10-02,COMPLETED,INTERVENTIONAL,['NA']
241,NCT05556161,HbA1c change,Social support,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
242,NCT04115917,Discomfort During Scleral Depression with Schocket Depressor and Cotton Tipped Applicator,Retinal pathology,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
243,NCT03786146,Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers.,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
244,NCT02827708,Change in HbA1c,Change in Urinalysis,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
245,NCT05417841,HbA1c,Time Above Range,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
246,NCT03805191,The extent of change in MAGE,The control rate of HbA1c,Gene polymorphism,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
247,NCT05532553,Assessment of carotid atherosclerosis,,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
248,NCT05446493,Serum YKL-40 and platelets indices in erectile dysfunction,Effect of tadalafil on Erectile dysfucntion patients,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
249,NCT01603940,Endothelial Function,Vascular Stiffness by Augmentation Index,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
250,NCT04284033,"Number of infusion set failures due to ""unexplained hyperglycemia""",Duration of infusion set wear,,2017-02-14,WITHDRAWN,INTERVENTIONAL,['NA']
251,NCT01938521,Fasting and postprandial Clock Genes expression in peripheral blood cells (PBC),Fasting HbA1c,"fasting and postprandial glucose, Insulin, GLP-1, asymmetric dimethylarginine (ADMA),and lipid plasma levels",2013-09,COMPLETED,INTERVENTIONAL,['NA']
252,NCT01473953,Number of Treatment Emergent Adverse Events (TEAEs),Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
253,NCT03214367,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in HbA1c at Week 52,,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE3']
254,NCT03557541,type 2 diabetes new onset,HOMA-B (homeostasis model assessment B cell function),,2014-05,COMPLETED,INTERVENTIONAL,['NA']
255,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,Number of subjects with abnormal oral glucose tolerance test (OGTT),,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
256,NCT06295913,LDL-ox as marker of oxidative status,Aspartate aminotransferase (transaminase AST),,2024-03,RECRUITING,INTERVENTIONAL,['NA']
257,NCT00442325,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,"The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
258,NCT04552600,To evaluate safety of Nuvastatic - Letter Score,To evaluate short-term visual outcomes on DRSS,,2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
259,NCT00054925,Change in Weight,,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
260,NCT05753436,Heart Rate,Serum Ferritin,,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
261,NCT00862602,Glucose tolerance,Insulin,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
262,NCT00831779,Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Insulin Secretion at Week 12 (Last Observation Carried Forward [LOCF]),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
263,NCT00623610,Evidence of clinically relevant beta cell function.,,,2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
264,NCT05007977,Change in glucagon between euglycemia and hypoglycemia,Change in cortisol between euglycemia and hypoglycemia,Symptom score during hypoglycemia,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE1']
265,NCT04867629,Proteomic biomarkers,Oxidative stress biomarkers,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
266,NCT00171496,Incidence of biopsy-proven acute rejection (BPAR) or graft loss or death within the first 6 months post-transplantation.,"incidence of BPAR or graft loss or death within the first 3 months post-transplantation, as well as the incidence of each individual event within 3 and 6 months post-transplantation.",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
267,NCT00453817,"Semi-quantitative assessment of intrahepatic MRI signal on T2*-weighted sequences, at 6 days, 6 weeks, 6 months and 1 year after transplantation","Islet graft function assessed by exogenous insulin requirements, HbA1c, mean amplitude of glucose excursions (MAGE) and fasting C-peptide.",,2005-06,TERMINATED,INTERVENTIONAL,['PHASE1']
268,NCT04019821,Postprandial Glycemia,Time in postprandial glucose range between 70 to 180 mg/dl (4.0-10.0 mmol/L),,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
269,NCT03913793,Six minute walk test distance,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
270,NCT01665989,Change in weight (percent weight loss from baseline to 6 months),Cost effectiveness and savings,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
271,NCT06152042,To assess the effect on endogenous insulin secretion,Incidence of adverse events,,2023-12-28,RECRUITING,INTERVENTIONAL,['PHASE2']
272,NCT00982358,The primary objective of the study was to evaluate the anti-inflammatory effect of VAL by analyzing the reduction of the inflammatory markers interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) in serum after 16 weeks of treatment.,"To explore the effect of 160/320 mg valsartan on coronary perfusion, in the group of patients with angiographically documented CAD",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
273,NCT06186245,Length of stay in the medical intensive care unit (in days).,mortality,,2023-12-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
274,NCT00606034,Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c),Patient Satisfaction With Insulin Delivery Method Via Insulin Delivery Rating System Questionnaire (IDRSQ),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
275,NCT01951183,Change from baseline in HbA1c,Safety: Incidence of adverse events,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
276,NCT01344668,Improvement in A1C at 12 months,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
277,NCT00095056,Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment,Safety and Tolerability of Sitagliptin Over 54 Weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
278,NCT01095822,How therapy with valsartan (160mg/daily) in combination with aliskiren (150-300mg/daily) affects platelet/coagulation/fibrinolytic biomarkers in recently diagnosed hypertensive patients with type 2 diabetes mellitus.,"Whether combination therapy is superior over monotherapy with aliskiren with regard to the improvement of hemostatic biomarkers (platelet aggregation, expression of GP IIb/IIIa, and plasma levels of antithrombin-III).",,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
279,NCT06157684,Infant birthweight percentile,need for insulin or metformin during pregnancy,feasibility and acceptability,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
280,NCT04190199,Nutritype signature of T2DM risks in women post-GDM,Smoking habit and exposure,,2020-05,UNKNOWN,OBSERVATIONAL,['NA']
281,NCT03920683,Toe-brachial index,Coronary angiography,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
282,NCT02990299,Hemoglobin A1c,Diabetes Self-efficacy,Health Coach Satisfaction,2017-03-24,COMPLETED,INTERVENTIONAL,['NA']
283,NCT03546062,Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
284,NCT00628056,The primary end point of the Perhexiline intervention study will be the change in cardiac PCr/ATP ratio.,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
285,NCT05586594,To see how many patient with diabetes diagnosed at early age with features not suggestive of type 1 or type 2 are found to have MODY monogenic diabetes (commonest subtypes) among young Emirati patients,To find out the antibodies present in young patient with diabetes and if they are helpful in ruling out monogenic diabetes,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
286,NCT05056376,Achievement of CDC's benchmark for type 2 diabetes risk reduction as a binary outcome (yes/no),Correlation between self-reported and measured physical activity,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
287,NCT01802541,insulin resistance,,,na,COMPLETED,INTERVENTIONAL,['NA']
288,NCT03343366,Glycated Hemoglobin (HbA1c),HOMA-IR,,2018-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
289,NCT04603885,BDNF DNA demethylation in percentage,Processing speed,,2020-10-27,UNKNOWN,INTERVENTIONAL,['NA']
290,NCT01853332,Social Adjustment Scale,Health Risk Factors,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
291,NCT04943692,Change in HbA1c,Incidence of adverse events,,2021-08,SUSPENDED,INTERVENTIONAL,['PHASE3']
292,NCT00821379,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
293,NCT05476016,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes, included suspected de novo DM diagnosis based on HbA1c",,2022-08-29,COMPLETED,INTERVENTIONAL,['NA']
294,NCT05237271,CPV-measured cost difference,CPV-measured Assessment of use case types,,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
295,NCT03341312,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm,,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1']
296,NCT02262832,Serum hemoglobin A1C,Bone mineral density &amp; metabolism,,2014-10-09,RECRUITING,INTERVENTIONAL,['PHASE3']
297,NCT05065892,Neutralizing antibody level,Adverse events following vaccination,,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
298,NCT04919499,Part B: Number of subjects with drug related Adverse Events (AEs) from drug administration until end of study (EOS),Part B: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) from drug administration until end of study (EOS),,2021-07-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
299,NCT00798915,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",The effects of xenin-25 on GIP action in persons with type 2 diabetes,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
300,NCT02020616,Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint,"Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC [τ,ss]) of LY3053102",,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
301,NCT02796248,Presence of stigma,Well-Being Index,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
302,NCT01403961,Compare incidence of immediate post surgery complications in diabetic patients with HbA1c > 7 and patients with HbA1c ≤ 7,,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
303,NCT06110728,Number of missed behavioral health visits,,Changes in weight,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
304,NCT00229268,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
305,NCT06180655,Study Feasibility: Intervention safety,Objective measures using an Oura Ring: Heart Rate Variability,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
306,NCT01046994,Diabetes control as defined by FSG and HbA1c,Assessment of patient BMI,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
307,NCT01997424,Steatosis,Steatosis (serum),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
308,NCT00379652,"Potential outcomes for the future intervention include systolic blood pressure, diastolic blood pressure, and hemoglobin A1c",,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
309,NCT02987751,Changes in HbA1c,Number of participants treated related to adverse events,,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE4']
310,NCT04786340,"Incidence of Treatment Emergent Adverse Events as assessed by dermal assessment (Draize score 0.0-4.0) score of skin erythema, edema pruritus and dryness score) of the dosing area",Neuropathy Total Symptom Score-6 (NTSS-6),,2020-11-20,COMPLETED,INTERVENTIONAL,['PHASE2']
311,NCT01399385,"To develop, implement, and optimize new non-invasive methods for characterization of the micro-environment in the thoracic and abdominal area utilizing specialized techniques",,,2011-07-06,RECRUITING,INTERVENTIONAL,['NA']
312,NCT00809705,"Tmax, log (AUC), log(Cmax)of paracetamol",Multiple dose pharmacokinetics of Taspoglutide,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
313,NCT03566511,Change in Arterial Spin Labeling (ASL) signal measured using 3T MRI from 2 hours post dosing to 4 hours post dosing,,,2018-06-12,SUSPENDED,INTERVENTIONAL,['PHASE2']
314,NCT06201806,Glycemic Responses (GR),Assessment of Appetite:,,2019-01-02,COMPLETED,INTERVENTIONAL,['NA']
315,NCT04893148,Changes in glycated hemoglobin (HbA1c),Changes in weight,,2020-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
316,NCT05152121,AUC,hypoglycemia epizode,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
317,NCT01104701,Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population,Number of Chemistry Laboratory Values of Potential Clinical Importance Observed During Treatment Period - ITT Population,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
318,NCT00970567,"glucose metabolism, time course of positive ketone bodies",,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
319,NCT04416841,Global cognition-Montreal Cognitive Assessment at 36 Weeks,"Quality of life-Medical Outcomes Study 36-item Short-Form Health Survey at 24, 36 weeks",functional Magnetic Resonance Imaging (fMRI),2020-06-03,COMPLETED,INTERVENTIONAL,['NA']
320,NCT03513939,"To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch",Proportion of participants with a reduction in HbA1c >1mg%,,2019-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
321,NCT02020850,Toe-Brachial Index,Ankle-Brachial Index,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
322,NCT05233592,Total Daily Insulin Resistance (TDIR),Change in Time in Hyperglycemia,Post-hoc t-test,2022-03-08,COMPLETED,OBSERVATIONAL,['NA']
323,NCT03859856,ovarian volume,,,2018-11-25,COMPLETED,OBSERVATIONAL,['NA']
324,NCT01565733,Frequency of severe hypoglycaemic episodes,Average plasma glucose level at bedtime and at night,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
325,NCT06283576,Cancer detection,Overall survival,,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
326,NCT02177643,Hepatic Function Panel,,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
327,NCT00529191,Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus,HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
328,NCT04616391,Between group TIR difference,Between group difference in the Diabetes Quality of Life (QoL) questionnaire score,Number of Severe Hyperglycemia episodes,2020-11-02,UNKNOWN,INTERVENTIONAL,['NA']
329,NCT04014582,Change in diabetes self-care,Change in diabetes specific self-efficacy,Daily self-efficacy,2019-07-20,COMPLETED,INTERVENTIONAL,['NA']
330,NCT05599477,Reduction in HbA1c,Costs and cost-effectiveness.,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
331,NCT00687999,"Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy",,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
332,NCT02657213,Assessment of the Minimed 640G insulin pump with Smartguard activation in preventing the number of severe and non-severe hypoglycaemia in patients with diabetes type 1 at risk of severe hypoglycemia,Study of average cost per patient for each therapeutic strategy supported from the point of view of society,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
333,NCT05859165,24h AUC of Nutren Diabetes group with Fresubin Diabetes group,Albumin,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
334,NCT02833389,Percentage of Participants with Adverse Events,Serum Concentration of UTTR1147A,,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
335,NCT03542370,Blood Pressure - Systolic Blood Pressure (randomized and non-randomized controlled trials),Inflammation - C-Reactive Protein (randomized and non-randomized controlled trials),,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
336,NCT03751735,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires,,,2017-01-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
337,NCT01824264,Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks,Change from baseline in renal threshold for glucose excretion,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
338,NCT00117026,Lower-limb nerve conduction velocity,"Serum advanced glycation end products (AGEs) and markers of inflammation (CRP, IL-6, VCAM-1)",,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
339,NCT01175629,Determine the prevalence of lifetime and current psychiatric conditions including PTSD in Vietnam Era Twin Registry members who served during the Vietnam Era.,Characterize the level of current disability in Vietnam Era Twin Registry members who served during the Vietnam Era.,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
340,NCT05121844,Change in weight,Time in range,,2021-11-02,RECRUITING,INTERVENTIONAL,['NA']
341,NCT00198510,Resolution of Vitreous Hemorrhage,Visual Acuity,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3']
342,NCT05951270,Apple polyphenols and glucose homeostasis in prediabetics,Apple polyphenols and fecal microbiota composition,,2022-01-14,TERMINATED,INTERVENTIONAL,['NA']
343,NCT05988957,Describe CGM data use,Describe overall experience of receiving a NFA during CGM initiation,,2023-08-01,COMPLETED,OBSERVATIONAL,['NA']
344,NCT01950676,Change in glycemic control (HbA1c) between the intervention and the control group,Treatment satisfaction as measured by DTSCs and DTSQc,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
345,NCT00541775,Hemoglobin A1C (A1C) at Week 18,2-hour Post-meal Glucose (PMG) at Week 18,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
346,NCT00649246,autoantibodies against the pancreas and type 1 diabetes,Risk factors for type 1 diabetes,,1997-07,COMPLETED,OBSERVATIONAL,['NA']
347,NCT01580475,"Changes from baseline in glycemic control measurements (follow-up for 21 months) at training (9 months), detraining (3 months) and retraining (9 months)",Measurement of muscular strength in patients with type 2 diabetes,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
348,NCT02246400,Change in measure of Health-related quality of life from baseline to 6-months follow up.,Body weight,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
349,NCT02094846,Glycated hemoglobin,Physical activity,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
350,NCT05609279,Proportion of enrolled participants providing serum samples for metabolomic analysis,,,2021-02-18,RECRUITING,OBSERVATIONAL,['NA']
351,NCT01735643,HbA1c,weight,,2011-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
352,NCT03036800,Weight loss of ≥15% at 52 weeks,Patient quality of life,Waist circumference,2017-11-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
353,NCT00602953,Disposition Index (DI),,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
354,NCT05104944,Quality of life and resource data collection - patient diary.,Progression of foot deformity as documented by measuring radiological foot alignment angles.,Economic Evaluation - Reported through a patient diary,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
355,NCT02291250,Plasma Glucose Area Under the Curve,Plasma Insulin Area Under the Curve,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
356,NCT05385575,Number of participants with abnormal clinically significant electrocardiogram (ECG),The efficacy of KN056 by analyzing HbA1c (Glycosylated hemoglobin) changes,,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1']
357,NCT01510223,Gastric emptying by 13C octanoic acid breath test,Food intake by buffet meal,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
358,NCT04045184,Compare hemoglobin A1c levels between groups with high versus low dietary fiber intake,,,2018-10-20,RECRUITING,OBSERVATIONAL,['NA']
359,NCT05186389,Metagenomic analysis,Clinical associations with metagenomic analysis,,2022-01-26,UNKNOWN,OBSERVATIONAL,['NA']
360,NCT04007640,fibroinflammatory lesions at histology in obese patients,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma,,2019-06-18,RECRUITING,INTERVENTIONAL,['NA']
361,NCT00134524,Subject tolerance to the MME procedure,"Quality of Life assessments at baseline, post-procedure and 6 month follow-up",,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
362,NCT02098733,Number of Participants With Adverse Drug Reactions,Fasting Insulin Level,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
363,NCT02967406,Dementia,Blood lipids,Cognitive function,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
364,NCT01594060,,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
365,NCT05610722,HbA1c,Percentage of sensor readings below 54 mg/dl,"The time required to review insulin and glucose data, make and send recommendations",2022-11-06,RECRUITING,INTERVENTIONAL,['NA']
366,NCT00157586,"The rate of decline of glomerular filtration rate (GFR).GFR is measured at baseline,and at 6,12,18,24,30 and 36 months after randomization",Major cardiovascular events,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
367,NCT05740514,"The effect of T1D on skeletal muscle health, quantified by physiological parameters (detailed in description)","The effect of a detraining period on skeletal muscle health compared to baseline, quantified by physiological parameters (detailed in description)",,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
368,NCT06074601,Clinical validation of cell-free RNA-based biomarkers of adverse pregnancy outcomes,Discovery of multi-omic biomarkers of adverse pregnancy outcomes,,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
369,NCT00676767,Glycemic Response,,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
370,NCT01349114,Change in Flow-mediated Dilation,Mean Central Aortic Pressure at 3 Months,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE4']
371,NCT05852054,Primary care visit (PCV) completion,Dysglycemia and hypertension cases detected,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
372,NCT00263419,Progression of albuminuria,Cardiovascular risk factors,,2005-01,UNKNOWN,INTERVENTIONAL,['NA']
373,NCT05166447,Major adverse cardiovascular events (MACE) (Register data),Chronic Kidney Disease (CKD) Stage 3/4/5 (Blood samples),,2021-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
374,NCT01399346,"tmax(ins), time to maximum observed serum insulin aspart concentration","t10%max(ins), time to reach 10% of maximum observed serum insulin aspart concentration",,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
375,NCT04993482,Change in 24-hour movement composition from baseline over one year and two-year follow-up,Change in Advanced Glycation Endproducts from baseline to one and two-year follow-up,Explanatory variables: physical environmental factors,2021-08-29,RECRUITING,OBSERVATIONAL,['NA']
376,NCT03330548,Change in Low-density lipoprotein (LDL),Change in Hemoglobin A1C (HgbA1c),,2015-07-09,COMPLETED,INTERVENTIONAL,['NA']
377,NCT02977130,Glycated hemoglobin (HbA1c),,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
378,NCT05814393,HbA1c (24 Weeks) lowering effect,HbA1c lowering effect,,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE3']
379,NCT06246175,Area Under the Concentration Versus Time Curve (AUC) of HRS9531 From Time Zero to Infinity (AUC0-inf),Incidence and severity of adverse events,,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1']
380,NCT04387422,Glucose kinetics during hyperglycemic clamps before and after induction of IAH,Antecedent physical activity - sleep quality,,2020-08-12,RECRUITING,INTERVENTIONAL,['NA']
381,NCT01885208,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target: (Yes/no),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
382,NCT03959514,Area under the glucose infusion rate-time curve of insulin aspart,Area under the serum insulin aspart concentration-time curve from 0-60 minutes,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
383,NCT03844126,Transition preparedness,,,2018-04-13,COMPLETED,INTERVENTIONAL,['NA']
384,NCT05223556,Accuracy in the diagnosis of referral retinal lesions,Satisfaction of participants as measured by questionnaire,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
385,NCT00044395,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
386,NCT04021602,Introduction of Solid Food,Baby's Height,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
387,NCT03713996,Change in Insomnia Severity Index,Change in Random Glucose Level,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
388,NCT00279084,Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period.,Quality of life: SF 36 auto-questionnaire,,2004-01,UNKNOWN,INTERVENTIONAL,['NA']
389,NCT04769765,"Number of patients on the basic diabetic program, included in the study, who have completed at least three of the four scheduled follow-up visits.",Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Number of follow-up visits per patient per center.,Complications,2022-05-04,RECRUITING,INTERVENTIONAL,['NA']
390,NCT05215210,change in fasting plasma glucose concentrations,change in HOMA-B levels,change in creatinine,2022-03-23,COMPLETED,INTERVENTIONAL,['NA']
391,NCT04244110,Usability of the Diacare platform,,,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
392,NCT03555994,To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment,Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300μg (Parts A and B) by assessment of changes in haematology and clinical chemistry parameters,,2018-05-31,COMPLETED,INTERVENTIONAL,['PHASE2']
393,NCT05958602,Change in HbA1C of Participants,App Engagement,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
394,NCT01510522,Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6,Rate of reported adverse events,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
395,NCT01175486,Diabetic nephropathy,Diabetic nephropathy,,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
396,NCT04674384,Occurrence of Serious Adverse Events (SAEs) deemed potentially related to the dietary programmes.,Percentage of contacts with Dietitian conducted face to face after baseline (for ILED and CLED),,2022-01-19,RECRUITING,INTERVENTIONAL,['NA']
397,NCT02488278,Operating the GlucoMe device: obtaining a glucose reading and recording the results,Documenting specific user errors and inefficiencies related to the use of the device and application,,2015-07,WITHDRAWN,INTERVENTIONAL,['NA']
398,NCT05989256,Inpatient hypoglycemia event rates,Number of Inpatient hospitalizations with a hyperglycemic event,,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
399,NCT05046158,Incidence of wound closure,Clinician Acceptability,,2021-08-16,RECRUITING,INTERVENTIONAL,['NA']
400,NCT04828512,Survival,major complications of cirrhosis,,2007-01-02,UNKNOWN,OBSERVATIONAL,['NA']
401,NCT04979130,Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups,Differences between treatment groups in plasma hs-CRP,Exploratory: determine the effect of semaglutide as compared to placebo on intestinal microbiota in relation to changes in intestinal permeability and inflammatory markers,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
402,NCT03915990,the diagnostic value of Umbilical artery Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,he diagnostic value of MCA Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
403,NCT01330121,Adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management,Change in lipids after 90 days,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
404,NCT01214590,Diabetic neuropathic pain,Nerve conduction velocity,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
405,NCT06016478,Change in total peripheral resistance during acute hyperglycemia,Change in 24-hour ambulatory blood pressure monitoring,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
406,NCT05478252,Change in Glycated Haemoglobin (HbA1c),Anti-semaglutide Antibodies Level (Measured as Titre),,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE3']
407,NCT02500303,Further surgery,Co-morbidities,,2014-03,UNKNOWN,OBSERVATIONAL,['NA']
408,NCT03338010,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®),Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year),,2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE3']
409,NCT03307486,Occurrence of type 2 DM after GDM,Fetal weight at birth vs eating habits,,2015-09-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
410,NCT04071977,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,"Correlate the levels of total antioxidant capacity (TAC) in systemic samples, aqueous humor and vitreous humor with the glycosylated hemoglobin value of patients with proliferative diabetic retinopathy.",,2020-03-25,COMPLETED,INTERVENTIONAL,['PHASE2']
411,NCT01835431,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L),,2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
412,NCT02407132,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention.","Change in Mean Triglycerides From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention",,2015-06,COMPLETED,INTERVENTIONAL,['NA']
413,NCT05415683,Data Collection,,,2022-06-22,RECRUITING,OBSERVATIONAL,['NA']
414,NCT01690091,insulin sensitivity,heart function,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
415,NCT02811575,Number of lymphocyte TCD4 Th17 in colon sample,Bacteria production,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
416,NCT03770728,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2019-08-01,TERMINATED,INTERVENTIONAL,['PHASE3']
417,NCT01399645,To determine liver fat fraction evolution induced by liraglutide and insulin,,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
418,NCT04794283,neonatal hypoglycemia on day 0 of life will be meassured,Hyperbilirubinemia during the first week of life will be meassured,,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA']
419,NCT00339703,,,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
420,NCT02709031,Time to potassium rescue,Average levels of magnesium in patients on cicletanine with and without magnesium,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
421,NCT00760578,Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test,Change From Baseline in HDL,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
422,NCT06129994,Ecological Momentary Assessment (EMA) methods for measuring depression,Hemoglobin A1c,,2023-11-07,RECRUITING,OBSERVATIONAL,['NA']
423,NCT03077386,Acute care utilization,Acute care costs,,2018-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
424,NCT00235196,Clinical effectiveness of CAM in DFU by comparing the reduction in wound area between 2 treatment groups.,Wound characteristics,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
425,NCT02162901,Body weight,,,2014-03-13,COMPLETED,INTERVENTIONAL,['NA']
426,NCT00684528,The efficacy and safety of Metformin VS Metformin + Janufer in the community setting,,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
427,NCT01570946,Progression to diabetes,Improvements in Quality of Life,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
428,NCT00755287,Absolute change from baseline in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
429,NCT00225264,Absolute change from Baseline in carotid intima-media thickness.,"Incidence of cardiovascular events as a composite of cardiovascular mortality, nonfatal MI, nonfatal stroke, coronary revascularization, carotid endarterectomy/stenting, hospitalization for unstable angina and hospitalization for CHF",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
430,NCT00239538,Changes from baseline in the mean SBP and DBP as measured by ambulatory blood pressure monitoring (ABPM),Metabolic and inflammatory marker changes from baseline,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
431,NCT01089790,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3']
432,NCT01022619,apnea-hypopnea index,growth and development during the 1st year of life,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
433,NCT04938557,The time spent with glucose levels between 3.5-7.8 mmol/L based on CGM measures (Time In Range TIR 3.5-7.8mmol/L),Hospital length of stay (infant).,,2019-09-26,COMPLETED,INTERVENTIONAL,['NA']
434,NCT00823992,Absolute change from baseline in HbA1c,"Safety:Adverse events,clinical laboratory tests, vital signs,physical examination, ECG, anti-taspoglutide antibodies\n",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
435,NCT02214654,circulation endothelial cell,,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
436,NCT03137316,intact parathyroid level,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
437,NCT02123901,Change from baseline in vascular reactivity,Change from baseline in blood chemistry,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
438,NCT06178250,Ductus venosus volume in ultrasound,,,2021-09-22,COMPLETED,INTERVENTIONAL,['NA']
439,NCT05405244,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water by TaqIA Allele Status (A1 vs. A2/A2),,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
440,NCT04034511,Change in hemoglobin A1c,Change in Hemoglobin A1c,,2020-01-21,COMPLETED,INTERVENTIONAL,['NA']
441,NCT03118713,The percentage of change of Urine Albumin-to-Creatinine Ratio (UACR),Change from baseline in Quality of Life as measured through Audit of Diabetes-Dependent Quality of Life-19 (ADDQoL-19) questionnaire,,2017-04-25,TERMINATED,INTERVENTIONAL,['PHASE4']
442,NCT04094662,Average Daily Pain Score (ADPS),Five Level EuroQol-5D (EQ-5D) version,Actigraphy signal collected from a wrist-worn medical-grade sensor,2019-09-18,COMPLETED,INTERVENTIONAL,['PHASE3']
443,NCT03939793,Adherence Rate,,Change in Glycosylated Hemoglobin,2019-05-15,COMPLETED,INTERVENTIONAL,['NA']
444,NCT03960463,Change in tissue oxygenation from baseline to 4 weeks,Presence of scar tissue,,2017-05-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
445,NCT00276471,Ability to communicate between patient wand and the device.,Improvement in co-morbid parameters,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
446,NCT05783700,BIOIMPEDANCEMETRY,Resting heart rate,,2023-10-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
447,NCT06000722,Delphi Round 2,,,2023-12-05,RECRUITING,OBSERVATIONAL,['NA']
448,NCT00927394,Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8,"Number of Patients With Adverse Events, Serious Adverse Events and Death",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
449,NCT00446381,"Levels of intravitreal VEGF, TGFbeta, ET-1, PDGF, IGF-1,angiopoietin, HIF 1 alpha, HIF 1 beta pre and post injection of intravitreal Macugen.",Effect on concomitant diabetic macular edema post injection of intravitreal Macugen,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
450,NCT03299010,Factors that have sufficient power to classify Chinese DM patients in primary care into risk group in terms of total CVD and all-cause mortality,,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
451,NCT01240759,Change from Baseline to Week 12 in Hemoglobin A1c (HbA1c),Safety assessments,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
452,NCT05105620,Fréchet inception distance (FID) score.,,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA']
453,NCT03681054,Child: Neonatal body fat%,Percentage of participants on GDM medication,,2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
454,NCT02467881,Actigraph Accelerometry,EQ-5D Quality of Life Survey,,2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
455,NCT00344136,,,,2000-09,COMPLETED,OBSERVATIONAL,['NA']
456,NCT06330948,Hematology Test,,,2024-03,RECRUITING,INTERVENTIONAL,['NA']
457,NCT04869605,"the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes",,,2021-05-06,UNKNOWN,OBSERVATIONAL,['NA']
458,NCT02240420,Behavior change,Weight loss,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
459,NCT04032197,Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries,Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery,,2019-08-12,COMPLETED,INTERVENTIONAL,['PHASE1']
460,NCT02459561,HbA1c reduced by 20%,To estimate the cost-effectiveness of the EndoBarrier device compared with conventional treatment.,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
461,NCT01407640,Validation of cutaneous insulin tests,Immunogenetic of patients with IA (Insulin Allergy),,2012-02-06,COMPLETED,INTERVENTIONAL,['NA']
462,NCT04460573,Adherence to offloading,Physical Activity,,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
463,NCT02772679,Survival of Tregs,"Analysis of general immune response as assessed by, for example, viral tetramer+ CD8 cells and effects of Treg infusions on peripheral blood cells measured by flow cytometry including T cell subsets, B cells and other innate cell subsets",,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1']
464,NCT03342495,Health services utilization,Variation in SF-12 Scores,Youth/Caregiver Satisfaction,2018-02-06,COMPLETED,INTERVENTIONAL,['NA']
465,NCT00468676,"Glycated Hemoglobin (HbA1c) at Baseline, 6 Months and 12 Months",Health Care Costs,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
466,NCT04933851,Diabetes Distress Scale,Diabetes Support and Isolation Questionnaire,Body Mass Index (BMI),2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
467,NCT03484741,Adverse events,Blood insulin level,,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
468,NCT03638362,TCJ and hsCRP,fasting triglycerides,,2009-08-21,COMPLETED,INTERVENTIONAL,['NA']
469,NCT03959501,Change in serum ketone levels after treatment,Change in homeostasis model assessment 2 steady-state beta-cell function,,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE4']
470,NCT02309424,Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC),Number of participants with adverse events,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
471,NCT06152887,Change in numeric rating scale (NRS) scores in pain diary,Quantitative sensory testing,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
472,NCT06184568,Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss,"Percent Change from Baseline in Triglycerides, Total Cholesterol, LDL-c, HDL-c, non-HDL-c",,2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE3']
473,NCT00575159,Mean of Derived Plasma Glucose Parameters,"The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK279782 Over Period",,2008-03-31,COMPLETED,INTERVENTIONAL,['PHASE2']
474,NCT03940482,Change in glycaemic control of patients as measured by >= 5% reduction in glycosylated haemoglobin (HbA1C) over a 12 week period.,Change in a levels of ketonemia (Serum Beta-Hydroxybutyrate 0.5-3.0 mmol/L) over a 12 week period.,,2019-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
475,NCT03428945,Change from Treatment Assignment Glucose Tolerance to Abnormal Glucose Tolerance or Diabetes,,,2018-08-15,TERMINATED,INTERVENTIONAL,['PHASE2']
476,NCT01418911,,,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
477,NCT02357043,Accuracy - Blood Glucose Level Obtained by Layperson With the Dario Meter Compared to Blood Glucose Level on Yellow Springs Instrument Obtained by Nurse/Technician,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
478,NCT00438126,increased self-reported leisure physical activity,resting blood pressure,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
479,NCT00237588,Insulin sensitivity assessed with hyperinsulinaemic isoglycaemic glucose clamp(GDR),Microalbuminuria,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE4']
480,NCT02597127,Percentage Change in LDL-C From Baseline to Day 180,Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
481,NCT02135549,Postprandial serum glucose area under the curve in mg*hr/dL over four hours,Peak blood serum excursion at 2 hours from baseline in mg/dL,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
482,NCT00520962,,,,1997-06,COMPLETED,OBSERVATIONAL,['NA']
483,NCT02354235,Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose Level,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
484,NCT00855608,The main outcome measure will be visual acuity improvement (3 lines),central foveal thickness and angiographic lesion size,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
485,NCT01002235,Dose limiting toxicity,Pain Levels,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
486,NCT03804658,Glucose variability,Health Literacy,,2019-01-13,RECRUITING,OBSERVATIONAL,['NA']
487,NCT01861756,"Overall Decisional Comfort (0-100, 100=no Conflict)",Glycemic Control (HbA1c),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
488,NCT04303364,Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy,Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy,,2020-10-02,RECRUITING,OBSERVATIONAL,['NA']
489,NCT01870713,"different proteins detected between obese persons, type 2 diabetes patients prior to surgery, 10 days after surgery and 3 months after surgery.",evaluating the change in glucose between the baseline evaluation and the follow-up evaluation.,,2010-10,UNKNOWN,OBSERVATIONAL,['NA']
490,NCT02455414,Change in regional brain volume,Change in disease severity score,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
491,NCT01762085,occurrence of plantar foot ulceration wound,Visual Analog Pain Score,Incidence of falls during the study,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
492,NCT01753934,Memory score on ImPACT testing,White matter volume on MRI using diffusion tensor imaging,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
493,NCT01075282,Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),"Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
494,NCT01351701,Risk factors associated with different grades of severity of DFI,Percentage sensitivity to different empiric antibiotics,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
495,NCT03867942,Gemigliptin Cmax,,,2019-03-21,UNKNOWN,INTERVENTIONAL,['PHASE1']
496,NCT04957173,The primary outcome of this study will be weight loss in the participants.,,,2021-10-14,WITHDRAWN,INTERVENTIONAL,['NA']
497,NCT06330233,Electrophysiological examination of the peroneal nerve of the lower limb,infrared thermography testing,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
498,NCT05437848,Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs,Change in coefficient of variation as measured by CGM over 7 days,,2022-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
499,NCT00818142,Adherence to insulin regimen.,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
500,NCT03959306,Effect on Markers of Endothelial Dysfunction(The change in the level of soluble intercellular adhesion molecule ( ICAM) in serum using ELISA kit),Effect on Quality of Life ( Using Diabetes-39 questionnaire ),,2019-04-24,UNKNOWN,INTERVENTIONAL,['PHASE2']
501,NCT05487352,gestational diabetes mellitus,"neonatal weight, height and head circumference",,2021-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
502,NCT00541710,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
503,NCT04831216,"Hemoglobin A1c (HbA1c), %",,,2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
504,NCT04600128,Change in blood glucose levels,,Insulin,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
505,NCT05873322,The extent of beta cell function at week 22/23/28,,,2022-08-30,RECRUITING,OBSERVATIONAL,['NA']
506,NCT00935441,Glycemic control (HbA1c),Systolic blood pressure control in patients with elevated blood pressure at baseline,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
507,NCT00108524,Change From Baseline in Body Weight at 48 Weeks,Change From Baseline in Blood Sugar at 48 Weeks,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
508,NCT03269799,sulcus bleeding index,,,2017-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
509,NCT02178501,Change from Baseline in endothelial function status 3 months,Change from Baseline in glycometabolic control at 3 months,Safety Measures,2013-01,COMPLETED,INTERVENTIONAL,['NA']
510,NCT01093651,Plasma HIV Viremia (Viral Load),Self-reported Symptoms,,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
511,NCT01412710,Blood Lipid,Glycemic Control,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
512,NCT05131139,Safety Objective: To demonstrate safety of the Eversense 524 CGM System and ROME CGM System.,,,2021-10-20,RECRUITING,INTERVENTIONAL,['NA']
513,NCT02276742,Urinary sodium will be determined from a time 24-hour urine sample,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
514,NCT06081413,improvement in obesity-related diseases,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
515,NCT04219787,Primary endpoint,Secondary endpoints,,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
516,NCT04790006,Safety and tolerability assessed by incidence and severity of adverse events,Apparent clearance (CL/F),,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
517,NCT01802034,Change in disease progression,,,2013-02,RECRUITING,OBSERVATIONAL,['NA']
518,NCT02457130,Platelet reactivity,,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
519,NCT06067399,To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control.,To determine if changes in RDW levels correlate with the presence of other comorbidities and complications.,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
520,NCT02064647,Time spent with postprandial glucose level in target range,Frequency & duration of postprandial hypoglycemia,Satisfaction/ease of use of Trend Arrow Adjustment Tool,2014-07,COMPLETED,INTERVENTIONAL,['NA']
521,NCT01494987,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
522,NCT02477865,HbA1c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-03-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
523,NCT00840307,Pancreatic and Liver Triglyceride (Fat) Content,,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
524,NCT02383238,Microcirculation,Macrovascular circulation,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
525,NCT01332149,Change From Baseline in Mean Pain Score at Endpoint,Change From Baseline in HADS Depression Total Score at Endpoint,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3']
526,NCT01060059,Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12.,"Factors of Higher Creatinine, Higher Fasting High Density Lipoprotein (HDL) Cholesterol, Higher Fasting Cholesterol, and Higher Fasting Triglycerides Which Were Associated With Treatment Choice at Baseline",,2010-04,COMPLETED,OBSERVATIONAL,['NA']
527,NCT00737269,,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
528,NCT03418415,Changes in glucose metabolism from baseline to 6 months,Changes in renal function up to 2 years,,2018-01-18,UNKNOWN,INTERVENTIONAL,['NA']
529,NCT03633266,Mean change from baseline in best-corrected visual acuity (BCVA),chang from baseline in retinal neovascularization,,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
530,NCT04487678,Change in venous blood pH,Gastro-intestinal distress symptoms via a questionnaire,,2023-08,WITHDRAWN,INTERVENTIONAL,['NA']
531,NCT02068989,Percentage of Subjects with an HbA1c greater than or equal to 6.5%,,,2013-02,TERMINATED,OBSERVATIONAL,['NA']
532,NCT03126786,Mean Change From Baseline in Best Corrected Visual Acuity Letter Score,Mean Change From Baseline in Central Subfield Thickness,,2017-07-11,COMPLETED,INTERVENTIONAL,['PHASE2']
533,NCT02634229,Identification of novel predisposition gene,Correlation between genotype and HbA1c,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
534,NCT03150030,Part 2: Difference in MAGE,Part 2: Correlation between plasma glucose variation and risk of clinical relevant arrhythmias,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
535,NCT04362540,The primary outcome measure for the study will be the mean difference in values of the HOMA-IR (as a surrogate for insulin resistance) in those with NAFLD vs. those without NAFLD 6-12 weeks post partum,MRI scan to confirm the presence of NAFLD at 6-12 weeks post partum.,,2019-05-05,RECRUITING,OBSERVATIONAL,['NA']
536,NCT04147637,Percentage time in range 4-10mmol/L,Change in dose of insulin,,2020-10-14,WITHDRAWN,INTERVENTIONAL,['NA']
537,NCT05207774,obesity,omental and subcutaneous fat inflammation,,2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
538,NCT01710553,"Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2",Safety profile,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
539,NCT00992641,Glucose metabolism,Transcriptomics and metabolomics data,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
540,NCT03842813,The primary endpoint is Target Lesion Failure (TLF) rate at 1 year,Stent thrombosis at 1 year in the sub-group of patients with a short planned dual-therapy,,2019-04-09,UNKNOWN,OBSERVATIONAL,['NA']
541,NCT05567692,Type 2 diabetes incidence in Descendance population,Study of interactions between risk factors on type 2 diabetes incidence,,2023-02-10,RECRUITING,OBSERVATIONAL,['NA']
542,NCT01499108,Change in ambulatory blood pressure,Washout analysis,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
543,NCT03437421,Change in longitudinal strain,,,2018-02-04,COMPLETED,INTERVENTIONAL,['NA']
544,NCT06221969,Relative change in body weight,"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-01-16,RECRUITING,INTERVENTIONAL,['PHASE3']
545,NCT03838900,Measure of Loop Safety by Self-Report of Hospitalization Events,Measure of Loop Safety by Self-Report of Hospitalization Events,Loop Follow-Up General Data Collection,2019-01-17,COMPLETED,OBSERVATIONAL,['NA']
546,NCT01907399,quantification of Treg,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
547,NCT00354341,Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15,Percentage of Participants With Stable Hb Levels Between 13 to 15 g/dL,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
548,NCT05909046,Rate of postpartum diabetes mellitus screening,Prediabetes or type 2 diabetes,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
549,NCT03081598,"To evaluate the efficacy of PBI-4050 400 mg, 800 mg, and 1200 mg",To evaluate the effect of PBI-4050 on frequency of hypoglycaemia events,,2017-05-29,TERMINATED,INTERVENTIONAL,['PHASE2']
550,NCT04219215,Change in rate of glucose disappearance,,,2020-02-01,COMPLETED,INTERVENTIONAL,['NA']
551,NCT03618420,Glomerular Filtration Rate (GFR),Renal Oxygenation,,2018-10-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
552,NCT02453685,Change in HbA1c (Glycosylated Haemoglobin),Total Daily Insulin Dose,,2015-08-31,COMPLETED,INTERVENTIONAL,['PHASE4']
553,NCT03049605,Motor and sensory conduction velocity of the lower limb nerves,,,2014-01-25,COMPLETED,INTERVENTIONAL,['PHASE2']
554,NCT04661358,Worsening of diabetic retinopathy,Visual acuity loss from any cause,,2021-03-05,RECRUITING,INTERVENTIONAL,['PHASE3']
555,NCT01754181,Time spent in glucose reference intervals,"Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia)","Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC in conditions identical meals for each trigger level (50 or 75%). Measuring AUC during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night.",2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
556,NCT01492465,Subject incidence of anti-AMG 876 antibodies.,Pharmacodynamic parameters:,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE1']
557,NCT05663606,TIR,HbA1c,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
558,NCT01368978,Efficacy,,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
559,NCT00223574,glycated hemoglobin,diet satisfactio,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
560,NCT04222894,Plasma Lipids,Food Acceptability: The Food Acceptability Questionnaire,,2020-06-26,COMPLETED,INTERVENTIONAL,['NA']
561,NCT05831644,Pharmacodynamic effect,,,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE1']
562,NCT03260881,EAT inflammation,EAT GLP-1R,,2018-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
563,NCT01474603,body weight change from baseline (non-diabetic patients),change from baseline of inflammatory and metabolic parameters,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
564,NCT01783210,Gestational diabetes mellitus.,Mode and timing of delivery,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
565,NCT05372809,Incidence of index ulcers closed,Wound infection,Incidence of adverse events of the index ulcer,2022-04-28,TERMINATED,INTERVENTIONAL,['PHASE3']
566,NCT02916251,PD endpoint: Plasma glucose profiles above baseline: tmax,Safety endpoints: Antidrug antibodies incidences,,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
567,NCT06017089,Primary Safety Endpoint (Hypoglycemia),Basal Insulin,,2023-11-10,RECRUITING,INTERVENTIONAL,['NA']
568,NCT03349840,Comparison of the glycemic control of insulin glargine U100 with insulin degludec in patients with type 2 diabetes from baseline to end of Ramadan.,Incidence of Treatment-Emergent Adverse Events,,2018-01-07,TERMINATED,INTERVENTIONAL,['PHASE4']
569,NCT04259112,Serum cystatin C (CysC) level,Renal tissue oxygen saturation,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
570,NCT00656851,Myocardial Fatty Acid Esterification,Fasting Glucose Insulin and HOMA,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
571,NCT05937373,Disparities in Continuous Glucose Monitoring (CGM) accuracy - serum and arterial glucose values,Disparities in Continuous Glucose Monitoring (CGM) accuracy - interference amount,,2023-08-04,RECRUITING,INTERVENTIONAL,['NA']
572,NCT02213549,Change in 2h glucose concentration after the oral glucose tolerance test (OGTT) from baseline,Change in serum triglyceride from baseline,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
573,NCT02359617,Mean absolute relative difference between sensor readings and capillary glucose readings,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
574,NCT01459601,FBS (fasting blood sugar),HbA1C,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
575,NCT04404556,Barriers to Diabetes Adherence questionnaire - Youth report Time Pressure/Planning Subscale,Type 1 Diabetes and Life -Parent Report,,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
576,NCT04236609,Rate of Target lesion failure TLF,Bleeding,Target vessel revascularization (TVR),2020-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
577,NCT01196533,Comparison of the TensorTip Accuracy Against Hospital Periodical Readings.,,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
578,NCT00307749,Nerve Conduction Studies,Clinical Global Impression,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
579,NCT00928876,"to determine the effect of Interleukin-1 receptor antagonist on insulin sensitivity, as derived from glucose infusion rate measured by euglycemic hyperinsulinemic clamp",systemic inflammation,,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
580,NCT01541215,Change in HbA1c (Glycosylated Haemoglobin),Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156,,2012-11-13,COMPLETED,INTERVENTIONAL,['PHASE3']
581,NCT05943886,AUC,Assessment of the incidence of anti drug antibodies (ADA) developed against HEC88473 after dosing,,2021-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
582,NCT01876563,erytrocyte thioredoxin reductase,GENE EXPRESSION OF TBP-2,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
583,NCT06185348,Body mass index (BMI) variation after 6 months of treatment with hybrid closed loop (HCL),description of metabolic parameters at 24 months,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
584,NCT04791267,Acute care service use,Medication adherence,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
585,NCT05645653,Medication Adherence,Treatment burden,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
586,NCT00846300,Change in blood pressure,,,2001-08,COMPLETED,INTERVENTIONAL,['NA']
587,NCT03745157,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Change in selected patient reported outcomes: Diabetes Therapy Related Quality of Life (DTR-QoL),,2018-11-21,COMPLETED,OBSERVATIONAL,['NA']
588,NCT03093298,Altered gene expression in the endocrine secretome following Roux-en-Y gastric bypass surgery,,,2014-12-12,COMPLETED,INTERVENTIONAL,['NA']
589,NCT00252876,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight","Central obesity (waist circumference, hip circumference, waist/hip ratio)",,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
590,NCT01129258,PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.,"Lactate (change from Day -1 baseline), at times specified in the SOA.",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
591,NCT01457911,Absolute change in HbA1c,"Hematology, Serum chemistry and lipids",,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
592,NCT02392117,Change in the number of any hypoglycaemic episodes,"Change from baseline in HR-QoL (health-related quality of life) questionnaire scores (PROs (patient reported outcome): SF-36 (short form 36), and DTSQ(Diabetes Treatment Satisfaction Questionnaire ))",,2015-03-16,COMPLETED,OBSERVATIONAL,['NA']
593,NCT02513641,Insulin Sensitivity,2-hour Insulin Area-under-the-curve Via Oral Glucose Tolerance Test,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
594,NCT05918068,Glycated Hemoglobin (HbAlc),"Indoleamine 2,3 dioxygenase (IDO)",,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
595,NCT01547156,Change in Hba1c(for diabetes patients),Change in FÍNSIK scores,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
596,NCT02212951,Post-standardized meal glucose exposure (AUC),Draize injection site erythema and edema scoring,,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
597,NCT06141278,Change of SBP at baseline and at 12 month,Treatment rate at baseline and at 12 month,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
598,NCT04779164,Femoral cartilage thickness,radiographic knee osteoarthritis,,2020-09-04,COMPLETED,INTERVENTIONAL,['NA']
599,NCT04814147,Weight loss (kg) at 12 months of sleeve gastrectomy,Pre and post-operative hip circumference,,2021-03-13,RECRUITING,OBSERVATIONAL,['NA']
600,NCT00762736,Change from Baseline in glycosylated hemoglobin.,Change from Baseline in matrix metalloproteinase-9.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
601,NCT06130215,Time above Range (>180mg/dl and >250mg/dl),Diabetic Ketoacidosis,Ped Quality of Life Survey,2023-11-15,RECRUITING,INTERVENTIONAL,['NA']
602,NCT03955107,time in range at Week 8 after enrollment,adverse pregnancy outcomes,,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
603,NCT01345500,Total weight loss,Biochemical/social outcomes,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
604,NCT02786979,Number of participants with abnormal laboratory values and/or adverse events related to treatment,Change from baseline in value of TNF-α,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4']
605,NCT01165983,Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside,"Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL",,2009-11,COMPLETED,INTERVENTIONAL,['NA']
606,NCT05115747,Mean changes in the glycosylated hemoglobin level (HbA1c) at six months.,Mean changes in the health-related quality of life at six months.,,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
607,NCT04227431,Change in glycosylated haemoglobin (HbA1c),"Reason(s) for starting Tresiba®, at time of switch/add-on, if available",,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
608,NCT02899390,Body weight change,Change in the Perceived Stress Scale (PSS) -14 score,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
609,NCT05303857,Central (aortic) pulse pressure assessed by Sphygmocor XCEL,Renal perfusion of both kidneys assessed by Arterial Spin Labeling MRI,,2022-03-03,RECRUITING,INTERVENTIONAL,['PHASE4']
610,NCT04652999,Patient satisfaction with the relaxation intervention,Heart rate,Clinical Data,2019-03-19,COMPLETED,INTERVENTIONAL,['NA']
611,NCT00700765,Major hypoglycaemic events,Variability in fasting blood glucose (FBG) and average plasma glucose level,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
612,NCT02160275,Mean sensor glucose concentration,Time that the control algorithm is inactive,Glucagon use,2014-06,COMPLETED,INTERVENTIONAL,['NA']
613,NCT05735340,A1C,,,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
614,NCT03297879,The change of HbA1c,,,2013-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
615,NCT03975556,Change in levels of metabolic risk factors,Changes in diet satisfaction: diet satisfaction scale,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
616,NCT02040337,Sensitivity and specificity of T cell repertoire analysis to classify Type I Diabetes,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
617,NCT00316537,Assessment of ulcer size as determined by weekly ulcer tracings,"Assessment for complete wound closure. ""Complete wound closure"" will be defined as full epithelialization of the wound with the absence of drainage and lack of dressing requirement for an interval of at least 2 weeks.",,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
618,NCT04003194,Change in Glucose,Change in Hemoglobin A1c,,2009-03-01,COMPLETED,INTERVENTIONAL,['NA']
619,NCT03242005,Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemia,Compare Pro-set® vs. Quick- set® for duration of wear,,2017-09,WITHDRAWN,INTERVENTIONAL,['NA']
620,NCT00238550,"Improvement in pain symptoms, including pain perception and sleep quality, utilising daily diaries and validated pain questionnaires during 12 week treatment period and after 3 month cessation of treatment",MR spectroscopy of the chemical constituents in the deep nuclei of the brain will be analysed before and after 12 week treatment period.,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
621,NCT03087266,Levels C-Reactive Protein,Endothelial Function,,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
622,NCT02071979,Wound Size,Wound recurrence,,2014-04,TERMINATED,INTERVENTIONAL,['NA']
623,NCT00481286,Change in systolic blood pressure; change in Hemoglobin A1C; change in low density lipoprotein,"Attainment of benchmark levels for SBP, A1C, LDL; self-management performance (self-report); completion of group clinic",,2007-04,COMPLETED,INTERVENTIONAL,['NA']
624,NCT01778556,Total Body Insulin Sensitivity,Endogenous Rate of Appearance of Palmitate,,2013-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
625,NCT05275400,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Status Version (DTSQ),,2022-03-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
626,NCT00440284,glycosylated hemoglobin (GHb),"mild and severe hypoglycemia, insulin dosage, blood pressure and body-mass-index (BMI).",,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
627,NCT00916604,"Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG","Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
628,NCT05482789,Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose,Area Under the Plasma Concentration Versus Time Curve (AUC) of exenatide,,2023-04-12,RECRUITING,INTERVENTIONAL,['PHASE4']
629,NCT04080518,To demonstrate that SGLT-2 inhibition induces urea-dominated renal water conservation within the renal concentration mechanism. ( Change from baseline in urinary osmolyte concentration,Analysis of glycogen and fat content in skeletal muscle and liver,,2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE4']
630,NCT00946426,Insulin sensitivity,Hepatic glucose output,,2009-07,WITHDRAWN,OBSERVATIONAL,['NA']
631,NCT05815342,Change in HbA1c,Coefficient of variation,,2023-04-11,COMPLETED,INTERVENTIONAL,['NA']
632,NCT02019082,The plasma level of VEGF(pg/ml) and NO (microM),Wound surface area(cm2),,2011-03,COMPLETED,INTERVENTIONAL,['NA']
633,NCT03769701,Proportion of women who achieve glycemic control.,,,2018-12-07,UNKNOWN,INTERVENTIONAL,['NA']
634,NCT03978286,Effect of antidepressant treatment (sertraline versus vortioxetine) in triglycerides control in depressed type 2 diabetic patients.,Effect of antidepressant treatment (sertraline versus vortioxetine) in anthropometric variables in depressed type 2 diabetic patients.,,2016-06-30,COMPLETED,INTERVENTIONAL,['PHASE4']
635,NCT04590703,Evaluation of incidence of adverse events,,,2020-06-24,COMPLETED,OBSERVATIONAL,['NA']
636,NCT00236210,The percentage of patients who attained a significant reduction in their global cardiovascular risk at 6 and 12 months. This was determined a priori by the investigators to be an increase in the ACTION Score of 5 or more.,"Secondary outcomes were change in the average ACTION Score, change in individual risk domains as measured by the ACTION Score, patient satisfaction, and quality of life, all after 6 months and 12 months, comparing intervention versus control.",,2004-08,COMPLETED,INTERVENTIONAL,['NA']
637,NCT00355680,Regression of new vessels,Bruch's membrane rupture,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
638,NCT00467675,,,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
639,NCT01039324,Emergency department encounter rates among patients in the study population.,Provider satisfaction among providers with contact with patients for whom intervention was appropriate.,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
640,NCT04535960,Proximal tubular natriuresis,"Urinary EGF,FGF2,Eotaxin,TGFa,G-CSF,Flt-3L,GM-CSF,Fractalkine,IFNa2,IFNy,GRO,IL10,MCP-3,IL-12P40,MDC,IL-12P70,PDGF-AA,IL-13,PDGF-BB,IL-15,sCD40L,IL-17A,IL-1RA,IL1a,IL9,IL1B,IL2,IL3,IL4,IL5,IL6,IL7,IL8,IL10,MCP-1,MIP-1a,MIP-1B,RANTES,TNFalpha,TNFB,VEGF",,2019-01-24,RECRUITING,INTERVENTIONAL,['PHASE2']
641,NCT03683368,Time to infusion set failure due to an occlusion,Glucose variability,,2018-10-09,COMPLETED,INTERVENTIONAL,['NA']
642,NCT06271382,Ankle Brachial Index,,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
643,NCT00657605,Change in Weight,Change in Glucose Levels,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
644,NCT02093676,change in self monitoring of blood glucose,change in parental monitoring,,2014-07-30,COMPLETED,INTERVENTIONAL,['NA']
645,NCT05333055,Aqueous Humor Levels of Angiopoietin-2,Aqueous Humor Levels of Additional Disease State Biomarkers,Correlation of Biomarkers,2022-04-11,UNKNOWN,OBSERVATIONAL,['NA']
646,NCT01743014,Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy,Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy,,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
647,NCT02708758,incidence of large for gestational age,incidence of cesarean section,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
648,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,All-cause Mortality at 1 Year (Safety Outcome),,2020-04-23,COMPLETED,INTERVENTIONAL,['NA']
649,NCT00553475,Change From Baseline at Week 13 in Mean Weekly Pain Scores,Patient Global Impression of Change,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
650,NCT01405547,Infant growth,Getational hyperglycemia and insulinemia (insulin resistance/sensitivity),,2009-03,COMPLETED,OBSERVATIONAL,['NA']
651,NCT04327713,Total cardiovascular disease (CVD) incidence,Arrhythmia incidence,,2020-03-28,UNKNOWN,OBSERVATIONAL,['NA']
652,NCT02789722,Evaluation of transcriptome analysis.,Clinical evaluation: weight.,,2016-08-15,COMPLETED,INTERVENTIONAL,['NA']
653,NCT02213003,procedural complications,,,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
654,NCT01186107,Angiographic in-segment late loss,target-vessel revascularization,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
655,NCT04030013,Evaluate the effect of diabetes education given to renal transplant recipients with new onset diabetes after transplantation .,comparison of type of diabetes education,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
656,NCT01657474,Mean time to healing,Percent change in wound area,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
657,NCT00700817,Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78,"Hypoglycaamic Episodes, Weeks 52-78",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
658,NCT01606930,Adherence to anti-hypertensive drug treatment at three months,Systolic and Diastolic Blood Pressure at three months,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
659,NCT03378271,Accuracy of CGM and FGM,The evaluation of patients preferences and experience of the two glucose monitoring systems.,,2016-05-05,COMPLETED,INTERVENTIONAL,['NA']
660,NCT01435603,Percent Change in Body Weight,Percent Change in Physical Activity,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
661,NCT02390167,Percent of Self-Test Fingerstick Blood Glucose (BG) Results (From Subjects WITH Diabetes) Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Percent of Self-Test Alternate Site Palm Blood Glucose (BG) Results (From Subjects WITH and WITHOUT Diabetes) Within +/- 15 mg/dL (<75 mg/dL) and Within +/- 15% (>= 75 mg/dL) of Laboratory Glucose Method,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
662,NCT02406443,Percent Change in Fractional Excretion of Sodium (FENA),Change in Effective Renal Plasma Flow (ERPF),,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
663,NCT01121029,C-peptide levels before and after the hematopoietic stem cell transplantation,Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
664,NCT04101604,Peripheral blood mononuclear cell (PBMC) signatures,PBMC cell types frequencies,,2019-09-26,UNKNOWN,OBSERVATIONAL,['NA']
665,NCT01068730,Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax),Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis,Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]),2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
666,NCT03819127,Evaluation of cognitive decline,Rate of Glycated hemoglobin (%),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
667,NCT04646941,the new onset and types of tumor in T2DM patients,,,2020-06-10,RECRUITING,OBSERVATIONAL,['NA']
668,NCT00698932,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
669,NCT05663554,Change in HbA1c% at 12 months,Change in weight bias at 12 months,,2023-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
670,NCT01774500,"Combined hospital admission, seizure recurrence, or death at day 7",Recurrence of seizure,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
671,NCT02099981,The vascular response to flicker,Contrast sensitivity,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
672,NCT03248401,Change of carotid artery atherosclerosis,Change of carotid artery atherosclerosis 3,Body composition,2016-09-26,COMPLETED,INTERVENTIONAL,['PHASE4']
673,NCT03524404,Program engagement,,,2018-03-28,COMPLETED,INTERVENTIONAL,['NA']
674,NCT01348568,change in serum lipids,cancer cell proliferation (in vitro),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
675,NCT04916093,Changes in HbA1c (%),Changes in Renal function tests,,2019-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
676,NCT02715258,Change in HbA1c From Baseline at Week 24,Change in Body Weight From Baseline at Week 24 in Subjects With a BMI ≥ 25 Kg/m2,Proportion of Subjects Who Achieve an HbA1c < 7%,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
677,NCT01293396,Area Over Basal for Postprandial Triglycerides,Area Over Basal for Postprandial C-peptide,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
678,NCT05760118,Revised Osteoporosis Knowledge Test,Osteoporosis Health Belief Scale,,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
679,NCT05463705,"Rate of prescriptions for SGLT-2i or GLP-1RA among eligible patients in each arm, compared across study arms","Change in Hemoglobin A1c (A1c) over the 6-month intervention period among eligible patients, compared across study arms",,2023-05-04,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
680,NCT02607566,Feasibility as measured by study completion,Diabetes Self-Care,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
681,NCT01297062,"Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 3 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 500 pg/mL)","Plasma Exenatide Concentrations at Steady State on Day 1, 2 and 3",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
682,NCT02917902,Change in HbA1c (measured as part of routine care),"Change in Body Mass Index, measured in kg/m^2, weight in kilograms, height in meters",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
683,NCT00587132,Number of Subjects With Evidence of Pancreatic Tumor or Any Secondary Findings of Pancreatic Tumor as Shown by CT.,,,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
684,NCT03653013,Improved Glycemic Control measured by assessment of glycemic control (HgbA1C),,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
685,NCT06192251,Participant Feedback,Participant Feedback,,2023-11-06,RECRUITING,OBSERVATIONAL,['NA']
686,NCT03267576,Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2,Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL,,2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE4']
687,NCT00679042,Number of Subjects Reaching the Efficacy Goal,Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score,,2007-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
688,NCT04473326,Medication Adherence,Glycemic Control,,2021-02-04,COMPLETED,INTERVENTIONAL,['NA']
689,NCT01252524,Change in Hemoglobin A1c from baseline,Adverse outcomes,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
690,NCT03124134,Safety and Tolerability,Post prandial insulin,,2017-04-18,COMPLETED,INTERVENTIONAL,['NA']
691,NCT00846716,Onset and progression of diabetic nephropathy,Progression of diabetes mellitus change from the baseline in HbA1c change from the baseline in albumine/creatinine ratio change from the baseline in cystatin C onset and progression of diabetic retinopathy safety assessment,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
692,NCT01794052,Change in compliance to therapy and follow-up rate among people with hypertension and/or diabetes.,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
693,NCT01059799,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),,2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
694,NCT02597101,Insulin Sensitivity at 6 Months From Baseline,Change From Baseline in the Serum Levels of Inflammatory Markers,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
695,NCT01505036,"Rate of patients who attain,Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.",Changes in Blood Pressure,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
696,NCT01860599,"Measures of Endothelial Function by studying number, function and gene expression of endothelial progenitor cells (identified as CD34+ cells)",Measures of Vacular Reactivity,Measures of Insulin Sensitivity by measuring inflammatory molecules as a surrogate of insulin resistance,2010-03,COMPLETED,INTERVENTIONAL,['NA']
697,NCT01215968,Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy,Number of Participants With Clinically Significant Effects,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
698,NCT04615351,Prediabetes or Diabetes,Prediabetes or diabetes at 15 months postpartum,,2020-11-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
699,NCT00556244,Snellen BCVA and epiretinal membrane formation measured with OCT,central macular thickness measured bt OCT,,2007-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
700,NCT03437551,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
701,NCT04907838,Leg blood flow,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
702,NCT05897372,urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline,incidence of symptomatic hypotension,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
703,NCT03828890,Family Physicians Screening for Diabetic Retinopathy - Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist,Screening Impact - Percentage increase in the screening rates for Diabetic Retinopathy using retinal imaging.,Patient Satisfaction,2019-06-12,COMPLETED,INTERVENTIONAL,['NA']
704,NCT03220425,The change in the level of glycosylated haemoglobin(HbA1c),,,2001-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
705,NCT04805853,the change level of cardiac extracellular volume (ECV),Changes in score of Patient Health Questionnaire-9(PHQ-9),,2020-02-20,UNKNOWN,OBSERVATIONAL,['NA']
706,NCT01524809,Area under the serum insulin curve 6-14 hours after dinner at day 15,Adverse events,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1']
707,NCT06167616,LADA,Type 2 diabetes,,2010-09-01,COMPLETED,OBSERVATIONAL,['NA']
708,NCT05031000,Analysis of system accuracy based on DIN EN ISO 15197,,,2021-09-03,COMPLETED,INTERVENTIONAL,['NA']
709,NCT06043843,Compare first incidence rate of hypoglycaemia or severe hypoglycemia between intervention and control groups in Ramadan,Compare the weight changes after Ramadan as compared to pre-Ramadan weight,,2021-02-16,RECRUITING,INTERVENTIONAL,['NA']
710,NCT06293742,Midazolam PK parameters: Cmax,ECC5004 PK parameters: Ctau,,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1']
711,NCT03804892,IMTG utilisation during exercise,,,2019-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
712,NCT02964715,Change in serum FGF 21,Change in MRI features of NASH,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
713,NCT00806975,"HbA1c change rate from the start to 12 and 24 weeks are investigated and compared. Furthermore, using a questionnaire sheet ""IDSQ-J"" related to the insulin infusion device, the patient's usability and satisfaction with KwikPen® or FlexPen® are performed.","As the secondary endpoints, the incidence of hypoglycemia, changes in body weight (BMI) and blood pressure, and the dose of insulin are investigated and compared before and after the changeover.",,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
714,NCT04140201,The 80 participants will be evaluated through reduction of macular edema,The 80 participants will be evaluated through reduction of cardiovascular risk,,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
715,NCT04304729,Vascular structure (Pulse-wave velocity),Hypertension,,2017-01-12,SUSPENDED,OBSERVATIONAL,['NA']
716,NCT05202002,"Rate of type II Diabetes Mellitus (DM) diagnosis, as diagnosed by the 75gm oral glucose tolerance test (OGTT)",Rate of exclusive breastfeeding,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
717,NCT04646746,Postprandial glycemic response,Postprandial GIP (Glucose-dependent insulinotropic polypeptide) response,,2021-02-08,COMPLETED,INTERVENTIONAL,['NA']
718,NCT00340613,Hemoglobin A1c,Urine microalbumin,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
719,NCT03236116,Homa-Percent Beta,Compliance,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
720,NCT02485132,Total incidence rate of hypoglycemia episode,,,2016-03,TERMINATED,OBSERVATIONAL,['NA']
721,NCT05575206,Insulin secretion capacity,Glucose tolerance status,,2023-09-15,RECRUITING,OBSERVATIONAL,['NA']
722,NCT05887271,Change in the distance walked during 6 minute walk test (6MWT),Exploratory outcome: change in fibroinflammatory biomarker panel,,2023-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
723,NCT03962686,methylase status,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
724,NCT01566110,Metabolic Control,Continuous Glucose Monitoring,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
725,NCT05478291,Effects of vitamin D supplementation on physiology of atherosclerosis,,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
726,NCT02876393,Presence of DMO evaluated from the optical coherence tomography (OCT) images,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
727,NCT03403556,Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C),Mean change from baseline to week 24 in HOMA-B,,2018-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
728,NCT05004428,Percentage of Type 2 Diabetes Mellitus (T2DM) patients with Chronic Kidney Disease (CKD) in database.,Annual average costs among patients,,2021-08-14,COMPLETED,OBSERVATIONAL,['NA']
729,NCT00264927,Serum sodium,"Safety: Physical examination, vital signs, adverse events, ECG, hematology, serum chemistry",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
730,NCT04924777,HbA1c Levels,,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
731,NCT04537923,"Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)",Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score,,2020-10-19,COMPLETED,INTERVENTIONAL,['PHASE3']
732,NCT00106340,Time to HbA1c >8%,Change from baseline in body weight at 5 years,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
733,NCT03212950,Time within range 3.9 - 10 mmol/l (70 - 180 mg/dl),,,2017-07-10,COMPLETED,INTERVENTIONAL,['NA']
734,NCT05692388,Self-Care Behavior,,,2023-01-23,RECRUITING,OBSERVATIONAL,['NA']
735,NCT03040414,Non-inferiority for Percent of Time <54 mg/dL (3.0 mmol/L) During the Entire 24-hour Period.,Key Safety Outcome 3) Number of Severe Hypoglycemia Events,Human Factors and Diabetes Technology Attitude and Human Factors Questionnaires,2019-06-03,COMPLETED,INTERVENTIONAL,['NA']
736,NCT00224237,,,,2005-12,COMPLETED,OBSERVATIONAL,['NA']
737,NCT01191320,Change in HbA1C,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
738,NCT03019510,fasting glucose level,beta cell function,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
739,NCT05820295,Number of emergency department visits or hospital admissions,"Efficiency, as measured by the total number of care-coordinator hours used",,2023-05-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
740,NCT01334034,Number of adverse events,Area under the glucose infusion rate-time curve,,2011-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
741,NCT03470961,Incidence and severity of adverse event,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
742,NCT03072901,Evaluation of Effectiveness of the EndoBarrier GI Liner upon weight loss,,,2010-12,TERMINATED,OBSERVATIONAL,['NA']
743,NCT02655770,Change in diastolic properties as assessed by CMR.,Echocardiographic indices of diastolic dysfunction,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
744,NCT04764968,Difference in percentage of time in range between the two study periods,Percentage of participants with treatment-induced or treatment-boosted anti-dasiglucagon antibodies,Number of device failures/malfunctions,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
745,NCT04547790,Change in HbA1c,Change in weight,,2020-12-23,COMPLETED,INTERVENTIONAL,['NA']
746,NCT04905485,Difference in VIOME's Type 2 diabetes risk score,,,2021-05-21,UNKNOWN,INTERVENTIONAL,['NA']
747,NCT01010100,The principal objective was to determine if the administration of small doses of Acarbose could prevent or delay the appearance of Type 2 DM in a population of subjects with impaired glucose homeostasis.,Delay in the conversion to diabetes mellitus,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE3']
748,NCT01597843,Registration for MHV,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
749,NCT03667300,UACR percent change at Week 24,eGFR change at Week 12,,2017-03-16,COMPLETED,INTERVENTIONAL,['PHASE2']
750,NCT02542722,Incidence of type 2 diabetes in subjects at risk,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
751,NCT00832390,Change From Baseline in A1C at Week 24,,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
752,NCT01819493,Body Mass Index,Blood Pressure,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
753,NCT05866497,CAVI measurements,,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA']
754,NCT00406133,Time With Glucose Level <=70 mg/dL (for the Cohort With Baseline HbA1c <7.0%),Total Costs: Direct and Indirect Costs,26-week A1c Level <7.0% (for Cohort With Baseline HbA1c <7.0%),2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
755,NCT00976495,Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]),Adjusted Mean Change From Baseline in Nighttime (0100 to 0600 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF]),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
756,NCT01733524,Glycemic control,Self Management of Diabetes in Adolescents,Health care burden,2012-10,COMPLETED,INTERVENTIONAL,['NA']
757,NCT01214824,Change in HbA1C From Baseline to 6 Months,Proportion of Time in Hypoglycaemia (<3.9mmol/L)-Unmasked,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
758,NCT03435328,salivary volume,Eight-item visual analogue scale xerostomia questionnaire,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
759,NCT00448487,"same as in ICARE: composite major CVD outcomes (non fatal MI, Stroke and CVD death)",,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
760,NCT00589680,Hospital length of stay,Time to correction of glucose level and anion gap,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
761,NCT03001999,Feasibility of study procedures,Changes in SDSCA Scores,Hemoglobin A1c,2017-01,COMPLETED,INTERVENTIONAL,['NA']
762,NCT00933101,Determine the impact of glycemic control on vascular oxidative stress/inflammation in adolescents with Type 1 diabetes mellitus,To determine the impact of glycemic control and vascular oxidative stress/inflammation on vascular health in adolescents with T1DM,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
763,NCT01809093,Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
764,NCT00785577,Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks,Number of Participants With Neurological Treatment Emergent Adverse Events (TEAEs),,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
765,NCT01486966,Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment,Incidence of Hypoglycaemic Episodes,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE4']
766,NCT01299844,Hemoglobin A1c,Diabetes Knowledge Test Score,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
767,NCT05999773,SGLT-2 inhibitors related adverse events,Adverse events classification,,2023-07-15,RECRUITING,OBSERVATIONAL,['NA']
768,NCT03826290,Per-patient change in Hemoglobin A1c (HbA1c) levels from beginning to end of evaluation period,Cost of diabetes medications prescribed,User opinions of the diabetes dashboard,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
769,NCT05803772,Change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) as measured in blood samples,Number of Participants Reported with At least One Treatment Emergent Adverse Event (TEAE),Change from baseline in AUC0-2h of OGTT as measured by Flash Glucose Monitoring (FGM),2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
770,NCT01486290,Hemoglobin A1c,Economic impact,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
771,NCT02401243,Percentage of patients reaching fasting SMPG ≤5.6 mmol/L without nocturnal (midnight to 6:00 am) hypoglycemia (confirmed or symptomatic or severe),Percentage of patients with adverse events,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
772,NCT00532610,Continuous holter monitor & ECG each treatment period:,"12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
773,NCT02624908,Self monitoring and continuous monitoring blood glucose levels,,,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
774,NCT00923975,Number of Participants Out of 50 Rated Successful (<=3) by Healthcare Professionals When Participants Performed Specific Software Tasks,Number of Participants Out of 50 Who Rated Their Satisfaction With The Following as Good to Excellent (>=3),,2009-06,COMPLETED,INTERVENTIONAL,['NA']
775,NCT02119754,Clinical Response,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
776,NCT04977427,Intraocular Inflammation,Macular Edema,,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
777,NCT05123248,Gestational Diabetes Mellitus (GDM),Plasma glucose measures from OGTT,"Applicability, acceptability, compliance of the unblinded CGM device use in a GDM pregnancy",2018-10-16,RECRUITING,INTERVENTIONAL,['NA']
778,NCT05245825,Hemoglobin A1C,Stool classification,,2021-11-20,RECRUITING,INTERVENTIONAL,['NA']
779,NCT02355197,neonatal outcome assessed by neonatal ICU admission,oxidative stress parameters: non enzymatic and enzymatic oxidative stress parameters in neonatal blood in women with GDM named malondialdahyde and superoxide dismutase,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
780,NCT02899949,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
781,NCT00240422,Change from baseline of renal plasma flow (RPF) in response to L-NMMA infusion at the end of treatment.,Changes from screening in ECG at the end of the study,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
782,NCT05407233,Change in Pain assessment,Analyze cost-utility,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
783,NCT01555788,Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl),Percentage of time spent in hyperglycemia,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
784,NCT03579797,Eye health management,,,2015-01-01,UNKNOWN,OBSERVATIONAL,['NA']
785,NCT04464772,System Performance,,,2020-07-10,COMPLETED,OBSERVATIONAL,['NA']
786,NCT05566847,HbA1c<9%,Hypoglycemia events post-intervention start,,2022-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
787,NCT00304538,"1) Evaluate the safety and tolerability of VLD-glucagon in doses of 2, 4 and 8 ng/kg/minute when infused overnight 2) Evaluate the PK profile in plasma of VLD-glucagon 3) Evaluate the pharmacodynamic activity of these doses by measuring glucose levels",Compare the number of times and amount of time subjects have glucose levels < 70 mg/dL when treated with VLD-glucagon vs. the control infusion,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
788,NCT06334484,change in time spent in tighter glucose range after 24 months of hybrid closed loop system,,,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
789,NCT02874612,Evidence of a correlation between negative diabetes health outcomes and psychosocial functioning over a 1 year period,Number of participating rating themselves as having diabetes quality of life as assessed by the PedsQL Diabetes 3.2 measure,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
790,NCT00535886,"The primary outcome measure will be the ratio of total to high density lipoprotein (HDL) cholesterol. Blood draws will take place at screening, three weeks, and five weeks.","Related secondary outcome measures include concentrations of low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG) and Lp(a) measured at screening, three weeks, and five weeks.",,2005-11,COMPLETED,INTERVENTIONAL,['NA']
791,NCT00342992,Cancer,Causes of mortality,,1995-03-03,COMPLETED,OBSERVATIONAL,['NA']
792,NCT00816010,"Composite endpoint of death and/or CVD related hospitalisations (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia requiring hospital admissions, lower extremity amputation and stroke) by 24 months.","Number of hospital admissions, total number of days of hospitalization",,2008-07,TERMINATED,INTERVENTIONAL,['NA']
793,NCT01473576,Muscle protein fractional synthetic rate,Plasma nitrate,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
794,NCT01992133,Change in glucose metabolism as assessed by change in Insulin sensitivity index as calculated by HOMA -IR28,Change in plasma 25-OH- Vitamin D level pre and post replacement,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
795,NCT00412906,"Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score","Mean Arterial Pressure, heart rate, Temperature,",,2006-11,COMPLETED,INTERVENTIONAL,['NA']
796,NCT02666807,Change from Baseline in NF-KB at 10 weeks,Change from Baseline in insulin (µlU/ml) at 10 weeks,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
797,NCT04071808,Blood norepinephrine content,,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
798,NCT04050098,bioequivalence study,,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
799,NCT01272973,Frequency of adverse events (AEs),Terminal phase elimination half-life,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
800,NCT03106246,Determine whether these EVs contain islet-specific antigens,Mutivariate analysis will be performed with patient parameters and EV parameters,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
801,NCT03845868,Incidence of cardiovascular diseases,,,2013-04-16,RECRUITING,OBSERVATIONAL,['NA']
802,NCT00541450,Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,,2008-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
803,NCT05849701,Wound volume,Wound volume,,2022-03-10,COMPLETED,INTERVENTIONAL,['NA']
804,NCT00760292,,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
805,NCT02377076,HbA1c,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
806,NCT02709629,Change from baseline in diabetes self management as reflected in the diabetes self-management questionnaire,Change from baseline in diabetes self-management as reflected in scores on the diabetes self-management questionnaire at 35 weeks,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
807,NCT00569959,LDL-Cholesterol,Other lipid parameters,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
808,NCT01252810,Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.,Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
809,NCT03729479,Systolic blood pressure,Weight loss,,2018-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
810,NCT03116009,Large for gestational age or macrosomia,Glycemic control,,2017-03-19,TERMINATED,INTERVENTIONAL,['PHASE3']
811,NCT02556398,area under the curve (AUC) above target (> 180 mg/dL),,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
812,NCT00806520,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
813,NCT05351190,A1c,Quality of Life - GMSS T2DM Version,,2022-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
814,NCT02157155,Insulin signaling expressed as a CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.,Cytokines and stress hormones,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
815,NCT05118945,Time in glucose range 70 - 180mg/dl (%),mean daily insulin amount before study start,,2021-03-03,COMPLETED,OBSERVATIONAL,['NA']
816,NCT05866536,Change in HbA1c values,Change in insulin usage,Exploratory: Change in hypoglycemia,2023-05-04,RECRUITING,INTERVENTIONAL,['PHASE2']
817,NCT02347020,Food Intake,Cardio-metabolic risk profile,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
818,NCT06268977,Effect of adding SGLTi on BMI,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
819,NCT01786564,Oral Disposition Index,,,2011-12-06,COMPLETED,OBSERVATIONAL,['NA']
820,NCT04863872,Self-reported severe hypoglycemia,,,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
821,NCT04204733,Moderate to vigorous physical activity (subjective),,,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
822,NCT00775684,Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL),PG 50 (the Plasma Glucose Level at Which Half-maximal Insulin Secretion is Achieved During the Glucose-potentiated Arginine Test) at Baseline and 6 Months,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
823,NCT01696266,Incidence of any hypoglycaemic event,Incidence of probable symptomatic hypoglycaemic events,,2012-09-05,COMPLETED,OBSERVATIONAL,['NA']
824,NCT03859934,Change of insulin signalling,Change of assessment of resting energy expenditure (REE),,2019-09-26,COMPLETED,INTERVENTIONAL,['PHASE1']
825,NCT00370084,Gastric emptying assessment,"Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution",,2005-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
826,NCT03929601,C-Peptide Response to 2-hr MMTT at 24 months post-randomization,Analysis of changes in immune responses to known diabetes antigens and a neoantigen over time by treatment group,,2023-10-30,RECRUITING,INTERVENTIONAL,['PHASE2']
827,NCT01358929,Safety: Incidence of adverse events,Change in meal tolerance test,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
828,NCT01479062,Change from baseline in diabetes risk markers,Change from baseline in physical activity and dietary factors,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
829,NCT06187493,prevention of the development of DKD and alter its natural progression.,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
830,NCT02663661,Test the hypothesis that immunological abnormalities are associated with abnormally high glucagon responses to a meal and reduced glucagon responses to insulin induced hypoglycemia.,Correlate metrics derived from a minimally-invasive Continuous Glucose Monitor (CGM) home test with glucagon responses to a meal and hypoglycemia measured in the hospital.,,2016-03-16,COMPLETED,INTERVENTIONAL,['NA']
831,NCT00645528,Barriers to Insulin Treatment Total Sum Score Visit 2 (Week 2),Number of Patients Experiencing a Severe Hypoglycemic Event,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
832,NCT04082000,Adverse Events (AEs) and Serious Adverse Events (SAEs),Improvement in sleep disturbance,,2019-04-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
833,NCT04663659,length of stay in intensive care,,,2020-03-15,COMPLETED,OBSERVATIONAL,['NA']
834,NCT02886013,Prevalence of the FTO rs9939609 and PPARy rs1801282 polymorphisms.,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
835,NCT00184626,HbA1c,Fasting plasma glucose value,,2004-09-10,COMPLETED,INTERVENTIONAL,['PHASE4']
836,NCT00476710,Bile Acid Pool Size and Kinetic Parameters,Resting Metabolic Rate,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
837,NCT01248286,Homeostatic model assessment (HOMA) index.,Sirtuin 1,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
838,NCT04191902,differences in glycemic control,,,2021-01-05,UNKNOWN,OBSERVATIONAL,['NA']
839,NCT04306406,A high-sensitivity C-reactive protein (hs-CRP) measured in milligrams per liter,"3,4-Dihydroxyphenylacetic acid (DOPAC) measured in nanograms per milliliter",,2015-01-07,COMPLETED,INTERVENTIONAL,['NA']
840,NCT01872611,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
841,NCT00338949,Change in Visceral Fat Mass From Baseline to Week 26,,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
842,NCT01931982,Change in coronary flow reserve (CFR),Change in Endothelial function:,Change in waist circumference,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
843,NCT02813668,Number of Participants Reaching Two or More Cardiometabolic Risk Goals,Number of Patients With Prediabetes or Newly Detected Diabetes That Achieve Normoglycemia Rates,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
844,NCT04981808,CGM time in range,Time above CGM range,Health-related quality of life,2021-08-18,COMPLETED,INTERVENTIONAL,['NA']
845,NCT01187576,"to examine whether an extended multi-professional PAR intervention, based on SDT, is effective in increasing and maintaining the self-reported physical activity level in patients with newly diagnosed type 2 diabetes or hypertension or both.",,,2010-11,WITHDRAWN,INTERVENTIONAL,['NA']
846,NCT03939065,Differences in CGM percent time over 140 mg/dl,Statstrip glucose,beta-cell function,2020-06-12,TERMINATED,INTERVENTIONAL,['NA']
847,NCT05654831,"Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations",Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
848,NCT04207853,plantar pressure,,,2019-08-08,UNKNOWN,INTERVENTIONAL,['NA']
849,NCT05986253,Postprandial blood glucose area under the curve (AUC),Postprandial serum insulin concentration,,2023-08-07,RECRUITING,INTERVENTIONAL,['NA']
850,NCT00898950,"Change in markers of oxidative stress, endothelial function, glycaemic control, and insulin resistance",Change in inflammatory markers,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
851,NCT03832790,BMI,,,2019-12-04,COMPLETED,OBSERVATIONAL,['NA']
852,NCT02094534,"Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements","Mean Nighttime, Daytime, and Fasting Glucose Levels",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
853,NCT01024244,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2']
854,NCT06181227,Safety of AVD-104,Treatment effect - vision,,2023-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
855,NCT00846144,Identify humans with marginal Cu status that may benefit from copper supplementation and normalize their GSIS.,,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
856,NCT01531517,Healing of the Ulcer,local reaction that may be due to study drug,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3']
857,NCT02877186,Taxa abundance before and after one-week of three times daily diet soda consumption,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
858,NCT02060240,Insulin mediated skeletal muslce blood flow and capillary recruitment,Quantification of endothelial derived Vasodilators,"Correalte changes in fitness to vasodilators, blood flow, and insulin sensitivity",2014-02,COMPLETED,INTERVENTIONAL,['NA']
859,NCT00101712,Change from baseline in HbA1c at 52 weeks,Coefficient of failure for HbA1c between 24 weeks and 52 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
860,NCT05134129,Differential lipid compounds,,,2021-04-25,RECRUITING,OBSERVATIONAL,['NA']
861,NCT01774968,Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c),Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4']
862,NCT05294653,Occurrence of Atherosclerotic Cardiovascular Disease(ASCVD) high risk rating,Occurrence of subclinical ASCVD(coronary artery calcium),Occurrence of rheumatic diseases,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
863,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,Changes in the concentrations of N-nitroso compounds in feces.,,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
864,NCT04972175,Incidence of adverse event,,,2021-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
865,NCT02621008,blood pressure,stress mindset scale,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
866,NCT04591015,Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 180 Days,"Knowledge, Attitudes and Practice Toward COVID-19 Survey - Change From Baseline to 180 Days",,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
867,NCT04714411,Clostridioides difficile Infection,,,2020-11-05,RECRUITING,OBSERVATIONAL,['NA']
868,NCT02228122,A measure of the presence/absence of biofilms in over five weeks when exposed to Aquacel Ag+ Extra dressing.,Size of the wound and an indicator of healing,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
869,NCT02456428,Hospitalization for incident heart failure,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
870,NCT04940897,Measure incidence of adverse events,,,2021-10-25,COMPLETED,INTERVENTIONAL,['NA']
871,NCT02575937,Change in Glycosylated hemoglobin (HbA1c),Food Frequency Questionnaire（FFQ）,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
872,NCT01334684,Fasting glucose change after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,Change in fasting insulin levels after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
873,NCT05902546,Insulin Resistance (Homa-IR),,,2023-01-07,COMPLETED,INTERVENTIONAL,['NA']
874,NCT02783469,Neuropathic Pain,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
875,NCT00454662,"Composite of following events: Sudden death, Cerebrovascular events, Coronary events, Renal dysfunction","All deaths, Death from cardiovascular events, Glucose metabolism, Incidence of primary outcomes events, New onset of atrial fibrillation, Safety, Withdrawal rate",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
876,NCT02730741,Compare number of treated patients who have had diarrhoea in the verum group and in the placebo group between Visit 2 and Visit 5. Diarrhoea evaluated using the Bristol stool scale (types 5 to 7),,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
877,NCT06256523,Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study,HbA1c control rate (proportions of subjects with HbA1c < 6.5 % and HbA1c < 7.0 %),,2022-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
878,NCT00978744,Gaps in care; compliance with quality measures,Costs of care,,2008-12,UNKNOWN,OBSERVATIONAL,['NA']
879,NCT04754581,Individual steps of muscle glucose uptake (post-exercise),,,2021-03-30,RECRUITING,INTERVENTIONAL,['NA']
880,NCT02039934,Improvement of Insulin sensitivity by high intensity interval training,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
881,NCT03519217,Evaluate possible risk factors among diabetic infants,Detection of gene mutation responsible for infantile diabetes through gene sequencing,,2020-06-05,UNKNOWN,OBSERVATIONAL,['NA']
882,NCT05633810,"First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.",MoCA Scores Assessed Over Time,,2022-12-21,RECRUITING,INTERVENTIONAL,['PHASE3']
883,NCT00770679,Change in Endothelial Function as Measured on MRI in the Legs,,,2008-06,TERMINATED,INTERVENTIONAL,['NA']
884,NCT05255497,The effect of biodex balance training on motor nerves,,,2017-09-02,COMPLETED,INTERVENTIONAL,['NA']
885,NCT04964388,Trabecular bone score,Sclerostin and Bone formation markers,,2021-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
886,NCT01662193,change in adipocytokines from baseline at 8 weeks,change in blood pressure from baseline at 8 weeks,,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
887,NCT03968055,Contacts with the care provider,Hemoglobin A1c,,2019-03-25,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
888,NCT05415826,CRT,Intraretinal hemorrhage,,2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
889,NCT01171248,Ambulatory blood pressure (AMBP),Diabetic late complications,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
890,NCT01131650,Prevalence of diabetic retinopathy,associated risk factors of diabetic retinopathy,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
891,NCT04700436,"Triglyceride (TG) change rate (percent, %)",Electrocardiogram (12-lead ECG),,2020-01-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
892,NCT01619332,Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test,Change from baseine in Gastric inhibit polypeptide (GIP) (Part III),,2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
893,NCT02769884,CGM percent time < 60 mg/dl,% of subjects with mean CGM <169 (eHbA1C < 7.5%),Safety Criteria 4: No seizures or loss of consciousness while system is on and functional,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
894,NCT01820273,changes in incretines in the bariatric patient,Diabetes control,,2013-04,WITHDRAWN,OBSERVATIONAL,['NA']
895,NCT01872299,"Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.","Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexia",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
896,NCT03816761,Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median,Total Insulin Dose Per Day,,2019-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
897,NCT03700801,HbA1c,Rate of hypoglycemia,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
898,NCT01712594,Amount of time spent in the target range defined as 3.8-8.8 mmol/l (70 to 160 mg/dL) YSI glucose during in-clinic overnight visits,Glucose AUC above 8.8mmol/l (160 mg/dL) YSI glucose obtained during in-clinic overnight visits,All descriptive endpoints stratified by the accuracy of the sensor based on mean absolute relative difference (MARD) overnight,2013-05,COMPLETED,INTERVENTIONAL,['NA']
899,NCT02354222,Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose Level,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
900,NCT02536820,glycosylated hemoglobin (HbAc1 %),Follow-up lost,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
901,NCT04516018,area under the curve (AUC) of the glucose tolerance test,skeletal muscle GLUT4 translocation,Shivering activity,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
902,NCT05703152,Change from baseline in quality of life on the short form-36 questionnaire (SF-36) at 8 weeks,Body Mass Index (BMI) measurement,,2022-10-31,COMPLETED,INTERVENTIONAL,['NA']
903,NCT03415139,Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (multivariable analysis).,,,2019-03-12,RECRUITING,OBSERVATIONAL,['NA']
904,NCT01253733,Health related self-efficacy,Quality of Life,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
905,NCT05979779,"Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)",Change from baseline in HbA1c at 6 months (26 weeks).,,2023-09-05,RECRUITING,INTERVENTIONAL,['PHASE2']
906,NCT06081387,Vitamin D,Food consumption and adherence to the Mediterranean diet,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
907,NCT04631289,Incidence of AKI,,,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
908,NCT03742219,Triglycerides,24 hour dietary recall,,2017-06-05,TERMINATED,INTERVENTIONAL,['NA']
909,NCT05180721,Change in A1C value,Health care engagement - negative,,2022-10-03,RECRUITING,INTERVENTIONAL,['NA']
910,NCT01633177,Incident type 2 diabetes,HbA1c levels,,2010-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
911,NCT00657930,Efficacy (HbA1c),Insulin dose change,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
912,NCT00623194,Insulin Detemir-insulin Aspart Cross-reacting Antibodies,Vital Signs: Pulse,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
913,NCT00638872,reduction of ulcer rate,safety and tolerability of the compound,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
914,NCT01903356,Incidence Rate of Adverse Events (AE),Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment.,,2013-07-11,COMPLETED,OBSERVATIONAL,['NA']
915,NCT02721888,Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate,Modification of visceral fat by Magnetic Resonance Imaging (MRI),,2012-07-10,TERMINATED,INTERVENTIONAL,['PHASE4']
916,NCT01951651,Hepatic Fat Content,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
917,NCT06163482,Concentration of Glucose,Concentration of fatty acids,,2023-03-28,RECRUITING,OBSERVATIONAL,['NA']
918,NCT00417989,Change in A1c From Baseline to 52 Weeks,Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
919,NCT00928057,Percent (%) Absolute Change in Fructosamine,Relative Injection Pain Score Assessed by Subject,"Reported Injection Site Leakage Events, by Pen Needle Type and Droplet Size",2009-06,COMPLETED,INTERVENTIONAL,['NA']
920,NCT02449603,Change of mean amplitude of glycemic excursions,Number of participants with clinical hypoglycemia,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
921,NCT00870818,"The Number of Participants Who Experience an Adverse Event, Serious Adverse Event or Adverse Event of Special Interest.",Human Anti-human Antibody (HAHA) Levels,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
922,NCT01265537,Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection,eGFR at 6 Months,,2011-06-24,COMPLETED,INTERVENTIONAL,['NA']
923,NCT04489043,Oral glucose tolerance test (OGTT),Anthropometric measures,,2019-09-05,UNKNOWN,INTERVENTIONAL,['NA']
924,NCT02536248,Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period,Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period,,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
925,NCT05990205,Change in weigth loss,Change in HbA1c,,2018-04-17,RECRUITING,INTERVENTIONAL,['PHASE2']
926,NCT01945060,Low Blood Glucose Index (LBGI),,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
927,NCT03194100,serum METRNL concentration,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
928,NCT00111228,Hemoglobin A1c (HbA1c) - Change From Baseline to End of 3 Month Study Period,"Average Blood Glucose - Change From Baseline to End of 3 Month Study Period, Calculated as Average Blood Glucose at 3 Month - Average Blood Glucose at Baseline",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
929,NCT05504785,Observe correlation of glucose control and post-operative adverse clinical events,Compare the CGM and Accu-Chek time-match glucose measurements,,2020-08-01,TERMINATED,INTERVENTIONAL,['NA']
930,NCT06285396,Motility index,Integrated area under response curve (AUC),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
931,NCT06034574,%MARD lab phase,%MARD home phase,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
932,NCT01360697,Percentage of patients who attain 2 or more of the 'ABC'targets,Default rates at the end of the study,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
933,NCT00595374,HbA1c,Incidence of hypoglycaemic episodes,,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
934,NCT00678886,Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12,"Percent Change From Baseline in CD3/TCR Modulation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8",,2008-07-29,COMPLETED,INTERVENTIONAL,['PHASE3']
935,NCT01079637,treatment failure rate,Foot temperature,,2010-05,TERMINATED,INTERVENTIONAL,['NA']
936,NCT05084079,The time to glycemic goal,Change of insulin dosage,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
937,NCT05307120,Acceptability,Health-related quality of life,Health literacy,2022-01-13,RECRUITING,INTERVENTIONAL,['NA']
938,NCT05073237,change in beta cell function,change in serum lipidomics,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
939,NCT03039569,Eat >= 5 Servings Fruit and Vegetables,Degree of Concern of CVD Event in Lifetime,,2017-02-28,COMPLETED,INTERVENTIONAL,['NA']
940,NCT00351676,"Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups.",Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians.,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
941,NCT03630263,Metabolic fuel utilization,Self reported satiety scores,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
942,NCT01435642,Mean HbA1c (glycosylated haemoglobin),To quantify quality of life,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
943,NCT00336349,VAS of pain,blood flow of feet,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
944,NCT01825382,Patient Reported Outcomes as it relates to hypoglycemia fear and quality of life.,Improvement in glucose control and indices off glucose variability from SMBG and CGM data.,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
945,NCT01551381,Platelet aggregation,Renal function,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2']
946,NCT03658655,Total daily insulin,HbAlc,,2018-06-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
947,NCT03908606,clinical attachment level,,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA']
948,NCT00634673,postprandial serum fatty acids,serum endothelin serum fibrinogen,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
949,NCT03955952,Composite of All-Cause Mortality and Cardiovascular Outcomes,Incidence of Atrial Fibrillation,Percentage Change in Triglycerides,2019-06-05,COMPLETED,OBSERVATIONAL,['NA']
950,NCT01284634,Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels,Change From Baseline To The EOT In Mean Serum Triglyceride Levels,,2011-05-03,COMPLETED,INTERVENTIONAL,['PHASE2']
951,NCT05199636,Blood pressure,HbA1C,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA']
952,NCT01300273,"monitor podocyte loss by detecting nephrin, podocin, and synaptopodin mRNA in urine particulates with quantitative reverse transcriptase-PCR.",,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
953,NCT01056887,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
954,NCT01968044,HbA1c change,Albuminuria,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
955,NCT02758522,Glycemic control,Differences in hospital stay days,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
956,NCT03530644,Performance evaluation,Safety by paucity of adverse events,,2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
957,NCT00474630,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,Change in Food Craving Inventory Carbohydrates Subscale Score,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
958,NCT00980746,"Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain",,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
959,NCT02183415,Number of patients with abnormal changes in clinical laboratory parameters,Plasma glucose levels,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
960,NCT03172247,Combined endpoint of diabetic hospitalized patients,,,2016-12-01,COMPLETED,OBSERVATIONAL,['NA']
961,NCT06182852,HbA1c,Body fat,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
962,NCT05754190,[General Study] Acute-Chronic Pain Transition Probability,[Sub-study] Treatment outcome prediction in chronic low back pain and failed back surgery syndrome patients,,2023-06-20,RECRUITING,OBSERVATIONAL,['NA']
963,NCT03377699,Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery,Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no),,2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE3']
964,NCT00470262,Insulin Sensitivity,IMCL,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
965,NCT05540249,Peri-operative Change from baseline HOMA-IR,High-sensitivity C-reactive protein (hs-CRP),Mechanical ventilation time,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
966,NCT05901831,Change in Urinary albumin-to-creatinine ratio (UACR),Number of participants with Hyperkalaemia,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3']
967,NCT03662334,Part 3: Time to Achieve Plasma Glucose >90 mg/dL After Release of Hypoglycemic CSII Clamp,Part 3: Insulin Analog Serum Concentration as a Function of Time Following Termination of Insulin Infusion,,2013-10-03,COMPLETED,INTERVENTIONAL,['PHASE4']
968,NCT02227303,Weekly changes over 8 weeks as compared to baseline in quality of life as measured by the PROMIS® Global Health questionnaire (global physical health and global mental health subscale scores and social and overall health scores).,,Changes from baseline to 4 and 8 weeks in compliance with exercise goals as measured by active minutes (provided by the Fitbit Flex; requires subject input of data).,2014-08,COMPLETED,INTERVENTIONAL,['NA']
969,NCT03062592,Blood glucose,c-peptid,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
970,NCT02866539,Number of pre-diabetes achieving euglycemic status,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
971,NCT01220804,Optical reflectivity as measured by optical coherence tomography,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
972,NCT04377321,colchicine for treatment of type diabetes patients,,,2019-10-10,COMPLETED,OBSERVATIONAL,['NA']
973,NCT03752567,Percent of Participants With Adherence to the PDTA,Economic Impact,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
974,NCT04313088,Proportion of days with improved bowel movements,Nocturnal diarrhea,,2022-07-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
975,NCT02748434,Blood glucose levels,,,2016-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
976,NCT05718375,Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline,,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE2']
977,NCT05987410,Six Minute Walking Test (6MWT) distance in meters,Peak Oxygen Uptake (VO2),,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
978,NCT00806858,"The change in subjects' satisfaction with insulin therapy, measured by change from visit 1 to visit 2 in subject treatment satisfaction scores on the DTSQ (Diabetes Treatment Satisfaction Questionnaire)",Number of clinical technical complaints,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
979,NCT05556291,Change from baseline in bodyweight & BMI,Percentage of patients who discontinued investigational drug due to adverse events,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
980,NCT03950245,iAUC glucose,Beta-cell glucose sensitivity (β-GS),,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
981,NCT06140030,Anxiety Symptoms,Glycemic control,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
982,NCT00575471,Change in HbA1c from baseline for rivoglitazone compared to placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to placebo,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
983,NCT02001051,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),Correlation Between Dermal Thickness and Patients With Subclinical Hypercortisolism,,2013-11-27,TERMINATED,INTERVENTIONAL,['PHASE2']
984,NCT02309502,"prevention on the developing of proliferative diabetic retinopathy (assessed with slitlamp, color fundus, and fluorangiography)",Pain assessment (questionnaire),,2012-10,WITHDRAWN,INTERVENTIONAL,['NA']
985,NCT01181674,Normoglycemia on Therapy,Number of Participants With Severe Hypoglycemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
986,NCT02565940,dermal sample,,,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
987,NCT06236750,Safety Endpoint: Incidence of Adverse Events,,Safety Endpoint: Incidence of Device Deficiencies,2023-08-04,RECRUITING,INTERVENTIONAL,['NA']
988,NCT05754775,Remission,Weight loss,,2023-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
989,NCT05153070,Treg variation,incidence of adverse events at month 24,,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
990,NCT02332824,Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12),Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12),Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE),2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
991,NCT04847778,Number of daily insulin injections irregularities,Change in Insulin Treatment Satisfaction Questionnaire (ITSQ-change) Score.,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
992,NCT00968006,Change in circulating CD34+KDR+ endothelial progenitor cells,Change in SDF-1alpha concentrations,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
993,NCT03630458,Glycemic response,Appetitive response,,2018-06-11,COMPLETED,INTERVENTIONAL,['NA']
994,NCT01574508,Glycated albumin levels,Number of participants with adverse events,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
995,NCT02247596,Change from baseline in Resting Energy Expenditure via indirect calorimetry at 2 weeks,Change from baseline in Glycated hemoglobin at 2 weeks,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
996,NCT02858830,Lower body muscle strength measured by knee extension,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
997,NCT02824874,"Css,max of Lobeglitazone","swing[(Css,max-Css,min)/Css,min] of Lobeglitazone",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1']
998,NCT05326958,average weighted corneal nerve fiber thickness (CNFTh),,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
999,NCT05446753,Change in cardiovascular health risk indicators,Change in body composition,,2022-06-17,RECRUITING,INTERVENTIONAL,['NA']
1000,NCT01025934,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
1001,NCT02122926,Cardiac medication adherence,Hospital Readmissions,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
1002,NCT05507892,Kidney Transcript Changes,Renal Plasma Flow (RPF),,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1003,NCT05240274,Diagnosis of post-transplant diabetes,diagnosis of PTDM in OGTT screen fails,,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE2']
1004,NCT00721617,Change in Diastolic Blood Pressure From Baseline to 8 Hours,C-peptides Levels for Intralipid/Dextrose Infusion,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
1005,NCT03720080,Adjustments of basal rate insulin infusion 670G,,,2019-05-16,TERMINATED,OBSERVATIONAL,['NA']
1006,NCT00736879,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants,Number of Participants With Marked Laboratory Abnormalities in 24 Week Double Blind Treatment Period - Treated Participants,,2008-09-22,COMPLETED,INTERVENTIONAL,['PHASE3']
1007,NCT05260281,does AI augment diagnostic performance of resident,does physical consultation augment diagnostic performance of AI,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA']
1008,NCT04285151,Visual acuity improvement,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1009,NCT00458133,Hemoglobin A1C,"metabolic measures, including serum cholesterol and triglycerides",,2007-04,COMPLETED,INTERVENTIONAL,['NA']
1010,NCT02850224,Number of participants with improved health-related quality of life as assessed by the PEDsQL.,,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
1011,NCT01947075,"Proportion of patients with each disease among all febrile patients, overall and stratified by HIV status","Proportion of febrile patients with acute respiratory infection infected with a certain respiratory pathogen, compared to the proportion of healthy controls infected with the same pathogen.",Strength of association between each febrile disease and diabetes mellitus and between acute respiratory infections and indoor air pollution,2013-07,COMPLETED,OBSERVATIONAL,['NA']
1012,NCT05481021,Identify any self-reported stressors associated with burnout,To compare any change in presence of burnout from previous cross-sectional study (5 years ago),,2022-07-05,COMPLETED,OBSERVATIONAL,['NA']
1013,NCT00129792,weight loss,Cortisol levels,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
1014,NCT00961025,To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects,To evaluate the safety and tolerance of DA-1229,,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
1015,NCT05562063,Changes in Left Ventricular mass in CMRI,Changes in The Kansas City Cardiomyopathy Questionnaire (KCCQ),,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
1016,NCT03196895,change in medication,change in psychological functioning (attitude towards glucose monitoring questionnaire),,2017-06-28,COMPLETED,INTERVENTIONAL,['NA']
1017,NCT00883558,Postprandial Glucose Excursion,Number of Participants With Hypoglycemic Events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1018,NCT05281029,Change from Baseline of HbA1c at 24 weeks,The rate of subjects who reached the target value of less than 7% (reasonable HbA1c goal) of HbA1c.,,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA']
1019,NCT02947828,Presence of painful diabetic polyneuropathy,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
1020,NCT04481737,Change in average fidelity scores,Change from baseline level of cardiovascular disease risk to 3-months and 6-month follow-up,Change from baseline patient satisfaction to 3-months and 6-month follow-up,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
1021,NCT04658264,Reduction in 2 hours post meal blood sugar,,,2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
1022,NCT05578352,Insulin autoimmune antibody,T cell,,2022-08-05,RECRUITING,INTERVENTIONAL,['NA']
1023,NCT03648554,Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone),Weight,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1024,NCT02883829,"Changes in attitudes, beliefs, and intentions about alcohol",,,2017-04-04,COMPLETED,INTERVENTIONAL,['NA']
1025,NCT05533996,Diagnosis of gestational diabetes (GDM),Labor dystocia,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1026,NCT02230137,HbA1c level,Satisfaction survey,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
1027,NCT03510000,Comparison of mean glucose levels between AP with empagliflozin with simple meal announcement strategy and AP without empagliflozin with carb-counting.,Morning capillary ketone concentration,,2018-05-15,COMPLETED,INTERVENTIONAL,['NA']
1028,NCT00563875,Platelet aggregation,,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
1029,NCT02922296,Metabolic status of adult SCD subjects,Genetic and genomic predictors in SCD subjects,,2015-05-01,RECRUITING,OBSERVATIONAL,['NA']
1030,NCT01125215,"Pain relief from pain score reduction, using visual analog scale (VAS)",,,2009-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1031,NCT05159570,Differences in lipolysis rate,Changes in signaling in muscle and adipose tissue,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1032,NCT01363791,Non-Alcoholic Fatty Liver (NAFL) Analysis,,,2009-05,UNKNOWN,OBSERVATIONAL,['NA']
1033,NCT01402362,Percent of patients with Diabetes Mellitus or impaired glucose tolerance,Prevalence of hypertension and hyperlipidemia,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
1034,NCT01268267,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1035,NCT02384265,Change from Baseline in Hemoglobin A1c at 12-months,Change from Baseline in Systolic and Diastolic Blood Pressure at 12-months,,2012-06-21,COMPLETED,INTERVENTIONAL,['NA']
1036,NCT05172401,Frequency of adverse device effects and frequency of serious adverse device effects,,,2022-09-15,WITHDRAWN,INTERVENTIONAL,['NA']
1037,NCT03071016,To record the mean change in HbA1C from baseline,To record the change in blood pressure,,2017-03-04,COMPLETED,OBSERVATIONAL,['NA']
1038,NCT01804478,Muscle Blood Flow,Skin Blood Flow,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
1039,NCT02009995,Testing of Strength,EuroQOL EQ-5D questionnaire,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
1040,NCT01317979,,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
1041,NCT03820635,correlation coefficient between serum level of osteoponton and the rate of different aspects of vascular affection as discussed previously,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
1042,NCT03170544,GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 1 Diabetes Mellitus (T1DM) (Part 3),Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Part 4,,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1043,NCT05074849,A Change in Adherence to prescribed footwear is being assessed,A change in Perception of Benefits is being assessed,A change in Acceptability and Ease of Use is being assessed,2024-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1044,NCT04499287,postprandial insulinemia,postprandial oxidative stress,,2014-09-17,COMPLETED,INTERVENTIONAL,['NA']
1045,NCT03678831,Expression levels in femoral spinal adipocytes of mRNAs of 18 genes compared to those of adipocytes isolated from the subcutaneous adipose tissue in the same patient,the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to presence or absence of metabolic syndrome,,2020-06-30,RECRUITING,OBSERVATIONAL,['NA']
1046,NCT02207712,The number of intravitreal injections of ranibizumab required by each study eye at 48 weeks,Adverse events rates,Changes in sleep pattern.,2014-11,TERMINATED,INTERVENTIONAL,['NA']
1047,NCT03341559,Perfusion in lower extremities,,,2018-03-20,COMPLETED,OBSERVATIONAL,['NA']
1048,NCT03724526,"Combined changes in HbA1C, SBP and LDL-cholesterol levels, simultaneous modeled using a scaled marginal model.",Change in ACC/AHA Risk Score of CVD,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
1049,NCT01176201,"Metabolic profiling and identification of 14C-labeled parent compound and metabolites of SLV337 in plasma, urine and feces (Part 2)","Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part 1 and Part 2)",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1050,NCT00547274,,,,2003-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1051,NCT03415880,The effect of a LiPA intervention program on increasing carotid distensibility in patients with type 2 diabetes.,The effect of a LiPA intervention program on microvascular function,,2018-11-08,COMPLETED,INTERVENTIONAL,['NA']
1052,NCT01999361,allosensitization after complete islet graft loss,,,2009-01,RECRUITING,INTERVENTIONAL,['NA']
1053,NCT03434288,Time for identification of bacteria responsible for foot osteomyelitis,Time for identification of sensitivity/resistance to antibiotics of the bacteria responsible for foot osteomyelitis,,2018-02-08,COMPLETED,OBSERVATIONAL,['NA']
1054,NCT02587741,The incidence of diabetic retinopathy,oxidative stress,Metabolic indices,2015-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1055,NCT02388815,Point Accuracy,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
1056,NCT04307875,Prevalence of hypertension,CAPS-5,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1057,NCT01128374,HbA1c percentage,gene polymorphisms,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
1058,NCT01775059,Safety endpoint,Accuracy endpoint,Accuracy endpoint,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
1059,NCT01813708,disease control,Self-Efficacy,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
1060,NCT04939038,Number of patients with delayed diabetic foot ulcer healing,Number of patients with all-cause death,Number of serious adverse events,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1061,NCT02001766,Glucose metabolism,,,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1062,NCT05378282,Differential Expression in blood and urine of diabetic patiens with and without diabetic nephropathy assesed by RNA seq,"Molecular data, Whole messenger RNA sequencing",,2021-09-03,COMPLETED,OBSERVATIONAL,['NA']
1063,NCT04299763,HbA1c,,,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE2']
1064,NCT00298740,Glucose Control as Assessed by Mean Glucose Levels,,,2003-02,COMPLETED,INTERVENTIONAL,['NA']
1065,NCT03676465,Family Communication Inventory Questionnaire,Change of Insulin Parameters,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
1066,NCT05297045,Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population,"Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events",,2022-03-29,TERMINATED,INTERVENTIONAL,['PHASE2']
1067,NCT00567047,• Pharmacokinetic measures,• Safety and tolerability measures,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1068,NCT01026688,Patient is receiving a statin,Change in treatment recommended following an LDL-cholesterol level above 2.0 mmol/L,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
1069,NCT05560568,Sleep efficiency,,,2023-01-20,RECRUITING,OBSERVATIONAL,['NA']
1070,NCT02792400,Difference in postprandial glucose excursions,Resting energy expenditure,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
1071,NCT01381887,Plasma concentrations of glucose,Adverse events,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1072,NCT01868698,Doppler ultrasound,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1073,NCT04539769,Diabetes remission rate,,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1074,NCT02310724,cardiovascular risk lipid values,healthcare usage,,2014-03-01,COMPLETED,OBSERVATIONAL,['NA']
1075,NCT00579813,Changes in Fat Inflammation Following Pioglitazone,,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1076,NCT02358408,Evaluation of System Accuracy according to ISO 15197 (see description),,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1077,NCT04227379,HbA1c percent time in control,blood pressure control,,2023-01-30,RECRUITING,INTERVENTIONAL,['NA']
1078,NCT02581488,Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment.,Target Ulcer Infection Rates in Each Treatment Group During the Treatment Period as Determined by Investigator-reported Adverse Events,Time to Closure for Ulcers Achieving Closure by End of Follow-up,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1079,NCT05983120,Determining the effect of SCLT-based education on Quality of Life,Determination of Body Mass Index (BMI),,2021-08-19,COMPLETED,INTERVENTIONAL,['NA']
1080,NCT06189417,Mean and proportion increase in glycemic control,Acceptability of a community-based club intervention led by Health Extension Workers,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1081,NCT05324488,Biomarker identification,Biomarker validation,,2015-10-21,RECRUITING,OBSERVATIONAL,['NA']
1082,NCT00753142,First-Phase Insulin Release (FPIR),Number of Participants With Beta-cell Failure,,2004-03,COMPLETED,INTERVENTIONAL,['NA']
1083,NCT01336751,Change from baseline in hemoglobin A1c (HbA1c) levels at week 24,Number and severity of hypoglycemic events and time of occurrence of hypoglycemic events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1084,NCT04412746,Diabetes-related factors risk,,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
1085,NCT02909725,Change in Time Spent Sedentary,Maternal Insulin Resistance,Maternal Body Weight Change,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
1086,NCT00598013,Insulin Resistance and Insulin Secretion,carotid intima-media thickness,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
1087,NCT03254446,Change in Joint British Society recommendations on the prevention of cardiovascular disease 3rd iteration (JBS3) risk score,Change in HbA1c,Safety profile of TRC150094,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
1088,NCT02664233,Change in weight measures from baseline to 3 months,Usability of the connected interface technology as indicated by a System Usability Scale,,2015-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1089,NCT04283942,Change of liver fat content in %,Change of lipid profile: free fatty acid,Change of brain functional MRI,2020-07-30,COMPLETED,INTERVENTIONAL,['NA']
1090,NCT00214825,Coronary microvascular function assessed by myocardial perfusion reserve measured by MRI,Proteinuria,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1091,NCT05041816,Changes in NIS,,,2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
1092,NCT02585622,Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.,Cost-effectiveness of cell therapy,,2017-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1093,NCT04721509,change in HbA1c of experimental group,No change in HbA1c of control group,,2021-02,UNKNOWN,INTERVENTIONAL,['NA']
1094,NCT00555217,"A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death","A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.",,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1095,NCT05870293,Diabetes potentiation scale,,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
1096,NCT03798080,Change in HbA1c,Immunogenicity (antibody variables),,2019-02-19,COMPLETED,INTERVENTIONAL,['PHASE3']
1097,NCT05884814,Change in interstitial glucose time in range,Change in interstitial glucose time in hyperglycaemia,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
1098,NCT06097065,Number and types of proteins/peptides differential characteristic peaks,ROC curve and area under curve AUC of clinical predictive diagnostic model,,2022-05-20,RECRUITING,OBSERVATIONAL,['NA']
1099,NCT05565716,Feasibility: Acceptability of SMART-HABITS-4-Health,Reach,,2023-08-21,RECRUITING,INTERVENTIONAL,['NA']
1100,NCT00529399,The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1101,NCT00473733,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
1102,NCT01210001,HbA1c Change From Baseline for Pio and Met Background Medication Patients,Body Weight Change From Baseline,Hypoglycaemic Events,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1103,NCT01838122,Prevalence of HbA1C in both arms of the cohort of subjects,,,2013-04,UNKNOWN,OBSERVATIONAL,['NA']
1104,NCT02839174,Hemoglobin A1C,patient-physician relationship,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
1105,NCT00039013,Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30),Change in body weight from Baseline to each intermediate visit and Week 30,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1106,NCT04962139,The proportion of subjects with complete closure of Target Ulcer,The proportion of patients with Target Ulcer recurrence,,2021-08-10,RECRUITING,INTERVENTIONAL,['PHASE3']
1107,NCT02997319,Disposition index,Plasma Melatonin,Depression,2017-02-24,COMPLETED,OBSERVATIONAL,['NA']
1108,NCT05659147,Frequency of genetic mutations in patients progressing to diabetes vs. those not,,,2023-01-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
1109,NCT02099513,"Perception of perceived usefulness, attitudes, and experiences",,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
1110,NCT00814190,The primary endpoint is the A1c level or the change in A1c level.,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1111,NCT01468376,Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations,Safety and tolerability of GLU-xx formulations,,2011-02,TERMINATED,INTERVENTIONAL,['PHASE1']
1112,NCT01488383,change in capillary blood glucose levels,"Adverse reactions of treatments (nausea, diarrhea, vomiting, allergic signs)",,2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
1113,NCT03857191,Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation,To assess the effect of Weight loss on OSA,,2019-03-22,COMPLETED,OBSERVATIONAL,['NA']
1114,NCT01580904,Fasting Glycemia,LDL Cholesterol,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
1115,NCT00160160,Blood pressure reduction,Comparison of responder rates,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
1116,NCT01646320,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1117,NCT03387683,Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment.,Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment.,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1118,NCT01606475,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
1119,NCT01268696,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
1120,NCT04045938,HbA1c,Inflammation - C-reactive protein (CRP),,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1121,NCT03683784,Prevalence of diabetes in Fayoum,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
1122,NCT02279524,Change From Baseline in Mean Liver Fat,Change From Baseline to Week 52/Termination in ALT,Change From Baseline to Termination/Early Termination in HbA1C,2015-04-29,COMPLETED,INTERVENTIONAL,['PHASE2']
1123,NCT05183191,Diagnostic accuracy of the hypoglycemia warning system using in-vehicle data to detect hypoglycemia (blood glucose <3.9mmol/L) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Technology acceptance of the hypoglycemia warning system,,2021-11-29,COMPLETED,INTERVENTIONAL,['NA']
1124,NCT04373265,Dose-limiting Toxicity (DLT),Plasma Concentrations of Relacorilant in Combination with Pembrolizumab in Patients with Advanced ACC and Glucocorticoid Excess,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
1125,NCT03527368,Weight Change,Glycated albumin,,2018-09-24,COMPLETED,INTERVENTIONAL,['NA']
1126,NCT00916188,"Insulin Sensitivity, oxidative Stress, lipid Profile",,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
1127,NCT01515384,Pancreatic uptake and clearance of 18F-AV-133 tracer as determined by SUVR,,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE1']
1128,NCT02947568,Association of genetical factors with NFS and HSI,Association of pathological tyrosine isoforms with hepatic setatosis indices,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
1129,NCT01561976,Area Under Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC (0-infinity)],Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2012-01-30,COMPLETED,INTERVENTIONAL,['NA']
1130,NCT04175665,Change in HbA1c,Proportion of patients who achieve weight loss ≥10%,Weight change in patients prescribed semaglutide as fourth line therapy (excluding insulin use),2020-01-06,COMPLETED,OBSERVATIONAL,['NA']
1131,NCT04228822,Dyslipidemia,Glucose variability,,2020-11-10,COMPLETED,INTERVENTIONAL,['NA']
1132,NCT04801199,Change in HbA1c level,Frequency of adverse events,,2020-01-26,COMPLETED,INTERVENTIONAL,['PHASE3']
1133,NCT01220089,weight change,cost effectiveness,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1134,NCT01828931,HbA1c levels,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
1135,NCT04784650,"Presence of foot problems (no = 0, yes = 1)",Indication of peripheral arterial disease (PAD),,2021-01-31,COMPLETED,INTERVENTIONAL,['NA']
1136,NCT01578980,Percent Time of Active CTR,Frequency of Unplanned System Resets or Restarts,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
1137,NCT01977833,"Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test","Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge","Postprandial Insulin plasma levels, after breakfast,lunch and dinner meal test",2013-10,UNKNOWN,INTERVENTIONAL,['NA']
1138,NCT02818322,time of ulcer healing,,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
1139,NCT06128265,Change in glucose homeostasis measured by Continuous Glucose Monitor (CGM),"Weight in kg, measured from screening through study completion.",,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
1140,NCT05477017,Variation in HbA1c values (% -point),Evaluation of the main side effects and the withdrawal rate,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1141,NCT00252525,The primary outcome measures are cardiovascular morbidity and mortality.,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
1142,NCT01934660,Our primary outcome of interest is vascular inflammation measured by standard uptake values from PET/CT and PET/MRI imaging with FDG,"As a tertiary analysis, we will add novel biomarkers to the above models including HDL efflux, HOMA-IR and inflammatory mediators to understand the association of each biomarker on vascular disease markers",,2013-12-02,COMPLETED,OBSERVATIONAL,['NA']
1143,NCT01357876,"To investigate the relationship between the glucose lowering action of metformin and lipid metabolism including, but not limited to, fasting lipids and prandial TGs",To measure sparse metformin profiles on the days when the PD endpoints are measured,,2010-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1144,NCT00870831,OGTT will be performed every 6 months for 5 years in subjects with a functioning Islet Transplant,The OGTT reflects the function of the Islet transplant and could be used as an indication of Islet Transplant function,,2000-10,TERMINATED,OBSERVATIONAL,['NA']
1145,NCT03164785,Change in urine albumin creatine ratio (ACR).,Incidence of Treatment-Emergent Adverse Events,,2017-07-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1146,NCT00462436,Primary Outcome: Reduction of total and LDL cholesterol,"Improved markers of glycemic control - fructosamine, HOMA",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1147,NCT06333665,Disease-free survival,perioperative 90-day mortality,,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1148,NCT01895179,Change in Glucose Tolerance,Change in Inflammation and Metabolic Markers,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1149,NCT04141241,hs-CRP (high-sensitivity C-reactive protein),Body Temperature,,2016-03-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1150,NCT01854593,Reoperation,Silicon Oil Tamponade,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1151,NCT05687474,Feasibility - reliability,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
1152,NCT00845897,Plantar Flexor Muscle Strength,Barefoot Plantar Pressure,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
1153,NCT00842556,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,To assess the safety and tolerability in healthy subjects,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1154,NCT01766570,Change in cardiometabolic statute from baseline to the end of intervention.,Change in anthropometric measurements from baseline to the end of the intervention.,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
1155,NCT05476861,Insulin omission,Waist circumference,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
1156,NCT01161797,glucose variability,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
1157,NCT03212755,The number of patients with high level of immunoglobulin in serum,,,2017-08,UNKNOWN,INTERVENTIONAL,['NA']
1158,NCT03204552,Change in BMI,,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA']
1159,NCT00760110,Death,Macrovascular complications,,1997-11,COMPLETED,OBSERVATIONAL,['NA']
1160,NCT00105846,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
1161,NCT04625595,Change in total daily insulin use,Cytokine level from in vitro presentation of antigen by HLA-DQ8,,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1162,NCT03747471,Change from baseline Diabetes distress (DD) 3 months:,Change from baseline HbA1C at 3 months:,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
1163,NCT02990832,Infection assessed as per Infectious Disease Society of America (IDSA) guidelines,Safety and complications (incidence of adverse events),,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
1164,NCT03460964,Glucose measurements,Acceptability of sensor,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
1165,NCT02421198,Change in percentage overweight,Waist circumference,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1166,NCT02745015,Metabolic,Periodontal 3,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
1167,NCT02320461,Myocardial infarction (Incident cases),,,2008-08,UNKNOWN,OBSERVATIONAL,['NA']
1168,NCT02868788,change in plasma dipeptidyl peptidase IV enzyme level from baseline,change in plasma incretin level from baseline,,2016-06-14,UNKNOWN,INTERVENTIONAL,['NA']
1169,NCT05585983,Change in fasting residual β cell (C-peptide) function.,Variation of blood glucose.,Treatment-emergent events of diabetic ketoacidosis (safety outcome),2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE4']
1170,NCT01844479,Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking,Gait Speed Variability Dual Task,Sudomotor Function,2012-12,COMPLETED,INTERVENTIONAL,['NA']
1171,NCT01342497,Rate of healing of diabetic foot ulcers (% reduction in area from baseline),Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1172,NCT01028287,Percentage of patients achieving less than 300 mg protein per 24 hours after 6 months of Acthar Gel.,Percentage of patients achieving greater than 50% reduction in urinary proteinuria after 6 months of Acthar Gel.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1173,NCT03335371,Sentinel - Time to Maximum Concentration (Tmax),Change From Baseline in Basal Insulin Use,,2017-10-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1174,NCT00353587,Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema,,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1175,NCT03704389,Diabetes overtreatment in the elderly,,,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
1176,NCT02422446,Change From Baseline in Endothelial Function at 12 Weeks Using Reactive Hyperemia Index (RHI),"Change in Endothelin-1 (ET-1), High-sensitive C-reactive Protein (hsCRP), and Oxidized LDL Between Baseline and 12 Weeks",,2015-04,TERMINATED,INTERVENTIONAL,['PHASE3']
1177,NCT01244646,Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire,"Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance",,2010-12,TERMINATED,OBSERVATIONAL,['NA']
1178,NCT03527277,Endogenous glucose production,non-high density lipoprotein cholesterol (non-HDL-C),Eating motivation,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1179,NCT05744232,Global score of disordered eating psychopathology,Weight,Safety/ New cases needing referral to specialist services,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
1180,NCT05134025,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise.",,Comparison of the maximum iG concentration,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
1181,NCT02318108,Hemoglobin A1c,,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
1182,NCT03159494,Blood pressure,Physical acitity,,2014-02-14,COMPLETED,INTERVENTIONAL,['NA']
1183,NCT00849017,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Albiglutide Plasma Concentration at Weeks 8 and 24,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1184,NCT00006305,Number of Participants With All-Cause Mortality,"Number of Participants With Death, Myocardial Infarction, or Stroke",,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1185,NCT04877730,Time in Range (TIR) 70-180 mg/dL From Breakfast Time + 5 Hours,Units of Insulin Injected Between 2 Hours Before and 5 Hours After Dinner,,2021-05-21,COMPLETED,INTERVENTIONAL,['NA']
1186,NCT03689530,Change in Body Weight at 6 Months,Change in Controlled Motivation to Prevent Diabetes Using the Treatment Self-Regulation Questionnaire (TSRQ - Controlled),,2018-10-02,COMPLETED,INTERVENTIONAL,['NA']
1187,NCT05433584,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in the IWQOL-Lite-CT - Physical Functioning Domain,,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
1188,NCT05908708,Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system,Sleep quality as assessed by a questionnaire,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
1189,NCT05459285,Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞),Elimination constants (λz),,2022-05-31,COMPLETED,INTERVENTIONAL,['PHASE1']
1190,NCT04889157,Maximum observed plasma concentration,Number of participants with laboratory abnormalities,,2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1191,NCT01926457,Umbilical Cord C-Peptide >90th percentile,Return to prepregnancy weight,Diagnosis of Preeclampsia,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1192,NCT00950040,Percentage heavy drinking days,HbA1c levels,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
1193,NCT06277466,Correlation between T2DM susceptibility gene expression and clinicopathological features,Baseline LDL-C of controls with different genotypes,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
1194,NCT03938740,Basal/bolus ratios during the last 2 weeks of the treatment period,,,2019-03-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1195,NCT01755572,Change in plasma ANP level at 21 Days,Office-measured heart rate;Treatment difference for liraglutide compared to crossover with placebo,Change in HDL,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1196,NCT03695731,brown adipose tissue activation,Energy expenditure,,2018-10-15,UNKNOWN,INTERVENTIONAL,['NA']
1197,NCT01480297,Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1198,NCT05778370,Correlation between HBA1c level and thickness of both macula and choroid in patients with type II diabetes mellitus,,,2023-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1199,NCT05261373,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from blood pressure,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
1200,NCT05929066,Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA1 Subset,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE3']
1201,NCT01217905,Investigate the safety and tolerability of AZD7687 following administration of single and multiple doses,Evaluate the pharmacokinetics (PK) (plasma and urine) of AZD7687 and it´s glucuronic acid metabolite (AZ13128940) after single and multiple doses,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1202,NCT05806502,Endothelium-dependant increase in forearm blood flow,,,2018-11-01,RECRUITING,INTERVENTIONAL,['NA']
1203,NCT01752985,Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment With BMS-813160,Dose-Response Relationship Using Change in Baseline Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment,,2013-03-18,TERMINATED,INTERVENTIONAL,['PHASE2']
1204,NCT00915707,Disposition Index reflecting Diabetes Risk as a result of decreased sleep duration and/or quality.,,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
1205,NCT03288740,Area under the semaglutide plasma concentration time curve at steady state (semaglutide 1.0 mg),Incidence of anti-semaglutide antibodies (positive/negative) at follow-up,,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE1']
1206,NCT03786133,Total bacterial load,Genotypes of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans,,2016-06-10,COMPLETED,OBSERVATIONAL,['NA']
1207,NCT03865901,Negative predictive value (NPV) and positive predictive value (PPV) of the Mellitus GCD59 ELISA for gestational diabetes mellitus screening,Sensitivity and specificity of the GCD59 ELISA to that of glucose load test (GLT) using two or more abnormal oral glucose tolerance test (OGTT) results,Sensitivity and specificity of the GCD59 ELISA across relevant subgroups,2019-05,WITHDRAWN,OBSERVATIONAL,['NA']
1208,NCT01829464,Change From Baseline in HbA1c at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
1209,NCT04769141,Medication dosing optimization,(CURATE.AI) pilot deployment using prospective data,,2021-08,UNKNOWN,OBSERVATIONAL,['NA']
1210,NCT02846233,Change in A1c at the End of Study Period,Changes in Treatment Satisfaction Scores (DM-SAT Total Score),,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1211,NCT03296800,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion 0-48 hr,,2017-09-27,COMPLETED,INTERVENTIONAL,['PHASE1']
1212,NCT01035320,"Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.",Compare effects of simvastatin alone with those of placebo on thrombogenic mechanisms. Compare the effects of simvast. + ezetim. with those of simvast. alone on inflammatory variables. Assess how the treatment effect relate to renal function.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1213,NCT03057158,"Proportions of differentially methylated CpG sites between cohorts, from Illumina EPIC chip",Gene expression (from PCR),,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
1214,NCT01273584,Birth Weight centile (z-score),2nd trimester miscarriages,,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1215,NCT00394524,Mean Blood Glucose (BG) in mg/dl Among Glucommander Group Compared to Standard Insulin Infusion,Mean Hospital Length of Stay in Days Among the Glucommander Group Compared to Standard Insulin Infusion,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
1216,NCT01313975,Incidence of sodium-fluid disturbances,Associated changes in natriuretic peptide levels,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
1217,NCT01736124,Diabetes Self-management,Prospective Memory,,2015-04-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1218,NCT04798937,Transition Readiness Assessment Questionnaire (TRAQ) scores,Hemoglobin glycated values,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
1219,NCT02853630,Changes in Insulin secretion rate,Number of participant treated related to adverse event,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1220,NCT02477163,Changes in the value of laboratory investigations,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1221,NCT01791907,HbA1c,Health economics,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
1222,NCT02989142,"prevalence of participants with at least one of the following four complications: pregnancy-induced hypertension, gestational diabetes mellitus, caesarean section, large-for-gestational age baby",Number of women who gave at least 6 months breast feeding,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
1223,NCT04380584,prediction of diabetic nephropathy,,,2019-11-30,COMPLETED,OBSERVATIONAL,['NA']
1224,NCT03916211,amputation rate,Wong-Baker Faces Pain Rating Scale,,2019-04-20,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1225,NCT06154915,Determine the functional contribution of macrophages to diabetic chronic foot ulcers,,,2022-09-09,RECRUITING,OBSERVATIONAL,['NA']
1226,NCT02718547,Change of at least 50 micron in Macular edema,,,2017-03-26,UNKNOWN,INTERVENTIONAL,['NA']
1227,NCT00356109,To test that preprandial AIR Insulin is non-inferior to preprandial injectable insulin (insulin lispro) with respect to mean change in HbA1c from baseline to endpoint.,To assess rate and incidence of hypoglycemia,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1228,NCT01496339,Glycosylated hemoglobin (HbA1c),The random glucose level,,2012-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1229,NCT06004219,Diabetes Distress Screening Scale (DDS17),,,2023-11-21,RECRUITING,INTERVENTIONAL,['NA']
1230,NCT01827826,Program feasibility: Attendance,Physical activity level,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
1231,NCT01219803,HbA1c,"Ins(0h,1h,2h),blood lipids",,2010-08,UNKNOWN,INTERVENTIONAL,['NA']
1232,NCT04949958,Body fat percentage,,,2022-04-15,COMPLETED,INTERVENTIONAL,['NA']
1233,NCT02501616,Reactive hyperemic index to measure endothelial function,Urine β2 microglobulin,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1234,NCT00082316,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
1235,NCT04328896,CGM-Tele-monitoring effects on hypoglycemia,CGM - Tele-monitoring effects on HbA1c,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
1236,NCT02318693,Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13,"Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)",,2015-02-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1237,NCT03049709,agreement of diastolic central blood pressure measurements,,,2015-05-01,COMPLETED,OBSERVATIONAL,['NA']
1238,NCT01279161,Identification of the effect of the FTO gene polymorphism on the development of overweight/obesity in insulin treated children,• Comparison of frequency distribution of FTO gene polymorphism involved in the pathogenesis of obesity in children with diabetes versus children without diabetes.,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
1239,NCT02122250,user engagement,Diabetes and Physical activity knowledge,Single item: whether you would recommend the website to others,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1240,NCT04988204,Number of participants in the program at the end of the study,Bilirubin level,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA']
1241,NCT04075513,Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis,Number of Hypoglycemic Events Per Participant Year During the On-treatment Period,,2019-10-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1242,NCT04101396,Clinical characteristics of participants,Participants' satisfaction,,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
1243,NCT00348179,Vascular abnormalities as measured by the SyphmgnoCor equipment,,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
1244,NCT01812122,Cardiovascular disease risk factor,hypoglycemic index,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1245,NCT03707379,HbA1c,LDL-C,,2016-03-01,RECRUITING,OBSERVATIONAL,['NA']
1246,NCT03529903,Change in Physical Activity,,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA']
1247,NCT00786019,"Ejection Fraction: Percentage of Blood Leaving the Heart Before and After Exercise at Baseline, After a Vitamin C Infusion, and After Exercise Training",,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
1248,NCT00494715,Progression to ESRD (i.e. need for renal replacement therapy by chronic dialysis or renal transplantation),"Doubling of serum creatinine (versus baseline), Rate of GFR decline, Incidence of fatal and non-fatal cardiovascular events (stroke, acute myocardial infarction, sudden death), Albumin to creatinine ratio and 24-hour urinary protein excretion.",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1249,NCT00901472,Improvement in glucose tolerance,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
1250,NCT03843840,Test retest reliability,,,2019-02-15,COMPLETED,OBSERVATIONAL,['NA']
1251,NCT00607503,Safety of bedtime administration of the epinephrine simulating β2 adrenergic agonist terbutaline to reduce the incidence of nocturnal hypoglycemia without compromising glycemic control in youth with type 1 diabetes (T1D).,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1252,NCT03491930,Change in weight,"Change in quality of life by ""SF-12v2"" questionnaire",,2018-06,WITHDRAWN,INTERVENTIONAL,['NA']
1253,NCT01585948,The incidence and extent of coronary artery disease between diabetics and non-diabetic patients.,TCF7L2 gene polymorphims and the incidence and extent of coronary artery disease.,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
1254,NCT02003872,Excess weight loss,liver fat infiltration,,2015-01,TERMINATED,INTERVENTIONAL,['NA']
1255,NCT04068272,Epitheliopathy,Anterior segment inflammation,,2019-09-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1256,NCT03253328,Stump Healing using the Bates-Jensen Wound Assessment Tool,Determine effect size to power a larger trial,Stump Healing,2016-12-15,SUSPENDED,INTERVENTIONAL,['NA']
1257,NCT02784275,Change of Body Weight From Baseline,Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline,,2016-06-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1258,NCT00294723,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156,Hypoglycaemic Episodes,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
1259,NCT04959071,Comparison of mean healing time of wounds in diabetic foot ulcers among Vac and conventional dressings,,,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
1260,NCT00786721,Near Infrared Spectroscopy to assess muscle mitochondrial OXPHOS function.,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
1261,NCT01329822,Fetuin-A,cardiovascular risk factors,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
1262,NCT04132401,Area under the receiver operating characteristic curve of the algorithm,,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
1263,NCT02496390,Improvement in Homeostasis model assessment [HOMA] score.,Modulation of lipid and hormone metabolism,,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1264,NCT03049631,Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental,Changes in blood pressure in 12-week intervention of active treatment vs Experimental,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs Experimental,2017-05-18,COMPLETED,INTERVENTIONAL,['NA']
1265,NCT03456271,fracture,,,2017-07-01,TERMINATED,OBSERVATIONAL,['NA']
1266,NCT02765399,Change in ApoCIII Level,Mean Fractional Catabolic Rate of VLDL2-apoB100,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1267,NCT00390273,Lactate production following exogenous lactate overload,Parameters modelizing elimination of lactate following muscular exercise test (bi-exponential model).,,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1268,NCT06154746,aeffect of risk factors in progression of diabetic retinopathy.,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1269,NCT05629221,Haemoglobin glycated (Hb1Ac) mean changes,Time spent for telemedicine visits,,2022-12-30,RECRUITING,INTERVENTIONAL,['NA']
1270,NCT00965991,Number of Participants Assessed for Glucose Control,Failure Rate of the Drug to Control Blood Glucose,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
1271,NCT02520258,Blood glucose,C-peptide,Interval changes in frequency distribution of microbes found in stool samples (Phase II - cohort 1),2015-08,COMPLETED,INTERVENTIONAL,['NA']
1272,NCT01677299,Within Treatment Comparison Based on Ratios of AUCs of PYY,,,2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1273,NCT03131232,The effect of empagliflozine on glucose metabolism,- echocardiographic parameters (if collected) with determination of the systolic and diastolic left ventricular function,,2015-12-10,UNKNOWN,OBSERVATIONAL,['NA']
1274,NCT01560546,Lean body mass,Sexual function,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1275,NCT00313001,Superiority as assessed by HbA1c reduction,Patient satisfaction,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1276,NCT03765112,Perfusion density,Change in perfusion density in patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR over the follow up of one year,,2018-09-20,UNKNOWN,INTERVENTIONAL,['NA']
1277,NCT01392677,Adjusted Mean Change From Baseline in HbA1c Levels,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1278,NCT05602441,Change in glycated haemoglobin from baseline to 12 months post intervention,Change in diabetes distress measured by Diabetes Distress - Screening Scale 17 (DDS-17) from baseline,,2021-01-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1279,NCT02824003,Change in fasting hepatic lipid content,"Safety and Tolerability will be assessed by determining the incidence, severity, dose relationship of adverse effects, and changes in laboratory evaluations",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1280,NCT05367622,Medication compliance,Diabetes health literacy assessment scale,,2022-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1281,NCT00904020,"Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)",QoL: Patient Global Assessment of Patch Satisfaction,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1282,NCT02987348,Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction,Health care utilization,,2015-06-30,COMPLETED,OBSERVATIONAL,['NA']
1283,NCT05803421,"Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]",Pharmacokinetics (PK): Plasma Serum Concentrations of Orforglipron,,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE3']
1284,NCT01994746,Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir,Time to Maximum Change From Baseline Concentration (Tmax) of Glucose,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1285,NCT06240273,Fasting glucose level will be assessed before and after the trial.,,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1286,NCT02474823,Result of ESAP testing,Result of PSG testing,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
1287,NCT01050868,To compare the difference between the self-monitoring blood glucose (SMBG) value achieved at 6 hours after meals with induced post-prandial hyperglycemia and the mean target value of 110 mg/dL. Target post-prandial range is 80-140 mg/dL.,"To compare the absolute relative difference (RAD, multiplied by 100) between the SMBG value and the target value between the calculators",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
1288,NCT04084418,Daily blood glucose standard deviation,Effects on physical activity (steps/day),,2019-10-15,TERMINATED,INTERVENTIONAL,['NA']
1289,NCT01100125,The change of HbA1C,the change of insulin dose,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1290,NCT00781547,Glucose tolerance,Progress of atherosclerosis (IMT),,1999-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1291,NCT04869761,Adverse events and/or serious adverse events,,,2021-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1292,NCT05939271,- What is the incident amputation rate in persons with and without DM in the Netherlands in the period 2011-2020?,"- Does the presence of a formal multidisciplinary foot clinic / team in a hospital make a difference, especially when comparing previous and actual macrovascular complication rates?",,2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1293,NCT02989961,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of autologous Resticutis injection by clinical examination,,2013-11-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1294,NCT05354245,Peripheral insulin sensitivity,Stool consistency,,2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
1295,NCT01676272,"Proposal for a multi center site randomized, prospective controlled head-to-head clinical trial comparing a bioengineered skin substitute to a human skin allograft.",,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
1296,NCT00533559,"we will measure insulin secretion, calculate disposition index and insulin clearance during a hyperglycemic clamp. We will also measure insulin sensitivity during a euglycemic hyperinsulinemic clamp","During the hyperglycemic clamp we will also measure Free Fatty Acid, C-peptide and triyglycerides. During the euglycemic hyperinsulinemic clamp we will determine the insulin sensitivity index and the disposition index.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1297,NCT02003677,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,,2013-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1298,NCT03917784,Matsuda index,total bilirubin,,2019-02-25,UNKNOWN,INTERVENTIONAL,['PHASE4']
1299,NCT02290067,User performance of blood glucose monitoring systems indicated by patient [questionnaire],,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1300,NCT02826759,"serum concentration of sphingosine-1-phosphate, micromol per liter","serum concentration of ceramide, micromol per liter",,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
1301,NCT03337828,Homeostatic model assessment (HOMA) index change after each alcohol-free beer phase.,Micriobota change after each alcohol-free beer phase.,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
1302,NCT03776227,AUC 0-72h (area under the curve),Area under the curve (AUC),,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE1']
1303,NCT02994966,Foot ulcer recurrence,Determinants of ulcer formation,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1304,NCT03199716,Daily frequency of blood glucose monitoring (BGM),HbA1c levels,Responsibility for diabetes care,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1305,NCT01115621,Effect of dietary intervention on the development of islet autoantibodies,Effect of dietary intervention on the development of Type 1 diabetes.,,2001-02,UNKNOWN,INTERVENTIONAL,['NA']
1306,NCT05947370,Differences of blood glucose levels between BBR and placebo treatment groups during the glucose tolerance test.,Differences of serum calcium levels between BBR and placebo treatment groups during the glucose tolerance test.,Differences of QT-interval duration between BBR and placebo treatment groups during the glucose tolerance test.,2022-10-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1307,NCT02851745,Increase in LV systolic function,Changes in diastolic LV function,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1308,NCT00337038,endothelial function,blood pressure and glycemic control,,2006-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1309,NCT00150085,"Proportion of patients who no longer require a hypoglycemic agent, or who move from insulin to an oral agent, or who no longer meet the American Diabetes Association criteria, or a relative improvement in mean glycosylated hemoglobin at 12 and 26 weeks","Safety assessed by death, graft loss, biopsy supported clinically manifested acute rejection, change in kidney function, change in liver function, serious adverse events and adverse events at 12 and 26 weeks",,2004-02,TERMINATED,INTERVENTIONAL,['PHASE4']
1310,NCT00094263,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
1311,NCT01779609,Flow mediated dilation,Maximal Oxygen Uptake,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1312,NCT03037918,Whole body insulin sensitivity index,Microbiome analysis,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
1313,NCT02157298,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1314,NCT01904422,Glycated hemoglobin (HbA1c),Tumor Necrosis Factor (TNF),clinical attachment level (CAL),2013-03,COMPLETED,INTERVENTIONAL,['NA']
1315,NCT00149331,Preference for Insulin therapy,Satisfaction with the education session,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1316,NCT00475371,Determine the safety and tolerability of ascending doses of MKC253 Inhalation Powder,Pharmacokinetic (PK) parameters of plasma GLP-1,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1317,NCT04682067,Number of participants with >80% completion of daily ecological momentary assessments (EMA) completed,Number of participants with biochemically verified abstinence at 4 weeks post quit,,2021-01-08,COMPLETED,INTERVENTIONAL,['NA']
1318,NCT02436551,prevalence of gestational diabetes,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
1319,NCT02974413,Glycemic control,Weight,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
1320,NCT00825695,functional transcranial doppler measures,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1321,NCT02701257,Insulin Area Under the Curve in the 3.5 Hours Following the Insulin Bolus,PG AUC in the 3.5 Hours Following the Meal,,2016-03,TERMINATED,INTERVENTIONAL,['NA']
1322,NCT06195566,"Validation of the Mission T2D (MT2D) algorithm outputs, that predicts the real time risk for developing pre-diabetes.",,,2024-01-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1323,NCT01676233,Change in 24-hour blood glucose profile measured by continuous glucose monitoring,Change in HbA1c from baseline to each treatment end by treatment,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1324,NCT03437798,Correlation of CDC-AAP periodontal condition questions vs. periodontal disease diagnosis,,,2018-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1325,NCT01234597,Changes in Hemoglobin A1c (HbA1c) level,Changes in insulin glulisine dose,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1326,NCT04127890,Weight loss,,,2017-03-07,COMPLETED,INTERVENTIONAL,['NA']
1327,NCT06046560,Proportion of patients with prescriptions of SGLT2i or GLP1-RA at any time,Short-form Patient Activation Measure (PAM),Change in laboratory measured HbA1c,2021-03-22,COMPLETED,INTERVENTIONAL,['PHASE4']
1328,NCT04664764,to compare the effectiveness of insulin degludec to insulin glargine and NPH,,,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE4']
1329,NCT05066152,HOMA-IR,Dietary cholesterol,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
1330,NCT03587623,Serum Copeptin concentration,,,2018-07-04,COMPLETED,OBSERVATIONAL,['NA']
1331,NCT02974309,HbA1c,Sleep Duration,Cortisol,2017-09-15,RECRUITING,INTERVENTIONAL,['NA']
1332,NCT01562782,Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate,Peak Glucose in 2 Study Groups,,2012-04-02,COMPLETED,INTERVENTIONAL,['NA']
1333,NCT00191282,Number of Participants Who Experienced a Primary Combined Outcome,Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18,Summary of Reasons for Deaths,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1334,NCT02551835,HbA1c,Two-hour glucose,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
1335,NCT05909800,Differences in AUC in C-peptide stimulation test,Genetical analysis,,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1336,NCT02559479,Change in insulin resistance (HOMA index).,"Change in lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, non HDL cholesterol, triglycerides and apolipoproteins).",,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
1337,NCT03652480,Glycemia,Subjective Outcomes Determination (SOD) score,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
1338,NCT04799938,Level of Growth Diferantiation Factor-15,Level of VO2max,,2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
1339,NCT01714986,"Intervention with Affect School with Script Analysis and Basic Basal Awareness Therapy in patients with diabetes, psychological symptoms and high HbA1c",Self-image,,2009-03,WITHDRAWN,INTERVENTIONAL,['NA']
1340,NCT01759823,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function,,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1341,NCT06116149,Difference in mean 12-month weight reduction (primary health-related outcome),Difference in proportion of participants meeting intervention goals at 12 months,Sustainability (Participants): comparison of the proportion of participants maintaining DPP goals at six months after their participation in the DPP has ended,2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
1342,NCT04605991,Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12,Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) - Glycemic Control Domain Score at Week 12,,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1343,NCT04688359,Measurements behind the Icelandic heart association risk calculator,Hip-to-Waist ratio,LDL cholesterol changes from start point to endpoint in both groups,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
1344,NCT00382564,,,,2006-09-25,COMPLETED,OBSERVATIONAL,['NA']
1345,NCT00789711,"Number of all (Major/Minor/Nocturnal) hypoglycaemic events, reported as serious adverse drug reactions.",Number of major (including nocturnal) hypoglycaemic events,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
1346,NCT02107326,Effect of Webdia Software use on HbA1C,Effect of Webdia Software use on the incidence of hypoglycaemic events,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
1347,NCT05742230,Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) at Week 12,"Change From Baseline in blood pressure at Week 4, 12",Occurrence of major renal events,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
1348,NCT02252224,The number and incidence rate of adverse events and serious adverse event including unexpected adverse drug reactions,Changes in 2-hr PPG before and after administration of Forxiga,,2014-09-23,COMPLETED,OBSERVATIONAL,['NA']
1349,NCT05179668,Δ Left ventricular mass indexed to body surface area,Δ Body weight [kg],,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1350,NCT00785005,,,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
1351,NCT03107208,Rate of Rebound Hyperglycemia,Evaluation of CGM and POC Glucose Monitoring During DKA Treatment in Children.,,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE4']
1352,NCT00953914,autonomic modulation assessed by heart rate variability,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
1353,NCT00424762,Peak Oxygen Uptake (VO2),Percentage of Patients Developing New or Worsening Peripheral Edema,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1354,NCT02710448,"the percentage of patients in stage 1 of chronic kidney disease (CKD) each category of renal function whose rate of erythrocyte metformin remain within the therapeutic range, at each stage of treatment.","the percentage of patients in stages 3-5 of CKD each stage renal disease with a blood erythrocyte remaining within the therapeutic range or higher, and but without significative hyperlactatemia (≥ 2.5 mmol / l) in the latter case.",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1355,NCT01060670,Incidence of Complete Wound Closure,Change in Short Form Health Survey (SF-36) Quality of Life Metrics,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
1356,NCT03304626,Number of Participants With Acute Cellular Rejection Between Study and Control Groups,Number of Participants With Adverse Events,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
1357,NCT02366351,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
1358,NCT02292290,Composite,HbA1c only,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1359,NCT04571723,Change in Health Mindset,waist circumference,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
1360,NCT03528031,Visceral adiposity,24-hour diet recall,,2018-06-19,COMPLETED,INTERVENTIONAL,['NA']
1361,NCT04999189,Change in blood pressure,,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
1362,NCT01088594,Time-course absolute urinary sodium excretion calculated on the Day 1 of each study period,Creatinine clearance calculated on Day 1 of each study period,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1363,NCT00620282,Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF),Number of Hypoglycaemic Episodes,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1364,NCT00073255,,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1365,NCT05925946,Reversal of diabetes,Insulin Resistance,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1366,NCT01947855,Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1367,NCT01079364,Self Measured Blood Glucose (SMBG),Adverse Events (excluding hypoglycemic events),,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4']
1368,NCT03947073,Total number of women who failed management with diet alone,Total number of neonates with a preterm birth,,2019-06-12,COMPLETED,INTERVENTIONAL,['NA']
1369,NCT05348122,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,,2022-06-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1370,NCT00486291,Change From Baseline in HbA1c at Week 28.,Absolute Weight Change (kg) From Baseline to Week 28,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1371,NCT03864744,Change in hepatic lipid content (steatosis) after total pancreatektomy or pancreaticoduodenectomy,Changes in NAFLD/NASH biomarkers,,2019-01-30,UNKNOWN,OBSERVATIONAL,['NA']
1372,NCT01594281,Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS),Number of PRP Laser Spots Until EOCS,,2012-12-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1373,NCT05561855,The change of HbA1c from baseline,The change in depression severity from baseline,,2022-10-07,COMPLETED,INTERVENTIONAL,['NA']
1374,NCT01486862,Percentage of subjects achieving HbA1c (glycosylated haemoglobin A1c) below 7.0%,Adverse events,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1375,NCT02634216,Effect of Capros on Blood Glycemic Index,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1376,NCT00567112,Half Life (t½) for OCT (Fasted) and DFC (Fasted),t1/2 for OCT (Fasted) and OCT (After Meal),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1377,NCT05632029,Malondialdehyde,Glutathione,,2022-10-20,RECRUITING,INTERVENTIONAL,['NA']
1378,NCT02961595,Appearance of type 1 diabetes associated auto-antibodies in serum,Presence of enterovirus RNA in stools,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1379,NCT05966727,Measurement of serum persistent organic pollutants (POPs) concentrations by mass spectrometry.,Measurement of serum POPs concentrations by mass spectrometry after bariatric surgery,,2024-03-31,RECRUITING,INTERVENTIONAL,['NA']
1380,NCT02768818,Glucose metabolism changes,Admission to Neonatal Intensive Care Unit (NICU),,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1381,NCT04450693,Complete wound healing,Patient-reported mobility,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1382,NCT03376789,Change in HbA1c,Change in 8-point SMBG,,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3']
1383,NCT01356849,Change from baseline to Week 12 in Urinary Albumin to Creatinine Ratio (UACR),Differences in change from baseline to each post baseline measure for each of the Kidney Disease Quality of Life (KDQOL) Kidney Disease Targeted Scales,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1384,NCT01314222,The primary endpoint of this study is the average pain score for BMS-954561 vs. placebo.,"Evaluate the tolerability and safety of BMS-954561 in patients with DPNP as measured by the frequency and severity of adverse events, frequency of severe adverse events, and discontinuations due to adverse events.",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1385,NCT02246582,Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD),Retrospective Analysis (MARD for the GSR With Minimum and 1 Additional Calibration),,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1386,NCT00504673,Body weight loss,Incidence of hypoglycaemia,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1387,NCT06084052,Device questionnaire,Reduction in CO2 comparing carbon dioxide emitted due to ulcer treatment vs carbon dioxide emitted due to device manufacture,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
1388,NCT03970889,Change in the number of missed meal boluses,Positive predictive value of a Klue meal alert,,2018-10-12,COMPLETED,INTERVENTIONAL,['NA']
1389,NCT03226990,pressure areas,denture retention,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
1390,NCT05660928,Composite outcome of proportion of patients with controlled disease,Number of glycohemoglobin measurements,Program adherence,2022-12-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1391,NCT04784130,Clinical Outcomes-A1c,Behavioral outcome - medication adherence; questions,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
1392,NCT01873066,The proportion of time spent in the target glucose range from 3.9 to 10.0 mmol/l based on CGM,"The proportion of time with glucose levels in significant hyperglycaemia, as based on CGM (glucose levels > 16.7 mmol/l)",Utility evaluation,2014-08-28,COMPLETED,INTERVENTIONAL,['NA']
1393,NCT06077162,Hemoglobin A1c,Dietary intake - 24 hour recall,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1394,NCT03686657,Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients,Change from baseline in Adiponectin,,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1395,NCT00542009,Body weight,"Change in following parameters: Post-prandial and fasting glucose, and insulin",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1396,NCT01868542,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline.,Incidence of Adverse Events,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1397,NCT05531838,Incidence of diabetes,HbA1c increased by 0.5%,,2022-10-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1398,NCT04613076,Depression change,Proportion of participants with change in glycosylated hemoglobin,Utilization of health care services,2019-09-03,COMPLETED,INTERVENTIONAL,['NA']
1399,NCT02261194,Change in depressive symptoms,Change in life space,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1400,NCT02805283,Condition-specific treatment satisfaction,Self-reported body weight,,2016-06-22,COMPLETED,OBSERVATIONAL,['NA']
1401,NCT00069836,Change from baseline in HbA1c,"Insulin dose, FPG,glycaemic responders, beta-cell function, hypoglycaemia, treatment satisfaction",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1402,NCT00556114,Medical exam tool,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
1403,NCT01105923,Intervention acceptance,Quality improvement based on problem list accuracy/completion,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
1404,NCT05318183,Change in fasting plasma glucose,Intestinal whole wheat phytochemical: phenolic compounds,Gut microbiota relative abundance,2022-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1405,NCT05971940,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Scores,,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE3']
1406,NCT04643873,Muscle mass amounts in the trunk and extremities,6 minutes walk test,,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA']
1407,NCT00743756,Weight Loss in the elderly african american population,Endothelial Function (assessed by pulse-wave analysis); sympathetic activity; insulin sensitivity,,2006-04,TERMINATED,INTERVENTIONAL,['NA']
1408,NCT01086137,Salivary Biomarker Levels,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1409,NCT05788341,Positive Islet Autoantibodies,,,2023-05-30,RECRUITING,OBSERVATIONAL,['NA']
1410,NCT00701090,Change From Baseline in HbA1c at Week 30,Percent of Patients With A1C <6.5% at Week 30,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1411,NCT03965013,Number of treatment-emergent adverse events,Maximum observed serum NNC0268-0965 concentration after a single dose,,2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1412,NCT02713841,Bioavailability,,,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1413,NCT04763525,Glycosylated haemoglobin,Intracellular water,,2018-10-04,COMPLETED,INTERVENTIONAL,['NA']
1414,NCT01257087,Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6%,Number of Participants With Microvascular Events,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1415,NCT06124547,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2023-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1416,NCT05076955,Healing Rate,Wound Closure,,2021-03-31,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1417,NCT01117350,Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period,Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1418,NCT02810691,Plasma glucose area under the curve,Post-meal peak plasma glucose,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1419,NCT00634842,Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7%,"Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1420,NCT01051011,Glycemic control assessed by HbA1c,"Meal tolerance test (in a subset of patients): Glucose, insulin, C-peptide, glucagon values",,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
1421,NCT00972283,Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1422,NCT05335629,Effect on ST2 (suppression of tumerogenicity 2) level in the acute phase after myocardial infarction,Echocardiographic changes due to intervention,,2022-06-01,COMPLETED,INTERVENTIONAL,['NA']
1423,NCT00821977,Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.,Measure: To evaluate the body weight change from baseline with vildagliptin compared to placebo after 24 weeks of treatment as monotherapy in patients with T2DM,,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1424,NCT00502515,Rate of epidermal nerve fiber regeneration,"Safety: physical examination, clinical laboratories, adverse event reporting",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1425,NCT06169982,Pharmacokinetics (PK): Area under the concentration curve during one dosing interval at steady state (AUCss) of LY3209590,"PK: Total amount of glucose infused during one dosing interval at steady state (Gtot,SS) of LY3209590",,2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
1426,NCT00103935,"Assess the safety, tolerability, and pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC) injection in subjects with type 2 diabetes (T2DM)",Change in seven-point glucose concentrations from Baseline to Week 14 and Week 15,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1427,NCT01057693,Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase,Patient Global Evaluation of Study Medication (GESM) (Double-Blind Phase),,2010-03-31,COMPLETED,INTERVENTIONAL,['PHASE3']
1428,NCT04724967,Number of Participants at Each Dry Skin Scale,,,2021-03-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1429,NCT01564719,Metabolic Syndrome,Stress,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1430,NCT03443180,Change in the plasma-induced transcriptional assay,Leukocyte analyses,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
1431,NCT05791942,MyChart letter opened,Completion rate of one screening/test,,2023-03-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1432,NCT04375020,gaba improve c peptide levels,,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA']
1433,NCT01173926,Area under the glucose infusion rate curve,Area under the serum insulin aspart concentration-time curve,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1434,NCT01841398,Effectiveness of a 12 Month Culturally-Specific Multi-media Intervention on Heart Health Risk,Change in Hypertension Status,,2012-06,UNKNOWN,INTERVENTIONAL,['NA']
1435,NCT03620357,HbA1c,,,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
1436,NCT06079008,The proportion of cardiac valve calcification between survival group and mortality group,,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
1437,NCT01948037,Change from the intensity of numbness and cold feeling at 4 weeks. Change from the improvement of the pain index at 4 weeks.,Change from ankle-brachial index at 4 weeks,Change from flow velocity values at 4 weeks,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
1438,NCT03530579,Change in hip-to-waist ratio measurements,,,2014-02-13,COMPLETED,INTERVENTIONAL,['NA']
1439,NCT04323462,Wound Healing,time to ulcer healing,amputation,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1440,NCT02276950,All-cause mortality,Composite,,2011-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1441,NCT02278939,Count of Participants Who Completed the Study,Change in Body Mass Index (BMI),,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1442,NCT00308451,Primary(baseline versus final): AUCg as recorded from a 2-hour OGTT with 75 g glucose beverage; fructosamine; fasting plasma glucose.,"Secondary (baseline versus final): Lipid panels (Total-C, HDL, LDL, VLDL), lipid ratios , apolipoprotein A and B.",,2003-11,COMPLETED,INTERVENTIONAL,['NA']
1443,NCT00241904,HbA1c,Patients' Satisfaction With Care and Health Care Utilization,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1444,NCT05103306,Changes in HbA1c From Baseline to months 36,Percentage of patients with at least 1 episode of genitourinary tract infections,,2017-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1445,NCT01970241,Mean POC Glucose Level Between Groups,Episodes of Hypoglycemia Between NPH and Control Groups,Correlation of C-peptide With Length of Stay,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1446,NCT03804970,Proportion of scheduled eye care visits attended over 1 year,Visual acuity in the better seeing eye.,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA']
1447,NCT04117022,Full-field flicker ERG (ffERG) Measurements: magnitude (microvolts) and the phase (milliseconds) and the area ratio for magnitude and the area ratio for Phase,Optical coherence tomography angiography (OCTA): radial macular and optic nerve capillary density (number/square millimeter),,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
1448,NCT03719911,Change in Hemoglobin A1c,,,2018-08-05,COMPLETED,INTERVENTIONAL,['NA']
1449,NCT03495349,"Occurrence of adverse effects in patients treated by antibiotherapy for diabetic foot infection, assessed by clinical or biological methods",,,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
1450,NCT02256332,Post prandial blood glucose positive incremental area under the curve,Post prandial insulin area under the curve,Intestinal discomfort,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1451,NCT00657943,Carotid intima media thickness,adverse events,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1452,NCT03445702,Lactate to pyruvate ratio,Genomic testing,,2018-10-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1453,NCT06200532,Ease of use scores,,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1454,NCT03739034,high density lipoprotein cholesterol,full plate,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
1455,NCT01117831,Lipids goal achievement,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1456,NCT01455142,Maximum observed serum insulin aspart concentration,Maximum glucose infusion rate,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1457,NCT00633997,"Skin concentration of vildagliptin and its two metabolites, LAY151 and LAF237-O-Glucuronide, compared to the plasma concentration on Day 10","10 day's treatment with vildagliptin 50 mg orally twice daily on hematology, blood chemistry and physical exams in healthy volunteers and patients with type 2 diabetes",,2008-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1458,NCT01482247,Functional transcranial doppler measures,Finger Blood Flow - Plethysmography (PAT),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1459,NCT05365438,Volume of carotid artery plaque,Changes of gut microbiota,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
1460,NCT04529889,Change of obesity status during childhood and adolescence,Change of type 2 diabetes during childhood and adolescence,,2012-02-01,RECRUITING,OBSERVATIONAL,['NA']
1461,NCT02061124,Incremental and total area under the Concentration-Time Curve (AUC 0-240 min),Incremental and total area under the Concentration-Time Curve (AUC 0-240 min),Visual analog scale score,2014-02,COMPLETED,INTERVENTIONAL,['NA']
1462,NCT05271045,serum HbA1c (mg/dL),TAC (mg/dL),,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
1463,NCT06152536,Physiopathology of glucose after two different meals,Physiopathology of insulin after two different meals,,2022-06-09,RECRUITING,INTERVENTIONAL,['NA']
1464,NCT04391088,number of diabetic patients up to date with their mandatory and recommended vaccinations,number of patients vaccinated during hospitalization,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
1465,NCT06334133,Change in incidence of Level 2 or Level 3 hypoglycemia,To assess the incidence of adverse events,11-item/Short Form Hypoglycemia Fear Scale,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1466,NCT01358981,Number of Participants With Clinically Significant Adverse Effects,C-Peptide Area Under the Effective Concentration Curve (AUEC),,2011-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
1467,NCT05338567,Validation of the accuracy of the predicted length of the small intestine,Building prediction formulas through machine deep learning,,2019-10-02,RECRUITING,OBSERVATIONAL,['NA']
1468,NCT05019508,We will assess the predictive ability of fetal Cardiac Function Parameter for diagnosis of Gestational Diabetes Mellitus by oral glucose tolerance tests,Secondary neonatal outcomes,,2021-08-13,UNKNOWN,OBSERVATIONAL,['NA']
1469,NCT01236365,Hs-CRP Levels Assessed at Randomization and 6 Months,Descending Aortic Strain,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1470,NCT03743779,weight,adherence,,2018-09-09,COMPLETED,OBSERVATIONAL,['NA']
1471,NCT01092806,The primary objective is to compare insulin secretion (Secr2.phase) between the two different formulations of Tac.,insulin sensitivity,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1472,NCT06322212,Assess anxiety in T2DM adults with thiamine treatment.,,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1473,NCT06123871,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1474,NCT02432586,Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 2,Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 2,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1475,NCT05873049,Artificial dermis (AD) or split-thickness skin graft (STSG) take rate,Vancouver scar score on 180 days,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1476,NCT02324842,Fasting Plasma Glucose (FPG) at 4 Months,Body Mass Index (BMI) at 4 Months,Change in 24-hour Blood Pressure at Study End Compared to Baseline.,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1477,NCT03830216,CGM time in range,Change in patient reported outcomes - HCS,Number of insulin dose administrations,2019-05-30,TERMINATED,INTERVENTIONAL,['NA']
1478,NCT04789993,Type of additional autoimmune diseases at type 1 diabetes diagnosis,Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto,,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA']
1479,NCT02752412,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-17,COMPLETED,INTERVENTIONAL,['PHASE3']
1480,NCT01867970,Physical activity,Physical activity in daily life,Health status,2013-04,COMPLETED,INTERVENTIONAL,['NA']
1481,NCT05602532,TyG index in type 2diaberes Mellitus,,,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1482,NCT01538485,Increase of regulatory FOXP3+ T cells,serum calcium level,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1483,NCT05639478,Change From Baseline of the Foot and Ankle range of motion at 12-week,Implementation at 12 weeks,,2023-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1484,NCT05435677,"Dose-normalised AUCSema,0-tz: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose",Adverse events,,2022-06-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1485,NCT03761251,Hemoglobin A1c,,,2018-10-31,COMPLETED,INTERVENTIONAL,['NA']
1486,NCT04738591,Glycated Hemoglobin (HbA1C),Retention rate,International Physical Activity Questionnaire (IPAQ),2020-12-30,COMPLETED,INTERVENTIONAL,['NA']
1487,NCT02064348,"QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points","QTcI, based on ECG (electrocardiogram) recordings obtained at 2 out of 8 time points",,2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1']
1488,NCT01557296,Metabolic Control - HbA1c,"gastrointestinal symptoms - Questionnaire: Patient Assessment of upper Gastrointestinal Disorders Symptoms, Gastrointestinal Symptom Rating Scale",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1489,NCT00285909,PPAR-gamma activated gene expression,Postprandial changes of HPA-axis activity,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1490,NCT00534105,Cholesterol,LDL,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
1491,NCT05099367,Exploring PGI2 pathway in skin microvascular reactivity,role of PGI2 pathway on cell migration in vitro,,2021-10-01,RECRUITING,INTERVENTIONAL,['NA']
1492,NCT05129735,Improvement of quality of life score from baseline to 12-weeks,Improvement in LDL cholesterol levels from baseline to 12-weeks,,2022-09-15,UNKNOWN,INTERVENTIONAL,['NA']
1493,NCT00322621,Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint,Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1494,NCT04509362,TIR (70-180 mg/dl,Diabetic Ketoacidosis,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
1495,NCT00478595,Relative change from baseline in in body weight,Safety: overview of adverse events,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
1496,NCT03034798,Blood glucose concentrations,Participants estimated blood glucose concentration,,2015-01-14,COMPLETED,OBSERVATIONAL,['NA']
1497,NCT00969007,5% weight loss,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1498,NCT02807974,Change from baseline in sitting systolic and diastolic blood pressure,Time course of urine-albumin-to-creatinine ratio,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1499,NCT03211195,Assessment of PK parameter: AUC,Treatment emergent adverse events (TEAE),,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1500,NCT05431140,Diabetes Treatment Satisfaction Questionnaire (DTSQc),Time spent by the HCP,,2022-06-20,RECRUITING,OBSERVATIONAL,['NA']
1501,NCT01432938,Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin,Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1502,NCT03678896,Change from baseline in hemoglobin A1c levels at 6 months,Change from baseline in self-reported health,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
1503,NCT00797615,The primary outcome measure will be the between-group differences in BMI and body fat.,Secondary outcomes will include dietary intake and physical activity.,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1504,NCT05576298,Area under the glucose infusion rate curve from administration to end of clamp from time zero to 24 hours,Maximum glucose infusion rate,,2021-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1505,NCT01421966,Proportion of patients with complete healing/closure of their target ulcer at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up.,Proportion of patients whose Target Ulcer completely closed during the core double blind treatment phase and remained closed at the FU12 follow-up visit.,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1506,NCT00592332,Catecholamine levels,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
1507,NCT06165159,The primary outcome corresponds to the score obtained after completing the study questionnaire. The questionnaire is completed at the participation agreement.,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1508,NCT06085703,Change of olfactory brain activation by fMRI,Change of metabolism,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1509,NCT04306289,Changes in Pain severity,Changes in Neuropathic Pain Symptom,,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA']
1510,NCT06203002,Change from Baseline to Week 8 in Average Daily Pain Score (ADPS),Change from Baseline to Week 8 in Total Neuropathic Pain Symptom Inventory (NPSI) Score,,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1511,NCT02709915,Insulin Dose,Clock Gene mRNA expression,Body Weight,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1512,NCT03821675,Change in Wound Size in Response to Electrical Stimulation Therapy,Change in Tissue Oxygen Saturation in Response to Electrical Stimulation,Change From Baseline in Skin Perfusion in Response to Electrical Stimulation,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
1513,NCT05992974,Number of participants with gestational diabetes,,,2023-08-31,RECRUITING,OBSERVATIONAL,['NA']
1514,NCT00635492,Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months.,Percentage of Patients Hospitalized Between Baseline and 24 Months,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
1515,NCT02515461,Changes in glomerulus basal lamina assessed using transmission electron microscopy.,Protein concentration in urine,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
1516,NCT01610518,postprandial blood glucose,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
1517,NCT01535495,Area of retinal neovascularization on fundus photography,Early Treatment Diabetic Retinopathy Study visual acuity in study and fellow eye,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1518,NCT00129233,"Composite cardiovascular events including fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, admission due to heart failure, coronary intervention and sudden cardiac death",renal function,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1519,NCT00947726,Decrease transepidermal water loss and foot dryness in study subjects.,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
1520,NCT02465411,HbA1c in venous sample,Number of self-reported severe hypoglycaemic events per year,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
1521,NCT05683392,Number of other serious device-related adverse events,Number of interventions for study meal challenges,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1522,NCT04144374,Omadacycline Tissue Penetration.,Omadacycline Area Under the Curve (AUC) in Tissue,,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1523,NCT01951729,Insulin secretion rates during each treatment.,Plasma pancreatic polypeptide levels during each treatment.,Plasma xenin-25 levels during each treatment.,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1524,NCT04654676,"Changes in mean amplitude of glycemic excursions in mmol/L, Standard deviation of the mean glucose levels in mmol/L, M value in mmol/L, Mean absolute glucose in mmol/L, Continuous overlapping net glycemic action in mmol/L, Lability index in mmol/L","Area under curve above 10.0mmol/day, area under curve below 3.9mmol/day",,2018-09-15,COMPLETED,INTERVENTIONAL,['PHASE4']
1525,NCT03039933,Decrease in scores on the Hypoglycemia Fear Survey,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1526,NCT03508739,Intact glucagon like peptide-1 (GLP-1) levels after the mixed meal,"Neprilysin enzyme (drug) activity at baseline, during sacubitril/valsartan, and during valsartan",,2018-06-01,SUSPENDED,INTERVENTIONAL,['PHASE3']
1527,NCT06230276,Difference in an area under the curve of a glucose concentration change 4 hours after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems.,Difference in CGM parameters after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems using insulin aspart.,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
1528,NCT05368220,Impact on clinical decision-making and clinical trajectories,,,2022-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1529,NCT00925080,"IVBG System accuracy will primarily be assessed relative to ISO 15197 criteria (i.e., within ±15 mg/dL at YSI glucose levels < 75 mg/dL, and within ±20% at YSI glucose levels >75 mg/dL).",,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
1530,NCT05072353,Healing,amount of adipose stem cells used for grafting,,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1531,NCT00706693,To determine if sucrose and fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.,To determine preferred mode of treatment for hypoglycemia after completing the study.,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1532,NCT02998944,Obesty,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
1533,NCT06105931,Change in triglycerides from baseline to 1 year,,,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE1']
1534,NCT01634464,"Long-term evidence of early human programming of obesity measured biochemical perinatal biomarkers, and the offspring growth and development.",,,2007-03,UNKNOWN,OBSERVATIONAL,['NA']
1535,NCT01725815,Health Related Quality of Life (HRQOL),Medication Adherence,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1536,NCT03323294,Fatty Acid Oxidation in Type 2 Diabetes with metformin,,,2017-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1537,NCT00145925,Composite of new or substantially worsening nephropathy or microvascular eye disease.,"Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1538,NCT05087225,measurement of blood glucose one month after first or second shot of mRNA based covid-19 vaccines,enhancements of hypoglycemic effects of metformin and insulin by PEG,,2021-11-11,UNKNOWN,OBSERVATIONAL,['NA']
1539,NCT03815487,Reduction of Sensor Glucose,,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
1540,NCT05893797,Difference in the Average Number of Missed Bolus Doses (MBDs),Change from Baseline (Run in Week 0) in Health Care Provider (HCP) Questionnaires,,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
1541,NCT00138541,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1542,NCT05081011,Attitudes Toward Medication Adherence,Glycemic Improvement,,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
1543,NCT01149421,Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP),Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1544,NCT01752803,Hb A1c,inflammatory markers,Lipoproteins,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
1545,NCT01392560,Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1546,NCT03387826,Platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods,"VerifyNow P2Y12 assay % inhibition, using the TRAP-induced response at the end of the 2 study periods",,2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1547,NCT02061488,"Assessment of time spent in target range (glycemia between 70 and 145 mg/dl) and in hypoglycemia (glycemia <70 mg/dl), during the night (11 PM to 8 AM)",Assessment of glucose values during the night (glycemia and interstitial glucose values),,2014-03,COMPLETED,INTERVENTIONAL,['NA']
1548,NCT01811849,Time to 1/2 maximal insulin concentration,AUC 0-30 and AUC 0-60,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1549,NCT00736515,"Decreasing value of FPG and HbA1c, dosage of insulin and control rate of FPG",Weight change,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1550,NCT01909687,Analysis of system accuracy,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1551,NCT05139784,To define the frequency and phenotype of autoimmune T lymphocytes reactive to islet antigens in the different study groups.,To define the differences between lymphocytes in the blood and those in pancreatic lymph nodes.,,2022-10-24,RECRUITING,OBSERVATIONAL,['NA']
1552,NCT03560271,Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24,Proportion of subjects with decrease in HbA1c of ≥ 1.0% from Baseline at Week 24,,2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1553,NCT04163757,type 2 diabetes,,,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
1554,NCT03851848,Talocrural joint dorsiflexion ROM will be measured using a universal goniometer,Foot plantar pressure distribution (FPP) will be measured using Platform Pedography system,,2019-03-03,UNKNOWN,INTERVENTIONAL,['NA']
1555,NCT03654313,Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6570,Immunogenicity rate,,2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE1']
1556,NCT05882071,"Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)",Time from drug initiation to death all cause,,2023-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1557,NCT02587780,Blood glucose response,Body fat percentage,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
1558,NCT00960882,DMMET-01 Plasmatic concentration,glycated hemoglobin,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1559,NCT02549495,Systolic blood pressure,Disease control,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
1560,NCT01334229,Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period,Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1561,NCT00693511,Insulin sensitivity,Change in visceral abdominal adipose tissue,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
1562,NCT05762653,Degree of impairment of exocrine pancreatic function,Factors associated with pancreatic fibrosis,,2022-02-03,RECRUITING,OBSERVATIONAL,['NA']
1563,NCT01365091,"AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets",Number of Participants With Death as Outcome and Serious Adverse Events (SAEs),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1564,NCT03730610,Effects of exercise training - brain inflammation,Effects of exercise training - ectopic fat,,2019-01-30,COMPLETED,INTERVENTIONAL,['NA']
1565,NCT00976937,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1566,NCT05878444,Presence of our bacteria in feces,Adverse effect,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1567,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
1568,NCT01316484,"Qualitative, Content Analysis of Cognitive Debriefing Data",,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
1569,NCT04691219,Effect on glycated hemoglobin (A1C) (efficacy),Self-reported adverse events (safety),,2019-05-26,COMPLETED,INTERVENTIONAL,['NA']
1570,NCT01025557,Food intake,Blood glucose,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1571,NCT06120881,Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM),Co-efficient of variation of glucose,,2024-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1572,NCT02716519,Target Ulcer Complications,"During the post-acute phase, weekly surgical procedures for target ulcer treatment",,2016-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1573,NCT04291391,Differences between groups in circulating C-reactive protein (CRP) at Week 4,Change from Baseline in Phospholipids Classes Quantifications in Red Blood Cells at Week 4 and Differences Between Groups at Baseline and Week 4.,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
1574,NCT02421393,Effect of intervention on bone quality (trabecular bone score),Effect of intervention on fracture incidence (history or medical records and vertebral morphometry),Effect of intervention on coronary heart disease 10-year risk,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
1575,NCT02750111,Blood Glucose,,,2016-05,UNKNOWN,OBSERVATIONAL,['NA']
1576,NCT05774015,Fasting Blood Glucose (FBG),Serum creatinine,,2023-09-25,RECRUITING,INTERVENTIONAL,['NA']
1577,NCT01038895,Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.,"Average night, systolic and diastolic blood pressure",,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
1578,NCT01095653,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1579,NCT03970031,"Change in the weighted average of standardized AST, CK-18, and HbA1c values (standard deviations) from baseline to Week 26","Time to first event of death or adjudicated non-fatal MI or USA hospitalization, adjudicated hospital admission for HF, adjudicated nonfatal ischemic stroke, or liver event in all randomized subjects.",,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1580,NCT00442988,,,,2000-10,COMPLETED,OBSERVATIONAL,['NA']
1581,NCT00414999,"Part B: Safety & tolerability of 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 14 days, assessed up to 7-14 days following dosing.",Systemic pharmacokinetics (Part B only),,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1582,NCT01472432,Capillary Density,iNOS,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1583,NCT04634500,Change from baseline in HbA1c,,,2020-11-18,COMPLETED,INTERVENTIONAL,['PHASE3']
1584,NCT02672280,Percentage of wound closure as determined,Percentage area of re-grafting as determined,,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1585,NCT06254014,HbA1c,blood pressure,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1586,NCT01887431,Change in Glycosylated Hemoglobin (Hba1c),Patients' satisfaction,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
1587,NCT01408888,Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1588,NCT03029351,change from baseline in albuminuria levels,Change in Nrf-2/keap-1,,2017-01-10,TERMINATED,INTERVENTIONAL,['PHASE4']
1589,NCT01650129,Glycosylated haemoglobin A1c (HbA1c),Insulin doses,,2000-12-13,COMPLETED,INTERVENTIONAL,['PHASE3']
1590,NCT05057065,Efficacy of NAs therapy,Incidence of liver fibrosis and cirrhosis,,2021-09-15,UNKNOWN,OBSERVATIONAL,['NA']
1591,NCT04105348,effect of IBD on DM,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1592,NCT02523222,Treatment failure of at-risk infants,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1593,NCT02589639,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.,Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs),,2015-10-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1594,NCT01251510,GLP-1 secretion,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
1595,NCT03485092,left ventricular global longitudinal strain (GLS),Intensification of diuretic therapy,DNA and epigenetics,2018-03-16,COMPLETED,INTERVENTIONAL,['PHASE4']
1596,NCT00823940,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F","Pharmacodynamic parameters may include change from baseline in glucose, insulin, C-peptide and AUC following administration of IV glucagon in a standardized GC test with and without prior administration of GSK1362885",,2009-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1597,NCT02942069,Blood glucose response measured with CGM,,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
1598,NCT05546138,Progression and regression of neuropathy,Correlation between central and peripheral measurements,fMRI as a marker for progression of neuropathy,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1599,NCT00740519,Incidence of serious adverse drug reactions including major hypoglycaemic events,HCP time used on titration training,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
1600,NCT00308386,"% of patients at goal for all three parameters (HbA1C <7, BP <130/80, LDL <100)",Physician satisfaction - survey filled out by physician,,2006-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1601,NCT05516966,Incidence of Adverse Events (Safety and Tolerability),Immunogenicity: anti-HRS9531 antibody,,2022-10-12,RECRUITING,INTERVENTIONAL,['PHASE1']
1602,NCT00306436,composite criteria reflecting a good glycemic and arterial pressure status. Success defined by all measurements of HbA1c < 6.5% and of systolic (diastolic) pressure <=135 (85) mmHg if proteinuria is < 1g/24h or <= 125 (75) if proteinuria is => 1g/24h,,,2006-05,UNKNOWN,INTERVENTIONAL,['NA']
1603,NCT04894903,Number of Diabetes Care Gaps at 12 months,Reported Services Completed Outside Vanderbilt System,,2022-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1604,NCT04383015,Time in glucose target range during exercise intervention,Recovery Interstitial Glucose,,2018-10-31,COMPLETED,INTERVENTIONAL,['NA']
1605,NCT01427699,Safety and Tolerability,Preliminary Efficacy,,2011-06-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1606,NCT04001231,Ctrough,The presence and titer of anti-exenatide antibodies,HbA1c,2020-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1607,NCT04556760,Change in glucose AUC(0-4) versus baseline compared to prednisolone following a standardised MMTT,Safety and tolerability of AZD9567 by assessing the number of participants with adverse events,,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE2']
1608,NCT03968354,Measure of RANKL mRNA expression in the liver,NF-kB pathway in hepatocytes and Kupffer cells,,2020-02,UNKNOWN,OBSERVATIONAL,['NA']
1609,NCT00784966,The functional capability of the islet allograft to normalize glucose metabolism in the absence of insulin therapy.,Reduction in insulin requirements in those patients who do not achieve insulin independence with improved metabolic control.,,2011-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1610,NCT04055480,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM).,"Total, basal and bolus insulin dose",Utility evaluation is the frequency and duration of use of the closed-loop system at home.,2019-08-10,COMPLETED,INTERVENTIONAL,['NA']
1611,NCT02130180,Mean Optic Nerve Sheath Diameter,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
1612,NCT02302599,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D,safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1613,NCT02298556,Absolute change in systolic blood pressure,Blood pressure variability (daily or hourly) in home blood pressure measurement,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1614,NCT02745613,Insulin sensitivity,Myokine concentrations,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
1615,NCT01801631,Change in Diabetes related distress,Change in Biomedical variables,Change in Spousal support,2011-10,COMPLETED,INTERVENTIONAL,['NA']
1616,NCT01115205,Change in haemoglobin A1c (HbA1c) levels,Compliance with walking sessions,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1617,NCT02801448,Delta-HbA1c,Delta-fasting blood glucose,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1618,NCT03213093,the rate of incidence of diabetic foot ulcer,Neurovascular response to pressure,,2017-12-01,RECRUITING,INTERVENTIONAL,['NA']
1619,NCT03848533,Nuclear anomalies frequency,Serum Lactate,Treatment attachment,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
1620,NCT01959984,The c-peptide level.,"The plasma glucose, insulin, c-peptide and relevant incretin hormones level during ""75g Oral Glucose Tolerance Test"", ""100g Standard Noodles Tolerance Test"" and ""100g Steamed Bread Tolerance Test"".",Safety,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
1621,NCT05654805,change in insulin resistance (Matsuda),change in IGF-1 and its binding proteins,change in faecal excretion of BCAA metabolites,2022-12-15,RECRUITING,INTERVENTIONAL,['NA']
1622,NCT02510664,Acceptability: Number of Participants That Felt the Intervention Was Well-Received,"Provider-family Relationship, Provider-report",,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1623,NCT01289587,Aerobic fitness,Adherence/Attendance: Number of physical activity sessions attended,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
1624,NCT00933998,Epidermal Nerve Density Count,,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
1625,NCT01374854,c-peptide area under the curve during OGTT,insulin area under the curve during OGTT,,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1626,NCT02314533,urinary albumin to creatinine ratio (mg/g),,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1627,NCT00208221,Microalbuminuria,systolic blood pressure,,2006-08,TERMINATED,INTERVENTIONAL,['PHASE3']
1628,NCT02029924,Area under the curve (AUC),"Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1629,NCT04285983,Percentage of Participants who had One or More Adverse Reactions,,,2020-03-01,COMPLETED,OBSERVATIONAL,['NA']
1630,NCT05574231,Effect on medical diseases,,,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1631,NCT05448105,User Experience - Acceptance,Change in Diabetes Readiness for Change,,2022-12-22,COMPLETED,INTERVENTIONAL,['NA']
1632,NCT02195856,Hepatic perfusion,Plasma incretin concentration,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1633,NCT03190798,Change in Pulmonary capillary wedge pressure (PCWP),Change in Pulmonary capillary wedge pressure (PCWP),,2017-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1634,NCT00790205,Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population),Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population),,2008-12-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1635,NCT02926079,Metabolic flexibility - Mother,Oxygen consumption rates in umbilical cord mesenchymal stem cells,,2017-05-23,COMPLETED,OBSERVATIONAL,['NA']
1636,NCT03742440,Number of Participants With Complete Closure of the Index Ulcer,Total Adverse Events,,2018-11-20,COMPLETED,INTERVENTIONAL,['PHASE4']
1637,NCT03593746,Glycemic control,Other Biochemical Analyzes,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
1638,NCT02466217,Immune cells phenotyping expressed as the each cell type % within total PBMCs,Characterization specific and common variations in immune cells frequencies between patients - between Disease cohorts,,2015-07-29,COMPLETED,OBSERVATIONAL,['NA']
1639,NCT01083212,PK of AZD1656 when administered with placebo or following repeated dosing of gemfibrozil by assessment of AUC and Cmax.,"Safety of AZD1656 when administered with placebo or following repeated dosing of gemfibrozil by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables including 24-h plasma glucose, physical examination and adverse events",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1640,NCT02252965,Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period,Percentage of Subjects Who Are Compliant to Treatment,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1641,NCT00252018,Improvement of endothelial function as measured by FMD,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
1642,NCT02621489,The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT).,"Gene expression (Affymetrix) e.g., transcription factors of sirtuins (SIRT) and nitric oxide synthase (NOS)",,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1643,NCT06288269,1 year survival death,,,2023-11-01,COMPLETED,OBSERVATIONAL,['NA']
1644,NCT02150109,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
1645,NCT06277258,Number of Participants with adequate glycaemic control,Maternal satisfaction,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
1646,NCT01604213,Reduction in serum levels of Interleukin 6 (IL-6),Improvement in other markers of athero-thrombosis and inflammation:,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1647,NCT06069518,Average glucose concentration detected in 24-hour periods.,Magnitude and duration of periods1s of hiccups (<70 mg/dl) and hyperglycemia (>180 mg/dl) recorded in 24-hour periods.,,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1648,NCT01856790,Peak Post-prandial Venous Glucose Levels,the Incremental Meal-related Glucose Area Under Curve (AUC),Mean Nocturnal Glucose Levels,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1649,NCT06132204,PK parameters of HRS-7535: AUC0-inf,Adverse events,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1650,NCT00945711,define general characteristics of the diabetes and eating disorder population,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1651,NCT01294436,Mean Change in Seated Systolic Blood Pressure,,Mean Change in Body Weight,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1652,NCT03607604,Urinary C-peptide Creatinine Ratio (UCPCR),Prevalence of MODY,,2015-04-01,UNKNOWN,OBSERVATIONAL,['NA']
1653,NCT04932928,Change in HbA1c,Change in the Korean Version of Revised Summary of Diabetes Self-Care Activities Questionnaire (SDSCA-K) survey score,Change in CGM glucose variability,2021-03-23,RECRUITING,INTERVENTIONAL,['NA']
1654,NCT05620576,Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change from Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L),,2022-11-14,COMPLETED,INTERVENTIONAL,['PHASE2']
1655,NCT02358096,Mean change of log transformed urinary albumin to creatinine ratio (UACR) from baseline to end of treatment,Proportion of subjects with either >30% or >40% or >50% reduction in AER from baseline to end of treatment,,2015-03-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1656,NCT04646473,HbA1c,Problem solving,,2021-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1657,NCT00787605,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP),Evaluate the Safety and Tolerability,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1658,NCT02188186,Change of HbA1c,Lipid profile,Body composition,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1659,NCT02573662,Change in insulin sensitivity,Change in insulin sensitivity,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
1660,NCT03135015,Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours,ISSI-2 Index of Beta-cell Function,Effect of Capsules vs. Tablets,2017-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
1661,NCT03726008,Changes of biological indicator,Basic information of maternal,,2018-01-22,TERMINATED,INTERVENTIONAL,['NA']
1662,NCT01339208,Change in HbA1c % from baseline,Patient satisfaction,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1663,NCT05917132,Fasting and postprandial lipid metabolite production in response to dietary lipid intervention in abdominal obesity and type 2 diabetes,Gut microbiota in response to a 2 day dietary lipid intervention in abdominal obesity and type 2 diabetes,,2023-06-12,RECRUITING,INTERVENTIONAL,['NA']
1664,NCT00376181,Change from Baseline in Glycosylated Hemoglobin.,Change from Baseline in Systolic Blood Pressure,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
1665,NCT01671345,Patients Active Participatory Communication Behaviors,Hemoglobin A1c,,2013-11-27,COMPLETED,INTERVENTIONAL,['NA']
1666,NCT00927524,Insulin levels,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
1667,NCT06199440,Primary Outcome,Secondary Outcome,,2022-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1668,NCT05759637,Hidden Hypercortisolism prevalence in a sample of Obese patients,,,2022-05-06,RECRUITING,OBSERVATIONAL,['NA']
1669,NCT02917928,Change in Oral Glucose Tolerance Test,Change in general cognitive function,Change in body composition,2016-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1670,NCT02650726,anti-inflammatory ability of HDL,endothelium-dependent flow-mediated dilatation (FMD),,2014-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1671,NCT03525769,Death,Hepatocellular carcinom,Chronic kidney disease,2018-05-05,RECRUITING,OBSERVATIONAL,['NA']
1672,NCT03109951,Abnormal Glucose Levels After Colonoscopic Preparation,Number of Participants With Self-treatment and Relief of Hypoglycemic Symptoms,,2017-03-25,COMPLETED,INTERVENTIONAL,['NA']
1673,NCT02040025,Change from baseline in TCOM (Transcutaneous oximetry measurement) values,Change from baseline in hemoglobin A1C laboratory values,,2014-04,TERMINATED,OBSERVATIONAL,['NA']
1674,NCT06054841,Two hour glucose tolerance test,Primary care,,2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
1675,NCT04932356,HbA1c Result,patient motivation,,2021-05-10,RECRUITING,INTERVENTIONAL,['NA']
1676,NCT01270061,HIV testing rate,Linkage to care,,2012-04,WITHDRAWN,INTERVENTIONAL,['NA']
1677,NCT00911482,Spillover of free fatty acids from chylomicrons,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
1678,NCT00241605,Change from baseline in HbA1c at week 48.,Change from baseline in FPG at week 48. Time to glycemic control. Change from baseline in C-peptide and insulin at week 48.,,2003-06-25,COMPLETED,INTERVENTIONAL,['PHASE4']
1679,NCT03700645,hs-CRP,Diastolic function,,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1680,NCT02000700,Plasma concentrations of canagliflozin following multiple oral doses of canagliflozin,Number of participants with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1681,NCT05441072,Ptosis,,,2022-12-19,RECRUITING,OBSERVATIONAL,['NA']
1682,NCT05354518,Simulation Design Scale,Semi-Structured Focus Group Training Activity Evaluation Form,,2022-04-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1683,NCT00557518,Change from baseline in albumin excretion rate (µg/min),"Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations",,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
1684,NCT03217409,Low density lipoprotein cholesterol (LDL-C) (%),Fibroblast Growth Factor 21,,2017-08-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1685,NCT02924064,The Changes in HbA1c at Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1686,NCT01967992,Hemoglobin A1c,Hemoglobin A1c,Body weight,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1687,NCT02134132,ABI,Quality of life,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1688,NCT02435693,Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded,Quality of Life score,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
1689,NCT05263310,Any incidence of hypoglycemia,Medication-Related Outcome: Aggregate measure of diabetes medication deprescribing,,2022-04-25,RECRUITING,INTERVENTIONAL,['NA']
1690,NCT00198913,weight,psychometrics,,2002-06,COMPLETED,INTERVENTIONAL,['NA']
1691,NCT04514523,Acceptability - Clinicians,Feasibility 3,,2020-04-28,COMPLETED,INTERVENTIONAL,['NA']
1692,NCT01675271,VO2max,mental health,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
1693,NCT01869933,Ocular Safety and Tolerability,Systemic Safety and Tolerability,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1694,NCT01004757,myocardial diastolic function,"triglycerides, insulin resistance",,2008-02,UNKNOWN,INTERVENTIONAL,['NA']
1695,NCT01997762,Change in beta cell function,Change in insulin sensitivity,change in plasma levels of resveratrol and resveratrol metabolites,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1696,NCT01244971,Glycemic control,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1697,NCT00660998,Sexual Encounter Profile Question 3,Safety and Tolerability,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1698,NCT01088165,The influence of adalimumab treatment in comparison to treatment with fumaric acid esters on the functional integrity of the endothelium will be monitored by flow mediated dilatation (FMD),Influence of adalimumab in comparison to fumaric acid esters on biochemical cardiovascular and metabolic risk factors,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1699,NCT00338104,Percentage of Blood Glucose Values Between 80 - 140,Percentage of Glucose Levels > 180 mg/dL,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1700,NCT03687840,Step Length,Symmetry Index,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
1701,NCT04657367,Plasma microRNAs,,,2020-02-03,RECRUITING,OBSERVATIONAL,['NA']
1702,NCT04581421,Liverfat,Insulin clearance determined during steady state insulin infusion,,2020-12-03,COMPLETED,INTERVENTIONAL,['NA']
1703,NCT05396079,Assessment of Flow-Mediated Dilatation,,,2023-03-28,COMPLETED,INTERVENTIONAL,['NA']
1704,NCT00841919,Pre and post- prandial glucose levels,High excursions of blood sugars (>300 mg/dl).,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1705,NCT02355145,Change in the frequency of usage by physicians of the main criteria for selecting the add-on therapy in patients with inadequately metformin-controlled type 2 diabetes,Number of years until starting the add-on therapies after diagnosis,,2015-04-02,COMPLETED,OBSERVATIONAL,['NA']
1706,NCT03993145,Adherence,Changes in HbA1c,Participant satisfaction,2020-02-07,COMPLETED,INTERVENTIONAL,['NA']
1707,NCT02984514,Activity of brown adipose tissue in correlation to exogenous insulin needs using the tracer 18F-deoxy glucose in positron emission tomography measurements,Glucose uptake in muscle in correlation to exogenous insulin needs; assessment using the tracer 18F deoxy glucose in positron emission tomography measurements.,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
1708,NCT00111631,Absolute change from baseline in HbAlc\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1709,NCT04253613,IL-10 level in GCF,,,2013-01-15,COMPLETED,OBSERVATIONAL,['NA']
1710,NCT05526157,Descriptive summary of patient comedications,Descriptive summary of temporal changes in the baseline characteristics of medication-specific cohorts,,2022-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1711,NCT03960255,Proportion (%) of patients with complete wound healing at 24 weeks,Proportion of patients who Die,,2021-02-20,RECRUITING,OBSERVATIONAL,['NA']
1712,NCT02457858,"Islet yield using BMX-010, compared to current standard islet isolation data",AE/SAE morbidity within 1 month post-transplant,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1713,NCT01538589,Adverse events,Total dose of insulin infused subcutaneously,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
1714,NCT01715818,"Time to first occurrence of any component of the composite event (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke) as adjudicated by the Clinical Events Committee (CEC)","Time to first occurrence of a composite with components as adjudicated by the CEC: all-cause mortality, non-fatal MI and non-fatal stroke (in each of the subgroups with or without evidence of T2D at baseline)",,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1715,NCT03187145,Number of patients with full stomach,the mean gastric emptying time of clear liquid and light meal,Correlation of diabetes mellitus complications with delayed stomach empty,2017-06-15,UNKNOWN,OBSERVATIONAL,['NA']
1716,NCT01269034,The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.,"Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1717,NCT05655117,The detection rate of macular oedema in the intervention group vs. control group.,The screening rate for macular odema,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1718,NCT05975528,Changes of Cellular senescence markers,Changes of body composition using Inbody (cm2),,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1719,NCT04949568,Glucose Variability data from continuous glucose monitor (CGM) will be downloaded directly from participants provided (blinded) FreeStyle Libre Pro,"Diabetes Distress Scale (DDS) (17-item), using Numerical Rating Scale: 0-6",,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1720,NCT02150707,Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio,Albumin:creatinine ratio,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
1721,NCT05422092,The activity of CEPT in pmol/mL/min,The activity of CEPT in pmol/mL/min,,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1722,NCT04534894,fluorescence characteristics of NAD(P)H in venous blood by FLIM can assist early diagnosis of diabetic cardiomyopathy,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1723,NCT02638246,Percentage of days conducted at least 4 tests per day.,Feasibility,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
1724,NCT05473325,Signal to Noise,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1725,NCT02546401,Area Under Curve (AUC) of glycemia,Area Under Curve (AUC) during 4H after a high-fat meal,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1726,NCT04266171,Change in HbA1c from baseline,Compliance/Satisfaction Questionnaire,,2020-01-16,UNKNOWN,INTERVENTIONAL,['NA']
1727,NCT00634608,health information experiences of the patient,clinician feedback on the health information prescription process,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
1728,NCT05058690,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when fasting blood sample test results are compared against FatHealth algorithm results,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when oral glucose tolerance test results are compared against FatHealth algorithm results,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1729,NCT05762120,Weight Loss,,,2023-02-03,RECRUITING,INTERVENTIONAL,['NA']
1730,NCT03604419,The change from baseline value of HbA1c will be compared between treatments,"The change from baseline value of Fasting Plasma Glucose at Weeks 2, 4, 8, and 12",,2018-06-13,COMPLETED,INTERVENTIONAL,['PHASE2']
1731,NCT04475380,Target lesion failure (TLF) at 2-year follow up in all-comers,Clinically indicated target lesion revascularization,,2018-09-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1732,NCT04765631,"The main outcome is the comparison of total volumetric bone mineral density (vBMD) at the tibia and distal radius, in type 2 diabetics compared to non-diabetic subjects.",,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
1733,NCT00877890,Change in HbA1c From Baseline to Week 24,Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1734,NCT01454401,Ulcer Healing Within 20 Weeks,Ulcer Healing Within 12 Weeks.,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1735,NCT02589626,Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,,2015-10-29,COMPLETED,INTERVENTIONAL,['PHASE4']
1736,NCT06011512,"Proportion of participants developing diabetes mellitus during the study period, measured in changes of HbA1c.",Duration and cumulative glucocorticoid dosage,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
1737,NCT03907618,HbA1c,,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
1738,NCT00121355,,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1739,NCT02603510,Frequency of infusion set occlusions,Number of adverse events,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1740,NCT04617405,"Association between the level, content and bioactivity of exosomes in serum and plasma Versus Insulin sensitivity at five times during pregnancy.",Association between the body weight Versus Insulin sensitivity at five times during pregnancy.,,2021-01-11,RECRUITING,OBSERVATIONAL,['NA']
1741,NCT02275091,small LDL particles,,,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
1742,NCT04149054,Sallis Self Efficacy for Physical Activity Scale,Body weight,,2014-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1743,NCT02360774,Change in Body Weight,Change in Glycemic Control,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1744,NCT01474772,DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period),Euro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1745,NCT00955903,Change in Abdominal Fat Mass,Weight Change/Maintenance,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1746,NCT03362554,Change in insulin sensitivity,Body mass,,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1747,NCT00490672,Proportion of patients able to reach treatment goals.,The safety of the drug product used in the study will be assessed using the procedure for adverse drug reactions reporting for marketed medicinal products regulated by the Malaysian regulatory authority.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
1748,NCT04952948,Change in blood pressure in type-2 diabetes,,,2016-08-23,COMPLETED,INTERVENTIONAL,['NA']
1749,NCT03816488,Feasibility: recruitment rate (total number per month),Number of participants with inflammation,,2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1750,NCT00417729,Oxidative stress,Adiponectin,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1751,NCT04232995,Berg Balance Scale,,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
1752,NCT00548197,Best Corrected Visual Acuity,Anatomic Status of the Retina,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1753,NCT05369065,Device success,Change of anti-hypertensive medications,,2022-01-27,RECRUITING,INTERVENTIONAL,['PHASE1']
1754,NCT01022762,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1755,NCT05404178,Diabetic Foot Self-Care Questionnaire,Foot Care Behavior Scale,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA']
1756,NCT00539409,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect Metabolic Integrity in patients with Diabetes Mellitus. Monitor results of QOL questionnaires, Hgb A1C levels, medications to see if patients complications improve",,,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1757,NCT05163912,Acceptability,,,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1758,NCT03147677,Changes in 24h urinary protein quantity by comparing visits at week 20 with the baseline,Changes in urinary albumin / creatinine (UACR) of morning urine by comparing visits at week 20 with the baseline,Incidence of all adverse events (AEs) and serious adverse events (SAEs),2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1759,NCT00754689,Change from baseline in A1C,Percent change from baseline in HDL-C,,2008-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
1760,NCT03374462,Improvement in A1C Levels,Acceptability of home-based telemedicine,,2017-11-27,COMPLETED,INTERVENTIONAL,['NA']
1761,NCT01581736,insulin sensitivity,acetylation of mitochondrial adenine nucleotide translocase,,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1']
1762,NCT01151293,,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
1763,NCT05752929,Number of paticipants with Glicemic control,Number of participants with hypoglycemia,,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1764,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",,,2007-04-27,COMPLETED,OBSERVATIONAL,['NA']
1765,NCT03614039,liver stiffness (LS),cytokines levels,,2015-09-15,COMPLETED,INTERVENTIONAL,['NA']
1766,NCT05608265,Successful performance of the real-time eye tracking function by post-image processing,Image Quality as assessed by user assessment of image quality parameters,,2022-08-31,COMPLETED,INTERVENTIONAL,['NA']
1767,NCT00872846,Evaluation of the of device and/or procedure related adverse events,Significant decrease in the HbA1c values from baseline,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1768,NCT02628301,Microvascular Insulin Sensitivity,Whole Body Insulin Sensitivity,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
1769,NCT04184947,3 point major adverse cardiovascular events (4P-MACE),Revascularization,Occurrence of adverse events,2014-03-01,COMPLETED,OBSERVATIONAL,['NA']
1770,NCT01517568,"Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces",Adverse events,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1771,NCT00964587,HbA1C,Barriers to Self-Management,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1772,NCT00606112,"Safety and Tolerance of a single intravenous dose of trodusquemine (MSI-1436) in obese, type 2 diabetics",,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1773,NCT03709966,Physical activity measurements,Motivation and auto-regulation of physical activity,Cardiometabolic measurement: Low-density lipoprotein cholesterol (LDL),2017-12-07,COMPLETED,INTERVENTIONAL,['NA']
1774,NCT04591925,Days of successful insulin delivery through the SteadiSet™ insulin infusion device versus a commercially available insulin infusion set,,,2021-02-05,TERMINATED,INTERVENTIONAL,['NA']
1775,NCT02180646,Plasma Glucose Level Post-meal (AUC [0-4]),Post-meal Level of Glucose-dependent Insulinotropic Peptide (GIP) (AUC),Post-meal Glucagon-like Peptide-1 (GLP-1) Level (AUC ),2011-12,COMPLETED,INTERVENTIONAL,['NA']
1776,NCT00518102,"The number of reported cases of cancers of all kinds, grouped by organ site in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).",The number of reported deaths from cancer in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
1777,NCT00741585,"To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.","To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment.",,2008-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1778,NCT02942914,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics: Average Glucose from 8-Point Glucose Profiles in Participants with T2DM treated with Placebo or LY3209590,,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
1779,NCT04016012,Change in Blood glucose levels,Change of Body Mass Index (BMI),,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1780,NCT01954472,Feasibility measured by recruitment and retention rates,Exercise history,,na,WITHDRAWN,INTERVENTIONAL,['NA']
1781,NCT02461394,Acceptance criteria defined by ISO 15197:2013 (see description),,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1782,NCT04622371,SF-36,,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA']
1783,NCT03230266,"Collection of catheters for intra-peritoneal insulin infusion from implanted pumps presenting obstructions or not : collection of biological and device samples (blood, catheters, insulin)",Associated conditions related to the patient and to infused insulin,,2017-06-02,TERMINATED,INTERVENTIONAL,['NA']
1784,NCT00662857,Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1785,NCT05022615,"Number of Ungradable ETDRS Images within the 7 standard fields of Clarus, Optos, and Standard 7 Field imaging",Reason Image Quality is compromised per image grader,,2021-09-29,COMPLETED,OBSERVATIONAL,['NA']
1786,NCT04964713,major adverse cardiovascular events,,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1787,NCT02481466,Change from baseline of the maximum vessel wall volume of the carotid arteries by MRI at year 1 and 3,Atrial Fibrillation and heart failure,Cognitive Assessment,2016-11-25,COMPLETED,INTERVENTIONAL,['NA']
1788,NCT04784975,High-resolution peripheral quantitative computed tomography (HRpQCT) strength of cortical and trabecular bone.,Glycemia,,2021-04-23,COMPLETED,OBSERVATIONAL,['NA']
1789,NCT03804879,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change From Baseline in Waist-to-hip Ratio,,2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1790,NCT02320526,Glycemic control,"Rate of dissappearance during a 2-step (pancreatic + hyperinsulinemic) hyperglycemic clamp, as a measure of glucose effectiveness + insulin sensitivity",Resting energy expenditure and respiratory exchange rate,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1791,NCT02290600,"Accuracy of continuous glucose sensor output by individualizing sensor bias in subjects with type 1 diabetes, assessed by quantifying the improvement in CGM accuracy as measured by MARD (mean absolute relative difference).",Continuous Glucose Monitor sensor failure,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
1792,NCT02516657,Mean weekly blood glucose,Total Daily insulin dose,Amylase level,2012-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1793,NCT04943926,Diabetes remission,Changes in quality of life,Changes in appetite/satiety and ketones from baseline,2022-01-04,RECRUITING,INTERVENTIONAL,['NA']
1794,NCT03644199,Glucose levels,Evaluation of gastric emptying,,2011-03-30,WITHDRAWN,INTERVENTIONAL,['NA']
1795,NCT03086330,Change in HbA1c,Change in Fundoscopy,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
1796,NCT03929679,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),,2019-05-28,COMPLETED,OBSERVATIONAL,['NA']
1797,NCT01892917,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-09,TERMINATED,OBSERVATIONAL,['NA']
1798,NCT00913367,Mean change in HbA1c from baseline to the last visit,Adverse events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1799,NCT04289948,Work Package 3,Work Package 3: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel.,,2019-03-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1800,NCT05651490,Change in HbA1c over 18 months,Cost-effectiveness of PST-D,,2020-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1801,NCT01240252,Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle.,Quantitative assay of the ability of insulin to clear glucose from the blood in insulin resistant patients.,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1802,NCT01658579,Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]),Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1803,NCT01394887,presence of inflammation,presence of type 2 diabetes,,2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1804,NCT02049814,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Change From Baseline in Body Weight Over Time,,2014-05-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1805,NCT04692415,Changes from baseline in arterial stiffness after treatment,Changes from baseline in CRP,,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
1806,NCT01407289,Mean blood glucose,Number of glucose measurements in hyperglycaemic ranges,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1807,NCT06151964,Drug accumulation ratio for Cmax of AZD9550 following repeat weekly SC doses,Effect of AZD9550 on amino acid levels in blood versus placebo,,2023-09-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1808,NCT01740817,Muscle Insulin Sensitivity-M Value,Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
1809,NCT01213940,Change in Late Outgrowth Endothelial Progenitor Cells,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1810,NCT06169033,Area under curve (AUC) of the T2DM remission prediction model after 1 year,Area under curve (AUC) of the T2DM relapse model,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
1811,NCT05251116,System Performance,,,2021-12-11,COMPLETED,INTERVENTIONAL,['NA']
1812,NCT06096506,Change in Hemoglobin A1c (HbA1c),Change in Diabetes Management by the Nourishing the Community Through Culinary Medicine survey (NCCM),,2023-11-08,RECRUITING,INTERVENTIONAL,['NA']
1813,NCT01271062,Acute insulin response (AIR) to glucose during IVGTT will be used as a primary variable characterizing the beta cell function,• Plasma concentrations and adipose tissue expression of selected adipokines and inflammatory cytokines characterizing the adipoinsular axis,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1814,NCT02985502,Quality of Life Questionnaire,,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
1815,NCT05018026,Sugar Levels,Overall Diet Quality,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
1816,NCT00930956,Blood glucose,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1817,NCT04616066,The effect of phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes,Determine whether date phytoestrogens affect insulin resistance,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
1818,NCT01212133,The number of serious adverse drug reactions (SADRs) during the study period,Frequency of hypoglycaemic episodes,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
1819,NCT02173457,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who discontinue the trial due to hyperglycemia,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1820,NCT01331681,Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF),Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF,,2011-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1821,NCT01219400,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemia,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1822,NCT05081817,Difference in glucose measurement,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
1823,NCT01794364,Apparent Volume of Distribution (Vz/F),,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1824,NCT03599401,Change in Glycosylated Hemoglobin levels,Change in Clinical attachment level,,2016-10-15,COMPLETED,INTERVENTIONAL,['NA']
1825,NCT03849612,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-02-21,COMPLETED,INTERVENTIONAL,['NA']
1826,NCT02129946,Fasting and postprandial insulin,Satiety-producing effect,3-Day food records,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1827,NCT02912728,Time in glucose range 70-180,Satisfaction Questionnaire,,2017-01-30,COMPLETED,INTERVENTIONAL,['NA']
1828,NCT01956305,determine glycemic response,To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1829,NCT03506711,Change in coronary cross sectional area (mm2),,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
1830,NCT01574365,Adverse event collection and assessment,Profile of Pharmacokinetics,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
1831,NCT01819272,Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks,Change in HbA1c (%) at 12 Weeks,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1832,NCT02218268,Determine the Difference Between Acute Effect of a Mixed Meal on Radial Artery Stiffness in Subjects With Type I Diabetes Mellitus Who do and Who do Not Take an Additional Bolus of Insulin.,,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1833,NCT00991380,Physical Activity,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1834,NCT02486341,Intraday glycemic variability measured by the average of MAGE index (Mean amplitude of glycemic excursions) everyday of exploitable recording by the participant.,Fragility level (Rockwood criteria),,2016-03-31,COMPLETED,INTERVENTIONAL,['NA']
1835,NCT01765946,Longevity gene expression,Monocyte polarization status,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1836,NCT00489242,"To assess the difference in CFV/CFR (coronary flow velocity/coronary flow reserve) in diabetic versus non-diabetic patients and to correlate CK-MB, TnI and HsCRP release after otherwise successful coronary stenting.","Correlation of CK-MB, Troponin-I and HsCRP release with CFR<2.0, FFR<0.8 in diabetic vs non-diabetic group. Evaluation of 30-day Major Adverse Cardiac Events (MACE) defined as death, MI, or urgent revascularization.",,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1837,NCT05258630,Retention in assessments,Diabetes medication adherence,,2022-02-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1838,NCT03583268,Percent time spent </= 3.9 mmol/L as measured by continuous glucose monitor,Continuous overall net glycemic action (CONGA-mmol/L) as measured by continuous glucose monitor,Muscle mass as assessed by DEXA,2013-05,COMPLETED,INTERVENTIONAL,['NA']
1839,NCT00950677,Glucose,exenatide concentrations,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1840,NCT01824862,foveal sensitivity,Retinal thickness,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
1841,NCT00359879,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12,Changes in self-monitored blood glucose (SMBG) profile from Baseline through Week 12,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1842,NCT02261545,Serum Fasting Blood Sugar(FBS),Serum HDL cholesterol,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1843,NCT05434754,To test the effect of a text message-based T1D transition intervention compared to control at 12 months in the Self-Efficacy for Diabetes management scale. A higher score indicates better self-efficacy.,Evaluate the impact of this text message-based intervention costs compared to usual care costs,Evaluation of intervention fidelity,2022-01-16,RECRUITING,INTERVENTIONAL,['NA']
1844,NCT01781533,the percentage of glucose values obtained every 15 min in predefined glucose ranges,Accuracy of the glucose monitoring unit,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
1845,NCT04142229,Time in target glucose range,Socially evaluated cold-pressor test (SECPT),Questionnaire Score,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
1846,NCT02779556,Hemoglobin A1C (HbA1C),Diabetes Knowledge (0-13),,2016-11-07,COMPLETED,INTERVENTIONAL,['NA']
1847,NCT00546325,"Change in physical examinations, vital signs, laboratory parameters, adverse events","Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1848,NCT01991548,User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
1849,NCT03283566,Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT,Ratio of C-peptide AUC to Glucose AUC in Response to MMTT Adjusted for Infused Islet Cell Mass,,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1850,NCT05870280,The hypoglycemıc attıtudes and behavıor,The risk perception,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1851,NCT02729246,Change from Baseline of beta cell function,Change from Baseline of beta cell function,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1852,NCT01052272,Peak Early Filling Rate Normalized to EDV,,,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1853,NCT01159184,,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
1854,NCT02928939,Patients with diabetes mellitus and systemic corticosteroids,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
1855,NCT00703599,Lowering of insulin-dependence and anti-hyperglycemic medication dosages,"No detrimental change seen in kidney function tests, liver function tests and other haematological parameters.",,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1856,NCT04025320,Pain Quality Assessment Scale,Sensory organization test (SOT),,2019-09-27,COMPLETED,INTERVENTIONAL,['NA']
1857,NCT06205030,HOMA-estimated insulin resistance,Inflammatory biomarkers,lipid profile,2024-06-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1858,NCT00101764,,,,2005-01-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1859,NCT00917930,"to evaluate the effective prevalence of glucose metabolism alterations in patients with chronic ischemic heart disease and stable chronic heart failure, without previous diagnosis of diabetes mellitus",to evaluate the potential beneficial effect of physical training on the glycometabolic state,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
1860,NCT01939782,"Metabolic Clock Gene Expression in Peripheral Blood Cells(PBC),",Serum Cortisol,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
1861,NCT04795271,Change in the maximum plantar pressure (kPa),,,2020-11-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1862,NCT03582956,Peripheral Sensitivity to High Dose Insulin,,,2019-01-01,TERMINATED,INTERVENTIONAL,['NA']
1863,NCT00491465,fructosamine,3 days CGMS & SBGM profile,,2007-07,UNKNOWN,INTERVENTIONAL,['NA']
1864,NCT05268705,The primary endpoint is the difference between study arms in difference from start to end plasma glucose concentration during 45 min fasted cycling (assessed by YSI (Yellow Spring Instruments 2900 STAT Plus)).,Change in plasma glucose from injection of glucagon to peak plasma glucose assessed by YSI during observation phase 3,,2022-02-03,COMPLETED,INTERVENTIONAL,['NA']
1865,NCT01288898,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by the ASP1941 glucose concentration changes in blood and urine,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1866,NCT03999125,Best Corrected Visual Acuity,Injection Count,,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE4']
1867,NCT02748330,P2Y12 reaction unit (PRU),Non-coronary artery bypass graft (CABG) related major or minor or minimal bleeding,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1868,NCT03439592,cardiac deaths,,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1869,NCT05356884,Change in Adult Waist Circumference (WC) 6 - 12 months,Change in Adolescent Waist Circumference (WC) 6 - 12 months,,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1870,NCT04273412,incidence of gestational diabetes mellitus,feto-maternal,,2018-10-13,COMPLETED,INTERVENTIONAL,['NA']
1871,NCT04028427,Change in Diabetes Self-Management Questionnaire,Change in HbA1c level,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
1872,NCT04053504,Monthly Intervention Calls Completed by Parent Leaders,Change in Degree of Impact of diabetes on the family system,,2019-05-04,COMPLETED,INTERVENTIONAL,['NA']
1873,NCT00000542,,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1874,NCT04648618,Cytokines,,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1875,NCT03569501,neonatal leptin,maternal fasting plasma glucose concentration,,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA']
1876,NCT02126605,Percent agreement between DAD alerts and glucose readings,"Psychosocial variables (quality of life, fear of hypo-/hyperglycemia, diabetes distress, self-efficacy, and DAD experiences)",,2014-07,UNKNOWN,OBSERVATIONAL,['NA']
1877,NCT02401880,• Change in glucagon release (AUC0-180 min) during Liquid Meal Test (LMT) from V3 to V4 between the two treatment groups (Linagliptin vs. placebo),• Change in glucagon release (AUC0-180 min) during LMT from V2 to V3 during treatment with Empagliflozin (V2 vs. V3),,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1878,NCT05483140,Program Effectiveness,Medication Usage use,Quality of Life (QOL) SF-12,2022-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1879,NCT04569721,Number of Procedure Related Complications,Change in Fasting C-peptide Levels,,2021-02-19,WITHDRAWN,INTERVENTIONAL,['NA']
1880,NCT02795052,Change in Neurologic Function,,,2016-06,RECRUITING,INTERVENTIONAL,['NA']
1881,NCT04217161,Blood glucose measurement,Hypoglycemia events,,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1882,NCT03369899,System Related adverse device effects,,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA']
1883,NCT00998335,Hepatic Steatosis,Percent Change From Baseline in Vascular Inflammatory Markers,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1884,NCT04184622,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,,2019-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1885,NCT01841073,Glycaemic Control,Food Intake in Gram at 9 Weeks,Percentage Change in Body Weight,2011-03,COMPLETED,INTERVENTIONAL,['NA']
1886,NCT00882336,"Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history.","Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate.",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
1887,NCT00497536,CV SSPIasp,"• Δ SSPIAsp (S.C. /I.V.) • AUC IAsp • Tmax IAsp • Cmax IAsp - Bioequivalence of Iasp under SS (GIR, S-FFA, S-glycerol)",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1888,NCT00816608,The development of diabetes,DM complication,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
1889,NCT03027219,Flow change,,,2017-01-31,COMPLETED,OBSERVATIONAL,['NA']
1890,NCT06298799,Genetic variants and miRNA expressions associated with changes in BMI.,Genetic variants and miRNA expressions associated with changes in A1c.,Demographic parameters that affect GLP1 AG therapy.,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
1891,NCT04865809,Change in BOP - Bleeding on Probing (percentage),,,2021-05-12,COMPLETED,INTERVENTIONAL,['NA']
1892,NCT01145534,blood glucose,Salivary glucose level,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1893,NCT00094757,Change From Baseline in A1C at Week 18,Change From Baseline in FPG at Week 54,,2004-10-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1894,NCT03555565,Percentage of Participants Who Had One or More Adverse Events,Change From Baseline in Fasting Insulin Level,,2017-02-28,COMPLETED,OBSERVATIONAL,['NA']
1895,NCT05824572,Patient Activation Measure-Short Form,Patient Satisfaction Questionnaire-18,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1896,NCT02344641,The change in plasma NT-proBNP level after using exenatide for 4 weeks,,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
1897,NCT02760017,fasting glucose levels,Plasma endothelin-1 levels,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
1898,NCT00641550,"Maternal outcome: preterm labor, weight gain, preeclampsia, gestational diabetes Perinatal outcome: birthweight, Apgar scores, body composition, admission at neonatal intensive care unit","Doppler flow velocimetry indexes: pulsatility, resistance and A/B relation (uterine arteries, fetal middle cerebral artery and umbilical arteries)",,2008-04,UNKNOWN,INTERVENTIONAL,['NA']
1899,NCT03810846,Rate of Enjoyment,Medication,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
1900,NCT03818711,Glycemic control (A1C),Quality of Parental Involvement,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
1901,NCT00156897,Absolute weight loss compared to baseline,Changes in other safety parameters,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1902,NCT01935349,The proportion of HT/ DM patients who have achieved the target blood pressure.,"GOPC consultation, SOPC, A&E and hospital attendance rates in the past 12 months.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
1903,NCT02933164,CGM Relative Difference to Laboratory Reference reported as MARD,,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
1904,NCT03235362,"YHR1705, YHR1706 Css, max",,,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1905,NCT00365781,"Evaluate and examine the effect of treatment on laboratory results, vital signs, and adverse events.",,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1906,NCT05038761,Mean absolute relative difference (MARD%),AE with special concern: erythema/edema under the adhesive patch or at the insertion site,,2021-10-08,COMPLETED,OBSERVATIONAL,['NA']
1907,NCT04194450,Plasma Glucose,Monocyte Histone Acetylation,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
1908,NCT02769728,Changes in insulin sensitivity,Changes in beta-cell function,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
1909,NCT04970940,"Css,max of AJU-A51R1 and AJU-A51R2",,,2020-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1910,NCT02354911,Change from baseline in the mean 2-hour area under the curve (AUC) for plasma c-peptide at 12 and 24 months,Change from baseline in Total Daily Insulin Dose,,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1911,NCT01500005,arterial stiffness,blood pressure holter,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1912,NCT00813995,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2008-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1913,NCT04935671,Depression,Tryptophan,,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1914,NCT01901757,"Metformin, rosuvastatin Cmax, AUClast","Metformin, rosuvastatin Vd/F",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1915,NCT02561078,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Body Weight,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
1916,NCT01346046,Continuing validation of SCOUT DS algorithm,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
1917,NCT04348565,Self-efficacy level in diabetes management,Quality of life Measurement,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
1918,NCT00908271,Absolute oral bioavailability,Electrocardiograms (ECGs),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1919,NCT04170998,Change from baseline in HbA1c (%) After 24 weeks,Change from baseline in 7-point SMBG After 24 weeks,,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1920,NCT00812591,Ratio between the plasma glucose level and the glucose concentration at the subcutaneous insulin delivery site,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1921,NCT01099618,Length of Remission,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1922,NCT05383859,Change in Physical activity recommendations (mean),Change in HbA1c (Mean percentage),,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
1923,NCT03209258,Shift ('improvement') in functional recovery (death or disability) defined by the modified Rankin Scale (mRS),Residence,,2017-12-12,COMPLETED,INTERVENTIONAL,['NA']
1924,NCT02366598,Blood pressure,Energy/fatigue,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1925,NCT00425178,Pharmacokinetics,Wound improvement,,2005-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1926,NCT04765358,Time in Range (TIR),,,2020-08-24,UNKNOWN,INTERVENTIONAL,['NA']
1927,NCT05480657,Efficacy - Insulin independence,Efficacy - Durability of insulin independence - long term,,2022-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1928,NCT05095259,Glycogen concentration,Hypoglycemia awareness status,,2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1929,NCT04170543,Urine albumin:creatinine ratio (UACR),Safety and tolerability by clinical laboratory evaluations,Safety and tolerability by assessment of vital signs,2019-11-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1930,NCT00099619,Change in HbA1c (glycosylated hemoglobin) from the baseline of the first period (16-weeks of exenatide or insulin) to the end of each 16-week period.,Change in patient-reported outcomes from Baseline to the end of each 16-week period,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1931,NCT05951621,2-h postprandial plasma glucose,"Self-Rating Anxiety Scale, SAS",Maternal and infant complications during childbirth,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1932,NCT00791661,Number of Participants Who Discontinued Treatment Due to an Adverse Event,24-hour Weighted Mean Glucose (WMG) Concentration,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1933,NCT02954692,Mean change from baseline in HbA1c,Mean change from baseline in Diabetes Treatment Satisfaction Questionnaire (DTSO) scores,,2016-11-30,COMPLETED,INTERVENTIONAL,['PHASE4']
1934,NCT02393573,Change in fasting blood glucose,length of hospital stay,,2015-11,TERMINATED,INTERVENTIONAL,['NA']
1935,NCT01512108,Incidence of Treatment Emergent Adverse Events (AEs),Change in FPG From Baseline to Week 52,,2012-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1936,NCT01115257,,,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
1937,NCT04256486,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c(%) From Baseline at various time points",,,2022-04-21,RECRUITING,INTERVENTIONAL,['NA']
1938,NCT05770687,Major adverse cardiac and cerebrovascular events,Changes in echocardiograhic parameters,,2020-08-01,RECRUITING,OBSERVATIONAL,['NA']
1939,NCT03567408,activated clotting time(ACT),30-day bleeding events,,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1940,NCT00001223,To develop a database and collection of samples obtained from patients with CF during their clinical care to allow for future research,,,1988-01-01,RECRUITING,OBSERVATIONAL,['NA']
1941,NCT05140798,Change in resting metabolic rate,Change in serum cortisol,,2016-04-25,UNKNOWN,OBSERVATIONAL,['NA']
1942,NCT04906213,Number of Genital infections,Changes in Hemoglobin A1C as measured by blood work,Adverse events will be collected form the medical record and patient report,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
1943,NCT01144338,Primary Safety Outcome MACE Events,Secondary Efficacy Outcome Hospitalization for HF,,2010-06-18,COMPLETED,INTERVENTIONAL,['PHASE3']
1944,NCT04711083,correlation between nocturnal oxygen desaturation and glycemic control,,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA']
1945,NCT02344433,Accuracy of family members identified (defined as the agreement of first and second degree relatives identified by both the tool (VICKY or MFHP) and the genetic counselor),Family and provider communication (Communication of family health history with family members and health care providers),,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1946,NCT01767441,change in glucose response (pAUC) to mixed meal test between baseline and 1 month after undergoing bariatric surgery or being put on low calorie diet,changes in active GLP1 systemic bioavailability during a mixed meal test between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,change in HbA1c between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,2013-02,COMPLETED,OBSERVATIONAL,['NA']
1947,NCT05477433,Measures frequency of psychiatric problems with diabetes mellitus type 1,,,2022-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1948,NCT03805633,Change in glucose during oral glucose tolerance test (oGTT),Hemoglobin A1c (HbA1c),,2018-02-02,WITHDRAWN,OBSERVATIONAL,['NA']
1949,NCT01741103,change from baseline in mean glucose concentrations,Change in NFkappaB following meal challenge.,,2011-06,WITHDRAWN,INTERVENTIONAL,['NA']
1950,NCT01046721,superior mesenteric (SMA) blood flow,Peripheral resistance,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
1951,NCT05115188,Glucose values in the oral glucose tolerance test,Participant preference - qualitative measurement,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1952,NCT04507685,Change in Matsuda index for whole body insulin sensitivity,Change in Faecal characteristics- including short chain fatty acids (SCFAs).,Change in dietary intake (diet checklists),2020-10-19,COMPLETED,INTERVENTIONAL,['NA']
1953,NCT03472846,detection of microRNA concentration in serum,microRNAs and changes in bone metabolism under treatment,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1954,NCT05229718,"Change in diabetes-related distress, measured by Problem Areas in Diabetes (PAID)","Change in alcohol use, measured by Alcohol Use Disorders Identification Test Consumption (AUDIT-C)",,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1955,NCT02852980,Glycemia realized after childbirth,Percentage of women who have pursued the dietary and hygiene rules,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
1956,NCT06155539,Differential metabolites,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1957,NCT04459936,Responders (Dichotomised: responder/non-responder),Serum Urate,Hospitalisation,2020-11-24,WITHDRAWN,INTERVENTIONAL,['NA']
1958,NCT03002675,The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men,Visualisation of BAT as measured with MRI scan compared to FDG-PET CT,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
1959,NCT00965302,Diabetes remission,c-reactive protein,,2009-08,TERMINATED,INTERVENTIONAL,['NA']
1960,NCT01846767,Peak Delta over baseline in 13CO2 breath enrichment,Per cent dose recovered,Diabetes classifications and measures of insulin resistance,2012-04,COMPLETED,INTERVENTIONAL,['NA']
1961,NCT00205335,Hemoglobin A1C,Satisfaction with care,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
1962,NCT00971659,the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast,"mean daily blood glucose (BG) from 7-point 24h BG profiles, fasting BG, self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid profiles, HOMA-IR index, hypoglycemic episodes",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1963,NCT01267448,"The proportion of responders in each arm. Responder: FBG 70-300 and/or PPBG <400 mg/dl (week1-6), FBG 70-250 and/or PPBG <300 mg/dl (week 7-12) and without metabolic exclusion criteria, repeat ED visits, hospitalization or significant hypoglycemia.",The number of fold increase in beta cell function in the 2 arms.,,2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1964,NCT01888315,Safety and efficacy of renal denervation,Safety and efficacy of renal denervation,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1965,NCT05741125,Acceptability (Satisfaction): The Percentage of Participants Who Were Satisfied with the Delivery and Content of the Intervention,Changes in Binge Eating Episodes,,2024-01-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1966,NCT01771250,VLDL-TG Clearance Rate,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1967,NCT02868931,Changes in Glycemic Control Measured by A1c,Severe hypoglycaemia,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
1968,NCT02758483,Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes.,"Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes",,2017-03-23,COMPLETED,INTERVENTIONAL,['NA']
1969,NCT03577119,Changes in insulin sensitivity and β-cell function: OGTT,Changes to Colonic microbiota structure: relative abundance,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1970,NCT01486771,Establish efficacy of intravitreal pegaptanib sodium injections in causing regression of high risk proliferative diabetic retinopathy as compared to panretinal photocoagulation,Establish the efficacy of intravitreal pegaptanib injections in preventing the loss of best corrected visual acuity,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
1971,NCT00087516,Change From Baseline in A1C at Week 24,Change From Baseline in 2-hr PMG at Week 104,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1972,NCT01977495,Enrollment and participation rates,Uptake of Device Usage,Change in Hemoglobin A1c,2013-12,COMPLETED,INTERVENTIONAL,['NA']
1973,NCT00141232,Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl),Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1974,NCT04424238,glycemic qualification rate,pregnancy outcome,,2016-03-15,UNKNOWN,INTERVENTIONAL,['NA']
1975,NCT03420040,Change in fasting blood glucose between baseline to week 4,,,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA']
1976,NCT05967260,Probability of overnight hypoglycemia,Change in weight,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1977,NCT01817777,Change From Baseline in HbA1c Values at Week 28,Number of Participants Withdrawn From the Study Due to the Following Reasons: Withdrawal of Informed Consent; Lost to Follow-up,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
1978,NCT01621178,Change From Baseline in Hemoglobin A1c (HbA1c),Participants With Events of Allergic/Hypersensitivity Reactions,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1979,NCT01389362,Resolution/progression of foot ulcer based on PEDIS,Hospital admission/attendance/stay,,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1980,NCT06049420,physical activity,Self-efficacy,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1981,NCT04200391,"Glucagon treatment success, defined as an increase in glucose level to ≥ 70 mg/dL or an Increase of ≥ 20 mg/dL from glucose nadir within 30 minutes after receiving 1 mg glucagon IM",Plasma glucose levels following glucagon administration,,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
1982,NCT03681691,Change in Uptake of Glucose and Ketone Bodies in Whole Brain and Alzheimer's Disease-related Regions of Interest.,Change in Short-term Memory and Executive Function Composite Scores.,Number of Microbleeds,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1983,NCT05349591,Adverse Events,Stimulated C-peptide level,,2022-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1984,NCT02332005,change from baseline in peroneal motor nerve conduction velocity,change from baseline in VPT conduction velocity measurement,,2014-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1985,NCT01731080,calcification score,site of calcification,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
1986,NCT01984827,ECG Analysis,Proportion of Participants with Adverse Events,,2019-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1987,NCT00941369,"Health Assessment, Patient treatment satisfaction and Quality-of-Life",Hypoglycemia assessment,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1988,NCT04120077,glycosylated hemoglobin (HbA1c) percentage,Color Contrast Threshold Sensitivity (minimal percentage contrast detection for each pre-specified wavelength),Macular pigment optical density (MPOD) in relative density units,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
1989,NCT04055428,Change in energy expenditure after natriuretic peptide augmentation,Impact of Natriuretic Peptide Genotype on Study Endpoints,Change in Metabolomic Profile,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE2']
1990,NCT00810420,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
1991,NCT00521937,Complete wound closure at week 12,Time to complete wound healing,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1992,NCT03847116,Light-to-moderate alcohol consumption (LMAC) and risk of prevalent type 2 diabetes mellitus (T2DM),LMAC and incident risk of T2DM,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
1993,NCT03462420,Change of shoulder performance from baseline to 6 weeks after physiotherapy,Physical activity level,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA']
1994,NCT03804411,Body mass index,Molecular-genetic markers of endothelial damage,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1995,NCT01613716,Visual Acuity,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1996,NCT03203811,AUC,Insulin,,2017-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
1997,NCT04496154,Fasting WAT IL-1β secretion,Insulin sensitivity and secretion,Post-hoc analysis of WAT receptors for apoB-lipoproteins and fatty acids,2013-09-05,COMPLETED,INTERVENTIONAL,['NA']
1998,NCT01579136,change in blood pressure over time,,,2011-12,TERMINATED,INTERVENTIONAL,['NA']
1999,NCT00627445,Change in Glycosylated Haemoglobin A1c (HbA1c),Number of Nocturnal Hypoglycaemic Episodes,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2000,NCT00600262,,,,2005-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2001,NCT05285449,High-sensitivity C-reactive protein,,,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2002,NCT01424046,HbA1c,Microalbuminuria,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2003,NCT00449930,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting,,2007-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2004,NCT00335101,Quality of diagnostic information,Diabetes mellitus,,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2005,NCT05073068,Nocturnal respiratory exchange ratio,Blood glucose levels following the exercise intervention measured continuously using a continuous glucose monitor device,Feet sensitivity based on a clinical foot assessment,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
2006,NCT00629434,A1c,Diabetes Treatment Satisfaction Questionnaire,,2001-06,TERMINATED,INTERVENTIONAL,['NA']
2007,NCT00793754,Thrombin generation,C-reactive protein,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
2008,NCT05248776,Efficacy in lowering plasma glucose during the Oral Glucose Tolerance Test (OGTT) after 2 weeks of CPL207280 treatment,CPL207280 concentration immediately prior to dosing (Ctrough),,2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE2']
2009,NCT06054126,Cardiac function evaluated by echocardiography,Cardiovascular events,,2010-01-01,RECRUITING,OBSERVATIONAL,['NA']
2010,NCT01846377,Change in fasting insulin from baseline to immediate post intervention (approximately 3 months post baseline assessment) and 2-months post intervention (approximately 5 months post baseline assessment),Change in Fruit and Vegetable Intake,Change in Moderate to Vigorous Physical Activity,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2011,NCT03309254,Glycemic response,Respiratory quotient and fat oxidation,,2016-01-18,COMPLETED,INTERVENTIONAL,['NA']
2012,NCT01122316,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
2013,NCT00148538,HbA1c at the end of the 6-month exercise period,quality of life,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2014,NCT01886170,For Phase II of the Study: Change in Hemoglobin A1C,For Phase II of the Study: Understanding of diabetes control,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2015,NCT01611883,Change in Glycated Hemoglobin (HbA1c) From Baseline,Percent Change in Non-HDL-cholesterol From Baseline,,2012-07-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2016,NCT01975935,Difference in Hemoglobin A1c Values,Change in Weight,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2017,NCT02529449,Safety assessed by Adverse events,,,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2018,NCT04281069,glycaemia,Hemoglobin A1c,systolic and diastolic blood pressure,2019-03-01,COMPLETED,OBSERVATIONAL,['NA']
2019,NCT00289354,Pharmacoeconomic outcomes (as deduced by changes in HbA1c),"ANCOVAs: Treatment outcomes based on treatment group compared to gender, ethnicity, age, co-morbidities, Rx medications, glycemic states at entrance, lipid status at entrance.",,2003-03,COMPLETED,INTERVENTIONAL,['NA']
2020,NCT01063868,Number of Subjects With Treatment-emergent Adverse Events (TEAE),,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
2021,NCT01499095,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,Change in HbA1c From Month 6 to Month 9,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2022,NCT05823337,five-day second hour postprandial glucose average,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2023,NCT01883037,Does HemoCue Glucose 201 RT provide lab-quality results in the analysis of glucose values during oral glucose tolerance tests?,Is HemoCue Glucose 201 RT method cost saving relative to the traditional laboratory method for analysing glucose values taken during oral glucose tolerance tests?,2. To see if the HemoCue Glucose 201 RT offers sufficient advantages to make it a viable alternative to conventional testing,2013-06,COMPLETED,OBSERVATIONAL,['NA']
2024,NCT05031429,"Safety, as indicated by hypoglycemia","Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)",,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
2025,NCT00141453,Renal Composite Outcomes,Reciprocal (1/Serum Creatinine) of Serum Creatinine,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2026,NCT05497960,Program satisfaction,Perceived Stress Scale Center for Epidemiologic Studies Depression Scale (CES-D),,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
2027,NCT02795559,Serum acetate response,Post-lunch ghrelin response,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2028,NCT01620476,Area under the plasma liraglutide curve,Adverse events,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2029,NCT01213888,To evaluate the effect of a copper chelator in suppressing post-PRP macular edema in eyes with retinal neovascularization.,,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
2030,NCT00738153,"The incidence of serious adverse drug reactions, including major hypoglycaemic events",Sub -group analysis of hypo risk,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
2031,NCT00786136,An absolute increase in SCr >=0.5mg/dL（>=44.2μmmol/L）or a >= 25% increase in SCr from baseline to 72h after the procedure,"The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2032,NCT02104466,Change from baseline in average weekly pain on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at week 12,Patient satisfaction,Use of medications at baseline and throughout 12-week intervention period,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2033,NCT05808699,Sensitivity and Specificity Corrected for Enrichment,"Observed Sensitivity and Specificity, Level II",Precision substudy,2023-03-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2034,NCT03664583,Mental Health Using the Short-Form 12 Health Survey Version 2 (SF-12v2) - Mental Component Summary score.,Collaboration Using the Partnership Self-Assessment Tool (PSAT),,2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2035,NCT05632055,miRNA profile,FGF21 profile,,2000-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2036,NCT01346085,The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion,Any Adverse Event Throughout Follow-up,,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2037,NCT04968171,Partial clinical remission time,Albumine to creatynine ratio ACR [mg/g],,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
2038,NCT03130244,Mean change in HbA1c,Mean change in diabetes medication,,2019-09-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2039,NCT03544892,Time in Range,Diet Quality,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
2040,NCT01409408,Renin activity and concentration,Correlation of drug effects and left ventricular mass and function (systolic and diastolic),,2011-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2041,NCT00901992,A1c values,weight (Body mass index),,2009-05,COMPLETED,INTERVENTIONAL,['NA']
2042,NCT02879422,Proliferative retinopathy diabetic,,,2013-10-16,COMPLETED,INTERVENTIONAL,['NA']
2043,NCT00556465,Proteinuria,"blood pressure,serum creatinine,GFR,c-reactive protein,",,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2044,NCT01979471,The difference in change in estimated cardiovascular risk between advanced care and usual care groups,"Achievement of individual and the ""triple target""",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2045,NCT00225849,"Composite event of cerebro/cardiovascular (CV) death, nonfatal cerebral stroke (of any cause) and nonfatal myocardial infarction (MI)",Severe side-effects that lead to interruption of the study medication.,,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
2046,NCT05287737,Pancreatic islet function,Histological examination pancreas,,2022-06-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2047,NCT01542450,The ratio of area under the glucose infusion rate curve (AUCGIR) 0-5 hours to AUCGIR 0-24 hours,Adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2048,NCT01588639,Occurrence rate of serious adverse drug reactions including severe hypoglycaemic events,Number and ratio of missed injections,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
2049,NCT02445170,Health-related quality of life measured by the HRQoL score,The 15D health-related quality of life instrument,,2015-07,WITHDRAWN,OBSERVATIONAL,['NA']
2050,NCT02566330,Excess Weight (%),C-peptide (nmol/L),,2015-10,COMPLETED,OBSERVATIONAL,['NA']
2051,NCT04091516,Weight loss,Body Composition,,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2052,NCT03016910,Changes in plaque morphology stratified by cardiovascular risk factors.,Impact of asymtomatic CAD in diabetes on future events.,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
2053,NCT03471104,Change in Diabetes Distress Scale (DDS),Change in Glycosylated hemoglobin A1c (HbA1c),,2018-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
2054,NCT03835923,Change in HbA1c,"Number of the combined endpoint ""4P-MACE""",,2019-02-12,COMPLETED,INTERVENTIONAL,['NA']
2055,NCT02150824,The percentage of patients with drug- related adverse events,Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2056,NCT00390520,Glucagon counterregulatory response to hypoglycemia of the last 30 min of the 2.5 mM hypoglycemic clamp after 4 weeks treatment,"Safety based primarily on frequency of adverse events, number of notable abnormal laboratory values, and frequency and severity of hypoglycemic events",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2057,NCT04182646,Change in NAFLD activity Score,Changes in Glycemic control,,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA']
2058,NCT01877200,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
2059,NCT01054092,HbA1c,"Safety assessed by adverse events, vital signs laboratory tests and 12-lead ECGs",,2010-01-14,COMPLETED,INTERVENTIONAL,['PHASE3']
2060,NCT02600377,HbA1c,Diastolic blood pressure,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
2061,NCT04538352,Change in HbA1C ≤ 7.5%,Total daily insulin dose,,2021-01-18,COMPLETED,INTERVENTIONAL,['PHASE4']
2062,NCT00708604,Percent of subjects who have achieved insulin sufficiency post transplant.,HgAlc</= 6.5%,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2063,NCT00871936,Reduction in HbA1c,Adverse Events,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2064,NCT03571100,Patient Comfort,Patient Comfort,,2018-05-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2065,NCT01789788,Safety: Incidence of adverse events,Pharmacodynamics of RO681135: Blood analysis,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2066,NCT03646916,Post-operative blood sugar,,,2020-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2067,NCT03744975,Plasma cGMP Response,Renal response,,2018-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2068,NCT03743285,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
2069,NCT05649891,Degree of indication of interventions performed thanks to Do-Confirm Emergency Manual use,Structured interviews,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2070,NCT02240680,Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.,Change From Baseline in Fasting Plasma Glucose (FPG),,2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE4']
2071,NCT03121196,Epices score distribution,Adverse perinatal outcomes,,2017-05,UNKNOWN,OBSERVATIONAL,['NA']
2072,NCT03847194,Diabetes Distress,Adherence,,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2073,NCT01379729,Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT. Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during hyperglycemic clamp at 180 mg/dl.,Changes from Baseline,,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
2074,NCT03410277,Neurochemical response to HG before and after induction of IAH,Antecedent physical activity,,2018-05-24,RECRUITING,INTERVENTIONAL,['NA']
2075,NCT04854083,HbA1c,"Change in the oxygen uptake and perfusion in subcutaneous and intra-abdominal adipose tissue, brown adipose tissue, skeletal muscle, gut and liver",,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE4']
2076,NCT03643783,Change in T2DM parameters and sPRR after surgery,,,2018-09-11,COMPLETED,OBSERVATIONAL,['NA']
2077,NCT01440517,Evidence of Active Myocardial Angiogenesis/Remodeling,Uptake of 99mTc-maraciclatide Agent in Diabetic Subjects With Heart Failure With Preserved Left Ventricular Fraction and Subjects With Diabetes Mellitus and Asymptomatic Diastolic Dysfunction,,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2']
2078,NCT03314272,Percentage of patients who had hypoglycemic events,,,2018-05-16,COMPLETED,INTERVENTIONAL,['NA']
2079,NCT00237640,"- Primary outcomes include HbA1c, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides levels.",,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2080,NCT01504724,Central macular thickness,Retinal nerve fiber layer thickness,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2081,NCT04411277,Primary outcome is time in range (TIR),-Glucose Variability,,2020-08-05,COMPLETED,OBSERVATIONAL,['NA']
2082,NCT02629263,HbA1c (%),HOMA-IR (mU/mmol/l),,2015-09,COMPLETED,OBSERVATIONAL,['NA']
2083,NCT01029795,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period,,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2']
2084,NCT01754792,To assess hidrocarbonated metabolism parameters before and after pinitol/placebo administration,To evaluate oxidative stress on mitochondrial function before and after pinitol/placebo administration,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2085,NCT02035995,Retinal evaluation,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2086,NCT02982330,Incremental area under the glucose curve (continuous glucose monitor),Mean Blod Glucose (continuous glucose monitor),Satiety VAS 100,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2087,NCT00382239,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12,"Changes in body weight, waist size and waist/hip ratio from Baseline to Week 12",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2088,NCT00260156,Change from baseline in hyperglycemia and arginine-stimulated first phase insulin secretion at 52 weeks,Beta-cell function parameter derived from standard meal challenge,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2089,NCT04470310,HbA1c,The change in lipid profile from baseline at week 12 and 24,,2015-12-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
2090,NCT03609463,Feasibility (Acceptability of Intervention),% Weight Change,Change in Health-Related Quality of Life,2018-03-27,COMPLETED,INTERVENTIONAL,['NA']
2091,NCT05177107,Percent area reduction of study ulcer through Week 13,Microbiological eradication of the target pathogen,Treatment-emergent AEs due to phage therapy,2021-11-24,RECRUITING,INTERVENTIONAL,['PHASE2']
2092,NCT05580536,Understanding Health Implications of Genomics at 6 months,Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months,,2023-02-17,RECRUITING,INTERVENTIONAL,['NA']
2093,NCT02906930,Change in HbA1c,PGI-C Item: Scores of the Two Individual Items (Used for Validation of the IWQOL Questionnaire),,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
2094,NCT02925299,The primary outcome is the centralised measurement of glycated haemoglobin (HbA1c) at 6 months.,"HbA1c <7.0%, HbA1c <7.5%, Relative reduction ≥10% from baseline. o Absolute reduction ≥0.5% from baseline o Absolute reduction ≥1% from baseline o Absolute reduction ≥1% from baseline or HbA1c <7.0%",Health Economic Evaluation,2017-05-12,COMPLETED,INTERVENTIONAL,['NA']
2095,NCT00562952,Reduction in cardiac events,Reduction in NT-proBNP,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2096,NCT00904761,exercise capacity,,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
2097,NCT01964833,Change in the clinical attachment level at 180 days.,Cytokines in the crevicular fluid,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2098,NCT01990092,Change in plasma methylmalonic acid (MMA) levels,Change in neuropathic symptoms as measured by the Neuropathy Total Symptom Score-6 questionnaire (NTSS-6),,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
2099,NCT00315627,Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia,Restoration of Hypoglycemia Awareness 1 Year After Transplantation,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2100,NCT05791201,Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT),Part C: Change in HbA1c values,,2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2101,NCT05203653,percent time spent in hyperglycemia,capillary glucose,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
2102,NCT04721145,Change in Personal CGM Use,Using Personal CGM,,2021-01-25,COMPLETED,INTERVENTIONAL,['NA']
2103,NCT03562208,C Peptide,A1C,,2018-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2104,NCT02338193,Change in Body Weight,First Phase Insulin Secretion (IGI/HOMA-IR),,2015-09-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2105,NCT00387452,Time and frequency domain measures of heart rate variability,Linear transfer-function analysis of cerebral autoregulation during upright tilt,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
2106,NCT02200965,Assessment of change in completion of nine key care processes in diabetes,Assessment of change in surrogate markers that define hard outcomes in diabetes,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2107,NCT00577174,Examine the relationship between mitochondrial function and insulin resistance in obese and non-obese children,"Evaluate the relationship of obesity, timing of puberty and related changes in hormone levels to mitochondrial function and the development of insulin resistance and/or impaired glucose tolerance in longitudinal analyses",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
2108,NCT04034524,"Time until first composite CV event (myocardial infarction, stroke)",Time until first episode of acute cholecystitis,Change from baseline HbA1c,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2109,NCT03750695,Percent Change in Endothelial Function,,,2018-11-20,COMPLETED,INTERVENTIONAL,['NA']
2110,NCT05160142,% Change in Hemoglobin A1c,Change in primary caregiver self-efficacy for healthy meal planning and eating score,,2019-09-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2111,NCT03603704,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2112,NCT00232362,annular tissue Doppler velocity,,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2113,NCT04334213,"AUCtau,ss of CKD-501, D745, D150","Fluctuation of CKD-501, D745, D150",,2020-05-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2114,NCT05653518,Glucose Time-in-Range,Insulin sensitivity,Human CD14+CD16- monocytes,2023-09-09,RECRUITING,INTERVENTIONAL,['NA']
2115,NCT02835014,Number of patients with a positive depression screening,Improvement in Diabetes Control defined by HbA1C equal or lower than 8.5%,,2017-04-26,COMPLETED,OBSERVATIONAL,['NA']
2116,NCT05754424,Area under the glucose infusion rate-time curve of insulin aspart,,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
2117,NCT06112418,The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.,The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.,The safety objective is to assess harm with the 2 prevention strategies,2024-03-06,RECRUITING,INTERVENTIONAL,['NA']
2118,NCT00190970,The objectives of this study is to evaluate the effect of ruboxistaurin on subjects with diabetic peripheral polyneuropathy,Ruboxistaurin will improve quantitative sensory testing and increase nerve fiber density in subjects with diabetic peripheral polyneuropathy.,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2119,NCT03356262,Body mass index (BMI),Dyslipidemia,,2005-07-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2120,NCT03714451,Change in glycemic variability,Change in glucose levels,Eating behavior,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
2121,NCT01969747,"Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo",,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2122,NCT04499638,How is the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2123,NCT04201912,Toll like receptor 2 activity,Toll like receptor 4 activity,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
2124,NCT03692208,Documentation of Diabetes Goal,Patient Ability to Reach Personalized Goals,Health Care Utilization,2018-10-29,COMPLETED,INTERVENTIONAL,['NA']
2125,NCT00362518,The goal is to determine the effects of the vitamin C and vitamin E on surrogate markers of atherosclerosis following an atherogenic meal in type 2 diabetes,To determine changes in surrogate markers of atherosclerosis in type 2 diabetes,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2126,NCT03731637,Determine sensitivity and specificity of serum CA 19-9 in pre-symptomatic pancreatic ductal adenocarcinoma in subjects with new-onset hyperglycemia and diabetes,,,2018-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2127,NCT00287183,Primary endpoint of efficacy will be assessed by comparing the treatment groups based on the change in urinary albumin-creatinine ratio (UACR),To evaluate the effect of treatment with TTP488 on UACR,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2128,NCT01633710,Presence or absence of peripheral arterial disease,,,2009-05,TERMINATED,OBSERVATIONAL,['NA']
2129,NCT00559286,Changes in Elongation-Index (EI) Method: To determine the elongation index (EI) we use the Laser assisted optical rotational cell analyzer (Lorrca).,Decrease of RBC aggregation (using Laser assisted optical rotational cell analyzer (Lorrca),,2007-12,TERMINATED,INTERVENTIONAL,['PHASE4']
2130,NCT01509755,HbA1c (glycosylated haemoglobin),Adverse events,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2131,NCT05081037,Body fat mass at the end of the 6 month intervention period,"Change in fasting lipid profile from baseline, 6 months, 12 months, 24 months and 36 months",Change in quality of life from baseline at 36 months (34-38 months),2021-09-06,RECRUITING,INTERVENTIONAL,['NA']
2132,NCT02892604,Percent time of active insulin closed-loop delivery,Percent time with blood glucose in target range,,2015-11-24,TERMINATED,INTERVENTIONAL,['NA']
2133,NCT03224533,Diabetes Outcome- Combined Definition,Sex Interaction,,2015-06-01,COMPLETED,OBSERVATIONAL,['NA']
2134,NCT03156478,Change in body weight,Usage of the Internet intervention,,2017-04-10,RECRUITING,INTERVENTIONAL,['NA']
2135,NCT00419484,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
2136,NCT01074762,Stroke,Amputation,,1989-03,COMPLETED,INTERVENTIONAL,['NA']
2137,NCT02807155,Number of Routine Diabetes Clinic Visits,Arizona Integrative Outcomes Scale,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
2138,NCT01342614,Blood pressure measurement,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2139,NCT04237493,Hyperglycemia,Hyperosmolar hyperglycemic state,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
2140,NCT02287506,Time to optimum treatment following diagnosis.,Mean glycaemic control,,2015-08-28,TERMINATED,INTERVENTIONAL,['NA']
2141,NCT00935766,Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.,Change in hsCRP,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3']
2142,NCT01046110,Change in Glycosylated Haemoglobin (HbA1c),Change in Fasting Plasma Glucose (FPG),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2143,NCT05017571,Change in Homeostatic model assessment of insulin resistance (HOMA-IR),Change in Matsuda Index,,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2144,NCT02067923,Mixed Meal Tolerance Test (MMTT) C-peptide levels,Safety experience,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
2145,NCT02612675,Area under the blood glucose curve (AUC 0-240),,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
2146,NCT05088265,System Usability Scale,,,2021-10-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2147,NCT04560998,Change in maximum walking distance on a constant load treadmill test,Change in Short Form 36 (SF-36) physical functioning domain,,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2148,NCT05092620,Biospecimens collected,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
2149,NCT02585427,Triglycerides response of different treatments,Gastric inhibitory polypeptide response of different treatments,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
2150,NCT03094819,Qualified eye examination rate,Participant perceptions,,2016-03-17,UNKNOWN,INTERVENTIONAL,['NA']
2151,NCT05535478,Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use,Feasibility of the STRIDE Educational Program,,2023-01-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2152,NCT02520050,Absolute and relative change in HbA1c,Absolute and relative change in energy intake,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
2153,NCT02738086,Study-Related Adverse Events,"Late Life Function and Disability Scale, Limitation",,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
2154,NCT03696810,LOR ratios,Retinal Thickness,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
2155,NCT04141891,Decisional Conflict Scale (DCS) Scores at Day 0 (Post-intervention),Occurrence of self-reported crashes,,2019-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2156,NCT05165706,Change from baseline in plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay,,,2019-01-31,RECRUITING,INTERVENTIONAL,['NA']
2157,NCT05628584,Differences in postprandial glycemia,Gastrointestinal symptoms,,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2158,NCT05461560,Changes in maximal incremental capillary blood glucose level (iCmax) between baseline and endpoint within the intervention group vs. control.,Changes in area under the curve of incremental capillary blood glucose levels (iAUC) in the intervention group vs. control,,2021-12-05,RECRUITING,INTERVENTIONAL,['NA']
2159,NCT02363907,Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device,,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
2160,NCT03235219,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline in Insulin Sensitivity as Assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-%S),,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2161,NCT03602989,Sensitivity and specificity,,,2018-07-05,UNKNOWN,OBSERVATIONAL,['NA']
2162,NCT00895921,Change in Glucose Disposition,Akathisia,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2163,NCT02829268,Number of Participants With Treatment-related Adverse Events as Assessed by Liver Function Tests,Changes in Neurological Functions in Participants Assessed by the Wolfram Unified Rating Scale (WURS),,2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2164,NCT01440530,Diabetes Knowledge,Diabetes Self Care,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
2165,NCT03934970,Comparison of diagnostic accuracy of Diffusion tensor imaging of peripheral nerves in comparison to Diabetic Neuropathy Examination in diabetic patients.,Identifying cut-off value for abnormal diffusion tensor apparent diffusion coefficient in diabetic neuropathy.,,2015-04-30,COMPLETED,OBSERVATIONAL,['NA']
2166,NCT04820348,Adherence to wearing continuous glucose monitoring (CGM) devices to measure glucose levels.,Feasibility of assessing the comorbidity of depressive/anxiety symptoms and type 2 diabetes and the impact of depression and anxiety on diet-medication adherence and lifestyle choices.,,2021-04-09,COMPLETED,OBSERVATIONAL,['NA']
2167,NCT01175928,Nerve Conduction Studies,Quality of life questionnaires,,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2168,NCT05170867,HbA1c,Proportion of subjects losing more than 50% of baseline excess weight,,2022-01-14,RECRUITING,INTERVENTIONAL,['NA']
2169,NCT01087866,Percentage of fetal macrosomy,,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2170,NCT03259984,DNA methylation of genes in insulin resistance,mRNA expression of genes,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
2171,NCT02835287,Incidence of composite major cardiovascular disease events,Cost-effectiveness,,2016-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2172,NCT05913193,Nutritional status risk by MUST,Global Leadership Initiative on Malnutrition (GLIM) Diagnosis of Malnutrition,Calf Circumference,2023-12-15,RECRUITING,OBSERVATIONAL,['NA']
2173,NCT01256892,,,,na,COMPLETED,INTERVENTIONAL,['NA']
2174,NCT03551535,Adherence rate,Neonatal hypoglycemia rates,,2018-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
2175,NCT00797212,Number of AST Results Within +/- 15mg/dL or +/- 20% of Fingerstick (FS)Blood Glucose Results,Percentage of Participant Ratings for Overall Testing Experience With This Meter,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
2176,NCT00656422,To describe changes in hepatic fat content between groups.,To evaluate safety between groups.,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE3']
2177,NCT03794934,Percentage of time in target range 70-180 mg/dL,Percentage of time in target range 70-180 mg/dL,,2019-02-26,UNKNOWN,INTERVENTIONAL,['NA']
2178,NCT04007133,Compliance rate with statin measured by the Girerd test,Compliance rate with statin according to risk factors,,2018-01-31,TERMINATED,OBSERVATIONAL,['NA']
2179,NCT01764919,Assess the Sensitivity and Specificity of [124I]FIAU PET-CT Scanning in Detecting Osteomyelitis as Determined by Bone Biopsy in Patients With Diabetic Foot Infection.,Assess Any Additional Information That [124I]FIAU PET-CT Scanning Provides Compared to MRI,"Explore the Performance of [124I]FIAU PET-CT Compared to MRI in Detecting Osteomyelitis by Chronic Kidney Disease (CKD) Stage (Stage 1+2, Stage 3, and Stage 4+5).",2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
2180,NCT03270436,Change in Mean Body Weight (kg),Change in Proportion of Participants Engaging in Sufficient Levels of Physical Activity,Change in Perceived Family Support for Exercise and Dietary Habits,2018-01-08,COMPLETED,INTERVENTIONAL,['NA']
2181,NCT05440968,"Attendance of patients with knowledge of their risk for diabetes type 2 to a confirmatory test, oral glucose tolerance test",Describe the causes of non-performance of the confirmatory test throughout a brief questionnaire,,2022-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2182,NCT02294175,"Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed),With Phenylethyl Alcohol (PEA) Plating","Satisfaction: Wound Pain, Day 8",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
2183,NCT02282475,Assess visceral adipose fat and intrahepatic lipid stores change during pregnancy,Compare glucose tolerance in pregnant women with gestational diabetes to those with normal glucose tolerance,,2014-11-30,COMPLETED,OBSERVATIONAL,['NA']
2184,NCT00021580,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
2185,NCT00042601,Change in food intake of participants on Pramlintide,Effect of pramlintide on postprandial metabolic and hormonal responses,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2186,NCT00699179,Change in HbA1c from baseline,Number of adverse drug reactions (ADR),,2008-06,COMPLETED,OBSERVATIONAL,['NA']
2187,NCT00437606,AUCo-inf and Cmax of plasma and urine GK Activator (2) and M4. AUC0-6 of plasma glucose.,"AEs, laboratory parameters.",,2007-03,TERMINATED,INTERVENTIONAL,['PHASE1']
2188,NCT03457168,New-onset CKD,Cardiac events,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
2189,NCT06315725,"Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption.",Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumption,,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2190,NCT05798637,Rate of platelet activation,Rate of platelet heterogeneity,,2020-02-10,RECRUITING,OBSERVATIONAL,['NA']
2191,NCT00713830,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2192,NCT03533478,Macular retinal thickness,Visual acuity,,2015-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2193,NCT01511900,Frequency and severity of adverse events,Changes from baseline in vital signs,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2194,NCT01662999,AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population,Number of Participants With Change From Baseline in ECG Interval - Safety Population,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2195,NCT03764280,Percentage of time of sensor glucose levels spent in target range (defined to be between 3.9 mmol/L and 10.0 mmol/L).,Number of participants experiencing hypoglycemia requiring oral treatment during,,2018-07-02,COMPLETED,INTERVENTIONAL,['NA']
2196,NCT02014220,blood glucose,food intake,satiety,na,COMPLETED,INTERVENTIONAL,['NA']
2197,NCT02531386,System accuracy criteria (see description),,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2198,NCT00999856,demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement,duty of care,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
2199,NCT02754817,Change in HbA1c (Hemoglobin A1c),Percentage of responders for HbA1c below 7 percent (53 mmol/mol) with no hypoglycaemic episodes,,2016-04-26,COMPLETED,OBSERVATIONAL,['NA']
2200,NCT01512654,Percentage of total time spent by patients in safe range (70-180mg/dL),Score of patient survey regarding the acceptability of DIAdvisor-2 system,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
2201,NCT01852136,Overall Pen Needle Preference,Pen user group subset comparisons,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
2202,NCT05268237,"Incidence, nature and severity of adverse events",Serum concentration of liraglutide,,2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2203,NCT00907114,center subfield mean thickness using Stratus OCT measured in microns,"macular volume using Stratus OCT, measured in cubic millimeters",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2204,NCT01900470,Change in standardized score,Patient Activation,Medical Adherence,2013-07,COMPLETED,INTERVENTIONAL,['NA']
2205,NCT02496221,Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion,Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick,,2015-06-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2206,NCT05887180,"Rate of adverse cardiovascular and cerebrovascular events (MACCE ""Plus"" events)",Incremental cost-utility relation (societal perspective),,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2207,NCT05898750,Blood glucose level,Insulin level,,2023-04-22,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2208,NCT04504968,Difference in physical function,Health-related quality of life,,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2209,NCT05322304,neuropsychological function,,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
2210,NCT04131049,Postprandial glucose response by continous glucose monitoring,,,2019-06-24,COMPLETED,INTERVENTIONAL,['NA']
2211,NCT04030364,Program retention,Hypothetical program cost per patient,,2019-09,UNKNOWN,INTERVENTIONAL,['NA']
2212,NCT04051632,Successful implementation of hybrid closed loop technology,Assess impact of hybrid closed loop technology on glycemic control by analysis of sensor glucose data.,,2018-06-13,COMPLETED,OBSERVATIONAL,['NA']
2213,NCT00169832,Change in plaque volume in one SVG (by IVUS),14 Fluid retention,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2214,NCT04208620,Clinical laboratory evaluations,Proportion of subjects achieving > 5% body weight loss,,2020-01-21,COMPLETED,INTERVENTIONAL,['PHASE1']
2215,NCT01614782,Number of participants who discontinued from study drug due to an adverse event,Apparent terminal half-life (apparent t1/2) following once daily administration of MK-5823,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE1']
2216,NCT02058641,Macrophage cell count and surface expression of markers of M1 and M2 polarization in blister fluid,Time to healing of cantharidin-induced blisters,,2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2217,NCT01866748,Part B: Number of treatment emergent adverse events (TEAEs),Part B: Change in body weight from baseline,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2218,NCT06158503,Bone remodeling improvement,HbA1c change,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2219,NCT03078231,Number of subjects whose EyeArt results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME).,,,2017-02-17,COMPLETED,OBSERVATIONAL,['NA']
2220,NCT03136484,Change in HbA1c,Change in CoEQ: Individual Items,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
2221,NCT01498367,HbA1c levels,Economic Evaluation (Cost-Effective Analysis- Cost Utility Analysis),,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2222,NCT03487887,Glycemic variability,Hypogliaemia,,2018-03-19,COMPLETED,OBSERVATIONAL,['NA']
2223,NCT04537624,Change in Glycated haemoglobin (HbA1c ),HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No),,2020-08-24,COMPLETED,OBSERVATIONAL,['NA']
2224,NCT00364312,Quality of life,Self-efficacy,,2004-05,UNKNOWN,INTERVENTIONAL,['NA']
2225,NCT04092023,Glycemic control,QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19),,2018-10-02,COMPLETED,INTERVENTIONAL,['NA']
2226,NCT01292018,Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months,Control of dyslipidemia by all commercial available brands hypolipidemics drugs,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
2227,NCT04897802,Change in oxytocin concentration (pg/mL),Alexithymia assessment,,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE4']
2228,NCT04624516,The time of plantar foot diabetic ulcer recurrence incidence,callus,,2019-09-04,COMPLETED,INTERVENTIONAL,['NA']
2229,NCT03677609,Patient adherence: Vaccine and screening recommendations,Physician mindset: Mindset Beliefs Survey,,2018-01-04,COMPLETED,INTERVENTIONAL,['NA']
2230,NCT05985135,Protein synthesis,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2231,NCT00285194,"-Immune activity and pharmacokinetic assessments included hOKT3γ1 (Ala-Ala) level and half-life, monoclonal antibody coating and modulation of CD3 on peripheral blood T cells, and anti-hOKT3γ1 (Ala-Ala) antibody responses.","-Proportion of subjects with slet graft loss will be defined as a return to insulin therapy for >30 days, absence of basal and arginine-stimulated C-peptide, re-transplantation, or patient death;",,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2232,NCT01022177,retinal perfusion by HRF/OBF/RVA,,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
2233,NCT04849845,Post-prandial Glucose Excursion,"Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose",,2021-04-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2234,NCT00701831,Time to dose titration,Physician Satisfaction Questionnaire,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2235,NCT03651531,Hgb A1c,Incidence neonatal hypoglycemia,,2018-01-03,TERMINATED,INTERVENTIONAL,['PHASE3']
2236,NCT01392573,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change in Body Weight,,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2237,NCT04107259,IRAPe,,,2019-01-19,COMPLETED,OBSERVATIONAL,['NA']
2238,NCT00167830,Improvement in fitness measures,Improved family cohesiveness,,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2239,NCT02431234,Serum RANKL concentrations,,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
2240,NCT00820573,Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).,Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2241,NCT00631488,Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels,Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2242,NCT02400515,Glucose levels,Low Density Level (LDL) Cholesterol levels,Hospital Anxiety and Depression scale (HADS),2007-08,COMPLETED,INTERVENTIONAL,['NA']
2243,NCT05026424,Post-prandial glycemic markers,Insulinogenic index,,2021-08-02,COMPLETED,INTERVENTIONAL,['NA']
2244,NCT02330484,Hypoglycemic Medication adherence rates using electronically monitored adherence (MEMS cap) data,MEMS cap data compared to PHQ-9 and AIS assessment,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
2245,NCT01228032,Quality of healthcare services received,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2246,NCT00417131,,,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
2247,NCT02958956,Number of 10 Most Common Cancers Associated Cases,Number of 10 Most Common Cancer Cases By Dose of Pioglitazone,,1997-01-01,COMPLETED,OBSERVATIONAL,['NA']
2248,NCT04028960,Percentage of Time With Dangerous Hypoglycemia,Glucose Management Indicator (GMI),,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE2']
2249,NCT04817228,Change from baseline in wound biofilm presence before and after treatment,,,2021-04-21,COMPLETED,INTERVENTIONAL,['PHASE2']
2250,NCT04863235,Changes in self-compassion from pre-intervention to 12 week follow-up (20 weeks),Personal Growth Initiative as a potential mediator,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2251,NCT00873561,To assess the effect of repeated administrations of NBI-6024 on endogenous insulin production as measured by C-peptide levels in adult and adolescent patients with new onset type 1 diabetes mellitus,"To examine the effects of repeated administrations of NBI-6024 on insulin usage, glycemic control, and immune function (immunodynamics and pharmacodynamics) To examine the safety and tolerability of repeated administrations of NBI-6024",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2252,NCT00454623,,,,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
2253,NCT05046015,Change from Baseline in Overall Dry Skin Score,Skin barrier,Cracks/ Fissures,2016-09,COMPLETED,INTERVENTIONAL,['NA']
2254,NCT04569409,Proportions of subjects who achieved complete wound closure,Change rates in wound size and depth compared to baseline groups,,2020-07-14,RECRUITING,INTERVENTIONAL,['PHASE3']
2255,NCT03462017,Change in Flow Mediated Dilation (FMD),Assessment of PK parameter: AUC0-24,,2018-03-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2256,NCT00819325,"The primary IVUS endpoint of the study was the change in three-dimensional neointimal plaque volume within the stented segment at follow-up, compared to baseline.","The secondary IVUS endpoint was the change in the two-dimensional NIA within the stent, using the cross-sectional slice showing the smallest LA on follow-up and comparing it to the corresponding baseline slice.",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2257,NCT02325206,reduction of intravenous insulin dose,urinary glucose excretion,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2258,NCT01774149,Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.,Change in HbA1c,Empowerment,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2259,NCT00410800,,,,1996-08-19,COMPLETED,OBSERVATIONAL,['NA']
2260,NCT04132739,Changes in strength,,,2019-03-01,TERMINATED,INTERVENTIONAL,['NA']
2261,NCT00984737,To determine the prevalence of newly diagnosed hyperglycemia in coronary ICU.,"To search for the cases with stress hyperglycemia and inquire its relationship with disease severity and functional outcomes, such as longevity of ICU stay.",,2007-05,COMPLETED,INTERVENTIONAL,['NA']
2262,NCT01990638,left ventricular diastolic function,exercise capacity,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
2263,NCT01071785,"Changes on the components of metabolic syndrome (according to IDF and WHO criteria): blood pressure, waist, body mass index (BMI), triglycerides, high-density lipoprotein (HDL) cholesterol, glucose values (HBA1c) and urinary albumin excretion.",changes on serum fatty acids and serum cholesterol,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2264,NCT02327754,Change from baseline in urine albumin creatinine ratio,"sUA, eGFR, L-FABP, HbA1c, SBP, DBP, TC",,na,COMPLETED,INTERVENTIONAL,['PHASE2']
2265,NCT00755404,To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by measuring insulin requirement,To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements),,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2266,NCT02820558,Stage A Safety: Side effects reported for entire cohort,C-Peptide Levels (large cohort),sP Longevity,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
2267,NCT03437694,Hypertension,,,2018-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2268,NCT00069784,"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)",Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG,Number of Patients With First Occurrence of Any Type of Cancer,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2269,NCT02438397,MAGE: mean amplitude of glycemic excursion/MODD: mean of daily differences,,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2270,NCT00396357,Change from baseline in hemoglobin A 1 c (HbA1c) after 24 weeks of treatment,Change from baseline in fasting plasma glucose after 24 weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2271,NCT02069197,Change of body mass index from baseline in 9 months period,To evaluate safety of ketogenic diet as a treatment of obesity.,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2272,NCT01798238,Glycosylated hemoglobin,Glycosylated hemoglobin <6.5% subject percent,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2273,NCT00277732,The difference between the study groups in the change of blood glucose and HbA1c,Frequency of eye and foot examination,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
2274,NCT01056315,Average Pain Intensity,Assessment of Rescue Medication Usage During the 4-week Titration.,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2275,NCT06290349,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,,2024-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2276,NCT02506452,Wound closure observed at up to 12 weeks following baseline visit defined as 100% re-epithelialization without drainage confirmed at 2 weeks following initial observation of closure.,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
2277,NCT03169205,Maternal outcome,fetal outcome,,2017-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2278,NCT02535715,Hepatic Glucose Production (Co-primary Outcome),Plasma Free Fatty Acid Concentrations,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2279,NCT01368536,Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone,"Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone",,2011-05,TERMINATED,INTERVENTIONAL,['PHASE4']
2280,NCT00787215,Glucose intolerance status by OGTT,Glucose intolerance status predicted by Chinese University Diabetes Risk Score validated by OGTTT,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
2281,NCT05281562,Effect of supplemental immunonutrition on wound healing in patients with diabetic foot ulcers as assessed by the Pressure Ulcer Scale for Healing (PUSH) Tool 3.0.,"Long term effect of supplemental immunonutrition on wound healing in patients with diabetic foot ulcers on rates of ulcer recurrence, infection, surgical intervention, and amputation.",,2022-07-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2282,NCT01045707,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2283,NCT04980014,Percentage of Participants With Abnormal Laboratory Findings Reported as AEs,Change From Baseline in Diastolic Blood Pressure,,2015-10-02,COMPLETED,OBSERVATIONAL,['NA']
2284,NCT02208921,The proportion of T2DM patients with Chronic Kidney Disease (CKD),Frequency of patients with HbA1C less than 7% in T2DM patients with and without CKD,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
2285,NCT01967901,Quality of life,Kidney function,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
2286,NCT00563433,Reduction in clinical signs and symptoms of infection,Wound depth.,,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2287,NCT02548273,CHANGE FROM BASELINE IN CENTRAL CORNEAL THICKNESS AT 3 MONTHS,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2288,NCT05078255,Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM)),,,2022-01-27,RECRUITING,INTERVENTIONAL,['NA']
2289,NCT04503564,Rate of Infusion Set Survival at End of Day 7,,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
2290,NCT01577719,Effectiveness of a 6 month culturally-specific multi-media intervention on Heart Health Risk,Change in the MI risk score and clinical events,,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
2291,NCT00074633,,,,2000-01,COMPLETED,INTERVENTIONAL,['NA']
2292,NCT00944450,Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin),,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2293,NCT00229918,Central macular thickness,Increased intraocular pressure,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2294,NCT00934336,"Assay of isoprostane-F2, an indicator of lipid peroxidase derivative production, in the 24 hour urine",,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
2295,NCT04426474,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline to Week 12 in Fasting Insulin,,2020-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2296,NCT04907708,Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues,Percentage of immuno-antigens present in placental tissue,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
2297,NCT04657016,Percentage of Participants with ≥5% Body Weight Reduction,Change from Baseline in Waist Circumference,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
2298,NCT06053359,Semi-structured and Open-Ended Interview Questions,Social Determinants of Health Questionnaire,,2024-04,WITHDRAWN,OBSERVATIONAL,['NA']
2299,NCT03674281,Percentage of Time of Blood Glucose in Range 70-180 mg/dL,Sleep Patterns,,2018-09-24,COMPLETED,INTERVENTIONAL,['NA']
2300,NCT01956162,"Evaluate the efficiency of ""Orthèse Diabète"" compared to ""conventional"" removable devices, in terms of the proportion of diabetic patients whose principal ulcer will heal completely.",Patients satisfaction with the prescribed device,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2301,NCT03569735,Cognitive disorder (occurrence of cognitive disorder),Usual gait speed,,2018-05-26,RECRUITING,OBSERVATIONAL,['NA']
2302,NCT00778804,Framingham 10-year risk index,"Blood pressure, cholesterol, 6 minute walk test, glucose and A1c, CVD knowledge and risk perception",,2004-07,COMPLETED,INTERVENTIONAL,['NA']
2303,NCT03952143,Change From Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants With HbA1c <7% and ≤6.5%,,2019-05-27,COMPLETED,INTERVENTIONAL,['PHASE3']
2304,NCT02844907,AIM3: To determine the fasting GLP-1 effect.,,,2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2305,NCT05155917,the rates of hypoglycemia,ICU Mortality rate,,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2306,NCT04735640,Change in fasting plasma glucose,Maintenance of acquired dietary and physical activity changes,,2021-04-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2307,NCT00516464,"To evaluate the effect of ranibizumab on vitrectomy complications such as recurrent vitreous hemorrhage, postoperative retinal detachment rates, and development of intraoperative retinal breaks.",,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
2308,NCT02035891,The incidence of overt nephropathy,Death from any cause,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
2309,NCT01951547,Effect of periodontal intervention on probing attachment levels of diabetics with periodontal disease,Effect Of periodontal intervention on hs-CRP levels in diabetics with periodontal disease,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
2310,NCT03829800,Change from baseline Subjective appetite at 180 minutes,HbA1c,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
2311,NCT00328393,Median of systolic 24-hour ambulatory blood pressure,Median of 24-hour diastolic ambulatory blood pressure,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2312,NCT01860547,Serum Alanine aminotransferase (ALAT),Body composition,"Subclasses of serum lipoproteins, serum fatty acids and lipid classes of serum",2008-06,COMPLETED,INTERVENTIONAL,['NA']
2313,NCT02372253,Functional Beta Cell Mass,Hypoglycemic Events,Beta Cell Markers,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2314,NCT05670366,Database which contains food intake data (type of food) retrieved from the diary app.,,,2022-09-26,RECRUITING,INTERVENTIONAL,['NA']
2315,NCT02695706,Skin acceptability through the self perception of patients.,Instrumental Performance Measures,,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2316,NCT00921570,Flow mediated dilatation,"TWEAK, PTX-3, Systolic Blood Pressure and Diastolic Blood Pressure",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2317,NCT03785951,Change in fasting and day long insulin levels,Change in body composition,Metabonomics,2018-12,UNKNOWN,INTERVENTIONAL,['NA']
2318,NCT04125784,Changes from baseline in diabetes mellitus type II prevalence,Changes from baseline in therapeutic regimes within those patients who were identified as having diabetes mellitus type 2 in the first study in 2014,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
2319,NCT02818192,Change in albumin excretion over time.,Change in estimated glomerular filtration rate (eGFR) over time.,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
2320,NCT02355717,Bone strength-strain index,Serum C-terminal telopeptide of type 1 collagen (CTX),,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
2321,NCT02361138,Plasma glucose concentration of SHR3824.,Serum creatinine,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2322,NCT00876213,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2323,NCT02994277,System connectivity,Meal composition's effect in the efficacy of the system to control glycaemia,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2324,NCT05213988,Glucose tolerance,,,2018-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2325,NCT04155060,The primary outcome was 28-day mortality,,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
2326,NCT01914302,Blood Volumes measured in microliters,Pain rating measure on a 0-20 Gracely Scale,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
2327,NCT01455441,HbA1c,Myocardial echocardiography,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2328,NCT03377946,Changes of gut microbiota composition,"Composite changes of weight, waist circumference and BMI",Changes of Intestinal endocrine function,2017-12-21,UNKNOWN,INTERVENTIONAL,['NA']
2329,NCT04905459,Specificity of ARDA mtmDR for detection of mtmDR in UWF images,,,2021-09-30,COMPLETED,OBSERVATIONAL,['NA']
2330,NCT03848767,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
2331,NCT06216340,Weight change,Incident diabetes,Changes of C-reactive protein,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
2332,NCT00539396,Change in blood glucose following a standard meal,Mean change from baseline HbA1c,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2333,NCT02290184,Feasibility for Participant Enrollment and Retention,Change in Waist Circumference,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
2334,NCT01488916,incremental areas under the curves of plasma glucose after meal challenge,"Meal-related glycemic excursion indexes (∆G, ∆T, BR)from the meal test",,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
2335,NCT00698126,Number of major hypoglycaemic events reported as serious adverse drug reactions,Quality of Life (QoL),,2007-10,COMPLETED,OBSERVATIONAL,['NA']
2336,NCT06236672,change in HbA1c (%),,,2023-02-15,COMPLETED,OBSERVATIONAL,['NA']
2337,NCT02366572,Subjective Appetite,Energy/fatigue,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
2338,NCT02375828,Acceptability of an oral solution of glibenclamide (Hedonic visual scale),No alteration in metabolic control of the disease,,2015-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
2339,NCT02333539,Frequency of Insulin Pump Adherence Behaviors,Change in Glycemic Control (A1C),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
2340,NCT04020822,Accuracy of Sensor Glucose Before and After Acetaminophen Administration,,,2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
2341,NCT02705430,HbA1c < 7%,Lipid membrane fatty acid composition analysis,,2018-06-20,UNKNOWN,INTERVENTIONAL,['NA']
2342,NCT03741153,the percentage of diabetic patients with pseudo-exfoliation syndrome,,,2019-01,UNKNOWN,OBSERVATIONAL,['NA']
2343,NCT01487811,Maximum drug concentration of the two formulations (Cmax),Frequency of adverse events,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2344,NCT04021251,Validation of predictive algorithms for determining blood glucose levels,,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA']
2345,NCT01030744,Self-Monitoring of Blood Glucose,,,2015-12,WITHDRAWN,OBSERVATIONAL,['NA']
2346,NCT03426709,Diabetes control measured by VR d= Hb glucosidal,System Usability Scale (SUS),,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
2347,NCT05544435,Summary of diabetes self-care activities scale (SDSCA),Metabolic variable values,,2019-09-25,COMPLETED,INTERVENTIONAL,['NA']
2348,NCT05658991,Retinal function amplitude,Retinal function latency.,,2022-12-11,RECRUITING,INTERVENTIONAL,['NA']
2349,NCT01377935,Hospital admission for acute kidney injury,Hospitalizations for acute kidney injury and/or death due to acute kidney injury,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
2350,NCT05744856,The acceptability of the self-care intervention,Self-care of GDM,Costs,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
2351,NCT00179777,Number of Participants With Type 1 Diabetes Mellitus,Number of Participants With Diabetes Associated Autoantibodies,,2002-05-06,COMPLETED,INTERVENTIONAL,['NA']
2352,NCT00711217,Wound healing,Clinical outcome data,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2353,NCT03748433,Time Spent in Hypoglycaemia,,,2019-01-03,TERMINATED,INTERVENTIONAL,['NA']
2354,NCT03539627,Systolic blood pressure,Dynamics of renal function (proteinuria detecton),,2018-11-07,COMPLETED,OBSERVATIONAL,['NA']
2355,NCT06198543,differential proteins of exosomes,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2356,NCT01495013,Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing LDL levels,,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2357,NCT01475552,"Peak cardiac enzyme level (CK-MB,troponin-I)",The rate of periprocedural myocardial infarction,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2358,NCT05266742,Patient Identification Form,,,2019-12-15,COMPLETED,INTERVENTIONAL,['NA']
2359,NCT00185159,Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine,Safety and tolerability,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2360,NCT01687582,Improvement of PASI score,Evolution of BMI,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2361,NCT00592735,weight loss,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
2362,NCT05416060,Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months,Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 6 months,,2023-03-23,RECRUITING,INTERVENTIONAL,['NA']
2363,NCT05588258,Assessment of the skin quality of participants' feet before and after the cream application intervention using a validated questionnaire.,,,2021-11-02,COMPLETED,INTERVENTIONAL,['NA']
2364,NCT03987802,Adverse Events (AEs),Change in HbA1c,,2021-01-20,COMPLETED,OBSERVATIONAL,['NA']
2365,NCT01455922,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2366,NCT00228878,Researchers will assess whether pulsatile IV insulin therapy can successfully reverse the abnormal underlying metabolism in diabetic patients to the point of improving their quality of life.,,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2367,NCT02891928,Anteroposterior displacement amount of the center of pressure with regard to the center of mass.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2368,NCT00824616,Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic),,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2369,NCT04971317,Health Perceptions of SSBs Post-Intervention or Post-Control,,,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
2370,NCT00413348,Change in inflammatory response to E. coli endotoxin injection,,,2006-11,UNKNOWN,INTERVENTIONAL,['NA']
2371,NCT06109311,"Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)",Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Domain and Summary Scores,,2023-11-10,RECRUITING,INTERVENTIONAL,['PHASE3']
2372,NCT01372852,"plasma adiponectin concentration, isoform distribution and activity.",,,2010-05,UNKNOWN,OBSERVATIONAL,['NA']
2373,NCT04109508,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state","t½,sema,SS; terminal half-life of semaglutide at steady state",,2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2374,NCT05615740,Vascular density in central and peripheral retina - healthy subjects,Vascular density in central and peripheral retina - diabetic patients,,2022-05-02,RECRUITING,INTERVENTIONAL,['NA']
2375,NCT05984459,Diabetes remission,Decreases in poglycemic drug treatments,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA']
2376,NCT06044532,Change of skin hydration on the dorsum of the forearm after two and a half hours of wearing the sham device.,Change of skin blood flux induced by oral glycemia tolerance test,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
2377,NCT00746460,Feasibility of using health care providers other than physicians within a GMF to conduct a CV risk assessment and intervention on primary prevention patients,Satisfaction of the patient,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2378,NCT03399994,In-stent neointimal volume,Procedural success,,2018-05-21,COMPLETED,INTERVENTIONAL,['NA']
2379,NCT05508425,Abdominal bloating after glucose solution administration,,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
2380,NCT00037297,,,,2001-07,COMPLETED,OBSERVATIONAL,['NA']
2381,NCT00309465,Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2382,NCT01607931,Incretin effect,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
2383,NCT04618458,Parent BMI,Child stress,Child tanner stage,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
2384,NCT00663884,Change of HbA1c before and after administration of test drug,"Change of CRP, 8-OHdG and Nitrotyrosine before and after administration of test drug",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2385,NCT04897113,Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count,"scales of the ""Health-Promoting Lifestyle Profile""",,2021-05-12,UNKNOWN,INTERVENTIONAL,['NA']
2386,NCT05160272,Circulating C-peptide by iAUC of C-peptide during an IVGTT,Ctrough-ss (Day 28) and the change from baseline to Day 28,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2387,NCT00013598,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2388,NCT05524259,The incidence of PCOS patients in the two study arm that give birth before 37 completed weeks of gestational age.,"The incidence of neonatal outcomes in the two study arms (e.g. incidence of neonatal intensive care unit (NICU) admissions, incidence of Neonatal hypoglycaemia).",Cost-effectiveness of myo-inositol supplementation using Health Technology Assessment (HTA) analyses.,2019-06-21,RECRUITING,INTERVENTIONAL,['NA']
2389,NCT04791787,Hepatic Fat Content,Fructosamine level,,2020-11-25,COMPLETED,INTERVENTIONAL,['NA']
2390,NCT03144050,Clinical risk category,Ulcer incidence,,2017-04-14,UNKNOWN,OBSERVATIONAL,['NA']
2391,NCT02501538,Tissue Perfusion as Measured by TCPO2,Percent Wound Area Reduction,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
2392,NCT02452632,Change from baseline in HbA1c at the end of treatment,Percentage of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit,,2015-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2393,NCT01975428,Participant Perceptions of Utility of Monitoring,Total Health Care Utilization and Costs.,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
2394,NCT02638805,Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting,Change in body weight,Change from baseline in cholesterol,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2395,NCT04043260,Percentage of readings below 54 mg/dl,Change in HbA1C post study treatment,,2019-11-27,COMPLETED,INTERVENTIONAL,['NA']
2396,NCT05620251,humoral immune response after second vaccine dose,Adverse events,,2021-09-03,COMPLETED,OBSERVATIONAL,['NA']
2397,NCT03902925,Pain score,Surgical complications,Anesthetic medications,2019-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2398,NCT00650897,Depressive symptoms,Diabetes self-care,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
2399,NCT02578498,Peak glucose value,Plasma glucose variation,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2400,NCT05539963,Number of participants with no clinical need for further additional surgical procedure or debridement to treat infection at the index site,Number of systemic antibiotic free days since trial surgery,,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
2401,NCT04427488,Circadian Rhythm Evaluation with Morningness Eveningness Questionnaire,Ferrans&Powers Quality of Life,,2020-06-15,COMPLETED,INTERVENTIONAL,['NA']
2402,NCT00211510,Change in A1c From Baseline to 26 Weeks,Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
2403,NCT01699100,plantar pressure of region of interest,Plantar pressure of non-region of interest,plantar pressure of midfoot area,2011-09,COMPLETED,INTERVENTIONAL,['NA']
2404,NCT02532855,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
2405,NCT01186952,Total fat mass,visceral fat thickness,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
2406,NCT02728687,BPI pain interference improvement 3 months,incidence of side effects,,2017-03-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2407,NCT06296251,Body fat mass,AST,,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2408,NCT03555656,Incidence of foot ulcers,incidence of foot ulcers,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
2409,NCT05971524,Glycemic control,Triglycerides,,2023-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2410,NCT03189407,Change in estimated glomerular filtration rate,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
2411,NCT01564797,Effect of the intervention on physical activity levels in diabetics and pre-diabetic participants,Effect of the intervention on changes in knowledge and attitudes about diabetes,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
2412,NCT03025451,Weight,Fasting Glucose,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2413,NCT00065312,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
2414,NCT05662189,pancreatic beta cell function (BCF),,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
2415,NCT01593059,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,TERMINATED,OBSERVATIONAL,['NA']
2416,NCT01302756,Gestational diabetes,Gestational hypertension,,2012-04,WITHDRAWN,INTERVENTIONAL,['NA']
2417,NCT01828970,Mean plasma glucose level measured 3 times just before the first hemodialysis session,Deaths and major cardiovascular events,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2418,NCT02800044,accuracy,acceptability,,2017-03-14,TERMINATED,INTERVENTIONAL,['NA']
2419,NCT00849563,Percentage of weight loss,Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR),,2009-04,COMPLETED,INTERVENTIONAL,['NA']
2420,NCT01331343,Difference in Change in A1c (%) between continuous use of CGM and control,Difference in change in A1c (%) between biweekly use of CGM and continuous use of CGM,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2421,NCT03680079,HbA1c,Depression screening,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
2422,NCT02754739,Insulin resistance assessed by HOMA-IR (homeostatic model assessment index for insulin resistance),"Biomarkers predicting cardiovascular diseases, assessed by plasminogen activator inhibitor-1 (PAI-1) (ng/mL)",,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE4']
2423,NCT05412264,Increased pedometer steps,Waist circumference,Questionnaire,2014-01,TERMINATED,INTERVENTIONAL,['NA']
2424,NCT00005140,,,,1977-09,COMPLETED,OBSERVATIONAL,['NA']
2425,NCT01663207,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
2426,NCT04579406,adverse cardiovascular events,"NPY, CGRP, SP and TRPV1",,2020-10-15,RECRUITING,OBSERVATIONAL,['NA']
2427,NCT02619877,Proportion of re-epithelialization,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2428,NCT06028139,HbA1c,Healthcare cost as measured by WPAI,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2429,NCT01781884,C-peptide value,HbA1C level,Daily dosage of insulin (units/kg).,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
2430,NCT01764373,Change in aerobic fitness,Change in pain experienced,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2431,NCT02130505,Postprandial change in leukocyte activation,Correlation between acute glycemia and leukocyte activation,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2432,NCT00803777,Number of Duplicate Subject BGM Results Within +/- 15mg/dL or +/- 20% of Healthcare Professional Capillary Results,Average Within Replicate Coefficient of Variation CV (Precision),,2008-12,COMPLETED,INTERVENTIONAL,['NA']
2433,NCT04325126,serum RBP4 level,,,2020-04-01,RECRUITING,OBSERVATIONAL,['NA']
2434,NCT06190405,Large-for-gestational age,Rate of hypertensive disorders of pregnancy,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2435,NCT01617304,change in AGE levels in skin from baseline to 4 weeks,change in HbA1c from baseline to 4 weeks,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2436,NCT00506272,average blood glucose,,,2007-12,UNKNOWN,INTERVENTIONAL,['NA']
2437,NCT01498159,Hemoglobin A1c,LDL Cholesterol,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2438,NCT00903500,Dexa scan,"Questionnaires on psycho-social determinants of physical activity, on environmental determinants of physical activity and a motivational questionnaire",,2007-07,COMPLETED,INTERVENTIONAL,['NA']
2439,NCT03437109,The prevalence of hypogonadism in patients with T2DM,,,2017-12-06,COMPLETED,OBSERVATIONAL,['NA']
2440,NCT00839150,,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
2441,NCT02411032,Medication refills,LDL cholesterol,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
2442,NCT01987674,HbA1c,Postprandial glycemia,Homeostasis model assessment of insulin resistance (HOMA-IR),2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2443,NCT00964184,HbA1C,insulin,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2444,NCT00782717,Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery,Percent of Patients With a Decrease of More Than 5 Letters in Best-corrected Visual Acuity (BCVA).,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2445,NCT04484480,Medial-Lateral Stability Index,,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
2446,NCT03331432,Glucose tolerance,,,2015-10-28,COMPLETED,INTERVENTIONAL,['NA']
2447,NCT00864838,Intraocular pressure (mmHg),,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2448,NCT02015806,Optimal medication adherence to all cardiovascular or non-depression chronic disease medications,Optimal adherence to cardiovascular medications among subjects who are suboptimally adherent to these medications at time of randomization,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
2449,NCT00306696,Changes in Haematocrit following 7 days diuretic adminstration.,"Total body fluid & extracellular fluid, body weight, haematocrit & haemoglobin.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2450,NCT00703209,"To determine if nerve decompression of lower extremities in patients suffering from painful symptomatic diabetic neuropathy with chronic nerve compression, has a significant impact on alleviation of pain, and improvement in quality of life.","To measure changes in quality of life. This includes medication changes, pain relief, restoration of sensation, etc.",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
2451,NCT01684709,12-month glycemic control,Secondary effects upon adjustment to diabetes,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
2452,NCT03809793,Insulin Sensitivity,Change in intramuscular DAGs,,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
2453,NCT02322762,Anti-diabetic treatments prescribed by physicians in a real-world setting.,Use of Healthcare resources.,,2014-12-30,COMPLETED,OBSERVATIONAL,['NA']
2454,NCT06031389,Detection of intestinal flora difference between intervention group and control group with diabetic nephropathy by bacterial 16srDNA sequencing,Statistical analysis of the degree of proteinuria relief in intervention group and control group.,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2455,NCT01588470,Myocardial Glucose Uptake,Change in Hemoglobin A1c,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2456,NCT01155284,2 Hour C-peptide AUC in Response to MMTT,2 Hour C-peptide AUC in Response to MMTT,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2457,NCT03654521,Fetal interventricular septum thickness,,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
2458,NCT02266030,Coronary artery stenosis,Lipid metabolism,Heart rate,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2459,NCT02399657,The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center),Number of eyes having increased intraocular pressure,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2460,NCT01042769,"Effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke",Tolerability and long-term safety profile,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2461,NCT00701454,"prevalence of diabetes, hypertension and hyperlipidemia",,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
2462,NCT01241448,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),The 30-Day Adjusted Rate of Hypoglycemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2463,NCT02768480,Glycemic Control,Death,Blood Pressure,2015-06,COMPLETED,INTERVENTIONAL,['NA']
2464,NCT03891927,change of fasting glucose after intervention by extra virgin olive oil,"change at Lipid profile (cholesterol, TG, LDL, HDL) after intervention .",,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
2465,NCT01506895,Change from baseline in Spectral Domain Optical Coherance Tomography,Plasma concentration versus time curve (AUC) of study drug,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2466,NCT01562561,HbA1c (glycosylated haemoglobin),Adverse events,,2001-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2467,NCT01667900,Pharmacokinetics: Half-life of Dulaglutide,Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4]),,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2468,NCT00837408,Type 2 Diabetes,,,2009-02-03,COMPLETED,OBSERVATIONAL,['NA']
2469,NCT00114998,,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
2470,NCT04954313,Association between changes in oral health and changes in systemic health (Flow-mediated dilation),Impact of treatment on triglycerides,,2021-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
2471,NCT05046886,Mean Amplitude of Glycemic Excursion (MAGE),HbA1c Levels,,2021-12-14,RECRUITING,INTERVENTIONAL,['NA']
2472,NCT03179280,post-prandial euglycaemia (PPG),,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2473,NCT03453281,Central macular thickness,Uncorrected visual acuity (number of letters),,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2474,NCT01999374,Duration of sustained islet allograft function,,,2013-03,RECRUITING,OBSERVATIONAL,['NA']
2475,NCT05379686,Percentage of time in target glucose range (PG: 3.9 - 10.0 mmol/l) during and for 1-hour after dynamic physical exercise,Coefficient of variation in PG concentrations,,2022-09-21,RECRUITING,INTERVENTIONAL,['NA']
2476,NCT03368586,FGM accuracy,Sensor related-issues,,2016-07-02,COMPLETED,OBSERVATIONAL,['NA']
2477,NCT06118671,Change of HbA1c,Change of LDL-c,,2023-11-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2478,NCT00446810,Endothelial function (flow mediated dilatation - ultrasound- and reactive hyperemia- laser doppler-),Parameters of autonomic neuropathy,,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
2479,NCT02564913,nailfold videocapillaroscopy,,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
2480,NCT04888780,Quality Criteria for Consumer Health Information (DISCERN) Website Evaluation Scale,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
2481,NCT01400659,CGM-Glucose Area Under the Curve,frequency of adverse events (incl. SAE),,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
2482,NCT04547244,CRTd responders rate,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
2483,NCT01306110,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
2484,NCT04754919,"The rates of diabetes related hospital episodes, including Diabetic Ketoacidosis, between the 2 study groups before and after transition",To compare the proportion of young people in the study groups who fail to attend at least one out-patient adult diabetes appointment during the first year after transition,,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
2485,NCT01633021,Social &amp; relational factors from family network data,Cognitive network utility evaluation,,2012-07-05,COMPLETED,OBSERVATIONAL,['NA']
2486,NCT02918591,Change of Soluble Klotho,Change of HbA1c,,2017-11,UNKNOWN,INTERVENTIONAL,['NA']
2487,NCT05315908,Timeliness of Testing,Number of Household Members Referred for Testing,,2020-11-01,TERMINATED,INTERVENTIONAL,['NA']
2488,NCT00288977,independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes at one year post final transplant,,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
2489,NCT05336019,Retention rate,Glycated Hemoglobin A1c (HbA1c),,2022-10-01,COMPLETED,INTERVENTIONAL,['NA']
2490,NCT00305604,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24,Rapidity of Onset of Action as Determined by Home Glucose Monitoring After 1 Week,,2006-03-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2491,NCT04634591,Changes in GI hormones concentrations during the mixed meal tolerance test (MMTT),Adipose tissue methylome,,2015-09-10,RECRUITING,OBSERVATIONAL,['NA']
2492,NCT03919877,Classification of metabolic subphenotype,Change in area under the curve (AUC) of blood glucose level,,2018-05-24,RECRUITING,INTERVENTIONAL,['NA']
2493,NCT01174381,Proportion of participants who change their lifestyle characteristics related to NCDs,Proportion of participants with decrease in Body Mass Index following lifestyle modification programme,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
2494,NCT04569630,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycemia warning system (HEADWIND) in detecting hypoglycemia (blood glucose < 3.9 and < 3.0 mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Perceived working alliance with IVA,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
2495,NCT04976426,multidimensional network biomarkers,,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2496,NCT02945332,Miles walked,Waist circumference change,Food consumption change,2016-10,COMPLETED,INTERVENTIONAL,['NA']
2497,NCT06062069,Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baseline,Change in insulin doses from baseline when comparing CT-868 to placebo.,Time in hyperglycemia as per CGM metrics.,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
2498,NCT02224742,Healing,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2499,NCT01521520,,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
2500,NCT00922194,Change in Glycosylated Haemoglobin (A1C) From Baseline at 12 Months or More,,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
2501,NCT04049149,Incidence of any diabetes-related micro/macrovascular endpoints (Part 3 of study),Changes in patient's Depression Anxiety Stress (Part 3 of study),,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2502,NCT03072407,"the number of AEs and the finding from the physical examination, the abnormal lab results",Disposition Index,,2015-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
2503,NCT00878891,Percent of time in normoglycemia (0.8 - 1.10 g/L),Adverse events due to the device,,2009-04,TERMINATED,INTERVENTIONAL,['NA']
2504,NCT01461330,Change from Baseline in Blood Pressure at 4 weeks,Change from Baseline in glucose control at 4 weeks,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
2505,NCT03349684,Absolute change in the levels of glycosylated hemoglobin (HbA1c),Number of participants with adverse events,,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2506,NCT03802487,Pharmacokinetic (PK) parameter: Absolute Bioavailability (F),Safety: Adverse events,,2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1']
2507,NCT01591681,Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl,Percent of Nights With Sensor Glucose >250 mg/dL,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2508,NCT04697485,Change in NT-proBNP,Compliance,,2021-01-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2509,NCT03765359,Changes in the insulin need during pregnancy,Inflammatory markers,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2510,NCT05954819,Change of Diabetes Self-Management,,,2023-07-28,COMPLETED,INTERVENTIONAL,['NA']
2511,NCT02838784,Ulcer recurrence,Number of grafts and graft size(s),Health economic outcomes,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
2512,NCT04597957,Change in weight (pounds) in intervention and control group.,Number of visits to Clinic based farmers market (the mercardo) per participant in Fresh Rx program.,,2018-07-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2513,NCT03982238,total testosterone levels,free testosterone,,2019-06-15,COMPLETED,INTERVENTIONAL,['PHASE4']
2514,NCT01814137,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Fasting Plasma Glucose (FPG),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2515,NCT04606576,Mean change from baseline in A1C,Mean change in fasting glucose,,2020-12-15,TERMINATED,INTERVENTIONAL,['PHASE3']
2516,NCT01240070,Cardiovascular events,cardiovascular risk factors changes,,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2517,NCT03208751,Change in VO2peak in ml/kg/min,Change in max. Watts/kg bodyweight,,2011-04-01,UNKNOWN,INTERVENTIONAL,['NA']
2518,NCT02977598,"Atherogenic index of plasma (AIP) values compared with glucose metabolism parameters like HbA1c, Fasting Plasma Glucose and 2-hour plasma glucose levels.",,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
2519,NCT01223651,Accuracy of continuous glucose monitoring system (CGMS).,The effect of altitude on the recognition of hypoglycaemic symptoms.,,2012-01,TERMINATED,INTERVENTIONAL,['NA']
2520,NCT00653185,Change from baseline in glycosylated hemoglobin,Body weight,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2521,NCT04417218,Change in Plasma 2-AAA Concentration From Baseline,,,2020-08-17,COMPLETED,INTERVENTIONAL,['NA']
2522,NCT01066130,"Psychosocial well-being as measured by interview with a medical social worker, Hospital Anxiety and Depression Scale, General Coping Questionnaire, Social Situation Questionnaire, and self-reported satisfaction with psychosocial treatment","Medical parameters that show whether the patient has reached treatment goals for his or her disease; for example, glycated hemoglobin (HbA1c) for diabetes and the Disease Activity Score (DAS) for rheumatoid arthritis",,2001-01,COMPLETED,INTERVENTIONAL,['NA']
2523,NCT05559515,A1C,return to normoglycemia,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
2524,NCT00390637,For adults: body weight loss maintenance,For Children: Change in BMI-Z-score,For adults: Identify traits gene - diet interactions that determine responses to the dietary intervention.,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2525,NCT02790957,Wound healing rate,Incidence of adverse events and reactions,,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2526,NCT02176278,Attainment of at least 3 treatment targets,Incidence of all-diabetes related endpoints,Changes in albuminuria,2014-06,COMPLETED,INTERVENTIONAL,['NA']
2527,NCT01111955,Lowering of fasting plasma glucose (FPG) throughout the study to see if there is a decrease from baseline,"Pharmacodynamics (measuring daily glucose, glucose AUC, HbA1c, lipid profiles, HPA markers, free testosterone, and SHBG)",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2528,NCT02339311,Patient Activation,Diabetes associated health indicators,,2012-06,TERMINATED,OBSERVATIONAL,['NA']
2529,NCT02799563,Test 1 scores,Scores on Standardized exams,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
2530,NCT02257190,Glycemic control,Insulin sensitivity,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
2531,NCT00551954,forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal,"forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2532,NCT03670602,Change From Baseline in Glycemic Control,Changes in Working Memory,Changes in Relative Reinforcing Efficacy of Unhealthy Food,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
2533,NCT02111226,Blood Pressure,Blood Pressure,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
2534,NCT01908348,Endothelial function,,,2013-07-18,COMPLETED,INTERVENTIONAL,['NA']
2535,NCT00363987,changes in urine protein and GFR,plasma lipids,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2536,NCT03785275,Beta cell mass,Beta cell mass vs. beta cell function,,2017-12-06,TERMINATED,OBSERVATIONAL,['NA']
2537,NCT06222775,Glycated hemoglobin,Changes in Medication cholesterol,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA']
2538,NCT06041399,the presence of diabetic peripheral neuropathy,,,2012-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
2539,NCT00717288,Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3,Reversion to Intravenous Insulin for Failure of Glycemic Control,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2540,NCT01038648,1. Rate of conversion of IGT to diabetes. 2. Relative reduction of incidence of diabetes by Sitagliptin among people with IGT compared to Placebo. 3. Increase in reversal of IGT to NGT,1. Beneficial effects in beta cell function. 2. Changes in insulin resistance 3. Improvement in cardiovascular risk factors by Sitagliptin.,,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2541,NCT04604548,Treatment Emergent Adverse Events (TEAE),Heart rate (bpm),,2021-08-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2542,NCT05972954,Number of Treatment Emergent Adverse Events (TEAE),Pharmacokinetics: Cmax [ng/ml],,2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2']
2543,NCT04104243,Comparison of Engagement and Retention of Men vs Standard Diabetes Prevention Program,Compare change in hemoglobin A1c over 6 months,,2021-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2544,NCT03826381,Prevalence of NAFLD and actual estimate of liver signal measured by MR spectroscopy,"NAFLD, as measured by MR spectroscopy, and its association with glucose profiles in relation to impaired renal function",,2019-05-06,COMPLETED,OBSERVATIONAL,['NA']
2545,NCT06334302,Delta postprandial glucose level,Labeled Magnitude Scale (gLMS),,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2546,NCT01077570,Number of serious adverse drug reactions (SADRs) including major hypoglycaemic (low blood sugar) events,Change in postprandial blood glucose (PBG),,2010-03,COMPLETED,OBSERVATIONAL,['NA']
2547,NCT01552603,Mean Percent of Time in Target Blood Glucose Range,Mean Deviation From Target Blood Glucose,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2548,NCT00842972,,,,na,COMPLETED,OBSERVATIONAL,['NA']
2549,NCT01217476,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares",Relative Wound Area Regression of 40% or More at 6 Week,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2550,NCT00854503,Glucose tolerance assessed by HbA1c and fasting glucose,insulin-resistance assessed by clamp. Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers.,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2551,NCT01101568,AUC(0-inf) and Cmax of simvastatin/simvastatin acid alone and in the presence of GSK1292263,"PK parameter values: AUC(0-24h), Cmax, tmax and t1/2 for GSK1292263 and assessment of steady-state",,2010-04-14,COMPLETED,INTERVENTIONAL,['PHASE1']
2552,NCT00353600,,,,1994-08-19,COMPLETED,OBSERVATIONAL,['NA']
2553,NCT01996995,complete cure of the target nail,Change surface healthy target nail / all clinically infected toes patients free of hyperkeratosis,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2554,NCT02101151,glycemic control,Obesity Parameter,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2555,NCT04588259,Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol]),Number of Treatment Emergent Hypoglycaemic Episodes Classified Both According to the ADA Definition and NN Definition: Hypoglycaemic Episodes From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal,,2020-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2556,NCT02973477,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Glucose Variability,2017-01-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2557,NCT06064058,HBA1C,,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
2558,NCT05762432,Reduction in Wound Area,Dressing Changes,,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2559,NCT04100278,LDL-c change,DASS-C21scale score change,Diabetes complications,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
2560,NCT02812238,Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast,,,2016-06-23,COMPLETED,INTERVENTIONAL,['NA']
2561,NCT06236334,Diabetes risk based on HbA1c level (mmol/mol),"Habitual food intake (frequencies, number and grams)",,2024-02,RECRUITING,INTERVENTIONAL,['NA']
2562,NCT00732524,The primary outcome was the patients' ability to avoid repeat ED visits or hospitalization in either of the discharge regimens.,The secondary outcomes included the number of subjects who reached a fasting or pre-meal BG goal of 80 to 130 mg/dl and assessment of the beta cell function at the beginning and end of the study as measured by C-peptide levels during OGTT testing.,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2563,NCT02467478,Urinary Function Marker in CKD,Resting Metabolic Rate (RMR),,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2564,NCT00367445,Variability of blood glucose over a period of 72 hours,Insulin pharmacokinetics,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2565,NCT01809288,"Determine if there are differences in African, African-American and white women in the relationship between triglyceride levels, (a frequently used screening test for diabetes and heart disease) glucose tolerance status and insulin resistance.",Determine if there are race or ethnic differences in the pancreatic secretion of insulin relative to the degree of insulin resistance.,,2013-09-26,COMPLETED,OBSERVATIONAL,['NA']
2566,NCT01147718,The pharmacokinetic parameters of digoxin with and without albiglutide,Safety of digoxin with and without albiglutide,,2010-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2567,NCT05276401,To Assess the Number of Participants With Treatment-related Adverse Events After Nu-3 Gel Use on cDFU as Assessed by CTCAE v4.0,,,2022-03-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2568,NCT03104933,Levels o Copeptin as predictor of vasopressor requirements (measured by index inotropic and vasopressor dependency ratio) and fluid requirement,Levels of proADM and Copeptin as predictors of lactate clearance,,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
2569,NCT06002997,Number of pregnant women with Periodontal disease,Percantage of HbA1C (Glycosylated haemoglobin),,2012-05-03,COMPLETED,OBSERVATIONAL,['NA']
2570,NCT03002116,Mean foot tissue temperature,,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
2571,NCT01754662,"Insulin resistance, lipid profile",Endothelial function,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2572,NCT02480465,The mean percent change of HbA1c,"Safety evaluation - physical examination, vital sign, laboratory, adverse event",,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2573,NCT00529815,This study will determine if a real-time continuous glucose monitoring system is a more effective method of improving glycemic control in patients with type 2 diabetes than is episodic self blood glucose monitoring in the both the short- and long-term.,"The results of this study could also provide information on the impact of the two methods of glycemic monitoring on number of hypoglycemic and hyperglycemic events, and quality of life.",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
2574,NCT05219812,Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention,Number of participants with treatment emergent adverse events (TEAE),,2022-02-16,COMPLETED,INTERVENTIONAL,['PHASE2']
2575,NCT02081014,Serious Adverse Events,Glucose Tmax (Post-insulin),,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2576,NCT01137812,Change in HbA1c From Baseline to Week 52,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2577,NCT00044148,,,,2002-07-16,COMPLETED,INTERVENTIONAL,['PHASE2']
2578,NCT00468117,Proportion of patients w/HbA1c </= to 6.5% and an absence of severe hypoglycemic events or a reduction in HbA1c of at least 1 point and an absence of severe hypoglycemic events,"Reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, serum creatinine, c-peptide levels, MMTT, Clarke Survey, FSIGT, CGMS, number of hypoglycemic events, renal impact, cardiovascular impact, and quality of life",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2579,NCT05210504,Change in level of 2-AAA in urine,,,2022-03-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2580,NCT03689374,Change From Baseline in Glycated Haemoglobin (HbA1c),Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2581,NCT04159922,Score of the Bortner self-questionnaire,,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
2582,NCT01242137,HbA1c,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
2583,NCT04233138,Users' satisfaction of the SUPPORT platform,Knowledge about diabetes self-management,,2020-02-05,UNKNOWN,INTERVENTIONAL,['NA']
2584,NCT06134986,Change in percent body weight,Change in ketones,,2023-11-20,RECRUITING,INTERVENTIONAL,['NA']
2585,NCT04335565,Postprandial glucose levels,Subjective feelings of satiety,,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA']
2586,NCT01364298,Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84,Number of Participants With Adverse Events (AEs),,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2587,NCT03169530,Cardiovascular Disease or Death,Diabetes,Pre-Diabetes,2018-02-05,TERMINATED,INTERVENTIONAL,['NA']
2588,NCT00427986,"Retinal thickness estimated by the fast protocol of the StratusOCT (0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 min).","Side effects during the three-hour examination period, to evaluate if caused by galactose per se or by an increase in intracapillary osmotic pressure.",,2007-01,TERMINATED,INTERVENTIONAL,['NA']
2589,NCT01751360,Blood Glucose,,,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2590,NCT03509441,Assessing level of edema via T2 mapping,Urine test for creatinine levels,,2015-01-15,COMPLETED,OBSERVATIONAL,['NA']
2591,NCT04460092,Pain when insulin injection,,,2020-05-25,UNKNOWN,INTERVENTIONAL,['NA']
2592,NCT01094418,Nerve conduction parameters,Clinical neuropathic scoring system,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
2593,NCT04023539,Glycated hemoglobin,Blood pressure,,2019-09-04,COMPLETED,INTERVENTIONAL,['NA']
2594,NCT00668954,Percent change of oxidant stress and lipid oxidation,High Sensitivity C-reactive protein HsCRP,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
2595,NCT03328845,Oxidative stress markers with the new slow insulin analogues,Diabetes treatment satisfaction questionnaire (DTSQ).,,2017-01-20,COMPLETED,INTERVENTIONAL,['PHASE4']
2596,NCT04297592,Periprosthetic joint infections,Wound complication,,2020-06-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
2597,NCT02695082,Incidence of Acute Kidney injury (AKI),,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
2598,NCT03550963,between-group difference in glucose control,between-group difference in undesirable clinical outcome,,2018-06-23,UNKNOWN,INTERVENTIONAL,['NA']
2599,NCT04983979,Proportion of patients on Maximum dose (300mg) Irbesartan therapy at 12 weeks compared to placebo,Change in GFR at the end of study from baseline,,2022-06-17,TERMINATED,INTERVENTIONAL,['PHASE2']
2600,NCT01294423,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Body Weight,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2601,NCT05610046,Glycaemic response (Matsuda index),Gutt insulin sensitivity index,,2023-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2602,NCT02169570,Change in chest X-ray,Change in Random Blood Sugar (RBS),,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2603,NCT06106035,HbA1c,Food Cost,,2024-02-13,RECRUITING,INTERVENTIONAL,['NA']
2604,NCT03522870,Glycosylated Hemoglobin A1c,EQ-5D-5L,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
2605,NCT06140485,Comparing the mean change in HbA1c levels between the experimental arm and the active-control arm,Comparing the mean change in weight between the experimental arm and the active-control arm,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2606,NCT00881543,"secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets",Washout of dipeptidyl peptidase IV inhibitors after one month without the drug,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
2607,NCT02256293,Acceptability,Diabetes self-management,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2608,NCT03985306,Qualitative assessment of the inforatio technique,,,2019-03-20,COMPLETED,INTERVENTIONAL,['NA']
2609,NCT05757713,"Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)",CD3 receptor occupancy,,2023-07-25,RECRUITING,INTERVENTIONAL,['PHASE4']
2610,NCT01982565,Measure the efficacy of the NOx generating dressing,Measure the rate of repeat ulcers and breakdown in healing.,,2013-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2611,NCT01114438,Change From Baseline in SF 36v2 Quality of Life Assessment,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
2612,NCT05256875,Measurement of the agreement between the prevalence rates of non-adherence obtained by LC-MS/MS and the prevalence as diagnosed by (Medication Possession Ratio) MPR ≤0.80,Determination of significant predictors of non-adherence as diagnosed by urine LC-MS/MS,,2022-08-30,RECRUITING,OBSERVATIONAL,['NA']
2613,NCT02347553,To measure changes in electrolyte levels and QT interval on electrocardiography between hypoglycaemic and euglycaemic states,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
2614,NCT00707434,Mean Relative Difference in Patient Glucose Monitoring: Continuous Glucose Monitoring (CGM) Device as Compared With Point of Care (POC) Glucose Testing,,,2008-06,TERMINATED,INTERVENTIONAL,['NA']
2615,NCT06232421,Number of patients with trophic ulcers cured,percentage reduction in the non-epithelialized area of the wound surface in relation to the initial one,,2024-02-08,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2616,NCT00318656,Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment,"Glycaemia According to CGMS (MAGE), mg/dL",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2617,NCT02730949,efficacy of DCI oral supplementation on metabolic control,Insulin Requirement (I.R.) IU/kg,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2618,NCT06117358,Prevalence of Pre-Diabetes in Overweight and Obese children and adolescents in Assiut governorate,,,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2619,NCT04537520,Wound area,,,2020-07-02,COMPLETED,INTERVENTIONAL,['NA']
2620,NCT00747383,Comparison of GLP-1 response at baseline and after 3 months treatment of both groups.,,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
2621,NCT04089462,Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l),Question about patient preference regarding the two study arms,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
2622,NCT06218992,MMP-9,Thermal imaging: Ocular surface temperature (OST),,2023-12-30,RECRUITING,OBSERVATIONAL,['NA']
2623,NCT04176276,Urine expression of miR-25,,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
2624,NCT04738799,"Change in time in range, under controlled conditions","Change in satiety, as measured by Visual Analog Scale (VAS)",,2021-04-29,COMPLETED,INTERVENTIONAL,['NA']
2625,NCT00385697,Mean HbA1c Change From Baseline in Segment 1,Mean HbA1c Change From Baseline in Segment 1,,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2626,NCT02057861,reversal of diabetic patients,hemodynamic changes,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2627,NCT04945070,HbA1C,Treatment Satisfaction,hsCRP,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
2628,NCT04810676,Cmax of CKD-383,CL/F of CKD-383,,2021-04-16,COMPLETED,INTERVENTIONAL,['PHASE1']
2629,NCT00442845,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks.,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2630,NCT01148238,T-reg,"HLA, anti-GAD, anti-IA2, white blood count, CRP, fasting C-peptide, HbA1c",,2012-08,WITHDRAWN,OBSERVATIONAL,['NA']
2631,NCT00000112,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
2632,NCT05950282,"Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis.","Identify any significant interactions or relationships between the primary outcomes (Fasting Insulin and HOMA-IR) and the demographic and clinical factors, including age, sex, race/ethnicity, BMI, and PCOS diagnosis.",,2023-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2633,NCT04228484,Change in [plasma C-peptide] / [plasma glucose] after near-normalisation of plasma glucose,,,2020-01-07,COMPLETED,INTERVENTIONAL,['NA']
2634,NCT00414986,HEDIS-like measures of acute phase management of depression,Patient report (by survey) of their primary care experience,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
2635,NCT01617031,Intensity of platelet agregation following exposure to 0.5 mg/ml arachidonic acid,Closure time after exposure of total blood to Collagen-epinephrine,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
2636,NCT00288678,"Through the health manager's coordination and consultation, diabetic patients will have better glycemic control for fasting plasma glucose, HbA1c, and blood cholesterol level.","Patients in the intervention group will have better health status such as lower hospitalization rate, shorter length of stay in hospitals, and fewer diabetic complications.",,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2637,NCT06137469,Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min),Immunogenicity indicators: anti-Noiiglutide antibodies,,2023-12-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2638,NCT03254368,"Safety and tolerability as assessed by change in medication use, vital signs, physical examination findings, mental well-being questionnaires, laboratory evaluations, and electrocardiogram results",Change in patient reported outcomes measures,,2017-09-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2639,NCT03416127,Glycosylated Hemoglobin (A1C),Diastolic Blood Pressure,,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE2']
2640,NCT00730392,The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC).,"Secondary end points are insulin dose and number of insulin injection discontinued, if any",,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2641,NCT03640221,Muscle sympathetic nerve activity (bursts/minute),Arterial baroreflex gain.,,2018-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2642,NCT00104182,HbA1C,Blood glucose,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2643,NCT01980524,MYCL,Ejection Fraction,Stroke Volume,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2644,NCT05187806,Comparison of the pretest-posttest Diabetes Self-management Instrument-35 scores,Comparison of the pretest-posttest HbA1c values,,2017-02-07,COMPLETED,INTERVENTIONAL,['NA']
2645,NCT00350103,Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase,Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale Scores at Visit 8,,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
2646,NCT05334173,Excess Weight Loss (%EWL),Remission or improvement of Obstructive Sleep Apnea Syndrome,Quality of life after surgery,2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2647,NCT05257460,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on continuous glucose monitoring (CGM),Total bolus insulin dose (units/day),Utility evaluation is the frequency and duration of use of the closed-loop system at home,2022-01-25,COMPLETED,INTERVENTIONAL,['NA']
2648,NCT03631108,Iris Vessel Geometric Characteristics,,,2018-10,UNKNOWN,OBSERVATIONAL,['NA']
2649,NCT06310148,The cost-effectiveness for delivering the CDCC Pilot Scheme on the incremental cost-effectiveness ratio,Amount of direct medical costs between two groups,,2024-01-18,RECRUITING,INTERVENTIONAL,['NA']
2650,NCT00287404,,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
2651,NCT05594706,"Correlation of 1,5-anhydroglucitol levels in patients with longstanding disease with indirect markers of beta-cell function and mass",,,2023-01-27,RECRUITING,OBSERVATIONAL,['NA']
2652,NCT01102959,Number the answers correct or incorrect on carbohydrate counting in portions of real food,,,2010-03,UNKNOWN,INTERVENTIONAL,['NA']
2653,NCT01425866,Mean change in glycated haemoglobin (GlyHb),Change in blood pressure,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2654,NCT01665352,Change from baseline in HbA1c (%) as compared to placebo,Subject achievement of body weight loss ≥ 2%,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2655,NCT00387101,To determine the efficacy and safety of Dermal-LSR plus Standard of Care (SOC) for the treatment of chronic diabetic foot ulcers in comparison to treatment with SOC alone.,,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
2656,NCT05944549,Percent weight loss,Change in food security as assessed by the National Health Interview Survey(NHIS) Food Insecurity Screener,,2023-05-12,RECRUITING,INTERVENTIONAL,['NA']
2657,NCT01083108,The primary outcome of the study is the change in total body insulin sensitivity due to RYGBP alone using the euglycemic hyperinsulinemic clamp technique.,"The secondary outcomes are changes in insulin sensitivity, insulin secretion, and gut hormones due to caloric restriction alone, caloric restriction plus RYGBP, and RYGBP alone.",,2011-03-31,TERMINATED,INTERVENTIONAL,['PHASE2']
2658,NCT02568280,Mean change in plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2015-10-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2659,NCT02012972,NCDs and NCD risk factors in the study population by time on ART,Changes in NCD risks or prevalence,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
2660,NCT00309231,Efficacy,,,na,WITHDRAWN,OBSERVATIONAL,['NA']
2661,NCT00157729,"Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.",mean changes in creatinine,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2662,NCT01473147,Mean amplitude of glycaemic excursions (MAGE),homeostasis model assessment(HOMA),,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2663,NCT05810545,Maternal health - Gestational diabetes mellus,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
2664,NCT01741181,Endothelial function as assessed by the reactive hyperemia index and endothelial progenitor cells,No. of circulating endothelial cells and endothelial microparticles,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2665,NCT03078491,Change in duration of hypoglycemia,Barriers and facilitators of CGM use,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
2666,NCT01643967,Evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot.,Evaluate the release of ozone in the environment by equipment MEdplus after insufflation rectal in patients with diabetic foot.,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
2667,NCT01005069,Reduction of venous Fasting Plasma Glucose from baseline,Change in lipid profile from baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2668,NCT00207233,Change in expression of selected adipocyte metabolic genes,,,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2669,NCT04237129,GIRmax,Safety and local tolerability,,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1']
2670,NCT02672748,Adult BMI change,child BMI z-score change,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
2671,NCT00482976,"Improvement in selective measurements of oxidative stress, endothelial activity and vascular abnormalities which will correlate with PKC activity in the peripheral monocytes.",Safety of ruboxistaurin,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2672,NCT02181842,Blood Glucose-Related Laboratory Parameters (HbA1c Values) at Each Time Point,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),,2009-01-26,COMPLETED,OBSERVATIONAL,['NA']
2673,NCT04926298,Time spent in hyper and hypoglycemia during Marathon,Time spent in hyper and hypoglycemia during PR1 and PR2,,2020-08-15,UNKNOWN,OBSERVATIONAL,['NA']
2674,NCT06251895,SII,readmission,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
2675,NCT02322268,Glycemic control,Lipid profile,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2676,NCT01542489,Change in HbA1c (glycosylated haemoglobin),Number of adverse events,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
2677,NCT05038137,Assess feasibility and adherence to time period of eating recommendations in both study groups.,Continuous Glucose Monitor (CGM) derived metrics,,2022-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2678,NCT02073188,Proportion of participants performing at least 30% of the recommended Self-Monitoring Blood Glucose tests after 6 months from randomization,Type of overall contacts between centers and participants,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2679,NCT01923389,Number of Participants With Positive Anti-PF-05231023 Antibodies and Neutralizing Antibodies.,Observed Accumulation Ratio (Rac) for Cmax and AUCtau of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold),,2013-09,TERMINATED,INTERVENTIONAL,['PHASE1']
2680,NCT04768673,AUClast,CL/F,,2021-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2681,NCT05377385,Usability of and problems encountered with the Omnipod Dash insulin administration system,Metabolic control of type 1 diabetes mellitus,,2022-04-13,COMPLETED,OBSERVATIONAL,['NA']
2682,NCT03528720,The earliest and most frequently occurring fundus quadrant of diabetic retinopathy in fundus fluorescein angiography.,,,2017-06-13,COMPLETED,OBSERVATIONAL,['NA']
2683,NCT02308254,Blood Pressure,Blood glucose concentration,Stroke volume,2013-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2684,NCT02325622,Association between mean plasma glucose concentration and glycated hemoglobin in cirrhosis,,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
2685,NCT02614170,Measure C-peptide and Insulin in Healthy Individuals,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
2686,NCT03185741,Medication Adherence: Pill Count,Treatment Knowledge,,2018-01-05,COMPLETED,INTERVENTIONAL,['NA']
2687,NCT06028503,Reduction in Hemoglobin A1C,Health literacy,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2688,NCT04725630,Blood glucose levels via hemoglobin A1C,Diabetes Competing Demands scores,Proportion of energy from ultra-processed foods,2021-05-29,RECRUITING,INTERVENTIONAL,['NA']
2689,NCT00845156,Insulin Resistance,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
2690,NCT06068205,"In 48 subjects with type 1 diabetes with and without microvascular complications, the average stiffness of red blood cells, measured using atomic force microscope and quantified using Young's modulus, will be measured.",,,2023-09-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2691,NCT01755494,Area under plasma concentration time curve (AUC) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets,"Safety and tolerability assessment based on medical review of AE reports:physical examination, ECG, heart rate, blood pressure, lab test",,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2692,NCT00521820,Progression of Congestive Heart Failure.,All cause mortality.,,2000-06,TERMINATED,INTERVENTIONAL,['PHASE3']
2693,NCT04595370,Percent change from baseline in UACR at 12 weeks,Percent change from baseline in UACR at 12 weeks to assess dose-response relationship,Change from baseline in eGFR over time,2021-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
2694,NCT05050266,Engagement in virtual care for preventive services,Participation and engagement: ROSE,,2021-10-21,RECRUITING,INTERVENTIONAL,['NA']
2695,NCT00466362,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
2696,NCT02150889,Differences in insulin sensitivity between groups,Differences in fitness level between groups,Differences in body composition between groups,2014-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2697,NCT02727608,Increased survival of ICC´s transplanted as measured by peak c-peptide,Bleeding,Effect of eculizumab on IBMIR,2016-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2698,NCT00713011,Change in Proteinuria,Change in index of glycemia (HbA1c),,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2699,NCT01509001,glucose control,haemodynamic improvement,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2700,NCT05524987,Effectiveness outcome: Systolic Blood Pressure,Effectiveness outcome: HbA1c,Implementation outcome: Sustainability,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
2701,NCT06272565,Untargeted metabolomics for metabolic profile using UHPLC/MS,Central subfield thickness,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2702,NCT05413746,Changes in wound size,Time to removal of non-viable tissue from wound bed,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
2703,NCT05961163,"Composite index of nausea, vomiting, tiredness/fatigue, vertigo, circulation problems/syncopes, muscle cramps, headache, extrasystoles, palpitations, edemas, shortness of breath, depressive mood, anxiety, mental confusion","Reasons for drop out (eg, bad health condition, hospital admission, death)",,2023-07-24,TERMINATED,OBSERVATIONAL,['NA']
2704,NCT01130558,Mean blood Glucose,rate of use of sliding scale insulin,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
2705,NCT00731432,The primary endpoint of the study will be the comparison between THPP and PP in reducing the gingival index (GI) at the site of patch placement,Beta-glucuronidase enzyme found in gingival crevicular fluid (GCF) of the tested sites. The GCF will be collected from the second most posterior tooth in all four quadrants.,,2008-08,SUSPENDED,INTERVENTIONAL,['PHASE2']
2706,NCT04536285,Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.,Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in Egypt,,2020-05-01,COMPLETED,OBSERVATIONAL,['NA']
2707,NCT01962701,Fetal plasma copeptin concentration,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2708,NCT02212665,Changes in insulin sensitivity,Patient-reported outcome measure,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2709,NCT02556554,Change(s) in Behavior and/or Concerns of Diabetics.,Evaluation of Maternal and Fetal Outcomes.,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2710,NCT05230589,Change in Glycated haemoglobin (HbA1c ),"DTSQs, (Diabetes Treatment Satisfaction Questionnaire, status) change in absolute treatment satisfaction",,2022-01-11,RECRUITING,OBSERVATIONAL,['NA']
2711,NCT00325962,To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial systolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension.,To assess the safety of oral dosing of 6R-BH4 in subjects with poorly controlled hypertension,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2712,NCT01789021,Differences in accuracy between blood glucose monitoring systems across the overall tested glucose range by comparing the mean absolute value of relative (percent) difference (MARD) between the meter value and the reference value,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
2713,NCT04186377,Change of ulcer surface area,Incidence of amputations,,2020-05-15,TERMINATED,INTERVENTIONAL,['PHASE2']
2714,NCT05398783,Mean difference and limits of agreement between measured and predicted BSA,,,2022-10-25,RECRUITING,OBSERVATIONAL,['NA']
2715,NCT03654989,"Comparison of wound closure between the 3 groups: iontophoresis of treprostinil, iontophoresis of placebo, and standard of care, over12 weeks.",Evaluation of safety via the appearance of the wound,,2020-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2716,NCT01463449,Low grade inflammation in adipose tissue after weight loss induced by gastric bypass,Quantity of fat in the liver,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
2717,NCT01206647,percentage of patients with stable HbA1c,impact of the switch on:,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2718,NCT01610219,Change in Dietary Intake,Change in Parent BMI,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
2719,NCT05441267,Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+),Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE),,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE4']
2720,NCT03580967,Change in depressive symptoms measured by Hamilton Depression Rating Scale (HAM-D),,,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2721,NCT05204134,Severe Hypoglycemic Events,Patient Reported Outcomes,,2022-03-24,COMPLETED,INTERVENTIONAL,['NA']
2722,NCT06037538,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-04-19,COMPLETED,INTERVENTIONAL,['NA']
2723,NCT00343603,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
2724,NCT00517465,Glucose AUC,Pharmacokinetic parameters,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2725,NCT02977442,Effects of exercise on mitochondrial dynamics,Insulin sensitivity,,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2726,NCT01852968,alterations in hippocampal glucose transport kinetics,alterations in hippocampal neurochemistry,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
2727,NCT05147324,Change in percent time in range,Change in hemoglobin A1c percentage,,2021-12-13,COMPLETED,INTERVENTIONAL,['NA']
2728,NCT03992248,Hepatic glycogen,Insulin sensitivity,,2019-01-31,COMPLETED,INTERVENTIONAL,['NA']
2729,NCT05481944,Left ventricular myocardial longitudinal strain measured by MRI (%),Epicardial fat volume measured from ECG gated Dixon MRI images,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2730,NCT01580917,Latency time after occlusive loading,Response time to Maximum Flow,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
2731,NCT00636766,Ultrasound and immunohistochemical parameters of plaque stability; novel cardiovascular risk factors,Long-term cardiovascular outcomes,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
2732,NCT03813316,The percentage of participants achieving an A1C value of ≤ 7% at 24 weeks,The percentage of participants on antihypertensive therapy at Week 24.,,2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2733,NCT05126251,The scores of short form health survey (SF-36),,,2021-12-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
2734,NCT00439101,To determine if daily administration of megestrol acetate (MA) for 3 months compared to placebo prevents weight loss or improves weight gain in children with cancer-associated anorexia-cachexia.,To evaluate toxicities associated with MA in pediatric oncology subjects.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
2735,NCT01650324,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2736,NCT00485056,The primary endpoint will be the TDI E' ratio which is the relatively preload independent measure of ventricular diastolic function.,E/E' measured by TDI (a non-invasive measure of preload).,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2737,NCT00837759,Change in C-peptide,Change in ZnT8 Autoantibody Titer,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
2738,NCT01689051,Femoral artery blood flow,Leg glucose uptake,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2739,NCT01228240,,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2740,NCT01086150,Pain Scores From Composite Visual Analog Scale,"Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2741,NCT03165240,Percentage of patients with drug related Adverse Events (AEs),Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine,,2017-10-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2742,NCT01556529,"HbA1c, incidence of typical diabetes complications",quantitative diabetes typical complication risk profile,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2743,NCT03718715,change from baseline in the fecal microbiota composition by detecting bacteria families with help of relative abundance (%) and diversity metrics,correlation between microbiota and beneficial glucose lowering response,,2019-02-20,UNKNOWN,OBSERVATIONAL,['NA']
2744,NCT00398853,Insulin Sensitivity as assessed with hyperinsulinemic-euglycemic clamps,"body weight and fat distribution, myocellular and intrahepatic lipid content as assessed with MRS scans",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2745,NCT06027151,PERIODONTAL POCKET DEPTH (PPD),RECESIION OF GINGIVAL MARGIN:,,2022-10-06,COMPLETED,INTERVENTIONAL,['NA']
2746,NCT00949169,We compared prevalence of large artery stenosis according to carotid IMT group and evaluated whether maximal IMT ≥ 1.0 mm could predict for significant CAD by MDCT.,We performed invasive coronary angiography in some patients (N=14) and analyzed association for degrees of CAD between two angiographic methods.,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
2747,NCT04438018,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),Fear of diabetes complications,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
2748,NCT02109978,Response to diabetes therapy and rate of diabetes progression,Collection of samples for analysis of potential biomarkers,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
2749,NCT02612844,The number of treatment emergent adverse events,The maximum glucose infusion rate,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2750,NCT00479791,"Insulin, and glucose",Triglycerides,,1997-04,COMPLETED,INTERVENTIONAL,['NA']
2751,NCT05198895,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes (AEs, SAEs), including any safety outcomes listed in the comments, such as potential, suspected de novo diabetes diagnosis cases based on HbA1c readings",,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
2752,NCT00361738,Change in Mean Plasma Glucose (MPG) from baseline to week 4.,"Glucose parameters (change from baseline to week 4 in fasting and post prandial plasma glucose) ; Change in HbA1c and fructosamine ; Safety: physical examination, adverse events, ECG, laboratory tests",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2753,NCT00988689,Appetite,Palatability of treatments,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2754,NCT00973492,"MAGE, ADRR, Lability Index and LBGI computed with the blood glucose measurement or CGMS",anti-insulin antibodies by ELISA,,2007-09,UNKNOWN,OBSERVATIONAL,['NA']
2755,NCT02682940,"Aggregate reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by meter or logged home blood glucose values <56 mg/dL at 3 months, compared to the monthly rate of hypoglycemia in the baseline period.",Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).,"Average ratings of ""acceptable"" or better from self-reported survey clinician feedback on the utility of Vigilant in managing patients.",2016-05,TERMINATED,INTERVENTIONAL,['NA']
2756,NCT01610934,Fasting Plasma Glucose,Plasma concentrations of incretin hormones,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2757,NCT00622284,HbA1c Change From Baseline at Week 104,Change in Baseline Lipid Parameter Triglyceride at Week 104,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2758,NCT01863810,Numerical pain rating scale (NRS),Adverse events,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
2759,NCT02956655,The remission rate of diabetes,Uric acid (mmol/l),,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
2760,NCT02621476,Percent of Participants Using Mail Order Pharmacy (MOP) After Intervention,,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
2761,NCT00566813,Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events,,,2004-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2762,NCT01046435,"Serum levels of C-reactive protein, fibrinogen,erythrosedimentation rate and white blood cell count","Clinical periodontal parameters: probing depth, bleeding on probing, clinical attachment level",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
2763,NCT03961542,blood glucose measurements after with or without chewing,,,2017-12-22,COMPLETED,INTERVENTIONAL,['NA']
2764,NCT01855243,Mean BG After First Day of Hospitalization,Mortality Rate,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2765,NCT05979077,Participant Tool and Workflow Survey,To evaluate the impact of a patient-facing EHR-enabled questionnaire on glycemic control and visit efficiency.,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
2766,NCT02791490,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Receiving Glycemic Rescue Therapy,,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE3']
2767,NCT02402504,Subjective Appetite,Physical Comfort,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2768,NCT01052597,to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patients,"To examine the effectiveness of curcumin on the reduction of blood sugar, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance",,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
2769,NCT03466177,Retinal biomarkers for AD: receiver operating characteristic (ROC),Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years and more,,2018-03-01,RECRUITING,OBSERVATIONAL,['NA']
2770,NCT04562467,Change in the frequency of ALDHhiSSClowCD133+ cells in individuals treated with IPE compared to SOC for 3 months,,Changes in the concentration of serum inflammatory markers from baseline to the 3-month visit in individuals treated with IPE compared to SOC,2020-09-24,COMPLETED,INTERVENTIONAL,['PHASE4']
2771,NCT00922389,Adverse events and laboratory parameters,Trans Cutaneous partial pressure of Oxygen: TCpO2,,2009-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2772,NCT03345004,Change in Stimulated C-peptide During a MMTT,Change in Body Mass Index (BMI),,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
2773,NCT01487109,To assess the change in urinary albumin to creatinine ratio,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2774,NCT03935919,Sensor accuracy in the perioperative period,Standard deviation of sensor glucose levels in the postoperative period,,2019-08-13,COMPLETED,OBSERVATIONAL,['NA']
2775,NCT05333822,blood glucose improvement in type 2 diabetic patients by continuous glucose monitoring.,insulin C-peptide gastric emptying,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
2776,NCT05813912,Change in glycated haemoglobin (HbA1c),Relative change in weekly insulin icodec dose,,2023-09-22,RECRUITING,INTERVENTIONAL,['PHASE3']
2777,NCT01971047,BG concentration differences at 1 and 2 hours post intervention and post operatively,Number of perioperative complications,,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2778,NCT01444443,Number of hypoglycemic events,Time spent in euglycemia (3.9-8.0 mmol/l); mean blood glucose level; LBGI,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
2779,NCT02222909,Change in Emergency Department Visits + Hospital Days,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2780,NCT05423938,Postprandial glycemic response,Postprandial insulin response,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
2781,NCT01346072,Body Weight,,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2782,NCT03250403,pain,Conduction velocity,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
2783,NCT04634214,Severity of COVID 19 among people with and without diabetes,Length of hospital stay,,2020-11-16,UNKNOWN,OBSERVATIONAL,['NA']
2784,NCT06202079,Change in HbA1c,Change in ADA and Nab of GZR4,,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2']
2785,NCT01276288,Urinary Sodium Excretion Over 24-hour run-in Periods,"Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2786,NCT00678990,Safety,,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
2787,NCT03639545,Arterial function,Glycemic control,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2788,NCT01486914,Area under the Curve (AUC) (insulin aspart),Adverse events,,2003-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
2789,NCT06144554,Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time < 54 mg/dL o Percentage of time in range 70-180 mg/dL,,,2023-09-25,RECRUITING,OBSERVATIONAL,['NA']
2790,NCT03579420,Treatment success at 6 months,Waist circumference,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2791,NCT00793273,Change in FPG (fasting plasma glucose) of treatment,Insulin dose and concomitant oral antidiabetic medication time period between diagnosis of type 2 diabetes and insulin initiation,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
2792,NCT00642538,AUC 0-240 min post-prandial serum glucose,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2793,NCT04401904,AGE-RAGE Measurement in Plasma,6 Minute Walking Distance,,2020-06-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2794,NCT01183013,Change From Baseline in HbA1c After 30 Weeks of Treatment.,Incidence of Rescue Therapy During the First 30 Weeks of Treatment,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2795,NCT00993070,"Pain relief from pain score reduction, using visual analog scale (VAS)","Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC)",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2796,NCT06198725,The 2h C-peptide level of the MMTT test,Triglyceride,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
2797,NCT05673837,volumetric Bone material density (vBMD),Trabecular area,Other structural and remodelling measures from bone histomorphometry,2021-12-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2798,NCT03092752,Percentage of Comorbidities by OAD Classes.,Number of Prescriptions of OAD by Each Renal Impairment (RI) Stages,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
2799,NCT00546702,Change of HbA1c.,"Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins.",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2800,NCT02984813,Flavoprotein fluorescence index,Humphrey visual field testing (24-2),,2016-04-15,TERMINATED,INTERVENTIONAL,['PHASE1']
2801,NCT00099866,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA B at 52 weeks,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2802,NCT05609266,Incident type 2 diabetes,,,1990-01,COMPLETED,OBSERVATIONAL,['NA']
2803,NCT05881837,Percentage change in body weight,Change from baseline in glycosylated haemoglobin (HbA1c) after 32 weeks of treatment,,2023-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2804,NCT05933161,Estimated average glucose (eAG) values based on fructosamine lab values,Number of hypoglycemic unawareness episodes,,2023-11-10,RECRUITING,OBSERVATIONAL,['NA']
2805,NCT02728414,change from baseline in glycosylated hemoglobin change at 3 months,change from baseline in c peptide at 3 months,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
2806,NCT01538576,HbA1c (glycosylated haemoglobin),Adverse Events,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
2807,NCT05157815,Change in plasma HbA1c concentration,Change in Fasting Insulin (mIU/L).,Change in TNF alpha,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
2808,NCT02676648,HbA1c,Body Weight Percent Lost,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
2809,NCT00732121,Change from baseline in the integrated response to the mixed meal test of markers of bone turnover following 8 weeks of treatment with sitagliptin vs. placebo.,Change in insulin secretion during the mixed meal test.,,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
2810,NCT01043770,The proportion of people in the intervention and control groups with prevalent metabolic syndrome according to the IDF criteria.,Changes in general self-efficacy as measured by GSE,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
2811,NCT03551925,Change in Adherence to Refills and Medication Scale (Seven-item) (ARMS-7) Score,Change in Blood pressure,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
2812,NCT04501991,Lipid profile,,,2020-03-11,COMPLETED,OBSERVATIONAL,['NA']
2813,NCT05946148,>30% Liver Fat Fraction reduction,Shearwave Elastography (SWE),,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
2814,NCT04480801,Percentage of patients developing a foot ulcer,Change in foot care practices,,2020-09-15,COMPLETED,INTERVENTIONAL,['NA']
2815,NCT04141475,change of LVEF between before and after 12 weeks of treatment,,,2020-11-24,TERMINATED,INTERVENTIONAL,['NA']
2816,NCT05407662,Baseline all-cause healthcare costs by place of service,"sMRA continuing user questions - Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM v1.4) - validated PROM the evaluates patients' perception of sMRA treatment effectiveness, convenience, and overall satisfaction",,2022-11-02,COMPLETED,OBSERVATIONAL,['NA']
2817,NCT06284785,Difference in kidney oxygenation before and after bariatric surgery,"Difference in kidney oxygenation between obese, hyperfiltering men and women with T2D versus non-diabetic lean controls",,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
2818,NCT00908921,Change in glycosylated hemoglobin (HbA1c) rate,Percentage of patients achieving HbA1c <7.0,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2819,NCT04791358,Referrals,,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
2820,NCT04874922,metabolic control variables evaluation form (fourth),Pregnancy Outcomes Evaluation Form for Mother and Baby,,2021-05-15,COMPLETED,INTERVENTIONAL,['NA']
2821,NCT02551640,Differences in the change in physical activity levels between control and intervention groups as measured by daily physical activity measured by the Gear Fit device provided to participants in both groups,Differences in the change in C-reactive protein between control and intervention groups,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
2822,NCT02590094,Visual Acuity,Time,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2823,NCT03726983,Newborn baby weight,Change of Health Promotion Scale,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
2824,NCT03202095,Change from Baseline in Hamilton Depression Rating Scale,,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2825,NCT06325670,Number of binge eating episodes,HbA1c,Blood Pressure,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
2826,NCT04509856,Diabetes knowledge level (DKL),Blood pressure,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
2827,NCT01345734,Incidence of serious adverse drug reactions (SADRs),"Change in HbA1c (glycosylated haemoglobin)""",,2011-09-01,COMPLETED,OBSERVATIONAL,['NA']
2828,NCT02107976,Whether acute changes in glycemia and/or red blood cell ascorbate (vitamin C) modify RBC deformability.,Whether RBC vitamin C concentrations can be increased by vitamin Csupplementation over several weeks in diabetic subjects.,,2019-06-14,RECRUITING,INTERVENTIONAL,['PHASE1']
2829,NCT01903044,"Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions",Survival without amputation,,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2830,NCT02487537,"change in combined levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2831,NCT00764244,Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years,Evolution of visual field in each group,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2832,NCT01000922,To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments,"To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2833,NCT03228706,"Change of medication adherence at baseline, and at 3, 6 and 12 months after intervention.","Change of intention to adhere at baseline, and at 3, 6 and 12 months after intervention.",Sustainability of the Program,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
2834,NCT02765347,HbA1c,,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2835,NCT03623607,Patient acceptance of diabetes self-management education delivered via an e-learning platform.,To conduct iterative rapid-cycle usability testing of the enhanced Diabetes To Go program content and processes and establish a Diabetes To Go program toolkit for widespread implementation,Implementation effectiveness evaluation,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
2836,NCT01748305,Need for medication for diabetes,Mode of delivery,,2012-12,TERMINATED,INTERVENTIONAL,['NA']
2837,NCT01137903,Number of healing patients,Quality of life,,2010-04,UNKNOWN,INTERVENTIONAL,['NA']
2838,NCT00441129,Difference in HbA1C From Baseline and 6 Months,Change From Baseline in Total Daily Dose (TDD),,2006-06,COMPLETED,INTERVENTIONAL,['NA']
2839,NCT01298154,Food Intake,Blood Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2840,NCT02816099,Comparaison of linear correlation coefficients between plasma concentrations of apoC1 and CETP activity,,,2014-11-20,COMPLETED,INTERVENTIONAL,['NA']
2841,NCT01002547,"Liver Histology (Kleiner's et al Criteria, Hepatology 2005)",LDL-cholesterol,,2010-06-24,COMPLETED,INTERVENTIONAL,['PHASE4']
2842,NCT05355090,Change in HbA1c,Change in body weight,,2022-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2843,NCT00308646,,,,2004-10,TERMINATED,OBSERVATIONAL,['NA']
2844,NCT01507597,Plasma Glucose response to the GLP-1 infusion / glucose clamp,Food Intake,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2845,NCT02627534,Probing Depth,Clinical Attachment Level,Gingival Recession,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2846,NCT04313998,Early Child Development,,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
2847,NCT01956851,correlation of kisspeptin levels with GLP 1,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
2848,NCT01511042,Frequency of Intermediate Phenotypes in Subjects with Diabetes Mellitus versus Hypertension,Frequency of salt sensitive subtype in Diabetics versus hypertensives,,1999-12,TERMINATED,OBSERVATIONAL,['NA']
2849,NCT00630617,Body Mass Index,Knowledge and attitudes,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
2850,NCT01505426,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2851,NCT01858506,Change in lifestyle knowledge,Weight and waist circumference,Medical regimen for diabetes management,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2852,NCT02681497,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
2853,NCT05066516,AUC,Vd,,2020-06-25,COMPLETED,INTERVENTIONAL,['PHASE1']
2854,NCT00759889,To analyze and image wounds using microscopy and molecular techniques,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2855,NCT03774069,Percentage of readings below 54 mg/dl (3.3 mmol/l),Number of physician override Advisor recommendation,,2020-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
2856,NCT00456027,"The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement.",,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2857,NCT06299800,Glycated assessment at first visit,"Tumour characterization in the considered population, detected at the first clinical visit",,2024-02-04,RECRUITING,OBSERVATIONAL,['NA']
2858,NCT06319703,Change in Hemoglobin A1C (HbA1c) Test Scores,International Physical Activity Questionnaire (IPAQ) Short-Version Score,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2859,NCT04984226,FACIT-F Fatigue (PRO),PROMIS Fatigue (PRO),Inflammatory cytokines. TNF-alpha and IL-6,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2860,NCT05209061,Evaluation of metabolic profile,Appendix biofilm,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
2861,NCT01421355,Change in Brachial Artery Diameter,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2862,NCT06092515,Red blood cell membrane fatty acids concentrations,Anemia,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
2863,NCT02148523,Statin Adherence,Morisky Medication Adherence Scale (MMAS),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2864,NCT06231225,Post-COVID-19 Functional Status scale,Dyspnoea-12 (D-12) scale,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2865,NCT00298428,Primary biological end-point: To compare SIPA levels in DM vs. MS vs. no DM/MS patients,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2866,NCT04938843,Glycemic control,Liver fat function test GGT,,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA']
2867,NCT02147522,Response Rate - 50 Percent or Greater Reduction in Patient Health Survey-9 (PHQ-9) Score Since Baseline,Change From Baseline in MOS Short-Form Health Survey Physical Component Summary (PCS),Change From Baseline in Self-Efficacy for Managing Chronic Disease (SEMCD) Score,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2868,NCT02316665,change in mean nocturnal glycemia,Change in mean heart rate after intervention,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
2869,NCT04329871,Glycemic control while using the Medtronic MiniMed 670g system,Efficacy of Quality of Life and satisfaction while using the MiniMed 670g system,,2020-03-24,UNKNOWN,OBSERVATIONAL,['NA']
2870,NCT00874809,What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.,What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
2871,NCT02416765,Mean glucose levels as measured by the glucose sensor.,Total carbohydrate intake,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2872,NCT05928260,HbA1c,Quality of Life,,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
2873,NCT06032325,biomarkers,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2874,NCT00254800,Assessment of Pharmacokinetics profile of exenatide measured by AUC and Cmax,"Safety and Tolerability assessment by Adverse events, clinical laboratory evaluations, vital signs, ECG blood glucose, body weight, physical examination and exenatide antibodies.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2875,NCT03862690,Change in glycosylated haemoglobin A1c (HbA1c),Change in health-related quality of life (EQ-5D),,2020-05-28,WITHDRAWN,OBSERVATIONAL,['NA']
2876,NCT00117793,Limb Pistoning,Frustration (PEQ Scale),,2005-08,COMPLETED,INTERVENTIONAL,['NA']
2877,NCT02477761,Plasma glucose concentration,Plasma glucose-dependent insulinotropic polypeptide concentration,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
2878,NCT02537587,Incremental area under the blood glucose response curve,Insulinogenic index,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2879,NCT02258698,Number of adverse outcomes in relation to Insulin resistance measured as HOMA (homeostasis model assessment),Number of adverse outcomes in relation to Insulin resistance measured as irisin,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
2880,NCT03825562,Glycemic control,Psychological flexibility assessed by CAMM,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2881,NCT06186102,"Change in Physical performance, peak oxygen consumption (VO2max)",Days alive and out of hospital,Skeletal muscle satellite cell (MuSC) proliferation assays,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2882,NCT02643225,The Number of Participants Who Were Diagnosed With Fetal Macrosomia (Birth Weight),Interventricular Septum Thickness,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
2883,NCT03496597,surface of the central retinal avascular zone,,,2018-02-23,UNKNOWN,OBSERVATIONAL,['NA']
2884,NCT01264497,Change from baseline in relative insulin response,Number of subjects with a change in the control of diabetes,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2885,NCT05143827,60-min glucose,AUC glucose 180 min,,2021-11-20,RECRUITING,INTERVENTIONAL,['NA']
2886,NCT02609815,gut microbiota composition change from baseline,HbA1c change,PYY,2015-11-01,COMPLETED,INTERVENTIONAL,['NA']
2887,NCT04744714,Neonatal outcomes,annual follow-up results,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
2888,NCT01330251,Changes in fecal microbiota,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
2889,NCT01458210,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Ethinyl Estradiol (EE),,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2890,NCT02464033,Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment,GAD65-induced MCP-1 Secretion,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2891,NCT00035906,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2892,NCT02302443,Incidence and severity of treatment emergent adverse events,Area under the concentration-time curve (AUC) of HM12470 following a single dose,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2893,NCT02051647,Change in copeptin levels upon examination stress comparing copeptin levels prior and after examination,Correlation to cortisol as the classical stress marker,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
2894,NCT01212120,Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion.,,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
2895,NCT01053195,Incidence of type 2 diabetes,Cost-effectiveness of the lifestyle intervention,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
2896,NCT03862716,Proportion of participants achieving drug-free diabetes remission,Proportion of participants achieving drug-free diabetes regression,"the change in time range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear",2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
2897,NCT01806727,Predicted Cardiovascular Risk,Predicted Cardiovascular Risk,Health Costs,2013-04,COMPLETED,INTERVENTIONAL,['NA']
2898,NCT00300911,"Plasma Brain Natriuretic Peptide levels, echocardiographic measurements were made before the treatment and repeated after three months and six months of the treatment",,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2899,NCT05079399,Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathy,Change in retinal thickness in optical coherence tomography angiography (OCT-A),,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
2900,NCT01588587,Frequency of cancers,Receptor for AGE concentration,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
2901,NCT04530292,Measurement of HbA1c (%) one year after the discovery of diabetes.,Percentage of time spent wearing the sensor for patients with Freestyle sensor,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
2902,NCT03508934,Decrease in hypoglycemia during the hospitalization,,,2018-07-01,RECRUITING,INTERVENTIONAL,['NA']
2903,NCT03362398,Human plasma concentration of 12 participants will be measured after 1.5 h,,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
2904,NCT02637973,Change in liver fat content,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2905,NCT03447275,The difference in serum vitamin B6 concentrations between cases and controls,The difference in serum and urine vitamin B6 vitamers between patients with advanced global vascular risk versus those with a low vascular risk,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
2906,NCT01908530,Difference to the Venous Blood Glucose MARD,Acceptability Questionnaire,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
2907,NCT06170515,HbA1c Performance,Type of errors as displayed,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
2908,NCT01505673,Glycemic Control Measured by HbA1c,Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2909,NCT00993187,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With HbA1C < 7.0% at Week 30,,2010-05-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2910,NCT00338702,Time to definitive closure,,,2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2911,NCT01145742,Blood pressure,LDL Cholesterol,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
2912,NCT00286741,Systolic Blood Pressure,"Cost-effectiveness, Proportion of Patients With LDL < 100, Health Services Utilization, Quality of Life (as Measured by DQoL), Patient Empowerment (as Measured by DES).",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2913,NCT00166036,Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels,Change in Flow-mediated Dilatation (FMD),,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2914,NCT00308347,"Combined endpoint of doubling of serum creatinine, ESRD or death.",Secondary parameters: number of cardiovascular events and changes in proteinuria. Tertiary parameters: quality of life and healthcare resource utilization.,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2915,NCT00940173,"To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels",To determine whether DIABECELL(R) causes an improvement in quality-of-life,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2916,NCT03526289,food intake,bone turnover markers,,2017-11-08,COMPLETED,INTERVENTIONAL,['NA']
2917,NCT03382015,Average Daily Glucose Levels,Triglycerides,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
2918,NCT00528918,Hypoglycemic events,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2919,NCT05768191,To compare improvements from baseline in patient HbA1c when aggressively treated with insulin human isophane plus rapid acting human insulin vs treatment with Premix human insulin,"correlation between patient QoL and glucose variability as measured by CGMS (baseline, week 16 and week 32)",,2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE4']
2920,NCT03104829,HbA1C,Diabetic self-care behavior score,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
2921,NCT01944124,Systolic Blood Pressure,,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
2922,NCT03175120,Change in HbA1c,Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1,,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
2923,NCT01537705,VAS,Routine Blood Panel,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2924,NCT01194830,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2925,NCT03876015,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
2926,NCT03921242,Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses,Difference in Laboratory-Measured eGFR (mL/min),,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
2927,NCT01371266,"Area under the curve glucose, response for OGTT. Glucose-120 min OGTT-AUC",Serum Lipids,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
2928,NCT00001870,,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2929,NCT00381719,Reduction in Daily Pain Score,Quality of Life questionnaires,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2930,NCT03154073,Insulin Sensitivity Index (μmol·kg^-1·min^-1·pM^-1),Change in 24-hour Glycemic Control (glucose AUC),,2017-07-20,COMPLETED,INTERVENTIONAL,['NA']
2931,NCT02934737,Markers of progression of diabetes,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
2932,NCT00673231,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Fasting Plasma Glucose (FPG),Proportion of Participants With Lack of Glycemic Control,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2933,NCT00829387,Numeric Rating Scale (NRS) Pain Intensity,Beck Depression Inventory (BDI),,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2934,NCT00135057,Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2935,NCT02404896,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
2936,NCT03138746,insulin sensitivity,change in inflammatory cytokines,,2018-08-13,COMPLETED,OBSERVATIONAL,['NA']
2937,NCT00127296,Combined measure of accuracy and precision between target and measured amounts of insulin dispensed (mean square percent difference),Precision (coefficient of variation),,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2938,NCT04625452,Loss-to-follow-up at 24 weeks,"Change of TTT sub-scales means from 12 to 24 weeks in the ""Theoretical Model of Change"" scores",Means change from baseline to 24 weeks in the level of triglycerides (TGC) (mg/dl).,2020-08-13,UNKNOWN,INTERVENTIONAL,['NA']
2939,NCT03864991,Changes in HbA1c,Episodes of acute complications,,2018-10-29,UNKNOWN,INTERVENTIONAL,['NA']
2940,NCT01326026,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2941,NCT06281899,Time to the First Occurrence of Any of the Components of the Composite: ≥30% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death,Changes in the quality of life,Compliance to carbohydrate intake,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
2942,NCT00946972,"Adverse events, laboratory values, vital signs, ECGs",Incretin levels,,2009-07,TERMINATED,INTERVENTIONAL,['PHASE1']
2943,NCT02053051,Post-prandial hypoglycaemia,Number achieving target HbA1c ( ≤ 53 mmol/mol ),Acceptability questionnaire (non-validated),2013-11-12,COMPLETED,INTERVENTIONAL,['NA']
2944,NCT06310980,Time in range,DIDS,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2945,NCT00320502,Safety,Myocardial ischemia by 24-hour continuous 12-lead ECG,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2946,NCT05577728,Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol),Number of hypoglycemic episodes leading to an inpatient admission or emergency room encounter.,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
2947,NCT01254084,"Fating plasma glucose, Steady state plasma glucose in Somatostatin-Insulin-Glucose Infusion Test","Body weight (BMI, hip-waist ratio)",,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2948,NCT03717207,syncope recurrence,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2949,NCT04504370,Change in HbA1c,Change in Body Mass Index,,2020-04-27,COMPLETED,INTERVENTIONAL,['PHASE3']
2950,NCT01627977,Visibility of the membrane after injection of the dye,Usefulness of the dye,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2951,NCT03241303,Plasma glucose,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
2952,NCT03834610,"Improvement in Penile Doppler parameters after treatment including peak systolic velocity in (cm/sec), end diastolic volume in (cm/sec) and resistive index (RI) that = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity.",,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
2953,NCT03878745,BD Nano™ PRO Pen Needle Compared to Terumo Nanopass® (Injection Pain),BD Nano™ PRO vs Terumo Nanopass® (Leakage),Compare BD Nano™ PRO vs Terumo Nanopass® (Needle Breaking),2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
2954,NCT00729079,The primary outcome measure is weight loss with a goal of 7% of initial weight.,;Fat intake less than 25% and saturated fat less than 10% Fiber intake of at least 25 grams per day;Fasting blood sugar < 100 mg/dL; Absence of tobacco use,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
2955,NCT03372824,Glycated albumin reference interval in pregnancy,Admission to neonatal intensive care unit,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
2956,NCT05124405,To evaluate the feasibility of the ( PA) Physical Activity intervention.,,,2018-05-24,SUSPENDED,INTERVENTIONAL,['NA']
2957,NCT02580591,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD)),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,,2015-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2958,NCT02212522,Genetic and environmental risk factors of T1D predisposition,"Undertake a prospective research of G and E risk factors of ""death in bed"" syndrome in diabetic adolescents",,2004-11,UNKNOWN,OBSERVATIONAL,['NA']
2959,NCT02690467,Fructosamine levels,Number of episodes of insulin leakage at injection site,,2016-09-06,UNKNOWN,INTERVENTIONAL,['NA']
2960,NCT04225455,To compare the data generated from the continuous glucose monitoring system (CGMS) Dexcom G6® with their routine self-glucose monitoring in pilots with class 1 and class 2 certificates,Previous 6 months logged data,,2019-12-05,RECRUITING,OBSERVATIONAL,['NA']
2961,NCT00034788,Time to complete ulcer healing.,Incidence of complete ulcer healing and reduction in total ulcer area at end of study. Incidence of adverse events throughout study.,,2000-12,TERMINATED,INTERVENTIONAL,['PHASE3']
2962,NCT02355288,"Successfully enrolled, eligible and consenting patients within the first year of enrollment.",Quality of Life (QOL),,2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA']
2963,NCT00579228,Carotid intima media measurement change,,,2007-04-25,COMPLETED,OBSERVATIONAL,['NA']
2964,NCT04920279,Validity of the Turkish Version of Activities-specific Balance Confidence Scale in Patients With Diagnosis of the Diabetes Mellitus Before.,,,2018-06-11,COMPLETED,OBSERVATIONAL,['NA']
2965,NCT01095068,,,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
2966,NCT02098395,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2967,NCT01993511,Change in beta-cell function after RYGB.,Change in insulin sensitivity after RYGB.,Change in insulin clearance after RYGB.,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
2968,NCT00913497,Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days,Occurrence of Hypoglycemia;,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2969,NCT05444842,healing rate,,,2022-07-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2970,NCT01035879,Evaluate the effect of MBX-2982 on the absolute and percent change from baseline and placebo in mean weighted average of 14-point blood glucose levels associated with a standardized breakfast and lunch,Evaluate the effect of MBX-2982 on additional glycemic parameters.,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2971,NCT06292962,Neuropathic pain scores,Quality of life score,,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2972,NCT03199261,Bioequivalency between the 2 formulations of rE-4,,,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE1']
2973,NCT00362960,proteinuria (total urinary protein excretion) from baseline.,Evaluate safety and tolerability of all treatments.,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2974,NCT03011177,HbA1c,,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2975,NCT03475069,Quality of life,Body mass index,,2013-10-20,COMPLETED,INTERVENTIONAL,['NA']
2976,NCT02411825,Number of adverse events,Change from baseline in HbA1c,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2977,NCT01972113,Change in beta-cell function,"Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)",,2013-09,UNKNOWN,INTERVENTIONAL,['NA']
2978,NCT01393808,Changes in urinary albumin excretion from baseline at 4 month.,Ambulatory and 24-hour blood pressure profile.,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2979,NCT06071208,prevention of diabetic complications,,,2023-10-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2980,NCT01030978,"2-hour plasma glucose, category of glucose tolerance (IGT, NGT, T2DM)",Family assessment device (FAD) score,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
2981,NCT03899402,Change in HbA1c following dapagliflozin,Diabetic ketoacidosis assessment,,2019-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2982,NCT06021145,Percentage of time of glucose levels spent in the target range (empagliflozin vs placebo),Fasting ketone levels,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE4']
2983,NCT00905255,"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring",Change From Baseline in Fasting Plasma Glucose (FPG) for All Patients at Week 52 and 76,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for All Patients During On-Treatment Period,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2984,NCT00593424,Paired t-test or Wilcoxon signed rank test will be used to evaluate the change in fasting triglycerides with the diets.,Post-prandial lipids will be evaluated by t-test or Wilcoxon signed rank test for AUC of triglyceride and remnant lipoprotein measured by immunoseparation.,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
2985,NCT04311853,Implementation of new evidence-based nutrition practice guidelines,Improved health outcomes,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
2986,NCT03313297,Skin 11β-HSD1 activity,Skin RNA-seq gene expression profiling,,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2987,NCT01346033,Validation of SCOUT DS algorithm for detecting known type 2 diabetes,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
2988,NCT03755934,Change in the weekly average of the average daily pain scores,To characterise the dose-response relationship of MEDI7352 on chronic pain in subjects with PDN,,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE2']
2989,NCT04749030,Number of adverse events of severity grade 2 or more assessed by CTCAE v5.0 during the first week after first intervention (FMT or placebo).,Blood samples.,,2021-06-15,COMPLETED,INTERVENTIONAL,['NA']
2990,NCT05996380,Safety endpoints: Number of Adverse Events,,,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1']
2991,NCT01140932,ERG,Retinal Vessel Caliber,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
2992,NCT03134170,Hemoglobin A1C,Preventative care,,2015-08-01,UNKNOWN,INTERVENTIONAL,['NA']
2993,NCT02964572,changes in the secretion of IL-1 beta from peripheral blood mononuclear cells,"Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride",,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2994,NCT05767177,Glucemia following a Mixed Meal Test:,Enteroscopy: mucosal glucose-transport capacity,"Glucemia, insulinemia and GLPi-emia following the Mixed Meal Test",2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
2995,NCT00320970,Urinary carboxymethyllysine,,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
2996,NCT01315756,"Improved glycemic control, HbA1c","Lipids, self-care, lifestyle changes, complications, quality of life.",,2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2997,NCT00167284,Lipids,Patient and physician barriers to diabetes care,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
2998,NCT05176795,Gut microbiota composition,Fecal contamination with nanoparticles,,2022-03-16,RECRUITING,OBSERVATIONAL,['NA']
2999,NCT05415644,The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals area under the drug-time curve (AUC0-∞),Adverse events,,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3000,NCT04533659,Glycemic control,In-home self-monitoring of blood glucose,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
3001,NCT05888688,Volumetric quadriceps skeletal muscle mass (cm^3),Sarcopenia assessment,quadriceps musculoskeletal Biopsy Analysis,2023-12-06,RECRUITING,OBSERVATIONAL,['NA']
3002,NCT01352663,Change in HbAlc from baseline till the end of treatment period.,Percentage change in immunogenic response.,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3']
3003,NCT02806739,Number of Participants With Adverse Events That Are Related to Treatment,Effects of Soy Intake on C-reactive Protein (CRP),,2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3004,NCT03216564,Urinary albumin creatinine ratio (ACR) measured biochemically,Blood pressure,Patient Reported Outcome: Quality of life,2017-05-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
3005,NCT01589835,HbA1c Progression to diabetes,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3006,NCT00297583,serum insulin concentrations,Adverse events and hypoglycemic episodes collection,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3007,NCT02831361,changes from baseline HbA1c at week 25,Changes of HOMA-β at week 25,Changes of Triglyceride at week 25,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
3008,NCT02435329,Impaired endothelial function in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as measured by:,Impaired bone metabolism in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as assessed by:,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
3009,NCT04882332,Correlation between Metformin Usage Index and Vitamin B12 status among Egyptian patients with type 2 diabetes,,,2021-05-05,UNKNOWN,OBSERVATIONAL,['NA']
3010,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
3011,NCT05114018,Insulin sensitivity by Matsuda Index,Adverse events,,2020-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3012,NCT06131372,Change in urinary albumin-to-creatinine ratio (UACR),"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3013,NCT01566981,Change From Baseline in HbA1C at 1 Year.,Change of the Following Parameter : HbA1C,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3014,NCT00820703,To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.,To pilot the collection of data that may be considered useful in planning future studies of Nexagon® administered topically to diabetic foot ulcers.,,2009-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3015,NCT03951168,Diabetes Specific Quality of Life,HDL-C,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
3016,NCT03919656,Metabolomics changes in urine,Changes in albuminuria,,2019-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
3017,NCT02467790,Pharmacokinetic index,Incidence of adverse events and serious adverse events,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
3018,NCT01469065,Change From Baseline (Day -1) in Mean Daily Glucose at Day 14,Change From Baseline in Fasting Lipid Parameters at Day 14 and 16,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3019,NCT01880372,Decreased progression of diabetic retinopathy.,Changes in the plasma level of glutathione as measured by ELISA technique,Changes in visual acuity as measured by electronic visual testing algorithm,2013-09,TERMINATED,INTERVENTIONAL,['NA']
3020,NCT00955201,Peroneal Nerve Conduction Velocity,Short Form-36V: Mental Component Score,Age,2010-01-14,COMPLETED,INTERVENTIONAL,['NA']
3021,NCT00402194,Insulin-stimulated Leg Glucose Uptake,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
3022,NCT05090488,Change from baseline HbA1C at 3 months and 6 months,Change from baseline quality of life,,2020-12-14,UNKNOWN,INTERVENTIONAL,['NA']
3023,NCT02843724,Clinically meaningful reduction of HbA1c above and beyond that of control arm,Adverse Events,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3024,NCT01512680,Difference between HbA1c at Month 12 and Month 0 > 0.5%,"Better score at surveys of quality of life (SF-6D, DQOL) and auto-management",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3025,NCT04491253,Self-management: diabetes,Social support,,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
3026,NCT01222078,Proportion of Anti-otelixizumab Neutralizing Antibodies,Terminal Phase Half-life (Thalf) of Otelixizumab,,2010-11-22,TERMINATED,INTERVENTIONAL,['PHASE2']
3027,NCT05054842,Changes in HbA1c relative to baseline,Evaluate the concentration of the main metabolite of SP2086 in Type 2 diabetes,,2021-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3028,NCT00388986,AUC0-tau of glyburide,"AEs, laboratory parameters.",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3029,NCT03207269,Fasting Plasma glucose,Fasting continuous glucose monitoring glucose,,2017-07-20,COMPLETED,INTERVENTIONAL,['NA']
3030,NCT02152371,Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c),Rate of Hypoglycemic Events up to 28 Weeks,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3031,NCT03033433,Stage 2: Number of Participants with Adverse events and Serious adverse events that are related to treatment,Stage2: Change from baseline in biomarker( serum fructosamine) testing results.,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3032,NCT05566977,Efficacy of the adoptive T regs transfer,Prevention or stop progression to organ failure,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3033,NCT04572009,percentage of time in glycemic target,changes in activity over time,,2021-01-12,COMPLETED,INTERVENTIONAL,['NA']
3034,NCT06107153,Change in hemoglobin A1c,Hypoglycemia,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
3035,NCT03362762,"Characteristic of type 2 diabetes patients, treated with insulin in Guadeloupe",Describe the relation between the rate of HbAC and the plan of insulinothérapie,,2013-12-16,COMPLETED,OBSERVATIONAL,['NA']
3036,NCT01713465,Frequency of participants with increase in treatment adherence scores,Frequency of participants with increase in Satisfaction to Medical Care,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
3037,NCT05636007,nocturnal hypoglycemia,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
3038,NCT03739268,plasma glucose,Appetite measured by visual analog scale,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
3039,NCT06295900,Patient Introduction Form,Patient Follow-up Form,Visual Comparison Sleep Scale,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
3040,NCT01018017,Mean clinical chemistry parameters including serum creatinine,"Muscle histology and biomarkers of oxidative capacity-succinate dehydrogenase content Complex I, Complex II/III, complex IV.",,2010-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3041,NCT02505893,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),72-hour Continuous Glucose Monitoring,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3042,NCT02227875,Change in HbA1c From Baseline to 24 Weeks,Change in Cross-Reactive Insulin Antibody Percent Binding for Lantus Assay Over Time,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3043,NCT05549570,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",,2017-10-22,COMPLETED,INTERVENTIONAL,['PHASE1']
3044,NCT02010541,Glycaemic control,knowledge on diet and diabetes management,Quality of Life measures,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
3045,NCT00337298,Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer,24 hour ambulatory blood pressure (mmHg),,2006-07,COMPLETED,INTERVENTIONAL,['NA']
3046,NCT02368600,Proportion of subjects developed GDM,Proportion of neonates born with macrosomia,,2015-04-21,COMPLETED,INTERVENTIONAL,['NA']
3047,NCT06041412,the presence of DPN,,,2012-02-01,RECRUITING,OBSERVATIONAL,['NA']
3048,NCT01871428,Change in HbA1c,Safety: Incidence of adverse events,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3049,NCT06172166,Continuity of care,Diabetic Ketoacidosis,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3050,NCT01813799,Difference in average 24-h pain intensity (Likert scale) between before and after IP administration,Average daily dose of acetaminophen,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3051,NCT02373059,Patient Involvement Questionnaire,Patient Medication Adherence Questionnaire,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
3052,NCT02204527,Ambulatory Blood pressure monitoring,,,2015-10,TERMINATED,INTERVENTIONAL,['NA']
3053,NCT02081586,Computer System Usability Questionnaire (CSUQ),Body Mass Index Change,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3054,NCT05175677,Impact on diabetes control in the study population,Lifestyle modification for diabetic patients,,2022-03-10,COMPLETED,OBSERVATIONAL,['NA']
3055,NCT00069628,HbA1c value obtained 6 months after randomization,Diabetes Self Management Profile at 6 months,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3056,NCT04369703,Assess relative change,,,2020-01-28,COMPLETED,OBSERVATIONAL,['NA']
3057,NCT01630512,change in severity of depressive symptoms,intersession changes in mood,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3058,NCT02030600,Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,FPG (Fasting Plasma Glucose),,2014-01-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3059,NCT00771576,Pancreas [11C] DTBZ binding,,,2006-09,COMPLETED,OBSERVATIONAL,['NA']
3060,NCT03534193,Effectiveness of tablet education in newly diagnosed type 1 diabetes,Improved subject compliance with glucose monitoring,,2017-04-17,SUSPENDED,INTERVENTIONAL,['NA']
3061,NCT02175121,Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern,Apparent Clearance (CL/F),,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3062,NCT01821846,The incidence of SADRs (Serious Adverse Drug Reactions),Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions),,2013-11-20,COMPLETED,OBSERVATIONAL,['NA']
3063,NCT00331448,,,,2000-06,UNKNOWN,OBSERVATIONAL,['NA']
3064,NCT05723445,Change in percent time in target range 70-180 mg/dL,Change in intestinal fatty acid binding protein (I-FABP),,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
3065,NCT02683902,Weight loss,"Weight, waist circumference and total body fat loss after 3 and 6 month of end of intervention",,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
3066,NCT02521675,percentage of time spent over 24 hours in hyperglycemia (> 180 mg / dL) (> 10 mmol / L),"Comparison between number of hypoglycemic events predicted by the prediction function ""DIABRASPORT"" and number of hypoglycemic events actually occurred.",,2016-01,COMPLETED,INTERVENTIONAL,['NA']
3067,NCT05824286,Change in measured HbA1c from baseline to 24 weeks,The rate of severe hypoglycemic events and confirmed hypoglycemic events during the 24 weeks of the study,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
3068,NCT01228500,Time to healing,,,2008-01,WITHDRAWN,INTERVENTIONAL,['NA']
3069,NCT05838222,Feasibility measure,Hypertension,,2023-05-08,COMPLETED,INTERVENTIONAL,['NA']
3070,NCT03717909,Visual acuity (VA),Pancreatic beta cell reserve - glycated haemoglobin or equivalent,PMBC - Biomarker 2,2018-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3071,NCT02264951,plasma GIP,plasma CCK,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
3072,NCT01968265,The effect of ISIS-GCCRRx on serum fructosamine,The tolerability of ISIS-GCCRRx,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3073,NCT02967211,Change in HbA1c (percentage %),Change in fasting plasma glucose,,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE4']
3074,NCT01041144,HbA1c,PP2hr Lipid profile,,na,COMPLETED,INTERVENTIONAL,['NA']
3075,NCT05347030,The change in the value of 2-hour blood glucose from baseline at the end of the 12-week treatment,The change from baseline of blood pressure,Incidence of Adverse Events,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
3076,NCT01760707,Exercise capacity,maximal oxygen pulse,,2002-11,COMPLETED,INTERVENTIONAL,['NA']
3077,NCT04822480,Medical expenditures,Coping self-efficacy,Implementation,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
3078,NCT00108927,,,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
3079,NCT03147274,Change from baseline self-care adherence at 12 months,Change from baseline hemoglobin A1c at 12 months,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
3080,NCT01099137,The change of HbA1c,HbA1c < 7.0% without hypoglycemia,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3081,NCT00660907,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Body Weight Reduction of at Least 5%,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3082,NCT02661906,Improvement in quality of life,Improvement in lipid profile,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
3083,NCT02152891,Change in rate of EMS Calls,,,2015-11-01,COMPLETED,INTERVENTIONAL,['NA']
3084,NCT03161652,Vasoinhibin vitreous levels,Blood pressure,,2017-05-24,RECRUITING,INTERVENTIONAL,['PHASE2']
3085,NCT02290925,Glycosylated Haemoglobin,Renal Adverse Effects - 2,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3086,NCT03663322,Fasting glucose,A1C,,2018-11-15,UNKNOWN,INTERVENTIONAL,['NA']
3087,NCT01107171,Hemoglobin A1c (HbA1c),"The rate of adverse events,the blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3088,NCT01686945,Number of treatment emergent adverse events (TEAEs) recorded,Change from baseline in glycosylated haemoglobin type A1c (HbA1c),,2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
3089,NCT01189422,Dose regimen,,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3090,NCT02060357,Endothelial stent coverage,MACE,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3091,NCT00655603,Glucose turn-over,"The inhibitory effect of GLP-1 on glucagon, and the role of this in its anti-diabetic potential, measured by looking at glucose turn-over.",,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
3092,NCT01739205,Weight loss,Inflammation,Other outcomes,2008-01,COMPLETED,INTERVENTIONAL,['NA']
3093,NCT05316662,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",,2022-04-06,RECRUITING,OBSERVATIONAL,['NA']
3094,NCT02558270,Change in endogenous glucose production,Changes in hormones involved in hypoglycemia counter regulation,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3095,NCT05394727,Change from baseline in Plasma insulin concentrations to week 4,,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
3096,NCT03851666,Effect of the treatment on reduction of the HbA1c level (%),Effect of the treatment on evolution of the subject weight,,2018-08-09,COMPLETED,INTERVENTIONAL,['NA']
3097,NCT03549559,11C-Martinostat Binding,,,2018-09-07,UNKNOWN,INTERVENTIONAL,['NA']
3098,NCT03440203,Activities of daily living,,,2017-05-11,COMPLETED,OBSERVATIONAL,['NA']
3099,NCT02011178,Glomerular filtration rate,Lipids,Quality of life score,2014-03,WITHDRAWN,INTERVENTIONAL,['NA']
3100,NCT01467141,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of Adverse Events (AEs),,2002-06-19,COMPLETED,INTERVENTIONAL,['PHASE4']
3101,NCT01475786,The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.,,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3102,NCT05596760,EHR documentation of Goals of Care discussions,Anxiety and depression (HADS),,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
3103,NCT01807377,HDL cholesterol,,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3104,NCT04825795,Prevalence of obstructive coronary disease,Change in coronary calcium score,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
3105,NCT02426073,"Inflammatory markers (TNF-α, interleukin-1, interleukin-2, interleukin-6, RANKL, Myostatin and GDF11)",,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3106,NCT01924312,Brain T2 hyperintensity volume on MRI,Total brain volume,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3107,NCT05442398,HbA1c,,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3108,NCT04161651,changes in quality of life evaluated questionnaires (DTSQ),Any adverse event related to study device,,2019-11,UNKNOWN,INTERVENTIONAL,['NA']
3109,NCT02227212,Ease-of-use / ease of learning questionnaire,Number of participants with site injection site reactions / hypersensitivity reactions,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3110,NCT02756832,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Percentage of Participants Who Used Healthcare Resources,,2016-09-20,COMPLETED,OBSERVATIONAL,['NA']
3111,NCT00394030,Pharmacokinetic measurements for different injection sites after one dose.,Pharmacodynamic measurements at three different times after one dose.,,2006-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
3112,NCT01582308,Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough,Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax),,2012-06-21,COMPLETED,INTERVENTIONAL,['PHASE1']
3113,NCT00031213,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
3114,NCT02312427,Serum BNP level with and without DPP-4 inhibitor use.,"Other neurohormonal factors (Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptid)",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3115,NCT03235440,Change in Body Weight,Body Image Assessment of Children (BIA-C):,,2017-06-19,COMPLETED,INTERVENTIONAL,['NA']
3116,NCT00099515,Hypothesis that std training for HIIP system is noninferior to intensive training by 1.2 mmol/L with respect to overall 2-hr postprandial glucose excursion of (SMBG) in type 2 diabetes patients that have been on preprandial trmt with HIIP,Compare the test meal blood glucose profiles of preprandial HIIP administration with standard training and with intensive training,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3117,NCT00591227,Hospital Length of Stay,Frequency of Hypoglycemia During Emergency Room Therapy With Insulin,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
3118,NCT06287840,Bone Strength (Failure load),Alkaline phosphatase,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
3119,NCT00184561,Change in HbA1c,after 24 weeks of treatment.,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3120,NCT00519480,"Home diary of blood sugar results, adverse events and drug dosing.",fluid intake & output,,2007-09-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3121,NCT04799925,Effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.,,,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA']
3122,NCT00488930,"Measure changes in dendritic cells at baseline, 6 months and 1 year following weight loss",,,2007-06,TERMINATED,OBSERVATIONAL,['NA']
3123,NCT04975464,COVID 19 survey,,,2011-11-15,UNKNOWN,OBSERVATIONAL,['NA']
3124,NCT04567563,Change in ulcer area and overall healing rate,tissue perfusion,,2020-11,UNKNOWN,INTERVENTIONAL,['NA']
3125,NCT00569595,"Serum glycosylated hemoglobin, heart rate recovery step test","Total Cholesterol, BMI, waist circumference, healthy eating, physical activity, perceived health status, patient satisfaction, mood",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3126,NCT01222429,"indices of renal function (serum creatinine, microalbumin)",,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
3127,NCT05579977,"Placebo-adjusted, percent change from baseline in body weight at Week 32 in Obesity",Assessment of mental health as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) in Obesity,,2022-10-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3128,NCT04757285,determine stress hormones in serum cortisol and copeptin,correlation of psychological stress with stress hormone copeptin,,2020-05-10,COMPLETED,OBSERVATIONAL,['NA']
3129,NCT05661799,Change in amount of physical activity assessed by the French Version of GPAQ,Progressive medical data assessed by a specific form for the study,,2021-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3130,NCT00873925,C-Peptide following the 1 year mixed meal tolerance test,Peripheral Blood T-cell assays,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3131,NCT03623139,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,Change in urinary biomarkers of carbohydrate intake,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
3132,NCT01633086,Neuopathic Pain Scale,the likelihood of reusing the nitric oxide gel recorded,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3133,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol,Change in FPG From Baseline to Week 78,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3134,NCT01563887,The change in the number of hypoglycemia-related driving mishaps,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
3135,NCT01698385,Change from Baseline in oral glucose tolerance test at variable time frames,Change from Baseline in weight at variable time frames,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3136,NCT00523042,"Changes in lung function, chest X-rays, or asthma exacerbation frequency",Preprandial insulin doses,,2007-08-30,TERMINATED,INTERVENTIONAL,['PHASE3']
3137,NCT03486964,Post-prandial plasma glucose,Cardiovascular death,,2018-03-27,COMPLETED,OBSERVATIONAL,['NA']
3138,NCT05577650,Prevalence of chronic kidney disease,,,2023-01-09,COMPLETED,OBSERVATIONAL,['NA']
3139,NCT00726505,The change in urinary glucose excretion dynamics,Glucose effects on tubular markers,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1']
3140,NCT01240980,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",The single-dose pharmacokinetics parameter apparent clearance from plasma after extra-vascular administration (CLT/F) of BMS-903452 will be derived from the plasma concentration versus time data,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3141,NCT02307279,Co-Primary Outcome: Percentage of Subjects Who Achieve Body Weight Loss ≥ 5%,Change in Hemoglobin HbA1c in Subjects With Type 2 Diabetes at Baseline,Assess Safety and Tolerability of Administration of Gelesis100,2014-11,COMPLETED,INTERVENTIONAL,['NA']
3142,NCT04275141,In vivo kinetics of lactate,DNA Banking,,2022-01-17,RECRUITING,INTERVENTIONAL,['NA']
3143,NCT04016155,Difference in time in hypoglycaemia,Fear of hypoglycaemia,,2019-07-17,UNKNOWN,INTERVENTIONAL,['NA']
3144,NCT03066284,Impact of IPT on QoL of children and adolescents from their perspective and their parents' perspective,,,2016-03-14,UNKNOWN,OBSERVATIONAL,['NA']
3145,NCT02555332,75g oral glucose tolerance test (OGTT) positive or not,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
3146,NCT06005051,Changes in postprandial metabolites response as measured by micro-sampling,Changes in personal metabolic states through the day as measured in micro-sampling by Olink proteomics,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3147,NCT04370171,Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.,"Number of conventional hospitalizations, in intensive care and deaths.",,2020-05-04,COMPLETED,OBSERVATIONAL,['NA']
3148,NCT05286892,Perceived Competence Scale,,,2023-04-30,RECRUITING,INTERVENTIONAL,['NA']
3149,NCT06190717,Primary Effectiveness Endpoint,Freedom from Events through 30 and 90 Days,Intervention to Assist Maturation Rate,2024-02-21,RECRUITING,INTERVENTIONAL,['NA']
3150,NCT01759953,Knowledge on insulin therapy for diabetes,Attitudes regarding diabetes/insulin,Reasons for not finishing the game,2014-07,COMPLETED,INTERVENTIONAL,['NA']
3151,NCT03562078,Hemoglobin,high frequency (HF),,2017-05-22,UNKNOWN,INTERVENTIONAL,['NA']
3152,NCT02837094,To examine the risk of C19A3 GNP administration in terms of general safety and induction of hypersensitivity.,To study the immune responses to C19A3 GNP generated in the draining (axillary) lymph node.,,2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
3153,NCT04090242,Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES) From Baseline to End of Study,Patient Satisfaction at Study End,Number of Hours of Patient Engagement With App,2019-09-06,TERMINATED,INTERVENTIONAL,['NA']
3154,NCT05266404,Volume of distribution (apparent) following extravascular administration (based on terminal phase) (Vz/F),Number of subjects with adverse events (AEs),,2022-03-21,COMPLETED,INTERVENTIONAL,['PHASE1']
3155,NCT03207711,frequency of eating in response to cravings (primary mechanistic outcome),Perceived Stress (secondary mechanistic outcome),,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
3156,NCT02107469,Improvement of NTSS-6 SCORE in per cent from baseline,Assessment of compliance regarding medication and dietary recommendations (score).,Patient Diary,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3157,NCT02684929,Change in glucose disposal,Change in gene expression in adipose tissue,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
3158,NCT02249910,Area under the digoxin plasma concentration-time curve,Number of hypoglycaemic episodes,,2014-09-18,COMPLETED,INTERVENTIONAL,['PHASE1']
3159,NCT06150209,Time Closure in Diabetic foot ulcers Managed with Vendaje,Reduction of wound volume in diabetic foot ulcers treated with Vendaje,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3160,NCT01509742,Area under the Curve (AUC) glucagon,Adverse events,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3161,NCT00682903,"The HbA1c, the witness of the quality of the metabolic balance, in 6 and 12 months. We shall compare the deltae of HbA1c between the period of inclusion and 6 and 12 months following the training course in the ""fonctional"" insulin therapy",,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
3162,NCT05607576,Post radiation Dexcom G6 transmitter functional duration,,,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3163,NCT04407234,PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen,PK: Cmax of Acetaminophen at Steady State For T2DM,,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
3164,NCT04061200,Albuminuria,Inflammatory and endothelial biomarkers,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3165,NCT03566810,Maximum Observed Plasma Concentration (Cmax) of Metformin,Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings,,2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3166,NCT03515421,Marketing Claims Evaluation questionnaire.,,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
3167,NCT04696653,Change in self-efficacy as assessed by an adapted version of Compeau & Higgins' task-focused self-efficacy scale,Change in the percent of individuals diagnosed with dyslipidemia who received lifestyle counseling,,2021-02-24,COMPLETED,INTERVENTIONAL,['NA']
3168,NCT04229628,Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3169,NCT02848547,Incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme.,Long-term impact of healthy lifestyle through mobile phone based text messaging,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
3170,NCT02456051,Pancreatic cancer diagnosis,Mortality,,2015-04,TERMINATED,OBSERVATIONAL,['NA']
3171,NCT02383537,miRNA profiling,,,2017-04,UNKNOWN,OBSERVATIONAL,['NA']
3172,NCT04306939,Common disease mechanisms and repurposing of medications.,Patient Reported Global Health Assessment,,2014-11-01,SUSPENDED,OBSERVATIONAL,['NA']
3173,NCT01944618,Incidence rates of spontaneously reported hypoglycaemia in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice,Subgroup analyses may be conducted for selected safety parameters,,2013-10,TERMINATED,OBSERVATIONAL,['NA']
3174,NCT03102892,Salivary glucose - collection of stimulated saliva in 10 minutes and measured with a colorimetric kit,Capillary glycemia measured by a glucometer,,2017-04-24,TERMINATED,INTERVENTIONAL,['NA']
3175,NCT00134277,Primary patency after 6 months,Proving the superiority or non-superiority of one treatment procedure to another treatment procedure,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
3176,NCT05696366,Change in HbA1c,Change in subject self reported ambulatory insulin dosing,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3177,NCT00127192,Change From Baseline in HbA1c at Week 12,Change From Baseline in Fasting Plasma Glucose at Week 12,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3178,NCT05368454,Change in HbA1c,Change in diabetes distress,,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3179,NCT04388059,glycemic control in morbid obese diabetic adolescents.,weight loss in morbid obese diabetic adolescents.,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
3180,NCT01756105,Efficacy of metformin in treatment of gestational diabetes based on capillary glycaemia with an objective of less than 6 measures out of range,,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE2']
3181,NCT00674518,Improve physical activity and dietary behaviors among sedentary patients,"Improve biomarkers of obesity including glucose, lipid levels, CRP, leptin and insulin.",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
3182,NCT01405261,Overview of Treatment Emergent Adverse Events (AEs),The time to maximum concentration (tmax) of NNC 0113-0987 in plasma,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3183,NCT04696640,Change in hemoglobin A1c (HbA1c),Remote patient monitoring survey,,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
3184,NCT01571817,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3185,NCT01873859,Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use.,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3186,NCT05477628,zBMI,Dietary Quality,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3187,NCT01857973,Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform),Percentage of Time in Euglycemic Range - Phase 7,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
3188,NCT05514184,Dietary adherence to PLAFOND vs. standard-of-care renal diet assessed by diet diaries,Glycemic status by continuous glucose monitoring (GCM),,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3189,NCT01004848,Change in Weight From Baseline to 6 Months,Knowledge & Attitudes About Diabetes Risk,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
3190,NCT04739215,"Main Structural Objective: Changes in serum levels of procollagen type I C-terminal propertied (PICP, ng/mL)",Changes in high sensitivity troponin T (pg/mL),,2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
3191,NCT01656915,Cytokines,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
3192,NCT02987738,Time in Range 70-180%,Reduction of Insulin dose,,2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3193,NCT03278158,"Safety and tolerability of single ascending oral doses of XEN-D0501, (1, 2, 4 and 8 mg) versus placebo in type 2 diabetic patients in treatment with metformin (Incidence of adverse events in type 2 diabetic patients)",,,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
3194,NCT03965000,Changes in the gene expression,,,2019-01-24,UNKNOWN,OBSERVATIONAL,['NA']
3195,NCT01727349,Measure of risk of developing type 2 diabetes in at-risk families,,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA']
3196,NCT04563598,Total earnings from employment and/or self-employment by study year (all study participants),Ever received Supplemental Security Income (SSI) benefits at age 65 since randomization (all study participants),Ever retired during first 10 years after randomization (all study participants),2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
3197,NCT02639988,Time to the addition of a new treatment for type 2 diabetes in months,Proportion of patients with increased HOMA-IR between 2 visits in %,,2016-04-13,SUSPENDED,OBSERVATIONAL,['NA']
3198,NCT00797134,Retinal thickness.,Choroidal Thickness,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
3199,NCT02740283,Rate of GDM diagnosed in 18-20 gestational week.,,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
3200,NCT04521634,Stroke Primary outcome - MRS,,,2020-09-30,COMPLETED,OBSERVATIONAL,['NA']
3201,NCT04909580,Decisional Conflict,Genetic Counselling Satisfaction Scale (modified version),,2013-09-05,COMPLETED,INTERVENTIONAL,['NA']
3202,NCT04253431,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3203,NCT01344928,,,,na,UNKNOWN,INTERVENTIONAL,['NA']
3204,NCT02775266,Serum Resistin Levels and HBAIC Levels,Clinical Attachment levels,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3205,NCT02470637,Assessment of PD parameter: Area under the glucose infusion rate curve within 24 hours after administration of the investigational medicinal product or until administration of rescue insulin (GIR-AUC0-end),Number of patients with adverse events,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3206,NCT01538290,,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
3207,NCT00966368,Maximum observed Insulin Degludec concentration after single dose,Terminal half-life for Insulin Degludec,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3208,NCT00791479,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3209,NCT04112069,Percentage of Time With CGM Glucose Values <54 mg/dl,,Number of Episodes of Diabetic Ketoacidosis (DKA),2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
3210,NCT05349955,Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure.,Secondary Outcome of Phase 2: All-cause death,The time rate of glycemic target range,2022-11-21,RECRUITING,INTERVENTIONAL,['NA']
3211,NCT05422352,Nerve Growth Factor,,,2021-01-14,COMPLETED,INTERVENTIONAL,['NA']
3212,NCT05755321,Characterization of neural progenitors cells,,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3213,NCT01574157,Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1),Change in Estimated Glomerular Filtration (eGFR),,2012-11-05,COMPLETED,INTERVENTIONAL,['NA']
3214,NCT03305367,Gastrointestinal tolerability,,,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
3215,NCT01481116,Change From Baseline in HbA1c at Weeks 78 and 104,"Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104",,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3']
3216,NCT02177786,Change in eGFR From Baseline at Week 48,Percentage of Participants Achieving at Least a 30% Reduction From Baseline in Albuminuria (As Measured by Urine Albumin to Creatinine Ratio) at Week 48,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3217,NCT02733211,Percentage of glucose sensor readings within 70 to 180 mg/dl (3.9 to 10 mmol/l) during the night (23:00-7:00 h),Percentage of sensor glucose readings >300 mg/dl,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
3218,NCT02224365,Blood Pressure,Body Composition,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3219,NCT03906513,changes in the characteristics of the subbasal corneal plexus at confocal,- changes in clinical signs and symptoms of ocular surface damage,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
3220,NCT03193944,Achieving 25 (OH) D upper than insufficient serum 25(OH) D level >30 ng/l.,Improved blood pressure,,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3221,NCT04573920,Change in proteinuria for FSGS patients at 1.5 mg dose,,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3222,NCT05055219,Progression of glucose tolerance,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
3223,NCT05829239,Change in insulin sensitivity,Change in intrahepatic triglyceride content,Change in the transcriptome in adipose tissue,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3224,NCT05368142,Wound healing rate up to 30 days,Pathogenic bacteria positive rate,,2022-05-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
3225,NCT02748980,The coronary microcirculation dysfunction is measured by index of microcirculatory resistance,,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
3226,NCT00238836,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3227,NCT05758545,Complete wound healing,Quality of life survey,,2023-06-19,RECRUITING,INTERVENTIONAL,['NA']
3228,NCT03660293,"The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.",Identification of risk factors for developing diabetic cardiac insult.,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
3229,NCT00104572,Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density,Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3230,NCT04845412,Rate of Hearing loss,,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
3231,NCT00763074,,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
3232,NCT05593575,Percentage change from baseline in UACR,The change trend of eGFR,,2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3233,NCT00552370,"To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®, each of varying intensity and defined by their end-of-study target for self monitored blood glucose (SMBG).",To compare the number of subjects whose final A1c is <7.0% at the end of the study for the 5 dosing algorithms.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3234,NCT03625648,Time to ESRD or death,Rate of change in eGFR per year during the study period,,2019-11-18,RECRUITING,INTERVENTIONAL,['PHASE4']
3235,NCT04834245,the percentage of a reduction rate of the diabetic foot ulcer after intervention,,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
3236,NCT04894916,User Experience,Change in Medication Adherence,,2021-06-12,COMPLETED,INTERVENTIONAL,['NA']
3237,NCT03023228,Assessment of change in Diabetes knowledge as measured by an 11-item diabetes knowledge survey,Medication adherence (Modified Morisky Medication Adherence Scale 4-item),,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3238,NCT04558775,Proportion of participants who have DFU wound recurrence by 16 weeks after complete wound healing,Clinician assessment of DFU wound recurrence,,2020-06-17,COMPLETED,OBSERVATIONAL,['NA']
3239,NCT05158244,"Number of participants with clinically significant, abnormal 12-lead ECG parameters",Plasma Decay Half-Life (t1/2) of PF-07081532,,2021-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
3240,NCT03313024,T cell population content at the time of preeclampsia diagnosis compared to controls and verified by flow cytometry,,,2017-09-26,RECRUITING,OBSERVATIONAL,['NA']
3241,NCT03426085,Sudomotor Function,Inflammatory Markers Tumor Necrosis factor α (TNF α),,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3242,NCT03516994,Proportion of Whites who complete advance care planning,Patient Quality of Life,,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3243,NCT01467063,Insulin Sensitivity,Glucagon-like Peptide 1 (GLP-1),,2011-10,COMPLETED,INTERVENTIONAL,['NA']
3244,NCT06253429,Changes in urinary albumin excretion rate,,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
3245,NCT04431947,Duration of Sleep,Impact of Sleep on Glycemic Variability,,2020-03-13,COMPLETED,OBSERVATIONAL,['NA']
3246,NCT01277900,Gastric Bypass in the Treatment of Type 2 Diabetes in Patients with a BMI of 25 to 35 kg/m2,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
3247,NCT04334499,Quantitation of mitochondrial DNA in vitreous humor and serum samples,Evaluation of mtDNA quantitation versus ocular comorbidities as described in electronic medical record.,,2020-02-21,WITHDRAWN,OBSERVATIONAL,['NA']
3248,NCT04573335,All-cause mortality,COVID-19 illness,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
3249,NCT01304615,consumption of Self-made Meals,Percent Body fat,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3250,NCT04219124,Plasma concentration of 3-hydroxybutyrate,Plasma acylcarnitines measured by targeted metabolomics,,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE4']
3251,NCT00099944,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3252,NCT04076007,24 hour Ambulatory Blood Pressure monitoring after 2 weeks placebo juice,Insulin sensitivity,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
3253,NCT01498731,Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.,Length of hospital stay,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
3254,NCT01973413,Percent Time Near Normoglycemia,Glycemic Events,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
3255,NCT02671331,Excess weight loss (EWL),Protein malnutrition,,2016-01,TERMINATED,OBSERVATIONAL,['NA']
3256,NCT00653341,Percentage of subjects reaching target HbA1c = or < 7% at endpoint and not experiencing symptomatic nocturnal hypoglycemia,"Safety data (Adverse events, vital signs, laboratory values, etc.)",,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3257,NCT00470795,GCSI score,SF-12 Health Survey Questionnaire; C-13 acetate breath test,,2009-06,SUSPENDED,INTERVENTIONAL,['PHASE3']
3258,NCT02553382,Change in HbA1c,Change in 24h ambulatory systolic blood pressure,Change in Hs-CRP,2015-11,COMPLETED,INTERVENTIONAL,['NA']
3259,NCT00362011,Hemoglobin A1c,"compliance (plasma fatty-acids, returned supplements, diet records, body weight).",,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3260,NCT04402710,"Acceptability as assessed by semi-structured exit interviews with participants which will include questions related to their thoughts and feelings about the study and whether they believed the study was acceptable (e.g. content, timing).",Change in Cognitive Emotion Regulation strategies from baseline to 6 weeks (intervention end),,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
3261,NCT01089829,"The primary outcome of the study is to identify the neurovascular risk factors for foot ulceration as renal function declines, and to develop a suitable foot protection programme for CKD patients.",The secondary outcome measure is to identify whether dialysis modality choice influence foot ulcer development and should this be used to inform patient choice of dialysis.,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
3262,NCT01939470,Change from Baseline in Bone Mineral Density at Year 1 and Year 2,Change from Baseline in C-reactive Protein at Year 1 and Year 2,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
3263,NCT01047735,Feasibility of performing a randomized trial comparing two major types of bariatric surgery versus a lifestyle weight loss intervention (LWLI) induced by diet and increased physical activity in moderately obese patients with T2DM.,Preliminary information regarding the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss with diet and increased physical activity.,,2009-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3264,NCT03630445,"Appetite ratings (Visual Analog Scale, VAS)",Breath hydrogen (fermentability),,2015-06-02,COMPLETED,INTERVENTIONAL,['NA']
3265,NCT03666065,maximum insulin concentration,Time to GIR Max,,2020-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3266,NCT05623189,Primary Endpoint,Endpoint 28,,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2']
3267,NCT02755064,Relationship between gastric emptying and glycemia,Number of subjects with delayed gastric emptying,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3268,NCT01236794,Insulin Sensitivity,QOL,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3269,NCT03463564,Change in glucose variability,Diabetes treatment satisfaction,,2016-01,RECRUITING,INTERVENTIONAL,['PHASE4']
3270,NCT02680457,Glycemic Variability: Mean Amplitude of Glucose Excursion (MAGE),Glycemic Variability: Area Under the Curve of Glucose,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3271,NCT00720317,"We aim to screen African-American diabetic patients with retinopathy to ascertain whether sickle trait is present, and if so whether there is increased severity of diabetic retinopathy in the group with sickle trait.",,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
3272,NCT05458167,Time-in-range of Hedia Diabetes Assistant bolus calculator with physical activity module,Time-below-range of Hedia Diabetes Assistant bolus calculator with physical activity module,Usability of Hedia Diabetes Assistant bolus calculator with physical activity module,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
3273,NCT05454891,Glucose Area Under Curve [AUC],Percentage of time between 70-140 mg/dL,,2022-07-15,RECRUITING,INTERVENTIONAL,['PHASE4']
3274,NCT01946997,Normative retinal thickness data for comparison,,,2006-07,COMPLETED,OBSERVATIONAL,['NA']
3275,NCT05089942,Efficacy of Recombinant Human Insulin Patch ZJSRM2021,Pain assessment of Recombinant Human Insulin Patch ZJSRM2021,,2021-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
3276,NCT04039945,presence of multiple islet autoantibodies,,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
3277,NCT05072587,Serum 7-Ketocholesterol (7-KC),World Health Organization (WHO-5) Index of Well Being,,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA']
3278,NCT02910076,glucose level,,,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3279,NCT01790945,% change in Diabetic Retinopahy/Diabetic Macular Edema diagnosis with pre-screening system compared to post-screening system,Change in HgA1C from Primary Care Physician referral to post retinal specialist visit,Time from PCP referral for patient to see an ophthalmologist and appointment with retinal specialist,2013-02,UNKNOWN,OBSERVATIONAL,['NA']
3280,NCT03522311,Visual acuity measurement,Presence of postoperative vitreous hemorrhage,Presence of postoperative retinal detachment,2013-01,COMPLETED,OBSERVATIONAL,['NA']
3281,NCT01608620,Coronary heart disease (CHD) analysis,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
3282,NCT04992312,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics (PK): AUC of Nasal Glucagon,,2022-03-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3283,NCT01282567,Dosage of plasma insulin concentration and blood glucose every 20 minutes during 6 hours and 40 minutes,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3284,NCT01375270,Insulin Secretion,"Plasma Cytokines (IL-6, TNF, IL-1beta, IL-1ra)",,2011-04,COMPLETED,INTERVENTIONAL,['NA']
3285,NCT02956642,Change in HbA1c Levels,Change in fasting lipid panel.,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
3286,NCT00770952,Change from Baseline in Homeostatic Model Assessment - Beta cell.,Change from Baseline in Total Cholesterol,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3287,NCT00013910,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
3288,NCT06203106,Biobank,,,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
3289,NCT01047865,"Retrospective and prospective analysis of pancreas transplant recipients to determine frequency, and time course of autoantibody recurrence of disease. Prospective follow up to: monitor autoantibody levels, monitor and phenotype autoreactive T",Monitor autoantibody levels as well as phenotype autoreactive T cells in peripheral blood.,,2005-05,RECRUITING,OBSERVATIONAL,['NA']
3290,NCT03845114,Decrease in plasma glucose levels during exercise,Amount of carbohydrates needed to treat a hypoglycemic event,,2019-06-30,RECRUITING,INTERVENTIONAL,['NA']
3291,NCT01451398,Change From Baseline to Week 24 in HbA1c,Change in Body Weight From Baseline to Week 24,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3292,NCT04558827,Effectiveness of Intervention: Changes in Insulin Dosage,Feasibility: Percent of day compliant with Carbohydrate target,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
3293,NCT02353923,Change in Electronic-ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing,Change in Blood levels of circulating endothelial progenitor cells (EPC),,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
3294,NCT00467285,Changes in BMD 0.33 Radius,Changes in CTx at Follow up,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
3295,NCT01546844,"Change in Hemoglobin A1c - In control, over time.",Disease Management,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
3296,NCT00498537,reduction in proteinuria,Changes in GFR and incidence of hyperkalemia,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
3297,NCT01147250,"Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina",Percent Change From Baseline in the Urinary Albumin/Creatinine Ratio (UACR) at Week 108,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3298,NCT02389335,"Roles of interferon gamma, interleukin-2, tumor necrotizan factor alpha in the pathogenesis of type 1 diabetes",,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
3299,NCT01967849,Glucose Tolerance,Insulin resistance,Gene Expression,1999-09,RECRUITING,INTERVENTIONAL,['NA']
3300,NCT02962492,Change in Beta-hydroxybutyrate Levels in Blood,Change in Total Insulin Dose,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
3301,NCT00613782,Insulin Resistance,Bone microarchitecture,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3302,NCT01820377,Waist Circumference,Parent Lifestyle Behaviours Questionnaire,Social Determinants of Health,2010-10,COMPLETED,INTERVENTIONAL,['NA']
3303,NCT04620967,Time in range,Ketoacidosis,,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3304,NCT04958356,"Number of participants with confirmed positivity for at least one diabetes-associated autoantibody (insulin autoantibodies and antibodies to GAD65, islet antigen 2 and zinc transporter 8) or confirmed positivity for tissue transglutaminase antibodies",,,2018-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3305,NCT02858843,Change in units of insulin used over a period of 6 months to 1 year.,Pulmonary function test (PFT) forced expiratory volume at one second (FEV1) measurements,,2016-08-01,TERMINATED,INTERVENTIONAL,['NA']
3306,NCT04642755,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,,2021-04-19,RECRUITING,OBSERVATIONAL,['NA']
3307,NCT04810507,Effect of Improving Glycemic Variability,Average nighttime (18:00~07:59) blood glucose change after 12 weeks compared to baseline,,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3308,NCT00499824,Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%,"HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
3309,NCT00603590,Systolic Blood Pressure,LDL Cholesterol,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3310,NCT03679273,PEDIS score,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3311,NCT05679115,Change of long-term blood glucose concentration measured as glycated hemoglobin at 1 year,,,2023-01-10,RECRUITING,INTERVENTIONAL,['NA']
3312,NCT03332472,HbA1c,Standard deviation,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
3313,NCT01965665,Change in Sepsis Rate,,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
3314,NCT05330247,Change in glycated hemoglobin (HbA1c) after 12 months on the CRHP diet compared with the CD diet,Change in hepatic fat content after 12 months on the CRHP diet compared with the CD diet,Change in Health Literacy after follow-up at 24 months on the CRHP diet compared with the CD diet,2022-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3315,NCT04643899,Carbohydrate balance,MES sessions check,,2021-03-29,COMPLETED,INTERVENTIONAL,['NA']
3316,NCT04304430,Combined categorized endpoint,Proportion of patients attaining blood pressure target,,2018-10-18,COMPLETED,OBSERVATIONAL,['NA']
3317,NCT04970810,A1c,Diabetes Self-Efficacy,,2021-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3318,NCT03429088,Feasibility of identifying and recruiting sufficient number of participants into a telephone-based physical activity intervention.,Physical Activity Self-Regulation,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
3319,NCT02445833,Changes in blood pressure levels at 6 and 12 months,Satisfaction with treatment,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
3320,NCT04838405,Incidence of Treatment-Emergent Adverse Events as assessed by self-report,Change in mean insulin levels,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE1']
3321,NCT04210089,Complete Healing Rates,Patient Complications,,2020-10-13,RECRUITING,INTERVENTIONAL,['NA']
3322,NCT00515801,plasma glucagon concentrations during insulin induced hypoglycemia with and without glibenclamide pretreatment,cognitive function during insulin induced hypoglycemia with and without glibenclamide pretreatment,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3323,NCT02029833,Abdominal imaging of visceral and subcutaneous abdominal fat,Lipopolysaccharide (LPS),,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3324,NCT02994316,Interest of copeptin dosage as a severity marker in children under the age of 16 with diabatic ketoacidosis,Correlation between plasma copeptin levels and other markers used in management of diabatic ketoacidosis in the first 36 hours after diagnosis- Plasma copeptin levels at diagnosis of diabate mellitus type 1 without ketoacidosis in children,,2016-10-03,COMPLETED,INTERVENTIONAL,['NA']
3325,NCT00610038,assess continuously the capillary glycaemia for three consecutive days and evaluate the insulin secretion under insulin and sulfonylureas,To assess the kinetics of glibenclamide in children,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3326,NCT05606913,HbA1c change from baseline at week 28,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3327,NCT05930561,Annualized number of aflibercept injections in the study eye,Percentage of subjects with a ≥2 and ≥3-Step Diabetic Retinopathy Severity (DRS) improvement from baseline on the ETDRS-DRSS,"Incidence and severity of treatment-emergent adverse events and serious adverse events, including clinically significant changes in safety parameters",2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2']
3328,NCT05607979,Primary Endpoint,Change in Pain Scores over time (60 days),,2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3329,NCT05904769,Blood glucose level,,,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
3330,NCT02261831,rDNA comparison between cases and controls,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
3331,NCT02432391,Change from baseline glycosylated hemoglobin at 6 months,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3332,NCT02742662,Change in body weight in kg,Change in plasma triglycerides,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
3333,NCT03839641,Overnight Respiratory Exchange Ratio,Slope of Respiratory Exchange Ratio,,2019-01-14,COMPLETED,INTERVENTIONAL,['NA']
3334,NCT00313742,The difference between plasma glucose concentrations immediately pre-exercise and the minimum plasma glucose concentrations (nadir) in the period 0-150 min following exercise,Incidence of adverse events during the trial,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3335,NCT00134147,Glycosylated hemoglobin,Safety based on adverse events reported and laboratory tests,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3336,NCT01219582,Change in Hemoglobin A1c (HbA1c) levels,Percentage of patients with satisfaction of treatment,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
3337,NCT01152957,Glycemic Control,Cholesterol,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
3338,NCT03531905,Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C),Percent Change From Baseline to Week 12 in HbA1c,Number of Participants With Any Treatment-emergent Adverse Event (TEAE),2018-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3339,NCT01678469,link between plasma concentrations and dietary intakes of lipophilic micronutrients and risk of developing a Gestational diabetes mellitus,,,2011-11-28,COMPLETED,INTERVENTIONAL,['NA']
3340,NCT05799976,Care gap order rate,,Care gap completion rate,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3341,NCT03947879,Change in hemoglobin A1c,Change in waist circumference,,2019-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
3342,NCT02122666,Sarcoplasmic Reticulum Composition,Lean and Fat Body Mass,,2014-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3343,NCT01937598,Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC),AUC Active GIP,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3344,NCT05366868,Time from study drug initiation (Week 0) to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16.,Time from Week 0 to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16 by patient characteristics,,2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE4']
3345,NCT00286598,Change in weight-bearing physical activity (steps/day),Foot-related self-care,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3346,NCT00481117,"Safety labs, ECGs, vital signs, adverse events.",Pharmacodynamics (lab samples) and Pharmacokinetics (lab samples),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3347,NCT00725127,"To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration in subjects with impaired fasting glucose or type 2 diabetes on primary prevention of cardiovascular, cerebrovascular and renal fatal, and non-fatal events.","To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between subjects with and without metabolic syndrome.",,2008-10,RECRUITING,INTERVENTIONAL,['PHASE4']
3348,NCT00156078,Mean pain score,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3349,NCT03380416,Liver fat content,Biochemical parameters,,2017-04-04,COMPLETED,INTERVENTIONAL,['NA']
3350,NCT01519466,Time in Target Blood Glucose Range,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 60.,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3351,NCT00005474,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
3352,NCT04104321,Double Blind Part: To evaluate the effect of Aramchol compared to placebo on composite long-term outcome,,,2019-09-23,SUSPENDED,INTERVENTIONAL,['PHASE3']
3353,NCT01724502,Protein Concentration of Mitochondria,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
3354,NCT04991142,Feasibility of measuring meal quantity and composition using CGMs,Feasibility of measuring impact of gut microbiota on estimations of meal composition using CGMs,,2021-09-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3355,NCT01593371,Serum concentrations of leptin,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
3356,NCT02617160,Percentage of glucose readings within range of 70-180 mg/dl,Percentage of glucose readings below 50 mg/dl,Device Satisfaction,2016-05,TERMINATED,INTERVENTIONAL,['NA']
3357,NCT04405895,Change in Clock Genes mRNA,Change in Overall Glycemia,,2020-05-31,UNKNOWN,INTERVENTIONAL,['NA']
3358,NCT04385888,Glycemic Variability,Inflammatory cytokines (e.g. IL-6),,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3359,NCT02201199,Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing,"Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters)",,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3360,NCT06268743,Gut microbiome diversity through 16S ribosomal RNA genes,,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3361,NCT05701813,"Efficacy on insulin-resistance, measured with the HOMA-IR index","Improvements in triglycerides, total cholesterol and HDL cholesterol.",Effect on BMI (Body Mass Index),2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3362,NCT02597309,Reduction in insulin recuirement,,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3363,NCT04762251,HbA1c,Adherence,,2021-02-17,RECRUITING,INTERVENTIONAL,['NA']
3364,NCT03356340,End-stage Renal Disease,,,1993-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3365,NCT01480804,change in hemoglobin A1c,"Change in clinical, functional and psycho social tests and questionnaires",,2006-11,COMPLETED,INTERVENTIONAL,['NA']
3366,NCT04583800,Heart failure (≥ stade B).,Major cardio-neuro-vascular events,,2021-06-22,RECRUITING,OBSERVATIONAL,['NA']
3367,NCT04668651,Antral content,Perioperative respiratory complications,,2021-01-12,COMPLETED,OBSERVATIONAL,['NA']
3368,NCT04886388,The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups,The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups,,2021-04-22,COMPLETED,INTERVENTIONAL,['PHASE3']
3369,NCT02334241,Favourable healing outcome (FHO),Number of local cares requiring instrumental debridement (surgical or sharp debridement).,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
3370,NCT01768559,Change in Body Weight From Baseline to Week 26,"Percentage of Participants Who Reached the Target of HbA1c <7%, Had no Weight Gain at Week 26, and Did Not Experience Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia During 26-Week Treatment Period",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3371,NCT01681147,Barriers Associated With Poorer Adherence to Diabetes Screening Guidelines and Weight Loss Goals,Exercise Frequency in Women With Gestational Diabetes Post-Partum,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
3372,NCT00287807,"Glycemic control; HbA1c at baseline, 3 months, 6 months, 9 months and 1 year (endpoint)",bodyweight; Bodymass index at baseline and endpoint,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3373,NCT05468632,Change in glycated haemoglobin (HbA1c),Having at least 1 severe hypoglycaemic episode,,2022-07-05,COMPLETED,OBSERVATIONAL,['NA']
3374,NCT02123628,Primary outcome measure was the proportion of patients of each group with remission of diabetic foot osteomyelitis at the end of follow-up.,tolerance to treatment in each group of patients,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3375,NCT01169818,Change (decrease) in mean hemoglobin glycosylated (HbA1c) level,PROMs (patient reported outcome measures) scores from the DTSQs/c (diabetes treatment satisfaction questionnaire status) and EQ-5D (European quality of life - 5 dimensions),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3376,NCT02105792,Response to diabetes therapy,Collection of samples for analysis of potential biomarkers,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
3377,NCT02117063,Change in mean score for the PACES scale after 6-months of intervention,Changes in anthropometric and biochemical indices of metabolism and possible PCOS,,2012-04,RECRUITING,INTERVENTIONAL,['NA']
3378,NCT02103595,Perception of pain during infusion set insertion assessed by means of a visual analogue scale (VAS),Insulin set replacement pattern,,2013-11-01,COMPLETED,INTERVENTIONAL,['NA']
3379,NCT02572856,Feasibility of Instrument: Count of CGM Instrument Issues,,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
3380,NCT01932476,Change in Markers of Autoimmunity,Gastrointestinal Symptoms,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3381,NCT06071975,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11, ≤14, ≤18, ≤22, ≤26, ≤30, ≤34, ≤43, ≤47, ≤52",Number and severity of adverse events (AE),2023-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
3382,NCT02439684,The specificity of the use of HbA1c,DM risk,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
3383,NCT02528396,AUClispro 0-30min (timepoint 0 = time of dosing),Local tolerability injection site reactions,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3384,NCT04238949,Hemoglobin A1c,Healthcare costs,,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3385,NCT01832077,cost-effectiveness,Cost-effectiveness of van,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
3386,NCT03021811,Rate of complete wound closure,Impact of treatment on Health-related Quality of Life (CWIS questionnaire),,2015-10,COMPLETED,INTERVENTIONAL,['NA']
3387,NCT05622981,Change from baseline body mass index (BMI) percentile at 24 weeks,Adherence to follow-up scheduling,,2023-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3388,NCT01529541,The Change in HbA1c from baseline to week24.,change from baseline to week 24 in HOMA-IR,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3389,NCT04060693,Measurement accuracy of IMD,Safety evaluation: paucity of adverse events,,2019-12-10,WITHDRAWN,INTERVENTIONAL,['NA']
3390,NCT03027960,urine sodium concentrations via ion selective electrodes,blood volume,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3391,NCT01582451,Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c),Number of Participants With Change in Anti-LY2605541 Antibodies,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3392,NCT03358745,Area under the curve of postprandial glycemia,"Area under the curve (AUC) of postprandial Glucagon-like peptide (GLP-1), Peptide YY (PYY) and glucose-dependent insulinotropic polypeptide (GIP)",,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
3393,NCT01451372,Daily Usage of Blood Glucose Test (BG Testing),Frequency of Sensor Usage Per Month,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
3394,NCT05039957,Complication rate,,,2021-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3395,NCT04758884,"To compare changes in HbA1c at 6 months in a group of patients with T1D in the reference area of the ""Hospital Comarcal de l´Alt Penedès"" followed by telemedicine versus to the usual management in consultation.",Differences in terms of number of unplanned contacts with the specialist in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3396,NCT05147116,Mean AUC (Area Under the Curve) Plasma [Glucose],Sleep efficiency (time in bed + time asleep),,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
3397,NCT02105324,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5,Percentage of Participants Using Pramlintide During the Usual Care Period,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3398,NCT03267758,change in baseline flow mediated dilation (FMD) at 6 weeks,,,2018-05-15,RECRUITING,INTERVENTIONAL,['NA']
3399,NCT02686177,Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group,Difference of Circulating soluble adhesion molecules as endothelial activation markers: ICAM-1 and VCAM-1 concentration at 4 weeks of treatment from baseline (Liraglutide versus control group),,2016-05-18,COMPLETED,INTERVENTIONAL,['PHASE4']
3400,NCT00558571,"Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG",HbA1c,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3401,NCT01999452,Change of HbA1c,,,2015-10,WITHDRAWN,INTERVENTIONAL,['NA']
3402,NCT04427982,DES Score,,Glycated Hemoglobin (A1c),2020-09-03,COMPLETED,INTERVENTIONAL,['NA']
3403,NCT00690326,incremental physical activity,glycosylated hemoglobin,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
3404,NCT05725889,"Finger tap, visual and auditory reaction test data within 10 seconds",,,2021-07-15,COMPLETED,OBSERVATIONAL,['NA']
3405,NCT05324189,Specificity of identification of referable and non-referable Diabetic,The accuracy of identification of referable and non-referable DR for early diagnosis of DR,,2022-04-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3406,NCT00254254,Number of adverse events,,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3407,NCT03984058,Recruitment Yield as assessed by number of participants enrolled from electronic medical records (EMR),Adherence to Pap Therapy as assessed by the ResMed AirView Remote Monitoring system,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
3408,NCT01441518,Perinatal mortality and morbidity rates,Costs,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3409,NCT01487629,Central subfield macular thickness (CSFT) change,Best-corrected visual acuity change,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3410,NCT02601729,Evolution over time of HbA1c,Quality of life measured by the Diabetes Quality of Life for Youth for children,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
3411,NCT00105352,"Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals",,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
3412,NCT05088616,Change in A1c (from baseline to 90 days and 180 days),Change in identity and level of cultural connectedness (using part of Multigroup Ethnic Identity Measure survey questions) (from baseline to 90 days and 180 days),,2021-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3413,NCT05795439,HbA1C,Diet Acceptability,,2023-07-11,RECRUITING,INTERVENTIONAL,['NA']
3414,NCT03254381,Number of exercise classes attended at trial completion (6 months),Change in blood glucose levels as measured by finger prick glucose test,,2017-11-02,COMPLETED,INTERVENTIONAL,['NA']
3415,NCT05589155,Long term change in diabetes via fasting blood glucose,Quality of Life after using mHealth apps assessed by World Health Organization Quality of Life BREF questionnaire,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
3416,NCT00032734,serum sodium concentration,safety assessment,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3417,NCT02312596,Percent of wounds healed,Quality of Life score,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3418,NCT01307995,,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
3419,NCT03064906,Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL),Effect of changing setpoints,,2017-03-18,COMPLETED,INTERVENTIONAL,['NA']
3420,NCT05038020,To Investigate the Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline.,To Evaluate the Changes From Baseline in the Workplace Productivity and Activity Impairment General Health (WPAI-GH) Questionnaire.,,2021-08-17,TERMINATED,INTERVENTIONAL,['PHASE2']
3421,NCT05829642,Number of Participants with hospital readmission,Number of hypertension patients (all risk levels) with drug prescription appropriate,,2020-11-24,COMPLETED,OBSERVATIONAL,['NA']
3422,NCT02070510,Area under the lisinopril concentration-time curve,Maximum observed lisinopril plasma concentration,,2014-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3423,NCT05409235,Proportion of participants who have improved by ≥ 2 steps from baseline in Diabetic Retinopathy Severity Scale (DRSS) scores,Time to administration of rescue therapy,,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE2']
3424,NCT01644500,Change From Baseline in HbA1c at 26 Weeks,Visual Analog Scale (VAS) Score at 26 Weeks,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3425,NCT03180710,Cmax_total,Number of hypoglycaemic events in each treatment arm,,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3426,NCT03794752,Response Speed to Visual-motor Skills to Identify Shapes and Objects With the Head-mounted Electronic Visual Enhancement Device,,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
3427,NCT05769712,Elasticity of the supraspinatus tendon,Thickness of the supraspinatus tendon,Blood flow within the supraspinatus tendon,2021-03-01,RECRUITING,OBSERVATIONAL,['NA']
3428,NCT04135365,"Cognitive Function: Behavior Rating Inventory of Executive Function, Second Edition",Imaging,,2021-01-18,COMPLETED,OBSERVATIONAL,['NA']
3429,NCT04008147,insulin,alpha glycoprotein,,2019-07-03,RECRUITING,INTERVENTIONAL,['NA']
3430,NCT03498001,Change from Baseline Concentration of intramyocardial triglycerides at 6 months,,,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
3431,NCT05733962,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Treatment Satisfaction (DTSQs) Questionnaire,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3432,NCT00550095,Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks.,Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (< 130/80),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3433,NCT01940003,Glycemic control,Birth injury,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3434,NCT01073020,Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up.,Cardiovascular Risk,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3435,NCT05822232,Efficacy endpoint,,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA']
3436,NCT01531855,24 hour blood glucose area under the curve,Ketogenesis,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
3437,NCT03545841,Maximal aerobic capacity,Vascular stiffness,,2015-03-09,COMPLETED,INTERVENTIONAL,['NA']
3438,NCT05322213,Change in Vascular Endothelial Function,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3439,NCT03903042,Image Quality of Aurora camera,Outcome of artificial intelligence algorithm,,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA']
3440,NCT02501876,The rate of conversion to Alzheimer's disease (AD),The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
3441,NCT01085292,Safety and tolerability of multiple intravenous doses of NOX-E36 in healthy subjects and patients with type II diabetes mellitus,Multiple dose pharmacokinetics and pharmacodynamics of NOX-E36 in healthy subjects and patients with type II diabetes mellitus,,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3442,NCT03407833,Ability to establish organoid cultures,,,2018-02-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3443,NCT00234871,Changes in urinary albumin:creatinine ratio,"Changes in blood pressure (BP), BP control, ABPM, proteinuria, GFR lipid parameters, glycemic control, quality of life, CRP, oxidative stress markers, clinical safety labs and adverse events.",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3444,NCT00566865,pharmacodynamics of mitiglinide,safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3445,NCT00883038,Insulin resistance,Visceral to subcutaneous fatty tissue ratio,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3446,NCT00261417,"Dose-response relationship of tesaglitazar in subjects with type 2 diabetes by the assessment of the effects of each of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) to placebo with respect to fasting plasma glucose",Assess the safety and tolerability of tesaglitazar compared to placebo,,2004-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3447,NCT03978884,Proportion of Subjects achieving Target Blood Pressure,,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3448,NCT01779089,Change in 24 hour urine protein/creatinine ratio (average of 2 values) baseline compared to 6-months in placebo vs minocycline,Change in urine and blood biomarkers in minocycline vs placebo treated patients at baseline vs 6 mos,Safety,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
3449,NCT00606138,Number of Participants With Occurrence of Adverse Events,"Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment",,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3450,NCT01329016,Study drug dosage in pregnancy,Determine GLY and MET PK parameters,,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3451,NCT02183350,Assessment of tolerability by investigator on a 4-point scale,Change in plasma glucose levels,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3452,NCT02087293,Discontinuation of mediation,Adverse drug reaction awareness,Call metrics,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
3453,NCT02657876,Number of participants with adverse events through study completion,,,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
3454,NCT05535985,Incidence of postoperative delirium,Expression of peroxisome proliferators-activated receptor-γcoactivator-1α (PGC-1α),Mini-mental state examination (MMSE) score,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3455,NCT06256614,"The Blood glucose of Time in Range (TIR, %) of type 1 diabetes mellitus.","The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0",,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
3456,NCT02610036,presence of microangiopathy,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
3457,NCT04208295,Autonomic adrenergic measure,,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
3458,NCT00558909,Global tolerability - number of patients by category,PTF (peak trough fluctuation).,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3459,NCT05404295,The efficacy of UCB-PL in ulcer healing by assessing the change in ulcer size.,,,2019-06-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3460,NCT02668250,Incidence of a composite of mortality or major postoperative morbidity.,,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
3461,NCT02751398,subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography,the impact of dapagliflozin on resting diastolic function,,2016-08-18,COMPLETED,INTERVENTIONAL,['PHASE4']
3462,NCT01645891,Complete (100%) wound closure defined as complete re-epithelialization without drainage,Total Bates-Jensen Wound Assessment Tool Score,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
3463,NCT02672059,Diagnosis of neuropathy,Synovium tissue collection for RNA,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
3464,NCT05146869,Change from baseline in active glucagon-like peptide1 concentration,Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.,,2021-12-30,COMPLETED,INTERVENTIONAL,['PHASE1']
3465,NCT01945840,Weight loss,Glycaemia,,2013-10,RECRUITING,INTERVENTIONAL,['NA']
3466,NCT01069549,,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
3467,NCT05296759,Pittsburgh sleep quality index,,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3468,NCT00861341,Percent Platelet Aggregation Induced by Collagen,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3469,NCT02316522,DNA methylation,Micro-RNAs,,2014-10-23,COMPLETED,OBSERVATIONAL,['NA']
3470,NCT00541697,Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment,Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment,,2005-01-19,COMPLETED,INTERVENTIONAL,['PHASE3']
3471,NCT03906383,Diameter change of retinal vessels,,,2017-11-21,COMPLETED,INTERVENTIONAL,['NA']
3472,NCT00938405,To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.,"In addition change in insulin dose at one, two and three months from baseline will be evaluated.",,2009-07,COMPLETED,INTERVENTIONAL,['NA']
3473,NCT00704314,insulin sensitivity,ectopic lipid deposition in liver and muscle,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
3474,NCT04314427,Glucose control,Changes in glycemic control,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
3475,NCT02459496,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,"change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)",,2013-09,UNKNOWN,INTERVENTIONAL,['NA']
3476,NCT01800734,1. Composite plasma glucose and hormone responses to a mixed meal 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
3477,NCT04533646,Time in Target,Hypoglycemia duration,,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3478,NCT05809843,The measurements of retinal and choriocapillary vessel density in type 1 diabetic patients undergoing artificial pancreas device,,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA']
3479,NCT04099550,Weight (Kg) change,lipid profile,,2019-12-06,UNKNOWN,INTERVENTIONAL,['NA']
3480,NCT06148649,Change from baseline of HbA1c at week 12,Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs),,2023-12-10,RECRUITING,INTERVENTIONAL,['PHASE2']
3481,NCT06222476,renal magnetic resonance imaging(MRI),HOMA2-IS,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3482,NCT01230749,Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG),Change From Baseline to Day 29 in Body Weight,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3483,NCT02352480,Time to heal,W-QOL (Quality of life with chronic wounds) score,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
3484,NCT05338125,Electrophysiological properties,Endocrine deficiencies,,2020-12-10,TERMINATED,INTERVENTIONAL,['NA']
3485,NCT06219590,Numerical rating pain scale,,,2023-10-28,RECRUITING,INTERVENTIONAL,['NA']
3486,NCT05234944,Acceptability,Glycemic Outcome - Time in Range,,2022-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3487,NCT00929539,Change in glycosylated hemoglobin (HbA1c) levels,Safety and tolerability data,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3488,NCT02312375,Insulinogenic index,"Urinary albumin creatinine ratio, urinary protein creatinine ratio",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3489,NCT03557151,Glycosylated Hemoglobin (HbA1c),Diabetes Self Management Profile - Parent Proxy Report,Type 1 Diabetes and Life (T1DAL) Scale - Caregiver Report,2018-07-13,COMPLETED,INTERVENTIONAL,['NA']
3490,NCT06052371,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument,,,2023-10-16,TERMINATED,OBSERVATIONAL,['NA']
3491,NCT01787916,Assessment of Changes in Glycemic Control by HbA1c.,Assessment of Changes on Adipose Tissue,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3492,NCT04593693,"Goal of therapy: The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft",Evaluate overall satisfaction from clinicians,Determine performance satisfaction of dressing components on periwound,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
3493,NCT02159378,Serum fructosamine rate,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
3494,NCT01152242,"Part II: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR (AUC of glucose infusion rate), GIRmax (maximum level of glucose infusion rate), over the duration of action of glargine",Part II: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3495,NCT00044694,Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28,Change in serum fructosamine from Baseline (Day 1) to Day 14 and to Day 28,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3496,NCT01591525,,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
3497,NCT01371747,Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group,Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3498,NCT01375738,Blood sugar stabilization after gastrectomy,,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
3499,NCT02110979,Knowledge score,Decisional conflict,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
3500,NCT00000462,,,,1987-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3501,NCT04239521,Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata,Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
3502,NCT05044442,Severe hypoglycaemia (using continuous glucose monitoring),area under the curve of episodes of hypoglycaemia and hyperglycaemia,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
3503,NCT06064786,GCF levels of fetuin A and hsCRP evaluation in all groups,,,2023-08-01,COMPLETED,OBSERVATIONAL,['NA']
3504,NCT01239550,Low dose basal insulin detemir will potentiate weight loss in obese patients with type 2 diabetes mellitus undergoing a hypocaloric diet intervention by improving dopamine signaling,Neuropsychiatric functions,,2011-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3505,NCT05990517,C-peptide change,Quality of life score,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3506,NCT00464854,Achievement of a fasting blood glucose of 130 mg/dl and a mean daily glucose level of 180 mg/dl during hospitalization,Hypoglycemia of < 60 mg% (symptomatic and asymptomatic),,2005-07,TERMINATED,INTERVENTIONAL,['NA']
3507,NCT04774822,To determine the sensitivity and specificity of RETINA-AI Galaxy to detect vision-threatening diabetic retinopathy in the primary care setting,,,2021-03-25,COMPLETED,OBSERVATIONAL,['NA']
3508,NCT01556152,Mean 24-hour average pain intensity (API) score,"Pharmacokinetics: Cmax, Tmax, AUC 0-tau, AUC0-24",,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3509,NCT00313547,Heart rate variability,Impact of selected pharmacogenetic polymorphisms,,2006-04,TERMINATED,INTERVENTIONAL,['PHASE4']
3510,NCT04766450,Concentration of Glutathione peroxidase,,Toronto clinical scoring system,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE4']
3511,NCT01939834,Time in range overnight,Time within target range,,2013-12,TERMINATED,INTERVENTIONAL,['NA']
3512,NCT04414579,Time to stabilization of rising blood sugar by CGM after correction bolus,Treatment related impact measures between arms,,2019-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
3513,NCT01499472,healed ulcer,,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
3514,NCT05509881,Percent (%) of time in target glucose range (70-180 mg/dl),Hypoglycemia Fear,Participant feedback on continuous glucose monitoring training sessions,2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
3515,NCT04272099,"Glycemic control, health related quality of life and clinical phenotypes of PG1","Psychometric evaluation of the health literacy, health-related quality of life, self-esteem and self-efficacy questionnaires in PG1",,2017-06-20,RECRUITING,OBSERVATIONAL,['NA']
3516,NCT04634890,Total cholesterol,Subcutaneous adipose tissue transcriptome,,2016-08-11,UNKNOWN,INTERVENTIONAL,['NA']
3517,NCT03841591,Rate of maternal weight gain per week,Incidence of macrosomia,,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3518,NCT00790556,Mean Change From Baseline in Hepatic Glucose Production (HGP) at Day 14,,Hepatic Glucose Production (HGP) at Baseline,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3519,NCT05123157,Mortality among patients with diabetic foot,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
3520,NCT02688075,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at 6 and 12 Months,Number of Participants with Adverse Events (AEs) and Serious AEs,,2015-11-13,COMPLETED,OBSERVATIONAL,['NA']
3521,NCT01728714,"Number of people with type 2 diabetes treated with oral antidiabetics assessed as compliant with treatment after 1 year educational programme on diabetes, compared with normal clinical practice.","Measure level of satisfaction of the patient with treatment and medical care following 1 year educational programme on diabetes, compared with normal clinical practice.",,2014-05-19,COMPLETED,OBSERVATIONAL,['NA']
3522,NCT01173991,Glycated haemoglobin (HbA1c),Hypoglycemia (capillary glucose<50 mg/dl),,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3523,NCT02798393,Decrease in Pain (MPI Pain Scale),Improvement in Sensation,Safety Assessment (incidence of treatment related AEs at each follow up visit),2016-06,TERMINATED,INTERVENTIONAL,['NA']
3524,NCT00256867,Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy,Number of of Participants With Laboratory Evaluations of Potential Clinical Concern at Any Time Post-baseline,,2005-08-18,COMPLETED,INTERVENTIONAL,['PHASE3']
3525,NCT02538055,Quality of Life (SF12),Diet - eating unhealthy foods because of pain in the past 7 days,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3526,NCT00678704,The Erectile Function (EF) domain score of IIEF calculated as the sum of scores from Questions 1 to 5 and 15,Safety data,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3527,NCT04031300,Safety evaluation: paucity of adverse events,Device usability,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
3528,NCT04094064,Mean Absolute Relative Difference (MARD) Between Continuous Glucose Monitor (CGM) Value and Venous Blood Glucose (vBGM),,,2020-02-19,COMPLETED,INTERVENTIONAL,['NA']
3529,NCT02931656,Change from Glycemic level,Change from Fetal heart rate,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
3530,NCT00885352,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26,,2009-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3531,NCT05541458,Body Weight - 12 month,,,2022-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3532,NCT02193984,Changes in HbA1c levels.,Changes in distress.,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
3533,NCT03865394,Changes in wound size,Record of adverse events,,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3534,NCT05666843,Cardiometabolic risk profile (DIAL risk score),Skeletal muscle fat infiltration,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
3535,NCT02607865,Change in HbA1c: Week 26,Change in CoEQ: Scores From the 4 Domains and the 19 Items,,2016-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3536,NCT00961480,The area under the plasma concentration-time curve (AUC) after administration of sitagliptin/metformin (50/500; 50/850; 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.,"Peak plasma concentration (Cmax) for metformin after administration of sitagliptin/metformin (50/500; 50/850, 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3537,NCT00145379,HbA1c after the two intervention periods,"Insulin need, hypoglycaemia frequence, body weight, lipid profile, blood pressure after the two intervention periods",,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3538,NCT03226210,The primary endpoint was the between-group difference of MAGE,,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3539,NCT01097551,Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit),"Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
3540,NCT06043245,Type 2 Diabetes (T2D) remission.,Epicardial fat,,2023-06-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3541,NCT00976391,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26,"Change From Baseline in Body Weight at Weeks 36, 48 and 52",,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3542,NCT04594603,To record the vascular changes that may be present in the macular after uncomplicated phacoemulsification surgery by using OCTA,,,2021-04-13,RECRUITING,OBSERVATIONAL,['NA']
3543,NCT00784511,2-hr post load glucose,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3544,NCT05219942,Total crystalline insulin consumption,,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
3545,NCT06078683,Changes in maximal exercise performance,Change in Cardiac function after acute ingestion of KE or placebo,Change in stiffness,2023-06-06,RECRUITING,INTERVENTIONAL,['NA']
3546,NCT00885118,Change From Baseline in 8-point Glucose,"CLR,ss",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3547,NCT02475109,Number of Patients with Adverse Events,Time to first rescue treatment,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3548,NCT03526445,Hepatic lipid metabolism,Changes in appetite sensation,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
3549,NCT00784745,Incremental GLP-1 response during the mixed meal test. Assessed as AUC during the 4 hour test.,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
3550,NCT04702477,Intervention Attendance,Program satisfaction and barriers for attending sessions,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
3551,NCT04618354,Bone mineral density,LH,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
3552,NCT02734667,Time Spent in Hypoglycemia (< 70 mg/dL),C-peptide,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3553,NCT04302012,Agreement between multiple EyeArt operations,,,2019-12-18,COMPLETED,OBSERVATIONAL,['NA']
3554,NCT00580710,Brain response to blood glucose levels,,,2001-08,COMPLETED,OBSERVATIONAL,['NA']
3555,NCT00823225,Major amputation free survival,"Total survival, major amputation rate, rate of complete ulcer healing, rate of adverse events",,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3']
3556,NCT04529317,Blood glucose fluctuations,Nutrient intake recorded,Serum albumin in g/dL,2016-05,COMPLETED,INTERVENTIONAL,['NA']
3557,NCT05856877,"Comparison of the blood-brain-barrier permeability in different age, weight, sex and metabolic risk groups",,,2023-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3558,NCT03956914,Changes of blood glucose,Waist-hip ratio (WHR),,2016-06-02,COMPLETED,INTERVENTIONAL,['NA']
3559,NCT00917449,To evaluate the efficacy of long term (18 months) L-Arginine therapy in preventing or delaying clinical onset of type 2 diabetes mellitus in subjects with impaired glucose tolerance (IGT) and Metabolic Syndrome.,Define if the treatment with L-arginine can ameliorate insulin sensitivity and endothelial dysfunction and find new risk profiles and candidate genes able to characterize the sub-group of patients at higher risk to develop type 2 diabetes mellitus.,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3560,NCT01889784,Change in muscle oxygen uptake after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,Change in baroreflex sensitivity after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,Change in heart rate after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
3561,NCT05687812,Plasma c-peptide levels changes,Appetite regulation,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
3562,NCT02504086,Change in diabetes self-management behaviours as measured by Summary of Diabetes Self Care Activities (SDSCA; Toobert et al 2000),"Perceived usefulness and perceived ease of use of online support as measured by the Unified Theory of the Acceptance and Use of Technology (UTAUT) for telehealth (Kohnke et al., 2014 based on Venkatesh et al., 2003)",,2015-08,TERMINATED,INTERVENTIONAL,['NA']
3563,NCT00173641,,,,2005-09,UNKNOWN,OBSERVATIONAL,['NA']
3564,NCT02182830,Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks,Change From Baseline in Trough Seated DBP (mmHg) at Week 24,,2014-07-25,COMPLETED,INTERVENTIONAL,['PHASE3']
3565,NCT02692040,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],Body Weight (Percentage Change From Baseline),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3566,NCT02963441,Sufficient vs. Insufficient Image Quality Output From IDx-DR,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3567,NCT00980187,"Better metabolic effects of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus.","Better safety of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3568,NCT01592539,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
3569,NCT01046422,Fasting Plasma Glucose Improvement,Lipid profiles,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3570,NCT03911843,Number of Participants With Insulin Demand Adjusted for HbA1c %(IDAA1c) <9,,,2017-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3571,NCT04496817,Change in Retina Function,,,2022-07-11,RECRUITING,INTERVENTIONAL,['NA']
3572,NCT04040777,Mortality rate,,,2015-06,RECRUITING,OBSERVATIONAL,['NA']
3573,NCT01648244,Change in A1c,Demographic variables,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3574,NCT05145998,Change in baseline blood glucose over 3 hours (glycemic response),Change in satiety sensation,,2018-05-23,COMPLETED,INTERVENTIONAL,['NA']
3575,NCT00201292,,,,2005-03,UNKNOWN,OBSERVATIONAL,['NA']
3576,NCT05363761,Device success,Hypertension Control:,,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
3577,NCT02776722,Chronic glycemic outcome - fasting insulin,,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
3578,NCT01689090,Diameter changes of retinal vessels,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
3579,NCT05446337,Facilitators and Barriers,Value-Based Healthcare,,2022-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3580,NCT03909269,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
3581,NCT04012983,measurement of the level of FGF21 (pg/ml) in gingival crevicular fluid of healthy controls,measurement of the level of chemerin (ng/ml) in gingival crevicular fluid of healthy controls,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
3582,NCT04422821,Mean glycemia results (fasting and 1-h postprandial glucose concentrations),Neonatal glycemia,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
3583,NCT01390636,Variation in Glycemic Profiles of ED-DMT1 and ED/only,Impact of Dietary Intake on Glucose Profiles of ED-DMT1 and ED/only,,2011-07,TERMINATED,OBSERVATIONAL,['NA']
3584,NCT00331162,Acute Rejection,Health Status and Quality of Life,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3585,NCT04269655,Percentage time in severe hyperglycemia of interstitial glucose values,Hospital readmission rate,CGM Satisfaction,2020-02-25,TERMINATED,INTERVENTIONAL,['NA']
3586,NCT04892771,Number of wound,Adequate footwear,,2021-05-20,COMPLETED,OBSERVATIONAL,['NA']
3587,NCT01980914,Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl,Alteration in Cardiac Rhythm,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3588,NCT04042441,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Time period from initiation to discontinuation of treatment with Ryzodeg®,,2019-07-29,COMPLETED,OBSERVATIONAL,['NA']
3589,NCT01413542,"The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).",Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3590,NCT03646799,AUClast of Metformin,CL/F of Metformin,,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
3591,NCT01134107,Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use,Number of Participants Who Achieve or Maintain a Glycated Hemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than 7%,Change From Baseline to 12 Weeks Endpoint for Each Treatment in Blood Pressure,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3592,NCT04298970,iAUC,,,2020-03-03,COMPLETED,INTERVENTIONAL,['NA']
3593,NCT00493727,This research will test the possibility the Mucomyst given by mouth for a month will decrease oxidative stress and slow the disease.,Reduction of proteinuria,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
3594,NCT05141968,"Percent of HbA1c in children with T1DM for both intervention, and control groups.","Concentration of Vitamin D for both intervention, and control groups",,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
3595,NCT00263965,Whole-body insulin sensitivity by assessing the M value during high (80 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.,Safety and tolerability of tesaglitazar in patients with type 2 diabetes.,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2']
3596,NCT01925443,Muscle function,Quality of life,,2015-12,SUSPENDED,INTERVENTIONAL,['NA']
3597,NCT01699763,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),,2012-10,COMPLETED,INTERVENTIONAL,['NA']
3598,NCT01039532,Glycaemic control,Weight gain Hypoglycaemic episodes Adverse effects Cost effectiveness,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
3599,NCT03888872,Measuring Nerve Conduction Velocity,,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
3600,NCT04330079,Percent change in global myocardial perfusion reserve (MPR) index,"Change in blood pressure(systolic, diastolic both )",,2020-05-21,TERMINATED,INTERVENTIONAL,['PHASE4']
3601,NCT00753896,Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events,Change in Blood Pressure From Baseline to Week 52,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3602,NCT04966754,Rate of mortality,Quality of life,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
3603,NCT01432405,Hepatic Fat,Plasma Adipocytokines,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3604,NCT04254653,Evaluate diabetes nutrition education program impact on self efficacy for healthful eating,,,2020-02-20,UNKNOWN,INTERVENTIONAL,['NA']
3605,NCT01767688,Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞),Number of Participants Discontinued From Study Due to AEs,,2013-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
3606,NCT02099929,ODILE minimal model analysis,Glucose metabolism,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
3607,NCT04392284,Treatment credibility,Changes in lipids,,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
3608,NCT00595504,Change in Abdominal Fat (DEXA).,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3609,NCT05481034,Percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/L,Proportion of participants with sensor glucose in the target range (3.9 - 10.0 mmol/L for >70% of the time.,Nature and severity of adverse events,2023-01-11,COMPLETED,INTERVENTIONAL,['NA']
3610,NCT00191581,"The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in IDDM patients treated BID with human insulin mix 50/50, vs the 2-hour PPBG excursion in patients treated BID with insulin lispro mix 50/50",Effects on fasting blood glucose values obtained throughout the study;,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3611,NCT04342455,"diagnosis accuracy (including sensitivity,specificity of the low-dose radiation and contrast agent exposure protocol for coronary CTA)",kidney function,,2018-10-07,UNKNOWN,INTERVENTIONAL,['NA']
3612,NCT01546558,"Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3613,NCT00815828,To compare the frequency of women who use insulin in the group who participate in the exercise program with the group that don't do the exercises,To verify the impact of the exercise program on the adequacy of capillary glycemic control of the pregnant women,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
3614,NCT04050553,Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL,Mean Change in Heart Rate from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL,,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3615,NCT05197114,Feasibility and acceptability of the virtual summerlunch+At Home program,Changes in glycemic control as measured through HbA1C levels,,2022-01-25,UNKNOWN,INTERVENTIONAL,['NA']
3616,NCT02240381,Expression of Helios or glycoprotein A repetitions predominant in alpha4beta7+Foxp3+ Tregs versus alpha4beta7+Foxp3- conventional T cells,Post-HCT donor derived Th1 and Treg subsets,,2014-11-20,TERMINATED,INTERVENTIONAL,['NA']
3617,NCT00472888,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
3618,NCT04854187,Absolute change in fasting blood glucose for people with diabetes using air purifier and facemask,,,2021-03-25,RECRUITING,INTERVENTIONAL,['NA']
3619,NCT01636258,"Effect of ""FRESH"" Program on Weight Loss",Sleep,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3620,NCT00097292,Development of type 1 diabetes,Metabolic and Autoantibody Assessments,,2004-02,RECRUITING,OBSERVATIONAL,['NA']
3621,NCT00430040,Brachial artery vascular reactivity at 6 months,"Oxidative stress in Mononuclear cells, serum and plasma at six months",,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
3622,NCT04530617,Rate of hospitalizations and oxygen use,,,2020-10-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3623,NCT04671043,Hypoglycaemia,Area under the glucose curve post exercise,,2022-02-04,COMPLETED,INTERVENTIONAL,['NA']
3624,NCT01398826,,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA']
3625,NCT04754334,Mean change in A1C,The mean change in fasting plasma glucose,,2021-03-16,TERMINATED,INTERVENTIONAL,['PHASE3']
3626,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,Cost-benefit analysis,,2019-10-09,RECRUITING,OBSERVATIONAL,['NA']
3627,NCT01379170,Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function,Thyroid hormone-induced change of lipid content in skeletal muscle and liver and brown adipose tissue activity,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
3628,NCT05726461,Time in range(TIR),Frequency of serious adverse events about device,,2023-02-11,RECRUITING,INTERVENTIONAL,['NA']
3629,NCT00830076,Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations,Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations,,2008-12-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3630,NCT02588950,Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R,Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R,,2016-01-12,TERMINATED,INTERVENTIONAL,['PHASE1']
3631,NCT01488734,25OH Vitamin D level,Markers of inflammation and metabolic control,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3632,NCT01074268,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3633,NCT03981627,ΔAUCPG(0-4h),Safety and tolerability (Adverse Events recording),,2019-06-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3634,NCT02874963,Biochemical parameter: high sensitive C-Reactive Protein - hs-CRP (mean value in mg/L),"Mean probing depth (PD) (mean in mm, as a measure of periodontal parameter)",,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
3635,NCT00633425,Change in interstitial glucose levels between the observation and maintenance phases.,HbA1c and fasting blood glucose levels.,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3636,NCT06154135,Time in range,Reasons to stop using the DBLG-1 device,Patients who stop using the DBLG-1 system,2022-12-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3637,NCT03463941,Health Educators' Perceptions of Feasibility as Measured by Semi-structured Interviews,Goal Attainment as Measured by Days Per Week That Participants Exercised for 30 Minutes or More,,2019-01-05,COMPLETED,INTERVENTIONAL,['NA']
3638,NCT00814008,retinal blood flow after 1 hour of insulin clamp,"Mean blood velocities in ophthalmic artery, posterior ciliary arteries and central retinal artery after 1 hour of insulin clamp",,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3639,NCT00608049,"Systolic blood pressure (SBP), Low Density Lipoproteins (LDL) cholesterol, High Density Lipoproteins (HDL) cholesterol, triglycerides, and insulin sensitivity",Overall CVD risk using risk equations,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3640,NCT01343589,fatty acid composition in plasma,phytanic acid,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3641,NCT02845791,The primary endpoint is to detect a change in objectively measured MVPA of 10 minutes per day within the intervention group at 6 months.,Blood Pressure (Parent(s)/guardian(s)),,2016-07,COMPLETED,INTERVENTIONAL,['NA']
3642,NCT01918865,Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy,"Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy",,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3643,NCT01181986,Reactive Hyperemia Index (RHI),Plasma Glucose,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3644,NCT06035874,The change in liver fat content,Change between groups in HDL levels,,2023-10-15,RECRUITING,INTERVENTIONAL,['NA']
3645,NCT02925559,Glycemic Variability,Hypoglycemia,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3646,NCT01316367,HbA1c level,Body Mass Index (BMI),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3647,NCT00958269,"Safety and tolerability of dutogliptin as assessed by analysis of AEs/SAEs, laboratory data, vital signs, and ECGs",Per cent ex vivo DPP4 inhibition after drug dosing,,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3']
3648,NCT00113620,Pain rating scale obtained from patient diaries,Additional diary rating scales and scores obtained from clinic visits,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3649,NCT01928199,2-hour Oral Glucose Tolerance Test-derived Blood Sugar,6 Month OGTT Result (Completion of Washout From Study Drug),"Hemoglobin A1c, 6 Month",2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3650,NCT01488877,Number of Participants With Confirmed and Severe Hyperkalemia,Change From Baseline in Sitting Pulse Rate at Day 15,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE1']
3651,NCT03244800,Cohort 1: Percent Change From Baseline in Body Weight to Day 50,Cohort 1 and Cohort 2: Number of Participants With Positive Anti-drug Antibodies (ADA) to MEDI0382,,2017-09-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3652,NCT00507494,proteinuria,"efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3653,NCT02683746,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,Trough Plasma Concentration of Albiglutide Over Time,,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE3']
3654,NCT02811172,Collection of samples: mother's milk,Bioactive peptides,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3655,NCT01924637,Mean change in plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3656,NCT02629406,Endothelial precursor cell account (EPC),,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
3657,NCT04783376,Capillary blood glucose levels six hours after the test meals.,assessment of serum triglyceride level three hours after the test meal following each intervention,,2021-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3658,NCT02866734,"The overall, & at different fee level, uptake (as a percentage of participants) of screening from those at-risk patients who attend private GP's","Prevalence of DR (overall, and for sight-threatening diabetic retinopathy) among diabetic patients in private primary care",,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
3659,NCT00502359,,,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
3660,NCT02168816,Number of Participants With Bone Infection,Number of Participants With Ulcer Resolution,,2014-03-19,TERMINATED,INTERVENTIONAL,['PHASE2']
3661,NCT03575988,"pulmonary function parameters(diffusing capacity for carbon monoxide of lung/unit volume,DLCO/VA,%)","Vascular endothelial function(endothelin-1,ET-1,μmol /L)","Serum lipid(Triglycerides,TG(mg/dl))",2018-07-03,UNKNOWN,OBSERVATIONAL,['NA']
3662,NCT00044460,Change in HbA1c from baseline to Week 24.,Change in FPG (fasting plasma glucose) from baseline to Week 24; characterize the effects of rosiglitazone on the albumin-creatinine ratio at Week 24.,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
3663,NCT05149625,Hemoglobin A1c (HbA1c),"Fasting, postprandial plasma glucose",,2022-11-27,RECRUITING,INTERVENTIONAL,['NA']
3664,NCT00566475,hemoglobin A1c,"glucose levels, hypoglycemia, quality of life, satisfaction",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
3665,NCT02457975,Visual Acuity as assessed by the Early Treatment of Diabetic Retinopathy Study (EDTRS) Classification,Spectral Density-Optical Coherence Tomography (SD-OCT),,2015-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3666,NCT03840343,Adverse Events,Kidney Function,,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE1']
3667,NCT02844660,Study Safety Measurement,Cost effectiveness of treatment,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
3668,NCT01851694,Second-phase insulin response during GPA test,Change in insulin secretion among CF groups,,2013-05,RECRUITING,INTERVENTIONAL,['NA']
3669,NCT01100892,"Change in lung function (FEV1, FVC)","Change in effort-dependent lung function: MIP, MEP, SnIP",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3670,NCT04207541,Proportion of insulin initiation,,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3671,NCT00950898,plasma glucose levels,plasma insulin,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
3672,NCT01241370,"Comparison of retinal microvascular endothelial function in obese insulin sensitive, insulin-resistant and type 2 diabetic subjects with retinal microvascular endothelial function in lean healthy control subjects.",Comparison of the Oral Glucose Tolerance Test (OGTT) in the different subject groups with skin and retinal endothelial function.,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3673,NCT02201550,Change in number of specific immune cells in blood detected by flow cytometry,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
3674,NCT05941000,Change in Diabetes Distress,Change in Health-Related Problem-Solving,,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3675,NCT01640834,Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose,Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3676,NCT00596297,Intra- and postoperative intra-ocular bleeding,Visual acuity,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3677,NCT02017171,iGFR at the End of the Wash-out Period,Fatal or Non-fatal Cardiovascular Events,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3678,NCT03885869,The Evaluation of Dual Task Performance,,,2019-03-25,COMPLETED,OBSERVATIONAL,['NA']
3679,NCT01101503,The metabolic memory effect of endothelium-dependent arterial dilation,,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3680,NCT03560505,Common fibular nerve fascicle properties,,,2018-05-16,COMPLETED,OBSERVATIONAL,['NA']
3681,NCT04978974,Effects of stress management program as assessed using Coping Strategies Questionnaire,Effects of stress management program as assessed using Baseline,,2019-05-03,COMPLETED,INTERVENTIONAL,['NA']
3682,NCT01275235,Risk of type 2 diabetes mellitus (T2DM),,,2012-12,TERMINATED,OBSERVATIONAL,['NA']
3683,NCT01054300,Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin,,,2010-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
3684,NCT02610738,Participant feedback on teaching,Change in perceived stress - parent participants,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
3685,NCT00775736,"The number of serious adverse drug reactions, including major hypoglycaemic episodes, reported during the study period.",Weight changes,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
3686,NCT03159299,Change in Hemoglobin A1C From Baseline,Change in Diabetes Self-Efficacy From Baseline,Fidelity of Yo Puedo Sessions,2017-05-08,COMPLETED,INTERVENTIONAL,['NA']
3687,NCT03700580,100% epithelization,80% epithelization,,2012-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3688,NCT04124302,Postprandial glycemia,Hypoglycemia Episodes,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3689,NCT03401697,Number of Type 2 Diabetes patients that initiate HCV treatment,HCV cure rate,,2018-01-23,COMPLETED,OBSERVATIONAL,['NA']
3690,NCT04052815,Change from Baseline Glycated hemoglobin at 12 months,Dietary assessment of fat consumption,Rosenberg self-esteem,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3691,NCT05493345,Feasibility and fidelity,Loneliness,,2022-08-05,RECRUITING,OBSERVATIONAL,['NA']
3692,NCT05564481,glycemic variability,Diabetes self-management,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3693,NCT02945540,Measuring patient satisfaction at childbirth by a questionnaire on satisfaction of hospital care,Neonatal blood glucose measurement,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
3694,NCT01520428,HbA1C,HbA1c,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
3695,NCT02763943,Patient reported survey results regarding psychosocial status from baseline to end of study,,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
3696,NCT01140438,insulin secretion,glycemic control,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
3697,NCT00389350,HbA1c,,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3698,NCT01705210,Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations,Cardiovascular risk factors,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
3699,NCT05584085,Change from baseline HbA1c at 3 months post-intervention,Psychological flexibility,,2022-10-15,RECRUITING,INTERVENTIONAL,['NA']
3700,NCT05087758,Wound Healing,Incidence of Treatment Emergent Adverse Events,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
3701,NCT02798757,Composite outcome measure. % change to the concentrations of specific metabolites.,,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3702,NCT04475861,PEDIS,,,2018-10-31,WITHDRAWN,INTERVENTIONAL,['NA']
3703,NCT00451321,Number of Participants With Positive Epstein Barr Virus (EBV) Viral Load,Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c),,2006-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
3704,NCT05994755,"association between hypoglycemia, glycemic variability and cardiac arrhythmias","association between hypoglycemia, glycemic variability and heart failure",,2023-10-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3705,NCT01677611,Skeletal muscle sirtuin 1 (SIRT1) expression,Liver function,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3706,NCT04917471,Percentage recovery of left ventricular function,,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
3707,NCT06269120,Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%,Change in high sensitive C-reactive protein (hsCRP),,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3708,NCT03437330,Change in skeletal muscle H202 concentration between baseline and end of treatment (EoT),Change in plasma FFA levels,,2021-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3709,NCT02156336,Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.,Occurrence of Serious Adverse Events after randomization,,2014-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3710,NCT05820477,Change in Self-Management (Person with Diabetes),Diabetes Distress (Person with Diabetes),Change in emotional support (support person),2023-04-25,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3711,NCT01225653,The diameter of retinal arterioles,The severity of diabetic retinopathy,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3712,NCT04063930,Urinary albumin creatinine ratio (UACR),Urinary potassium,Safety outcome - Electrocardiogram,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
3713,NCT05965869,Evaluate the integration of the intervention,Provide acceptability data of the intervention,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3714,NCT00515632,"HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters.","Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3715,NCT05290207,endocrine hormone changes,,,2022-01-06,COMPLETED,OBSERVATIONAL,['NA']
3716,NCT03988764,Proportion of patients carrying mutations in previously unstudied genes that meet statistical criteria of pathogenicity for monogenic diabetes.,Risk-prediction score for monogenic diabetes mutation in antibody negative T1D patients,,2019-09-24,RECRUITING,OBSERVATIONAL,['NA']
3717,NCT05197101,vaginal birth rate,,,2022-01-17,UNKNOWN,INTERVENTIONAL,['NA']
3718,NCT00486681,compare glycemic control of patients hospitalized in 3 departments,mean of % of glycemia for patients in warning phase with or without diabetologist intervention,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
3719,NCT03050619,Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK,Baseline Characteristics (as Measured by Concomitant Medications) of Patients Starting Index Prescriptions Off-label,,2016-09-10,COMPLETED,OBSERVATIONAL,['NA']
3720,NCT00331487,Change in fasting triglyceride level,Apolipoprotein C-III.,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3721,NCT03522597,Breastmilk and infant microbiomes,Hormones and cytokines in infant serum,,2018-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3722,NCT01850615,Change From Baseline in HbA1c,Number of Adverse Events,,2013-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
3723,NCT00460018,Postpartum weight retention,breastfeeding duration,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3724,NCT01653392,Infant Outcomes,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
3725,NCT02605889,Improvement of blood postprandial glucose levels,Improvement of Nursing Diagnoses,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
3726,NCT05256043,Length of hospital Stay,,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
3727,NCT01864460,Autonomic Function: heart rate variability,balance,Sweat gland nerve fiber density,2013-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3728,NCT02031341,"Fore-arm insulin uptake measured as ([A]-[V]) x F in pmol/min where A = arterial insulin concentrations, V= venous insulin concentrations, F = fore arm plasma flow;",,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
3729,NCT04143412,Urinary albumin/creatinin ratio (UACR),Serum K,,2019-02-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3730,NCT02981966,Endogenous Glucose Production Measurement,Renal Glucose Production Measurement of Change,,2019-05-23,COMPLETED,INTERVENTIONAL,['PHASE4']
3731,NCT01055080,Beta-cell autoantibodies,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
3732,NCT01435616,Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c),Percentage of Participants With Equal or Above 2- and 3-fold ULN for Alanine Transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) and Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3733,NCT00651105,GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects,"Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3734,NCT00780650,Change in level of catecholamines in blood from baseline,,,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3735,NCT04092569,"Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 9 months",The Chinese version of the Diabetes Empowerment Scale Questionnaire - Short Form,,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA']
3736,NCT01702298,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C),,2012-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3737,NCT05935410,Glycemic Control (Hemoglobin A1C [HbA1C]),,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3738,NCT05368402,"The proportion of responders at week 27/28 (visit 4), with responders defined as ""patients with an HbA1c reduction from baseline of ≥0.50% (absolute difference) without episodes of severe hypoglycemia",Incidence of Treatment Emergent Adverse Events (TEAEs) recorded from the beginning of study treatment to up to the end of study participation,,2022-07-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3739,NCT06291129,Bleeding on probing,,,2022-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3740,NCT03005288,Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48,Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial,,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3741,NCT00495469,Mean Change From Baseline in Hemoglobin A1c (Glycosylated Hemoglobin) (HbA1c) at Week 12,Number of Participants With Abnormal Hematology Value of PCI at Any Time on Therapy,,2007-08-17,COMPLETED,INTERVENTIONAL,['PHASE2']
3742,NCT04550520,Maximal increase in copeptin level,Maximal Change in oxytocin,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
3743,NCT02529982,Change in pancreatic B-cell function,Waist circumference,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
3744,NCT04489966,Abdominal fat Abdominal fat,The 10-year risk assessment table for Ischemic cardiovascular disease,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA']
3745,NCT00524875,early post-vitrectomy vitreous hemorrhage,Visual improvement,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
3746,NCT04516200,sway index of sensory integration test,risk of fall index,,2020-08,UNKNOWN,INTERVENTIONAL,['NA']
3747,NCT05168657,"Percentage of individuals with mean CGM glucose <183 mg/dL (corresponding to an estimated HbA1c of <8.0%) on days 3-14, by group.","Percentage of individuals with mean CGM glucose <154 mg/dL (corresponding to an estimated HbA1c of <7.0%) on days 3-14, by group.",,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
3748,NCT02571738,"Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, by the End of Single-Blind Treatment Visit with follow-up confirmation of continued closure at 2 consecutive study visits 2 weeks apart","Percentage of patients who achieve complete wound closure, defined as 100% re-epithelialization as determined by the Investigator, who participate in the Open-Label Treatment Phase","Change in Quality of Life from Baseline, as determined by the Cardiff Wound Impact Schedule (CWIS)",2015-10,TERMINATED,INTERVENTIONAL,['PHASE3']
3749,NCT00543751,,,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3']
3750,NCT03819335,Empowerment,Satisfaction with the app,,2019-04-09,COMPLETED,INTERVENTIONAL,['NA']
3751,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18),,2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3752,NCT02447172,Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),Percent of Subjects That Had an Amputation Associated With the Target Ulcer,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3753,NCT04667728,Change From Baseline in HbA1c at 3 Months,,Change From Baseline in daily fat intake at 3 Months,2017-05-30,COMPLETED,INTERVENTIONAL,['NA']
3754,NCT00001612,,,,1997-05,COMPLETED,OBSERVATIONAL,['NA']
3755,NCT02898766,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
3756,NCT02916576,System accuracy criteria (see description),,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3757,NCT00727220,Change in HgBA1c,,,1999-11,COMPLETED,OBSERVATIONAL,['NA']
3758,NCT02246959,Change in LDL cholesterol from baseline to 12 months,Statin Adherence,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
3759,NCT01625598,Sensitivity of detecting moderate non proliferative diabetic retinopathy or more severe DR and/or significant macular edema on a person-specific basis.,Specificity on an eye-specific basis [Clinical examination only],,2012-04,COMPLETED,OBSERVATIONAL,['NA']
3760,NCT06246799,Number of subjects failing to achieving HbA1c <6.5% Long-term,Change in body weight,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3761,NCT05948592,3. Percentage of patients that achieve a 50% reduction in wound surface area by week 4,4. Percentage of patients with target strain not-susceptible to TP-102 for TP-102 versus Placebo at EOT;,,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3762,NCT03369821,"Measure beta cell function in EET1D compared to T1D, NDM and non-diabetic controls.",Association of maternal and paternal non-inherited HLA alleles with EET1D,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
3763,NCT01966432,Treatment for Drug Use or Alcohol,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3764,NCT01756703,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3765,NCT01030861,Rate of New Diabetes Per Year,Number of Participants With Adverse Events,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3766,NCT01086111,insulin sensitivity and beta cell function,changes in plasma levels of gut hormones and inflammation markers,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
3767,NCT01194479,Norepinephrine (pg/mL),Blood Glucose Levels (Average),,2010-08,COMPLETED,INTERVENTIONAL,['NA']
3768,NCT04915066,Permanent discontinuation of insulin pump use.,type of diabete,,2021-06-29,COMPLETED,OBSERVATIONAL,['NA']
3769,NCT02839226,"comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases",Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3770,NCT04784637,Number of SAE or ADE Related to the Use of ATM / WST and BAM Modules.,INSPIRE Questionnaire,,2021-07-23,COMPLETED,INTERVENTIONAL,['NA']
3771,NCT02460081,Transcutaneous oxygen measurement (TCOM),Patient Global Impression of Change in Neuropathy (PGICN),,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3772,NCT02450500,Participants acceptability of intervention by focus group,"Health status, well being, food intake and exercise levels by questionnaires",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3773,NCT03896360,Proportion of participants achieving a normal 2-hour glucose (less than 140mg/dl) and/ or greater than or equal to 15% improvement in 2-hour glucose,,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
3774,NCT04195243,Flow Mediated Dilation,Blood pressure,,2019-12-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
3775,NCT04712916,Change in value of blood pressure readings,,,2017-06-10,COMPLETED,INTERVENTIONAL,['NA']
3776,NCT01418456,Time to healing of foot ulceration in each group,• Percentage of patients in each group that are healed at 20 weeks.,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
3777,NCT05740254,Mean change in weight in excess of the 95th percentile at week 24 compared to baseline,Mean change in systolic and diastolic blood pressure at week 24 compared to baseline,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
3778,NCT01123239,Hemoglobin A1c,Health-related quality of life,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
3779,NCT06246578,Difference between paired Dexcom and Libre glucose values,,,2024-01-19,RECRUITING,INTERVENTIONAL,['NA']
3780,NCT04279444,Insulin resistance (HOMA-IR),"Triglyceride, glucose, and insulin AUCs",,2020-06-16,COMPLETED,INTERVENTIONAL,['NA']
3781,NCT04186702,central subfield thickness (CST),patient compliant-complications,,2014-09-10,COMPLETED,INTERVENTIONAL,['NA']
3782,NCT03092310,Percent time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM).,Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).,,2017-03-20,COMPLETED,INTERVENTIONAL,['NA']
3783,NCT01580462,,,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
3784,NCT03514238,Insulin Sensitivity,,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
3785,NCT01106287,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3786,NCT06003751,Systemic Adverse events,,,2023-08-05,RECRUITING,INTERVENTIONAL,['PHASE2']
3787,NCT01722240,HbA1c (%),Body Weight,,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3788,NCT00151021,Step-count bout ratio = 7 day average of steps taken during 10 minute bouts in one day divided by total steps taken during the same day,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
3789,NCT02681874,Increase in Healthy Food Dietary Patterns,Improvement in Parental Feeding Behaviors,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
3790,NCT02134860,Insulin resistance,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3791,NCT03324971,Change in Hemoglobin A1c,,,2017-06-02,COMPLETED,INTERVENTIONAL,['NA']
3792,NCT01682902,Mean change in plasma glucose concentration,Number of episodes of infusion set occlusions,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3793,NCT01136096,Exercise behavior,Exercise behavior,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
3794,NCT06048510,Incidence of GDM diagnosed during pregnancy.,Neonatal morbidity 4,,2023-12-18,RECRUITING,INTERVENTIONAL,['NA']
3795,NCT02750267,Percent of Sensor Glucose Readings Between 70-180 mg/dL,End of Night Blood Glucose,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
3796,NCT02561377,glycemic control,Incidence rate of diabetes,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
3797,NCT00829699,Percent change in flow mediated dilation of brachial artery,Change in Lipid measures,,2009-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3798,NCT00600730,fMRi scans,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
3799,NCT02600338,Mean arterial pressure,,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
3800,NCT01297387,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
3801,NCT03816293,Surgical Site Infection Rate per 100 surgeries,Dehiscence incidence and rate per 100 surgeries,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
3802,NCT04540536,Change in hemoglobin A1c after three-month follow-up visit after remote continuous glucose monitoring monitoring and secure text messaging.,,Average time spent by medical provider per participant per day.,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
3803,NCT02981069,Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug.,Change in Plasma Insulin Concentration,,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
3804,NCT06336512,Estimation of Gestational DM,,,2023-01-15,COMPLETED,INTERVENTIONAL,['NA']
3805,NCT05409027,Pharmacokinetics (Cmax),Urinary HSD-1 Ratio,,2021-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3806,NCT02933424,Change in body composition,Meal challenge,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3807,NCT00835861,Blood Glucose Measurements,Number of Babies With Adverse Neonatal Outcomes,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3808,NCT02333851,Differences in mean daily blood glucose concentration,Total daily Insulin use in International Units per Kg of weight,,2013-06,TERMINATED,INTERVENTIONAL,['PHASE4']
3809,NCT03281616,Body weight reduction,Blood HbA1c,,2014-06-01,COMPLETED,INTERVENTIONAL,['NA']
3810,NCT04127448,Change in Verbal fluency test (VFT) from baseline to 6th week,Change in Random Blood sugar (RBS) from baseline to 6th week,Change in respiratory rate in breaths/min from baseline to 6th week.,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
3811,NCT03495362,Changes in islet function,Changes in hepatorenal function,,2018-03-13,UNKNOWN,INTERVENTIONAL,['NA']
3812,NCT00773279,HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®,"Hypoglycaemic Episodes, Number of Events Per Subject Day",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3813,NCT05428943,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Serum samples collected to determine glucose levels (mmol/L) pre and post mixed meal tolerance test,,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE1']
3814,NCT06173934,Characteristics of gastric emptying(the gastric half-emptying time ) in patients with type 1 diabetes.,The blood glucose,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
3815,NCT01646047,Changes in visual function,Changes in retinal structure,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3816,NCT00408993,Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score,Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3817,NCT03061266,Glycated hemoglobin (HbA1c),quality of life using questionnaire,,2016-03-09,UNKNOWN,INTERVENTIONAL,['NA']
3818,NCT01282957,Rate of use of the three home-based technologies,"Usability and functionality of the study's online web portal, Way to Health, and wifi-enabled home health monitoring devices",,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3819,NCT05284344,Gastric-half emptying time of the 75 g glucose drink,Heart rate,,2021-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3820,NCT06223204,Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.,"Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) using the Clarke Error Grid.",,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3821,NCT03477786,development of microalbuminuria,development of cardiovascular events,,2013-10-28,UNKNOWN,INTERVENTIONAL,['NA']
3822,NCT01272583,Glucagon Response to Acute Hypoglycaemia,Symptomatic Hormone Responses to Acute Hypoglycaemia.,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
3823,NCT06115460,Percentage of Time in range,Level of Stromal cell-derived factor-1 (SDF-1),,2022-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3824,NCT01607450,Myocardial Glucose Uptake.,GLP-1 Concentrations,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3825,NCT03396146,Measurement of pancreatic polypeptide for calculating the area under the curve,Measurement of fecal elastase level,,2018-06-14,COMPLETED,INTERVENTIONAL,['NA']
3826,NCT00738660,Reduction in albumin excretion rate,"24 hr ambulatory BP reduction,nocturnal BP reduction, proportion of dippers",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3827,NCT05039645,Patient Adherence,DFU Incidence rates and severities,,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
3828,NCT03411395,Blood glucose response,Capillary blood glucose response,,2016-10-13,COMPLETED,INTERVENTIONAL,['NA']
3829,NCT02895750,Efficacy of once daily Metformin XR on 24-h blood glucose control,Tolerability of Metformin XR in mild to moderate (CKD) 2,,2017-08-30,COMPLETED,INTERVENTIONAL,['PHASE2']
3830,NCT02074683,Durability of Relief and reduction of foot pressure,Assessment of pain and skin lesions,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
3831,NCT01695629,changes between control and diabetic patients,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
3832,NCT00535535,"A comparison of the iAUC in VLDL TG palmitate 4 hours after F:G1:1, 1g/kg, vs. 1) fructose 0.5g/kg, and 2) F:G:1:1, 2g/kg.",Linear regression analysis of the relationship between the iAUC in VLDL TG palmitate after oral fructose and markers of carbohydrate and lipid flux,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3833,NCT03342274,Weight loss,Triglycerides,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA']
3834,NCT02027103,Serum concentrations of osteoprotegrin,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3835,NCT05560386,Body Mass Index (BMI),Emotional Eating Score,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
3836,NCT04665102,Validation of Image classification by transfer learning algorithm,,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
3837,NCT05694741,"Adverse Events (AEs), and Serious Adverse Events (SAEs)",Maximum observed concentration (Cmax),,2022-12-20,TERMINATED,INTERVENTIONAL,['PHASE1']
3838,NCT02891954,Urinary glucose excretion (during the time interval 24-48 hours after first administration of canagliflozin),Serum uric acid,,2016-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1']
3839,NCT01511198,Body weight,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3840,NCT03302377,Feasibility of recruitment,Physical activity change,,2017-10-03,COMPLETED,INTERVENTIONAL,['NA']
3841,NCT01517919,"Changes in clinical, self-care and diabetes-related quality of life from baseline","Changes in clinical, self-care and diabetes-related quality of life from baseline",,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3842,NCT01026194,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3843,NCT01493388,Percentage of adolescents between 13 and 15 years with HbA1c less than 7.5%,Type and dose of insulin treatment,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
3844,NCT02168491,Change in HbA1c From Baseline to End,Change in Body Weight From Baseline to End of Study,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3845,NCT04564911,Change from baseline HbA1c at week 24,Number of individuals requiring medication up-titration from baseline to week 24,,2020-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3846,NCT06334172,Insulin secretion - c-peptide,Procollagen type I N-terminal propeptide (P1NP),,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
3847,NCT00450489,,,,2008-06,WITHDRAWN,OBSERVATIONAL,['NA']
3848,NCT06146036,Incremental Area Under the Curve (AUC),Blood pressure,,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3849,NCT01235039,Serum insulin concentration,Glucose infusion rate,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3850,NCT01483781,Change in hematology laboratory analytes,Change in percent Hemoglobin A1c (HbA1c),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3851,NCT06066528,Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76,Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L),,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
3852,NCT00357370,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2,"Adjusted Mean Total Daily Dose of Insulin (TDDI) Change From Baseline at Week 12 (LOCF), Including Data After Up-titration of Insulin) - Cohort 2",,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3853,NCT00912002,Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]MK-0941 (160 µCi).,Number of Participants Who Discontinued the Study Due to An Adverse Event,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3854,NCT02523001,uAQP2,Cholesterolemia,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
3855,NCT02932514,Usability of the Eversense CGM System over 180 days will be evaluated through Study Questionnaires.,,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
3856,NCT00439985,quality of life,parent-child collaboration,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
3857,NCT05505669,Changes in frequency of circulating biomarkers that correlate with beta cell death from type 1 diabetes patients compared to other cohorts,,,2022-03-29,RECRUITING,OBSERVATIONAL,['NA']
3858,NCT00789295,Postprandial response triglyceride of chylomicrons and large VLDL,Lipolytic activities,,2004-03,COMPLETED,INTERVENTIONAL,['NA']
3859,NCT04702672,Postprandial glycemic response,Visual analogue scale (VAS),,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3860,NCT00795600,Absolute Change in Trunk Fat Mass,Number of Non-serious Adverse Events,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3861,NCT02059005,Change in Substance Use Rates From Baseline,Number of Hospitalizations and Use of Emergency Services,,2014-11-18,COMPLETED,INTERVENTIONAL,['NA']
3862,NCT01142908,Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent),HBA1C in Diabetic Patients,,2011-11-01,COMPLETED,INTERVENTIONAL,['NA']
3863,NCT03164538,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,Change in Hemoglobin A1c,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
3864,NCT04100551,relationship between renal function and podological grade,factors associated with the occurrence of complications and comorbidities,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
3865,NCT03398577,Percent reduction in interleukin (IL)-1β levels,Percent change in Adiponectin levels,,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3866,NCT01937858,Correlation,,,2012-07,TERMINATED,OBSERVATIONAL,['NA']
3867,NCT03596983,Protocol adherence rates measured by the percentage of participants completing greater than or equal to 4 daily sleep diary entries per week for 80% or more of the intervention period.,,,2019-04-10,COMPLETED,INTERVENTIONAL,['NA']
3868,NCT04663282,Change in HbA1c,Serum INS068 concentration,,2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3869,NCT06177691,C-peptide,Hospitalizations,,2021-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3870,NCT00577148,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in serum hyaluronate and hepatic transaminases (AST/ALT),,2008-02,TERMINATED,INTERVENTIONAL,['PHASE3']
3871,NCT00488423,To assess the effect of gastric by-pass surgery to decrease lipotoxicity.,To examine the effect of roux-en-Y compared to gastric banding on pancreatic B cell recovery or insulin secretion in response to oral and IV glucose.,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3872,NCT02272348,To assess the impact of therapeutic education by functional insulin therapy in patients with type 1 diabetes on their ability to disease self-management.,"To assess the validity, the concordance and the sensitivity to change of EAD questionnaire (specific for self-management of diabetes) in comparison with CIDS test",,2015-02-10,TERMINATED,INTERVENTIONAL,['NA']
3873,NCT01476345,Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus,Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3874,NCT01709305,Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2),Percentage of Participants With a GI AE of Abdominal Pain (Phase 2),,2012-11-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3875,NCT06115616,g of glucose,,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3876,NCT02068027,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3877,NCT00639613,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
3878,NCT02916706,Change in HbA1c From Baseline to Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3879,NCT05559892,Quality of Life as measured by SF-12,Self-Care,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
3880,NCT00707616,Disposition Index,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
3881,NCT05955339,Quality of Life - Physical functioning,Visit communication style and shared decision-making,Caregiver engagement in clinic visit [Caregiver outcome],2024-01-24,RECRUITING,INTERVENTIONAL,['NA']
3882,NCT00988182,"Blood glucose, Insulin, Subjective appetite",Physical comfort,,na,COMPLETED,INTERVENTIONAL,['NA']
3883,NCT00434811,Proportion of participants with a HbA1c less than 7.0% AND free of severe hypoglycemic events,"Acute insulin response to glucose insulin sensitivity, and disposition index derived from the FSIGT test",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3884,NCT02344992,Area under the blood glucose time curve: AUCbg(0-2h),"Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3885,NCT02171351,Sympathetic nerve reactivity in response to a single session of neuromuscular electrostimulation,sympathetic nerve reactivity in response to a single session of voluntary muscular contractions,comparison of sympathetic nerve reactivity between the different groups and procedures,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
3886,NCT01565096,Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min),Drug related adverse events,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3887,NCT02276144,Compare prevalence of obstetric complications between non-alcoholic fatty liver and normal pregnant women,,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
3888,NCT04816890,Body weight change from baseline to week 16 of treatment,Hypoglycaemic episodes,,2021-03-23,COMPLETED,INTERVENTIONAL,['PHASE2']
3889,NCT03221452,Change in Diabetes Self-Care Activities,Center for Epidemiologic Studies Depression Scale,,2016-09-02,UNKNOWN,INTERVENTIONAL,['NA']
3890,NCT02204397,Safety and tolerability,Composite C-Peptide efficacy according to specific parameters,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3891,NCT01831765,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change in PPG (Postprandial Glucose),,2013-08-26,COMPLETED,INTERVENTIONAL,['PHASE3']
3892,NCT00793884,Social and Demographic Characteristics,Change in Diastolic Blood Pressure,,2008-10,SUSPENDED,OBSERVATIONAL,['NA']
3893,NCT00628212,Change From Baseline in HbA1c at Week 12,Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3894,NCT01578096,Hemoglobin A1c,Diabetes specific distress,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3895,NCT05514925,Intraoperative bleeding,Visual acuity,,2017-11-21,RECRUITING,INTERVENTIONAL,['PHASE4']
3896,NCT02084004,Change in HbA1c from baseline to week 12,Adverse effects,,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3897,NCT03889977,Changes in blood triglycerides,Changes in substances that react with thiobarbituric acid (TBARS),,2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
3898,NCT01989975,Subject Experience After Using the Carelink Connect Device,Number of Participants With Investigational Device Deficiencies,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
3899,NCT01544881,"PK measures for RAA (8U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing","Area under serum glucose infusion rate (GIR AUC 0-360) for RAA (8U) as measured by: GIR AUC 0-360 timepoints: 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3900,NCT00347698,Score on a patient satisfaction scale at six months and one year,Complications associated to each treatment,,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3901,NCT00533442,Event-Specific Survival Comparisons,"Overall Pancreas Transplant Function at 12, 36, and 60 Months Post-transplant.",,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3902,NCT03550976,Incidence of gestational diabetes,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3903,NCT06070103,"Depression ,Anxiety and stress disorders among diabetic patients in Assuit University Hospitals.",,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3904,NCT04455867,Neuropsychological function,Cognitive Status,,2017-12-21,RECRUITING,OBSERVATIONAL,['NA']
3905,NCT06301022,serum potassium,,,2022-12-15,RECRUITING,OBSERVATIONAL,['NA']
3906,NCT00800410,Hemoglobin A1c,Diabetes specific emotional distress,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3907,NCT00139659,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco),Severe Hypoglycemic Event Rates,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3908,NCT03728647,nursing hours,insulin performance rate,,2013-08-16,COMPLETED,INTERVENTIONAL,['NA']
3909,NCT03675269,Change in wound size,,,2018-09-05,WITHDRAWN,INTERVENTIONAL,['NA']
3910,NCT01699074,Effect of KWG on vascular and glycemic measures,Effect of KWG on vascular and glycemic measures,KWG and satiety,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3911,NCT03280524,Quality of Life Questionnaire SF-36,,Stanford Health Assessment Questionnaire,2016-01,COMPLETED,INTERVENTIONAL,['NA']
3912,NCT03720197,Number of non-severe hypoglycemic episodes,Number of steps,,2019-02-20,RECRUITING,OBSERVATIONAL,['NA']
3913,NCT00371007,"HbA1c, safety and tolerability",Plasma glucose,,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3914,NCT05604352,Assessing the safety of the DiaSole insole,acceptability of DiaSole to health care professionals (HCPs),,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3915,NCT04083820,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
3916,NCT01884363,Change in reactive hyperemia index occurring between baseline and 12 weeks (end of intervention),Change in blood levels of hormones produced by fat cells between baseline and 12 weeks (end of intervention),Change in heart rate variability between baseline and 12 weeks post-intervention,2013-06,COMPLETED,INTERVENTIONAL,['NA']
3917,NCT02346344,"Repeatability of the meal tolerance test and the arginine stimulation test, as indicated by the ICC (intraclass correlation coefficient)",,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
3918,NCT02022111,Percentage of Combined Improvement of Depressive Symptoms and CVD Risk Factors,Cost Utility in the Treatment Arm and Usual Care Arms,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
3919,NCT05769868,Ejection Intraventricular Pressure Difference (EIVPD) measure,Matrix metalloproteinase-1 (MMP-1),,2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE3']
3920,NCT05048719,Change From Baseline in HbA1c in LY3502970 as Compared to Placebo,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970,,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3921,NCT05869734,Sleep efficiency,Self-management of urologic health,,2023-05-30,RECRUITING,INTERVENTIONAL,['NA']
3922,NCT03800901,Change in the percentage of evidence-based diagnostic and treatment decisions made in the simulations.,Impact of available CME and ABIM MOC on retention rate,,2019-01-11,COMPLETED,INTERVENTIONAL,['NA']
3923,NCT03119584,Improvement in frequency of bowel movements,,,2015-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3924,NCT00944060,body weight,"dietary fat intake, fruit and vegetable intake, physical activity, stress, affects",,na,COMPLETED,INTERVENTIONAL,['PHASE3']
3925,NCT00918138,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,"Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal",Participants With Reported Hypoglycemic Adverse Events During Treatment Period,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3926,NCT00194558,Hemoglobin A1c,Satisfaction with care,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
3927,NCT01447121,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Study Staff Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method When Testing Subject Blood Glucose (BG),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3928,NCT05773209,Changes in subfoveal choroidal thickness,Changes in DR grading,,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3929,NCT01061060,Symptomatic improvement by Total Symptom Score (TSS),Change in mean rate of blood flow in the toes,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3930,NCT01935466,Bladder cancer rate,,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
3931,NCT00865033,Bioequivalence according to US FDA guidelines,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3932,NCT00806169,Best Corrected Visual Acuity,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3933,NCT01810822,Albumin to Creatinine Ratio,,,1994-05,COMPLETED,OBSERVATIONAL,['NA']
3934,NCT00588380,Insulin Secretion at 150-180 Minutes.,Insulin Secretion at 210-240 Minutes,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
3935,NCT01804803,Changes in HbA1c from baseline value,"Subgroup analyses of changes in HbA1c from baseline according to patients' age (<45 yrs, >45yrs), type of diabetes (type 1, type 2), and diabetes duration (<5 yrs, >5 yrs)",,2013-09-09,COMPLETED,INTERVENTIONAL,['NA']
3936,NCT00655798,inflammation parameters,glucose and fat response,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
3937,NCT00535483,,,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
3938,NCT01397513,Fibrin network permeability,Platelet microparticles,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3939,NCT02608853,Incidence of all malignant neoplasms,Incidence of acute pancreatitis,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
3940,NCT02691429,ocular inflammation,complications of the posterior segment,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3941,NCT01769404,Concentration of Epinephrine,Concentration of Norepinephrine,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3942,NCT04031417,Hypoxia and low humidity on the endothelial function in healthy volunteers and patients with type 2 diabetes using Wilcoxon signed rank test,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3943,NCT04521452,Change in aortic valve calcium volume at week 96 from baseline,Time of major cardiovascular event,,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3944,NCT00251953,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
3945,NCT02202876,Acute oxidation,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
3946,NCT06063109,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Pharmacokinetics - PTF,,2023-10-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3947,NCT02664207,Post-operative complications,,,2016-01-26,RECRUITING,INTERVENTIONAL,['NA']
3948,NCT01927562,Changed in Mixed Meal Tolerance From Baseline to 3 Months,,,2013-07-13,COMPLETED,INTERVENTIONAL,['NA']
3949,NCT05404061,Prospective assessment of gut hormone response pre and post-surgery: Change in Peak plasma level of gut hormones after meal ingestion.,Change in Genetic factors,,2018-08-01,RECRUITING,INTERVENTIONAL,['NA']
3950,NCT00132418,"Incidence of medically important infections, defined as infections that result in hospitalization or treatment with intravenous antibiotics","Infections associated with antimicrobial use; physical examination, vital signs, clinical laboratory assessments; symptom assessment, withdrawals, deaths, and serious adverse events",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3951,NCT00005479,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
3952,NCT00491543,Pharmacokinetics,,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3953,NCT02252757,Measuring Cardiac Output for wireless transmission as per discharge guideline,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
3954,NCT03380403,Infection control,Osteomyelitis evaluation,,2010-01-01,COMPLETED,INTERVENTIONAL,['NA']
3955,NCT05144737,Change in body mass index over a 6-month period,Change in resting metabolism over a 12-month period,Change in pain severity over the 12-month period,2021-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3956,NCT00223340,Document changes made to study procedures to better implement this study's interventions that are designed to reduce risks of heart disease and stroke,Assessment of Chronic Illness Care (ACIC) Surveys,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
3957,NCT05489172,Sallis Self Efficacy for Physical Activity,Weight loss,HbA1C level,2020-02-01,COMPLETED,INTERVENTIONAL,['NA']
3958,NCT00954967,Smoking abstinence: Self reported abstinence (6 or more months without smoking) confirmed by an expired air carbon monoxide concentration of 6 parts per millions or less,Total time (minutes) spent in the intensive smoking cessation intervention,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
3959,NCT00690768,amount of intraoperative intra-ocular bleeding,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3960,NCT05219526,Measurement performance: System accuracy,,,2022-01-03,COMPLETED,INTERVENTIONAL,['NA']
3961,NCT00198497,Vitreous hemorrhage resolution,Visual Acuity,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3962,NCT03751813,lower blood stress markers via venous draw,,,2019-03-21,TERMINATED,INTERVENTIONAL,['NA']
3963,NCT00343980,Treatment difference in HbA1c,Hypoglycaemia,,2006-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
3964,NCT04885712,Changes in HbA1c,,,2021-05-28,COMPLETED,INTERVENTIONAL,['PHASE3']
3965,NCT00570102,Positivity for two or more diabetes-associated autoantibodies and/or clinical type 1 diabetes,,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3966,NCT00494884,Change from baseline in HbA1c,Change in systolic and diastolic blood pressure,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3967,NCT04161131,Hemoglobin A1c (HbA1c),Frequency of Blood Glucose Monitoring,,2019-12-09,COMPLETED,INTERVENTIONAL,['NA']
3968,NCT01023906,Sensory/hedonic rating,Genetic Variation,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
3969,NCT05286853,Primary Composite Endpoint,Second Secondary Endpoint: Time to End Stage Renal Disease,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3970,NCT01179945,Blood glucose area under the curve (AUC),Metabolite Profiles,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
3971,NCT01076075,Number of Participants Discontinuing Study Drug Due to An Adverse Event,Change From Baseline in Fasting Plasma Glucose at Week 24,,2010-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3972,NCT03085524,Restenosis,,,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3973,NCT05929196,Blood sample relative permittivity,Mathematical model of blood glucose dependence on blood dielectric parameters,,2023-07-12,COMPLETED,INTERVENTIONAL,['NA']
3974,NCT03192605,Glucose (mmol/L),,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
3975,NCT03567824,Change in Serum Magnesium Concentration,Change in HbA1c,,2026-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3976,NCT04518813,Safety evaluation of the Investigational Medical Device by reporting of adverse events,Device function,,2020-09-24,COMPLETED,INTERVENTIONAL,['NA']
3977,NCT02429297,Change from baseline on self-care behaviors and health at 16 weeks (questionnaire),"Evaluate program feasibility (questionnaire, satisfaction, and usage rates)",,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3978,NCT00892372,,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
3979,NCT02579837,Proportion of participants with Actionable Eye Disease (AED),Proportion of participants with Diabetic Maculopathy (DME),,2016-03,COMPLETED,INTERVENTIONAL,['NA']
3980,NCT01594333,Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization,Number of Subjects With New Onset Type 2 Diabetes,Number of Subjects With Atrial Fibrillation,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3981,NCT05290506,change from baseline in insulin sensitivity/resistance index after 12-week treatment,change from baseline in beta-cell function after 12-week treatment,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3982,NCT05444595,Body weight,Program acceptability from community health workers and study participants,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3983,NCT01832181,Adiposity in the offspring,adipocytokine profile in the offspring,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
3984,NCT05763069,Feasibility of Home monitoring of high-risk pregnancies,Placenta-associated biomarkers: improving CTG prediction of adverse outcomes?,,2022-11-21,RECRUITING,OBSERVATIONAL,['NA']
3985,NCT05166200,Glucose positive area under the curve (AUC),Glucose Concentrations,Sensory Questionnaire,2022-03-11,COMPLETED,INTERVENTIONAL,['NA']
3986,NCT00661063,pain evaluation by visual analogue scale,pain evaluation by amount of rescue medication required,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
3987,NCT03390231,Changes of inflammation-related markers in diabetic patients after Stem Cell Educator therapy,Metabolic control in fasting C-peptide levels,,2017-11-27,UNKNOWN,INTERVENTIONAL,['PHASE2']
3988,NCT03201406,Mortality,,,2017-06-20,UNKNOWN,OBSERVATIONAL,['NA']
3989,NCT03920085,Clinical Evaluation of Blood Glucose result (mg/dl) from LifeScan Blood Glucose Monitoring Systems by comparison of a blood glucose result (mg/dl) obtained from a reference instrument (YSI2900) to demonstrate accuracy (%).,,,2019-01-08,COMPLETED,INTERVENTIONAL,['NA']
3990,NCT01648218,Blood glucose - inpatient,Mortality,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE4']
3991,NCT05380596,Adherence to treatment - Brief Medication Questionnaire (BMQ),Quality of life measured by DQOL-Brazil;,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3992,NCT06203860,"Time to first occurrence of major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure (HF).",Cost-effectiveness ratio of implementing a Cardio-Metabolic Clinic,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
3993,NCT02498054,Success rate to categorize blood glucose values into accepted ranges.,Actual time taken to categorize blood glucose values into accepted ranges on the questionnaire provided.,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
3994,NCT04187443,Treatment-emergent adverse events,Average mean change in best corrected visual acuity,,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
3995,NCT02796534,"Prevalence of obstructive sleep apnea syndrome by oxymetry, confirmed by polysomnography",Incidence of new cardiovascular events and changes in microangiopathic complications of diabetes patients depending on the presence of sleep apnea syndrome and to the adherence to CPAP treatment in case of sleep apnea syndrome treated,,2016-07-28,COMPLETED,OBSERVATIONAL,['NA']
3996,NCT05869344,Glucose postprandial levels,,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
3997,NCT05711602,Mini Nutritional Assessment (MNA),,,2023-01-09,COMPLETED,INTERVENTIONAL,['NA']
3998,NCT00005116,,,,na,COMPLETED,INTERVENTIONAL,['NA']
3999,NCT01536600,Change in HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),,2004-09,COMPLETED,OBSERVATIONAL,['NA']
4000,NCT05709847,Verbal memory,Processing Speed,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
4001,NCT00412269,,,,1998-02,COMPLETED,OBSERVATIONAL,['NA']
4002,NCT05139472,Peak Pulmonary Capillary Wedge Pressure (PCWP),6 minute walk time,,2021-11-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4003,NCT03417466,Mean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values),Consensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
4004,NCT04621929,New kidney stone formation (mm2) as determined by non-contrast CT scan,Change in urinary uric acid parameters,,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
4005,NCT00370565,"HbA1c is measured at Weeks -4, -1, 0, 6, and 12 of comparative treatment. The baseline value is the mean of the Week -1 and Week 0 values.","A patient satisfaction and preference questionnaire will be administered at screening, at baseline, during active therapy, and at the end of the study.",,1999-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4006,NCT03021837,The length of time that maternal glucose levels remain elevated after steroid administration.,,,2012-08-24,COMPLETED,OBSERVATIONAL,['NA']
4007,NCT00561158,"Fat intake (measured by Food Frequency Questionnaire) including: percent calories from fat, percent calories from saturated fat.",Cultural relevancy,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4008,NCT01904383,Percentage of Participants With Drug Related Adverse Events,The Mean Change From Baseline to Last Observation of the Treatment Period in Haemoglobin A1c (HbA1c),,2013-07-01,COMPLETED,OBSERVATIONAL,['NA']
4009,NCT00732147,Endogenous glucose production,Endogenous VLDL-Triglyceride production,,2009-04,WITHDRAWN,INTERVENTIONAL,['NA']
4010,NCT00312156,HbA1c,Hypoglycaemia,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4011,NCT03016832,ACR,High sensitivity C,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4012,NCT01631084,Incidence of all diabetes-related clinical endpoints,Proportions of patients with improved control of risk factors,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
4013,NCT00907374,Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio,Endothelial Dysfunction,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
4014,NCT03280758,Lipid profiles,Functional performance,,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA']
4015,NCT00496405,Retinal thickness,Best corrected visual acuity,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4016,NCT01820169,Improvement in HbA1c in 6 months,5. Doctor's opinion for Accu-Chek 360° View.,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
4017,NCT02427464,Number of Participants With Treatment-emergent Adverse Events.,Participants With at Least a 50 Percent Reduction in Average 24-hour Pain Score From Baseline to Day 180,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4018,NCT04004273,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner,Change in macronutrient intake,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
4019,NCT01303042,pre- and postprandial glucose levels in SMBG,Total score of Questionnaire on QOL,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
4020,NCT05666895,"Measure of inflammatory markers like (platelets-lymphocyte ratio, red blood cell distribution width) changes in DKA patients and affection of these changes on inflammation development and prognosis of DKA","Hematological parameters (RBC, Hct , Hb MCV, PLT ,WBC) which are used as an alternative approach to estimate the extent of dehydration in DKA patients",,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4021,NCT00709514,The incidence of complete ulcer closure,The time of healing rate and change in ulcer area,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4022,NCT05777330,Progression to persistent dysglycemia and stage 3 type 1 diabetes,,,2023-08-09,RECRUITING,INTERVENTIONAL,['NA']
4023,NCT00306072,The primary variable to be measured was positive AUC (0-180 minutes) for plasma glucose.,· Positive AUC 0-180 (0 to 120) minutes for serum insulin,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4024,NCT00219440,glucose,blood pressure,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4025,NCT01062048,Mean change in 2hr-postprandial glucose (PPG),,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
4026,NCT05566912,Completing the surveys,,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA']
4027,NCT01929863,Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores,Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7,,2013-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4028,NCT05999110,Change in Respiratory Compensation Point (RCP - VO2),Change medical appointments number related with Knee Osteoarthritis,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
4029,NCT02041377,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Strongly Agree or Agree or Are Neutral With Questionnaire Statements,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
4030,NCT01110577,Intra-class correlation coefficient (ICC) for repeated hepatic fat fraction (HFF) measurements from the LIPOQuant method,ICC for repeated HFF measurements from the 3-point Dixon method,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
4031,NCT02060266,"Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces",Maximum observed semaglutide plasma concentration,,2014-02-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4032,NCT05609747,high sensitivity C- reactive protein- hsCRP.,Clinical and Radiographic success,,2021-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4033,NCT03552523,Average Time Spent With CGMG Less Than 54 mg/dl,,,2017-07-28,COMPLETED,INTERVENTIONAL,['NA']
4034,NCT05963152,Chronic change in Colour Trails Test score,12 week acute change in Colour Trails Test score,,2023-07-20,RECRUITING,INTERVENTIONAL,['NA']
4035,NCT01162694,The primary endpoint is the A1c level or the change in A1c level,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-07,SUSPENDED,INTERVENTIONAL,['NA']
4036,NCT04203147,LDL-Cholesterol,Self-Care Behaviors,Resource Utilization and Cost,2020-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4037,NCT00136773,Change from baseline in the urine albumin/creatinine ratio after 52 weeks,Change from baseline in a marker of heart failure after 52 weeks,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4038,NCT04476472,Time in Range 70-180 mg/dL,Body Mass Index (BMI) (kg/m^2),,2020-09-08,COMPLETED,INTERVENTIONAL,['NA']
4039,NCT01008163,"Change from baseline in the fasting plasma glucose and postprandial glucose [after 2 hours, oral glucose tolerance test (OGTT) (75 g)] and HbA1c",Lipid profile,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4040,NCT02925156,Difference in body weight index (BMI) between high and low activity energy expenditure (AEE) groups.,,,2008-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4041,NCT00649909,The outcome measure is the laboratory Aspirin Resistance.,"To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.",,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4042,NCT04759495,Changes in glycated haemoglobin (HbA1c),"Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor",,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4043,NCT05737654,Change in quality of life,,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
4044,NCT00661362,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4045,NCT05467345,Number of results from the Contour Next and Contour Plus Elite BGMSs reference values within ±20% of reference values,,,2022-08-24,COMPLETED,OBSERVATIONAL,['NA']
4046,NCT01508065,Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by Clark error grid with measurements of venous blood as the comparing value,The safety of the Glucometer CGM-305 in evaluating blood glucose levels,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
4047,NCT00141986,change in 25(OH)D from baseline,changes in urine calcium:creatinine ratio,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4048,NCT01552499,The proportion of completely healed ulcers in patients treated with amniotic membrane vs. standard of care,Mean time to complete healing,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
4049,NCT01412905,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
4050,NCT05439226,HbA1C,Metabolomics,,2022-07-05,RECRUITING,INTERVENTIONAL,['NA']
4051,NCT01664624,Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1,Change From Baseline to Day 11 in 24-hour Average Plasma Glucose,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4052,NCT00525577,Change from baseline in HbA1c to the 6-month time point is identical in the study groups (placebo and AGI-1067 treatment groups),• Change of HbA1c from baseline throughout the study • Change of FPG from baseline throughout the study•,,2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4053,NCT03063229,Total metabolic Rate (TMR),,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
4054,NCT02821117,Change in Time in Range,,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA']
4055,NCT00727857,Percent Change From Baseline in Glycosylated Hemoglobin,Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4056,NCT05200390,Change in percent time in range of 70-180mg/dL (%TIR),Percentage of patients at goal % CV,,2022-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4057,NCT04129190,Oral Glucose Tolerance,,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
4058,NCT00566124,"Area under GIR-curve, maximal glucose infusion rate, time to maximal glucose infusion rate.",,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4059,NCT02305355,The mean percent change of Triglyceride(TG),The mean percent change of apolipoprotein B,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4060,NCT01856595,Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach),Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B,,2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
4061,NCT01527747,Change in fasting and postprandial triglyceride concentrations,Changes in glycemia,,2012-01,SUSPENDED,INTERVENTIONAL,['PHASE4']
4062,NCT04998032,HbA1c,salvage treatment,,2021-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4063,NCT00198471,Vitreous detachment,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4064,NCT03398538,Percentage of index ulcers healed at 12 weeks,Difference in cellulitis and/or infection at 12 weeks,,2017-12-26,COMPLETED,INTERVENTIONAL,['NA']
4065,NCT05881447,Incidence of cardiovascular- and non-classic risk factors of CKD:,Assessment of Hypertension incidence,,2023-06-21,RECRUITING,OBSERVATIONAL,['NA']
4066,NCT02995629,Perceived patient pain assessment,Time of treatment,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
4067,NCT01176253,Use the assays to detect beta cell destruction throughout the early time-course of type 1 diabetes mellitus,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
4068,NCT03030209,Number of participants with new-onset diabetes mellitus as defined by American Diabetes Association,Number of participants with new-onset exocrine insufficiency,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
4069,NCT00394875,lipid profile,health care consumption and costs,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
4070,NCT02216201,Identification of participants with abnormal SUDOSCAN electrochemical skin conductance scores,,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA']
4071,NCT00230087,(2) HOMA model- determined by the OGTT method,"Change in serum levels of proinflammatory cytokines (ie IL-6, TnF-αR2)",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4072,NCT05761743,Assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus,Assess the changes in skeletal profile after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
4073,NCT01201785,Collagen Induced Aggregation,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4074,NCT02706119,Hypoglycemia symptoms,Blood glucose coefficient of variation (CV),Adverse events,2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4075,NCT04803708,3. Incidence and severity of treatment-emergent SAEs and relationship to IP from first administration until EOS.,"Changes in wound/ulcer healing from to baseline in terms of wound complete closure and partial closure (25%, 50% and 75%) at EOT.",,2021-03-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4076,NCT05034380,Change from baseline in skeletal muscle whole genome nucleosome maps,Cholesterol,,2014-09-14,COMPLETED,INTERVENTIONAL,['NA']
4077,NCT00411970,Subjective postoperative recovery,Intra- and postoperative complications,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4078,NCT03899623,"The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence（AI） system compared with reference standard (ophthalmologist).",,,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA']
4079,NCT01508949,Change in weight,Adverse events,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4080,NCT05838287,Change in Diastolic function,PCr:ATP ratio,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE4']
4081,NCT01301521,Water-soluble Cinnamon,,,2013-06-11,COMPLETED,INTERVENTIONAL,['NA']
4082,NCT00462631,Late lumen loss at 9 months,Target vessel failure,,2007-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4083,NCT02834689,Mean 24 hour glucose levels (mmol/l),Time spent above 10 mmol/l glucose,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
4084,NCT01165944,HgA1c,Continuous glucose monitoring,,2009-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4085,NCT00523393,Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis,Markers of inflammation and vascular risk in diabetes,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
4086,NCT03534921,Healthcare interventions - referrals,,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
4087,NCT00807976,Prevalence of orthostatic hypotension,"Adverse events, Score risk profile questionnaire, Heart rate, Gender, Body mass index, Medication, Smoking, History of cardiovascular disease, Family history of cardiovascular disease, Duration of diabetes mellitus, Glycosylated haemoglobin, Insulin use",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
4088,NCT04597229,Change of fasting serum insulin,,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
4089,NCT01940835,Mean Interleukin 15 (IL-15) Expression,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
4090,NCT05363774,Number of treatment emergent adverse events (TEAE) in T2D QW cohort,"Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in the MAD QW s.c. cohort",,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE1']
4091,NCT06220968,Cavernosal blood glutathione level,,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4092,NCT05616351,Compliance with the hospital in-house guidelines for diabetic foot infections with regard to antibiotic treatment,Relapse of diabetic foot infections (number),,2022-10-12,COMPLETED,OBSERVATIONAL,['NA']
4093,NCT03626623,Number of Wounds With Wound Closure,Indirect Diabetic Foot Ulcer (DFU) Product(s) Costs,,2019-05-21,TERMINATED,INTERVENTIONAL,['NA']
4094,NCT05426096,Hyperglycemia (glucose >180 mmol/dL),Glucose at first PACU measurement,Incidence of surgical site infection,2022-10-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4095,NCT01521910,Rate of decline of GFR,,,1995-04,COMPLETED,INTERVENTIONAL,['NA']
4096,NCT03665974,Pre-pregnancy BMI,,,2013-01-05,COMPLETED,OBSERVATIONAL,['NA']
4097,NCT01849965,The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed 2 weeks later) after initiation of treatment.,The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed two weeks later) after initiation of treatment.,Incidence of and time to target ulcer recurrence after confirmed complete wound closure has been established.,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3']
4098,NCT02861157,STARx Transition Readiness Questionnaire,Quality of Life,,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4099,NCT05061030,Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.,Change in peak C-peptide,Peripheral blood mononuclear cells,2022-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4100,NCT04754464,BFM,HOMA-IR,WHtR,2020-05-13,COMPLETED,INTERVENTIONAL,['NA']
4101,NCT01127659,Insulin Sensitivity,Body Composition,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4102,NCT05065879,Neutralizing antibody level,Adverse events following vaccination,,2021-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4103,NCT01869959,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline to Day 28 in The Patient Health Questionnaire (PHQ-9) Score,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4104,NCT03441919,"Arterial wall inflammation, measured by 18F-FDG-PET/CT","Arterial wall inflammation, measured by 18F-FDG-PET/CT",,2018-01-18,COMPLETED,OBSERVATIONAL,['NA']
4105,NCT03189225,"Venous blood collected for impact assessment of Biochemistry parameters on 3 LifeScan Blood Glucose Monitoring Systems (OneTouch Ultra 2, OneTouch Verio, OneTouch SelectPlus).",,,2016-08-01,COMPLETED,INTERVENTIONAL,['NA']
4106,NCT05811078,Implementation of trainings containing peer interactive group support to adolescents and application of scales,Evaluation of Data,,2023-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4107,NCT03565458,"Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, empagliflozin",metabolic ratio of gemigliptin,,2018-04-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
4108,NCT00728156,To compare the effect of Clopidogrel in reduction of thrombogenicity in patients with T2DM and CAD with placebo,To characterise features in T2DM patients responsible for increased thrombogenicity,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4109,NCT03044860,Evaluation of differences in enteroendocrine cells (density and mRNA expression) along the intestinal tract of healthy individuals compared with type 2 diabetes patients.,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
4110,NCT03550066,Acceptance of Health Message,Diabetes Prevention Behavior: Intention,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
4111,NCT01142297,Implant Stability Quotient (ISQ),Clinical Success of Implants,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
4112,NCT01870934,Comparison of 3D image and normal assessment of wounds,Comparison of 3D and 2D image assessment of wounds,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4113,NCT00771680,Serious adverse drug reactions including major hypoglycaemic events,Quality of Life (QoL) as assessed by patient questionnaire,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
4114,NCT00375960,11 point numerical pain rating scale (NPRS) daily diary,daily sleep interference score,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4115,NCT05337098,24-hour glycemic control,Monocyte chemoattractant protein-1,,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
4116,NCT05735873,Change from Baseline to 12 weeks in Numeric Pain Rating Scale,Change from Baseline to 12 weeks in diastolic blood pressure,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4117,NCT02887898,Change in HbA1c,Change in treatment satisfaction,Adherences to bolus calculator use,2016-09,COMPLETED,INTERVENTIONAL,['NA']
4118,NCT01955746,Type 1 diabetes gene,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
4119,NCT01908894,Speed of absorption (TINS-50%-early) of BIOD-123 and BIOD-125 versus Humalog.,,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4120,NCT06099067,3-point MACE,,,2020-05-15,COMPLETED,OBSERVATIONAL,['NA']
4121,NCT01627899,Change in A1C From Baseline to Week 24,Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks,,2012-10-01,TERMINATED,INTERVENTIONAL,['NA']
4122,NCT00326326,HDL-C Safety and Efficacy,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4123,NCT00468351,"Central Macular Thickness, Best Corrected Visual Acuity",Intraocular pressure; lens status,,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
4124,NCT03962296,The change(Improvement)in the hard exduates,The change of total macular volum(TMV),,2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE4']
4125,NCT04084171,Primary Outcome,CGM Consensus Goal,,2019-09-26,COMPLETED,INTERVENTIONAL,['NA']
4126,NCT02546063,Average of the postprandial area under the glucose curve (AUC) measured over three hours after each meal's start using Continuous Glucose Monitoring,User satisfaction,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
4127,NCT04051359,The rate of treatment failure defined as patients needing additional hypoglycemic therapy by long-insulin acting analogue detemir evaluated by capillary glucose levels,,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
4128,NCT01062269,Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.,Weighted vs. Unweighted BASA Scale,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4129,NCT02666924,Glycemic control,Albuminuria screen,Diabetes self knowledge assessment,2017-10-31,COMPLETED,INTERVENTIONAL,['NA']
4130,NCT03132571,BMI,Waist Circumference (Inches),,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4131,NCT02482662,proportion of OGTTs falsely negative,preference of participants regarding the two tests (OGTT vs. SMBG),,2014-11,COMPLETED,OBSERVATIONAL,['NA']
4132,NCT01352390,Number of Participants that schedule an appointment for receipt of a Pap smear.,Number of Participants that schedule an appointment for receipt of a Fasting plasma glucose test,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
4133,NCT02994095,PACIC score,,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
4134,NCT04932213,Change from baseline in pupillary diameter,Change from baseline in central corneal thickness (CCT),,2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4135,NCT01423877,Insulin Resistance,Vitals status,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
4136,NCT01217463,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition",Relative Wound Area Regression of 40% or More at 6 Week,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4137,NCT05661474,the proportion of patients complete responders,,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4138,NCT01105858,Diabetes,,,2010-11-16,RECRUITING,OBSERVATIONAL,['NA']
4139,NCT03530930,Change From Baseline in Visual Analogue Scale for Pain,Patient global assessment of osteoarthritis,,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE4']
4140,NCT03863054,Percentage change in ulcer size,Pain at wound site,,2018-08-17,COMPLETED,OBSERVATIONAL,['NA']
4141,NCT06003400,Change in wound size between V1 and the last treatment,,,2023-03-29,RECRUITING,INTERVENTIONAL,['NA']
4142,NCT05263232,average 24h blood glucose levels,Culturing human primary myotubes to assess circadian reporter characteristics,mRNA in peripheral blood mononuclear cells (PBMC) of markers involved in the molecular clock,2022-03-16,COMPLETED,INTERVENTIONAL,['NA']
4143,NCT02117154,Area Under The Curve for Glucose excursion,"Measurement of HbA1c, fructosamine, Glycated albumin levels",,2013-06,COMPLETED,OBSERVATIONAL,['NA']
4144,NCT00548522,The documentation of Cpeptide in women with type 1 diabetes who are pregnant,,,2007-08,TERMINATED,OBSERVATIONAL,['NA']
4145,NCT04582448,"AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4146,NCT00968786,"blood pressure, blood glucose, body weight and visceral fat levels.",albuminuria,,2008-08,UNKNOWN,INTERVENTIONAL,['NA']
4147,NCT02829177,Improved Albuminuria,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4148,NCT02835859,Measure in glucose concentrations,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
4149,NCT05736484,Change in mean daily step count from baseline to the end of the 26 week intervention period.,Participants' acute care utilization throughout the entire study (Baseline to end of study [52 weeks]).,,2023-09-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4150,NCT04014660,Autoimmunity,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
4151,NCT06218147,Percent of glucose time in range assessed by using continuous glucose monitor,Amount of fasting blood glucose,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
4152,NCT02737722,"Number of Participants With Normal and Abnormal Cultures at Visits 2, 3, 4, and 5",Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the Per-Protocol Population,,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4153,NCT01498913,Body weight,Adverse events,,2001-08-30,COMPLETED,OBSERVATIONAL,['NA']
4154,NCT03006666,Patient Activation Measure (PAM) scores,,,2017-07-13,COMPLETED,INTERVENTIONAL,['NA']
4155,NCT01500798,Measured GFR assessed by plasma clearance of Tc99m-DTPA,Circulating endothelial cell assessments,,2012-01-31,TERMINATED,INTERVENTIONAL,['PHASE1']
4156,NCT00902616,Improvement in microcirculation,Effect of L-arginine on clinical parameters of neuropathy,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4157,NCT03882970,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4158,NCT05492916,Percentage Change in Body Weight,Change in San Francisco Chinese Food Security Module Score,,2023-06-27,RECRUITING,INTERVENTIONAL,['NA']
4159,NCT04454957,Healthcare expenditures,Patient Health Questionnaire,,2020-08-24,RECRUITING,INTERVENTIONAL,['NA']
4160,NCT00760526,Number of Participants With a Decrease >=0.5% HbA1c With no Severe Hypoglycemic Events,Parental Quality of Life Measures: CGM Satisfaction Scale,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4161,NCT01709123,Blood Glucose Levels,Blood Levels of Cytokines/Inflammatory Biomarkers,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
4162,NCT01654172,Change in Fasting Brain Blood Flow,Change in diabetes control,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
4163,NCT05222373,Change from Baseline HbA1c to 6 months,Change from Baseline Quality of Life to 6 months,Intervention Implementation Adaptability,2023-12-07,RECRUITING,INTERVENTIONAL,['NA']
4164,NCT02293135,Peripheral microcirculation measured using Laser Doppler flowmetry,Reactive Hyperemia Index (RHI),,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
4165,NCT01316107,change from baseline in hemoglobin A1c (HbA1c),"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2011-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
4166,NCT00229112,Clinical Cure/Improvement at discontinuation of IV antibiotic therapy.,Clinical Cure: 1. Day 5 of IV antibiotic therapy; 2.10 days after completion of all antibiotic therapy.,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4167,NCT01751399,Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541,,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4168,NCT02365129,Change from Baseline in BAT mass and activity evaluated with Positron emission tomography/computed tomography (PET/CT),Change from Baseline in Basal Heart Rate Variability: with a heart rate monitor,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
4169,NCT05201846,Time in range,Perceived stress scale of parents,,2022-01-18,UNKNOWN,INTERVENTIONAL,['NA']
4170,NCT01018602,development of type 2 diabetes mellitus by criteria of ADA 1997,,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4171,NCT05304975,Generation of variability data on the primary outcome measure (cognition) from baseline to 6 months on which to base a formal power calculation for a large-scale trial,,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
4172,NCT01654380,Part B: Glycodynamics: Maximum Rate of Glucose Disposal,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4173,NCT02907684,Liver fat %,Plasma leptin,4 day food diaries,2017-03-29,COMPLETED,INTERVENTIONAL,['NA']
4174,NCT01715012,Safety,Scarring of skin graft donor site,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE2']
4175,NCT01919489,Glycemic Control at Hospital Discharge and 6 Months Follow up,Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4176,NCT00998699,Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose),Measurement of serum concentrations of XOMA 052,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4177,NCT01917669,Are peak (nM) calcium responses to bradykinin enhanced along the continuum of disease in skin fibroblasts from the 4 patient groups?,Are glucose utilization rates (a.u./min) measured in skin fibroblasts from the 4 patient groups different with disease progression?,"What component of peripheral metabolic dysregulation (HbA1c (%), adiponectin (ug/mL), cholesterol (mg/dL)) is associated with changes in calcium responses (nM) in skin fibroblasts?",2013-10,WITHDRAWN,OBSERVATIONAL,['NA']
4178,NCT01494935,Insulin Sensitivity,ceramides and diacylglycerol,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
4179,NCT06319300,time in target range (3.9-10.0 mmol/L ),Other/Serious Adverse Events,,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4180,NCT00603031,phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose,maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine),,2008-01,COMPLETED,INTERVENTIONAL,['NA']
4181,NCT06099509,Completion of 75-gram oral glucose tolerance test,,Patient satisfaction,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
4182,NCT00441077,Intentions to seek information about family history.,,,2007-02-19,COMPLETED,INTERVENTIONAL,['NA']
4183,NCT00824148,Level of HbA1c concentration,Number of hypoglycemic events,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
4184,NCT02244814,Neonatal adiposity,Placental fatty acid transporter protein-2 expression,Infant Adiposity,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4185,NCT01214239,HbA1c Change From Baseline at Week 24,Number With HbA1c at Least Lowering 0.5%,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4186,NCT00116922,Development of diabetes based on 1 positive OGTT or 2 fasting glucose levels,"Lipids, CBC, CRP, homocysteine, adiponectin, insulin, proinsulin, and routine biochemistry will be done annually",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4187,NCT05457933,Noninferiority in mean differences between groups in their daily blood glucose concentrations,Diuretics Use,,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
4188,NCT01829256,Change in kidney function as measured by estimated glomerular filtration rate based on cystatin C(eGFRcys),"Change in blood pressure, glucose/HbA1c and urine albumin",,2014-05,COMPLETED,INTERVENTIONAL,['NA']
4189,NCT03758742,"Mean 24-hour glucose levels, peak glucose levels, and mean amplitude of glycemic excursions (MAGE), as measured using continuous glucose monitoring",Dosage of cardiovascular medications used,Intervention satisfaction and feedback,2019-09-10,COMPLETED,INTERVENTIONAL,['NA']
4190,NCT05165628,"Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters.",Duration of clinic/home care visits across groups,,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE1']
4191,NCT01718522,Number (n) of Excursions <70 mg/dl Per Sensor Day at Baseline and 3 Months,Interstitial Sensor Glucose Excursions After Meals (Amplitude of Excursions) at Baseline and 3 Months,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
4192,NCT02784236,To analyze the metabolic impact measured through HbA1c of a telemedicine program by MenaDiab® online platform in the care of patients with DM1.,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4193,NCT02287285,Beta Cell Sensitivity (BCS),Maximal Beta Cell Function,,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4194,NCT01202266,Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145,Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
4195,NCT02969863,Percentage of Time Spent With Dexcom CGMG < 60 mg/dl,,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4196,NCT05006872,Mean adherence to antidiabetic drugs (%),Self-efficacy to manage Diabetes (DSES-S),International Physical Activity Questionnaire (IPAQ),2021-10-06,UNKNOWN,INTERVENTIONAL,['NA']
4197,NCT03863431,Whole-body insulin sensitivity index,Subjective appetite ratings,,2019-05-22,UNKNOWN,INTERVENTIONAL,['NA']
4198,NCT01429506,weight loss,glycemic control,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
4199,NCT00722631,Effect of treatment on the nominal change in FDG uptake of atherosclerotic plaque from baseline after 4 months of treatment as measured by FDG-PET/CT imaging.,All cardiovascular events and all cause death for 5 years,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
4200,NCT04866264,Subjective effectiveness questionnaire of eNutrition Optimizer,systolic and diastolic blood pressure,,2021-11-11,RECRUITING,INTERVENTIONAL,['NA']
4201,NCT03999268,Change from baseline in psychological insulin resistance at 6 months,Provider Satisfaction,Provider usability,2019-11-25,COMPLETED,INTERVENTIONAL,['NA']
4202,NCT04436900,Angiography with fluorescein,,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA']
4203,NCT00563225,"To evaluate safety & efficacy of Insulin glargine ( injection at bedtime, once a day) on the changes of HbA1c.","To evaluate the efficacy of Insulin glargine (injection at bedtime, once a day) on the changes of FPG.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4204,NCT01868555,Adverse events (AEs),Area under the serum insulin aspart concentration curve,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4205,NCT05491005,HbA1c,Diabetes complications follow-up,proBNP,2022-08-31,RECRUITING,INTERVENTIONAL,['NA']
4206,NCT01837121,Not-attended rate,Satisfaction with care,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
4207,NCT02952352,Weight,Stages of Change for weight loss,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
4208,NCT00162305,To assess the safety and tolerability of multiple oral doses of BMS-512148 administered alone or concomitantly with metformin in diabetic subjects,To identify potential biomarkers in both urine and blood,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4209,NCT00489879,"HbA1c, fasting blood glucose level, Weight change, Blood pressure level in the morning, lipid profiles","exercise time during one week, self reported change in dietary habit, fat consumption ratio",,2007-07,COMPLETED,INTERVENTIONAL,['NA']
4210,NCT00177398,Time to mean 24 hour plasma glucose < 180 mg/dl,Outpatient glycemic control and self management practices,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4211,NCT05577286,balance,,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4212,NCT04786262,Proportion of Participants Free of Severe Hypoglycemic Events With Either a Glycosylated Hemoglobin (HbA1c) <7.0% or a ≥ 1% Reduction in HbA1c From Baseline,Changes in Stimulated C-peptide,,2021-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4213,NCT00434616,"Major amputation of the index limb or persisting, unchanged critical limb ischemia",survival without amputation,,2007-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4214,NCT04589689,Adolescent quality of life,Hemoglobin A1c (HbA1c),,2020-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4215,NCT04977635,"Change in patient-reported outcomes between baseline and 2 year timepoint as measured by WHO-5, PAID-20 and WHOQOL surveys",,,2016-06-08,COMPLETED,OBSERVATIONAL,['NA']
4216,NCT05144802,Assess accuracy of interstitial glucose values measured respectively by FreeStyle® Libre and Dexcom® G6 compared to blood glucose values in standardized hypoxemia conditions in patients with diabetes and in healthy volunteers.,Tolerability of acute hypoxia,,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
4217,NCT02068872,Safety of Sleeve Gastrectomy,Weight Loss,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4218,NCT03440502,the incidence of complete failure of spinal block.,determine the effect of DM on the other spinal block criteria,,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA']
4219,NCT01249677,Improvements in first and second phase insulin secretion,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4220,NCT00308308,Compare the Mean Change From Baseline to Week 52 in HbA1c,Severe Hypoglycemia Event Rate,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4221,NCT06254339,Dyslipidemia,The China-PAR project model,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
4222,NCT01242826,Area under the serum insulin aspart concentration-time curve from 0 to 24hours,Number of hypoglycaemic events,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4223,NCT02597049,Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand),Number of Participants With Adjudicated Cardiovascular (CV) Events,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4224,NCT02920918,Change From Baseline Ventilatory Efficiency at 12 Weeks,,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4225,NCT05915884,Change in triglyceride index,,,2023-06-10,RECRUITING,OBSERVATIONAL,['NA']
4226,NCT03883412,Microvascular Blood Volume - change from baseline,Insulin Sensitivity-Change from baseline,,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE4']
4227,NCT06188572,Ferrans&Powers Quality of Life Index Diabetes Version,,,2023-05-01,COMPLETED,OBSERVATIONAL,['NA']
4228,NCT00423215,Measure of Glycolysated Haemoglobin (HbA1c) level reduction,Patient's satisfaction,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
4229,NCT02695433,Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs control treatment.,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs control treatment.,Changes in blood MCP-1 in 12-week intervention of active treatment vs control treatment.,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
4230,NCT01894568,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c),Percentage of Participants With Total and Nocturnal Hypoglycemic Events (HE),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4231,NCT02544347,omentin levels,clinical attachment level,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
4232,NCT02924207,change in hemoglobin A1c from baseline,actual cost and change in frequency of drug side effects,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
4233,NCT03018938,Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c),Change From Baseline to Week 48 in Self-Efficacy About Insulin Therapy Questionnaire (SEITQ) Score,,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4234,NCT03167996,Initial User Assessment,,,2016-06-23,COMPLETED,INTERVENTIONAL,['NA']
4235,NCT05904743,Change in HbA1c,CGM-measured hypoglycemia events (both a safety and efficacy endpoint),Patient-reported outcome (PRO) questionnaires,2023-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
4236,NCT04992299,Recruitment Feasibility: Percentage of Eligible Adolescents who Enroll,Assessment Feasibility: Percentage Accuracy of Protocols,,2022-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4237,NCT01902316,measurement of the amount of plasma peptides,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
4238,NCT04286529,C-Peptide Level,PROMIS 10 Questionnaire,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE1']
4239,NCT00858273,Glutathione Concentration,Plasma Protein Bound 3-nitrotyrosine,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
4240,NCT04051229,Blood collection_insulin follow up 2,VO2 peak,,2019-10-29,TERMINATED,INTERVENTIONAL,['NA']
4241,NCT03869281,Fracture incidence,,,2019-12-07,COMPLETED,OBSERVATIONAL,['NA']
4242,NCT04031222,Inflammatory markers,,,2017-05-19,COMPLETED,OBSERVATIONAL,['NA']
4243,NCT05498974,PAID,Metabolomics,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
4244,NCT01960231,fasting and post glucose load glucose level,fasting and post glucose load c-peptide,glucose metabolism measured by CGMS,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
4245,NCT02228642,Prevalence of Hypoglycemia Associated Autonomic Failure in the inpatient setting as assessed by hypoglycemia symptom scores,Measures of cognitive function following a hypoglycemic event,Measure of cognitive function,2014-08,COMPLETED,OBSERVATIONAL,['NA']
4246,NCT05222477,"Sleep quality (0 is best, 3 is worst)",Abdominal and pelvic floor muscle electrical activity,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
4247,NCT03761797,Number of Participants With Adverse Drug Reactions (ADRs),,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
4248,NCT06206005,Crestal bone loss around implants,Probing depth,,2023-12-04,RECRUITING,OBSERVATIONAL,['NA']
4249,NCT01465672,"diagnostic accuracy, i.e. difference of copeptin levels between patients without and patients with postoperative DI, of copeptin in the diagnosis of water disturbance in neurosurgical patients",,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
4250,NCT00818077,Glycemic Response to the Fixed Meal,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
4251,NCT05492305,subjective effect of GLP1 receptor agonist on mental health,mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks,,2022-09,RECRUITING,OBSERVATIONAL,['NA']
4252,NCT03427931,Percentage Time in Range 70-180 mg/dL by CGM,Percentage Time in Range <70 mg/dL by CGM,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
4253,NCT01340924,Glucose tolerance assessed using a 75g-Oral Glucose Tolerance Test (OGTT) in mothers,Physical activity,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
4254,NCT00935467,Evidence of steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,To assess the safety and tolerability of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4255,NCT05154045,Glucose positive area under the curve (AUC),Glucose Concentrations,Sensory Questionnaire,2022-04-09,COMPLETED,INTERVENTIONAL,['NA']
4256,NCT00800176,Absolute Change in HbA1c,Percentage of Participants With at Least One Adverse Event,,2009-01-22,COMPLETED,INTERVENTIONAL,['PHASE2']
4257,NCT05684341,Change from baseline in HbA1c at Week 24,Number of participants with adverse events during the 24-week study period,,2023-02-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4258,NCT02560090,Change of Self-management Success Measured by Diabetes Self-Management Assessment Survey Tool from Baseline to Study Completion,Change of Diet Measured By a 24-item Introduction to the Lifestyle Survey from Baseline to Study Completion,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
4259,NCT05571306,Changes in Diabetes Distress levels,Changes in Blood lipds,Changes in Resilience measured using the Conner-Davidson Resilience Scale,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
4260,NCT04217291,Changes in Glycosylated Hemoglobin A1c (HbA1c),Changes in abdominal weight relative to baseline at 8 and 16 weeks.,,2019-12-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4261,NCT04073641,"Diabetes membership survey of health, access to care, support and services",,,2019-04-11,COMPLETED,OBSERVATIONAL,['NA']
4262,NCT02194517,HbA1c (glycated hemoglobin),Glucose Area Under the Curve (AUC),Treatment satisfaction,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4263,NCT02208115,Acute subjective appetite responses,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4264,NCT02216552,Efficacy Outcome,Efficacy Outcome,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4265,NCT01588366,Change From Baseline to Day 28 in Hepatic Glycogen Content,Change From Baseline to Day 29 in Insulin Response to an Arginine Stimulation Test (AST) (Part A),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4266,NCT02723539,Proportion of participants who are clinically cured,Proportion of participants who are microbiologically cured,,2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4267,NCT04263675,Study the mechanisms linked to the effect of breastfeeding on the growth of children in women who have had GDM.,"Associate level of hormones related to satiety and energy metabolism (i.e. endocannabinoids, ghrelin, leptin) in the human milk of women with or without GDM and the growth of the child.",,2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4268,NCT05130593,Palatability of Bar,Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.,,2021-10-25,COMPLETED,OBSERVATIONAL,['NA']
4269,NCT06297980,Glucose standard deviation,Glucose standard deviation,,2024-03-15,RECRUITING,INTERVENTIONAL,['NA']
4270,NCT02718638,Changes in cytokines plasma levels,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4271,NCT06039293,Number of Steps,General Quality of Life,Aerobic Capacity,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4272,NCT05181254,Proportion of patients who change their risk profile,Blood pressure,,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
4273,NCT01001689,Maternal body composition,Proportion of newborns with birth weight over the 90th percentile for gestational age,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4274,NCT01161043,Glucose Sensor Accuracy When Compared to SMBG: Proportion of Glucose Sensor Readings That Met Accuracy Criteria [Time Frame: Days One Through Six of Sensor Use],Device Related Moderate or Device Related Severe Adverse Events,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4275,NCT04857996,Ocular and systemic safety and tolerability of a single IVT injection of UBX1325 evaluated by incidence of treatment emergent adverse events (TEAEs),Proportion of patients without macular fluid as assessed by SD-OCT,,2021-06-25,COMPLETED,INTERVENTIONAL,['PHASE2']
4276,NCT03945968,incidence of postoperative complications,mortality after abdominal surgery,,2019-07-01,RECRUITING,OBSERVATIONAL,['NA']
4277,NCT00399997,Patient-reported health related quality of life at 4 and 10 months,Patient-reported compliance with national guidelines for physical activity at 4 and 10 months,,2005-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4278,NCT02627898,"Change from Baseline in Aortic Pulse Wave Velocity measured in meters / second, at 12 weeks",Change from Baseline in central systolic blood pressure measured in mm / Hg at 12 weeks,Change from Baseline in Body and visceral fat measured in centimeters ^ 2 at 12 weeks,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4279,NCT00021801,,,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4280,NCT03404895,Number of days to ulcer healing,Total number of subjects with minor and major amputations,,2018-04-13,RECRUITING,INTERVENTIONAL,['NA']
4281,NCT00561171,ABPM,sitting PB,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4282,NCT01051245,"Combined outcome assessing adequate control of hypertension, LDL-cholesterol and glycated hemoglobin",Quality of care process measures,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
4283,NCT05484427,metabolic control (HbA1c concentrations) at Month 9,Patient´s satisfaction of regular and telemedicine (email) visits.,,2021-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4284,NCT05330208,Incidence of reaction of the injection sites,Immunogenicity,,2022-04-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
4285,NCT03479788,REM OSA,,,2018-06-04,COMPLETED,OBSERVATIONAL,['NA']
4286,NCT01536639,HbA1c (glycosylated haemoglobin),Adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
4287,NCT02662842,Comparative Infusion Set Wear Comfort,Overall Infusion Set Preference,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
4288,NCT04660006,Change from baseline of retinal thickness up to 3 months post-cataract surgery.,Development of new cystoid macular edema,,2019-05-27,UNKNOWN,OBSERVATIONAL,['NA']
4289,NCT02480244,Change in BMI,Change in blood pressure,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4290,NCT05202470,The Problem Areas in Diabetes Scale (PADS),,,2022-01-06,COMPLETED,INTERVENTIONAL,['NA']
4291,NCT00944619,Percentage of plasma glucose values in target (3.9-8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4292,NCT05944718,Impact of continuous and intermittent CGM use on blood glucose levels in comparison to standard of care in people living with type 1 diabetes,5. Cost of continuous and intermittent CGM use from a user and provider perspective,,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
4293,NCT05716308,Criteria for visual acuity changes,,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
4294,NCT01260857,Report of Adverse Events occurence (Safety),% of patients reaching BP goal of <140/90 mmHg and <130/80 mmHg for DM and proteinuric patients,,2013-03,WITHDRAWN,OBSERVATIONAL,['NA']
4295,NCT01941719,Patient Interpretation of Neuropathy (PIN) Questionnaire,Foot Complications,,2008-05-02,COMPLETED,INTERVENTIONAL,['NA']
4296,NCT05500937,Changes of HbA1c,Rate of MACE,,2021-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4297,NCT02805543,The correlation between the bilateral retrobulbar RI and bilateral kidney RI in 34 patients,,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
4298,NCT04528212,Sirtuin1 (SIRT1) (ng/ml),Triglyceride (mg/dl),,2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4299,NCT00891683,To evaluate the potential efficacy of AEG33773 in reducing chronic pain due to DPN,To explore AEG33773-dependent pharmacodynamic (PD) effects in blood of patients,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4300,NCT04047537,Hemoglobin A1c,Change from baseline in Laboratory Complete Blood count Values,,2019-08-06,TERMINATED,INTERVENTIONAL,['NA']
4301,NCT03751501,Change in Visual Acuity (Letters),Number of AEs/SAEs,,2018-11-22,UNKNOWN,INTERVENTIONAL,['NA']
4302,NCT00654381,Examination of Long-term Safety of Linagliptin (52-week Treatment),Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4303,NCT00734448,Insulin sensitivity index (HOMA-IR) and continuous glucose monitoring profile,baby weight at delivery,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
4304,NCT03060980,Reduction in weight,,,2017-03-03,TERMINATED,INTERVENTIONAL,['PHASE3']
4305,NCT01189890,Number of Participants Discontinuing Study Treatment Due to An AE,LS Mean Change From Baseline in Participant Body Weight at Week 30,,2010-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
4306,NCT00549133,"Evaluation of the effect of irbesartan on nitric oxide (NO), which has key role in the endothelial dysfunction and the development of pressure vasomotor response, compared to standard therapy (atenolol)","Evaluation of the effect of irbesartan on chronic inflammatory process and tendency for procoagulation, associated with endothelial dysfunction, compared to atenolol.",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4307,NCT02418091,Change in Blood Pressure,Change in taking medicine as prescribed,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
4308,NCT05038046,Change from Baseline in Nerve Conduction Velocity at 3 months,heart rate variability,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4309,NCT02950181,Observing Cerebral oximetry readings when patients present to the pediatric emergency department,,,2014-07-29,TERMINATED,INTERVENTIONAL,['NA']
4310,NCT06223490,Skin fold thickness and estimation of total body fat,,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
4311,NCT06132126,Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters,Part A and Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC),,2023-11-17,RECRUITING,INTERVENTIONAL,['PHASE1']
4312,NCT05649137,Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction greater than or equal to (>=) 5% (yes/no),Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes,,2023-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4313,NCT00469833,Insulin Concentration in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,HbA1c Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
4314,NCT03160196,Proportions of participants with normal Hb1Ac,,,2018-01,UNKNOWN,INTERVENTIONAL,['NA']
4315,NCT01512979,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in FPG by Visit Over Time,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4316,NCT05919927,Sum score of the Z-scores of the performed standardized neuropsychological tests,,,2018-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4317,NCT05243810,Incidence of intervention-related adverse events collected throughout the trial,Quantitative progression of local inflammatory biomarkers over the course of the intervention versus screening and baseline.,,2022-11-28,COMPLETED,INTERVENTIONAL,['NA']
4318,NCT02501850,Change in blood levels of Lipoprotein (a) (Lp(a)),,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
4319,NCT00521690,"Incidence of serious adverse events, including major hypoglycaemic events",Incidence of hypoglycaemic episodes,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4320,NCT02214641,Glycated hemoglobin (HbA1C),Summary of Diabetes Self-Care Activities (SDSCA),,2014-10,COMPLETED,INTERVENTIONAL,['NA']
4321,NCT01572402,Postprandial plasma concentrations of gastrointestinal peptides,Postprandial plasma lipids,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4322,NCT05452993,diabetic retinopathy screening rate,consistance between artificial intelligence and ophthalmologist re-read for doubtful images,,2022-09,UNKNOWN,INTERVENTIONAL,['NA']
4323,NCT02202161,Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding,Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10),,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4324,NCT02537704,Change in body weight,Change in liver enzymes [AST and ALT],,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
4325,NCT02961517,Effect of sociodemographic characteristics,Preference for online,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
4326,NCT01516242,Patient satisfaction with NovoPen® 4 insulin delivery system,Hypoglycaemia,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
4327,NCT05057806,ATPmax production,Patient-Reported Outcomes Measure Information System (PROMIS),,2021-01-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4328,NCT04259047,Decline in Verbal Memory,,Dementia,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
4329,NCT01347671,Change in mean daily pain intensity score,Plasma concentration,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4330,NCT02771821,Glycated Hemoglobin,Waist Circumference,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
4331,NCT02662400,Improvement in insulin sensitivity after stem cell transplantation,Improvement in β cell function after stem cell transplantation,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4332,NCT03814512,Change in Total Sleep Time,,,2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4333,NCT00957268,AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alogliptin,Observed Effect at 24 Hours Post-dose (E24) of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
4334,NCT04354142,Carbohydrate (CHO) Counting Efficiency (Time to count),Implementation outcomes: Acceptability,,2018-07-12,COMPLETED,INTERVENTIONAL,['NA']
4335,NCT00682097,"AUC0-24h, Cmax",Parameters of glucose metabolism,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4336,NCT02911311,The primary outcome is mean visual acuity change(BCVA),change of central retinal thickness,,2019-10-12,UNKNOWN,INTERVENTIONAL,['NA']
4337,NCT04361097,Creatinine Clearance,Lactate,,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
4338,NCT02823600,Usability of the RetinaVue Hand-Held 100 Camera,Pre-and Post-eye Exam Rates in the Diabetic Dialysis Population,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
4339,NCT02274207,Days to patient discharge,Rate of adverse event,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
4340,NCT02475421,Metabolic clearance rate of glucagon,The volume of distribution of glucagon,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
4341,NCT01452893,difference in cognitive function before and after physical stress,differences in counterregulatory hormonal response to physical stress,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
4342,NCT02934893,Hemoglobin A1C,Patient satisfaction questionnaire,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
4343,NCT03161912,Mean change of visual acuity (VA) from baseline to 12 months as evaluated in routine clinical practice per cohort and per country.,"Mean change in VA by number of injections during the first 6 months, the first year, and the 2-year treatment period.",,2017-11-24,COMPLETED,OBSERVATIONAL,['NA']
4344,NCT03710928,Hemoglobin A1C change,Highly Processed Food Withdrawal Scale (ProWS),,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
4345,NCT01270763,High density lipoprotein cholesterol,Physical activity/fitness,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
4346,NCT00485758,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4347,NCT02478853,"Implementation of the new care framework assessed with interviews, chart audit and questionnaires",Fidelity of care to framework measure with chart audit,,2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4348,NCT00001859,,,,1999-06-04,COMPLETED,OBSERVATIONAL,['NA']
4349,NCT04965051,HbA1c,Insulin dose,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
4350,NCT00425009,HbA1c at 13 weeks,Blood lipids at 13 weeks,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4351,NCT03512132,Anti-inflammatory effect,,,2018-04-24,RECRUITING,OBSERVATIONAL,['NA']
4352,NCT05071287,Gut Metabolomics,Glycemic Control,Fecal Metabolomics,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
4353,NCT01819844,"Average Blood Glucose Over the Closed-loop Control Period, as Determined From GlucoScout Measurements.",Accuracy of the CGM Device Using the GlucoScout Measurements as the Standard.,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4354,NCT01278160,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline,Number of Treatment Emergent Hypoglycaemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4355,NCT02662114,Change in HbA1c after switch to Tresiba®,"Reason(s) for discontinuing Tresiba®, if applicable and available",,2015-12-08,COMPLETED,OBSERVATIONAL,['NA']
4356,NCT00494013,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),Number of Injections of Basal Insulin Analog at Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4357,NCT04270942,Safety and tolerability of teplizumab treatment,Change in T-cell Subpopulations,,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4358,NCT05963022,Change from Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants Who Achieved Weight loss of ≥15%,,2023-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4359,NCT00231530,The percent change in body weight and change in Hemoglobin A1c from enrollment to Week 60.,"Change from enrollment or baseline to Week 60 in BMI, waist circumference, glucose tolerance, lipid profile; safety measures, such as adverse events, throughout study.",,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4360,NCT01264809,Change in daily physical activity measured by SenseWear Pro3 Armband®. Participants were instructed to wear the monitor for seven days during all waking hours except bathing.,Benefits obtained after the physical activity counseling,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
4361,NCT05174507,Number of symptomatic hypoglycemia,Change in RNA sequencing (RNAseq) in peripheral PBMC,,2022-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4362,NCT03767790,Time in target glucose range,Unanticipated adverse device effects (UADE),Device Issues,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
4363,NCT00516074,Change in Mean 24-hour Heart Rate From Baseline to Endpoint,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4364,NCT03384758,rHb,,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
4365,NCT04467606,Rate of foot infection and readmission for foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
4366,NCT03078725,Failure rate,incidence of medication side effects,,2017-06-20,WITHDRAWN,INTERVENTIONAL,['PHASE4']
4367,NCT02692716,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke",Change in Triglycerides - Ratio to Baseline,,2017-01-17,COMPLETED,INTERVENTIONAL,['PHASE3']
4368,NCT01997281,Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal,AUC of Plasma Total GLP-1 Levels After Lunch,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
4369,NCT00392028,"blood,tissue and bone drug levels",,,2006-11,WITHDRAWN,INTERVENTIONAL,['NA']
4370,NCT03394352,Continuous Glucose Monitor metrics,,,2018-01-17,COMPLETED,INTERVENTIONAL,['NA']
4371,NCT03008057,"serum Fasting blood suger,",serum YKL40,,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4372,NCT00496145,"Hemoglobin A1c, Health Distress, Symptoms of Hypoglycemia, Symptoms of Hyperglycemia","Amount of exercise,self-efficacy, communication with physician,fatigue, activity limitation,physician visits",,2002-08,COMPLETED,INTERVENTIONAL,['NA']
4373,NCT04876274,HbA1C,Score of Simplified True / False Version of Diabetes Knowledge Scale,Score of Newest Vital Sign,2020-07-14,COMPLETED,INTERVENTIONAL,['NA']
4374,NCT03757845,Quantity of ERBB receptors expressed on atrial endothelial cells,Quantity of specific lipids in plasma,,2018-12-15,TERMINATED,INTERVENTIONAL,['NA']
4375,NCT00269061,Changes in interstitial fluid volume in the lower extremities as measured by MRI.,"Assessments of other indicators of fluid volume changes, including labwork evaluation, fluid compartment volume measurement, direct measurement of the calf.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4376,NCT04217759,Change in diabetes risk score from week 0 to week 13,Facilitation (PA) score,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
4377,NCT00960453,"To evaluate the pharmacodynamics (activity of Dipeptidyl peptidase-IV enzyme) after repeated administrations of sitagliptin 25, 50 and 100 mg",,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4378,NCT00445627,evaluate phenotype of T2DM,,,2007-06-18,COMPLETED,OBSERVATIONAL,['NA']
4379,NCT05550480,Time spent with glucose value <3.0 mmol/l (level 2 hypoglycemia),Hypoglycemia awareness,,2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
4380,NCT01462227,Glucose Infusion Rate (mg/kg.Min),Norepinephrine (pg/mL),,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4381,NCT01615081,Acute 3-h changes from baseline in the postprandial concentration of glucose,ad libitum energy intake (EI),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4382,NCT04380077,postoperative vitreous hemorrhage rate,visual acuity,,2020-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4383,NCT00925977,Treatment satisfaction,Hypoglycemic events,,2009-07,TERMINATED,INTERVENTIONAL,['NA']
4384,NCT02463487,Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound,Number of Participants With Wound Dehiscence After Hospital Discharge,,2015-06-02,COMPLETED,INTERVENTIONAL,['NA']
4385,NCT03597568,Vascular endothelial function,Oxidative stress,,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4386,NCT04614038,Non-healing status based on change in wound area over 12 weeks,Effect of various patient biometry and wound conditions on non-healing status based on change in wound area over 12 weeks,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
4387,NCT01033773,Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit,Change in Hemoglobin A1C From Baseline to End of Intervention at 30 Days,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
4388,NCT02262806,Serum triglycerides,,,2014-10-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4389,NCT01703208,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change,Percentage of Participants Achieving a Target A1C <7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin,Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory),2012-10-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4390,NCT04660305,Area under the glucose infusion-rate curve of insulin aspart,,,2020-12-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4391,NCT00012688,,,,na,COMPLETED,INTERVENTIONAL,['NA']
4392,NCT02671136,Counts of Each Subgingival Bacterial Species,,,2016-08-18,TERMINATED,INTERVENTIONAL,['NA']
4393,NCT04280016,Wound measurement size,Waist circumference,,2021-05-14,UNKNOWN,INTERVENTIONAL,['NA']
4394,NCT00641043,HbA1c Change From Baseline to Week 24,Percentage of Patients Who Have an HbA1c Lowering by 0.5% at Week 24,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4395,NCT06080802,HRQOL using Minnesota Living with Heart Failure Questionnaire for quality-of-life evaluation (MLFHQ),Change in body weight,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4396,NCT01340664,Change in HbA1c From Baseline to Week 18,Percentage of Patients With HbA1c <7% at Week 18,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4397,NCT01726764,Change in Area Under Curve (AUC) 0-24h of metformin,Change in messenger RiboNucleic Acid (mRNA),Hypericin/hyperforin,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4398,NCT03859401,Number of hypoglycemic occurrences in relation to exercise activity,CGM-based High Blood Glucose Index,Total Amount of Rescue Carbohydrates,2019-04-12,COMPLETED,INTERVENTIONAL,['NA']
4399,NCT03014908,Metabolic phenotype of type 1 diabetes mellitus,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
4400,NCT03135964,The reduction rate of pressure ulcer size,The reduction rate of diabetic foot ulcer size,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
4401,NCT06246435,Assessment of body mass index ( BMI in kg/m^2)as anthropometric measurements,estimation of lipid profile,,2014-02-20,COMPLETED,OBSERVATIONAL,['NA']
4402,NCT05188625,Attendance rate,Foetal outcome 2,,2021-01-13,COMPLETED,INTERVENTIONAL,['NA']
4403,NCT00501709,lnsulin independence,,,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4404,NCT04362917,Measurement of beta cell function during the first phase of the first clamp procedure,Measurement of beta cell function during of Second Phase of the first clamp procedure,"Test-retest variability of the above mentioned variables (first phase, second phase, Unmethylated and methylated DNA, fasting PI:C",2017-11-14,COMPLETED,OBSERVATIONAL,['NA']
4405,NCT03281512,Diabetes,Overweight,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
4406,NCT05444153,Participants acheiving body weight reduction greater than or equal to (>=) 5% (Yes/No),Change in Control of Eating Questionnaire (CoEQ) score - Craving for Savory domaina,,2022-10-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4407,NCT00543621,"HbA1c, Fasting blood glucose,blood pressure, weight loss",,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4408,NCT03238898,pain intensity on a 0-10 severity scale,the Cramp Threshold Frequency (CTF),,2014-09-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4409,NCT06057662,Problem Areas in Diabetes (PAID),,,2023-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4410,NCT05597943,Malama app as intervention,Postpartum hemoglobin A1c level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
4411,NCT02186080,Difference between baseline and peak serum LPS,mRNA expression level of inflammatory markers in the adipose tissue,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
4412,NCT00776854,Decrease of Bioburden Effect In diabetic Foot Ulcer,,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
4413,NCT00853801,Providers improve their ability to diagnose and treat metabolic syndrome/pre-diabetes.,Assess changes in insulin resistance using the HOMA-IR index and in vascular inflammation status using C-Reactive protein in the intervention and control groups.,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
4414,NCT01595594,Clinical Attachment Level,Microbial Load,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4415,NCT03152084,Change in 24-hour Sodium Excretion From Baseline to Start of Treatment,Number of Patients With AEs and SAEs,,2017-07-12,TERMINATED,INTERVENTIONAL,['PHASE4']
4416,NCT05983562,To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study,Overall acceptability,,2023-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4417,NCT01402232,contrast-induced nephropathy,Follow-up major adverse cardiovascular and clinical events,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4418,NCT01517412,Change in HbA1c From Baseline to Week 24,Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4419,NCT04123067,Degree of Disability or Dependence in the Daily Activities,"Concentration of Stress Response Markers Including Cortisol, Norepinephrine and Epinephrine",,2020-09-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4420,NCT01370837,Induration Size as a Response to Intracutaneous Candida Albicans.,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4421,NCT02160184,Percentage of time in target range (3.9-8.0 mmol/l) YSI glucose during the in clinic overnight visit.,,,na,UNKNOWN,INTERVENTIONAL,['NA']
4422,NCT01228526,Percent of study ulcers healed,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
4423,NCT03648918,Autoantibody Measurement,,,2001-08,RECRUITING,OBSERVATIONAL,['NA']
4424,NCT03083899,Patient reported outcome,Diabetes Dependent quality of Life,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
4425,NCT02448498,Change in Hemoglobin A1c across study visits,"Change in Dietary Intake, as measured by Food Frequency Questionnaire",,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4426,NCT00501488,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
4427,NCT05949957,Glucose Tolerance Changes,Social-emotional development (Children),Child's Sleep Habits,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
4428,NCT03174821,The change of 8-hydroxy-deoxyguanosine (8-OHdG),The change of superoxide dismutase (SOD),,2010-10-20,COMPLETED,INTERVENTIONAL,['NA']
4429,NCT03247608,Re-admissions rate,Biometrics change,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
4430,NCT03686917,CHAT-P Score,Multicultural Quality of Life Index,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
4431,NCT00843388,"albuminuria, expected decrease","plasma renin, angiotensin, aldosteron",,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
4432,NCT00264394,Reduction in total cholesterol in the entire SHCS population,"The reduction in total cholesterol, systolic and diastolic blood pressure, and Framingham 10-year CHD risk score in individuals with a greater than or equal to 10% 10 year risk of CHD (according to the Framingham risk profile)",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4433,NCT06007157,24-hour Blood Pressure,Hydration state,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
4434,NCT02313428,Wound Closure,Quality of Life for subjects- SF-36,,2020-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4435,NCT05651919,"Comparison of the inflammatory profile of PBMC from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF",,,2023-05-23,RECRUITING,OBSERVATIONAL,['NA']
4436,NCT00041405,,,,2001-07,COMPLETED,OBSERVATIONAL,['NA']
4437,NCT00859599,Number of subjects who completely healed and time to 100% wound reduction.,"Time to 50% wound reduction, Subjects with increased ulcer and/or wound reduction less than 20%, Wound status, Elimination of gram-positive and anaerobic bacteria from the wound, Hospitalization caused of foot ulcer, Presence and level of amputation",,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
4438,NCT01868529,Area under the glucose infusion rate curve,Area under the serum insulin concentration curve at steady state,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4439,NCT01930188,Change in HbA1c (Glycosylated Haemoglobin) From Baseline,Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4440,NCT06085339,Feasibility: Retention Rate,Screen Time,,2023-10-23,RECRUITING,INTERVENTIONAL,['NA']
4441,NCT02616809,Evidence of change in blood glucose following changes in posture and increasing energy expenditure,,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4442,NCT03911323,Sensitivity and specificity,,,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA']
4443,NCT01906086,high sensitive C reactive protein (mg/l),Adiponectin (ng/ml),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
4444,NCT05459701,VCAM-1 (ng/ml),,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4445,NCT01053078,Cerebral Blood Flow,Hypoglycemia Symptom Score,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4446,NCT00468754,Variability of blood glucose characterised by the standard deviation of the mean blood glucose,Daily insulin requirement,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
4447,NCT01726829,The percentage of nights mean overnight sensor glucose levels was within90-140 mg/dl,Artificial Pancreas Satisfaction Questionnaire,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
4448,NCT00791128,% of Excess Weight Loss (EWL),HbA1c Values at 12 Months,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4449,NCT05248412,Health outcomes,Healthcare service utilization,Burden of diseases due to indirect effect of COVID-19,2021-06-21,RECRUITING,OBSERVATIONAL,['NA']
4450,NCT00570739,Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks,Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4451,NCT04035993,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycaemia warning system (HEADWIND) to detect hypoglycaemia (blood glucose <3.9mmol/l and <3.0mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Cognitive and emotional trust in the recommendations of the EWS,,2019-10-07,COMPLETED,INTERVENTIONAL,['NA']
4452,NCT05594563,Number of participants with treatment-related adverse events as assessed by CTCAE v5,"Biomarkers of β cell stress at 3, 6, 9, and 12 months after treatment.",,2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2']
4453,NCT04522882,Glucose level modification,Medication intake,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
4454,NCT04944264,Connor-Davidson Resilience Scale (CD-RISC),Implementation Facilitators,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
4455,NCT03144505,"Changes from baseline HbA1c at 3, 6, 9 and 12 months",Changes from baseline quality of Life at 12 months,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
4456,NCT04448262,inflammatory cells,perceived Health state,,2019-07-10,TERMINATED,OBSERVATIONAL,['NA']
4457,NCT02293577,Time with blood glucose >300 mg/dL,Physical Activity,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
4458,NCT05111301,CGM Time Above 180 mg/dL,Coefficient of Variation (CV),Unanticipated Adverse Device Effects,2021-11-30,COMPLETED,INTERVENTIONAL,['NA']
4459,NCT04245267,Glycemic control after the program,"Health-related Quality of Life perception assessed by EQ-5D Indexed score (0-1, higher score means better Quality of life perception)",Blood pressure of the patients who attended the program compared with patients attended in primary care units (wait-list),2017-01-07,UNKNOWN,INTERVENTIONAL,['NA']
4460,NCT04600622,Average Feasibility Score,Change in Family and Friend Involvement in Diabetes score,,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
4461,NCT06206525,Clinical significant hypoglycemia,Clinical significant hyperglycemia,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4462,NCT00982371,"1 Tesla peripheral MRI assessment at non dominant distal radius: Trabecular bone micro-architecture parameters Tb.Th, Tb.Sp, Tb.N, BV/TV, bone CSA, marrow space","Calcium, vitamin D and vitamin K dietary intakes; TUG (sec); grip strength; DXA assessment of hip, lumbar spine, total body; physical activity",,2008-09,COMPLETED,OBSERVATIONAL,['NA']
4463,NCT00815178,Maximum inspiratory pressure,autonomic modulation assessed by heart rate variability,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
4464,NCT05353790,Changes in Kidney function markers,Changes in Cognitive Function-6,,2021-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4465,NCT05022875,Change in Hypoglycemic Events,Change in Diabetes Knowledge Questionnaire score over time,,2021-04-23,UNKNOWN,INTERVENTIONAL,['NA']
4466,NCT04697758,Safety as Assessed by Incidence of Adverse Events (AEs),,,2020-12-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4467,NCT04549415,Number of participants with newly diagnosed diabetes mellitus,Lipid profile markers,,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4468,NCT02076880,Change of area under the curve of post prandial glycemia,"Change in insulin sensitivity, Change in insulin secretion, Change in incretins",,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
4469,NCT06231771,Proportion of patients with complete healing/closure of the target ulcer at any time during the 6-weeks period.,The proportion of patients with at least 50% closure of target ulcer during the 6-weeks period,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4470,NCT01269996,To evaluate the treatment efficacy,proportion of patients with HbA1c <6.5% in 1 year,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4471,NCT00536549,"HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profiles",three day diary meals and seven day physical activity diary,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
4472,NCT04115592,Postprandial glucose,Postprandial insulin,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
4473,NCT01195090,The Percentages of Patient Achieving an A1C <7%,Baseline High-density Lipoprotein Cholesterol (HDL-C),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4474,NCT05229445,time in range,,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
4475,NCT00327912,Gastro-intestinal side effects,Eating pattern,,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
4476,NCT05295706,Change in HbA1C,Change in the Behavioral Strategies - Engagement and Intentions score,,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4477,NCT02236962,brown adipose tissue activity,,,2012-04,UNKNOWN,INTERVENTIONAL,['NA']
4478,NCT01983917,Change of diabetic retinopathy risk factors,Motivation for adhering to treatment recommendations and follow-up,,2012-09,WITHDRAWN,INTERVENTIONAL,['NA']
4479,NCT00964262,To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,To examine the effect on glucose control and pharmacodynamic parameters of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
4480,NCT04872647,Change of HOMA2-IR,EVS,,2020-12-18,UNKNOWN,INTERVENTIONAL,['NA']
4481,NCT06275971,Time within the target range of 100-180 mg/dL,Mortality within 30 days of surgery,,2022-11-24,RECRUITING,INTERVENTIONAL,['NA']
4482,NCT01099956,Increase of Interleukine 6 in group DTI versus control group,"Increase of others cytokines (IL1-beta, l'IL-4, l'IL-10 and TNF alpha) and increase of High sensitivity CRP in group DTI versus control group",,2010-04,COMPLETED,OBSERVATIONAL,['NA']
4483,NCT03763474,Change from 6 months glycosylated hemoglobin at 12 months in the 2 groups,Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4484,NCT01778049,Change From Baseline of HbA1c After 24 Weeks of Treatment.,Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4485,NCT00360217,Lowering of triglyceride level,Alteration of LDL particle size,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
4486,NCT05042505,Changes from baseline to month 12 in liver and pancreatic fat content.,"Safety assessment at months 3, 6, 9 and 12",,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
4487,NCT01285934,C-peptide,Stimulated C-peptide levels during mixed meal tolerance test,,2009-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4488,NCT02813863,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4489,NCT03563313,Time in Target Range,BMI,Any Adverse Event Rate Per 100 Person-years,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
4490,NCT01426685,sudden cardiac death,non-fatal cardiovascular event,,2007-08,UNKNOWN,OBSERVATIONAL,['NA']
4491,NCT05975242,Spanish-language Diabetes Self-Efficacy Scale (DSES-S),Weight,Mobile Device Proficiency Questionnaire (MDPQ),2023-04-04,RECRUITING,INTERVENTIONAL,['NA']
4492,NCT04474808,Feet Care Feelings,,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
4493,NCT05844748,"The Effect of Training Given by Motivational Interview Technique on Self-Efficacy Perception, Level of Adjustment to Disease and Metabolic Parameters in Type 2 Diabetes Patients",,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
4494,NCT00515099,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2']
4495,NCT03868813,Users' Expectation from a Health Coaching System,,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
4496,NCT00907075,"Average percent deviations from the assigned eating system score for full days, meals, and snacks for each group during each evaluation period throughout the intervention (days 23-28 and days 51-56).",Change in dietary macronutrient composition from baseline to end of treatment.,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
4497,NCT02713477,Measurement of plasma glucose concentrations,Measurement of anti-insulin antibodies,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4498,NCT02289612,Satiety-producing effect for each pudding and control product,3-Day food records,Heart rate and blood pressure,2014-11,COMPLETED,INTERVENTIONAL,['NA']
4499,NCT01138488,Area under the serum insulin aspart concentration-time curve,Maximum observed insulin aspart concentration of NN5401 (insulin degludec/insulin aspart) observed,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4500,NCT05236335,Cardiac Output (L/min),Exercise capacity (METs),,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
4501,NCT01487798,Frequency of hypoglycaemic episodes,Diabetes Treatment Satisfaction Questionaire,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4502,NCT01527643,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,,2003-11-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4503,NCT02548000,Quadriceps Muscle Quality measure by echo intensity,Quadriceps muscle power capacity measure by rate of torque development.,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4504,NCT03632759,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.,,,2018-08-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4505,NCT02250677,Differences in physical performance between two groups of statin treated patients,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
4506,NCT02945449,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire,,2017-01-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4507,NCT01370616,Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV),Percentage of Participants Who Discontinued Treatment Due to an AE,,2011-09-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4508,NCT06202950,Glycemic control form,,,2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4509,NCT02194595,"Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)",Baseline-adjusted glycemic control at 8 weeks,Baseline-adjusted insulin sensitivity at 20 weeks,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4510,NCT03651466,"Incidence, nature and severity of Adverse events",Pharmacokinetics(PK) variables,,2017-08-31,COMPLETED,INTERVENTIONAL,['PHASE1']
4511,NCT02234973,mean HbA1C of patients with diabetes (A1C ≥ 8.0% at baseline),,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
4512,NCT00993096,Area (AUC) under the glucose infusion rate curve,Area (AUC) under the insulin aspart concentration time curve,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
4513,NCT00780715,HbA1c Change,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4514,NCT02896010,Yield of Recruitment,Adherence to physical activity goal,,2016-10-10,COMPLETED,INTERVENTIONAL,['NA']
4515,NCT02953249,Wound healing change after tooth extraction through epithelialization,Radiographic analysis of bone repair,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
4516,NCT03274089,Hemoglobin A1c,Health-related quality of life questionnaire,,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA']
4517,NCT02890836,Early preterm delivery (Danish),Chronic hypertension,Body mass index (BMI),2016-02,COMPLETED,OBSERVATIONAL,['NA']
4518,NCT04264572,Change in hemoglobin A1C for patients with poorly controlled type 2 diabetes mellitus,Change in diabetes quality of life for patients with poorly controlled type 2 diabetes mellitus as measured by Diabetes Quality of Life (DQoL) instrument,,2020-01-21,RECRUITING,INTERVENTIONAL,['NA']
4519,NCT03956797,Incidence of Anesthesia-Related Adverse Events,Pain of Intravitreal Injection (Follow-Up): VAS,,2019-04-15,COMPLETED,INTERVENTIONAL,['NA']
4520,NCT04544527,all-cause mortality,chronic complications of diabetes,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
4521,NCT00063674,,,,2003-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4522,NCT02065674,,,,2014-02,AVAILABLE,EXPANDED_ACCESS,['NA']
4523,NCT00705536,Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone),Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}]),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4524,NCT01997021,Area under the insulin curve in response to meal tolerance test,24-hour Glycemic variability,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4525,NCT00775333,"Sensory function (Semmens-Weinstein), motor function (Abductor Pollicis Brevis (APB)-strength, grip strength)","Pillar pain, cold intolerance, and patient satisfaction.",,2003-12,COMPLETED,OBSERVATIONAL,['NA']
4526,NCT03491241,left ventricle ejection fraction,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
4527,NCT02666521,Frequency of mild hypoglycaemic episodes,Frequency of severe hypoglycaemic episodes,Incidence and severity of hypoglycaemic episodes,2012-07-20,COMPLETED,OBSERVATIONAL,['NA']
4528,NCT00729326,Change in Time-averaged Glucose During a 24 Hour Period,Episodes of Hypoglycemia (Overall),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4529,NCT01545024,Glycemic control,autonomic nerve disturbance,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
4530,NCT02145572,"Differences in metabolite concentrations measured by mass spectrometry, comparing blood and urine samples from obese adolescents with type 2 diabetes, obese adolescents without diabetes, and age-matched healthy non-obese controls.",,Validation of presence of DENND1A isoform in the urine of adolescent females with polycystic ovarian syndrome,2014-05,COMPLETED,OBSERVATIONAL,['NA']
4531,NCT03422965,Perifoveal vessel density,Foveal Avascular Zone,,2017-05-08,UNKNOWN,INTERVENTIONAL,['NA']
4532,NCT05491252,Change in Glycemic Control (HbA1c),Self Care Behaviors,,2022-04-21,COMPLETED,INTERVENTIONAL,['NA']
4533,NCT04952766,Protective humoral response after vaccination,Clinical protection after vaccination,,2021-03-26,COMPLETED,INTERVENTIONAL,['PHASE4']
4534,NCT05407376,Change in HbA1c between baseline and 6 months,Analyze the difference in difference of patient-reported nutritional security between the intervention and control group.,,2021-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4535,NCT04840368,"Changes in Peak Oxygen Consumption (VO2peak), expressed in mL/Kg/min","Change in Executive function, assessed by the Trail making test",,2021-05-03,UNKNOWN,INTERVENTIONAL,['NA']
4536,NCT00545727,Blood glucose level,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
4537,NCT05953532,Measure of Engagement in Personal Healthcare,Glycemic control,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
4538,NCT03052283,"Development and evaluation of a diary for assessment and quantification of abdominal symptoms, a CF-specific PROM following FDA recommendations","Effects of a new therapy with CFTR-modulator on abdominal symtoms, quantified with the CFAbd-Score",,2017-01-26,RECRUITING,OBSERVATIONAL,['NA']
4539,NCT01591902,Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.,Change from baseline in HbA1c by intensification of concomitant diabetic treatment,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4']
4540,NCT04009642,The difference in myocardial FA extraction fraction (%) between T2D patients and non-diabetic controls at rest.,,,2018-03-05,COMPLETED,OBSERVATIONAL,['NA']
4541,NCT01120444,Blood Glucose,Insulin levels,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4542,NCT00670683,Incidence of adverse events,Clinical laboratory abnormality,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
4543,NCT01482455,Blood flow,Interstitial insulin concentration,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
4544,NCT03761186,Change in insulin use,Time taken to complete the Trail making test A+B,Frequency of intake of different foods measured by a Food frequency questionnaire (FFQ),2018-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4545,NCT00768651,Weight Change From Baseline After 6 Months of Therapy,Blood Glucose Laboratory Value Before Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4546,NCT00740922,The primary objective of this study is to retrospectively evaluate the safety of sterile becaplermin gel vs. sterile placebo gel treatment 12 months or more after the last dose was administered.,The secondary objective of the trial was to evaluate recurrence of the Target Ulcer if it had healed in the previous trial.,,1999-07,COMPLETED,OBSERVATIONAL,['NA']
4547,NCT03730727,Postprandial blood glucose concentrations.,Postprandial blood glucose control.,,2017-10-09,COMPLETED,INTERVENTIONAL,['NA']
4548,NCT05727592,Fasting blood glucose,Renal profile,,2023-03-20,COMPLETED,INTERVENTIONAL,['NA']
4549,NCT04597697,"AUC,Ico,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
4550,NCT05291975,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Neuropathic Pain Symptom Inventory (NPSI),,2022-02-17,RECRUITING,INTERVENTIONAL,['NA']
4551,NCT06023810,Wagner's ulcer classification scale,Watson Patient Satisfaction Assessment Form According to Healing Processes,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4552,NCT01534013,Percentage Time in Euglycaemia,Insulin Requirement in Units/kg/hr,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4553,NCT02835495,Adherence to the Lifestyle Weight Loss Intervention,,Cholesterol (Lipid Panel),2017-11-15,COMPLETED,INTERVENTIONAL,['NA']
4554,NCT02426606,Postprandial blood insulin,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
4555,NCT01785134,Insulin Sensitivity at 2 Years,Blood Lipids,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
4556,NCT00728377,Gestational diabetes diagnosis assessed through glucose tolerance test.,Adoption and maintenance of exercise during pregnancy,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
4557,NCT04676906,The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compounds,,,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE1']
4558,NCT00656682,% Change in Body Weight,% Change in Body Weight,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
4559,NCT05795582,Comparison of the values of upstroke time (TMS) obtained by a new method of measurement by PPG (photoplethysmographic) technique and IPSo,,,2023-06-14,RECRUITING,INTERVENTIONAL,['NA']
4560,NCT00529048,Progress in Incretin effect in patients with T2DM compared with healthy subjects,GIP and GLP-1 responscurvs,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
4561,NCT05937984,Change in PROMIS-29 v2.0 Profile,Change in nerve conduction assessments,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4562,NCT02317172,Changes in subjective dry mouth score,Satisfaction of the edible gel-based artificial saliva,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4563,NCT04177420,"Geriatric Depression Scale-15, GDS-15",,,2018-03-23,UNKNOWN,INTERVENTIONAL,['NA']
4564,NCT01323088,"Abdominal obesity, visceral fat","insulin sensitivity by a 3-hour hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, liver fat and intramyocellular lipid by 1H-magnetic resonance spectroscopy.",,2010-08,COMPLETED,INTERVENTIONAL,['NA']
4565,NCT04621045,Acceptability of PATH intervention,Change from baseline in Barriers Exercise Self-efficacy (BARSE) scale at 12 weeks,,2020-10-27,COMPLETED,INTERVENTIONAL,['NA']
4566,NCT01478776,postprandial ASP,gene expression of C5L2,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
4567,NCT01960179,"Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.",Absolute change in body weight,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4568,NCT02449213,Insulin resistance,glycated hemoglobin (HbA1c),,2016-03-11,COMPLETED,OBSERVATIONAL,['NA']
4569,NCT05224258,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]),,2022-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4570,NCT03478254,Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM,Number of Participants Who Have Taken Related Sick Leaves,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
4571,NCT01186354,Accurate understanding of genetic risk information,Impact on behavior change,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4572,NCT03556605,"Change in A1c from baseline at 12 weeks in intervention group compared to control group. At this point, control group subjects will cross-over to the same treatment as the intervention group for an additional 12 weeks.",,,2018-07-30,UNKNOWN,INTERVENTIONAL,['NA']
4573,NCT03136822,Recovery of the wound 100%,Recovery of the wound 80%,,2017-04-26,COMPLETED,INTERVENTIONAL,['NA']
4574,NCT02185963,Functional HDL-C,Patients with LDL-C < 70 mg/dl and HDL > 40 mg/dl in men; > 50 in women,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4575,NCT00634868,The wound healing process,,,2008-08,TERMINATED,INTERVENTIONAL,['NA']
4576,NCT00530023,Change in A1C From Baseline to Week 15,Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4577,NCT00797888,HbA1c,diabetes self-care activities,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
4578,NCT04311021,The main study parameter will be the current prevalence of IAH and exposure to SH in the past 12 months.,Answers to questionnaire,,2020-01-23,UNKNOWN,OBSERVATIONAL,['NA']
4579,NCT00311298,Weight gain,Mortality,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4580,NCT00274118,Change from baseline in glomerular filtration rate GFR after five years of treatment.,Resting 12-lead ECG,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4581,NCT00979628,"Mean Blood Glucose Levels (Measured in mg/dL) at Randomization Are Compared to Mean Blood Glucose Levels After First Day of Treatment Among Subjects Treated With Basal Plus, Basal -Bolus and SSRI Treatments","Number of Patients With Hypoglycemia Events (Blood Glucose Levels < 70 mg/dL) During Their Hospital Stay That Are Treated With Basal Plus, Basal-bolus and SSRI Treatments",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4582,NCT02639130,total AUC Glucose over 4 hour following the meal,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4583,NCT00266240,"HbA1c mean change from baseline, compared to placebo.",Pharmacokinetic and exposure-response relationship,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4584,NCT04235621,% of Patients with Change in Treatment,,,2019-12-20,TERMINATED,OBSERVATIONAL,['NA']
4585,NCT01005498,Laboratory findings and body composition,,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4586,NCT01981031,End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure),Number of Adverse Events,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4587,NCT01600534,Change in glycosylated hemoglobin,Change in weight after pregnancy,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4588,NCT00766441,Occurrence of hypoglycemia,"Body weight, fasting blood sugar, HbA1c, triglycerides, total cholesterol, LDL-C, HDL-C. CGMS to define glycaemic excursions",,2008-08,TERMINATED,INTERVENTIONAL,['PHASE4']
4589,NCT05411640,Australian type 2 diabetes risk assessment tool (AUSDRISK),Borg rating of perceived exertion (RPE),,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4590,NCT01257412,change in glycosylated haemoglobin A1c (HbA1c).,mean change from baseline in fasting plasma glucose (FPG),,2012-01,SUSPENDED,INTERVENTIONAL,['PHASE3']
4591,NCT02432547,Number of intravitreal aflibercept injections over 24 months,Mean change in treatment interval over time,Development of new proliferative diabetic retinopathy on wide-field fluorescein angiography,2017-06-15,COMPLETED,INTERVENTIONAL,['PHASE4']
4592,NCT04440839,Specialty Consultation,Amputation,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
4593,NCT03941184,Incidence Rate of SCAD,SCAD recurrence,Odds of validated rheumatoid arthritis in SCAD cases compared to controls,1995-01-01,COMPLETED,OBSERVATIONAL,['NA']
4594,NCT00687284,Change in glycaemic control as measured by HbA1c.,Change in waist and hip perimeter,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
4595,NCT03588000,absolute change in % HbA1c from baseline to 12 months,change in blood glucose from baseline to 24 month,change in health economics indexes from baseline to 24 months,2018-11-23,COMPLETED,INTERVENTIONAL,['NA']
4596,NCT01835964,Change Between Pre and Post Challenge Glucose Variability,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4597,NCT03597815,Apnea-Hypopnea Index,CPAP compliance,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4598,NCT02162004,Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00.,Positive Incremental Area Under the Curve,Mean absolute relative difference.,2014-06,TERMINATED,INTERVENTIONAL,['NA']
4599,NCT04403945,the comparison of the density of total length of the small perfusd vessels(PDV) in the acquisition window between the 3 groups,Correlation comparison: The correlation between SDF vascular parameters and the clinical data of the subjects was compared,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
4600,NCT04383990,Hypoglycemia incidence,Acute diabetes complications,,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
4601,NCT03875755,Rate of patients requiring insulin therapy during pregnancy,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge. This biolgical collection is optional,,2020-03-04,RECRUITING,INTERVENTIONAL,['NA']
4602,NCT01353469,Change in HbA1c from baseline to the end of treatment,Change in fasting plasma glucose from baseline to the end of treatment,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4603,NCT00899483,The difference in the mean left ventricular end-systolic volume index (LVESVI) after CABG and the amount of new permanent injury detected in the late CMRI study,Glycaemic control will be assessed 2 hours pre-operatively and 72 hours post-operatively. Measurement timings will be standardized allowing comparison of glycaemic control during different time-periods.,,2009-07,UNKNOWN,INTERVENTIONAL,['NA']
4604,NCT01767389,"For treatment utilization patterns: treatment modification (discontinuation of the index ADA, switching of the index and concomitant ADA, and add-on therapy) will be assessed.",,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
4605,NCT02566317,Mean Change in Sitting Time at Work From Baseline to 12 Months,Clustered Metabolic Risk Score From Baseline to 12 Months,Dynamic Glucose Control,2016-01-15,COMPLETED,INTERVENTIONAL,['NA']
4606,NCT00739180,"Abdominal obesity, visceral fat","Insulin sensitivity and secretion, glucose tolerance",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
4607,NCT01951677,Safety,Efficacy,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4608,NCT01744236,"Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1.",Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters:,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4609,NCT02660827,Age 2-13 Years Old Subjects Change in A1C,Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL,,2016-04-18,COMPLETED,INTERVENTIONAL,['NA']
4610,NCT02962921,Left ventricle ejection fraction (%),Time needed to exert insulin effect on myocardial function (hour),A' (centimeters),2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4611,NCT02521116,Difference of oxygen saturation of retinal vessels between DVA and Oxymap T1,Difference of retinal vessel diameter between DVA and Oxymap T1,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4612,NCT04153929,Absolute Change in HbA1c From Baseline to 16 Weeks,Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks,,2020-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
4613,NCT03826472,Fasting Glucose Measured Using Continuous Glucose Monitoring,Inhibitory Control Task (Percent Correct),,2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4614,NCT02237352,House localization,Protein expression,Albuminuria,2014-09-15,UNKNOWN,OBSERVATIONAL,['NA']
4615,NCT00194259,Effects of OSA on weight,,,2001-08,UNKNOWN,OBSERVATIONAL,['NA']
4616,NCT03870997,Number of Participants With Self-reported Influenza Vaccination in People With Diabetes,,,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
4617,NCT03178773,Change in HBA1c From Baseline,Change in Partner Distress Scale From Baseline,,2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2']
4618,NCT02847390,Hyperglycemia,,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
4619,NCT02711059,quality of life - self estimation protocol,cognition,,2015-10,WITHDRAWN,INTERVENTIONAL,['NA']
4620,NCT00461630,Major Vascular Event,Mortality,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4621,NCT05916131,The number of participants recruited to reach 20 participants that complete the intervention,Percentage of participants finding message content helpful (positive) at the end of the intervention,,2023-09-19,RECRUITING,INTERVENTIONAL,['NA']
4622,NCT01817959,"Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent (IEQ)/kg",β-cell Function as Assessed by Transplant Estimated Function (TEF) in Efficacy Population 1,Frequency of Patients Positive/Negative for Autoantibodies Against Class II Human Leucocyte Antigen (HLA) in Efficacy Population 1,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4623,NCT03284996,Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus by measuring changes in renal resistive index using Doppler ultrasonography,,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
4624,NCT03205150,Change From Baseline in Alanine Aminotransferase (ALT) at Week 12,Change From Baseline in Aspartate Aminotransferase (AST) at Week 12,,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4625,NCT01978613,Number of treatment emergent adverse events recorded,Maximum observed NNC0113-0987 plasma concentration,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4626,NCT06201611,The mean nerve action potential amplitude (sural and tibial nerves) between Arm 1 and Arm 3 at 24 weeks follow-up.,The proportion of patients who progress to develop severe neuropathy,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4627,NCT01880476,Changes from baseline in the Summary of Diabetes Self-Care Activities questionnaire,Changes from baseline in number of hypoglycemic events per week (blood glucose <4.0 mmol/L),Partnership and collaboration questionnaire,2013-06,COMPLETED,INTERVENTIONAL,['NA']
4628,NCT02890693,Self-reported symptoms of depression (mother) measured by Edinburgh Postnatal Depression Scale,Laboratory (mother): miRNA,"Self-reported life events (mother, partner) measured by Life Events Questionnaire",2016-09,COMPLETED,INTERVENTIONAL,['NA']
4629,NCT02250066,Incidence of Diabetes in 322 Subjects with Prediabetes,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4630,NCT04198350,Safety of the procedure with regards to opthalmic complications,,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4631,NCT01170442,Area under the curve of HA1C.,incidence of hypercalciuria,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3']
4632,NCT04651816,Subject Retention,Opinions about PSH DPP program,,2021-05-25,COMPLETED,INTERVENTIONAL,['NA']
4633,NCT03235492,Salivary glycated albumin vs. glycosylated hemoglobin (HbA1c),,,2017-08-24,WITHDRAWN,INTERVENTIONAL,['NA']
4634,NCT02227849,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Change in Blood Pressure,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4635,NCT04633941,Weight,Physical Activity Level,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
4636,NCT05967312,Proportion of patients with ACR test in the last 12 months,"Proportion of patients with newly diagnosed albuminuria (i.e., since randomisation)",,2022-11-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4637,NCT05990933,Monocyte count,Distribution of monocyte subset,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4638,NCT01302145,"Safety assessed by incidence of adverse events, vital signs, 12-lead ECG and glucose monitoring",Pharmacokinetics assessed by metformin plasma concentration change,,2009-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
4639,NCT02872922,Percentage of the endothelium-dependent vasodilation (%FMD),Percentage of the endothelium-independent vasodilation (%NMD),,2016-12-10,COMPLETED,INTERVENTIONAL,['NA']
4640,NCT04146155,Initial and absolute claudication distance,Changes from baseline in HbA1c,,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4641,NCT04430582,Assessment of working memory,Assessment of psychomotor speed,,2020-08-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4642,NCT02499107,Food Intake,subjective appetite,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4643,NCT01572090,Change in body fat,Change in BMI,,2006-01,UNKNOWN,INTERVENTIONAL,['NA']
4644,NCT04952324,carriers of the MTHFR gene mutation have higher serum homocysteine concentrations in the blood,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
4645,NCT02004886,Number of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in 3-hour Insulin Total AUC at Week 4,,2006-08-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4646,NCT00262197,LDL-cholesterol levels and test rates in the 12 months post-intervention.,Charlson comorbidity score,,2001-12,COMPLETED,INTERVENTIONAL,['NA']
4647,NCT02451917,Number of Hypoglycemic Events,,Estimated Glomerular Filtration Rate (eGFR) Calculated by CKD-EPI,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4648,NCT01489189,Mean Change in Visual Acuity From Baseline,Number of Eyes With Greater Than or Equal to 10 Letter Vision Loss,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4649,NCT00360698,Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%,Rate of Severe Symptomatic Hypoglycemia,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4650,NCT00319189,Insuline release,Plasma endothelin-1,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
4651,NCT06309654,Superoxide dismutases (SOD),,,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
4652,NCT01754142,"Effectiveness of Kombiglyze XR as assessed by change from baseline in Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hr PPG)","Safety information related to overdose, drug-to-drug interaction and laboratory abnormalities based on incidence rates of AEs",,2012-11-24,COMPLETED,OBSERVATIONAL,['NA']
4653,NCT04283162,The rate of the progression of diabetic retinopathy,Changes in metabolic biomarkers such as HbA1c,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4654,NCT03939442,diabetes remission,,,2019-02-10,COMPLETED,OBSERVATIONAL,['NA']
4655,NCT03636529,serum uric acid,Serum triglycerides,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
4656,NCT00622089,The following parameters will be evaluated at Week 12 and Week 24: • Proportion of subjects who reach the lipid goal as defined in the protocol from baseline • Proportion of subjects who meet the HbA1c goal as defined in the protocol from baseline,,,2008-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4657,NCT03466567,"Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide","Cmax,E1247,SD, maximum observed SNAC metabolite E1247 plasma concentration on the concentration-time curve after a single dose of oral semaglutide",,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1']
4658,NCT05040971,Change to normoglycemia (Normoglycemia is defined as having both HbA1c below 6.0% (below 42 mmol/mol) and FPG below 5.5 mmol/L (below 99 mg/dL),Change in lipids - Very low density lipoprotein (VLDL) cholesterol,,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4659,NCT01890629,Mean Amplitude Glycemic Excursion,Glucose Standard Deviation in CGMS data,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4660,NCT00904202,"Average daily pain intensity (BPI Questions 3,4,5, and 6)","Safety assessments include adverse events; dermal assessments/sensory testing, clinical laboratory tests, vital sign measurements and physical/neurological examination",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4661,NCT04304963,LIG optimum detection of hypoglycemia,Secondary outcome 10,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
4662,NCT02007278,Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE),"Number of Patients With Any Adverse Events, Serious Adverse Events and Death",,2014-01-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4663,NCT05925920,Safety and Tolerability of ENT-03,effect on insulin and insulin sensitivity,,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE1']
4664,NCT05577169,Acceptability of intervention in the study population.,"Hemoglobin A1c (HbA1c, %)",Child and Adolescent Social Support Scale (CASSS) questionnaire,2022-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4665,NCT02553213,Change of blood glucose,,Changes of body composition,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
4666,NCT05751525,IQ score,"Hyperactivity, emotional problems, conduct problems, peer relationships, prosocial behaviour.",,2016-07-01,RECRUITING,OBSERVATIONAL,['NA']
4667,NCT00639626,Blood Sugar,Lean Body Mass,,2008-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4668,NCT00348374,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment,Change From Baseline in Standard Deviation of 24-hour Glucose Values Measured by Continuous Glucose Monitoring System (CGMS),,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4669,NCT05794789,Change from baseline in children's moderate to vigorous physical activity to 6 months,Social Identity,,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
4670,NCT04803357,Health of baby using delivery and post delivery well baby assessments,,,2021-04-10,RECRUITING,INTERVENTIONAL,['NA']
4671,NCT04088552,Change in abdominal circumference,Change in knowledge regarding hypertension,,2020-03-07,COMPLETED,INTERVENTIONAL,['NA']
4672,NCT02947620,Change in LDL Cholesterol,"Change in Insulin, HOMA-β, HOMA-IR after 4, 8, 12, and 16 weeks of treatment with investigational products compared to baseline.",,2015-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4673,NCT00347100,A1c values,Adverse events including hypoglycemia,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4674,NCT02065752,Plasma concentration of metformin following the single dose of drug administration,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4675,NCT00260234,"Safety - will be evaluated by the incidence, grade, and type of adverse events, changes in laboratory parameters, evaluation of the implant site and physical exams.",Functional duration - will be determined by stimulated C-peptide from OGTT.,,2005-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4676,NCT03453970,"Change from baseline diastolic blood pressure (DBP) at 6 months, change from baseline diastolic blood pressure at 12 months and change from baseline diastolic blood pressure at 18 months.","Change from the baseline level of adherence to the diet at 6 months, change from the baseline level of adherence to the diet at 12 months and change from the baseline level of adherence to the diet at 18 months.",Participation in the program,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
4677,NCT05552859,Difference in the mean change from baseline to Week 24 in HbA1c level (Gla-300 vs IDeg-100),"Number of participants with adverse events (AEs)) and serious adverse events (SAEs), including adverse events of special interest (AESIs)",,2022-12-05,TERMINATED,INTERVENTIONAL,['PHASE4']
4678,NCT05752591,Genetic predisposition,,,2018-05-25,COMPLETED,OBSERVATIONAL,['NA']
4679,NCT01387737,"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events",Change in Blood Pressure,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4680,NCT01013571,Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia,Adherence with the patient-managed monitoring algorithm,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4681,NCT01729403,Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate),Safety: Incidence of adverse events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4682,NCT02897219,Change from baseline in HbA1c,Safety assessed by laboratory tests: Urinalysis,,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
4683,NCT01425905,Insulin Resistance at 12 months in CB depression prevention versus HE control group.,"CB, depression, prevention, group, will, show, greater, improvements, in, mediators, (eating, behavior, fitness, and stress biomarkers) than the HE control group.",,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4684,NCT00996437,"Safety (Injected-related, Ocular Drug-related and Systemic Drug-related)",Very Severe Visual Acuity Loss (Defined as <20/800),,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4685,NCT02649374,Bacterial population diversity,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4686,NCT03699709,change (from baseline) in healthy and unhealthy food purchases (measured using the Healthy/Unhealthy Food Acquisition Survey) at 6 months and 12 months,"Process evaluation: intervention dose received (i.e., number of lessons included in the curriculum completed by participants)",,2020-02-27,COMPLETED,INTERVENTIONAL,['NA']
4687,NCT03601884,"Difference in Diabetes Management Self-Efficacy Scale (DMSES) scores between OHP+TAU (experimental group) and TAU alone (control group), and within OHP plus TAU across time","Difference in HbA1c between OHP+TAU (experimental group) and TAU alone (control group), and within OHP plus TAU across time",,2018-10-05,COMPLETED,INTERVENTIONAL,['NA']
4688,NCT05370781,Change in Regimen Adherence,Change in Adherence to gender norms,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
4689,NCT04446767,Wound assessment,,,2020-06-30,COMPLETED,INTERVENTIONAL,['NA']
4690,NCT05629403,HOMA-IR,,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
4691,NCT03020264,Number of confirmed or severe hypoglycemia,Number of death due to hypoglycemia,,2017-11-28,TERMINATED,INTERVENTIONAL,['NA']
4692,NCT02386982,24-hour glucose change,"Composite measure of adverse events monitoring, physical examinations,12 lead ECGs, vital sign,and safety laboratory measurement",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4693,NCT02478762,Foetal glycated hemoglobin,Treatment satisfaction,,2015-03,TERMINATED,INTERVENTIONAL,['PHASE3']
4694,NCT02517866,Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12,"Change From Baseline in DBP at Week 12 in ""Treatment-Naïve"" Participants",,2015-07-13,COMPLETED,INTERVENTIONAL,['PHASE4']
4695,NCT03557697,Change in Average Plasma Glucose Concentration measured by Hemoglobin A1c (HbA1c) Levels,Minutes of Sleep as Measured by ActiGraph Watch,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
4696,NCT00004360,,,,1995-09,COMPLETED,OBSERVATIONAL,['NA']
4697,NCT02386540,Number of emergency department visits,"Qualitative analysis of action plans (Health coach documentation notes will be analyzed, data will be coded to identify themes such as type of goals, barriers to care, and resources identified in the action plan)",,2015-02-06,COMPLETED,INTERVENTIONAL,['NA']
4698,NCT00395603,Percentage reduction in ldl-c at end-point after 6 weeks.,,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
4699,NCT00211471,tyo investigate the use of anecortave acetate in rubeosis iridis,mean change in VA(ETDRS) from baseline to 24 months,,2002-03,TERMINATED,INTERVENTIONAL,['PHASE2']
4700,NCT00039026,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4701,NCT02047643,Count of Participants Experiencing a Hypoglycemic Event During Scheduled Exercise,Count of Participants With Hypoglycemia in the Post Exercise Period,,2014-03-12,COMPLETED,INTERVENTIONAL,['NA']
4702,NCT01517555,Area under the curve of post prandial plasma glucose,Adverse events,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4703,NCT05446415,Changes mRNA expression levels of active L cells,,,2020-02-05,RECRUITING,INTERVENTIONAL,['NA']
4704,NCT02138006,Cardiovascular Mortality,Morbidity of Cardiovascular Complications,,1982-09,COMPLETED,INTERVENTIONAL,['NA']
4705,NCT03705260,Hemoglobin A1C,Change in rate of symptomatic hypoglycemia requiring medical intervention,,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
4706,NCT03656341,Manchester Foot Pain and Disability INdex,Foot Health Score,,2018-09-27,COMPLETED,INTERVENTIONAL,['NA']
4707,NCT04063046,early prognosis (Delirium),intraoperative vasopressor use,,2019-11-12,UNKNOWN,INTERVENTIONAL,['NA']
4708,NCT00138567,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 52 weeks and 104 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4709,NCT04233580,Number of Participants Who Healed,Tissue Oxygenation (StO2) of the Dorsal Foot,,2020-07-09,COMPLETED,INTERVENTIONAL,['NA']
4710,NCT01953393,Beta-cell function,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
4711,NCT01208558,Change of waist circumference,Change of quantity and dosage of blood sugar-lowering drugs,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4712,NCT04091373,Area under the plasma concentration time curve,"Incidence of treatment-emergent adverse events, including those related to changes in vital signs (including body temperature, heart rate, blood pressure) and safety laboratory evaluations (including hematology, chemistry, plasma glucose, urinalysis).",,2019-09-27,COMPLETED,INTERVENTIONAL,['PHASE1']
4713,NCT05761886,Proportion of items self-reported by pharmacist - Fidelity,Change in barriers to medication adherence,,2023-05-16,RECRUITING,INTERVENTIONAL,['NA']
4714,NCT05310526,food intake of 400g of vegetables per day,Professionals' perception regarding the incorporation of MAC guidelines into practice (implementation component),,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
4715,NCT04149548,The number of diabetic fetuses who will have undesirable effects,,,2019-11-05,UNKNOWN,OBSERVATIONAL,['NA']
4716,NCT02681185,HbA1c,Survey of Quality of Life,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
4717,NCT02821104,C4 Copy Number,Insulin Sensitivity,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
4718,NCT05004948,Change in Glycated hemoglobin% (HbA1c%),The maximum oxygen uptake (VO2max),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
4719,NCT04910997,Peak aerobic capacity (fitness),Depression questionnaire,,2021-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
4720,NCT02413060,HbA1c,,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
4721,NCT03752840,Pinhole visual acuity (logMAR) in people aged 60 years and older,Cost-effectiveness of the screening intervention,"Bilateral presenting blindness in people aged 60 years and older, defined as presenting visual acuity worse than Snellen 20/400 (Metric Snellen worse than 6/120; logMAR worse than 1.3) in the better-seeing eye",2019-04-21,RECRUITING,INTERVENTIONAL,['NA']
4722,NCT00404963,"Safety will be monitored by assessing adverse reactions,changes in laboratory values (hematology, clinical chemistry, urinalysis),changes in vital signs (oral body temperature,60 second respiratory rate, blood pressure and heart rate), and ECG changes.","Blood levels of GSK376501 Effects of GSK376501 on the body, by measuring changes in insulin, glucose, and other markers",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4723,NCT05863793,Peroneal Motor Nerve Conduction Velocity,Sural Sensory Nerve Conduction Velocity,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
4724,NCT06037252,Percent Change From Baseline in Body Weight,Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC),,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
4725,NCT03983551,Change in urinary albumin-to-creatinine ratio,Change in systolic blood pressure,,2016-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4726,NCT02697201,Effects of lipid infusion on mitochondrial fission,Insulin sensitivity,,2016-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4727,NCT00737126,Change in albumin excretion rate,"Change in serum homocysteine, thrombomodulin and von Willebrand factor.",,2004-01,COMPLETED,INTERVENTIONAL,['NA']
4728,NCT01076023,"Incidence of cardiovascular events, including fatal and non-fatal acute coronary syndromes (acute myocardial infarction [AMI] or unstable angina), fatal or non-fatal stroke, and other cardiovascular death.",Outcomes of current anti-diabetic treatment,,2010-02,UNKNOWN,OBSERVATIONAL,['NA']
4729,NCT05806723,change in testosterone level after atorvastatin treatment,change in DHEAS levels after atorvastatin treatment,change in vitamin D level after atorvastatin treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4730,NCT04071626,"Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange",Serum Ketone Bodies (Betahydroxybutyrate),,2020-03-01,TERMINATED,INTERVENTIONAL,['PHASE4']
4731,NCT04640064,Hb A1C pre and post Confinement in Latin American children with Type 1 Diabetes,,,2020-11-22,UNKNOWN,OBSERVATIONAL,['NA']
4732,NCT01961466,Correlations between glycemic balance (HbA1c) and the score on the Bortner self-questionnaire,Scores on the scales,,2010-12-01,COMPLETED,OBSERVATIONAL,['NA']
4733,NCT00871507,Incremental glucose AUC after an oral glucose tolerance test (OGTT),Safety and Tolerability,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4734,NCT00106366,HbA1c,Glucose profiles,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4735,NCT04975230,Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark],Diabetes Symptom Checklist Revised (34-item),,2022-04-29,COMPLETED,INTERVENTIONAL,['NA']
4736,NCT00204282,Nurse practitioner run group visits will improve compliance with established American Diabetes Association guidelines for screening and preventive care,Compliance with established American Diabetes Association guidelines for screening and preventive care will lower cardiovascular risk,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
4737,NCT01833988,Percentage of Time With a Low Plasma Glucose Reading (Less Than 70mg/dl) in the Bionic Pancreas Arm as Compared to Insulin Pump Arm,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Carbohydrate Interventions for Hypoglycemia at Night,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean Insulin Total Daily Dose,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4738,NCT03734445,Change in Homeostatic Model Assesment for Insulin Resistance (HOMA-IR) from baseline to 12 and 24 weeks,Changes in Intestinal microbiota patterns from baseline to 12 and 24 weeks,Changes in plasma zinc from baseline to 12 and 24 weeks,2020-01-09,UNKNOWN,INTERVENTIONAL,['NA']
4739,NCT02750098,Aqueous humor glucose concentration,Hemoglobin A1c,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
4740,NCT01191268,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),"Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4741,NCT03329651,Difference in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Difference in peripheral glucose uptake as assessed by rate of glucose disappearance from blood,,2017-11-10,COMPLETED,INTERVENTIONAL,['NA']
4742,NCT02974699,Plasma Amino Acid Levels,Change in Plasma Amino Acid Levels,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4743,NCT00770575,Change in the intima-media thickness of the common carotid artery.,Change from Baseline in Pulse wave velocity.,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4744,NCT01263496,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4745,NCT02691312,Number of participants diagnosed with retinopathy,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
4746,NCT02643797,Systolic blood pressure (SBP); mmHg units,Morisky Medication Adherence Scale (MMAS) - patient-reported outcome,Cost-effectiveness using the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model,2016-03-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4747,NCT04449120,Change in fasting insulin level,Change in culinary habits measured by Culinary Habits Frequency Questionnaire (CHFC),,2020-06-01,COMPLETED,INTERVENTIONAL,['NA']
4748,NCT05401708,Correlation between blood and urinary tests and complications in patients with type 1 and 2 diabetes mellitus and prediabetes (cross-sectional),,,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4749,NCT05929170,"Assessing the results of gastric sleeve surgery, by weight loss","Assessing the half and one-year results of gastric sleeve surgery, weight loss. (We try to find a confluence between the perioperative parameters and the expected outcome)",,2021-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4750,NCT00071422,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4751,NCT04253860,Pain perception,C Reactive Protein ultra-sensible,,2019-02-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4752,NCT04614623,Hemoglobin A1c (HbA1c) Change From Baseline to 6 months (End of study),Mean blood glucose (MBG) Change From Baseline to 6 months (End of study),PedsQL-Diabetes Module Change from Baseline to 6 months (study end),2020-11-01,UNKNOWN,INTERVENTIONAL,['NA']
4753,NCT00487981,Pain Rating at 6 Months Post Activation Compared to Baseline,,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
4754,NCT02001480,ECG surrogate markers compared to cardiac events,Continuous glucose monitoring is performed to identify episodes of hypoglycaemia,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
4755,NCT02703350,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4756,NCT00325624,A1c,,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4757,NCT03560375,Change in body weight,Change in frailty syndrome,,2018-05-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
4758,NCT03578991,Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).,The Resource Utilization in Dementia (RUD).,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
4759,NCT05708859,Reduction of total non-calcified coronary plaque volume,Change in HgA1c lab values in the blood.,,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4']
4760,NCT00678522,"GFR, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, albumin excretion rate and free water clearance.","AVP, Ang-II, Aldo, ANP, BNP, PRC, BP, HR.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4761,NCT04296825,"Changes in lipid profiles (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in millimole per liter)","Changes in gut hormones (amylin, ghrelin, GLP-1, PP and PYY in petagram per milliliter)",,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4762,NCT04410718,Plasma glucose levels and left ventricular ejection fraction,Diabetes status and change high-sensitivity troponins,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA']
4763,NCT06264661,Insomnia,Gene expression analysis of PER2,,2022-08-08,COMPLETED,INTERVENTIONAL,['NA']
4764,NCT05647226,HbA1C <6.5% (48mmol/mol),HbA1C <6.5% (48mmol/mol),,2022-01-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4765,NCT00689026,The Percentage of Patients That Received a Quality of Colonoscopy Preparation Rating of <=2 on a 5 Point Likert Scale.,,,2008-05,TERMINATED,INTERVENTIONAL,['NA']
4766,NCT05770154,Peak torque,Dynamic balance,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4767,NCT00797823,Effectiveness of Closed Loop Diabetes Control,Percent of Time Venous Blood Glucose <70 mg/dl,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4768,NCT05621551,Hs-Troponin-I,Hs-Troponin-I,Length of in-hospital time,2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE4']
4769,NCT03726697,Admission to NICU for hypoglycemia,Pain scale,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
4770,NCT02273050,Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue,Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4771,NCT05210530,Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.,The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.,,2022-01-24,COMPLETED,INTERVENTIONAL,['PHASE1']
4772,NCT04833660,Quality of life after intervention to be assessed with Short Form 36-Item Health Survey,,,2021-04-30,UNKNOWN,INTERVENTIONAL,['NA']
4773,NCT05510531,Change in outcome expectancy,Participants perspective of the intervention,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
4774,NCT03146208,Role of endothelial bio markers in patients with coronary artery disease,,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA']
4775,NCT02361606,Youth satisfaction of the program. (Questionnaire regarding the degree that the session was helpful.),"Change in glycemic control. (HbaA1c levels, obtained from medical records)",Youth expectations of the program. (Questionnaire regarding the expectations of the possible benefits of the program.),2009-03,COMPLETED,INTERVENTIONAL,['NA']
4776,NCT03049228,Cellular respiration ex vivo,Basal energy metabolism,,2017-03-21,COMPLETED,OBSERVATIONAL,['NA']
4777,NCT02480062,Glycated haemoglobin (HbA1c),Cost,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
4778,NCT01601574,Change in HbA1c,Secondary Endpoints,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4779,NCT01919788,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and mRNA expression of target genes in muscle- and fat-tissue.",Metabolism,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
4780,NCT00151749,addition of WelChol® to current antidiabetic therapy,other oral drugs,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4781,NCT05418179,Inflammatory parameters,Total Body lean mass Percentage (%),,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
4782,NCT04135248,Rate of self-reported hypoglycaemia,Number of days needed to break the fast,,2019-04-18,UNKNOWN,OBSERVATIONAL,['NA']
4783,NCT01221545,"Primary Objective to assess the safety and tolerability of AZD1656, following oral administration of single ascending supratherapeutic doses of AZD1656 to patients with type 2 diabetes mellitus in a fasted state.",Secondary objective to evaluate glucose levels and insulin secretion in type 2 diabetes mellitus patients following oral administration of single ascending supratherapeutic doses of AZD1656,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4784,NCT02700048,Within Person Difference in Peak Epinephrine During Hypoglycemia,Naloxone Pharmacokinetics,,2016-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4785,NCT01556880,incidence rate of DM,incidence of DM,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
4786,NCT04647773,Compare the change from baseline in Average Daily Pain Score （ADPS） between HSK16149 and placebo at week 13.,Pharmacokinetic (PK) characteristics of HSK16149 capsules in Chinese patients with diabetic peripheral neuropathic pain.,,2020-12-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4787,NCT00770302,Pharmacokinetic variables for saxagliptin after single and multiple oral doses of 5 mg saxagliptin,"Safety variables (adverse events reported, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests after single and multiple oral doses of 5 mg saxagliptin",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4788,NCT03461510,fMRI performance in relation to dysglycemia,,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
4789,NCT01390480,Increase and function of regulatory T-cells,Calcium levels,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
4790,NCT02631265,Percentage of time of capillary blood glucose levels spent below 4 mmol/L,Relative difference between capillary blood glucose levels and sensor glucose levels,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
4791,NCT00999635,Reduction in peak pressure,Comparison of cost,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4792,NCT05228522,Glucose Tolerance,Dietary behaviors,,2021-12-12,RECRUITING,INTERVENTIONAL,['NA']
4793,NCT00695474,"Vitamin D status and its association with inflammation, glycemic control, lipids and blood pressure.","Lifestyle (exercise, sun exposure, food intake)",,2008-06,COMPLETED,OBSERVATIONAL,['NA']
4794,NCT03773185,Amyloid load,,,2018-12-15,WITHDRAWN,OBSERVATIONAL,['NA']
4795,NCT03793101,Visual acuity,Corneal Incision thickness,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4796,NCT05133765,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise",To compare the influence of carbohydrate feeding before versus during exercise on the physiological responses to dynamic physical exercise,Comparison of the maximum iG concentration,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
4797,NCT05852132,Incidence of proliferative diabetic retinopathy (PDR),,,2024-05-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4798,NCT05404711,Feasibility of CGM use to determine Type 2 Diabetes Risk,Acceptability of CGM use for at-home T2D risk evaluation in youth,,2022-10-11,COMPLETED,INTERVENTIONAL,['NA']
4799,NCT02537470,Glycosylated haemoglobin A1c (HbA1c) at Week 12,"Safety endpoints include AEs, incidence of urinary tract infections, incidence of genital fungal infections, vital signs, ECGs and standard laboratory tests",,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4800,NCT05678712,time below range (CGM),Sensitivity and specificity of algorithm,Diabetes-related quality of life,2022-03-09,COMPLETED,INTERVENTIONAL,['NA']
4801,NCT04904406,Changes in body weight of ≥2 kg,Cardiac biomarkers,Cardiac MRI substudy secondary outcome lipid,2020-10-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
4802,NCT00000154,,,,1976-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4803,NCT03362983,Quality-of-care outcome measures (n=131),Interdisciplinary learning (n=20),,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
4804,NCT02161250,resistant starch effects,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4805,NCT06129448,Effect of Tumor necrosis factor- α (TNF-α) on cardiac functions,,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4806,NCT01002053,Interval worsening of the severity of neuropathy,New functional neuropathy defined as any new sensory or motor deficit compared to preoperatively.,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
4807,NCT04081883,Comparison between biosensor to CGMS responses,,,2023-01-27,COMPLETED,INTERVENTIONAL,['NA']
4808,NCT03117998,Change in Average Daily Total Insulin Use,Continuous Glucose Monitoring (CGM) - Change in Percent Time Spent in Hypoglycemia (Blood Glucose Range <55 mg/dL) at Week 12,,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
4809,NCT03880760,Change in concentration of blood glucose (AC),Change in concentration of TGF-β1,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
4810,NCT01866137,Changes in copeptin levels after a psychological stress test in healthy volunteers,Changes in copeptin levels after a psychological stress test in patients with central diabetes insipidus,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
4811,NCT04043065,Beta-cell secretion,"Appetite, satiety, and general well-being",,2019-01-28,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4812,NCT05266885,High incidence of HTN in Diabetics,,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA']
4813,NCT02871180,Hypoglycemia,Blood glucose profile,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
4814,NCT05793645,Assessment of adherence,Description of Adverse events,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
4815,NCT00046462,To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy,Change in serum lipid profile,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4816,NCT05687656,Wound Healing area using digital image,Adverse events,Presence of protease levels,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
4817,NCT03272269,Incidence of all adverse events reported for subjects,Assessment of residual beta cell function and markers of metabolic control,Assessment of T lymphocyte immune response to IMCY-0098,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
4818,NCT01467323,HbA1c (glycosylated haemoglobin A1c),Occurrence of adverse events,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4819,NCT02341690,"Changes in Physical activity from baseline to 52 weeks, measured with accelerometrics","Body temperature, measured by an ear thermometer",Changes in physical activity habits and diabetic motivation from baseline to 52 weeks - patients will be asked to answer 4 questions regarding their physical activity habits,2015-01,COMPLETED,INTERVENTIONAL,['NA']
4820,NCT00983775,(time to) maximal glucose infusion rate,(time to) maximal insulin concentration,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
4821,NCT03161964,Ratio of Self-reported Hypoglycemic Episodes to Total Hypoglycemic Episodes Determined by Continuous Glucose Monitoring (CGM),Mean Blood Glucose,,2017-10-19,TERMINATED,INTERVENTIONAL,['PHASE2']
4822,NCT05519163,New-onset diabetic foot,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
4823,NCT02948777,LDL Pool Size of ApoB100 Before and After Evolocumab,Mean ApoB48 iAUC Before and After Evolocumab,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4824,NCT00450710,Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.,Hormonal effect and effect of the operations on diabetes related and total mortality.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4825,NCT04722900,Body height,Magnetic resonance imaging,,2021-01-15,RECRUITING,OBSERVATIONAL,['NA']
4826,NCT01394341,Plasma liraglutide concentration (pmol/L),Cardiovascular risk factors (lipids and blood pressure),,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4827,NCT02914886,Relative thickness as assessed by MRI,Side effects,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4828,NCT01798264,Number of Subjects With Study Drug-Related Adverse Events,Change in Weight From Baseline to 4 Weeks,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4829,NCT05491421,To assess safety and tolerability of multiple escalation doses of ZT002 in healthy participants with a BMI range of 26 kg/m2 to 40 kg/m2 and a body weight of ≥80 kg through incidence severity of serious adverse events in MAD Cohorts.,The anti-drug antibody (ADA) response through testing serum or plasma of the participant post dosing in SAD and MAD cohorts.,,2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE1']
4830,NCT04981613,"Urinary protein remission rate, %","Time of participants achieving end stage renal disease (ESRD) or requiring dialysis or kidney transplantation, or blood creatinine doubling, or renal death, or all-cause death, days","Number of participants with treatment-related adverse events as assessed by reproductive toxicity (menorrhea or amenorrhea or infertility), %",2021-07-28,RECRUITING,INTERVENTIONAL,['NA']
4831,NCT03089463,Perfusion measurement,Ulceration incident,,2017-11-27,SUSPENDED,OBSERVATIONAL,['NA']
4832,NCT01326533,Insulin Sensitivity,Beta Cell Function,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4833,NCT04234217,Plasma norepinephrine levels,,,2019-11-26,RECRUITING,INTERVENTIONAL,['NA']
4834,NCT04835350,The safety of the prototype device Pancreas4ALL,Quality of life of patient living on closed loop system Pancreas4ALL,,2021-02-19,UNKNOWN,INTERVENTIONAL,['NA']
4835,NCT03006952,N terminal brain natriuretic peptide (NT-pro BNP),serum creatinine concentrations,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4836,NCT00574912,Maximum Glucose Infusion Rate,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4837,NCT03002246,Comparison Between 5D Limb Vol and 2D Birth weight Prediction,Birth weight Predictions in Suspected Growth Abnormalities,,2017-01-06,COMPLETED,OBSERVATIONAL,['NA']
4838,NCT03249259,Cognitive function,Glucose metabolism,Hypoglycemia,2016-03-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4839,NCT01059825,Change From Baseline in HbA1c at Week 12,Number of Participants Who Discontinued Study Medication Due to an AE,,2010-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
4840,NCT01684722,Change in Estimated Glomerular Filtration Rate,Change in NT-proBNP,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4841,NCT00708578,HbA1c values,Fasting Blood Glucose level,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4842,NCT01318109,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4843,NCT02672176,Diabetes Self-Efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at 9-months,Perceived Stress Measured by PSS,PROMIS Physical Function,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4844,NCT02493309,Blood glucose Area Under the Curve (AUC),Blood Pressure,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
4845,NCT05048264,Change in blood glucose measures,,,2023-05-04,RECRUITING,OBSERVATIONAL,['NA']
4846,NCT01692002,Study 3: Incremental area under the insulin profile,Insulin,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4847,NCT00593489,Insulin Prescription Rate - the Number of Insulin-eligible Patients Per 12 Months Who Are Prescribed Insulin in Each Family Physician (FP) Practice,Physician Score for Self-efficacy of Insulin Initiation & Titration,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
4848,NCT00187785,retention of medical information,patient satisfaction,,2005-09,TERMINATED,INTERVENTIONAL,['NA']
4849,NCT05933356,The Positive and Negative Syndrome Scale (PANSS),,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
4850,NCT02159144,browning of subcutaneous white adipose,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4851,NCT06115876,Conversion to Pre-Diabetes,,,2022-05-23,RECRUITING,OBSERVATIONAL,['NA']
4852,NCT04093856,"Volumetric bone mineral density (vBMD) at the spine, hip, radius and tibia",Health-related quality of life,,2020-01-14,COMPLETED,OBSERVATIONAL,['NA']
4853,NCT00788840,Weight change,Glycaemic control,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4854,NCT03959423,Change in Percentage of Euglycemia,Change in Percent of Time in Hypoglycemic Range (<70 mg/dL),,2019-07-24,COMPLETED,INTERVENTIONAL,['NA']
4855,NCT05580120,A Measure of Quality of Life in the Elderly,,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
4856,NCT02434315,Change from Baseline - time in glucose range - for penultimate sensor wear,,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
4857,NCT05528770,Difference in Daytime Time-in-range,Difference in Overall Time-below-range,,2022-10-20,COMPLETED,INTERVENTIONAL,['NA']
4858,NCT04608136,Change from baseline Insulin at 180 minutes,Changes in fat intake following dietary intervention,,2020-09-21,COMPLETED,INTERVENTIONAL,['NA']
4859,NCT00031239,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
4860,NCT00547872,Death and myocardial infarction,Symptomatic heart failure,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4861,NCT00233311,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
4862,NCT04287439,Change in pain severity,Change in Quality of life status,,2018-06-08,COMPLETED,INTERVENTIONAL,['NA']
4863,NCT05067075,Average percentage time in target glucose range,neonatal hypoglycemia,postpartum 2 hour 75 gram OGTT results from mother,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
4864,NCT03126513,Efficacy of G-POEM in gastroparesis in percentage of scintigraphic improvement at 4hrs,security of G-POEM in gastroparesis,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4865,NCT01721811,Retinal oximetry during hyperglycemia,,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
4866,NCT00995345,Change in HbA1c From Baseline (Week 0) to Week 24,Percentage of Patients Requiring Rescue Therapy for Elevated Glucose,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4867,NCT01572753,AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing,t1/2; the terminal half-life of semaglutide,,2012-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4868,NCT05902156,The Metabolic Parameter Monitoring Form,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4869,NCT05377320,Imaging surveillance,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4870,NCT05392452,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L,"Peri- and postoperative costs (perspectives: hospital, statutory health insurance system)",Number of clinically significant hyperglycaemic events (>20.0 mmol/L) with ketonaemia (beta-hydroxybutyrate >1.0 mmol/L),2022-08-09,COMPLETED,INTERVENTIONAL,['NA']
4871,NCT01630928,Change in blood pressure,Effect of RDN on subclinical organ injury: Impedance cardiography,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4872,NCT01795144,Incretin Effect,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4873,NCT02434744,"Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy",Changes in Serum Levels of Non-Esterified Free Fatty Acids,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4874,NCT02882477,C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT,,,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4875,NCT03936049,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
4876,NCT05499702,Rate of leucine oxidation in response to rising glucagon concentrations,,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
4877,NCT05336214,Change in practice-reported prescriptions of Continuous Glucose Monitors,Implementation and Maintenance,,2022-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4878,NCT00084110,,,,1993-08,TERMINATED,OBSERVATIONAL,['NA']
4879,NCT00508599,Insulin resistance and orthostatic response,"Change in glucose, insulin, and orthostatic impairment.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
4880,NCT05924932,glycated hemoglobin,mean sensor glucose value,Safety and Tolerability,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
4881,NCT03371303,exit orders after hospitalization,,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
4882,NCT03331289,Change in EGP From Baseline to Post-oral Glucose Load.,,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
4883,NCT03888157,Change in HbA1c (mmol/mol),Changes in quality of life (EQ VAS),,2019-03-10,COMPLETED,OBSERVATIONAL,['NA']
4884,NCT01879917,Beta-cell function,Postprandial glucagon,Hypoglycemia,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4885,NCT00037258,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
4886,NCT00528879,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Percentage of Participants Achieving Hemoglobin A1c (HbA1C) ≤6.5% at Week 24 (Last Observation Carried Forward [LOCF]),Number of Participants With Orthostatic Hypotension,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4887,NCT01904032,Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort,Change in Diastolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort,,2013-11-21,COMPLETED,INTERVENTIONAL,['PHASE2']
4888,NCT01689129,Change from baseline in HbA1c,Number of Patients with various types of Hypoglycemia Events,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4889,NCT06279234,Number of Participants With Change From Baseline in Physical Examination,Renal Clearance (CLr),,2024-02-20,RECRUITING,INTERVENTIONAL,['PHASE1']
4890,NCT05611684,blood lipid changes,Inflammation factors,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4891,NCT01919476,Change in markers for glucose intolerance.,Change in metabolic markers,Change in satiety markers,2011-09,COMPLETED,INTERVENTIONAL,['NA']
4892,NCT03597035,Left Ventricular Mass,,,2018-07-17,TERMINATED,INTERVENTIONAL,['PHASE4']
4893,NCT02791295,Weight change,Retention of weight change,,2016-10-04,COMPLETED,INTERVENTIONAL,['NA']
4894,NCT02584582,Glucagon concentration (postprandial),triacylglycerol (TAG),,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4895,NCT02509429,Time spent with blood glucose <70 mg/dl,Score of the Hypo Fear Survey,,2015-06-16,COMPLETED,INTERVENTIONAL,['PHASE2']
4896,NCT01475565,Change from Gestation Week 12-14 in Insulin Sensitivity at Gestation Week 32-34,Change from Gestation Week 12-14 in Physical Activity at Gestation Week 32-34,,2013-05,TERMINATED,OBSERVATIONAL,['NA']
4897,NCT04484259,P2Y12 reaction units (PRU),,,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE4']
4898,NCT03127696,Proportion of subjects with at least 20% lean-associated microbiota in recipients after FMT compared with subjects receiving lifestyle intervention alone up to week 24,Changes in liver stiffness to assess improvement of other metabolic disease weeks 24 compared with baseline,,2017-04-26,COMPLETED,INTERVENTIONAL,['NA']
4899,NCT00292890,"HbA1c levels, insulin doses and the number of experienced hypoglycaemic events",blood glucose measurements and the experiences of the patients,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
4900,NCT01664247,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%),Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2),,2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4901,NCT00961662,Change From Baseline HbA1c After Six Months of Treatment in Patients With Type 2 Diabetes Mellitus,Body Weight Loss (Compared to Baseline),,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4902,NCT01190436,Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12,Number of Participants With Adverse Events (AEs),,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4903,NCT02315495,Blood glucose concentrations at pre-defined intervals,half-emptying time (T50),,2015-04-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4904,NCT03925064,ultrasonographic myocardial performance index values,,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA']
4905,NCT00539435,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress.",,,2007-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4906,NCT01408277,Mean Percent Change in Wound Area,,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4907,NCT00014911,Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.,Percent of Participants With Detectable Fasting Basal C-Peptide Levels,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4908,NCT00308256,Patient's acceptance of the disease evaluated by an analogical visual scale rating,Episodes number of severe hypoglycaemia having required an intervention of a third party or a hospitalization.,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
4909,NCT04800679,Extent of neovascular tissues in disc-diameter measured by investigator according to the wide-field FAG,Central retinal thickness according to macular OCT,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4910,NCT04335331,A1c order,Weight,,2020-02-27,COMPLETED,OBSERVATIONAL,['NA']
4911,NCT04582357,Physical activity program attendance,Security,,2020-12,WITHDRAWN,INTERVENTIONAL,['NA']
4912,NCT02772783,Nucleus Accumbens Blood Flow,"Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation",Metabolomics,2016-07,COMPLETED,INTERVENTIONAL,['NA']
4913,NCT00945204,"The percentage of participants reaching target control of HbA1c (7.0), and blood pressure (<140/80) and cholesterol (<4 mmol/l),",Control of risk factors in all patients with type 2 diabetes in participating practices using anonymised routine data,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
4914,NCT00879203,,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4915,NCT05352815,Change in glycated haemoglobin (HbA1c),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",,2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4916,NCT04032561,Sleep Duration,HbA1c,,2019-01-08,COMPLETED,OBSERVATIONAL,['NA']
4917,NCT04259606,Brachial - ankle index,Lipid profile,,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA']
4918,NCT01722227,Mean weekly blood glucose concentrations.,HbA1c,,2012-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4919,NCT00231634,Percent change in body weight and change in Hemoglobin A1c (HbA1c) from baseline to Week 52.,"Change from baseline to Week 52 in BMI, FPG; safety evaluations (adverse events, hypoglycemic events) throughout study.",,2001-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4920,NCT04256447,Urinary sodium concentrations,,,2018-05-02,COMPLETED,OBSERVATIONAL,['NA']
4921,NCT01144728,Evolution of Fasting Plasma Glucose (FPG),Change in Weight,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4922,NCT03928132,"Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire",Acceptability Questionnaire,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4923,NCT01694758,Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1,The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
4924,NCT02973412,HBA1C level (%) measured from a blood sample,Continuous Glucose Monitoring (CGM),,2016-12-07,RECRUITING,OBSERVATIONAL,['NA']
4925,NCT01486238,Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.,Proportion of Subjects Requiring Macular Laser Treatment at Week 12 and Week 24.,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4926,NCT01767831,Ability of Behavioral Intervention to Improve Glycemic Outcome,Relationships Between Physiology and Behavior Transferred to In Silico Environment,,2013-03,TERMINATED,OBSERVATIONAL,['NA']
4927,NCT01445899,Efficacy (Stratum II),Anatomical changes in retina and retinal nerve fiber layer morphology (Stratum II),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4928,NCT02082756,Change in 2-hour postprandial blood glucose between baseline to week 12,Adverse effects,,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4929,NCT06150690,Glycated hemoglobin,Islet area,,2012-08-21,RECRUITING,OBSERVATIONAL,['NA']
4930,NCT01618552,Physician use of self-efficacy enhancing interviewing techniques,Healthcare Climate Questionnaire,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4931,NCT04335513,Continuous glucose monitor (CGM) % time >140 mg/dL,Diabetes attitude survey change over time,Change in Diabetes Knowledge from 6 month to 12 months follow-up.,2020-04-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4932,NCT04298684,Percentage of patients in each group who had at least a 20% decrease in one or more nodules of more than 2 cm at 2 years.,Percentage of adiponectin receptor expression in thyroid tissues after TN surgery,,2021-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
4933,NCT02336217,Number of hypoglycemic episodes,ADDQOL score,,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4934,NCT01253304,Pharmacokinetics: Apparent Volume of Distribution (Vz/F),,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4935,NCT02689778,Effect of oral pirfenidone (1800 mg) in glomerular filtration rate,Number of patients with treatment related adverse events,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4936,NCT05674110,Change in Diabetes knowledge,Change in Hemoglobin A1c,,2023-01-09,RECRUITING,INTERVENTIONAL,['NA']
4937,NCT01926041,Number of Participants With New-onset Type 2 Diabetes Mellitus (DM),HbA1c Change Between Baseline and 6 Months,10-year Probability of Regression to Normoglycemia,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4938,NCT06035536,Percentage of index ulcers healed at 12 weeks,Change in pain levels during the clinical investigation,"Cost to closure (both treatment groups; all wounds, and only closed wounds)",2023-06-08,RECRUITING,INTERVENTIONAL,['NA']
4939,NCT01467401,HbA1c (glycolated haemoglobin),Number and severity of hypoglycaemic episodes,,2002-08-19,COMPLETED,INTERVENTIONAL,['PHASE4']
4940,NCT01859598,the Change of Hypoglycemia During Follow-up.,Overall Weight Gain From Visit 1 to Visit 3,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
4941,NCT05217290,The Effect of Health Education Given to Prediabetes Patients by Video Conferencing on Self-Management and Exercise Status,,,2022-01,UNKNOWN,INTERVENTIONAL,['NA']
4942,NCT03366337,Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12,,,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2']
4943,NCT04450407,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2020-07-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4944,NCT04614870,Positive predictive value of the device in the determination of infection in wounds with clinical signs of infection,Likelihood of infection,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
4945,NCT02580513,Insulin Sensitivity,Heart rate,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
4946,NCT00241423,Time-averaged serum glucose during a 24-hour period,To compare the effects of exenatide and placebo on serum glucose,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4947,NCT02639507,average (mean) improvement in Best Corrected Visual Acuity (BCVA) as measured with Snellen visual acuity,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
4948,NCT01960205,oral glucose tolerance test,,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
4949,NCT03814395,Numbers of participants with adverse pregnancy outcomes,Fetal Humerus Length,,2018-06-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4950,NCT00012753,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
4951,NCT06319287,Primary endpoints,Secondary Endpoint,Tertiary Endpoints,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2']
4952,NCT00709319,Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 6 Months,Surgical Complications From Baseline to Six Months,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
4953,NCT04194515,bile acid profile,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4954,NCT01878045,End-Stage Renal Disease,Death,,2013-11-07,SUSPENDED,OBSERVATIONAL,['NA']
4955,NCT01364584,Peak Oxygen Consumption (VO2 Peak),Echocardiographic Measures - Lateral E:E',,2010-10,COMPLETED,INTERVENTIONAL,['NA']
4956,NCT02488057,Beta Cell Function,Presence of genetic polymorphisms,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4957,NCT00949221,"Comparison of the effect of 2 strategies of real time continuous glucose monitoring vs conventional SMBG on glycated haemoglobin = HbA1c measured at inclusion, 3, 6, 9, 12 months",Medico-economic evaluation,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4958,NCT01128985,The concentration of canagliflozin and major metabolites (M5 and M7) in blood will be measured by protocol-specified pharmacokinetic parameters.,"The safety and tolerability of canagliflozin will be determined by monitoring adverse events and findings from laboratory evaluations, vital signs measurements, and ECG measurements reported.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4959,NCT04721847,Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS),Diabetic peripheral neuropathic pain impact measure,,2020-08-13,COMPLETED,INTERVENTIONAL,['NA']
4960,NCT05497674,rongliflozin:Cmax ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone.,the number of participants with adverse events (AE) in Cohort B,,2022-02-21,COMPLETED,INTERVENTIONAL,['PHASE1']
4961,NCT00967798,Number of Participants With Conversion to Cystic Fibrosis Related Diabetes,Change in Percent Predicted FEV1,,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4962,NCT05138029,Review the patient's vision before surgery,Review the patient's vision for 6 months after surgery,,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
4963,NCT00642434,Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4964,NCT04282005,Assessment of liver inflammation and fibrosis,"Assessment of bile acids in fasting and postprandial phase in response to a mixed meal test (MMT) in a subset of patients (total no.=18; 6 RYGB, 6 SG, 6 lifestyle intervention)",,2020-02-13,UNKNOWN,INTERVENTIONAL,['NA']
4965,NCT02849080,Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no),Change in DTSQ- Sustainability,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
4966,NCT04355832,Change in the level of catecholamines in plasma,,,2020-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4967,NCT01467375,Frequency of hypoglycaemic episodes,HbA1c (glycosylated haemoglobin),,2001-01-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4968,NCT05719181,Effect of Recombinant Human Bone Morphogenetic The Primary outcome will be measuring the effect of rhBMP- 2/ACS in improving the secondary stability of dental implant by using RFA in comparison to control group.,,,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE1']
4969,NCT03698708,Center for Epidemiologic Studies - Depression Scale Revised (CESD-R),Hemoglobin A1c (HbA1c),Treatment Satisfaction Survey,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
4970,NCT01596920,"Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, anytime up to the Day 84 Visit",percent of wounds achieving complete closure,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4971,NCT01472666,Postprandial triglyceride response,"Postprandial apolipoprotein-48 (apoB-48), 6 hour",,2011-10,COMPLETED,INTERVENTIONAL,['NA']
4972,NCT03933956,Change in amino acid metabolome signature,,,2020-01-09,TERMINATED,INTERVENTIONAL,['PHASE3']
4973,NCT00549757,Percentage of Participants With All Cause Mortality (Extension Phase),Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase),Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase),2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
4974,NCT01525693,"The primary endpoint of this study is the overall proportion of patients whose HbA1c is less than 6.5%, measured at the end of one year follow up.",The clinical effectiveness of each regimen measured by the proportion of patients reaching the target glycemic control,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
4975,NCT03064841,"Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) Guidelines.",Follow up Duration of Type 2 Diabetes Related Risk Factors in Clinical Practice,,2017-03-09,COMPLETED,OBSERVATIONAL,['NA']
4976,NCT00956800,"Columbus Research Foundation will take the objective data that constitutes the defined end-points of the study and enter it for each patient into an Access data base, using the established data base management system of Columbus Research Foundation.",,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4977,NCT03705195,Difference in insulin secretion and incretin effect between two matched clamps (presence and absence of low dose gliclazide),"Insulin secretory response analysed by KCNJ11 Genotype (E23K, E23E, K23K)",,2018-08-03,COMPLETED,INTERVENTIONAL,['NA']
4978,NCT00239148,To evaluate the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,To evaluate the pharmacokinetic (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4979,NCT02767596,Change in body weight,,,2016-07-12,TERMINATED,INTERVENTIONAL,['PHASE4']
4980,NCT01631643,Change in A1C from baseline to week 24,Change in 30 day mean glucose comparing first month to last month after 24 weeks,,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE4']
4981,NCT00904176,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4982,NCT04532385,Change from baseline in TNF-α at week 12,Change from baseline in body water at week 12,,2018-06-12,COMPLETED,INTERVENTIONAL,['NA']
4983,NCT05067621,Change in Protein Density Fat Fraction (PDFF),Triglycerides,Changes in liver fibrosis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2']
4984,NCT00685984,Post-occlusive hyperaemia endothelium-dependent brachial artery dilation,biologic markers of endothelial function,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
4985,NCT05112146,Post-prandial glucose,T max glucose,,2018-08-20,COMPLETED,INTERVENTIONAL,['NA']
4986,NCT01766778,Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12,"Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability",,2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE4']
4987,NCT01648647,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
4988,NCT02805361,The mean change in HbAlc from mean baseline and at Month 12.,Changes from baseline in Diastolic Blood Pressures,Capture influence of the combined effect of fasting and hot climate on the level of total ketone bodies levels in T2DM subjects treated with Dapagliflozin,2016-08-21,COMPLETED,OBSERVATIONAL,['NA']
4989,NCT02799121,Complete Wound Closure,Neuro-QoL,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4990,NCT06140537,Albuminuria,safety and tolerability,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4991,NCT00160732,decrease in incidence of hypoglycemic events,absence of complications from the procedure and side effects of the medication,,2003-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4992,NCT02505516,Number of diabetic patients on metformin therapy,,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4993,NCT01747356,12-month TVF occurrence,Patient related adverse events,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
4994,NCT02531776,Area under curve (AUC) of skin blood perfusion increase,"Skin reactions (bleeding, bruising, redness, swelling) on a scale from 0 to 4.",,2014-12,COMPLETED,INTERVENTIONAL,['NA']
4995,NCT00354939,Frequency of subjects with conventionally detected hypoglycemia,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4996,NCT02306005,Factors influencing relationship between insulin treatment and lipoproteins,Development of Diabetic kidney disease,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
4997,NCT02026817,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4998,NCT05477173,Measures frequency of psychiatric problems with diabetes mellitus type 1,,,2022-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4999,NCT04286464,Swabs during respiratory infection,Sputum,,2003-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5000,NCT03103126,The effects of home-based combined exercise on insulin sensitivity compared to physical activity advice during the 6 week study period,Self-efficacy to regulate exercise scale,,2019-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
5001,NCT00987363,AngioRNM and/or AngioTC changes,Clinically objective improvement in the ischemic limb,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5002,NCT00931034,Change in body weight from baseline to week 24,"Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
5003,NCT03095651,Maximal Glucose Infusion Rate,Apparent Terminal Half-life,,2017-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5004,NCT00239707,"GIP, glucose, insulin measured frequently during infusions","GLP-1, ghrelin measured frequently during infusions",,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5005,NCT00762112,Adverse event occurrence.,Change from baseline in inflammation marker C-reactive protein.,,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
5006,NCT03842683,Optimal Time Shift of Continuous Glucose Monitoring Measurements,Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction,,2016-06-06,COMPLETED,OBSERVATIONAL,['NA']
5007,NCT04255381,Safety: Number of Participants Who Experienced an Adverse Event,Percent Time AP System Active,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
5008,NCT04028076,Change in Hemoglobin A1c,Adherence to Refills and Medications Scale for Diabetes (ARMS-D),,2019-07-10,COMPLETED,INTERVENTIONAL,['NA']
5009,NCT04531631,first phase insulin response to glucose,Area under curve of GLP-1 levels,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE2']
5010,NCT00639080,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
5011,NCT03577158,Number of hypoglycaemias,Rate-of-change of glucose during exercise (ROCe) and recovery (ROCr),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
5012,NCT02776696,Percentage of glucose sensor readings within 70 to 180 mg/dl,Closed-loop acceptance questionnaire,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5013,NCT01308008,Six Minute Walk Distance,Physical Activity,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
5014,NCT01375166,Retinal blood flow velocities,,,2013-03-06,TERMINATED,OBSERVATIONAL,['NA']
5015,NCT00734474,Glycosylated Hemoglobin (HbA1c) Change From Baseline,Antibodies to LY2189265,Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5016,NCT01478672,SF-36,EQ-5D,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
5017,NCT05403437,Evaluation of PGP severity,Evaluation of Body Mass Index (BMI),,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5018,NCT02443155,Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline,Cmax of Glucose at Week 80 Relative to Baseline,,2015-11-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5019,NCT04009239,Glucose control in response to mTRF,Difference in substrate oxidation rhythms between experimental conditions,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
5020,NCT03605979,Glycemia measured by continuous glucose monitoring (CGM) and pump,,,2012-07-01,COMPLETED,OBSERVATIONAL,['NA']
5021,NCT04543630,Implant survival,Effect of implant placement and graft material on hematological and inflammatory parameters,,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5022,NCT04240964,Composition of the DFO Metagenome,,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
5023,NCT05605704,rate of fasting glycemia level reduction,,rate of H1B1C balance variation,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5024,NCT05250999,Toronto Clinical Neuropathy scoring system,,,2021-07-15,COMPLETED,INTERVENTIONAL,['NA']
5025,NCT00153179,Difference in Insulin-mediated Skeletal Muscle Glucose Utilization Between Test Agent and Placebo,,,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5026,NCT03586830,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12,,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE2']
5027,NCT01214356,Change in Urinary Albumin:Creatinine Ratio (ACR),Decrease in Estimated Glomerular Filtration Rate (eGFR),,2010-08,COMPLETED,INTERVENTIONAL,['NA']
5028,NCT02120755,Reduction in Wound Size,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5029,NCT01856881,Subject incidence of anti-AMG 876 antibodies,Pharmacodynamic parameters,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE1']
5030,NCT02211651,Quantity of macrophages,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
5031,NCT01943357,Metabolic control HbA1C,Health care utilization,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5032,NCT00686816,weight loss,Weight maintained,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5033,NCT01147276,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemic,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5034,NCT00790699,"The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.","The Secondary Outcome Will Measure Patient Satisfaction, Opinions and Attitudes Toward Using the Multiple Injection Port for Insulin and Symlin Administration Compared to Standard Symlin Injections (Measured Through Using Questionnaires).",,2009-08,TERMINATED,INTERVENTIONAL,['NA']
5035,NCT05995756,overall mean absolute relative difference (MARD),,,2021-12-20,COMPLETED,OBSERVATIONAL,['NA']
5036,NCT01486901,Maximum serum insulin concentration (Cmax),Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5037,NCT00228865,"Using repetitive respiratory quotients, we will assess the success of the reversal of the abnormal underlying metabolism in diabetic patients from primarily fat metabolism to carbohydrate metabolism.",,,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5038,NCT06314061,Time in range (TIR) of CGM glucose levels,Complications,Staff experience,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5039,NCT01868230,Child Length,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
5040,NCT01496443,AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter for TAK-875,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5041,NCT00716092,GLP-1 (Glucagon Like Peptide 1) AUEC (0-2h) (Area Under Effect Curve) Change From Baseline at Day 28,Plasma Glucose Area Under Effect Curve (AUEC) (0-3h) Change From Baseline at Day 28,Exploratory Sensitivity Analysis of Plasma Glucose AUEC (0-3h) Change From Baseline at Day 28,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5042,NCT03222765,Sudomotor Index,depressive symptoms,,2015-03-15,UNKNOWN,INTERVENTIONAL,['NA']
5043,NCT01507038,Change from baseline in HbA1c at week 12,"Change from baseline in 1,5-anhydroglucitol at week 12",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5044,NCT00501202,The mean of the last 7 average daily DPN scores of the first treatment period on days when study drug is taken.,"The means of the last 7 average daily DPN pain scores with no use of rescue medication, the last 7 current daily DPN pain scores, the last 7 maximum daily DPN pain scores, and the last 7 daily sleep interference scores.",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5045,NCT04558645,General Quality of life,Dyspnea,,2020-09-18,COMPLETED,OBSERVATIONAL,['NA']
5046,NCT05110365,sphygmomanometer,(EuroQoL five-dimensional instrument ),,2021-06-26,COMPLETED,INTERVENTIONAL,['NA']
5047,NCT00306098,a1c less than 6.5 without severe hypoglycemia,assessment of EXN to improve islet survival at time of islet transplantation - number of subjects achieving insulin independence with a single infusion,,2000-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5048,NCT00289848,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5049,NCT00508937,LDL subclasses,Apolipoprotein A1,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
5050,NCT04263168,Changes in glycemic index prior and following bariatric surgery,,,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
5051,NCT00568074,HbA1c,adverse events,,2003-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
5052,NCT02371876,Percent of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding Views/Behaviors Related to Self-Monitoring Blood Glucose,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5053,NCT03037593,incidence of gestational diabetes,Shoulder Dystocia,,2017-06-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5054,NCT05351476,Change from baseline whole-body lipolysis at 12 weeks,Change in adipogenesis,,2022-05-20,RECRUITING,INTERVENTIONAL,['NA']
5055,NCT03450200,"Change in signs of DPN after intervention, at follow-up",Change in walking speed,,2017-06-17,COMPLETED,INTERVENTIONAL,['NA']
5056,NCT04014192,Change from baseline to post-treatment in islet alpha cell secretory function.,"Change from baseline to post-treatment in urinary output of uric acid, sodium, calcium, and phosphorus.",,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5057,NCT01795248,Change in glucose tolerance,Deterioration in glycaemic status,Changes in bonemarkers,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5058,NCT02577536,Number of women delivering at each gestational week,Number of live births,,2017-09-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5059,NCT02726490,efficacy of glyburide compared to glucovance,neonatal hypoglycemia,,2016-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
5060,NCT05479565,The values of highly sensitive CRP in pregnant women with gestational diabetes are higher compared to healthy pregnant women.,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
5061,NCT02958072,Healing of malleoli ulcer (YES/NO),"Z scores of combined plasma concentration of growth factors, cytokines and inflammatory markers",,2016-11,COMPLETED,INTERVENTIONAL,['NA']
5062,NCT01703637,Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12,The side effect of each drug.,change from baseline in content of NOS,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
5063,NCT01994291,Mean Letter Change From Baseline at Week 12 in Best Corrected Visual Acuity (BCVA),Plasma Concentration of PF-04634817 up to Week 12,Number of Participants With Change in Ophthalmoscopy Examination Results in Study Eye After Administration of Ranibizumab or Masked Sham Therapy at Week 8,2013-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5064,NCT02165228,Metabolic Syndrome Extent,Mindfulness,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5065,NCT01215435,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11,Number of Treatment Emergent Hypoglycaemic Episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5066,NCT01343446,Coping style of Patients with Diabetes suffer from Sleep Disorder,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
5067,NCT00998595,the fraction of each group that participates in postpartum follow up and glucose tolerance testing 4-12 weeks post partum.,the fraction of women in each group that attends a referral visit,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
5068,NCT02418637,Feasibility (Likert scale),,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5069,NCT02623608,"Area under the curve (AUC) of postprandial triglyceridemia (0-4h) after each intervention, compared to the reference meal","Area under the curve of postprandial glycemia (0-4h) after each intervention, compared to the reference meal",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
5070,NCT00846391,Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4,,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2']
5071,NCT04589351,Urinary albumin creatinine ratio (UACR),Magnetic resonans estimate of kidney parenchymal triglyceride fraction,Urine extracellular vesicles,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5072,NCT00396227,Change from baseline in HemoglobinA1c (HbA1c),Incidence of prespecified adverse events while on treatment with study drug,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5073,NCT00663624,to determine whether initiation of hyperglycemia management in the ED with scheduled aspart insulin for patients versus usual care with type 2 diabetes will result in a decrease in subsequent hospital length of stay.,"to determine diff. in the mean BG during the ED stay, the mean BG achieved during hospital, frequency of hypoglycemia during the ED and hospital visits among those treated with the scheduled protocol insulin regimen vs. usual hyperglycemia mgmt",,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5074,NCT01091025,To identify if using the selective approach to screen for CFRD is as accurate as screening all patients with OGTT at annual review.,Which is the more cost effective way of screening all patients with OGTT?,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
5075,NCT05977309,Comparison of the effects of topical ozone therapy and placebo on the healing of diabetic foot ulcers.,Comparison of topical ozone therapy and placebo groups for diabetic foot ulcer infection,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5076,NCT02056366,Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,Number of Patients with Adverse events as a Measure of Safety,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5077,NCT02588859,Medication usage in enrolled subjects,Reduction in HbA1C,,2015-10-30,COMPLETED,OBSERVATIONAL,['NA']
5078,NCT02548741,Plasma methylglyoxal (MG) concentration (μM),The urine imidazolinone (IMZ) concentration (nM),,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
5079,NCT01009580,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5080,NCT00709150,Reduction in symptoms of major depression,Quality of life,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5081,NCT00287651,Serial fundus photography,,,2005-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5082,NCT05468411,Overall liking for meals,,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
5083,NCT01728467,Change in plasma glucose following treatment with RVX000222 compared to placebo,Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5084,NCT00448903,total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.,incidence of major bleeding and the incidence of adverse events.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5085,NCT02469207,Number of donors from which induced Pluripotent Stem Cells were generated,Levels of baseline and stimulated gut hormones detected,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
5086,NCT00540709,Primary efficacy data was HbA1c.,Secondary efficacy data included HbA1c.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5087,NCT00865592,To demonstrate safety and tolerability of dutogliptin,To demonstrate maintenance or lowering of fasting blood glucose,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3']
5088,NCT04930276,the glycemic qualification rate,pregnancy outcome,,2021-03-05,UNKNOWN,INTERVENTIONAL,['NA']
5089,NCT01883622,"Glucose variability indexes during first, second and third trimester of pregnancy","Association between HbA1c and glucose variability indicators in the three trimesters pf pregnancy, in the three groups of women",,2004-01,COMPLETED,OBSERVATIONAL,['NA']
5090,NCT00975065,Hemoglobin A1c at 24 weeks,"Hypoglycemic events, Gastro-Intestinal events, other adverse events at each visit",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5091,NCT01400191,Endogenous glucose production,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5092,NCT02861781,comparison of miRNA,changes in miRNA in plasma level,,2016-02-02,RECRUITING,OBSERVATIONAL,['NA']
5093,NCT02745821,"Prevalence of number of vessels fulfilling each of 4 permutations of fractional flow reserve (FFR) and coronary flow reserve (CFR) ie FFR ≤0.80 CFR ≥2.0, FFR ≤0.80 CFR <2.0, FFR >0.80 CFR ≥2.0 and FFR >0.80 CFR <2.0.",Change in index of microvascular resistance (IMR) in target vessel,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
5094,NCT02193113,Number of participants with Adverse Events as a measure of safety and tolerability,Best Corrected Visual Acuity as measured by ETDRS EVA,Change in retinal thickness from baseline,2014-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
5095,NCT05464186,Fat mass,Diastolic blood pressure,Food and beverage intake pattern,2022-12-28,RECRUITING,INTERVENTIONAL,['NA']
5096,NCT05998525,changes in cardiac epicardial fat volume quantified in cm3 and evaluated by simple cardiac tomography.,Mortality due to cardiovascular causes,,2021-06-21,COMPLETED,INTERVENTIONAL,['PHASE3']
5097,NCT01775579,"metformin, rosuvastatin AUC","Metformin, Rosuvastatin Vd/Fss",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5098,NCT03680482,glycemic response in blood,Insulin response in blood,Through food provided ad libitum (objective appetite),2016-01-11,COMPLETED,INTERVENTIONAL,['NA']
5099,NCT02214329,Gait,Functional Performance,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
5100,NCT00172536,Diastolic heart function,Blood test,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
5101,NCT00576862,Evolution of efficacy parameters between first study visit (V1) and last study visit (V5),,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5102,NCT01422421,important secondary composite endpoint,new onset or deterioration of heart failure,,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
5103,NCT02137031,HbA1c,Frequency of Diabetic Ketoacidosis,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
5104,NCT03884647,DELPHI's reliability,,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
5105,NCT05123196,Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period,Proportion of CGIC responder at each assessment point,,2021-11-16,COMPLETED,INTERVENTIONAL,['PHASE2']
5106,NCT02013843,Body mass index standard deviation score,Change in quality of life assessed by PedsQL,cost effectiveness,2013-03,COMPLETED,INTERVENTIONAL,['NA']
5107,NCT00460499,glycemic control,free fatty acid levels,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5108,NCT02690766,Change in Body Weight,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5109,NCT00184665,HbA1c,Hypoglycaemia,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5110,NCT01338870,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Loss in Body Weight From Baseline,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5111,NCT01277614,decrease body mass index,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5112,NCT05661149,Percentage time spent in the euglycaemic range specific for pregnancy (63-140 mg/dL),,,2023-05-11,COMPLETED,OBSERVATIONAL,['NA']
5113,NCT01094769,Urine albumin/creatinine ratio (UACR),muscle sympathetic nerve activity (MSNA),,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5114,NCT04959552,Characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations,,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
5115,NCT05373004,estimated glomerular filtration rate,the change in Urine Albumin Creatinine Ratio (UACR),"the rates of clinical events (myocardial infarction, ESRD, congestive heart failure, and stroke)",2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5116,NCT02816749,Wound healing time(days),Negative bacterial culture time (days),,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
5117,NCT05892861,The change of cognitive function from baseline at 3 and 6 months,The change of dietary control belief from baseline at 3 and 6 months,The change of health behavior frequency per week from baseline at 3 and 6 months,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
5118,NCT00882882,Bioequivalence based on AUC and Cmax,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5119,NCT00091949,"Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction","Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure",,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5120,NCT04086043,Changes in glycosylated hemoglobin from baseline to 6 months,Changes in blood urea nitrogen (BUN) up to 2 years,,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA']
5121,NCT01831102,total adiponectin concentration,Insulin sensitivity,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
5122,NCT00710008,"ATP-Synthesis, liver lipid content, skeletal muscle lipid content",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
5123,NCT04006028,Non-diabetic renal disease,Patient survival,,2019-06-06,COMPLETED,OBSERVATIONAL,['NA']
5124,NCT06041971,Mean Sensor Glucose Value,,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
5125,NCT01547104,fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo,Body Weight,,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
5126,NCT00715663,Patient and doctor's convenience,Patient satisfaction on devices,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
5127,NCT00538174,Urine safety markers,24h urine,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5128,NCT00579150,Primary Outcome,Secondary Outcome Measure,,2009-01,TERMINATED,OBSERVATIONAL,['NA']
5129,NCT05542147,Endothelial Function,Platelet aggregation induced by arachidonic acid,Haematopoietic stem/progenitor cells (HSPCs),2022-07-03,RECRUITING,INTERVENTIONAL,['NA']
5130,NCT04082702,Waist circumference: Number of participants above the recommended level,Cortisol (ng/mL),,2013-02-22,COMPLETED,INTERVENTIONAL,['NA']
5131,NCT00943371,15-Hour weighted mean plasma glucose (WMG) concentration,4-Hour weighted mean plasma glucose (WMG) concentration,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1']
5132,NCT00542178,"Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy",Development or Progression of Macular Edema,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5133,NCT01601236,Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12,"Percent Change From Baseline of Serum Total Cholesterol, Triglycerides, LDL, HDL, Lp(a), Albumin, and Cortisol",Change in Mean HbA1c,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5134,NCT02488616,Percentage of time of glucose levels spent between 3.9 and 10.0 mmol/L,Number of days with hypoglycemic events less than 3.1 mmol/L,,2018-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5135,NCT02404207,Change in lipid profile,Change in waist circumference,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5136,NCT00314717,Self-blood-glucose-monitoring results,perceptions of diet treatments,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5137,NCT05596656,positive skin prick test,,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA']
5138,NCT02338921,Glycemic target goal achievement rate,Glycemic target goal achievement rate,body weight change,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5139,NCT06280703,Part C: PK: Concentration of LY3938577,Part C: PD: Glucose infusion rate (GIR) of LY3938577,,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
5140,NCT04051008,Change in Nutritional Quality of Purchases,Nutritional Quality of Foods Consumed,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
5141,NCT01192373,Exercise capacity and oxygen consumption,metabolic and hormonal profile,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5142,NCT00617565,2-hr postprandial plasma glucose (PPPG) excursion,Fasting plasma glucose,,2003-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5143,NCT04058730,Glycosylated Haemoglobin less than 6.5 mg/dl,,,2015-04-01,UNKNOWN,INTERVENTIONAL,['NA']
5144,NCT01857076,Diabetes remission evaluated by patients glycemic rates,Number of Late Adverse Events,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
5145,NCT05787990,Presence of Diabetes Nephropathy,Severity of diabetes peripheral neuropathy,,2021-10-14,RECRUITING,OBSERVATIONAL,['NA']
5146,NCT01219465,C peptide release test,Immunologic reconstitution parameters,,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5147,NCT04255238,Chages from baseline HbA1c at Week24,,,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
5148,NCT04497805,Proportions of subjects who achieved complete wound closure.,Durability of complete wound closure for the additional 24 weeks.,,2020-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
5149,NCT06326489,Variations in HbA1c,changes in The Pediatric Quality of Life Inventory™ 4.0 Short Form 15 Generic Core Scales questionnaire scores,,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE4']
5150,NCT02320721,Change in HbA1c From Baseline to Week 26,Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment,"Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment",2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5151,NCT02887677,Ambulatory systolic aortic pressure,HbA1c,,2016-10,TERMINATED,INTERVENTIONAL,['PHASE4']
5152,NCT03356457,• Measurement of hormone changes during hypoglycemia,cognitive function,,2017-11-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5153,NCT02577003,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Body Weight at Week 24,,2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5154,NCT05682495,Pharmacokinetics parameters of Metformin in the fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
5155,NCT01650259,Percentage of Participants With Adverse Drug Reactions (ADRs),Change From Baseline in HbA1c at the Last Observation During the Observation Period.,,2012-07-23,COMPLETED,OBSERVATIONAL,['NA']
5156,NCT01973920,Adverse events and serious adverse events occurence,To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs routine use,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5157,NCT05720377,Body Mass Index,IL-6,,2024-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
5158,NCT03968224,Change in Weight,Change in Triglycerides level,Change in Cytokines Level,2018-07-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5159,NCT02804750,Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events,Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5160,NCT02353416,Advanced glycation end products levels,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
5161,NCT02586545,"Change from baseline Hemoglobin A, Glycosylated (HbA1c) at 12, 24 and 36 months",The proportion of patients who meet national standard indicators reflecting quality of care,"Change from baseline diabetes symptoms at 12, 24 and 36 months",2015-08,COMPLETED,INTERVENTIONAL,['NA']
5162,NCT00065663,,,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5163,NCT00335465,adverse events,changes of myocardial structure and left ventricular systolic and diastolic function,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5164,NCT00415688,Hemoglobin A1c,Serum lipoproteins,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5165,NCT05888909,change in estimated glomerular filtration rate (eGFR) from baseline,,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
5166,NCT00772174,Increase in High-Density Lipoprotein cholesterol levels.,"The change from Baseline in Laboratory Parameters (hematology, chemistry and urinalysis).",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5167,NCT00658463,"Fractional Catabolic Rates (FCR)of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I","Production Rates (PR) of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5168,NCT03388229,association between frequency of food group/item consumption and HbA1c among T2D patients,"To measure the percentage of frequency of consumption of food groups among T2D patients ,",,2017-08-08,COMPLETED,OBSERVATIONAL,['NA']
5169,NCT00182026,A1c,incremental cost/quality-adjusted life-year [QALY],,2005-06,UNKNOWN,INTERVENTIONAL,['NA']
5170,NCT00174642,Insulin doses,Adverse events,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5171,NCT02384902,Serum creatinine (and blood urea nitrogen (BUN) (mg/dL) were measured by colorimetric method and enzymatic colorimetric method using commercial assay kit.,"Serum levels of high sensitive C- reactive protein (hs-CRP) (mg/L) were quantified by using an ultrasensitive latex-enhanced immunoturbidimetric assay (Randox Laboratory Ltd., Belfast, United Kingdom).",Fasting blood sugar (FBS) and lipid profile concentrations (mg/dl) were measured using commercially available enzymatic reagents adopted to an auto-analyzer system.,2014-05,COMPLETED,INTERVENTIONAL,['NA']
5172,NCT04008745,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 8-weeks,Change from Baseline Functional balance at 8-weeks,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
5173,NCT05104593,Change in healthcare appointments,Change in number of participants with advanced directives,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5174,NCT01433406,Adverse events,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5175,NCT03849339,AUClast of Metformin,Vd/F of Metformin,,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
5176,NCT04284722,Incidence of Perioperative Hyperglycemia,Mortality,,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5177,NCT06256549,"Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks",The overall incidence of adverse events and the incidence of serious adverse events,,2023-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5178,NCT03950973,Change in HbA1c as measured by an HbA1c machine,Change in Unmet Social Risk Factors as measured by participant questionnaire,,2019-06-26,COMPLETED,INTERVENTIONAL,['NA']
5179,NCT02395315,Differences in alveolar bone vascularity among well-controlled and not well-controlled diabetic patients.,RANK-L to OPG ratio,Implant surgery-related complications,2015-12,COMPLETED,OBSERVATIONAL,['NA']
5180,NCT05061459,Expression levels of circANKRD36 in the development and progression of DN.,Correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in the development and progression of DN.,,2021-10,UNKNOWN,OBSERVATIONAL,['NA']
5181,NCT01945099,"Peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between CL alone and CL+PH20preRx and CL+INS-PH20",Peak post-prandial insulin levels following meals,Area Under Curve meal-related insulin excursion following meals,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5182,NCT01220557,Changes in Glycemic Control Measured by A1c,Evaluation of the Diabetes Education Course,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5183,NCT04888598,Vessel density,Vessel density,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
5184,NCT00790309,Determine to what extent improvements in glycemic control can be attributed to caloric restriction after weight loss surgery,Determine changes in inflammatory markers after weight loss surgery,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
5185,NCT02598791,food intake,procollagen type 1 N-terminal propeptide (P1NP),,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5186,NCT00903851,Mean change from baseline to Week 3 in average pain intensity as measured from patient diaries using Brief Pain Inventory Question 5.,"Assessment of safety was based on AEs, skin assessment, physical examination, vital signs, clinical laboratory data, and plasma lidocaine levels",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5187,NCT00350064,Change in Abdominal Visceral Fat,Endothelial Function,,2004-04,UNKNOWN,INTERVENTIONAL,['NA']
5188,NCT01991769,endothelial function,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
5189,NCT03604224,Change From Baseline in Mean Weight,,,2018-09-05,COMPLETED,OBSERVATIONAL,['NA']
5190,NCT02565368,Cmax of Lobeglitazon and metformin,Vd/F of Lobeglitazon and metformin,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5191,NCT00744237,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5192,NCT04642313,"Effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus",Gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus,Effect of magnesium and/ or potassium on quality liver function tests (LFTs) among insomnia patients with diabetes mellitus,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA']
5193,NCT00167570,Durability during household and community mobility.,"User perceptions of comfort, fit, and function.",,2003-04,COMPLETED,OBSERVATIONAL,['NA']
5194,NCT05862311,Evaluation of bone metabolism biomarkers in different periodontal conditions,Plaque index,,2020-03-12,COMPLETED,INTERVENTIONAL,['NA']
5195,NCT00569907,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
5196,NCT05535322,Major acute cardiovascular events,Therapeutic inertia,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
5197,NCT03609996,Clinical regression of neovascularization not requiring further treatment beyond RBZ,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
5198,NCT01129960,Change From Baseline to Endpoint in Mean Pain,,,2010-11,TERMINATED,INTERVENTIONAL,['PHASE3']
5199,NCT01393873,rapid changes in the level of retinopathy,,,2011-07,TERMINATED,OBSERVATIONAL,['NA']
5200,NCT01817595,Time required to teach meter/internet platform,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
5201,NCT04159766,Change in plasma glucagon,,,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
5202,NCT02142309,"The primary outcome is maintenance of metabolic control (glycemic durability), defined as time to primary failure with a HbA1c value >7% on maximally tolerated doses of the assigned drug.",Continuous glucose monitoring for 72 consecutive hours at least once each year of follow-up,Changes of triglyceride level from baseline each year of follow up,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
5203,NCT02586831,Proportion of regulatory T cells,Incidence of immune response adverse events,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5204,NCT00551564,Insulin resistance,Body composition,,2007-07-31,COMPLETED,INTERVENTIONAL,['PHASE1']
5205,NCT00337610,Change From Baseline in A1C at Week 18,Change From Baseline in A1C at Week 30,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5206,NCT01740778,Blood Glucose Reading,Pain Scale Rating,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
5207,NCT00804921,Intra-ocular pressure variation after intra-vitreous injection of bevacizumab,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
5208,NCT04684602,Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.,,,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5209,NCT03739580,Salvage limb rate (for CLI patients),Major Adverse Events at 12-month Post Procedure,,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA']
5210,NCT02501343,Changes in venous blood pH,Changes in hunger and satiety scores,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5211,NCT05646147,Reliability of standard bedside tests and the maximal systolic acceleration (ACCmax),Wound healing and ACCmax,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5212,NCT01658501,Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator,Proportion of subjects reaching HbA1c targets (<7.0%) after 20 weeks of dosing,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5213,NCT04260438,"Cmax of CKD-501, D759, D150, CKD-393",,,2020-04-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5214,NCT01657630,Study device acceptance,preprandial SMBG (self monitoring blood glucose),,2012-09,COMPLETED,OBSERVATIONAL,['NA']
5215,NCT06328010,Data collection of 5000 patients,Different types of wounds/injuries heal rate,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5216,NCT02685774,Cmax of Metformin,Vd/F of Metformin,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5217,NCT00511030,,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
5218,NCT03560323,Cardiac Function,Myocardial energetics,,2019-01-07,RECRUITING,INTERVENTIONAL,['PHASE1']
5219,NCT01356381,"Measure: effect of treatment on insulin sensitivity, assessed as glucose Rd (rate of glucose disposal).",,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5220,NCT01651845,"Evaluate effectiveness of the UHN handheld PRODIGI™ imaging device for real-time and non-invasive detection and tracking of pathogenic bacterial presence, contamination and infectious status in complex wounds over time.",,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
5221,NCT03823664,Cardiorespiratory fitness,Pulmonary functions,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
5222,NCT02888769,Change in systolic blood pressure obtained in office during each interview,Change in proportion of non-smokers,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
5223,NCT00917553,The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group,Number of Participants Who Developed Vitreous or Preretinal Hemorrhage,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5224,NCT02183935,Change in BMI (BMI SDS),"Change in emotional and behaviour problems, body image and eating disorder symptoms",Safety profile of DJL in adolescents.,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5225,NCT06294704,time spent within glycemic target 70-180 mg/dL,Time spent in level 2 hypoglycemia (< 50 mg/gdl),,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5226,NCT01876992,% Cyclic Amine Mono Phosphate (cAMP) Response Element Binding Protein (CBP) White Blood Cell (WBC) Phosphorylation (Metformin Treated vs no Treatment),Fasting Blood Glucose.,Effect of Dose Escalation,2012-01,TERMINATED,INTERVENTIONAL,['NA']
5227,NCT01058772,C-section rate,Indication for Cesarean Section,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
5228,NCT04315909,Wound Size,Pro-Oxidant Antioxidant Balance at baseline and after the intervention,,2019-08-28,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5229,NCT05370612,Percentage of Time Where Blood Glucose is between 70-140 milligrams per deciliter (mg/dL),Qualitative Outcome: Interviews to understand Participant Sense of Control around Glucose Monitoring,,2022-08-08,RECRUITING,INTERVENTIONAL,['NA']
5230,NCT03713437,Levels of differentially methylated insulin DNA from infancy to early adulthood in people with cystic fibrosis,Correlation between level of differentially methylated insulin DNA and use of CFTR modulator therapy.,,2019-04-04,COMPLETED,OBSERVATIONAL,['NA']
5231,NCT02232503,The prevalence of diabetic retinopathy as the proportion of patients with DR (any stage) in a given subgroup according to DM duration,Evaluate the impact of risk factors on the prevalence of Diabetic Retinopathy and Diabetic Macular Edema,Identification of patients with extreme phenotypes and family history of DM with eye complications,2015-02,COMPLETED,OBSERVATIONAL,['NA']
5232,NCT06089070,Feasibility of CGM use measured with Feasibility of Intervention Measure.,Problem Areas in Diabetes,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
5233,NCT01352767,efficacy,Satisfaction,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5234,NCT05159089,Metabolic participants outcomes,Socioeconomic participant status,Medication patients intake,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
5235,NCT00229437,Change from Baseline in composite measure of maximal nerve conduction velocity (Nerve Conduction Studies).,Change from Baseline in quality of life index (SF-36 Health Survey).,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5236,NCT00134329,Relation of erectile dysfunction with sex steroids,"Optimalisation of the healthcare for diabetic patients, so that the quality of life for male diabetic patients can be improved",,2005-05,COMPLETED,OBSERVATIONAL,['NA']
5237,NCT04858321,Insulin sensitivity,Cardiac output,,2021-05-24,COMPLETED,INTERVENTIONAL,['NA']
5238,NCT03939624,Cardiovascular death,Heart failure,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
5239,NCT01175811,Change in Haemoglobin A1c (HbA1c) From Baseline to 24 Week Endpoint,Percentage of Participants Experiencing a Severe Hypoglycemic Episode,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5240,NCT03725657,Measure of sleep expenditure through wrist accelerometer,Measure of insulin dosage,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA']
5241,NCT02569684,Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
5242,NCT01645332,Reduction of A1c level,Adverse events,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5243,NCT00351650,,,,2006-07-09,COMPLETED,OBSERVATIONAL,['NA']
5244,NCT04093635,Management of diabetic foot ulcers.,,,2019-11,UNKNOWN,OBSERVATIONAL,['NA']
5245,NCT04324736,Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19,describe the care management of hospitalized subjects with diabetes and COVID-19,,2020-03-10,COMPLETED,OBSERVATIONAL,['NA']
5246,NCT01255384,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
5247,NCT04511468,Change the Risk of T2DM Progression,The assessment on the Safety of the ZCC Supplementation for the respondents,Change in Vitamin C Level (optional),2021-06-23,UNKNOWN,INTERVENTIONAL,['NA']
5248,NCT05662332,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Treatment Experience in Diabetes Injection Device Experience Questionnaire (DID-EQ) in Device Characteristics,,2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5249,NCT00401115,"Safety and tolerability as assessed by visual acuity, intraocular pressure, slit lamp and indirect ophthalmoscope",Visual Acuity,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5250,NCT01468116,,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
5251,NCT01680926,insulin demand per day,body weight,,2009-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5252,NCT00551538,Combined morning and evening mean 2 hour postprandial plasma glucose during each 24 hour inpatient period.,Insulin dose and body weight,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5253,NCT05613400,The change in the TH BMD after 18 months of simvastatin compared with ezetimibe,The changes in TBS after 18 months of simvastatin compared with ezetimibe,,2022-04-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
5254,NCT00745433,HbA1c,Variability in FPG (Fasting Plasma Glucose),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
5255,NCT05993871,Demonstrate the findings of nerve ultrasound CSA of right ulnar nerve.,Diabetic neuropathy quality of life evaluation using Euro quality of life -5 dimensions -5 levels scale.,,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5256,NCT00409240,"Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study",,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5257,NCT04931030,Change from baseline urine microalbuminuria at 12 weeks,Change from baseline Interleukin-6 (IL-6) at 12 weeks,,2019-03-15,COMPLETED,INTERVENTIONAL,['NA']
5258,NCT06227221,The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal,"Drug safety: gastrointestinal symptoms, rashes, fatigue, bleeding, anemia, infections, cardiovascular events, etc.",,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5259,NCT00936234,Endothelial Function,Number and Function of Progenitor Cells,,2009-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5260,NCT02009514,Glucose below 4.0 mmol/l,Glucose below 4.0 mmol/l during specified time intervals,Standard deviation of glucose during specified time intervals,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5261,NCT02653027,Change in Fasting Glucose,Change in Fasting Insulin,,2018-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
5262,NCT03072563,Composite outcome,,,2017-03-07,UNKNOWN,OBSERVATIONAL,['NA']
5263,NCT04183257,Homeostatic Model Assessment of Insulin Resistance,Glycated Hemoglobin (HbA1C),,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
5264,NCT05180591,Change in HbA1c values,Change in adjusted HbA1c,Exploratory: Change in overall inflammation,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE2']
5265,NCT01416766,Change in blood pressure (BP),Satisfaction,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
5266,NCT03462069,Assessment of PD parameters in blood,Assessment of pharmacokinetic (PK) parameters: tmax,,2018-03-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5267,NCT02486484,vision before and after ziv-aflibercept,central macular thickness before and after ziv-aflibercept,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
5268,NCT00867386,Patient and graft survival.,Reversal or halting of diabetic complications,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
5269,NCT00421733,Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).,Change From Baseline to the Last On-treatment Observation in Intact Parathyroid Hormone (iPTH) Levels.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5270,NCT01114542,Area under the glucose infusion rate curve during one dosing interval of Insulin Degludec at steady state,Area under the concentration-time curve during one dosing interval at steady state for insulin glargine,,2010-05-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5271,NCT01952145,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,,2013-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
5272,NCT03821220,Physical activity level assessed through average weekly steps,Vitamin C intake 0<mg/day<2500,,2019-02-15,UNKNOWN,INTERVENTIONAL,['NA']
5273,NCT05199350,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,,2021-11-17,COMPLETED,OBSERVATIONAL,['NA']
5274,NCT03236558,"Variability of the diversity of antigen-receptors' repertoires, expressed by regulatory T cells from type I diabetes patients and healthy controls.",Ratio between TCR diversities expressed by Treg cells vs. conventional T cells.,,2018-03,WITHDRAWN,INTERVENTIONAL,['NA']
5275,NCT02860611,Difference in T helper cytokines between groups,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
5276,NCT04302168,Birthweight,Gene expression of glucose transporters,,2020-04-01,RECRUITING,INTERVENTIONAL,['NA']
5277,NCT00999050,Hemoglobin A1C changes,improvement in glycemic control,,2009-10,UNKNOWN,INTERVENTIONAL,['NA']
5278,NCT06176599,Effective rate,Urinary microalbumin/urinary creatinine,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5279,NCT01564485,Systolic BP Pressure,,Change in Treatment by PCP,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5280,NCT05035368,The mean difference in glucose infusion rate (GIR) from baseline,Change in average (previous 3 days) daily insulin requirements,,2021-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5281,NCT03338439,Diastolic Blood Pressure,Vascular event,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
5282,NCT04457440,Changes in 2-hr oral glucose tolerance (mg/dl),Changes in dietary composition,,2020-07-01,SUSPENDED,INTERVENTIONAL,['NA']
5283,NCT05378620,Change in Baseline Self-Efficacy for Diabetes Scale at 6 months,Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months; % Units,Participant Satisfaction,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
5284,NCT04843592,the patient's compliance after using SOKARY mobile app,,,2019-08-30,COMPLETED,OBSERVATIONAL,['NA']
5285,NCT02461589,Change in HbA1c (Glycosylated Haemoglobin),Change in Systolic and Diastolic Blood Pressure,,2015-09-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5286,NCT02340507,Daily blood glucose profile (easured for each low and high GI treatment as the area under the curve over 24 hours using CGMS),Energy intake (The amount of food consumed at the ad libitum lunch is measured by weighed quantities (in grams converted to kilocalories) based on the difference of the weight of food before and after consumption),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
5287,NCT02767440,change in parent weight over 6 months,change in home food environment over 6 months,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5288,NCT02026843,Aqueous secretory angiogenic and anti-angiogenic protein concentration,,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
5289,NCT03366532,Mortality,,,1980-08,COMPLETED,OBSERVATIONAL,['NA']
5290,NCT00566189,Improvement or reversal of type 2 diabetes mellitus,Retardation of progression or regression of albuminuria as detected by microalbuminuria assay in 24-h urine collection,,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5291,NCT02473081,Hemoglobin A1c,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5292,NCT04041739,detect magnitude of fungal infection as an etiology causing persistent non healed diabetic foot osteomyelitis,detect response of healing of resistant infected osteomyelitis to antifungal therapy,,2020-01,UNKNOWN,OBSERVATIONAL,['NA']
5293,NCT05537233,Proportion of adults with T1D achieving composite outcome (CGM-measured time in range (TIR)>70% with time below range (TBR) of <4% and reduction in body weight by 5%) at 26 weeks in the semaglutide group compared to placebo group,Change in NAFLD biomarkers,Change in ectopic fat volumes in the abdomen and around the heart,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5294,NCT03558581,Glycemic control - HbA1< 7%,Improve Knowledge assessed by questionaries DKNA,Improve attitude and coping of Diabetes assessed by questionaries ATT-19,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
5295,NCT00235014,Phase A: microalbuminuria; Phase B: progression from microalbuminuria to macroalbuminuria.,"Course of albumin excretion over time, GFR, blood pressure (BP), incidence of major CV events, overall and CV mortality, HbA1c, progression of retinal changes.",,1997-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5296,NCT03934281,Epidermization rate at 6 months.,Epidermization rate at 2 months,,2018-06-27,COMPLETED,INTERVENTIONAL,['NA']
5297,NCT01238289,mean percent change Hemoglobin A1c (HbA1c),"Body mass index, blood pressure and lipid changes",,2006-09,COMPLETED,INTERVENTIONAL,['NA']
5298,NCT02065050,Hemoglobin A1c,BMI,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
5299,NCT01548248,Change in HbA1c (glycosylated haemoglobin),Number of adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
5300,NCT03793673,Social Determinants of Health Tool,Cost to Payor as as assessed using the Team Costs- YA,Standard Care - Tools Questions,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
5301,NCT03289338,Time for resolution of active Charcot foot,Time for radiologic resolution/reduction on MRI,,2016-06-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5302,NCT03660371,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
5303,NCT00374595,Carotid Intima Media Thickness (CIMT),,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
5304,NCT02909894,Blood glucose Area Under the Curve (AUC),Cognitive function - Part 4 - Rapid Visual Information Processing Test,,2016-05-26,COMPLETED,INTERVENTIONAL,['NA']
5305,NCT05535842,"Changes in diabetes knowledge among patients and carers in the intervention group using GLOW Quiz at baseline, interim (3 months) and end-of-trial (6 months).",GLOW App usability perception among patients and carers in the intervention group will be measured at the end-of-trial (6 months).,,2022-11-28,RECRUITING,INTERVENTIONAL,['NA']
5306,NCT00692237,"Left Ventricular Torsion Defined as Change in Ventricular Mid-wall Rotation (°) Measured by Cine-Cardiac Magnetic Resonance (CMR) Imaging With Tagging, Before and After Three Months of Treatment With Sildenafil and Placebo (100 mg/Day).",Ejection Fraction (EF) Defined as the Volume of Blood Ejected With Each Beat Was Measured on Cine-Cardiac Magnetic Resonance (CMR) Images Before and After Three Months Treatment With Sildenafil and Placebo (100 mg/Day).,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5307,NCT03150901,dIABETIC FOOT ULCERS INCIDENCE,,,2015-02-20,COMPLETED,OBSERVATIONAL,['NA']
5308,NCT00804414,Compare the proportion of patients in the two arms who have complete healing of target ulcer,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5309,NCT00795262,Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo.,"Comparison of patients treated with quinapril plus lipoic acid versus quinapril plus placebo in the following areas: a) Changes from baseline in high sensitivity C-reactive protein, adiponectin, and leptin",,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5310,NCT02611232,FPIR (first phase insulin response),Serum C-peptide AUC,,2015-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
5311,NCT01771185,Hb A1a,Lipidic control,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
5312,NCT03823092,polarization sensitivity,,,2017-11-09,UNKNOWN,OBSERVATIONAL,['NA']
5313,NCT00712478,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5314,NCT03341026,Accuracy,Reliability,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
5315,NCT05552339,Number of patients with Urine albumin-creatinine ratio (UACR) values between 30 and 299 mg/g and above 300 mg/g,Location of HCP,,2023-08-18,RECRUITING,OBSERVATIONAL,['NA']
5316,NCT01063361,serum lipids,"creatine, urea, and c-peptides in 24 hour urine collection",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5317,NCT01437332,,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
5318,NCT02776007,Libre-user evaluation questionnaire,Glycemic control measured by HbA1c,Average fasting blood glucose level,2016-07,COMPLETED,INTERVENTIONAL,['NA']
5319,NCT00592527,HbA1c,Incidence of adverse events,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5320,NCT03710083,Mean Absolute Relative Difference (MARD),,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
5321,NCT05019807,Follow-up rate in patients with diabetic macular edema receiving education materials about diabetes and its complications.,,,2020-12-18,COMPLETED,INTERVENTIONAL,['NA']
5322,NCT05107063,Percentage Change Rate From Baseline in the Modification of Diet in Renal Disease(MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 24 After Routine Care of Pravastatin Administration,Number of Participants With Treatment-emergent Adverse Events After Routine Care of Prevastatin Administration,,2016-01-20,COMPLETED,OBSERVATIONAL,['NA']
5323,NCT00443521,Vitreous haemorrhage,Safety and Tolerance of the treatment,,2005-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5324,NCT05336071,Area under the plasma concentration versus time curve (AUC0-inf ) of INS068 injection,Number of subjects with adverse events and the severity of adverse events,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5325,NCT00317954,Changes in blood pressure,Changes in glomerular filtration rate,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5326,NCT01387165,The achievement of the planned completed number of questionnaires.,Assessment of fasting blood glucose,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
5327,NCT04879511,Glycemic control(HbA1c%),circulating neuregulin-4 level,,2018-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5328,NCT00094770,Change From Baseline in HbA1c at Week 52,Number of Participants With Drug-related LAEs at Week 104,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5329,NCT04601740,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-11-17,COMPLETED,OBSERVATIONAL,['NA']
5330,NCT01833559,The incidence of GDM at the second gestational trimester,Gestational outcomes,Child growth measures,2012-06,UNKNOWN,INTERVENTIONAL,['NA']
5331,NCT03089528,intubation difficulty,adverse outcomes related to tracheal intubation.,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
5332,NCT04755946,Absolute change in Estimated glomerular filtration rate (eGFR),Change in serum irisin level,,2021-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5333,NCT03484689,Dropout rate,The Audit of Diabetes-Dependent Quality of Life (ADDQOL),,2018-07-14,COMPLETED,INTERVENTIONAL,['NA']
5334,NCT04732208,Sensitivity and Specificity of the AI in detecting any grade of diabetic retinopathy in those with established diabetes mellitus (DM),To compare the diagnostic ability of the AI in mydriatic and non-mydriatic eyes,,2022-04-20,COMPLETED,OBSERVATIONAL,['NA']
5335,NCT00099905,Change from baseline in HbA1c at 24 weeks,Change from baseline in fasting lipids at 24 weeks,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5336,NCT05999656,Rate of wound area change,Change in Wagner scale,,2023-05-28,RECRUITING,INTERVENTIONAL,['NA']
5337,NCT02946541,HbA1c,HbA1c response rate,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5338,NCT06329674,Changes in HbA1c,,,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE3']
5339,NCT04192292,Difference in incretin effect between mixed meal tests,Variation in blood glucose during intervention blocks analysed by continuous glucose monitoring,,2019-10-08,COMPLETED,INTERVENTIONAL,['NA']
5340,NCT00571220,Change in incretin,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
5341,NCT02455076,Change in HbA1c Concentration Inpatient,Change in Diastolic Blood Pressure,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5342,NCT02971228,"Safety and Tolerability as Measured by Adverse Events, Local Tolerability of Infusion Site Reactions, and Clinical Laboratory Parameters",Bionic Pancreas User Opinion Survey,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5343,NCT04262661,Part 2: Number of treatment emergent adverse events,Maximum observed serum NNC0472-0147 concentration at steady state,,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5344,NCT04386187,gamma-glutamyltransferase (GGT),Triglycerides,Triglycerides,2020-07-28,COMPLETED,INTERVENTIONAL,['NA']
5345,NCT06187129,cross sectional area of peripheral nerves using nerve ultrasound,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5346,NCT05793788,Opening link within SMS Text message,Completion rate of one screening/test,,2023-03-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5347,NCT03387735,UCLA Loneliness Scale,Falls Requiring Medical Attention,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
5348,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
5349,NCT01029886,Change in HbA1c From Baseline to Week 26,Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5350,NCT02651480,Blood pressure,Quality of Life and Mood,,2016-02,SUSPENDED,INTERVENTIONAL,['NA']
5351,NCT03717233,Forefoot plantar pressure,Measures of fall risk,,2018-10-18,COMPLETED,INTERVENTIONAL,['NA']
5352,NCT01336322,Beta-cell function,Glucose control,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5353,NCT02622672,Fasting glucose,high sensitivity interleukin (hs-IL-6),,2016-01-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5354,NCT02586519,Rate of Wound Resolution,Complication Rates,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
5355,NCT00972452,"The overall aim of the project is to determine whether or not acute exercise training influences postprandial metabolic, vascular or autonomic nervous system responses in individuals with insulin resistance or T2D.",,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5356,NCT00976261,"Part B: Safety, tolerability parameters: adverse events, gastro-intestinal side effects, subject reported outcomes, clinical laboratory results, ECGs and vital signs",Part B: 3-O-Methyl-Glucose Kinetics,,2009-10-17,COMPLETED,INTERVENTIONAL,['PHASE1']
5357,NCT01892280,Change in glycemic control from baseline to 1 year,Psychosocial factors (self-report surveys),,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5358,NCT00935129,Treatment satisfaction,continuous glucose measurements,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5359,NCT03444064,Adverse Events,Stimulated C-peptide level,,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5360,NCT01058889,"System availability, acceptance, transmission rate",HbA1c,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5361,NCT01000519,"Hemoglobin A, Glycosylated (Hba1c). Measuring unit: percentage",Cholesterol,,2002-12,COMPLETED,INTERVENTIONAL,['NA']
5362,NCT02500706,Change From Baseline in HbA1c 26 Weeks After Randomisation,Change From Baseline in Body Mass Index 26 Weeks After Randomisation,,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5363,NCT01099163,glycosylated hemoglobin,oxidative stress (MDA),,2009-01,COMPLETED,INTERVENTIONAL,['NA']
5364,NCT01666028,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM) adjusted for sensor error.,"Number of episodes of hypoglycaemia, severe hypoglycaemia as well as nature and severity of any other adverse events.",Duration of use of the closed-loop system at home.,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5365,NCT05700513,Fasting blood glucose,High-sensitivity C-reactive protein level,,2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5366,NCT01235429,hemoglobin A1c,Quality of life,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5367,NCT03655535,2 hr PPG,Change in oral hypoglycemic medication,,2018-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
5368,NCT06098417,soluble biomarkers of liver fibrosis,Biobank,,2015-09-22,RECRUITING,OBSERVATIONAL,['NA']
5369,NCT02075307,DNA damage in peripheral blood mononuclear cells,Insulin resistance,Thiol/Redox changes,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5370,NCT02796378,Physical performance measured by VO2-max,Difference in mitochondrial function measured by respirometry,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
5371,NCT01545791,"Number of serious adverse drug reactions (SADRs), including major hypoglycaemic events",Quality of Life as assessed by a treatment satisfaction questionnaire,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
5372,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5373,NCT05145374,Measurement of Glucose Concentration,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
5374,NCT05411952,Change in mean of HbA1c from baseline to 6 months,Change in mean of Mediterranean Diet Quality Index Scale (KIDMED) from baseline to 6 Months,,2020-08-13,COMPLETED,INTERVENTIONAL,['NA']
5375,NCT00209417,Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.,Assessment of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-enhanced Multi-detector-row Helical Computed Tomography (MDCT) Examination.,,2005-06,TERMINATED,INTERVENTIONAL,['PHASE4']
5376,NCT01478737,Reoperation,Rebleeding,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5377,NCT02772926,Serum levels of Carboxymethyl-lysine,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
5378,NCT05836350,fasting plasma glucose levels,cardiac function: tricuspid regurgitation systolic jet velocity,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5379,NCT00424437,Primary outcome is 24 week change in baseline in HbA1c,Patient satisfaction and preference.,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5380,NCT04591704,Lung involvement,,,2020-03-20,UNKNOWN,OBSERVATIONAL,['NA']
5381,NCT02657083,"to evaluate the safety and efficacy of blood glucose control using the DreaMed MD-AID in children and adolescents with T1D during and after planned physical activity, in a controlled in-hospital environment.",to evaluate the physiologic responses and risk of hypoglycemia among children and adolescents with T1D after afternoon exercise during closed-loop control in a controlled in-hospital environment,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
5382,NCT02847091,Percent change from baseline in insulin dose,Safety assessed by biochemistry,,2016-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
5383,NCT05628662,Percentage of CGM time in glucose range 70-180 mg/dl during the study.,Number of acute metabolic events during the study,,2021-10-22,COMPLETED,INTERVENTIONAL,['NA']
5384,NCT06155487,"Part B (MAD): Heat pain tolerance (The Maximum temperature that the subject can tolerate, ℃)",Part B (MAD): Number of participants with SAE,,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE1']
5385,NCT01211847,Triglyceride-lowering efficacy of DCCR,Improvement in other lipid profiles with DCCR,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5386,NCT05563987,Change in Diabetes Distress Scale,Psychological flexibility,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
5387,NCT01536652,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
5388,NCT04404699,Correlation of stimulation TcPO2 parameters with the type of peripheral arterial flow,Correlation of stimulation TcPO2 parameters with macrocirculation parameters,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
5389,NCT05238012,HbA1c levels,non HDL-C levels,,2022-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5390,NCT01967186,C-peptide derived from the Mixed Meal Tolerance Test (MMTT),,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
5391,NCT02248454,"Predictors of fat ""sensitivity""",,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
5392,NCT03061227,Brain activity,Change in hormone levels,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
5393,NCT02109835,Greater than 20% increase in plaque volume,Greater than 20% increase in coronary artery calcium score,"Incidence of major adverse cardiovascular events (MACE) during the 18-month follow-up period. MACE is defined as incidence of cardiac death, non-fatal myocardial infarction, STEMI and NSTEMI, unstable angina, late revascularization and onset of angina",2012-09,UNKNOWN,OBSERVATIONAL,['NA']
5394,NCT00551590,To asses the effect of sitagliptin compared to placebo and to coadministration of sitagliptin and the GLP-1 receptor antagonist exendin(9-39)NH2 on the incretin effect after an oral glucose challenge.,"Plasma glucagon, plasma GIP, plasma GLP-1, Insulin, C-peptide, plasma glucose profiles. 13CO2 exhalation kinetics assessing gastric emptying",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5395,NCT04732611,Blood Glycose,Endothelial function,,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
5396,NCT04083339,Peak VO2 during cardio-pulmonary exercise test (CPET);,Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score,Changes in echocardiographic parameters,2019-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5397,NCT06330987,Fetal Autonomic Nervous sysTem Evaluation (FANTE),Obstetric Complications and mode of Delivery,,2019-08-13,RECRUITING,OBSERVATIONAL,['NA']
5398,NCT00351234,To see if the number of hypoglycemic events decreases with treatment of carnitine on type I diabetic patients. The measurements will be taken after the second 72-hour continuous glucose monitoring.,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
5399,NCT01322321,Measure: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 13 months,Measure: anti-ACZ885 antibodies,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5400,NCT05857007,Comparison of CGM with fingerstick blood glucose values in critical care setting.,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
5401,NCT06080542,Interstitial glucose,Lactate,PHYSICAL ACTIVITY,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
5402,NCT05184868,Area under Curve for Glucose Infusion Rate,,,2022-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5403,NCT04899271,Proportion of patients with HbA1c <7% and daily insulin requirement <0.50 IU/Kg/day,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),,2020-12-14,TERMINATED,INTERVENTIONAL,['PHASE2']
5404,NCT05421780,Change in blood amino acid concentration,Change in blood pressure,,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5405,NCT03042936,Change From Baseline Hemoglobin A1c,Change From Baseline Shuttle Run Speed,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5406,NCT00939250,Glycosylated Hemoglobin,Quick Inventory of Depressive Symptoms - Self Report,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5407,NCT01961024,VLDL-TG storage in adipose tissue,18F-THA fractional storage,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
5408,NCT00825643,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemia,Body weight and its change from trial start,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
5409,NCT04128995,Glycemic Control,Diabetic Kidney Disease,,2019-12-15,RECRUITING,INTERVENTIONAL,['PHASE4']
5410,NCT05974878,Functionality,Anxiety level,,2023-05-18,COMPLETED,INTERVENTIONAL,['NA']
5411,NCT02687256,Time to an infusion set failure due to an occlusion,signs of infection at insulin infusion site,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5412,NCT00906529,Length of Hospitalization Stay,Time to becoming medically stable for discharge,,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5413,NCT05069727,Time in Range( 70-180 mg/dl),Severe Hypoglycemia,Total Daily Insulin,2021-11-21,COMPLETED,INTERVENTIONAL,['NA']
5414,NCT04375449,Glucose-iAUC(0-180min),GLP-1-iAUC(0-120min),,2020-05-04,COMPLETED,INTERVENTIONAL,['NA']
5415,NCT00886366,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)","Pharmacodynamic variables (P-Glucose, S-Insulin and C-peptide)",,2009-04,TERMINATED,INTERVENTIONAL,['PHASE1']
5416,NCT01202461,Best-corrected visual acuity,Central subfield macular thickness,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5417,NCT01425255,sleep quality,Glycemic control,,2011-08,WITHDRAWN,OBSERVATIONAL,['NA']
5418,NCT02236754,Mean BPND (non-displaceable binding potential),,,2013-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
5419,NCT05115682,Exercise-induced Changes in 24 Hour Interstitial Glucose Concentration,Metabolic Response to Exercise,,2021-11-10,UNKNOWN,INTERVENTIONAL,['NA']
5420,NCT02248272,Serum levels of glucose,Lipidemic profile,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
5421,NCT03083795,Self-reported social support,Weight,,2017-04,UNKNOWN,INTERVENTIONAL,['NA']
5422,NCT03087877,Interference Effect for the G6 CGM,Duration of interference effect for the G6 CGM,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
5423,NCT04129268,Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
5424,NCT00838903,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104,Change From Baseline in Body Weight at Week 156,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5425,NCT03371082,Immunogenicity,Efficacy - The number and percentage of subjects who achieve a HbA1c of < 7.0%,,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3']
5426,NCT06191614,Change in fasting plasma glucose (FPG) after 12 of DEXINEURO® tab administration compared to baseline,,,2022-05-19,COMPLETED,OBSERVATIONAL,['NA']
5427,NCT03502031,Combination Therapy - RAAS inhibition and Spironolactone to lower UP/Cr,Combination Therapy - RAAS inhibition and Spironolactone that develop hyperkalemia,,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
5428,NCT02730377,Time to Inadequate Glycaemic Control,Change in Pulse,,2016-03-28,COMPLETED,INTERVENTIONAL,['PHASE4']
5429,NCT02241993,Difference between very large sensor accuracy errors (≥50% from reference glucose) with the simultaneous use of four sensors vs one sensor.,Difference between mean absolute relative difference with the simultaneous use of four sensors vs one sensor.,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
5430,NCT01855763,Neonatal morbidity,Maternal hypertensive complications,treatment acceptability and cost of drug,2008-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5431,NCT03197324,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),,,2017-07-24,COMPLETED,INTERVENTIONAL,['PHASE1']
5432,NCT02411682,Postprandial Glucose,Postprandial Free Fatty Acids,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
5433,NCT01007266,To evaluate the effect of a minimally invasive intervention (the buddy system) on hemoglobin A1c levels in adolescents with T2DM.,"To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.",,2009-10-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5434,NCT02689362,Absolute variation of the values obtained in the baseline for the HbA1c,"Absolute variation of the values obtained in the baseline for the parameter, body weight.",,2017-08-08,COMPLETED,INTERVENTIONAL,['PHASE2']
5435,NCT01375491,MMP Activity,CRP,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5436,NCT01868646,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5437,NCT00131846,New onset type 2 diabetes (WHO criteria 1998),Gout (American College of Rheumatology 1997 criteria C),,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5438,NCT02405767,Change in impedance,Impedance of different wound tissues,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5439,NCT00222846,Dietary adherence,Waist circumference,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
5440,NCT01921881,Glucose area under curve (AUC) 0-2 hours,Other metabolic markers,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5441,NCT05161897,"Change in glucose tolerance [Time Frame: baseline, 10 days, 20 days, and 30 days]","Change in dietary intake [Time Frame: baseline, 10 days, 20 days, and 30 days]",,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
5442,NCT05198674,Office Systolic Blood Pressure change at 6 months - Subgroup Diabetes (Type II),Evaluation of slope of eGFR,,2021-10-20,RECRUITING,INTERVENTIONAL,['NA']
5443,NCT01035281,To evaluate the efficacy of nabilone compared to placebo in the treatment of diabetic neuropathy-associated peripheral neuropathic pain (DPN).,To evaluate safety and tolerability of nabilone for the treatment of neuropathic pain in subjects with diabetic peripheral neuropathy.,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5444,NCT00116207,Global [11C]HED Retention Index (RI),Inflammation,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5445,NCT06110143,Prevalence of gestational diabetes,,,2021-11-13,RECRUITING,INTERVENTIONAL,['NA']
5446,NCT03926598,Participant Task Completion Rate for Usability Testing Session,,,2019-06-05,COMPLETED,OBSERVATIONAL,['NA']
5447,NCT05199077,percentage change,Changes of ECG examination results,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5448,NCT02487680,Area under the curve for Glucose after ingestion of a test meal,Area under the curve for insulin after ingestion of a test meal,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5449,NCT01158417,NF-Kb,GLP-1,,2008-12,TERMINATED,INTERVENTIONAL,['NA']
5450,NCT00736632,"Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP)",Urine Calcium to Creatinine Ratio.,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
5451,NCT02315092,Comparison of number/variety of bacteria obtained by fluorescence-guided sampling vs. standard practice,Assessment of the clinical functionality of the K2 Imaging Device,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
5452,NCT00266695,Sustained Moderate Visual Loss (SMVL),Number of Participants Receiving Treatment With Panretinal Photocoagulation,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5453,NCT05182359,The relation of prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) to CVD-T2D test risk assessment in the Informed group vs. Uninformed group.,"Survey of healthcare providers on the impact of SomaLogic's CVD-T2D calculator on patient care, medication prescription, and risk perception.",The change in prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) after revealing the Metabolic Factors test results at the end of the study in the Informed group.,2022-01-26,COMPLETED,INTERVENTIONAL,['NA']
5454,NCT01456195,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Meal Tolerance Test (MTT),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5455,NCT04271631,Change from Baseline Hb1A1c at 3 months,Self-Monitoring Blood Glucose,,2019-06-12,UNKNOWN,INTERVENTIONAL,['NA']
5456,NCT02388958,Postpartum weight change measured in kilograms,Change in dietary choices during versus after pregnancy measured with the Personal Diabetes Questionnaire,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
5457,NCT01594567,Blood Pressure (BP) Analysis,,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
5458,NCT00552903,For patients with diabetes: blood HbA1c at target level (7% or less),"Improvement in body mass index, health-related quality of life (15D instrument), amount of exercise, diet, smoking cessation; for patients with heart failure also use of emergency services and NYHA class",,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5459,NCT05254496,Changes in HgbA1c,Changes in blood pressure,,2022-04-04,RECRUITING,INTERVENTIONAL,['NA']
5460,NCT03527667,Proportion of CO readings completed,Cigarettes per day,,2018-06-22,COMPLETED,INTERVENTIONAL,['NA']
5461,NCT01039116,2 year change in insulin resistance via HOMA-IR,"Change in dietary intakes of energy, fat, carbohydrate and selected essential nutrients. Change in minutes/day spend in moderate- and high-intensity physical activity. Improvement or stabilization of self-esteem.",,2005-03,COMPLETED,INTERVENTIONAL,['NA']
5462,NCT01351181,SPAQ score,,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
5463,NCT01714895,Normalized current signal from the CGM devices,,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
5464,NCT02490085,Percentage of time of plasma glucose concentrations spent in the target range,Number of patients experiencing at least one hypoglycemic event requiring treatment,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5465,NCT03224234,Number of Participants Experiencing Insulclock Device Malfunctions,Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) Score,,2017-11-29,COMPLETED,INTERVENTIONAL,['NA']
5466,NCT02768506,Weight loss,Diabetes remission,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
5467,NCT01196728,Safety measurements,PK samples for CM3.1-AC100,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5468,NCT03609697,Percent weight change,Carotid artery intima-media thickness (cIMT),,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5469,NCT00001733,,,,1998-03-06,COMPLETED,OBSERVATIONAL,['NA']
5470,NCT03091920,Change From Study Baseline Over Time in Estimated Glomerular Filtration Rate (eGFR),,,2017-02-28,COMPLETED,INTERVENTIONAL,['PHASE2']
5471,NCT03365531,Hepatic Triglyceride by MRS,Diet Tolerability,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
5472,NCT02709707,Accuracy of blood glucose measurements as performed by lay users,Assessment by lay users of the ease of use of the iGlucose Blood Glucose Monitoring System,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
5473,NCT00133718,Reduction in 10-year absolute CHD risk,Effects on health related quality of life,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5474,NCT02641184,Major adverse cardiovascular events (MACE),New-onset diabetes,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
5475,NCT05001815,Time in range (TIR) at 34 weeks of gestation,"Questionnaires (Self-rated Depression Scale, SDS)",,2021-12-15,UNKNOWN,INTERVENTIONAL,['NA']
5476,NCT02764021,Changes in glycated hemoglobin (HbA1c) at the end of 6 weeks of isoenergetic low carbohydrate diet compared to 6 weeks of the recommended antidiabetic control diet.,Changes in insulin-like growth factor-binding protein 3 (IGFBP-3) at baseline to week 6 will be compared to changes from week 6 to 12. Changes in IGFBP-3 will be assessed from week 12 to 36.,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
5477,NCT05797285,Wound Closure,Change in Quality of Life,Number of Adverse Events Observed,2023-02-28,COMPLETED,INTERVENTIONAL,['NA']
5478,NCT02481141,Change From Baseline in Fasting Blood Glucose,Change From Baseline in Triglycerides (Component of Lipid Profile),,2014-07,COMPLETED,INTERVENTIONAL,['NA']
5479,NCT01190904,Composite outcome of all-cause mortality,MACCE,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
5480,NCT00660309,Change From Single Dose Peak to Steady State Peak in Renal Plasma Flow (RPF) After Aliskiren or Irbesartan,Change From Baseline in Retinal Blood Flow After Aliskiren or Irbesartan,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5481,NCT02113163,"AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa",,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5482,NCT02420054,Change of insulin secretion,Insulin signalling cascade proteins,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
5483,NCT02282423,Transcription Factor Response to Exercise,,,2014-05,TERMINATED,INTERVENTIONAL,['NA']
5484,NCT05603793,Stunting,Bone age,Household Dietary Diversity Scale (HDDS),2022-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5485,NCT01724554,Mean Change in Capillary Non-Perfusion,,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5486,NCT00714441,"Distress. Patient distress will be assessed across several measures including: the 20-item CES-D, the 17-item DDS, the PHQ8, and screening items from the SCID to rule out psychosis.",Lipids,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5487,NCT00418522,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population,"Change From Baseline in Diabetes Treatment Satisfaction Questionnaire-Status, Diabetes Treatment Satisfaction Questionnaire-Change, Diabetes-39, Mental Health Inventory-17, and SF-36 Vitality Domain Questionnaire",Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5488,NCT02516358,Change in glycaemic blood levels during ICU stay,Neuron Specific Enolase (NSE) blood levels and glycaemic disorders,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
5489,NCT04456166,Incidence of gastric ultrasonography score as low risk (grade 0 or 1),The incidence of nausea and vomiting,,2020-06-22,COMPLETED,OBSERVATIONAL,['NA']
5490,NCT00820807,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",,2009-01,TERMINATED,INTERVENTIONAL,['NA']
5491,NCT01613807,Hemoglobin A1C,Birthweight of Infant,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5492,NCT01203774,HbA1c at Three Months of Each Period of Treatment,Compliance and Patient Satisfaction,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5493,NCT04417127,Viral Suppression,Change in glycated hemoglobin (HbA1c),,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5494,NCT02061059,The cost-effectiveness of shoes produced with and without plantar pressure measurements.,Differences in plantar pressures between the two shoes produced.,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
5495,NCT00231725,To collect complaint data on the Pre-filled Pen B when used by persons with type 2 diabetes to self-administer insulin in take-home situations for 2 months.,To assess overall patient perception of the device's performance through a patient questionnaire.,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5496,NCT02467998,Healing,Side effects and adverse Events During Therapy,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
5497,NCT04101383,AUC(0-t),,,2017-10-16,COMPLETED,INTERVENTIONAL,['NA']
5498,NCT00442767,"Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone","Measure of Glucagon Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone.",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5499,NCT01301456,Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements,Number of Participant With Anti-Drug Antibodies (ADA): Stage 2,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5500,NCT04410419,Mean difference of preoperative glucose between the two groups,Rate of peri-operative insulin use,,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5501,NCT01153516,Response in Glucagon AUC at Baseline vs. Following Gastric Bypass,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
5502,NCT03845179,C-peptide,Lipids,heart rate,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
5503,NCT02643277,Comparison of the glycaemic outcome measured as improvement in HbA1c (≤ 7.0% (53mmol/mol)) in the intervention group in comparison with the conventional care.,Adherence to the prescription,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
5504,NCT03188835,BAT triglyceride content,hormonal responses,,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
5505,NCT06074458,Change in percentage of participants who remain on AID as measured by medical record review,Episodes of severe hypoglycemia as measured by chart review,,2024-01-29,RECRUITING,INTERVENTIONAL,['NA']
5506,NCT03433573,Point Accuracy Determined as % within Consensus Error Grid Zone A,,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA']
5507,NCT04006392,Participants With a 30% or Greater Change in Visual Analog Scale (VAS) Pain Scores,,,2019-02-15,TERMINATED,INTERVENTIONAL,['NA']
5508,NCT06335225,HbA1c,Waist hip ratio,,2024-03-13,RECRUITING,INTERVENTIONAL,['NA']
5509,NCT01389505,Functional Macular Evaluation,Structural Macular Evaluation,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
5510,NCT02458027,Blood Pressure,Energy/Fatigue,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
5511,NCT01843959,"Percentage of the population in the U.A.E that are positive for adenovirus -36, specifically in children.",,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
5512,NCT00911833,,,,2009-05-19,COMPLETED,OBSERVATIONAL,['NA']
5513,NCT02115412,Adherence determinants,Medication usage,Adverse Events,2014-07,COMPLETED,OBSERVATIONAL,['NA']
5514,NCT01755416,"Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone",,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5515,NCT02008942,Time to 99% Inhibition of Serum Thromboxane,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5516,NCT03006081,Improvement of retinal nonperfusion,Factors associated with the progression of retinal nonperfusion 3 (Anatomical),Safety outcome; Adverse effect of intravitreal aflibercept (Eylea) injection,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
5517,NCT00730275,Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin,Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo,,2008-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
5518,NCT02087124,Dose-response of whey protein as pre-meal on apolipoprotein B48 after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min),Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min),Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -15 - 360 min),2014-03,COMPLETED,INTERVENTIONAL,['NA']
5519,NCT00069576,Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex,Number of Children at 5-10 Year Follow-up With Impaired Fasting Glucose ≥100 mg/dL,Mean Gestational Age at Birth,2002-10,COMPLETED,INTERVENTIONAL,['NA']
5520,NCT05854251,Change in insulinogenic index (IGI) concentration following a standardized mixed-meal test,,,2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE2']
5521,NCT03550443,Time to onset of a ≥ 30% decrease in eGFR from baseline or ESRD,Change in eGFR from baseline at each evaluation time point,,2018-05-30,TERMINATED,INTERVENTIONAL,['PHASE3']
5522,NCT01747083,Cmax,AUClast,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5523,NCT06124495,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2023-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
5524,NCT00228904,To evaluate objective testing performed including nerve conduction velocity in diabetic patients treated with pulsatile intravenous insulin therapy,"To obtain patient questionnaires and perform objective testing to analyze, compare and measure progress",,2005-02,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5525,NCT02662010,Change in Advanced Glycation Endproducts (AGE) Levels,Change in HbA1C Levels,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
5526,NCT04465721,Adherence,Lipid profile,,2021-06-14,RECRUITING,INTERVENTIONAL,['NA']
5527,NCT01581476,Albumin creatinine ratio,Quality of Life and Health Economics,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5528,NCT01499511,Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack),Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
5529,NCT01479075,Insulin sensitivity,Energy metabolism,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5530,NCT03956173,QTc prolongation.,Oxidative stress markers (8-oxoGuo),,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
5531,NCT03009864,changes of albumin-to-creatinine ration,the rate of doubling the baseline with serum creatinine value,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
5532,NCT01038050,"Number of endothelial progenitor cells, endothelial function(FMD)",,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
5533,NCT00135096,"Compare change in weight from baseline to study week 52 in the per-protocol population of premeal Apidra vs postmeal Apidra, in patients receiving Lantus as basal insulin",,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5534,NCT05483816,Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) between somatotopic and non somatotopic stimulation at feet,changes in speed and cadence in the 10 meter and 6 min walk test,Changes in reflex,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
5535,NCT00573261,Assessing the Change of Parameters of Autonomic Nerve Function Such as Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.,To Assess the Change in Disability Scale Upon Treatment of Pregabalin in Comparison to Placebo.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5536,NCT04414280,Time in range,The Parent's fear of hypoglycemia scale - modified version of the Hypoglycemia Fear Survey for use with parents,"Correlation between 'duration of type 1 diabetes of the patient (years)' and 'quality of life in partners of T1D patients using hybrid closed-loop therapy', the latter being measured by the DIDP-FM questionnaire. Note: only in case of substudy",2020-03-12,RECRUITING,OBSERVATIONAL,['NA']
5537,NCT04875780,Percent weight change,User feedback as assessed by an online exit questionnaire,Diabetes incidence,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
5538,NCT01043354,medication adherence,exercise adherence,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
5539,NCT03767478,"Primary outcome measure: sural nerve conductivity measured using a nerve conduction study at 6 months. This includes conduction velocity (m/s), calculated using distance and latency (ms), and sensory nerve action potential (SNAP) amplitude (μV).",Secondary outcome measure: device credibility and expectancy measured using modified credibility and expectancy questionnaire.,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5540,NCT01596504,Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours,Change From Baseline to Day 56 in the Cumulative Score Mean on the Appetite Perception Using a Visual Analogue Scale After Standardized Solid Breakfast,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5541,NCT00549887,"The estimation of the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and a short-acting human insulin therapy within the first year following the switch.","The estimation of the total costs (direct and indirect) associated with switching, in either direction, between rapid-acting analog and short-acting human insulin within the first year following the switch",,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5542,NCT01711385,Occurrence of follow-up visit to physician regarding screening result,Improved periodontal measures,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
5543,NCT00035750,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
5544,NCT06159192,• Numerical Rating Pain Scale,,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
5545,NCT03015519,Time to reach half of the maximum plasma concentration (t1/2) of albiglutide: Part A,Change from Baseline in Children's Depression Inventory 2 Self Report Short Version [CDI 2: SR(S)],,2017-08-14,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5546,NCT02070835,healing rate,recurrent rate,complication rate,2014-04,COMPLETED,INTERVENTIONAL,['NA']
5547,NCT00385671,"Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine",Number of Patients With Treatment-Emergent Elevated Laboratory Analytes,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5548,NCT00135941,"To compare improvements from baseline in patient reported outcomes (quality of life, treatment satisfaction) when aggressively treated with insulin glargine plus rapid acting insulin glulisine vs treatment with Premix insulin","change in A1c (baseline to week 24), reported hypo events (throughout the trials), correlation between patient reported outcomes and glucose variability as measured by CGMS (baseline, week 8 and week 20).",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5549,NCT04590833,Processing speed,BMI,,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA']
5550,NCT04817215,Mean change from baseline (Visit 1) in A1C at 26 weeks,Safety of repeat administration of ORMD-0801 in inadequately controlled T2DM subjects,Means and mean changes from baseline over time for C-peptide,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5551,NCT05195333,World Health Organization Quality of life Short Form for measurement of quality of life,Body mass index (BMI) measurement,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
5552,NCT05786703,CHANGE IN BLOOD PRESSURE LEVEL,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
5553,NCT02310932,cholesterol,medication adherence,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5554,NCT06033508,inflammatory markers,,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5555,NCT02503943,"Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) change","Insulin resistance assessed by fasting serum insulin and HOMA-IR, and control rate of diabetes.",,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
5556,NCT06111183,Incidence of Wound Closure,Incidence of target ulcer related hospital visits,,2023-07-21,RECRUITING,INTERVENTIONAL,['PHASE2']
5557,NCT00417950,Postprandial hyperglycemia,Postprandial oxidative stress,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
5558,NCT01793350,Efficacy of BC-DN-01,Safety of BC-DN-01,,2013-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5559,NCT05331339,HbA1c,Mean fasting glucose,,2022-11-02,COMPLETED,OBSERVATIONAL,['NA']
5560,NCT03349944,HbA1c,Oral glucose tolerance test,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
5561,NCT02325271,Placental growth factor,Blood pressure,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
5562,NCT03374774,Proportion of patients who are using BIAsp 30 as their primary insulin,Diabetes Pen Experience Measure (DPEM) Scores (frequency of each item),,2017-11-13,COMPLETED,OBSERVATIONAL,['NA']
5563,NCT00821665,Hyperglycemia,Hyperglycemia,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
5564,NCT01217112,The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment,The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5565,NCT01303315,Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment,Glycemic and metabolic parameters,,2011-01,TERMINATED,INTERVENTIONAL,['NA']
5566,NCT02650596,left ventricular ejection fraction measured by 3D echocardiography,differences in the incidences of treatment-emergent adverse events,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
5567,NCT02762695,Systolic and Diastolic Blood Pressure,Medication adherence,,2016-05-04,UNKNOWN,INTERVENTIONAL,['NA']
5568,NCT01977859,Difference in level of B-type Natriuretic Peptide (BNP),Difference in responses of lean and obese subjects,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5569,NCT01533142,weight loss,remission of diabetes mellitus type 2,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
5570,NCT02343354,Change in post 75 gram glucose load 2-hour glucose value in mothers and fathers,Change in diastolic blood pressure in mothers and fathers,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
5571,NCT03972215,Differences of serum C-peptide levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Differences of blood glucose levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Heart rate and QT-interval duration using electrocardiogram before and after drug treatment.,2019-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5572,NCT01643382,Incidence of Poor Graft Function After Kidney Transplant,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
5573,NCT01891474,Glucose Variability assessed by 3 day SMBG,Michigan Diabetes Knowledge Test,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
5574,NCT04277780,# od hospital re-admissions,Severity of first hypoglycemic event,,2018-10-31,TERMINATED,INTERVENTIONAL,['NA']
5575,NCT02871817,Amsler Grid,Assess repeatability of mobile application testing,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
5576,NCT06007508,Does early administration of insulin glargine result in a change in ICU length of stay when compared to usual care for the treatment of diabetic ketoacidosis?,The change in duration of elevated anion gap when compared to usual care,,2022-05-31,TERMINATED,INTERVENTIONAL,['PHASE2']
5577,NCT00576667,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in hepatic transaminases (AST/ALT),,2008-01,TERMINATED,INTERVENTIONAL,['PHASE3']
5578,NCT02471040,Cognitive Function,,,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE1']
5579,NCT05543083,Insulin Resistance,Adiposity,Intervention Acceptability,2023-06-02,RECRUITING,INTERVENTIONAL,['NA']
5580,NCT01339637,Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals,Compare SCOUT DS and FPG to HbA1c,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
5581,NCT05164263,SAFETY and TOLERABILITY Outcomes,Efficacy outcomes,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE4']
5582,NCT00316667,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
5583,NCT01638260,Change in weight from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks),Health-care related costs,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE4']
5584,NCT02849899,Diabetes event,The cost-effectiveness ratio,,2018-10-26,RECRUITING,INTERVENTIONAL,['PHASE3']
5585,NCT03313856,Modification in HbA1c in patients with type 2 diabetes after of administration of combination with Guazuma ulmifolia and Tecoma stans,"Renal safety of administration of guazuma, tecoma through the determination of serum creatinine",,2010-01-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5586,NCT01185574,Metabolic control,depressive symptoms,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5587,NCT01496820,Postprandial blood glucose(PPG),HDL-cholesterol,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5588,NCT05801432,The change in coronary atherosclerosis detected by initial and follow-up CCTA,,,2021-08-24,RECRUITING,OBSERVATIONAL,['NA']
5589,NCT01142895,,,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
5590,NCT00222768,Method development of dose-responsive measurement of insulin-stimulated glucose uptake of adipose tissue using 18-FDG and Positron Emission Tomography,To assess regional variation in insulin-stimulated glucose uptake in adipose tissue.,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
5591,NCT05492071,Brachial Artery Mean Flow Velocity,,Magnitude of Maximum Mean Flow Velocity Change,2022-08-08,COMPLETED,INTERVENTIONAL,['NA']
5592,NCT06178094,Waist circumference value,,,2022-02-21,COMPLETED,INTERVENTIONAL,['NA']
5593,NCT01824017,The consistency of an ELISA-based RLIP76 assay in the serum of human subjects with metabolic syndrome.,"Effect size of correlation of RLIP76 levels with treatment measures of metabolic syndrome such as hemoglobin A1c, LDL, and triglyceride levels.",,2012-12,COMPLETED,INTERVENTIONAL,['NA']
5594,NCT02420262,Change in HbA1c (Glycosylated Haemoglobin),Responder for HbA1c Below or Equal to 6.5 %,,2015-07-26,COMPLETED,INTERVENTIONAL,['PHASE3']
5595,NCT00999375,"Change in glycemic control, change in dietary intake","Change in social cognitive mediators of behavior; change in psychosocial status; change in body composition, lipids, oxidative stress, and inflammation",,2009-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
5596,NCT02206607,Change From Reference in Weighted-Mean-Daily-Glucose (WMDG) on Day 1,Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5597,NCT06037486,Analysis of system accuracy based on DIN EN ISO 15197,,,2022-10-17,COMPLETED,INTERVENTIONAL,['NA']
5598,NCT05392231,Early prediction of gestational diabetes,,,2022-02-10,COMPLETED,OBSERVATIONAL,['NA']
5599,NCT00804596,Percentage of Participants Rated as <=3 (Comprehension of Labeling),Number of Capillary Blood Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
5600,NCT05851820,overall length of hospital stay,,,2020-09-25,COMPLETED,OBSERVATIONAL,['NA']
5601,NCT02312063,Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction,Correlation of Estimated Seafood Intake With HbA1c Reduction,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5602,NCT02371694,Glycaemic excursion,Number of hypoglycaemic events in the 24h post-test meal,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5603,NCT04556851,HbA1c change from baseline at week 24,Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia,,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE3']
5604,NCT05243160,PANSS-6 (positive and negative syndrome scale),Adverse interactions,,2022-02-11,UNKNOWN,INTERVENTIONAL,['NA']
5605,NCT05230615,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction From baseline (week 0) to",,2021-11-21,COMPLETED,OBSERVATIONAL,['NA']
5606,NCT04267770,Change in Basal Insulin Rate,,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA']
5607,NCT05565924,The functional balance,Fasting blood glucose level,,2022-01-02,COMPLETED,INTERVENTIONAL,['NA']
5608,NCT01353391,"A composite of: pregnancy loss, preterm birth, birth injury, moderate/severe respiratory distress, neonatal hypoglycemia, and NICU admission > 24 hours.",Shoulder dystocia,,2011-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
5609,NCT03161327,Positive Predictive Value of Digital ABI in Diagnosing PAD,,,2017-07-15,COMPLETED,INTERVENTIONAL,['NA']
5610,NCT03123237,Renal Counts,,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
5611,NCT02204839,24 hour blood glucose area under the curve,Ketonaemia,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5612,NCT01573949,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
5613,NCT04124484,HBA1c,body weight,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
5614,NCT00926068,Complete ulcer closure,Incidence of improved ulcers,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
5615,NCT02979860,Insulin Resistance,Metabolic Measures,Acceptability/Feasibility,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
5616,NCT02131246,Mean plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5617,NCT00497003,Endothelial function and insulin stimulated endothelial function,Insulin stimulated glucose uptake,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5618,NCT03864432,Cmax of Gemigliptin,,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5619,NCT03359590,The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment.,,,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5620,NCT03145649,Infant head circumference at day 90,,,2010-01-12,COMPLETED,OBSERVATIONAL,['NA']
5621,NCT03215043,Glucose,alanine aminotransferase,visceral fat area,2017-07-02,COMPLETED,INTERVENTIONAL,['NA']
5622,NCT04114903,Change in Plasma Insulin,Stanford Leisure-Time Activity Categorical Item (L-Cat),"Daily online survey of cannabis use, alcohol use, exercise and diet",2019-11-08,RECRUITING,OBSERVATIONAL,['NA']
5623,NCT04161170,Change of HbA1c (glycated hemoglobin) at 6months from baseline,time in range of >250 mg/dL by CGMS in interventional group C,,2019-11-20,UNKNOWN,INTERVENTIONAL,['NA']
5624,NCT05542537,Household Food Insecurity as assessed by the U.S. Department of Agriculture self-report food insecurity measure,Skin carotenoid level as assessed by The Veggie Meter,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5625,NCT04626089,Viral Load,Incidence of adverse event,,2021-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5626,NCT01105429,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",Excretion of the investigational drug and metabolites from the body,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5627,NCT05174078,Change in participants' body weight,Nutrition Education: Self-Efficacy for Managing Chronic Diseases Scale,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5628,NCT02645448,Concentration of glucose and hyperglycemia prevalence,Correlation between heart rate variability and glucose 24 hours,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
5629,NCT03782155,Wound healing:Number of cells per clauster in tissue sample of wound.,,Incidence of treatment- adverse events,2021-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5630,NCT03890822,Minimal lumen area,Change in minimal lumen area,,2019-03-25,UNKNOWN,OBSERVATIONAL,['NA']
5631,NCT02710617,System accuracy criteria (see description),,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
5632,NCT00205725,Effects of olanzapine/ziprasidone/haloperidol on glucose regulation,Explore treatment-related effects on glucose effectiveness,,2000-11,COMPLETED,INTERVENTIONAL,['NA']
5633,NCT00783744,Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 %,"Frequency of subjects with FBG ≤ 100 mg/dl (5.5 mmol/l), 100 mg/dl < FBG ≤ 120 mg/dl (5.5 mmol/l < FBG ≤ 6.6 mmol/l), 120 mg/dl < FBG ≤ 150 mg/dl (6.6 mmol/l < FBG ≤ 8.3 mmol/l) and > 150 mg/dl (> 8.3 mmol/l)",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5634,NCT02426294,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 26 from baseline,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 12 from baseline,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5635,NCT01788241,Patient Perceived Health Status,Biochemical correlates,,2009-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5636,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),,,2015-04-01,RECRUITING,OBSERVATIONAL,['NA']
5637,NCT00788853,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2008-11,COMPLETED,OBSERVATIONAL,['NA']
5638,NCT02211261,Number of Participants With Positive Anti-drug Antibody (ADA) Result,"Observed Accumulation Ratio Based on Cmax (Rac,Cmax) of PF-06293620 (MAD Cohorts)",,2014-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
5639,NCT04734015,Change in Adult Participant Fasting HbA1c,Change in Depression and Depressive symptoms - Adult and Youth participants,Change in Diabetes Empowerment - Adult participants,2021-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5640,NCT05377268,Assessment of lipohypertrophy by US machine,,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5641,NCT00145392,,,,2002-09,COMPLETED,OBSERVATIONAL,['NA']
5642,NCT02079376,improvement of HbA1c,Relationship between blood TG level and the GCM efficacy,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
5643,NCT04156685,Part B : AUClast under fed condition,Part B : t1/2 under fed condition,,2019-08-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5644,NCT06258148,Changes in glycosylated hemoglobin (HbA1c) from baseline at 24 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
5645,NCT02724566,Delta between Glucose Infusion Rate,Clinic sign of apelin toxicity,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5646,NCT04955691,Time in the optimal glucose range,Time spent with hyperglycemia,Human Factors,2021-07-29,RECRUITING,INTERVENTIONAL,['NA']
5647,NCT01967030,Incident Type 2 Diabetes,Maternal waist circumference,Metabolite profiles,2008-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5648,NCT02326259,Progression of diabetic retinopathy,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
5649,NCT03474393,Change in HbA1c,DTSQ,,2018-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5650,NCT03237767,Glycaemic control (measured using arm-mounted Freestyle Libre continuous glucose monitor),Physical activity,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
5651,NCT04170790,Heart Rate,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
5652,NCT05880654,Effect of SRP on GCF levels of IL-39 & IL35,,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
5653,NCT00005487,CVD,,,1999-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5654,NCT04631965,Emergency admissions,Change in employment status,Adolescent-friendliness of healthcare services in pediatric and adult hospitals,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5655,NCT04973644,HbA1c concentration,Diabetes Treatment Satisfaction Questionnaire,,2021-08-21,UNKNOWN,INTERVENTIONAL,['NA']
5656,NCT05099770,Primary Composite Endpoint,Secondary Composite Endpoint,,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5657,NCT01515930,Diabetes Management Scale,Blood Glucose Testing Frequency,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
5658,NCT02623478,Pharmacokinetics (PK): Area under the Concentration Curve (AUC) of Insulin Lispro,Pharmacodynamics (PD): AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5659,NCT04272840,Transfer/KM Level 3: Change in average dietary GI,"Maternal Weight, during pregnancy",,2019-10-24,UNKNOWN,INTERVENTIONAL,['NA']
5660,NCT03014479,Change From Baseline in Total Score for All Question Items in the Diabetes Therapy Related -QOL (DTR-QOL) Questionnaire at the End of Study,Number of Participants With Hospitalization for Type 2 Diabetes (Excluding Educational Hospitalization Without Worsening of Diabetes),,2017-02-18,COMPLETED,INTERVENTIONAL,['PHASE4']
5661,NCT01401790,Patients' health (reported number of hypoglycemias and nocturnal hypoglycemias),Family satisfaction with the software application,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
5662,NCT05590442,The rate of mild cognitive impairment occurrence,Montreal Cognitive Assessment (MoCA) score,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
5663,NCT04829045,Homeostasis model assessment- insulin resistance (HOMA-IR),Incident of treatment adverse events in terms of intensity (grades 1 - 5),,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
5664,NCT00198757,at 52 weeks of maintenance,changes in medication costs and health related quality of life.,,2002-07,COMPLETED,INTERVENTIONAL,['NA']
5665,NCT05516797,Difference in change in 14-day CGM-derived TIR,Difference in Change in HbA1c,"Difference in change in the CGM-derived metric, Mean amplitude of glucose excursion, from Baseline to 3-month Post-Dietary Change period",2022-09-22,COMPLETED,INTERVENTIONAL,['NA']
5666,NCT02971865,Consumer Assessment of Healthcare Providers and Systems (CAHPS),Patient Health Questionnaire-9 (PHQ-9,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5667,NCT00926744,Objectively measured amount of physical activity,Incidence of musculoskeletal and joint pain,,2006-04,UNKNOWN,INTERVENTIONAL,['NA']
5668,NCT01002768,Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration,Hypoglycaemic symptoms score during recovery from hypoglycaemia,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5669,NCT00597233,Prandial blood glucose lowering profile,Serious adverse events,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5670,NCT00726778,"To test phenotype-genotype associations between each one of the AIMs and measures of FI, SI and AIRg after adjusting for body composition in a sample of AA, HA and EA prepubertal children.",,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
5671,NCT00843479,Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects.,GLP-1 Area Under the Curve (AUC),,2009-06,COMPLETED,OBSERVATIONAL,['NA']
5672,NCT02381119,change in fasting insulin levels,20 nutrition-related SNPs (single nucleotide polymorphisms),,2015-05,COMPLETED,INTERVENTIONAL,['NA']
5673,NCT04344301,Acceptability of Intervention Measure (AIM),,Stigma Scale for Chronic Illness (SSCI-8),2020-08-31,COMPLETED,INTERVENTIONAL,['NA']
5674,NCT01023698,Stabilization of proliferative diabetic retinopathy,,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
5675,NCT04091854,C peptide,8-iso PGF2α,,2018-12-12,UNKNOWN,OBSERVATIONAL,['NA']
5676,NCT02467972,Change in satiety,Change in biochemical parameters,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5677,NCT03318913,High performance liquid chromatography,,,2017-10-23,COMPLETED,INTERVENTIONAL,['NA']
5678,NCT03468894,Change in Workplace sitting time,Change in perceived vigor,,2018-03-22,WITHDRAWN,INTERVENTIONAL,['NA']
5679,NCT04485871,Fasting white adipose tissue NLRP3 inflammasome activation,Physical activity,,2019-12-19,RECRUITING,INTERVENTIONAL,['NA']
5680,NCT05863884,Blood Glucose Level,Diabetes Self-Management Score,COVID-19 Vaccination Confidence and Uptake,2022-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5681,NCT00766909,Insulin Sensitivity,plasma glucagon,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5682,NCT01561508,change in stimulated c-peptide,change in total daily insulin dose per kilogram,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5683,NCT03027726,microRNA expression in circulating exosomes and in blood peripheral mononuclear cells,Inflammation and biochemical cardiovascular disease risk factors,Confounding variable: Socio-demographic variables:,2017-03-07,COMPLETED,INTERVENTIONAL,['NA']
5684,NCT04257565,Wound Healing,Physical Function,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
5685,NCT05663931,Mean glucose levels,Infection,,2023-01-10,RECRUITING,INTERVENTIONAL,['NA']
5686,NCT00822198,intraepidermal nerve fiber density in ankle and thigh,clinical assessment of peripheral neuropathy,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
5687,NCT02081599,Change From Baseline in HbA1c,Change From Baseline in 2-hour Postprandial Plasma Glucose,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5688,NCT03298542,Number of Participants With Treatment Related AEs and SAEs Reported From Week 52 to Week 78,Incidence of Antibodies to Golimumab,,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
5689,NCT00770835,Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).,Urinary albumin excretion.,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5690,NCT05662930,Heart Rate,Health related Quality of life,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
5691,NCT04919954,Tebipenem Pivoxil Hydrobromide Tissue Penetration,Tebipenem Pivoxil Hydrobromide Area Under the Curve (AUC) in Tissue,,2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5692,NCT05120388,number of participants with insulin requirement,number of participants with diabetes at postpartum,,2022-01-11,RECRUITING,INTERVENTIONAL,['NA']
5693,NCT03651622,Change in Time in Clinical Hypoglycemia - Randomization 3,Change in Time in Target Glucose Range - Randomization 3,,2018-11-12,COMPLETED,INTERVENTIONAL,['NA']
5694,NCT05163054,Incidence of hypoglycemia,Life quality.,,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5695,NCT00430755,"Detection of Medical Problems (by Number of Problems Reported by Computer Assisted History, That Were Not Reported by Physician Taken History)",,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
5696,NCT02295085,Incident cancer during the period of cohort follow-up,Incident renal disease during the period of cohort follow-up,Other incident conditions during the period of cohort followup,1990-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5697,NCT05282680,Cardiovascular complications in diabetes,Diabetes progression,,2014-02-01,RECRUITING,OBSERVATIONAL,['NA']
5698,NCT03867773,Change from baseline to week 8 in body weight,"Change from baseline to week 8 in sex steroid levels (estrogen, androgens, sex hormone binding globulin)",,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
5699,NCT00108901,Cognition (Executive function),Academic achievement,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5700,NCT00468364,,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
5701,NCT04653220,Change in postprandial blood glucose over 240 minutes period,Change in postprandial plasma active GLP-1 over 240 minutes period,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
5702,NCT01095965,HbA1c as a measure of glycemic control,Body mass index,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
5703,NCT00995540,Injection tolerability,C-peptide,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5704,NCT02545062,The differences between the MoCa test score in diabetics and in a control group of non diabetics,"The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease",,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
5705,NCT00364377,Lowering of Fasting Glucose,,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5706,NCT02982798,Cmax of Metformin and rosuvastatin,,,2017-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5707,NCT00455598,Change and % change from baseline Adiponectin,concomitant medications,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5708,NCT01714102,Reduction in Insulin resistance,Changes in gene expression in stool,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5709,NCT01600937,Physical Activity Behavior,Musculo-skeletal disturbances,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5710,NCT03550105,Glycemic Control,Carry Over Effect of Muscle Endurance,,2018-06-05,COMPLETED,INTERVENTIONAL,['NA']
5711,NCT03037970,Successful wound healing for at least two consecutive measurements. (Efficacy),Complication rate,,2017-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
5712,NCT02104804,Change in HbA1c From Baseline to Week 24,Analysis of Change in Mean Total Daily Dose of Insulin From Baseline to Week 24,,2014-05-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5713,NCT03708380,Continuation with the dietary intervention after initial period when study participants may choose to pay for meals developed on their own,Fourth Point-of-Care HbA1c Test,,2019-03-25,TERMINATED,INTERVENTIONAL,['NA']
5714,NCT04424537,Change in fasting blood glucose level,Change in Muscle function as measured by relative power of jump,,2024-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
5715,NCT01517321,"Incidences of adverse experiences and change in vital sign, safety lab etc. as parameters of safety and tolerability",Fasting plasma glucose,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
5716,NCT00657319,HbA1C,"General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)",,2007-10,COMPLETED,OBSERVATIONAL,['NA']
5717,NCT03343782,Adverse events,Hemoglobin A1c (HbA1c) level,,2017-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5718,NCT02200666,Adverse event incidence,,,2014-10-03,COMPLETED,OBSERVATIONAL,['NA']
5719,NCT02403427,postprandial glucose,Glucose variability parameters,Patients' acceptances to use VoiceDiab system,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
5720,NCT00684086,self-efficacy to manage diabetes,communication with physicians,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
5721,NCT05721599,Change from baseline calf circumference,,,2023-04-13,RECRUITING,INTERVENTIONAL,['NA']
5722,NCT01834378,HOMA IR,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5723,NCT00461331,Number of Participants With Glycemic Control (Glucose Levels Between 180-300 mg/dL) 24 to 100 Hours After Line Change,"Oxidative Stress Marker 48, 72 and 96 Hours After Keeping the Same Pump Infusion Line in Place",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5724,NCT05442918,Venous blood gas levels,,,2020-01-15,COMPLETED,OBSERVATIONAL,['NA']
5725,NCT04709887,Healing rate of wound surface,Recurrence rate of foot ulcer,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
5726,NCT00638716,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5727,NCT02586155,Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE,Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2),,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5728,NCT03969719,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16,Change From Baseline in HbA1c at All Timepoints Other Than Week 16,,2019-07-18,COMPLETED,INTERVENTIONAL,['PHASE2']
5729,NCT05041244,Wound closure,Adverse events,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
5730,NCT00128336,Weight,Change in mood state,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5731,NCT03622957,Glomerular Filtration Rate [ml/min/1.73m2],CV Events (Yes/No),,2018-08-10,UNKNOWN,OBSERVATIONAL,['NA']
5732,NCT01089556,Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form,Number of Participants Who Discontinued From Study Between Week 8 and Week 16 Endpoint,Number of Participants Who Discontinued From Study Between Baseline and Week 8 Endpoint,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5733,NCT03358121,Asprosin dynamics,,,2017-07-11,COMPLETED,OBSERVATIONAL,['NA']
5734,NCT02827266,Percentage of Participants With Hemoglobin Greater Than (>) 11 Grams per Deciliter (g/dL) After 8-Week Correction Phase,Number of Participants per Type of Diabetes,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5735,NCT01077323,"Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During ""Past Use"" Period) - Time on Drug Analysis","Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis Among Initiators of Exenatide, Diabetics Initiating Other Antidiabetic Drugs, and the Non-diabetes Cohort - Intent to Treat Analysis",,2004-09,COMPLETED,OBSERVATIONAL,['NA']
5736,NCT00551356,Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast,Total Insulin Doses,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5737,NCT00351884,Change from baseline in HbA1c at 24 weeks,Change from baseline in body weight at 24 weeks,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5738,NCT05354297,Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs,Change from baseline in medication adherence as assessed by a medication adherence survey after 3 and 6 months,Quantify the number of medical insurance claims made by subjects within each of the OneTouch Solutions programs using data harvested from a large medical insurance dataset,2022-07-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5739,NCT04623697,Stimulated insulin secretion,Fasting blood glucose,,2020-11-01,RECRUITING,OBSERVATIONAL,['NA']
5740,NCT02384941,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5741,NCT01103648,C reactive protein,Tumor necrosis factor alpha,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
5742,NCT01254552,Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus,Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5743,NCT00418366,Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers,Safety and tolerability in patients with renal insufficiency,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5744,NCT02677454,Mean Absolute Relative Difference (MARD),questionnaire,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5745,NCT01931280,Change in glycosylated hemoglobin,Change in weight after pregnancy,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5746,NCT04383314,Change in Self-reported physical function of participants after intervention,Number of participants with Osteoarthritis,,2021-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5747,NCT00461617,Hemoglobin A1C (HbA1C),One-hour postprandial glucose level (PPG1),,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5748,NCT00382096,Change from baseline in HbA1c,Change from baseline in body weight,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5749,NCT00913562,Flicker induced vasodilatation,,,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5750,NCT00854594,Provider Abilities Scale - Subscale From the Midwest (MW) Clinicians' Network,Attitudes Toward Healthcare Teams Scale and Subscales,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5751,NCT06185491,Coefficient of variation of individual HGI distribution,"Glycation gap, determined from comparison between HbA1C measured and HbA1C derived from glycated albumin",,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5752,NCT03332771,Change From Baseline in Hemoglobin A1c at Week 52,Percentage of Participants With Adverse Events (AEs),Percentage of Participants With Hypoglycemic Events,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5753,NCT04927871,Change of weight in kilograms,Percentage of Completion of the program.,,2020-11-16,COMPLETED,INTERVENTIONAL,['NA']
5754,NCT01991795,"Composite of Cardiovascular (CV) Death, MI or Stroke",All-cause Death,Permanent Discontinuation of Study Medication Due to Any Bleeding Event,2014-02-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5755,NCT04873050,Regression to normoglycemia,Change in body weight,,2022-01-13,RECRUITING,INTERVENTIONAL,['PHASE4']
5756,NCT00326573,"HbA1C at 6 months, end of intervention and one year follow up",quality of life at baseline and end of one year intervention,,2001-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5757,NCT03980808,Frequency of Engagement in Diabetes-Related Health Behaviors,,,2020-10-29,COMPLETED,INTERVENTIONAL,['NA']
5758,NCT04702490,Safety and tolerability of MET409 with or without empagliflozin (incidence of adverse events),Pharmacodynamic profile of MET409 alone or in combination with empagliflozin,,2020-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
5759,NCT00004364,,,,1995-12,UNKNOWN,OBSERVATIONAL,['NA']
5760,NCT00309192,Macular edema reduction or stabilization 6 months after treatment.,Tolerance of the treatment.,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5761,NCT05531877,No undersizing,Adequate Girth,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
5762,NCT00303394,HbA1c,Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5763,NCT01297738,Cerebral binding of [123I]FP-CIT to serotonin- and dopamine transporters and correlation with changes in in vivo and ex vivo insulin sensitivity,Insulin signalling pathways,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
5764,NCT00434850,Proportion of Insulin-independent Subjects,"Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index (DI)",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5765,NCT05709938,Mid night blood glucose level,,,2019-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5766,NCT03268005,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Body Mass Index (BMI),,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
5767,NCT05110625,Change from Baseline Glycated Hemoglobin (HbA1C) at 6 months,Quantification of alcohol consumption - FISTERRA,Follow-up rate,2021-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5768,NCT02287532,"Efficacy data: change in HbA1c, measured at 1 year minus the value baseline",,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
5769,NCT00815399,Circulating Endothelial microparticles,"Glucose profile, lipid profile, hemoglobin A1c, carotid intima-media thickness",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5770,NCT02716870,Inflammation,,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
5771,NCT04733612,Change from Baseline Quality of Life Assessed by SF-36v2 at 6 months,Change from Baseline Energy Intake at 6 months,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA']
5772,NCT05896319,Change in residual socket volume,Change in pain assessment,,2022-09-07,COMPLETED,INTERVENTIONAL,['NA']
5773,NCT06042517,Glucose metabolic clearance rate,High blood glucose index (HBGI),,2023-09-30,RECRUITING,INTERVENTIONAL,['NA']
5774,NCT02557620,Area under the semaglutide concentration-time curves,Area under the the single dose concentration-time curve,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5775,NCT03093636,% Time Within Target Range,,,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
5776,NCT02218619,C-peptide measurement as reflection of insulin secretion,liver function tests,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5777,NCT01159249,"Measure AEs, vital signs, laboratory evaluations",HOMA-B,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5778,NCT05717387,Change in percent of time in range (glucose between 3.9-7.8mmol/L) over 6 months measured with continuous glucose monitoring.,Change in quality of life,,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
5779,NCT05169034,System Performance,,,2021-12-14,TERMINATED,OBSERVATIONAL,['NA']
5780,NCT02068508,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),Number of Participants Who Received Specific Daily Dose of Insulin Product at Each Time Points,,2009-07-30,COMPLETED,OBSERVATIONAL,['NA']
5781,NCT03282981,Measurement of timolol serum during the treatment phase,The time to wound closure between the two groups,,2018-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5782,NCT02839044,"Absolute change in ongoing calcium deposition quantified as volumetric bone metabolic rate (CSUVMEAN x cm3) in the femoral artery between baseline and 6 months after baseline, as determined by 18F-NaF PET/CT imaging.",,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5783,NCT00282685,Improvement of neurological score: modified NIS(LL)+7,Heart rate variability,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5784,NCT03364387,"Composites of Myocardial Infarction, Hospitalization, Revascularization, Death",Heart failure,,2018-03-05,COMPLETED,OBSERVATIONAL,['NA']
5785,NCT00455520,Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12,Change From Baseline in Brief Pain Inventory (BPI) Total Pain Score Over the Last Week of the Maintenance Period at Week 12.,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5786,NCT04604093,Impact on time above 180 mg/dL in subjects with type 2 diabetes,,,2020-10-20,COMPLETED,OBSERVATIONAL,['NA']
5787,NCT01185236,change of ApoB/ApoA1,safety,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
5788,NCT03726762,Weight loss,HA1C,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5789,NCT00692562,kidney function,autoantibodies,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5790,NCT05713266,All cause higher level of care utilization,Highly likely+somewhat likely COVID-19 related healthcare utilization,,2022-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5791,NCT02002091,Number of Patients With Erectile Dysfunction,Number of Patients That Died From Cardio Vascular Cause,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
5792,NCT03324776,Percentage change from baseline HbA1c,Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS,,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE3']
5793,NCT02505334,Change in Glycosylated Haemoglobin (HbA1c) (Week 26),Change in Calcitonin,,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE3']
5794,NCT00279045,Time from randomization to the primary action point (monotherapy failure).,"Comparison of effects of long-term treatment with Rosiglitazone, Metformin, Glyburide: - maintenance/restoration of beta-cell function: HOMA IS, progression of microalbuminuria, fibrinolytic markers (PAI-1,fibrinogen, CRP).",,2000-01-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5795,NCT02978807,Prevalence of Gestational Diabetes via venous 75 gm oral glucose tolerance test,"Specificity, Sensitivity, positive predictive value, and negative predictive value of alternative point of care screening strategies",,2012-07,COMPLETED,OBSERVATIONAL,['NA']
5796,NCT03905863,Percentage Reduction in Ulcer Area (cm^2).,Number of Adverse Events,,2019-06-04,COMPLETED,INTERVENTIONAL,['NA']
5797,NCT03004664,Patients will improve their capacity for diabetes self-management: Measured through change in Patient Activation,Patients will successfully self-manage their diabetes as measured though change (reduction) in chronic stress levels,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
5798,NCT00166673,Navigator Accuracy,Exploratory assessment of impact of Navigator on HbA1c,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5799,NCT00351936,Change From Baseline in Triglycerides,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5800,NCT03240432,Time spent with glucose level <70 mg/dL,Time spent with glucose level <54 mg/dL,Glycemic variability (coefficient of variation),2017-09-26,COMPLETED,INTERVENTIONAL,['NA']
5801,NCT00441844,Monocyte function,Plasma biomarkers,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5802,NCT03422263,Maximum oxygen uptake,Body constitution (Muscle mass predicted II),Echocardiographic parameters (E/e' avg),2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
5803,NCT04970719,Rescue treatment,Time to recovery,,2021-07-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5804,NCT02983812,Hospital readmission within 30 days of discharge,Total health care cost utilization in 6 months after discharge,,2017-01-23,COMPLETED,OBSERVATIONAL,['NA']
5805,NCT03787511,Proportion of patients with small fiber neuropathy,values of the DN4 questionnaire in diabetic patients,,2019-03-05,RECRUITING,INTERVENTIONAL,['NA']
5806,NCT00499356,Incident foot ulcers,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
5807,NCT06164535,serum amyloid-β,HOMA-IR,,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5808,NCT04261361,Glycemic control,DM-specific distress,,2018-12-12,COMPLETED,INTERVENTIONAL,['NA']
5809,NCT01200394,Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12,Plasma Concentration Versus Time Summary of PF-00489791,Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5810,NCT01476449,Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.,"Percentage of Patients Anatomically ""Dry.""",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5811,NCT00062764,Number of Patients With Improvement in Liver Histology,Mean BMI Change,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5812,NCT00858013,The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate,HOMA-IR,,2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE4']
5813,NCT01348685,subjective appetite and short term food intake,,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
5814,NCT05030844,The change in diabetes self managament of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Management Scale,Metabolic control variables,,2021-07-14,COMPLETED,INTERVENTIONAL,['NA']
5815,NCT01120119,C peptide,Glycometabolic control,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
5816,NCT05362968,Lipid control,Diabetes risk hormones,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
5817,NCT05447806,Average hospital length of stay (LOS),Hospital revenue,Provider's practice performance,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
5818,NCT01895387,Plasma Lp-PLA2 activity,PBMC Lp-PLA2 activity,LDL particle size,2012-01,COMPLETED,INTERVENTIONAL,['NA']
5819,NCT04289818,Change from Baseline HbA1c at 6 months,Change of Body mass index at 6 months,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
5820,NCT02985099,Defect depth reduction (%),plaque index,,2015-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5821,NCT00977262,PBMC gene expression profiles,Endothelial function,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5822,NCT03506750,Changes of intraocular VEGF and PLGF of patients with proliferative diabetic retinopathy post-IVC (intravitreous injection of Conbercept).,Effect of IVC on postoperative complications,,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
5823,NCT06247748,Baseline-corrected difference of Corrected QT interval after multiple subcutaneous injections of JY09 injection,Immunogenicity,Relative abundance,2023-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5824,NCT06022601,HbA1c,Systolic and Diastolic Blood pressure,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
5825,NCT01370005,Mean 24-hour Systolic Blood Pressure Change From Baseline,Orthostatic Blood Pressure,Confirmed Hypoglycaemic Adverse Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5826,NCT05765903,Number of moderate-high risk participants with 30-day post-discharge hospital readmission,90-day post-discharge emergency department usage,,2024-03-31,WITHDRAWN,INTERVENTIONAL,['NA']
5827,NCT05217953,Change in HbA1c,AUC of glucose below 3.5 mmol/l,,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
5828,NCT01910051,anthropometric measures and metabolic biomarkers indicative of prediabetes,intra-subject and inter-subject variability of analyzed biomarkers,"the correlation between anthropometric data, medical history, and biomarkers with regard to metabolic risk",2013-09-25,COMPLETED,OBSERVATIONAL,['NA']
5829,NCT03595267,Kidney Failure Risk,,,2019-10-01,RECRUITING,OBSERVATIONAL,['NA']
5830,NCT05094401,Mean change in HbA1c,Change in Medications,,2021-10-04,TERMINATED,INTERVENTIONAL,['PHASE3']
5831,NCT02749890,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5832,NCT02825251,Change in Glycosylated Haemoglobin (HbA1c),Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets,,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5833,NCT02071498,adherence,safety medication use,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
5834,NCT03810378,Hemoglobin A1c (HbA1c),Blood pressure,Adherence to diet protocols,2019-06-05,COMPLETED,INTERVENTIONAL,['NA']
5835,NCT03254979,Implementation of the recommended clinical intervention by health care porfessionals,Lifestyle change at patient level,,2017-03-15,COMPLETED,INTERVENTIONAL,['NA']
5836,NCT01808690,Change in Insulin Sensitivity,Change in Aortic Wall Sheer Stress (WSS),Change in Brachial Artery Distensibility,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5837,NCT03264352,Composite of Major Adverse Cardiovascular and Cerebrovascular Events,Cancer,,2018-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
5838,NCT03648996,Carotid Femoral Pulse Wave Velocity (cfPWV),Insulin-stimulated Leg Blood Flow,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5839,NCT02144909,Change from Baseline diabetes management functioning as measured by the Problem Areas in Diabetes questionnaire at 3 months and 6 months,Change from Baseline weight in kg at 3 months and 6 months,Change from Baseline dietary patterns as a questionnaire at 3 months and 6 months,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5840,NCT02024399,Improved body compositon (decrease in % fat; increase in % lean tissue) using DEXA,"Improved levels of fitness using ACSM guidelines / assessments to measure such constructs of fitness as flexibility, muscle strength, cardiovascular endurance and agility.",Quality of life as perceived by the children and the parents.,2004-08,COMPLETED,INTERVENTIONAL,['NA']
5841,NCT00436176,Rate of HbA1c control (<7%),Rate of blood pressure control (< 140/90 mmHg),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5842,NCT01187069,HbA1c,Problem Areas In Diabetes scale (PAID),,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5843,NCT01050803,BMI,Audit of Diabetes-Dependent Quality of Life (ADDQOL),,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5844,NCT03335501,Change in plasma glucose levels 1 hour after the meal,Number of hypoglycemic events less than 3.3 mmol/L (>20 minutes).,,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5845,NCT00695526,the change of total to HDL cholesterol ratio,the change of UAE,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5846,NCT00437918,7 point SMBG (self monitoring of blood glucose),HOMA-beta for predicting the effectiveness of each agents,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5847,NCT05043636,Cardivascular Autonomic Neuropathy assesed by Vagus,Blood pressure in supine and standing position,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5848,NCT04234581,Hemoglobin A1c,2-AAA,,2019-08-13,TERMINATED,INTERVENTIONAL,['NA']
5849,NCT00395746,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5850,NCT00894868,To evaluate the effect of vildagliptin on left ventricular function in patients with T2DM and CHF (NYHA class I-III) by showing that vildagliptin is at least not inferior to placebo with respect to change in left ventricular ejection fraction (LVEF).,To evaluate the efficacy of vildagliptin in patients with T2DM and CHF (NYHA class I-III) by assessing the HbA1c reduction with vildagliptin compared to placebo after 16 weeks of treatment.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5851,NCT00563004,Reduction in fasting plasma glucose of more than 20% in the treatment group compared to placebo,Reduction by half in the daily dose of oral hypoglycemic agents compared to baseline,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
5852,NCT04760444,Self-Care Activities,Diabetes Distress,,2021-05-15,COMPLETED,INTERVENTIONAL,['NA']
5853,NCT05374343,Plasma concentrations of rongliflozin,Change from baseline in 24-hour urine glucose excretion in varying degrees of kidney function,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE1']
5854,NCT01887964,Changes in metabolic syndrome risk components,Changes in blood glucose indices,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
5855,NCT00143338,"To assess in patients with type 2 diabetes mellitus the effects, if any, on lung lining fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5856,NCT00695682,This is a pilot study to study the safety and tolerability of intravitreal Infliximab in patients with refractory diabetic macular edema and choroidal neovascularization (CNV),Incidence and severity of adverse events,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
5857,NCT01377558,Change in HbA1c-level (haemoglobin A1c),Follow up of all parameters mentioned above,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
5858,NCT05417425,Incidence in wound closure by week 12 of treatment,Increase in physical function and ambulation,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
5859,NCT00867022,Serum Noradrenalin level,"Heart rate variability: LF, VLF, HF",,2004-08,COMPLETED,OBSERVATIONAL,['NA']
5860,NCT03932084,Glucose fluctuation,Blood lipids,,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA']
5861,NCT02325960,Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS),body composition,Exploratory Objective assessed by the relationships between oxidative stress and inflammatory markers and MAGE,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5862,NCT02059187,Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24,Percentage of Participants With Hemoglobin A1C <6.5% at Week 24,,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5863,NCT05713448,Prevalence of patients with type 1 diabetes and obesity,,,2021-02-24,RECRUITING,OBSERVATIONAL,['NA']
5864,NCT00285844,Adipose Cell Size Distribution,Adipose Tissue Gene Expression,Insulin-Mediated Glucose Uptake,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5865,NCT03392441,Change in Structural MRI,,,2017-11-30,COMPLETED,INTERVENTIONAL,['NA']
5866,NCT01600924,Independent predictors of reduced muscle and bone strength,Relation of changes in predictors with reduced muscle and bone strength,,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5867,NCT01899872,Circulating endothelial progenitor cells,Forearm vascular reactivity,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
5868,NCT01628627,"Change in Nerve Conduction Velocity of the Deep Peroneal, Tibial, or Sural Nerve",Number of patients with treatment-related adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5869,NCT04298229,"Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight",Hospital Readmission,,2020-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5870,NCT03974139,cerebrospinal fluid /plasma leptin ratio,Score of the Dutch Eating Behaviour Questionnaire (DEBQ),,2020-07-03,RECRUITING,INTERVENTIONAL,['PHASE2']
5871,NCT01020123,HbA1c: Change From Baseline to 4 Month,EC50 to Characterise the PD Properties of AZD1656.,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5872,NCT00675493,Change in HbA1c from baseline,Number of adverse drug reactions (ADR),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5873,NCT05802927,Postprandial blood glucose,Appetite,,2023-07-05,COMPLETED,INTERVENTIONAL,['NA']
5874,NCT05670600,Change in pain level at 4th and 8th weeks compared to baseline.,Effect of neuropathic pain on quality of life at 4 and 8 weeks change from initial state,,2021-07-19,COMPLETED,INTERVENTIONAL,['NA']
5875,NCT01939496,Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6,"Change From Baseline in the Difference in Seated Heart Rate (HR) and Standing HR to Day 2, to Week 3, and to Week 6",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5876,NCT04298515,Nefratin-1 in insulin resistance,,,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA']
5877,NCT01043965,"myocardial blood flow velocity, myocardial blood flow reserve",,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5878,NCT06143215,Recurrence rate,Minor amputation rate,,2023-12-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5879,NCT02709057,Incident diabetes,The change in insulin sensitivity during a 3 year follow-up,Incident cardiovascular disease,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
5880,NCT03865290,Change in effect of Gastrointestinal symptoms on Quality of Life,Severity of gastrointestinal symptoms - Nepean Dyspepsia index,,2019-04-02,RECRUITING,INTERVENTIONAL,['PHASE2']
5881,NCT02793505,Spontaneous abortion,Pregnancy complications,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
5882,NCT06320054,Clinical Outcomes,Patient Reported Outcomes,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5883,NCT05728411,Rate of foot ulceration,Mean or median self-efficacy for diabetes,"Utilization (outpatient visits, emergency room visits, hospitalizations) - any vs. none and number",2023-10-02,RECRUITING,INTERVENTIONAL,['NA']
5884,NCT00385528,"Psychological distress, quality of life",health care utilization,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5885,NCT04529473,Glycated haemoglobin (HbA1c),Blood Pressure,Adverse Events (AE),2021-02-03,COMPLETED,INTERVENTIONAL,['NA']
5886,NCT04854603,Insulin,Food pleasantness,,2021-09-02,COMPLETED,INTERVENTIONAL,['NA']
5887,NCT05619406,Primary Outcome,Secondary Outcome,,2022-08-20,RECRUITING,INTERVENTIONAL,['NA']
5888,NCT05870358,Biochemical Findings: RANKL/OPG,,,2021-02-18,COMPLETED,INTERVENTIONAL,['PHASE4']
5889,NCT02581098,Wound macrophage isolation to determine miR-21,,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5890,NCT00005168,,,,1984-08,COMPLETED,OBSERVATIONAL,['NA']
5891,NCT03178019,Intergroup analysis of the associations between DPP4 activity and markers of inflammation,"Intergroup analysis of the associations between DPP4 activity and insulin resistance indexes, heart rate and blood pressure variability, and measures of adiposity",,2014-02-01,COMPLETED,OBSERVATIONAL,['NA']
5892,NCT03987308,The percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin,The percentages of subjects with greater than 3% weight loss,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
5893,NCT01186003,Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl),Reduction in Time to Get Back to Control of Glycemia (140-180 mg/dl) if Rebound Hyperglycemia Occurs,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
5894,NCT01732705,Insulin sensitivity,,Glycogen content in skeletal muscle,2012-09,COMPLETED,INTERVENTIONAL,['NA']
5895,NCT04857073,Birth weight,Number of NICU admission,,2021-04-10,COMPLETED,INTERVENTIONAL,['NA']
5896,NCT00862433,Measure Vitamin E Kinetics,,,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5897,NCT04930224,oestradiol,,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
5898,NCT03626909,Patients meeting their HgbA1c treatment goal,Community Health Worker adherence,,2018-01-14,COMPLETED,OBSERVATIONAL,['NA']
5899,NCT01416649,Sleep duration and sleep efficiency,,,2011-02-01,COMPLETED,OBSERVATIONAL,['NA']
5900,NCT00789737,Percent Change in Hemoglobin A1c,"Change in Postprandial Plasma Glucose, 2 Hours After a Meal Tolerance Test",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5901,NCT01794091,"All cause mortality, cardiovascular death, myocardial infarction or stroke",,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
5902,NCT04262700,A1c change from baseline after 12 weeks,,,2020-02-07,UNKNOWN,INTERVENTIONAL,['NA']
5903,NCT00969592,fractional and total glucose infusion rates,fractional and total insulin areas under the curve (AUC),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5904,NCT03821662,Change from Baseline Glycated hemoglobin (HbA1C),Change from Baseline Medication Adherence Assessment Scale,,2019-04-11,COMPLETED,INTERVENTIONAL,['NA']
5905,NCT00252837,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Audit of Diabetes Dependent Quality of Life (ADDQoL). ADDQoL will only be applied in Poland.,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3']
5906,NCT05408234,Ankle Brachial Index,,,2022-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5907,NCT01197898,Change From Baseline in Extent of Presence/Absence of Epithelial Tongue.,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5908,NCT05140304,Mean area of FAZ in various stages of diabetic retinopathy and difference between these groups in superficial and deep capillary plexuses,,,2021-11-30,UNKNOWN,INTERVENTIONAL,['NA']
5909,NCT02660242,Glycemic Response During Exercise and Early Recovery,CGM Metrics During Late Recovery - Time > 250 mg/dL,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5910,NCT01113216,Identification of Genes or other factors that influence the development of CFRD,,,2008-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5911,NCT05765214,CRC-KPSS change and screening uptake,,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
5912,NCT02028975,Plasma levels of biological markers of orosensorielle perception fatty acids,Measure the detection threshold for linoleic acid,,na,UNKNOWN,INTERVENTIONAL,['NA']
5913,NCT02057952,Change in Body Weight From Baseline to 6 Months.,Change in Diastolic Blood Pressure Baseline to 12 Months,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5914,NCT02058147,Change in HbA1c From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5915,NCT04019431,Body Mass Index change from baseline,Safety (subjective unit) change from baseline,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
5916,NCT05708040,Time in Range,Health-Related Quality of Life in Patients with Type 1 Diabetes,,2022-08-19,COMPLETED,INTERVENTIONAL,['NA']
5917,NCT04787978,"Change in cardiovascular health (a composite measure of blood pressure, cholesterol, glucose, physical activity, smoking status, and body mass index).",Change in Patient Activation,,2020-02-29,COMPLETED,INTERVENTIONAL,['NA']
5918,NCT06108388,Hematopoietic colony formation in ALDHhiSSClow regenerative cell subsets,Frequency and absolute number of circulating ALDHhiSSClowCD133+ progenitor cells,,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5919,NCT02695810,Mean amplitude of glycaemic excursions (MAGE) as assessed by continuous glucose monitoring,Responsiveness to interventions in individuals with different glucose tolerance status (impaired fasting glycaemia vs. impaired glucose tolerance),,2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
5920,NCT05067452,Change in food security severity from baseline to twelve weeks by study arm,Change in diabetes self-efficacy from baseline to twelve weeks by study arm,Change in health-related quality of life (healthy days) from twelve weeks to twenty-four weeks by study arm,2021-11-08,RECRUITING,INTERVENTIONAL,['NA']
5921,NCT01123187,Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation,Evaluation of kidney function,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
5922,NCT04940962,Kinetics of the appearance of endocannabinoids produced by visceral adipose tissue explants in culture medium estimated by the area under the curve in obese subjects and in controls.,,,2021-09-29,RECRUITING,INTERVENTIONAL,['NA']
5923,NCT05431660,Plantar pressure senses,Vibration sense,Individuals' information about diabetic foot,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5924,NCT01473329,HbA1c,Changes in Lipids,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
5925,NCT03028220,"% Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL)",Glucose Variability Measured by CONGA,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
5926,NCT05507697,Change of nerve conduction velocities in the lower extremity,Change of glycosylated hemoglobin (HbA1c),,2022-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5927,NCT01056198,Bates-Jensen Wound Assessment Score - Modified (BWAT-m),Percent of Wound Area Change From Baseline at the End of 12 Week Follow-up,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5928,NCT03047200,Restoration of sustained euglycemia without exogenous insulin or with reduced insulin dosage in patients who underwent pancreatic islet cell after kidney transplantation,To assess total islet mass needed to achieve sustained euglycemia with or without exogenous insulin.,,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5929,NCT01882907,Non-inferiority of HbA1C Change From Baseline in Vildagliptin + Metformin Group Compared With Pioglitazone + Metformin Group,"the Mean Changes of Insulin, C-peptide, HOMA-IR, HOMA-beta From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups",the Numbers of Participants With Adverse Events Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5930,NCT00709683,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,"Average post-breakfast (90-120 mins), post-lunch (90-120 mins), post-dinner (90-120 mins) plasma glucose level",,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5931,NCT01989754,Progression of Albuminuria,Cardiovascular (CV) Death,,2014-01-16,COMPLETED,INTERVENTIONAL,['PHASE4']
5932,NCT01079195,Reduction in Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to Study End,Evaluation of Adverse Events (AEs) Leading to Discontinuation of Tarka and a Summary of All AEs Possibly or Probably Related to Tarka by Frequency and Severity,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
5933,NCT06251323,Hemoglobin A1c,,,2025-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5934,NCT04819178,Diabetic ketoacidosis,Hypoglyceamia,,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA']
5935,NCT03256747,Glucose levels,Oxygenation tissue,,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
5936,NCT02285231,2-h oral glucose tolerance tests (OGTTs,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5937,NCT04720170,Intra-epidermal Nerve Fiber Density,Patency of Lateral Plantar Artery,Medial Plantar Sural Nerve Action Potential Amplitude,2021-02-15,UNKNOWN,INTERVENTIONAL,['NA']
5938,NCT00348231,daily profile of blood glucose,QOL,,2004-11,UNKNOWN,INTERVENTIONAL,['NA']
5939,NCT04767672,Glycated hemoglobin,Fecal Short-Chain Fatty Acids (SCFA),Blood pressure,2021-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5940,NCT05107544,Time change in range,Change in mood of adolescents,,2021-09-04,COMPLETED,INTERVENTIONAL,['NA']
5941,NCT00973271,The effect of DCCR on triglycerides in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,The effects of DCCR on Apo B and non-HDL in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5942,NCT02129231,Total antioxidant capacity,nerve conduction studies,alanine aminotransferase,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5943,NCT03006471,Number of Participants With a Dipper Reverse Circadian Blood Pattern at Week 12,Number of Participants With Prediabetes Plus Prehypertension at Week 12,,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
5944,NCT05021705,renal biopsy,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
5945,NCT05654285,"Glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), glucose-dependent insulinotropic polypeptide (GIP), pancreatic polypeptide (PP), leptin, and ghrelin",,,2016-02-08,COMPLETED,INTERVENTIONAL,['NA']
5946,NCT05772169,Prevalence of Hypercortisolism,Effect of Treatment on Non-neoplastic Hypercortisolism,,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE4']
5947,NCT00754130,Number of Participants Who Discontinued Study Drug Due to an AE,"Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5948,NCT01676220,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5949,NCT05647824,Fingerstick Test: Obtain TV4 BGMS performance data in the hands of lay users with diabetes using fingerstick capillary blood obtained with Microlet NEXT® lancing device.,Subject Questionnaire on the Usability of TV4 BGMS,,2020-02-05,COMPLETED,OBSERVATIONAL,['NA']
5950,NCT05786521,6 minute walking distance,,,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
5951,NCT04769037,Persistent confirmed multiple beta-cell autoantibodies,Measurement of Safety parameters,Stool calprotectin,2021-04-22,RECRUITING,INTERVENTIONAL,['NA']
5952,NCT04506216,Eating disorders in men and women,Blood glucose monitoring,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
5953,NCT03290768,Program Completion Rate (%),Coaching Participation Rate,,2017-09-13,COMPLETED,INTERVENTIONAL,['NA']
5954,NCT01776528,Safety and tolerability,Pharmacodynamics,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5955,NCT04828304,Efficacy PLASOMA - wound surface area reduction,Patient acceptability,,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5956,NCT03165110,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success in Interpreting the Expanded Graph and My Readings View in the Onyx App System,Average Change in Total Daily Insulin Dose From Study Start to End of Study,,2017-03-17,COMPLETED,INTERVENTIONAL,['NA']
5957,NCT05380544,Patient and clinician acceptability of the trial process and ESWT,"Validity, reliability and responsiveness of virtual follow-up for wound healing in research",,2022-04-13,RECRUITING,INTERVENTIONAL,['NA']
5958,NCT00556751,"Development of resting ECG abnormalities, specifically isolated non-specific ST-segment and T-wave abnormalities",,,1985-01,COMPLETED,OBSERVATIONAL,['NA']
5959,NCT00231621,Percent change in body weight and the percent change in fasting serum triglycerides from baseline (Week 0) to Week 60.,"Absolute change in body weight, body mass index, triglycerides, and absolute and percentage changes in cholesterol measures from baseline to Week 60. Safety evaluations throughout study.",,2001-05,TERMINATED,INTERVENTIONAL,['PHASE3']
5960,NCT01342263,Healthcare utilization,Health outcomes,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
5961,NCT01102452,The daily blood glucose level will be monitored by the CGMS (continuous glucose monitoring system)device,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
5962,NCT06173232,Primary Objective,,Exploratory Endpoint,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
5963,NCT04437485,Hemoglobin A1c at 6 Months,Depressive Symptoms,,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE2']
5964,NCT01324921,Positive AUC for plasma glucose concentration,Positive AUC for serum insulin concentration,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5965,NCT03136289,Adolescent prediabetes and diabetes.,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
5966,NCT04380064,Postoperative ERM Development,Visual Acuity,,2020-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5967,NCT04417452,Maturation of the gonadal regulation,,,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5968,NCT00836030,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
5969,NCT04795726,Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR),Change in severity of diabetic retinopathy (DR),,2021-03-10,COMPLETED,INTERVENTIONAL,['NA']
5970,NCT00351000,Change From Baseline on Fasting Insulin,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5971,NCT05706155,Change in Glycated Hemoglobin,Adherence to a plant-based diet,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
5972,NCT00627471,Mean difference in HbA1c (efficacy),"Minor, severe and nocturnal Hypoglycaemic events (safety)",,2008-01,TERMINATED,INTERVENTIONAL,['PHASE4']
5973,NCT02812498,glycosylated hemoglobin HbA1c,Cost analysis by patient estimation through a questionnaire of the overall cost and time saved thanks to the service,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
5974,NCT01322035,Measure erythrocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic Gastric Bypass.,Measure hepatocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass.,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
5975,NCT06173245,Change of subfoveal choroidal thickness (SFCT),Change of visual acuity (VA),,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
5976,NCT00841087,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic Blood Pressure (BP),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5977,NCT00979368,Exposure to the investigational drug will be measured to assess safety and tolerability,To assess the single dose Pharmacokinetics of BMS-816336,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5978,NCT01718015,"Concentrations of IGF-I and II, sCD-163, VEGF, NGF and BDNF in cerebrospinal fluid and blood.","Nerve conduction studies: Nerve velocity, Amplitude, F-waves, Motor Unit Number Estimate (dominating arm and non-dominating leg)",Protein profile of the cerebrospinal fluid using mass spectrometry.,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
5979,NCT04863755,Change from Baseline Blood Pressure at 4 months,Change from Baseline HDL cholesterol at 4 months,,2017-05-09,COMPLETED,INTERVENTIONAL,['NA']
5980,NCT05210972,Coronary artery disease severity,Correlation of HbA1c to CAD severity,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
5981,NCT04848480,Change in Glycosylated Haemoglobin (HbA1c) at Week 26,Change in Body Weight,,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE3']
5982,NCT03893422,CRP,Hospital Anxiety and Depression Scale,,2017-10-22,COMPLETED,INTERVENTIONAL,['NA']
5983,NCT03044132,Time (days) required for wound bed preparation (granular bed after placement of DermACELL AWM).,"The number of adverse events after DermACELL AWM application including infection, hospitalization, and reoperation.",,2017-01-15,COMPLETED,INTERVENTIONAL,['NA']
5984,NCT02668328,Mean Amplitude of Glycemic Excursion (MAGE),,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
5985,NCT00833677,Diabetes Self Efficacy,Diabetes Specific Conflict,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
5986,NCT01682759,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue,Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54,,2012-09-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5987,NCT00570687,EGP AOC0-480 - Meal Challenge,,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5988,NCT03320031,glucose variability,hypoglycemia,,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
5989,NCT03088670,Mean change of HbA1c,Adverse event,,2013-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
5990,NCT05843929,Diabetic foot exam: dermatologic examination,Diabetes Self-Care,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5991,NCT03893526,Blood Glucose,Plasma Concentrations of Amino Acids,,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE4']
5992,NCT01376323,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Number of Participants With HbA1c < 7.0% and < 6.5%,,2011-07-13,COMPLETED,INTERVENTIONAL,['PHASE2']
5993,NCT05544643,Percentage of sets that failed due to unexplained hyperglycemia,,,2022-08-04,COMPLETED,INTERVENTIONAL,['NA']
5994,NCT04855292,Safety and tolerability assessed by incidence and severity of adverse events,The occurrence of TG103 anti-drug antibodies (ADA),,2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5995,NCT05943626,Insulin sensitivity change from baseline,Average (per week) daytime alertness change from baseline,,2023-06-13,RECRUITING,INTERVENTIONAL,['NA']
5996,NCT00810290,HgbA1c,Change in quality of life.,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
5997,NCT02793427,Serum AGEs,,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
5998,NCT01281228,Differences in neuronal activity in CNS reward and satiety circuits,Self-reported hunger,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
5999,NCT03238547,Diagnostic Sensitivity and Specificity,,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
6000,NCT01001611,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Change from baseline in glycemic parameters (Fasting Plasma Glucose, C-peptide, Homeostasis Model Assessment of Insulin Resistance(HOMA-IR), Homeostasis Model Assessment of β-cell function(HOMA-β), Quantitative Insulin Check Index(QUICKI))",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6001,NCT02872402,Weight retention,Time physically active,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6002,NCT00896610,Blood glucose level,,,2009-05-13,TERMINATED,OBSERVATIONAL,['NA']
6003,NCT03889210,Rate of change in plasma glucose concentration,Correlation with physical activity,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
6004,NCT00914524,The change in the urinary protein/creatinine ratio from baseline to the end of treatment.,The change of creatinine clearance,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6005,NCT04484987,Adipose tissue gene expression,Peripheral diurnal rhythmicity in in peripheral mononuclear blood cells,,2020-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6006,NCT03021187,Change in HbA1c (Week 26),Change in DTSQs: Individual Items and Treatment Satisfaction Score (6 of the 8 Items Summed),,2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6007,NCT02748122,Change in score on Quality of Life questionnaire,,,2015-10,TERMINATED,INTERVENTIONAL,['NA']
6008,NCT02169531,Change from Baseline Hemoglobin A1c (HbA1c) at up to 27 weeks.,Change from Baseline Lipid Profile at up to 27 weeks.,Change from Baseline Symptoms at up to 27 weeks.,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6009,NCT05971082,remission of fatty liver disease,,,2023-08-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6010,NCT02081118,Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks,Glycated albumin,Number of Participants with Immunogenicity by HM11260C,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6011,NCT04741568,"Change in Diabetes Eating Problem Survey Revised (Markowitz et al., 2010)",Change in Children's Eating Behaviour Questionnaire (Wardle et al. 2001),Feasibility Outcomes: Usability of Online Content (Google Analytics),2021-06-07,COMPLETED,INTERVENTIONAL,['NA']
6012,NCT05538819,Hospitalizations and emergency visits for heart failure,Hospitalizations for acute myocardial infarction or stroke,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
6013,NCT02555631,Change in Weight in Pounds,Number of Participants That Participated in Each Session,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6014,NCT01251757,Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs),Percentage With Good (<=100mg/dL) Low Density Lipoprotein (LDL) Control,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6015,NCT01444534,Quality of Life,Self-monitoring of blood glucose (SMBG),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
6016,NCT05714761,Percentage of participants with at least 72 hours of CGM data downloaded.,Negative predictive value (NPV),,2023-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6017,NCT01096667,Change From Baseline on 24-hour Average SBP at Week 4,Number of Participants Who Discontinued Study Drug Due to an AE,,2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE2']
6018,NCT00065793,apoB concentration of LDL with apoC-III,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
6019,NCT01680133,Change from baseline in insulin sensitivity of adipose tissue and skeletal muscle lipolysis,Baseline skeletal muscle lipid accumulation,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6020,NCT00789308,Level of stimulated c-peptide at 90-minute derived from the mixed-meal tolerance test (MMTT),Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation,,2008-07-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6021,NCT04865770,"Change in kidney inflammation (medulla), T1 mapping (MRI)",Change in kidney function (creatinine clearance) (urinalysis,,2021-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6022,NCT04133922,change in insulin sensitivity between baseline and 2 hour insulin clamp,change in pulse wave velocity between baseline and 2 hour insulin clamp,,2019-10-14,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
6023,NCT03514108,Met-HeFT combined endpoint: Death or hospitalization with worsening heart failure or acute myocardial infarction or stroke or urgent heart failure visit,Met-HeFT secondary endpoint: Hospitalization or death caused by lactate acidosis.,,2018-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
6024,NCT04332354,glycemic profile after bariatric surgery,identification of predictive factors for diabetes remission 1 year after surgery,,2016-03-30,COMPLETED,OBSERVATIONAL,['NA']
6025,NCT01790724,Physical Activity,Psychosocial outcomes,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
6026,NCT05208424,Short-term outcome,,,2020-02-27,COMPLETED,OBSERVATIONAL,['NA']
6027,NCT02963922,Participants Losing at Least 5% of Baseline Body Weight,Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone,,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6028,NCT03788642,Ulcer Healing Rate,Clinical Success - Complications,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
6029,NCT02803489,Sensitivity and specificity of the tele-notifications,"Clinical events including medical consultations, hospitalizations and adverse events",,2016-04-08,TERMINATED,INTERVENTIONAL,['NA']
6030,NCT01790308,the percentage of the patients who maintain glucose control 1 year after short intensive therapy,the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients,,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
6031,NCT02268916,Social Participation,,Physical Function,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
6032,NCT00627380,The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test.,Safety: CD4 count and plasma HIV RNA,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6033,NCT00095082,HbA1c,Insulin Treatment Satisfaction,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6034,NCT01840358,Frequency of hypoglycemias,Frequency of hyperglycemias,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
6035,NCT05358444,Survey Administration Feasibility as assessed by mean time for administration of surveys to participants,Change in caregiver attitudes regarding child health behaviors,,2022-07-08,COMPLETED,INTERVENTIONAL,['NA']
6036,NCT00771693,"Co- primary platelet response variables: U46619 stimulated platelet P- selectin activation, platelet-leukocyte aggregation, platelet-platelet aggregates and platelet-monocyte aggregates.",To elucidate if short-term lowering of blood glucose by insulin infusion (pretreatment standardization of blood glucose) reduces platelet activity in patients with T2DM.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6037,NCT05193929,Percentage of index ulcers healed,Changes in wound quality of life from screening visit to end of study ( per W-QoL),Cost to Closure,2021-12-15,RECRUITING,INTERVENTIONAL,['NA']
6038,NCT01528254,Time to Initial Treatment Failure,"Percentage of Participants With Adverse Events, Serious Adverse Events and Death",,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
6039,NCT03580226,Uric Acid,,Management,2015-01,COMPLETED,OBSERVATIONAL,['NA']
6040,NCT01440140,Percentage of CGM (Continuous glucose monitoring) values in target (3.9 - 8.0 mmol/l).,Glycaemic control assessed by fructosamine and HbA1c,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6041,NCT00212914,The proportion of patients screened in each group,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
6042,NCT02112071,endothelial function measured by brachial artery flow mediated vasodilation,24-hour albuminuria,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
6043,NCT04030091,Endothelial function,Diabetes treatment satisfaction questionnaire,,2019-09-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6044,NCT02301806,"Change in endothelial function during the OGTT evaluated by flow-mediated vasodilatation (FMD). The change is defined as below, assuming the peak value and changes of FMD will be observed at t=60 min.",Change in endothelial function during OGTT* evaluated by endo-PAT. Change in endothelial function after 12-week treatment at the fasting state evaluated by endo-PAT and FMD.,Change in the number of EPCs after 12-week treatment,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6045,NCT00370942,Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group,Long term safety variables,,2006-04-01,TERMINATED,INTERVENTIONAL,['PHASE2']
6046,NCT02038764,Number of Participants With Serum Anti-PF-06342674 Antibody Response Listed by Visit,Accumulation Ratio (Rac) on Day 71,,2014-06-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6047,NCT01024790,Depression,,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6048,NCT00971243,Change in HbA1c From Baseline to Week 24,"Adverse Events, Laboratory Tests, Vital Signs, Etc.",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6049,NCT03464812,Program completion,Patient and referring provider satisfaction,,2017-08-04,COMPLETED,INTERVENTIONAL,['NA']
6050,NCT00995787,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG","Pharmacodynamic variables: 24 h plasma glucose, Insulin",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6051,NCT03052400,Hemoglobin A1c,Basal Insulin Dose,,2017-02-03,TERMINATED,INTERVENTIONAL,['PHASE2']
6052,NCT01667783,Change in HbA1c from baseline to final data collection,Change in insulin secretion,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6053,NCT05771090,Characteristics of volatile organic compound (VOC) signals measured by the Sokru device,Oxygen saturation,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
6054,NCT04874415,Moderate to Vigorous Physical Activity (MVPA),Daily Step Count,,2021-11-16,RECRUITING,INTERVENTIONAL,['NA']
6055,NCT04247451,Efficiency of nutritional therapy: Dietary intake (food diary; in Kcal) compared to caloric need (indirect calorimetry; Kcal),"Evaluation of choice for oral nutritional supplements, enteral nutrition and parenteral nutrition (%)",,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
6056,NCT00082251,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6057,NCT00797563,Number of Capillary and Venous Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,Number of Partipants Who Gave These Ratings for Overall Testing Experience With This Meter,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
6058,NCT02016846,Glucose levels 2 hours after 75 gr OGTT,,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6059,NCT00211536,Incidence of Severe Hypoglycemia Events,Low Blood Glucose Index (LBGI);,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6060,NCT00933491,Radiographic Bone Level,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
6061,NCT03520608,prevalnce of irrational use of pain reliever drugs,Generalized Anxiety Disorder Screener (GAD-7),,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
6062,NCT01713023,Compare the effects of fructose and glucose and TAS1R2 in postprandial metabolism of individuals with type 1 diabetes,Effect of fructose or glucose on leptin levels,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
6063,NCT01526941,"Steady state area under the glucose infusion rate profile, 6-12 hours",Adverse events,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6064,NCT02738996,Postprandial glucose excursions measured with Area under curve,"Qualitative exploration of the knowledge, beliefs and experiences of those with type 2 diabetes on the use of technology to decrease sedentary behaviour and improve glycaemic control",,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
6065,NCT05757258,"Association between incidence of MALE and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels","Association between incidence of cardiovascular death and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels",,2019-10-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6066,NCT01857167,insulin resistance,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6067,NCT03257501,System Related adverse device effects,,,2017-08-22,COMPLETED,OBSERVATIONAL,['NA']
6068,NCT00838916,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Albiglutide Plasma Concentrations at Week 8 and Week 24,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6069,NCT00477191,Change in CRP Levels From Baseline to 6 Months of Treatment in Subjects With Psoriasis and Metabolic Syndrome,Change in the Safety and Tolerability of Etanercept in Patients With Psoriasis and Metabolic Syndrome Over a 6-month Period.,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
6070,NCT01279317,Postprandial Glycemic Incremental Area Under the Curve,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
6071,NCT05443802,Metabolic complications,Episode of severe hypoglycaemia in patients suffering from first ketoacidosis episode,,2022-08-16,RECRUITING,INTERVENTIONAL,['NA']
6072,NCT05037526,Composite adverse pregnancy and neonatal outcome,Respiratory distress syndrome,,2021-09-24,RECRUITING,INTERVENTIONAL,['NA']
6073,NCT02927951,Decrease in fall risk associated with walking assessed with the Physiological Profile Assesment,Patient Global Impression of Change (PGIC),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6074,NCT02469558,insulin sensitivity,,Quality of Life,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6075,NCT00904592,"incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation",Symptoms scores of TCM,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
6076,NCT06021158,Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L),"Area under the sensor glucose concentration-time curve (AUC) from 0-1 hours, 0-2 hours, 0-3 hours, 0-4 hours, and 0-5 hours after the end of announced exercise periods",,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
6077,NCT01752127,in-segment late lumen loss (mm)at 12month,procedure success rate,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
6078,NCT04877366,Post-prandial glycemic excursion (ARMs A and B),Matsuda Index (ARMs A and B),Plasma IL-6 iAUC (ARMs A and B),2021-07-21,COMPLETED,INTERVENTIONAL,['NA']
6079,NCT04365400,Change in HbA1c From Baseline to Week 26,"Change in HbA1c From Baseline to Weeks 4, 8, 12, 16 and 20",,2020-10-13,TERMINATED,INTERVENTIONAL,['PHASE2']
6080,NCT06249399,Bladder Sensation,Patient Information Form,,2023-05-03,COMPLETED,INTERVENTIONAL,['NA']
6081,NCT04461041,Left Ventricular (LV) mass,Hematocrit,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6082,NCT00747006,Lunch Plasma Glucose Excursion - Amendment 1 (Humalog Treated Type 2 Subjects),Lunch Plasma Glucose AOC(0-240) - Amendment 1 (Humalog Treated Type 2 Subjects),,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2']
6083,NCT02366416,Change of bloodglucose,Change of musculoskeletal pain,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
6084,NCT00559884,Urine:,lab tests:,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6085,NCT05792072,Changes in brain plasticity,influence on nerve conduction,,2023-05-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6086,NCT06055582,Glycemic indices as per Continuous glucose monitoring system (CGMS) & HbA1c (%),,,2022-02-11,COMPLETED,INTERVENTIONAL,['NA']
6087,NCT00758082,Comparison of HbA1c means,Number of hypoglycemias (moderate and severe) during the 3-month period,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6088,NCT02271776,systemic insulin sensitivity,skeletal muscle and adipose tissue gen and protein expression,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
6089,NCT03618628,Peak Plantar Pressure,,,2016-05-24,COMPLETED,INTERVENTIONAL,['NA']
6090,NCT00951912,Percentage Change in Low Density Lipoprotein Cholesterol,Total Energy Intake at Follow-up,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6091,NCT01175824,Change in HbA1c From Baseline to 24 Weeks Endpoint (Intention-to-Treat Population),The Number of Participants With Severe Hypoglycemic Episodes,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6092,NCT03243253,"association between densities of fast food (FFR) and full service restaurants (FSR) with mortality from CVD and stroke, and the prevalence of type 2 diabetes (T2D).",,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
6093,NCT00756613,The Long Term Effect of Intensive Glycemic Control in Type 2 Diabetes on Major Cardiovascular Complication.,Patients Reported Health Related Quality of Life,,2008-02-01,COMPLETED,OBSERVATIONAL,['NA']
6094,NCT04426708,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf;,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of fu;,,2019-02-18,COMPLETED,INTERVENTIONAL,['PHASE1']
6095,NCT01698775,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period),Change From Baseline in eGFR at Week 54,,2012-10-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6096,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,Number of Open Tests,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
6097,NCT02475499,Incident pancreatic cancer,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
6098,NCT00729196,Percent change in weight,Change in HbA1c,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
6099,NCT01684748,Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time),,Collagen Gene Expression in Skeletal Muscle (Change Over Time),2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6100,NCT05830318,System Usability Scale,Cardiovascular events,,2023-08-23,RECRUITING,OBSERVATIONAL,['NA']
6101,NCT00007800,,,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6102,NCT02280174,"Measurement of the Area Under the Curve of Plasma apoB-48 Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
6103,NCT05029804,Pedometer,,,2021-09-30,UNKNOWN,INTERVENTIONAL,['NA']
6104,NCT02970838,Change in HbA1c value,Change in diet history,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6105,NCT02989688,Blood glucose response curve,Flavour acceptability scale for ONS product,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
6106,NCT02255682,Difference in myalgia,Difference in mitochondrial function,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6107,NCT00717483,,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6108,NCT00449605,Change from baseline in glycemic measure HbA1c,Relative change from baseline in HDL-C,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
6109,NCT03823027,Tolerability measured as evaluation of Adverse Events,Performance measured as changes in body fat %,Explorative Endpoint on changes in microbiome diversity (species not defined),2019-01-28,COMPLETED,INTERVENTIONAL,['NA']
6110,NCT01542476,Change in Patient-Reported Outcomes (PRO) using World Health Organization 5 (WHO-5) item Well-being Index: Insulin Treatment Appraisal Scale (ITAS),Adverse events,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
6111,NCT01865279,Area under the glucose infusion rate curve (trial part 2 only),Area under the serum insulin concentration curve,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6112,NCT06206317,Static Two-Point Discrimination Test,,,2024-02-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6113,NCT01472809,Safety and tolerability,Pharmacodynamics,,2011-12,SUSPENDED,INTERVENTIONAL,['PHASE1']
6114,NCT04013594,Glycemic variability,hand grip strength,,2019-08-20,COMPLETED,INTERVENTIONAL,['NA']
6115,NCT06229795,Effect on,Effect on,,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE3']
6116,NCT02166294,Number of participants with adverse events,Time to Initial Wound Closure,,2014-06,TERMINATED,INTERVENTIONAL,['NA']
6117,NCT02955238,Change in Carotid Intimal Medial Thickness (CIMT) Measurement,Medication Adherence,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6118,NCT00829062,The aim of this project is to present evidence based practice to Missouri Medicaid to expand coverage of continuous subcutaneous insulin infusion (CSII) in pediatric patients with diabetes. - Hemoglobin A1C,Glycemic variability as shown by continuous glucose recording,,2009-01,WITHDRAWN,INTERVENTIONAL,['NA']
6119,NCT02416193,Trail Making Test Part B,Semantic Fluency Test,,2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2']
6120,NCT03353818,Physical activity,Estimated VO2max,,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
6121,NCT00846638,Drinking outcome,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6122,NCT01580098,HbA1c,Number of Hospitalisations,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
6123,NCT05346614,Rate of diabetes remission,Compliance,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6124,NCT01546597,"Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6125,NCT02433262,To measure the prevalence of GDM diagnosed using WHO versus IADPSG criteria,To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG),,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
6126,NCT01172743,,,,2009-06,TERMINATED,OBSERVATIONAL,['NA']
6127,NCT04989634,Incidence of gestational diabetes mellitus,Incidence of premature birth,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6128,NCT06283277,Third trimester clavicle length measurement,Neonatal actual clavicle length,,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6129,NCT00694122,Blood Glucose,Growth Hormone,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6130,NCT00473330,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6131,NCT02471794,Change in A1C using the A1C blood test,Change in low-density lipoprotein cholesterol (LDL) using LDL measurement,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
6132,NCT05738577,glycemic control according to apelin level,Detection of the relation of apelin and lipid profile in diabetic patients,,2023-02-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6133,NCT04133493,Wound Healing,Pain reduction: visual analogue scale (VAS),Histology assessment from biopsies,2019-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6134,NCT02934113,Change in Weight,,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
6135,NCT02042664,intracardiac triglyceride,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6136,NCT03202979,Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale,Frequency of treatment-related adverse events,,2017-05-16,COMPLETED,INTERVENTIONAL,['PHASE2']
6137,NCT02196350,percentage of participants that reach normoglycemia,change in indices for hepatic insulin resistance,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
6138,NCT06059833,magnesium perecentage,,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6139,NCT02397421,Change in LV end systolic volume (absolute value and indexed for BSA) or LV end diastolic volume (absolute value and indexed for BSA),"The safety of dapagliflozin use in diabetic, heart failure patients with regard to worsening HF, hospitalization and death will be evaluated",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6140,NCT00136188,Change in renal endothelial function,,,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6141,NCT03936634,Arm B - Auto-antibody positive first degree family members,Arm B - Auto-antibody positive first degree family members - Framework,,2016-11-14,UNKNOWN,OBSERVATIONAL,['NA']
6142,NCT00328848,Quality of medical management,Opportunity costs of caregiver time,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
6143,NCT03610178,NR3C1,Methylation of candidate genes,,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
6144,NCT01472328,Skeletal muscle insulin sensitivity,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
6145,NCT01943214,Body constitution of type II diabetes mellitus patients,Diabetic neuropathy of type II diabetes mellitus patients,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
6146,NCT00867425,Change in weight,Health Related Quality of Life,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6147,NCT05551858,Adverse events,Change in Pain Measurements numeric score from baseline to end of treatment with proglumide compared to Placebo,,2022-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6148,NCT02274272,Change in blood fat,Change in the DM marker,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6149,NCT01590758,Number of Participants With Clinical Response,Number of Participants With Treatment-emergent Adverse Events (TEAE),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6150,NCT02154347,Change From Baseline in HbA1c,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
6151,NCT01779596,exercise induced blood flow,exercise induced Flow Mediated Dilation,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6152,NCT04015388,"Evaluate performance of glucose predictive models, clinical decision support algorithms, and performance measures in simulated real-time setting.","Further development of GlyCU system functionality (simulation, training, and clinical decision support capabilities) and identification of necessary steps for integration with the OSUWMC electronic health record database.",,2014-08-19,COMPLETED,OBSERVATIONAL,['NA']
6153,NCT06320600,The currency analysis of diabetes classification,To establish a model for predicting diabetic neuropathy,To establish a model for hypoglycemic therapy,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
6154,NCT00225225,modification of the diet prevents weight gain.,develop specific dietary recommendations,,2002-10,TERMINATED,INTERVENTIONAL,['NA']
6155,NCT03942471,Change in HbA1c Measurements after Mindfulness Training,,,2015-10-14,COMPLETED,INTERVENTIONAL,['NA']
6156,NCT02569151,Death,"new, worsened, or improved microvascular and macrovascular events",,2016-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6157,NCT00819741,Change in Glycosylated Haemoglobin A1c (HbA1c),Haematology: Haemoglobin,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6158,NCT03556033,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,Inflammatory/atherogenic phenotype of circulating monocytes from the participating patients,2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
6159,NCT04058626,Diagnostic Accuracy,,,2019-03-04,COMPLETED,OBSERVATIONAL,['NA']
6160,NCT04120259,Measurement of Fasting Blood Sugar,,,2019-04-22,COMPLETED,INTERVENTIONAL,['NA']
6161,NCT05388643,Gestational Diabetes Mellitus,Patient Satisfaction with Diabetes Screening Method,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6162,NCT01824407,Complete closure,Rate of amputation and other adverse events,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6163,NCT03334643,Postprandial glycemic response,,,2018-06-04,COMPLETED,INTERVENTIONAL,['NA']
6164,NCT05176132,Prevalence of unrecognized obesity-related diseases,SDOI attitude to physical activity questionnaire,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
6165,NCT06327711,Fasted Insulin,Conicity Index,Urine biomarkers - inflammation,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6166,NCT01068197,Change in BMI z-score between the two dietary groups,"Differences in subjective, hormonal, and metabolic between the two dietary arms",,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6167,NCT02759107,Number of Participants With One or More Serious Adverse Event(s) (SAEs),Pharmacodynamics (PD): Ratio of AUC of Glucose on Day 23 to Baseline (Part C),,2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6168,NCT01129557,Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.,Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE4']
6169,NCT02036892,Hemoglobin A1c,Center for Epidemiological Studies Depression Scale,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
6170,NCT03168633,HbA1C values of patients after 6 months,percentage of messages opened and read,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
6171,NCT00850096,Continuous Glucose Monitoring (CGM),Overall Glycemic Control,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6172,NCT01586442,PIIINP,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6173,NCT01068665,Change in Glycosylated Haemoglobin (HbA1c),Change in Fasting Plasma Glucose (FPG),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6174,NCT04867707,Change in glycocalyx integrity,Change in Vascular function,,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6175,NCT06245252,fasting blood glucose levels,score of fatigue severity scale,,2024-02-10,RECRUITING,INTERVENTIONAL,['NA']
6176,NCT02517242,Glycated Hemoglobin,Presence of asyntomatic hypoglycemias,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
6177,NCT01749345,Quality of life,Low density lipoprotein (LDL) Cholesterol,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
6178,NCT02191111,Change in Service Counts From Baseline to End of Intervention Period,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
6179,NCT01137695,Glucose control,adverse effects,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
6180,NCT02014740,Echocardiographic Epicardial Fat Thickness,,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6181,NCT03059719,Incidence of treatment-emergent AE (safety and tolerability),PB-119 blood concentration,,2015-04-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6182,NCT04708145,DRSS Level Achievement in the VOYAGE study,Incidence of Adverse Events,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6183,NCT05322200,"Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated ""Plaque Maps"" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo.",Evaluate the effect of oral Semaglutide on levels of biomarkers of oxidative stress.,,2022-08-31,RECRUITING,INTERVENTIONAL,['PHASE4']
6184,NCT05078697,microbiota,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
6185,NCT00172406,,,,na,COMPLETED,OBSERVATIONAL,['NA']
6186,NCT04790526,HBA1c,Joint error position test,,2021-07-12,COMPLETED,INTERVENTIONAL,['NA']
6187,NCT03195855,Change in maximum ankle range of dorsiflexion in stance phase when both feet are in contact with the ground (double support phase).,Change in functional reach test,To investigate the compliance/adherence rates of the home exercise programme,2018-05-11,COMPLETED,INTERVENTIONAL,['NA']
6188,NCT03811587,Dosage of antidiabetic medication used,,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA']
6189,NCT04145804,The achievable percentage of time in range (TIR) 70 - 180 mg/dL for the whole study population after 3 months.,Percentage of time spend in Auto Mode,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6190,NCT02217306,Contrast Sensitivity,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6191,NCT00000159,,,,1983-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6192,NCT05207020,Collect glucose values (after a test meal),,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
6193,NCT03369145,Leukocyte cell-derived chemotaxin 2 (LECT2),Body fat percentage,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
6194,NCT00787670,To determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with Type 2 Diabetes Mellitus (T2DM),To elucidate the mechanisms by which surgically induced weight loss reduces over time the risk of CVD in morbidly obese subjects with T2DM.,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
6195,NCT01279928,,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
6196,NCT04737499,Change of Concentration of HbA1c,Change of Score of Quality of life,,2016-07-05,COMPLETED,INTERVENTIONAL,['NA']
6197,NCT01471509,Change in blood glucose concentration,Change in serum insulin concentration,,1982-08,SUSPENDED,INTERVENTIONAL,['NA']
6198,NCT01966393,Percentage of time of glucose levels (as measured by continuous glucose sensor) spent in the hypoglycemic range.,Number of patients with at least one hypoglycemic event with or without symptoms below 3.0 mmol/L based on glucose sensor reading,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6199,NCT02552355,Glucose Tolerance,Glucose Profiles From Real-Time Continuous Glucose Monitoring,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6200,NCT00511732,Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6201,NCT05453357,Overall Feasibility of Remote Glucose Monitoring,Changes in self-efficacy,,2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6202,NCT00841867,To determine differences in glucose metabolism between subjects who have had partial pancreatectomy due to a benign lesion and those who have not had such a surgery.,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
6203,NCT02851849,Change from baseline in HbA1c,Change from baseline in body weight,"Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1)",2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6204,NCT01527539,HbA1c,Occurence of hypoglycaemic episodes,,2001-11-23,COMPLETED,INTERVENTIONAL,['PHASE3']
6205,NCT03631186,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-09-12,COMPLETED,OBSERVATIONAL,['NA']
6206,NCT00810823,"What is the factor ""X"" that cause the remission of type 2 diabetes after gastric bypass",,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6207,NCT04128150,Evolution of retina diseases,,,2018-01-17,UNKNOWN,OBSERVATIONAL,['NA']
6208,NCT02244879,C reactive protein (CRP),Metabolic and oxidative markers,body composition and bone mineral density,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6209,NCT05849753,Percent sensor glucose time-in-range,Technology Attitudes,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA']
6210,NCT01023243,Completion of foot exam,Patient report in validation of Natural Language Processing,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
6211,NCT03398356,Serum Levels of DMA at Different Time Points,,,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE4']
6212,NCT02313805,The total number of educational points addressed for the safe and effective use of insulin (of the possible 21 specified),"The number of educational points addressed under each of the four educational domains: insulin side effects, recognition and treatment of hypoglycemia, administration of insulin, and drawing up insulin using the syringe method.",,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
6213,NCT00473525,Evaluation of Dose Response in HbA1c (%),Incidence of Adverse Events,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6214,NCT03559621,weight-loss goal,Sence of Coherence,,2019-04-14,COMPLETED,INTERVENTIONAL,['NA']
6215,NCT06136793,Participant Cardiometabolic Disease Markers: Waist circumference,Household Supports for cardiometabolic disease reduction measures: Family Collective-Efficacy,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6216,NCT00555854,HbA1c,"Lipids profile ,blood pressure, waist, BMI and medication Questionnaire: PAID PCD HCCQ TSRQ Health Care Behavioural a",,2005-12,COMPLETED,INTERVENTIONAL,['NA']
6217,NCT06050642,Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care],E.2 Number and relevance of impact that can have an impact on diabetes [Comparison: Enhanced Care vs Standard Care],,2023-09-04,RECRUITING,INTERVENTIONAL,['NA']
6218,NCT00444483,The primary outcome measure regarding patients metabolic control was the improvement of quality of life six months after DTTP.,A secondary objective of the study was the comparison of QoL- subscale in patients already on insulin therapy with those newly on insulin therapy.,,na,COMPLETED,INTERVENTIONAL,['NA']
6219,NCT03139864,Comparison of substrate utilization between infants with type 1 diabetes and infants without type 1 diabetes during exercise,Comparison between infants during 10 days before and 4 days after exercise of blood glucose modification,,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA']
6220,NCT04216875,Change in score result before and after the introduction of the diabetes score criteria for treatment of diabetes patients in the primary care setting,Evaluation of practice tool used for the documentation and evaluation of the diabetes score,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
6221,NCT04092959,Change from Baseline Systolic Blood Pressure at 3 months,Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion,,2019-09-20,UNKNOWN,INTERVENTIONAL,['NA']
6222,NCT01010035,to identify the removal of the free and esterified cholesterol in type 2 diabetes patients,,,2006-09,COMPLETED,OBSERVATIONAL,['NA']
6223,NCT00817973,Triglyceride levels,Incretin levels,,na,COMPLETED,INTERVENTIONAL,['NA']
6224,NCT01300338,Mean Change in Diastolic Blood Pressure,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6225,NCT03500016,Cardiorespiratory fittness/maximal oxygen consumption,Plasma and tisue metabolomics,Lipid profile,2018-02-26,COMPLETED,INTERVENTIONAL,['NA']
6226,NCT04561609,Change in Monofilament test,Change in skin temperature,,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA']
6227,NCT01607684,Frequency of gastric peristalsis,Influence of age on parameters of diabetic polyneuropathy measurable by magnetic marker imaging,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6228,NCT05625321,Dietary Intake,Perceived Quality of Life,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
6229,NCT01226966,Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%,Change in Body Weight at Month 24,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
6230,NCT01840085,The proportion of all subjects reporting Adverse Events and Serious Adverse Events related to study treatment,,Proportion of all subjects treated and terminating prematurely due to adverse events related to study treatment.,2015-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6231,NCT04710940,Completion of diabetes self-management training (Aim 3),Hemoglobin A1C (HbA1C) (Aim 3),Predictors of guideline-concordant diabetes care (Clinical utilization) (Aim 1),2021-01-13,COMPLETED,INTERVENTIONAL,['NA']
6232,NCT03455868,"Change in areal bone mineral density at lumbar spine, hip and radius",Change in cutaneous Advanced glycation end products (AGEs),Prevalence and incidence of non-vertebral fractures,2018-03-15,RECRUITING,OBSERVATIONAL,['NA']
6233,NCT01259206,Increased Calcaneal Spur Incidence in Patients With Obesity and Type 2 Diabetes Mellitus,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
6234,NCT00742547,HbA1c,incidence of diabetes-related complications,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
6235,NCT03961659,Change of olfactory brain activation by fMRI,Olfactory threshold test,,2019-05,UNKNOWN,INTERVENTIONAL,['NA']
6236,NCT01948479,ulcer recurrence rates,peak pressure reduction with the addition of the intervention,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
6237,NCT01104142,,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
6238,NCT04907721,Differences in the calculated GLUSENTIC index between individuals with or without MASLD without diabetes,"Simple linear regression between the variables, pancreatic steatosis and amino acid stimulated glucagon or insulin levels in individuals without diabetes.",Differences in fetuin-B,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
6239,NCT00859638,Physical Functioning Inventory (PFI),Eight Foot Walk Test,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
6240,NCT03438162,Medication adherence assessment method,Adverse events questionnaire,,2018-04-01,COMPLETED,INTERVENTIONAL,['NA']
6241,NCT05296044,Changes in HbA1c,,,2022-04-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
6242,NCT01762657,Insulin Requirements Among Patients Treated with Oral Cyclosporine and Oral Lansoprazole,Glucagon C-peptide (under the curve) and Hemoglobin A1C levels among patients with existing type 1 diabetes treated with Cyclosporine and Lansoprazole,,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6243,NCT04371653,Number of Participants With an Increase in Flora Diversity in Fecal Samples,Monitor subjects' health information,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6244,NCT05421715,Evolution of glycemic control hemoglobin (HbA1c) between inclusion and 6 months,Evolution of knowledge about diabetes and glycemic targets between inclusion and T6 months,,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
6245,NCT05724888,Retention for follow-up measurements,BREQ2 (Behavioral Regulation in Exercise Questionnaire-2) change,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6246,NCT02339909,Number of Patients Attending Screening Appointment,Number of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6247,NCT00256607,1) Determine the cross-sectional relationship between baseline levels of novel CVRF and the,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6248,NCT04684030,The change of glycated hemoglobin (HbA1c) level,The number of participants with improved clinical glycometabolic parameters,,2020-08-28,UNKNOWN,INTERVENTIONAL,['NA']
6249,NCT02753400,"Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values",,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6250,NCT03257566,Screening the incidence of hypothyroidism in patients with type 1 diabetes,,,2017-11,UNKNOWN,OBSERVATIONAL,['NA']
6251,NCT04390295,Adjusted Mean Change in HbA1c Levels,The number of volunteers with adverse events as a measurement of safety,,2017-11-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
6252,NCT05073978,maternal outcomes,,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
6253,NCT05479591,Change in Glycated Haemoglobin A1c (HbA1c),Change in body weight,,2022-07-30,WITHDRAWN,OBSERVATIONAL,['NA']
6254,NCT01086189,Postprandial glucose and insulin,Postprandial satiety,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
6255,NCT01023581,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Fasting Plasma Glucose Over Time,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6256,NCT02815943,lipid metabolism,physical activity,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6257,NCT04058639,wound healing time in weeks,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
6258,NCT03010319,"Percentage of Subjects With Complete Wound Closure, as Assessed by the Investigator, at or Before Week 12 of the Treatment Phase","Rate of Wound Closure, as Assessed by Computerized Planimetry.",,2017-01,COMPLETED,INTERVENTIONAL,['NA']
6259,NCT01113099,Statin prescription at hospital discharge,,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
6260,NCT01147731,The pharmacokinetic parameters (AUC and Cmax) of R and S-warfarin isomers with and without albiglutide,The effect of albiglutide on the pharmacodynamics of warfarin as determined by the International Normalisation Ratio (INR).,,2010-06-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6261,NCT02434094,Human factors feedback,,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
6262,NCT01234155,Glycemic Control,Body Composition,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6263,NCT05348551,Assessment of the proportion of pediatric patients with access to remote monitoring,Evaluation of patients' (and parents') perception of telemonitoring using a scale,,2022-05-20,UNKNOWN,OBSERVATIONAL,['NA']
6264,NCT01754467,Acceptability of NEAT!,Changes in Total Sedentary Time,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
6265,NCT02186353,Change from week 0 in peripheral insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 12,Change from week 0 in physical activity (assessed by accelerometry) at week 12,,2014-09,WITHDRAWN,INTERVENTIONAL,['NA']
6266,NCT01070433,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6267,NCT00696982,"arterial stiffness, defined as change in augmentation index measured by means of a non-invasive technique using the commercially available SphygmoCor System, and the results of the 24 hour blood pressure monitoring","The secondary end results would be oxidative stress parameters, as evaluated by oxidized LDL and Isoprostanes, and markers of inflammatory status, including measurements of pro-inflammatory interleukins and performance of highly sensitive CRP test.",,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
6268,NCT01192139,Metformin Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6269,NCT04120623,the effect of dapagliflozin combined with CSII on glucose profile,"the effects of dapagliflozin combined with CSII on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)",,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6270,NCT01168297,Diabetes,,,2010-07-06,COMPLETED,OBSERVATIONAL,['NA']
6271,NCT00604383,Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period,Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6272,NCT02389010,Number of closed skin ulcers within 4 weeks of treatment with cord blood platelet gel (CBPG) vs standard local medications,Cost of treatment,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6273,NCT05327595,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PD: Change from Baseline to Day 28 in Oral Glucose Tolerance (OGTT) 2 Hour Glucose,,2022-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6274,NCT04381429,Change of time in range of blood glucose variation (70-180 mg/dl) versus baseline at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months) is assessed.,Other CGM parameters: Time in range of blood glucose 70-140 mg/dl,,2020-08-17,RECRUITING,INTERVENTIONAL,['PHASE4']
6275,NCT03737799,Diabetes type defined by insulin requirement at 3 years,Wellbeing (SF12 questionnaire),,2016-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6276,NCT04339530,HOMA-IR (Homeostasis modelling assessment-Insulin resistance),Augmentation index,,2019-07-01,SUSPENDED,OBSERVATIONAL,['NA']
6277,NCT03960814,Age at death of cardiovascular disease,,,2019-05-21,COMPLETED,OBSERVATIONAL,['NA']
6278,NCT03901898,Number of patients who have attended screening,,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
6279,NCT03399825,Evaluation of the sensitivity and specificity of OCTA,,,2018-01,WITHDRAWN,OBSERVATIONAL,['NA']
6280,NCT00348855,"Number of patients who reach all the therapeutic goals defined by the guidelines in the total study population, in the sub-group of patients with hypertension, but free of type-2 diabetes (T2D), and in the sub-group with hypertension and T2D.","Levels of blood pressure, LDL-Cholesterol, tobacco consumption in the whole population plus levels of HbA1c and aspirin use in the TD2 population",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6281,NCT06028386,Days to complete wound closure,Changes in quality of life,,2023-08-15,RECRUITING,INTERVENTIONAL,['NA']
6282,NCT01947790,The changes of LVM,The changes of endothelial function,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6283,NCT03414736,Frequency of GI AEs,Adverse events (AEs),,2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
6284,NCT04243746,Serum high density lipoprotein (HDL) (mmol/L),Incidence of treatment-emergent adverse events [Safety ],,2020-03-03,COMPLETED,INTERVENTIONAL,['NA']
6285,NCT02596581,gingival crevicular fluid chemerin level,clinical attachment level,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
6286,NCT00950209,"To determine whether an acute elevation of plasma insulin, secondarily to plasma insulin infusion, modulates the production and the clearance rates of intestinal TRL-apoB48 in type 2 diabetic patients in the fed state",To determine if this is a direct effect of insulin or an indirect effect due to the decrease of plasma FFA or the decrease of plasma glucose.,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6287,NCT03017352,Change in HbA1c,hsCRP (High-Sensitivity C-Reactive Protein),,2016-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6288,NCT00329225,HbA1c at each visit,FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6289,NCT05984979,VOC Patterns over time as boxplots,Correlation between VOCs and subgroups,,2023-08-07,RECRUITING,OBSERVATIONAL,['NA']
6290,NCT00327418,or unstable angina or resuscitated cardiac arrest or stroke.,baseline in various lipid and lipoprotein parameters.,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6291,NCT02672436,The ulcer closure rate,Adverse event incidence,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE2']
6292,NCT01465152,Change of % HbA1c (glycosylated haemoglobin) in blood,Treatment compliance,,2002-03-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6293,NCT02200991,Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast,Proportion of patients with adverse events,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6294,NCT04477694,Comparison of stomach ache and other effects in diabetic and non-diabetic patients in colonoscopy under sedoanalgesia,,,2020-12-27,RECRUITING,OBSERVATIONAL,['NA']
6295,NCT02277509,Percent Change in BMI,Sustained changes in HbA1c,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6296,NCT02374879,System Accuracy (SA) evaluation,,,2015-02-01,COMPLETED,INTERVENTIONAL,['NA']
6297,NCT00000153,,,,1984-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6298,NCT05040009,Screening for diabetic foot and diabetic complication in patients attending at Diabetic center,,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6299,NCT00940797,Insulin sensitivity,"Creatinine, Total Cholesterol, HDL, Triglycerides, Uric acid, AST, ALT, FA, DHL",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6300,NCT04815278,Blood Pressure at Month 12,Medication Covariates,Scores on Effort-Reward Imbalance Scale,2021-09-17,RECRUITING,INTERVENTIONAL,['NA']
6301,NCT03202875,Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR),Number of adverse events (AEs),,2012-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
6302,NCT01263509,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6303,NCT03059550,Percentage of OGTT performed after an acute coronary syndrome,Profile of the patients according to their glucose abnormalities,,2013-03-01,UNKNOWN,OBSERVATIONAL,['NA']
6304,NCT01622816,ETDRS Letter Score,ETDRS Letter Score Consistency,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
6305,NCT02012465,Incidence of hyperglycemia,Remission of primary oncologic diagnosis at one year,,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6306,NCT04903756,Analysis of audio-recorded consultations between surgeons and patients.,Analysis of healthcare professional interviews,,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6307,NCT02938026,Change of weight,,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
6308,NCT01363609,food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%),GLP-1 analog treatment related changes in obese patients with type 2 diabetes in brain arterial blood flow.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
6309,NCT01686620,Change in HbA1C,Daily blood glucose measures,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6310,NCT03700502,resting-state functional Magnetic Resonance Imaging,,,2016-06-05,UNKNOWN,OBSERVATIONAL,['NA']
6311,NCT03907423,serum levels of Sortilin,,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
6312,NCT00901043,Brachial artery flow mediated dilation (FMD),"Change in weight, waist circumference, blood pressure, fasting lipids, fasting insulin, HBA1c and glucose levels",,2007-10,COMPLETED,INTERVENTIONAL,['NA']
6313,NCT02899572,Measurement of HbA1c according to the randomisation group,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
6314,NCT03988413,Change of urinary routine,Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of SYHA1402,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6315,NCT01009528,Outcome and process measures from the danish diabetes guideline,Interview data concerning the impact of the electronic feedback system in the intervention clinics,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
6316,NCT05234281,Changes in level of patient activation,Changes in level of functioning,,2021-05-01,RECRUITING,INTERVENTIONAL,['NA']
6317,NCT04468243,Point of Care HbA1c Test,,,2021-04-01,TERMINATED,INTERVENTIONAL,['NA']
6318,NCT03360981,Major adverse cardiac events (MACE),stem cells isolated in epicardial fat.,,2017-09-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
6319,NCT01898572,Carotid Intima Media Thickness (CIMT),CIMT,Diet intake,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
6320,NCT02713997,Maximal acute C-peptide response to glucose (ACRmax),Severe Adverse Events,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6321,NCT04635280,"Description of Patient satisfaction and experience at Day 90 by the ""You and your management by your home healthcare provider"" questionnaire","Evolution of patients' clinical profile : Percentage of time spent over a 4-week period in glycemic target range, in hypoglycaemia and in hyperglycaemia",,2021-05-10,COMPLETED,INTERVENTIONAL,['NA']
6322,NCT02366767,Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes,Efficacy of Hybrid Closed-loop System in Comparison With Control,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
6323,NCT03358264,Vascular function,,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6324,NCT04092140,Electromyogram,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
6325,NCT03829046,Number of Adverse Events,Alpha5/Beta3 Activation Levels,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6326,NCT02106585,fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval),,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6327,NCT04892069,Change in Glycated Haemoglobin (HbA1c),Change in the occurrence of severe hypoglycaemic events before and after initiation of treatment,,2021-05-27,COMPLETED,OBSERVATIONAL,['NA']
6328,NCT05574335,Acceptable T cell phenotype signature by the change from baseline in the CD4 Treg/Tem ratio,Insulin use (U/kg/day),,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6329,NCT00350701,Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo,Change in Inflammatory Mediator C-Reactive Protein (CRP) Following Treatment With Testosterone,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6330,NCT01864564,Number of Participants With a Composite Perinatal Outcome,Large for Gestational Age,,2013-06-18,COMPLETED,INTERVENTIONAL,['NA']
6331,NCT05369078,Collect and evaluate TEAEs (including clinical AEs and Lab AEs) of THR-1442 in healthy subjects during study,Select and evaluate pharmacokinetic characteristics(Cmax) of THR-1442 in healthy subjects during the study,,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6332,NCT01906970,"Measurement accuracy, glucose control quality, safety, handling and functionality of ClampArt®",,,2013-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6333,NCT00948116,Development of contrast induced nephropathy (CIN) which will be defined as an increase in Cr of ≥ 44 μmol/l within 72 hours post-procedure.,,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
6334,NCT04961931,urine phosphorus concetration,,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6335,NCT06149793,"Feasibility, safety, tolerability",,,2023-12-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6336,NCT00001346,,,,1992-11,COMPLETED,OBSERVATIONAL,['NA']
6337,NCT05786534,Weight will be measured before and after the trial,,,2022-12-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6338,NCT01731431,"Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemia","Rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization",,2012-05-18,COMPLETED,INTERVENTIONAL,['PHASE3']
6339,NCT03100383,Gestational Weight Gain (GWG).,Eating behavior,,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
6340,NCT02479399,Incidence of malignant tumor,Safety developed by adverse events and laboratory tests,,2014-07-17,COMPLETED,OBSERVATIONAL,['NA']
6341,NCT01085682,Incidence of Type 2 Diabetes Mellitus,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6342,NCT00228605,Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients,Assess the patients' overall medication performance,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6343,NCT02400450,LDL-Cholesterol,Food Consumption Patterns,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
6344,NCT06232746,Anastomosis Patency,,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6345,NCT04107207,Blood Sugar Levels,vulvovaginal health,,2019-11-11,COMPLETED,INTERVENTIONAL,['NA']
6346,NCT01189461,Mean Total Number of Injections,Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 48 (End of Treatment),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6347,NCT02629705,Insulin sensitivity assessed by hyperinsulinemic clamp: M-value,Glycemia during OGTT,"Markers of systemic inflammation including lymphocyte activation, cytokines and adipokines",2015-10,COMPLETED,INTERVENTIONAL,['NA']
6348,NCT00509262,Percentage of Participants With Hypoglycemic Events,Change From Baseline in Body Weight at Week 54,,2007-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6349,NCT02863276,Postoperative protein balance (leucine) (umol/kg/h),Postoperative glucose metabolism: Glucose clearance (ml/kg/min),,2009-12,COMPLETED,INTERVENTIONAL,['NA']
6350,NCT03652389,reduction in the levels of HbA1c,,,2018-12-18,COMPLETED,INTERVENTIONAL,['NA']
6351,NCT04028089,Glycaemic excursion during an oral glucose tolerance test,Time of delivery,Epigenetic modification,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
6352,NCT02072096,Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia,Change From Baseline of Estimated Glomerular Filtration Rate (eGFR),Change From Baseline in Mini-mental State Examination (MMSE) Score,2014-02,TERMINATED,INTERVENTIONAL,['PHASE4']
6353,NCT00001203,,,,1985-04-22,COMPLETED,OBSERVATIONAL,['NA']
6354,NCT01447979,estimation of the failure rates of system components,percent time of active CTR,,2012-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6355,NCT05873920,atrial fibrillation recurrence,,,2023-05-09,RECRUITING,OBSERVATIONAL,['NA']
6356,NCT00748072,The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.,,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6357,NCT02129595,"insulin sensitivity: overall, muscle- and liver specific",brown adipose tissue activity,Blood pressure,2014-04,COMPLETED,INTERVENTIONAL,['NA']
6358,NCT01763346,Steady State Beta Cell Compensation,,Glycemia,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6359,NCT01183455,Mixed-Meal Tolerance Test (MMTT)-Stimulated 2-hour C-peptide Area Under the Curve (AUC),Pharmacokinetic Parameters of Aralast NP,,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6360,NCT04501341,Decreasing total daily dose of insulin (>= 30%),HbA1c,,2016-03-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6361,NCT06283992,Proportion of Participants Who Login to the Portal,Proportion of participants that are re-admitted,,2024-03-31,RECRUITING,INTERVENTIONAL,['NA']
6362,NCT05600179,Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
6363,NCT04171648,Change from Baseline Blood Glucose Response (Glycemic Response),waist to hip ratio,,2020-03-02,TERMINATED,INTERVENTIONAL,['NA']
6364,NCT02650206,Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry).,Macrophage polarization: M1 to M2 ratio in adipose tissue and peripheral blood according to cell surface markers (measured by flow cytometry),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6365,NCT03964987,ARNm expression,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
6366,NCT00196989,Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control,Change from Baseline (Day 1) in QUICKI at Week 16,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6367,NCT01124617,Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12,Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Scores at Week 12,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6368,NCT00518115,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6369,NCT05478070,Maternal outcomes,,,2022-05-15,RECRUITING,INTERVENTIONAL,['NA']
6370,NCT00529204,Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy,Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
6371,NCT01398995,Comparison of glucose excursion (change in blood glucose) between baseline and the end of exercise between the four conditions.,Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise compared between the four conditions.,,2011-05,TERMINATED,INTERVENTIONAL,['NA']
6372,NCT05231031,Serum cortisol level,The perceived stress score (PSS),,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
6373,NCT03363464,All-cause mortality,"Acute kidney injury (Inpatient, any position)",,2017-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6374,NCT01497600,Area under the glucose infusion rate curve,Adverse events,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6375,NCT01498900,HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),,2004-08,COMPLETED,OBSERVATIONAL,['NA']
6376,NCT01885260,The effect of ISIS-GCGRRx on serum fructosamine,The tolerability of ISIS-GCGRRx,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6377,NCT04789473,Polygenic Risk Score Prediction for Gestational Diabetes,Impact of Social Determinants of Health on Risk,,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA']
6378,NCT00116831,Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18,Number of Other Cardiovascular Events,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6379,NCT01605422,"Effect of pulse consumption on satiety in acute, single bolus controlled feeding trials.",,,2011-10,UNKNOWN,OBSERVATIONAL,['NA']
6380,NCT01772251,Adverse events and serious adverse events occurence,• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,• Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs. placebo,2013-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6381,NCT04512885,success rate,satisfaction measured by auto-questionnaire,,2020-07-16,COMPLETED,OBSERVATIONAL,['NA']
6382,NCT03657537,Cognitive composite score (global score),Symbol Digit Modalities Test (SDMT),,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
6383,NCT01431807,Adverse events,,,2011-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6384,NCT04747639,iAUC insulin 250,gastro-intestinal symptoms,,2015-10-28,COMPLETED,INTERVENTIONAL,['NA']
6385,NCT01776099,metabolic improvement of type 2 diabetes,,,2012-11,UNKNOWN,INTERVENTIONAL,['NA']
6386,NCT03459079,Change in intrahepatic triglycerides (IHTG) quantified by proton magnetic resonance and spectroscopy (¹H-MRS),Change in plasma biomarkers of liver fibrosis.,,2018-08-14,COMPLETED,INTERVENTIONAL,['PHASE2']
6387,NCT00910130,,,,2008-07,UNKNOWN,OBSERVATIONAL,['NA']
6388,NCT00720889,Total body insulin sensitivity,Glycerol turnover and free fatty acid concentration,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6389,NCT01973361,Change in wound surface area,Number of wounds healed,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
6390,NCT06230705,Cardiovascular Risk Factor Knowledge,,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6391,NCT00004572,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
6392,NCT06005142,Fasting Glycemia,Microbiota composition by 16S rRNA gene sequencing,,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6393,NCT00821795,"For Transition From Inpatient to Outpatient Care, Evaluate Glycemic Control in Subjects Randomized to Receive 70/30 NPH/Regular Insulin or Aspart Analog 70/30 Mix Bid- Main Outcome Will be HbA1c During Transition Outpatient Therapy Phase.",Twice Daily Blood Glucose Monitoring Using Telehealth Transmitter,,2009-03-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6394,NCT03645109,Changes in the parameters that make up the glycemic profile,"Changes in calcium, phosphorus and vitamin D3",,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
6395,NCT03683888,Epicardial fat thickness (EAT),Hemoglobin A1c (HbA1c) percentage (%),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
6396,NCT01648153,Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT),t1/2,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6397,NCT02373150,Safety and tolerability of imeglimin: laboratory assessments,,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6398,NCT01113671,Reverse Cholesterol transport of the HDL,Serum inflammatory markers,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6399,NCT01374568,Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo,,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4']
6400,NCT05926414,HbA1c (%) changes,,,2023-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6401,NCT03181737,Diabetes Self-Management Questionnaire (DSMQ-R),Subjective usefulness of the program,,2017-08-03,TERMINATED,INTERVENTIONAL,['NA']
6402,NCT04665570,Mean change in HbA1c,Descriptive analysis of adverse events (AEs),,2020-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6403,NCT03794336,Overall Gastrointestinal tolerability,Medication possession ratio (MPR),,2019-06-29,COMPLETED,INTERVENTIONAL,['PHASE4']
6404,NCT01559025,Beta cell function,Glycemic variability,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6405,NCT02050074,Change in the gut hormone glucagon-like peptide 1 (GLP-1),,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6406,NCT02769481,Change From Baseline in HbA1c at Week 60,Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.,,2016-08-15,COMPLETED,INTERVENTIONAL,['PHASE3']
6407,NCT04550585,Low-literacy based education on diabetes knowledge,,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
6408,NCT04627402,Macular thickness,Incidence of complications,,2020-11-12,UNKNOWN,INTERVENTIONAL,['NA']
6409,NCT01255254,Metabolic control,Inflammation,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
6410,NCT04916132,Prevalence,Death,,2021-08-10,RECRUITING,OBSERVATIONAL,['NA']
6411,NCT02587975,Serum concentration of C-terminal telopeptide after treatment in comparison with the baseline,,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
6412,NCT00449891,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
6413,NCT02097277,Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12,Percentage of Participants With ANTI-BMS-986036 Antibody Response,,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE2']
6414,NCT02210845,Three months average blood glucose (A1c),A1c,body mass index (BMI),2018-07,UNKNOWN,INTERVENTIONAL,['NA']
6415,NCT03694470,"The proportion of patients who were new users of SGLT-2 inhibitors in 2015, 2016, 2017",Number of participants with co-morbidities,,2018-04-15,COMPLETED,OBSERVATIONAL,['NA']
6416,NCT03512236,AUCPram_0-8h,Safety and tolerability (Adverse Events recording),,2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE1']
6417,NCT01364428,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6418,NCT00206258,Area under the curve for glucose,Glucagon and gastric emptying,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6419,NCT02582840,24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set,Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6420,NCT01784471,Changes in total peripheral resistance as assessed by impedance cardiography (ICG) from baseline to day 30,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6421,NCT00585936,,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
6422,NCT03578887,Weight Regain,,,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6423,NCT02219269,Contraceptive method continuation and satisfaction,If Contraception is Accessed in post-partum or post-abortion setting,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
6424,NCT03668470,HbA1c level,coefficients of variation (CV),,2019-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
6425,NCT00118963,Glycemic control (HbA1c).,"Markers of endothelial dysfunction, inflammation and fibrinolysis including Small-dense-LDL, Lp(a) and Apo B100, von Willebrand-factor, ICAM, VCAM, selectin, endothelin, Amadori-protein, CRP, fibrinogen, IL-6, TNF-alfa, ADMA, PAI- and t-PA-activity",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6426,NCT03874715,Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),,2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6427,NCT04103671,progression rate of severe non proliferative diabetic retinopathy,The change of quality of life,,2019-12-04,RECRUITING,INTERVENTIONAL,['NA']
6428,NCT03388762,GlycoMark,Adverse events,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
6429,NCT06156124,Clinical problems,Sociodemographic data,,2023-06-13,RECRUITING,OBSERVATIONAL,['NA']
6430,NCT02845557,Area under the curve for incretin hormone,Incretin effect,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
6431,NCT03767608,Comparison between groups,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6432,NCT06100796,Response Rate,,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
6433,NCT03162237,Blood glucose,Cytokine detection,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6434,NCT02367690,Presence of Local Skin Reactions (LSR),Ulcer Closure,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6435,NCT04083248,Acceptability of intervention: Semi-structured Diabetes Study Acceptability Interview Guide,,,2019-09-20,TERMINATED,INTERVENTIONAL,['NA']
6436,NCT00804986,Change in Hemoglobin A1C (HbA1c) From Baseline to Week 12 Endpoint,Percent of Participants Domain Scores Indicating No Problems on European Quality of Life (EuroQol) at Baseline and Week 12 Endpoint,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6437,NCT01414556,"glucagon/insulin(c-peptide) absolute, incremental and area under curve values",plasma gut hormones and nutrients,,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6438,NCT05094037,Number of foot ulcers,,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA']
6439,NCT06288529,Development of post-contrast acute kidney injury,,,2023-07-15,COMPLETED,OBSERVATIONAL,['NA']
6440,NCT05641402,Experienced Acceptability of the text messages for people with type 2 diabetes,Rating of fidelity to intended behaviour change technique,,2022-07-14,RECRUITING,INTERVENTIONAL,['NA']
6441,NCT05702931,Mean sensor glucose (mmol/L),Incidence of self-reported hypoglycaemic episodes,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
6442,NCT04439903,"Technology Expectation and Technology Acceptance Questionnaires: Perceived Ease of Use, Usefulness and Trustworthiness of the System at Baseline and Week 5 (Post-intervention)",Diabetes Distress Scale at Baseline and Week 5 (Post-intervention),Potential Correlation Between System Use and Changes in Perceived Emotional Burden at Baseline and Week 5 (Post-intervention),2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
6443,NCT00608348,Muscle sympathetic nerve activity,,,2002-04,COMPLETED,INTERVENTIONAL,['NA']
6444,NCT02445911,Number of Participants With One or More Treatment-Emergent Adverse Events,Accumulation Index (AI),,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6445,NCT02027259,Change in 10-year UKPDS coronary event risk and PHQ-9 depression scores.,,,2012-01-19,COMPLETED,INTERVENTIONAL,['NA']
6446,NCT06334068,Number of days at home after surgery (DAH-30).,Quality of Recovery15 (QoR-15),Change in diabetic management at 30 days,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6447,NCT00956735,Lipids and lipoproteins,Mood and perceived stress,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6448,NCT02002975,Changes From Baseline in Metabolic Syndrome Parameters (Diastolic Blood Pressure) at Final Assessment Point,"Association Between Patient Baseline Characteristics, Including Any Metabolic Syndrome-related Risk Factors, and Onset of New Cerebral and Cardiovascular Events",,2007-10-16,COMPLETED,OBSERVATIONAL,['NA']
6449,NCT05579626,Number of Participants with death,All cause mortality,,2023-03-14,RECRUITING,INTERVENTIONAL,['NA']
6450,NCT01372163,Number of participants with Adverse Events as a measure of safety and tolerability.,"Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.",,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1']
6451,NCT04216654,association between microalbuminuria and infection by H. pylori in type 2 diabetic patients.,,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
6452,NCT02758275,Changes of mean score adherence to treatment from baseline at 6 and 12 months,Changes of mean systolic blood pressure from baseline at 6 and 12 months,,2016-04-28,COMPLETED,INTERVENTIONAL,['NA']
6453,NCT00532506,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
6454,NCT03159546,System Related adverse device effects,,,2017-05-13,COMPLETED,OBSERVATIONAL,['NA']
6455,NCT04515992,Change from baseline of HbA1c,,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
6456,NCT03191201,"Change from baseline in glucose homeostasis status, assessed by a dynamic two-step hyperglycaemic clamp investigation.",Change from baseline in the Homeostasis Model Assessment (HOMA-2) index at 28 days,Change from baseline in circulating miRNAs,2017-06-21,TERMINATED,INTERVENTIONAL,['PHASE4']
6457,NCT01613105,Data collection on pre treatment concomitant diseases,Safety variables will be summarized using descriptive statistics based on adverse events collection,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6458,NCT05147961,"Development of type 2 diabetes, diagnosed by fasting or post-challenge plasma glucose concentrations meeting the American Diabetes Association criteria.",Bioinformatics and systems biology methodologies,,2022-05-25,RECRUITING,INTERVENTIONAL,['NA']
6459,NCT03159052,The number of volunteers with adverse events as a measure of safety,Adjusted Mean Change in Fasting Plasma Glucose,,2017-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6460,NCT04976517,readmission,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
6461,NCT04926415,Change in Adiponectin Plasma Concentration induced by sham taVNS,Changes in Autonomic Function induced by sham taVNS,,2021-06-14,COMPLETED,INTERVENTIONAL,['NA']
6462,NCT01103414,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.,Changes in LDL Particle Size Subfractions From Baseline to Week 12,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6463,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,Ascertain Sample Stability,,2019-05-21,RECRUITING,OBSERVATIONAL,['NA']
6464,NCT01448174,normalization of serum LDL cholesterol,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6465,NCT03578094,Assessment of the anthropometric measurements of the infant according to the breastfeeding patterns,,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA']
6466,NCT01514305,Absolute Relative Difference (%) to Reference Standard,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
6467,NCT02911948,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire,,2016-09-21,COMPLETED,INTERVENTIONAL,['PHASE3']
6468,NCT00859079,time to reach a plasma glucose below 115 mg/dl,number of hypoglycaemic episodes,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6469,NCT04767880,Concentration differences in blood glucose following an OGTT,Continuous glucose measurements (CGM),,2021-04-26,COMPLETED,INTERVENTIONAL,['NA']
6470,NCT04504305,effect of investigational product on diabetic individual suffering from diabetic neuropathy assessed by 11 point numeric rating scale.,effect of investigational product on diabetic individual suffering from diabetic neuropathy assessed by Neuropathy total symptom score - 6 .,,2020-07-23,COMPLETED,INTERVENTIONAL,['NA']
6471,NCT00130481,Low density lipoprotein,Glycated hemoglobin (HbA1c),,2005-04,COMPLETED,INTERVENTIONAL,['NA']
6472,NCT01091896,Recurrent vitreous hemorrhage incidence after vitrectomy,Visual outcome,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6473,NCT00723307,Difference in progression of carotid intima-media thickness (measured in millimetres) between groups treated with metformin and placebo,Difference in progression of carotid total plaque volume (measured in cubic millimetres) between groups treated with metformin and placebo,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6474,NCT06130917,Numeric pain rating scale,,,2023-11-05,RECRUITING,INTERVENTIONAL,['NA']
6475,NCT05847400,predictors of CKD among T2DM patients attending Assiut University Hospitals. To classify our patients into stages according to KDIGO guidelines,the possible risk factors contributing to progessing CKD in T2DM patients.,,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
6476,NCT00842426,Body Mass Index,Patient and Physician Satisfaction,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6477,NCT02587936,"All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension",30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization),,2016-07-18,COMPLETED,INTERVENTIONAL,['NA']
6478,NCT04385862,To assess the validity of the Dexcom G6 CGM system measurements in IV insulin therapy patients hospitalized in the intensive care unit of the CHUM compared to the blood glucose measurements made using the Accuchek Inform II glucometer,"Assess the obstacles to the integration of the use of the CGM in the intensive care unit, namely the technical problems encountered and remote data management.",,2020-07-27,WITHDRAWN,OBSERVATIONAL,['NA']
6479,NCT04094415,Change in HbA1c (measured in mmol/mol),Patient completed the study under treatment with semaglutide (yes/no),,2019-10-28,COMPLETED,OBSERVATIONAL,['NA']
6480,NCT02421055,Number of Participants With Complete Diabetes Remission at 3 Months,BMI Reduction,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
6481,NCT00411411,Restoration of the Insulinotropic Effect of GIP,"Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6482,NCT03519841,Generation and validation of predictive models by ISUP and MARD measures,Safety evaluation: paucity of adverse events,,2018-04-13,COMPLETED,INTERVENTIONAL,['NA']
6483,NCT00937326,Apparent Volume of Distribution After Oral Administration (Vd/F) at Day 1 and Day 28,Change From Baseline in HOMA-percentage of Beta Cell Function at Day 28,,2009-08-19,COMPLETED,INTERVENTIONAL,['PHASE2']
6484,NCT00979459,Maximum Plasma Concentration (Cmax) for MK-1006,Number of Participants Who Discontinued Study Medication Due to an Adverse Event,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6485,NCT01828125,Incremental area under the curve of plasma glucose concentrations,Time for 75% of glucagon appearance,,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6486,NCT04559191,the normalized absolute change in total atheroma volume on serial intravascular ultrasound imaging.,the frequency of hypoglycemia,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6487,NCT01585051,24 hour mean blood pressure,HOMA,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6488,NCT00160017,HbA1c,"These intermediate outcomes will be measured as well, in both the intervention and the control group.",,2005-01,COMPLETED,OBSERVATIONAL,['NA']
6489,NCT02673554,Insulin secretory response after GIP bolus or infusion.,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6490,NCT02041286,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Strongly Agree or Agree or Are Neutral With Questionnaire Statements,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6491,NCT02311075,Change from Baseline in EET concentration during endothelial stimulation,Change from Baseline in ROS concentration during endothelial stimulation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
6492,NCT05454059,HbA1c levels,Clinical attachment level (CAL),,2020-10-22,COMPLETED,INTERVENTIONAL,['NA']
6493,NCT04437641,Smoking prevalence,Parental smoking evolution,,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA']
6494,NCT02260609,100% granulation of wound as determined by the investigator,Closure of wound defined by 100% re-epithelialization,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6495,NCT02285205,changes from baseline in controlled attenuation parameters (CAP),,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6496,NCT06319560,To compare the shearwave elastography of the placenta between the two groups,Hospital admission,,2024-01-02,RECRUITING,INTERVENTIONAL,['NA']
6497,NCT03497260,Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l),Carbon dioxide production during exercise,,2019-01-04,COMPLETED,INTERVENTIONAL,['NA']
6498,NCT01043510,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6499,NCT00473811,"Our outcomes are recruitment and retention rates, as well as physiological measures (HbA1c, blood pressure, and body mass index), dietary GI scores and acceptability of the intervention",,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6500,NCT05238142,Primary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL),,2022-02-25,RECRUITING,INTERVENTIONAL,['NA']
6501,NCT00227383,Solid-phase gastric emptying time and score on Gastroparesis Cardinal Symptom Index(GCSI) at 2 weeks,,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
6502,NCT02251301,Change from baseline in glycemic control assessed by continuous glucose monitoring at end of week 12 of intervention,Change from baseline in peak oxygen uptake as a measure of aerobic fitness at end of week 12 of intervention.,Change from baseline in task switching capabilities at end of week 12 of intervention.,2015-01,COMPLETED,INTERVENTIONAL,['NA']
6503,NCT00272402,Clinical inertia,Direct Medical Costs,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
6504,NCT01755273,Resolution of diabetes,,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
6505,NCT03480022,Free Androgen Index (FAI),Diastolic Blood Pressure (BP),,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
6506,NCT02464878,The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets.,"Cardiovascular Events [Death, Cerebrovascular Accident (CVA), Myocardial Infarction (MI)] and Changes in Atherogenic Profile for GLASSIA Treated Versus Control Subjects",,2017-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6507,NCT03100084,Rate of acute cesarean section (due to suspected fetal distress),Abnormal intrapartum CTG patterns,,2016-09-15,UNKNOWN,OBSERVATIONAL,['NA']
6508,NCT04039763,Change in glycated haeomglobin (HbA1c),,,2020-09-03,RECRUITING,INTERVENTIONAL,['NA']
6509,NCT01415271,HbA1c,unplanned hospitalizations,,2011-10,TERMINATED,INTERVENTIONAL,['NA']
6510,NCT03723486,Change in HOMA-IR,Gut Hormone,,2015-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6511,NCT03406377,Change in HbA1c in Subjects With Type 2 DM,Change From Baseline of Fasting Plasma Glucose (FPG).,,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6512,NCT01829061,The objective is to conduct reproducibility testing using duplicates of each of 3 levels of HbA1C,Obtain CLIA Waiver Status for the Quo-Test,,2013-04,TERMINATED,OBSERVATIONAL,['NA']
6513,NCT02378259,Body Mass Index (kg/m2),Attention,Cancer or precancerous lesions,2014-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6514,NCT03574909,Perinatal mortality,Sepsis,,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
6515,NCT04523155,Change in Glucose Metabolism,Change in Triglycerides,,2020-08-24,COMPLETED,INTERVENTIONAL,['NA']
6516,NCT00614783,Produced SCOUT DS measurement algorithm.,Intra- and inter-day Scout test reproducibility.,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
6517,NCT04345107,GIP concentration changes before and after meal.,"Stable Valley concentration (ctrough, SS).",,2020-05-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6518,NCT00455403,Change in Carotid Intima-media Thickness From Baseline to Year 1,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
6519,NCT01162993,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"Effect SCS on health related quality of life, quality of sleep, mood, blood glucose control, large/small nerve fibre functions, predictive factors success of SCS treatment, small fibre loss/regeneration, cost-utility and cost-effectiveness",,2010-04,UNKNOWN,INTERVENTIONAL,['NA']
6520,NCT01083433,Glycemic Control,Diabetes Knowledge,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
6521,NCT00972244,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6522,NCT01402388,"Lifestyle impact on GLP-1, HbA1c and fasting glycaemia.",,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
6523,NCT02592616,Ad-libitum meal energy intake,Satiety,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
6524,NCT06278207,Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone.,"Proportion of participants who down-titrate from 20 mg daily dose to a 10 mg dose daily at the 1, 3, 6, and 12 months mark",,2024-02-15,RECRUITING,OBSERVATIONAL,['NA']
6525,NCT05009433,Childhood outcomes: changes in diastolic blood pressure,Covid-19 disease,The serotonin transporter (5-HTTLPR) polymorphism,2021-06-24,RECRUITING,INTERVENTIONAL,['NA']
6526,NCT05704491,SPEZ,,,2023-01-30,RECRUITING,OBSERVATIONAL,['NA']
6527,NCT05472142,Change in DSMES Referrals,Change in A1c Levels,,2023-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6528,NCT03234101,All-cause mortality,,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
6529,NCT03030300,partial-remission rate,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6530,NCT01965509,To assess HbA1C levels after treatment,To assess Fasting blood glucose levels,To assess number of participants with Adverse Events as a Measure of Safety and Tolerability,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6531,NCT04796428,Primary Objective,Secondary Objectives - biomarkers,Safety Objectives,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
6532,NCT00905073,insulin dose,renal function,,1990-02,COMPLETED,INTERVENTIONAL,['NA']
6533,NCT02975297,Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges,Post-quit Craving as Assessed by the Questionnaire of Smoking Urges,,2016-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6534,NCT00032474,,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6535,NCT01112696,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI): Proportion of Glucose Sensor Readings That Met Accuracy Criteria,Device Related Moderate or Device Related Severe Adverse Events,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
6536,NCT01846312,Fluctuation in islet autoantibodies titers,Fluctuation in T-cell specificity profiling (mainly for CD8 (cluster of differentiation 8) T-cells),,2013-05,COMPLETED,OBSERVATIONAL,['NA']
6537,NCT03367377,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Average Glucose from 7-Point Glucose Profiles,,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6538,NCT01869621,Heritability,Single nucleotide polymorphisms (SNPs),,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6539,NCT06250192,Birthweight standard deviation score,Continuous glucose monitoring metrics 1 months post delivery,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
6540,NCT01837069,"Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism",Modified Composite of Cardiovascular Events,Each Individual Endpoint of the Composite of Cardiovascular Events,2014-02,TERMINATED,INTERVENTIONAL,['PHASE4']
6541,NCT04707469,Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52),Change From Baseline in Pulse (Week 68),,2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
6542,NCT01728116,Primary Safety Endpoint: Early Device Removal Due to Device-Related SAE,Percentage of Subjects Who Achieve % Total Body Weight Loss Greater Than or Equal to 5% at 12 Months,,2012-12,TERMINATED,INTERVENTIONAL,['NA']
6543,NCT04054843,Maternal plasma afamin levels In first trimester GDM prediction,,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
6544,NCT06229847,"mindful eating, its subgroups and diabetes control in patients with type 2 diabetes","mindful eating, its subgroups and the presence of obesity in patients with type 2 diabetes",,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
6545,NCT05570877,Time to complete healing,Safety of use,,2022-01-11,RECRUITING,INTERVENTIONAL,['NA']
6546,NCT03215498,"Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 30 min",Number of hypoglycaemic episodes,,2017-07-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6547,NCT05975827,2-week reduction rate of wound area,2-week wound healing rate,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6548,NCT05422235,Changes passive ankle stiffness compared with baseline and last measurement and Follow-up,Changes vibration test compared with baseline and last measurement and Follow-up,,2022-11-12,RECRUITING,INTERVENTIONAL,['NA']
6549,NCT05911659,Platelet Reactivity Index and maximum platelet aggregation,,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
6550,NCT02351323,Weight gain,Change in A1C,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6551,NCT05660538,Change from Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS),Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2022-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
6552,NCT00122421,Compliance with process measures at 30 days after the index primary care visit,Percentage of pharmacist recommendations accepted by primary care providers within 30 days after index visit,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
6553,NCT03370874,Proportions of subjects who achieved complete wound closure,Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations,,2018-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
6554,NCT03087032,"change in HbA1c level after 24 weeks,with a noninferiority margin of 0.3%",changes in serum lipid profile,,2019-01-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
6555,NCT02035566,Re-hospitalization,Compliance with recommended (by discharging physician/primary health professional) drug therapy use for heart failure,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
6556,NCT00648284,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
6557,NCT04056208,Fasting plasma glucose concentration,Change in the composition of the gut microbiome,,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6558,NCT02719756,Dynamics (delta from the baseline) of blood glucose variability - integral index of glycemia (LBGI-HBGI) after 3 months of therapy,Percentage of diabetes mellitus patients achieved individual target HbA1c,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
6559,NCT01516255,Maximum time-matched mean difference between the baseline subtracted QTci intervals,Serial electrocardiography,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6560,NCT01492062,Test the feasibility of using MMPPC controller for closed loop insulin delivery in a monitored inpatient clinical research environment.,Efficacy,,2011-02,WITHDRAWN,INTERVENTIONAL,['NA']
6561,NCT02016911,Area under the semaglutide plasma concentration curve,Maximum observed SNAC plasma concentration,,2013-12-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6562,NCT00488527,Number of severe hypoglycemia,- Change in body weight initial visit vs. final visit,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6563,NCT02589873,Body weight lost,Stress and well-being,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6564,NCT04756102,diagnosis of gestational diabetes,,,2018-01-30,COMPLETED,OBSERVATIONAL,['NA']
6565,NCT01017718,"How many children and adolescents suffering from diabetes mellitus type 1 (duration of disease > 1 year, age 8 to 18a, insulin requirement > 0.5 IU/kg/d) show pathological nerve conduction velocity?",Is there a correlation between nerve conduction velocity in our study patients and the Young Score?,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
6566,NCT01666223,Change in GLP-1,Change in bile acid composition,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6567,NCT05599633,Change of high density lipoprotein cholesterol (HDL-C) level,Change of heart rate from baseline,,2022-01-10,RECRUITING,INTERVENTIONAL,['NA']
6568,NCT01135992,HbA1c (Glycosylated Haemoglobin),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6569,NCT00518362,To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of diabetic nephropathy,To investigate the safety and tolerability of TW vs ARB. To access whether TW can delay the progression to ESRD or creatinine-doubling in diabetic nephropathy with heavy proteinuria.,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
6570,NCT01570140,Health Related Quality of Life,Clinical parameters,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
6571,NCT05296447,To evaluate the long-term safety of RGX-314,Proportion of participants with any sight-threatening ocular diabetic complications,,2022-04-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6572,NCT01926522,Change from Baseline of 10-metres walk test,Followup change from Baseline of the Glycated Hemoglobin (HbA1c),,2013-09,COMPLETED,INTERVENTIONAL,['NA']
6573,NCT00489229,Measuring arterial stiffness (pulse wave velocity and augmentation index),"Measuring fasting blood sugar and 2 hours post prandial sugars, fasting insulin level, HbA1c, and total cholesterol level.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6574,NCT02937441,Optic Nerve Sheath diameters will be measured from 3 mm back of globe.,,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
6575,NCT00005365,,,,1993-02,COMPLETED,OBSERVATIONAL,['NA']
6576,NCT00777712,Determine molecular mechanisms underlying impaired wound healing in diabetes,Characterize mechanisms responsible for dysregulated wound inflammatory cell function in patients with diabetes,,2008-09-01,RECRUITING,OBSERVATIONAL,['NA']
6577,NCT04328363,Glucosa level,Reversion to normal glucose,,2020-10,UNKNOWN,INTERVENTIONAL,['NA']
6578,NCT06113341,Participant downloaded and actively used the app (Yes/No),Change in laboratory measured FPG,,2024-05-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6579,NCT04461405,Feasibility of the intervention,Patient Health Questionnaire-9,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
6580,NCT00710424,Number of Responders at the 30% Improvement Level at the End of Treatment,Change From Baseline in Mean Intoxication 0-10 Numerical Rating Scale Score at the End of Treatment,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6581,NCT00761176,The Incidence of Wounds Reaching Complete Closure,,,2008-07,TERMINATED,INTERVENTIONAL,['NA']
6582,NCT05329376,"Screening for depression, anxiety and common mental health disorders in elderly",Perception of stress:,,2023-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6583,NCT02694575,EPC,Renal function,,2015-03-01,COMPLETED,OBSERVATIONAL,['NA']
6584,NCT05749874,Time to first occurrence of composite endpoint of new-onset diabetes and major cardiovascular events.,Time to newly diagnosed cancer,Subgroup analysis 10 for primary outcome measure,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
6585,NCT04670094,Mortality up to 3 months from admission,Correlation between admission to ICU and in-hospital mortality,,2020-12-30,COMPLETED,OBSERVATIONAL,['NA']
6586,NCT03762096,Change in endothelial function,Effects of resveratrol on molecular signaling,,2018-03-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6587,NCT01770054,Prevalence of metabolic syndrome,Genetic testing,determination of the prevalence of hyperinsulinemia,2013-01,COMPLETED,OBSERVATIONAL,['NA']
6588,NCT01706211,"To determine the effectiveness of BRL 49653C (2 mg bd) compared to placebo when added to sulphonylurea therapy, for 24 weeks in out-patients with NIDDM.","To assess the clinical safety of BRL 49653C (2 mg bd) compared to placebo when added to sulphonylurea therapy, for 24 weeks in out-patients with NIDOM.",,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6589,NCT00872560,Weighing of reflux of insulin,Reactions at injection sites,,1998-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
6590,NCT01409330,whole body insulin sensitivity,pancreatic fat,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
6591,NCT00804297,mean glucose level for the non-octreotide group is higher than the octreotide group,number of hypoglicemic events,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6592,NCT04232774,Incidence of Serious Device- and Procedure-Related Complications,Procedure Success,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
6593,NCT01945645,Modelled cardiovascular disease risk,Smoking,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
6594,NCT01071850,Mean change from baseline in Hemoglobin A1c (HbA1c),Proportion of subjects achieving target goal of HbA1c <6.5%,,2010-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6595,NCT00924937,"Combined apparition of hard cardiovascular events (myocardial infarction, revascularization, ischemic stroke, documented peripheral artery disease or cardiovascular death) after a median follow-up of 7 years.",Subgroup analysis,Further Studies,2009-11,COMPLETED,INTERVENTIONAL,['NA']
6596,NCT05681468,Effect of diets on LDL-cholesterol levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months).,Effect of diets on inflammatory markers (C-reactive protein (CRP)) by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months).,Change in fatty acid composition to confirm adherence to the diets at 6 months,2023-09-18,RECRUITING,INTERVENTIONAL,['NA']
6597,NCT04545411,Change in Vascular Endothelial Function,,,2021-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6598,NCT06031428,Hemoglobin A1C,"Quality of Life (Short Form Health Survey, SF-12)",,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6599,NCT00994682,"Liver Histology (Using Kleiner et al Criteria, Hepatology 2005)",Bone Mineral Density,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6600,NCT01455064,Clarke Error Grid Analysis,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
6601,NCT04692688,Percent of Subjects with an improvement in Diabetic Retinopathy Severity Score (DRSS),Mean Change in Central Subfield Thickness (CST),,2021-04-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6602,NCT05788731,The proportion of patients integrating the common law system,Proportion of patients resorting to one or more consultations with a general practitioner.,,2023-01-18,COMPLETED,OBSERVATIONAL,['NA']
6603,NCT01068951,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
6604,NCT02624830,Metabolic control,Insulin secretory response to a glucagon test,,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
6605,NCT05306028,Blood glucose control rate,HbA1C control rate,Overall survival，OS,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
6606,NCT02499185,"Number of participants diagnosed with AKI stage 2 or 3 using the updated rifle ""KDIGO"" guidelines",Number of participants who need renal replacement therapy,persistence of renal dysfunction at 30 days,2015-04-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6607,NCT05591235,Insulin resistance,,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6608,NCT00983021,"Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes",The area under the NN1250 concentration-time curve after single-dose,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6609,NCT04149262,1-hour glucose levels on Novorapid,Occlusion events in Novorapid,,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
6610,NCT05968131,Change in Quality of Life,,,2021-10-27,COMPLETED,INTERVENTIONAL,['NA']
6611,NCT03921216,Interstitial fluid-to-serum ratio for LDL cholesterol,,,2019-04-17,SUSPENDED,OBSERVATIONAL,['NA']
6612,NCT04177303,Change in GLP-1 (glucagon like peptide) and GIP (gastric inhibitory peptide) postprandial secretion,Change in gut microbiome analysis,,2019-11-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
6613,NCT02099110,Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach,Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach,,2014-04-22,COMPLETED,INTERVENTIONAL,['PHASE3']
6614,NCT00889486,change from baseline in gastric half-emptying time,change from baseline in gastroparesis symptoms and health-related quality of life,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6615,NCT01621308,glycaemic regulation,Macrovascular complications of diabetes,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
6616,NCT05592288,Blood Glucose Measurement,Brand Loyalty Scale,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6617,NCT00266253,HbA1c mean change from baseline compared with placebo.,Pharmacokinetic and exposure-response relationship,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6618,NCT03662217,Evaluation of the total daily time of plasma glucose levels,Change in Fructosamin parameter,Patients Diet compliance evaluation,2018-10-28,UNKNOWN,INTERVENTIONAL,['NA']
6619,NCT02229227,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters,,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3']
6620,NCT04774224,The primary endpoint of the study is the change from baseline of plasma C-peptide area under the curve (AUC) over 2 hours following a mixed meal.,"The composite outcome assessing both the frequency, and when relevant, the severity of all adverse events.",,2020-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6621,NCT01754415,International Physical Activity Questionnaire (IPAQ),The physical fitness assessment,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
6622,NCT03592355,Days until third available appointment,Revenue from virtual or in-person visit,,2018-04-13,TERMINATED,INTERVENTIONAL,['NA']
6623,NCT00006331,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
6624,NCT05061602,Biomechanical and Viscoelastic Properties,Lower Limb Function,,2021-09-20,COMPLETED,OBSERVATIONAL,['NA']
6625,NCT00337142,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
6626,NCT05513729,The activity of CEPT in pmol/mL/min,The activity of CEPT in pmol/mL/min,,2022-08-18,RECRUITING,OBSERVATIONAL,['NA']
6627,NCT05159856,Prevalence of cardivascular autonomic neuropathy assed by VagusDevice in children and adolescent with type 1 diabetes (T1D) > 12 months,The association between early markers of diabetic complications and glycemic control,,2022-05-03,RECRUITING,OBSERVATIONAL,['NA']
6628,NCT03717194,Global Longitudinal Strain (GLS),Body Fat Mass,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6629,NCT02775253,The changes of UCP-1 expression in subcutaneous white adipose before and after cold acclimation program,,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
6630,NCT01903070,ΔAUCGLP-1-OGTT(0-240),,,2013-07-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6631,NCT03806920,hepatic insulin extraction,additional endocrine parameters,,2016-11-05,COMPLETED,INTERVENTIONAL,['NA']
6632,NCT01909908,Incidence of adverse events,,,2013-02,TERMINATED,INTERVENTIONAL,['NA']
6633,NCT04841096,Mean difference change between groups in HbA1c concentration,Incidence of adverse events and reactions,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3']
6634,NCT06180109,Time of the maximum measured plasma concentration (Tmax),,,2023-07-30,COMPLETED,INTERVENTIONAL,['PHASE1']
6635,NCT01915550,Proper Glycemic Control,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6636,NCT04320069,Percentage of Time >180 mg/dL,Coefficient of Variation,,2020-06-09,COMPLETED,INTERVENTIONAL,['NA']
6637,NCT02537834,Change from Baseline in HbA1c at 52 weeks,Change in Free Fatty Acid,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6638,NCT01232608,Atherosclerosis,Visceral obesity,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
6639,NCT00575874,Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6640,NCT04129424,The preprandial insulin dose of insulin pump at the end of the 6-day follow-up,The frequency of errors in patency of needle fixation,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6641,NCT06017349,The results were analyzed by consensus error grid (CEG),Accessibility evaluation Questionnaire for non-invasive glucose meter,,2022-09-21,COMPLETED,INTERVENTIONAL,['NA']
6642,NCT01684956,Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately),Difference in mean visual analog pain score between insulin and glucagon with intradermal injection,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
6643,NCT05284071,"Diabetes Treatment Satisfaction Questionnaire (change, DTSQc), at 3 months","Summary of adherence in the population, from baseline to 3 months, from 3 months to end of investigation and from baseline to end of investigation.",,2022-03-14,COMPLETED,INTERVENTIONAL,['NA']
6644,NCT02459106,Levels of miRNA will be measured as well as the adipose tissue specific miRNA.,,,2015-05-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6645,NCT02315300,Glucose Levels < 65 mg/dl,Association anf temporal coincidence of glycemic variability as assessed by changes in glucose excursion as well as mean amplitude of glycemic excursion (MAGE),,2014-11,COMPLETED,INTERVENTIONAL,['NA']
6646,NCT03624062,Immunologic Analysis,Insulin Use,,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE1']
6647,NCT00974051,Blood Glucose Nadir,Percent of Nighttime Glucose Levels >250 mg/dl,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
6648,NCT00715585,A1C,dietary behavior,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6649,NCT01434407,Urine AGE,Urine isoprostanes,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6650,NCT03140865,Change in performance on cognitive measures.,Change in brain volumes on magnetic resonance imaging (MRI).,,2014-01,RECRUITING,OBSERVATIONAL,['NA']
6651,NCT03241706,Glucose Infusion Rate,Peripheral Glucose Uptake,,2018-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6652,NCT06186843,Weekly one day food recall,Triglycerides,"Urine electrolytes (Na, K, Cl, Ca, Phosphorous)",2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6653,NCT01194258,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period,Mean Daily PPG Excursions,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6654,NCT00253786,"Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B",Urinary protein/creatinine ratio in Protocol B,,2005-11-11,COMPLETED,INTERVENTIONAL,['NA']
6655,NCT03089632,Changes in upper gastrointestinal symptoms assessed by the Gastroparesis Cardinal Symptoms Index (GCSI),Changes in glycemic control assessed by continuous glucose monitoring,,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA']
6656,NCT01632163,Change in HbA1c,Anti-lixisenatide antibody assessment,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6657,NCT00170742,regression of neovascularization.,Determine tolerability and safety,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6658,NCT03176056,The reduction of medication effect score (MES),The improvement of carotid intima-media thickness (IMT),,2016-02-02,COMPLETED,INTERVENTIONAL,['NA']
6659,NCT00311922,A1C,Patient satisfaction,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
6660,NCT05441982,24-hour glycemic control,Monocyte chemoattractant protein-1,,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
6661,NCT04810260,Diabetes quality of life measured by the Diabetes Quality of Life instrument,Patient Health Questionnaire-9 for depression,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
6662,NCT02000687,determine the rate of allosensitization in patients after failed islet transplantation,,,2008-12,RECRUITING,OBSERVATIONAL,['NA']
6663,NCT05992545,Changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores,"Change in lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (mg/dL)",Persistent changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores,2022-06-13,COMPLETED,INTERVENTIONAL,['NA']
6664,NCT05689424,Percentage of suppression of endogenous glucose production,,,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6665,NCT02637154,Change in glycaemic variability,Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml),,2015-10-15,UNKNOWN,INTERVENTIONAL,['NA']
6666,NCT00807092,Change in IAUC (Incremental Area Under the Curve) for Postprandial Glucose (0-4 Hours) Over 3 Main Meals,Hypoglycaemia Based on Self-reported Episodes,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6667,NCT04892680,Change in HbA1c at 6 months from baseline,Change in medication adherence at 6 months from baseline,Health care utilization at 6 and 12 months from baseline,2021-03-04,TERMINATED,INTERVENTIONAL,['NA']
6668,NCT02326129,"Compare 11β-HSD1 activity and 5α-reductase activity among obese adolescents with T2D, obese adolescents without T2D and normal weight controls",Metabolic signatures correlate with parameters of glucose tolerance,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
6669,NCT01466075,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
6670,NCT02205528,Change in HbA1c,Change in percent HbA1c,,2014-08-18,COMPLETED,INTERVENTIONAL,['PHASE2']
6671,NCT01562678,Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6672,NCT01798225,Periodontal Pocket Probing Depth (PD),,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6673,NCT05377502,Serum glucose levels,,,2021-12-15,RECRUITING,OBSERVATIONAL,['NA']
6674,NCT02908555,Glycemic control,Executive functioning,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6675,NCT01237314,4-hour glycemic response at 3 time points,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
6676,NCT05292495,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,ADA：anti-drug antibody,,2022-03-31,UNKNOWN,INTERVENTIONAL,['PHASE1']
6677,NCT04215536,"Composite outcome of Stroke, MI, and Mortality",,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
6678,NCT05923632,Quality of Life Scale for Children with Type 1 Diabetes (PedsQL 3.0),Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6679,NCT05766488,Hemoglobin A1c,Perceived or experienced benefits and barriers to device use,,2023-07-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6680,NCT05162183,Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up),,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
6681,NCT04881799,Change in body mass index,,,2022-07-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6682,NCT00503152,Development of persistent microalbuminuria (i.e. urinary albumin excretion rate >20 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits). Whenever a patient will be found to have 2 of 3 collections in the,Regression to low-normal albuminuria (i.e. urinary albumin excretion rate <7 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits); Albuminuria (considered as a continuous variable); Serum creatinine (v,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6683,NCT00310297,"Time to GLUmax (Tmax, min)","Time to maximum concentration (Tmax, min)",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6684,NCT05574062,Continuation Phase Primary Endpoint: mean in HbA1c,Continuation Phase Secondary Endpoint 3- Time spent in target range (70 to 180 mg/dL [3.9-10.0 mmol/L]),,2023-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6685,NCT02874313,Change from baseline in of retinal microaneurysm or hard exudates,Change from baseline of intraocular pressure,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6686,NCT00763802,CSME needing Photocoagulation,Vision Loss,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
6687,NCT06247514,Disordered Eating Behaviors (DEBs) - Change in Participant-Reported Outcomes (PROs),Change in participant's HbA1c,,2024-01-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6688,NCT05151705,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,Pharmacodynamic：Serum c-peptide,,2021-12-20,UNKNOWN,INTERVENTIONAL,['PHASE1']
6689,NCT05958927,Retinal nerve fiber thickness and macular thickness in pregnant women with impaired blood sugar and/or gestational DM,,,2023-04-13,RECRUITING,OBSERVATIONAL,['NA']
6690,NCT01692938,Repeatability of Microperimetry Tests in Normal and With Pathology Participants Based on 3 Microperimetry Tests Taken for Each Participant for a Given Operator-device Combination.,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
6691,NCT00929812,"Changes in satiety scale, total and acylated ghrelin concentrations.","Changes in glucose, insulin and NEFA concentrations.",,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6692,NCT00469092,Glycosylated Haemoglobin A1c (HbA1c),Number of Subjects Reporting Treatment Emergent Adverse Events,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6693,NCT01782092,Lowered A1C Levels,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
6694,NCT03426423,Continuous smoking abstinence,Continuous smoking abstinence,Exploratory microbiota outcome,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
6695,NCT01283854,Diagnosis of gestational diabetes mellitus,"Obstetric outcomes (rates of medical intervention during labour, birth weight, newborn anthropometrics and incidence of newborn hypoglycemia)",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
6696,NCT04423302,Fasting plasma glucose concentration at V3 with a 3 times a day regimen,Proportion of subjects having an improvement or a deterioration of their glycemic status from V1,,2020-07-08,COMPLETED,INTERVENTIONAL,['NA']
6697,NCT05446948,the efficiency of stripping membrane,best corrected visual acuity (BCVA),Post-operative complications,2022-07-11,COMPLETED,INTERVENTIONAL,['NA']
6698,NCT02261441,Cardiovascular risk factors,,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
6699,NCT00286468,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6700,NCT05822674,Stress hyperglycemia Ratio,Inflammatory markers,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
6701,NCT00935220,"DPP-4 Inhibition: E_24,ss",DPP-4 Inhibition: E_24,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6702,NCT01102946,Fluorescein leakage area (mm2),Rod pathway integrity and oscillatory potential amplitudes,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6703,NCT01183104,Number of Participants With Hypoglycaemia,Change From Baseline in Body Weight at 52 W,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6704,NCT05840497,Gestational diabetes,Maternal and fetal pregnancy outcomes,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
6705,NCT00673894,Postprandial Glucose Area Under the Curve (AUC),Fructosamine,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6706,NCT04058015,in-hospital mortality,,,2019-06-03,COMPLETED,OBSERVATIONAL,['NA']
6707,NCT01075698,The effects of ARB therapy and that of standard therapy except ARB on the biomarker levels (UACR and BNP),"The effect of the two treatments on the incidence of events, and the relationship between the incidence of events and the biomarker levels (UACR, BNP, urine 8-hydroxy-2-deoxyguanosine, serum adiponectin, serum high-molecule adiponectin, eGFR)",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6708,NCT04694053,Fournier's gangrene evolution after treatment,,,2020-11-04,COMPLETED,OBSERVATIONAL,['NA']
6709,NCT03181165,Proportion of participants not on glucose-lowering medications,Diastolic Blood Pressure,Intervention Satisfaction,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
6710,NCT01853072,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6711,NCT02628106,the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6712,NCT01130480,Successful rate of blood glucose control (the proportion of patients with HbA1c <7%),To evaluate the change of quality of life in the 6 months by the health questionnaire SF-36,,2010-05-31,COMPLETED,INTERVENTIONAL,['NA']
6713,NCT02916667,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight (+100 gr) compared to offspring of participants with GDM with lower Chrono Biological score.,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight above the 90 percentile compared to offspring of participants with GDM with lower Chrono Biological score.,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
6714,NCT00777621,Glucoregulatory function,,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6715,NCT02790645,Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).,Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
6716,NCT01034618,Glucose and insulin homeostasis.,Plasma amino acid profiles,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
6717,NCT03695913,Participant Satisfaction With Continuous Glucose Monitoring,Utility of CGM Feedback for Changing Diet,,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
6718,NCT03781024,Patients' perspective through a patient led Survey of Health and quality of life via patient reported outcome measures using Visual analogue scale given at Baseline and follow up. Measuring effectiveness and quality of life from 0 to 10,Visual Analogue scales,,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA']
6719,NCT02730962,Insulin Sensitivity,Adverse Event Rates,,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2']
6720,NCT02408705,"Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose",Change in fasting plasma glucose during each period detected by blood at the begin of the visits and measured by a laboratory (tube: lithium heparin plasma),Number of self-reported hypoglycaemic episodes during each period,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6721,NCT02137720,HbA1c,Cholesterol,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
6722,NCT02408120,Mean Daily BG Levels,Mean Daily Dose of Insulin,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6723,NCT04198857,Neonatal hypoglycemia,Glucose readings over glycemic target,,2021-10-18,RECRUITING,INTERVENTIONAL,['NA']
6724,NCT02568501,Change in HbA1c by 3 months,Glucose Monitoring Adherence by 6 months,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6725,NCT05300022,Intervention Retention,Child Perceived CGM Benefits and Burdens,Child BMI Z-score,2022-11-10,RECRUITING,INTERVENTIONAL,['NA']
6726,NCT03489031,basal/total ratio,hypoglycemia,,2016-04-11,COMPLETED,OBSERVATIONAL,['NA']
6727,NCT03945903,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
6728,NCT03503552,Bone mineral density,Urine Markers,,2015-02-13,COMPLETED,OBSERVATIONAL,['NA']
6729,NCT02512276,Medication Adherence,Healthcare Utilization - Hospitalizations,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6730,NCT05564039,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score,,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6731,NCT05369793,Change in HbA1c,Changes of Douleur Neuropathique-4 (DN4) questionnaire (DN4),Major adverse cardiovascular events (MACE),2022-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6732,NCT02703155,proportion of annual screening for Cystic Fibrosis Related Diabetes(CFRD) in children between 10years and 17 years with Cystic Fibrosis(CF) using the Home OGTT device.,Variability- timing of sample,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
6733,NCT00985101,endothelial damage,,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
6734,NCT04132934,Proportion of patients with at least one Hypoglycemia event,,,2019-03-11,COMPLETED,OBSERVATIONAL,['NA']
6735,NCT01077401,Deaths Due to Myocardial Infarction,Mean Change in Retinal Thickness at Month 6,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6736,NCT06119035,Glucose levels will be analyzed,Serum samples,,2023-11-06,COMPLETED,INTERVENTIONAL,['NA']
6737,NCT03997409,Change in HbA1c,Change in Diabetes Burden as Measured by the Problem Areas in Diabetes: Teen Version (PAID-T) Report,,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
6738,NCT02086955,Effectiveness of nurse-led intervention for high risk patients with diabetic foot ulceration/amputation,,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
6739,NCT02379299,Number of CHO interventions to treat hypoglycemia,,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6740,NCT05043467,Incidence of major adverse events (AEs) and any AEs that occurred during the administration period of lobeglitazone,"Changes in glycated hemoglobin (HbA1c) and glucose, lipid parameters",,2019-01-02,COMPLETED,OBSERVATIONAL,['NA']
6741,NCT03262415,Mean absolute relative difference (MARD),,,2017-02-17,COMPLETED,OBSERVATIONAL,['NA']
6742,NCT02961192,Change in mean daily steps,Change in LDL-C levels,,2017-02-13,COMPLETED,INTERVENTIONAL,['NA']
6743,NCT01342042,To compare treatment arms in terms of change from baseline to endpoint in HbA1c,To compare treatment arms in terms of change from baseline to endpoint in body weight,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
6744,NCT01446705,Health Care Quality: Affect of HIE on LDL Levels of Participants.,Health Care Quality: Care Sensitive Admissions,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
6745,NCT05753696,proteinuria,urinary albumin/ creatine,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
6746,NCT00372086,HbA1c,adiponectin,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6747,NCT05939869,Risk of CVD Event,,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
6748,NCT05887791,Glucose iAUC,Satiety assessment,Amino acids,2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6749,NCT02224118,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),Number of Participants Exhibiting Anti-Drug Antibodies for CNTO 3649 at any Visit,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6750,NCT04696159,Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor,Change from Baseline on Gastroparesis Cardinal Symptom Index,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
6751,NCT03644004,Performing oral glucose tolerance test in order to detect type 2 diabetes,,,2018-10-30,COMPLETED,OBSERVATIONAL,['NA']
6752,NCT04649203,TSS (Total Symptom Score),,,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
6753,NCT05562492,Time spent in the target glucose range between 3.9 and 10.0 mmol/L based on CGM glucose levels,Percentage of time of CGM availability,Human Factors Evaluation - Questionnaires,2023-04-12,RECRUITING,INTERVENTIONAL,['NA']
6754,NCT01729117,Change in BMI,Severe Hypoglycemic Events,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
6755,NCT03088475,Self-efficacy: change is being assessed,Unplanned medical consultation,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6756,NCT00060931,Change from baseline in HbA1c at 5 months,"Blood pressure at 3 and 5 months Body weight at 3 and 5 months Lab levels (glucose, insulin, triglycerides, cholesterol, and albumin:creatinine ratio) at 3 and 5 months.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6757,NCT03333044,Percent of patients that experience a reduction in HbA1c of >0.5%,Referral to community services,,2019-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6758,NCT03714594,Glucose Metabolism,,,2018-07-24,COMPLETED,INTERVENTIONAL,['PHASE2']
6759,NCT05622123,Correlation between residual beta cell mass and function,Correlation with other parameters,,2023-02-23,RECRUITING,INTERVENTIONAL,['PHASE2']
6760,NCT03832907,Number of Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading,"Percentage of Dexcom G6 CGM Sensor Values Within 15/15%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG",,2019-02-21,COMPLETED,INTERVENTIONAL,['NA']
6761,NCT02787551,Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period,Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Single Arm Extension Period,,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6762,NCT04000867,Overall Pain reduction,Improved Activities of daily living,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
6763,NCT02026830,Causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6764,NCT05677685,CFU (Colony Forming Units),Adverse Events,,2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6765,NCT03483155,the incidence of Cardiovascular disease,,,2018-04-15,UNKNOWN,OBSERVATIONAL,['NA']
6766,NCT03549104,Fear of Hypoglycemia,Glycemic Variability,,2019-01-14,COMPLETED,INTERVENTIONAL,['NA']
6767,NCT03850314,LDL Cholesterol levels,HbA1C levels,,2019-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6768,NCT00808535,,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
6769,NCT00789035,Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment,Trough Concentrations of Empagliflozin in Plasma,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6770,NCT00741702,systolic blood pressure,"Change in diastolic blood pressure, change in urine albumin status and incidence of adverse events",,2001-09,COMPLETED,INTERVENTIONAL,['NA']
6771,NCT01618409,Patient Understanding of their Medication Regimen,Self-reported Adherence,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6772,NCT05037591,"Blood Glucose ""change"" is being assessed",waist-to-hip ratio (WHR),,2021-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6773,NCT01686711,Glycosylated Hemoglobin (HbA1c),,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6774,NCT03967561,Glycated Hemoglobin levels (HbA1c),"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Long Form.",,2019-06-10,UNKNOWN,INTERVENTIONAL,['NA']
6775,NCT01505803,"Inflammation & oxidative stress (CRP, TNF-α, IL-1, IL-2, IL-6, IL-10 F2 isoprostanes, NF-κB, MPO, other)",Plasma fatty acids,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6776,NCT02670915,Change in the Percentage of HbA1c,Change in Anti-insulin Aspart Antibody Development: Total,,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6777,NCT04313803,Cost of care for fee-for-value patients (specifically PMPM savings),Evaluation of HEDIS performance for those using CGM compared to historical utilization and the broader T2DM cohort within Intermountain Healthcare.,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
6778,NCT01387425,Success rates and safety at week 24 in the varenicline vs placebo. Success rates will be defined as the Continuous Quit Rate since last visit. Maintain abstinence during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm.,"""Change from Baseline in BMI""",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
6779,NCT04812171,Influence of diabetes mellitus on apical periodontitis healing after non-surgical endodontic treatment,Association of glycated hemoglobin level (HbA1C) with apical periodontitis healing,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
6780,NCT01488474,Minimal current threshold for distal motor response at needle tip nerve contact,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6781,NCT02548650,Maximal Platelet Aggregation in DM,Maximal Platelet Aggregation in Non-DM,,2016-03-25,COMPLETED,INTERVENTIONAL,['PHASE4']
6782,NCT01041690,Intra- and post-operative bleedings were recorded.,Best Corrected Visual Acuity,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
6783,NCT00812253,Hospital Length of Stay,Cardiac Output,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6784,NCT02098746,Frequency of Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
6785,NCT04177147,Number of participants with hypoglycemia during the study period,"Number of participants with changes to prescriptions for diabetes or antibiotics: new, refilled, changed, or discontinued","Number of A1c, glucose, and creatinine blood tests",2016-01-14,COMPLETED,INTERVENTIONAL,['NA']
6786,NCT05743387,Mean HbA1c (in percent),Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs),Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals,2023-05-13,RECRUITING,INTERVENTIONAL,['NA']
6787,NCT00309751,Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C),Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6788,NCT02558452,Development of donor specific antibodies (DSA),Quality of life measures,,2016-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6789,NCT00025883,"Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin",,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6790,NCT00005152,Coronary heart disease (CHD),,,1980-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6791,NCT01612741,Data collection on pre treatment concomitant diseases,Safety variables will be summarized using descriptive statistics based on adverse events collection,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6792,NCT05925556,change in Self-Care Inventory from baseline to 6 weeks; higher score = better self-care; range 1-5; also change over ecological momentary assessment period,change in Quality of Marriage Index and intimacy subscale from Personal Assessment of Intimacy in Relationships from baseline to 6 weeks; higher numbers = better; range = 1 to 7; also change over ecological momentary assessment period,change in self-efficacy subscale from Multidimensional Diabetes Questionnaire from baseline to 6 weeks; higher numbers = greater efficacy; range = 0 to 100%; also change over ecological momentary assessment period,2023-08-02,RECRUITING,INTERVENTIONAL,['NA']
6793,NCT03531177,Waist circumference,Physical activity,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
6794,NCT02772263,Change in rate of EMS calls over 1 year,Change in Canadian Diabetes Risk (CANRISK) score over 1 year,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6795,NCT02114476,Diabetes mellitus,metabolic syndrome,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
6796,NCT04761094,HbA1C,Hospital admission,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
6797,NCT00108004,Understand management issues in subjects with type 1 and type 2 diabetes mellitus,,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6798,NCT02127216,Improvement in hemoglobin A1c,Adherence to diabetes care plan,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
6799,NCT03767556,EVALUATION OF LUNG VOLUMES AND CAPACITIES,EVALUATION OF INSPIRATORY MUSCLE STRENGTH,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
6800,NCT00958061,Determine the prevalence of lifetime and current psychiatric conditions including PTSD among women who served during the Vietnam Era.,Characterize the level of current disability in women who served during the Vietnam Era.,,2010-03-01,COMPLETED,OBSERVATIONAL,['NA']
6801,NCT01681693,Plasma glucose,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6802,NCT03993132,Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - ITT Analysis,Incidence Rate of Hospitalization for Heart Failure (HF) - ITT Analysis,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
6803,NCT06173804,Acceptability,MoCA,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6804,NCT03254849,Blood Pressure reduction,,,2017-12-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6805,NCT02634515,"PD: GIRmax, maximum glucose infusion rate",Assessment of local tolerability at the injection site,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6806,NCT03341013,Maximum observed plasma concentration of MEDI0382,Clinical laboratory assessments (urinalysis),,2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1']
6807,NCT03355092,Mean reduction in HbA1c,,,2018-02-23,WITHDRAWN,INTERVENTIONAL,['NA']
6808,NCT04834089,Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum,Deaths,Proportion of patients with change in COVID-19 disease progression,2021-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6809,NCT02409329,Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c),Change in Self-reported Medication Adherence,Change in Glycemic Control - REACH Only vs. Control & REACH+FAMS vs. Control,2016-05-23,COMPLETED,INTERVENTIONAL,['NA']
6810,NCT00832481,To investigate the effects of monotherapy of either repaglinide or metformin on glucose excursion after 3 months treatment in newly diagnosed type 2 diabetes patients in China,,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
6811,NCT00453934,,Number and type of adverse events.,,2007-05,TERMINATED,INTERVENTIONAL,['PHASE4']
6812,NCT01117584,Change from baseline in HbA1c at Week 12,Achievement of target goal (HbA1c <6.5%) at Week 12,,2010-04-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6813,NCT00351507,Effect on gastric emptying,"Effect on endogenous glucose appearance, glucose appearance and glucose disposal",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6814,NCT03989232,Change in HbA1c,Change in Pulse Rate,,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
6815,NCT01496625,"Interaction of key parameters of phenotype with genetic variants, and characterization of new experimental models of eye health and disease.",,,2012-06-18,RECRUITING,OBSERVATIONAL,['NA']
6816,NCT01477476,Frequency of Adverse Events,,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6817,NCT05443568,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction",,2023-03-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6818,NCT01934842,Non Inferiority of Analyte Levels,,,2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
6819,NCT01373450,Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM,"Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM",,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6820,NCT01456026,Postprandial Change from Baseline in Flow Mediated Dilatation,Postprandial Change from Baseline in Microcirculation (Laser-Doppler measurements of reactive hyperemia at the hand),,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6821,NCT05973422,Serious adverse device effects (SADE),System Usability Scale (SUS) at baseline and 15 days for the Pump Assembly,,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6822,NCT00508287,Safety: incidence of adverse events,"PD Measures: Fasting and postprandial serum glucose (AUC), serum insulin, and plasma glucagon concentrations. Acetaminophen plasma concentrations will be measured after a single dose of acetaminophen",,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6823,NCT04624737,Progression to severe retinopathy,Comparison of algorithms prediction to human prediction.,,2020-12-21,RECRUITING,OBSERVATIONAL,['NA']
6824,NCT01994811,Prevalence of non-communicable diseases,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
6825,NCT02114814,Hemoglobin A1c,Health-related Quality of Life (SF-12),,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6826,NCT03315052,Acute cellular rejection (ACR),Infection,,2019-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
6827,NCT00717223,Literacy levels and HbA1c,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6828,NCT02136602,To study interventricular septal thickness in fetus of diabetic mother and correlate it with good glycemic control.,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6829,NCT00267839,"Bone parameters after 6, 12 and 18 months",Quality of live after 12 and 18 months,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3']
6830,NCT01253694,Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns.,Evaluate the main change in BCVA (best corrected visual acuity) score over time,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6831,NCT02940418,Safety of using allogenic ASC assessed by any adverse events,,,2017-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
6832,NCT01758016,vascular complications in pregnancy,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
6833,NCT05641090,Trail Making Test-B and Stroop test,Nitric oxide,,2021-12-16,RECRUITING,INTERVENTIONAL,['NA']
6834,NCT05189470,Complete healing,Change in Wound-QoL global score from baseline to end of follow-up,One-year amputation rate,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
6835,NCT01098461,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6836,NCT00124397,Flow mediated vasodilatation (FMD) on atorvastatin,CV events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6837,NCT00213070,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6838,NCT02514954,"Delta AUCBG,0-2h",Local tolerability,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6839,NCT02632032,Changes in HbA1c,Changes in weight,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6840,NCT00696657,HbA1c,Percentage of Subjects Developing Anti-semaglutide Antibodies,,2008-06-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6841,NCT00320112,Change in Glycemic Control (HbA1c),Number of Participants With Insulin Starts at 6 Months,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6842,NCT00259896,Pharmacodynamic measurements during 7 days of dosing.,Pharmacokinetic measurements during 7 days of dosing.,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6843,NCT00543010,,,,2002-11,TERMINATED,INTERVENTIONAL,['PHASE3']
6844,NCT00303134,Insulin independence 12 months after final islet infusion,Mixed meal test,,2003-08-01,TERMINATED,INTERVENTIONAL,['PHASE1']
6845,NCT01951235,Change in HbA1c,"Safety will be assessed by the incidence of adverse events (AEs), physical examination, relevant changes on laboratory tests, vital signs, and 12-lead electrocardiograms (ECG)",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6846,NCT04897815,Changes of cerebral blood flow on fasting and 1 hour postprandial.,The relationship between the fluctuation of blood glucose and the change of cerebral blood flow.,,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA']
6847,NCT05729516,change in glycemic control,changes in perceived diabetes self-efficacy,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6848,NCT04562454,fluctuation of blood glucose after eating different food,,,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6849,NCT05029297,"To demonstrate the efficacy and the non-inferiority of a new formulation of the capsaicin topical solution in ""roll-on"" compared to capsaicin in cream.",Grade of compliance/complacency of treatment.,,2010-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6850,NCT05329844,AUC0-t of Vildagliptin for the test and the reference products,Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
6851,NCT04684836,Continuity of care as assessed by attendance at follow-up appointment,Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ),,2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
6852,NCT04240171,HbA1c %,IL-34 (pg./ml),,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
6853,NCT06037499,Blood glucose measurement using BGMS,,,2023-03-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6854,NCT04543032,Measurement of stride length,Assessment of Quality of life,,2021-01-05,COMPLETED,INTERVENTIONAL,['NA']
6855,NCT05073835,Weight loss,GLP-1 levels,,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6856,NCT02999841,Change of the visceral fat area in square centimeter assessed by abdominal CT scans from baseline to 24 weeks.,Change of brain natriuretic peptide in nanograms per milliliter from baseline to 24 weeks.,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
6857,NCT05320510,Change of HbA1c concentration,Change of TC concentration,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6858,NCT01493934,Change of glycemia,insulin resistance,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6859,NCT03246828,Change in plasma glucagon from baseline (0min),Continuous glucose monitor recordings,,2017-07-03,COMPLETED,INTERVENTIONAL,['NA']
6860,NCT02377583,Depression (CDI) score,Hippocampal volume and mean diffusion,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
6861,NCT05274295,Reduction rate of the wound size,Improvement Wound pain,,2022-02-28,UNKNOWN,INTERVENTIONAL,['NA']
6862,NCT05851469,Clinical performance,Adverse events,,2023-05-31,COMPLETED,INTERVENTIONAL,['NA']
6863,NCT05725330,self-management scale,anthropometric measurements (Body Mass Index),,2023-02-25,RECRUITING,INTERVENTIONAL,['NA']
6864,NCT01392898,Body weight change (measured body weight at 26 weeks minus baseline body weight),Measuring change in insulin dose (insulin dose at 26 weeks minus insulin dose at baseline),,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
6865,NCT04838431,LGA,,,2018-06-01,TERMINATED,OBSERVATIONAL,['NA']
6866,NCT05937152,Change in pain intensity,Pain relief at 24 weeks,,2024-04,RECRUITING,INTERVENTIONAL,['PHASE2']
6867,NCT03323996,Semi-Structured interviews,,,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA']
6868,NCT04104451,SAE,Change in A1c,,2019-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6869,NCT05409131,Percent of time in range 70-180 mg/dL,Change in Diabetes Quality of Life (DQL)-brief total score,,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6870,NCT00695565,Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation,Change in Blood Pressure From Baseline to Week 12,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6871,NCT00889785,Lipids,self-care behaviors,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6872,NCT06313164,Reduced glutathione (GSH) levels in erythrocyte hemolysate change in patients with type 2 diabetes mellitus,Postprandial Insulin (PPI) Levels Change in Patients with Type 2 Diabetes Mellitus,,2023-06-20,COMPLETED,INTERVENTIONAL,['NA']
6873,NCT04064203,p-glucagon,growth hormone,,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
6874,NCT04524832,"Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS)",Change in blood pressure,,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
6875,NCT01381900,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6876,NCT03988140,Change from baseline Peri-implant Probing Depth (PPD) at 24 months.,Markers on peri-implant crevicular fluid,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
6877,NCT02750007,Number of Treatment Emergent Adverse Events(TEAEs),The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
6878,NCT03073551,Glucose levels,Maternal weight gain,,2010-07-27,UNKNOWN,INTERVENTIONAL,['NA']
6879,NCT06031987,63-140 mg/dL Time in Range,fetal:Meconium aspiration,,2022-01-26,RECRUITING,INTERVENTIONAL,['NA']
6880,NCT05925829,Safety of SVF and aaPRP in Type 2 Diabetes Patients,,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6881,NCT06236256,Improvement of glucose measures in older individuals,Grip strength,WHO-5,2024-01-09,RECRUITING,INTERVENTIONAL,['NA']
6882,NCT01850199,Median blood glucose (Interquartile range),Time from glucose criteria for insulin prescription to actual insulin starting,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6883,NCT01043445,"The effect of this newly discovered GPR 119 agonist on gut hormone responses, in particular GLP-1 in response of the different meals administered to the subjects","Glucose homeostasis, gall bladder contraction in response of the different meals administered to the subjects",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
6884,NCT00044421,Reduction in the progression of DPN measured by composite score,"Vibration sensation;Electrophysiology of tibial, peroneal and sural nerves;Neurological signs;Neuropathic symptoms;Clinical global impression of change;Health outcome measures",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6885,NCT02815787,The area under the plasma concentration-time curve (AUC) of Glyburide,The number of volunteers with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6886,NCT00888628,Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.,Reduction of Insulin Requriements,,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6887,NCT04293367,Change in Post-absorptive Lipid Oxidation,Glucose Disposal Rate (GDR) during the Hyperinsulinemic-Euglycemic Clamp,,2009-06-01,COMPLETED,INTERVENTIONAL,['NA']
6888,NCT05294861,Gut Microbiome,Overall Glycemia,,2022-04-28,UNKNOWN,INTERVENTIONAL,['NA']
6889,NCT00642681,To measure Serum FDKP AUC,,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
6890,NCT01638429,Gastric Emptying,% Stool Dry Weight,,2012-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6891,NCT04247620,Glycemic Control (HbA1c),Social Vulnerability (CDC/ATSDR Social Vulnerability Index),,2020-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6892,NCT00959725,Best-corrected visual acuity,Macular thickness,,2009-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6893,NCT02128581,Calories consumed during buffet meal test,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6894,NCT03180281,"Fasting blood glucose,glycosylated hemoglobin(GHbA1c)",Incidence of hypoglycemia,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6895,NCT00371306,Maternal glucose at delivery,Infant complications,,2002-09,UNKNOWN,INTERVENTIONAL,['NA']
6896,NCT01655186,Mean change in body weight as measured by Dual Energy X-ray Absorptiometry (DXA),"Frequency, intensity and relationship of study drug to adverse events and serious adverse events, as well as clinical, and laboratory test result abnormalities",,2012-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6897,NCT01780272,The number of electroencephalogram (EEG) identified arousals,Total sleep time,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6898,NCT01818310,Amputation-free survival,Quality of life outcome,Blood glucose and pancreatic function response,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6899,NCT05537480,Obtain CGM data concomitant with OGTT to determine what CGM metrics obtained in pregnant women with and without a high risk of GDM correlate best with the diagnostic OGTT (obtained via the 2-step and 1-step approaches),Determine what CGM metrics obtained in pregnant women correlate best with the need for pharmacologic management of GDM,,2022-01-14,RECRUITING,INTERVENTIONAL,['NA']
6900,NCT01235819,change in insulin requirement,C peptide response,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6901,NCT03220919,Doses,Hypoglycemia,Adverse effects,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
6902,NCT03736083,Change in Diabetes Treatment Satisfaction Questionnaire- Parent version,Change in Glycemic control measured by A1c,Percentage of glucose sensor readings above 180 mg/dl,2019-09,WITHDRAWN,INTERVENTIONAL,['NA']
6903,NCT05685927,Changes in parameters defining sarcopenia in relation to weight-loss or glycemic improvement,"Correlation analyses of primary measures with metabolic parameters including insulin resistance, HbA1c, metabolic economy, bioenergetics, and low-grade systemic inflammation (hs-CRP)",EMG assessment of myopathic changes,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
6904,NCT00101751,HbA1c and Incidence of hypoglycemia,Postprandial glucose from 8-point SMBG spontaneously reported adverse events; any changes from baseline,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6905,NCT01624116,Change in body weight and fructosamine levels during Ramadan fasting.,Change in renal profile from baseline to end of Ramadan,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6906,NCT00910767,Percentage of plasma glucose values in target (3.9 - 8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
6907,NCT00478322,"Assessment of ECGs, physical examinations and laboratory values for adverse events",,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6908,NCT00500331,Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12,Number of Participants With Change From Baseline in Standard Laboratory Parameters of Potential Clinical Concern,,2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2']
6909,NCT03987919,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,,2019-07-30,COMPLETED,INTERVENTIONAL,['PHASE3']
6910,NCT01447992,estimation of the failure rates of system components,percent time of active CTR,,2011-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6911,NCT01739829,To establish the safety and efficacy of xenotransplantation of DIABECELL,,,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6912,NCT04033042,Risk/benefit analysis,Number of encountered Device Deficiencies,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
6913,NCT05299502,Fasting plasma glucose,Gestational Diabetes Mellitus diagnosis,,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
6914,NCT00877123,interleukin-10 level,hs-CRP level,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6915,NCT04503408,Time of activities of daily living test,,,2019-09-13,COMPLETED,OBSERVATIONAL,['NA']
6916,NCT01934686,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
6917,NCT00925119,Change in Free Fatty Acid Kinetics,Change in Insulin,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE4']
6918,NCT00697580,insulin sensitivity,adiposity,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
6919,NCT03179254,Postoperative blood glucose level,,,2010-03-22,COMPLETED,INTERVENTIONAL,['PHASE4']
6920,NCT01082445,Tissue oxygenation improvement,Oxidation status reduction,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6921,NCT05791955,MyChart letter opened,Completion rate of one screening/test,,2023-05-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6922,NCT03325322,Effect on Mesenchymal stem cell function including cell migration,Number of participants with treatment-related adverse events including hospitalization,,2018-01-02,SUSPENDED,INTERVENTIONAL,['PHASE2']
6923,NCT02282397,Phase 2 (T1DM),Phase 2 (T1DM) - Insulin Use Outcomes,Phase 1 (T2DM) - Post-Hoc A1C Outcome,2014-09,COMPLETED,INTERVENTIONAL,['NA']
6924,NCT04510506,Combined Triple Label Surveillance and Randomized substudies: Change in insulin sensitivity (Si) over time,Both substudies: Change in percent time <70 mg/dL,,2020-11-19,RECRUITING,INTERVENTIONAL,['NA']
6925,NCT03321279,"Change in mean daily step count from the baseline period to the intervention period, using a wearable pedometer (Nokia Steel) to measure step count.","Functional decline from admission to 3 months post-discharge, measured using validated survey assessments.",,2018-01-11,COMPLETED,INTERVENTIONAL,['NA']
6926,NCT05230342,Evaluation of the total daily interstitial glucose over 140 mg/dl,16s ribosomal gene analysis,,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6927,NCT04501406,The proportion of pioglitazone-treated patients relative to placebo achieving an improvement of ≥2 points in non-alcoholic fatty liver disease activity score (NAS) without an increase in fibrosis stage.,Mean change in liver fibrosis,Glycemic control,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
6928,NCT03174340,Prescription of insulin during the follow-up,Compliance with the exercise (in the exercise group only),Dosage of short-acting insulin,2008-02-21,COMPLETED,INTERVENTIONAL,['NA']
6929,NCT01709851,Point Accuracy of the microdialysis signal,Rate accuracy of the microdialysis signal,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
6930,NCT04054934,"Affects of reversal circadian clock on sleep quality among both healthy and T1DM adolescents (mainly T1DM), controlled for BMI-SDS, and mean HbA1c in T1D patients.",Metabolic parameters according to night/day sleep cycle among healthy and among T1D patients,,2022-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6931,NCT02809963,Liver fat content,potassium,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6932,NCT00101530,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
6933,NCT00639665,Hemodynamic Measurements,Blood Pressure,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
6934,NCT02370537,Part B: Baseline Corrected Cmax for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.,,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6935,NCT04101669,Change in HbA1c,Questionnaire,,2019-09-09,RECRUITING,INTERVENTIONAL,['NA']
6936,NCT00815217,"wound measurements, healing of wounds, pictures of wounds",,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
6937,NCT00948324,beta cell function;fast blood glucose;,,,2008-06,SUSPENDED,INTERVENTIONAL,['PHASE4']
6938,NCT04113694,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 6,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 7.,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
6939,NCT01107015,HBA1c at One Year,,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6940,NCT00646724,Glucose and C-peptide levels,Complete Blood Count,,2008-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6941,NCT04033705,"The time spent within, above and below the target glucose range (4-10mmol/L) in the post operative period",Post operative infections,,2019-06-11,COMPLETED,OBSERVATIONAL,['NA']
6942,NCT00802269,Pain (NRS-11 scale),,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6943,NCT06118931,Average 24-hour glucose total area under the curve (AUC) over 7 days,TRE fasting window adherence,Safety and Adverse Events,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6944,NCT06176703,Glycemic control,Quality of life,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
6945,NCT04037098,Decreased of gestational diabetes incidence,,,2022-07-31,WITHDRAWN,INTERVENTIONAL,['NA']
6946,NCT00716170,Plasma glucagon responses,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6947,NCT04656210,Atrophy difference based on two cerebral MRI volumetries,changes in amyloid biomarkers in blood at 4 years of inclusion,,2021-10-14,RECRUITING,OBSERVATIONAL,['NA']
6948,NCT02797314,Trabecular Bone Score,,,2017-03-28,RECRUITING,INTERVENTIONAL,['NA']
6949,NCT03702465,Difference in glucose regulation between the control and intervention arm,Number of participant withdrawals in the trial,,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
6950,NCT01874080,Point estimates and 90% CIs for the ratio of geometric means for AUC(INF) for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon),"Safety assessments based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6951,NCT01208948,occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years,The time to CSME development,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6952,NCT03536910,Changes in copeptin levels after general or spinal anesthesia,,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
6953,NCT00614055,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6954,NCT00818935,Glycated Haemoglobin,"body weight, homocysteine, C-reactive protein, plasma lipids and lipoproteins, fasting body glucose, insulin, insulin resistance, serum urea, creatinine, C-peptide",,2004-06,COMPLETED,INTERVENTIONAL,['NA']
6955,NCT04940572,Preservation of auditory function.,Quality of sleep assessment on adult population - Qualitative questionnaire (no scale),,2021-11-26,RECRUITING,INTERVENTIONAL,['PHASE2']
6956,NCT03799185,Prevalence of dyslipidemia,Prevalence of cardiovascular associated risk factors,Dietary assessment,2016-01-04,COMPLETED,OBSERVATIONAL,['NA']
6957,NCT06025422,During the procedure difference in the mean in-shoe PPP by ROI associated with each toe gap standard,During the procedure PTSR associated with habitual footwear,,2023-03-13,RECRUITING,OBSERVATIONAL,['NA']
6958,NCT06148376,Precentage of patients whose prandial insulin is wthdrawn,Diabetes treatment satisfaction,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6959,NCT03029390,Insulin sensitivity,Creatinine levels,,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6960,NCT01893242,Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death,Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6961,NCT03393338,Number of emergency room visits and hospitalizations over 12 months,Physician Trust,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
6962,NCT02739217,Description and number of abnormal laboratory values and adverse events that are related to treatment.,Change from baseline of antidiabetic treatment,Change from baseline in hyperinsulinaemic-euglycaemic clamp measurements.,2016-02-22,COMPLETED,INTERVENTIONAL,['PHASE2']
6963,NCT00651378,Percent change in LDL-C level from baseline to the study endpoint.,"Adverse events, laboratory test results, vital signs.",,2004-09-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6964,NCT01260246,To demonstrate improvement in liver disease (based on liver biopsy)with sitagliptin.,In individuals with NASH and DM2: To determine the correlation between changes in histology with changes in hepatic fat demonstrated by MRI and changes in fibrosis by Fibroscan.,,2010-12,TERMINATED,INTERVENTIONAL,['NA']
6965,NCT04553380,Incidence of hypoglycemia,Daily doses of insulin at the study end point.,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6966,NCT02177747,Diabetic retinopathy grading,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6967,NCT04354740,Major adverse cardiac events (MACEs),In hospital mortality,,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
6968,NCT06283849,sedentary time,,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6969,NCT04259489,Glycemic achieving rate,The days of Hospitalization due to hypoglycemia,,2020-01-31,UNKNOWN,INTERVENTIONAL,['NA']
6970,NCT03658317,renal resistive index,stage of diabetic nephropathy,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
6971,NCT03347968,Maximum international normalized ratio (INRmax),Clinical laboratory assessment (urinalysis),,2017-11-27,COMPLETED,INTERVENTIONAL,['PHASE1']
6972,NCT01480362,Time until wound closure within the maximum study treatment time,Adverse Events,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
6973,NCT02449187,AUC(last),Vd/F,,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6974,NCT04324424,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of CLr (if applicable),,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE1']
6975,NCT05736536,Changes of readiness to change for weight loss (behaviour),Changes in body fat composition (anthropometric),,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
6976,NCT03883230,GLYWD test result,Clinician's wound characterization,,2017-07-27,COMPLETED,OBSERVATIONAL,['NA']
6977,NCT00302042,Change in Weight,Change in Dietary Composition,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
6978,NCT02717078,Change in hemoglobin A1c from baseline to week 12,24-hour diet recall,,2017-06-19,COMPLETED,INTERVENTIONAL,['NA']
6979,NCT04771403,Percent of Time With Sensed Glucose <70 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units/Day),,2021-02-23,COMPLETED,INTERVENTIONAL,['NA']
6980,NCT00300976,"The occurrence of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death",All-cause mortality (deaths due to any cause),Changes in QOL (EQ-5D),2006-05,UNKNOWN,INTERVENTIONAL,['NA']
6981,NCT04223895,"Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337","Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337",,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6982,NCT05196958,Weight loss,Impact of aGLP1 on the treatment already in place to regulate blood glucose,,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
6983,NCT01334645,Copeptin value,"Troponin, Myoglobin and Creatin Kinase values. Clinicals and paraclinicals events .",,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6984,NCT03933696,Cognition,Melatonin Levels,,2019-01-02,RECRUITING,INTERVENTIONAL,['NA']
6985,NCT05222490,Estimate of a difference in temperature between two feet per subject,To evaluate the usability of FeeSee device by patient and healthcare providers,,2021-07-13,UNKNOWN,INTERVENTIONAL,['NA']
6986,NCT02587286,Change in HbA1c,Change in HbA1c,mHealth intervention satisfaction,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6987,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6988,NCT01537497,Modulation of carbohydrate and lipid metabolism,Area under the curve (AUC) of PF-05175157 after single oral doses,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6989,NCT00947427,C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6990,NCT00349128,Change in fasting triglycerides.,Assessment of lipid and glucose metabolisms.,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6991,NCT03037099,Dietary glycemic index,Systolic blood pressure,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
6992,NCT01199692,,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
6993,NCT05838209,clinical attachment level,clinical attachment levels,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA']
6994,NCT01966978,Mean Change From Randomization in A1c at Week 26,Change in Short Form-36 (SF-36) Questionnaire Score,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6995,NCT00272064,Changes of glycosilated haemoglobin (HbA1c),Hypoglycemic episodes,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6996,NCT02243176,Absolute Change From Baseline in HbA1c at Week 24 (DAO),Change From Baseline in Body Weight,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6997,NCT01885546,User's ability to obtain the enhanced meter feature,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6998,NCT01154348,Safety and pharmacokinetics of multiple-dose oral co-administration of S-707106 and metformin in fed state in patients with type 2 diabetes mellitus,The effect of multiple doses of metformin on pharmacokinetics of S-707106,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6999,NCT06278935,Participant satisfaction,DFU-related outcomes,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7000,NCT01288300,Changes in glycosylated hemoglobin (Hba1c)from baseline at 3 and 6 months,Changes in diabetes self-empowerment from baseline to 3 and 6 months,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
7001,NCT04498156,Preferences regarding chronic kidney disease in T2D,Time point of communicated CKD diagnosis,,2020-09-16,COMPLETED,OBSERVATIONAL,['NA']
7002,NCT02094911,Change in fasting insulin,Process indicators,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
7003,NCT06264271,difference in HbA1c,differences in coefficient of variation,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
7004,NCT02035059,Development of Gestational Diabetes in second/third trimester,,,2014-05-01,COMPLETED,OBSERVATIONAL,['NA']
7005,NCT00989547,insulin production,"Insulin Dose, Autoantibody levels, T-cell functional response assays, Cytokine levels",glycated hemoglobin (HbA1c),2008-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
7006,NCT00853944,Islet function as measured by hyperglycemic clamp,Change in insulin requirement (absolute and % decrease from pre-transplant dose),,2009-07,TERMINATED,INTERVENTIONAL,['PHASE3']
7007,NCT00224276,,,,na,COMPLETED,OBSERVATIONAL,['NA']
7008,NCT04164966,Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples,,,2019-11-27,RECRUITING,OBSERVATIONAL,['NA']
7009,NCT01280682,Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide,HbA1c Levels,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7010,NCT00899470,Metformin T-half and T-max,Number of Participant With Clinically Relevant Physical Examination Abnormalities,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7011,NCT01880827,Splanchnic blood flow,GIP and GLP-1 blood concetrations,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7012,NCT00949442,HbA1c,Need of additional prandial insulin,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7013,NCT01333774,Change in HbA1c value between initial and final visit,Number of participants with adverse events in both study groups. The influence of different approaches to dietary advising on the appearance of adverse events.,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
7014,NCT01213563,efficacy and safety of an intensive glycaemic protocol after bariatric surgery,,,2009-01,TERMINATED,INTERVENTIONAL,['NA']
7015,NCT03165877,Objective satiety,Adherence to treatment,,2016-05-31,COMPLETED,INTERVENTIONAL,['NA']
7016,NCT03312595,Percentage of Participants With Wound Closed,Time to Wound Closure,,2017-09-14,COMPLETED,INTERVENTIONAL,['NA']
7017,NCT02977039,Glycemic control,quality of life,,2019-11,WITHDRAWN,INTERVENTIONAL,['NA']
7018,NCT05256303,"Total cost, hospitalization",Percent of day lying down,Qualitative interviews,2022-02-16,COMPLETED,INTERVENTIONAL,['NA']
7019,NCT05394571,ratio of patients who reached the HbA1c target of equal to or below 7%,The effect of the level of physical activity on the HbA1c changes,,2021-08-15,COMPLETED,OBSERVATIONAL,['NA']
7020,NCT04907019,AUC0-∞,CLz/F,,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7021,NCT01549964,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Plasma Glucose (FPG),,2012-04,TERMINATED,INTERVENTIONAL,['PHASE3']
7022,NCT02085876,"To determine a correlation coefficient > 0.80, alpha 0.05 and beta 0.20 between the MRI markers relevant.",To determine the correlation between the unsaturated fat measurements and MRI Lipidomics Spectro analysis.,,na,UNKNOWN,OBSERVATIONAL,['NA']
7023,NCT02989649,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction,,2016-12-22,TERMINATED,OBSERVATIONAL,['NA']
7024,NCT01698008,Evidence for Improved Diabetic Care With Mobile Phone Application Use,,,2012-01-28,COMPLETED,INTERVENTIONAL,['NA']
7025,NCT01553266,Change from 12 months prior to intervention in HbA1c up to 12 months during the intervention,MDET educators' quarterly debriefing session group discussions regarding intervention issues,,2012-03-01,COMPLETED,OBSERVATIONAL,['NA']
7026,NCT01150292,Platelet function induced by collagen,Evaluation of cellular and plasmatic redox status,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
7027,NCT01084005,HbA1c Change From Baseline to Week 24,Number of Patients With Rescue Therapy,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7028,NCT01490879,Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment,Incidence of adverse events,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7029,NCT01232491,Change From Baseline in Body Weight,Rate of Nocturnal Treatment Emergent Hypoglycaemic Episodes,,2010-10-29,COMPLETED,INTERVENTIONAL,['PHASE4']
7030,NCT04627103,Weight Loss,Albumin - Nutritional Status,,2021-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7031,NCT03889600,Feasibility - Implementation fidelity: percentage of indicated referrals that are made,Limited Efficacy - 30-Day readmission rate,Process Outcome- Referral Completion: percentage of patients who receive services post-referral,2021-03-02,WITHDRAWN,INTERVENTIONAL,['NA']
7032,NCT01081938,Glycaemic parameters assessment,"Incidence of symptomatic, nocturnal and severe hypoglycemias",,2010-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7033,NCT05104047,Gracely Pain Scale,Subjective Peripheral Neuropathy Screen (SPNS),Neurological Sensory Testing (NST),2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
7034,NCT05878431,Neuropathic Pain Impact on Quality of Life Questionnaire (NePIQOL),,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
7035,NCT03240289,Patient satisfaction and feedback,Diabetes self-efficacy (Measured using the Perceived Diabetes Self-Management Scale),,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7036,NCT02577016,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in FPG at Week 24,,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7037,NCT04934228,Adipose Tissue Sample: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment,,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
7038,NCT04854512,Change in HbA1c,HbA1c response (Metformin DR vs. metformin IR),,2021-05-18,SUSPENDED,INTERVENTIONAL,['PHASE3']
7039,NCT04066400,Effect of ATI-free Nutrition on hepatic inflammation,Quality of Life using the chronic liver disease questionnaire (CLDQ),,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7040,NCT01961622,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring,Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 08:00 to 23:00,Effect of study intervention based on pre-study glycaemic control,2014-04,COMPLETED,INTERVENTIONAL,['NA']
7041,NCT05360537,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change of intra and extra-hospital mortality,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7042,NCT00659711,"Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients",Change in Oxidative Stress From Baseline to 12 Weeks,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
7043,NCT04885153,Changes from Baseline Vascular Cell Adhesion Molecule-1 (VCAM -1) at 3 Months,,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
7044,NCT05037058,Proportion of patients receiving guidance on individualized physical activity,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
7045,NCT04705558,change in glycated hemoglobin,change in Body composition,,2020-07-20,UNKNOWN,INTERVENTIONAL,['NA']
7046,NCT01697631,HbA1c (glycosylated haemoglobin),"Hypoglycaemic episodes (minor, major or nocturnal)",,2002-07-22,COMPLETED,INTERVENTIONAL,['PHASE4']
7047,NCT02859116,Tissue collection,,,2016-07-21,COMPLETED,OBSERVATIONAL,['NA']
7048,NCT04251559,Gestational diabetes mellitus risk faktors,,,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
7049,NCT01388192,Change of glucose metabolism after pancreaticoduodenectomy,,,2011-11,UNKNOWN,OBSERVATIONAL,['NA']
7050,NCT01264796,quality of life,,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
7051,NCT01931137,Area under the serum insulin 338 concentration-time curve,Number of treatment emergent adverse events,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7052,NCT01078103,,,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
7053,NCT05145452,Muscle endurance,Physical performance,,2021-01-14,SUSPENDED,INTERVENTIONAL,['NA']
7054,NCT04127084,changes of 8-OH-dG,Change in angiotensin,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
7055,NCT01076842,The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks.,Hypoglycemia weight waist-hip ratio frequency of hypoglycemia weight FBGL lipid levels CBC CMP biometric parameters of activity heat flux galvanic skin response heart rate level of physical activity and energy expenditure,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7056,NCT01318135,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7057,NCT04583462,Change between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.,Change between below- knee arterial calcification score progression between T0 and T2years with initial below-knee arterial calcification score ≤ and >400 (subgroup analysis),,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE3']
7058,NCT01659294,diabetes distress (DDS),Depressive Symptoms Severity,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7059,NCT04655131,Number of positive events for each protein amount.,,,2018-06-18,COMPLETED,INTERVENTIONAL,['NA']
7060,NCT02938832,Diabetes incidence,Quality of Life,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
7061,NCT02478190,ED Length of Stay,Return ED visit for any reason,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
7062,NCT03712046,Diagnostic accuracy of 18F-FDG PET-CT for the diagnosis of diabetic foot osteomyelitis,,,2019-01-15,TERMINATED,INTERVENTIONAL,['NA']
7063,NCT02157350,Proliferative diabetic retinopathy progression/regression.,"Retinal vessel geometry (caliber, fractals and tortuosity)",Retinal areas of non-perfusion.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7064,NCT05741437,2. Cmax of CKD-378: Maximum plasma concentration of the drug,,,2023-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7065,NCT03985566,Change in insulin response,Change in glucose trajectories over 14 days of continous glucose monitoring,,2018-07-03,COMPLETED,INTERVENTIONAL,['NA']
7066,NCT03948347,Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic),Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2,,2019-06-25,RECRUITING,INTERVENTIONAL,['NA']
7067,NCT03143816,Change in Time in Range (%) (70-180 mg/dl) With TI on CGM,Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM,,2017-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
7068,NCT00799643,"The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.","Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy",,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7069,NCT00366301,Percentage Reduction in C-reactive Protein (CRP),,,2006-08,TERMINATED,INTERVENTIONAL,['PHASE4']
7070,NCT00159536,pre-eclampsia,Snoring and sleep quality,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7071,NCT01991054,Change in Hba1c (%) in study groups,serum albumin,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7072,NCT01307137,Compare changes in weight and hemoglobin A1c between participants receiving peer-led care (with or without TAP intervention) and those receiving UC over 12 months.,"Compare changes in health care utilization (physician visits, emergency visits, and days in hospital) among treatment groups (UC, PC, and TAP).",,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
7073,NCT03009513,Area under the plasma concentration versus time curve (AUC),,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7074,NCT05958264,Determination of DeBacker Score of sublingual microcirculation of children,Differences of DeBacker Score of sublingual microcirculation with parameters of healthy children in the same age categories,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
7075,NCT04400344,Current state of diabetic foot care education and knowledge base among diabetic educators,,,2020-06-13,UNKNOWN,OBSERVATIONAL,['NA']
7076,NCT00525889,Incidence and severity of adverse events and laboratory anomalies,HbA1c levels,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7077,NCT04226378,Glycated hemoglobin (A1C),Annual incidence of severe hypoglycemia,A1C stratified by age cohort,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
7078,NCT01433380,Changes in carbohydrate and lipid metabolism,"Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC)",,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7079,NCT04511715,Percentage of patients with equal or more than 2 stages of progression in diabetic retinopathy staging,Number of visits,,2020-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7080,NCT05687643,Peak plantar strain,Regional Peak Plantar pressure,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7081,NCT04493177,"Prevention of overweight/obesity mothers, determined by loss in body mass index (BMI)",Changes in blood concentration of lipids: intervention,,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7082,NCT00334919,Cytokines,Lipids,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7083,NCT01817127,Human milk glycans,Human Milk Transcriptomics,Alkaline phosphatase levels,2009-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7084,NCT05894252,Quality of life Short Form 36 Health Survey Questionnaire (SF-36) t2,Health Locus Control (Multidimensional Health Locus of Control form C- MHLC) t2,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7085,NCT03385265,Parent Diabetes Distress,Behavioral Pediatric Feeding Assessment Scale_Problem,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7086,NCT01842282,Hepatic Steatosis by MRI,Weight,,2013-07-19,TERMINATED,INTERVENTIONAL,['PHASE2']
7087,NCT05427916,Number of Participants With Healing Complication,Patient Satisfaction,,2022-07-12,TERMINATED,INTERVENTIONAL,['NA']
7088,NCT05863611,Frailty has an effect on balance in patients with type 2 diabetes.,Frailty has an effect on the risk of falling in patients with type 2 diabetes.,,2023-05-20,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7089,NCT02212067,Area under the serum insulin concentration time curve from 10-120 minutes after a 25 g glucose bolus i.v. infusion (IVGTT).,Slope of the ISR vs. glucose curve (dose-response relationship),,2014-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7090,NCT03655067,Center for Epidemiological Studies - Depression Scale (CES-D),Problem Areas in Diabetes - Teen version,,2020-12-15,COMPLETED,INTERVENTIONAL,['NA']
7091,NCT02676401,Adverse events,Change from baseline in Urine Albumin to Creatinine Ratio (UACR),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7092,NCT00954343,Percentage decrease of ulcer size twelve weeks after treatment begin (i.e. first shock wave treatment) compared to the baseline (ulcer size at first treatment),Tissue oxygen concentration after shock wave treatment,,2009-08,WITHDRAWN,INTERVENTIONAL,['NA']
7093,NCT05505721,Body mass index (kg/m2),,,2021-03-16,COMPLETED,OBSERVATIONAL,['NA']
7094,NCT00018239,,,,1999-10,COMPLETED,INTERVENTIONAL,['NA']
7095,NCT00001987,Diabetes control,,,1976-02-01,RECRUITING,OBSERVATIONAL,['NA']
7096,NCT00202748,Change in self-reported activity,Quality of life,,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
7097,NCT00247455,Plasma GLP-1 concentration,C-peptide/insulin ratio as marker of hepatic insulin extraction,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
7098,NCT02609243,change in hepatic fat content confirmed by proton magnetic resonance spectroscopy by 3 T MR imaging,change in distribution of body fat confirmed by MR-Imaging by 3 T whole body imager,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
7099,NCT04097483,Diabetes Distress Scale (DDS),Research nurse qualitative and quantitative evaluation about Treatment Adherence and diseases management.,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7100,NCT00175253,,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7101,NCT01243424,The First 3-point Major Adverse Cardiovascular Events (3P-MACE),CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study,,2010-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7102,NCT02155361,Pain Scores on the Neuropathic Pain Scale (NPS),Motor amplitude (microvolt) of tibial nerve,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7103,NCT04473274,Adverse events attributable,A1c,,2020-05-21,COMPLETED,INTERVENTIONAL,['PHASE4']
7104,NCT05887635,Tolerability Endpoint:,Change in ALT and AST from baseline to 24 weeks post procedure.,,2023-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7105,NCT02856516,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7106,NCT06148688,International Physical Activity Questionnaire,Blood Sugar Monitoring Form,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
7107,NCT00767351,,,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
7108,NCT00845468,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
7109,NCT01003184,Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26),Hypoglycemia Rate Per Year,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7110,NCT00082381,Change in Glycosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7111,NCT03292185,Area under the plasma liraglutide concentration time curve,Local tolerability at the injection site,,2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
7112,NCT02956811,Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks,Change in diastolic function and global longitudinal strain,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
7113,NCT04106050,Change in Nerve Excitability from Baseline (Day 1) to Last Treatment Visit (Day 8) as Determined by Compound Muscle Action Potential Threshold Tracking (CMAP-TT) in the Median Nerve of Healthy Participants,Time to Reach Maximum Observed Concentration (Tmax),,2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7114,NCT02276859,Postprandial glycemia,Mean amplitude of glycemic excursion,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7115,NCT02512523,Mean amplitude of glucose excursion (MAGE),"Safety (All AE including SAE, hypoglycemia, laboratory tests, vital sign, and physical examination)",,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
7116,NCT01527630,"Cmax, maximum insulin aspart concentration","t½, terminal half-life",,2002-11-16,COMPLETED,INTERVENTIONAL,['PHASE1']
7117,NCT01313156,"Metabolic Syndrome, Type 2 Diabetes",,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7118,NCT01145066,Leptin,PBMC Leukotriene Stimulation,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7119,NCT02160717,Beta-Cell Function measured as Disposition Index,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
7120,NCT04642378,Time in target glucose range,Daily insulin dose,,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA']
7121,NCT00923962,Coronary metabolite uptake,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
7122,NCT00399347,,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
7123,NCT02045758,Non-Inferiority of Analyte Levels,,,2014-12,UNKNOWN,INTERVENTIONAL,['NA']
7124,NCT03437135,presence or not of an ear wax cap,frequency selectivity of the patient,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA']
7125,NCT00493935,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
7126,NCT04259775,Percent of patients at target range from baseline to 26 weeks,Problem Areas in Diabetes Scale (PAID),,2022-09,WITHDRAWN,INTERVENTIONAL,['NA']
7127,NCT00283049,Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12,"Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia",,2006-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7128,NCT01351922,"Percentage of patients having complications (dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications)",,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
7129,NCT01341717,Reduction in HbA1c from baseline,Change in lipid profile from baseline,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7130,NCT01842620,Geometric Means for Maximum Plasma Concentration of the Study Drug (Oxemet) to the Reference Drug (Glafornail) From 0 to 36 h,Time to Reach Maximum Plasma Concentration (Tmax) of the Study Drug (Oxemet) and the Reference Drug (Glafornail) Over Period,,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE4']
7131,NCT02140983,OGTT,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7132,NCT01868568,Area under the insulin aspart concentration curve,Area under the serum insulin 454 concentration curve,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7133,NCT01410357,SF-36 Health Survey at 60 Weeks; Physical Health Component,Comparison of ISMI (Stigma Resistance) Score Between TTIM and TAU at 60 Weeks,Comparison of PMHSMS (Perceived Mental Health Self-Management Scale) Score Between TTIM and TAU at 60 Weeks,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7134,NCT00732160,Insulin Secretion,Insulin Sensitivity,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
7135,NCT05794152,Adverse birth outcomes,Number of participants developing type 2 diabetes,,2023-03-21,RECRUITING,INTERVENTIONAL,['NA']
7136,NCT06067451,To determine the impact of SMART Goal setting on BMI z-scores To determine the impact of SMART Goal setting on BMI z-scores,Temporal changes in Lipids,,2023-12-10,RECRUITING,INTERVENTIONAL,['NA']
7137,NCT02148250,Duration (in Hours) of 20 % Dextrose Infusion Requirement,Total Glucose Required to Maintain Euglycaemia,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7138,NCT02324010,Gastric emptying,Appetite,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7139,NCT02702440,Body weight,,,2015-05,UNKNOWN,OBSERVATIONAL,['NA']
7140,NCT03002155,Chair Stand Test (5x Sit-to-Stand) at 12-week Session,Adverse Events,Recruitment,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7141,NCT01325064,subclinical organ damage,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
7142,NCT04444375,Manchester Foot Pain and Disability Index,,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
7143,NCT01030926,Area under the NN1250 concentration-time curve after single dose,Time to maximum observed NN1250 concentration after single dose,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7144,NCT04688671,Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS),Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4,,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7145,NCT00364767,"enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle","insulin sensitivity (oral glucose tolerance test) and related factors (adiponectin, HbA1c)",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
7146,NCT00426413,,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
7147,NCT05586542,Adverse events,Cost,,2022-10-03,RECRUITING,INTERVENTIONAL,['PHASE1']
7148,NCT05276778,Patients' acceptance of diabetic retinopathy screenings in general practice,,,2022-02-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7149,NCT02736253,The cases applied amputation(minor or major) and The cases applied major amputation,To Decide Independent Risk factors for AMPUTATION and - for MAJOR AMPUTATION.,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
7150,NCT01154374,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7151,NCT03368937,System Suitability,,,2017-12-08,COMPLETED,INTERVENTIONAL,['NA']
7152,NCT05086549,Rate of change in albuminuria (urine ACR),Rate of change in proteinuria (urine PCR),,2021-09-29,COMPLETED,OBSERVATIONAL,['NA']
7153,NCT05101135,Changes in HbA1c,,,2021-11-17,UNKNOWN,INTERVENTIONAL,['PHASE3']
7154,NCT03993990,Foot infection and recurrence of foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,,2019-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
7155,NCT02674828,number of consecutive weeks step goal met,Habitual Total Weekday Activity Score,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
7156,NCT00457938,"Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,",,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
7157,NCT01647438,Change in Saturated Fat (% of Daily Kilo-calories From Fat) Intake,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7158,NCT05928637,Cmax,,,2023-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7159,NCT05870462,Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months,Changes in the frequency (%) of circulating ALDHhiSSChi pro-inflammatory granulocyte precursors in individuals treated with semaglutide versus usual care for 6 months,,2023-04-29,RECRUITING,INTERVENTIONAL,['PHASE4']
7160,NCT05489536,Incidence of GDM,Physical Activity,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7161,NCT03589092,GDM Identification,Clinical outcomes determination,,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
7162,NCT02015299,change from baseline carotid-(right) femoral arterial Pulse Wave Velocity (PWV) at 26 weeks,Subclinical vascular inflammation (FDG PET-CT),Lifestyle,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7163,NCT03798717,Mean AUC (Area Under the Curve) Plasma [Glucose],Change in Inflammatory Status,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
7164,NCT05188573,Clinical performance of test: Specificity,Stage Shift,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7165,NCT00534014,To determine the optimal oral dose of vitamin C and E to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals.,"To study the effects of vitamin C on fibrinogen, insulin, glucose, PAI-1, adiponectin, free MDA, Oxy LDL,CRP, cholesterol, and FFA.",,2006-01,COMPLETED,INTERVENTIONAL,['NA']
7166,NCT00842361,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic BP (Blood Pressure),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7167,NCT04057339,Change in glycemic parameters,Change in hs-CRP,Change in mitochondrial structure and gene expression in skeletal muscle,2019-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7168,NCT03627455,MACE,,,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
7169,NCT02505308,Maximal Insulin Secretion (composite measure) following formal stimulation (GPAIS) test,Faecal elastase,,2015-03-04,COMPLETED,INTERVENTIONAL,['NA']
7170,NCT01816672,Compare time to heal in Wagner 1 and 2 diabetic foot ulcers at 12 weeks treated with AutoloGel versus usual and customary care,Number of patients with adverse events as a measure of tolerability,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
7171,NCT04682054,counts of each cell type,,,2021-01-15,UNKNOWN,INTERVENTIONAL,['NA']
7172,NCT04705506,Markers of vascular calcification,,,2017-02-05,COMPLETED,INTERVENTIONAL,['NA']
7173,NCT01344278,Primary outcome: meeting the postpartum weight goal,physical activity,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
7174,NCT00985842,Oxygen in tissue,,,2009-11-01,COMPLETED,INTERVENTIONAL,['NA']
7175,NCT03571217,choroidal thickness (CT),,,2014-10-01,RECRUITING,OBSERVATIONAL,['NA']
7176,NCT02820298,T1/2 (Apparent Terminal Elimination Half-life),,,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE1']
7177,NCT00106236,hemoglobin A1c,health-related QOL (Quality of Life),,2003-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7178,NCT01501877,Point prevalence abstinence from smoking,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
7179,NCT03332836,Number of participants with adverse events,AUC of HM12460A,,2017-10-25,TERMINATED,INTERVENTIONAL,['PHASE1']
7180,NCT05656924,Difference in step counts between the two groups,Difference in Prosthesis Evaluation Questionnaire (PEQ) scores in the two groups,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7181,NCT05555095,"Patient satisfaction, 1-item researcher generated question",,,2022-09-26,RECRUITING,OBSERVATIONAL,['NA']
7182,NCT00671424,Serum sodium and potassium concentrations:,weight:,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7183,NCT06017544,MACE,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
7184,NCT06035523,Percentage of index ulcers (the ulcers being treated in the study) healed at 12 weeks,Change in subjects reported pain levels (NPRS),Cost to closure,2021-12-29,RECRUITING,INTERVENTIONAL,['NA']
7185,NCT00494312,"Incidence of liver inflammation or injury greater than 3 times the upper limit of normal, as monitored by serum alanine aminotransaminase elevation.","Change from Baseline or greater than 1.5 times the upper limit of normal (whichever is greater) in the level of alanine aminotransferase, aspartate aminotransferase, total or direct bilirubin, alkaline phosphatase or gamma-glutamyl transpeptidase.",,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7186,NCT06254274,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Fasting Serum Glucose,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2']
7187,NCT00752180,Mean AUCins.0-12h and Cins.max,"PK endpoints: AUC0-4h, AUC0-6h, AUC6-12h,tmax, t½ and elimination rate constant.PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-12h, AUCGIR0-12h, GIRmax and tGIRmax .Safety endpoints: AEs, hematology, biochemistry, urinalyses, physical exam",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7188,NCT02923323,Association between interstitial glucose concentration and EEG power,Association between interstitial glucose concentration and neurocognitive functions,DTI assessment of brain MRI according to HbA1c,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7189,NCT03855449,Task Analysis Wireframe Development part 2,,,2019-06-05,RECRUITING,INTERVENTIONAL,['NA']
7190,NCT02470039,Change in fasting plasma glucose (FPG),area under the serum insulin concentration-time curve,,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7191,NCT05631119,collect biospecimen samples,,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
7192,NCT02055014,Glycated haemoglobin (HbA1c),Weight,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
7193,NCT02648204,Change in HbA1c,Change in Pulse Rate,,2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7194,NCT05768958,Ad libitum energy intake (KJ) after exercise compared with rest,Borg RPE,,2023-03-22,RECRUITING,INTERVENTIONAL,['NA']
7195,NCT03794232,Incidence of blood sugar reversal to normal after intervention,Body weight,,2016-05-30,COMPLETED,INTERVENTIONAL,['NA']
7196,NCT04755647,To measure the methemoglobin percent level during NORS compared to hypotonic saline administration in participants withe DFU,To measure the efficacy of NORS compared to placebo on the change in wound area in participants with DFU,,2021-02-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7197,NCT01725126,Change From Baseline in Fasting Plasma Glucose (Safety Laboratory) Values During the Double-blind Treatment Period of Part B and C,Tmax of Metformin During the Double-blind Treatment Period of Part C,,2013-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7198,NCT03112005,Number of subject eyes whose EyeArt results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,,2017-04-17,COMPLETED,OBSERVATIONAL,['NA']
7199,NCT01529918,Patient's uptake and preferences,"The comparison of yield of actual diabetes detected from those who have high risk at self risk-assessment, compared to the usual diabetes detection rate in a random sample from the practice within a one year period.",,2009-11,UNKNOWN,INTERVENTIONAL,['NA']
7200,NCT02811484,Change in HbA1c,Change in total dose insulin,,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7201,NCT00802152,Hemoglobin A1c (HbA1c) or Systolic blood pressure (SBP),Patient-entered device data,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
7202,NCT04228003,Decreased Gastrointestinal Symptoms,Improvement in A1C,,2021-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
7203,NCT02227862,Change in HbA1c From Baseline to 24 Weeks,Proportion of Patients With HbA1c < 7%,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7204,NCT06228898,changes in hematologic inflammatory markers with glycemic control,,,2022-01-15,COMPLETED,OBSERVATIONAL,['NA']
7205,NCT05278806,Hypertension control,Breast cancer screening rates,,2022-03-24,COMPLETED,INTERVENTIONAL,['NA']
7206,NCT03595384,Participant Satisfaction With Overall Program,Waist Circumference,,2018-04-29,COMPLETED,INTERVENTIONAL,['NA']
7207,NCT02712255,Physical activity,Physical activity,Habitual sedentary behavior,2016-03,WITHDRAWN,INTERVENTIONAL,['NA']
7208,NCT00757588,Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF]),Change From Baseline in Mean Total Daily Dose of Insulin (MTDDI) (LOCF),Percentage of Participants With Reported and Confirmed Hypoglycemia,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7209,NCT02413567,Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs),,,2015-03-23,COMPLETED,INTERVENTIONAL,['NA']
7210,NCT05579119,Change of the mean daily blood glucose levels during hospital,Mean length of stay in days in the hospital among different groups,,2022-07-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7211,NCT01177332,Intrahepatic lipid content (IHL) and hepatic ATP and PI concentrations,"Substrate oxidation and blood plasma levels of FFA, triglycerides, glucose and catecholamines",,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7212,NCT04824586,Intraoperative level of glucose,Insulin quantities,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7213,NCT03506776,change from baseline foot assessment as evidenced by a diabetic foot ulcer,change from baseline foot assessment evidenced by presence or absence of redness,,2017-08-21,COMPLETED,INTERVENTIONAL,['NA']
7214,NCT00879697,Total Walking Distance,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7215,NCT02360527,"Retinal neurodegeneration among three groups of type 2 diabetic patients patients with AD, patients with MCI and patients without AD or MCI.",,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
7216,NCT04029480,Number of Participants Who Discontinue Study Treatment Due to an AE over 54 weeks,Change from Baseline in FPG at 54 Weeks,,2019-10-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7217,NCT00712673,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7218,NCT02798744,Change from baseline in Total PYY at 24 weeks,Change from baseline in liver functioning to 24 weeks,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7219,NCT00150423,Safety Efficacy,,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7220,NCT00322075,patients´satisfaction,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7221,NCT00747175,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)",Pharmacodynamic variables,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7222,NCT03367806,All-cause mortality,Cancer mortality,,1999-01,COMPLETED,OBSERVATIONAL,['NA']
7223,NCT01503892,Increased intraepidermal nerve fiber density,Subjective improvement,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
7224,NCT00464594,FPG >= 140mg/dl and HbA1c >= 7.0%,,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
7225,NCT05443191,Change in Glycated haemoglobin (HbA1c ),"DTSQs, change in absolute treatment satisfaction",,2022-10-20,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7226,NCT02289235,Change in score of fatty liver in fibroscan,Number of patients with adverse events,,2019-05-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7227,NCT00194909,"Our primary outcome will be a reduction in the weekly average 11 point Likert pain scale (0 - no pain, 10 - worst possible pain) at 8 weeks.","Secondary outcomes will include the Rand-36 quality of life scale, McGill visual analogue scale (VAS) and a sleep interference scale.",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE4']
7228,NCT04492384,rate of letal outcomes depending on pre-existing disease,,,2020-06-29,COMPLETED,OBSERVATIONAL,['NA']
7229,NCT04891315,Correlation of sVAP-1 levels with Fetal outcomes: Miscarriage,Correlation of sVAP-1 levels with patient characteristics: Medications at time of booking,,2021-07-25,TERMINATED,OBSERVATIONAL,['NA']
7230,NCT03170752,Proportion of patients who are comprehensively screened to the number of eligible patients seen in the intervention group compared to the control group as assessed by the completeness of CV Screening Checklist data collection form.,The patient and NP factors that influence participation in the CASP as assessed by content analysis of patient and NP feedback questionnaires.,,2017-09-28,COMPLETED,INTERVENTIONAL,['NA']
7231,NCT02023411,SUV Max on PET/CT Scan at 12 Months,Clinical Events,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7232,NCT00382473,The degree of improvement in fat oxidation during submaximal exercise obtained by indirect calorimetry after subjects have completed an eight week aerobic exercise program.,Increase in fat oxidation from non-plasma sources after the eight week intervention.,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
7233,NCT02535169,Changes in the oral disposition index measured by oral glucose tolerance test,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
7234,NCT00829660,A composite cardiovascular outcome defined as the time after randomisation to the first occurrence of any one of the following: -Cardiovascular death -Non-fatal MI -Non-fatal stroke -Hospitalisation for Unstable Angina -Hospitalisation for Heart Failure,"Resource use, costs and cost effectiveness",,2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE4']
7235,NCT03053336,Change in physical activity level (counts/min from accelerometers),Blood pressure (mmHg),Social support for exercise assessed using a 6 item questionnaire,2017-02-21,COMPLETED,INTERVENTIONAL,['NA']
7236,NCT04237311,Semen quality assessment,Semen quality assessment,,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA']
7237,NCT03170089,Patient awareness,Oral hygiene,,2017-06-30,UNKNOWN,INTERVENTIONAL,['NA']
7238,NCT01881919,Risk of getting hyperuricemia assessed by the measure of plasma uric acid.,Metabolomic and metabonomic profiling of blood plasma,Primary health assessment,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7239,NCT00455325,Insulin Sensitivity,Triglycerides,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7240,NCT00712439,The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the mean daily pain score from the baseline week to end of efficacy treatment period (Treatment Week 4) in patients with DPN.,"Secondary efficacy measures will include changes from baseline in average daily sleep interference scores, SF-MPQ, BPI,NPS, PGIC, and CGIC.",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7241,NCT05365152,Time required for blood sugar to reach target,,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
7242,NCT00434772,glucose,hospitalisation days,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7243,NCT02155023,difference between calibrated measurements and reference,evaluate necessary run-in procedures by assessment of error over time,Malfunction of the systems,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7244,NCT00005135,,,,1991-09,COMPLETED,OBSERVATIONAL,['NA']
7245,NCT00286624,• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.,• The impact of islet transplantation on the quality of life of transplant recipients.,,2003-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7246,NCT01306981,Best corrected visual acuity,Extent of retinal neovascularisation,,2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
7247,NCT06045598,Lumbal proprioception,Dynamic Balance,,2023-09-10,RECRUITING,OBSERVATIONAL,['NA']
7248,NCT01087086,Glucose Profile,Fatty Liver biomarkers / Non invasive liver scoring system.,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
7249,NCT02435199,"The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS).",The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events.,,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7250,NCT03602846,APGAR Score,Method of Delivery,Glycated Hemoglobin (HbA1c),2015-01,COMPLETED,OBSERVATIONAL,['NA']
7251,NCT02089126,HbA1c Changes,,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
7252,NCT01427257,Pharmacokinetics,Safety/Tolerability,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7253,NCT01032629,"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke",Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment,,2009-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7254,NCT03473262,Changes in Fasting Plasma Glucose From Baseline to Week 24,Percentage of Patients With At Least 1 Episode of Genitourinary Tract Infections Between Baseline and Week 24,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
7255,NCT02042339,ICG (indocyanine green) video angiography,High performance 3D LifeViz™ system,Endothelial progenitor cells,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
7256,NCT00882726,Safety and tolerability of a single IV or SC administration of CNTO 3649 in healthy participants; Safety and tolerability of multiple SC injections of CNTO 3649 in Type 2 Diabetic Patients,"Pharmacokinetics, pharmacodynamics and immunogenicity of CNTO 3649 following single and multiple administrations.",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7257,NCT06060886,Number of patients with a therapeutic response to aripiprazole or paliperidone,Number of patients with side effects,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7258,NCT06156137,The composite adverse outcomes,,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
7259,NCT04441658,The changes in HbA1C level,The changes in blood glucose level,,2020-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7260,NCT00701155,Incidence of serious ADRs incl. major hypoglycemias,Variability in fasting Blood Sugar and average plasma glucose levels,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
7261,NCT01064687,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7262,NCT05874635,App engagement,,,2023-05-11,RECRUITING,INTERVENTIONAL,['NA']
7263,NCT04849143,Wound size reduction,,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
7264,NCT02607345,the difference in glycemic index between 25gr. Zusto® and 25gr. Glucomedics®,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
7265,NCT01977560,Skeletal muscle insulin sensitivity,Skeletal muscle mitochondrial metabolites,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
7266,NCT04472962,The area over the curve (AOC).,Satiety (assessed by visual analog scale after pre-exercise meal) during the in-clinic period,,2020-08-14,COMPLETED,INTERVENTIONAL,['NA']
7267,NCT05795309,Percentage time spent in glucose target (3.9-10mmol/L),Percentage time spent in hyperglycaemia (>10mmol/L),,2023-08-16,RECRUITING,INTERVENTIONAL,['NA']
7268,NCT00173940,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
7269,NCT01441921,Changes from baseline in circulating levels of glucose and insulin according to the intervention arm,Changes from baseline in telomeric length of leukocytes (LTL),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
7270,NCT05243238,MNSI score for neuropathy,,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
7271,NCT06145360,Number of participants achieved HbA1c level i.e. <7%,systolic blood pressure and diastolic blood pressure,,2023-12-31,RECRUITING,INTERVENTIONAL,['PHASE4']
7272,NCT05870670,"AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment Period",Number of Treatment Emergent Adverse Events (TEAEs),,2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7273,NCT03544411,Change of malondialdehyde,Change of Glutahione,,2018-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7274,NCT03581266,Investigate glucose kinetics after ingestion of wheat and rye breads,,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
7275,NCT05266261,Bone mineral density,Bone turnover markers,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7276,NCT00747968,steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.,,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7277,NCT01494298,ApoB Levels in African American Men With Diabetes and Those Without.,Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
7278,NCT00322257,HbA1c,Fasting plasma glucose,,2006-05-01,TERMINATED,INTERVENTIONAL,['PHASE3']
7279,NCT06188013,differential proteins of exosomes,,,2024-01-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7280,NCT04143321,Seattle angina questionnaire 1,Seattle angina questionnaire 5,Exercise tolerance test 3,2018-09-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7281,NCT00552734,Decrease in A1c of at least 0.4% in the insulin guidance software group as compared to the control group at 6 months and/or 1 year.,"Hypoglycemic episodes, weight gain, insulin dose, frequency of self monitoring of glucose",,2005-07,COMPLETED,OBSERVATIONAL,['NA']
7282,NCT03748810,Changes in fasting plasma glucose from baseline to week 156 (3-year),Percentage of patients with at least 1 episode of genitourinary tract infections between baseline and week 156 (3-year),,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
7283,NCT03660189,Time to anion gap closure in hours,Total volume of intravenous fluids administered,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
7284,NCT05726409,Satisfaction with the mobile application,Change in nutrition knowledge,,2023-09,WITHDRAWN,INTERVENTIONAL,['NA']
7285,NCT01002807,Blood samples to measure the pharmacokinetic parameters Cmax and AUC for the combination products versus each investigational product alone,"Safety and tolerability measures (adverse events, physical exams, vital signs, ECGs, and clinical laboratory assessments)",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7286,NCT00102466,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= 0.5% after 52 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7287,NCT02667327,Incidence of complete wound closure at Week 12 based on investigator assessment,Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period,,2018-11-21,TERMINATED,INTERVENTIONAL,['PHASE3']
7288,NCT04079660,fasting capillary blood glucose level,LOS,,2021-02-01,COMPLETED,OBSERVATIONAL,['NA']
7289,NCT00755846,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 85.,Mean Percent Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg/dL).,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7290,NCT03067480,Time Spent in Target Range,,,2017-06-06,TERMINATED,INTERVENTIONAL,['NA']
7291,NCT05399134,Postprandial glycemic response of novel staple foods in Type 2 diabetics,,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
7292,NCT00711490,Change in Visual Acuity From Baseline to 6 Months,"Change in Fluid Leakage in the Macula of the Study Eye From Baseline to 12 Months, as Measured on Fluorescein Angiography (FA)",,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7293,NCT02970357,The DIAPASON questionnaire,Psychological indicators,,2016-01-26,COMPLETED,INTERVENTIONAL,['NA']
7294,NCT01108120,The recurrence rate of diabetic foot ulcers,cardiovascular events during the follow up period,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7295,NCT04665999,Insulin sensitivity computed using a Kalman filter-base algorithm embedding a model of glucose-insulin dynamics.,,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
7296,NCT03601910,Cmax of CKD-380 and D308,,,2018-07-16,UNKNOWN,INTERVENTIONAL,['PHASE1']
7297,NCT05315037,Assess glucose response to different resistance training methods,To assess for correlation between lactate and glucose using different resistance training methods,,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7298,NCT04537676,Quality of Life Score (ulcer-specific),,,2020-09-15,UNKNOWN,OBSERVATIONAL,['NA']
7299,NCT03464045,occurence of renal cancer,occurence of other urinary tract cancers,,2016-11-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7300,NCT00131664,Mean Change From Baseline in A1C at Month 6,Mean Change From Baseline in Adiponectin at Month 12,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7301,NCT03204240,Change in beta cell function,Change in muscle fatigue,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7302,NCT01564550,VLDL1 and VLDL2-triglyceride secretion rate (µmol/min),,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
7303,NCT02582242,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Patient-reported Treatment Satisfaction as Assessed by the Diabetes Treatment Satisfaction Questionnaire (Status) (DTSQs),,2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE4']
7304,NCT01690572,MACE-rate,OCT-measurement,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
7305,NCT00604669,Mortality,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
7306,NCT03113448,Visual analog scale (0-100 mm.),Neuropathic Pain Scale (NPS),,2017-01-19,COMPLETED,INTERVENTIONAL,['PHASE3']
7307,NCT03572166,The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.,Frequency of test preference at follow up visit,,2018-09-03,COMPLETED,INTERVENTIONAL,['NA']
7308,NCT01680341,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes,,2012-08-31,COMPLETED,INTERVENTIONAL,['PHASE3']
7309,NCT00856284,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104,Change From Baseline in Body Weight Over Time,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7310,NCT00001395,,,,1994-03,COMPLETED,OBSERVATIONAL,['NA']
7311,NCT04863313,Change of blood glycated hemoglobin (HbA1c) concentration from baseline to week 12.,Adherence to the intervention at week 12.,,2021-03-11,COMPLETED,INTERVENTIONAL,['NA']
7312,NCT03144271,Number of Adverse Events,Morning fasting glucagon,,2007-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7313,NCT03280914,Control rate of hypertension,Medical cost,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
7314,NCT04537884,Ocular and systemic safety and tolerability of a single intravitreal injection of UBX1325 evaluated by the incidence of dose limiting toxicities (DLTs) and treatment emergent adverse events (TEAEs),Plasma concentration of UBX1325 following a single intravitreal injection,,2020-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7315,NCT06327633,Change of olfactory brain activation by fMRI,Change of metabolism,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
7316,NCT01843127,Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT),"Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7317,NCT00231673,Change in peroneal nerve conduction velocity (NCV) from baseline to the end of the double-blind phase.,"Changes from baseline to the end of the double-blind phase in NCVs of the sural sensory nerve and ulnar (motor and sensory) nerve, and changes in amplitudes and latencies of the peroneal motor, sural sensory, and ulnar nerves. Adverse event reporting.",,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7318,NCT02607410,improvement in HbA1c levels,improvement on alpha cell function with a meal test,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7319,NCT04891575,Change in tobacco use,,,2021-09-11,RECRUITING,INTERVENTIONAL,['NA']
7320,NCT05177172,Glucose tolerance,Subjective appetite variables,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
7321,NCT05806190,Time spent in hypoglycaemia,Hospital Anxiety and Depression (HADS) Score,,2023-04-17,COMPLETED,OBSERVATIONAL,['NA']
7322,NCT05451147,OBJECTIVE PARAMETERS,SUBJECTIVE PARAMETERS,,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7323,NCT03807596,Gain in clinical attachment level,,,2017-03-16,COMPLETED,INTERVENTIONAL,['NA']
7324,NCT04082585,Correlation of Global Health Scores to Social Determinants of Health,Change from Baseline - HDL Cholesterol Ratio,,2019-09-04,COMPLETED,OBSERVATIONAL,['NA']
7325,NCT05736263,Comparison of CGM-derived percentage time in range (TIR) when temporary target is enabled or disabled during exercise,CGM-derived percentage time below range (TBR < 54 mg/dl) during and after exercise trials,Associations between sleep quality and glycemic variations,2023-03-31,RECRUITING,INTERVENTIONAL,['NA']
7326,NCT00727896,"Behavioural changes resulting in diet, better adherence to treatment.","Reduction in HbA1c, other glycemic measures and improvement in blood lipid parameters",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7327,NCT01178723,blood glucose balance,lipid profile,,na,UNKNOWN,INTERVENTIONAL,['NA']
7328,NCT00906919,A1C,Cholesterol levels,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
7329,NCT00831129,Change in High-sensitivity C-reactive Protein,Change in Body Mass Index,,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7330,NCT03983499,HbA1c Blood Value,Generalized Anxiety Disorder 7-item (GAD-7),,2015-07-16,COMPLETED,INTERVENTIONAL,['NA']
7331,NCT00854113,VZ/F,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7332,NCT01285245,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7333,NCT04322032,Cmax,,,2020-04-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
7334,NCT01221519,"Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.","pharmacodynamics of AZD1656 following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-4) for insulin",,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7335,NCT02768987,Change from baseline in daily physical activity energy expenditure over 24 weeks,Change from baseline in push-up test over 24 weeks,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7336,NCT05147896,Change in structural arterial wall characteristics,"Correlations between changes in rate of cIMT reduction, % of endothelial function improvement and rate of arterial stiffness reduction on one hand and changes in concentration of sdLDL, % of HbA1c and concentration of hsCRP on the other",,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
7337,NCT03940209,HbA1c,Health-related Quality of Life,,2019-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7338,NCT00335413,Changes in glomerular filtration rate,Changes in fractional albumin clearance,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7339,NCT03197363,Death or the occurrence of diseases,,,2018-11-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7340,NCT03397147,Child Sleep Quality,Parental Diabetes Distress,,2018-07-05,COMPLETED,INTERVENTIONAL,['NA']
7341,NCT04515849,To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks,To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in ECG,To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on rate pressure product,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2']
7342,NCT00684658,Pediatric Quality of Life Inventory (PedsQL),Diabetes Conflict,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7343,NCT02737423,"Improvement in painful diabetic neuropathy by the use of vitamin D Injections (600,000 IU) assessed with the DN4 Neuropathic Pain Diagnostic Questionnaire","Improvement in painful diabetic neuropathy by the use of vitamin D Injections (600,000 IU) assessed with the SF-Mac Gill Pain Questionnaire.",,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7344,NCT01052714,Beck Anxiety Inventory (BAI) Mean Total Score Change Per Week From Baseline to Termination,,,2010-09-01,COMPLETED,INTERVENTIONAL,['NA']
7345,NCT03607448,System Performance,System Related Adverse Device Effects,,2018-07-23,COMPLETED,OBSERVATIONAL,['NA']
7346,NCT01783327,Change from baseline quality of life over 12 months,Change from baseline quality adjusted life years over 12 months,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
7347,NCT00361608,,,,2008-07,WITHDRAWN,OBSERVATIONAL,['NA']
7348,NCT00468039,glycosylated hemoglobin (HbA1c)at Baseline and week 24,"Safety assessed by monitoring and recording all adverse events, serious adverse events.",,2007-03-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7349,NCT01826409,Glucose profiles during meal tolerance test,Change in lipid profiles,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7350,NCT03968380,Glucose Tolerance,Waist circumference,,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA']
7351,NCT02859818,Self-efficacy evaluated with the 10 items-SEDM,"Outcome expectations, socio-structural factors and personal goals",,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
7352,NCT04618744,Number of treatment-related adverse events,Percent change in liver fat content,,2020-11-24,COMPLETED,INTERVENTIONAL,['PHASE2']
7353,NCT02304497,PRF levels of insulin like growth factor -1 (IGF-1),,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
7354,NCT01080976,Search Engine Preference,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
7355,NCT04379726,TASK 4: incidence of post-transplant diabetes in subjects without CFRD,TASK 3: variations of other respiratory and muscle-performance parameters,,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA']
7356,NCT02898155,Rate of potentially avoidable admissions,Standardized Rate of potentially avoidable admissions,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
7357,NCT00427154,Change in HbA1c,Change in body weight,,2007-01-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7358,NCT06104358,Sleeping Metabolic Rate (SMR) change from Baseline to 6 Months (26 weeks),,,2023-11-17,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7359,NCT04267601,Change of HbA1C,,,2017-07-06,UNKNOWN,OBSERVATIONAL,['NA']
7360,NCT00728351,HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy,Changes in the fasting lipid profile,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7361,NCT03283657,Intent to treat questionnaire: Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
7362,NCT06007404,Monocyte /macrophage populations by flow cytometry,Triglycerides (MMTT),,2023-09-06,RECRUITING,OBSERVATIONAL,['NA']
7363,NCT03008395,Hemoglobin A1c,Diabetes Distress,,2017-10,WITHDRAWN,INTERVENTIONAL,['NA']
7364,NCT02615353,Insulin Sensitivity,Body Composition,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA']
7365,NCT00501878,Pupil diameters were measured.,blood pressure and heart rate were measured,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7366,NCT03753087,Change in 6-minute walking distance (6MWD),Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score,,2019-01-16,COMPLETED,INTERVENTIONAL,['PHASE4']
7367,NCT00690755,Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles,,,2000-05,COMPLETED,OBSERVATIONAL,['NA']
7368,NCT06203067,HbA1c,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7369,NCT00340938,,,,2004-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7370,NCT02702011,Change From Baseline in 24 Hour UGE on Day 7,,,2016-03-20,COMPLETED,INTERVENTIONAL,['PHASE2']
7371,NCT06069583,Self-efficacy for diabetes management,Cost effectiveness (HbA1c),"Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider",2024-01-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7372,NCT02814838,Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13,Proportion of Patients With HbA1c <7% and Absence of Episodes of Severe Hypoglycaemia From the Previous Visit in Patients With Screening C-peptide < Median Value,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7373,NCT02513888,fasting glucose (mg/dL),TC (mg/dL),,2013-02-01,COMPLETED,INTERVENTIONAL,['NA']
7374,NCT05144750,Change in Food Security,Self Reported Improved Health,,2021-12-06,COMPLETED,INTERVENTIONAL,['NA']
7375,NCT01858532,Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),,2013-05-17,TERMINATED,INTERVENTIONAL,['PHASE3']
7376,NCT06320756,Therapist Satisfaction feedback collected through 3 quantitative questions and 1 free text qualitative question on the app,Change in mental health distress as measured by the Diabetes Distress Scale (DDS-17),,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
7377,NCT04227626,Average plasma glucose over the closed-loop control period,Dextrose dosing (g/kg),,2021-04,WITHDRAWN,INTERVENTIONAL,['NA']
7378,NCT02180152,Weight gain after postprandial walks in obese pregnant women.,,,2015-03,WITHDRAWN,INTERVENTIONAL,['NA']
7379,NCT00678145,Change in the counterregulatory responses to hypoglycemia compared to controls,Symptom scores,,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7380,NCT01667016,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
7381,NCT00592241,Validate safety while using the ADI Insulin Pump by intended users. This objective will be assessed by independently and successfully carrying out a list of tasks.,Evaluate user's satisfaction.,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
7382,NCT02356848,Ulceration,step count,,2015-09-03,COMPLETED,INTERVENTIONAL,['NA']
7383,NCT05169359,Change from pre-visit diabetes distress score at 1 week post visit,Promis,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
7384,NCT02588729,"Oral glucose tolerance test (OGTT), fasting and 2 hours blood glucose level after intake up til 75gr glucose (1.75gr/kg body weight)",HbA1c,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
7385,NCT01476384,Glycocalyx permeability,Microvascular density,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
7386,NCT04430660,Change in percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),,,2020-08-19,COMPLETED,INTERVENTIONAL,['NA']
7387,NCT02459691,Change in weight from baseline,Clinically significant weight loss,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
7388,NCT02536768,HIV viral supression using lab data,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
7389,NCT02188823,Hemoglobin A1c,Body weight,,2014-07,TERMINATED,INTERVENTIONAL,['NA']
7390,NCT00511719,"Intra-patient and inter-patient comparison of CV % between treatments was based on a t-test.for bioavailability (ie, SI AUC0-540 min) & bioeffect (ie, GIR AUC0-540 min)","Safety variables included adverse events (AEs), clinical laboratory tests, HbA1c, pulmonary function tests, electrocardiograms, vital signs, physical examinations, and diabetes-specific signs",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7391,NCT04107935,Change From Baseline in Glycemic Control,Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months,,2020-02-04,TERMINATED,INTERVENTIONAL,['NA']
7392,NCT06135532,salivary IL-13 level (pg/ml),serum IL-13 level (pg/ml),,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7393,NCT00470860,Knowledge related to blood pressure and lipid management for diabetes patients,,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
7394,NCT00467649,The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia,Phase 2: Change in Body Weight at Week 36,Hypoglycemia Adverse Events,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7395,NCT06279637,Glycemic Control (Hemoglobin A1C [HbA1C]),,,2024-03-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7396,NCT02985853,Capillary Blood Glucose,,,2008-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7397,NCT00574405,"Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI.",Patient Satisfaction With Mode of Therapy and Patient Compliance With Treatment Recommendations.,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
7398,NCT01749020,Determine if the consumption of DC rich in polyphenols can induce a change in insulin sensitivity,Determine if the consumption of DC rich in polyphenols can induce a change in high sensitivity CRP,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
7399,NCT00996645,Primary Disease-Related Outcomes: mean BP and mean LDL level.,Efficacy of intervention,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
7400,NCT05410080,The diagnostic value of middle cerebral artery (MCA) Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients,The diagnostic value of ductus venosus Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients.,,2022-06-15,RECRUITING,OBSERVATIONAL,['NA']
7401,NCT02757937,Change in Diabetes Self-Efficacy Scale Score from Baseline to 4 Months,Change in glycated haemoglobin (HbA1c) from Baseline to 6 Months,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
7402,NCT00335712,Fasting Blood Glucose at week 8,"Other glycemic control parameters (e.g., HbA1c, glycoalbumin)",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7403,NCT04035395,Rate of Change in Hemoglobin A1c,Rate of Change in Self-efficacy: Diabetes Self-Efficacy Scale,,2016-09-29,COMPLETED,INTERVENTIONAL,['NA']
7404,NCT00905528,Change in eGFR after 1 year,,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
7405,NCT00690066,C-peptide area under the concentration curve (AUC) response (MMTT),Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies,,2008-06-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7406,NCT04540016,"Area under the concentration-time curve (AUC0-t, AUC0-∞)",,,2020-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7407,NCT00700648,Incidence of SAEs (serious adverse event),Other safety & efficacy measures,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
7408,NCT03338023,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®),Rate of Documented Symptomatic Hypoglycemia,,2018-03-23,COMPLETED,INTERVENTIONAL,['PHASE3']
7409,NCT06305286,Number of Participants who are insulin-independent post- first and final transplant,Number of Participants with glycosylated hemoglobin (HbA1c) <7.0%,Change in variability after final islet cell transplant and years after discontinuation of AT-1501,2024-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7410,NCT04214600,Change of Glycated Hemoglobin A1c (Hb A1c) After the Cognitive Behavioral Therapy Sessions,Change of Depression Score on Beck's Depression Index,,2019-04-30,COMPLETED,INTERVENTIONAL,['NA']
7411,NCT03445377,Sensor Glucose readings within target range,Total daily insulin dose,,2018-07-16,COMPLETED,INTERVENTIONAL,['NA']
7412,NCT05585697,Plasma concentration of Osteocalcin,trabecular separation distance,,2022-10-07,COMPLETED,OBSERVATIONAL,['NA']
7413,NCT04945161,"Primary endpoint:Q-RT-PCR, for the inflammation stage and the remodeling stage",Secondary endpoint (5): wound reduction rate of each target gene in each group,Safety endpoint(3):Change from baseline in laboratory tests,2021-02-23,COMPLETED,INTERVENTIONAL,['NA']
7414,NCT01445951,Change From Baseline to Week 24 in HbA1c,Proportion of Responders Achieving HbA1c <= 7.0%,Severe Hypoglycemia Event Rate,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7415,NCT00525304,Medical service use patterns,Quantitative and qualitative survey ratings,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
7416,NCT05335863,Areas under the glucose metabolism curve for the determination of the glycemic index,,,2021-11-03,COMPLETED,INTERVENTIONAL,['NA']
7417,NCT01977391,"All-cause and cardiovascular mortality in elderly Korean men and women according to BMI, waist circumference, and presence of diabetes",Survival probability among study populations,,1999-08,COMPLETED,OBSERVATIONAL,['NA']
7418,NCT04450563,Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 5 mg),Rise in ketone level between interventions,,2020-11-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7419,NCT01657318,,,,2012-09-01,TERMINATED,OBSERVATIONAL,['NA']
7420,NCT06005012,Change in fibrosis due to NAFLD,Change in ALT,,2023-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
7421,NCT02228252,Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min).,Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),2014-08,COMPLETED,INTERVENTIONAL,['NA']
7422,NCT01289990,Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment,Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7423,NCT04337723,ABI/WIFI adoption,ABI/WIFI sustainability,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
7424,NCT02306122,Duration of Nonadherence Event,Probability of Pharmacist Action Triggered,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
7425,NCT05007197,Effectiveness of education,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
7426,NCT00577590,Percent Change in Plasma Triglycerides,,,2003-10,COMPLETED,INTERVENTIONAL,['NA']
7427,NCT02967900,Correlation of OCT Measurement of blood vessel density with rate of wound healing,"Correlation of OCT Measurement of blood vessel density at baseline, with rate of wound healing",,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
7428,NCT04988594,Changes from baseline in parameters associated with glucose homeostasis,Changes in oxidative stress parameters,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
7429,NCT01922492,Changes of insulin secretory function,Adverse effects,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
7430,NCT02045290,Change in insulin resistance (IR) from baseline to 13 weeks,Change in Adipose IR from baseline to 13 weeks,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7431,NCT00869102,Insulin secretion,,,2009-05,WITHDRAWN,INTERVENTIONAL,['NA']
7432,NCT03979768,Number of Participants with undiagnosed type 2 diabetes,Explore if there was any difference in the number of participants with a high risk of developing type 2 diabetes in the risk test only (RTO)- group and the group that also offered a HbA1c-measurement (HbA1c-group),,2016-09-15,COMPLETED,INTERVENTIONAL,['NA']
7433,NCT05767255,To compare the percentage of hypoglycemia,Evaluate associated adverse effects,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7434,NCT04888390,Oxygen consumption (VO2),MEP (maximal exspiratory pressure),,2021-04-20,RECRUITING,INTERVENTIONAL,['NA']
7435,NCT01680211,Change in Blood Sugar and lipid profiles,Clinical laboratory evaluations,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7436,NCT03563794,blood glucose,hypoglycemia,,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
7437,NCT05150041,Change in HbA1c(%),changes in patient satisfaction level,,2020-04-07,COMPLETED,INTERVENTIONAL,['NA']
7438,NCT03600116,Identification of Volatile Organic Chemical Indicators of Hypoglycemia,,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA']
7439,NCT01785771,Change in HbA1c between Week 39 and Day 0,,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
7440,NCT03404037,Serum Endostatin Level as a Marker for Coronary Artery Calcification in Type 2 Diabetic Patients with Coronary Heart Disease,,,2017-03-02,COMPLETED,OBSERVATIONAL,['NA']
7441,NCT02305199,Postoperative glucose level,Postoperative Stress hormone level,,2015-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
7442,NCT05302050,Change in HbA1c,Significant change in HbA1c,,2022-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7443,NCT00194896,Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months.,Patients Positive for T Cell Responses to Islet Proteins at 36 Months.,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
7444,NCT02583919,Change in HbA1C,"Safety and Tolerability will be assessed by determining the incidence, severity, dose-relationship adverse-effects, and changes in laboratory evaluations within each dose cohort",,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7445,NCT05658744,Behavior change,,,2019-12-25,COMPLETED,INTERVENTIONAL,['NA']
7446,NCT01042301,Identification and characterization of new CD8+ T lymphocytes related to type 1 diabetes and its evolution (2009-2012),Identification and characterization of new profiles of humoral and cellular markers (including T cell reactivity and miRNA) related to type 1 diabetes (2010-2014).,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
7447,NCT00865683,Insulin sensitivity,Interleukin-6 (IL-6),,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
7448,NCT00732602,plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
7449,NCT02686281,Number of Participants with Serious and Non-Serious Adverse Events,Area Under the Concentration-Time Curve,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
7450,NCT03215069,Baseline-adjusted ISSI-2 at 48-weeks,Glucose tolerance status at 48-weeks,Quality of life at 48 weeks,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7451,NCT05521061,HbA1C levels,Total daily dose of insulin,,2022-05-28,RECRUITING,INTERVENTIONAL,['NA']
7452,NCT01339390,Change in Weight (From Baseline),,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7453,NCT04903496,"The proportion of non-diabetic patients with established cardiovascular disease, or chronic kidney disease, or at high cardiovascular risk among all non-diabetic patients","Serum creatine concentration (μmol/L) at the latest visit for all patients, as well as the trends for inpatients over time (2015, 2017, and 2019 respectively)",,2021-09-06,COMPLETED,OBSERVATIONAL,['NA']
7454,NCT03323281,Measuring memory,Measuring memory,Measurement of cognition by the Mini Mental State Examination (MMSE),2019-12-07,RECRUITING,OBSERVATIONAL,['NA']
7455,NCT01947569,The incidence of treatment-emergent adverse events.,2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).,,2013-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7456,NCT02212158,Change in Baseline HA1c at 12 months post baseline,Change from baseline in Children's Hope Scale at 60 weeks,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
7457,NCT04669912,Changes in percentage of time spent in range 70-180 mg/dL during second month of lockdown compared to before lockdown,Evolution of glucose sensor use compared to before lockdown.,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
7458,NCT00562172,Glucose Homeostasis and glycemic control status,"Insulin resistance parameter, Hypoglycemic episode, symptomatic, Weight change, Lipid profile, Inflammatory markers (CRP, Adiponectin, etcs), Patient satisfaction with diabetes treatment, Urine analysis, Creatinine",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7459,NCT03334370,Change of the proportion of patients who have achieved a HbA1c <7.5%.,"Service utilization outcomes measured by hospital attendance rates at baseline and 12, 24, 36 and 48 months after enrollment.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
7460,NCT02057848,Plasma glucose,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7461,NCT03332849,Number of participants with adverse events,AUC of HM12470,,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
7462,NCT01884714,Measure circulating inflammatory markers and fatty acids associated with obesity and diabetes.,Measure standard clinical and anthropometric parameters in obese and diabetic participants following a standardized meal.,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7463,NCT03787836,Exercise responders following additional exercise program,Body mass index,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
7464,NCT01217892,Adjusted Mean Change in HbA1c Levels,"Proportion of Participants With HbA1c<7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7465,NCT06037551,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7466,NCT02235584,The potentiating effects of GLP-1 on second phase insulin response when clamped at at bloodsugar of 7 mmol/l,Second phase insulin response to GIP infusion at 7mmol/l,Total insulin response to arginine infusion,2009-07,COMPLETED,INTERVENTIONAL,['NA']
7467,NCT04589533,Variation in fasting glycemia between the two groups of Centres during phase 3 of the study,Description of characteristics of patients with T2DM hospitalized in Internal Medicine,,2019-09-19,UNKNOWN,OBSERVATIONAL,['NA']
7468,NCT00368953,"""In-stent late lumen loss"" at follow-up-angiography (9 months)","Combined MACE (cardiac death, myocardial infarction, emergency bypass, stent thrombosis, target lesion revascularization)",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7469,NCT00875290,Reduce blood glucose variability among 0-3 year old children with type I diabetes.,Number of adverse events,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
7470,NCT00325117,Change from baseline to endpoint on HbA1c at 12 weeks,Adverse events profile after 12 weeks of treatment,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7471,NCT03704818,Digit Symbol Substitution Performance Response to Hypoglycemia,,,2018-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7472,NCT05243368,Ulcer evaluation,Concentration of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor A (VEGFA),Hydration status,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
7473,NCT00326196,The Hypothesis Being Tested is That a Strategy of Initial Surgical Revascularization is Superior to Percutaneous Intervention in Preventing Death or Myocardial Infarction in Diabetics With Severe Ischemic Heart Disease Assessed up to 4 Years.,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE4']
7474,NCT01420198,Caloric intake,Blood pressure,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7475,NCT01837680,Glycemic Control,Neonatal Hypoglycemia,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
7476,NCT04625751,Change in blood levels of gastrointestinal hormones and markers of metabolism following meal test,,,2021-04-07,RECRUITING,OBSERVATIONAL,['NA']
7477,NCT06199505,Change in HbA1c,Change from baseline in ADA and Nab,Change from Baseline in Body Weight,2023-11-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
7478,NCT04971252,Estimate risk of thrombosis or bleeding for the 3 study groups by plateletcrit,,,2021-07-07,COMPLETED,OBSERVATIONAL,['NA']
7479,NCT05259644,Change in Body Weight,Change in fasting blood glucose,Change in the IWQOL (The Impact of Weight on Quality of Life) questionnaire,2022-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7480,NCT02744820,Number of Participants with Serious and Non-Serious Adverse Events,Time to reach steady state,Preliminary effect on %HbA1c (Cohort 4 only),2016-04,TERMINATED,INTERVENTIONAL,['PHASE1']
7481,NCT03141710,Change of oral glucose tolerance test (OGTT),Change of fermentation markers,,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA']
7482,NCT03130894,type 2 diabetes,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
7483,NCT01142050,ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;,Serious adverse event frequency and severity,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
7484,NCT03973827,Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.",,2019-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7485,NCT02711839,HbA1c After Intervention,Triglyceride After Intervention,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7486,NCT01620333,Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 70),Adverse events,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7487,NCT00005184,,,,1985-12,COMPLETED,OBSERVATIONAL,['NA']
7488,NCT01892020,2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test,Incidence of AEs (Adverse Event),,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7489,NCT01423266,"Change from Baseline in adiposity (and body composition; i.e., % body fat))",Change from Baseline in levels of quality of life,Change in Cardiac Function,2009-12,COMPLETED,INTERVENTIONAL,['NA']
7490,NCT05676034,To assess the safety and tolerability of AMX0035in adult participants with Wolfram syndrome,To evaluate the effect of AMX0035 on HbA1c levels,,2023-03-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7491,NCT01030679,Change from baseline in fasting plasma glucose at 8 weeks,Adverse event profile after 8 weeks of treatment,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7492,NCT01758380,Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority,"Number of patients with treatment emergent adverse events (AEs), serious AEs, discontinuation due to AEs, deaths or laboratory abnormalities as assessment of safety and tolerability",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7493,NCT04023487,"Change in glycemic control, using Glycated Hemoglobin (HbA1C)",Change in cost to payor,Background Information,2019-10-22,COMPLETED,INTERVENTIONAL,['NA']
7494,NCT02691897,HbA1c,Number of patients with adverse events,,2019-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7495,NCT03823339,Change in laboratory measured glycosylated haemoglobin A1c (HbA1c),"Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable",,2019-01-29,COMPLETED,OBSERVATIONAL,['NA']
7496,NCT00001625,,,,1997-04-03,COMPLETED,OBSERVATIONAL,['NA']
7497,NCT06190938,"The Demographic characteristics were classified into four groups: Gender, Financial status, Educational level, and Profession.",,,2022-06-23,COMPLETED,OBSERVATIONAL,['NA']
7498,NCT00604344,HbA1c,Insulin antibodies,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7499,NCT04836221,Feasibility of an active management strategy for comorbidities,Provider perspectives on acceptability of active management of comorbidities,Preliminary changes in social support,2021-05-05,COMPLETED,INTERVENTIONAL,['NA']
7500,NCT02229396,Change in HbA1c From Baseline to Week 28,Change in Systolic Blood Pressure From Baseline to Week 28,,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7501,NCT04984200,Overall agreement between the results from multiple EyeArt operations,,,2021-07-13,COMPLETED,OBSERVATIONAL,['NA']
7502,NCT02091336,fetal growth,insulin requirements to achieve glucose targets,need of c section,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
7503,NCT02131701,improvement in physical fitness,changes in body composition,changes in muscle strength,2006-10,COMPLETED,INTERVENTIONAL,['NA']
7504,NCT00797524,Retinal leakage and retinal thickness.,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7505,NCT03755960,Visual analogue Scale (VAS) general complaints and pain,neurophysiological assessment of Nervus Suralis height of amplitude of action potential,,2019-03-02,COMPLETED,INTERVENTIONAL,['NA']
7506,NCT05312450,The change of postprandial blood glucose,Serum metabolomics,,2022-03-10,RECRUITING,OBSERVATIONAL,['NA']
7507,NCT02413398,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.,,2015-06-15,COMPLETED,INTERVENTIONAL,['PHASE3']
7508,NCT03068078,"Glycemic control, dyslipidemia and metabolic markers",Gut dysbiosis,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
7509,NCT05854979,Gastric Volume in RLD Position,Incidence of aspiration,,2023-08-09,RECRUITING,OBSERVATIONAL,['NA']
7510,NCT05517772,Semi-structured interviews,Patient reported outcomes,,2022-06-16,COMPLETED,OBSERVATIONAL,['NA']
7511,NCT01511835,OGTT,Number of newborn infants requiring Neonatal Intensive Care (NIC),,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
7512,NCT01678820,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With A1C Level <7% at Week 16,,2012-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7513,NCT05546281,"Forced food categorization task according to the categories ""healthy / unhealthy""",Type 1 Diabetes Distress Scale (T1-DDS),,2022-10-01,RECRUITING,OBSERVATIONAL,['NA']
7514,NCT01816633,Time to heal,Number of patients with adverse events as a measure of tolerability,,2013-10,TERMINATED,INTERVENTIONAL,['NA']
7515,NCT00340678,Number of Participants With Decline in GFR,Glomerular Volume,,1995-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7516,NCT01643031,"Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.","Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days",,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
7517,NCT04082884,Percentage of Time in Target Range of 70-180 mg/dL.,Average Sensor Glucose Level,,2020-06-25,COMPLETED,INTERVENTIONAL,['NA']
7518,NCT06120569,HbA1C less than 7%,ratio of albumin (mcg/L) to creatinine (mg/L)ratio,,2024-09-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7519,NCT01968668,Change of urinary albumin-to creatinine ratio,Change in serum potassium concentration,,2013-10-28,COMPLETED,INTERVENTIONAL,['PHASE2']
7520,NCT00220207,Hemoglobin A1c,,,2003-09,COMPLETED,INTERVENTIONAL,['NA']
7521,NCT00949351,Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathy,Change of Urinary TGFb1 compare to baseline,,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
7522,NCT05692934,Pharmacokinetics parameters of Metformin in the fast and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
7523,NCT00236379,Change in the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test (which shows how the body regulates glucose),Changes in measurements of metabolism and glucose regulation; changes in results of tests and questionnaires evaluating the effectiveness and safety (including laboratory tests and anthropomatic measurements) of medications used to treat schizophrenia,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
7524,NCT02128815,change from baseline A1C after one year,change from baseline in quality of life at 1 year,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7525,NCT05156736,Burden of atherosclerotic plaque assessed via coronary computed tomography angiography,Incidence of hypertension in mm Hg measured by Omron digital BP apprataus,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
7526,NCT00296374,Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.,Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7527,NCT02800252,Periodontal pockets with mean probing depth (PD) ≥5mm,Plaque index (%),Glycated hemoglobin,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
7528,NCT04496921,Change in serum vitamin K levels from baseline at 6 months,Glycemic marker levels,,2020-08-10,WITHDRAWN,INTERVENTIONAL,['NA']
7529,NCT01439178,"intraocular VEGF levels (pg/ml) in both groups (measured in aqueous humor), using multiplex beads immunoassay",,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
7530,NCT01916265,AUCGlucose of different glucagon dosages given s.c.,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7531,NCT03598621,"Cmax,sema,SD, the maximum plasma semaglutide concentration after a single dose subcutaneous semaglutide administration","Number of site-initiated technical complaints with or without co-reported adverse events: DV3372 device, 1.0 mg/mL versus PDS290 semaglutide pen-injector, 1.34 mg/mL",,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7532,NCT01271777,Glucose Infusion Rate (GIR),Changes in HGP (Hepatic Glucose Production),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7533,NCT00073268,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7534,NCT04035031,Area under the curve for glucagon-like peptide I in oral glucose tolerance test clamp,Area under the curve for somatostatin in oral glucose tolerance test clamp following dapagliflozin compared with placebo,,2020-01-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7535,NCT02949024,Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events,CLS-TA Injections,,2016-11-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7536,NCT01855321,Percentage of improvement in Glycemic control after Vitamin D therapy.,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7537,NCT01382628,Structural and metabolic changes,Relationship between collagen changes and system changes,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
7538,NCT02540993,"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death","The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death",,2015-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
7539,NCT00602914,Blood samples for PK and PD will be collected,"Feedback from study participants and staff on their overall impression with the MicronJet device, using questionnaires",,2008-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7540,NCT01098994,Demonstrate the presence of HDL dysfunction among individuals with the Haptoglobin 2/1 and 2/2 compared to those with the Hp 1/1 phenotype and improvement in HDL dysfunction with natural d-α-tocopherol supplementation,Assessment of adherence to the clinical trial study protocol in a random sample of individuals with type 1 diabetes recruited from the ACR and CHP/EDC Diabetes Registries,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
7541,NCT02640118,PPG excursions measured as incremental area under curve (iAUC),"glucagon, gastrin, cholecystokinin, GIP, GLP-1, oxyntomodulin",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7542,NCT02864212,Invasive blood pressure,,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
7543,NCT00655330,urinary albumin excretion or proteinuria at week 48,,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
7544,NCT00768040,"Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment",,,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7545,NCT03921593,Quantification of Quality of Life,Estimate cost-effectiveness of pancreas transplantation,,2018-11-04,UNKNOWN,OBSERVATIONAL,['NA']
7546,NCT00748137,24 hours BGL > 8.3mmol/l (CGMS),HbA1c,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
7547,NCT01435707,fasting blood glucose,visual analogue scale of subjective pain,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
7548,NCT01798420,Hemoglobin A1C LEVEL,Glucose levels,Weight,2012-04,COMPLETED,OBSERVATIONAL,['NA']
7549,NCT00656864,Change in incretin-mediated insulin secretion and receptor regulation of glucose-dependent insulinotropic peptide (GIP) in patients with type 2 diabetes.,Change in adipocyte GIP receptor mRNA expression levels.,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7550,NCT05369052,Vital signs - heart rate,Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators,,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE3']
7551,NCT04457531,Mean maximal nerve conduction velocity,low density lipid Protein cholesterol (LDL-C).,"Amino acids, lipid metabolites, vitamins, neurotransmitters and other metabolites",2020-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7552,NCT00366132,Time to Complete Wound Healing,"o Durability of wound closure (i.e., status of wound at one week following determination of ""healed"")",,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7553,NCT00963768,The number of patients with adverse events as a measure of safety and tolerability,Renal glucose threshold,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7554,NCT00994253,"The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics.","Secondary measures include evaluation of serum and urine biomarkers related to endothelial function, the renin-angiotensin system, oxidative stress, and inflammation.",,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7555,NCT04677699,Diagnosis of Celiac Disease,Severity of disease at diagnosis,,2020-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7556,NCT06065852,Facilitate translational and epidemiological research,,,2009-11-06,RECRUITING,OBSERVATIONAL,['NA']
7557,NCT00106704,Change From Baseline in A1C at Week 24,Change From Baseline in FPG at Week 24,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7558,NCT03792646,Postural Balance (sway velocity) change from baseline,Inflammatory biomarkers - plasma concentration change from baseline (Tumor necrosis factor-alpha),,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7559,NCT00001313,,,,1992-05-10,COMPLETED,OBSERVATIONAL,['NA']
7560,NCT00920582,Mean Change From Baseline in HbA1c Between Teplizumab and Placebo,Number of Participants With Serious Adverse Events,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3']
7561,NCT00751842,Meal Stimulated C-peptide (area under the curve),Insulin Dose,,2008-09,TERMINATED,INTERVENTIONAL,['PHASE3']
7562,NCT03262116,Percentage of Time Spent With CGM Glucose < 54 mg/dl,Total Daily Dose of Insulin,,2019-03-19,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7563,NCT01186965,Process data,Diabetes knowledge,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
7564,NCT02498990,Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months,"Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months",,2015-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7565,NCT00667732,The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment,The Percentage of Per Protocol Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7566,NCT01861392,Postural balance training diabetic type 2,Quality of life of diabetics type 2,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
7567,NCT04978649,Composite of Major Renal Events,Cancer,,2021-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7568,NCT06259318,Optimism,,,2023-06-21,COMPLETED,INTERVENTIONAL,['NA']
7569,NCT02140424,Rate of bone mineral accrual,Change bone microarchitectural parameters in patients with diabetes vs. controls,Association of bone mineral accrual with moderate-to-vigorous physical activity,2013-08,RECRUITING,OBSERVATIONAL,['NA']
7570,NCT00824694,Principal endpoints will be measured 48 weeks after group assignment and include the number of medication changes and HbA1c. Interim analysis will include HbA1c measurement at 3 mont intervals.,"Secondary endpoints include changes in patient attitudes toward SMBG, daily carbohydrate consumption, physical activity level, BMI, and medication compliance (for subjects on OHA).",,2009-03,COMPLETED,INTERVENTIONAL,['NA']
7571,NCT05943899,Association between SGLT2i intake and hepatic fibrosis,,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
7572,NCT01067924,Change in physical activity as measured by the GODIN physical activity questionnaire,"Change in Hemoglobin A1C, BMI, six minute walk-test, QoL, and self-efficacy.",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
7573,NCT02317835,Detection of hot spots on a foot thermal map image,,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7574,NCT01046318,Clinical laboratory tests,Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF),,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7575,NCT06057077,change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow up,the change in weight after follow up of one year,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7576,NCT01410773,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL(<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Alternative Site (AST) Palm Blood Glucose (BG) Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7577,NCT00812578,Insulin secretion and insulin resistance,"Glycemic control, lipid status, inflammatory markers, BMD",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7578,NCT01058733,physicians' labour time and frequency of contact with the online communication system required for reviewing the patients' information and sending recommendations,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
7579,NCT06256172,"5 readings of Respiratory Data (FEV1, FVC, FEV1/FVC ratio) in L using the Respiratory unit in Medlink is acquired and the average value is reported.",,,2023-06-16,COMPLETED,INTERVENTIONAL,['NA']
7580,NCT05654142,"Assess changes in weight at baseline 0, 6, 12,24 and 52",,,2023-04-17,RECRUITING,INTERVENTIONAL,['NA']
7581,NCT01984372,Incidence of AEs (Adverse Events) by preferred term,Incidence of severe hypoglycaemia,,2013-11-06,COMPLETED,OBSERVATIONAL,['NA']
7582,NCT01679899,Markers of bone remodeling,Calcitonin,Levels of aminotransferases,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7583,NCT03495908,Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis.,"Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Intent-to-treat Population Secondary Outcome, Non-inferiority Hypothesis.",Evaluate the Change in Glucose Patterns Between Groups Based on 7-point Glucose Profiles.,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
7584,NCT02685345,change in 24 hour weighted mean glucose,change in derived glucagon AUC,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7585,NCT02121483,t1/2,Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7586,NCT05422807,Change in Body Mass Index (Weight Status) at 6 months and at 12 months,Waist circumference (weight status),Teen Quality of Life,2011-04,COMPLETED,INTERVENTIONAL,['NA']
7587,NCT01575483,Adverse events occurrence,"Effectiveness of Onglyza® measured by Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2-hr post-prandial glucose (2-hr PPG) comparing baseline data",,2012-03-01,COMPLETED,OBSERVATIONAL,['NA']
7588,NCT01135901,Diabetes mellitus type 2,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7589,NCT02815722,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7590,NCT00837577,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,,2009-02-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7591,NCT01863914,Primary patent rate of AV fistula,Composite outcome measurement of the overall shunt-related complication rate,Composite outcome measurement of systemic pro-inflammatory response,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7592,NCT01814267,Assess the incremental cost-effectiveness ratio from the french health system perspective,Assess acceptability of telemedicine care (compliance and satisfaction) for patients and nurses.,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7593,NCT04586907,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Maximum Concentration (Cmax) of LY3537021,,2020-11-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7594,NCT04271709,Proportion of Subjects with Visual Acuity Worse than 20/40,,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7595,NCT02222506,Safety and tolerability of the KLOX BioPhotonic System in patients with diabetic foot ulcers.,Wound volume reduction over time.,Impact of treatment on Health-related quality of life.,2013-04,COMPLETED,INTERVENTIONAL,['NA']
7596,NCT01304225,Incidence of severe visual loss after 1 year,Retinal sensitivity,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
7597,NCT03121027,Anemia,,,2011-05-11,COMPLETED,OBSERVATIONAL,['NA']
7598,NCT00865345,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI-Yellow Springs Instruments),Device Related Moderate or Device Related Severe Adverse Events,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
7599,NCT01862263,Percentage of patients with hyperglycemic events evaluated with CGM,"Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin",,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
7600,NCT01972724,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose at Week 24,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
7601,NCT00741390,"Difference in Lancing Pain for Device Pair at Visit 2. (For Subjects Assigned to Arms A, B, C Only)",Reported Device Preference Within Lancing Pair at Visit 2,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
7602,NCT03509454,The microvascular function by estimating the glycocalyx thickness,peripheral neuropathy,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
7603,NCT02405260,Change in HbA1c (Glycosylated haemoglobin),Pulse,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7604,NCT00537719,Change from baseline of the time to 50% gastric emptying (gastric emptying t½) of the solid and liquid components of a meal at 72 hours after dosing in healthy volunteers.,Exploratory correlation of % contents remaining in stomach after a meal.GSK716155 concentration before meal & at the time gastric emptying is complete. Safety and tolerability parameters each visit.,,2007-12-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7605,NCT04949152,MACE,,,2016-06-01,RECRUITING,OBSERVATIONAL,['NA']
7606,NCT01735123,"Intestinal permeability will be determined at the age of 3, 6, 9 and 12 months with the lactulose/mannitol test Intestinal permeability at the age of 9 months assessed with the lactulose/mannitol test",Serum metabolic profile,Intestinal microbiome,2013-01,COMPLETED,INTERVENTIONAL,['NA']
7607,NCT00564395,Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
7608,NCT05865353,Shear data,,,2023-02-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7609,NCT01915264,Incidence of severe hypoglycemia or documented symptomatic or asymptomatic hypoglycemic events reported as adverse events,Number of patient with adverse event (Tolerability),,2015-08,WITHDRAWN,OBSERVATIONAL,['NA']
7610,NCT04633642,Change From Baseline Myofibroblasts Formation (Myofibroblasts Content) at 6 Weeks,Wound Size,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
7611,NCT05814965,hs-CRP,,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA']
7612,NCT02203084,Albumin/creatinine ratio,,,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
7613,NCT00008801,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7614,NCT01692028,HOMA-IR,Blood pressure,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
7615,NCT05935514,Change in HbA1c% at 6 months,Percentage of patients achieving 10% weight loss at 12 months,Change in glucose variability (coefficient of variation) at 12 months,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
7616,NCT04516759,Clinical Improvement by Day 14,Intubation/Mechanical Ventilation,,2020-08-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7617,NCT03411460,Satisfaction of patient-determined hospital care at discharge in the two groups,Number of hypoglycmic events with the corresponding glucose level,,2017-04-19,TERMINATED,INTERVENTIONAL,['NA']
7618,NCT05621811,Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary total score from baseline to week 12,,,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7619,NCT03139019,Outcome measure: Measure of decrease in weight loss across 16 weeks,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
7620,NCT01890876,Glucose tolerance,Cardiovascular fitness,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7621,NCT06315127,Donor milk supplementation and exclusive breastfeeding rate at 4 months,Exploring donor milk supplementation and head circumference measurements,Exploratory outcome: exploring donor milk supplementation and maternal cortisol concentrations,2023-11-28,RECRUITING,INTERVENTIONAL,['NA']
7622,NCT00519727,safety and tolerability,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7623,NCT02648685,the proportion of basal/post-prandial blood glucose contributed to the overall glycaemia(HbA1c),,,2015-11-30,COMPLETED,OBSERVATIONAL,['NA']
7624,NCT00569998,Evaluation of overall pen preference,Adverse events,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7625,NCT00160485,Newborn birth weight,Incidence of neonatal metabolic derangement,,2004-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7626,NCT01537445,Kidney function,Kidney hemodynamics and oxygenation,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
7627,NCT01778348,"Time spent overnight in the target glucose range (3.9 to 8.0 mmol/l), as assessed by adjusted continuous subcutaneous glucose monitoring (CGM)",Episodes of symptomatic hypoglycaemia,Utility Evaluation,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7628,NCT01275040,Between group differences in HbA1c categories,Between group differences in patients where LDL cholestrol and creatinine was measures,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
7629,NCT00699426,insulin secretion,blood pressure,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7630,NCT02573519,Difference in total gastrointestinal transit time between diabetic patients and healthy subjects,Difference in regional transit times in diabetic patients´s 3D-transit before and after Malone antegrade continence enema,,2015-10,TERMINATED,INTERVENTIONAL,['NA']
7631,NCT03451838,the number of paticipants who will have babies with macrosomias,,,2018-03-03,UNKNOWN,OBSERVATIONAL,['NA']
7632,NCT04608058,Change in Self-management behavior,Change in Glycated hemoglobin A1c,,2019-07-30,COMPLETED,INTERVENTIONAL,['NA']
7633,NCT00339833,Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7634,NCT03890588,Number of Patients With Referral to Nephrology,,,2019-04-17,COMPLETED,INTERVENTIONAL,['NA']
7635,NCT02450097,Change from baseline in fasting serum insulin in 6 months.,,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7636,NCT04782934,Incidence of sensor failure,Post explantation follow-up,"Assessment of influence of interference substances (i.e. ethanol, lactate, ketones, paracetamol, acetylsalicylic acid, sorbitol, fructose, aspartame, ibuprofen, caffeine and ascorbic acid [Vitamin C])",2021-02-25,COMPLETED,INTERVENTIONAL,['NA']
7637,NCT04557228,Change in Insulin-stimulated blood flow,Change in Vascular function,,2023-03-17,RECRUITING,INTERVENTIONAL,['NA']
7638,NCT01747967,Correlation between residual insulin secretion and T-cell responses against beta-cell antigens.,Correlation between residual insulin and glucagon secretion.,,2011-11-15,COMPLETED,INTERVENTIONAL,['NA']
7639,NCT00783315,Weight,Lipid levels,,2008-02-01,COMPLETED,INTERVENTIONAL,['NA']
7640,NCT06185790,Faecal microbiome composition analyses via DNA isolation,Blood ketone concentration,,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
7641,NCT02072551,Mean insulin secretion output,glucago secretion output,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
7642,NCT01974544,"Change in the microvascular complications of type 2 diabetes, specifically peripheral and sympathic neuropathy.",How many patients not requiring antidiabetic agents,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
7643,NCT05292066,Toronto clinical neuropathy score,,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7644,NCT05764629,Hemoglobin A1c (HbA1c),Adverse events,,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7645,NCT01827280,Change from Baseline in microcirculation function at 30 days,Change from Baseline in endothelial function at 30 days,Change from Baseline in incretins and inflammation markers at 30 days,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7646,NCT03738982,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)",Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
7647,NCT02500628,Heart Rate Variability (Frequency Domain),Number of Patients Reporting Side Effects From the Medication,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7648,NCT04570735,Correlation between morphometric and functional and metabolic biomarker data obtained by magnetic resonance spectroscopy (MRS) in 3 different patient groups,Correlation between metabolic MRS biomarkers and urine and plasma metabolites quantification.,,2020-10-07,UNKNOWN,OBSERVATIONAL,['NA']
7649,NCT04477928,"Demonstrated feasibility of large-scale population screening, as evidenced by:",Assessment of costs associated with implementation of study compared to potential impacts on cost and quality of life.,,2020-07-17,RECRUITING,OBSERVATIONAL,['NA']
7650,NCT01312207,visual acuity change after surgery,Optical coherence tomography findings,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
7651,NCT02811874,HbA1c,Weight,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
7652,NCT00461136,To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.,To investigate whether there is a change on biomarkers of inflammation and cardiovascular risk.,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7653,NCT04662879,Earlier detection of pancreatic ductal adenocarcinoma (PDAC),Depression and Anxiety as early indicators,,2021-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7654,NCT05345327,Rate of decline in eGFR,Quality of life measured by EQ-5D-5L,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7655,NCT01273558,RTG values using the MMTT and the stepwise hyperglycemic clamp methods,Rate of Urinary glucose excretion (UGE) during the MMTT and the hyperglycemic clamp procedure,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7656,NCT02229097,postprandial glycaemia,fructosamine,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7657,NCT01093794,Cmax for Sitagliptin and Metformin,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7658,NCT03301792,Effect of Diabetes Group Care on postpartum weight retention,Psychosocial Stress and Depression,,2017-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7659,NCT01231308,The primary end-point will be the control of hyperglycemia (HbA1c <6.5% + FG<126mg/dl).,"Short (2 yrs) and long term (5 yrs.) achievement of 'adequate"" glycemic control, mean change in HbA1c from baseline.",,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
7660,NCT04432337,Variation in the plasma concentration of cytokines IL-1β and IL18,Compare the plasma levels of IL-1β and IL18,Compare the plasma concentration of reactive protein C (CRP) the level of activation of the NLRP3 inflammasome in circulating blood monocytes.,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
7661,NCT01053793,Glycemic response,Bioavailability of polyphenols from potatoes,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
7662,NCT05368623,To determine the sensitivity and specificity of RETINA-AI Galaxy v2.0 for diabetic retinopathy screening in the primary care setting.,,,2022-11-03,COMPLETED,OBSERVATIONAL,['NA']
7663,NCT03970772,Changes in glucose values from baseline to 30 minute,"Coefficient of Variation, by CGM",,2019-04-15,COMPLETED,INTERVENTIONAL,['NA']
7664,NCT06191328,HbA1c,Serum lipid profile,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7665,NCT02032173,Number of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 6 Months,Evaluation of the Spaced Out Follow-up on Visual Functions and Quality of Life,,2014-05-19,TERMINATED,INTERVENTIONAL,['PHASE3']
7666,NCT00221455,"Clinical Outcome Measures: HbA1c, LDL,and the presence or absence of clinically significant proteinuria.",Technology Adoption will be measured by tracking the patient usage of the various portal features,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7667,NCT00659828,Weight,Bone Mineral Density,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7668,NCT00690235,Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine,,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7669,NCT02854202,Plasma glucose,Change in body weight,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
7670,NCT02579655,"Composite rate of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, hospitalizations for chronic disease-related ambulatory care sensitive conditions",Overall health care costs,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7671,NCT00494663,"1. The primary efficacy endpoint will be change from baseline to the end of treatment (Study Visit 6, Week 16) in HbA1c","1. Change from baseline to Week 8 in total and LDL-cholesterol (LDL-C) 2. Change from baseline to the end of treatment (Week 16) in the following : Seated blood pressure (systolic, diastolic and mean arterial pressure) Fasting blood glucose",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
7672,NCT02628392,change in HbA1c,change in triglyceride,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7673,NCT03001583,Weight loss,Weight loss,,2019-10-30,WITHDRAWN,INTERVENTIONAL,['NA']
7674,NCT04879758,"Changes in Calories Burn between baseline and 4-week post-intervention, and between baseline and 6-month follow-up","Changes in Self-reported Psychological Status between baseline and Immediate post-intervention, between baseline and 4-week post-intervention, and between baseline and 6-month follow-up",,2021-07-07,RECRUITING,INTERVENTIONAL,['NA']
7675,NCT05640869,Change in A1c,Physical activity change,"Change in Processes of Change for Weight Loss including the following processes: emotional re-evaluation, weight consequences evaluation, supporting relationships, and weight management actions",2023-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7676,NCT03552757,Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo,Change in Calcitonin - Semaglutide 2.4 mg Versus Placebo,,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7677,NCT00607347,Correlation of area under curve (AUC) up to 24 hour time point of atenolol plasma drug concentrations and glucose/insulin values obtained from OGTT and triglycerides,"HDL-cholesterol, fatty acids, total cholesterol",,2008-02,COMPLETED,INTERVENTIONAL,['NA']
7678,NCT04124211,Safety of FMT,Blood chemistry panel,,2019-08-25,UNKNOWN,INTERVENTIONAL,['NA']
7679,NCT03538743,Number of Participants With Abnormal Electrocardiogram (ECG) Interval,Renal Clearance (CLr) of PF-06882961 on Day 28,,2018-06-25,COMPLETED,INTERVENTIONAL,['PHASE1']
7680,NCT00339885,"T2D status, quantitative traits measurements",,,1996-06-01,COMPLETED,OBSERVATIONAL,['NA']
7681,NCT01429467,Correlation of HbA1c and level of cortisol,Change in levels of cortisol following CGM,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7682,NCT01920984,"Vitreous levels of Fractalkine, Cyr61, and VEGF of patients with proliferative diabetic retinopathy",,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
7683,NCT06305208,Change in the number and dose of anti-diabetic medications,Changes in health-related quality of life scores (EuroQol-5D-5L),,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
7684,NCT04864327,HbA1c,BP(systolic and diastolic blood pressure),,2011-05-05,COMPLETED,INTERVENTIONAL,['NA']
7685,NCT01065337,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred",Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7686,NCT01475461,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7687,NCT03309007,Change in Leucocyte LC3 Score,,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7688,NCT02101229,Time spent in blood glucose range [70-180 mg/dl],time spent below 70 mg/dl and above 180 mg/dl,,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7689,NCT05267925,Homeostatic Model Assessment of Insulin Resistance,Blood urea nitrogen (BUN),PROMIS-29 Health-related Quality of Life,2022-01-08,TERMINATED,INTERVENTIONAL,['NA']
7690,NCT04619836,Effects to quality of care with questionnaire,How to guide patients,,2020-06-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7691,NCT01792206,The change in brachial artery Flow Mediated Dilataion with paracalcitol (1mcg/day)compared with placebo for 3 months.,Biomarker Measurement,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
7692,NCT00909480,Change in HbA1c From Baseline,"Number of Subjects Having the Adverse Event ""Incorrect Dose Administered""",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7693,NCT01397942,Insulin sensitivity,Urine and blood samples,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
7694,NCT02147860,DiAs time within target,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
7695,NCT03010683,"Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.",Endothelial Glycocalyx and Coronary Flow Reserve.,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7696,NCT03315988,"Change from Baseline 3-hour post-challenge glucose levels at 1, 8 and 12 weeks.","Semi-structured interviews with the completers, at the end of the study, to investigate perception responses having been on a vegan diet.",,2017-10-04,COMPLETED,INTERVENTIONAL,['NA']
7697,NCT05343884,Diagnostic Failure,Secondary end-points,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
7698,NCT02868606,Transfer to intensive care unit (y/n),In-hospital death (y/n),,2015-07,COMPLETED,OBSERVATIONAL,['NA']
7699,NCT02077127,Genetic association,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
7700,NCT03688919,Change From Baseline in Youth Future Orientation (Objective Measure) at 8 Weeks (Z-score),Change From Baseline in Self-Care Inventory Revised at 8 Weeks (Z-score),,2019-05-13,COMPLETED,INTERVENTIONAL,['NA']
7701,NCT01819922,Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose,Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7702,NCT03351478,Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,,2017-11-27,COMPLETED,INTERVENTIONAL,['PHASE3']
7703,NCT03407599,"AUC(IAsp),0-12h, area under the serum insulin aspart concentration-time curve from 0 to 12 hours",Number of hypoglycaemic episodes,,2018-01-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7704,NCT04930679,Fasting blood glucose,,,2018-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
7705,NCT05508490,prevalence of acute kidney injury in diabetic ketoacidosis,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7706,NCT01567254,Blood glucose values before and after listening to the recording.,"The delta of HA1C between before and after three months of periodic listening to auditory guided imagery, compared to listening to music.",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7707,NCT01619592,Quality of Life (QoL),,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7708,NCT00238498,Change from baseline in HbA1c at 12 weeks,Change from baseline in HOMA IR at 12 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7709,NCT01782547,Change in Hemoglobin A1c,Change in Diabetes Knowledge,Telehealth intervention satisfaction,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7710,NCT05253768,Percentage of change in weight compared with baseline.,Safety of FMT,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7711,NCT00876980,HbA1C,Fasting glucose & fructosamine microalbuminuria blood pressure lipids endothelial function,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7712,NCT01127308,Number of Participants Experiencing an Adverse Event (AE),,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7713,NCT00681460,newborn weight,"parameters of metabolic control in mother and newborn, insulin resistance, inflammatory reaction, oxidative stress, fetal growth,",,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7714,NCT01983813,Adherence of medical regimen/treatment to all of the Guideline Advantage criteria that apply.,"Control of blood pressure, low density lipoprotein cholesterol and hemoglobin A1c.",,2014-03-19,COMPLETED,INTERVENTIONAL,['NA']
7715,NCT00155454,Recurrent vitreous hemorrhage rate,,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
7716,NCT03838783,Time in range within 6 hours,Change in TRIM-D Score,,2018-05-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
7717,NCT06286566,Number of complication,Valuation of patient satisfaction,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7718,NCT01327209,,,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
7719,NCT05054712,To describe the prevalence of metabolic liver diseases (NAFLD and GH) by different diagnostic approaches in the population of patients with T1D.,To study the relationship between metabolic liver diseases in patients with T1D and the presence of microvascular and macrovascular complications.,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
7720,NCT00632008,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7721,NCT05694520,The incidences of adverse maternofetal outcomes,Change from baseline the inflammatory factors at 2 months,,2023-06-10,RECRUITING,INTERVENTIONAL,['NA']
7722,NCT04494139,Healthy food intake,Systolic Blood pressure,,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA']
7723,NCT04513587,Change in Waist circumference,Change in Sense of coherence,,2019-09-01,RECRUITING,INTERVENTIONAL,['NA']
7724,NCT05915338,Fırst follow - up survey,Last test survey,Durabılıty test for both groups,2022-10-01,COMPLETED,OBSERVATIONAL,['NA']
7725,NCT00163683,"The primary outcomes include: HBAIc and lipids (Cholesterol, HDL-cholesterol, Triglycerides) at study entry and 6 months after dietary intervention","Key secondary outcomes include: TNF-a, IL-6, High sensitivity CRP, plasma carotenoids and serum fatty acids.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
7726,NCT05834868,Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment,Change From Baseline in 2-hour Postprandial Glucose (PPG) Excursion at Week 26,,2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE3']
7727,NCT04946799,Fasting insulin at follow-up,International Physical Activity Questionnaire - Short Form at baseline,,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
7728,NCT01387633,blood pressure,Self-monitoring of blood glucose,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
7729,NCT06048757,Change in daily insulin dose requirement,App usability,,2023-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7730,NCT00491023,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
7731,NCT02126423,Kirby Bauer disc diffusion antimicrobial susceptibility,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
7732,NCT06040164,Change in 2-oleoyl-glycerol (2-OG) levels in saliva and plasma,Oral health impact profile,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7733,NCT00994812,Miscarriage rates,Effects of metformin versus placebo on the rates of gestational diabetes during pregnancy,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7734,NCT04589325,Residual insulin secretion,HbA1c,Change in International Physical Activity Questionnaire (IPAQ) scores from baseline and week 52.,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
7735,NCT05331586,Excessive gestational weight gain,Pelvic Floor and sexual disorders during pregnancy,,2022-07,UNKNOWN,INTERVENTIONAL,['NA']
7736,NCT01541956,Change from baseline in hemoglobin A1c(HbA1C) after 24 weeks of treatment with vildagliptin,"Number of patients with adverse events, serious adverse events and death",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7737,NCT04536480,Change in total body fat mass (kg),Change in BMI in excess of the 95th percentile (%BMIp95),Adult eating behavior Questionnaire,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
7738,NCT06240403,SAT microvascular endothelial cell β-galactosidase,,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7739,NCT05942079,Change in adherence to treatment,,,2022-09-15,RECRUITING,OBSERVATIONAL,['NA']
7740,NCT01101204,Antiinflammatory effects of combined antidiabetic and hypolipemic treatment,Coagulation parameters,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
7741,NCT03362151,Delta glucose (maximum rise from baseline glucose) mg/dL,percent time glucose <70 mg/dL,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7742,NCT03004612,Change from basal fasting and post2h OGTT glucose levels at 12 and 24 months,Incidence of type 2 diabetes,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7743,NCT04682626,A1c,25OHD,,2020-12-25,COMPLETED,INTERVENTIONAL,['NA']
7744,NCT00334711,HbA1c reduction,Incidence of Hypoglycemia,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
7745,NCT06068114,Pyloric distensibility,Autonomic function testing,,2022-10-05,RECRUITING,OBSERVATIONAL,['NA']
7746,NCT04549324,The association between sleep apnea and systolic function in patients with diabetic nephropathy.,Association between 2D atrial global strain as determined during echocardiography and sleep apnea in patients with diabetic nephropathy.,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
7747,NCT00133952,Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48,Number of Participants Requiring Repeat Focal Photocoagulation at Any Time From Baseline Though Month 24,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7748,NCT01193179,"Adverse events, clinical laboratory tests",Secondary Outcome HbA1c,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7749,NCT05442840,Change in Baseline Hemoglobin A1C (HbA1C) at 10 months,Modifiable Risk Factor - Blood Pressure,,2022-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7750,NCT00417924,Patient satisfaction post-examination,,,2004-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7751,NCT00734253,Change in serum creatinine from baseline to end of study.,"SCr slope, change in PCR, Cystatin C slope and change from baseline.",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7752,NCT02991534,Referrals to Health Promotion and Disease Prevention Services,Depression screen (PHQ-4),,2016-11-15,COMPLETED,INTERVENTIONAL,['NA']
7753,NCT00639600,"Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves","Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs",,2008-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7754,NCT01395303,,,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
7755,NCT00069537,Accuracy of the GlucoWatch G2 Biographer and CGMS,,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7756,NCT01991470,"Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System","Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7757,NCT01119404,,,,2003-06,UNKNOWN,OBSERVATIONAL,['NA']
7758,NCT00406991,Retinal blood flow,Retinal arterial diameter,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7759,NCT00005205,,,,1987-08,COMPLETED,OBSERVATIONAL,['NA']
7760,NCT04749693,time in 70 - 180 mg/dL glycemic range,incidence of the system on the necessary healthcare professional charge,,2021-05-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7761,NCT01195662,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants,"Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue",,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7762,NCT06268392,Ultrasound fetal weight estimation,,,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7763,NCT02518581,Activity-induced energy expenditure,,,2015-08-12,COMPLETED,INTERVENTIONAL,['NA']
7764,NCT05096858,Insulin use,,,2020-06-01,RECRUITING,OBSERVATIONAL,['NA']
7765,NCT04521712,Pancreatic beta cell function,Maternal diabetes mellitus,,2021-09-17,RECRUITING,INTERVENTIONAL,['NA']
7766,NCT06327815,Change in HbA1c from baseline,To evaluate the difference in adherence of FDC versus co-administered dual therapy by Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire in Chinese patients with T2DM.,SDBG (Standard Deviation of Blood Glucose),2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7767,NCT00004992,Development of diabetes,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7768,NCT03008824,Differences in B12 levels between GDM and Controls,Predictors of abnormal post-natal OGTT in the first trimester,Validation of newborn adiposity measured by skin-fold thickness and objective measurement by PEAPOD,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
7769,NCT04192019,Time to hypoglycaemia,Any adverse events,,2023-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
7770,NCT02969798,Glucose tolerance status,,,2014-01-01,RECRUITING,INTERVENTIONAL,['NA']
7771,NCT00056290,Safety,,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7772,NCT03382873,Weight loss,Decreased Glycemia,,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA']
7773,NCT01146886,Assessment of tolerability by the investigator,Total urinary corticosteroids (5α-THF + 5β-THF + THE + UFF + UFE) as an indicator of the activation of the HPA axis,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7774,NCT02423798,Sensor Survival,,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
7775,NCT04451980,Adipose tissue T cell surface marker phenotype and antigen receptor sequence,Circulating T cell surface marker phenotype,,2017-08-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7776,NCT03648281,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-08-24,COMPLETED,OBSERVATIONAL,['NA']
7777,NCT03900286,A change from baseline in HbA1c,The Three Factor Eating Questionnaire,,2020-01-16,RECRUITING,INTERVENTIONAL,['NA']
7778,NCT03650712,age- and sex-based nomograms for OGIS (oral glucose insulin sensitivity),evaluate the relationships between age and sex-based quantiles for c-peptide and number of pulmonary exacerbations in the previous 12 months,Correlation between CGM standard deviation of sensor glucose values and b-cell glucose sensitivity,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
7779,NCT05249881,Change in glycemic Index in Diabetes mellitus type-2 Patients,Weight Changes in Obese People,,2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7780,NCT00486941,Self-reported physical activity,Glucose tolerance (OGTT),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7781,NCT01971125,Prevalence of Left Ventricular Dysfunction in patients with type II diabetes,,,2006-07,COMPLETED,OBSERVATIONAL,['NA']
7782,NCT04939766,Change in burden of diabetes following activation of closed loop,Glycemic variability,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
7783,NCT05633784,Change in tolerance capacity,Assessment of physical activity.,,2022-08-18,RECRUITING,INTERVENTIONAL,['NA']
7784,NCT03930004,Left atrial dysfunction,,,2018-07-06,COMPLETED,OBSERVATIONAL,['NA']
7785,NCT03682445,Change in HbA1c level.,,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
7786,NCT03829514,Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry,,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7787,NCT03024788,prevalence of retinopathy,incidence of retinopathy,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
7788,NCT04023734,Medication adherence,Patients' willingness to maintain the intervention,,2019-08-16,COMPLETED,INTERVENTIONAL,['NA']
7789,NCT03165812,Type 2 Diabetes Mellitus (T2DM) patients in SADJB-SG group achieving glycated hemoglobin (HbA1c) level of less than 7% (with or without diabetes medications) in 2 years as compare to patients in IMT group.,Identification of genetic biomarkers.,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
7790,NCT00589459,Prevalence of undiagnosed pre-diabetes or undiagnosed diabetes,,,2001-10-01,COMPLETED,OBSERVATIONAL,['NA']
7791,NCT05066542,Percent Weight Loss Efficacy,% Fat,,2021-06-11,UNKNOWN,INTERVENTIONAL,['NA']
7792,NCT00225628,4) Compliance to guidelines regarding the screening and management of osteoporosis,2) Physician satisfaction regarding follow-up of abnormal test results,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
7793,NCT04027530,Renal oxygenation measured by BOLD-MRI (R2*),Total insulin extraction,,2020-12-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7794,NCT02679287,Hemoglobin A1c,Hemoglobin A1c by Study Session,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
7795,NCT00922402,Average time to glycemic target (90-130 mg/dL),Evaluation of organizational impact,,2009-06,WITHDRAWN,INTERVENTIONAL,['NA']
7796,NCT00907881,Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores,Correlation Between HbA1c Values at Baseline and Hypoglycemia Scores at Week 12,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
7797,NCT03895437,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Events of Special Interest,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7798,NCT04203927,Myocardial microvascular perfusion,Pulse Wave Velocity ( PWV),,2020-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7799,NCT00906659,macular volume (measured in mm3),,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
7800,NCT02863354,Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,"Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center",,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7801,NCT00413465,"Renal plasma flow, Glomerular filtration rate, Plasma cytokine content, Endotoxemia score, Plasma angiotensin II and renin content, Plasma thromboxane B2 content, Plasma PAI-1 content","Mean arterial pressure, Heart rate, Oxygen saturation, Body temperature,",,2006-11,UNKNOWN,INTERVENTIONAL,['NA']
7802,NCT06336122,Number of participants with change in A1c,Social Network Scale,,2024-02-21,RECRUITING,INTERVENTIONAL,['NA']
7803,NCT01974778,BAT activity,,,2014-03,TERMINATED,INTERVENTIONAL,['NA']
7804,NCT01684813,Number of patients who achieve inhibition of platelet aggregation greater that 50%,Number of participants who are non-responsiveness to antiaggregation therapy as a measure of efficacy,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7805,NCT02707380,Paired T-test to compare test-retest Perceived dyspnea,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7806,NCT04915014,The Excess Weight Loss percentage (EWL%),Change of physical activity assessed by the International Physical Activity Index (IPAQ) score.,,2021-07-23,RECRUITING,INTERVENTIONAL,['NA']
7807,NCT05542901,Joint Position Sense,Functional Capacity,,2022-09-13,COMPLETED,INTERVENTIONAL,['NA']
7808,NCT05436041,Variance and Within-Provider Covariance of Patient Change in Diet Quality (measured via Healthy Eating Index),Impact of Nutri on Patient Diet Quality (measured via Healthy Eating Index),Impact of Nutri on PCP Diet Counseling Competency,2022-06-14,COMPLETED,INTERVENTIONAL,['NA']
7809,NCT04770532,Change in HbA1c (glycated haemoglobin),Change in body weight,,2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7810,NCT01049737,"Left ventricular mass index by cardiac ultrasonography, Intima media thickness by carotid ultrasonographic investigation and tonometry for measurements of the carotid, femoral and radial pulse pressure wave form and pulse wave velocity",Cardiovascular morbidity and mortality,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
7811,NCT02803905,A1c </= 6.5% and no severe hypoglycemia,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7812,NCT05928572,Phase 1 CGM-derived time in range (TIR),Total healthy eating index (HEI) score,Phase 2 CGM-derived time in range (TIR),2023-07-25,RECRUITING,INTERVENTIONAL,['NA']
7813,NCT00699686,Change in endothelial progenitor cell count,Change in body weight,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7814,NCT01744392,Medication Possession Ratio at 6 Months,Pulse at 6 Months,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
7815,NCT03565770,Difference between the rate of glycosylated hemoglobin (HbA1c) before randomization (baseline) and the rate of glycosylated hemoglobin after 6 months coaching (measure M6).,Binary variable attendance = 80% honored appointments,,2018-09-29,UNKNOWN,INTERVENTIONAL,['NA']
7816,NCT01354925,Difference in mean 4-point SMBG during days 23-30 of treatment between the two groups.,,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7817,NCT03458286,Total wound healing,Diabetic foot ulcer reoccurrence rates,,2018-04,UNKNOWN,INTERVENTIONAL,['NA']
7818,NCT04223973,Estimation of A1C based on average blood glucose measured by continuous glucose sensor,Compare pump tolerance for the active group (Medtrum Pump) vs Control Group Patients (comparator device) in order to assess non inferiority,,2020-01-29,COMPLETED,INTERVENTIONAL,['NA']
7819,NCT04513704,"Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10)","Time to maximum observed semaglutide plasma concentration after the 10th dosing (tmax,0-24h,sema,day10)",,2020-08-28,COMPLETED,INTERVENTIONAL,['PHASE1']
7820,NCT04504396,Change in HbA1c,Change in Body Mass Index,,2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE3']
7821,NCT02316054,"cardiac death,or Q-wave myocardial infarction (MI), or the need for myocardial revascularization > 3 months after SPECT",myocardial revascularization > 3 months after SPECT,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
7822,NCT04246190,"AUClast of CKD-501, D759 and CKD-396",,,2020-02-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
7823,NCT00109369,Glycemic control,Functional status,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
7824,NCT00225342,Angina status at 3 months,Biochemical markers of inflammation at 3 months,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7825,NCT05385211,Exocrine pancreatic insufficiency,,,2022-04-30,COMPLETED,OBSERVATIONAL,['NA']
7826,NCT00157222,,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA']
7827,NCT02146079,Area under the plasma semaglutide concentration-time curve,Number of treatment emergent adverse events (TEAEs) from baseline to follow-up,,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
7828,NCT00317915,Development of overt nephropathy,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
7829,NCT04061473,glucagon excursions measured as incremental area under the curve (iAUC),food intake,,2019-04-02,COMPLETED,INTERVENTIONAL,['NA']
7830,NCT01995656,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics: Area Under the Curve (AUC) of LY3108743,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7831,NCT06194240,12-Item Short Form Health Survey,Generic Adherence Profile for Chronic Diseases,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
7832,NCT00435019,Glycosylated Haemoglobin A1c (HbA1c),Observed Insulin Antibody Values,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7833,NCT03090464,Change from baseline to end of study (Month 6) in HbA1c levels,Proportion of patients in both cohorts who intensify antihyperglycemic treatment from Visit 1,Change in baseline to Month 6 in Morisky Medication Adherence Scale (8-item) (adherence),2017-05-08,COMPLETED,OBSERVATIONAL,['NA']
7834,NCT05147701,Safety (adverse events),,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
7835,NCT01729156,Whole Body Glucose Rd,VLDL-TG Oxidation,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7836,NCT05565534,"Number of in-person, virtual or phone contacts with the NP",Number of participants with Chemotherapy Dose Reductions,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
7837,NCT00659932,Hemoglobin A1C (HbA1C),Diabetes Quality of Life (ADDQoL),,2002-05,COMPLETED,INTERVENTIONAL,['NA']
7838,NCT04123054,Change in HbA1c levels,Mean sensor glucose level during:,Recurrent themes from semi-structured interviews,2020-03-05,RECRUITING,INTERVENTIONAL,['NA']
7839,NCT02393872,Body mass index (BMI),,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
7840,NCT03825926,Edinburgh postpartum depression scale (EPDS) follow up GDM or non-GDM,Expenditure on GDM after the diagnosis,,2019-06-01,RECRUITING,OBSERVATIONAL,['NA']
7841,NCT02249897,CML SERUM LEVELS,MULTIFOCAL ELECTRORETINOGRAPHY,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7842,NCT05975541,Fecal calprotectin levels identification,assessment of the circadian rhythm trough MEQ questionnaire,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
7843,NCT02675257,Improvement of glycaemic control as measured by the HbA1c,Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36),Inflammatory Marker: Adiponectin,2015-07-01,COMPLETED,INTERVENTIONAL,['NA']
7844,NCT02827669,HbA1c,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
7845,NCT00109434,Hypoglycemia defined as <=70 mg/dL.,Changes in epinephrine and glucagon levels.,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
7846,NCT01301196,Sedentary behaviour,Psychosocial indicators,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
7847,NCT03613857,Ischemic or hemorrhagic stroke,,,2017-04-15,COMPLETED,OBSERVATIONAL,['NA']
7848,NCT05319990,Insulin Sensitivity,Effective Renal Plasma Flow (ERPF),,2022-03-09,RECRUITING,OBSERVATIONAL,['NA']
7849,NCT02692313,Flow mediated dilation (FMD) of the brachial artery,,,2016-06,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7850,NCT00523913,"The safety profile (adverse events, laboratory parameters and other observations) of BRL49653C administered for 52 weeks will be evaluated.","The efficacy profile (HbA1c, FPG and Insulin) of BRL49653C administered for 52 weeks will be evaluated.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7851,NCT00133692,First occurrence of death or nonfatal myocardial infarction (MI) or nonfatal stroke,Compliance,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7852,NCT05484817,Prevalence of impaired cardiac function in type 2 diabetes diagnosed by echocardiography,Biomarker measured by blood test,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
7853,NCT03542487,Patient A1c,Flowsheet Entry Values (descriptive),,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
7854,NCT02086539,Enrollment into the Habit Formation study,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
7855,NCT04451915,The occurrence of materno-fetal complications,Number of complications in each subgroup of the late GDM management group,,2020-11-30,RECRUITING,INTERVENTIONAL,['NA']
7856,NCT04909632,The differentiation of tongue features mellitus and pre-diabetes,The tongue coating metabolic markers in patients with diabetes,,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
7857,NCT00791076,Total Amount of Insulin Administered While on Placebo/PP.,Frequency of Hypoglycemia Defined as < 60 mg/dl.,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
7858,NCT03299790,ECG (Electrocardiogram),Maximal oxygen uptake (ml/O2/kg/min),,2017-10-06,COMPLETED,INTERVENTIONAL,['NA']
7859,NCT05353699,"Implementation change: Change from Baseline Implementation at 3, 6,9 months",Qualitative assessment-maintenance:,,2022-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7860,NCT00833716,AUC of NN9535,"Laboratory safety, adverse events",,2009-02-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7861,NCT03508323,HbA1c,,,2018-04-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7862,NCT01109797,"Measure and compare change in self-efficacy and change in diabetes knowledge, diabetes quality of life, family conflict, and treatment satisfaction for and between the two groups.",Make exploratory baseline comparisons between the two groups of HgbA1c,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7863,NCT02725502,Effect of Linagliptin on insulin requirement in T1DM patients,Effect of linagliptin on glucagon level during mixed meal test in T1DM patients,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
7864,NCT01066039,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7865,NCT04711226,Efficacy- Insulin independence,Efficacy- HbA1c,Exploratory- Pharmacokinetic Parameters- (t1/2),2021-02-19,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7866,NCT02361489,A1C,Hypoglycemia,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
7867,NCT01023646,"Glucose, Insulin, Free Fatty Acids.","Fasting and non-fasting plasma lipids and lipoproteins, C reactive protein (CRP), HbAIc.",,2007-12,COMPLETED,INTERVENTIONAL,['NA']
7868,NCT04689074,Biological samples collection for establishment of the first National Microbiome Biobank,,,2021-02-03,COMPLETED,OBSERVATIONAL,['NA']
7869,NCT01618188,Area under the glucose infusion rate curve,Time to maximum glucose infusion rate,,2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7870,NCT04207099,Rate of change in wound area of diabetic foot ulcers in ARM 2 vs ARM 1,Wound Healing Rate,,2020-02-14,UNKNOWN,OBSERVATIONAL,['NA']
7871,NCT04916314,HbA1c,Diabetes related quality of life and distresses; EQ5D score,Participants' experience of using the app-based support,2021-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7872,NCT01419652,periprocedural glucose,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7873,NCT04884425,Change in the EQ-5D-5L tool score,,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
7874,NCT02715934,Provider referral,Patient participation,Summary of Diabetes Self-care Activities Measure (SDSCA),2016-04,COMPLETED,INTERVENTIONAL,['NA']
7875,NCT05852639,To evaluate the efficacy (sensitivity & specificity) of fetal cerebroplacental ratio at term in prediction of adverse neonatal outcome in pregnancies complicated by gestational diabetes,To evaluate the incidence of adverse neonatal outcome in both groups,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
7876,NCT02733991,Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.,Mean Time Spent of Sensor Glucose Values Within Range and Including 70-180 mg/dL.,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
7877,NCT00970060,Dermal and epidermal nerve fiber densities,"Clinical assessments of neuropathy, pain, body mass index, muscle strength, and glycemic control (glycosylated hemoglobin or A1C)",,2008-06,COMPLETED,INTERVENTIONAL,['NA']
7878,NCT03167866,HbA1c levels at 6 months from beginning of messages,Diabetes Quality of Life questionnaire,,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
7879,NCT06317142,Postprandial hepatic and muscle glucose uptake determined by Fluorodeoxyglucose-Positron emission tomography ([18F]-FDG-PET) combined with oral glucose tolerance test (OGTT),Whole body gluconeogenesis after acipimox treatment determined by deuterated water,Body composition determined by Bodpod,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
7880,NCT00220961,Prevention of Type 2 Diabetes,Change in Atherosclerosis,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7881,NCT00687453,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7882,NCT01504620,Accuracy of the blood glucose meter in comparison to a standard reference,Hematocrit Interference (Helios),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7883,NCT04522921,Change in fat mass/fat free mass,Inflammatory markers,,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7884,NCT02347787,Short Form Health Survey (SF-12) Physical Component Score (PCS),Hospital Admission - Mean Length of Stay (Among Participants With Hospitalization),,2015-01-28,COMPLETED,INTERVENTIONAL,['NA']
7885,NCT03182582,Bacterial Load Pre- and Post-Sharp Debridement,Percent Change in Wound Size - 1 Week Post-debridement,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
7886,NCT01508897,"Cmax, maximum concentration",Adverse events,,2004-05-28,COMPLETED,INTERVENTIONAL,['PHASE1']
7887,NCT01771835,Quantification of retinal venous pressure (RVP),Quantification of ET-1 in correlation with RVP,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
7888,NCT00286572,Death and/or major adverse cardiac events,,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
7889,NCT02470156,Wellness Coaching Program Effectiveness on Goal Success,Economic Assessment of the Intervention,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
7890,NCT01309022,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
7891,NCT00184574,HbA1c,Other glycemic variables,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7892,NCT02547337,Intestinal blood flow acquired with PET and DWI (ml ml-1 min-1),,,2015-09-10,COMPLETED,OBSERVATIONAL,['NA']
7893,NCT02225951,3-hr postprandial glucose response,,,2014-07,TERMINATED,INTERVENTIONAL,['NA']
7894,NCT01478841,Peripheral insulin-sensitivity,biochemical parameters,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
7895,NCT03266133,Self-reported sleep duration,Preeclampsia,,2017-11-27,COMPLETED,INTERVENTIONAL,['NA']
7896,NCT02444325,effect of group prenatal care on maternal diabetes self-care activities as measured Diabetes Self-Care Activities Measure,Contraception,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
7897,NCT00505960,HbA1c,BP control,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7898,NCT06138821,Change in Liver Fibrosis measurement at 12 months compared to baseline,Change in eating behaviors compared to baseline,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7899,NCT02132338,Glycated hemoglobin level before and after intervention,body mass index,Loss of participants in the intervention by forfeit,2014-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7900,NCT01704417,"BGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise","BGminimum,30-180min,post-exe, minimum blood glucose concentration",,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7901,NCT02911792,GFR (Glomerular Filtration Rate) Change After Treatment,,,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
7902,NCT02136654,Change in A1C or blood pressure (systolic or diastolic blood pressure),change in health status,Procedure related outcomes,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
7903,NCT04099745,Accuracy of different blood glucose monitoring systems (CGM and FGM) with intravenous blood glucose level as the gold standard,forty-day blood glucose fluctuation of FGM,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
7904,NCT02009254,blood glucose,food intake,subjective appetite,na,COMPLETED,INTERVENTIONAL,['NA']
7905,NCT05558878,Effect of Ambroxol on Superoxide dismutase,Effect of Ambroxol on clinical outcome : Pain assessment using the Numeric rating scale NRS,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7906,NCT02053714,Changes in knowledge of diabetes self-management from baseline to six months as evidenced by scores on the Stanford Diabetes Self-Management Questionnaire.,Changes in diastolic and systolic blood pressure from baseline to six months.,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7907,NCT04006938,Fasting blood sugar level,,,2019-07,UNKNOWN,INTERVENTIONAL,['NA']
7908,NCT00252694,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7909,NCT05899023,Percent of Patients who Complete at least One In-Person Follow-up Outpatient Visit,Percent of Patients who Start on Diabetes Medications within 6 Months of Diagnosis,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7910,NCT01028846,Endogenous Glucose Production (EGP),,,2011-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
7911,NCT00202033,HbA1c,blood glucose testing frequency,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7912,NCT01158625,"Blood pressure, nighttime blood pressure and 24 h blood pressure",Urine albumin excretion,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
7913,NCT00353691,Change in HbA1c from baseline to Week 24 or last evaluable ontreatment value.,Mean change in body mass index (BMI) from baseline to Wk 12 and Wk 24 or last evaluable on-treatment value,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7914,NCT00732862,HbA1c,Catecholamines,,1998-02,COMPLETED,INTERVENTIONAL,['NA']
7915,NCT00978835,Blood Pressure,Hemoglobin A1c,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7916,NCT05247034,Rate-dependent depression on the frequency of stimulation of the H reflex,Diabetes 39 Instrument,,2021-06-04,RECRUITING,INTERVENTIONAL,['NA']
7917,NCT03556631,hemoglobin A1c in percentage,weight in kilograms,,2020-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7918,NCT03881995,Brain insulin sensitivity,Body weight,Hypoglycemia time of day,2019-03-18,TERMINATED,INTERVENTIONAL,['PHASE4']
7919,NCT06330480,Effectiveness of the albuminuria screening,Cost-effectiveness of screening strategies compared to standard of care: treatment effectiveness based on actual observed event rates,"Overall effectiveness of broader population-based screening strategies applied to screening on heart failure, coronary artery disease, and type 2 diabetes.",2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7920,NCT02056210,CD34+ stem cell mobilization in diabetic vs non diabetic subjects,EPC (endothelial progenitor cell) mobilization within diabetic patients,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7921,NCT03790579,Dietary acid load,,,2014-01-05,COMPLETED,OBSERVATIONAL,['NA']
7922,NCT05071820,Percent weight lost at 12 months from baseline weight,change in hemoglobin A1c,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
7923,NCT00701181,Mean Change from Baseline in the Best Corrected Visual Acuity Score,Mean Changes in Macular Volume from Baseline,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE2']
7924,NCT03890900,Change from baseline hemoglobin A1c to 3 and 6 months,Change from baseline LDL cholesterol to 3 months and 6 months,,2020-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7925,NCT03903016,Assessment of PK parameter :INS-AUClast -,Adverse Events,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
7926,NCT02830048,Decrease in fasting plasma glucagon concentration,Pre-dose plasma concentration of glibenclamide,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7927,NCT00803660,The percentage of patients achieving the BP<130/80 mmHg,The number and percentage of patients with positive proteinuria by treatment groups,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7928,NCT00745342,"Glycemic control, assessed by hemoglobin A1c","Parent involvement in diabetes management tasks, measured using the Diabetes Family Responsibility Questionnaire (youth and parent versions)",,1999-03,COMPLETED,INTERVENTIONAL,['NA']
7929,NCT00886574,Maximal and mean intima media thickness (IMT) of both common carotid artery of the cilostazol group in comparison with the aspirin group,Events of hemorrhagic vascular complication,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
7930,NCT05383209,Percentage of subjects improving ≥2 steps in the Diabetic Retinopathy Severity Scale (DRSS) score each EYP-1901 dose level versus the sham IVT injection group.,Rates of ocular (study eye and fellow eye) and non-ocular Treatment-Emergent Adverse Events,,2022-08-31,RECRUITING,INTERVENTIONAL,['PHASE2']
7931,NCT05979246,marginal bone loss,Survival rate,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7932,NCT02502071,Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy,,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7933,NCT00800085,The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7934,NCT02001805,Body Composition,Activity level and diet,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
7935,NCT00472095,Hemoglobin A1c,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
7936,NCT01318122,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7937,NCT02915198,"Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization",Time in days to Diabetes Outcome,,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE4']
7938,NCT05269589,Hemoglobin A1C (HbA1C),Blood pressure,,2022-02-18,RECRUITING,INTERVENTIONAL,['NA']
7939,NCT03285230,Health outcomes,,,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7940,NCT01950806,Change in biomarkers of insulin resistance compared with control diet,Change in plasma lipid profile compared with control diet,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7941,NCT01085773,Glycated hemoglobin (HbA1c).,"Adherence, Anthropometry,Blood pressure, Lipid profile, VO2max and quality of life.",,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7942,NCT04108299,Satisfaction Questionnaire Score,Change in International Physical Activity Questionnaire (IPAQ)-short version Score,,2021-04-21,COMPLETED,INTERVENTIONAL,['NA']
7943,NCT00616811,Safety and tolerability in patients with T2DM and severe renal insufficiency over 24 weeks of treatment,Efficacy of vildagliptin versus sitagliptin in patients with T2DM and severe renal insufficiency by assessing the hemoglobin A1c (HbA1c ) and fasting plasma glucose (FPG) reduction from baseline,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7944,NCT06171230,Pain intensity measured with the Numeric Rating Scale (NRS),Pain Disability Index (PDI) Limitations in daily activities,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
7945,NCT03095196,All cause deaths.,,,2012-09-01,COMPLETED,OBSERVATIONAL,['NA']
7946,NCT03479671,Insulin Sensitivity,,,2020-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7947,NCT05915260,The association of pericardial- and epicardial fat with myocardial function and MACE after 5 year,"Characterization of the progression of diabetic cardiomyopathy over 5 years, including LV+RV function, the coronary microvascular function, the coronary macrovascular function, fibrosis, aortic stiffness, per and epicardial fat, perfusion of other organs",,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7948,NCT02518334,Oral glucose tolerance test,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
7949,NCT01710774,healing time for leg ulcer and/or diabetes related foot ulcer,"A new foot ulcer appears, the incidence of amputation and survival.",,2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7950,NCT00646542,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency.,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7951,NCT03263728,Prevalence of myocardial ischaemia,Major adverse cardiovascular events,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
7952,NCT03511521,Glycemic Control,Percentage of Glucose Values Within the Hypoglycemic Range,,2018-03-27,TERMINATED,INTERVENTIONAL,['PHASE4']
7953,NCT01469312,Change in Blood Glucose,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7954,NCT00479258,To Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period,7 Point Home Glucose,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7955,NCT05819138,Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV),Change in Renal Vascular Resistance (RVR),,2023-06-21,RECRUITING,INTERVENTIONAL,['PHASE3']
7956,NCT05475587,Body constitution of body constitution questionnaire (BCQ),,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
7957,NCT01331317,Change in plasma NT-proBNP,Change in Urinary Albumin Excretion Rate,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7958,NCT01151072,Area under the serum Insulin Degludec concentration-time curve (only for subcutaneous administration),Back-extrapolated initial serum Insulin Degludec concentration after single-dose (only for intravenous administration),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7959,NCT02124590,Change in Acylcarnitine/Carnitine ratio,Change in Mitochondrial Function,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
7960,NCT01387334,HbA1c,compliance of home-based resistive exercise training,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7961,NCT03980236,Change in A1c,,,2019-05-06,TERMINATED,INTERVENTIONAL,['NA']
7962,NCT00550329,,,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
7963,NCT05925933,Metabolomics profile,,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7964,NCT00513630,"Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization",new peripheral vascular events,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7965,NCT01773707,Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance,Change in C-peptide response to Oral Glucose Tolerance Test (OGTT),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7966,NCT05656963,Specific link between high incidence of thrombotic events in patients with membranous nephropathy and diabetic nephropathy,,,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7967,NCT04233489,Change in Brief Infant Toddler Social Emotional Assessment (BITSEA) score,Change in M/CHAT R/F score,,2020-01-03,TERMINATED,INTERVENTIONAL,['NA']
7968,NCT01225081,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-09-15,COMPLETED,INTERVENTIONAL,['PHASE3']
7969,NCT01889914,changes from baseline in insulinoresistance measured by biological tests of hyperinsulinemic euglycemic clamp in the two groups of treatment 6 months after the start of the treatment.,"change from baseline in weight at three, six, nine and twelve months in the two groups.",,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
7970,NCT05163964,The change of baseline continuous glucose monitoring (CGM) profile among prediabetes adults at 6 months.,The change of chronotype among prediabetes adults at 6 months.,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
7971,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,,2017-11-01,RECRUITING,OBSERVATIONAL,['NA']
7972,NCT03771417,Skeletal Muscle Mass,Mitochondrial Function,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
7973,NCT00585897,Hemoglobin A1c,Fasting glucose,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
7974,NCT05697484,diabetes control,Usability and satisfaction,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7975,NCT03020485,Change in post prandial Blood glucose for 180 minutes period,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
7976,NCT06239636,Safety as assessed by number of treatment related adverse events accoridng to CTCAE v 5.0,Score in diabetes treatment satisfaction questionnaire,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7977,NCT00358059,Treatment adherence,Diabetes-related quality of life,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7978,NCT00917267,Change in HbA1c From Baseline to Week 26.,Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7979,NCT01421147,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),Rate Per 30 Days of Hypoglycemic Events,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7980,NCT00549874,Myocardial blood flow regulation,biomarkers of oxidative/nitrosative stress,,2002-02,COMPLETED,INTERVENTIONAL,['NA']
7981,NCT02972528,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of allogenic Platelet Lysate injection by clinical examination,,2018-02-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7982,NCT03995498,Percentage of time of interstitial glucose concentrations spent between 4.0-10.0 mmol/L,Total number of confirmed hypoglycemia episodes requiring treatment,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
7983,NCT03314467,Presence of obstructive sleep apnea in diabetic patients is a predictive factor for diabetic retinopathy occurence,Correlation between severity of obstructive sleep apnea and presence of diabetic retinopathy,,2017-10-06,COMPLETED,OBSERVATIONAL,['NA']
7984,NCT03365349,Change from baseline IPQR (Illness Perception Questionnaire) score at 3 months,comparison of the two groups concerning answers to qualitative interviews at T 3 months after the intervention,,2012-02-01,COMPLETED,INTERVENTIONAL,['NA']
7985,NCT00949663,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",We will develop an assay to measure the normal fasting and postprandial concentrations of endogenous xenin-25 and determine whether they are altered in T2DM.,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7986,NCT03664089,Weight loss,Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel,,2018-09-10,COMPLETED,INTERVENTIONAL,['NA']
7987,NCT06029517,Change in SSB intake for men affiliated with Native American athletic communities,Change in body weight,,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
7988,NCT01210664,Number of Participants Experiencing Severe or Life Threatening Laboratory Abnormalities,Hemoglobin A1c,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7989,NCT02542631,Change in A1C From Baseline to the Completion of 24 Weeks of Basal and Bolus Insulin Therapy,Number of Participants With Severe Hypoglycemic Event,Change in Quality of Life From Baseline to Week 24,2015-08-01,COMPLETED,INTERVENTIONAL,['NA']
7990,NCT05615558,Insulin sensitivity,Diabetes treatment satisfaction measured by the diabetes treatment satisfaction questionnaire,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
7991,NCT01602718,change in short physical performance battery,change in inflammation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7992,NCT02106039,Better diabetes control in diabetes patients with tuberculosis under treatment,Association between glycemic control and clinical-microbiological response to TB treatment,,2014-04-28,COMPLETED,INTERVENTIONAL,['NA']
7993,NCT04382521,Participant's mean ratings of message utility to measure acceptability of the text-message intervention,Change in physical function measured by 6-minute test,,2020-09-22,COMPLETED,INTERVENTIONAL,['NA']
7994,NCT00745914,Change in carotid plaque volume,"Change in inflammatory markers include C-reactive protein, interleukin-6, adiponectin, metalloproteinases",,2008-09,COMPLETED,INTERVENTIONAL,['NA']
7995,NCT01151891,Pedal puncture wounds,Infection in pedal puncture wounds,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
7996,NCT05908448,Accuracy,,,2024-02-07,RECRUITING,OBSERVATIONAL,['NA']
7997,NCT01403025,The incidence of SADRs (Serious Adverse Drug Reactions),The incidence rate and type of ADRs (Adverse Drug Reactions),,2011-07-19,COMPLETED,OBSERVATIONAL,['NA']
7998,NCT00497666,,,,2007-08,UNKNOWN,OBSERVATIONAL,['NA']
7999,NCT02037867,Liver and cardiovascular-related mortality,All-cause mortality,,2013-05,RECRUITING,OBSERVATIONAL,['NA']
8000,NCT03612037,Glycemic control,Blood lipids,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
8001,NCT02563457,Hemoglobin A1c blood level,,Quality of life,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8002,NCT02826044,Cumulative excretion of SP2086,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
8003,NCT00504712,Change in Arterial Stiffness,Change in IMT,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8004,NCT06270836,Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS),Safety and Tolerability of KSI-301 5 mg compared to sham treatment,,2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8005,NCT02146404,Brain lactate concentration,Hormone response,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8006,NCT03378908,Glycemic profile below pregnancy target capillary blood glucose concentration,Point-of-care glycated hemoglobin (HbA1c),,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
8007,NCT01717313,"Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)","Change From Baseline in FPG at Week 54 (Phase A + Phase B, FAS Population)",,2012-12-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8008,NCT05165368,Pain Intensity Level,Pain Quality Assessment,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
8009,NCT02388113,glycosylated hemoglobin (HbA1c),,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
8010,NCT04943523,Grip strength,Erythrocyte fatty acid profile,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
8011,NCT05078658,Change in continuous glucose monitoring time in target range (3.9-10.0 mmol/l) during the LCD period compared to the RCD period,Differences in urine metabolome between the LCD and RCD periods,,2021-09-22,RECRUITING,INTERVENTIONAL,['NA']
8012,NCT00542399,Total daily basal and bolus insulin,documentation of hypoglycemic and hyperglycemic episodes,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8013,NCT05112445,OCTA metrics and predict progression to PDR and/ or CI- DME,,,2022-05-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8014,NCT02185482,change in depression using SCL-90 depression scale,Glycemic control measured using glycosylated hemoglobin levels,Global assessment of improvement using Patient Global Impression,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8015,NCT04315519,Cardiorespiratory Fitness,The Strength of Hamstring Muscle,,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA']
8016,NCT00320008,Years of life years gained,Diabetic neuropathy,,1992-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8017,NCT03249896,Percentage of patients who have excessive gestational weight gain (EGWG),Neonatal intensive care unit admission,,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA']
8018,NCT00598871,Number of Participants With Treatment Emergent Adverse Events (TEAEs) After Treatment With Thymosin Beta 4 in the Target Eye of Diabetic Patients During Vitrectomy,Number of Participants With Corneal Epithelial Wound Healing at Day 14 (End of Treatment),,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8019,NCT02305784,Blood concentration of YKL-40 (ng/ml),Change of Blood concentration of YKL-40 (ng/ml) during an exacerbation,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
8020,NCT00704236,Glucose Disposal Rate,"Fasting Plasma Glucose,Postprandial Plasma Glucose,HbA1c,triglyceride,cholesterol,HDL-c and LDL-c,lipid levels ,body weight, blood pressure",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8021,NCT04605497,Average time-in-range over a 24 hour period,Average time-in-range while asleep,,2021-02-11,RECRUITING,INTERVENTIONAL,['NA']
8022,NCT00119938,"Composite measure of diabetes self-care activities, developed from the Summary of Diabetes Self-Care Measure","Biological markers of diabetes care (hemoglobin A1c, blood pressure, LDL cholesterol)",,2004-09,COMPLETED,INTERVENTIONAL,['NA']
8023,NCT00506662,Change in Glycosylated Haemoglobin (HbA1c) at Month 7,"Mean Number of Total Hypoglycaemic Episodes, Months 5-7",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE4']
8024,NCT01156597,Increased HDL-Cholesterol and Decreased Triglycerides,Cholesterol Efflux Capacity of HDL,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8025,NCT05177250,Bisphenol A and paraben detection in urine samples of diabetic (n=50) and non diabetic persons (n=50),,,2022-02-20,RECRUITING,INTERVENTIONAL,['NA']
8026,NCT05631535,Changes in body weight,Changes in perception of health-related quality of life,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
8027,NCT01652729,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8),,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8028,NCT00521742,Change in the walking distance during a standardized 6-minute walk test.,Change in Body Weight,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8029,NCT00395343,Change From Baseline in A1C at Week 24,Percent of Patients With A1C < 6.5% at Week 24,Change From Baseline in A1C at Week 24,2006-12-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8030,NCT02535299,physiological parameter:glycosylated hemoglobin A1c,physiological parameter:TNF-α,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
8031,NCT01724736,Change in the ratio of Bacteroidetes to Firmicuites ratio in the stool comparing the baseline value to the completion of study value.,Gastrointestinal Symptoms,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8032,NCT04999124,Diabetes complications,haemoglobin A1c (%),,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
8033,NCT03925948,Change in Health literacy as assessed by the Newest Vital Sign,Change in Diabetes self-efficacy measured with Stanford Diabetes Self-Efficacy scale,Change in Quality of Life as assessed by the EuroQol Quality of Life scale,2015-05-06,COMPLETED,INTERVENTIONAL,['NA']
8034,NCT03723707,Percent of Patients Who Reach Consensus Target HBA1c,,,2018-12-03,COMPLETED,INTERVENTIONAL,['NA']
8035,NCT04928248,Change in hemoglobin A1c (HbA1c) levels,Change in body mass index (BMI) levels,Rate of use of the Disease Manager's diabetes module,2021-09-23,COMPLETED,INTERVENTIONAL,['NA']
8036,NCT05179954,Apolipoprotein C turnover rate,Apolipoprotein B-100 concentration,,2022-05-09,RECRUITING,INTERVENTIONAL,['NA']
8037,NCT02389114,Food intake,Physiological Outcomes,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8038,NCT01714232,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),,2012-10,COMPLETED,INTERVENTIONAL,['NA']
8039,NCT02342834,Plasma glucose response during the Oral Glucose Tolerance Test,Endothelial function assessed as the reactive hyperemia index by an EndoPAT device,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8040,NCT00673543,Time point at which glucose elevation occurs after glucocorticoid administration (greater than 50% increase in the patient's baseline blood) glucose level.,Pre-corticosteroid insulin amount,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
8041,NCT00410436,Change in HbA1c,"serum C-reactive protein,",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8042,NCT00615264,Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months,Change From Baseline in Mixed-meal Stimulated C-peptide AUC at 24 Months,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8043,NCT01121471,change in plasma glucose AUC,change in body composition,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
8044,NCT00596063,The primary objective is to test for bioequivalence based on AUC0-12h and Cmax between Wockhardt's Insulin Human Regular for injection and Novolin® R,"PK endpoints: AUC, tmax and t½ PD endpoints: AUC-GIR, GIRmax and tGIRmax Safety endpoints: AEs, haematology, biochemistry, urinalyses, physical examination, vital signs, ECGs, blood glucose and local tolerability.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8045,NCT01441986,Area under the blood glucose (BG) concentration-time profile,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8046,NCT02137174,HBA1C,Hypoglycemia rate,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8047,NCT02927639,Change in Self-Care Inventory (SCI) Score From Baseline to 6 Months,Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months,,2018-07-31,COMPLETED,INTERVENTIONAL,['NA']
8048,NCT04927858,Prevalence of a History of CVD Among Swedish Patients With T2DM Who Started Empagliflozin Treatment Between 1st of January 2015 and 31st of December 2017,,,2018-04-02,COMPLETED,OBSERVATIONAL,['NA']
8049,NCT00846248,insulin resistance,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
8050,NCT03056456,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Following Administration of Each Study Arm With a Standard Dual-wave Bolus,Glucodynamics (GD): Change From Baseline Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Glucose Relative to MMTT Following Administration of Each Study Arm With a Standard Dual-wave Bolus,,2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8051,NCT06177210,Establish a cohort of participants who achieved T2D remission through bariatric surgery,Qualitative interviews,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
8052,NCT01353833,Kinetic parameters of Treg proportions variation within CD4+ T cells in peripheral blood,Improvement of residual secretion of insulin assessed by the AUC of peptide C during a standardized test meal in IL-2 vs placebo treated patients,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8053,NCT02443753,Safety and Tolerability will be evaluated as the incidence of AEs and SAEs/UADEs.,Efficacy as measured by Change in HbA1c (%),,2015-05,TERMINATED,INTERVENTIONAL,['NA']
8054,NCT03815552,time in range,time of hypoglycemia,,2018-10-08,COMPLETED,INTERVENTIONAL,['NA']
8055,NCT00001853,Diabetes and Heart Disease Risk,,,1998-10-21,RECRUITING,OBSERVATIONAL,['NA']
8056,NCT03903965,OCT Angiography parameters,aqueous humor cytokines levels,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
8057,NCT04800861,glycemic control,average per patient,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
8058,NCT05951140,Improve eating behavior towards healthier choices,Calculation of the Polygenic Risk Score,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
8059,NCT01227473,"insulin resistance, as measured by the homeostatic model assessment-insulin resistance (HOMA-IR)",Insulin resistance as measured by the HOMA-IR,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8060,NCT02222350,change in 24-hour weighted mean blood glucose,change in postprandial plasma glucose level,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8061,NCT02914691,Change in Urinary Peptide Patterns (Proteomics),,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8062,NCT00960791,"Total recovery of radioactive dose, rate and routes of excretion of total radioactivity, metabolic pattern and metabolic profile, and PK variables of AZD1656 (AUC, Cmax, tmax, t1/2, Total Ae, CL/F and CLR)",Plasma Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8063,NCT00064714,Change in basal C-peptide level,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8064,NCT05391659,AUC,false positives and false negatives,,2021-06-17,RECRUITING,INTERVENTIONAL,['NA']
8065,NCT00264901,Comparison of the change from baseline to end of treatment,Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8066,NCT03739125,Change from baseline in Glycosylated Hemoglobin (HbA1c),Evaluate safety of CKD-501 from number of participants with adverse events,,2017-11-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8067,NCT04476693,Total trial area under the curve (AUC) for insulin.,Total trial area under the curve (AUC) for triaclyglycerol,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
8068,NCT01472588,Weight Loss,Physical Activity,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8069,NCT06131411,Glycated haemoglobin (HbA1c),Adherence to Mediterranean Diet,,2023-11-07,RECRUITING,INTERVENTIONAL,['NA']
8070,NCT05571800,Effect of mango consumption on glycemic control evaluated by HOMA-β,Effect of mango consumption on anthropometric measure WC/HC ratio,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
8071,NCT02490098,Mean day-and-night glucose levels,Total carbohydrate intake,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8072,NCT03404700,Difference of insulin levels compared between different test breakfasts,"Difference in total energy intake (kcal) compared between Remote Food Photography Method (RFPM), 7-day food record and 24-hour recall",,2018-05-22,COMPLETED,INTERVENTIONAL,['NA']
8073,NCT00478972,Relative change from baseline in body weight,Safety: Overview of adverse events,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
8074,NCT00544921,A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8075,NCT01067950,"The primary end-point is the 5-year evaluation of efficacy/failure rate, a composite end-point including: (i) patient mortality and (ii) renal function impairment",Secondary objectives are to evaluate and to compare the safety and the efficacy of the two treatments (IPT versus IIT).,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8076,NCT03801824,Post meal blood glucose level,Maternal weight gain,Level of post-meal blood glucose,2014-04,COMPLETED,INTERVENTIONAL,['NA']
8077,NCT00953186,Ulcer healing,QoL,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8078,NCT01741480,ICU Transfer,Mortality,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
8079,NCT05733195,GDM（Pregnancies with gestational diabetes mellitus and no gestational diabetes）,,,2022-05-04,RECRUITING,OBSERVATIONAL,['NA']
8080,NCT05479214,Maternal Blood glucose readings,Neonatal outcomes,,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
8081,NCT02855307,Percentage of time of plasma glucose levels spent below 3.9 mmol/L,Mean time (minutes) to the first hypoglycemic event,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8082,NCT02449460,all cause mortality,Cardiovascular mortality,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
8083,NCT05259033,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),,2022-04-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8084,NCT06006468,Number of multi-islet autoantibody positive participants,Number of participants developing Coeliac disease,,2023-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8085,NCT00825383,glucose and lipid metabolism,"calcium isotope absorption in the gastrointestinal tract, stool mineral content, 24 h urinary mineral concentration, and serum chemistry including mineral concentration.",,1993-01,COMPLETED,INTERVENTIONAL,['NA']
8086,NCT02461511,glycated hemoglobin measure,hopitalization,,2015-03,WITHDRAWN,OBSERVATIONAL,['NA']
8087,NCT04327622,Prevalence of diabetes foot complications: neuropathy risk,Association between foot risk variables and the presence of a foot ulcer,,2020-03-03,COMPLETED,OBSERVATIONAL,['NA']
8088,NCT01232673,Major limb amputation,Tissue perfusion measurements,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8089,NCT02550548,Beta cell sensitivity,,,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE1']
8090,NCT01969084,Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise.,Changes in Circulating Endothelial Progenitor Cell Phenotypes,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8091,NCT03702660,Glucagon,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8092,NCT02402361,Risk factors and determinants for neuropathic pain,,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
8093,NCT00013052,,,,na,COMPLETED,INTERVENTIONAL,['NA']
8094,NCT02236481,Glycated Hemoglobin,Plasma levels of glucose,,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4']
8095,NCT06287736,Change in PROMIS quality of life in relation to pain level,change in neuropathic symptoms using Michigan Neuropathy Screening instrument,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8096,NCT04168372,Rate of appearance of blood glucose from gluconeogenesis,Whole body fructose oxidation,,2019-09-15,RECRUITING,INTERVENTIONAL,['NA']
8097,NCT04578964,Determining the effect of cardiovascular risk factors on the mean age of the first acute coronary syndrome,Model for calculating the acute coronary syndrome age,,2014-01-02,RECRUITING,OBSERVATIONAL,['NA']
8098,NCT03241212,Change in knowledge about type 1 diabetes,Percent of text messages responded to in the study.,,2017-09-12,COMPLETED,INTERVENTIONAL,['NA']
8099,NCT04497532,Amniotic fluid index (AFI) after 2 weeks,,,2021-03-20,UNKNOWN,INTERVENTIONAL,['NA']
8100,NCT01556594,Number of Participants With at Least One Adverse Event,Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8101,NCT00400283,To determine the safety and the tolerability of ascending multiple oral doses of NNC 55 0414 in patients with type 2 diabetes.,,,2001-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
8102,NCT01068171,decrease in size of wound,non-healing wound,,2010-05,WITHDRAWN,INTERVENTIONAL,['NA']
8103,NCT04577976,Safety of the SMBG devices. The safety of self-monitoring of blood glucose (SMBG) when used to manage diabetes in a pediatric patient population will be characterized: Serious Adverse events,,,2020-09-23,TERMINATED,OBSERVATIONAL,['NA']
8104,NCT05857943,Sensitivity and Specificity,,,2023-03-29,COMPLETED,INTERVENTIONAL,['NA']
8105,NCT04090840,Weight loss,Hemoglobin a1c,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8106,NCT01686139,Frequency of Adverse Events,,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
8107,NCT01724385,The percentage of eyes that vitreous hemorrhage has been completely resolved,The change in best corrected visual acuity (BCVA) from baseline,Numbers of injection,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8108,NCT03840278,The Ratio of Cumulative Drug Doses Delivered to Cumulative Drug Doses Attempted for Insulin and Dasiglucagon,Mean Grams of Carbohydrate Per Day to Treat or Prevent Hypoglycemic Events (Reported Daily by Subjects),,2019-05-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8109,NCT01049412,Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles,Glycemic Variability in Fasting Blood Glucose (FBG) at Week 8 Endpoint,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8110,NCT05659537,Percentage of Participants with AEs and SAEs,Mean Change from Baseline in Hemoglobin A1c (HbA1c),,2022-12-29,COMPLETED,INTERVENTIONAL,['PHASE4']
8111,NCT00824603,We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program.,pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
8112,NCT01041768,Proportion of patients achieving diabetes complete remission (HbA1c 6% or below) or diabetes control (HbA1c between 7% and 6.1%) on free diet and with no antidiabetic medical therapy.,Stable reduction of preoperative HbA1c; BMI; mortality/morbidity; Major components of the metabolic syndrome; Diabetes complications; Improvement of beta-cell function; insulin resistance reduction ; Overall and CV disease mortality.,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
8113,NCT02474381,Infrapopliteal arterial patency of the affected extremity,Amputation rate of the affected extremity,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
8114,NCT00884819,Hepatic adiposity as assessed using MRI,"Reproductive parameters (androgens, hirsutism)",,2008-12,TERMINATED,INTERVENTIONAL,['NA']
8115,NCT04020445,"change in risk of hypoglycemia from baseline to 3, 6, 9 and 12 months",,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
8116,NCT00826904,Change in maternal postprandial lipemia,Correlation of neonatal adiposity and fetal growth,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
8117,NCT03383146,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,,2018-02-01,TERMINATED,INTERVENTIONAL,['PHASE3']
8118,NCT00629681,"Correlation between global status (as measured by the Clinical Global Impression of Change [CGIC] and the Patient Global Impression of Change [PGIC]) and changes in pain, anxiety, and sleep parameters",Course of mean pain score of patient's daily pain diary (NRS),,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8119,NCT01284608,Diabetes,Fracture Risk Assessment Tool (FRAx) assessment,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
8120,NCT01589029,Regression of retinal neovascularizations (NVE and NVD) in FA.,Change in HbA1c and inflammatory markers,,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1']
8121,NCT02827383,Continuous Glucose Monitor,Heart Rate,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
8122,NCT03479619,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,,2018-03-06,COMPLETED,INTERVENTIONAL,['NA']
8123,NCT00871416,"Location of the injected sterile, atmospheric air",Cutis/subcutis thickness on 14 recommended injection sites,,1997-04-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8124,NCT05307237,Infection Rate,Electronic Medical Record (EMR) - Derived Outcome: fasting POC blood glucose,Process Indicators (Maintenance): Stakeholder and advisory board feedback,2022-04-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8125,NCT01023945,Change in plasma glucose levels,Change in serum insulin levels,,2009-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8126,NCT03068286,Anxiety (as measured by the 7 item Generalised Anxiety Disorder inventory),Patient Experience (As measured by the Patient Experience Questionnaire),,2017-01-01,TERMINATED,INTERVENTIONAL,['NA']
8127,NCT03002545,questionnaire SF-36,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
8128,NCT00915954,Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml,"Median Bioactive IGF-1 Area Under the Curve in Response to Placebo, OGTT, and rhIGF1 Testing",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8129,NCT01697150,Percent time of active CTR,Frequency analysis of lost data caused by system components,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
8130,NCT05813496,To compare the relative change in NCS parameters between the study arms,To assess safety of Thiotacid® as per the nature and severity of the recorded adverse events.,,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8131,NCT00754403,Change from randomization in Glycosylated Hemoglobin,Change from randomization in Creatine Phosphokinase,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8132,NCT01828242,HbA1C,Fasting Blood Glucose,Iron status,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8133,NCT01779115,Prevalence rates of Diabetes,Number of visits to physician offices,,1998-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8134,NCT05560971,Insulin sensitivity M value change before and 8 weeks after POA vs placebo intake,"Serum; fasting glucose, insulin, LDL cholesterol, hsCRP, circulating inflammatory cytokines (TNF-a, IL-6), FABP4, glucagon",,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
8135,NCT00082238,,,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
8136,NCT04624321,Change of long-term blood glucose concentration measured as glycated hemoglobin at one year,Insulin secretion,"Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.",2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
8137,NCT02197078,Number of Participants With Stroke,Number of Participants With Acute Renal Failure Requiring Dialysis,,2014-07-30,COMPLETED,OBSERVATIONAL,['NA']
8138,NCT01953757,Pain,Quality of life,Acceptability of vegan diet,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8139,NCT02634879,Physician performance,Patient satisfaction,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
8140,NCT05464043,Retrospective study: characterization of hyperglycemia and diabetes after liver or kidney transplantation,Prospective: analysis of impaired glucose tolerance (prediabetes) and diabetes after liver or kidney transplantation,,2019-06-20,COMPLETED,INTERVENTIONAL,['NA']
8141,NCT02693938,Glucose Infusion Rate,,Glycemic variability,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
8142,NCT05251480,Impact of Treatment on Quality of Life (WoundQoL),Mean and median reduction in wound area at 12 weeks,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8143,NCT03517527,Exercise Decisional Balance Scale,,,2015-10-25,COMPLETED,INTERVENTIONAL,['NA']
8144,NCT00548808,Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c),Safety: Number of Participants With Serious and Non-Serious Adverse Events,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8145,NCT05451914,Change in Blood Glucose Control,Satisfaction/Usability of My Diabetes Care (for Intervention Group),,2023-07-06,RECRUITING,INTERVENTIONAL,['NA']
8146,NCT00367978,Time from baseline to the achievement of first treatment success (defined as achieving a blood pressure (BP) <130/80 mm Hg). The proportion and cumulative proportion of patients who achieved first treatment success were also determined.,change from baseline in estimated glomerular filtration rate (EGFR) at Week 24,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8147,NCT03505268,The impact of telehealthcare intervention on the change of the glycemic control in children with type 1 diabetes,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
8148,NCT03824379,Change of Human Serum Osteocalcin level,Quality of Life (QoL) Assessment: D-39 Questionnaire,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8149,NCT00681850,"HbA1c, LDL-cholesterol, Systolic Blood Pressure","Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice",,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8150,NCT01450943,Wound Closure by Week 15,Cost Effectiveness,,2011-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8151,NCT05478967,Incidence of VH,Changes of BCVA,,2019-08-08,COMPLETED,INTERVENTIONAL,['NA']
8152,NCT01830998,MMSE Olfactory function dementia,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
8153,NCT03394313,Mortality,,,2017-09-15,RECRUITING,OBSERVATIONAL,['NA']
8154,NCT04371978,Time to clinical change,"Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.",,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE3']
8155,NCT02741050,Self-Report Changes in Physical Activity from Baseline to 6 Months,Self-Report Changes in Physical Activity from 6 Months to 12 Months,,2016-08,TERMINATED,INTERVENTIONAL,['NA']
8156,NCT02761018,Reduction in hemoglobin a1c,,,2017-08-08,COMPLETED,INTERVENTIONAL,['NA']
8157,NCT06289933,Cmax,,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1']
8158,NCT00642798,Pharmacokinetics of sitagliptin after administration of single and multiple 100-mg doses of sitagliptin to healthy chinese adult subjects.,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8159,NCT04864860,postprandial blood insulin concentration,side effect of ecklonia cava,,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8160,NCT06067139,2-hour post-load glucose (2hPG) (mg/dL),"Insulin resistance score (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)",,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
8161,NCT05276128,glucose tolerance,Appetite sensations,Cognitive test variable,2022-03-20,COMPLETED,INTERVENTIONAL,['NA']
8162,NCT00844090,Change in HbA1c Over Baseline,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
8163,NCT04078308,Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells,Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells,,2015-07-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8164,NCT05626413,The risk of cardiovascular disease and events among patients with diabetes,,,2015-01-01,RECRUITING,OBSERVATIONAL,['NA']
8165,NCT00135915,,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
8166,NCT03098654,Retention in HIV care,Cost-effectiveness of integrating NCD screening and care with HIV screening and care,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
8167,NCT00340093,,,,2002-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8168,NCT00153088,Non-transition to overt nephropathy,Change in renal parameters Composite endpoint,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8169,NCT06217302,eGFR at the end of the wash-out period following the treatment period,"Time to ≥40% eGFR decline from baseline, end-stage kidney disease, renal replacement therapy, or death from renal causes",Mean total daily insulin dose during the treatment period,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8170,NCT05377333,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Area Under the Concentration Versus Time Curve (AUC) of LY3457263,,2022-06-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8171,NCT00619697,HbA1c,Safety profile,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8172,NCT00251940,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"• Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8173,NCT05573477,Hemoglobin A1c (HbA1c) (ATB-1011+ATB-1012 vs. ATB-1011),Changes in glycemic parameters,Extension period: Changes in MSDBP,2022-11-16,RECRUITING,INTERVENTIONAL,['PHASE3']
8174,NCT04274660,Change in diabetes self-management as assessed by the Diabetes Self-Care Activities Measure,Cost effectiveness,,2017-09-08,COMPLETED,INTERVENTIONAL,['NA']
8175,NCT00885846,Fasting Blood Glucose,Fasting Cortisol,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8176,NCT01772680,Oral glucose Tolerance Test,Fructosamine,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8177,NCT03333525,Change Postprandial Glucose Concentrations,Postprandial insulin need,,2013-09-10,COMPLETED,INTERVENTIONAL,['NA']
8178,NCT04418427,Time to worsening of DME disease activity in the study eye.,"Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation",,2020-05-28,COMPLETED,INTERVENTIONAL,['PHASE2']
8179,NCT00506298,The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90,"The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8180,NCT01742741,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.,2013-05,COMPLETED,INTERVENTIONAL,['NA']
8181,NCT03421301,intestinal microbiota,inflammatory profile,,2014-08-07,COMPLETED,INTERVENTIONAL,['NA']
8182,NCT00842192,HbA1c,Number of adverse drug reactions (ADR),,2009-04,COMPLETED,OBSERVATIONAL,['NA']
8183,NCT03141892,System related adverse device effects and serious adverse effects,,,2017-04-13,COMPLETED,OBSERVATIONAL,['NA']
8184,NCT00578890,no osteomyelitis spreading and wound healing and no osteomyelitis relapse 12 months after wound healing,ulcer relapse 12 months after healing,,2008-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8185,NCT01701557,time to normalization of bicarbonate and pH,the length of treatment,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
8186,NCT01268644,HbA1c,Change in HbA1c From Baseline to Week 20 on Leptin Therapy,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1']
8187,NCT06313008,Troponin (ng/ml),FBG (mg/dl),,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
8188,NCT05050019,the incidence of disruptions to insulin pump therapy or continuous glucose monitoring in patients with diabetes mellitus as a result of hospitalization or medical test,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
8189,NCT03001336,Diabetic retinopathy which is diagnosed by the measurement of fundus fluorescein angiography. (Diabetic retinopathy is clinically graded based on the international clinical diabetic retinopathy severity scales.),24h-albuminuria,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
8190,NCT01355536,The prevalence of Diabetes Mellitus,Serum levels of insulin,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
8191,NCT05052918,Carotid ultrasound,,,2021-09-08,RECRUITING,INTERVENTIONAL,['NA']
8192,NCT00229658,Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period,Change in Body Weight From Baseline at Month 6,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
8193,NCT01524705,Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline,Weight Change During Trial,HbA1C Levels,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8194,NCT04451109,Rate of overall vaginal delivery,Rate of caesarean sections,,2020-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8195,NCT03407118,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm,Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm,,2018-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8196,NCT00168519,glucose metabolism,,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
8197,NCT05333159,Major adverse cardiovascular and cerebrovascular events (MACCEs),Changes of plasma lipid parameters,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
8198,NCT01012037,HbA1c Change From Baseline at Week 12,The Occurrence of a Treat to Target Efficacy Response (HbA1c <6.5 %) After 12 Weeks of Treatment,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8199,NCT04356742,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,,2020-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
8200,NCT04159558,Satisfaction with the mobile application assessed by an ad hoc questionnaire,Treatment adherence assessed by Morisky Medication Adherence Scale (MMAS),Health goals compliance assessed by an ad hoc questionnaire,2018-04-24,UNKNOWN,INTERVENTIONAL,['NA']
8201,NCT04096313,Analytical verification of Allegro - Urine Albumin comparison,,,2020-03-25,COMPLETED,OBSERVATIONAL,['NA']
8202,NCT05556954,The percent change in foot ulcer surface area (cm2) after 12 weeks of observation for either infected or non-infected diabetic foot ulcers,Proportion of participants that reach a 50% reduction in surface area of the DFU for both cohorts,,2022-10-13,RECRUITING,OBSERVATIONAL,['NA']
8203,NCT02198209,Liver glucokinase activity (chronic effect),Acute insulin response to glucose and the disposition index,,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8204,NCT03936036,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
8205,NCT02804932,Change in skeletal muscle mitochondrial function,,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
8206,NCT01068860,"Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.","Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8207,NCT06000371,"Dimensions of diabetic foot ulcer (manual measurement of length, width and depth of the ulcer by metal ruler).",,,2020-04-25,COMPLETED,OBSERVATIONAL,['NA']
8208,NCT04570527,Number of patient death during the follow up period,six-min walk distance (6MWD),,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8209,NCT03751657,Change in HbA1c [Millimoles/Mole (mmol/Mol)],Change in Anti-insulin 287 Antibody Level,,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE2']
8210,NCT01986855,Percentage of Participants Who Discontinued Study Treatment Due to an AE,Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach,,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8211,NCT04176731,Percentage of Time in Range 70-180 mg/dL During Overall (Days 1-14) and Standard Therapy Period (14 Days),"Total Daily Bolus Insulin (Units, Units/kg)",,2019-12-15,COMPLETED,INTERVENTIONAL,['NA']
8212,NCT00523835,,,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
8213,NCT00980941,Appetite,Palatability of treatments,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
8214,NCT03105011,Absolute change in laboratory-measured HgbA1C,,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA']
8215,NCT03721991,insulin production,metabolic parameters quality of life,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
8216,NCT02356757,Ulcerative and non-ulcerative Foot lesions,Cost-effectiveness,,2015-08-24,COMPLETED,INTERVENTIONAL,['NA']
8217,NCT05734313,Depressive symptom severity,Hemoglobin A1c (HbA1c),Anxiety symptom severity,2023-10-31,RECRUITING,INTERVENTIONAL,['NA']
8218,NCT01108276,Overall decrease in wound size,,,2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8219,NCT00167778,Local Dynamic Stability (Ankle During Turning With the Prosthesis on the Outside of the Turn),How Bothersome Was Your Pain?,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
8220,NCT00790491,"Validate the AUGMENT dietary and physical activity assessments using dietary recalls and accelerometer data,",Survey participating providers and patients to assess acceptability of AUGMENT within a clinical setting.,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
8221,NCT05095610,HbA1c difference,Insulin dose,,2021-11-01,COMPLETED,OBSERVATIONAL,['NA']
8222,NCT04663061,Change in Body Weight,International Physical Activity Questionnaire (IPAC) short form: sitting time,,2021-06-09,RECRUITING,INTERVENTIONAL,['NA']
8223,NCT03033407,glycated hemoglobin levels,change in blood pressure within each group,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
8224,NCT04756011,Evaluation of health-related quality of life (HRQL),,,2020-03-15,COMPLETED,OBSERVATIONAL,['NA']
8225,NCT01328639,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in Satisfaction with care,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
8226,NCT02320110,Correlation of irisin leves with risk factors for metabolic syndrome in Hispanic children,"Irisin plasma levels and adiponectin, leptin, insulin and resistin.",,2014-09,COMPLETED,OBSERVATIONAL,['NA']
8227,NCT05239572,"Uptake of health education (health promotion, awareness of risk factors)",Cost-effectiveness of NCD interventions,Impact of training of community health volunteers on their performance in NCD interventions.,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
8228,NCT02748018,SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c ≤ 8%,SAP Cohort: Change in A1C for all subjects,,2017-05-25,RECRUITING,INTERVENTIONAL,['NA']
8229,NCT04907760,Risk factors for type 2 diabetes in participants,program compliance,,2021-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8230,NCT01415037,Change in detection of posterior vitreous detachment: 20MHz annular array versus 10MHz single element,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
8231,NCT02066766,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2015-04-22,COMPLETED,OBSERVATIONAL,['NA']
8232,NCT03234946,Body Mass Index,Steps per day,,2017-06-19,UNKNOWN,INTERVENTIONAL,['NA']
8233,NCT03687827,"Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)",Mean Glucose Levels Using Flash Glucose Monitoring (FGM),,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8234,NCT05268393,Interventionist adherence to session manuals,Glycemic control,,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
8235,NCT00110240,Change from baseline in HbA1c at 24 weeks,Patients with endpoint HbA1c <7% after 24 weeks,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8236,NCT06246279,Reynolds Adjustment Screening Inventory for Adolescents,Glycemic Control - Hemoglobin A1C,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
8237,NCT01898702,Glycosylated hemoglobin A,Health services utilization,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
8238,NCT01660386,The acute phase and second phase of insulin secretion and C peptide secretion,"Alpha cell function,GLP-1 response",,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
8239,NCT00880139,Arteriolar to venous ratio,"Systolic/diastolic arterial blood pressure, pulse rate",,2009-06,TERMINATED,OBSERVATIONAL,['NA']
8240,NCT05965336,Biomechanical modulation of ankle stiffness,Changes induced by biofeedback in biomechanics during gait,,2024-05,RECRUITING,INTERVENTIONAL,['NA']
8241,NCT03103854,HbA1C at 12 months,HbA1C at 3 months,,2014-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8242,NCT00005530,,,,1994-05,COMPLETED,OBSERVATIONAL,['NA']
8243,NCT01700868,hemoglobin A1C (diabetes management),24-Hour Multi-Pass Dietary Recalls,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
8244,NCT02283411,Safety of the Abbott Sensor Based Glucose Monitoring Systems Was Characterized by Adverse Device Effects and Serious Adverse Device Effects Experienced by Study Participants.,The Point Accuracy of the Device Performance Was Evaluated in Reference to Capillary Blood Glucose (BG).,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8245,NCT02068885,"Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes",Change in Self-reported Binge Eating Score,Effect Modification by Amylase Gene Copy Number,2014-08-17,COMPLETED,INTERVENTIONAL,['NA']
8246,NCT01005121,24 hr urine protein collection,,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
8247,NCT02352246,loss of abdominal fat mass (g),Change from baseline in food behavior after training (visual analog scale from Flint et al. 2000),,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
8248,NCT01934712,Area under the serum insulin aspart concentration-time curve,Area under the glucose infusion rate (GIR) curve,,2013-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
8249,NCT05275231,Acceptability: Changes in Satisfaction questionnaire,Changes in weight of participant's social contact,,2022-04-04,COMPLETED,INTERVENTIONAL,['NA']
8250,NCT01417897,Nitrotyrosine,intact Proinsulin,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8251,NCT00005266,,,,1990-09,COMPLETED,OBSERVATIONAL,['NA']
8252,NCT00231387,"The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri.","These include magnetic resonance endpoints related to plaque lipid content, volume, plaque size and fibrous cap thickness. Colour duplex measurements, laboratory assays for glycaemia and lipids.",,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8253,NCT02574195,Percentage of patients with diabetes mellitus type 1 and type 2diabetes mellitus complications,"Structure of antidiabetic therapy (% insulin, % OAD mono, % OAD dual, % OAD triple)",,2015-08,COMPLETED,OBSERVATIONAL,['NA']
8254,NCT00686283,exercise adherence,cardiorespiratory fitness,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8255,NCT00295828,Regression of iris neovascularization and prevention of development of neovascular glaucoma,Development of neovascular glaucoma.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8256,NCT04826159,Change in cardiac PCr/ATP ratio with dobutamine stress (Stage 1 only) measured by 31P-MRS at baseline and at EOT with 200 mg BID of IMB-1018972,"Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs",,2021-04-21,RECRUITING,INTERVENTIONAL,['PHASE2']
8257,NCT01013792,Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit,,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
8258,NCT04030611,pulse examinatin,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8259,NCT01297946,Percentage of time of plasma glucose concentrations spent in target range (4.0-10.0 mmol/l from 4:00p.m.-11:00p.m. and 4.0-8.0 mmol/l from 11:00p.m.-7:00a.m.),Number of subjects with at least one exercise-induced plasma glucose measurement below 3.0 mmol/l.,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8260,NCT02522494,Resistance to Treatment Questionnaire (RTQ),Diabetes Self-Efficacy,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
8261,NCT00276497,Reduction in conversion of IGT to diabetes,benefits of the drug on anthropometric variables and biochemical parameters,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8262,NCT01819129,Change From Baseline in HbA1c,Change From Baseline in Body Weight,,2013-09-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8263,NCT00145093,To determine the effect of Baker's yeast treatment on glycemicic control and insulin resistance when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus,"To determine the effect of Baker's yeast treatment on serum lipids, blood pressure, body fat percentage and BMI when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8264,NCT04373967,glycated hemoglobin (HbA1c),Percentage of participants with clinically significant change from baseline in laboratory parameters.,,2020-04-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
8265,NCT05719740,"to test and evaluate the role of bone-derived factor (osteocrin) in glucose metabolism,in diabetic patients with risk of micro and macrovascular complications .","to identify bone-derived factor (osteocrin) may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus",,2023-02,RECRUITING,OBSERVATIONAL,['NA']
8266,NCT01264263,"Measurement of intima media thickness, visit 2","hs-C-Reactive Protein, visit 2",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
8267,NCT04125329,Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient,Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment,,2020-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8268,NCT01029444,Evaluate the effectiveness of Pulsed IV Insulin Therapy on the stabilization of blood glucose levels on patients with brittle or uncontrolled diabetes,,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
8269,NCT05225337,Change in percent body weight,Change in medication effect score (MES),,2022-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8270,NCT00044408,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8271,NCT00222885,Triple tracer PET method development for in vivo imaging of skeletal muscle metabolism,Testing of mathematical modeling of PET data,,2002-12,COMPLETED,OBSERVATIONAL,['NA']
8272,NCT05105919,Incomplete platelet aggregation inhibition by aspirin at 7 days.,Platelet aggregation response to various agonists,,2021-08-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8273,NCT04322071,Thematic Analysis,,,2020-02-26,UNKNOWN,OBSERVATIONAL,['NA']
8274,NCT01964521,Changes in Signs and Symptoms of Local Infection,Levels of Pain in Connection to Dressing Changes.,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
8275,NCT00359996,hemoglobin A1c,Urine microalbumin levels,,2000-06,COMPLETED,INTERVENTIONAL,['NA']
8276,NCT06055036,Cardiovascular Health,"Identify the organizational context and resources necessary to align, coordinate, and sustain academic-community-government partnerships focused on advancing cardiovascular health equity.",,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
8277,NCT06020846,Blood glucose level,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
8278,NCT02703337,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8279,NCT05908968,Reduction in wound area,Complete wound closure,,2017-09-19,COMPLETED,INTERVENTIONAL,['NA']
8280,NCT03646292,liver fat change measured by MRI-PDFF in co-localized regions of interest within each of nine liver segments,The changes in inflammation status,,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
8281,NCT00626249,Differences in exposure to fumaryl diketopiperazine (FDKP),Additional safety parameters,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8282,NCT03920397,Glycemic control after an adipose tissue-derived stem/stromal cells,Oral cholecalciferol 2000UI/day supplementation,,2015-03-01,COMPLETED,INTERVENTIONAL,['NA']
8283,NCT04048642,Change in total daily insulin requirements,Change in urinary catecholamines,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
8284,NCT02371343,Birth size,Insulin like growth factor DNA methylation,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
8285,NCT02726100,"The proportion of patients achieving at least two ""ABC"" goals",Mean change in the Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 month,Mean change in estimated glomerular filtration rate (GFR),2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8286,NCT00443755,Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR),Change From Baseline in the Inflammatory Biomarker Adiponectin,Change From Baseline in Fat-Free Mass (FFM),2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8287,NCT01600950,Pharmacodynamics: Duration of Action of LY2963016 and Lantus,Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8288,NCT05364476,Change of HbA1c after 16 weeks intervention,Change in EQ-5D-5L score,,2022-04-11,COMPLETED,INTERVENTIONAL,['NA']
8289,NCT02533453,Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs),"Evaluation of ""Subjective Improvement of Main Indication""",,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4']
8290,NCT01809730,Transfusion within 48 hours post-op,,,2012-05,WITHDRAWN,OBSERVATIONAL,['NA']
8291,NCT02895113,Changes in renal function in diabetic patients treated with aspirin,Relationship between changes of Thromboxane B2 excretion and renal function in diabetic patients treated with aspirin,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
8292,NCT03976271,Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA,Oxidative stress responses using oxidative stress marker,,2019-08-12,COMPLETED,INTERVENTIONAL,['NA']
8293,NCT04853030,Time above range 180 mg/dl,Mean glucose,,2021-04-06,COMPLETED,INTERVENTIONAL,['NA']
8294,NCT02443532,HbA1c (between-group difference in variation from baseline),"Severe hypoglycemia (incidence of episodes of hypoglycemia requiring hospitalization and/or help from third parties, self-reported)",,2012-03,TERMINATED,INTERVENTIONAL,['NA']
8295,NCT01298076,Visual acuity gain,Safety,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8296,NCT05357534,average running speed,,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8297,NCT00390975,Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET),The safety and tolerability of tegaserod,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE4']
8298,NCT00295334,"adherence, HbA1c, Glc","LDL, HDL, TG",,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
8299,NCT02211235,The percentage of time spent > 140 mg/dl on CGM,The number of excursions > 200mg/dl in 24 hours for one week,Characterize the relationships between markers of glycemia,2014-08,COMPLETED,OBSERVATIONAL,['NA']
8300,NCT06015685,Change in feasibility of intervention measure (FIM) scores,Change in urine microalbumin,,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
8301,NCT00388388,Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes,"Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects",,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8302,NCT01415544,Calibrate near-infrared spectroscopy-based glucose meter,Compare Noninvasive to invasive techniques,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
8303,NCT00398619,"Assessment of ECGs, laboratory results and physical exams for adverse events",,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8304,NCT01450787,Conjunctival Staining Score,Tear Film Osmolarity,Corneal Staining,2012-01,TERMINATED,OBSERVATIONAL,['NA']
8305,NCT06107816,Evaluate the impact of a F&V Rx on DSME/S retention in low-income adults.,Evaluate the impact of a F&V Rx on Food insecurity,Assess program implementation outcomes - Clinic/providers/staff - Implementation Outcomes Questionnaire (IOQ),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8306,NCT02263352,Change in Serum MDA,Change in Clinical attachment level (CAL),,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8307,NCT05743244,The area under the stimulated C-peptide curve (Y_AUC),,,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
8308,NCT05821322,Change in plasma glucose during exercise,Carbohydrate needed (g),,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
8309,NCT03865914,change in eGFR and urine protein from baseline,,,2017-11-30,RECRUITING,OBSERVATIONAL,['NA']
8310,NCT04417270,Comparison of values between two devices,,,2020-06-12,COMPLETED,INTERVENTIONAL,['NA']
8311,NCT01050166,Evidence of safety and efficacy of MRI imaging of transplanted human labeled islets,,,2008-08-15,COMPLETED,OBSERVATIONAL,['NA']
8312,NCT02933788,platelet reactivity testing,"Observation of Clinical laboratory data(total cholesterol, HDL, LDL and triglyceride",,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
8313,NCT02231658,Change from baseline (week -1) in the number of reflux episodes,Change from baseline (week -1) in the time of pH < 4.0 in the lower third of the oesophagus,,2015-07-16,TERMINATED,INTERVENTIONAL,['PHASE1']
8314,NCT01359241,Percent of plasma glucose values within target range 3.9-8.0 mmol/l,Frequency of hyperglycaemia,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
8315,NCT03504605,Self-compassion items,,Pediatric Inventory for Parents,2018-08-15,COMPLETED,INTERVENTIONAL,['NA']
8316,NCT00656435,The severity of intraoperative bleeding and vitreous clear-up time.,Percentage of prolonged vitreous clear-up (≥ 3 weeks) and recurrent hemorrhage rate.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8317,NCT00838799,Change in mean daily pain rating,50% reduction in pain,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8318,NCT01531569,"Terminal phase half-life of secoisolariciresinol, enterodiol and enterolactone.",Inflammatory markers,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8319,NCT05263011,"Changes in plasma tumor necrosis factor (TNF)-alpha, concentration",,,2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8320,NCT05331469,Hba1c reduction,Weight changes after intervention,,2021-07-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
8321,NCT02559128,Exercise capacity,Endothelial function,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
8322,NCT00292994,Metabolic Syndrome Score,,,2004-04,UNKNOWN,INTERVENTIONAL,['NA']
8323,NCT06190158,The magnitude of non-suppressible and renin-independent aldosterone production.,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8324,NCT06069076,Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.,correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.,,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8325,NCT00973401,"Changes in amplitude/implicit times, retinal vessel diameter, dark adaptation and OCT",,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
8326,NCT03765164,Diagnosis-Treatment,Workup Costs,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA']
8327,NCT03183726,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Wound size and depth measurement,,2016-01-11,COMPLETED,OBSERVATIONAL,['NA']
8328,NCT01843881,"Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline)",,,2012-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8329,NCT02559843,total antioxidant capacity,fasting blood glucose,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8330,NCT01777282,Number of Participants With Any Hypoglycemic Event,Time to Study Withdrawal Due to Hyperglycemia,,2013-02-23,COMPLETED,INTERVENTIONAL,['PHASE3']
8331,NCT01492283,The Incretin effect,Plasma glucagon response,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
8332,NCT01635062,The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy,Change in Urine Protein After Calcitriol/Placebo Therapy,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8333,NCT02836808,Diabetes control after 4 visits in a structured multidisciplinary program for patients with diabetes,Quality of life after 4 visits in a structured multidisciplinary program for patients with diabetes,Social-economic impact of living and eating expenses of a multidisciplinary intervention for patients with diabetes,2013-10-31,RECRUITING,INTERVENTIONAL,['NA']
8334,NCT05431686,"Perceived benefit of the SMA intervention content, as measured by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level)",CGM Benefits and Burdens scale,,2022-02-16,RECRUITING,INTERVENTIONAL,['NA']
8335,NCT06290947,Improvement in Aerobic Capacity,Change in Body Mass Index (BMI),,2022-03-06,COMPLETED,INTERVENTIONAL,['NA']
8336,NCT03208309,Cholesterol,,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8337,NCT00704197,To assess sex differences in adipose tissue gene expression in different fat depots,To assess sex differences in other characteristics of adipose tissue structure and function in different fat depots across sex including: preadipocyte kinetics; lipolysis and lipogenesis; macrophage content; and tissue oxygenation,,2007-08,TERMINATED,OBSERVATIONAL,['NA']
8338,NCT01785108,"Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30","Fasting C-peptide, change between baseline and month 6, 15 and 30",,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8339,NCT04498819,Feasibility: Adherence,Participant Attitudes: Diabetes Emotional Distress,,2020-11-09,COMPLETED,INTERVENTIONAL,['NA']
8340,NCT00625833,Change from baseline in weekly average pain score,Modified Brief Pain Inventory-Short Form,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8341,NCT00737776,HbA1c change,Diabetes Fear of Self-Injection Questionnaire (D-FISQ),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
8342,NCT02839031,Glycated hemoglobin (HbA1c) level,,,2015-03-11,TERMINATED,INTERVENTIONAL,['NA']
8343,NCT05383404,measured degree of dehydration,,,2022-06-25,RECRUITING,OBSERVATIONAL,['NA']
8344,NCT00588172,Change in glucose area under the curve after a mixed meal in response to metformin,Change in glucose disappearance and suppression of endogenous glucose production in response to metformin,,2010-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8345,NCT03388723,Epigenetic signatures in the cord blood of the offspring of GDM mothers.,Qualitative and quantitative comparison of epigenetic signatures in the offspring of GDM mothers [Indian and Danish cohort].,,2014-09-02,COMPLETED,OBSERVATIONAL,['NA']
8346,NCT00448526,time to the doubling of sCr,% change of urinary albumin and protein excretion from baseline,,1997-12,TERMINATED,INTERVENTIONAL,['NA']
8347,NCT03954834,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8348,NCT02417935,Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale (NRS),Number of Participants With a 30% and 50% Reduction in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point NRS at 12 Weeks,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8349,NCT03428295,Percentage of time in severe hyperglycemic range,,,2017-06-22,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8350,NCT03059277,Change in Central Subfield Thickness (CST),Number of Intravitreal Injections,,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8351,NCT00031226,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
8352,NCT05337644,Positive Intraoperative Indocyanine green test,,,2022-01-21,COMPLETED,OBSERVATIONAL,['NA']
8353,NCT01550809,The Area Under the Curve (AUC) of the Glucose Infusion Rate (GIR) During the 5-hour Postprandial Period (AUC-GIR0-5h).,The Area Under the Curve (AUC) of Plasma Glucose (PG) Above the Threshold of 140 mg/dl (AUC-PG>140).,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8354,NCT05418569,Self/Parent-reported questionnaires on hypoglycemia frequency,Self-reported smartphone application usage satisfaction,,2021-07-01,RECRUITING,INTERVENTIONAL,['NA']
8355,NCT05960656,Ketone Body Turnover (ketogenesis) during Study 2,Plasma Free Fatty Acids (FFS) Study 2,,2023-10-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8356,NCT00147719,To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride when added on to current therapy,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8357,NCT04013919,Glucose levels,,,2019-09-20,UNKNOWN,OBSERVATIONAL,['NA']
8358,NCT01126580,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8359,NCT00676208,Change in Confidence in Ability to Perform Teamwork,Change in Professionals' Attitudes About Diabetes,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
8360,NCT06094491,A1c,Low density lipoproteins,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8361,NCT00511472,Number of Participants Who Experienced an Adverse Event During the Study,Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8362,NCT03602963,Accuracy of the Dexcom G5 mobile continuous glucose monitoring (CGM) system by comparison of sensor glucose measurements with capillary blood glucose determinations,Patients' and parents' satisfaction with the Dexcom G5 mobile CGM system will be evaluated by a standardized questionnaire,,2018-07-09,COMPLETED,OBSERVATIONAL,['NA']
8363,NCT01630369,Decrease of Hb A1c ≥ 1%,Assessment of efficacy of education courses in Diabetes Schools,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8364,NCT02214719,Glucose control - A1c,Long term use,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8365,NCT01881009,Target Sensor Glucose 70-150 mg/dl,Target Sensor Glucose 70-180 mg/dl,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8366,NCT02530450,The Primary Outcome Measure Was Change in HgbA1c,"% Time Spent in Hypoglycemia, Hyperglycemia, and Euglycemia",,2011-05,COMPLETED,OBSERVATIONAL,['NA']
8367,NCT06314048,Diabetes distress measured at baseline and 12 months post-diagnosis.,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8368,NCT02266576,Change From Baseline in the Quality of Life Short Form Survey (SF-12),Change in From Baseline in Empowerment,Lipid Bioassays,2015-06,COMPLETED,INTERVENTIONAL,['NA']
8369,NCT00233259,Hemoglobin A1c,Social support,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8370,NCT03415295,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
8371,NCT03426345,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,2018-02-16,TERMINATED,INTERVENTIONAL,['PHASE3']
8372,NCT05307042,Decline renal concentration ability,Decline in kidney-function,,2022-05,UNKNOWN,OBSERVATIONAL,['NA']
8373,NCT01546766,Pupillary response,Pupillary response.,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
8374,NCT01067963,"Primary outcomes utilized in this study will be disease burden (measured as diabetes-related distress), quality of life (measured as health related QOL), and glycemic health (measured as hemoglobin A1C).",Secondary exploratory outcomes for quality of life include measures of health-related quality of life for diabetes and overall quality of life.,,2009-12,TERMINATED,INTERVENTIONAL,['NA']
8375,NCT02159417,The feasibility of the application of the action ETP in the MAPLS,The satisfaction of the staffs as for the implementation and the realization of the experiment,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
8376,NCT05758467,Cardiovascular health and oral health,,,2019-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8377,NCT03934593,The change in HbA1c,Occupational physical activity,Spiritual coping,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8378,NCT00451113,Safety and efficacy of Sitagliptin in an elderly population with type 2 diabetes,,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8379,NCT00730561,Change in nerve conduction velocity,,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8380,NCT02245399,change in HbA1c,urinary analyses,Estradiol level,2014-10,COMPLETED,INTERVENTIONAL,['NA']
8381,NCT03252964,Program Completion Rate (%),Coaching Participation Rate,,2017-07-28,COMPLETED,INTERVENTIONAL,['NA']
8382,NCT04447859,Gastrointestinal adverse events (GI-AEs),,,2020-02-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
8383,NCT02704494,Serum creatinin,Number of patients with adverse events,,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8384,NCT01422057,Major cardiovascular event,Total mortality,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
8385,NCT01834144,"Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.","Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.",,2013-05,TERMINATED,INTERVENTIONAL,['NA']
8386,NCT06114186,percentage of time with severe hyperglycemia,,,2024-01-16,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8387,NCT00481897,"Assignment to the diet intervention, decreases the prevalence of work absenteeism, as measured by the proportion of days that a participant is absent from work, compared with assignment to a control group.",Assignment to the diet intervention program promotes adherence and acceptability.,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
8388,NCT06035406,PK parameters：AUC0-∞；,Incidence and severity of adverse events (AEs),,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
8389,NCT02927678,"Rate of remission of osteomyelitis at one year after the cessation of antibiotic treatment, evaluated by white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography).",Negative predictive value of White Blood Cell SPECT/CT performed at the end of antibiotic treatment to predict the remission of osteomyelitis at one year.,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
8390,NCT00229684,Endogenous creatinine clearance,"The safety and tolerability of tesaglitazar in type 2 diabetics by assessments of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, body weight, and physical examination.",,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2']
8391,NCT02197299,Skeletal muscle total carnitine content,,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
8392,NCT00808431,"Growth trajectories (using BMI, waist circumference), body composition","Physical activity accelerometry change over time, parental self-efficacy, child feeding questionnaire (parental food habits), identification of medical home",,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8393,NCT01940302,Metabolic Control,,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8394,NCT06011356,Step count,Patient Activation Measure (PAM),,2023-08-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8395,NCT01983046,fat oxidation,Hormones that influence energy metabolism - Circulating metabolites - Inflammatory markers - plasma SCFA content; - Indirect markers of insulin sensitivity - Appetite (VAS-scoring).,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8396,NCT02100475,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment-emergent Confirmed Hypoglycaemic Episodes,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8397,NCT02665689,Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 12 Baseline Visit,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2016-01-18,TERMINATED,INTERVENTIONAL,['PHASE4']
8398,NCT04084886,Number of patients with genotype TCF7L2 by PCR,,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
8399,NCT01527656,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8400,NCT00360061,HBA1c,Modified Health Care Climate Questionnaire (at baseline only).,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
8401,NCT01319331,To assess participant safety & feasibility of study drug administration,Assess the effects of AAT on glycemic variability and A1c.,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8402,NCT01067209,"Primary outcome measure: cardiac function, myocardial fat deposition","Plasma lipidomics, liver fat deposition",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
8403,NCT04931537,Urinary Albumin Creatinine Ratio，UACR,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
8404,NCT00141401,Safety Efficacy,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8405,NCT05062460,Rate of adherence,Number of patients with brachial plexus palsy,,2021-07-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8406,NCT01298518,Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28,Area Under the Concentration-Time Curve AUC (0-24) of PF-04620110,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8407,NCT02545738,Change in albuminuria,24h heart rate,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8408,NCT03914183,The percentage of participants in the mCPN group who demonstrate an improvement (vs baseline performance) in the recommended site rotation techniques relative to the proportion of that in the control group.,the percentage of participating patients who decide to continue using mCPN upon study completion,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
8409,NCT06159543,8-iso-PGF2 alpha,Lean body mass,,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8410,NCT01165268,The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin,"Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8411,NCT00624767,To evaluate the effect on postprandial glycemic control of intranasal insulin compared to NovoLog,To evaluate the pharmacokinetics of intranasal insulin compared to NovoLog,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8412,NCT05408936,NT-proBNP,,,2022-06-03,RECRUITING,OBSERVATIONAL,['NA']
8413,NCT02686996,Change in insulin sensitivity measured by euglycaemic glucose clamp,Change in Resting systolic and diastolic blood pressure,Change in Other Tissue Analyses,2017-02-13,UNKNOWN,INTERVENTIONAL,['NA']
8414,NCT00446277,central corneal thickness,intraocular pressure,,2007-01,SUSPENDED,OBSERVATIONAL,['NA']
8415,NCT04560062,Proportion of patients with access to health care of diabetes,Proportion of patients with at least one disease complication,,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA']
8416,NCT01626469,Change in ophthalmic artery blood flow from baseline,Change in renal plasma flow (RPF) from baseline,,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8417,NCT01518205,Proportion of subjects obtaining the ulcer healing (Class 0A according to TEXAS classification) after 12 month from the study starts.,proportion of subjects with major amputation (these are usually below the knee or above the knee)- in agreement with the approved amendment,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
8418,NCT02973321,Change From Baseline in HbA1c to Week 26,Change From Baseline in Pharmacodynamic Biomarkers to Week 26 - Waist and Hip Circumferences,,2016-12-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8419,NCT00536250,hepatic fat content and abdominal fat ratio,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
8420,NCT00969566,The change of HbA1c,Homeostatic model assessment of insulin resistance (HOMA-IR),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8421,NCT04686201,Percentage of uncontrolled Diabetes Mellitus patients who have good control diabetes after using Diabetes Mobile Application,,,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
8422,NCT00044668,"Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit",,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8423,NCT01724645,HbA1C :Glycated Hemoglobin,Heart rate,Lipid modifying (oral medication),2010-09,COMPLETED,INTERVENTIONAL,['NA']
8424,NCT03414892,the mean change in glucose area under curve (AUC) from baseline.,the mean changes of post-prandial blood glucose from baseline,the changes of GA (Glycated albumin) from baseline,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8425,NCT04492566,Time in Target Glucose Range,Mean CGM Glucose Level,Fetal Outcomes: Neonatal Intensive Care Unit Admission,2020-07-27,COMPLETED,INTERVENTIONAL,['NA']
8426,NCT04616014,Number of Participants With Treatment-related Adverse Events.,Change From Screening in Liver Steatosis,,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8427,NCT03045250,Normative values for corneal confocal microscopy (CCM),Serum biomarkers - fibrinogen,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
8428,NCT01281605,To compare the change in HbA1c between two study groups at Week 24.,To evaluate the incidence of adverse events.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
8429,NCT01006291,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8430,NCT00272090,severe nocturnal hypoglycemias will be measured throughout the study period.,severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8431,NCT02606747,Foot sole tactile threshold,,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
8432,NCT00356421,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Percent (%),Change in Fasting Lipids From Baseline,Subject Reported Quality of Life From Baseline as Determined From Phase V System Measurement,2006-11,TERMINATED,INTERVENTIONAL,['PHASE4']
8433,NCT01369069,Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL),Stroke Specific Quality of Life (SSQOL),Death,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8434,NCT00179127,Time of Acidosis Correction,Total Hospital Stay,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
8435,NCT05939349,Glycemic control,Nutrition knowledge,Provider satisfaction survey,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8436,NCT02742233,Completely healing time of the participants'target ulcer during the treatment period.,Proportion of participants with complete healing during the treatment period.,New ulcers,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
8437,NCT04612868,"Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)","Imageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)",,2020-10-16,COMPLETED,INTERVENTIONAL,['NA']
8438,NCT05565651,Outcome percentage Phyla,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
8439,NCT02875821,changes in visceral fat area,Changes in liver fat,,2016-04-26,COMPLETED,INTERVENTIONAL,['PHASE4']
8440,NCT02018809,Statin Adherence,Morisky Medication Adherence Scale (MMAS),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8441,NCT01616563,Number of Participants That Have Reversal of Metabolic Syndrome,Changes in Continuous Metabolic Syndrome Risk Score,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
8442,NCT01879137,Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome.,,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
8443,NCT06283394,Percentage of food purchasing expenditures spent on eligible healthy foods,Qualitative results,,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8444,NCT01785043,Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.,The evaluation of other emerging potential cardiovascular risk factors,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8445,NCT01736059,Incidence and severity of ocular adverse events,The number of stem cells isolated and injected into the study eye,Incidence and severity of systemic adverse events,2012-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8446,NCT02796170,Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM,Change in Urinary AGT Levels From Baseline to 6 Weeks,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8447,NCT02025673,"Serum levels of betatrophin in type 2 diabetes patients, gestational diabetes patients and pregnant women",Correlation of betatrophin concentration with other variables,,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
8448,NCT00781001,Spontaneous Pain Score,Adverse events,,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8449,NCT04818242,Time in Range (TIR) Between 70-180 mg/dL,Number of Participants With Problems With Sensor Insertion,,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
8450,NCT01382303,Percentage Change in Proteinuia,Mean Change of TNF-a,,2010-10-25,COMPLETED,INTERVENTIONAL,['PHASE4']
8451,NCT00566215,Improvement or reversal of type 2 diabetes mellitus,Improvement of insulin sensitivity as measured by insulin tolerance test.,,2007-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8452,NCT03827434,Change in mortality among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care),,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
8453,NCT03297931,Food intake,,,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA']
8454,NCT04856670,Aqueous humor concentrations of inflammatory mediators at the onset of manual cataract surgery and following femtosecond laser treatment,Prevalence and severity of postoperative flare,,2021-05-25,UNKNOWN,OBSERVATIONAL,['NA']
8455,NCT03511898,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,,2018-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
8456,NCT00116792,In-stent and In-segment late lumen loss,(There are 3 more secondary endpoints not listed here.),,2004-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8457,NCT06313138,Symptom burden,Health literacy,,2023-07-15,COMPLETED,INTERVENTIONAL,['NA']
8458,NCT03521934,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)",Change From Baseline in Estimated Glomerular Filtration Rate (eGFR),,2018-06-15,TERMINATED,INTERVENTIONAL,['PHASE3']
8459,NCT04819815,Chronotropic index,Life Quality,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
8460,NCT01878682,"The accuracy of the VibraTip® device, as measured by a comparison with the Gold Standard, the 10g Semmes Weinstein Monofilament (MF) Test by a Diabetologist.",,,2014-02-06,COMPLETED,OBSERVATIONAL,['NA']
8461,NCT05195138,Feasibility: overall study retention,Type 2 diabetes stigma,,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
8462,NCT05025852,Body Mass Index (BMI) z-score,Neurocognitive development,,2022-05-11,RECRUITING,OBSERVATIONAL,['NA']
8463,NCT04856800,Maternal glycemic variability (GV),Weight of placenta,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
8464,NCT03972982,remission rate,,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8465,NCT00209170,"Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24",,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8466,NCT00330954,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
8467,NCT00479466,Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG),Change From Baseline to Week 12 in 2-Hour Post Prandial Glucose (PPG),,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
8468,NCT00539175,pain intensity,"Semmes-Weinstein sensation, proprioception, quality of life",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
8469,NCT01427920,Change in HbA1c (Glycosylated Haemoglobin) - PP,Patient Reported Outcomes Evaluated: Treatment-Related Impact Measures for Diabetes (TRIM-D) - Total Score,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8470,NCT04464694,Early postoperative vitreous haemorrhage,Mean Best-corrected visual acuity (BCVA) at Month 6,,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8471,NCT00945165,Hyperglycemia,Mean Blood Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
8472,NCT05707481,Change in Health related Quality of Life,"Change in Patients health related Knowledge, Attitude and Practice",,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
8473,NCT03109587,Change in microbiota composition,Change in inflammation in the gut,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
8474,NCT05169060,Change from baseline of omega-3 index at 16 and 24 weeks,Change from baseline in urine microalbuminuria levels after 16 and 24 weeks.,,2023-06-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8475,NCT02006836,AUCs With/Without Pomelo,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8476,NCT00253240,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
8477,NCT05917249,Change of the perfusion index at the end of the first session compared to baseline readings.,The total remission rate,,2023-06-07,COMPLETED,INTERVENTIONAL,['NA']
8478,NCT01724190,IDAA1c,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8479,NCT03184337,Change in body mass index,Change in self-assessed general health,,2017-04-24,COMPLETED,INTERVENTIONAL,['NA']
8480,NCT03956927,Organizational advantages and limitations,,,2019-05-24,COMPLETED,OBSERVATIONAL,['NA']
8481,NCT05326490,Change in HbA1c,,,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8482,NCT01343056,"Hemoglobin A1C (HbA1C, %)",Systolic Blood Pressure,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
8483,NCT04917458,Evaluating the effects of cholecalciferol for depression symptoms with BDI II score,Evaluating the effects of cholecalciferol against C-Peptide,,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
8484,NCT00398892,HbA1c change for lipoic acid vs placebo,Urine ACR change for lipoic acid vs placebo,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
8485,NCT04666987,Change in Glycated Haemoglobin (HbA1c),Treatment simplification (decrease in insulin dose or number of concomitant OADs) (yes/no),,2020-10-21,COMPLETED,OBSERVATIONAL,['NA']
8486,NCT00027456,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8487,NCT02635243,Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product,Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product,,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8488,NCT01671306,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
8489,NCT04889183,Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR),high sensitivity C-reactive protein (CRP),,2022-03-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
8490,NCT02241889,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Percent of Time of CBG>180 mg/dl,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8491,NCT03884920,HB-A1c,Lipid Profile,Kidney Function,2019-03-20,COMPLETED,OBSERVATIONAL,['NA']
8492,NCT00697450,Weight effect,Improvement in HbA1c levels,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
8493,NCT02046395,Change in Urine Microalbumin Creatinine Ratio,Change in the Level of Urinary Free Light Chains,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8494,NCT03143803,Mean amplitude glycemic excursion,Number of hypoglycemia episodes,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
8495,NCT00268645,"For efficacy: FBG (Fasting Blood Glucose), HbA1c",For safety: ICA (Insulin Cell Antibody),,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8496,NCT02290418,Composite measure of success of bariatric surgery as measured by Bariatric Analysis and Reporting Outcome System (BAROS),"Change in Quality of Life, as measured by Moorehead-Ardelt Questionnaire II","Change in Body Mass Index (BMI), measured in kg/m2",2012-01,UNKNOWN,INTERVENTIONAL,['NA']
8497,NCT00973726,"Changes in amplitude/implicit times, changes in dark adaptation, changes in vessel caliber, changes in Optical coherence tomography (OCT)",,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
8498,NCT00144144,Clinical laboratory data,Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness,,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8499,NCT00264589,cardiac function at rest and during exercise,substrate utilization during exercise,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8500,NCT02085681,Proportion of patients with confirmed Diabetic Retinopathy (DR) diagnosed at the eye hospital,Proportion of patients eligible for referral who had DR and who did not attend,Drivers of acceptance,2014-05,COMPLETED,INTERVENTIONAL,['NA']
8501,NCT03766620,Body Weight Change,Albumin Levels,Physician Product Satisfaction,2018-11-29,COMPLETED,OBSERVATIONAL,['NA']
8502,NCT01481675,Diabetes resolution at 12 months after surgery,Changes in PYY response to glucose,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8503,NCT02590016,Neonatal hypoglycemia,Proportion of participants needing insulin-glucose-infusion in the observational arm,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8504,NCT01128205,"The proportion adequate control of blood glucose, blood glucose and blood pressure or blood glucose and blood lipid, and blood glucose, blood pressure and blood lipid.",,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
8505,NCT01089569,HbA1c Change,Change From Baseline in Weight Changes,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
8506,NCT02266823,Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
8507,NCT00810992,Body mass index,Intima media thickness HbA1C Lipid status Platelet activation markers as prognostic biomarkers,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8508,NCT06144593,24-hour average sensor glucose,Fasting plasma concentrations of triacylglycerols,Explorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategy,2024-01,RECRUITING,INTERVENTIONAL,['NA']
8509,NCT03853941,Change in healthcare professionals' communication style,Fidelity of delivery,,2019-03-21,COMPLETED,INTERVENTIONAL,['NA']
8510,NCT05407467,HbA1c,Blood Pressure,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8511,NCT03770052,HbA1c at 24 week,total bilirubin,,2018-10-24,COMPLETED,INTERVENTIONAL,['PHASE4']
8512,NCT03729323,Blood pressure,,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA']
8513,NCT04005430,The primary outcome measure of the study is safety assessment.,Secondary outcome are assessment of anatomical changes in the macula as measured via optical coherence tomography (OCT).,,2019-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8514,NCT03693521,Change in physical activity level,Physical Activity on Prescription,,2019-10-07,COMPLETED,INTERVENTIONAL,['NA']
8515,NCT00302874,Mean blood glucose during hospitalization,"Disposition at discharge (home, nursing home)",,2003-02,COMPLETED,INTERVENTIONAL,['NA']
8516,NCT02292511,Global Cognitive Functioning,Antisaccade direction errors,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
8517,NCT00445913,The trial is designed to assure that the toxicity rate is acceptably low to warrant further study of the cell vaccine in efficacy trials.,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8518,NCT04285450,Homeostasis model assessment of insulin resistance (HOMA-IR),,,2019-10-27,COMPLETED,INTERVENTIONAL,['NA']
8519,NCT03648138,Hypothetical beverage choice,Negative reactions to the label,,2020-01-17,COMPLETED,INTERVENTIONAL,['NA']
8520,NCT04016987,changes in serum hemoglobin A1c level,Adverse events,,2020-09-08,UNKNOWN,INTERVENTIONAL,['NA']
8521,NCT00602472,HbA1c Change From Baseline to Week 24,Percentage of Patients Who Have a HbA1c Lowering by 0.5% at Week 24,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8522,NCT00802022,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"The practical- and technical feasibility of the procedures, predicting successful pain relief by SCS by classifying patients according to the MDNS. Define possible other predictors for successful pain relief.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8523,NCT01554566,serum lipids,C-peptide,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8524,NCT03998046,Number of Participants Who Achieved 5% Weight Loss Goal at 6 Months,Number of Participants Who Achieved 5% Weight Loss Goal in 12 Months,,2019-12-16,COMPLETED,INTERVENTIONAL,['NA']
8525,NCT04016584,"Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.",Participant evaluation of Diabetes Pueblo evaluated by questionnaire,"Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire",2019-05-10,COMPLETED,INTERVENTIONAL,['NA']
8526,NCT02730078,Diabetes-related distress,LDL-cholesterol,Adverse event,2016-04,COMPLETED,INTERVENTIONAL,['NA']
8527,NCT05337826,The co-primary implementation outcomes,Diabetes health related quality of life measures,,2022-04-20,RECRUITING,INTERVENTIONAL,['NA']
8528,NCT06303453,PainDETECT Tool,,,2024-02-25,RECRUITING,INTERVENTIONAL,['NA']
8529,NCT04270578,Glucose tolerance during 75 g oral glucose tolerance test,blood sample,,2012-05-23,RECRUITING,OBSERVATIONAL,['NA']
8530,NCT04117269,Percentage of diabetic foot ulcers healed,Time to healing,,2019-11-15,RECRUITING,INTERVENTIONAL,['NA']
8531,NCT02060279,"β-carotene, FABP4 and C16:1n7 palmitolate levels",Macrophage expression of genes involved in lipid and lipoprotein metabolism and adipose deposition,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
8532,NCT03334175,Palatability of Supplement,Change in Low Density Lipoprotein Levels,Number of Participants Who Had Plasma Metabolomics Performed,2018-05-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8533,NCT00231608,The mean change from baseline to Month 6 in abdominal visceral fat as assessed by computed tomography; the safety of Topiramate for up to 12 months of continued treatment in male subjects with abdominal obesity.,"Mean change and percent change in body weight, and mean change in total abdominal fat, subcutaneous abdominal fat, body composition, and body mass index from baseline to Month 6.",,1998-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8534,NCT05118217,Dynamic Vessel Analysis,Body Mass Index,,2021-11-18,UNKNOWN,OBSERVATIONAL,['NA']
8535,NCT01828229,Insulin sensitivity,visceral adiposity,aerobic fitness,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8536,NCT01488279,Insulin Sensitivity,Change in Insulin Secretion (AIRg or Acute Insulinogenic Response to Glucose),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8537,NCT00737815,Fasting insulin,Gene Expression,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8538,NCT03414216,Any recurrence of any ulcer at same location,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
8539,NCT04653779,The preference regarding convenience of medication,TSQM-9 scores,,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
8540,NCT01181453,Complete wound closure,Percent of wound closure by study end,,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8541,NCT00306384,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With a Clinical Response,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8542,NCT02763423,Changes from baseline exogenous insulin dose at different time points post treatment,titres of islet antigen antibodies,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8543,NCT05343624,Time in Range,Hypoglycemia,,2020-06-18,COMPLETED,INTERVENTIONAL,['NA']
8544,NCT01987206,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,,2014-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8545,NCT04076995,Area Under the Curve for Plasma osmolality,Mood assessment with a questionnaire,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
8546,NCT00546351,Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).,Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8547,NCT02344602,The Change in Effective Renal Plasma Flow (ERPF) After an 8 week Treatment with Febuxostat,The Change in Skin Biopsy Measures of Neurohormonal Activation After an 8 week Treatment with Febuxostat,,2012-12-18,COMPLETED,INTERVENTIONAL,['PHASE4']
8548,NCT00184821,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
8549,NCT05179135,Change in blood glucose during exercise,Plasma growth hormone area under the curve during exercise and in the recovery period after the exercise session.,,2022-01-19,COMPLETED,INTERVENTIONAL,['NA']
8550,NCT02504762,Assessing conventional CABG vs HCR in diabetic patients with multivessel CAD,Number of patients we can enroll in 1 year,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
8551,NCT01736865,Disposition Index,Number of Participants With Change in Glycemia,Effect of Vitamin D Supplementation on Plasma Concentrations of Surrogate Biomarkers of Cholesterol Absorption (Campesterol and β-sitosterol) and Endogenous Synthesis (Lathosterol and Desmosterol),2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8552,NCT00641251,LDL cholesterol < 100 mg/dl,,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
8553,NCT03025984,compliant diabetes care,,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8554,NCT01005420,Insulin Sensitivity,Cognitive Performance,,2007-02,WITHDRAWN,INTERVENTIONAL,['NA']
8555,NCT06047262,Change in HbA1c in blood of patients for dapansutrile compared to placebo,Change in fasting plasma glucose for dapansutrile compared to placebo,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8556,NCT02854748,"Cmax,ss of Lobeglitazone",AUCinf of Lobeglitazone,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
8557,NCT02813421,Percentage Time Within Target Blood Glucose (Range: 70-180 mg/dL),Number of Participants With Satisfaction of Transition to Pump Therapy,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8558,NCT00824668,,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8559,NCT01693406,Change in infant percent body fat from birth to 4 months,Change in Antioxidant capacity of human milk,Change in Human Milk Nutrient Composition,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8560,NCT03573856,Change from 0 to 12 months in fasting insulin,Change from 0 to 12 months in fasting glucose,Potential for sustained delivery,2018-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8561,NCT04591782,Impact of gut microbiome in glycemic response to pom juice vs. sugar water,,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
8562,NCT01058577,"plasma ion concentrations (sodium, potassium, chloride, calcium, magnesium) and osmolarity",blood glucose concentration,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8563,NCT01768611,Plasmatic Creatinine,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
8564,NCT04907006,Cmax,CLz/F,,2021-08-31,COMPLETED,INTERVENTIONAL,['PHASE1']
8565,NCT04025853,Evaluate the effectiveness of biomarkers to differentiate osteomyelitis from deep soft tissue infections in patients with diabetic foot ulcers.,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
8566,NCT01298245,The differences in the distribution of candidate genotypes and alleles between the study groups,the frequencies of haplotypes of different single nucleotide polymorphisms,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
8567,NCT01384045,Composite Measure of Guideline Concordance,Individual measures of guideline concordance,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8568,NCT05938712,Proximal tubular natriuresis with monotherapy,Safety: The number of allergic reaction events.,,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2']
8569,NCT00965458,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8570,NCT05747352,Glucose time,Glucose time,,2023-06-05,COMPLETED,OBSERVATIONAL,['NA']
8571,NCT00622856,consumption of health services,Changes in the wellbeing of adolescents and their parents,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
8572,NCT01513590,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent AEs (Adverse Events),,2012-01-16,COMPLETED,INTERVENTIONAL,['PHASE3']
8573,NCT02700503,Subject's BMI calculation Charted on CDC Stature for Age and Weight for Age Percentiles chart,Dietary records,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
8574,NCT06077461,State-Trait Anxiety Scale,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
8575,NCT01927315,Circulating progenitor cells,Triglycerides,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8576,NCT04380844,Diabetes Knowledge Questionnaire,,,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA']
8577,NCT01530347,correlation between the acetone values generated by study device and oxygen,Clarke Error Grid (segment 1 only),,2012-03,TERMINATED,INTERVENTIONAL,['PHASE1']
8578,NCT03939143,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),,2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8579,NCT02214056,Percentage of eligible patients who actually received the mobile team exam,GP and patient acceptability of the mobile team exam,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
8580,NCT02328599,Change in HbA1c,HbA1c < 6.5%,change in albuminuria,2018-04-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8581,NCT02059564,PK profile of acetaminophen,Safety and tolerability,,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
8582,NCT03314714,Assessment of intramyocellular lipid composition via mass spectrometry,,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
8583,NCT01978925,Medication Adherence,Quality of Life,Fasting plasma glucose for diabetic patients,2013-11,COMPLETED,INTERVENTIONAL,['NA']
8584,NCT01939366,Change in Average Pain Intensity.,,,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2']
8585,NCT01567033,Body Mass Index,Survey,,2012-04-26,COMPLETED,INTERVENTIONAL,['NA']
8586,NCT05015738,"Instructional Materials Motivation Survey (IMMS), 10. week (after the course finished)","Opinion Form on Diabetes Education Program supported by digital tools, for only experimental group, 10. week (at the end of the course)",,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
8587,NCT01241474,Change in insulin sensitivity assessed by hyperinsulinemic-euglycemic-eu-aminoacidemic clamp,Change in plasma inflammatory markers,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8588,NCT02206919,Popliteal FMD MRI technique correlates with albuminuria in those with early diabetic disease,Dietary risk factors related to chronic disease,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
8589,NCT05333718,clusters of type 2 diabetes,Metabolomics and genetic profile related to diabetes,,2022-03-08,RECRUITING,OBSERVATIONAL,['NA']
8590,NCT02299388,Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors.,"Change in Pulse Pressure, Mean Arterial, Diastolic and Nocturnal Blood Pressures.",Change in Urinary Sodium Excretion,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8591,NCT01753024,Screening and risk factors of exocrine pancreatic insufficiency in critically ill adult patients receiving enteral nutrition,Effects of pancreatic enzyme supplementation on nutritional status and clinical outcomes in critically ill patients with sepsis,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
8592,NCT03906786,Adherence to self-care behaviors. The Diabetes Self-Care Inventory-Revised,,,2019-03-07,UNKNOWN,INTERVENTIONAL,['NA']
8593,NCT00423501,Absolute change from baseline in HbAlc,"AEs, laboratory parameters, primary pharmacokinetic parameters",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8594,NCT05135676,Co-primary Outcome: CGM-measured percent time <54 mg/dL (non-inferiority),CGM Metrics by nighttime only (00:00 AM to 06:00 AM),Glucose Variability,2022-05-10,COMPLETED,INTERVENTIONAL,['NA']
8595,NCT05473286,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2022-09-30,WITHDRAWN,OBSERVATIONAL,['NA']
8596,NCT04141878,Change in DDPP Neuropsychological Test Battery,Change in Glycated Hemoglobin (Hemoglobin A1C),,2021-05-26,RECRUITING,INTERVENTIONAL,['NA']
8597,NCT00787839,"Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict Findings With the Oral Glucose Tolerance Test (in the Morning, After an Overnight Fast)",Cost to Identify a Single Case of High-risk Dysglycemia or Previously Unrecognized Diabetes,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
8598,NCT00379379,"Hypoglycemic activity, plasma insulin level, HOMA index","Triglyceride, cholesterol, free fatty acid",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
8599,NCT02659748,Insulin sensitivity,Bacterial microbiota,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
8600,NCT03412006,Change in urinary albumin to creatinine ratio (UACR),Number of patients with serious adverse events,,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8601,NCT06132477,Effect of GLP1-RA on Glycemic control,,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
8602,NCT03934944,Change in foot care behaviour as measured by the SDSCA,Proportion of participants who developed a new diabetic foot ulcer,,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA']
8603,NCT04910321,Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L,Change of body mass index,,2020-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8604,NCT05994937,Percent Change in Concentration of Tumor Necrosis Factor-alpha (TNFα) Biomarkers,,,2023-12-26,RECRUITING,INTERVENTIONAL,['NA']
8605,NCT05198284,Referrals,,,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
8606,NCT02299479,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline.,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline in Subjects With Activity Effect.,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
8607,NCT00935051,"MMP-1/TIMP-1 ratio at Week 0 assessed by ELISA and percent change in wound area of diabetic foot ulcer between week 0, week 4 and week 12","Correlation between MMP9, MMP13, MMP9/TIMP1 and MMP13/ TIMP1 ratios and wound healing expressed by the percent change in wound area between week 0, week 4 and week 12.",,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8608,NCT00564551,Weight loss,Inflammatory Markers,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
8609,NCT00206401,HbA1C,Glucose excursions,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8610,NCT05854797,Body Mass Index,,,2022-10-28,COMPLETED,INTERVENTIONAL,['NA']
8611,NCT03832933,Change in body weight by weight scale,Change in % FFM,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
8612,NCT02053272,Change from baseline to the end of treatment in mean glycosylated haemoglobin A1c (HbA1c) level.,Change from baseline to the end of study in mean Cannabis Withdrawal Scale (CWS) total score.,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8613,NCT00797186,change in microvascular perfusion,,,2008-11,UNKNOWN,INTERVENTIONAL,['NA']
8614,NCT03174548,Area under curve (AUC) of sotagliflozin,Number (%) of subjects with treatment emergent adverse events,,2017-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8615,NCT02027753,Response rate (percentage of patients who meet the target HbA1c ≤7%) at week 24 (6 months) after adding insulin therapy,Number of Patients with Adverse Events,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8616,NCT04461821,Change in Concentration of exhaled metabolites of pharmacotherapy,"Change in clinical endpoint (blood pressure, mmHg) for correlation between clinical endpoint and the abundance of exhaled metabolites",,2020-09-11,RECRUITING,OBSERVATIONAL,['NA']
8617,NCT04837989,Social Comparison Scale,Brief Illness Perception Questionnaire,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA']
8618,NCT03403686,Assessing CD34+ cells function,,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA']
8619,NCT03866005,Required number of anti-VEGF injections,Need for adjunctive laser photocoagulation and/or use of intravitreal steroids,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8620,NCT00093015,Time to All-cause Mortality or End Stage Renal Disease (ESRD),Time to Hospitalization Due to Acute Myocardial Ischemia,,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8621,NCT00312130,Change from baseline in acute insulin response to an iv glucose load at 6 weeks,Change from baseline in acute insulin response to an iv glucose load at 8 weeks,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8622,NCT04351945,Endocrine changes and their correction in heart and lung tranplant donors,Evidence of clinically definite postoperative complications,,2020-05-20,UNKNOWN,OBSERVATIONAL,['NA']
8623,NCT05148390,"Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')",Incidence of device disintegration (removability in one piece),,2022-04-24,COMPLETED,OBSERVATIONAL,['NA']
8624,NCT02235935,OCT results,Visual Acuity,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
8625,NCT03640988,"Skin perfusion, effect on oxygenation level, by visit","Wound healing, effect on wound closure, by visit",,2019-04-25,TERMINATED,INTERVENTIONAL,['NA']
8626,NCT02420470,"Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations, and the changes in relationships and biomarkers at 2.5 years.",Lifestyle and its changes at 2.5 years,,2015-04,RECRUITING,OBSERVATIONAL,['NA']
8627,NCT01751932,Mean Absolute Relative Difference (MARD),Accuracy of sensors per glycemic range and trial phase,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8628,NCT02164266,Incidence of adverse events (AEs),Fasting serum insulin (Part 2 only),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8629,NCT04699734,Indication of pain relieved extremity,Distribution of evoked pain,,2020-09-08,RECRUITING,INTERVENTIONAL,['NA']
8630,NCT03811548,Change in HbA1c From Baseline to Week 24,Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),Population pharmacokinetics assessment,2019-05-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
8631,NCT00428961,,,,2002-07,COMPLETED,OBSERVATIONAL,['NA']
8632,NCT04289753,Diabetes Overtreatment in the Elderly,Rate of Hypoglycemia Requiring Urgent Care Among Previously Tightly Controlled,Diabetes Overtreatment in the Elderly by Ethnicity,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
8633,NCT01523405,Diabetic Quality of Life using Modified 15 item DQoL (MDQoL) questionnaire,Disease modifying variables Body Mass Index (BMI) and Blood Pressure (BP),,2012-03,COMPLETED,OBSERVATIONAL,['NA']
8634,NCT05032001,Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve,,Change from baseline in A1c level at week twelve,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8635,NCT01387984,,,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
8636,NCT00694057,To evaluate the safety and tolerance of HE3286 10 mg per day (5 mg BID) compared to placebo from baseline to week 12.,To evaluate the effect of HE3286 on insulin sensitivity over time.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8637,NCT01311401,New incidences of Type II Diabetes Mellitus in Circassians minority in Israel,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
8638,NCT00789750,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8639,NCT00282659,"Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose",,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8640,NCT01099865,,,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
8641,NCT02010528,parental diabetes-related distress,psychosocial characteristics,objective measures,2013-12,COMPLETED,OBSERVATIONAL,['NA']
8642,NCT01044537,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf),Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8643,NCT02438943,Proportion of persons attending health centers in the Southeast Health region with normal lipid values,Proportion of persons attending health centers in the Southeast Health region with normal blood pressure values,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
8644,NCT04773834,Body Mass Index (BMI) (kg/m2),dDPP platform meal log (food item and calories/day),,2021-02-01,RECRUITING,INTERVENTIONAL,['NA']
8645,NCT00422058,Mean Change From Baseline in Body Weight at Week 20,Change From Baseline in Blood Pressure at Week 104,,2007-01-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8646,NCT05717205,mucosal nerve length density (MNLD),Immunohistochemical differences,,2023-02-16,RECRUITING,INTERVENTIONAL,['NA']
8647,NCT05752279,Hospital free days (HFD) up to day-28 after study enrolment,Cumulative potassium replacement,Cost-effectiveness,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8648,NCT04736225,HbA1C,self-care behavior,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
8649,NCT04585204,the difference of GDM detection rate of 50 gr- 100 gr OGTT and 75 gr OGTT,,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
8650,NCT02199028,Duration of Insulin Infusion Set Wear as a Measure of the Effect of Hyaluronidase Treatment,Pain Tolerability of Hyaluronidase Injections,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8651,NCT06127251,Retention Rate in each group,Changes in T2D risk score,Change in the Outcome Expectations for Exercise Scale questionnaires.,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8652,NCT04215523,"Composite outcome of Stroke, MI, and Mortality",,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
8653,NCT02752880,The Percentage Change in HbA1c Level From Baseline to 12 Weeks,The Percentage Change in 2hPG From Baseline to Week 12,,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8654,NCT05324930,Change in DFU size,Complete wound healing,,2021-12-02,COMPLETED,INTERVENTIONAL,['NA']
8655,NCT05278143,Severe hyperglycaemic events detection,Time in severe hyperglycaemia,,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA']
8656,NCT04040634,"Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure",Time to All-Cause Probable Dementia,,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8657,NCT00955669,Magnetic resonance angiography,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8658,NCT06268808,HbA1c,Frequency of hypoglycaemia events,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8659,NCT03736785,Change From Baseline in HbA1c,Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8660,NCT00741429,Change in FEV1 (L) from Baseline Visit in Parent Trial to Visit 2 of MKC-TI-126,Change in Hemoglobin Corrected DLco (mL/min/mmHg) from Final Assessment of Treatment Phase in Parent Trial to Visit 2 of MKC-TI-126,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8661,NCT05789706,Change from pre-intervention baseline in hemoblobin A1c,Change in Medication Adherence Score from baseline,,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
8662,NCT03158415,Lived experience,Diabetes Distress,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
8663,NCT04081766,Frequency of total episodes of hypoglycaemia,Time to the first hypoglycaemic attack,,2020-02-09,COMPLETED,INTERVENTIONAL,['NA']
8664,NCT03047486,Glucose Time below range (hypoglycemia < 70 mg/dl) from CGM recording,HbA1c,Medical time at each consultation,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
8665,NCT05717491,Fasting glucose value according to the level of precariousness,Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposures,,2021-12-14,RECRUITING,OBSERVATIONAL,['NA']
8666,NCT03294369,Prevalence of cardiovascular disease,,,2011-04-01,UNKNOWN,OBSERVATIONAL,['NA']
8667,NCT03986073,Glycosylated hemoglobin (HbA1c),GLP-1 (glucagon-like peptide-1),,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8668,NCT03234491,PostPrandial Blood Glucose,Venous Glucose Levels,,2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8669,NCT03423355,Change in blood EPO levels,Change of diastolic function parameters,,2021-09,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8670,NCT00258804,"Patient satisfaction before, during and after Ramadan.",,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8671,NCT01270542,"The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction Retinal Detachment Due to PDR",Improvement of Visual Outcomes in Patients Given Pre-operative Adjunctive Bevacizumab in Eyes Undergoing PDR Surgery.,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
8672,NCT01945996,Acceptability 2: Would Patients Recommend the Program to Family or Friends?,Change in Summary of Diabetes Self-care Activities - Carb Spacing Sub Score,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8673,NCT02468037,Improvement in glucose area under the curve.,Improvement in insulin secretory capacity,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
8674,NCT05145465,Waist size (cm),,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
8675,NCT03666923,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8676,NCT03723759,"AUCIAsp,0h-t - Area under the serum insulin aspart concentration-time curve from 0 to t hours after investigational medicinal product (IMP) administration, where t is end of exposure",Number of hypoglycaemic episodes in the treatment emergent period,,2018-10-26,COMPLETED,INTERVENTIONAL,['PHASE1']
8677,NCT02971202,Whole-body Glucose Utilization (Rd),Adipose Tissue Insulin Sensitivity,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8678,NCT02745808,Safety and Tolerability assessed by Adverse Events,Improvement in penile colour Doppler ultrasonography,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
8679,NCT05979584,4-week wound healing rate,Infection evaluation,,2023-11-15,RECRUITING,INTERVENTIONAL,['NA']
8680,NCT00976326,Area under the NN1250 concentration-time curve after single-dose,Number of adverse events,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8681,NCT06319716,Hemoglobin A1c (HbA1c) Levels,International Physical Activity Questionnaire (IPAQ) Short-Version Score,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8682,NCT03983187,the standard deviation of blood glucose,time in range,,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA']
8683,NCT00407849,Safety of intravitreal triamcinolone acetonide after 12 months of treatment.,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8684,NCT01743963,Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).,Feasibility/Reach/Adoption,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
8685,NCT03217630,Prevalence of full stomach,Mean gastric emptying time of clear liquid and light meal,Risk factors of delayed stomach empty in diabetic patients,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
8686,NCT05591690,Time spent with glucose levels above range,,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
8687,NCT01087242,glycosylated hemoglobin,"fasting blood glucose,2-hour postprandial blood glucose,true insulin,TG,TG、LCL-C、HDL-C、BMI,waistline, hipline,TCM syndrome and sign",,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
8688,NCT06025513,Standard pharmacokinetics/pharmacodynamics (PK/PD) endpoints as applicable after injection of a rapid-acting mealtime insulin,,,2024-02-16,RECRUITING,INTERVENTIONAL,['NA']
8689,NCT01648985,"Number of Stroke (fatal, non-fatal)",Number of patients with Diabetes,Number of patients with Small Vessel Disease SVD,2010-05,COMPLETED,OBSERVATIONAL,['NA']
8690,NCT03687580,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
8691,NCT03740581,Number of participants with complete wound closure (epithelialisation) at 12 weeks in both intensive and conventional treatment groups.,Incidence of any amputation.,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8692,NCT05835037,Zinc-dependent effect on HbA1c at 1 year,Zinc-dependent effect on HbA1c at 6 months,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
8693,NCT00576784,The proportion of patients with an increase in HbA1c by 0.5 % after 6 months of treatment compared to baseline HbA1c value,Absolute change of HbA1c Insulin resistance according to minimal model and HOMA-S analysis change of insulin resistance according to minimal model and HOMA-S analysis to baseline first phase insulin response,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8694,NCT05715307,Glycated haemoglobin (HbA1c) control rate,Number of participants with abnormal Renal function,,2023-02-09,RECRUITING,INTERVENTIONAL,['NA']
8695,NCT02059174,M1 Glargine Metabolite PK: Maximum Plasma Concentration (Cmax),M1 Glargine Metabolite PK: Area Under the Plasma Concentration Versus Time Curve Over the Second 12 Hours After Dosing (AUC12-24),,2014-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8696,NCT03242018,Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With Hypoglycemic Events,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
8697,NCT04684420,Maximum Observed Plasma Concentration (Cmax) of Metformin,Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin,,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8698,NCT04577183,Number of Participants With Reduction in Wound Size,,,2018-07-11,COMPLETED,INTERVENTIONAL,['NA']
8699,NCT04827615,Body weight,,,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8700,NCT01772914,Changes in copeptin levels after intake of a oral glucose tolerance test- and a mixed meal tolerance test liquid,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
8701,NCT01272804,Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14,Change From Baseline in Lactate Level at Day 6 and 14,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8702,NCT00926133,The prevalence of abnormal glucose regulation defined by an oral glucose tolerance test (OGTT).,Study the relationship between abnormal glucose regulation and prognosis after STEMI.,,2005-11,UNKNOWN,OBSERVATIONAL,['NA']
8703,NCT05142020,Significantly different proteins at 32-34 gestational weeks,,,2022-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8704,NCT02754219,Pharmacokinetic(Cmax of Evogliptin),,,2016-09-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8705,NCT04998461,Comparison of gene expression in USC (Urinary Stem Cells),,,2021-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8706,NCT01474083,Pharmacokinetic parameters of GK1-399 from plasma concentrations,Pharmacodynamic parameters of plasma glucose,,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8707,NCT00545870,To investigate the change in macular edema and the absolute change in visual acuity. To investigate the change of neovascularisation.,,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8708,NCT04014413,The efficacy of FMT in treating dysbiosis-associated disorder will be assessed by number of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome),Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,Any improvement or deterioration or recurrence of the underlying condition by clinical judgement of doctors,2019-07-15,RECRUITING,INTERVENTIONAL,['NA']
8709,NCT03458715,Glycated hemoglobin (HbA1c),Hypoglycemia event,,2017-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4']
8710,NCT01128621,Number of Participants With Relationship Between GSK1292263 Drug Exposures and Pharmacodynamic Parameters (Part B),,,2009-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
8711,NCT00377117,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
8712,NCT03230123,Percent reduction in glycated hemoglobin,Percent increase in GLP-1,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
8713,NCT05810311,Change in kidney oxygenation levels,Change in urinary reactive oxygen species (ROS),,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8714,NCT00739323,,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
8715,NCT04972955,New diagnosis of maternal diabetes or prediabetes based on 75g OGTT,Cost component analysis of CGM vs. 75g OGTT,,2023-07-04,RECRUITING,OBSERVATIONAL,['NA']
8716,NCT03504592,Completeness and accuracy of blood glucose record,Unscheduled health care access episodes,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
8717,NCT01821079,Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf),Plasma Decay Half-Life (t1/2),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8718,NCT05742243,Beta-cell function at 48 weeks,Adverse events,,2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2']
8719,NCT01464099,Maximum plasma concentration (Cmax) of insulin aspart,AUC (area under the curve) of insulin aspart,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8720,NCT04235504,HbA1c 6 Months Change Between AHCL and MDI,Hypoglycemic Events,HbA1c 12 Months Change Between Groups,2020-07-13,COMPLETED,INTERVENTIONAL,['NA']
8721,NCT01236846,serum 25-hydroxyvitamin D,Blood pressure,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
8722,NCT02033239,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8723,NCT02324569,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) That Occurred Before Start of Treatment Period II,Change From Baseline in Self-Monitoring of Blood Glucose Before Breakfast,,2014-12-27,COMPLETED,INTERVENTIONAL,['PHASE3']
8724,NCT05293340,"Time in range (TIR) between 140 and 180 mg/dL [TIR (140-180)]- Change from Prior to Intervention, to Final Two Weeks of Intervention",Regression analysis between average composite acceptability score on the weekly Avocado Acceptability Questionnaire and motives underlying the selection of food assessed by the Food Choice Questionnaire (FCQ),,2022-03-31,TERMINATED,INTERVENTIONAL,['NA']
8725,NCT02229110,The number of participants with change in allocation of care after intervention,Number of participants who meet their treatment goals,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
8726,NCT04219514,"Risk scores for severe hypoglycemia, non-severe daytime hypoglycemia, non-severe nighttime hypoglycemia",Exploratory causal estimates of different treatment regimens and hypoglycemia rates,,2020-02-10,COMPLETED,OBSERVATIONAL,['NA']
8727,NCT01614327,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs with and without the assistance of the RiskAnalyzer.,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs and the RiskAnalyzer,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8728,NCT00850824,glycosolated hemoglobin (HbA1c) levels,keeping specialty referral for medical exams,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
8729,NCT02647320,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Count of Participants With HbA1c Less Than 7.0% at Week 12,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8730,NCT03037528,Glycemic Control,Depressive Symptoms,,2017-01-27,COMPLETED,INTERVENTIONAL,['NA']
8731,NCT01035528,change from baseline to endpoint in myocardial diastolic velocity E',glucose control,,2005-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
8732,NCT00835757,The difference in means between DTI parameters (FA and MD) measured in the sural nerve between subjects with DPN and healthy control subjects.,The association between DTI parameters and clinical and electrophysiological measures of DPN,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
8733,NCT00316082,Change From Baseline in Hemoglobin A1 (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8734,NCT05884775,Change in Hemoglobin A1C (HbA1c),Total Number of Reports Viewed by Patients via PRO Interactive Dashboard,,2025-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8735,NCT02964247,Change in HbA1c,Subjects Who Achieve Weight Loss by 3% or More,,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8736,NCT04756141,Mean Absolute Relative Difference (MARD),Continuous Glucose Monitor (CGM) Calibrations,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA']
8737,NCT02915029,Patient Activation Measure (PAM) Level Greater Than 2,8-Item Morisky Score,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
8738,NCT01781013,Change from baseline in depression outcome at 6-months,Change from baseline in diabetes self-care score in 6 months,Change from baseline to 6 months in percentage of patients satisfied with care received for depression,2010-06,COMPLETED,INTERVENTIONAL,['NA']
8739,NCT01870297,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8740,NCT01205308,non-cholesterol sterols,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
8741,NCT01426802,Evaluate the safety and tolerability of vildagliptin 50 mg bid,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8742,NCT04956263,Concentration-time curve in plasma glucose (AUC(0-120min) ),Objectives for Insulin Requirements,,2021-06-17,COMPLETED,INTERVENTIONAL,['PHASE2']
8743,NCT05867017,Measure of free plasma glucose (FPG),Body Weight,,2023-07-10,RECRUITING,OBSERVATIONAL,['NA']
8744,NCT03061461,Wound size,Satisfaction,,2017-02-23,UNKNOWN,INTERVENTIONAL,['NA']
8745,NCT00437112,"Compare, in insulin-naive patients with type 2 diabetes on one or more oral antihyperglycemic medications, a regimen adding mealtime HIIP versus a regimen adding insulin glargine with respect to change in HbA1c from baseline to endpoint.",Patient reported outcome of Experience with Insulin Therapy Questionnaire,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8746,NCT04620590,Change in 24-hr sodium excretion,,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
8747,NCT00159211,Abdominal adipose tissue (on scan) variation at 6 month,inflammation gene expression in sub-cutaneous fat,,2005-05,TERMINATED,INTERVENTIONAL,['NA']
8748,NCT04630691,No difference,,,2012-12-01,COMPLETED,OBSERVATIONAL,['NA']
8749,NCT00600067,HbA1c Change From Baseline Week 0 to Week 56,Percent Weight Loss From Baseline to Week 56,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8750,NCT00990444,Identification of the lowest dose of oral insulin in dextran matrix that produces a significant lowering of post-prandial blood glucose.,To establish the dose(s) when administered in a multi-dose fashion that lowers plasma glucose levels versus placebo in patients with Type 2 diabetes,,2009-09,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8751,NCT05050500,The rate of heart failure occurrence,,,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE4']
8752,NCT02239458,Oral Disposition Index,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
8753,NCT00817505,"Pharmacokinetic variables ( Area under the plasma concentration vs. time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), terminal elimination half-life (t½) and apparent oral clearance (CL/F)","Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8754,NCT00558935,measurements of dyslipidemia,lipid functionality,,2007-10,TERMINATED,INTERVENTIONAL,['NA']
8755,NCT00652405,Pancreatic Polypeptide (PP),Cytokines excreted from PBMCs after in vitro stimulation with LPS,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
8756,NCT00248157,long-term safety and tolerability,monitor long-term efficacy,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3']
8757,NCT05678543,Offspring birthweight,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
8758,NCT03535935,Change in spot urine albumin-to-creatinine ratio,Change in lipids,Change in biomarkers related to inflammation and fibrosis,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8759,NCT01551667,Humoral immune response,Presence / absence of clonal complexes of the S. aureus strains,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
8760,NCT05089890,Bacterial and fungal species irreversibly bound to the dressing after 2 days (+ 1 day).,Wound fluid inflammatory biomarker levels at 14 days (±1 days) compared to baseline,,2021-10,UNKNOWN,INTERVENTIONAL,['NA']
8761,NCT06272695,Change in Time to glucagon treatment success at Week 6.,Change from baseline in hemoglobin A1c (HbA1c) at Week 6.,,2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE1']
8762,NCT00128089,Diabetes medication reduction,Patient satisfaction,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1']
8763,NCT01226043,Patient Overall Preference,Percentage of Patients Who Discontinued Investigational Product During the Observational Phase,Number of Patients With Hypoglycemic Events,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8764,NCT03149770,Change in Epinephrine Levels,,,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
8765,NCT00842894,Incidence of serious adverse drug reactions (SADRs),Change in body weight,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
8766,NCT03410173,Changes of cognitive function assessed by cognitive function scale after 12 weeks.,Fasting serum insulin.,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
8767,NCT02222376,Ulcer size,,Healing time,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8768,NCT02953977,Change from baseline weight,Changes in Stages of Change for healthy eating and physical activity,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
8769,NCT00196235,,,,1995-01,COMPLETED,OBSERVATIONAL,['NA']
8770,NCT04221360,AUClast of D390 and CKD-375,CL/F of D390 and CKD-375,,2020-01-29,UNKNOWN,INTERVENTIONAL,['PHASE1']
8771,NCT02685475,Sensory block duration,Rescue analgesic consumption,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
8772,NCT03314246,Change in HbA1c,Change in diabetes treatment satisfaction,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
8773,NCT06211556,Difference in change in FGF21 incremental area-under-the-curve,Difference in change in fasting plasma alanine aminotransferase,Difference in change in lipid parameters,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8774,NCT00446472,Completely healed wounds,,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
8775,NCT01823341,"Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period.",Percent of Mornings With Urine Ketones >/= 15 mg/dl,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8776,NCT04914910,Difference between treatment groups in change in TIR (3.9-10.0 mmol/l) from baseline to Week 14,Total daily carbohydrate intake,Difference in number of severe hypoglycaemia events (cognitive impairment requiring external assistance for recovery).,2021-06-08,COMPLETED,INTERVENTIONAL,['NA']
8777,NCT04016974,"AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state",Number of treatment-emergent hypoglycaemic episodes,,2019-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8778,NCT05498116,Change in Albuminuria,Change in Large Elastic Artery Stiffness,,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8779,NCT00463502,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
8780,NCT01201109,Patient self-reported outcome questionnaire,Nerve conduction study and vibrotactile sense,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
8781,NCT00676923,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8782,NCT04738032,Diabetes self-management behaviors,,,2020-08-26,COMPLETED,OBSERVATIONAL,['NA']
8783,NCT05786612,Percentage wound area reduction during the investigational test period of four weeks,Total treatment costs during the investigational test period based on the number of dressings used during the investigation and the unit price of the products,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
8784,NCT05583045,HbA1c,Creatinine,,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8785,NCT03259724,HbA1c,HOMA-IR,,2017-01-30,UNKNOWN,OBSERVATIONAL,['NA']
8786,NCT01406665,oGTT (WHO criteria)-defined impaired glucose tolerance or diabetes,Findrisk diabetes questionnaire score,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
8787,NCT00371982,"adiposity (total fat mass, adipocyte morphology), atherogenic markers and insulin sensitivity",and the impact of fish oil on systemic inflammatory markers and adipose tissue inflammatory genes.,,2002-12,TERMINATED,INTERVENTIONAL,['NA']
8788,NCT04982380,Glycosylated albumin,Serum lipid spectrum,,2021-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
8789,NCT04300205,Altered pain experience associated with chronic wounds,,,2020-02-25,COMPLETED,INTERVENTIONAL,['NA']
8790,NCT05449821,Asprosin Levels,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
8791,NCT01301833,Number of Participants With Adverse Events,Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8792,NCT04382794,Death,Clinical parameter of acute lung disease,,2020-05-14,COMPLETED,OBSERVATIONAL,['NA']
8793,NCT05158478,repeatability precision,,,2022-02-22,COMPLETED,INTERVENTIONAL,['NA']
8794,NCT04016558,Hemoglobin A1c (HbA1c),Self-compassion - Diabetes (SCS-D),,2019-09-15,COMPLETED,INTERVENTIONAL,['NA']
8795,NCT05439473,Effect of treatment with Curalin on the change in plasma HbA1c,Safety of Curalin as assessed by adverse events,,2021-08-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8796,NCT02372149,Change in Overall Neuropathy Limitations Score (ONLS) after 3 months,Adverse Events,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
8797,NCT04887688,Laser Speckle imaging,Wound swabs,,2022-10-05,RECRUITING,INTERVENTIONAL,['NA']
8798,NCT00071409,"assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs",,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8799,NCT00735501,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8800,NCT05710900,Type 2 diabetes remission,"Feedback of the intervention with participants, RDs and pharmacists",,2023-07-15,RECRUITING,INTERVENTIONAL,['NA']
8801,NCT00641407,Change in hemoglobin A1c (HbA1c) level from baseline to end point for each treatment group.,"Percentage of subjects achieving HbA1c ≤7%, incidence of self-reported hypoglycaemic episodes, comparison of SMPG values from 8-point profiles, insulin doses, and body weight.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8802,NCT02620553,Evaluation of Blood Glucose Levels,T-cell responses related to potential immune response to Insulin,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8803,NCT00998881,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8804,NCT02367534,hemorrhage,C-peptide,,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8805,NCT05855980,Wound healed,Functional outcome: FHSQ,,2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
8806,NCT02433678,Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use,Changes in Expression of Inflammatory Mediators,Change in Hypertension Mediators,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8807,NCT03165227,Percentage of patients with drug related Adverse Events (AEs),Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in 10-hour urine,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8808,NCT00957762,"To compare different methods of body composition analyses with the gold standard 4-compartment monitoring to determine accuracy and validity of those alternative, but less labor-intensive techniques.",To cross-validate the derived regression equations against the gold standard 4-compartment model in an independent group of persons with SCI.,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
8809,NCT01511393,"Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.","Environmental exposures (occupational history, radioiodine exposure, nuclear fallout)",,2012-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8810,NCT00520182,"Triglyceride level, glycated hemoglobin level, fasting plasma glucose","Weight, BMI, waist hip circumference, insulin resistance using HOMA (fasting glucose to fasting insulin ration), HDL-Cholesterol level.",,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8811,NCT00328172,Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12,Percentage of Patients With Absolute Efficacy Response (HbA1c <= 7.0%) at 12 Weeks,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8812,NCT05783115,visual analogue scale,skin temperature,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
8813,NCT02671968,"Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events",,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
8814,NCT04323189,Dipeptidyl peptidase 4 (DPP4),Mean heart rate,,2020-08-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8815,NCT04449198,Skeletal Muscle Mitochondrial Function,Change in Post Occlusive Reactive Hyperemia (PORH),,2020-10-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8816,NCT00797069,To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.,To compare the postprandial insulinemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8817,NCT02116426,Final diagnosis of ACS non ST + (yes/no),Number of patients taken in charge that day by ambulance staff.,,2015-07-29,COMPLETED,OBSERVATIONAL,['NA']
8818,NCT02315274,Glucose variability,Changes is severe hypoglycemia,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
8819,NCT02034695,The proportion of patients who have achieved a HbA1c level <7%.,"Service utilization outcomes measured by GOPC consultation, SOPC consultation, A&E and hospital attendance rates in the past 12 months.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
8820,NCT02104739,Monocyte NfkB Levels as Detected by Western Blotting,Peak Forearm Blood Flow,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8821,NCT04332003,Time to complete wound closure.,Change in oxygenation at the wound site,,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
8822,NCT05885906,Change in unstimulated Salivary flow rate,,,2023-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8823,NCT05897528,Hospital Mortality,,,2021-10-14,COMPLETED,OBSERVATIONAL,['NA']
8824,NCT05936242,Postprandial glucose response,,,2021-05-18,RECRUITING,OBSERVATIONAL,['NA']
8825,NCT06335771,Macrophage isolation in skeletal muscle tissue,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8826,NCT00063583,The primary endpoint will be the change in renal function from baseline to the end of the study period (12 months).,• Determine the relationship between % change in TGF-b1 levels and the change in GFR,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8827,NCT00881530,"Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements",Change From Baseline in Fasting Plasma Glucose (FPG) Over Time,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8828,NCT01303055,beta cell function evaluated from 75 g OGTT,"1,5-AG level",,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
8829,NCT02139943,Percentage of Participants With Adverse Events,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8830,NCT01926925,Plasma levels of markers of endothelial activation and vascular inflammation,,,2001-05,COMPLETED,OBSERVATIONAL,['NA']
8831,NCT04893135,RANKL/OPG level,Sudoscan measurement,,2021-10-11,COMPLETED,INTERVENTIONAL,['NA']
8832,NCT05351359,step count,body mass index,,2022-04-25,RECRUITING,INTERVENTIONAL,['NA']
8833,NCT00137046,Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco),Insulin Antibodies,,2002-05,TERMINATED,INTERVENTIONAL,['PHASE3']
8834,NCT01298882,Total insulin secretion concentration,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
8835,NCT00481598,"glycogen metabolism, gluconeogenesis, after 3 months of treatment;",,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
8836,NCT00065377,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8837,NCT00559767,,,,2006-06-30,COMPLETED,OBSERVATIONAL,['NA']
8838,NCT05486065,Change in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Severe Hypoglycaemic Episodes,,2022-08-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8839,NCT02999945,Fat Free Mass,macronutrients in breastmilk-protein,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
8840,NCT02082704,HbA1c levels,Patient's perceptions of the optimal parameters for the SE game intervention.,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
8841,NCT01514149,Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18,Time to Hyperglycemia Rescue,,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2']
8842,NCT05806554,Accuracy,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
8843,NCT01386645,Disposition Index,Glycemic Variability,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
8844,NCT02716623,Participant compliance with study specific CR diet,Presence of Tumor M2-PK,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8845,NCT01844037,Change in office systolic blood pressure (SBP) from baseline to 6 months,Change in office SBP,,2014-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8846,NCT06214520,HbA1c,Usability of the Empower+ app and Motivational Interviewing module,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8847,NCT02383940,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline in Number of Hypoglycemic Events/Day (<=70 mg/dL) by Self-Monitored Blood Glucose (SMBG) at Week 12,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8848,NCT00506961,The percentage of patients achieving the combined treatment goal of LDL-C < 100mg/dl and non-HDL-C < 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment,Percentage of patients achieving the LDL-C goal of <70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8849,NCT02147431,Change in mean glucagon concentration during hypoglycaemia (change from target level 5.5 mmol/L to nadir (target 2.5 mmol/L)),Time from termination of insulin infusion at nadir to reach plasma glucose level 4.0 mmol/L,,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
8850,NCT00967837,To measure progress of wound healing in subjects that have failed conventional wound care healing treatments for 60 days,,,2006-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8851,NCT04564586,Inactivity,Hemoglobin A1c,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8852,NCT02762370,Change From Baseline for Average Blood Glucose (mg/dL),Area Under the Effect (AUE) Curves for Average Blood Glucose - FX006 Versus TCA IR,Change in Average Blood Glucose From Baseline (Hour -48 to Hour -1) to Hour 1 to Hour 48 for FX006 32 mg Relative to TCA IR 40 mg.,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8853,NCT02073058,Clinical point accuracy as assessed by the Consensus Error Grid,"Composite measure: Clinical point accuracy (Clarke Error Grid), trend accuracy (R-deviation, Rate Error Grid and Continuous Glucose Error Grid) and lag time, performance of notifications (sensitivity and false notifications) and questionnaire responses.",,2014-02,COMPLETED,OBSERVATIONAL,['NA']
8854,NCT05282264,Acceptability of hybrid closed-loop systems,Hypoglycemia Fear,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA']
8855,NCT00519935,Metabolic Control: Hemoglobin A1c (HbA1c),Quality of life,,2001-07,COMPLETED,INTERVENTIONAL,['NA']
8856,NCT04026139,3-m timed up and go test [TUG],,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8857,NCT05033054,Change in serum klotho levels at 12 week,Change in serum magnesium levels at 12 weeks,,2022-11-20,RECRUITING,OBSERVATIONAL,['NA']
8858,NCT04807959,Reduction of Visceral Adiposity,Increase of Intracellular Fluid,,2016-10-27,COMPLETED,OBSERVATIONAL,['NA']
8859,NCT02488252,Change in spot urine albumin-to-creatinine ratio,Rate of CKD stage transition,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8860,NCT06318429,blood sugar,,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8861,NCT05487833,%triglyceride reduction,incidence of hypoglycemia,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
8862,NCT04313920,Plasma Glucose Concentration,Gastric Emptying,,2020-04-07,COMPLETED,INTERVENTIONAL,['NA']
8863,NCT02504658,Total Self-Efficacy Score on the Physical Activity and Healthy Food Efficacy Scale for Children,"Number of text message responses to Goal Setting Question, as a measure of Adherence",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8864,NCT05092399,Effects of VLCD,Effects of VLCD and bariatric surgery,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
8865,NCT00574340,Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2,,,2007-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8866,NCT05232812,Radiation exposure of 3-[11C]-OHB,,,2022-06-01,COMPLETED,INTERVENTIONAL,['NA']
8867,NCT01718093,To determine the glucose lowering effect of metformin and sitagliptin alone and as combination therapy when used as adjuncts to insulin in adolescents with T1DM.,,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8868,NCT02399826,Proportion of ulcers completely healed by amniotic memrane versus standard care,Proportion of ulcers healed by amniotic membrane versus standard care,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
8869,NCT01745549,hematic fructosamine levels,patient's satisfaction,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
8870,NCT00988377,Blood glucose subjective appetite Food intake at 30 min,physical comfort palatability,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
8871,NCT01704378,Occurrence of adverse events,7-point blood glucose profile,,2001-04-18,COMPLETED,INTERVENTIONAL,['PHASE4']
8872,NCT04745702,Oral Glucose Tolerance Test,TNF (Tumor Necrosis Factor - alpha),,2020-11-02,UNKNOWN,INTERVENTIONAL,['NA']
8873,NCT02176681,Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM,Mean HbA1C and Glycated albumin,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8874,NCT00729365,"Development of Microalbuminuria (High Urine Albumin). Hypertension, Urine and Blood Markers Will Also be Evaluated for Assessment of Kidney Disease State.",We Will Assess Changes in the Relative Stiffness of Your Arteries (Endothelial Dysfunction) in Persons With Type 1 Diabetes Over the 5year Study.,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8875,NCT00665093,HbA1c,"FPG, PG profile, weight, % of subjects on target",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8876,NCT02093221,Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC),Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime,,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8877,NCT02265809,"Change from baseline of CD4 T regulatory cells, CD4 T effector cells and CD25 expression on T regulatory cells during treatment with ultra low dose IL-2",Safety and tolerability,Recruitment analysis,2014-10-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8878,NCT05465616,Insulin Resistance,Fasting glucose,,2022-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8879,NCT02925312,Percentage Change in Hemoglobin A1C From Baseline to 3 Months,Frequency of Eye Exams,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8880,NCT02862730,Percent of Time With Sensed Glucose Between 3.9-10 mmol/L,Mean Amount of Glucagon Delivered,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
8881,NCT01154881,Area under the glucose infusion rate curve from 0-24 hours at steady state,Area under the insulin degludec concentration-time curve from 0-24 hours at steady state,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8882,NCT00068887,,,,1999-09,WITHDRAWN,OBSERVATIONAL,['NA']
8883,NCT03411213,Can diffuse optical tomography detect microvascular function?,Predicting coronary artery disease before angiography,,2016-01-11,COMPLETED,INTERVENTIONAL,['NA']
8884,NCT02082028,Change in HbA1c levels from baseline,Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS),,2012-06-27,COMPLETED,INTERVENTIONAL,['NA']
8885,NCT03414723,Assessment of PK parameter: AUCtau,Adverse events,,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
8886,NCT05417152,Scanning session completion status,,,2022-06-29,COMPLETED,OBSERVATIONAL,['NA']
8887,NCT01511861,,,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
8888,NCT00937703,Comparison HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group.,"Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8889,NCT02524782,Part B: Change in LDL-C from baseline to Day 36,"Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)",,2015-10-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8890,NCT02577159,Changes in fasting lipoprotein profiles,Changes in biomarkers for renal and hepatic function,,2015-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8891,NCT05890690,Difference in maximal increase in copeptin levels in plasma (pmol/l),,,2023-06-02,RECRUITING,INTERVENTIONAL,['NA']
8892,NCT00437554,Efficacy : Change in HbA1c between baseline and endpoint,"Safety: episodes of hypoglycemia, adverse events, laboratory values including hematology, blood chemistry and urinalysis, vital sign and physical examination, Frequency with hypoglycemic episode",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8893,NCT01136746,Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period,Number of Participants With Major Adverse Cardiovascular Events (MACE),,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3']
8894,NCT06125873,It controls blood Glycated hemoglobin level in type 2 diabetic patients.,Moringa leaf powder effect on body weight of patients,,2023-03-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
8895,NCT02476409,Change in Body Weight at 48 Hours Stratified by Copeptin,Change in Body Weight at Day 8,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8896,NCT04330911,Digital Spirometer,,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
8897,NCT00573456,The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes.,"The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure.",,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
8898,NCT03920098,Pandemic Anxiety Scale,Offspring body fat,,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA']
8899,NCT00522210,Hemoglobin A1C,Diabetes Quality of Life Questionaire-youth version,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
8900,NCT02802215,Number of participants with gestational diabetes by measuring plasma glucose levels ( mg / dl ).,Maternal adverse effects,,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8901,NCT00962806,Determine whether intensive exercise improves mitochondrial function by P31 MRS and mitochondrial number by peripheral blood analyses.,"Determine whether intensive exercise improves body composition, by DXA, and intramyocellular fat content, by 1H MRS.",,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
8902,NCT04564742,"The hierarchical composite endpoint of Death (CV death followed by non-CV death), Hosp due to heart failure (adjudicated followed by investigator reported), Non-fatal MI, AF/flutter event, New onset of T2DM, last visit NYHA class, and weight loss ≥5%",Time to death of any cause,,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
8903,NCT02082184,HbA1c at 6 Months,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 194.,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
8904,NCT01878370,Proportion of patients with perfect composite high risk score,cholesterol (LDL),Each metric within the composite scores,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8905,NCT00479609,"Insulin sensitivity,","Glucose tolerance, HbA1c levels, Abdominal obesity, prostate safety, Sexual function, Sleepiness, Urinary symptoms, Hypogonadal symptoms score",,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
8906,NCT01069926,"Change-from-baseline variables will be calculated for the safety variables listed below, as the post-treatment value minus the value at baseline",To evaluate the safety of AZD1656 in T2DM patients with various degrees of renal impairment. To describe the pharmacodynamics of AZD1656 in T2DM patients with various degrees of renal impairment by assessment of 24-hours glucose profile,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8907,NCT01683331,The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation,The Incidence of New Onset of Diabetes After Transplant (NODAT) 24 Months After Kidney Transplantation,"Incidence of Impaired Fasting Glycemia and Impaired Glucose Tolerance 6, 12 and 24 Months After Transplantation.",2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8908,NCT03961256,Progression From Prediabetes to Diabetes,Adverse Events for Exenatide SR Intervention,,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8909,NCT05591339,F-glucose,Time to Type-2 diabetes development,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE4']
8910,NCT01909245,"Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 5 years post-transplant",Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c < or = 7.0%,Incidence of Gastrin-17 use for treatment of islet graft dysfunction AND incidence of change or early discontinuation of Gastrin-17 treatment,2013-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8911,NCT00212303,Blood pressure at 6 months,Systemic inflammation at 6 months,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8912,NCT02836873,Change From Baseline in HbA1c at 24 Weeks,Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24,,2016-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
8913,NCT03491436,blood glucose 2 hours after meal 3,,,2017-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
8914,NCT00916357,Postprandial Glucose (PPG) Excursion Following a Liquid Meal,Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC]),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8915,NCT02445508,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve,Appetite as assessed by Visual analog scale score,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
8916,NCT02637245,Changes in disease state characteristics in response to therapy,Changes in visual acuity using ETDRS visual acuity assessment,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
8917,NCT01739868,To identify new biomarkers,Number of patients with others cardiovascular risk factors,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
8918,NCT00480805,To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4,To determine the safety anf tolerability of HYZAAR as compared to Ramipril as seen in overall adverse experiences for the duration of the study,,2001-08-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8919,NCT01258075,Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6,Number of Participants Requiring Rescue Medication Who Initially Met Rescue Criteria,,2011-02-24,COMPLETED,INTERVENTIONAL,['PHASE4']
8920,NCT02256189,Glucagon Counterregulation to Hypoglycemia,,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8921,NCT00505882,The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study.,mixed meal tolerance test-the C-peptide area under the curve The HOMA R and McAuley's index HbA1c The event rate of severe hypoglycemia Waist circumference Cardio C-reactive protein level DQOL Safety parameter,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8922,NCT00544518,The change of HbA1c from baseline to the end of treatment,the changes of fasting and after standard meal glucose and insulin level and plasma lipid level,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
8923,NCT05643768,Change from baseline insulin sensitivity after 6 weeks of IMST,Change from baseline Nitric Oxide-mediated Endothelial Dependent Dilation (EDD),Change from baseline proteomic analysis,2023-06-30,RECRUITING,INTERVENTIONAL,['NA']
8924,NCT00469365,"The primary outcome was the number of days from the index date until the next date on which the patient filled a prescription for any qualified medication, or until the end of the study follow-up period.","Secondary outcomes included indicators for whether the patient filled any medication within 30 days for their chronic disease, and whether the patient filled any medication within 30 days.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8925,NCT00433628,,,,2007-02-07,COMPLETED,OBSERVATIONAL,['NA']
8926,NCT05697991,Prevalence of hepatic steatosis in T2DM,Pathogenesis of progressive disease,,2015-03-23,RECRUITING,OBSERVATIONAL,['NA']
8927,NCT05267990,rate of major coronary heart disease,medical expenditure,,2022-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8928,NCT01901055,HbA1C Level,Vigilance,,2014-02-13,TERMINATED,INTERVENTIONAL,['NA']
8929,NCT02554877,Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo,"Changes From Baseline in Body Weight at Weeks 2, 4, 8, and 12.",,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8930,NCT00005481,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
8931,NCT01702012,Change in HbA1c (%),Change in fasting blood glucose (mg/dl),,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8932,NCT00016835,,,,2001-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
8933,NCT00711152,Change in glycated hemoglobin level,Hospitalizations with total length of stay,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8934,NCT00845793,Changes in the results of the nutrition quality questionnaire,Changes in anthropometric measures Changes in physical activity levels,,2009-04,UNKNOWN,INTERVENTIONAL,['NA']
8935,NCT01552408,Incidence and Severity of Ocular and Non-ocular Adverse Events (AE's) Through Month 36.,Mean Change in Peripheral Visual Field as Measured by Goldmann Visual Field at Screen and Month and 36.,,2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8936,NCT03338829,Frequency of glucose monitoring,,,2016-05-05,UNKNOWN,INTERVENTIONAL,['NA']
8937,NCT03549390,Insulin area under the curve (AUC),Physical fitness and suitability to exercise.,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
8938,NCT03764410,blood test for glycated hemoglobin,,,2016-12-20,COMPLETED,INTERVENTIONAL,['NA']
8939,NCT02241317,Hypoglycaemia,,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
8940,NCT00162357,Evaluate symptom-free heart blockages that develop following initial opening in patients with Type II diabetes mellitus based on Cardiolite imaging,Compare patient hospital and out-patient cost for cardiac care for each group of patients (MPI versus standard care).,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8941,NCT02467920,the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.,The incidence and rate of hypoglycaemic events during the study,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8942,NCT00213122,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
8943,NCT04153981,Number or Participants With Hypoglycemic Events,Change From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ),,2019-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
8944,NCT06141941,Glucose values,,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
8945,NCT00868790,Number of Participants Who Discontinued Study Treatment Due to an AE,Percentage Change From Baseline (BL) After 4-Week Treatment in Low-Density Lipoprotein C (LDL-C) Levels,,2009-03-24,TERMINATED,INTERVENTIONAL,['PHASE2']
8946,NCT01633684,Bone mineral Density,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8947,NCT01075347,Patients With Corneal Epithelial Healing Time Within 14 Days,"Patients With Corneal Complications Due to Delayed Surface Re-epithelization (e.g. Infectious Corneal Ulcer, Corneal Melting, Sterile Corneal Ulcer, Corneal Neovascularization)",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8948,NCT06273215,Pharmacokinetics of study drug,Genotype of OATP and BCRP,,2023-03-05,RECRUITING,INTERVENTIONAL,['PHASE4']
8949,NCT05856578,"Concentration of MBG, TIR, TAR, TBR, MAGE, MBG and LAGE","Concentration of adiponectin, leptin,IL-1,IL-6 andTNF-α",Incidence of hypoglycemia,2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
8950,NCT02137057,"Change of Heart rate variability during spinal anesthesia : total power, power of LF and HF, and LF/HF ratio",,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
8951,NCT01660789,BMI,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
8952,NCT02651181,"Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,during day time (6am-12am)",Incidence of Severe Hypoglycemia,Total insulin dose,2016-06,COMPLETED,INTERVENTIONAL,['NA']
8953,NCT00245882,HbA1c,Factors influencing adherence to diabetes regimen,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
8954,NCT04003259,Change in systolic and diastolic blood pressure (mmHg),Fitness index,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
8955,NCT06219850,Assessed changes from cardiorespiratory fitness,Assessed changes in Circadian Rhythms,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8956,NCT04108065,Gallbladder emptying,GDF15,,2019-10-02,COMPLETED,OBSERVATIONAL,['NA']
8957,NCT05912218,Lower limb atheroma plaque inflammation,Lower limb atheroma plaque progression,,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8958,NCT03380546,Composite endpoint: birth weight ≥ 90th percentile for gestational age (large for gestational age: LGA) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth injury.,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge.,,2018-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8959,NCT02645383,Visual analog score for pain,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
8960,NCT03517111,Food Insecurity,Parent and Adolescent Diet - Refined Grains (oz),,2018-09-26,TERMINATED,INTERVENTIONAL,['NA']
8961,NCT01474538,Glycosylated Hemoglobin A1C (HbA1c) at Endpoint,Percentage of Participants With Hypoglycemic Events,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8962,NCT00622323,"To determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, that would occur among Filipino patients with type 2 diabetes and inadequate glycemic control treated with exenatide",To evaluate the change from baseline to endpoint in HbA1c and body weight of Filipino patients with type 2 diabetes mellitus treated with exenatide who are taking metformin and/or a sulfonylurea but have not achieved adequate glycemic control.,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
8963,NCT02033499,Mean Difference in Health-related Quality of Life Scores From Baseline to 52 Weeks,Number of Participants on Specified Diabetes Medications at Baseline and Follow-up,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8964,NCT06101368,Dynamometry lower limb,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8965,NCT00768105,"Safety variables (AE, BP, pulse, weight, plasma glucose, laboratory variables and ECG)",Pharmacodynamic variables,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
8966,NCT00140647,"The change of the mean maximum carotid intimal medial thickness (IMT)evaluated across 12 segments involving the left and right common carotid, bifurcation and internal carotid arteries.",The change over time in the mean IMT across the common carotid far wall IMT of the right and the left carotid arteries.,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8967,NCT04192409,Change in glucose level measured by HbA1C level,low density lipoprotein,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
8968,NCT05926388,Insulin Administration Observation Form 2,,,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
8969,NCT03374176,Probing Depth,Total Count of All Teeth Lost Across All Participants,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8970,NCT05476276,Daily 0-10 pain NRS,Opioid Use Questionnaire (OUQ),Neuropathy Examination,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
8971,NCT02307695,Change of Mean amplitude of glycemic excursions (MAGE) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by continuous glucose monitoring system (CGMS),Change of insulin dosage (U/kg/d) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
8972,NCT03782259,Global Myocardial Strain,T2 Relaxation Time,hsCRP,2019-02-26,COMPLETED,INTERVENTIONAL,['PHASE4']
8973,NCT02521506,number of hypoglycemic events,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
8974,NCT01487408,HbA1c (glycosylated haemoglobin),Adverse events,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
8975,NCT02734277,Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC),Severity of Grade 3 or Higher Adverse Events (AEs) of Interest,,2016-08-18,RECRUITING,OBSERVATIONAL,['NA']
8976,NCT03527641,Homeostasis model assessment of insulin resistance (HOMA-IR),Everyday Discrimination Scale,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
8977,NCT02320344,Problem Areas in Diabetes,Triglycerides,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
8978,NCT01398592,demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with Sitagliptin,To assess the difference in FPG between vildagliptin and sitagliptin in patients with type 2 diabetes mellitus on concomitant treatment with metformin,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8979,NCT06050577,Procollagen type 1 N-terminal propeptide (P1NP),Body mass index (BMI),Osteogenic potential,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8980,NCT00298129,,,,2004-02,COMPLETED,OBSERVATIONAL,['NA']
8981,NCT00696111,Sleep recording/polysomnography,24-hour hormonal profiles,,2007-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8982,NCT06009055,Heart rate variability（HRV）,,,2023-09-17,RECRUITING,INTERVENTIONAL,['NA']
8983,NCT00961909,Change in hemoglobin A1c (HbA1c),"Change in metabolic parameters: glucose, insulin, C-peptide",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8984,NCT04270656,"Variation of hepatic steatosis, between the insulin pump therapy (CSII) vs Multi injection treatement (MDI) groups.","Calculation negative predictive values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.",,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA']
8985,NCT06235762,Heart Rate (HR) beats per minute (bpm),"Physical activity level (sedentary, moderate, advanced)",,2020-08-16,COMPLETED,INTERVENTIONAL,['NA']
8986,NCT01295177,% of Wound healing closing measured each week,Complete wound healing,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8987,NCT02503865,Systolic/ Diastolic Blood Pressures (mm Hg),Immunoassay Cortisole in Blood,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8988,NCT05835596,General Practitioner attendance 1 year postpartum,Clinical cardiovascular follow-up at recruitment hospital: serum biomarkers associated to cardiovascular risk,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8989,NCT03470454,affection of estimated glomerular filtration rate,change in serum uric acid,Affection of albumin creatinine ratio,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
8990,NCT00680706,Effect of Thiamine Supplementation on Dyspnea,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8991,NCT02346838,Change in insulin sensitivity.,Change in arterial stiffness.,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8992,NCT04437537,Wound Microbiome,Wound pH,,2022-05-15,UNKNOWN,OBSERVATIONAL,['NA']
8993,NCT03026218,Reduction in the number of individuals requiring pharmacotherapy for treatment of gestational diabetes,Reduction in the number of infants with neonatal hypoglycemia.,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
8994,NCT00365495,Mitochondrial respiratory measurements. The investigations are carried out by two rounds - one before Christmas and one after.,mitochondrial production of free oxygen radicals,,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
8995,NCT01144520,Ex vivo leukocyte function by measuring ROS production,Ex vivo NADPH oxidase gene and protein expression,,2010-03,TERMINATED,OBSERVATIONAL,['NA']
8996,NCT05184049,The change of resting-state functional Magnetic Resonance Imaging,Mean change of Montreal Cognitive Assessment,,2022-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8997,NCT02015130,"Composite endpoint: All cause mortality, non-fatal myocardial infarction, coronary revascularization, cardiac arrest with resuscitation, heart failure, non-fatal stroke, progression of nephropathy or retinopathy, severe hypoglycaemia and cancer",Quality of life,All cause hospitalization,2013-10,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8998,NCT03556098,plasma glucose concentration,Pulse,,2019-02-22,COMPLETED,INTERVENTIONAL,['NA']
8999,NCT03271879,"The primary endpoint is the burden of premature ventricular complexes, defined as the PVCs percentage of all beats in a pre-specified period captured on ICD or CRTD/P device",Left ventricular ejection fraction (EF),,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
9000,NCT00272077,SMBG values,results of CGMS,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9001,NCT03692884,The number of patients whoes Diabetic Kidney disease (DKD) is worsen,The number of patients who develop Diabetic foot,,2018-07-01,RECRUITING,OBSERVATIONAL,['NA']
9002,NCT01637324,,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
9003,NCT01240785,Birth Weight Per Arm,Child Outcome at 2 Years Per Arm,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9004,NCT00764361,Number of Participants Without Adverse Events,Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9005,NCT05144672,The relation between different stages of diabetic nephropathy and irisin level.,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
9006,NCT00498147,Rates of cardiovascular events and other complications of diabetes compared to provincial and national rates,"The secondary outcomes will be total mortality, CV- related events, and other selected complications of diabetes.",,2007-07,UNKNOWN,OBSERVATIONAL,['NA']
9007,NCT01805297,Rate of Resolved Post-operative Vitreous Hemorrhage.,Changes in Mean Central Retinal Thickness.,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9008,NCT01966380,Absorption of Wound Exudates.,,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2']
9009,NCT04726319,Changes in risk-appropriate screening based on family history,Attitudes towards the FHAMe intervention,,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9010,NCT00741026,Plasma Free Fatty Acid,Diastolic Blood Pressure,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
9011,NCT02815657,The area under the plasma concentration-time curve (AUC) of valsartan,The number of volunteers with adverse events as a measure of safety and tolerability,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9012,NCT02866565,Percentage of patients achieving 100% wound closure,change in quality of life assessed by the SF-36 QoL survey from baseline,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9013,NCT01729286,Complete wound closure,Nonserious and serious adverse events,,2012-09,TERMINATED,INTERVENTIONAL,['NA']
9014,NCT02489942,Number of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose (FPG) at the Last- Observation During Observation Period,,2015-06-12,COMPLETED,OBSERVATIONAL,['NA']
9015,NCT05797051,Microhyperspectral image of urine specimen,,,2023-05-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9016,NCT03912909,Reduction in muscle sympathetic nerve activity,Change in glycemic control,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9017,NCT02442921,Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.,,,2016-02-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9018,NCT04509193,Any major or clinically-relevant nonmajor bleed resulting in hospitalization,New-onset vascular dementia,,2020-08-21,COMPLETED,OBSERVATIONAL,['NA']
9019,NCT01691989,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9020,NCT05316298,Postoperative wound healing,Foot Function Index (FFI) scores,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
9021,NCT02414958,Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) ),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
9022,NCT02987556,Percentage of time spent in the tight glycemic control area 70-180 mg/dl continuously measured for 12 weeks,Percentage of time spent in blood glucose <70 mg/dl continuously measured for 12 weeks,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
9023,NCT03617770,Sleep Regularity,Diabetes Distress,,2019-01-09,COMPLETED,INTERVENTIONAL,['NA']
9024,NCT03467659,Appetitive behavior,,,2017-02-16,COMPLETED,INTERVENTIONAL,['NA']
9025,NCT01211717,"Measuring Pain, using the short form McGill pain questionnaire",Measuring Muscle strength of the studied muscle,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9026,NCT00422357,Blood pressure every two weeks.,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9027,NCT00754741,LDL-cholesterol Levels,Cardiovascular Morbidity and Mortality (Exploratory),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9028,NCT01612468,Change in HbA1c,Quality of life,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9029,NCT03527537,Composite Neonatal Outcome,Preeclampsia,,2021-05-04,RECRUITING,INTERVENTIONAL,['PHASE4']
9030,NCT01542554,Change in blood HbA1c,Change in blood pressure,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
9031,NCT04876079,Time spent of glucose levels < 4.0 mmol/L,Percentage of participants experiencing a rebound hyperglycemia (≥ 10.0 mmol/L) within the first hour following the first carbobydrates consumption,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
9032,NCT02017132,Changes in measurements of body mass indicators,Changes in blood pressure,Change in urinary cortisol-to-cortisone ratio,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
9033,NCT03178253,percentage of hypothyroidism in patients of type 2 diabetes with diabetic nephropathy,,,2017-06-30,UNKNOWN,OBSERVATIONAL,['NA']
9034,NCT04488887,coefficient of variation (CV),,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
9035,NCT06080451,Proportion of patient participants with subsequent follow-up visit within 3 months,Sustainability,,2023-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9036,NCT00432029,Forearm Blood Flow,,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
9037,NCT02366468,Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12),Number of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale,,2015-02-23,COMPLETED,INTERVENTIONAL,['PHASE4']
9038,NCT00280865,Absolute change from baseline to end of randomized treatment period in fasting plasma glucose (FPG),"To evaluate diabetes-specific instruments, Audit of Diabetes Dependent Quality of Life (ADDQoL) and The Diabetes Treatment Satisfaction Questionnaire (DTSQ) (s and c) in the study population and estimate the effect size of the instruments in patients r",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9039,NCT02232698,Time Spent <70 mg/dL,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 208,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
9040,NCT04507438,Change in Hemoglobin A1C,Change in creatinine,Change in albumin,2019-07-12,TERMINATED,INTERVENTIONAL,['PHASE2']
9041,NCT01516476,Change in hemoglobin A1c (HA1c),Safety (incidence of adverse events),,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
9042,NCT05109949,Pulse wave velocity,Blood pressure,,2020-03-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
9043,NCT02064881,Change in postprandial lipemia at 4 months,Number of Participants with Serious and Non-Serious Adverse Events,,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9044,NCT02133118,"The course of weight (Kg) after starting individual SU's, pioglitazone or insulin as add-on therapy.","The course of the glycaemic control (HbA1c %) , up to five years after starting individual SU's, pioglitazone or insulin as add-on therapy.",,1998-01,COMPLETED,OBSERVATIONAL,['NA']
9045,NCT02928666,Number of conflicting recommendations detected out of total number of conflicts,,,2018-10,UNKNOWN,INTERVENTIONAL,['NA']
9046,NCT02769377,HbA1c,Hypoglycemia,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9047,NCT02572414,Adherence to Department of Health and Human Services physical activity guideline,Adherence to 5-a-Day diet guideline,,2015-01-08,COMPLETED,INTERVENTIONAL,['NA']
9048,NCT00101426,Efficacy,Safety,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9049,NCT03937934,Change in number of days a week and minutes per day participants participate in physical activity and sedentary activity,Change in Systolic and/or Diastolic Hypertension mmHg,,2019-05-20,COMPLETED,INTERVENTIONAL,['NA']
9050,NCT05369871,Glycemic control evaluation for the 12-week main study,System satisfaction questionnaire evaluation,,2022-08-29,COMPLETED,INTERVENTIONAL,['NA']
9051,NCT04653805,Number of visits with the primary care team in the previous 12 months,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9052,NCT03763669,Insulin resistance,Fetal sonographic parameters,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
9053,NCT03082859,Mean 24-hour blood glucose concentrations (mmol/L),Glycaemic Variability (Glucose levels),Mood measured using the Brunel Scale of Mood States (BRUMS),2016-07,UNKNOWN,INTERVENTIONAL,['NA']
9054,NCT04255004,probability of healing at 24 months,rest pain,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
9055,NCT00533494,"HbA1c, LDL, systolic blood pressure",,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9056,NCT03970044,MAGE,Blood Glucose Time In Range,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9057,NCT00860392,Effects of increase in serum free fatty acid levels on ketogenesis as measured using a isotopic tracer and serum ketone body concentration in healthy lean subjects,Effects of increase in serum free fatty acid levels on ketogenesis as measured using a isotopic tracer and serum ketone body concentration in obese subjects,,2009-03-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9058,NCT04978662,chronotype,treatment,,2021-07-06,UNKNOWN,OBSERVATIONAL,['NA']
9059,NCT05969015,Glycemic control,Diabetes Attitude Questionnaire (ATT-19),Adverse Events,2022-01-15,RECRUITING,INTERVENTIONAL,['NA']
9060,NCT02470455,Change in Glycosylated Hemoglobin (HbA1c) from baseline,Lipid profile,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
9061,NCT01355718,Incidence of serious Adverse Drug Reactions (SADRs) including major (serious) hypoglycaemic episodes,Change in HbA1c,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
9062,NCT01845857,"Change in Health Status (symptoms, activities limitations)",Change in Health Care Utilization,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
9063,NCT03663738,HbA1c,Quality of life related to health,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
9064,NCT00374426,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9065,NCT00571519,Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,,2007-11-14,TERMINATED,INTERVENTIONAL,['PHASE3']
9066,NCT04881994,"Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma",Number of participants with adverse events,Half-life associated with the terminal slope (t1/2) of finerenone,2014-03-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9067,NCT00861952,Numeric pain scale (0-10) for immediate relief,Adverse event reports,,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
9068,NCT01510093,Pharmacokinetic profiles of endogenous insulin and Insulin Aspart,Pharmacodynamic glucose profiles,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9069,NCT00344240,Physical activity,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
9070,NCT05957224,Change in plasma glucose concentration post oral intake of shake,"Sensory analysis of taste, texture, smell and appearance of shakes",,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9071,NCT03328546,Physical functioning,,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
9072,NCT04663295,Change in Time in Target Range (% of Sensor Glucose (SG)): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L),"Time in Specific Range Stratified by Baseline HbA1c Ranges (< 7%, 7 - < 7.5%, 7.5 - 8%, > 8%)",,2020-10-31,COMPLETED,INTERVENTIONAL,['NA']
9073,NCT02310009,Beta-cell function,Glucose disposition,,2014-12,WITHDRAWN,INTERVENTIONAL,['NA']
9074,NCT05989867,steamed bun meal test result 3,glycemic control,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
9075,NCT01775813,Insulin Sensitivity,High Density Lipoprotein,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9076,NCT00961857,The area under the plasma concentration vs. time curve (AUC) after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,Peak plasma concentration (Cmax) of sitagliptin and metformin after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,,2005-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9077,NCT04477707,Progression of non-proliferative diabetic retinopathy (NPDR),Change in severity of diabetic retinopathy (DR),,2020-07-23,COMPLETED,OBSERVATIONAL,['NA']
9078,NCT01224548,weight,hip circumference,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9079,NCT01180530,The incidence of technical complaints related to adverse reactions,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9080,NCT00478335,24h Urine Volume,,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
9081,NCT05877378,Health-related effects on quality of life.,,,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9082,NCT03337412,Chronological evolution of the physical activity score of patients benefiting from the education program with intervention of the adapted physical activity educator,musculoskeletal disorders,,2017-11-13,COMPLETED,INTERVENTIONAL,['NA']
9083,NCT05370339,Assessment of facilitators and barriers to good sleep quality and duration,Identification of common causes of sleep disruptors in adolescents with type 1 diabetes,,2022-06-15,COMPLETED,OBSERVATIONAL,['NA']
9084,NCT03818568,glomerular filtration,Mortality,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
9085,NCT03191331,gestational weight gain (GWG),Eating habits,,2017-06-06,COMPLETED,INTERVENTIONAL,['NA']
9086,NCT00424333,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9087,NCT02100319,Changes From Baseline in Home Blood Pressure on Final Assessment Point (up to Week 24),Percentage of Participants Who Had One or More Adverse Events,,2014-03-03,COMPLETED,OBSERVATIONAL,['NA']
9088,NCT05389254,The CCU occupancy rate,Major adverse cardiovascular events after 3 months,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9089,NCT01486875,Incidence of major hypoglycaemic events,Fasting Plasma Glucose (FPG),,2006-01,COMPLETED,OBSERVATIONAL,['NA']
9090,NCT02835989,Change in number of repeat EMS calls,Change in number of hospital admissions,,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
9091,NCT05120219,Pharmacokinetics parameters of SHR3824 and Metformin after multiple dose: AUCss,The incidence and severity of adverse events/serious adverse events,,2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE1']
9092,NCT00615212,drug plasma levels flurbiprofen:,Daily predose trough GSK376501 plasma concentrations when administered alone for 7 days (Days 4-13).,,2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9093,NCT03243136,Type 2 diabetes,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
9094,NCT06167499,Rate of glycated hemoglobin HBA1c,Evaluation of long-term complications over 18 months,,2024-02-09,RECRUITING,INTERVENTIONAL,['NA']
9095,NCT00758680,Number of Participants Who Discontinued Treatment Due to an AE,Least Squares Mean Change From Baseline in 24-Hour Weighted Mean Glucose (WMG),,2008-08,TERMINATED,INTERVENTIONAL,['PHASE1']
9096,NCT04135287,HbA1c,Fasting Plasma Glucagon,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9097,NCT02109029,Part B: Pharmacokinetics: ISF-to-Serum Concentrations,,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9098,NCT00625781,Perinatal morbidity and intrauterine growth,Children´s future health,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
9099,NCT03069729,Pattern of thermal recovery,Correlation of DPN severity levels and DR severity levels,,2017-03-08,COMPLETED,OBSERVATIONAL,['NA']
9100,NCT01902043,"Process of care indicators and the following outcomes of care: HbA1C, quality of life (QoL), Patient Assessment of Chronic Illness Care (PACIC)",,Knowledge of and participation in the activities/projects of the Programme cantonal Diabète (PcD),2011-09,UNKNOWN,OBSERVATIONAL,['NA']
9101,NCT00600366,HbA1c,Incidence of adverse events,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9102,NCT04884633,Achieving good metabolic control of diabetes,The rate of significat glomerula filtration rate reduction,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
9103,NCT03987841,Hemoglobin A1c (A1C),Feasibility: Percentage of Sessions Attended,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
9104,NCT06163248,Change in insulin resistance (M value),Change in lipid profile (mg/dl),Hunger and satiety (score),2024-01-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9105,NCT00565318,Change in urinary excretion of: - Kidney injury molecule-1 (KIM-1) - Albumin,"Change in urinary excretion of: β2 microglobulin, macrophage inhibiting factor (MIF), monocyte chemo-attractant protein-1 (MCP-1), and other advanced glycation end-products (AGEs).",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9106,NCT03587948,Diabetic eye diseases,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
9107,NCT00290927,Safety of HMR1964,"change in HbA1C from baseline to week 16,consecutive change in HbA1C every 4 wks,plasma glucose parameters, symptomatic hypoglycemia (comparison of HMR1964 intensive therapy, mono-or OHA combination therapy, with OHA therapy).",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9108,NCT01752842,Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent,Change in C24:0/C16:0 Ceramide Ratio,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
9109,NCT00537251,"Compare efficacy of insulin glargine & short acting insulin (Lispro), NPH insulin regime as basal insulin and regular insulin for meal insulin for metabolic control, evaluated by means of HbA1c .",,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9110,NCT00221156,Cardiovascular event free survival time,Change in lipid profile,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9111,NCT01577095,plasma glucose,plasma insulin,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9112,NCT04018105,Area under the curve of D-Xylose,Area under the curve of GLP-1,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9113,NCT01874483,Occurrence of adverse events,"Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9114,NCT05614089,Time-in-range (TIR),Quality of Life (e.g. PedsQL Pediatric Quality of Life Inventory),,2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9115,NCT03376490,Muscle strength (Leg extension),Vitamin D deficiency,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
9116,NCT06083909,To explore the correlation of sarcopenia and obesity on insulin resistance,To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.,,2022-04-06,COMPLETED,OBSERVATIONAL,['NA']
9117,NCT00763815,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9118,NCT04357392,Number of patients with HbA1c <7% at 12 and 24 weeks,"Blood glucose fluctuation at 4, 12 and 24 weeks",,2020-05-20,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9119,NCT05672433,Area under the curve for glucose during mixed meal test (mmol/L*min),Food consumption in kilocalories (kcal),Fasting Homeostatic Model Assessment for Insulin Resistance by C-peptide (arbitrary unit).,2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9120,NCT05140551,To assess the implementation of COMPASS in terms of patient adherence to COMPASS online sessions and number and duration of therapist support calls attended.,,,2022-04-06,COMPLETED,INTERVENTIONAL,['NA']
9121,NCT04233203,MAGE,TIR-TAR-TUR,Severe adverse effects,2020-01-31,COMPLETED,OBSERVATIONAL,['NA']
9122,NCT05223569,Changes in visual acuity,Changes in visual acuity after 48 weeks,,2022-03-03,RECRUITING,INTERVENTIONAL,['NA']
9123,NCT06059326,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),Change from baseline of HbA1c,,2019-01-22,COMPLETED,INTERVENTIONAL,['PHASE2']
9124,NCT06260605,Education,,,2023-12-19,COMPLETED,INTERVENTIONAL,['NA']
9125,NCT05071950,Postprandial glucose (mg/dl),side-effects of D-allulose,,2021-03-10,COMPLETED,INTERVENTIONAL,['NA']
9126,NCT02903264,Gestational diabetes mellitus diagnosed by an endocrinologist,Leukocytosis as an indicator of inflammation,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9127,NCT00298844,,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA']
9128,NCT02075281,Change from baseline in body weight at 20 weeks,"Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week",Change from baseline in β-cell function at 20 week,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9129,NCT00839683,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the effect of dapagliflozin on the PK of simvastatin acid (active metabolite of simvastatin), when coadministered in healthy subjects",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9130,NCT02520076,To demonstrate AAT efficacy in preventing non-immunologic loss of transplanted islet mass in a single-donor islet transplant.,To demonstrate AAT efficacy in the prevention of long-term metabolic burn-out.,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9131,NCT00664534,Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint,Number of Participants With Adverse Events,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9132,NCT03544320,Change in hemoglobin A1c,Change in low-density lipoprotein (LDL) levels,Hospitalization,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
9133,NCT04797442,Fasting plasma glucose levels,Fat mass,,2021-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9134,NCT00333671,"Retinal thickness by fast retinal thickness mapping by optical coherence tomography at times 0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 minutes after the last swallow of glycerol.",dose dependent differences in the same time spectrum.,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
9135,NCT00072904,The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9136,NCT06239506,alternative FRs,levels of FPG,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
9137,NCT01068756,AUC (area under the concentration-time curve) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,Tmax (time of maximum observed concentration) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1']
9138,NCT04550468,Change from Baseline Hemoglobin A1c at 12 weeks,Continuous glucose monitoring,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
9139,NCT01110746,3 hour incremental area under the glucose curve after a standardized high glycemic index meal.,"Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe).",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9140,NCT01956357,Glycated hemoglobin,Global Histone Deacetylases activity,Sleep quality.,2012-08,COMPLETED,INTERVENTIONAL,['NA']
9141,NCT01220310,Self-Efficacy,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9142,NCT01283425,frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.,Adverse events (AE's) count with InsuPatch and without.,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9143,NCT03811288,Participants with a history of established cardiovascular disease (CVD),Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),,2018-12-10,COMPLETED,OBSERVATIONAL,['NA']
9144,NCT02723266,Lifestyle Management,Number of subjects reporting an unplanned pregnancy,,2018-03-16,COMPLETED,INTERVENTIONAL,['NA']
9145,NCT00543816,,,,2003-08,TERMINATED,INTERVENTIONAL,['PHASE3']
9146,NCT01546181,photoreceptor density,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9147,NCT03074630,Change in Plasma LDL Cholesterol,Urinary Sodium Excretion,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9148,NCT01705639,Glucose tolerance,Activity,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9149,NCT03711656,Sensitivity (SE) and specificity (SP) to predict Level 1 hypoglycemia,Number of Level 3: severe hypoglycemia,,2018-10-10,COMPLETED,INTERVENTIONAL,['NA']
9150,NCT02632929,Limb salvage,effective wound healing,Diabetic Foot Ulcer Quality of life Short Form survey,2015-05-30,COMPLETED,OBSERVATIONAL,['NA']
9151,NCT01834274,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Plasma Glucose (FPG),,2013-06,TERMINATED,INTERVENTIONAL,['PHASE3']
9152,NCT03324191,Effect of tea extract on serum triacylglycerol concentration following a high fat meal,Effect of tea extract on whole body lipid oxidation following a high fat meal,,2017-10-10,COMPLETED,INTERVENTIONAL,['NA']
9153,NCT00743327,Evaluation for the development of incident diabetes,"Evaluation for other cardiovascular risk factors, markers of inflammation and immunological changes",,2008-10,TERMINATED,OBSERVATIONAL,['NA']
9154,NCT05726006,To examine the prevalence of antibiotic resistance of invasive GBS isolates among non-pregnant people in Malaysia.,Detection of Sequence Type (ST),,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
9155,NCT03274362,Quality of life,Diabetes empowerment,,2017-09,UNKNOWN,INTERVENTIONAL,['NA']
9156,NCT01455909,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
9157,NCT04374578,Effect on glycemic variability,Effect on Glycemic Control,,2020-05-08,COMPLETED,OBSERVATIONAL,['NA']
9158,NCT00222781,"Compare triple tracer PET imaging of skeletal muscle in lean, obese and T2DM",Mathematical modeling of PET data.,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
9159,NCT02866435,"Change from baseline (i.e., normal glucose levels) cerebral blood flow, measured in ml/min/100g, at hypoglycemia",,,2016-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9160,NCT00229710,Body weight,"Central obesity (waist circumference, hip circumference, waist/hip ratio)",,2005-02,TERMINATED,INTERVENTIONAL,['PHASE3']
9161,NCT02914743,Dental care-seeking behavior,Change from baseline Hemoglobin A1c at 3 and 6 months,Clinician attitude towards the value of having a hygienist in the hospital setting,2016-11,COMPLETED,INTERVENTIONAL,['NA']
9162,NCT04286555,Systolic blood pressure (SBP),Symptoms experienced by participants as assessed by a questionnaire,,2021-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9163,NCT00937872,Define the intravenous pharmacokinetics of SRT2104.,Potential systemic metabolite burden of SRT2104 following administration.,,2008-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
9164,NCT03715010,Measure of glucose AUC during 2H OGTT (Frame: 10 weeks),Measure of body composition (Time Frame: 10 weeks),,2016-03-18,COMPLETED,INTERVENTIONAL,['NA']
9165,NCT02677779,Bacterial Load,Bleeding: Proportion of Patients With Bleeding Necessitating Haemostasis,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
9166,NCT00776763,Growth Factors and Other Cytokines Measurements,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9167,NCT00766857,Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction).,Exercise capacity and performance will be assessed by a 6-minute walking test,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9168,NCT01773798,Area under the glucose infusion rate curve,Area under the serum IAsp concentration-time curve,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9169,NCT00222508,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
9170,NCT03875625,Anthropomorphic measurements using BP machine,,,2019-04-01,RECRUITING,INTERVENTIONAL,['NA']
9171,NCT02831075,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
9172,NCT00305344,Children With T1D Underwent a Single Autologous UCB Transfusion,,,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9173,NCT04042285,Wound volume,Tissue integrity,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
9174,NCT05556005,Change from baseline Left ventricular functions at 3 months,Change from baseline Transforming growth factor beta 1 at 3 months,,2022-09-18,RECRUITING,INTERVENTIONAL,['PHASE2']
9175,NCT04831775,"Change in attention, visual scanning and motor speed at week 22",Change in perceived cognitive function at week 22,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
9176,NCT04891627,"It was aimed to compare IL-34 levels by taking gingival crevicular fluid in systemic healthy, periodontitis and diabetic patients with periodontitis groups.","It was aimed to compare CSF-1 levels by taking gingival crevicular fluid in systemic healthy, periodontitis and diabetic patients with periodontitis groups.",,2021-01-06,COMPLETED,OBSERVATIONAL,['NA']
9177,NCT01494025,Change in Body Weight,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
9178,NCT03790787,"AUCτ,ss",,,2019-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9179,NCT00248352,Change in 10 year cardiac risk as estimated by the UKPDS risk engine at 6 months post discharge compared to baseline measures obtained at time of discharge,Quality of life as assessed by questionnaire,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
9180,NCT00448032,Safety,Pharmacokinetics/Pharmacodynamics,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9181,NCT03353792,Brain Alternate Fuel Uptake,Change in Cognitive Function: Grooved Pegboard Test,,2017-11-01,TERMINATED,INTERVENTIONAL,['NA']
9182,NCT01859117,Adverse Events,Toe-brachial index (TBI),,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
9183,NCT03590041,Diabetes Distress - Change in Patient Reported Outcomes (PROs),Change in Patient HbA1c,,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9184,NCT01223196,Whole Body Insulin Sensitivity During the Euglycemic Insulin Clamp,Effect of Pioglitazone on TNF (Tumor Necrosis Factor) Alpha Converting Enzyme (TACE) Activity in Skeletal Muscle.,Percentage (%) of Haemoglobin A1C,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9185,NCT04025996,"Cross-sectional analyses will be performed to look at the association between diabetic retinopathy with left ventricular diastolic function, coronary flow reserve and urinary albumin excretion.",,,2018-02-20,UNKNOWN,OBSERVATIONAL,['NA']
9186,NCT02244736,Differences of endothelial function at baseline and during OGTT among the 3 groups.,Insulin resistance and endothelial function,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
9187,NCT02206074,Pulmonary gas exchange via MedGraphics CardiO2 Cardiopulmonary Diagnostic Systems,Functional capacity measured by 6-Minute Walking Test (6MWT),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
9188,NCT05449496,Post-transplant complications rates,Dietary complications,,2022-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9189,NCT01288885,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by ASP1941 glucose concentration changes in blood and urine,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9190,NCT01463813,Cancer,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
9191,NCT01252979,Heteroplasmy,,,2010-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9192,NCT06037369,DFU Quality of life,Diabetes-related foot self-care behavior,,2023-09-14,RECRUITING,INTERVENTIONAL,['NA']
9193,NCT00537277,Percentage of Subjects Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0%,Number of Treatment Emergent Serious Adverse Events (SAEs),,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9194,NCT04436822,Percentage of Readings Within 20% Agreement,,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
9195,NCT01507311,Insulin secretory burst mass,Adverse events,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9196,NCT04088929,Impact of Pure Green CBD tablets on diabetic neuropathy pain using a daily self-reported pain scale score.,Impact on the use of sublingual tablets as the route of administration,,2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE2']
9197,NCT02154074,level of blood insulin,vital signs,,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
9198,NCT04287387,Changes from baseline to post-treatment in composition in level of C-reative protein.,The linear relationship between gut microbiota and inflammation factors level.,,2020-03-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
9199,NCT04513197,Development of endocrine dysfunction (diabetes & prediabetes) after acute pancreatitis,2) To evaluate whether severity of acute pancreatitis have an impact on the development of endocrine dysfunction or not?,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
9200,NCT02308683,Post treatment mean HsCRP,Post treatment mean hgba1c,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9201,NCT02021890,improved physical fitness (physical activity exceeding 10 MET-hour/week,10% increase in 6-min walk test,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9202,NCT04386200,Change from baseline in Body Weight,Change from baseline in Quality of life by 36-item short form health survey (SF-36),,2019-02-13,UNKNOWN,INTERVENTIONAL,['NA']
9203,NCT03703544,Daily blood glucose profile,,,2017-12-15,COMPLETED,INTERVENTIONAL,['NA']
9204,NCT03985384,Rate of change in non-calcified plaque volume,Rate of change in total plaque volume,,2019-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
9205,NCT05823142,Sleep Health: Timing*,Diabetes distress symptoms,,2023-12-20,RECRUITING,INTERVENTIONAL,['NA']
9206,NCT00363844,tolerability,Plasma glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9207,NCT00740363,Insulin secretion,Cyclosporine/tacrolimus blood concentrations,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9208,NCT04869917,Weight,Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,,2022-03-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9209,NCT03288610,Preoperative copeptin level,Day 28 mortality rate,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9210,NCT03889496,Correlation between the tracer uptake (counts) and beta cell mass (mg),,,2015-11-16,TERMINATED,INTERVENTIONAL,['NA']
9211,NCT01034319,stage of change,program attendance,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
9212,NCT03552315,"The three-hour incremental area under the curve (iAUC) for capillary blood glucose, 0-180 minutes","The one-hour iAUC for intravenous Glucagon-like peptide 1 (GLP-1), 0-60 minutes",Difference in two-hour glucose (delta-glucose at 2h) from both capillary and intravenous blood.,2018-04-24,COMPLETED,INTERVENTIONAL,['NA']
9213,NCT01387659,Tolerability of Myfortic in combination with Simulect and Tacrolimus without steroids,Biopsy proven rejection,,2011-03,TERMINATED,INTERVENTIONAL,['NA']
9214,NCT00375492,Change From Baseline in Body Weight,Rate of Hypoglycemic Events,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9215,NCT01918345,For the Effectiveness Phase: Change in baseline-adjusted weight,Feasibility,Behaviour change,2014-07,COMPLETED,INTERVENTIONAL,['NA']
9216,NCT05162690,Intraepithelial nerve fiber density,corneal nerve fiber density,,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9217,NCT03805802,Fasting glucose,Inflammation: hsCRP,Waist circumference,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
9218,NCT02297620,Specify incidence rates of adverse drug reactions associated with a decrease in body fluids and their risk factors,Investigate the occurrence of adverse drug reactions other than the above,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
9219,NCT05799222,Hemoglobin A1c reduction,Program adherence,,2023-04-01,RECRUITING,OBSERVATIONAL,['NA']
9220,NCT05777746,"Composite of Estimated relative CVD risk (based on change in LDL-c , SBP and HbA1c)",Rate of Vitamin B12 and ferritin deficiency,Physical Activity (Metabolic Equivalent Tasks),2022-11-29,RECRUITING,INTERVENTIONAL,['NA']
9221,NCT04417725,Incidence and prevalence,Treatment patterns,,2008-04-01,COMPLETED,OBSERVATIONAL,['NA']
9222,NCT02403375,Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%,"Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)",,2015-05-17,COMPLETED,INTERVENTIONAL,['NA']
9223,NCT00327626,"Evaluate the effects of ISIS 113715 on insulin sensitivity, B-cell function, proinsulin/insulin ratio, fasting insulin, C-peptide and proinsulin.",,,2006-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9224,NCT00422487,"Determine the effect of MBX-2044 after 14 days administration, on efficacy parameters",,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9225,NCT03619031,Postprandial glucose response (AUC),Time to blood glucose peak,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
9226,NCT06190756,Echocardiography,,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
9227,NCT03301545,Change in Glycosylated Hemoglobin (HbA1c),Change in Fasting Blood Lipids,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA']
9228,NCT00621868,HbA1c level,Safety,,2008-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
9229,NCT05259735,To assess the change Health related quality of life with the introduction of clinical guideline,To determine the number of participants who adhere to the guideline,,2022-07-17,COMPLETED,INTERVENTIONAL,['NA']
9230,NCT00351546,Effect on insulin sensitivity at 6 weeks,Gluconeogenesis rate after 6 weeks of treatment,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9231,NCT05058807,5 times sit to stand test,Single leg stance test,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
9232,NCT02929654,A1c change from baseline after 12 weeks,,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
9233,NCT06084156,The primary pharmacokinetics parameter of AUC To assess the potential pharmacokinetic interaction between HSK7653 and metformin in health subjects.,"Pharmacodynamic responses of glucose, insulin and C-peptide will be evaluated",,2019-08-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9234,NCT00393705,Hemoglobin A1c (HbA1c) at 16 Week Endpoint,Total Daily Insulin Dose at 4 Weeks and 12 Weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9235,NCT05007301,Frequency of device deficiencies,,,2022-04-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9236,NCT02259634,Quality of Life,Healthcare Utilization,,2014-06,TERMINATED,INTERVENTIONAL,['NA']
9237,NCT00749606,Weight,International Physical Activity Questionnaire,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9238,NCT01440257,Subject incidence of adverse events,Change from baseline in hemoglobin A1c,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9239,NCT05929079,Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA2 Subset,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE3']
9240,NCT04443205,Foetal macrosomia,,,2020-06,UNKNOWN,OBSERVATIONAL,['NA']
9241,NCT00370656,Whether there is a reduction in subjective pain as assessed by the Brief Pain Inventory.,"Whether there has been an improvement in sleep continuity and subjective sleep, morning after cognitive and psychomotor performance, and quality of life (QoL).",,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9242,NCT02950272,cardiovascular events,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
9243,NCT03642717,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,,2018-08-21,COMPLETED,OBSERVATIONAL,['NA']
9244,NCT00482443,The difference in HbA1c between the patient in the DID group and in the standard education group.,"The differences between the two groups in terms of, lipid profile, blood pressure, the number of hypoglycaemic episodes, daily blood sugar fluctuation, total insulin dose, weight changes and patients' satisfaction with the treatment.",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
9245,NCT03010397,Phenotypic classification of DR in a 5-year period,mfERG assessement,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
9246,NCT02304081,Glucagon / insulin ratio during hyperglycaemic clamp phase (AUCGluc270-390min / AUCIns270-390min),"Blood Lipids (Triglycerides [mg/dl]; total, HDL, LDL cholesterol [mg/dl])",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9247,NCT05378672,Plasma glucose change from baseline at 30 minutes after IMP injection or at the time of rescue by intravenous (IV) glucose,Plasma glucose change from baseline at 15 minutes after IMP injection or at the time of rescue by IV glucose,,2023-05-09,RECRUITING,INTERVENTIONAL,['PHASE3']
9248,NCT06064721,peripheral circulation,,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9249,NCT00693771,HbA1c values,Adverse events including hypoglycemia,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9250,NCT00353990,To define the bioavailability of a solution of insulin Aspart infused in the Duodenum,Explore any influence of PH/ insulin concentration on PK /PD parameters,,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9251,NCT01653951,hemoglobin A1c,,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
9252,NCT05840250,Glycemic control,Satisfaction with CGM device,,2023-05-15,SUSPENDED,INTERVENTIONAL,['NA']
9253,NCT00376038,"Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine","Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9254,NCT02761434,Insulin sensitivity by matsuda & quicki Index,Energy substrate oxidation,,2016-04-13,COMPLETED,INTERVENTIONAL,['NA']
9255,NCT03950713,HbA1c values,Depression and Anxiety Stress Scale (DASS-21),,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
9256,NCT02067013,Cytokine Levels,Serum Pharmacokinetics,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
9257,NCT02386579,RANKL,P1NP,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
9258,NCT03310749,"Gemigliptin AUCτ,ss Geometric Mean Ratio (and 90%CI)",Tmax,Incidence of treatment-emergent adverse events,2016-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9259,NCT00206297,Area under the curve for glucose,glucagon and gastric emptying,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9260,NCT00569452,"Pilot trial to establish endpoints such as ""time within target range of a composite fasting day""","AUC, MAGE, HbA1c, body weight change",,2006-01,COMPLETED,INTERVENTIONAL,['NA']
9261,NCT06291155,Glomerular basement membrane (GBM) width and mesangial expansion,Kidney Transcript Changes,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9262,NCT03616392,"(Part 2) Css,max of CKD-501","(Part 2) Swing[(Css,max-Css,min)/Css,min] of CKD-501",,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9263,NCT01518023,Fasting blood glucose,HbA1c,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9264,NCT04492722,Change From Baseline in Reduction of Urine Albumin to Creatinine Ratio (ACR) to Week 20,Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) to Week 12,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE2']
9265,NCT02797730,PedsQL Family Impact score to assess Family Quality of Life,satisfaction score,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
9266,NCT01030341,Hypoglycemic Episodes,Change in Gastroparesis Cardinal Symptom Index (GCSI) Total and Mean Score and Patient Assessed Gastro-Intestinal Quality of Life (PAGI-QOL) Score,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
9267,NCT04025775,Time in the target glucose range (5.6 to 10.0 mmol/l),AUC of glucose below 3.5 mmol/l,Average inter-dialytic weight gain,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
9268,NCT04660643,Percent Change from Randomization (Week 36) in Body Weight,Change from Baseline in IWQOL-Lite-CT Physical Function Composite Score,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
9269,NCT00481429,"The performance of baseline biochemical biomarkers in plasma and urine in distinguishing patients who respond to rosiglitazone from those that do not, as classified by a change in HbA1C at 12 weeks.",Effect of treatment on a variety of other novel potential predictive biomarkers and markers of insulin sensitisation in diabetic patients.,,2007-05,WITHDRAWN,OBSERVATIONAL,['NA']
9270,NCT02215252,Daily Pain Numeric Rating Scale (NRS),Plasma Concentration of PF-05089771,,2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9271,NCT01757587,Proportion of patients responding to treatment (HbA1c less than 7%),"Compare HbA1c and other clinical and laboratory parameters (fasting plasma glucose (FPG), fasting lipids, weight)",Evaluate more precisely the optimized glycemic control through a glycemic holter,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9272,NCT01569893,Glycated hemoglobin (HbA1c) levels,Number of visits with specialists in diabetic center,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9273,NCT01679197,Liver Histopathology,Body Weight,,2012-10-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9274,NCT00568035,Determine the safety of a three times daily application of QR-333 as compared to placebo.,Determine the efficacy of QR-333 on symptoms of diabetic neuropathy and the impact of QR-333 on the daily activities (including pain and sleep disturbance) of subjects with symptomatic diabetic neuropathy as compared to placebo.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9275,NCT03376802,Sleep energy expenditure,Pharmacokinetics,,2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9276,NCT03737240,Change in Hemoglobin A1c (HbA1c),Total Daily Insulin Dose,,2019-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9277,NCT01779375,M/I,Clamp Measure of Insulin Sensitivity,OGTT Measures of ß-cell Function and Glucose Tolerance,2013-06-16,COMPLETED,INTERVENTIONAL,['PHASE3']
9278,NCT01170208,Change in Weekly Mean Blood Glucose From Week 4 to Week 16,Incidence of Severe or Serious Hypoglycemia.,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
9279,NCT02770079,Change in insulin sensitivity,Changes in the microbiota,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
9280,NCT03185078,VAS,,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA']
9281,NCT01607385,Gastrointestinal Symptom Rating Scale,"Pharmcokinetic measures of GSK2330672, GSK1614235, GSK2313533, and GSK2313537.",,2012-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9282,NCT00609856,Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity,Effect of pioglitazone vs. insulin glargine on BNP,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9283,NCT00290394,Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.,,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9284,NCT05662462,The primary clinical outcome is the proportion of participants with an A1c <6.5% in the third trimester before delivery,Doctor-Patient Communication Scale,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9285,NCT00419835,effect of treatment on proteinuria after 8 months of follow-up,incidence of hyperkalemia,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9286,NCT01511159,Ratio of the areas under the plasma NN 90-1170 curves,Adverse events,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9287,NCT06146933,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-11-01,COMPLETED,INTERVENTIONAL,['NA']
9288,NCT04094740,changes in serum hemoglobin A1c level,Adverse events,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
9289,NCT03476967,Cup area,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
9290,NCT00116545,flow mediated brachial artery vasoactivity,carbohydrate and lipid metabolism,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9291,NCT03122093,TTG-IgA Serology,Presence of Celiac Disease Complications,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
9292,NCT00231192,serum fructosamine,quality of life,,2005-10,WITHDRAWN,INTERVENTIONAL,['NA']
9293,NCT03429543,Percentage of Patients With Treatment Failure up to or at Week 26,Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks,,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
9294,NCT00207207,Level of diabetic control as measured by 7-month HbA1c.,Number of hypoglycemic episodes.,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9295,NCT03819790,Time in range within 12-hours (6 AM -6 PM) at week 13,HCP treatment satisfaction score,,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9296,NCT00497172,in-stent LL,Target lesion or target vessel revascularization,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9297,NCT00482079,To asses the effectiveness of MK0431 compared to placebo,To test the safety and tolerability of MK0431 in patients with type 2 diabetes,,2003-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
9298,NCT05804097,Major Amputations,"TcpO2 before, during and after HBOT",,2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE4']
9299,NCT00541567,Absolute change from baseline in body weight (kg) and HbA1c (%),"Waist circumference, fasting glucose and insulin, HOMA analysis, blood lipids (triglycerides, total cholesterol, HDL-C, LDL-C, ApoB) and systolic/ diastolic blood pressure",,2008-03,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9300,NCT02201602,Mean blood glucose level,Glycemic variability,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9301,NCT04918784,Number of Participants With 100% Re-epithelialization,Number of Treatment Applications,Incidence of Adverse Events,2021-05-05,COMPLETED,INTERVENTIONAL,['NA']
9302,NCT02199470,We aimed to evaluate the extent of β-cell function by determining fasting levels of C-peptide and those after meal stimulus.,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
9303,NCT00955747,Change in Hemoglobin A1C Level From Baseline,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9304,NCT04706377,serum vitamin B12 levels,Adverse events,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
9305,NCT02738879,Percentage of Participants Who Experienced One or More Adverse Events (AEs),Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30,,2016-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9306,NCT03310502,Skeletal muscle insulin sensitivity,Coronary flow reserve,,2002-04-17,RECRUITING,OBSERVATIONAL,['NA']
9307,NCT03861052,Change From Baseline in Hemoglobin A1c (HbA1c),Number of Participants With Anti-Tirzepatide Antibodies,,2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9308,NCT00767000,Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event,Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9309,NCT02806700,Patient Activation,HbA1c,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
9310,NCT03387787,Random blood glucose <9.9 mmol/l in percent,"Time of glucose measurements derived from CGM in the following ranges: 0-<2.2 mmol/l, 2.201-<3.9 mmol/l, 3.901-<5.5 mmol/l, 5.501-<7.8 mmol/l, 7.801-<9.9 mmol/l, 9.901-<16.6 mmol/l, ≥16.601 mmol/l",,2018-01-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9311,NCT04108455,Adverse Neonatal Events,Triglycerides,,2019-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9312,NCT01715649,Hemoglobin A1c,Knowledge,Participant engagement with telehealth technology,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9313,NCT00722241,SEVEN.2 System accuracy as compared to Yellow Springs Instrument (YSI) venous blood glucose measurements,,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
9314,NCT02713568,Area Under the Receiver Operating Curve (AUROC) for prediction of macrosomia (≥ P95),Comparative prediction rate for neonatal hyperbilirubinaemia,,2016-03-08,COMPLETED,INTERVENTIONAL,['NA']
9315,NCT04564131,life quality,,,2021-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9316,NCT01499524,To establish whether raised serum bile acids are associated with abnormalities in cholesterol and triglycerides in the mother and fetus mother and fetus.,"To establish the relationship between raised serum bile acids in the mother and fetus and abnormalities in: Glucose homeostasis, gut liver signaling hormones related to FGF 19 and C4 levels, Gut hormone secretion",,2011-11,COMPLETED,OBSERVATIONAL,['NA']
9317,NCT00142701,,,,1999-04,COMPLETED,INTERVENTIONAL,['NA']
9318,NCT05776563,Change in magnetic resonance spectroscopy (MRS) to assess brain glucose changes,,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
9319,NCT05966272,Change From Baseline in HbA1c after 20 weeks of treatment,Number of AEs During the Trial,,2023-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9320,NCT02627690,Modification of Diet in Renal Disease (MDRD),number of deaths,,2014-11-03,COMPLETED,OBSERVATIONAL,['NA']
9321,NCT01185561,Center for Epidemiologic Studies Depression (CES-D) Score,State-Trait Anger Expression Inventory (STAXI) Anger Expression Sub-test Score,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
9322,NCT02462057,Enrollment in 10% Level of Benefit,,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9323,NCT04276051,Number of Adverse Events Related to the Cryoablation,Fasting Insulin Level,,2020-10-23,COMPLETED,INTERVENTIONAL,['NA']
9324,NCT05626712,Number of Participants with Adverse Events,C-peptide during a 4-hour MMTT,,2023-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9325,NCT00757276,Diagnosis of diabetes insipidus(DI) centralis versus psychogenic DI,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
9326,NCT01921322,Time to Target,Glycemic Variability,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
9327,NCT00749047,Reduction in proteinuria,Reduction in non-fasting plasma glucose concentration,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9328,NCT04010344,Change in Blood Pressure control by poverty status from Baseline,Change in the acceptability and usability of the Akoma pa app score as assessed by the Marshfield System Usability Survey,,2019-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9329,NCT00437489,Change in HbA1c From Baseline,Hypoglycemia Event Rate Per Month,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4']
9330,NCT03766438,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,"Total cholesterol, HDL cholesterol, and triglycerides will be measured from the same blood sample used to derive the outcome measure. LDL-cholesterol will be calculated for each participant based on these values.",,2019-02-14,COMPLETED,INTERVENTIONAL,['NA']
9331,NCT01386671,Glycosylated hemoglobin (HbA1c),Dismutase superoxide,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9332,NCT02800668,weight loss in kg,effect on blood pressure measured in mmHg,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
9333,NCT02300779,Efficacy of the bowel preparation,Predictors of inadequate bowel preparation,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9334,NCT00110500,To determine the maximum tolerated dose (MTD) of a single treatment by intramuscular injection by SB-509.,"To evaluate the lower extremity clinical effects of SB-509 treatment on lower limb diabetic neuropathy by symptoms, neurological examination, and lower extremity electrophysiological testing.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9335,NCT01762826,OGTT result,Adverse obstetric outcome,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
9336,NCT01089179,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
9337,NCT03737422,prediabetes,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
9338,NCT04236206,Glycemic Control,Medication Adherence,Diabetes-related Knowledge,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
9339,NCT04700813,pathogenic mutations causing type 2 diabetes,,,2019-09-13,UNKNOWN,OBSERVATIONAL,['NA']
9340,NCT05237219,Change in hemoglobin A1c level,Change in 24-hour blood pressure,,2022-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
9341,NCT03323216,Interleukin 6 (IL-6) [µg/L],,,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA']
9342,NCT00354237,"improvement of peak VO2,",improvement of ventilatory threshold,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
9343,NCT00383877,HbA1c,Within-subject variation of self measured blood glucose (SMBG) before breakfast during the trial at the end of the trial,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9344,NCT04838392,RIGHTEST Continuous Glucose Monitoring System Performance,RIGHTEST Glucose Monitoring System Related Adverse Device Effects,,2021-07,UNKNOWN,INTERVENTIONAL,['NA']
9345,NCT00315588,Insulin Independence.,"Reduction in Severe Hypoglycemia, Improvement in Hypoglycemia Awareness",,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9346,NCT05593926,HbA1c levels,To investigate usability,,2022-11-16,COMPLETED,INTERVENTIONAL,['NA']
9347,NCT05730998,urinalysis,urine culture,,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
9348,NCT00344370,NCEP LDL-C Target Attainment,Percent Change From Baseline in LDL-C,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9349,NCT00558883,effect of treatment of leucocyte count before and after test meal,"identification of gene arrays are registered of relevant pharmacodynamic structures and metabolism ways. Histological examinations of bioptats; Blood: hsCRP, PAI1; Lymphocyte subpopulations; blood lipids, plasma glucose fasting and postprandial",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9350,NCT06302127,CVD 10-year risk,total cholesterol,,2024-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9351,NCT04928872,"Prediction models of postprandial plasma amino acid patterns in relation to the macronutrient content of predefined meals as assessed by plasma concentrations of amino acids, glucose, and/or triglycerides","Discordance of glucose measurement after an intake of the predefined meal as measured by a fingerstick, continuous glucose monitor, and certified laboratory",,2018-06-20,COMPLETED,OBSERVATIONAL,['NA']
9352,NCT03259217,complete healing,rate of ulcer recurrence,,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
9353,NCT00760955,Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.,Change in Fasting C-peptide.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9354,NCT02796456,Biological measure : Maternal apelinemia (Plasma Concentration),Placenta weight,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
9355,NCT01671293,Change From Baseline in Weight Parameter,Change of Baseline in Waist Circumference,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9356,NCT06174129,Factors associated with atrial fibrillation,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
9357,NCT03544645,compare the impact of audiovisual educational materials verses printed educational materials,,,2017-07-16,COMPLETED,INTERVENTIONAL,['NA']
9358,NCT05144971,Nova StatStrip A Glucose/Creatinine Meter System,,,2021-10-28,COMPLETED,OBSERVATIONAL,['NA']
9359,NCT02456636,Mean Weight Change Over 24 Months; Adjusted,Mean Change in Stress Measured by PSS; Unadjusted Except for Affiliation,,2016-02-15,COMPLETED,INTERVENTIONAL,['NA']
9360,NCT04845685,CGM accuracy,CGM recorded hyperglycemia episodes,,2024-06-01,SUSPENDED,INTERVENTIONAL,['NA']
9361,NCT03096535,Difference in brown adipose tissue (BAT) activity after cooling versus no cooling.,Difference in resting energy expenditure after cooling versus no cooling,,2017-04-02,COMPLETED,INTERVENTIONAL,['NA']
9362,NCT05008276,Glomerular Filtration Rate (GFR),Renal oxygenation,,2021-09-27,RECRUITING,OBSERVATIONAL,['NA']
9363,NCT02491528,The change of relative baseline HbA1c,,,2015-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
9364,NCT03126981,Insulin sensitivity index (SI),Interleukin-6 (IL-6),,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
9365,NCT02940873,Difference in severe hypoglycaemia between study arms,Quality of Life - general,Changes in treatment modality,2017-03-09,COMPLETED,INTERVENTIONAL,['NA']
9366,NCT01406717,Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs),Change From Baseline in Total Cholesterol,,2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9367,NCT02879383,"Change From Baseline at 12 Weeks in MR-PDFF, DMR vs Sham",,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9368,NCT02758899,Absolute Disc Glycosylation Levels,Rates of Fusion,,2014-03,TERMINATED,OBSERVATIONAL,['NA']
9369,NCT02466880,Change in Hemoglobin A1c,Change in Cholesterol,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
9370,NCT01003236,Change from baseline in urinary albumin-creatinine ratio,Change from baseline in serum creatinine,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9371,NCT05505864,Objectively measured total sedentary behaviour,Validate the modified SIT-Q (no unabbreviated name) questionnaire,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
9372,NCT05667220,Fasting blood glucose change,Fecal DPP4 activity change,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9373,NCT05947916,The difference of Time in Range (TIR),"Number of newborns with neonatal birth injury, shoulder dystocia, neonatal jaundice, neonatal respiratory distress syndrome (RDS)",Adverse event record,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
9374,NCT02791867,Reduction in glycated Haemoglobin measured: HBA1c,Reduction in serum triglyceride level (mmol/l),,2014-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9375,NCT02940379,Assessment of metoprolol PK parameter: AUC,Assessment of PK parameter: t1/2z,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9376,NCT01276912,HbA1c >= 6.5%,HbA1c >= 7.0%,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
9377,NCT03520413,Hemoglobin A1c,Patient Health Questionnaire-8,,2018-12-21,COMPLETED,INTERVENTIONAL,['NA']
9378,NCT02750280,Incidence of wound healing,Incidence of ulcer recurrence,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9379,NCT00861809,Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters),Food intake,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9380,NCT05396443,"Change in diet quality of adolescent participants, as measured by the Healthy Eating Index Scores",Change in high blood pressure status,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
9381,NCT03502304,Lipoproteins,Six minutes walking test,,2017-06-10,COMPLETED,INTERVENTIONAL,['NA']
9382,NCT06061172,Time spent in hospital during the preceding six months,Patient satisfaction with clinical performance as assessed by the European Task Force on Patient Evaluation of General Practice Care questionnaire,,2023-10-02,RECRUITING,INTERVENTIONAL,['NA']
9383,NCT00786500,HbA1c (glycosylated hemoglobin),"Body weight (BMI, hip-waist ratio)",,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9384,NCT02261168,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in liver volume and liver lipid concentration during the day,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
9385,NCT04572945,Percentage of foot abnormalities in diabetic CKD patient,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
9386,NCT04750577,Change from baseline in log transformed Urine Albumin Creatinine Ratio (UACR) measured in 10-hour urine after 20 weeks of trial treatment,Number of patients achieving UACR decreases in First Morning Void urine of at least 20% from baseline after 20 weeks of trial treatment,,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
9387,NCT04636411,Inflammation,Total or ionized Mg,,2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9388,NCT01152385,Change in Haemoglobin A1c (HbA1c),Change in High-sensitivity C-reactive Protein (Hs-CRP),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9389,NCT02041598,Change in Baseline Hemoglobin A1c at 6-Months,Change in Baseline Lipid Profile at 6-Months,,2009-07-01,COMPLETED,INTERVENTIONAL,['NA']
9390,NCT03668301,Central venous oxygen saturation,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9391,NCT01472185,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9392,NCT02136199,Frequency of use of decision aids in clinical encounters by weekly reports,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
9393,NCT00484198,Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,,2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
9394,NCT02083133,Hypoglycemia,,,2013-10-01,COMPLETED,OBSERVATIONAL,['NA']
9395,NCT00467688,Daily time spent in the hypoglycemic glucose range during continuous glucose measurement with and without real time access to glucose values and glucose alarms,Time spent in euglycemic and hyperglycemic glucose range Satisfaction with CGMS Diabetes related distress Treatment satisfaction Anxiety and depressive symptoms,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
9396,NCT02918175,Change in mean weekly step count,Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score,Change in plasma metabolic profile,2017-08-02,COMPLETED,INTERVENTIONAL,['NA']
9397,NCT02627911,"Percentage of time spent in the tight glycemic control area 80-140 mg / dl during the night, continuously measured for 3 days with CGM","Measurement of AUC during physical activity , the two hours, then to lunch time , during dinner and throughout the night",,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9398,NCT03581968,Percentage of time of sensor glucose levels spent in target range,Number of participants experiencing hypoglycemia requiring oral treatment during:,,2018-07-02,COMPLETED,INTERVENTIONAL,['NA']
9399,NCT01060332,"Body Constitution Questionnaire, BCQ",Diabetes Impact Measurement Scales,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
9400,NCT03315663,Effectiveness of Sweetch's PIP compared to usual care to lower A1C,Evaluation of whether intervention reduces blood pressure.,,2017-07-01,WITHDRAWN,INTERVENTIONAL,['NA']
9401,NCT05844644,The change in glycemic control as measured by change in weight (percentage of total weight) from baseline at Days 90 and 180 following the G4LP and supplementation with Release.,The change in quality of life from baseline at days 90 and 180 following the G4LP and supplementation with Release.,Clinically relevant changes in red cell distribution width (RDW) after 180 days.,2023-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
9402,NCT06325202,Towler questionnaire,all-cause mortality,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9403,NCT02561338,"After 12-week Treatment, the Change From Baseline in HbA1c",Change From Baseline in FPG,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9404,NCT03038789,"Descriptive analysis of the percentage (%) of adverse events (AEs), serious adverse events (SAEs), unexpected adverse events∙adverse drug reactions and AEs of special interest (AESI)",Number of Participants With Abnormal Laboratory Values,,2017-04-20,COMPLETED,OBSERVATIONAL,['NA']
9405,NCT00765830,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9406,NCT04262479,GAD65A titer in serum,Change in maximum C-peptide during Mixed Meal Tolerance Test (MMTT),,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9407,NCT01427569,The percent reduction in wound area at week 4 compared to the baseline visit,The percentage of lesions that demonstrate at least 50% reduction in area by the end of week 4 compared to baseline visit,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9408,NCT05808972,Number of participants with composite endpoint achievement,Total insulin dose received,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9409,NCT02122731,average daytime systolic and diastolic blood pressure,urine plasminogen and plasmin,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9410,NCT03732209,Change in delay discounting,Change in waist and hip circumference,Perceived treatment effectiveness and ease of use,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9411,NCT00605475,Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT ),"Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9412,NCT04169243,Time in Target at gestational week 32,Diet quality measuremen¨t,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
9413,NCT01050205,Changes in Weight Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.,Changes in Diastolic Blood Pressure (BP) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9414,NCT01006915,To determine if lower extremity nerve decompression in patients suffering from symptomatic diabetic peripheral neuropathy significantly alleviates pain.,Quality of Life,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
9415,NCT01265563,Change From Baseline in Urinary Albumin Excretion,"Urinary Alpha-1 Microglobulin, Inflammatory Cytokines and C-C Chemokines",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9416,NCT00012675,,,,na,WITHDRAWN,OBSERVATIONAL,['NA']
9417,NCT04009889,HOMA-IR value in week 36-40,,,2018-04-05,COMPLETED,INTERVENTIONAL,['NA']
9418,NCT04882293,Describe the proportion of subjects who reduced levels of LDL cholesterol,Events and adverse reactions presented.,,2022-02-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
9419,NCT00776607,Change in fasting serum C-peptide level over 24 months and (2) change in HbA1c level over 24 months in patients with LADA.,Hypoglycaemic events,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
9420,NCT06135935,The primary outcome will be area under curve for the plasma glucose response over 120 minutes after consumption of the ice creams.,CGM monitor readouts over 24 hours after consumption of the ice creams.,,2023-11-12,RECRUITING,INTERVENTIONAL,['NA']
9421,NCT06186063,Relative changes in the plasma levels of N-terminal propeptide of type I procollagen (P1NP),Changes in plasma concentrations of osteocalcin,,2024-02-12,RECRUITING,INTERVENTIONAL,['NA']
9422,NCT01600664,Quality of life,Hyperglycemia events,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
9423,NCT02306343,assessment of skin irritation,area under the curve,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
9424,NCT06141590,Cmax,,,2023-03-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9425,NCT02787785,All-Cause Mortality,Sudden Death in various subgroups,S-ICD device complications,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
9426,NCT02032459,Maternal Vitamin D Status,Vitamin D Status in relations to pregnancy complications,"Relationship of Vitamin D to maternal diet, etc.",2007-04,COMPLETED,OBSERVATIONAL,['NA']
9427,NCT05514548,Change in UACR from baseline to W16,Change in eGFR using cystatin C and the CKD-EPI formula from baseline to W16,,2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
9428,NCT02589756,persistent organic pollutants,Triglycerides,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9429,NCT01984489,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12,Change From Baseline in Body Weight at Week 12,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9430,NCT01216865,Angiographic evaluation of angiogenesis at ischemic limb,Rate and extent of amputations,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9431,NCT03792607,RNA sequencing analysis both in CD4+ and CD8+ cells,ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients,,2019-02-14,UNKNOWN,OBSERVATIONAL,['NA']
9432,NCT01206400,pioglitazone effect on testosterone level,,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
9433,NCT00947557,Hemoglobin A1c (HbA1c),Fasting Plasma Glucose (FPG),,2009-07,TERMINATED,INTERVENTIONAL,['PHASE3']
9434,NCT00311870,change in glomerular filtration rate from study start to study end,change in urinary albumin excretion rate,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9435,NCT02220257,Development of chronic complication of diabetes (retinopathy or neuropathy or nephropathy),,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
9436,NCT06109597,Complications associated with gestational diabetes mellitus,,,2022-05-23,COMPLETED,OBSERVATIONAL,['NA']
9437,NCT04699864,Manual Analysis of Retinal Images - Severity of Diabetic Macular Edema (DME),Performance of NeoRetina Algorithm - Diabetic Macular Edema (DME),,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9438,NCT00005761,,,,2000-05-23,COMPLETED,OBSERVATIONAL,['NA']
9439,NCT04854330,Cardiac output,VEGF,,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA']
9440,NCT01267591,RHPAT,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
9441,NCT04668612,Time in range (TIR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner.,Time above range (TAR) during 2 weeks receiving dual-wave bolus versus standard bolus,,2020-09-04,UNKNOWN,INTERVENTIONAL,['NA']
9442,NCT05593133,Dynamic Gait index,,,2021-01-05,COMPLETED,INTERVENTIONAL,['NA']
9443,NCT02883127,HbA1c,"Maternal after measurement of subcutaneous skin folds (biceps, triceps, suprailiac and subscapular).",,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
9444,NCT02416440,prevalence of diabetes mellitus and associated cardiometabolic and infectious risk factors using the oral glucose tolerance test,"inform health policy and public health programmes aimed at addressing the rise in NCDs in South Africa, which may also shape public health strategies in other African countries",,2014-01,COMPLETED,OBSERVATIONAL,['NA']
9445,NCT00462202,Observed ACR level from the first visit to the end of study,,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
9446,NCT01549769,Area under the curve,Maximum observed concentration,,2012-04-30,TERMINATED,INTERVENTIONAL,['PHASE1']
9447,NCT01438632,BG-AUC0-2h (mmol•min-1•l-1): area under the baseline-subtracted plasma glucose concentration time-curve from time 0 to 2 h after insulin injection and meal ingestion.,BG-AUC0-1h,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9448,NCT03590626,Change in liver fat,Change in Biochemical Markers,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
9449,NCT00873821,Change From Baseline to Day 13 in Weighted Mean Plasma Glucose Concentration,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
9450,NCT02280733,death,Wound related quality of life,,2005-01,RECRUITING,OBSERVATIONAL,['NA']
9451,NCT01634997,Hemoglobin A1c,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
9452,NCT03345901,Diabetic Retinopathy Worsening or Diabetic Macular Edema (DME) Development (Composite Outcome),,,2018-01-15,TERMINATED,INTERVENTIONAL,['PHASE3']
9453,NCT01510665,Change in maternal biomarkers in pregnancy in the third trimester,Pregnancy complications,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
9454,NCT00344500,Change in Predicted Trajectory of Mean Body Fat Percentage Per GLMM Analysis,,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
9455,NCT00542204,Hemoglobin A1C,"Patient psychosocial well-being (e.g., diabetes-related emotional distress)",,2008-03,COMPLETED,INTERVENTIONAL,['NA']
9456,NCT01143727,Wound Appearance,Percent Change in Wound Area,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9457,NCT00951899,Total Disposition Index,Lipid Values,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9458,NCT00468442,Insulin independence,"reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, quality of life",,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
9459,NCT01766752,The primary endpoint is the percentage of actions the system supports either to capture BG values or provide insulin dose suggestions according to the REACTION algorithm.,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9460,NCT01017848,development of diabetes using a predicting formula,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
9461,NCT05897216,AUCt of CKD-383,,,2023-07-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9462,NCT01040676,Hemoglobin A1c,Waist Circumference,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
9463,NCT04952779,Incidence of Adverse Events (AEs) by preferred term,Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG),,2021-06-02,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9464,NCT05397028,Efficacy of plant-based meal replacement system on A1-C levels,Efficacy of plant-based meal replacement system on insulin levels,,2022-12-08,TERMINATED,INTERVENTIONAL,['NA']
9465,NCT05779644,Abdominal fat distribution,,,2023-02-23,RECRUITING,INTERVENTIONAL,['NA']
9466,NCT00004363,,,,1995-12,COMPLETED,OBSERVATIONAL,['NA']
9467,NCT00572689,"glycemic control through insulin, glucose, c-peptide and glucagon assays",Exenatide Pharmacodynamics and Pharmacokinetics,,2013-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9468,NCT04376112,Medication adherence,,,2020-10,WITHDRAWN,INTERVENTIONAL,['NA']
9469,NCT01497587,Area under the insulin detemir concentration curve,Insulin detemir half-life,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9470,NCT00698802,HbA1c,Total daily insulin dosages,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9471,NCT00506194,Short-term intensive insulin therapy can decrease the insulin resistance and improve the Beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia.,Improve long term glycemic control,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
9472,NCT00064727,,,,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9473,NCT03092063,Change in Diabetes Self-Management Behaviors (Revised Summary of Diabetes Self-Care Activities),Glycemic control,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9474,NCT03724383,Changes in Quality of Life on SF36,Left Atrial Pressure,,2018-09-06,UNKNOWN,INTERVENTIONAL,['NA']
9475,NCT04462081,Percentage of Liver Fat as Measured by MRI-PDFF,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
9476,NCT02839512,Change in glycosylated hemoglobin A1c,Weight loss (%TBWL),,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9477,NCT00078052,cardiovascular disease,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
9478,NCT03956290,Percentage of patients who reduced eating duration by 4 hours,% of participants who achieve ≥ 5% weight loss,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
9479,NCT05173675,Hemoglobin A1C (HbA1c),Diabetes distress measured by the 2-item Diabetes Distress Screening Scale,,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9480,NCT01313286,Maximum Observed Drug Concentration (Cmax),,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
9481,NCT04473209,serum resistin,clinical attachment loss,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
9482,NCT04057521,Annual outpatient visit healthcare utilization per patient per 1000 patient years,Annual total healthcare expenditures per patient,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
9483,NCT01349387,Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
9484,NCT01064583,painfree walking distance,endothelial function,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9485,NCT01179165,Prevalence of cardiac abnormalities/disease according to different examination modalities,"Feasibility of transthoracic coronary Doppler examination/Coronary Flow Reserve, and diagnostic yield related to MRI",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9486,NCT04862390,Hypoglycemia incidence with fasting,Time below range (TBR),,2021-03-28,COMPLETED,OBSERVATIONAL,['NA']
9487,NCT03482674,Body weight reduction,Quality of life,,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA']
9488,NCT02161276,The decline glycosylated hemoglobin A1C and blood glucose level,The clinical composite safety evaluation of Tangning Tongluo Capsule in the treatment of type II diabetes participants,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9489,NCT01263470,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9490,NCT03251755,PSQI,ABI,,2017-05-24,COMPLETED,INTERVENTIONAL,['NA']
9491,NCT04526613,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,,2021-04-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9492,NCT01683266,Change In HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9493,NCT00947635,Cholesterol and fatty acid synthesis,Blood lipid levels,,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9494,NCT06308549,Diabetes Distress,Events of ketoacidosis/severe hypoglycaemia,MyDiaMate usage data,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9495,NCT00475345,"Incidence of nocturnal hypoglycemia (< 4mmol/L) occurring between 11pm and 7am, as determined with the Continuous Glucose Monitoring System (CGMS) and hemoglobin A1c","Nadir nocturnal BG, timing and duration of nocturnal hypoglycemia, fasting BG, lipid profile, psychosocial factors, total insulin dose, insulin sensitivity and body composition (weight, BMI, % fat, waist circumference).",,2000-08,COMPLETED,INTERVENTIONAL,['NA']
9496,NCT05759468,The primary endpoint is the change from baseline in UACR over the 6-month intervention period.,Assess the change in measure of fasting glucose as a measure of glycemic control over the 6 months intervention period.,,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE2']
9497,NCT01041859,Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12,Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9498,NCT04093752,Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia,,2019-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9499,NCT00499148,positive AUC for plasma glucose,positive AUC for serum insulin; adjusted peak values for plasma glucose and serum insulin; baseline plasma glucose and serum insulin concentrations; adjusted values for plasma glucose and serum insulin at individual postprandial time points.,,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9500,NCT01599143,PSS-10,Toronto Mindfulness Scale (TMS),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9501,NCT01018628,"To determine the pharmacokinetic profile of SRT2379 (25, 75, 250, 500, 1000, 2000, 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male volunteers after single and multiple dose administration in the fasted and fed states.",To identify other possible biomarkers suitable for future clinical assessment of oral SIRT1 activators.,,2009-12-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9502,NCT01963156,Medication adherence,Full adherence to medications for the treatment of diabetes or cardiovascular disease,Rates of de-synchronization,2013-11,TERMINATED,INTERVENTIONAL,['NA']
9503,NCT04819256,HbA1c,Implementation of care model,,2020-12-07,TERMINATED,INTERVENTIONAL,['NA']
9504,NCT04983277,UK Prospective Diabetes Study risk score,,,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9505,NCT01831804,AUC(0-t) of GSK1278863 (Part B),,,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE1']
9506,NCT04963998,Incidence of Treatment-Emergent Adverse Events,Rate of change in percent of fibrin tissue,,2019-10-02,COMPLETED,INTERVENTIONAL,['NA']
9507,NCT03487692,Hemoglobin A1C,CAHPS Provider Communication,Health center provider/staff satisfaction,2018-10-18,COMPLETED,INTERVENTIONAL,['NA']
9508,NCT04320719,number of patients with treatment,biological characteristics of patients,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
9509,NCT00682916,"without any altering of dietary habits or exercise routine, individuals shall lose or maintain body weight during the active phase as compared to the placebo phase.",blood lipid levels during the active phase will be improved relative to the placebo phase.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
9510,NCT00596427,Rate of Appearance of Exogenous Glucose (Glucose Absorption),Glucagon AUC,Glucose AUC,2007-11,COMPLETED,INTERVENTIONAL,['NA']
9511,NCT00325611,Quality and cost of care,Lower total costs 6 months past hospitalization,,2002-04,COMPLETED,INTERVENTIONAL,['NA']
9512,NCT01159938,Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 240 Minutes (Mins) Post-Breakfast,Change in Postprandial Pulse Wave Velocity (PWV),,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9513,NCT04706286,Cmax of CKD-393,,,2021-02-18,UNKNOWN,INTERVENTIONAL,['PHASE1']
9514,NCT00259727,Insulin secretion after a single dose of HIV protease inhibitor versus placebo (insulin secretion assessed by using the hyperglycemic clamp technique),Hepatic glucose production during a somatostatin infusion in the fasting and hyperinsulinemic state after a single dose of HIV protease inhibitor,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
9515,NCT03663803,changes in physical activity.,cholesterol,,2011-01-19,COMPLETED,INTERVENTIONAL,['NA']
9516,NCT00468403,Proportion of subjects with insulin independence,"Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9517,NCT03055468,Depression Clinical Remission,,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9518,NCT00548158,ETDRS visual acuity,retinal thickness measured by OCT,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
9519,NCT04742829,number of patients with improved/worsened macular edema,number of patients with improved/worsened blood parameters related to diabetes,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
9520,NCT00001344,,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9521,NCT01440790,Incremental Area Under the Curve over 4 hours in serum TRAP (total peroxyl radical-trapping potential),Change from baseline in serum TRAP over 6 hours,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
9522,NCT03352518,Generation and validation of predictive calibration models,Safety assessment of the intervention by the paucity of adverse events,,2017-12-28,COMPLETED,INTERVENTIONAL,['NA']
9523,NCT06204107,"Cmax of Empagliflozin, sitagliptin, metformin","Vd/F of Empagliflozin, sitagliptin, metformin",,2023-11-21,COMPLETED,INTERVENTIONAL,['PHASE1']
9524,NCT03325114,Hyperglycemia,,,2019-06-28,TERMINATED,INTERVENTIONAL,['PHASE2']
9525,NCT01472341,Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) According to Quartiles of Proinsulin/Insulin (PI/I) Ratio,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9526,NCT02493374,Mitigation of Type 2 Diabetes,,,2016-05,WITHDRAWN,OBSERVATIONAL,['NA']
9527,NCT05383391,"Studying patients' knowledge, practice and barriers of foot self-care among diabetic patients attending Sohag University Hospital",,,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9528,NCT00238472,Change from baseline in postprandial glomerular filtration rate at 12 weeks,Change in insulin AUC (0-240 minutes) at 12 weeks,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9529,NCT02316483,HBA1C >8.5% on total and gene-specific methylation.,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
9530,NCT03443986,Peripheral circulation,Plantar pressure distribution,,2018-02-26,UNKNOWN,INTERVENTIONAL,['NA']
9531,NCT05342740,Basic clinical and demographic information of participants in groups,,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9532,NCT01947699,Glucose levels throughout the day,,,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9533,NCT03358394,Mindfulness,,,2017-10-26,UNKNOWN,INTERVENTIONAL,['NA']
9534,NCT01822431,number of participants with abnormal results,,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
9535,NCT00405418,Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.,Physical examination,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9536,NCT00728143,Glycemic Index,Palatability,,1989-08,COMPLETED,INTERVENTIONAL,['NA']
9537,NCT00266643,Subscale of the UKU side effect rating scale to be measured during the switch period. The weeks during which the switch occurs are blinded.,"Weekly: Leeds Sleep Evaluation Questionnaire, Brief Profile of Mood States, Clinical Global Impression of Severity. Visits 2, 7, 11: Treatment Satisfaction Questionnaire for Medic",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9538,NCT01278121,Changes in microarray gene expression,"Inflammatory markers, hormonal dietary responses and blood lipids",,2011-02,COMPLETED,INTERVENTIONAL,['NA']
9539,NCT00590044,Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups,Difference in Time in Hours to Resolution of DKA Between the 2 Groups,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9540,NCT04288778,Percentage of Participants With Adverse Drug Reactions (ADRs),Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24,,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE4']
9541,NCT00361946,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
9542,NCT04974528,Change in HbA1c,Change in HbA1c,Change in percent predicted Forced Expiratory Volume in 1 Second (FEV1),2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9543,NCT05386186,Reduction of hemoglobin A1c from baseline at the end of the trial.,The level of weight gain,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9544,NCT00819975,Triglyceride levels,Incretin levels,,na,COMPLETED,INTERVENTIONAL,['NA']
9545,NCT03687320,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA']
9546,NCT06297239,prevalence of high level of Lp(a),,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
9547,NCT00290940,Mean change from baseline in HbA1C after 12 weeks compared to placebo,Proportion of subjects discontinuing or requiring rescue for continued or worsening hyperglycemia,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9548,NCT01888133,Change in steps/day,Change in A1c,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
9549,NCT02166372,Evaluate the natural course of the diabetes of obese patients over a period of 10 years,,,2014-03,RECRUITING,OBSERVATIONAL,['NA']
9550,NCT02646072,Level of aqueous inflammatory cytokines post treatment as assessed using Bio-plex Pro Assays,Changes from baseline in central subfield retinal thickness as assessed by optical coherence tomography,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9551,NCT00358033,"The number of patients who had non-compliance to ADA target goals in smoking, LDL cholesterol, blood pressure or Hb A1c.",,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9552,NCT02752113,Effect of empagliflozin plus linagliptin vs metformin plus insulin glargine on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion),"changes in albuminuria (urinary albumin to creatinine ratio [UACR]), assessed in the 24-hour urine",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9553,NCT04300764,Change in mean daily step count during hospitalization,Change in life space assessment,,2026-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9554,NCT00465478,Exogenous insulin requirement; Hemoglobin A1C; Glucose and C-peptide level;,"lipid profile, autoantibody， Quality of life",,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9555,NCT02898428,Hypoglycemia,,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
9556,NCT05277532,Time in Glucose target range (4-10 mmol/L) for tissue glucose from CGM.,Time below Glucose target range (< 4 mmol/L) for tissue glucose from CGM.,,2022-05-18,RECRUITING,INTERVENTIONAL,['NA']
9557,NCT03125369,% of patient achieve HbA1c<6%,BMI change (kg/m^2),,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
9558,NCT02012478,hemoglobin A1C,PAM scale,Summary of Diabetes Self-Care Activities,2014-02,COMPLETED,INTERVENTIONAL,['NA']
9559,NCT00124553,All measures to be compared at end of study (6 months),All measures to be compared at end of study (6 months),,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
9560,NCT04190849,Survival,Asymptomatic progression of liver disease,,2017-11-14,RECRUITING,OBSERVATIONAL,['NA']
9561,NCT03925805,Self-perceived health status (SF-12),Illness perception (IPQ-B),,2019-11-12,COMPLETED,OBSERVATIONAL,['NA']
9562,NCT00685698,Clinical Success (in ITT Population),"Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9563,NCT01498614,Prevalence of depression,Level of A1C,,2009-03,TERMINATED,INTERVENTIONAL,['NA']
9564,NCT02049034,Postprandial glucose kinetics,Postprandial and intestinal triglyceride-rich lipoproteins (TRL) kinetics,Post heparin lipoprotein lipase activity,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9565,NCT02779790,Blood pressure - diastolic blood pressure,,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
9566,NCT00239187,To assess the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,To evaluate the pharmacokinetics (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9567,NCT03320694,maternal glycemic control,Neonatal hypoglycemia,,2016-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9568,NCT00276393,Mean fasting glucose,Continuos glucose monitoring,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9569,NCT04986345,Change in ambulatory systolic and diastolic blood pressure,Change in plasma C-peptide,,2021-10-04,RECRUITING,INTERVENTIONAL,['NA']
9570,NCT00149435,Cardiac health,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
9571,NCT05962983,change in hemoglobin A1c% (HbA1c%),change in waist circumference (inches),eating motives,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9572,NCT00776243,Difference of incretin secretion before and after intensive insulin therapy,Factors affecting incretin secretion,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
9573,NCT02129868,Time spent with plasma glucose concentration in the target glucose range from 3.9 to 8.0 mmol/l.,Absolute relative difference between matched pairs of subcutaneous glucose sensor and reference plasma glucose.,nature and severity of any other adverse events,2014-04,COMPLETED,INTERVENTIONAL,['NA']
9574,NCT03076697,Disease diagnosis based on photography,Automated disease diagnosis,,2015-04-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9575,NCT03788915,Weight change,HbA1C change,Retention rate change,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA']
9576,NCT01364766,CGM usefulness score,Diabetes Comfort score,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
9577,NCT04916470,Change in body weight,Number of treatment emergent severe or clinically significant hypoglycaemia episodes,,2021-06-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9578,NCT00279318,"Appearance of one or more islet cell autoantibodies: GADA, IAA, or IA-2A confirmed at two consecutive visits.",Development of T1DM,,2004-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9579,NCT04857411,Change in Diastolic Blood Pressure,Newest Vital Sign (NVS),,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
9580,NCT03477838,Change in A1c,Glycemic Variability,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
9581,NCT01348867,To assess the effectiveness of the nurse consultant led clinic in improving glycemic parameters in patients with type 2 diabetes,A comparison of the patients' utility of healthcare services,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
9582,NCT02827903,change of HbA1c,,,2016-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9583,NCT05379296,Change from Baseline Serum insulin at 12 months,Change from Baseline C-reactive protein at 12 months,,2022-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
9584,NCT02674893,Modifications in wanting,Anthropometric modifications,,2014-02-04,TERMINATED,INTERVENTIONAL,['PHASE4']
9585,NCT02402517,Exercise intensity,Substrate Oxidation,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9586,NCT01660009,Flow induced Dilation of the Brachial Artery (FMD%),Mitochondrial superoxide production,,2012-06,TERMINATED,INTERVENTIONAL,['NA']
9587,NCT05026528,HbA1c,,Patient-reported outcome and experience measures,2021-11-30,RECRUITING,INTERVENTIONAL,['NA']
9588,NCT03074383,Change in glycated hemoglobin from baseline at 12 months,Variation of Summary of Diabetes Self-Care Activities Questionnaire (SDSCA) from baseline at 12 months,,2017-03-20,COMPLETED,INTERVENTIONAL,['NA']
9589,NCT01684917,Metabolomic Biomarker Discovery - Changes in Blood Plasma Cholesterol,Body Weight,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
9590,NCT01608776,Wound Reduction,,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE4']
9591,NCT02005848,Beta cell function,Safety parameters,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9592,NCT02018627,Tmax,Dermal Response (Draize Scale Grade for Edema Formation),,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9593,NCT00593567,"Number of Participants With a Clinical Outcome of ""Clinical Cure""",Time to Positive Clinical Response,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9594,NCT03104543,"Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)",Primary Care Provider Attitudes,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9595,NCT03510078,Cardiac ischemic events,Length of hospitalization,,2018-04-17,RECRUITING,INTERVENTIONAL,['NA']
9596,NCT05000996,Estimated 10-year risk of atherosclerotic cardiovascular disease,Blood inflammatory proteins,,2021-08-19,RECRUITING,OBSERVATIONAL,['NA']
9597,NCT05883267,Anxiety assessment - trait anxiety,VR Satisfaction and effectiveness assessment,,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
9598,NCT05498610,"Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose","Cmax,sema,SD The maximum plasma concentration of semaglutide after a single dose",,2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9599,NCT06095622,Improvement in blood glucose levels,,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
9600,NCT01930136,The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
9601,NCT04592263,Patient Reported Outcome,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
9602,NCT03042520,Number of participants with hepatocellular carcinoma (HCC) development during 5-year follow-up period after sofosbuvir-based treatment,Renal disease,,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
9603,NCT03056014,Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.,,,2018-11-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
9604,NCT03407222,change in daily step count after 12 weeks of intervention,low-density lipoprotein cholesterol,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9605,NCT04152408,Incidence of (Serious) Adverse Events,User satisfaction assessed by the Likert scale,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
9606,NCT05106231,laboratory-analysed HbA1C improvement (HbA1c level below 42mmol/mol or 6.5%),Diabetes knowledge improvement (scores in percentage),,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
9607,NCT02672839,Pharmacokinetics Analysis- Maximum Concentration (Cmax),Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9608,NCT01204294,Incidence of Adverse Events (AEs),Glycosylated Haemoglobin A1c (HbA1c),,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9609,NCT02731716,Improvement in Provider Performance,Primary Care Spending,,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9610,NCT04866823,Acceptability of Study Measures,Change in Time Below Range (Hypoglycemia),,2021-10-20,COMPLETED,INTERVENTIONAL,['NA']
9611,NCT00069368,Urinary Outcomes,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
9612,NCT01558271,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9613,NCT01593605,Glucose Control,Metabolic Markers,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9614,NCT03543449,Operative mortality,Perioperative time-weighted average glucose,,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA']
9615,NCT02175537,Waist circumference,Health Profile Survey,Social Network Relationships,2014-06,COMPLETED,INTERVENTIONAL,['NA']
9616,NCT00605111,HbA1c,FPG,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9617,NCT00386100,Change From Baseline in HbA1c at Week 80,"Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9618,NCT02184676,Autoreactive T lymphocytes,Incidence of autoantibodies,,2015-05-28,COMPLETED,INTERVENTIONAL,['NA']
9619,NCT03324451,Change in Glycosylated Hemoglobin (HbA1c) Levels,Change in Body Mass Index,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
9620,NCT00258674,"Change Score for ""Blood Pressure (b.p.) <130/80 mmHg""","Change Score for ""Semiannual HbA1c Assessment"" (as Determined From Medicare Claims Data)",,2000-01,COMPLETED,INTERVENTIONAL,['NA']
9621,NCT02919059,Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period regarding central systolic blood pressure,Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation index,,2016-12-13,UNKNOWN,INTERVENTIONAL,['PHASE4']
9622,NCT04797416,Difference value,,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9623,NCT04443842,Glycemic control,Change in physical activity level,Change in health service utilisation,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
9624,NCT01719003,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24,Body Weight Change From Baseline at Week 24,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9625,NCT05473806,Changes in Liver Stiffness Measurement at 24 weeks compared to baseline.,Analysis of predictors of HbA1c improvement after 24 weeks compared to baseline.,,2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9626,NCT02122835,exercise capacity,nitrite flux during exercise,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
9627,NCT05343767,To compare the hypoglycemic effect of two doses of a herbal medicinal product (NW Low-Glu) to that of Metformin as measured by the mean change in HbA1c levels in patients newly diagnosed with type II diabetes mellitus.,To compare the mean change in the 2h-post prandial glucose levels between each experimental arm and active-control arm (efficacy),To investigate the effect of NW Low-Glu on weight.,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
9628,NCT02760303,Metabolic Control,Diabetes Quality of Life,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9629,NCT05981547,Glucose variability,A analysis of CGM glucose data for progression of glycaemia in a sub group,,2023-11-22,RECRUITING,OBSERVATIONAL,['NA']
9630,NCT01021865,To determine whether hyperglycemia alters myocardial perfusion in subjects with type 2 diabetes,To determine whether GLP-1 modulates myocardial perfusion in subjects with type 2 diabetes.,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
9631,NCT05572502,Glycated hemoglobin,medication usage,,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9632,NCT02558491,Glucose Variability (Coefficient of Variation),Total Rescue Carbohydrates (CHO) (Grams),,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9633,NCT00788827,Number of Participants Who Experienced Adverse Events,Serum Creatinine,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9634,NCT01440660,Multimodal testing/imaging procedures - Brain Imaging,Multimodal testing/ imaging modalities (raw data),,2012-01,COMPLETED,OBSERVATIONAL,['NA']
9635,NCT01034111,Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose at Week 4,,2010-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9636,NCT06096311,Qualitative Results from Interviews,,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
9637,NCT00796848,To evaluate the effectiveness of continuous glucose monitoring in the reduction of hypoglycemia unawareness.,To assess the levels of epinephrine production in youth diagnosed with hypoglycemia unawareness with and without continuous glucose monitor wear.,,2009-03,WITHDRAWN,INTERVENTIONAL,['NA']
9638,NCT05963594,"Incremental area under the curve (iAUC) of post-prandial glycemic excursion induced by Oligomalt relative to maltodextrin over the observation period: iAUC 0-1 hour, iAUC 0-2 hours, iAUC 0-3 hours.",Plasma peptide tyrosine (PYY),Plasma peptide tyrosine (PYY),2023-01-23,COMPLETED,INTERVENTIONAL,['NA']
9639,NCT05687968,Fasting glucose,Triglyceride (TG),,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
9640,NCT04016415,Change in Hemoglobin A1c from Baseline to 6 months,Change in Perceived Stress Scale-10 from Baseline to 6 months,,2020-07-28,RECRUITING,INTERVENTIONAL,['NA']
9641,NCT01970462,Difference in Fasting Glucose,,Hypoglycemia,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
9642,NCT04982640,Acceptability as indicated by participant satisfaction ratings,Body Mass Index,,2022-10-24,RECRUITING,INTERVENTIONAL,['NA']
9643,NCT01409239,Difference Between Heart Rate Variability Between Intravenous and Subcutaneous Group,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9644,NCT05759676,Target lesion failure(Device-oriented composite endpoints),Procedural success rate,,2023-03-09,RECRUITING,OBSERVATIONAL,['NA']
9645,NCT00500175,incident foot ulcers,temperature spikes on foot zones,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
9646,NCT02974491,Evaluating adequacy of the dialysis treatment,,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9647,NCT03229161,Compliance to the prescribed IWT-intervention,Physical fitness,BMI,2017-01-03,COMPLETED,INTERVENTIONAL,['NA']
9648,NCT02585674,Percentage of patients reaching fasting SMPG target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of device Ease of Use using Ease of Use questionnaire,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9649,NCT05026775,Rate of Initiation,Reduction of Cardiovascular Risk,Rate of Mortality,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9650,NCT00543361,This study will assess the lipid lowering effectiveness of MK0767 compared to metformin over the course of 52 weeks.,MK0767 will be safe and well tolerated.,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3']
9651,NCT05570305,Change from baseline in albuminuria after 4 weeks combined zibotentan and dapagliflozin treatment versus four weeks treatment with zibotentan alone.,Change in systolic and diastolic blood pressure,Change in copeptin,2022-10-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
9652,NCT01934673,Proportion of patients having HbA1c ((glycosylated haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
9653,NCT01095666,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9654,NCT01793974,Identify variations in the human genome associated with LADA by genotyping cases and comparing allele frequencies to an existing control database,Identify associations between genetic variants with certain measurable risk profiles that can be used to judge the health status or well being of a LADA case.,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
9655,NCT00594399,12 Month Fasting Glucose,"Physical Activity, Endurance",,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9656,NCT01277965,Number of episodes of symptomatic or non-symptomatic hypoglycaemia,Duration of hypoglycaemia,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
9657,NCT00916838,,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
9658,NCT06317454,Identification of genetic factors affecting T1DM metabolic control,,,2021-11-11,RECRUITING,OBSERVATIONAL,['NA']
9659,NCT03686423,Apparent Diffusion Coefficient (ADC) in the Tibial Nerve,,,2018-11-28,COMPLETED,INTERVENTIONAL,['NA']
9660,NCT03234387,Maximal oxygen uptake (aerobic fitness),Insulin concentration,,2017-11-17,TERMINATED,OBSERVATIONAL,['NA']
9661,NCT04733690,Satiety,,,2021-02-04,UNKNOWN,OBSERVATIONAL,['NA']
9662,NCT03627039,"Cardiovascular composite (stroke, myocardial infarction, heart failure)",Costs,Tracer outcomes,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA']
9663,NCT02091778,Change in Peri-wound Skin,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
9664,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator,Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year,Major Ocular Adverse Events During First Year of Follow-Up,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9665,NCT01028391,"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54","Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54",,2007-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9666,NCT01951859,Decrease in area or closure of wounds/fissures due to Homeopathic Anti-inflammatory Topical Cream,,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
9667,NCT05844137,Acceptability of intervention by participants,Change in medication adherence,,2023-09-18,COMPLETED,INTERVENTIONAL,['NA']
9668,NCT01671189,Glycemic Control (hemoglobin A1c),Appointment Adherence Rate,,2012-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9669,NCT04161937,HbA1C,,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9670,NCT05979142,Composite standard,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
9671,NCT05951946,"Cmax,ss",,,2023-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
9672,NCT03374098,Changes in HbA1C values,Physical Activity,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9673,NCT04979559,Oral glucose tolerance test mean change from baseline,Likelihood ratio of screening instrument compared to American Diabetes Association criteria,Participant's acceptance of mobile health application,2021-05-25,UNKNOWN,INTERVENTIONAL,['NA']
9674,NCT04908904,Area under the curve for glucose,Area under the curve for GIP,,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
9675,NCT00903799,clinical efficacy,medico-economic evaluation of ENTERRA therapy,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9676,NCT01261143,TSS,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9677,NCT01513525,Area under the Curve (AUC) of liraglutide for each injection site,Adverse events,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9678,NCT01274364,Percentage of patients who attain 2 or more of the 'ABC' targets,Default rates at end of study,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
9679,NCT02956759,Proportion of eyes progressing to any degree of PDR,Sensitivity & specificity of the diagnosis of any degree of PDR among study ophthalmologists,Patient vision-related quality of life (VRQOL); composite and individual domain scores of the NEI VFQ25 questionnaire.,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
9680,NCT03700034,"Mean number of four selected ANC components delivered by the healthcare providers per visit, observed over two visits- the trial enrolment visit and the next routine ANC appointment.",Mean number of quality antenatal care components delivered in the enrolment visit,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9681,NCT02843399,Diabetes-related HCRU/costs,Medical Hypoglycemic events,Composite of A1C <7%/no weight gain/no hypoglycemia,2016-08-15,COMPLETED,OBSERVATIONAL,['NA']
9682,NCT03620266,Plasma levels of LDL cholesterol,Body composition with multi-frequency biothesiometry,,2021-09-30,RECRUITING,INTERVENTIONAL,['NA']
9683,NCT01202526,Change in insulin sensitivity after RYGB,Change in insulin secretion in response to oral glucose after RYGB,Change in insulin secretion after iv glucose-glucagon after RYGB,2010-09,COMPLETED,OBSERVATIONAL,['NA']
9684,NCT01955031,"To assess effectiveness of our telemonitoring program in Diabetes care, HbA1C assays will be compared between the two groups.The change of HbA1c between day 0, month 1,month 3, month 6, month 9 and month 12","For the telemonitoring arm, acceptability and satisfaction of the telemonitoring system by the health professionals with the number and time of connections leading to a medical decision (phone call or medical appointment) and a questionnaire",,2013-11,COMPLETED,INTERVENTIONAL,['NA']
9685,NCT02855684,Change in HbA1c from baseline,Change in daily basal insulin dose,,2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE3']
9686,NCT05457088,Dietary intake of macro- and micro-nutrients,Protein carbonyls in plasma,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
9687,NCT05076292,Incidence rate of hypoglycemia (PG < 3.9 mmol/l),Point accuracy with the Clarke Error Grid Analysis (CEGA) (using SMBG and YSI as the reference value),,2021-11-23,COMPLETED,INTERVENTIONAL,['NA']
9688,NCT02652754,Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood,,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9689,NCT00935922,Improved lipid profile,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9690,NCT03179137,Myocardial production of reactive oxygen species,Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia,,2016-10-01,UNKNOWN,OBSERVATIONAL,['NA']
9691,NCT05182970,Time to major CV event,Diabetes diagnosis,Hypoglycaemia,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3']
9692,NCT01252056,nephropathy development,Adverse events,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9693,NCT04234763,Postprandial 1H-NMR metabolites,Dietary Glycemic load(GL),,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9694,NCT03629301,Change in body weight,Number of participants achieving 5% of weight loss,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
9695,NCT03717896,plasma bicarbonate levels,hospital resource usage,Cognitive function: Test of Premorbid Functioning,2018-11-21,RECRUITING,INTERVENTIONAL,['PHASE2']
9696,NCT00852982,HbA1c,waist circumference,,2006-04,UNKNOWN,INTERVENTIONAL,['NA']
9697,NCT02579070,Percentage of patients developing a foot ulcer,Rate of change of score in quality of life from baseline and up to the final visit using the EQ-5D-5L,,2016-02-08,COMPLETED,INTERVENTIONAL,['NA']
9698,NCT02213146,Area under the curve (AUCins(0-1h)),Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 2 hours,,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9699,NCT04078854,Change in hemoglobin A1c (HbA1c) levels,Number of patients with mobility problems,,2020-07-08,TERMINATED,INTERVENTIONAL,['NA']
9700,NCT06065540,CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight,"CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of severe hypoglycaemic episodes (level 3)",,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE3']
9701,NCT01706133,Change in hand grip strength (HS) as a physical performance test,Evaluation of individual and institutional impact,Quantify hospital readmissions,2013-06,COMPLETED,INTERVENTIONAL,['NA']
9702,NCT00041444,,,,2002-06,COMPLETED,OBSERVATIONAL,['NA']
9703,NCT00793481,Changes in Microvascular,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9704,NCT05504239,Changes from baseline HbA1c at week 24,Changes from baseline in BMI at week 24,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE3']
9705,NCT02906709,Percentage of Participants Who Discontinued Study Drug Due to an AE Including Data After Glycemic Rescue (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only]),Percentage of Participants Achieving Hemoglobin A1c Goals (<6.5%) at Week 52 (Phase A+B),,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE4']
9706,NCT06042153,Change in TIR (70-180 mg/dl),Total score of Kidney disease QoL short form,,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE4']
9707,NCT04509791,the area under the stimulated C-peptide response curve,"continuous glucose monitoring (CGM) measurements ( time in range, time above time below)",,2020-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9708,NCT03006510,The proportion of patients (in each group) who ultimately have a hypoglycemic event,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
9709,NCT01584063,Physical Activity,"Metabolic (e.g., glucose)",,2004-02,COMPLETED,INTERVENTIONAL,['NA']
9710,NCT02472951,Insulin sensitivity,,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9711,NCT05637437,Health Related Quality of Life,Systolic and Diastolic Blood Pressure,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9712,NCT03049592,Utilization of LARC,Acceptability of contraceptive counseling intervention by patients and clinicians,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
9713,NCT05976191,Blood Glucose Measurement Patient Satisfaction Form,,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
9714,NCT04678284,Acceptability of Intervention,Diabetes Medication Adherence,,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
9715,NCT05376930,"Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP","Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP",,2021-09-16,COMPLETED,INTERVENTIONAL,['PHASE3']
9716,NCT00225888,Subjects' hemoglobin A1c (A1c) values,Subjects' self-care behaviors,,2004-10,TERMINATED,INTERVENTIONAL,['NA']
9717,NCT01651065,Weight,"Hemoglobin A1c (%, HbA1c)",Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.,2011-06,COMPLETED,INTERVENTIONAL,['NA']
9718,NCT04114357,Change in the gut microbiome profile,Changes in Beta cell Health.,Changes in phenotype of Mucosal Associated invariant T (MAIT) cells,2020-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
9719,NCT03550378,Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32,Number of Participants With Positive Anti-drug Antibodies (ADA) Titre to MEDI0382,,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE2']
9720,NCT01006603,Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.,Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β],,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9721,NCT05141214,Short-term behavior modification,Satisfaction Survey,,2023-02-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9722,NCT00174824,level recoded integer ETDRS retinopathy scale,the incidence of hypoglycemia,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9723,NCT01167881,The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.,The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9724,NCT00518427,Glycaemic controll will be asessed by HbA1c values,Incidence of symptomatic hypoglycemia and severe hypoglycemia,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9725,NCT01923181,Change in HbA1c (Glycosylated Haemoglobin),Number of Confirmed Hypoglycaemic Episodes Recorded,,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9726,NCT03243903,glycosylated hemoglobin (HbA1c),Self-monitoring of blood glucose(SMBG),Subject Satisfaction,2017-08-18,COMPLETED,INTERVENTIONAL,['NA']
9727,NCT01690169,Number of treatment emergent adverse events (TEAEs),"tmax, the time to maximum plasma concentration of NNC0113-0987",,2012-09-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9728,NCT00479986,"Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation)","Metabolic control (HbA1c, Glucose)",,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9729,NCT00304733,wound surface area reduction,time to wound healing (days),,2001-08,UNKNOWN,INTERVENTIONAL,['NA']
9730,NCT01522157,P-Triglycerides,P-HDL-Cholesterol,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
9731,NCT00943501,Number and type of adverse events,Pharmacodynamics: Fasting Plasma Glucose (FPG) and insulin,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9732,NCT01448070,"Area under the curve (glucose infusion rate (GIR)), 0-8h",Physical examinations and vital signs,,2002-10-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9733,NCT00975286,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,"Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24",Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9734,NCT03626155,Mean 24-hour glucose,Respiratory Exchange Ratio (RER),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
9735,NCT01497132,Beta cell function,Hypercalcemia,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9736,NCT06003530,Treatment related adverse events,Wound healing,,2022-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9737,NCT04605900,Change the 6 minutes walk test performance,Satisfaction with devices,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA']
9738,NCT05386160,capillary non-perfusion zone of non-proliferative diabetic retinopathy,Determination of inflammatory factors in anterior aqueous humor,,2022-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9739,NCT01245270,Plasma Insulin iAUC (Incremental Area Under the Curve; ng/ml*Min),Bioavailability in Urine,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9740,NCT05917587,blood flow response to insulin,Percentage of nitric oxide-dependent dilation,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9741,NCT03156361,Glucose area under the curve,total units Insulin,,2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
9742,NCT05518448,EGP,Plasma β-OHB,,2022-05-03,RECRUITING,INTERVENTIONAL,['NA']
9743,NCT02099838,Change of HbA1c From Baseline at Week 12,Change of LDL From Baseline at Week 12,Change of DBil From Baseline at Week 12,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9744,NCT01316094,changes in Hemoglobin A1c (HbA1c),"safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs",,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE3']
9745,NCT01753362,HbA1c,Glucose Concentrations,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9746,NCT01177813,Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks,Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP),Confirmed Hypoglycaemic Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9747,NCT02759055,Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke,,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
9748,NCT03697369,Discontinuation rate differences,Glycemic control and metabolic parameters differences:BMI SDS,,2015-05-31,COMPLETED,OBSERVATIONAL,['NA']
9749,NCT05962710,System Performance,,,2023-01-27,TERMINATED,OBSERVATIONAL,['NA']
9750,NCT00309127,Death and/or ESRD defined as need for dialysis or plasma creatinine 500mmol/l,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",,2003-05,COMPLETED,INTERVENTIONAL,['NA']
9751,NCT05112588,Diabetes mellitus type 2,Glucose tolerance,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9752,NCT03394157,excess weight loss,Resolution of diabetes,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
9753,NCT03745300,change in defect depth,change in modified Sulcus Bleding Index (mSBI),,2017-03-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9754,NCT01520818,HbA1c (glycosylated haemoglobin A1c),Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2),,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9755,NCT06157736,Describe evolution of the microbiome and metabolome during the early stages of new onset T1D,,,2023-10-06,RECRUITING,OBSERVATIONAL,['NA']
9756,NCT04964128,"Percentage of Time in Range (Phase 2, Software Release Tag 2.0)",,,2021-07-22,COMPLETED,INTERVENTIONAL,['NA']
9757,NCT01477957,Energy metabolism,Insulin sensitivity,,2012-09,RECRUITING,OBSERVATIONAL,['NA']
9758,NCT03723772,"AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state",Positive cross-reactive anti-human insulin antibodies,,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
9759,NCT03103867,Time in glucose target,hypoglycaemia fear in patients and caregivers,,2017-02-23,COMPLETED,INTERVENTIONAL,['NA']
9760,NCT01035801,AUC (Insulin and Blood Glucose),Frequency of Adverse Events,,2010-08-21,TERMINATED,INTERVENTIONAL,['PHASE1']
9761,NCT04626531,The Diabetes Quality of Life Scale,Website Analysis and Measurement Inventory,,2016-01-10,COMPLETED,INTERVENTIONAL,['NA']
9762,NCT00127634,To assess change in baseline to endpoint in HbA1c in type 1 diabetic patients.,To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to glycemic control as assessed by the 8-point self-monitored blood glucose profiles,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9763,NCT01680328,Injection Pain (VAS mm),Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9764,NCT00212641,Fasting Blood Glucose at 8 weeks,Pharmacodynamic parameters at all time points,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9765,NCT05512624,Pill Count Medication Adherence,,Incidence of seizure,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
9766,NCT01519674,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcome by Use of the Treatment Related Impact Measure - Diabetes.,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9767,NCT02789033,Biopsies,,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9768,NCT01286922,Insulin Sensitivity,Cardiorespiratory Fitness,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
9769,NCT03814915,Glycemic deterioration,,,2012-10-15,COMPLETED,OBSERVATIONAL,['NA']
9770,NCT03862521,"Change in hormone (epinephrine, norepinephrine, glucagon) response to hypoglycemia",Change in lipid profile from baseline to 6 months,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
9771,NCT04733508,Gene expression,,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
9772,NCT03734107,Diabetes-related hospitalizations,,,2018-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9773,NCT05762744,Exenatide effect on glucose disappearance rate,,,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9774,NCT00442858,,,,1999-01,COMPLETED,OBSERVATIONAL,['NA']
9775,NCT00717977,Glucose Variability Measure: Amplitude of Glycemic Excursions by Time of Day,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9776,NCT03772964,"Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to Metformin.",Measure Biogenesis of PBMCs.,,2019-01-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9777,NCT01490619,Change in Depressive symptoms from baseline to post intervention and change in Depressive symptoms over the two year study period.,Change in Glycemic Control from baseline to post-intervention and change in Glycemic Control over time during the two year study period.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
9778,NCT04763772,Step counts by Actigraphy.,,,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9779,NCT02827630,Week 4 Change in Systolic Blood Pressure,Number of Treatment-Related Adverse Events,Provider Reported Outcomes: Results from a provider satisfaction [to DH] questionnaire administered at the end of using DH.,2015-05,COMPLETED,INTERVENTIONAL,['NA']
9780,NCT06296550,HbA1c,Diabetes Distress Scale,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9781,NCT00979225,Rates of aggregate adherence by study group to all applicable pharmacotherapy rules during the study period.,Inpatient hospitalization rates.,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
9782,NCT00637338,"To describe the safety and tolerability of escalating, multiple, subcutaneously injected doses of PF-04603629 administered to subjects with T2DM.","To evaluate the effect of multiple, escalating, subcutaneously injected doses of PF-04603926 on additional exploratory efficacy biomarkers related to this drug's target in subjects with T2DM.",,2008-04,TERMINATED,INTERVENTIONAL,['PHASE1']
9783,NCT05977218,HbA1c (mmol/mol),Self-reported quality of life,24-hour dietary recall,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9784,NCT00804232,Primary Outcome Measure: the child's metabolic control as shown in HbA1C,"Quality of life, Satisfaction with care, Family impact and family climate, psychological variables, parental absenteeism from work; time use which is conditional on the child's diabetes etc), formal health care utilisation",,2008-01,UNKNOWN,INTERVENTIONAL,['NA']
9785,NCT04230694,Number of Hypoglycemia Events during hospitalization,Number of Hyperglycemia Events during hospitalization,,2021-09-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9786,NCT00996294,"Diabetes control, define by FSG and HbA1c",Diabetes control defined by FSG and HbA1c,,2007-11,UNKNOWN,INTERVENTIONAL,['NA']
9787,NCT03287297,Blood Glucose Level,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
9788,NCT00053534,,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
9789,NCT02040038,Change in Physical Activity,Change in Lipid Levels,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
9790,NCT00367055,Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment,Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9791,NCT01410292,glycemic control,measures of satiety and appetite,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
9792,NCT01508481,Incidence of diabetes,Insulin resistance,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9793,NCT03899883,Albumin Excretion Rate (AER),Change in serum uric acid (sUA),,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9794,NCT04307797,Part B - Changes in absolute concentrations of PCr and ATP defined by AHA 17- segment territory as a measure of cardiac energy status (determined by 31P-MRS),Part A/B - gastric inhibitory polypeptide,,2022-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
9795,NCT05572814,"Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record.",Quality of Life Outcome-PAM,,2022-09-30,RECRUITING,INTERVENTIONAL,['NA']
9796,NCT03627377,Hemoglobin A1c or HbA1c,Smoking - Change in Smoking through Recall,,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA']
9797,NCT01309620,Markers of oxidative damage,Vascular indices,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9798,NCT03880838,Diastolic Blood Pressure From One Year Before to One Year After Intervention,Five Years Before to Two Years After Intervention in Depressed Mood and Anhedonia as Assessed by the Patient Health Questionnaire-2 (PHQ-2) (Extended Time Frame),,2019-06-20,COMPLETED,INTERVENTIONAL,['NA']
9799,NCT03301519,Pancreatic Beta Cell Compensation for Insulin Resistance,Circulating adipokine levels,,2001-07-01,COMPLETED,OBSERVATIONAL,['NA']
9800,NCT05035966,Prediabetes,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
9801,NCT02330848,Diet Quality assessed using the Alternative Healthy Eating Index (AHEI),Physical Activity assessed by the International Physical Activity Questionnaire (IPAQ),,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9802,NCT02130804,Change in plasma C-peptide levels over a 2-hour oral glucose tolerance test,Change in physical activity,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9803,NCT00480493,Worry,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9804,NCT00156364,Structural-functional relationships in diabetic nephropathy through detailed quantitative studies of Podocytes.,We will continue our study the natural history of diabetic nephropathy.,We have compared the development of calcineurin lesions in the native kidneys of 14 tacrolimus- and 12 calcineurin-treated pancreas transplant alone recipients cured of type 1 diabetes.,1981-01,COMPLETED,OBSERVATIONAL,['NA']
9805,NCT01769183,Proportion with complete regression of neovascularization on fundus photography at one month,Mean Change in Visual Acuity from Baseline to 5 Months,Proportion with partial regression of neovascularization on fundus photography,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9806,NCT01889095,Number Of Hypoglycemic events,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9807,NCT00592397,"Changes in microarray gene expression profiles in blood and subcutaneous abdominal fat tissue from healthy obese men, as a consequence of changes in dietary macro nutrient composition.",Time to stabilization of gene expression changes due to dietary intervention.,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
9808,NCT03155412,Adipogenic capacity of preadipocytes,Lipid metabolism,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
9809,NCT05473078,Evaluate the attitudes by general practitioners towards pre-diabetes,,,2021-10-21,COMPLETED,OBSERVATIONAL,['NA']
9810,NCT03871660,Hyperglycaemia,,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
9811,NCT00686712,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9812,NCT03419195,Change in muscular mitochondrial function,,,2018-02-07,COMPLETED,INTERVENTIONAL,['NA']
9813,NCT01213212,"Glomerular Filtration Rate (GFR), absolute and percent change, at 6 months vs baseline.",Metabolic and inflammatory parameters.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9814,NCT01357304,Physical activity level,"Quality of life, measured using the EQ-5D questionnaire",,2011-03,COMPLETED,INTERVENTIONAL,['NA']
9815,NCT02491801,"Blood Glucose (Study 1, 2 and 3)",,"Food Intake Measured at 120 minutes (Study 1), and at 15 and 30 minutes (Study 3)",2015-03,COMPLETED,INTERVENTIONAL,['NA']
9816,NCT03242031,cost of treatment,,,2017-06-21,RECRUITING,INTERVENTIONAL,['NA']
9817,NCT03980990,Lactic Acidosis,All cause mortality at hospital discharge,,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE4']
9818,NCT06288555,The accuracy of the Ipswich touch test,,,2023-12-21,COMPLETED,OBSERVATIONAL,['NA']
9819,NCT04658693,Functional Gait Assessment (FGA),Neuropathic Pain Syndrome Inventory (NPSI),,2021-03-02,RECRUITING,INTERVENTIONAL,['NA']
9820,NCT04164784,HbA1c,UCAR,,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA']
9821,NCT05349916,Postprandial glycemic response,Postprandial insulin response,,2021-12-07,COMPLETED,INTERVENTIONAL,['NA']
9822,NCT05235672,GADA in serum of subjects with T2D,,,2021-01-30,COMPLETED,OBSERVATIONAL,['NA']
9823,NCT04109547,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Participants With Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1,,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9824,NCT01017523,Blood glucose control (hemoglobin AIc),Diabetes-related quality of life outcome (distress),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9825,NCT00643851,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9826,NCT04416204,Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes,Rates of Gluconeogenesis in Healthy Subjects,,2020-08-21,COMPLETED,INTERVENTIONAL,['NA']
9827,NCT04347291,Change in Psychosocial Well-being (Patient Participants) Sustained Post-intervention Effect,Change in Support Burden (Support Person Participants) Sustained Post-intervention Effect,Change in Support Person Involvement Alignment (Support Person Participants - Outcome & Mediator),2020-04-28,COMPLETED,INTERVENTIONAL,['NA']
9828,NCT03050645,Type 2 diabetes,"Questionnaires, physical activity (PAS 2), physical activity score",,2011-06,COMPLETED,OBSERVATIONAL,['NA']
9829,NCT00924105,Incidence of adverse events,Biological measures of glycemia and inflammation,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9830,NCT03017703,Insulin sensitivity measured by a insulin clamp,Vascular function,,2016-12-01,COMPLETED,INTERVENTIONAL,['NA']
9831,NCT04880005,"Change in a binary indicator, composed by a composite endpoint of HbA1c, systolic blood pressure, low-density lipoprotein cholesterol, no smoking, and normal albuminuria",Change in quality of life measured by European Quality of life - EQ VAS,,2021-05-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9832,NCT05643521,The primary outcome is the 1H-Magnetic Resonance Spectroscopy (MRS) determined liver TG content.,"Secondary outcomes are fasting and postprandial plasma glucose, insulin, and plasma TG concentrations after 2 days VLCD or LC compared with 2 days of eucaloric conventional diet.",Explorative outcomes,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9833,NCT02229240,Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26,"Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations",,2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
9834,NCT05676593,Rate of change in glycated hemoglobine at 3 months,Eating behavior questionnaire,,2023-05-03,RECRUITING,INTERVENTIONAL,['NA']
9835,NCT00241956,,,,2005-10,TERMINATED,OBSERVATIONAL,['NA']
9836,NCT04485351,Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic.,"Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.",,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
9837,NCT00505284,Mean Change in Average Pain Scores From Baseline at Each Study Week,Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9838,NCT01855087,Blood glucose level,,,na,COMPLETED,OBSERVATIONAL,['NA']
9839,NCT02632383,Glycemic control measured by HbA1c,Health Care Climate measured by HCCQ-questionnaire,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
9840,NCT03138616,Change in glucose metabolism,change in metabolism of calcium and phosphorus,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9841,NCT00542113,Diabetes knowledge and prevention of parents of elementary school children,Self-reported parental physical activity,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
9842,NCT00856908,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9843,NCT01719406,"Achieving 30 minutes of daily exercise, four or more times each week",Eating 5 or more servings of vegetables and/or fruits each day,HemoglobinA1C,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9844,NCT03531021,Adolescent Food Habits Checklist,Change in weight,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
9845,NCT05694169,Primary Endpoints is as follows:,Second Secondary Endpoint,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
9846,NCT04190212,Glucose variability,Changes in blood biomarker concentrations,Link between glucose variability and atrial fibrillation symptom severity,2021-11-18,RECRUITING,INTERVENTIONAL,['NA']
9847,NCT01957592,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2014-10,WITHDRAWN,OBSERVATIONAL,['NA']
9848,NCT04053621,hemoglobin A1c,arterial elasticity,,2021-01,UNKNOWN,INTERVENTIONAL,['NA']
9849,NCT05277558,Executive Function,,,2022-05-24,RECRUITING,OBSERVATIONAL,['NA']
9850,NCT03188263,Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT),Changes in Circadian Phase Measured by Dim Light Melatonin Onset (DLMO),,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
9851,NCT02082132,Frequency of MODY,Comparison of clinical and biochemical characteristics of other subtypes of diabetes,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
9852,NCT01923350,"In testing group, the number of women receiving a diabetes test per ADA Guidelines in the 6-month post-intervention period",Weight change from 6 to 9 months,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
9853,NCT06147245,Change in HbA1c (mmol/mol),Screening for diabetic nephropathy - Urine albumin (mg)/creatinine (g) ratio,Participants' acceptance of intervention,2023-10-09,RECRUITING,INTERVENTIONAL,['NA']
9854,NCT01055093,Change of insulin sensitivity (M-Value),Incidence of any diabetic complication,,2005-09,RECRUITING,OBSERVATIONAL,['NA']
9855,NCT03673111,Incidence of Treatment-Emergent Adverse Events (safety and tolerability),Body weight,,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9856,NCT01718457,percent change in BMI,percent in Triglycerides levels,change in C-peptide levels,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
9857,NCT00320060,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9858,NCT02219750,HbA1c,total insulin dose,C peptide,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9859,NCT03031886,energy expenditure,,Nitrogen production,2016-01-20,COMPLETED,INTERVENTIONAL,['NA']
9860,NCT00214565,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) (US only).,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
9861,NCT01373814,cardiac function,lipidomics,,2010-09-03,COMPLETED,OBSERVATIONAL,['NA']
9862,NCT05306990,Mean Change from baseline in Low Density Lipoprotein Cholesterol (LDL-C),,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
9863,NCT00762138,Assess the incidence of hematological immunologic other ae's association with the application of AutoloGel on exuding wounds such as leg ulcers pressure ulcers and diabetics ulcers and during the management of mechanically or surgically debrided wounds,Absence of coagulopathies caused by inhibitors to coagulation Factor V as determined by a significant prolongation of the (PT) time. Depletion of Factor V activity with a positive Bethesda Assay,,2008-09,TERMINATED,INTERVENTIONAL,['NA']
9864,NCT02696070,Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
9865,NCT03204149,Safety,Wound Healing,,2017-06-14,TERMINATED,INTERVENTIONAL,['NA']
9866,NCT05878587,Numeric Pain Rating Scale,Ankle Brachial Index,Goniometer,2023-03-31,COMPLETED,INTERVENTIONAL,['NA']
9867,NCT04585191,Patient-Reported Outcome: Number of Participants with Self-Reported Hypoglycemia,Patient-Centered Outcome: Number of Participants with improved scores on Perceived Efficacy in Patient - Physician Interactions,"HbA1c Change from baseline to study completion, an average of 1 year",2020-11-02,RECRUITING,INTERVENTIONAL,['NA']
9868,NCT05711043,Proportion of subjects with a clinically relevant reduction of insulin dose after 12 months,Cost-effectiveness,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9869,NCT02457897,Hemoglobin A1C,Muscle Glucose Uptake,,2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2']
9870,NCT02513277,Plasma glucose,Depression,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
9871,NCT03936829,Average daily insulin dosage,HbA1c level,,2019-04-28,RECRUITING,INTERVENTIONAL,['NA']
9872,NCT05913726,Clinician preparation time,Clinician learning,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
9873,NCT05800509,Number and percentage of participants with interventional health education as accessed by the medical record of their infants' body weight in kilograms.,,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9874,NCT05171998,To determine whether SARS-CoV-2-specific T-cells cross-react with insulin producing cells in the pancreas of people with Type 1 diabetes.,To determine if expression of HLA A*02 and/or HLA A*24 is more common in Type 1 diabetes patients with SARS-CoV-2 cross-reactive T cells,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
9875,NCT04786054,BED,NR3C1 Presence of variants of the GR gene (rs56149945; rs41423247),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
9876,NCT04303754,Postprandial blood glucose,Appetite,,2020-06-24,COMPLETED,INTERVENTIONAL,['NA']
9877,NCT00423488,"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment",,,2005-07-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9878,NCT03003507,Glycemic Variability,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9879,NCT01771614,Pancreatic endocrine function,Oxidative stress,,2016-08,WITHDRAWN,INTERVENTIONAL,['NA']
9880,NCT01173939,"MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic event",Frequency and type of adverse events,,2010-07,TERMINATED,INTERVENTIONAL,['NA']
9881,NCT01907516,Compliance With Home Blood Glucose Reporting,Subject Satisfaction,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9882,NCT02285881,"The between groups difference in the proportion of patients which achieve the treatment goals for HbA1c, blood pressure, and total cholesterol",The difference in coping style between baseline and 24 months within and between both groups as measured with the Diabetes Coping Measurement Questionnaire.,Process evaluation of the shared decision making ability of the general practitioners by using the Shared Decision Making Questionnaire.,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9883,NCT02155855,hemoglobin A1c,Frequency of contact with diabetes care team,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
9884,NCT01204580,Adiponectin and Asymmetric Dimethylarginine (ADMA) plasma level changes,Change of Tumor Necrosis Factor- Alfa (TNF-Alfa),,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9885,NCT02917031,Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks,Number of Participants With Adverse Events,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9886,NCT04235829,Correlation between early % total weight loss and % total weight loss 7 years following surgery.,Reduction or cessation in the treatment for either type 2 diabetes mellitus and hypertension 7 years following surgery..,,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
9887,NCT02520336,Postpartum Diabetes screening in GDM patients,,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
9888,NCT00287820,c-peptide,TD Scores,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9889,NCT02490553,airway obstruction,diabetes mellitus,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9890,NCT06139133,Gestational diabetes mellitus with 75g OGTT,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9891,NCT01785524,Change in Exercise Capacity - Claudication Onset Time (COT),Change In Vascular Function,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9892,NCT00097279,HbA1c,8-point plasma glucose profiles,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9893,NCT02647736,Half life of Copeptin,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
9894,NCT05945862,Triglycerides,Lifestyle,,2023-07-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9895,NCT00201227,practice adherence to diabetes guidelines,practice adherence to tobacco history taking guidelines,,2002-09,COMPLETED,INTERVENTIONAL,['NA']
9896,NCT01708044,Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment,Safety,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9897,NCT05400694,Insulin,Food pleasantness,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
9898,NCT04125160,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,,2019-11-12,COMPLETED,OBSERVATIONAL,['NA']
9899,NCT00308737,FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care,Change in Weight From Baseline at Month 24,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9900,NCT02646878,24 hour calibration requirement,,,2016-01,WITHDRAWN,INTERVENTIONAL,['NA']
9901,NCT03799796,Time-in-Range,Online peer support engagement,,2019-01-06,COMPLETED,INTERVENTIONAL,['NA']
9902,NCT02120794,Overall Mean Change in A1C,"Mean Change in A1C From Baseline to 1 Year, Stratified by Different A1c Subgroups",,2014-06,COMPLETED,INTERVENTIONAL,['NA']
9903,NCT00950963,Number of Patients With a Low Density Lipid (LDL) Value Less Than 100 mg/dL,Number of Patients With Hgb A1c Less Than 7 Percent at the End of the Study,Number of Total Emergency Department (ED) Visits and Hospital Admissions During the Follow up Period.,2005-09,COMPLETED,INTERVENTIONAL,['NA']
9904,NCT00642616,Change in Post-bronchodilator FEV1 From Baseline to Week 52,Change in HbA1C From Baseline to Week 52,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3']
9905,NCT01233063,Change in added sugar,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9906,NCT03904901,Anxety,BMI,,2018-07-20,UNKNOWN,INTERVENTIONAL,['NA']
9907,NCT04256720,Clustering of common lifestyle behaviours,Examine associations socio-demographic factors and lifestyle behaviours,,2018-12-10,RECRUITING,OBSERVATIONAL,['NA']
9908,NCT03426540,best corrected visual acuity,central retinal thickness,,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9909,NCT00659451,"Left ventricular mass, intraventricular septal thickness, fractional shortening; myocardial qualitative and diastolic function alteration; aortic strain and distensibility.",Heterogeneity of myocardial tissue; epicardial adipose tissue measurement,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
9910,NCT03707171,Changes of cognitive function assessed by cognitive function scale after 12 weeks.,Change of waist-to-hip ratio,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9911,NCT04190693,Serious Adverse Events,,,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9912,NCT03315780,Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]),Number of Participants Who Develop Hypoglycemic Events,,2017-10-28,COMPLETED,INTERVENTIONAL,['PHASE4']
9913,NCT00238862,Persistent corneal re-epithelialization (= lasting success),,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
9914,NCT04037436,Feasibility - Adherence,Resource use,,2019-09-24,COMPLETED,INTERVENTIONAL,['NA']
9915,NCT02356224,SHR3824 and its metabolites of concentrations to characterize SHR3824 harmacokinetics.,The number of patients with adverse events as a measure of safety and tolerability,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9916,NCT05804513,Growth hormone area under the curve.,Aldosterone peak,Heart rate,2023-04-17,RECRUITING,INTERVENTIONAL,['PHASE4']
9917,NCT04004793,Incidence of patients with diabetes remission,Net change in Albuminuria,,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9918,NCT00793741,Brain glucose concentration as measured by NMR spectroscopy,,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
9919,NCT02233140,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from baseline to 4 weeks.,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from 1 month to 3 months.,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
9920,NCT01469715,Absolute Relative Difference (ARD),,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9921,NCT00572806,Blood glucose value,Hypoglycaemic episodes,,2003-02-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9922,NCT03191435,Glycated hemoglobin in 12 weeks,Lung functions,,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA']
9923,NCT02346669,40% decrease in insulin resistance compared to baseline,Maintenance of altered of enteric microbiota in the three diet groups,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
9924,NCT00596687,Mean Blood Glucose Concentration,# Participants With Hypoglycemic Events,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9925,NCT03129165,Primary adherence at baseline screening,Global change in estimated risk at 12th months,,2015-05-11,UNKNOWN,INTERVENTIONAL,['NA']
9926,NCT03829982,Postprandial glucose (mg/dL),Core body temperature (CBT) and skin temperature,,2018-07-13,COMPLETED,INTERVENTIONAL,['NA']
9927,NCT04667182,Change from Baseline in Area Under the Curve (AUC) of CGM,Time Below Range (TBR) <70 mg/dL,,2021-01-25,WITHDRAWN,OBSERVATIONAL,['NA']
9928,NCT05742373,Changes in sirtuin molecule tissue expression,Change in dietary nutritional intake,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
9929,NCT01820871,fasting serum glucose and HbA1c,Lipid profile,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9930,NCT01870141,Change from baseline glycosylated haemoglobin (HbA1c) at 26th and 38th weeks [mmol/mol],Change from baseline Binge-Eating Disorders at 26th and 38th weeks (BES score),,2012-10,SUSPENDED,INTERVENTIONAL,['NA']
9931,NCT01614769,Incremental Weighted Average Blood Glucose Concentration Over 3 Hours of Hypoglycemic Recovery,,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9932,NCT03871049,blood sugar,,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA']
9933,NCT03590262,Change of hemoglobin A1c in percentage,Change of weight in kilograms,,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9934,NCT00993525,central macular thickness,,,2008-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9935,NCT04505566,Severity of Diabetic Retinopathy (DR),Progression of Diabetic Macular Edema,,2020-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9936,NCT02817152,"Probing depth change from baseline to 30, 90, and 180 days through periodontal probing","Plaque index change from baseline to 30, 90, and 180 days through periodontal probing",Glycated hemoglobin,2014-02,COMPLETED,INTERVENTIONAL,['NA']
9937,NCT01278823,Test the effect of gastric bypass surgery on glycemic control in obese type 2 DM patients,Determine the effects of gastric bypass surgery on pancreatic beta cell function and incretin hormone secretion in obese type 2 dm patients,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
9938,NCT00000466,,,,1987-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9939,NCT05601310,There are differences in the metabolic profile of diabetic patients with or without combined acute myocardial infarction,,,2017-05-23,COMPLETED,OBSERVATIONAL,['NA']
9940,NCT02283632,Assess change in glycosylated hemoglobin A1c,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9941,NCT04125082,Hypoglycemia,Quality of Life Questionnaires,,2019-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
9942,NCT02454153,Change in Continuous Glucose Monitoring System Standard Deviation,Change in Continuous Glucose Monitoring System Mean Glucose,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
9943,NCT00948311,,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
9944,NCT02834078,Change in Glycated hemoglobin,Change in Body Mass Index,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9945,NCT02664740,The relative reduction in wound surface area (%),The presence/absence of anti-phage antibodies in plasma samples,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9946,NCT03844646,Amount of Weight Lost (kg),Number of Participants Reporting at Least 5 Days of Moderate Physical Activity of 30 Minutes or More,,2019-08-01,TERMINATED,INTERVENTIONAL,['NA']
9947,NCT00058981,,,,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9948,NCT01326130,Diabetes and Hypertension control,Effects on physician practice,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
9949,NCT01087203,Change From Baseline in Average Diabetic Peripheral Neuropathy (DPN) Pain Score at Week 16,Serum Nerve Growth Factor (NGF),Number of Participants With Subcutaneous Doses of Study Medication,2010-03-30,TERMINATED,INTERVENTIONAL,['PHASE2']
9950,NCT04915716,blood glucose concentration,blood glucose concentration,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
9951,NCT01483651,Area Under the Curve for Glucose Above Baseline,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
9952,NCT04539288,T2DM,IGT,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA']
9953,NCT01336673,Proportion of patients who experience at least one gastrointestinal side effect,Change of Hemoglobin A1c level from baseline after at least 12 weeks of Glucophage XR® therapy,,2011-06,TERMINATED,OBSERVATIONAL,['NA']
9954,NCT04243850,measured glomerulair filtration rate (mGFR),proximal sodium excretion,,2020-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9955,NCT03594565,Difference in skin irritation before and after regular application of nsFP according to the modified Draize scale.,Change in glycated hemoglobin 6 months after nsFP use,,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9956,NCT02444845,Number of patients with anemia secondary to CKD,Use of treatment modalities for the management of anemia secondary to CKD,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
9957,NCT05923827,Change in HbA1c,Percentage of time <54 mg/dL,,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
9958,NCT03110796,"% of Wound Area Regression (WAR), as a measure of efficacy",,,2017-07-31,UNKNOWN,INTERVENTIONAL,['NA']
9959,NCT03777956,Pain intensity,Use of escape medicine (paracetamol) during treatment period.,,2019-01-15,TERMINATED,INTERVENTIONAL,['PHASE2']
9960,NCT03405532,Renal O2 extraction,Renal blood flow,,2018-01-11,SUSPENDED,OBSERVATIONAL,['NA']
9961,NCT02087995,"The Percentage of Agreement of the Continuous Glucose Monitoring System Glucose Values Comparing to a Laboratory Reference, Yellow Sprint Instrument (YSI) Measurement.",,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
9962,NCT04907110,Ex vivo muscle mitochondrial function,Exercise efficiency,,2021-08-10,COMPLETED,INTERVENTIONAL,['NA']
9963,NCT01486680,Remission of type 2 diabetes mellitus/ glycaemic control,Quality of Life,Weight loss (excess weight loss and actual weight loss),2011-09,COMPLETED,INTERVENTIONAL,['NA']
9964,NCT00989898,The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100).,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9965,NCT05714683,Number (Incidence) of adverse events (AEs),Dose of Rybelsus,,2024-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9966,NCT00387582,Prevention of vision loss at one year as evidenced by ETDRS visual acuity.,Reduction in retinal thickening based on Optical Coherence Tomography.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9967,NCT02497651,Postprandial response of glucagon-like peptide-1 (GLP-1),GLP-1 receptor expression in the skin,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
9968,NCT04877119,Predictive SFLT-1 / PLGF ratio cat-off point for preeclampsia,Correlation between SFLT-1 / PLGF ratio and placental histopathology,,2019-10-14,UNKNOWN,OBSERVATIONAL,['NA']
9969,NCT01220479,Bone mineral density and content,Body composition,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
9970,NCT01092390,urine protein excretion,Biomarkers of oxidation and inflammation,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9971,NCT01368081,Number of Patients With Drug Related Adverse Events,Change From Baseline in HbA1c,Confirmed Hypoglycaemic Adverse Events,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9972,NCT01931631,Hemoglobin A1c,Beck Depression Inventory II (BDI-II),,2014-01,SUSPENDED,INTERVENTIONAL,['NA']
9973,NCT00960765,,,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
9974,NCT04431687,"AUCtau,ss of CKD-501, D759, D150","Vd,ss/F of CKD-501, D759, D150",,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9975,NCT02462863,Improvement of type 2 diabetes,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
9976,NCT03675919,remission rate,outpatient costs,,2018-09-15,COMPLETED,INTERVENTIONAL,['NA']
9977,NCT00407108,Facility of surgical maneuvers,,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
9978,NCT00401089,SANS,BMI Body Mass index,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9979,NCT04570111,Adherence to the study diet,Infant weight,,2021-01-22,TERMINATED,INTERVENTIONAL,['NA']
9980,NCT00638313,"To evaluate the safety and tolerability of escalating, single subcutaneous doses of PF-04603629 administered to adult subjects with T2DM.",No secondary outcomes listed in the protocol.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9981,NCT00283842,Change in Mean Pain Severity Score From Baseline to 13 Weeks,Number of Patients With ≥50% Reduction in Mean Pain Severity Score.,,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3']
9982,NCT05134480,Graft failure,Endothelial cell density,,2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE3']
9983,NCT02735031,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,Gastrointestinal side effects,2017-02-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9984,NCT03568409,"Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.",Control of the glycemia.,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
9985,NCT04841304,Clinically significant arrhythmias,All-cause mortality,"Correlation between heart rate variability, daytime and nighttime heart rate, physical activity, and risk of arrhythmias",2021-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9986,NCT02500329,endothelial function (reactive hyperemic index),Glycated albumin,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9987,NCT05944432,HbA1c,Frequency of hypoglycaemia events,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA']
9988,NCT01771887,adhesion,Self-management behaviors,self-efficacy,2013-02,COMPLETED,INTERVENTIONAL,['NA']
9989,NCT03854695,Assess serum IgG titers,Characterize microbiology,Assess microbiome,2019-02-01,WITHDRAWN,OBSERVATIONAL,['NA']
9990,NCT04975022,GIRmax,tGIRmax,,2019-12-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9991,NCT01292798,Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline,Qualitative Assessment of Diabetic Macular Edema (DME),,2011-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9992,NCT01598610,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
9993,NCT00565162,"Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %.",,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9994,NCT02881528,Between group difference in reduction in beta cell demand as measured by serum glucose (mmol/L) and C-peptide (ng/mL),Feasibility of a randomized controlled trial in children who are at high risk of T1D as measured by attrition rates (%),Between group difference in Immunological t-cell response to diabetes,2016-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9995,NCT00256646,"The primary outcome measure is to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.",,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
9996,NCT05174728,Placental mitochondrial function at delivery,Placental lipid metabolism,,2017-07-20,SUSPENDED,OBSERVATIONAL,['NA']
9997,NCT03232034,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Blood pressure,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
9998,NCT01224054,Food tolerance in patients submitted to bariatric surgery,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
9999,NCT04840446,Adhesiveness and survivability of the adhesives,Assess user preference or acceptance of the adhesives worn during the study,,2021-02-08,COMPLETED,OBSERVATIONAL,['NA']
10000,NCT00814476,HbA1c,7 points glucose profile,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10001,NCT04083456,Physical Activity,Self-Efficacy for Managing Chronic Disease,FitBit Use Adherence,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
10002,NCT04469790,Continuous glucose monitor measures,Cardiac autonomic nervous system measures,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
10003,NCT02835183,Compare mean postprandial glucose level,Hyperglycemia events,,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
10004,NCT05813249,NAFLD regression,Fibrosis regression,,2023-02-15,COMPLETED,INTERVENTIONAL,['PHASE4']
10005,NCT01346098,incidence of complications after pancreatic surgery,Incidence of endocrine and exocrine pancreatic insufficiency,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10006,NCT03490318,"Sensitivity of the new pathway (ophthalmic grader pathway) in detecting active DMO/PDR, using the standard care pathway as the reference standard.","Proportions of patients unable to undergo imaging, with inadequate quality images or indeterminate findings.",,2017-10-26,COMPLETED,OBSERVATIONAL,['NA']
10007,NCT01584856,,,,2006-05,UNKNOWN,OBSERVATIONAL,['NA']
10008,NCT05248841,Maximum GIR (GIRmax),Number of subjects with adverse events (AEs),,2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10009,NCT06197412,2-week reduction rate of wound area,Mortality,,2024-01-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10010,NCT04520191,Number of participants with problems in their health care due to COVID-19 related isolation,,,2021-01-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10011,NCT06220773,The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10012,NCT02004366,Differences in Glycemic Control,Outpatient Mortality,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10013,NCT01897857,the compensatory changes in ulnar artery blood flow after radial artery cannulation,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
10014,NCT01848379,Change from Baseline in Clinical Attachment Level (CAL) at 6 and 12 Months,Glycated Hemoglobin (HbA1c),Cellular Immune responses,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
10015,NCT03794973,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Immunologic,,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10016,NCT03240978,change of fasting glucose,rate of non-responsiveness in the alleviation of insulin resistance to exercise intervention,,2016-09,SUSPENDED,INTERVENTIONAL,['NA']
10017,NCT04621890,Change in A1C (ΔA1C90-day) from baseline visit (visit 1) to 90-day visit (visit 2),Change in health-related empowerment from baseline visit (visit 1) to 90-day visit (visit 2) and to 180-day visit (visit 3).,,2022-02-14,RECRUITING,INTERVENTIONAL,['NA']
10018,NCT02078440,Pharmacokinetics,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10019,NCT04802395,SGLT2/ GLP1,,,2021-03-02,RECRUITING,OBSERVATIONAL,['NA']
10020,NCT00627029,Medicare program expenditures,Claims-based and patient-reported quality of care,,2000-09,UNKNOWN,INTERVENTIONAL,['NA']
10021,NCT03771781,Peak Plasma Concentration (Cmax),Area under the plasma concentration versus time curves (AUC),,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
10022,NCT06185296,CGM time in range,Change in perceived competence in Diabetes,Insulin dosing time,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10023,NCT01822717,Days per week participants performed foot inspection,Number of foot problems discovered,Acceptability,2010-09,COMPLETED,INTERVENTIONAL,['NA']
10024,NCT05728567,Inflammatory factors,,,2017-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10025,NCT00368368,"Vital signs, adverse events, laboratory parameters.","AUC, Tmax, Cmax, T1/2, CL/F, CLR for GK Activator (2) and metabolite. Glucose Cmax and Cmin, and percentage decrease in glucose from baseline.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10026,NCT05373212,CmaxTOTAL,Local tolerability,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10027,NCT05442853,Time in target blood glucose range (BG 70-180mg/dL),Pain Score,,2022-11-02,RECRUITING,INTERVENTIONAL,['NA']
10028,NCT00541229,24-hour Weighted Mean Glucose (WMG),,,2007-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
10029,NCT03494010,Duration of use of hybrid closed-loop (HCL) system,fasting glucose levels,,2018-08-31,WITHDRAWN,OBSERVATIONAL,['NA']
10030,NCT00848315,The primary outcome is improvement in metabolic control (HbA1c).,Efficacy of the intervention,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10031,NCT00893685,"Health related quality of life as assessed by the SF-36 questionnaire, at the beginning, at midterm and at the end of the trial period",Number of permanent transfers to elderly homes,,2009-05,UNKNOWN,INTERVENTIONAL,['NA']
10032,NCT05729776,"TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after the consumption of pizza meal vs control meal","TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after ""Medtronic pizza management"" and""Tandem T slim pizza management""",,2022-12-01,COMPLETED,OBSERVATIONAL,['NA']
10033,NCT04783441,Time in Range (70-180 mg/dl),Incidence of post-transplant infections during study period,safety endpoint Hypoglycemia,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
10034,NCT01188200,The primary variable is glucose concentration,Additional measures of glucose concentration,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10035,NCT06192108,Change from Baseline in Hemoglobin A1c: (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores,,2024-01-10,RECRUITING,INTERVENTIONAL,['PHASE3']
10036,NCT00596505,The changes of visual acuity,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
10037,NCT04632823,Change from Baseline Body Mass Index at 6 months,Change from Baseline Homeostasis ModelAssessment of Insulin Resistance at 6 months (HOMA-IR),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10038,NCT03796975,Change of liver enzyme after 24 weeks treatment as assessed by blood test,Change of weight and waistline after 24 weeks treatment as assessed by standard measurement,,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE4']
10039,NCT03816605,Expression of IRS-1 and GLUT-1 in different group,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
10040,NCT01759121,the probability of vitreous haemorrhage,change of ischemia area,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10041,NCT04466618,"Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39",,,2021-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
10042,NCT01722513,Primary Outcome,Secondary Outcome,,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
10043,NCT00111540,Change in lipids from Visit 1 to each protocol visit,,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10044,NCT02370927,Insulin concentrations,Lactate concentration,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
10045,NCT00715351,Body weight change,Changes in daily blood glucose values,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
10046,NCT00447213,Change in HbA1c from baseline,Preference for the study therapies,,2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10047,NCT06176443,Metabolic improvements of type 2 diabetes,Change of body mass index,,2020-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10048,NCT02565979,Change in Glucose Tolerance,Change in Quality of sleep,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
10049,NCT01323322,"To disentangle the relationship between race, SES, and health outcomes.",,,2009-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10050,NCT01672762,Change in HbA1c,"Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs",,2012-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
10051,NCT01947595,postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT)),distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager,"metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry",2012-03,COMPLETED,INTERVENTIONAL,['NA']
10052,NCT01822548,Absolute Change in the Endothelial Progenitor Cell (EPC) Number,Absolute Change in HbA1C Compared to Baseline,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10053,NCT01179048,"Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.,,2010-08-31,COMPLETED,INTERVENTIONAL,['PHASE3']
10054,NCT03540758,Endogenous glucose production (EGP),,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10055,NCT03538015,Change in Hypoglycemia Symptom Score,Frequency of CGM-Determined Hypoglycemic Episodes,,2019-04-22,TERMINATED,INTERVENTIONAL,['PHASE2']
10056,NCT02063048,Absolute weight loss in pounds,Patient Engagement Measures,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
10057,NCT01425424,"Prediabetes, Prehypertension and Vitamin D supplementation- A practice based clinical intervention",,,2012-04,TERMINATED,INTERVENTIONAL,['NA']
10058,NCT06000462,"Inter-arms differences in mean BMI, waist circumference, waist hip ratio, body weight (kilogram, kg), Body fat (%), and Muscle mass (%)",Frequency of adverse event from dapagliflozin,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10059,NCT01597713,Number of adverse events,Area under the serum insulin concentration-time curve (Trial part 2),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10060,NCT02863523,Change From Baseline in Glycosylated Hemoglobin (%),Change From Baseline in Diabetes Regimen-Related Distress,Change in Depressive Symptoms,2014-09,COMPLETED,INTERVENTIONAL,['NA']
10061,NCT03349489,Decrease in glucose levels,Total amount of carbohydrates needed to treat hypoglycemic events,,2018-05-18,UNKNOWN,INTERVENTIONAL,['NA']
10062,NCT05265312,Number of participants referred to Medical Nutrition Therapy,Number of participants who complete a follow-up PCP/team visit,,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10063,NCT02636491,normal glucose level,glucose sensor readings,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
10064,NCT01394952,"Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina,,2011-07-22,COMPLETED,INTERVENTIONAL,['PHASE3']
10065,NCT01068041,Urinary Albumin/Creatinine Ratio (UACR),Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10066,NCT04623151,5-item Foot Care Detection Behaviour Scale,,,2017-08-16,COMPLETED,INTERVENTIONAL,['NA']
10067,NCT02041832,First episode of atrial fibrillation,Correlation between echocardiographic parameters and incidence of atrial fibrillation,Correlation between biomarkers and incidence of atrial fibrillation,2013-10,COMPLETED,INTERVENTIONAL,['NA']
10068,NCT01804842,Rmax (0-24) of Plasma Glucose,,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10069,NCT03132129,Prevalence of early heart failure in type 2 diabetes,Remission of type 2 diabetes,,2017-10-24,RECRUITING,OBSERVATIONAL,['NA']
10070,NCT03675165,Diabetes Symptomatology (assessed using the Diabetes Symptoms Checklist - Revised),,Diabetes Risk (calculated using the Canadian Diabetes Risk Questionnaire),2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
10071,NCT05759442,Fasting Blood Sugar,,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
10072,NCT05566028,Change from baseline in HbA1c,Change from baseline in Fasting plasma glucose,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10073,NCT00222924,To measure the functional capacity of mitochondria in skeletal muscle of those with T2DM and those at increased risk of developing T2DM,To assess whether exercise and diet can improve mitochondrial function and morphology.,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
10074,NCT01422018,Changes in best-corrected visual acuity (BCVA),macular edema detected by optical coherent tomography,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
10075,NCT03330951,Glycemic Control markers in pregnancy,Admission to neonatal intensive care unit,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
10076,NCT00708266,Concentrations of IL-6 measured in effluent samples from subcutaneous tissue.,Cytokine concentrations measured in serum samples.,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
10077,NCT05038176,A1c,,,2022-02-12,COMPLETED,INTERVENTIONAL,['NA']
10078,NCT00670722,HbA1c after switch from human insulin to modern insulin treatment,Number of adverse drug reactions (ADR),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
10079,NCT00638573,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
10080,NCT01181830,Blood pressure,Inflammation,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10081,NCT02285985,Change from baseline in the secretion of cytokines/adipokines by adipose tissue,change in reactive hyperemic index,change in percent arteriole dilation,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10082,NCT03234751,IV infusion of nesiritide at a 3pmol/kg rate,,,2017-07-13,COMPLETED,INTERVENTIONAL,['PHASE1']
10083,NCT01771445,IL6,Copeptin,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10084,NCT02091596,Clinical Response,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10085,NCT01757756,fasting HDL cholesterol,,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10086,NCT02607306,Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira,Plasma Concentrations of Liraglutide,,2015-11-18,COMPLETED,INTERVENTIONAL,['PHASE3']
10087,NCT02294110,sensorial loss with pin prick test,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10088,NCT05504096,Risk prediction model of diabetes using PPG features on the wearables,Validate that in-ear and wrist-worn wearables both provide relative accurate heart rate and heart rate interval measurements.,,2021-10-08,COMPLETED,INTERVENTIONAL,['NA']
10089,NCT06056687,Matrix metalloproteinase 2 (MMP-2),,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
10090,NCT05607810,Severity of ocular and non-ocular AEs,"Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation",,2022-08-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10091,NCT00969956,Time to retinopathy,Waistlines,,2012-04,TERMINATED,OBSERVATIONAL,['NA']
10092,NCT03236415,Percentage of uncovered struts at time of follow-up optical coherence tomography,Major adverse cardiac events,Subgroup analysis between 4 and 6 weeks,2017-08,WITHDRAWN,INTERVENTIONAL,['NA']
10093,NCT01184703,HbA1c,LDL-cholesterol,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10094,NCT05579743,Proportion of participants who successfully complete a weekly wound scan,,,2023-01-06,RECRUITING,INTERVENTIONAL,['NA']
10095,NCT04008121,Binary assessment by the Principal Investigator of the feasibility of MB-102 imaging as compared to fluorescein dye,Number of participants with adverse events,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10096,NCT01040468,The primary objective of this study is to compare the rates of diabetes remission over one year.,"To examine the attitudes that patients, health care professionals, and insurance providers have toward the use of bariatric surgery to treat type 2 diabetes.",,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10097,NCT00637273,Change in HbA1c From Baseline to Week 26,Assessment on Event Rate of Treatment-emergent Hypoglycemic Events,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10098,NCT03458494,Glucose,CRP,,2018-02-15,UNKNOWN,INTERVENTIONAL,['NA']
10099,NCT02075567,Number of Participants with no Adverse Events as a Measure of Safety and Tolerability,Hormonal Response,Blood Lactate Concentration,2014-01,COMPLETED,INTERVENTIONAL,['NA']
10100,NCT00886821,Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22,Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1,Stage 2: Number of Participants With Anti-Drug Antibodies,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10101,NCT05888454,HbA1c levels (%),Change in dose of pharmacological interventions for T2DM,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
10102,NCT02124408,change in glycated hemoglobin levels,control of diabetic complications,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
10103,NCT00910507,Stage of Exercise Behavior,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10104,NCT04142944,Time in hypo glycaemia,,,2019-12-11,COMPLETED,INTERVENTIONAL,['NA']
10105,NCT02700555,Incidence of newly developed diabetes mellitus,3-year recurrence-free survival & 5-year recurrence-free survival,,2016-02,TERMINATED,OBSERVATIONAL,['NA']
10106,NCT00548782,decreased insulin secretion,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10107,NCT00174993,"Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization.",Time to Cardiovascular Mortality.,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10108,NCT04766008,Increase in lactate of 20%,Metformin associated lactic acidosis,Death,2020-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
10109,NCT01807221,Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90,Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits,Change From Baseline in Heart Rate at Specified Visits,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE2']
10110,NCT05704309,Cognitive Diagnoses,White matter microstructure,,2022-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10111,NCT04964921,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,,2021-12,UNKNOWN,OBSERVATIONAL,['NA']
10112,NCT00333853,Hemoglobin A1c (HbA1c),Measured hypoglycemia,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
10113,NCT04864639,Emergency Department (ED) Visits Within 30 Days Post Discharge,Unplanned Readmissions to the Hospital Within 30 Days Post Discharge,,2021-08-04,COMPLETED,INTERVENTIONAL,['NA']
10114,NCT03459638,Risk of obstructive sleep apnea syndrome (OSAS),,,2018-03-09,COMPLETED,OBSERVATIONAL,['NA']
10115,NCT05854875,Change in glucagon levels,,,2019-09-22,COMPLETED,INTERVENTIONAL,['NA']
10116,NCT06130865,Fullerton Advanced Balance Scale (FAB),,,2023-11-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10117,NCT02066831,HbA1c,quality of life,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10118,NCT05866406,Insulin sensitivity,Adipose tissue gene expression,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
10119,NCT03249974,Accuracy of Enlite sensor,skin reactions wih Enlite sensor,,2017-07-05,COMPLETED,OBSERVATIONAL,['NA']
10120,NCT03681704,ACR,,,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10121,NCT04087369,COPD control measure,Alcohol use,Projected scale cost(Maintenance),2019-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
10122,NCT03408678,Insulin sensitivity and secretion,Body fat distribution,,2017-01-23,COMPLETED,OBSERVATIONAL,['NA']
10123,NCT01403571,Weight,Fatty Acids (% composition),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10124,NCT04180332,Catalase estimation,Antioxidant estimation,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
10125,NCT03730168,concentration of serum intereukin6,concentration of serum tumour necrosis factor,,2018-05-13,COMPLETED,INTERVENTIONAL,['NA']
10126,NCT05940376,time to epithelial healing,any adverse effect of topical insulin or need for amniotic membrane transplantation,,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10127,NCT05159843,Knowledge in diabetes management,Mood of patient,,2022-01-10,UNKNOWN,INTERVENTIONAL,['NA']
10128,NCT02019264,Time From Randomization to First Occurrence of MACE+,Change From Baseline in Echocardiographically-Determined Pulmonary Arterial Systolic Pressure,,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4']
10129,NCT06331429,Change Social Skills (Baseline-Pre-Post),Change Resilience (Baseline-Pre-Post),Glycaemic control (Baseline-Pre-Post),2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10130,NCT01845870,determination of urinary albumin,determination of serum vitamin D metabolites,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
10131,NCT02750930,Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time,,,2016-10-07,TERMINATED,INTERVENTIONAL,['PHASE4']
10132,NCT05843019,P kortisol,,,2023-04-12,RECRUITING,OBSERVATIONAL,['NA']
10133,NCT00984841,Diabetes summary quality measure,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
10134,NCT05344768,β-cell function analysis,,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10135,NCT01571609,insulin secretion,Indirect calorimetry,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
10136,NCT03334773,Hemoglobin A1c levels (HbA1c),Diabetes management self-efficacy,,2017-01-16,COMPLETED,INTERVENTIONAL,['NA']
10137,NCT01121172,Serum Apelin Levels,Frequency of G212A Polymorphism of Apelin Receptor in Obese Children and Adolescents,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
10138,NCT01798914,,,,2008-10,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
10139,NCT02182895,Mean Daily Blood Glucose Levels During Hospital,Patient Satisfaction,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10140,NCT05344196,C-peptide,Health behavior,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
10141,NCT01957930,Ischemic Foot Ulcer,,Microvascular Endothelial Function,1984-01,COMPLETED,INTERVENTIONAL,['NA']
10142,NCT04467268,Total sleep time (TST),Multidimensional Assessment of Fatigue,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
10143,NCT04303819,Plasma total bile acids in fasting state,Body mess index,,2020-01-05,COMPLETED,OBSERVATIONAL,['NA']
10144,NCT01762059,Percentage of Time Blood Glucose Values Less Than 70 mg/dl (Co-primary Outcome),Difference of Outcome Measures on Day 1 vs. Remaining Days (Days 2-5) During the Closed-loop Period.,Mean Blood Sugar as Measured by Continuous Glucose Monitor (CGM) Readings,2013-01,COMPLETED,INTERVENTIONAL,['NA']
10145,NCT00847730,Ease of Use Assessment,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10146,NCT01637935,Incident Diagnosis of Bladder Cancer (10-year Analysis),Stage of Bladder Cancer (10 Year Analysis),,2004-07,COMPLETED,OBSERVATIONAL,['NA']
10147,NCT03448380,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,,2018-02-27,COMPLETED,OBSERVATIONAL,['NA']
10148,NCT03658564,VAS,HOMA,,2018-09-30,UNKNOWN,INTERVENTIONAL,['NA']
10149,NCT00035711,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
10150,NCT00409786,Change in Weight,Physical Activity,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
10151,NCT00845182,HbA1c,"Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10152,NCT02102048,Homeostatis Model Assessment-Insulin Resistance (HOMA-IR) value,insulinemia,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
10153,NCT05036876,Change in mean daily blood glucose concentration in hospitalized patients,"Average blood glucose (mg/dL), percentage time in target, percentage time below target, and percentage time above target in a subgroup of study participants.",,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
10154,NCT00371800,HbA1c,Compliance,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10155,NCT06053177,"The prevalence of undiagnosed fatty liver disease with evidence of fibrosis, obstructive sleep apnoea and heart failure in people with type 2 diabetes and prediabetes",Multi-morbidity screening,,2023-01-25,RECRUITING,OBSERVATIONAL,['NA']
10156,NCT03914547,Parents Hypoglycemia Fear,,,2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10157,NCT01140893,Change from baseline to 6 months of centrally measured HbA1c,Change from baseline in mean blood glucose value,,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10158,NCT05469659,Urine albumin-to-creatinine ratio (UACR),Albuminuria class,,2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10159,NCT00416741,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
10160,NCT05666570,The reduction in wound size of the target wound between baseline and end of study,Rate of Device Related Adverse Events,,2022-05-18,TERMINATED,OBSERVATIONAL,['NA']
10161,NCT01498926,Maximum serum insulin concentration,Adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10162,NCT05565248,Assess the clinical efficacy of VCTX211 units via evaluation of C-peptide increase from the baseline.,The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.,,2023-01-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10163,NCT00108485,Change in Proteinuria,,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3']
10164,NCT01156246,To assess the effect of food on the pharmacokinetics of dapagliflozin and metformin.,To examine the safety and tolerability of the fixed-dose combination tablet of dapagliflozin and metformin.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10165,NCT05424107,HbA1c levels,Decalogue of healthy eating,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
10166,NCT02324218,"Occurrence of new HepB diagnosis among non-DM patients between 0-80 years of age, in the UK CPRD or HES.","New-onset or prevalent HepB diagnosis among new-onset or prevalent DM and DM-free (non-DM) patients between 0-80 years of age, in the UK, regardless of the onset of HepB in relation to the diagnosis of DM.",,2014-10,COMPLETED,OBSERVATIONAL,['NA']
10167,NCT00318422,HbA1c,"Glycemic control parameters (fasting plasma glucose, -glucose profiles)",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10168,NCT00922376,Blood sugar levels (HbA1c),Self management,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
10169,NCT03666117,Prevalence of Hepatomegaly in children and adolescents,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
10170,NCT00065559,,,,2003-04,TERMINATED,INTERVENTIONAL,['NA']
10171,NCT00436475,"Chang in Disposition Index, a Measure of Beta Cell Function",Change in Hemoglobin A1c,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10172,NCT04949867,Percentage of time with glucose values < 3.9 mmol/l as measured by the continuous glucose monitor,Sleep efficiency measured by ActiGraph GT9X Link,,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4']
10173,NCT05350514,"Standardized uptake value ratio for cerebral to cerebellar comparison in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes","Atlas based region of interest fractional anisotropy in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes",,2022-07-19,COMPLETED,OBSERVATIONAL,['NA']
10174,NCT03330054,Frequency Of Eye problems In Type 2 Diabetes with Chronic Kidney Disease,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10175,NCT02832999,Insulin sentivity,body weight,Inflammation,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10176,NCT05305287,Effect of pioglitazone on hepatic mitochondrial TCA cycle fluxes,Effect of pioglitazone on hepatic gene regulatory networks,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10177,NCT05488119,Tracking people who complete the study,Changes in diabetes technology usage,,2025-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10178,NCT05420051,Change from Baseline Moderate to Vigorous Physical Activity (MVPA) at 16 weeks,Change from Baseline in positive affect (Positive and Negative Affect Schedule [PANAS] positive affect items) at 16 weeks,Change in triglycerides (milligrams per deciliter),2022-10-12,RECRUITING,INTERVENTIONAL,['NA']
10179,NCT03246295,Urinary samples were analyzed,Urinary samples were analyzed,,2015-10-20,UNKNOWN,OBSERVATIONAL,['NA']
10180,NCT00248131,long-term safety and tolerability,monitor long-term efficacy,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3']
10181,NCT04120974,Change in Glycemic Control,Change in Blood Glucose Levels,Effect on Behaviour: Injection in Lipohypertrophy Areas,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
10182,NCT01324011,Change in body weight,Change in psychosocial factors,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
10183,NCT03793283,Concentration of Hemoglobin A1C (HbA1C).,Safety related adverse events.,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10184,NCT05229640,Assess CFLD via abdominal imaging,,,2022-03-31,WITHDRAWN,INTERVENTIONAL,['NA']
10185,NCT05528393,PRL,OGTT,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
10186,NCT05628259,Diabetes Self-Management Scale,Triglyceride,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
10187,NCT01950637,"Level of patient dosing irregularity: missed, mistimed and reduced dose (HCP questionnaire)",Frequency of self-treated hypoglycaemia,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
10188,NCT03564431,the neuroimaging of Type 2 Diabetes and Depression,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10189,NCT00101673,Change from baseline in HbA1c at 12 weeks,Change from baseline in body weight at 12 weeks,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10190,NCT04533945,Change in Hemoglobin A1C (HbA1C),Duration of CGM use,,2020-03-25,COMPLETED,INTERVENTIONAL,['NA']
10191,NCT02971241,Young students survey,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10192,NCT02961088,Global measures of adiposity with established clinical relevance - body weight,Measures of adiposity by established imaging techniques - visceral adipose tissue [VAT],,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
10193,NCT05932966,Comparison of glycemic control obtained under closed loop according to the system used: SG versus CIQ,daily insulin dose,,2023-07-06,RECRUITING,OBSERVATIONAL,['NA']
10194,NCT05361148,Pancreas exocrine function,abnormal prior pro-insulin/insulin ratio and diabetes (subset),,2021-10-12,RECRUITING,OBSERVATIONAL,['NA']
10195,NCT00884013,percent of patients eligible for quality measures (ABCS),use of EHR clinical reminders,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
10196,NCT03121508,The Diabetes Self-Management Questionnaire,,,2017-04-24,WITHDRAWN,INTERVENTIONAL,['NA']
10197,NCT06262854,The composite primary endpoint of this study will be the incidence osteomyelitis recurrence or new osteomyelitis in adjacent sites or tissue infection at the site of osteomyelitis.,Direct medical costs,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10198,NCT01171976,Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12,EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10199,NCT04324684,rate of recovery,organ failure,,2020-03-31,COMPLETED,OBSERVATIONAL,['NA']
10200,NCT04541797,Cut-off value for myocardial perfusion index to predict ≥10% increase in myocardial blood flow as result of empagliflozin.,Improvement in exercise tolerance through performing a cardiopulmonary exercise test.,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10201,NCT02462421,Change in Fractional Excretion of Uric Acid (the Difference Between Data After Administration of Canagliflozin Minus Data Before Administration of Canagliflozin),Canagliflozin-induced Change in Fasting Plasma Glucose,,2015-06-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10202,NCT04906226,Peripheral skin temperature will be measured with a skin thermometer,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
10203,NCT00921011,vessel wall changes over time that precede plaque buildup,development of cardiovascular disease,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
10204,NCT00539851,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
10205,NCT03978715,number of lower limb complications,,,2021-04-14,COMPLETED,OBSERVATIONAL,['NA']
10206,NCT01760447,Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54,Percentage of Participants Initiating Insulin Glargine During Weeks 20-54,Baseline A1C,2011-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10207,NCT01201161,amount of intraoperative intra-ocular bleeding,visual acuity,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10208,NCT02867254,Sample collection from the periodontal pocket,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
10209,NCT01150617,Reduction of restenosis after peripheral angioplasty,Identification of new peripheral markers predictive of restenosis,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE4']
10210,NCT02298803,Change in Corrected QT Interval During Day Time Hypoglycaemia,deltaQTc,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10211,NCT03713684,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE3']
10212,NCT01390259,Hypoglycemic Events,Mean Glucose,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10213,NCT02137512,"Time Spent <70 mg/dL - Main Phase, Night Only","Time Spent >300 mg/dL - Main Phase, Day Only",Reported Serious Adverse Events - Extension Phase,2014-08,COMPLETED,INTERVENTIONAL,['NA']
10214,NCT03864549,Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.,Duration of time until pharmacotherapy for glycemic control is indicated,,2020-01-08,COMPLETED,INTERVENTIONAL,['NA']
10215,NCT01453413,Percent of Subjects Outside Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose,Percent of Subjects Outside a Second Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
10216,NCT00998712,endothelial function,,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
10217,NCT04160156,Glucose Standard Deviation (mmol/L),,,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
10218,NCT02861144,Change of HbA1c,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
10219,NCT05584293,Real world data from medical devices and clinical outcome in a registry,,,2020-09-11,RECRUITING,OBSERVATIONAL,['NA']
10220,NCT06309082,H-CEUS score,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10221,NCT04690907,Gestational weight gain (GWG),Eating habits III,,2020-12-03,COMPLETED,INTERVENTIONAL,['NA']
10222,NCT05148130,blood biochemistry indices,,,2018-09-11,UNKNOWN,OBSERVATIONAL,['NA']
10223,NCT00005130,,,,1984-01,COMPLETED,OBSERVATIONAL,['NA']
10224,NCT02785445,Exact and ±1 agreement to compared device,User performance,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10225,NCT01336738,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Body Weight Loss From Baseline,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10226,NCT03500640,Change in bodyweight,Change in physical function,Change in mood,2018-03-27,COMPLETED,INTERVENTIONAL,['NA']
10227,NCT02077946,Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction,Change in creatinine,,2014-02-10,COMPLETED,OBSERVATIONAL,['NA']
10228,NCT03481218,Personality traits associated with diabetes management,Differences in quality of life based on glycaemic control,,2018-01-30,COMPLETED,OBSERVATIONAL,['NA']
10229,NCT05251506,glycated hemoglobin level,success rate of measurement of blood glucose by laser lancing device,,2021-08-10,UNKNOWN,INTERVENTIONAL,['NA']
10230,NCT01549600,fasting serum glucose,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
10231,NCT01620424,The maximum insulin aspart concentration,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10232,NCT01669616,To compare the accuracy of SCOUT DS versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1c-defined dysglycemia.,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
10233,NCT01269606,Area under the curve (AUC) for IM treatment group,Adverse Events (AEs),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10234,NCT01383356,Area Under the Curve 0 to Last Measurable Value (AUC0-t),Area Under the Curve 0 to Inf (AUC0-inf),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10235,NCT06312553,Acceptability,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10236,NCT00212004,The time till the first cardiovascular composite endpoint,worsening of renal function,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE4']
10237,NCT01425580,Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography,Global LV function (echocardiography) expressed as ejection fraction (EF),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10238,NCT02906891,Reduction in the aggregate rate of nocturnal hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).,Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).,"Average ratings of ""acceptable"" or better from self-reported survey clinician feedback on the utility of Vigilant in managing patients.",2016-05,TERMINATED,INTERVENTIONAL,['NA']
10239,NCT04481243,Immunoglobulin G (IgG) Antibodies,,,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
10240,NCT04456465,moderate and severe pain (VAS score ≥4),Anxiety screening/assessment: GAD-7 scale,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
10241,NCT01990469,Change of HbAlc from baseline at Week 24,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10242,NCT00157339,"To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c.",To explore the impact of Human Insulin Inhalation Powder on peak flow and peak flow variability in the study with asthma patients.,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10243,NCT03674957,Bone mineral density,"Early life health conditions from linked administrative health records, from the Manitoba Population Healthy Research Data Repository",,2016-03,TERMINATED,OBSERVATIONAL,['NA']
10244,NCT02741037,Longitudinal % change in body weight,Longitudinal change in mother-daughter processes of mutual influence,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
10245,NCT01286350,Hemoglobin A1c,Health-related quality of life,Cost of intervention delivery,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10246,NCT03123809,Changes of total gastroparesis symptom scores (TSS),Percentage of changes of gastric emptying retention of the radiolabeled meal (%) at 2-4 hrs,,2017-01-10,RECRUITING,INTERVENTIONAL,['NA']
10247,NCT06269107,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE3']
10248,NCT00666861,,,,2008-04,TERMINATED,OBSERVATIONAL,['NA']
10249,NCT06072326,change from baseline in Urine Albumin-Creatinine Ratio (UACR),Change from baseline blood pressure,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10250,NCT02407626,Biomarker NT-proBNP,"Expression of TNF/IL1beta and microRNA (miR144, miR125b, miR208a)",,2015-09,TERMINATED,INTERVENTIONAL,['NA']
10251,NCT00490854,Mean change in Hemoglobin A1c (HbA1c) from baseline to the end of each treatment period of Primary Phase,Patient-reported outcomes questionnaires.,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10252,NCT02348801,Change in hemoglobin A1c,Change in composite cognitive score,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10253,NCT05174052,The effect of Dapagliflozin on change in burden of atrial fibrillation,Effect of Dapagliflozin on change in AF Effect on Quality of Life Survey,Effect of Dapagliflozin on change in Validated Echocardiographic Indices & Biomarkers of Atrial Myopathy,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10254,NCT04902807,Generate a diagnosis and therapeutic-decision tools,3- Ancillary study (pilot study),,2021-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10255,NCT02092896,Change from baseline in gastric emptying rate,Change from baseline in hypoglycemic symptom score,Frequency of Hypoglycemic episodes,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10256,NCT01901926,"Change in HbA1C levels from base line at 3, 6 and 9 months",Periodontal Pocket Depth,C-Reactive Protein,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
10257,NCT02954016,The proportion of subjects affected by serious adverse device effects (SADEs) as defined by International Standards Organization (ISO) standard 14155:2011.,12 Month Weight Loss in Kilograms,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10258,NCT00924573,Changes in HbA1c from baseline,Change in the ratio patients with < 7.0% of HbA1c,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10259,NCT01568242,Vitreous temperature,,,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
10260,NCT02793154,Part B: Assessment of Nausea by VAS Score,Part B: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD,,2016-09-26,TERMINATED,INTERVENTIONAL,['PHASE4']
10261,NCT02698618,Delta IMR pre-PCI,Severe microcirculatory impairment,Severe microcirculatory impairment in subject with BMI = or > 30,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
10262,NCT02580877,Change in mIAA Autoantibody Titer From Baseline,,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10263,NCT06312579,Gait speed,Community mobility,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10264,NCT02180191,The comparison of the gut microbiota composition,The relationship between metabolic parameters and the gut microbiota composition,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
10265,NCT04060732,Severe hypoglycemia rate,Feasibility of the device,,2017-05-05,COMPLETED,OBSERVATIONAL,['NA']
10266,NCT04287179,Change in glycosylated haemoglobin (HbA1c),Number of treatment emergent adverse events (TEAEs),,2020-03-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10267,NCT04278417,Change from Baseline in BCVA,Proportion of subjects with center-involved DME up to Week 96,,2020-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10268,NCT05457192,Glycosylated Hemoglobin (HbA1c) level,Spatiotemporal gait parameters,,2022-07,RECRUITING,OBSERVATIONAL,['NA']
10269,NCT04203823,Percentage of Time in Euglycemia - Cohort C,,,2020-07-20,COMPLETED,INTERVENTIONAL,['NA']
10270,NCT00567398,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10271,NCT03165643,DNA methylation level in macrosomia,,,2014-03-06,COMPLETED,OBSERVATIONAL,['NA']
10272,NCT05590858,pericoronary Fat attenuation index (FAI),level of pro-inflammatory cytokines such as IL-2 and IL-6.,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10273,NCT05199714,Each participant's percentage of time glucose levels spent in the target range,Total bolus insulin delivery for each participant,Safety Endpoints,2022-02-21,COMPLETED,INTERVENTIONAL,['NA']
10274,NCT04205942,change in microbial load,treatment related side effects - proliferative skin reaction,treatment related side effects - proliferative skin reaction,2016-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10275,NCT00774124,maternal blood glucose control,infant birthweight,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
10276,NCT00005193,,,,1986-09,COMPLETED,OBSERVATIONAL,['NA']
10277,NCT04008836,Number of Participants With Accurate BGMS Fingerstick Results,Number of Participants With Accurate BGMS Venous Blood Results,,2019-06-10,COMPLETED,INTERVENTIONAL,['NA']
10278,NCT04054804,The questionnaire Orthotic and Prosthetic Users Survey (OPUS) will be used.,System Usability Scale (SUS). The score range from 0-100 and a SUS score above a 68 would be considered above average and anything below 68 is below average.,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
10279,NCT00522470,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
10280,NCT00327210,Feasibility,Improved knowledge,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
10281,NCT03047278,Pharmacokinetic parameter (AUC),Pharmacokinetic parameter (Elimination half-life),,2015-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10282,NCT02305862,To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI,To evaluate the change from baseline in creatine kinase at 26 weeks,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
10283,NCT06287437,Percent Change in Body Weight from 24 weeks,Energy intake at 24 weeks,Change of body weight at 24 weeksl from baseline,2024-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10284,NCT00404950,,,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
10285,NCT05905588,Change in glycosylated hemoglobin (HbA1c),Number of participants with adverse events as a measure of safety and tolerability,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
10286,NCT02794155,Change in HbA1c,Mean Mixed Meal Tolerance Test,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10287,NCT02950142,Appropriateness,Laboratory test volume,Downstream or cascade clinical activities,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
10288,NCT02279407,Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo),Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10289,NCT03270956,Procedure and/or product related adverse events,Renal specific adverse events,,2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE2']
10290,NCT01889446,Post prandial insulin levels,,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
10291,NCT04729023,Best correct visual acuity,Working delay time,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
10292,NCT05317845,Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope,Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD,,2022-04-21,COMPLETED,OBSERVATIONAL,['NA']
10293,NCT00005134,,,,1988-09,COMPLETED,OBSERVATIONAL,['NA']
10294,NCT00138593,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10295,NCT04281992,Incidence of Wound Closure,Incidence of bacteria distribution,,2020-01-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10296,NCT01536613,Change in body weight,Occurrence of adverse events (non-serious and serious),,2004-09,COMPLETED,OBSERVATIONAL,['NA']
10297,NCT05094505,Changes from pre- to pos intervention on glycated haemoglobin,Changes from pre- to pos intervention in angiogenesis,Changes from pre- to pos intervention on lipid profile,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
10298,NCT00666172,"Measure endothelial function determined by brachial artery reactivity to stress, at baseline/following 6m program participation comparison of change between subj randomized to exercise with weight-loss intervention vs. those randomized to exerci...",,,2008-04-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10299,NCT02808715,"Number of participants with deleterious mutations in the PRDM-16 locus, using standard genomic methods",,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
10300,NCT01813773,Incidence and severity of adverse events of intravitreal aflibercept injection in the treatment of PDR.,Proportion of subjects with avoidance of vitrectomy,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10301,NCT05713058,Glycemic control,Body weight loss,Beta cell function,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
10302,NCT05767372,Evaluation of oxygen saturation (SPO2) and heart rate (HR),Evaluation of forced expiratory volume at one second (FEV1) and maximum voluntary ventilation (MVV),,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
10303,NCT00069056,,,,2003-09-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10304,NCT01042106,"Safety assessments include physical examination, laboratory variables and ECG.",Pharmacodynamics of DSP-8658 (how DSP-8658 acts in the body to affect glucose and lipid control): glucose and lipid levels will be measured at various time points throughout the study.,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10305,NCT00658866,Pharmacokinetics in tissue,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10306,NCT01353118,"Composite of Fasting Glucose, Glycosylated Haemoglobin c and Rates of Type 2 Diabetes Mellitus Remission.",A Composite of Microvascular Complications,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
10307,NCT00513214,Safety assessed by treatment-emergent adverse events.,,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10308,NCT02611596,hsCRP,prevalence of hs cTnT > 99th percentile,,2016-11,WITHDRAWN,INTERVENTIONAL,['NA']
10309,NCT00006159,,,,1994-03,COMPLETED,INTERVENTIONAL,['NA']
10310,NCT04388228,percentage registered diagnoses of DM 2 in the EHR,percentage registered diagnoses of heart failure,Diabetes follow-up quality indicator,2022-01-30,WITHDRAWN,INTERVENTIONAL,['NA']
10311,NCT04245982,histological tissue evaluation,,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10312,NCT01364350,effects of TODAY treatment assignment on long-term glycemic control,microvascular complications,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
10313,NCT02676609,2-hour postmeal blood glucose values between 80 and 180 mg/dl,Mean 2-hour postmeal blood glucose level,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10314,NCT00006432,,,,2000-01,COMPLETED,INTERVENTIONAL,['NA']
10315,NCT00387166,"Stress, psychosocial risk and resilient factors, socio-cultural factors, and bio-behavioral markers of cardiovascular risk",,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
10316,NCT00784433,Glycemic control,CVD status,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10317,NCT02753803,AUC,,,2016-07-27,COMPLETED,INTERVENTIONAL,['PHASE1']
10318,NCT04031599,Relative decrease in glucose levels during exercise compared to pre-breakfast levels (sub-study),Mean time (minutes) to the first hypoglycemic event (sub-study),,2020-07-10,COMPLETED,INTERVENTIONAL,['NA']
10319,NCT03312764,HbA1c reduction,Decreased cardiovascular risk,Implementation Context,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
10320,NCT04149067,0.5% in Hb1Ac and 1.5 kg in body weight,Evaluate the security of the treatment,,2017-06-05,COMPLETED,OBSERVATIONAL,['NA']
10321,NCT02412774,Weight loss,HA1C,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
10322,NCT00758069,Change From Baseline in 24-hour Weighted Mean Plasma Glucose,Change From Baseline in Plasma Glucose,,2005-07-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10323,NCT00151762,To evaluate safety and tolerability of colesevelam hydrochloride as add-on therapy,To assess effects on lipids and lipoproteins,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10324,NCT02112721,Follow up Insulin Sensitivity Measure using Euglycaemic glucose clamp,Follow up Acute Insulin Secretory Response- Intravenous Glucose Tolerance Test,Follow Up Pain Impact Questionnaire (PIQ-6 questionnaire),2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10325,NCT03442595,Percent Change in A1C,Composite of Risk for Hospitalizations and Emergency Room Visits Within 90 Days From Baseline,,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
10326,NCT01454700,difference in change in urine albumine excretion from baseline to end of study (12 months),difference in carotid intima media thickness (CIMT),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10327,NCT01664650,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10328,NCT04639492,Post-treatment changes of intestinal flora,Incidence of treatment-emergent adverse events(TEAE),,2020-11-02,COMPLETED,INTERVENTIONAL,['NA']
10329,NCT05644548,Vascular density of the retina,the foveal avascular zone (FAZ) size of the retina,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
10330,NCT03959865,HbA1c,Persistence,,2018-12-19,UNKNOWN,OBSERVATIONAL,['NA']
10331,NCT04760626,Change in HbA1c (glycated haemoglobin),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10332,NCT02286128,Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.,Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10333,NCT03422471,Modified Oxford Method Assessment of Baroreflex Function,,,2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10334,NCT02783807,Clinical Evaluation of Retina Camera Images from both Healthy and Diseased Subjects,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10335,NCT03977662,Incidence of Insulin independence,Beta cell function as assessed by Insulin-Modified Frequently-Sampled Intravenous Glucose ToleranceTest (FSIGT),,2019-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10336,NCT00738140,To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.,To evaluate the effects of intensive lifestyle modification on other markers of cardiovascular disease risk.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10337,NCT01097681,Plasma concentration of ASP1941,"Safety assessed by adverse events, vital signs, laboratory tests and 12-lead ECGs",,2010-02-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10338,NCT00005745,,,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
10339,NCT05417880,Triglycerides,Satisfaction with treatment and life,,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10340,NCT05057403,3-point MACE incidence rate,Non-alcoholic fatty liver disease prevalence,,2022-05-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10341,NCT04217369,Time in Range,Laboratory HbA1c,,2020-05-04,UNKNOWN,INTERVENTIONAL,['NA']
10342,NCT01884545,Triglycerides,Social Isolation,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
10343,NCT03403582,Postprandial blood lipids,Postprandial inflammation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10344,NCT05162014,Incidence Rate of Acute Pancreatitis,,,2021-12-20,COMPLETED,OBSERVATIONAL,['NA']
10345,NCT01799850,change in muscle glucose transporter expression,,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
10346,NCT01117311,Disposition Index,Gastric Emptying Half-time,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
10347,NCT00770081,Assessment of treatment emergent adverse events (including hypoglycemia events and other events of special interest),To assess hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) reduction from baseline after 52 weeks of treatment,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10348,NCT05437913,Change in Self-report psychological variables: interoceptive awareness (teens),Possible adverse effects,,2021-09-06,UNKNOWN,INTERVENTIONAL,['NA']
10349,NCT05946798,microvascular insulin-mediated dilation,endothelial cell NADPH oxidase expression,,2023-08-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10350,NCT00590226,Mean AM BG (mg/dl),Number of Patients With Hypoglycemic Events,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10351,NCT01472614,Reduction of A1c level,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10352,NCT05486390,HbA1c,Healthcare cost,,2023-02-17,RECRUITING,INTERVENTIONAL,['NA']
10353,NCT01224886,Oxidative capacity,Physical fitness,,2010-10,RECRUITING,INTERVENTIONAL,['NA']
10354,NCT01357252,Change from baseline in HbA1c,Responder rates - proportion of subjects reaching predefined HbA1c targets,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10355,NCT04881383,The sensitivity of the risk prediction function in detecting DM and pre-DM in primary care,Negative predictive value (NPV) of the risk prediction function in detecting DM and pre-DM in primary care,,2020-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10356,NCT02003014,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),,2009-02,COMPLETED,OBSERVATIONAL,['NA']
10357,NCT06292468,Spatiotemporal gait parameters,,,2023-07-07,COMPLETED,INTERVENTIONAL,['NA']
10358,NCT03594240,Change in plasma homocysteine,Change in HbA1c level,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10359,NCT00360984,prevention of severe hypoglycemia,Diabetes Quality Of Life of questionnaires.,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10360,NCT00760344,Change from baseline in glycosylated hemoglobin,Body weight.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10361,NCT02105597,Change in self-reported medication adherence,Change in health status,,2014-08,WITHDRAWN,INTERVENTIONAL,['NA']
10362,NCT00811460,Incremental area under insulin concentration time curve relative to basal insulin concentration,"Adverse events, laboratory parameters",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10363,NCT03698786,Plasma Acylated ghrelin concentration,Plasma Leptin concentration,,2017-05-24,COMPLETED,OBSERVATIONAL,['NA']
10364,NCT02299791,Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
10365,NCT02974816,Change in HbA1c from baseline,Number of hospitalizations(Change from baseline),,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
10366,NCT00910923,To assess the safety and tolerability of JNJ-38431055,"To assess the pharmacodynamic effects of JNJ-38431055 on plasma glucose and insulin, during a Meal Tolerance Test (MTT)",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10367,NCT06324604,"Safety of multiple, ascending dose levels of MTX-101",anti-drug antibody (ADA) formation,Receptor occupancy of MTX-101,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
10368,NCT01095991,To evaluate the effect of AZD1656 on the steady-state PK of sitagliptin and vice versa by assessment of AUC0-24 and Cmax,"To evaluate the safety of AZD1656 with and without sitagliptin by assessment of adverse events (AEs), physical examination, electrocardiogram (ECG), pulse, blood pressure (BP), weight and FPG.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10369,NCT00284232,HbA1c %,Confidence in new instrument quality,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10370,NCT02183558,Gestational Diabetes Mellitus,Anthropometric measures in offspring,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10371,NCT02211963,Assessment of tolerability by investigator on a 4-point scale,Amount of glucose excreted in urine,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10372,NCT00044707,To determine the effect of pramlintide on the PK of an oral medication,safety and tolerability as measured by analysis of laboratory values and adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10373,NCT03113006,Sensitivity and specificity of OCT angiography as an expression of disease activity in PDR,Change in quality of life between the groups,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
10374,NCT03917758,Long term changes from baseline of renin-angiotensin-aldosterone system parameters,Changes in long term glicemic control,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
10375,NCT02144948,Decrease in HbA1c levels,change in gastrointestinal condition,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10376,NCT01268345,blood glucose value,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
10377,NCT00795015,Percent of blood glucose values in the target range 80-120 mg/dl,"Percent of patient days with a low blood glucose, defines as less than 60 mg/dl",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10378,NCT04841668,Semantic verbal fluency,The percentage of time in glucose range (glucose level between 140-199 mg/dl),Number time awake,2021-04-10,RECRUITING,OBSERVATIONAL,['NA']
10379,NCT00699322,Glucose variability,"oxidative stress markers (oxidized LDL, N-carboxymethyl-lysine(CML), nitrotyrosine, 8-iso-prostaglandinF2α, 8-OhDG)",,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
10380,NCT00859898,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants,"Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10381,NCT02686476,Change in Liver Fat,subcutaneous fat,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10382,NCT06000735,Blood glucose time-in-range (TIR),,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10383,NCT06272136,Glucose changes will be measured noninvasively and transcutaneously in dynamic states of glycaemia,,,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
10384,NCT00867555,postprandial fat oxidation,,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
10385,NCT02875275,Change in postprandial plasma triglyceride over 360 minutes period,Change in postprandial plasma insulin over 360 minutes period,,2016-01-12,COMPLETED,INTERVENTIONAL,['NA']
10386,NCT03106870,Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation,Number of Participants With Neonates Who Were Hypoglycemic,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
10387,NCT03228459,Assessment of the impact of arterial ultrasound on cardiovascular events and mortality in a low/moderate cardiovascular risk population.,Association of spirometry alterations and cardiovascular events in a low/moderate cardiovascular risk population,,2015-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10388,NCT05626725,Change in blood glucose levels from start of exercise to nadir during or up to 30 min post exercise.,Total insulin delivery during (at least 15-min) of habitual PA and 30-min after,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
10389,NCT00521105,"Medical outcomes: HbA1c, rates of severe hypoglycemia, rates of DKA","Associated costs to the family (time away from school and work, travel, etc)",,2005-08,COMPLETED,INTERVENTIONAL,['NA']
10390,NCT02300181,Difference in plasma glucose profile including AUC and Cmax after taking 50 g carbohidrate.,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
10391,NCT04904718,Change in glucose control with the use of DreaMed,,,2021-12,WITHDRAWN,INTERVENTIONAL,['NA']
10392,NCT05831085,The event rate of major adverse cardiac or cerebrovascular events,The number of anti-anginal medications used,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10393,NCT03746769,"Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% (""complete response"")","Proportion of subjects who are free of severe hypoglycemic episodes (SHE) and have a HbA1c less than or equal to 7.0% (""partial response"").",Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring,2019-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10394,NCT01638299,Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Number of Safety Events and any additional information that can be used for product development,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10395,NCT01487421,HbA1c (glycosylated haemoglobin),Adverse Drug Reactions (ADRs) including Serious Adverse Drug Reactions (SADRs),,2003-07,COMPLETED,OBSERVATIONAL,['NA']
10396,NCT02181244,glycosylated hemoglobin,plasma LDL cholesterol,tumor necrosis factor alpha,2013-05,COMPLETED,INTERVENTIONAL,['NA']
10397,NCT02809365,Improvement of diabetes treatment satisfaction measured by the 'Diabetes Treatment Satisfaction Questionnaire' (DTSQ),Reduction in hypoglycemic events <70 mg%,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
10398,NCT00446459,The Number of Subjects With a 10% Decrease in PRA Level at Month 8.,The Number of Transplants With a Negative Crossmatch at Transplant.,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10399,NCT01368549,To determine if Metanx® improves neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6),To determine overall patient satisfaction with Metanx® using a 10-point satisfaction scale,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
10400,NCT03951753,Change From Baseline in Total Clamp Disposition Index (cDI),Change From Baseline in Food Intake During Ad Libitum Meal,,2019-06-28,COMPLETED,INTERVENTIONAL,['PHASE1']
10401,NCT04901143,Time in range,,,2021-07-17,COMPLETED,INTERVENTIONAL,['NA']
10402,NCT01611935,Number of Blood Products Transfused,Total Number of Complications,,2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10403,NCT00010751,,,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10404,NCT00222521,Hemoglobin A1c,Quality of life survey,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10405,NCT02111967,Measurements of serum vitamin B12 and serum holotranscobalamin concentrations,Questionnaire results,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
10406,NCT05184322,Number of treatment emergent adverse events (TEAEs),Incidence of anti-XW004 antibodies at end of study,,2022-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10407,NCT04660240,Rate of Target Lesion Failure (TLF),Technical Success,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10408,NCT01907854,Change in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Adverse Events (TEAEs),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10409,NCT02667769,Plasma glucose day- and night profiles,,,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
10410,NCT04166760,Difference in iAUC for insulin between WHE and speWHE,continuous glucose measurement (CGM),,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
10411,NCT01671514,"Change from baseline in pre-specified biomarker levels in blood, skeletal muscle, and urine",,"Change from baseline in quality of life, health, and nutrition questionnaires",2012-07,COMPLETED,INTERVENTIONAL,['NA']
10412,NCT02357420,Change From Baseline to Week 12 in Weekly Vomiting Episodes,Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time,,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE2']
10413,NCT02836704,Percentage of patients with at least one episode of hypoglycemia,Number of severe hypoglycemic events,,2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10414,NCT05668507,Change in Diabetes Distress,Change in % Time in Range,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10415,NCT03066440,Length of acidosis,Length of stay in the hospital,,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10416,NCT05307731,"The changes of glycosylated hemoglobin, compared with baseline",any adverse events,,2022-03-15,RECRUITING,INTERVENTIONAL,['PHASE4']
10417,NCT01473017,Anxiety and/or depression in Type 2 Diabetes,Quality of life,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
10418,NCT01871207,Ocular concentration of Erythropoietin and VEGF.,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
10419,NCT01200849,Understanding of prescription medication,Change in HbA1c or blood pressure readings,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
10420,NCT00849537,Macula diameter,Diabetic retinopathy,,2008-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10421,NCT03192475,Change in Bodyweight,Change in Mood,,2013-01-28,COMPLETED,INTERVENTIONAL,['NA']
10422,NCT00387972,Change from baseline in blood glucose regulation after 26 weeks of treatment,"Change from baseline in glycemic parameters, insulin, body weight and waist circumference, and safety measures",,2006-05,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10423,NCT05702073,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
10424,NCT03055702,Attendance Rate of the scheduled clinic appointment,,,2016-11-01,UNKNOWN,INTERVENTIONAL,['NA']
10425,NCT01034826,"fasting serum glucose, fasting plasma insulin,post prandial serum glucose, post prandial plasma insulin, hbA1c",,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
10426,NCT02243098,Area under the digoxin plasma concentration-time curve,Number of treatment emergent AEs (TEAEs),,2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10427,NCT04052919,transthoracic echocardiography,Physical activity questionaire,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
10428,NCT00573950,The effect on pulse wave velocity (PWV),"the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP",,2007-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
10429,NCT04608890,"Percentage of patients with a change in eye movement test in each class Resistance, Velocity, Pursuit, Wideness and OKN measured by the eye-tracking based test",Percentage of patients with a change in eye movement test in the Velocity class,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
10430,NCT00744367,Absolute change from baseline in HbA1c,"Safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10431,NCT00519142,change from baseline in HbA1c,change from baseline in fasting plasma glucose,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10432,NCT04976881,Knowledge of reproductive risks,Folic acid use,,2022-05-06,RECRUITING,INTERVENTIONAL,['NA']
10433,NCT04690309,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
10434,NCT01275027,HgA1c reduction,Diabetes medication,,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10435,NCT00934570,Reduction in BMI,Improvement in physical activity,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10436,NCT06292000,Peripheral insulin sensitivity,Sleep outcomes,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
10437,NCT00366249,Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.,Number of Patients With Microbiologic Response of Eradication.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10438,NCT05548205,Percentage Change in Hemoglobin A1c (HbA1c),Number of Hypoglycemic Events,,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10439,NCT01477034,Tumor Necrosis Factor alpha expression in adipose tissue,Fasting plasma lipopolysaccharide binding protein (LBP),,2011-11,COMPLETED,INTERVENTIONAL,['NA']
10440,NCT03323827,ANT Acetylation,,,2016-11,UNKNOWN,OBSERVATIONAL,['NA']
10441,NCT05303051,Assess the performance of the DNN score in different ethnicity and skin tones,Retrain the DNN algorithm,,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10442,NCT00363519,tolerability,Plasma glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10443,NCT01289119,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Percentage of Participants With a Decrease in HbA1c ≥2.0%,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10444,NCT03877406,HbA1c,Insulin resistance,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10445,NCT01702883,The primary measure will be adherence as measured by pharmacy refills in each group.,,,2012-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10446,NCT04007003,Change in Insulin Use,Change in Needle Re-Use,,2018-06-26,TERMINATED,INTERVENTIONAL,['NA']
10447,NCT03754608,Diagnostic Odds ratio for the MRI vascular cognitive impairment biomarker.,Correlation between the biomarker and cognition,,2018-11-07,COMPLETED,OBSERVATIONAL,['NA']
10448,NCT04534530,Cost-effectiveness analysis of routine screening for ischemic heart disease in T2DM patients,Budget impact analysis for Health Insurance of the most efficient strategy,,2023-06-05,RECRUITING,OBSERVATIONAL,['NA']
10449,NCT02117622,Incidence of adverse events (AEs) by preferred term,Incidence of confirmed hypoglycaemia,,2015-07-24,COMPLETED,OBSERVATIONAL,['NA']
10450,NCT03716141,Wound Healing,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
10451,NCT06068309,Proportion of days covered (PDC),Perception & Satisfaction Questionnaire (PSQ),,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
10452,NCT05459519,Changes in rate of platelet aggregation,Number of Participants with safety endpoint,,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
10453,NCT00807651,Exogenous insulin dose,HbA1c level,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10454,NCT01317459,Change in HbA1c,DDS scales,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
10455,NCT01880242,Target Lesion Failure,Clinical Procedure Success,,2014-05-13,COMPLETED,OBSERVATIONAL,['NA']
10456,NCT05063734,"Change From Baseline in BCVA ETDRS Letter Score, at Month 3, in Treatment-naïve Subjects in Part B of the Study",Incidence of Ocular and Non-ocular Adverse Events (AEs) and Serious Adverse Events (SAEs),,2021-08-27,TERMINATED,INTERVENTIONAL,['PHASE2']
10457,NCT00642915,Estimate the efficacy of combination therapy with Lantus plus Amarylin controlling blood glucose in Japanese patients with type 2 diabetes having failed oral antidiabetic drug therapy,Document the ability to preserve the endocrine pancreatic function with Lantus plus Amaryl combination therapy,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10458,NCT05377918,Anxiety,,,2022-01-31,COMPLETED,INTERVENTIONAL,['NA']
10459,NCT05225467,Blood ketone difference,Difference in ketone development between patient with and without diabetes mellitus.,Other,2022-03-15,COMPLETED,OBSERVATIONAL,['NA']
10460,NCT03642483,HbA1c,psychological health (Child Behavior),,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
10461,NCT05596383,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR),fasting insulin,,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10462,NCT01847313,MCP-1:Creatinine Ratio in Urine,sCD163:Creatinine Ratio in Urine,Safety in All Participants as Measured by Adverse Event Rate,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10463,NCT01088711,Number of Participants Withdrawing From Study Therapy Due to an AE,Plasma Glucose Concentration,,2010-03-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10464,NCT00877851,Between Group Differences in Goal Setting,Between Group Differences in Self-Efficacy and Barriers to Management of Diabetes,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
10465,NCT02479516,Elevated HBA1c,Blood Pressure,Health Behaviour questionnaire,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10466,NCT00101803,Change from baseline in HbA1c at 24 weeks,Patients with reduction in HbA1c >/= to 0.7% after 24 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10467,NCT04878120,Low blood glucose index (LBGI),Total number and amount of carbohydrate administered as rescue treatments,,2021-05-14,COMPLETED,INTERVENTIONAL,['NA']
10468,NCT00936663,Fasting Blood Glucose,Hypoglycemia,AUC for C Peptide,2009-07-06,TERMINATED,INTERVENTIONAL,['PHASE4']
10469,NCT01194245,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period,Mean Daily Postprandial Glucose (PPG) Excursions,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10470,NCT00327054,The primary end point for the trial is serum low-density lipoprotein (LDL) cholesterol concentration measured at six weeks after intervention.,Changes in serum creatinine after six weeks intervention,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10471,NCT00232583,Beta-cell Function - C-peptide AUC (Area Under the Curve),Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment,,2003-11,COMPLETED,INTERVENTIONAL,['NA']
10472,NCT00530686,1)Presence or absence of hypoglycemic unawareness 2) To assess incidence of hypoglycemic episodes 3) To assess insulin requirements in patients who did not become insulin independent.,To assess the achievement of insulin independence at 12 month and 24 month post transplant in patients who underwent allo islet cell transplantation.,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10473,NCT05766657,Body mass index (BMI),Metabolomic analysis,,2022-12-23,RECRUITING,INTERVENTIONAL,['NA']
10474,NCT00841347,The influence of sleep extension on leptin level for the obese teens group.,"Study the correlation between delta waves activity and psychological, behavioural, anthropometric and physiological markers of obesity and its co morbidities",,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10475,NCT01877213,Diabetes-related readmissions,Duration of rehospitalizations,,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
10476,NCT03389100,18F-MK6240 standardized update value ratio (SUVR),,,2018-07-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
10477,NCT00214591,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
10478,NCT05382533,"Fasting glucose, mmol/l (group C, D)",Zinc (µmol/l),Zinc (µmol/24 h),2022-05-30,COMPLETED,INTERVENTIONAL,['NA']
10479,NCT04326192,SUVmax,Ipsi- and contralateral BAT during SCS-activation,,2021-02-19,RECRUITING,INTERVENTIONAL,['NA']
10480,NCT00073294,,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
10481,NCT02402439,Insulin independence,Incidence of adverse events,,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10482,NCT06068439,decline of renal function,Change of renal function class,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10483,NCT01678235,Postprandial glycemia,Difference between the maximum and baseline glycemia,Questionnaire: Glycemic Index Knowledge,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10484,NCT05504005,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,,2022-08-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10485,NCT00806936,Percentage of patients achieving HbA1c below 7.0%,Comparison of scores of Insulin Treatment Appraisal Scale (ITAS),,2008-12,COMPLETED,OBSERVATIONAL,['NA']
10486,NCT02119819,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,Change From Baseline in Insulin Levels,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10487,NCT05099198,Time until failure to maintain metabolic control,HbA1C change from baseline,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
10488,NCT02821026,"The proportion of subjects with HbA1c ≤ 6.5% at 1 year AND free of severe hypoglycemic events from Day 28 to Day 365, inclusive, after the islet transplant",The incidence of discontinuation of immunosuppression,,2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10489,NCT02021591,Change in Score on the Summary of Diabetes Self-Care Activities Questionnaire (SDSCA),Change in Low-Density Lipoprotein,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
10490,NCT05365425,Volume of carotid artery plaque,changes of gut microbiota,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10491,NCT00778622,Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS),Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set,Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10492,NCT04657003,Percentage of Participants Who Achieve ≥5% Body Weight Reduction from Randomization,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
10493,NCT00953498,Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins,Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10494,NCT03542071,Child: Neonatal body fat%,Percentage of participants on GDM medication,,2018-07-20,TERMINATED,INTERVENTIONAL,['NA']
10495,NCT01720719,Liver fat content(%),Muscle enzymes,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
10496,NCT00292357,Healing velocity,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
10497,NCT00252772,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Patient-reported outcomes: Well-Being Questionnaire (W BQ12),,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3']
10498,NCT06134934,Experiences with and acceptability of intervention design(s),Costs,,2024-01-09,RECRUITING,INTERVENTIONAL,['NA']
10499,NCT01310452,The change in liver fat content and visceral fat mass,Safety profile,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
10500,NCT04271189,Assess the T2DM remission rate in patients with newly diagnosed T2DM treated with either POLYCHEM or with SDC for 16 weeks.,Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation,,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10501,NCT02054897,Change in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve (Yes/no):HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target,,2014-02-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10502,NCT04508751,Fetal Liver PDFF,Maternal Hepatic Fat PDFF,,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
10503,NCT02461225,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Change in Pain Rating on the Visual Analog Scale (VAS),,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
10504,NCT03812614,Change from baseline in patient glycemic control at 6 months,Change in self-efficacy of support person,Change in self-efficacy of support person,2019-09-23,COMPLETED,INTERVENTIONAL,['NA']
10505,NCT04089280,Adverse gastrointestinal symptoms related to metformin treatment,Oxidative stress markers - TAS,,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
10506,NCT04335396,presence of incresed non-HDL cholesterol level of the sera,Prevalence of polyneuropathy,,2018-05-28,UNKNOWN,OBSERVATIONAL,['NA']
10507,NCT05167513,Diabetes Quality of Life assessment using DQOL-13 questionnaire,Change from baseline in HbA1c % and fasting blood sugar FBS (mg/dl) to the last-observation on treatment,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10508,NCT01128153,"Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)","Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10509,NCT01015937,,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
10510,NCT05918523,Primary Endpoint: Long-term safety of REACT,Third Secondary Endpoint: Time from first injection to renal transplant.,,2023-12-11,RECRUITING,OBSERVATIONAL,['NA']
10511,NCT04825639,Prevalence of Acute Kidney Injury in the sepsis and DKA cohorts,Compare chloride levels in the AKI and non AKI groups,,2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
10512,NCT02885909,Glucose target,Orexin-A,,2016-09,RECRUITING,INTERVENTIONAL,['PHASE4']
10513,NCT00728403,"HbA1c levels and insulin sensitivity index using 3 different indices: ISI, HOMA, QUICKI","Cholesterol, triglycerides, fasting & post-prandial blood glucose and insulin, C-reactive protein, lipid peroxidation, blood pressure, endothelial function, body fat composition",,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
10514,NCT03012074,Number of participants with type II diabetes who adhere to using mobile technologies to self-monitor multiple types of diabetes-related data,Medication adherence Survey,"Explore health care providers' perspectives on using real-time data, by conducting one-time, individual interviews over a 2 month period.",2017-03-02,COMPLETED,INTERVENTIONAL,['NA']
10515,NCT02718703,System Use Evaluation - HCP ( HealthCare Professional) questionnaire,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
10516,NCT02269098,Medication Adherence,Hypoglycemia,ED Visits and Hospitalizations,2012-02,COMPLETED,INTERVENTIONAL,['NA']
10517,NCT03744039,Description Charcot foot's treatment,Register of Charcot foot,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10518,NCT00353834,The Primary Endpoint Was the Change in FMD at the End of the Study Compared to Baseline Measurements in Subjects Treated With Exenatide Compared to Subjects Treated With Lantus.,"Fourth Will be Changes in Insulin, Glucose, C-peptide, Lipids, and FFA Responses Following the MTT in Subjects Treated With Exenatide Compared With Subjects Treated With Lantus at the End of the Study Compared to Baseline Measurement",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
10519,NCT00296296,Estimated Glomerular Filtration Rate (eGFR) 1 Year Following Transplantation,Count of Participants With Biopsy Proven Acute Rejection at One Year Post Transplantation,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10520,NCT03436875,Microbiota,,,2023-01-01,WITHDRAWN,OBSERVATIONAL,['NA']
10521,NCT01964612,self-monitoring and self-control scale,health anxiety scale,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
10522,NCT00097084,HbA1c,Insulin Treatment Satisfaction,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10523,NCT01163006,fat oxidation,24h glucose pattern,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
10524,NCT00651014,Percentage of patients reaching LDL-C goal of < 2.5 mmol/L (97 mg/dL) at endpoint.,"Safety/tolerability: adverse events, laboratory test results, vital signs.",,2004-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10525,NCT00706680,"Percentage of patients developing New Onset Diabetes post transplant, as identified by an oral glucose tolerance test",Incidence of acute rejection,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
10526,NCT04007107,Intensity of Injection Site Pain,,,2019-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
10527,NCT01804777,Blood Pressure,Hypertension,,2013-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
10528,NCT05995262,HbA1c levels,,,2023-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10529,NCT02015910,Percent Wounds Healed,,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10530,NCT04505618,Correlation of Imaging,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
10531,NCT04573296,Change in body weight,change in liver function tests,Vitadio usability for HCPs,2020-02-26,COMPLETED,INTERVENTIONAL,['NA']
10532,NCT00977483,"Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint","NIS, NSC, TSS, LLF, QST, VDT, CDT and HP, QAE by means of the HRDB, amplitude CMAP, DL and MNCV on peroneal and tibial nerves, amplitude SNAP and latency on sural nerve, foot inspection, efficacy.",,1998-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10533,NCT06213896,To determine the accuracy of diagnosis with artificial intelligence algorithm,To determine the sensitivity and specificity of EyeCheckup v2.0 to detect retinal and optic disc diseases,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
10534,NCT00609102,Blood glucose,HbA1c levels,,2008-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10535,NCT02529969,Triglyceride,C-Reactive Protein,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10536,NCT05803473,Time in range,Recurrent hypoglycemic events,Questionnaires,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
10537,NCT05272839,Decrease of ≥ 0.5 points of percentage of HbA1c,Blood pressure,,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10538,NCT06321029,Feasibility of intervention and delivery modality,Diabetes Therapy-Related Quality of Life Questionnaire,,2023-10-19,RECRUITING,INTERVENTIONAL,['NA']
10539,NCT05766735,Change in Metformin at 13.5-months of follow-up,,,2023-08-08,RECRUITING,INTERVENTIONAL,['NA']
10540,NCT04243629,Time in target range,Number of hypoglycemia events,,2021-11-12,RECRUITING,INTERVENTIONAL,['NA']
10541,NCT00140543,At 1 year:Incidence of biopsy-proven (kidney) rejection episodes.,* % of steroid free patients: at 6 months and 1 year.,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10542,NCT02689479,The relationship between β cell mass calculated from the 11C-5-HTP PET scans and the MMTT C-peptide at 90 minutes,The incidence and severity of adverse events related to the PET investigation including allergic reactions,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
10543,NCT05573685,To estimate the effect size for changes in pain experience (interference) in the Treatment App group compared to the Digital Control App group,To estimate the effect size for changes in confidence in dealing with chronic pain in the Treatment App group compared to the Digital Control App group,,2022-10-10,COMPLETED,INTERVENTIONAL,['NA']
10544,NCT00737633,Change in HbA1c From Baseline to Week 72,Percent Weight Change From Baseline to Week 72,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10545,NCT03026426,Proportion of participants with a reduction of 50% or more in the Patient Health Questionnaire (PHQ-9) score at the 3-month assessment,Proportion of participants who improve level of activity at the 3- and 6-month assessments,,2017-01-24,COMPLETED,INTERVENTIONAL,['PHASE3']
10546,NCT01049750,Evaluation of diabetic neuropathy in patients with erectile dysfunction,Glycemic control,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
10547,NCT04460612,Change in oxygenation of feet and lower legs,,,2021-05-26,COMPLETED,INTERVENTIONAL,['NA']
10548,NCT04891887,Health related quality of life,Body weight,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10549,NCT03635437,Adverse events possibly or probably related to GABA treatment,Change in diabetes treatment satisfaction questionnaire,,2018-09-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10550,NCT02750527,number of familial hypercholesterolemia or pre-type-1-diabetes,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
10551,NCT05107154,Pediatric Quality of Life (PedsQL),Glycemic Control,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10552,NCT05764200,24 hour intestinal gas concentrations,Urine metabolites,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10553,NCT00262145,glucose and lipid uptake,lipid metabolism,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10554,NCT02144337,Feasibility: Number of Participants With Adverse Events,Change in Parental Hypoglycaemia Fear Using the Hypoglycaemia Fear Survey (HFS-Parent),,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10555,NCT06065930,Fasting Neuropilin-1 concentration in subcutaneous interstitial fluid,Metabolites in urine including acylcarnitines measured by Mass Spectrometry,,2023-05-05,RECRUITING,OBSERVATIONAL,['NA']
10556,NCT01159353,Area under the plasma glucose concentration curve (AUC) between 0 and 1 hour after insulin injection AUC(0-1h),Hypoglycaemia and adverse events,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10557,NCT02895139,Reduction of forefoot pressure to below safety threshold,Clinician confidence in orthotics service,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
10558,NCT01937416,Cell transplantation related side effect,Skin microcirculation measurement,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10559,NCT05093517,Muscle Insulin sensitivity,,,2021-11-10,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1']
10560,NCT04836546,Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis events,,,2021-04-13,RECRUITING,INTERVENTIONAL,['NA']
10561,NCT00701935,Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months,Assessment of Event Rate of Treatment- Emergent Hypoglycemic Event,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10562,NCT06108076,Cardiac Efficiency after chronic dosing (Left-ventricular function),Patient Reported Outcomes Measure Information System (PROMIS) - Physical Function,,2024-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10563,NCT01576328,Primary objective of the study is to assess the safety and tolerability of MPC therapy,,,2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10564,NCT04739241,Change in HbA1c levels,Change in the scores of the Diabetes Quality Of Life Questionnaire (EsDQOL) from recruitment to month 12.,,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4']
10565,NCT02694289,Units of Insulin used,"pro-BNP levels, pg/mL",,2016-11,WITHDRAWN,INTERVENTIONAL,['NA']
10566,NCT01585454,Gestational Weight Gain,Complications of Pregnancy and Delivery,,2012-03-27,WITHDRAWN,OBSERVATIONAL,['NA']
10567,NCT02073227,Plasma concentration of metformin following administration of a single dose of study drug,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10568,NCT04288063,Change in muscle mass as measured by D3 creatinine dilution method,Muscle Strength,,2020-09-18,COMPLETED,OBSERVATIONAL,['NA']
10569,NCT03904056,Fluorescein leakage area of active new vessels (FLA),Electroretinography,,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
10570,NCT05456477,Ratio of incremental area under the curve (iAUC) for C-peptide to iAUC for glucose,Interleukin-6,,2022-10-07,COMPLETED,INTERVENTIONAL,['NA']
10571,NCT03725917,Change in the integrity of the skin (Ulceration),Changes in the integral pressure-time,,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA']
10572,NCT00147836,"glycemic control, the improvement of β-cell l function and the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients","the effects of different interventions (oral anti-hyperglycemic agents, multiple daily injections and continuous subcutaneous insulin infusion) on glycemic control, β-cell function and the remission rate in newly-diagnosed type 2 diabetic patients",,2004-09,COMPLETED,INTERVENTIONAL,['NA']
10573,NCT05859958,Discharge disposition,,,2022-11-10,COMPLETED,OBSERVATIONAL,['NA']
10574,NCT04381598,Bio-marker (Ghrelin) levels in Gingival crevicular fluid.,Probing depth,,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10575,NCT03254095,Percentage of patients developing a foot ulcer,Time to ulceration,Body mass index,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
10576,NCT04011267,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 12-weeks,Quality Adjusted Life Years,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
10577,NCT02594748,Change from baseline in Audit of Diabetes Dependent Quality of Life at 3-month follow up.,Change from baseline in Blood sugar at 3-month follow up.,,2015-07,SUSPENDED,INTERVENTIONAL,['NA']
10578,NCT04151849,Urinary aldosterone at 3 months,Urinary aldosterone at 12 months,Ferritin,2019-11-07,COMPLETED,OBSERVATIONAL,['NA']
10579,NCT02877680,Acceptability - Number of Participants That Felt The Intervention Was Well-Received,"Parent-Adolescent Relationship Intervention Process Measure, Adolescent Report",,2017-07-31,COMPLETED,INTERVENTIONAL,['NA']
10580,NCT02304588,Frequency of Adverse Events,Relative Wound Area Regression of 40% or More at 6 Week,Reduced pain,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10581,NCT04185662,HbA1c,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
10582,NCT05787067,Evaluation of Participants' Insulin Injection Administration Skill Levels,,,2021-12-30,COMPLETED,INTERVENTIONAL,['NA']
10583,NCT00575588,Hemoglobin A1c (HbA1c) Change From Baseline to Week 52,Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c,Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10584,NCT04126759,Validation of predictive algorithms for determining blood glucose levels,Number of encountered Device Deficiencies,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
10585,NCT06095544,Hospital costs (US dollar),Perioperative complications,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
10586,NCT01859494,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (<75mg/dL) or Within +/-20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10587,NCT02248779,insulin sensitivity,,,2014-09-22,COMPLETED,OBSERVATIONAL,['NA']
10588,NCT05860413,Adherence to diet protocols,Insulin sensitivity,,2023-01-24,RECRUITING,INTERVENTIONAL,['NA']
10589,NCT01581073,"Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.",Number of Participants with Adverse Events baseline,,2012-02-16,COMPLETED,INTERVENTIONAL,['PHASE3']
10590,NCT00111670,Absolute change from baseline in HbAlc\n\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10591,NCT00384488,Weight loss,Reduction in progression to type 2 DM,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
10592,NCT03503045,Overtreatment for glycemia,Deintensification of treatment,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
10593,NCT05207995,Adverse effects associated with the therapy,,,2022-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10594,NCT04980027,Percentage of participants with Treatment Emergent Adverse Events (TEAEs),Change in DTSQs scores from Baseline to Week 12 and Week 24,,2021-06-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10595,NCT00786175,,,,2008-10,WITHDRAWN,OBSERVATIONAL,['NA']
10596,NCT02663544,Change in glucose tolerance,Change in pancreatic beta-cell function: glucose sensitivity,Change in the homeostasis model assessment (HOMA) insulin resistance index,2016-01,COMPLETED,INTERVENTIONAL,['NA']
10597,NCT02061618,Hemoglobin A1c,Physical Activity,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
10598,NCT03293914,"Difference in the daily rate of change of Glycated hemoglobin (HbA1C) during the year prior to baseline, compared to the period from baseline to post-intervention",Timeliness,,2017-09-18,COMPLETED,INTERVENTIONAL,['NA']
10599,NCT01449773,Change in the in vivo kinetics of intestinally derived apoB-48-containing lipoproteins between the two 8-week interventions,"Change in the plasma surrogates of cholesterol absorption (campesterol, beta-sitosterol) and synthesis (lathosterol) between the two 8-week interventions",,2008-04,COMPLETED,INTERVENTIONAL,['NA']
10600,NCT01307566,Change in Hemoglobine A1C from baseline,Change in ratio albumine to creatinine from baseline,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
10601,NCT00811317,Average Blood Glucose Over the Closed-loop Control Period,Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
10602,NCT04164030,Change in diabetes distress measured using the Diabetes Distress Scale,,,2019-08-26,UNKNOWN,INTERVENTIONAL,['NA']
10603,NCT03422185,"What is the true burden of hypertension, diabetes, and hyperlipidaemia?","Is infection, notably HIV infection or its therapy, associated with increased risk of NCDs?",,2013-05,COMPLETED,OBSERVATIONAL,['NA']
10604,NCT02192853,Correlation between the total and intact GLP-1 hormone during different doses of sitagliptin measured as total area under the curve (tAUC),Differences in Insulin measured as total Area under the curve (tAUC),,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10605,NCT03414320,Accepting mathematical model,,,2018-01-11,COMPLETED,INTERVENTIONAL,['NA']
10606,NCT04626570,Percentage of patients without food addiction,Evolution of quality of life,,2021-01-20,RECRUITING,INTERVENTIONAL,['NA']
10607,NCT00190502,C-peptide production,Insulin dose,,2000-11,UNKNOWN,INTERVENTIONAL,['NA']
10608,NCT04516694,HbA1c,Time in Range,,2020-09-10,COMPLETED,INTERVENTIONAL,['NA']
10609,NCT02868177,Changes in fasting glycemia,Changes in WHR (waist to hip ratio),Changes in physical activity score,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10610,NCT02817243,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
10611,NCT02528019,Effects of treatment on the nominal change in arterial stiffness from baseline after 6 months of treatment as measured by cardio-ankle vascular index,Change from baseline in circulating inflammatory markers,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
10612,NCT04844164,Change in 25(OH)D3 level,Serum vitamin D-binding protein,,2019-04-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10613,NCT02732886,Proportion of subjects with a target ulcer which achieves complete wound closure in 8 weeks,Change amount and change rate of the target ulcer size after using the investigational device,,2016-03-29,COMPLETED,INTERVENTIONAL,['NA']
10614,NCT01684943,For Continuous Insulin Monitoring: Time to Maximum Plasma Insulin and Time to Maximum Continuous Insulin Monitoring Insulin,Multiplex PK: Average Number of Hypoglycemia Events Over the Last Month at Baseline Categorized According to Baseline Use of Insulin Analog Found to Have the Most Favorable PK Profile for Each Individual,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
10615,NCT06014437,"Incidence of complete wound closure during treatment and follow-up (12 weeks). (Outpatient follow-up 2-3 times per week, standardized photographs and measurement of wound size)",,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10616,NCT00099723,Blood work,,,2004-10,TERMINATED,INTERVENTIONAL,['PHASE1']
10617,NCT03361709,Mean change in corneal endothelial cell density before and after phacoemulsification,Intraocular pressure,,2018-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10618,NCT01589445,Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin,Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10619,NCT04791449,wound healing time,,,2021-10-10,RECRUITING,INTERVENTIONAL,['NA']
10620,NCT00721552,Glucose tolerance as assessed by the area under the curve for glucose (AUCgluc) during a standardized meal test.,Beta-cell function as determined by hyperglycemic clamp tests and modeling analysis from mixed-meal tests.,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
10621,NCT05254535,Proportion of Patients Who Complete Annual Diabetic Eye Screening,Mean Implementation Cost,,2023-03-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10622,NCT02933853,Area under the serum insulin aspart concentration-time curve,Maximum glucose infusion rate,,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
10623,NCT00676260,Capillary filtration capacity.,Vascular Endothelium Growth Factor.,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10624,NCT01089192,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
10625,NCT00722397,Blood draw to be processed and analyzed to yield genetic data.,Laboratory values.,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
10626,NCT00787306,mean systolic blood pressure,Proportion of adults with 3 cardiovascular risk factors under optimal control,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10627,NCT00394303,"Perioperative cerebrovascular event defined as any new, temporary or permanent, focal or global neurological deficit.",Re-hospitalizations,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
10628,NCT01474317,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (<100mg/dL) or Within +/- 5to15% (>=100mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
10629,NCT00120341,"changes in sensation using, vibration perception threshold testing, monofilament testing, and the Michigan Neuropathy Screening Instrument",,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10630,NCT06127823,Percentage of insulin-treated,Admission to neonatal intensive care unit (NICU),Total net costs,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
10631,NCT03299153,total cholesterol,Diastolic BP,,2016-12-21,COMPLETED,INTERVENTIONAL,['PHASE4']
10632,NCT00837590,Vascular Function,,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1']
10633,NCT04476108,Change From Baseline in Average Pain Intensity as Measured by the NRS,Change From Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L) (United States),,2020-07-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10634,NCT01399580,Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR),The change from baseline to each post-baseline assessment of thoracic bioimpedance,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10635,NCT03651180,"Incidence of the composite endpoint of cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding in the two groups of study","Incidence of every single adverse event (cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding) in the two groups of study",,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
10636,NCT01030952,Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS),Change in Percent of 24 Hour Hyperglycemic Measurements,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10637,NCT02398383,Glucagon levels,Glucagon levels,,2015-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10638,NCT03167918,Changes in pulmonary function parameters,"Changes in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,",Changes in retrobulbar hemodynamics (RI),2014-07-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10639,NCT01694940,There is no primary outcome measure for this study,,,2010-12,RECRUITING,OBSERVATIONAL,['NA']
10640,NCT00605007,The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia.,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
10641,NCT01183468,C-peptide 2-hour AUC in Response to a Mixed-meal Tolerance Test at Week 52,,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
10642,NCT05936151,Change from Baseline in Glomerular Filtration Rate (GFR),Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h)),,2023-07-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10643,NCT03753997,Change in HbA1c from baseline to 52 weeks follow-up,score of Diabetes Treatment satisfaction questionnaire - change (DTSQc) at week 52,Change in systolic and diastolic blood pressure from baseline to week 52,2019-01-01,RECRUITING,INTERVENTIONAL,['NA']
10644,NCT01701570,Rating of perceived exercise effort (RPE) during exercise (Borg RPE scale),Serum lactate during exercise,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
10645,NCT00214214,to determine if Campath-1H can be used in patients recently diagnosed with type I DM,to determine if Campath-1H can eliminate or lower insulin requirements,,2005-10,WITHDRAWN,INTERVENTIONAL,['PHASE1']
10646,NCT05318326,HbA1c change from baseline at week 24,Fasting lipids From Baseline at Week 24 and Week 52,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10647,NCT05514535,Change in Glycated Haemoglobin (HbA1c),Change in Score of Short Form 36 Version 2 (SF-36 v2),,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE3']
10648,NCT04154904,Comparison of the Mean Relative Difference When Including Patterns in Hypoglycemia Prediction.,,,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
10649,NCT04313829,Measurement of Quality of Life (QoL) using the Euro Quality of Life 5 Dimension 5 Level (EQ-5D-5L) questionnaire,Measurement of HbA1c,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
10650,NCT02953262,Any My HealtheVet Patient Portal Use,Use of Secure Messaging,,2019-07-22,COMPLETED,INTERVENTIONAL,['NA']
10651,NCT01693302,Blood glucose area under the curve,Glucose values two hours after the beginning of the meal,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
10652,NCT03953963,Lack of serious adverse events (SAEs),Reduction in body weight,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
10653,NCT00126126,Amputee Mobility Predictor,Six-minute Walk Test,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
10654,NCT04732780,Hypoglycaemia Fear Survey 2 - Worry Subscale,,,2021-03-02,COMPLETED,OBSERVATIONAL,['NA']
10655,NCT01836523,Change From Baseline in Total Daily Insulin Dose,Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10656,NCT02302612,Composite CVD Goal,Patient Activation Measure (PAM) - 13 items,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10657,NCT00763451,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10658,NCT04421755,Cooking skills,,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
10659,NCT04725591,"The primary outcome is the time spent of the glucose level in the widened target range 3.9-10.0 mmol/L over the 2 last weeks of each cross-over period, as recorded by continuous subcutaneous glucose monitoring (CGM).",• Scoring of a questionnaire to evaluate the acceptance,,2023-01-19,RECRUITING,INTERVENTIONAL,['NA']
10660,NCT01874392,Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.,Test the Benefits of the AP Device Combined With the Technosphere® Insulin Powder System,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
10661,NCT01153243,Levels of inflammatory markers,"Levels of Vitamin D, PTH and Calcium",,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
10662,NCT04653532,The number and percentage of participants retained at 12-months.,Patient rapport with counsellor,Determine healthcare usage,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA']
10663,NCT00857623,Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment,Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Interference From Baseline to Day 28.,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10664,NCT03130699,Systolic blood pressure (SBP); mmHg units,Adherence to Refills and Medications Scale (ARMS) - patient-reported outcome,Pay for Performance (P4P) Clinical Metrics,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
10665,NCT01952535,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Pharmacodynamic variables will include maximum change (%) in fasting plasma glucose level, AUC0-4 of fasting plasma glucose , AUC of percent reduction in fasting plasma glucose from baseline versus time curve, time of minimum glucose level",,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10666,NCT00594152,Rate of loss of creatinine clearance,Change in cardiac function,,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10667,NCT02192424,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,insulin sensitivity,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10668,NCT01694173,"• Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",• Any reduction in requirement of insulin dosage measured as a percentage decrease from baseline • Improvement of HbA1c levels as compared to baseline,,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10669,NCT00242645,To test the effect of receiving computer tailored information about diabetes care before doctor visits and the differential effect of varying types of information,"Patient exit interviews after doctor visits about what happened during the visits, such as what was discussed, what tests and consults were ordered and what medications were added or changed.",,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1']
10670,NCT04411342,Prevalence of Normoalbuminuric chronic kidney disease,,,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10671,NCT00274274,HbA1c,Duration of education,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10672,NCT03820050,System Performance,,,2019-01-29,COMPLETED,OBSERVATIONAL,['NA']
10673,NCT03802942,Total number of patients with at least 1 documented low (equal or below 70 mg/dL) glucose levels,30-day readmission rate,,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10674,NCT01424891,NF-kappa B binding activity,Inflammatory markers,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
10675,NCT03908281,Liver fat (%),Continuous glucose monitoring,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
10676,NCT03623113,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,Change in urinary biomarkers of carbohydrate intake,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
10677,NCT03077893,Quantitative Sensory Testing (QST),Nerve Conduction Velocity (NCV) - Amplitude,,2017-03-09,COMPLETED,INTERVENTIONAL,['NA']
10678,NCT00938275,Characterize and compare the pharmacokinetic profile of a single 500 mg dose of SRT2104 administered as an oral suspension and as a capsule formulation.,Assess the safety and tolerance of SRT2104.,,2009-01-20,COMPLETED,INTERVENTIONAL,['PHASE1']
10679,NCT05456347,Visceral fat mass change.,Triglycerides change.,TNF-alpha change.,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
10680,NCT05098301,evaluate the performances of an insulin titration algorithm,measure time-in-range evolution adjustment of insulin therapy parameters,,2021-11-30,COMPLETED,OBSERVATIONAL,['NA']
10681,NCT06127355,Maternal fasting glucose concentration at 36 weeks,Infant birth weight,,2021-03-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10682,NCT00920725,Hours to achieve blood glucose less than 200mg/dl,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
10683,NCT02098980,Insulin Resistance,,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
10684,NCT05438251,Time to the ulcer grade down,Percentage of ulcer improvement,,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE4']
10685,NCT00451334,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
10686,NCT00696163,Change in Quality of Life from baseline (using QoLD questionnaire),Efficacy,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
10687,NCT04168541,Area under the blood glucose curve (ACU 0-240 minutes),Insulinogenic index [Change in Ins30/Change in Glu30],,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
10688,NCT04743453,"Evaluate the mean ΔmGFR, between baseline and one year after randomization.",,,2021-08-17,UNKNOWN,INTERVENTIONAL,['PHASE4']
10689,NCT04552470,Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline,Terminal Phase Half-Life (t1/2) of PF-06882961,,2020-10-26,COMPLETED,INTERVENTIONAL,['PHASE1']
10690,NCT03711682,Change in HbA1c,Change in Systolic Pressure,Change in Theoretical HbA1c,2018-03-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10691,NCT02262208,Glycemic variability by continuous glucose monitoring system,Oxidative stress,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
10692,NCT04285710,Bacterial Quantification Over Time,Subject Phototherapy Treatment Satisfaction: questionnaire,,2021-06,WITHDRAWN,INTERVENTIONAL,['NA']
10693,NCT04039503,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE3']
10694,NCT03377244,Mean Percent Body Weight (Pounds) Change,Change in Perceived Family Support for Exercise and Dietary Habits,,2018-09-30,COMPLETED,INTERVENTIONAL,['NA']
10695,NCT04666818,MODD= Adimensional coefficient calculated as mean of the daily serum glucose difference.,Cesarean section,,2020-11-26,COMPLETED,OBSERVATIONAL,['NA']
10696,NCT02105103,The primary objective is to evaluate the Accu-Chek Insight Insulin Pump and associated pump devices in routine practice. This will be expressed by the rate of error messages per 100 patient years (confirmed by pump uploads).,"Evaluate type and frequency of pump signals, i.e. reminders, errors, warnings, alarms, maintenance messages",,2013-10,COMPLETED,INTERVENTIONAL,['NA']
10697,NCT04258293,Platelet Count,,,2020-02-06,RECRUITING,OBSERVATIONAL,['NA']
10698,NCT01554631,Ratio of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load with Glucobay (Day 1) and without Glucobay (Day 0),Safety parameters,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10699,NCT00417716,Optical Coherence Tomography,,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
10700,NCT04206748,# of Neonates with hyperbilirubinemia-requiring therapy.,Effect of SMBG checks on pregnancy,,2019-11-12,RECRUITING,INTERVENTIONAL,['NA']
10701,NCT04591626,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Mean Insulin Glargine Doses,,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10702,NCT02029989,Metabolic Syndrome (MetS),,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
10703,NCT02221323,AUCINS.0-4h and AUCGIR.0-4h,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10704,NCT03305822,Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10) Following Each Treatment Arm,Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10705,NCT01569243,physical activity,Engagement to program,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10706,NCT01364337,blood pressure,"Urinary magnesium, potassium, sodium and creatinine",,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
10707,NCT00481663,Number of participants Who Discontinued Study Treatment Due to An AE up to Week 158,Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 52,,2003-08-19,COMPLETED,INTERVENTIONAL,['PHASE2']
10708,NCT01510847,The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST,The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE4']
10709,NCT00607646,Change in level of catecholamines in blood from baseline,,,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10710,NCT00455858,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20,Occurence of Hypoglycaemic Episodes,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10711,NCT01645696,Number of participants with adverse events,antibodies against the glucose binding protein,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
10712,NCT03952000,Endothelial function changes in response to exercise and feeding,Superoxide dismutase 3,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
10713,NCT00543491,,,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3']
10714,NCT00763347,Change from baseline in glycosylated hemoglobin.,Clinical laboratory evaluation (urinalysis).,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
10715,NCT05101330,Assessing PML understanding at Week 2. (Pilot Trial B),,,2021-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
10716,NCT06141434,Islet autoimmunity in the offspring,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
10717,NCT04484883,Resting Energy Expenditure (REE),,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
10718,NCT02009878,Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.,"Change From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.",,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10719,NCT03182296,Pancreatic uptake of 68Ga-NODAGA-exendin-4,"C-peptide, HbA1c",,2016-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10720,NCT02612805,Changes in levels of glycated hemoglobin,"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Short Form.",,2015-11,COMPLETED,INTERVENTIONAL,['NA']
10721,NCT03792321,Effects of testosterone replacement therapy on vascular morphology - intima-media thickness (IMT),Effects of testosterone replacement on hematocrit,,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10722,NCT04341935,Changes in Glucose Llevels,Changes in chest structures,,2021-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10723,NCT03607201,Mortality,,TIMI Score,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
10724,NCT01515657,Time to 99% Inhibition of Serum Thromboxane (TxB2),,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10725,NCT01055951,Device-related adverse outcome,Mechanical dysfunction and diabetes-related adverse outcome,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10726,NCT03990857,Change is being assessed in Weigh,Use of services in the last year,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10727,NCT01813305,Number of Participants With Complete Ulcer Closure During the Treatment Period,Percentage Change in Ulcer Size for Each Post-treatment Visit,Respiratory Rate Change From Baseline to Week 24,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10728,NCT03172494,Change in HbA1c,Plasma Concentration of Liraglutide,,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
10729,NCT05139914,Insulin-mediated endothelial nitric oxide synthase (eNOS) phosphorylation measured in endothelial cells (ECs) at 14 weeks,Circulating C-reactive protein (CRP) biomarkers of vascular health at 14 weeks,,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE4']
10730,NCT04479826,Time in ranges,,,2020-07-16,COMPLETED,INTERVENTIONAL,['NA']
10731,NCT00625859,Blood samples and urine samples,Hunger and craving will be assessed using two assessment tools: (1) a questionnaire to assess hunger and craving; and (2) a Visual Analogue Scale (VAS) to assess hunger.,,2008-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10732,NCT03084965,Change in HbA1c,,,2017-05-12,COMPLETED,OBSERVATIONAL,['NA']
10733,NCT01623375,Area under the serum insulin degludec concentration-of i.v. administration,"Volume of distribution of insulin degludec, estimated during the terminal phase",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10734,NCT00676338,Percentage of Patients Achieving HbA1c <=7% at Week 26,Change in Diastolic Blood Pressure From Baseline to Week 26.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10735,NCT00887445,"Safety and tolerability parameters: adverse event, vital signs, 12-Lead ECG, continuous lead II ECG monitoring, laboratory safety variables and physical examination.",Interaction with Midazolam,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE1']
10736,NCT01630759,Management decision comparison,Number of downloads missed,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
10737,NCT01806506,Excess Weight Loss From Baseline,LDH Level,Pulmonary Function Changes at 12 Months,2008-11,COMPLETED,INTERVENTIONAL,['NA']
10738,NCT00311324,Mean Hemoglobin A1c,Median number of minutes per day engaged in physical activity,,2001-02,COMPLETED,INTERVENTIONAL,['NA']
10739,NCT03596203,Pain level,Changes in pain medication,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10740,NCT03944200,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),,2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10741,NCT02527525,glycemic variability,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
10742,NCT00313183,To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes,To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10743,NCT02827890,"Css,max of Sitagliptin","swing[(Css,max-Css,min)/Css,min] of Sitagliptin",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10744,NCT05866900,Coefficient of variation (%),Height Z-score,,2023-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10745,NCT01835379,Percentage of Wounds Closed,Time to Wound Closure,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10746,NCT00541372,"Preference of the patient and amount of experienced hypoglycaemic events, bruises, backflow of insulin, bleeding and pain (VAS-scale)","HbA1c levels 1,5 anhydroglucitol and fructosamine levels Insulin dose",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10747,NCT03504683,Peak glucose and mean amplitude of glycemic excursions (MAGE) glucose values,Inflammatory biomarkers,Sleep Quality,2020-08-17,RECRUITING,INTERVENTIONAL,['NA']
10748,NCT01954771,Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS),HbA1c(%) at Endpoint,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
10749,NCT01354977,Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks.,Muscle Mitochondrial Area,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10750,NCT05000463,Pain Assessment,,,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA']
10751,NCT01295788,Adherence to CGM (hours per week),Perception of Barriers/Facilitators to RT-CGM Use,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
10752,NCT00309244,Change From Baseline in HbA1c to Week 52,Severe Hypoglycemia Event Rate,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10753,NCT04154046,New ulcers incurred,Incidence of new ulcers on feet,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
10754,NCT01296516,Incidence of glucose intolerance,Weight loss,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
10755,NCT06255288,Procedural uncertainties - Number of patients willing to participate.,Drop out rates,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
10756,NCT02776397,Oxidative Stress,Non HDL-Cholesterol,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
10757,NCT04464213,Rate of adverse event,Rate of cure rate,,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10758,NCT01527565,"Cmax, maximum insulin aspart concentration",Adverse events,,2003-01-20,COMPLETED,INTERVENTIONAL,['PHASE1']
10759,NCT02148991,Blood pressure measurement,Quality of Life questionnaire rating,Treatment compliance questionnaire rating,2014-07,COMPLETED,OBSERVATIONAL,['NA']
10760,NCT02814123,Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of regular insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.,"Gastrointestinal symptoms during the treatment optimization (i.e., the minimum 10 days prior to the 24-hour closed-loop visits) and during the 24-hour closed-loop visits.",,2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE2']
10761,NCT00860288,To evaluate the efficacy of vildagliptin as add-on therapy to metformin in patients with T2DM by assessing changes in HbA1c with vildagliptin added to metformin to that of placebo added to metformin after 24 weeks of treatment,To evaluate the long-term efficacy of vildagliptin compared to sitagliptin over the entire study duration as add-on therapy to metformin in patients with T2DM.,,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10762,NCT00456885,Change in Body Mass Index,REE,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10763,NCT00644501,"Preservation of endogenous insulin secretion/beta-cell function, as measured by mixed-meal tolerance test stimulated C-peptide secretion.",improved metabolic control and the insulin dose required to maintain it.,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10764,NCT02600091,Recruitment/Retention Rates,Acceptability,,2015-10-30,COMPLETED,INTERVENTIONAL,['NA']
10765,NCT01900834,Variation in CD8 (cluster of differentiation) +T-cell specificity profiling,Variation in HbA1c (glycosylated haemoglobin),,2013-07,COMPLETED,OBSERVATIONAL,['NA']
10766,NCT02262611,Change in diastolic blood pressure,Global assessment of tolerability by investigator on a 4-point scale,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
10767,NCT01675310,Gestational diabetes mellitus,insulin resistance,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10768,NCT02088294,Change in Physical activity,Change in Dietary intake,Change in Intuitive eating,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10769,NCT01296438,Area under the serum insulin aspart concentration-time curve,Area under the serum insulin aspart concentration-time curve,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10770,NCT00210275,Change in Behavioral intention related to referring patient for retinopathy screening,Change in Perceived Behavourial Control (Theory of Planned Behaviour),,2005-07,UNKNOWN,INTERVENTIONAL,['NA']
10771,NCT03214380,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Number of Participants With HbA1c <7%,,2017-07-14,COMPLETED,INTERVENTIONAL,['PHASE3']
10772,NCT00351832,Change from baseline on HbA1c at 12 weeks,Change from baseline on fasting lipids at 12 weeks,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10773,NCT01044875,Visual acuity measurement by logarithm of the minimum angle of resolution (logMAR),Patient pain score during laser procedure,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
10774,NCT02886208,BMI,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
10775,NCT04949022,Time in range (glucose between 3.9-10 mmol/l) before and during hybrid close loop insulin pump treatment,HbA1c before and during hybrid close loop insulin pump treatment,Sensor glucose coefficient of variation before and during hybrid close loop insulin pump,2021-08-23,UNKNOWN,INTERVENTIONAL,['NA']
10776,NCT01581099,Improvement in Metabolic Profile,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
10777,NCT01597154,Glycemic control determined by a standard fasting measure of glycosylated hemoglobin using internationally recognized DCCT assay,Cardiovascular structure and function,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
10778,NCT04926740,Time to DKA resolution (efficacy outcome),Major adverse kidney events,,2021-10-12,COMPLETED,INTERVENTIONAL,['NA']
10779,NCT01489163,postpartum body weight,postpartum glycemia,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10780,NCT02293837,Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants,Number of Participants Who Experienced Hypersensitivity Adverse Events,,2015-03-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10781,NCT05478707,Microvascular blood volume (MBV),"Skeletal muscle oxygenation, deoxyhemoglobin (HHb)",,2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2']
10782,NCT02076568,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10783,NCT00562250,Maximum plasma concentration and exposure to glimepiride and dapagliflozin when administered alone and administered together,Recorded adverse events,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10784,NCT02092597,Exocrine pancreas function,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10785,NCT02209051,Proportion of patients with complete wound closure (i.e. complete skin re-epithelialization without drainage or dressing requirements) at 6 weeks after initiation of study treatment,Changes in Quality of Life assessment,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
10786,NCT01733901,All-cause mortality,Medication adherence,,2012-11,UNKNOWN,INTERVENTIONAL,['NA']
10787,NCT00401622,Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS.,Change in Daily Glycemic Excursions Between the OneTouch® Ultra®2 and Control BGMS.,,2006-10-01,COMPLETED,INTERVENTIONAL,['NA']
10788,NCT02735837,Periodontal pocket,glycated hemoglobin (HbA1c),,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10789,NCT00282971,Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in FEV1 at Week 24 LOCF,,2006-03-06,TERMINATED,INTERVENTIONAL,['PHASE3']
10790,NCT01521962,Change in glycosylated hemoglobin (HbA1c; Japan Diabetes Society value),,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10791,NCT03370237,Diabetic foot ulcer risk score,Raters' level of confidence,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
10792,NCT05343065,The percentage of time a participant's glucose value is between 70 and 180 mg/dL will not be inferior to baseline.,,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
10793,NCT04564443,Proportion of wounds completely healed at or before 16 weeks,Kent Imaging - Snapshot camera,,2020-09-11,RECRUITING,INTERVENTIONAL,['NA']
10794,NCT03251846,HbA1c,Hypoglycemia,,2017-07-17,UNKNOWN,INTERVENTIONAL,['NA']
10795,NCT05633628,HbA1c,The Patient Preferences for Patient Participation (4Ps),,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
10796,NCT05275608,Change in metabolic control,Change in inflammatory status,,2022-11-07,RECRUITING,INTERVENTIONAL,['NA']
10797,NCT02159846,Allergy or hypersensitivity to preparation,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
10798,NCT01889667,Evaluate the Safety and Tolerability of ORMD-0801.,The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10799,NCT04014569,Percentage of sensor glucose readings within range of 70-180 mg/dl,Number of Diabetic Ketoacidosis events,Number of physician override advisor recommendations,2018-05-02,TERMINATED,INTERVENTIONAL,['NA']
10800,NCT02077218,"Feasibility, defined by the percentage of patients that enroll onto the study, successful completion of all study measurements, ability of studies to be interpreted, and achievement of the recruitment goal",,Expression of Lp-PLA2,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10801,NCT03525899,Time to macular hole closure,Best corrected visual acuity,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
10802,NCT03808311,Major cardiovascular events,Kidney outcomes,Cost-effectiveness,2019-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10803,NCT04794907,Risk Stratification,,,2022-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10804,NCT03685357,"RBDSQ (""Rapid eye movement Sleep"" Behavior Disorder Screening Questionnaire)",,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
10805,NCT04178603,Muscle glucose uptake during exercise and enhanced insulin sensitivity in recovery from exercise.,Posttranslational modification of proteins in muscle biopsies.,Changes in gene-expression in muscle as a result of exercise and during subsequent insulin stimulation.,2018-07-05,COMPLETED,INTERVENTIONAL,['NA']
10806,NCT01846533,Osteoprosis in type 2 diabetic patients- a cohort study,,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
10807,NCT01072331,"Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h (Breakfast, Lunch and Dinner)",Change From Baseline in Fasting Plasma Glucose,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10808,NCT05475431,The eradication rate by the per-protocol analysis,,,2020-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10809,NCT00046267,,,,na,COMPLETED,INTERVENTIONAL,['NA']
10810,NCT03209466,Ulcerated area,,,2017-05-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
10811,NCT03970720,Change in Hypoglycemia Symptom Recognition,Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes,,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10812,NCT05979519,Percentage Change in fasting blood glucose,Change in blood pressure,,2023-09-26,RECRUITING,INTERVENTIONAL,['NA']
10813,NCT02916563,Number of Successful Glucose Readings,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
10814,NCT03060538,Percentage of Participants with Adverse Events (AE),Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs),,2017-03-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10815,NCT01203111,Change in HbA1c level for patients with addition of glulisine at week 12,"Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe)",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10816,NCT04642261,Change in liver fat content,Changes of diastolic blood pressure,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10817,NCT05429554,improve the neurodegeneration and cardiovascular effect in diabetic patients,,,2022-06,RECRUITING,OBSERVATIONAL,['NA']
10818,NCT01357148,Number of Participants Taking Concomitant Medications,,,2009-03,TERMINATED,OBSERVATIONAL,['NA']
10819,NCT00469105,A1C,Patient satisfaction,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10820,NCT01240200,Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score,Number of Hypoglycemic Events,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10821,NCT04565756,The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Expansion phase.,To evaluate the percentage (%) of changes in ocular structural measures as assessed using ophthalmoscopy.,,2020-11-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10822,NCT04203173,Resource Utilization and Cost,Self-Care Behavior Brooks Medication Adherence Scale (BMAS),,2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10823,NCT02786134,Change in Global Myocardial Blood Flow in Response to Vasodilator,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
10824,NCT02115347,AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin,Number of Participants Who Experienced an Adverse Event,,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
10825,NCT03099928,Qualitative data,Change in optimism,,2015-03-01,COMPLETED,OBSERVATIONAL,['NA']
10826,NCT04406792,Participants with gestational diabetes that complete the recommended screening for Type 2 Diabetes Mellitus (T2DM),Participants with gestational diabetes who develop T2DM,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10827,NCT01770964,change in pain severity rating,,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
10828,NCT03670797,Oral mucosal alterations,Salivary glands function,,2018-12-25,COMPLETED,OBSERVATIONAL,['NA']
10829,NCT05393843,plasmatic glycated haemoglobin,therapy for diabetes,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10830,NCT00637546,Gait parameter: comfortable speed,Fear of falling (Falls efficacy scale),,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10831,NCT05521256,Number of adverse events,"For i.v. cohort and oral cohort- AUC0-∞,6856,SD/dose: Area under the NNC0113-6856 plasma concentration-time curve from 0 to infinity after a single dose divided by the dose administered",,2022-08-26,COMPLETED,INTERVENTIONAL,['PHASE1']
10832,NCT01134458,Cardiovascular Disease (CVD) Risk Knowledge Assessment,,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
10833,NCT03377335,Subclinical atherosclerosis,microRNAs,,2017-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
10834,NCT02662569,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12,,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3']
10835,NCT00795704,Hemoglobin A1C,Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages,,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10836,NCT00605137,Incidence of hypoglycaemic episodes,Insulin doses,,2004-05-21,COMPLETED,INTERVENTIONAL,['PHASE3']
10837,NCT05753124,Birth weight (in percentiles),Maternal and infant blood and urine samples,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
10838,NCT00866801,Coronary flow reserve,Diabetic autonomic neuropathy,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
10839,NCT03617081,Number of treatment emergent adverse events (TEAEs),"Cmax,SNAC,SD; the maximum plasma concentration of SNAC in plasma after a single dose of oral NNC0113-2023",,2018-08-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10840,NCT04214665,AUC0-t,(AUC0-inf - AUC0-t) / AUC0-inf,,2014-12-30,COMPLETED,INTERVENTIONAL,['PHASE1']
10841,NCT01697592,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3']
10842,NCT05176210,Incidence of dose-limiting toxicity (DLT) during the DLT observation period,Pharmacokinetics of PS1 - CL/F,,2023-12,RECRUITING,INTERVENTIONAL,['PHASE1']
10843,NCT01038102,Hepatic steatosis by MRT,Changes in adipose tissue gene expression and lipogenic enzyme activity,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10844,NCT01865318,Area under the glucose infusion rate curve,Area under the serum insulin degludec curve,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10845,NCT03211858,Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26,"Percentage of Participants With Treatment-Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)","Change in Daily Insulin Dose From Baseline to Day 1, Week 26 and Week 52",2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10846,NCT03005600,Development and validation of composite risk score for GDM with the risk factors of interest and/or point-of-care HbA1c,Identification and the impact of other novel risk factors on the diagnosis of GDM and other adverse maternal outcomes,,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
10847,NCT02971618,HbA1c (glycosylated haemoglobin),change of systolic and diastolic blood pressure,,2017-02-21,COMPLETED,OBSERVATIONAL,['NA']
10848,NCT00399724,Incidence of severe hypoglycaemia,"Quality of Life and treatment satisfaction before, during and at the end of treatment using the Diabetes Treatment Satisfaction Questionnaire",,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
10849,NCT01074489,Blood glucose levels,,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
10850,NCT02461641,Mean adjusted heal rate,Length of time to 100% healing of foot ulcer,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
10851,NCT00943787,Maximum Epinephrine Response (LBGI Groups),Maximum Epinephrine Response (ADRR Groups),,2006-01,COMPLETED,INTERVENTIONAL,['NA']
10852,NCT01805700,Changes in blood glucose level in all patients as a measure of tolerability,"Changes in heart rate, systolic and diastolic blood pressure in all patients.",,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10853,NCT04178525,Difference in proportions of ulcers completely healed for experimental group compared to control group.,To track diabetic ulcer recurrence for experimental group compared to control group in patients whose wound completely healed.,,2018-08-02,TERMINATED,INTERVENTIONAL,['NA']
10854,NCT01910441,Mean Amplitude of Glycemic Excursions (MAGE),,,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4']
10855,NCT02388984,"The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo",The severity of macular edema change from baseline at the end of week 24 compared to placebo,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
10856,NCT05950659,Plantar ulcer recurrence,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10857,NCT02485327,Assessment of PD parameter: area under the glucose infusion rate curve (GIR) necessary to maintain euglycemia during the euglycemic clamp over 8 hours,Assessment of PD parameter: time to GIRmax (GIR-Tmax),,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10858,NCT02561546,glycosylated hemoglobin (A1C),postprandial glucose (PPG),,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
10859,NCT05280496,HbA1C,Weight,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10860,NCT02680873,resolution of diabetes,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
10861,NCT03794531,Number of participants with self-reported medically-diagnosed chronic diseases,Difference in the number of participants with self-reported medically-diagnosed chronic diseases living urban vs. rural area,"Risk of clinically-measured metabolic syndrome (e.g. high blood pressure, elevated adiposity, elevated blood glucose, and out-of-normal-range blood lipids), according to dietary and psychosocial risk factors",2019-03-01,RECRUITING,OBSERVATIONAL,['NA']
10862,NCT04460326,Postprandial Glucose Control,Percent of Postprandial Time Spent With Hypoglycemia,,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10863,NCT05710913,Diabetes mellitus type II remission rate postoperatively,,,2023-01-05,RECRUITING,OBSERVATIONAL,['NA']
10864,NCT02272296,Tmax (min),T-INSAUC50% (min),Tolerability,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10865,NCT04118153,Change in frequency of TfH within total CD4 T cells (%),,,2021-03-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10866,NCT02342535,Change in Physical Activity (Minutes/Week),,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
10867,NCT03943979,Stability of changes in food intake,Change in neuropsychological test:Symbol digit modalities test (SDMT; Smith A. 1982).,,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
10868,NCT01807351,Number of subjects develope Diabetes Mellitus,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
10869,NCT01714011,Tapering off of previous psychoactive medication.,The proportion of reversed metabolic syndrome components among schizophrenia patients after treated with either aripiprazole or ziprasidone,Total cholesterol and LDL cholesterol among schizophrenia patients after treated with either aripiprazole or ziprasidone.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10870,NCT01197742,Documentation of the characteristics consecutive patients with acute STEMI or NSTEMI in daily hospital routine in Germany,Verification of the implementation of a therapy according to the guidelines for STEMI / NSTEMI in daily hospital routine,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
10871,NCT00563394,Reduction in clinical signs and symptoms of the infection,Wound Depth,,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10872,NCT01434901,The effects of Bethanechol on insulin secretion rates,,,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE1']
10873,NCT05286632,Evaluation of changes in Perceived Stress,,,2022-07-18,RECRUITING,INTERVENTIONAL,['NA']
10874,NCT03344692,Total area under the post-prandial triglycerides concentration-time curve from meal-time until 8h (AUC0-8h) after standardized high fat meal.,Effect of treatment with alirocumab versus placebo on fasting and post-prandial and glucose homeostasis following a standardized high-fat meal,,2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10875,NCT03596177,Percent Change in Body Weight From Baseline to Day 59,Number of Participants With Positive Anti-drug Antibodies (ADAs) to MEDI0382,,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE2']
10876,NCT01125956,Hemoglobin A1c,Experience of peer counseling,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
10877,NCT03523403,Gut microbiota profile,Plasma insulin levels,,2017-10-12,COMPLETED,INTERVENTIONAL,['NA']
10878,NCT02733185,"A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina",,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10879,NCT03157960,Changes in uric acid (µmol/L),,,2012-02-01,COMPLETED,INTERVENTIONAL,['NA']
10880,NCT01421459,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),Rate Per 30 Days of Hypoglycemic Events,Percentage of Participants With Treatment Emergent Antibody Response (TEAR),2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10881,NCT02205372,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Change from baseline in blood pressure,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10882,NCT01487070,Evidence of advancement of tractional detachment post injection of Macugen before surgical intervention.,Evaluate regression of neovascularization and progression of macular traction utilizing OCT and Fundus photographs,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10883,NCT04568486,Hemoglobin A1c,Health-related quality of life measures,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10884,NCT01311076,TGIRmax: Time to Reach the Maximum Glucose Infusion Rate (GIRmax) Pharmacodynamic Parameter.,Incidence of Hypoglycemia.,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10885,NCT04054076,Pressure time integral,Relation of different types of insoles and risk factors to pressure time integral,Costs for the assistive devices,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
10886,NCT04155645,Laboratory assessments: Clinical urinalysis,PD analysis: Levels of dyslipidemia related biomarkers.,,2019-11-21,COMPLETED,INTERVENTIONAL,['PHASE1']
10887,NCT05348733,Descriptive summary of secondary therapies used in participants with CKD and T2D.,Occurrence of hyperkalemia,Occurrence of newly diagnosed diabetic retinopathy or progression of existing disease at treatment initiation,2022-06-13,RECRUITING,OBSERVATIONAL,['NA']
10888,NCT05273073,Mean difference of homeostasis model assessment of insulin resistance (HOMA-IR),"Changes in gut microbial profiles (i.e., gut microbial composition, alpha diversity, beta diversity, and functional analysis)",,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
10889,NCT05595681,Time to complete ulcer healing,Amount of index ulcers completely healed,Other endpoints,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE1']
10890,NCT00673465,Pharmacodynamic: Change From Baseline in 24-hour Plasma Glucose (AUC/Duration) at Week 4 (Part 2 - India),Pharmacokinetic: Mean Plasma Tmax (Part 2 - India),,2008-04-17,COMPLETED,INTERVENTIONAL,['PHASE1']
10891,NCT05164562,musculoskeletal disorders of upper limb,,,2022-01-07,UNKNOWN,OBSERVATIONAL,['NA']
10892,NCT02248714,Change From Baseline in Glucose Coefficient of Variation(CV),Change From Baseline in HOMA-IR,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
10893,NCT04831060,Characterization of a panel of cytokines in gingival fluid of patients with periodontitis versus without periodontitis,Characterization of proteases (MMP) present in gingival fluid and unstimulated saliva,,2023-02-15,RECRUITING,OBSERVATIONAL,['NA']
10894,NCT01257815,The change in mean Best Corrected Visual Acuity (BCVA),Proportion of patients with 10 and 15 letter improvement or loss in BCVA,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10895,NCT01114321,The primary outcome is the plasma glucose concentration measured 120 min after the oral glucose surcharge intake.,Urinary glucose measurement,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
10896,NCT02447601,Plasma concentrations of simvastatin and simvastatin acid.,Incidence of adverse events and serious adverse events,,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE1']
10897,NCT04791371,Change in insulin sensitivity,,,2022-06-17,RECRUITING,INTERVENTIONAL,['NA']
10898,NCT04918732,Prevalence of NAFLD in risk groups followed by the general practitioner,To assess the work productivity and absenteism of the patient.,,2021-05-05,RECRUITING,INTERVENTIONAL,['NA']
10899,NCT01340079,Change from Baseline in hemoglobin a1c at 8 weeks after completion of the intervention.,Change from Baseline in physical activity at 8 weeks after completion of the intervention.,,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10900,NCT05182580,Number of Completed Care Encounters Among All Clinic Patients (With and Without Diabetes) Per Retina Specialist Clinic Hour,Number of Participants Who Were Very Satisfied or Satisfied With Autonomous AI,,2022-03-20,COMPLETED,INTERVENTIONAL,['NA']
10901,NCT00890331,Parental involvement and Disease care behaviors,"Glycohemoglobin levels, Adverse effects and Blood glucose variability",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10902,NCT01792284,Hemoglobin A1c (HbA1c) at 12 Weeks,Percentage of Participants With HbA1c <7.0% and ≤6.5% at 12 Weeks,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10903,NCT01476995,Agreement of ClearView Scan versus Active Diagnosis,Sensitivity and Specificity of ClearView Scan versus Active Diagnosis,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
10904,NCT00823680,Absolute change in mean daily plasma glucose,"Adverse events, lab parameters, vital signs, body weight",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10905,NCT04698486,Fatty acid oxidation in Heart (µmol/min),VLDL-triglyceride uptake in adipose tissue (percent),,2020-07-03,COMPLETED,INTERVENTIONAL,['NA']
10906,NCT03173963,Effect of empagliflozin on change in cortical interstitial fractional volume [Vv(Int/cortex) over the 3-year study period.,Effect of empagliflozin on development or progression of diabetic retinopathy determined by changes from baseline to 3 years of at least 2 Early Treatment of Diabetic Retinopathy Study levels in grading of standardized retinal photographs.,,2017-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10907,NCT03263351,Insulin secretion,Daily cortisol output,,2017-10-01,RECRUITING,INTERVENTIONAL,['NA']
10908,NCT01854723,Difference in A1C between groups at 6 months,Difference in number of visits with clinical pharmacist,,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10909,NCT05041491,Glycemia,Skeletal muscle content of COX4,,2021-11-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10910,NCT01193296,Glycemic variability assessed by MAGE (Mean Amplitude of Glycemic Excursion),"Unrecognized hypoglycemic periods recorded by CSGM, frequency and duration",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10911,NCT01557504,Number of Participants Who Discontinued Study Drug Due to an AE,,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
10912,NCT03675464,Number of participants with Hypertension,Genetic variations linked to lipolysis,,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA']
10913,NCT01486043,Length of Insulin Therapy (Days),Hemoglobin A1c,,2011-12,TERMINATED,INTERVENTIONAL,['NA']
10914,NCT00285896,"Area under curve (AUC)for plasma glucose, insulin, insulin secretion velocity and glucagon for the periods 0-48 hours(day 1-2) and 0-180 min (day 3). And also the lowest plasma glucose during the period 0-180 min day 3 and mean blood pressure",,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
10915,NCT00712842,Pattern ERG,Blood glucose,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
10916,NCT04155619,Insulin secretion,"Glycemic (""Peripheral"") Rhythm Phase",,2021-04-26,RECRUITING,INTERVENTIONAL,['NA']
10917,NCT04419467,Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR),Percentage of Subjects Positive for Anti-drug Antibodies,,2020-09-14,COMPLETED,INTERVENTIONAL,['PHASE2']
10918,NCT02394158,Development of Gestational Diabetes at any point during the course of pregnancy,Cost effectiveness of the intervention,Fetal hyperinsulinaemia,2015-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
10919,NCT02091323,fasting plasma glucose(FPG),hemoglobin A1c (HbA1c),weight loss,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
10920,NCT00482950,HbA1c,,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
10921,NCT05826678,Hypoglycemic Confidence Scale (HCS) change over 6 month study period,Family/social-level factors impacting technological device for care management,,2022-09-22,RECRUITING,INTERVENTIONAL,['NA']
10922,NCT01293578,Patient Satisfaction and knowledge,Physician adoption and satisfaction with the decision aid.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
10923,NCT03313752,Effect of dapagliflozin on myocardial insulin sensitivity,Gut microbiota composition change from baseline,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10924,NCT00984867,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10925,NCT01525225,"Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death",Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
10926,NCT05400863,change in BMI z-score between the two groups at 12 weeks,improvement of A1C due to metformin between the 2 groups at 12 weeks,metformin-induced rise in GDF15 in both groups at 12 weeks,2022-04-21,RECRUITING,INTERVENTIONAL,['NA']
10927,NCT03363100,A1c,,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
10928,NCT00836329,Proportion of participants with new neuropsychological deficits (20% decline on two or more neuropsychological tests),"Neuropsychological deficits (i.e., predictive utility of neuropsychological performance on presence, number, and volume of lesions)",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10929,NCT03516864,Tissue oxygenation is detected on both the MIMOSA Imager and Kent camera.,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
10930,NCT02373865,Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride,Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE4']
10931,NCT01542775,change from baseline in soluble receptor for advanced glycation endproducts (sRAGE) after 12 weeks of aerobic exercise,energy expenditure,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10932,NCT00960973,AIRg (acute insulin response to glucose) using FSIGT (frequently sampled intravenous glucose tolerance test),insulin sensitivity (FSIGT),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10933,NCT00737347,change in body weight,change in body composition,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10934,NCT03506022,Prevalence of obstructive sleep apnea syndrome confirmed by polysomnography an apnea hypopnea Index ≥ 15,,,2018-01-12,COMPLETED,INTERVENTIONAL,['NA']
10935,NCT05676619,Interrater reliability (Intraclass Correlation Coefficient) of 3D foot scans repeated at baseline (change),,,2023-02-16,RECRUITING,INTERVENTIONAL,['NA']
10936,NCT03047447,Hemoglobin A1c,Ketones (Blood),,2016-02-25,COMPLETED,INTERVENTIONAL,['NA']
10937,NCT05687890,Changes in urine protein creatinine ratio (UPCR) at Week 12,"Percentage of subjects achieving UPCR ≥30%, ≥40%, and ≥50% reduction from baseline",,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE2']
10938,NCT04527965,Between-group changes in liver fat content between baseline and month 12,Between-group changes in FIB-4 between baseline and month 12,Between-group changes in plasma lipids (ceramides) using a targeted lipidomic approach between baseline and month 12,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
10939,NCT05593549,Autophagic Flux Protein Expression,Blood Pressure,,2023-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10940,NCT05205876,Feasibility of the Eddii App as measured by frequency of use,User Engagement measured through app analytics,,2021-01-02,COMPLETED,INTERVENTIONAL,['NA']
10941,NCT01055808,Changes in Health Related Quality of Life (ITR-QOL) in insulin treated type 2 diabetes at baseline and 12 weeks after a significant change in insulin treatment regimen,Change from baseline in use of concomitant oral hypoglycemic drugs,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
10942,NCT00444899,HbA1c,,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
10943,NCT01537016,"To identify EPA wounds using WOUNDCHEK™ Protease Status diagnostic test, and to compare the healing outcomes of two treatment regimes (PROMOGRAN®, a protease modulating therapy and current standard of care) on chronic wounds with EPA.",Reduction in wound area and cost effectiveness,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
10944,NCT05099900,Experiences and technology usage among women,,,2021-11-08,UNKNOWN,OBSERVATIONAL,['NA']
10945,NCT03507829,incidence of NODAT,"Mental component summary (MCS) and physical component summary (PCS) derived from the Kidney Disease Quality of Life Short Form (KDQoL-SFTM) at 6, 12 and 24 months after kidney transplantation",,2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE3']
10946,NCT02716064,"The experience of patients, family members, primary health care providers, volunteers and community organizations with the TAPESTRY-CM program",Developmental decision evaluation - I,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10947,NCT02987335,Rate of Glucose Disposal (RD).,Insulin Secretion,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
10948,NCT04209348,Change in Physical Activity Assessed by ActiGraph Monitoring Device From Baseline to Follow-up,Birthweight-for-gestational-age Z-score,,2020-08-21,COMPLETED,INTERVENTIONAL,['NA']
10949,NCT00561704,"GFR, HbA1c and the adiponectin concentration.",,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
10950,NCT04716790,Wound Size,Health-related quality of life,,2021-04-20,UNKNOWN,INTERVENTIONAL,['NA']
10951,NCT00495794,Change in Systolic Blood Pressure,LDL Control,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
10952,NCT02935712,Safety of AZD8601 by assessing number of subjects with clinically significant urinalysis (Part B),,,2016-12-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10953,NCT01101269,Change in renal blood flow (RBF),Change in Proteinuria,,2010-02,TERMINATED,INTERVENTIONAL,['NA']
10954,NCT00924430,"Simvastatin and simvastatin acid: Cmax, tmax, AUC0-t, AUC, lz, and t1/2, as well as CL/F and Vz/F for simvastatin only","Safety and tolerability assessments including adverse events, clinical laboratory tests, electrocardiogram (ECG) and vital signs",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10955,NCT04022993,Antibody Response,Achievement of Glycated Hemoglobin < 7%,,2018-07-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10956,NCT01906294,"routine treatment data (composite of e.g. diagnostics, kind and dosage of pharmacological diabetes treatment)",,,2013-08,TERMINATED,OBSERVATIONAL,['NA']
10957,NCT01120899,Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 6 Months Compared to Baseline,"Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 24 Months Compared to Baseline",,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10958,NCT02616263,Change in metatarsal phalangeal joint angle (degrees) in people with diabetes from baseline and at a 3-year period,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10959,NCT05685875,Severe malaria,Severe malaria with kidney failure,,2022-06-07,RECRUITING,OBSERVATIONAL,['NA']
10960,NCT00873639,Change in HbA1c,Number of adverse drug reactions (ADR),,2009-04,COMPLETED,OBSERVATIONAL,['NA']
10961,NCT02081001,Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early),Infusion Site Discomfort Score at 30 Minutes,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10962,NCT04591691,"Proportion of participants with complete wound healing by week 12, defined as complete wound closure where there is skin re-epithelialization without drainage or dressing requirements",,,2020-10-14,RECRUITING,OBSERVATIONAL,['NA']
10963,NCT03363360,HDL-C,blood pressure,,2016-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10964,NCT03917576,Maximum heart rate,Heart rate post each HIIT-interval,,2018-01-04,COMPLETED,INTERVENTIONAL,['NA']
10965,NCT00672451,Albumin Concentration in Urine,Rate of Decline of GFR,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
10966,NCT02877771,Agreement between algorithm-recommended pump action,,Reference blood glucose,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10967,NCT04645992,Intraoccular pressure measurement,Intraoccular pressure measurement,,2020-11-20,UNKNOWN,INTERVENTIONAL,['NA']
10968,NCT01316068,Change from Baseline in urine albumin/creatinine ratio,Change from Baseline in urine albumin/creatinine ratio and serum creatinine,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
10969,NCT00029848,Change in body weight,Metabolic parameters,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10970,NCT03113110,OGTT-derived 2-hour blood glucose level,,,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10971,NCT05262257,Mini-Mental State Examination(MMSE),glycated hemoglobin(HbA1c、GHb),,2022-04-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10972,NCT02648217,Change in HbA1c (%) (Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes,,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10973,NCT00365170,Relative risk of major maternal hypoglycaemia,Other Adverse Events,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10974,NCT05612269,Reducing the risk of cancer among Diabetics with SGLT2 inhibitors,measurement of inflammatory factors like interleukin-6,,2022-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10975,NCT01722474,"To compare the ability of the non-invasive ASI Device to determine arterial stiffness as compared to SphygmoCor, CR-2000 CV Profiler and VP-1000.",,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
10976,NCT00404027,PPOS scores,Hemoglobin A1c,,2007-06-04,COMPLETED,OBSERVATIONAL,['NA']
10977,NCT02808351,Contrast-induced nephropathy,Major adverse renal events,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10978,NCT00205660,Change in Whole Body Sensitivity (mg/kg/Min),,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10979,NCT02753491,decreasing 300 cal daily food intake,loosing weight,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10980,NCT00391196,Percent change in body weight from baseline.,Change from baseline HbA1c to 1 year;,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3']
10981,NCT05875519,Glycemic level recorded before local anesthesia administration and 30 minutes following local anesthesia injection using glucometer,Healing score of the extraction socket,,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10982,NCT04024306,Number of patients who developed Steroid-induced diabetes mellitus,Number of patients who didn't develop steroid-induced diabetes mellitus,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
10983,NCT05619237,Quality Improvement,Patient satisfaction - overall satisfaction,,2022-12-06,COMPLETED,INTERVENTIONAL,['NA']
10984,NCT02048189,Mixed measurement of insulin secretion and insulin resistance,Decrease in the time spent in baseline and prandial hyperglycemia,,2012-03-08,TERMINATED,INTERVENTIONAL,['PHASE4']
10985,NCT01652716,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10986,NCT01106131,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Evaluate safety of CKD-501 from physical exam, vital sign, laboratory test, adverse events",,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10987,NCT00834496,The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients.,,,2009-01,WITHDRAWN,OBSERVATIONAL,['NA']
10988,NCT01250639,,,,2010-08,UNKNOWN,OBSERVATIONAL,['NA']
10989,NCT01306214,Change From Baseline in HbA1c After 18 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10990,NCT01628445,Change in A1c,Postprandial glucose reduction through measurement of 7 point glucose profile,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3']
10991,NCT03481374,VO2 max,,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
10992,NCT00869908,Number of serious adverse drug reactions and major hypoglycaemic events reported as serious adverse drug reactions,Change in PPG (postprandial glucose),,2008-11,COMPLETED,OBSERVATIONAL,['NA']
10993,NCT00240253,To evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes.,"To evaluate the effects of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes on markers of cardiovascular risk, fasting serum lipids, fasting plasma glucose, waist circumference, and patient-reported outcomes.",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10994,NCT04919603,Change in liver steatosis quantified by MRI-PDFF (percentage),Cardiovascular risk,,2021-06-15,UNKNOWN,INTERVENTIONAL,['NA']
10995,NCT00525330,The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.,To assess the safety and tolerability of KRP-104;,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10996,NCT02294370,glucose levels in tissue fluid,capillary glucose,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
10997,NCT06273631,Change of time in range (TIR),Change in autoimmunity from baseline,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10998,NCT05865717,Physical activity which will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University,Prevalence of Chronic Diseases according to each profession and BMI,,2023-02-15,COMPLETED,OBSERVATIONAL,['NA']
10999,NCT01910805,Change in Diabetes Risk Awareness from baseline to 12 months postpartum,Change in physical activity levels from baseline to 12 months postpartum,Change in physical activity levels from baseline to 6 months postpartum,2014-08,COMPLETED,INTERVENTIONAL,['NA']
11000,NCT02347514,glycosylated hemoglobin,Summary of Diabetes Self-Care Activities (SDSCA),,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11001,NCT04428658,Glycemic control,Patient-reported outcomes,,2022-09-15,RECRUITING,INTERVENTIONAL,['NA']
11002,NCT05506800,Incidence and mortality rate of cancer,Reproductive health,,2016-03-03,SUSPENDED,OBSERVATIONAL,['NA']
11003,NCT03803345,Maternal meal and snack distribution,Dietary data from food record app.,Birth head circumference,2019-03-28,COMPLETED,OBSERVATIONAL,['NA']
11004,NCT00834938,"Describe the endogenous response of incretins, orexins and anorexins to a mixed meal test in obese patients with DM2, in patients with DM2 undergoing RYGB with remission of DM2 and in patients without remission.",,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
11005,NCT01767012,Amount of aqueous flare measured with a Laser flare meter,Anterior capsule opacification (measured as brightness of anterior capsular reflect on slitlamp photographs),IOL tilt measured with a Purkinje-meter,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11006,NCT04343872,Change in Glycosylated Hemoglobin (HbA1c),,,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
11007,NCT01204593,Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)),Symptomatic hypoglycemias,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11008,NCT06006689,Change in UACR(urinary albumin ⁃ to ⁃ creatinine ratio).,TCM syndrome,Change in MCP-1.,2023-09-04,RECRUITING,INTERVENTIONAL,['PHASE2']
11009,NCT01816165,State 3 Mitochondrial Oxygen Consumption,Vascular Markers,Counterregulatory Hormones,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11010,NCT01790438,Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c),Change From Baseline to 26 Weeks in European Quality of Life (EQ-5D-3L) - Visual Analog Scales (VAS) Scores,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11011,NCT02324491,"Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations",Change in Patient Reported Outcomes (PRO) scores,,2014-12,TERMINATED,INTERVENTIONAL,['PHASE2']
11012,NCT00834626,Percentage of Participants Having Remission of Type 2 Diabetes,Percentage of Participants Achieving Remission in Hypertension,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
11013,NCT04026750,Change From Baseline in Peak Glucagon Response to Hypoglycemia,Number of Patients Returning to Blood Glucose =>70 mg/dL,,2019-09-15,TERMINATED,INTERVENTIONAL,['PHASE1']
11014,NCT02967354,[11C]5-hydroxy-tryptophan Uptake in the Pancreas,Hepatic Fat Content,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
11015,NCT06051565,Degree of vascular stenosis,Serum transferrin saturation,,2021-11-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11016,NCT03338855,Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment,,Fibroblast Growth Factor 21 (FGF21) Area Under the Curve (AUC) in Plasma After 5 Weeks of Treatment,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11017,NCT01101945,"To demonstrate safety and tolerability of dutogliptin/PHX1149Tas assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments",To demonstrate maintenance or lowering of HbA1c and fasting blood glucose,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
11018,NCT05243628,Change in HbA1c,Change in Coefficient of variation (CV),Change in Percent Predicted Forced Expiratory Volume in 1 Second,2022-03-31,COMPLETED,INTERVENTIONAL,['PHASE4']
11019,NCT02329366,"To identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (DFUs) using debrided tissue of patients with wounds",,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
11020,NCT04312802,Anaerobic threshold (AT) measurement correlation with cardiac perfusion,,,2018-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11021,NCT02268214,Adjusted Mean Change in HbA1c From Baseline at Week 24,Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events,,2014-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11022,NCT03751839,failure load in kN,measurement of serum periostin in ng/ml,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
11023,NCT01789593,Digit Symbol Substitution Test (DSST) score,Paced Auditory Serial Addition Task (PASAT) score,,2013-01-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11024,NCT04418869,Change in plasma glucose during exercise and recovery,Change in cardiac output.,,2014-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11025,NCT03861546,SMA program retention rate,Change in diet,,2019-03-03,COMPLETED,INTERVENTIONAL,['NA']
11026,NCT01703234,Flow Mediated Dilatation,FGF-23,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11027,NCT01281098,Regression of retinal neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11028,NCT03914924,Disease-related knowledge,Cardiometabolic Health Parameter: cardiac autonomic control,Morbidity associated with diabetes,2020-01-20,RECRUITING,INTERVENTIONAL,['NA']
11029,NCT03495284,Fasting blood glucose,Triglycerides,,2018-02-19,COMPLETED,INTERVENTIONAL,['NA']
11030,NCT00619034,Diameter of retinal blood vessels,Influence on retinal blood flow in diabetes,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
11031,NCT02045563,Determination of the existence of liver steatosis measured by magnetic resonance spectroscopy spectrometry,Measurement of monocyte expression of LDL receptors,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA']
11032,NCT05585268,Proportion of patients with one or more PIMs deprescribed,Mean number of total medications,,2022-10-03,COMPLETED,INTERVENTIONAL,['NA']
11033,NCT04980040,Percentage of Participants With Unexpected Adverse Drug Reactions (ADRs),Percentage of Participants With Overall Improvement and Final Effectiveness Assessment,,2014-04-19,COMPLETED,OBSERVATIONAL,['NA']
11034,NCT02554643,Attenuation of expression of proinflammatory genes verified by qPCR-array technique ranging from at least 5% in pre and post-intervention measurements,Enhance physical performance verified by oxygen consumption measurement on treadmill,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
11035,NCT02993809,Survival without major amputation,Thermography,,2018-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
11036,NCT01255163,Number of Participants With Incidence of Nausea,Body Mass Index (BMI),,2010-11-21,TERMINATED,INTERVENTIONAL,['PHASE2']
11037,NCT02083991,Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT),Cumulative frequency of infections,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11038,NCT02096874,Peripheral retinal ischemia,,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11039,NCT00754143,Safety and tolerability of FG-3019,Change from baseline in first morning urinary albumin creatinine ratio (ACR),,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11040,NCT01730014,Incidence of adverse events (AE),The maximal GIR (glucose infusion rate) observed,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11041,NCT05822648,Change over time in HbA1c,Change over time in self-reported caloric intake,,2023-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11042,NCT02181127,Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl,Episodes of Nausea Per Day on Glucagon vs Placebo,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11043,NCT04317703,bioequivalence study,,,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE1']
11044,NCT02294643,late lumen loss measured by quantitative coronary angiography,renal impairments as measured by increased microalbuminuria or decreased creatinine clearance,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11045,NCT04935749,Epidemiology,,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
11046,NCT00393510,Number of Participants With Limb Salvage,Time of Ulcer Healing,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11047,NCT01784965,Change in Weight Reported at 14 Weeks,Insulin Resistance in the Liraglutide vs.Placebo Group After Calorie Restriction,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11048,NCT00886665,Short-form (sf)- McGill pain questionnaire (SF-MPQ),Nerve conduction study,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
11049,NCT01030770,Number of patients requiring pars plana vitrectomy at week 7.,Grading of lens clarity using LOCS II (lens opacities classification system version II),,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11050,NCT05648903,Intervention primary outcome- Change in Hba1c (mmol/l),Intervention secondary outcomes- diabetes remission,Other study outcomes- engagement with the programme,2022-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11051,NCT00175734,To determine what hemoglobin level is best for diabetic dialysis patients. Specific parameters: endothelial cell function and related expansile capacity of blood vessels. *Assessed through labs and pulse wave velocity test,"Pulse rate, BP, respiratory rate, peripheral oxygen saturation, ECG during 6-min walk-test and Health Related Quality of Life Assessment as measured by questionnaires",,2005-08,UNKNOWN,INTERVENTIONAL,['NA']
11052,NCT02620072,Dysglycemia or diabetes,Progression to diabetes,Adverse events,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11053,NCT03727854,Change in HbA1c From Baseline,Change in Homeostatic Model Assessment of β-cell Function (HOMA-beta) From Baseline,,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
11054,NCT06026813,Plantar pressure,Balance,,2024-03-07,RECRUITING,OBSERVATIONAL,['NA']
11055,NCT03932630,Percentage of time in target glucose range (3.9 - 10.0 mmol/L),Percentage of time when pump was in Auto-mode,,2019-12,WITHDRAWN,INTERVENTIONAL,['NA']
11056,NCT01087645,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9925,,2010-03-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11057,NCT00641953,"Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain ""24 - Hour Average Pain"" scores",Change in weekly average sleep disturbance,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11058,NCT01929798,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,,2013-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11059,NCT00187564,4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status),2. Urine albumin/creatinine ratio,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
11060,NCT00601250,HbA1c Change From Baseline at Week 24,2 Hour Post-Prandial Glucose (PPG) Increment Over Fasting Plasma Glucose (FPG) at Week 24,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11061,NCT00833027,Change From Baseline in HbA1c at Week 24,Change From Baseline in HbA1c at Week 12,,2008-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11062,NCT04473430,"Differences in mean percentage time-in-hypoglycemia (< 70 mg/dL) during the intervention phase, compared to control in both phases (i.e. intervention-control vs. control-intervention).",Number of hospitalization or emergency room visits for diabetes ketoacidosis,,2020-11-05,COMPLETED,INTERVENTIONAL,['NA']
11063,NCT00552175,Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg),Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11064,NCT00505947,improvement in best corrected visual acuity,anatomical improvement of diabetic macular edema and improvement in diabetic retinopathy,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11065,NCT01180283,Evidence that lodenafil carbonate improves erectile function in patients with diabetes type 2.,Adverse events in type 2 diabetes patients taking lodenafil carbonate and laboratory tests changes after this treatment.,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11066,NCT05259475,Change in liver fat content.,Change in the composition of gut microbiota from baseline due to the diet intervention.,,2021-08-20,COMPLETED,INTERVENTIONAL,['NA']
11067,NCT03331861,Change in Minute Ventilation to Carbon Dioxide Production (VE/VCO2) Slope,Heart Failure Hospitalizations,Fasting Sugar,2019-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11068,NCT00503464,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
11069,NCT04899791,Change in blood cholesterol levels,Change in body weight,,2021-05-24,COMPLETED,INTERVENTIONAL,['NA']
11070,NCT02620644,Retinal Ganglion Cell Complex in microns by Optical Coherence Tomography measurements,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
11071,NCT03907189,Correlation of foot temperature data and daily activity in patients with emergent inflammation.,Correlation of foot temperature data and daily activity in patients without inflammation to the plantar foot.,Usage rate for the activity monitor,2019-03-25,UNKNOWN,OBSERVATIONAL,['NA']
11072,NCT05359341,Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group,The change in lipid profile in patients in sitagliptin group versus empagliflozin group,Percentage of adverse effects appeared in patients in sitagliptin group versus percentage of adverse effects appear in patients in the empagliflozin group.,2020-09-20,COMPLETED,INTERVENTIONAL,['NA']
11073,NCT03159559,myocardial perfusion reserve index (MPRI),,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11074,NCT05287906,Gastric inhibitory polypeptide,,,2022-04-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11075,NCT05510518,Number of obese women that will be diagnosed with late GDM diagnosis by the OGTT,neonatal hospitalization in intensive care rate,,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11076,NCT04279184,Psychometric validation of ICIQ-UI SF (questionnaire used to assess urinary incontinence),Objective characterization of urinary incontinence in women with and without diabetes,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
11077,NCT00954447,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in Incremental Post-prandial Glucose (iPPG) After 24 Weeks of Treatment,Number of Patients With HbA1c < 6.5 Percent,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11078,NCT02010827,Differences in Endogenous glucose production during the three days measured as total Area under the curve (tAUC),"differences in appetite, hunger, satiety between the three days",,2013-11,COMPLETED,OBSERVATIONAL,['NA']
11079,NCT03141073,Change from baseline in HbA1c,Incidence of Treatment-Emergent Adverse Events over time,,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11080,NCT05132660,Electroretinogram,HbA1c,,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1']
11081,NCT00256256,FDG-uptake in the brain and heart visualized by Positron emission tomography with and without GLP-1,Laboratory values (insulin secretion and counter-regulatory hormones),,2005-11,COMPLETED,INTERVENTIONAL,['NA']
11082,NCT00167934,Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal),,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
11083,NCT03115112,Change in HbA1c From Baseline to Week 24,Change in SBP in Subjects From Baseline at Week 24,,2017-10-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11084,NCT03029702,Proportion of participants who report suitability of the study procedures,Cord blood c-peptide,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
11085,NCT03047668,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN),,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
11086,NCT00251875,7. user metrics,,,2005-07,UNKNOWN,INTERVENTIONAL,['NA']
11087,NCT00752440,Inspiratory muscle strength,Variability of heart rate,,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11088,NCT04807348,percentage of HbA1c change from baseline,number of participants with lab abnormality,,2021-05-17,UNKNOWN,INTERVENTIONAL,['PHASE3']
11089,NCT01060540,Weight,Moderate Intensity Physical Activity,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
11090,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs),,2006-08,COMPLETED,OBSERVATIONAL,['NA']
11091,NCT06258473,Hypertension and Diabetes control,Hypertension and diabetes care cascade,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
11092,NCT00618995,Urinary 11-Dehydrothromboxane B2 (11-dTxB2),Prostaglandin I Metabolite (PGI-M),,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11093,NCT04409795,Glycated hemoglobin (HbA1c),Area under the plasma concentration versus time curve (AUC) of C-peptide,,2021-08-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11094,NCT03675360,Change in Hemoglobin A1c,Change in Body Weight,Change in Estimated Atherosclerotic Cardiovascular Disease Risk,2018-09-25,COMPLETED,INTERVENTIONAL,['NA']
11095,NCT00317707,cardiovascular deaths and hospitalization for cardiovascular causes,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11096,NCT04937348,"Anthropometrics: body weight [kg], length [cm], head circumference [cm].",Impact of maternal adipokines on breast milk composition.,,2019-12-13,COMPLETED,OBSERVATIONAL,['NA']
11097,NCT02001753,Changes of endothelium-dependent arterial dilation before and after CMR in type 2 diabetes,Changes of endothelial progenitor cells before and after CMR in peripheral blood,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11098,NCT04780425,Change in mean glaciated heamoglobin (HbA1c) at three months,Change in mean WHO quality of life (WHOQoL BREF) score at three months,,2021-01-26,COMPLETED,INTERVENTIONAL,['NA']
11099,NCT02389127,Level of HbA1c in T2DM and cirrhosis,,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
11100,NCT03407508,HbA1c,Gingivitis,,2018-10-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11101,NCT02077452,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Insulin, C-peptide, glucagon and glucagon-like peptide 1 up to 6hr post-dose following single dose and steady state (fasting and postprandial)",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11102,NCT00315016,blood pressure by home measurements,plasma angiotensins and bradykinins,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11103,NCT01738802,Change in the markers of oxidative stress and inflammation,Hemoglobin A1c,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
11104,NCT01500928,Device-related adverse outcome,Product quality (MTBF),,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
11105,NCT06207838,Between group difference in the percentage of time spent within range with sensor glucose (SG) between 70-180 mg/dL (TIR) (3.9-10.0 mmol/L).,Difference in physical capacity indices listed in screening visit: Four Square Step,,2023-09-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11106,NCT02302079,Percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) at Month 3,Absolute and percent change from baseline in excess CST in the study eye as assessed by SD-OCT at Months 1 and 2,,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11107,NCT00219102,Change from baseline in diastolic blood pressure after 12 weeks,Achieve mean sitting blood pressure control target of < 130/80 mmHg after 12 weeks,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11108,NCT02317003,Change in total energy expenditure by accelerometry at 3 months compared to baseline,Adherence of doctors and patients to the suggested strategy,,2015-03-16,COMPLETED,INTERVENTIONAL,['NA']
11109,NCT02907346,Change in A1c,,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
11110,NCT02984644,Change in EGP With Pancreatic Clamp: Study 3,Change in Glucagon Using Pancreatic Clamp: Study 3,,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11111,NCT03076112,Glycated hemoglobin,25-hydroxyvitamin D,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE3']
11112,NCT02625636,Number of patients with adverse events,Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t),,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11113,NCT01323348,Change in HbA1c,Body Mass Index,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11114,NCT04275804,Ulcer size,Foot function,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11115,NCT04650165,DR severity level,mfERG assessement,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
11116,NCT00950716,Lipid levels,"Cognitive-psychological-behavioral assessments: a) Depression Anxiety and Stress Scale (DASS21). b) Diabetes Empowerment Scale (C-DES). c) Summary of Diabetes Self Care Activities (SDSCA, Chinese version).",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11117,NCT04905823,Adverse events,Values of continuous glucose monitoring,,2021-03-31,COMPLETED,OBSERVATIONAL,['NA']
11118,NCT02783612,Assessing the compliance of the research group compared to the control group.,,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
11119,NCT01176578,Skeletal muscle capillarization,Cardiorespiratory Fitness,,2011-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11120,NCT00370721,visual acuity,pan retinal photocoagulation,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
11121,NCT01622634,Metabolic Syndrome Risk Factors,Satiety,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
11122,NCT03428932,Changes in Gray Matter Volume in the Brain,Changes in WASI-II Perceptual Reasoning Index (PRI),,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
11123,NCT05000021,Diabetes Distress Levels,Coefficient of Variation (CV) calculated from Continuous Glucose Monitoring (CGM),Hemoglobin A1c,2022-06-27,RECRUITING,INTERVENTIONAL,['NA']
11124,NCT01286090,The change from baseline in Gastroparesis Cardinal Symptoms Index (GCSI) score,The type of adverse events reported,,2003-07,TERMINATED,INTERVENTIONAL,['PHASE4']
11125,NCT01145547,Mean Area Under the Curve for Rise in Breakfast Post-prandial.,,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
11126,NCT01536431,Safety,T cell (immune) response to islet cell antigens,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11127,NCT05729282,Continuous glucose monitoring (CGM) profile,Fasting serum/plasma apolipoprotein B (ApoB) (relative/change),Deuterium tracer enrichment in body water (measured in saliva),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
11128,NCT00545337,Change of HbA1c,"Blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and basal insulins",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11129,NCT02004678,time to reach maximum plasma concentration (Tmax),number of patients experiencing laboratory adverse events,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11130,NCT00095030,Change in baseline HbA1c after 52 weeks,Change in lipids after 52 weeks; safety and efficacy when administered with metformin after 52 weeks,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11131,NCT02653300,Change in MRI-Proton Density Fat Fraction (MRI-PDFF),Mean Fibrosis Score CAP™ (FibroMax),,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE2']
11132,NCT01714674,Cardiac troponin T,Blood pressure,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
11133,NCT02194790,The difference of rate of estimated glomerular filtration(eGFR) decline,Change from baseline in Hemoglobin A1C,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
11134,NCT00870194,Change in HbA1c (Percent),Incidence of Confirmed Hypoglycemia(Overall),,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11135,NCT02739971,"Change from baseline in AGEs markers in serum (carboxymethyl lysine, CML and Methylglyoxal ,MG ) at 6 months",retention rate to the diet,Change in microbial diversity and composition of fecal microbiome following AGE reduction in diet,2016-06,COMPLETED,INTERVENTIONAL,['NA']
11136,NCT05098600,Measurement of Vitamin D levels,Identification and prevalence of possible exacerbating factors in patients with Alopecia Areata,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA']
11137,NCT00334581,The difference of urinary albumin excretion rate change,Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11138,NCT02597257,11-point Numeric Rating Scale,11-point Numeric Rating Scale,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
11139,NCT02268292,Metabolic syndrome,Arterial stiffness,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11140,NCT02385890,Subjective Appetite,Energy/fatigue measured by VAS questionnaire,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
11141,NCT03775057,Percentage of patients reaching fasting SMPG target without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of emotional well-being using WHO-5 well-being index,,2018-08-22,UNKNOWN,INTERVENTIONAL,['NA']
11142,NCT02248077,Complete Ulcer Closure,,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11143,NCT04823442,BAT glucose uptake,Changes in pancreatic and gut hormones,,2021-01-21,COMPLETED,INTERVENTIONAL,['NA']
11144,NCT05642143,"Evaluation of differences in bone turnover markers between T2D patients with and without previous fractures by biochemical analysis of different bone markers (CTX, P1NP, osteocalcin (OC), ucOC, sclerostin, osteoglycin and osteopontin).",Compare muscle mass and strength in T2D patients with and without neuropathy,The correlation between levels of Advanced Glycation End Products (AGEs) (assessed by skin autofluorescence) and bone material strength (assessed by microindentation).,2023-02-24,RECRUITING,OBSERVATIONAL,['NA']
11145,NCT03288233,Average end expiratory alveolar concentration of CO (ppm) 5 hours after lunch,,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
11146,NCT00290979,Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro,6-month safety data,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11147,NCT02204670,Hepatic Triglyceride Content,Post-prandial glucose,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
11148,NCT05212519,Whether suffering from gestational diabetes,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11149,NCT03745937,Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs Through the End of the Follow-up Period,Percentage of Participants Achieving Greater Than 5% Body Weight Loss From Baseline to the End of the Treatment Extension Period,,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11150,NCT01697228,Hemoglobin A1c,Baseline differences between vitamin D deficient & sufficient subjects,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11151,NCT01076088,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2010-11-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11152,NCT04510493,unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint),Number of antidiabetic treatment at three months,,2020-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
11153,NCT02169518,Paraoxonase activity is measured using a semi-automated microtitre plate method.,,,2012-07-05,RECRUITING,OBSERVATIONAL,['NA']
11154,NCT01663298,FGF2 methylation level,Wound healing indices (WHI),,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11155,NCT00862251,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).,Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11156,NCT03478969,"Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score","Amount of Waste, Inferred by Total Material Consumption",,2018-05-17,COMPLETED,INTERVENTIONAL,['NA']
11157,NCT05705869,Diagnosis of heart failure within 6 months,People diagnosed with HFrEF receiving GDMT within 6 months,"The number of patients in the NT-proBNP/echocardiography group with echocardiographic features of potential amyloid as assessed by the US2.ai algorithm report conclusion of ""amyloid to be considered""",2022-12-22,RECRUITING,INTERVENTIONAL,['NA']
11158,NCT05427890,Differences in behaviour intention between arms,Empirical evidence of using PMT constructs in developing interventions,Objective Risk Score,2022-06-20,COMPLETED,INTERVENTIONAL,['NA']
11159,NCT03193229,Total number of steps per day,Pace of steps per day,Sedentary minutes per day,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
11160,NCT02967653,"Raw Urine Osmolality value at 12 week follow-up, adjusted for baseline (UOsm in mOsm/Kg)","Raw Self-Reported Fluid Intake value 12 week follow-up, adjusted for baseline","Subgroup Analyses - Raw Urine Osmolality value at 12 week follow-up, adjusted for baseline in patients UOsm <300mOsm/Kg",2017-07-13,COMPLETED,INTERVENTIONAL,['PHASE2']
11161,NCT04316052,International Restless Leg Syndrome Study Group Rating Scale: (International tool for finding the severity of RLS),The Pittsburgh Sleep Quality Index (PSQI).,Epworth Sleepiness Scale (ESS),2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
11162,NCT06141980,Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %,,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11163,NCT04965506,The change in HbA1c from baseline to 20 weeks,Number of participants with treatment-related adverse events,,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11164,NCT03855514,Length of time that a wound achieves complete wound closure (CWC),Time to complete wound closure (CWC) by or on 24 weeks,,2019-02-08,UNKNOWN,INTERVENTIONAL,['NA']
11165,NCT01447147,Subject incidence of adverse events,Change from baseline in first morning urinary albumin:creatinine ratio (ACR),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11166,NCT02542059,Beta cell mass measured by uptake of 68Ga-exendin in the pancreas on PET images,Comparing uptake of 68Ga-exendin in the pancreas with blood glucose and insulin measured after glucose ingestion and arginine infusion,,2015-08,RECRUITING,OBSERVATIONAL,['NA']
11167,NCT02966626,Change in HbA1c,Change in body mass index,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
11168,NCT00236626,Mean change in insulin sensitivity from baseline to Month 9.,"Mean change, baseline to Month 9, in body weight and composition, Body Mass Index (BMI), lipid profile, fasting glucose; blood pressure; safety evaluations (adverse events) during study.",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11169,NCT01740921,change of baseline skin maximum hyperaemia at 4 months,change of baseline capillary density at 4 months,change of baseline adipose tissue inflammation at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11170,NCT01128829,The Effect of Sucralose on Insulin Concentration (Area Under the Curve; AUC),,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11171,NCT01542463,Fasting plasma glucose (FBG),Hypoglycaemic episodes,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
11172,NCT01649570,Incidence of hypoglycaemia,"Glycaemic control parameters: Glycosylated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPPG)",,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11173,NCT04518566,Patient activation score as measured by patient activation measure,HbA1c,,2021-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11174,NCT01733134,Dyspnea,Rehospitalization,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11175,NCT00224796,To determine the effect of V.A.C. ® Therapy on the incidence of complete wound closure.,To determine the effect of V.A.C. ® Therapy on the quality of life,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11176,NCT02740829,Endogenous glucose production following intranasal glucagon compared to placebo,,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11177,NCT00543738,,,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE3']
11178,NCT01736228,to establish the efficacy and safety of DIABECELL,Improvement in the quality-of-life of xenotransplant recipients,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11179,NCT03304938,Pittsburgh Insomnia Rating Scale,Diastolic Blood Pressure,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
11180,NCT04200586,Change in myocardial perfusion reserve index,,,2020-04-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11181,NCT02567994,Change of HbAlc from baseline at Week 24,,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11182,NCT01434186,Mean Change in HbA1c From Baseline to Week 16,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11183,NCT03620773,Glomerular Filtration Rate (GFR),Aortic Stiffness & Wall Shear Stress,Epigenetic profiling,2018-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11184,NCT05189938,Establish a relationship between laboratory-derived HbA1c and average glucose levels,,,2021-12-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11185,NCT03631121,Change of glycemic variation,,,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
11186,NCT04208282,Primary,Exploratory outcomes,Adverse Events,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
11187,NCT02769585,Change in weight (BMI),Degree of weight loss in obese versus overweight,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
11188,NCT03132181,Mode of action,Metabolism,,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
11189,NCT00611884,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11190,NCT03230786,Change from baseline in blood HbA1c at 12 weeks versus placebo.,Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo,,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11191,NCT00786825,Brain Glycogen Turnover Rate,,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11192,NCT01874366,Food Effect,Time to peak plasma concentration (t-max),,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
11193,NCT02773875,Amount of time sensor glucose levels are >250 mg/dl,Percent of time in range between 70-180 mg/dl,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
11194,NCT05980455,Scoring Change in Nausea Severity by GCSI-DD,Mean Change from Baseline in Quality of Sleep Scores,,2023-07-10,RECRUITING,INTERVENTIONAL,['NA']
11195,NCT01735253,Hemoglobin A1C,oral glucose tolerance test,insulin level,2009-12,COMPLETED,INTERVENTIONAL,['NA']
11196,NCT02189135,Number of patients with hypoglycaemia in usual care versus telemedicine during Ramadan,Glycaemic control of patients measured with HbA1c in patients under usual care versus telemedicine from baseline to end of treatment,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11197,NCT02308059,Pain scores on the visual analog scale,Neuropathic pain scores on the Leeds Assessment of Neuropathic Symptoms and Signs pain scale,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
11198,NCT03443635,High or Medium (Versus Low) Mediterranean Diet Adherence,Food Costs,,2018-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11199,NCT00607230,concentration of autoreactive t-cells,"Concentration of TNF, TNF-receptors, other cytokines, and c-peptide levels",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11200,NCT00781313,The primary aim is to ascertain the emergency preparedness among our families with diabetes mellitus and to obtain a percentage of unprepared to the ones who are prepared.,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
11201,NCT04465877,"Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28",,,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
11202,NCT01068652,Glycosylated Haemoglobin (HbA1c),Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11203,NCT01317576,Blood sampling to determine the concentration of cardiovascular risk factors in the blood before and after exercise,"Muscle biopsy to measure muscle mitochondrial density, muscle mitochondrial function and muscle lipid metabolism",,2011-03,COMPLETED,INTERVENTIONAL,['NA']
11204,NCT04074317,Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL,Insulin Area Under the Concentration (AUC) Curve,,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE2']
11205,NCT03031834,Changes in blood pressure response to standing,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11206,NCT02259088,Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12,Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward,,2014-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11207,NCT05747872,Change in ulcer surface area,,,2022-03-10,COMPLETED,INTERVENTIONAL,['NA']
11208,NCT02011633,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11209,NCT01867307,Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14),,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11210,NCT05921097,Comparison of axon-reflex flare responses with QST,Comparison of axon-reflex flare responses with NC-Stat DPNCheck,DPN severity and pain,2023-06-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11211,NCT01507272,AUC (area under the curve),"t½, terminal half-life",,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11212,NCT05606471,Muscle protein breakdown rate,Right vastus lateralis muscle fibre pennation angle,,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4']
11213,NCT03417076,absolute bioavailability (Fp.o.) of bexagliflozin tablets,adverse events,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11214,NCT04088851,"The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group.",,,2019-09-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11215,NCT00225277,Nominal Change From Baseline in Percent Atheroma Volume,Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events,Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11216,NCT02759289,Change in platelet activity in response to arsenic exposure measured by Regression models,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
11217,NCT03622424,weight loss of >5.0% in at least 35% of prediabetic subjects or in at least 25% of diabetic subjects on Gelesis200.,"improvement in FPG status, post-OGTT plasma glucose status, or post-OGTT plasma glucose AUC in ≥50% of subjects on Gelesis200.",Number of TEAE for Gelesis200 similar to placebo or clinically acceptable.,2017-08-22,COMPLETED,INTERVENTIONAL,['NA']
11218,NCT00177138,"Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance.","The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance.",,2004-07,TERMINATED,INTERVENTIONAL,['PHASE4']
11219,NCT02289066,markers of bone turnover (bone specific alkaline phosphatase and C terminal,Evaluation of the relationship between periodontal disease and diabetes control and complications,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
11220,NCT00434499,Improvement in insulin resistance,Improvement in endothelial dysfunction,,2007-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11221,NCT01829477,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3']
11222,NCT01774058,"The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.",,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
11223,NCT02632747,Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.,"Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril",,2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11224,NCT04971655,State-Trait Anxiety Inventory (STAI),,,2021-08-04,UNKNOWN,INTERVENTIONAL,['NA']
11225,NCT01492153,Change in body weight,Adverse events (AEs) including hypoglycaemic episodes,,2003-02-11,COMPLETED,OBSERVATIONAL,['NA']
11226,NCT04175496,Postprandial insulin response,,,2019-12-01,COMPLETED,INTERVENTIONAL,['NA']
11227,NCT01180608,cerebral neurobiological effect of pregabaline as treatment for neuropathic pain,cerebral neurobiological changes in relationship with dose dependent therapeutic effect of treatment with pregabaline,,2010-09,UNKNOWN,INTERVENTIONAL,['NA']
11228,NCT01108978,Evaluation absolute and percentage reductions in low-density lipoprotein cholesterol (LDL-C) by fasting biochemistry examination,"Evaluation of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides by fasting biochemistry examination",,2010-05,TERMINATED,INTERVENTIONAL,['PHASE4']
11229,NCT02008851,Number of adverse events related to study procedures or investigational product,Number of renal-specific adverse events,Changes in renal function over time,2013-12,TERMINATED,INTERVENTIONAL,['PHASE1']
11230,NCT01746563,Macular Evaluation,Structural Macular Evaluation,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11231,NCT02111291,Time to Well-established Granulation Tissue,Adverse Event,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11232,NCT01087073,"Lipids (HDL, LDL, total cholesterol, triglycerides)",Processes of care,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
11233,NCT02452086,"The blood serum level of VEGF(pg/ml), VEGFR-2(pg/ml), HIF-1α(pg/ml) and NO (pg/ml)",Ankle Brachial Index(ABI),,2013-06,COMPLETED,INTERVENTIONAL,['NA']
11234,NCT00839527,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Change From Baseline in Body Weight at Week 104 and Week 156,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11235,NCT03785379,Change from baseline Glycated Hemoglobin (HbA1c) at 6 months,Change from baseline Glycated Hemoglobin (HbA1c) at 12 months,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
11236,NCT05552872,Survival at 7 Days,SOFA Indexs,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
11237,NCT02799953,changes in systolic and diastolic blood pressure,changes in answering hypertension knowledge questions,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
11238,NCT00933530,"Characterize the pharmacokinetic profile of SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, and 3.0 g/day) when administered as a single dose and when administered as once daily for 7 consecutive days.",,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11239,NCT04142424,Number of subjects experiencing adverse events and serious adverse events,Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)],,2019-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11240,NCT06101901,Rate of patients who remain in a diabetic kidney disease clinical trial to trial completion,,,2024-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11241,NCT01890954,Percent of Time Spent Near Normoglycemia,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
11242,NCT05701254,"Compare cortical bone tissue levels of pentosidine (AGE), pyridinoline (normal enzymatic collagen crosslinks), and matrix-bound water between T1DM and controls.",Compare cortical bone tissue heterogeneity in nanoindentation measures of modulus and hardness between T1DM and controls.,,2019-06-18,RECRUITING,OBSERVATIONAL,['NA']
11243,NCT00123643,Flow Mediated Dilation,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11244,NCT01357135,Percentage of Participants With Strict Changes in Initial Dual Therapy,,,2009-07-15,COMPLETED,OBSERVATIONAL,['NA']
11245,NCT04317430,Estimated glomerular filtration rate (eGFR),Change of Urinary podocalyxin level,Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11246,NCT05993741,Plaque Control Record (PCR),Oral Health Related Quality of Life(OHRQoL),,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
11247,NCT04190511,Weight change during pregnancy,,,2019-12-10,COMPLETED,INTERVENTIONAL,['NA']
11248,NCT00018122,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
11249,NCT05195502,Evaluation of metabolic profile,Colonic biofilm,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11250,NCT00212329,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
11251,NCT06021119,peak postprandial plasma glucose (PPG) level in mg/dl,Time in range %,,2023-03-23,COMPLETED,INTERVENTIONAL,['PHASE3']
11252,NCT05370014,Change in patient-reported outcomes measurement information system (PROMIS) Global Health Scale,Change in Modified Medical Outcomes Study Social Support Survey Instrument (mMOS-SS),,2023-01-03,RECRUITING,INTERVENTIONAL,['NA']
11253,NCT01091909,postoperative complications,Delayed wound healing,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
11254,NCT05314036,Establishment of proposed Wellness Transformation Network clinical trial procedures.,Time course and curve analysis of Meal Induced Glycemia (MIG) scores response after the test meal administration.,,2022-01-17,COMPLETED,INTERVENTIONAL,['NA']
11255,NCT00412347,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
11256,NCT05505565,Progression of prediabetes,Glycemic metrics,,2023-06-05,RECRUITING,INTERVENTIONAL,['NA']
11257,NCT01027585,,,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
11258,NCT01698528,Glycemic Control as Determined by the Change in Absolute HbA1c Level,Time Health Care Providers and Subjects Spend on Managing the Insulin Titration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11259,NCT01130012,Number of at risk participants developing GDM during pregnancy,The effect of intervention on fetal growth,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
11260,NCT04085705,Presence of contact allergy for wound dressings,Presence of eczema,Past ulcers,2019-09-17,UNKNOWN,OBSERVATIONAL,['NA']
11261,NCT00650806,Percent Change in Body Weight From Baseline to Week 12,Change in Waist/Hip Ratio From Baseline to Week 12,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11262,NCT04420650,Change in subjective feeling of hunger and food craving,Diffusion-weighted imaging,,2020-05-26,COMPLETED,INTERVENTIONAL,['NA']
11263,NCT01814787,Number of Children With Documented Risk Factors for Type 2 Diabetes,,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
11264,NCT04808804,RNFL thickness,,,2021-06,UNKNOWN,OBSERVATIONAL,['NA']
11265,NCT05028140,Glycated hemoglobin,Adverse events,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11266,NCT03053518,Observed Incremental Area Under the Curve (iAUCobs),,,2017-06-30,TERMINATED,INTERVENTIONAL,['NA']
11267,NCT00102297,Pharmacokinetics,Bioactivity on urinary and plasma markers,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11268,NCT01830348,The proportion of subjects with a target ulcer which achieves complete wound closure (skin re-epithelialization without drainage or dressing requirements) up to 10 weeks (confirmed at a study visit 2 weeks later).,Time to the visit where the target ulcer achieves confirmed complete wound closure,"Incidence of target ulcer recurrence, time to ulcer recurrence, and number of days target ulcer remains closed after confirmed complete wound closure has been established.",2013-02,TERMINATED,INTERVENTIONAL,['PHASE3']
11269,NCT05099939,Change in lung function,CFRD diagnosis,,2021-11-25,RECRUITING,OBSERVATIONAL,['NA']
11270,NCT05786001,Oxygenation in lower limb angiosomes assessed by hyperspectral imaging.,,,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11271,NCT01313949,To assess the effectiveness of the training program in improving glycemic parameters in diabetic patients before and after the training.,"To assess the efficacy of the training in improving the participants' knowledge of diabetes, as compared to the control patients.",,2009-02,COMPLETED,INTERVENTIONAL,['NA']
11272,NCT00131755,Glycemic control (measured by blood glucose),Side effects,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11273,NCT01664637,Change from baseline in symptoms associated with diabetic gastroparesis,"Adverse events (AEs), vital signs, ECGs, clinical laboratory parameters",,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11274,NCT02345967,Number of Adverse Events,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11275,NCT01239849,Percentage of subjects in the total LDL cholesterol group achieving their LDL cholesterol target after 8 weeks of treatment.,"5. Safety of atorvastatin through laboratory assessment, physical examination, vital signs, and adverse events.",,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
11276,NCT00466518,Changes in pharmacokinetics,Determine tolerability of sitagliptin therapy in post-kidney transplant patients.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
11277,NCT00263861,Glycemic control as measured by Glycosylated Hemoglobin Assay,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
11278,NCT01634282,Incidence and severity of adverse events,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11279,NCT02883842,Change in glucose level measured by HbA1C level,Change in low-density lipoprotein cholesterol (LDL-C) level,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
11280,NCT04670666,Change from baseline in glycated hemoglobin (HbA1c) levels.,Incidence and severity of adverse events recorded during the study.,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11281,NCT06283264,1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11282,NCT00117780,Mean HbA1c,Hypoglycaemia,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11283,NCT00368394,"Outcome:In T1DM, glulisine, like RHI, displays dose proportionality in exposure over the dose range 0.075 to 0.3 U/kg, which partly only translates into dose proportionality in glucodynamics.",,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11284,NCT04112875,Changes in Endothelium-dependent and endothelium-independent vasodilation,Body composition by DXA,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11285,NCT01106651,Change in HbA1c From Baseline to Week 26,Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11286,NCT01087567,The need for rescue therapy,"A1c,C-peptide. Time to normoglycemia and rescue therapy. Mean glucose, mean FBG, HOMA-B, HOMA-IR. Hypoglycemic events (minor and major. Tolerability based on side effects.",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11287,NCT02472717,The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo,"The effect(s) of liraglutide on the enumeration of circulating T-cell subpopulations, and on activation of circulating T-cell subpopulations",The effect of liraglutide on levels of infiltrating dermal T cells and cytokines in psoriatic skin plaques from patients with psoriatic arthritis receiving liraglutide therapy for 12 weeks compared to those receiving placebo,2015-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11288,NCT00130312,Safety and tolerance of sulodexide therapy long-term,Change in urinary protein/albumin excretion,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE4']
11289,NCT02648854,Cmax of Metformin,Vd/F of Metformin,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11290,NCT02845024,Periodontal pocket depth,glycated hemoglobin (HbA1c),,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11291,NCT04523454,Questionnaire - Number of women who have had the importance of a planned pregnancy explained to them,,,2020-10-02,COMPLETED,OBSERVATIONAL,['NA']
11292,NCT02928952,Problem Areas in Diabetes Scale (PAID) -(Measures Diabetes Distress),Summary of Diabetes Self-Care Activities (SDSCA)- - Medication Adherence,Insomnia Severity Index (ISI),2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
11293,NCT03909841,Cognition,Quality of Life: The Chinese (Hong Kong) 12-item Short-Form Health Survey version 2,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
11294,NCT01250340,Changes of isoprostanes after study drug administration.,,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11295,NCT05692778,Experiences of using an eHealth tool supporting the foot assessment,Long term effect,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
11296,NCT04856683,Prediction of frailty,Inappropriate therapeutic regimen,,2020-08-10,RECRUITING,OBSERVATIONAL,['NA']
11297,NCT00221715,"Bypass permeability 5 years after surgery, assessed trough Doppler ultrasonography",leg salvage,,2002-07,COMPLETED,INTERVENTIONAL,['NA']
11298,NCT02019446,Side effects from laser treatment,Quality of Life,,2018-07,UNKNOWN,INTERVENTIONAL,['NA']
11299,NCT05577390,The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability,The impact of INF® Therapy and Standard Physical Therapy on inflammation,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
11300,NCT04614168,The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia,Four Choice Reaction Time Test,,2021-07-26,UNKNOWN,INTERVENTIONAL,['NA']
11301,NCT02406586,Change in Flow-mediated Dilation,Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP),,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11302,NCT00626080,"Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET",Weight change,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11303,NCT00719108,The area under the GIR-time curve at steady state from 240 to 300 minutes (AUCGIR-SS),"PD Endpoints: Area under the GIR-time curve from 0 to 7 hours, GlR at steady state. PK Endpoints: AUCINS-SS, AUCINS0-7h, CLtot, VSS, t1/2 ,Terminal rate constant Safety Endpoints: AE, Lab assessments, Vital signs, Phy Exam, ECG & Hypoglycemia.",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11304,NCT02370680,change in platelet aggregation,Safety as measured by the number and system class of adverse events reported in each treatment arm,urinary metabolites of prostacyclin and thromboxane,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11305,NCT02077348,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.",Ghrelin,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
11306,NCT02678390,Plasma Ketone Concentrations,Plasma Insulin Concentrations,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
11307,NCT04081064,Insulin sensitivity,Fasting Plasma glucose,Heart rate during exercise sessions,2019-01-15,UNKNOWN,INTERVENTIONAL,['NA']
11308,NCT01753921,Unique signal measured in Hertz,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
11309,NCT05080530,Change from baseline in serum vitamin D.,,,2021-10-29,RECRUITING,INTERVENTIONAL,['NA']
11310,NCT04270097,Genetic risk variants associated with increased risk of T2D in Emiratis,,,2016-03-23,UNKNOWN,OBSERVATIONAL,['NA']
11311,NCT00672204,The Proportion of Insulin-independent Subjects With Full Islet Graft Function,,,2007-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11312,NCT02327286,Incident diabetes mellitus,Weight at one year post randomization,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11313,NCT01713348,Time in Range,HbA1c,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11314,NCT05568277,Diabetes Self-Efficacy Scale,,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11315,NCT05497232,Patient survival & pancreas graft survival & renal graft survival,,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
11316,NCT00311818,"Frequency of subjects with HbA1c: ≤ 6.5 %, 6.5 %< HbA1c ≤ 7.0 %, 7.0 %<HbA1c ≤ 8.0 % and HbA1c > 8.0 %","Frequency of subjects with hypoglycemic events (overall, severe, nocturnal, symptomatic)",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11317,NCT00631774,The primary objective of this study is to evaluate the effect of a diet program including Glucerna SR as a meal replacement on postprandial glucose response after using Glucerna SR for 24 weeks in obese Asian subjects with type 2 diabetes,"evaluate the efficacy and safety of a meal replacement program with Glucerna SR vs. an EDP based on the nutrition therapy recommendations from the ADA on anthropometric measurements, lipid profile, meal-related metabolic changes and quality of life",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
11318,NCT00442156,OCT-measured retinal thickness and visual acuity,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
11319,NCT05984238,Percentage of patients off insulin at 24 weeks [efficacy],Secondary efficay endpoint 1 - HbA1c 48 weeks,,2023-08-03,RECRUITING,INTERVENTIONAL,['NA']
11320,NCT00013117,,,,na,COMPLETED,INTERVENTIONAL,['NA']
11321,NCT01680185,Glycosylated hemoglobin (HbA1c),Serum creatinine,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11322,NCT05543564,BCVA,,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
11323,NCT00541983,Glycated hemoglobin (HbA1c) at Days 0 and 28.,Assessment of inflammatory markers CRP and ESR collected at time points specified in the protocol.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11324,NCT02621580,"The rate of structural and functional changes to the retinal thickness following PASCAL PRP in severe PDR patients, assessed by optical coherence tomography.",,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
11325,NCT05984771,Measurement of electrochemical skin conductance,vitamin B12 levels,,2021-01-10,COMPLETED,INTERVENTIONAL,['NA']
11326,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.",,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
11327,NCT01153438,change in glucose tolerance after surgery (measured by glucose area under the curve),change in glucose tolerance before and after a GLP-1 receptor blocker is administered,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11328,NCT01805830,HbA1c,HOMA-IR,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11329,NCT01283113,Visceral fat level,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11330,NCT04011020,Incidence of Treatment Adverse Events in T1D Subjects,Efficacy of SCE therapy in immune modulation,,2022-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11331,NCT06275412,Glycemic Control,Diabetes-Specific Family Support,Intervention Satisfaction,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11332,NCT04416503,HbA1c levels (%),,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
11333,NCT05781334,Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors),,Number of participants with heart failure readmission,2023-06-09,RECRUITING,INTERVENTIONAL,['NA']
11334,NCT03320993,Plasma Glucose,AUC-PG,Hormones and metabolites,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
11335,NCT02024516,adiponectin change,Body Mass Index change,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
11336,NCT02081326,Change in HbA1c values in juvenile onset type 1 diabetics,Autoimmunity in juvenile onset type 1 diabetes (AOO<21 years),COVID-19 and BCG Adaptive Study: Reported Rates of Infectious Diseases,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11337,NCT03538106,Risk factors associated with a cesarean delivery in patients with diabetes type 1,Risk factors associated with an emergency cesarean delivery in patients with diabetes type 1,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
11338,NCT01172093,presence of OSA,glycemic control,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
11339,NCT02977884,Healthcare expenses,Absenteeism: Sick days on record at Ohio University Human Resources,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
11340,NCT03834207,Acceptability & usefulness of the C3-Cloud system,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
11341,NCT00380380,Evaluate the effects of acute effects of vildagliptin on gastric emptying,Effect on satiety,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11342,NCT05874726,Tissue sample repository,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
11343,NCT01225939,Compare the pharmacokinetics (Cmax and AUC) of the oral solution and the oral solid formulation of AZD8329.,"Investigate the safety and tolerability of AZD8329 administered as two different oral formulations.(Safety variables: Adverse events, Vital Signs, Clinical chemistry, Electrocardiogram (p ECG))",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11344,NCT02540733,Barthel index,,,2012-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11345,NCT02727348,Blood pressure or heart rate changes more than 30% of baseline after spinal or block is considered significant,S-LANSS score in who receive FSNB versus SAB.,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
11346,NCT05343494,Fidelity - sessions attended,Intervention acceptability,Qualitative interviews,2022-04-04,COMPLETED,INTERVENTIONAL,['NA']
11347,NCT00763412,CRP,C-Peptide,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
11348,NCT01144065,Comparison of hair cortisol and testosterone levels between the patients with acute MI and the 2 control groups,Correlation of hair cortisol and testosterone with the burden of coronary atherosclerosis in the MI group,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11349,NCT06177054,insulin need per kg,Hyperechogenicity detected by ultrasound,,2023-12-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11350,NCT01182701,"Determine the effectiveness of a cognitive/behavioral intervention program in improving health outcomes of quality of life, general health, glycemic control, and depression.",Determine the effectiveness of a cognitive/behavioral intervention program in enhancing adherence to self-management strategies.,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
11351,NCT05597605,"Primary Initial Performance Objectives: Confirm the ability to (c) recharge the SENSOR, ED and CHARGER.",Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure,Exploratory Analysis: Histopathology analysis of the biopsy,2022-09-21,COMPLETED,INTERVENTIONAL,['NA']
11352,NCT00162344,Examine the prevalence of ischemic heart disease in population of patients with diabetes mellitus and atypical chest pain.,"Determine the relative value of ETT, Duke Treadmill Score (DTS), MPI, ejection fraction (EF), clinical risk factors, and C-Reactive Protein (CRP) values for identifying patients at risk for cardiac events.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11353,NCT03315728,Understand the influence of community context on the implementation of the QI Strategy as assessed by the Consolidated Framework for Implementation Research,Glycated hemoglobin (A1C),,2017-10-26,COMPLETED,OBSERVATIONAL,['NA']
11354,NCT01703611,HbAIc decrease,Weight change,Blood pressure,2012-12,COMPLETED,INTERVENTIONAL,['NA']
11355,NCT02460718,patient activation,composite measure of healthcare utilization,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
11356,NCT00256633,The primary outcome measure will be to determine if DNA characteristics are associated with CV risk in type 2 diabetes mellitus.,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
11357,NCT01443156,Work Schedule,Preventive care habits,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
11358,NCT01881828,"Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.",Change in Blood Pressure,Change in Vascular Dysfunction,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11359,NCT00612144,Adjusted mean changes in HbA1c from baseline to the last visit,Abnormal change from baseline in clinical laboratory,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11360,NCT03128229,Proximal tubular injury,Proposed mediators of tubular dysfunction and injury,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
11361,NCT01839448,Presence/absence of abnormal glucose metabolism,Oral glucose tolerance test results if necessary,Number of pregnancies,2014-03-27,COMPLETED,OBSERVATIONAL,['NA']
11362,NCT03534687,Quantify the change in basal circulating sRAGE after 12-weeks of supervised aerobic exercise training.,Quantify the change in insulin sensitivity after 12-weeks of supervised aerobic exercise training.,,2018-12-20,COMPLETED,INTERVENTIONAL,['NA']
11363,NCT01962506,Non-inferiority of a single-sampling strategy of hs-cTn and copeptin compared with the dual hs-cTn sampling for the early diagnosis of NSTE-ACS in a selected cohort of consecutive patients admitted at the Emergency Department.,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
11364,NCT03590158,Glycaemia,Objective sleep,Plasma proteome,2018-07-17,COMPLETED,INTERVENTIONAL,['NA']
11365,NCT03940300,Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by hemoglobin A1c.,Improve glycemic control measured by continuous glucose monitoring (CGM),Participant experience with the program evaluated by questionnaire,2019-01-28,TERMINATED,INTERVENTIONAL,['NA']
11366,NCT05046873,"AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose","Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 after a single dose",,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11367,NCT06295874,Patient Introduction Form,Patient Follow-up Form,Comfort Rating Scale,2023-01-05,RECRUITING,INTERVENTIONAL,['NA']
11368,NCT05456906,preventable hospitalizations and/or preventable emergency department visits,,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
11369,NCT00762957,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3']
11370,NCT05569876,Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice data quantified as area under the receiver operating characteristic curve (AUROC),Physiological parameters indicative of hypoglycemia,Change in cognitive performance across the glycemic trajectory.,2022-11-11,COMPLETED,INTERVENTIONAL,['NA']
11371,NCT05018585,Change in hemoglobin A1c (HbA1c).,Number of episodes per patient of diabetic ketoacidosis between baseline and Month 24.,,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE3']
11372,NCT01823510,Thrombus Formation,Platelet Reactivity Index (PRI),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11373,NCT02413762,Macrovascular complication of diabetes mellitus - prevalence and incidence,Progression to NAFLD or NASH,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
11374,NCT02855645,Plasma Blood Sugar,,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11375,NCT02923453,HbA1c,serum creatinine,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11376,NCT04535830,the between-group difference in mean HbA1c,"the between-group difference in mean time in other biochemical indexes,such as LDL-C,TC,TG and so on",,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11377,NCT02644759,Exogenous insulin dose,HbA1c level,,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11378,NCT02446054,the change of glycosylated hemoglobin (HbA1c),the patients' compliance questionnaire,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
11379,NCT00372463,Self-efficacy,,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11380,NCT04807218,Change in hemoglobin A1c (Percent),Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications,Acceptability of referral over time,2021-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11381,NCT05129891,"AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose","tmax, API,day10; time from the 10th dose to maximal observed plasma concentration of API",,2021-11-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11382,NCT00391040,"HbA1c decrease, reduction of hypoglycemia, acute complications","treatment satisfaction, ability for diabetes management, diabetes knowledge",,2003-11,COMPLETED,INTERVENTIONAL,['NA']
11383,NCT05734989,Number of patients referred to PCPs (Primary Care Providers) for CKD screening,,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11384,NCT02078635,Change from baseline of the maximum vessel wall volume of the carotid arteries,initiation of statin therapy,Palatability of the test / control diets,na,WITHDRAWN,INTERVENTIONAL,['NA']
11385,NCT00801164,"The primary study endpoints are periodontal evaluation including clinical attachment level, pocket depth, plaque index, suppuration and gingival index score.","Secondary endpoints include glycated hemoglobin A1c (HbA1c) and systemic biomarkers (LPS, TNF-a, CRP, IL-6, serum insulin and glucose). Tertiary outcome measures include staining, calculus, opportunistic Candida infection, and patient satisfaction.",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11386,NCT00772265,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam.",,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11387,NCT01779362,"Insulin Sensitivity, M/I",ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11388,NCT00490867,Forearm blood flow,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11389,NCT03386344,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With Adverse Events (AEs),,2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3']
11390,NCT04931836,Chain in Serum Short Chain Fatty Acids (SCFA),Body Composition,,2021-07-29,RECRUITING,INTERVENTIONAL,['NA']
11391,NCT01848990,Change From Baseline to 12 Months in HbA1c,Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11392,NCT04668703,change in diabetic retinopathy severity score (DRSS),"change in the aqueous concentrations of VEGF, PIGF, interleukin- (IL-) 2, IL-5, IL-6, and IL-8",,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
11393,NCT01950663,Per Patient Referral Accuracy,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
11394,NCT03821961,Change in Uptake value of 18F-FDOPA PET/CT from baseline,Change in MAQOL scores of questionnaire from baseline,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA']
11395,NCT00359762,Time to Treatment Failure,Hypoglycemia Rate Per Year in Period III,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11396,NCT02263677,Change in Liver steatosis,,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11397,NCT02089451,Area under the serum insulin aspart concentration-time curve (only for subcutaneous administration),Maximum observed serum insulin aspart concentration (only for subcutaneous and intramuscular administration),,2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE1']
11398,NCT03868683,Glucose [,Insulin,,2018-08-20,COMPLETED,INTERVENTIONAL,['NA']
11399,NCT01050218,Change From Baseline in Mean Pain Score on the Numeric Rating Scale (NRS).,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11400,NCT03903757,RNA sequencing analysisin adipose tissues,Linear regression to correlate epigenetic biomarkers with HOMA index,,2019-12,UNKNOWN,OBSERVATIONAL,['NA']
11401,NCT03859817,Variations in ketone levels,Changes in glycated hemoglobin (HbA1c),,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA']
11402,NCT05990374,Effects of different GLP-1 on blood glucose,Effects of different GLP-1 on body fat mass,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
11403,NCT02768948,number of differentiation marker,,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
11404,NCT00959595,Touch thresholds in the sole of the foot (Semmes-Weinstein monofilaments),fMRI,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11405,NCT01743599,Retrograde ejaculation (a minimum of a total of 1 million sperm in postejaculatory urine),Erectile dysfunction,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
11406,NCT05013008,Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers,,,2021-08-18,COMPLETED,INTERVENTIONAL,['PHASE2']
11407,NCT02610088,Vascular function assessed by Flow-mediated vasodilation (FMD),Carotid intima-media thickness (cIMT) assessed by ultrasound,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11408,NCT00916292,Safety and tolerability of a single dose of FGF-1 topically administered in normal volunteers given an artificial dermal wound,Serum levels of FGF-1 after topical administration,,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
11409,NCT00031200,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
11410,NCT02858076,E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline),Retinal Neovascularization on Clinical Exam,,2016-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11411,NCT00542698,increased physical activity,"BP, BMI, & HgA1c (a long term measure of blood glucose)",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11412,NCT02910141,HbA1c,Weight or BMI,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11413,NCT01852214,P2Y12 Reaction Units,Platelet Reactivity Index,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
11414,NCT01570751,Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period,Number of Adverse Events (AEs),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11415,NCT06073457,Anastomosis Patency,,,2023-11-06,RECRUITING,INTERVENTIONAL,['NA']
11416,NCT00753766,Percent of Screened Participants That Are Eligible and Choose Participation,Percentage of Participants Who Need to Return to the Operating Room,,2005-10,TERMINATED,INTERVENTIONAL,['NA']
11417,NCT02282254,Percentage of time of plasma glucose levels spent below 4 mmol/L,Total number of hypoglycemic events requiring treatment,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11418,NCT01527552,"Cmax, maximum insulin aspart concentration",Adverse events,,2002-11-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11419,NCT02251834,Blood Pressure,A1C,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11420,NCT03253237,Glycemic variability in individuals with type 2 diabetes mellitus in primary care measured by continuous glucose monitor device,,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
11421,NCT04892199,The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).,Insulin sensitivity and beta cell function,,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
11422,NCT04340908,Difference in NTproBNP between the treatment and control study arms,Post operative atrial fibrillation,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11423,NCT01985711,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in general self-efficacy,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
11424,NCT01339143,Glycemic Variability,hypoglycemia,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
11425,NCT01890122,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination),Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11426,NCT01302743,Decrease in LDL Cholesterol,,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
11427,NCT03458338,Point prevalence of chronic kidney disease measured by lab values,Risk factors for chronic kidney disease measured by lab values and questionnaire,,2010-12-08,COMPLETED,OBSERVATIONAL,['NA']
11428,NCT03078933,Wound Closure rate,,,2017-03-20,UNKNOWN,INTERVENTIONAL,['NA']
11429,NCT04725799,Measurement of Glucose Concentration,,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA']
11430,NCT03165786,Hypoglycemia Fear Scale Score (HFS_2),Glycemic variability,,2016-10-26,COMPLETED,INTERVENTIONAL,['NA']
11431,NCT03792685,"The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.",The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.,,2009-09-24,COMPLETED,INTERVENTIONAL,['NA']
11432,NCT00251680,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol,Physical Examination,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11433,NCT01553968,Exercise-induced changes in acetylcarnitine concentrations and dynamics of acetylcarnitine restoration after exercise,Blood plasma glucose,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
11434,NCT02663245,Glycaemic control measured by HbA1c,evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL),,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11435,NCT06067685,Correlation coefficient between triglyceride levels and birthweight,Correlation coefficient between triglyceride levels and cord c-peptide levels,,2023-08-10,RECRUITING,OBSERVATIONAL,['NA']
11436,NCT05487079,Number of distinct phenotypes of type 2 diabetes within this population,Rate of progression of vascular disease within this population,,2022-01-17,RECRUITING,OBSERVATIONAL,['NA']
11437,NCT04917393,Rate of SADEs,Change in Glycemic control - fasting glucose,,2021-09-13,RECRUITING,INTERVENTIONAL,['NA']
11438,NCT01988987,Result of an early postpartum 75-gram oral glucose tolerance test (GTT) result,Result of a postpartum 75-gram oral glucose tolerance test (GTT),,2013-02-22,COMPLETED,OBSERVATIONAL,['NA']
11439,NCT01801254,postprandial blood glucose and triglycerides,,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11440,NCT02149992,overall mean glucose,metabolic differences,steady state,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
11441,NCT02589210,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
11442,NCT01261052,Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity,Measurement of APD and FMPD/APD Interventions in Controlling Post-prandial Blood Glucose With Reduced Insulin Sensitivity.,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11443,NCT00151697,Body weight,adverse effects,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11444,NCT00991549,"a reduced percentage of the calories introduced in the form of fat of at least 6.6%, in absolute value, in at least 25% of the subjects","relation between weight loss and change in insulin sensitivity, beta cell function, and insulin-mediated suppression of plasma non-esterified fatty acids",,2004-12,COMPLETED,INTERVENTIONAL,['NA']
11445,NCT03773731,EC50 of insulin in terms of intraplatelet VASP (vasodilator-stimulated phosphoprotein)-phosphorylation: group differences after 12 weeks of training,Fatty Liver Index (FLI),,2019-01-04,UNKNOWN,INTERVENTIONAL,['NA']
11446,NCT00631345,Fasting Glucose,Physical Activity,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
11447,NCT05688631,Dietary antioxidant capacity,Total body water,,2021-01-03,COMPLETED,OBSERVATIONAL,['NA']
11448,NCT05628532,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Distress Scale (DDS),,2023-02-03,RECRUITING,INTERVENTIONAL,['NA']
11449,NCT02282046,implant complications,resonance frequency analysis,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
11450,NCT03985293,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16,Number of Participants With Treatment Emergent ECG Abnormalities,,2019-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
11451,NCT03795389,DM199 urine concentrations of KLK1,Urine Kidney Injury Molecule-1 (Kim1),Blood glucose,2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11452,NCT03038373,Evidence of clinically definition of remission of type 2 diabetes by by fasting blood glucose level < 7.0 mmol and HbA1c <6.5%,,,2012-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11453,NCT00482183,"The primary angiographic end point is in-stent luminal late loss, as determined by quantitative angiography.","Secondary end points include the percentage of in-stent stenosis of luminal diameter, the rate of restenosis.",,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11454,NCT01293461,"To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.",To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only),,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11455,NCT00204009,,,,1992-07,COMPLETED,OBSERVATIONAL,['NA']
11456,NCT02036450,Time to adjudicated stroke or systemic arterial embolism,Time to death by any cause,Change from baseline in quality of life,2014-01,COMPLETED,INTERVENTIONAL,['NA']
11457,NCT00629707,Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient),"Brain NAA/Creatine Ratio & Brain Lactate Measured by MR Spectroscopy, Cerebral Blood Flow & Oxygen Saturation Measured by MR Perfusion Weighted Imaging & Near Infrared Spectroscopy, Mental Status Evaluated by Glasgow Coma Scale Scores.",,2008-06,COMPLETED,INTERVENTIONAL,['NA']
11458,NCT01396954,,,,2007-11,UNKNOWN,OBSERVATIONAL,['NA']
11459,NCT02806830,Comparison of the overall scores of the ocular discomfort questionnaire after the 2 first intravitreal injection in naïve patients,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11460,NCT00698048,Vasopressin and copeptin levels,,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
11461,NCT00214474,Changes in Minutes of Vigorous Exercise,Changes in Body Mass Index (BMI),,2002-11,COMPLETED,INTERVENTIONAL,['NA']
11462,NCT03091517,Change in HbA1c levels (Effectiveness),Degree of user satisfaction with the GlycoLeap program (Maintenance),,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
11463,NCT02700334,Glycosylated Hemoglobin,Diastolic Blood Pressure,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11464,NCT00932087,Level of plasma isoprostane and lipoperoxides,TXA2 and PF4 levels after platelet activation of control platelet exposed to LDL,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
11465,NCT01978405,The changes of endothelium-dependent arterial dilation before and after contrast administrated,,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
11466,NCT03591900,number of thalassemic patients with impaired glucose tolerance,control of diabetic thalassemic patients on insulin pump,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
11467,NCT01051830,Quality of life,Activities of Daily life,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11468,NCT03816618,Ulcer size,,,2020-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11469,NCT00647439,,,,2008-03-27,COMPLETED,OBSERVATIONAL,['NA']
11470,NCT03570632,Rate of hypertensive disorders of pregnancy,Neonatal morbidity,Neonatal body composition,2019-07-08,RECRUITING,INTERVENTIONAL,['PHASE4']
11471,NCT01623388,Evaluate blood sugar variability in Type I diabetics for differences in epigenetic signatures between Type I diabetics with little glycemic variability as compared to those with more pronounced glycemic changes.,,,2013-01,WITHDRAWN,OBSERVATIONAL,['NA']
11472,NCT02473926,Change From Baseline in Objective Physical Activity at 4 Months,Change From Baseline in Physical Function at 4 Months,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11473,NCT04239586,Metabolic control of diabetes measured by HbA1c in mmol/mol,"Effect on secretion of incretin hormones, assessed by oral glucose tolerance tests",,2017-04-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
11474,NCT00246844,,,,2005-10-26,COMPLETED,OBSERVATIONAL,['NA']
11475,NCT04567550,To evaluate the effect of RGX-314 on DR by the Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at week 48,To evaluate the incidences of ocular inflammation following SCS RGX-314 administration,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2']
11476,NCT01447524,Change from baseline in insulin secretion at 7 days.,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11477,NCT01130727,flow-mediated dilation (FMD),plasma levels of flavonols,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11478,NCT00334113,7-Day Physical Activity Recall (PAR),,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11479,NCT03262363,Change from Renal Function at 6 months,,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11480,NCT00855439,Confirmed Clinical Neuropathy (CCN),Cardiac Autonomic Neuropathy,Intra-epidermal Nerve Fiber Density,2008-06,COMPLETED,INTERVENTIONAL,['NA']
11481,NCT00473382,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11482,NCT06286878,Platelet aggregation using ADP,Platelet aggregation using ASPI at 30 (± 5) days after study therapy,Analyze the primary objective of the study in the following pre-specified subgroups:,2021-12-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11483,NCT03585153,Pancreas Volume Index,Urinary C-peptide/creatinine,,2014-02-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11484,NCT02341261,Change in Quality of Life (NQOL-DN) Questionnaire Results,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
11485,NCT01694212,Change of Central Macular Thickness,IL-12 concentration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11486,NCT00005131,,,,1985-07,COMPLETED,OBSERVATIONAL,['NA']
11487,NCT05593081,Change in serum hemoglobin A1c level,The incidence of chronic complications of diabetes mellitus,,2022-05-20,RECRUITING,OBSERVATIONAL,['NA']
11488,NCT01755156,Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B),Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B),,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11489,NCT05910840,Change from Baseline Hemaglobin A1c (HbA1c) at 18 months,Cost effectiveness (QOL),"Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider",2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11490,NCT00575172,"Cardiovascular events 1)Sudden death 2)New development or recurrence of apoplexy or TIA 3)New development or recurrence of AMI or and angina pectoris 4)Newly developed ASO, amputation of leg due to ASO","1)Total mortality 2)Changes in the mean IMT of common carotid arteries 3)Changes in the pulse wave velocity (PWV) (rt & 1t baPWV), ABI",,2003-03,COMPLETED,OBSERVATIONAL,['NA']
11491,NCT04672655,Change in Hemoglobin A1c (HbA1c) over time,Change in Glucose Monitoring System Satisfaction Survey - Version: Type 1 Diabetes (GMSS-T1D),,2021-02-17,RECRUITING,INTERVENTIONAL,['NA']
11492,NCT01554618,Percentage of Patients Positive for Anti-Drug Antibodies (ADAs) to Exenatide up to Week 24,Plasma Exenatide Concentrations to Week 52 Among Patients Who Received Open-Label Exenatide (Treatment Period),,2011-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11493,NCT01469468,"If the data permit, terminal elimination half-life of simvastatin and simvastatin acid",,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11494,NCT02632877,assessing change of ulcerated area,mRNA levels of Matrix metalloproteinase-1 (MMP-1),,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11495,NCT01068743,Metformin PK Parameter Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities",Metformin PK Parameter Tmax,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11496,NCT06334042,Serum Chromium Level,Lipid Profile,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
11497,NCT03167684,Glycemic control (mean 24-hour and nocturnal glucose),Systemic inflammation,Subjective sleep quality,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
11498,NCT03708419,Disposition index,DNA analysis,,2018-06-04,COMPLETED,INTERVENTIONAL,['NA']
11499,NCT05205005,Glygocalyx integrity - perfused boundary region,Popliteal artery flow mediated dilation,,2022-05-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11500,NCT06236607,Glucose time-in-range (TIR) of 70-180 mg/dL,Diabetic Ketoacidosis events,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11501,NCT01060917,skin tissue glucose concentration,"serum and urine electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium, urea, osmolarity, pH, lactate, p(O2), standard bicarbonate, p(CO2), blood glucose concentration",,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11502,NCT05983289,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),Inhibition Rate of Dipeptidyl Peptidase 4 (DPP4) Activities following single dose administration,,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11503,NCT05548699,Daily stress levels over time,Alcohol misuse over time,Stressful life events,2023-05-02,RECRUITING,OBSERVATIONAL,['NA']
11504,NCT02030249,Bone mass,Muscle (handgrip) strength,Urinary N-terminal telopeptide,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
11505,NCT00565799,"1) insulin sensitivity, 2) beta cell function and 3) plasma markers of inflammation",Identify genes and proteins in adipocytes from obese patients that affect clinical presentation versus those that are affected by obesity for future study.,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
11506,NCT02316821,"Change in glomerular filtration rate (GFR) measured by inulin clearance after 16 weeks of study drug administration, compared to baseline GFR",Profiles of pharmacokinetics of plasma RTA 402 concentration: Trough (Pre-dose) and peak (2-4 hours post dose) concentrations of study drug at steady state,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11507,NCT00542620,Glycosylated Haemoglobin A1c (HbA1c),"Percentage of Children Assessing Insulin Therapy Injection Pain as ""Very Happy Face""",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11508,NCT03689608,Postprandial glucose AUC,Postprandial triglyceride,Change in autophagic flux (DIRECT-Fast4flux),2018-09-26,COMPLETED,INTERVENTIONAL,['NA']
11509,NCT02928016,Capillary blood glucose,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11510,NCT05430139,Reference Intervals,,,2022-10-31,RECRUITING,OBSERVATIONAL,['NA']
11511,NCT02749032,GLP-1 feedback inhibition,Incidence of Treatment-Emergent Adverse Events - Safety and tolerability,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11512,NCT03837405,diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous,Weight change,Mindfulness,2018-12-12,COMPLETED,INTERVENTIONAL,['NA']
11513,NCT02980978,A1c (Laboratory Assessment),,Aspirin Use (as Noted in EMR),2016-04,COMPLETED,INTERVENTIONAL,['NA']
11514,NCT00271700,- Lab glucose values (percent of routine glucose readings between 60 and 180 mg/dL),- Quality of insulin orders using explicit criteria,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11515,NCT01296633,Medication regimen knowledge,Patient-provider communication assessment,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
11516,NCT05259449,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from cardiorespiratory fitness,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
11517,NCT03428308,Number of follow-up visits,Change in blood cholesterol (blood test),Success of intersectoral cooperation,2018-04,UNKNOWN,INTERVENTIONAL,['NA']
11518,NCT01826370,Frequency of Adverse Events and Serious Adverse Events,Change From Baseline to Week 24 of Fasting Blood Sugar,,2012-05,TERMINATED,OBSERVATIONAL,['NA']
11519,NCT00362778,Glycemic control,High-sensitivity C-reactive protein levels,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11520,NCT03368807,Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM,Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA']
11521,NCT04137705,Assessment of repeatability (precision under the same conditions in the same subjects: 2 separate MRI acquisitions on the same scanner) of body composition and multiple organ metrics.,Assessment of the reproducibility (precision under different measurement conditions: same participants scanned on separate MRI scanners at both 1.5T and 3T) of multiparametric MRI for the assessment of body composition and multiple organ metrics.,Assessment of the mean differences in body composition and multiple organ metrics between healthy participants and those with type 2 diabetes acquired with multiparametric MRI.,2019-11-04,RECRUITING,OBSERVATIONAL,['NA']
11522,NCT01964963,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Blood Glucose,,2011-08-03,COMPLETED,OBSERVATIONAL,['NA']
11523,NCT01786941,Changes in Branched-chain Amino Acid Metabolism in Pre-Diabetes at Baseline and post-intervention,Changes in Insulin Sensitivity at Baseline and post-intervention,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
11524,NCT01651117,Change in Glucose Control (Stage 2: Non-mentors v. Mentors),Change in Depression Symptoms (Stage 2: Non-mentors v. Mentors),,2012-09-01,COMPLETED,INTERVENTIONAL,['NA']
11525,NCT02459353,Glycemic Variability (Standard Deviation),blood pressure DBP,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11526,NCT00962962,Fasting Plasma Glucose,Measures of Glucose control,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11527,NCT00155610,,,,na,TERMINATED,OBSERVATIONAL,['NA']
11528,NCT03921203,ApoB48 levels in blood and interstitial fluid,,,2019-04-17,COMPLETED,OBSERVATIONAL,['NA']
11529,NCT03964571,Reduction in size of wound,Reduction in size of wound,,2019-10-09,RECRUITING,INTERVENTIONAL,['NA']
11530,NCT03248206,Change from baseline result of Manual tactile test at 12 weeks,Change from baseline result of peak torque of shoulder internal rotation assessing by Bi-planar isokinetic dynamometer (BID) at 12 weeks,,2017-08-23,COMPLETED,INTERVENTIONAL,['NA']
11531,NCT04305431,Facilitators and Barriers,Second Phase Secondary Outcome,,2021-02-25,RECRUITING,INTERVENTIONAL,['NA']
11532,NCT02274103,HbA1c,"Adherence to diabetes treatment using the Diabetes Self Management Profile (DSMP) (Harris et al, 2001).",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11533,NCT02864914,Incidence of diabetic ketoacidosis (DKA),Incidence of severe genital infections,,2016-03-15,COMPLETED,OBSERVATIONAL,['NA']
11534,NCT05847413,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL at 12 weeks.,,,2020-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11535,NCT05125445,change in margianl bone level,,,2021-02-11,COMPLETED,INTERVENTIONAL,['NA']
11536,NCT00747409,postprandial blood glucose at the end of the study and its change from baseline.,diastolic myocardial function,,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
11537,NCT01365416,,,,2011-12-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11538,NCT00410033,"Insulin aspart specific, human insulin specific and cross reacting antibodies",Incidence of hypoglycaemic episodes,,1989-12,COMPLETED,INTERVENTIONAL,['NA']
11539,NCT02137863,"Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin",complete blood count,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11540,NCT00257257,Absolute change in HbA1C from baseline to Month 6.,"Fasting glucose, fasting insulin, C-peptide, HOMA analysis, body weight, HDL-cholesterol, triglycerides, blood pressure, safety (physical examination, vital signs, laboratory tests, adverse events).",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11541,NCT02856633,Successful diagnosis of patient's condition by Vitaliti software as compared to patient's Medical Record,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
11542,NCT03938389,Change from Baseline to 26 weeks in β-cell function (first-phase insulin secretion),Change in Central Aortic Pressure (mmHg) from Baseline to 26 weeks,,2020-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
11543,NCT00467376,Adverse events,"blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11544,NCT03070678,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion) after each dose with sotagliflozin,,2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11545,NCT00997191,Best Corrected Visual acuity,Central Macular Thickness,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11546,NCT03892265,"Prevalence of CVD risk factors and diseases and their association with social and environmental determinants in an established longitudinal cohort of ~3,000 Haitian adults",Incidence of CVD risk factors and CVD during ~7 years of follow-up and their association with social and environmental determinants,,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11547,NCT00943917,Mean Change in HbA1c (ITT),,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11548,NCT03682250,QT intervals corrected for heart rate,Percentage of time below 3.5 mmol/L,,2018-09-17,UNKNOWN,OBSERVATIONAL,['NA']
11549,NCT03237975,Short form of the sense of coherence questionnaire (SOC-13),Diabetes Self-Efficacy Scale (DSES),,2017-03-27,UNKNOWN,INTERVENTIONAL,['NA']
11550,NCT05932953,"Prevalence of children,with current skin intolerance (eczema symptoms measured by questionnaire) to an insulin pump and/or blood glucose sensor assessed by an autoquestionnary.",Search for risk factors associated with skin side effect,,2022-05-15,RECRUITING,OBSERVATIONAL,['NA']
11551,NCT03916016,Blood Pressure,Blood glucose concentration,,2015-12-09,COMPLETED,INTERVENTIONAL,['NA']
11552,NCT00700856,"A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularization",events of heart failure evaluated according to the American Heart Association and the American Diabetes Association consensus on glitazones and heart failure,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11553,NCT01172977,Functional outcome six months after the cerebral ischemia,Mortality,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11554,NCT01628341,Percentage of insulin-treated patients experiencing at least one hypoglycaemia (severe/non-severe),"Change in planned daily activities; work: effectiveness, missing hours or days for sick leave",,2012-05,COMPLETED,OBSERVATIONAL,['NA']
11555,NCT03303196,Mean Plasma Glucose Level.,,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
11556,NCT03864705,Plasma metformin levels,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
11557,NCT05952219,Cmax,,,2023-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11558,NCT04163874,Mean score of the Emotional Burden section of the Diabetes Distress Scale,Each participant's total insulin delivery,,2020-02-14,COMPLETED,INTERVENTIONAL,['NA']
11559,NCT03258242,Mean change from baseline in Chinese medicine syndrome score chart at 48 weeks,Frequency and severity of ocular and non-ocular adverse events over time,Change of retinal blood flow density,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
11560,NCT06147518,Percentage of patients with glycemic control at 24 weeks (HBA1c <7.0 %),Number of patients with Mortality/ Liver transplantation in both groups,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11561,NCT01116531,Concentration of O-desmethyltramadol,Concentration of O-desmethyltramadol,,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11562,NCT00849342,Change in body weight and BMI,Change in blood pressure,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
11563,NCT06044064,Incidence of PDAC at 3 years,• Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11564,NCT03542682,Time to Maximum Glucose Infusion Rate,Area Under the Curve for the Glucose Infusion Rate,,2018-05-30,COMPLETED,INTERVENTIONAL,['NA']
11565,NCT04439630,postprandial insulin concentrations,subjective appetite variables,,2020-07-01,COMPLETED,INTERVENTIONAL,['NA']
11566,NCT05764811,measure the severity of fatty liver via MRI,measure the body mass index (BMI) before and after the treatment,,2020-03-06,COMPLETED,INTERVENTIONAL,['NA']
11567,NCT02010684,Change From Baseline in Depression Measures at 6 Months,Change From Baseline in Self-Efficacy (Diabetes Empowerment Scale) at 6 Months,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
11568,NCT02251431,ACR,,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11569,NCT01875341,Primary end-point: change in daytime and night-time mean systolic blood pressure,plasma renin and aldosterone,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11570,NCT01249742,Patients' Evaluation of Quality of Care,Degree of use of intervention,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
11571,NCT04507061,Mean change in urinary albumin-to-creatinine ratio (UACR) from baseline to the average of multiple time points during treatment,Number of subjects with early discontinuations,,2020-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11572,NCT03898076,The difference of Predictive A1c level from CGM data with Real A1c level from EMR,,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
11573,NCT04451837,Hba1c,,,2020-09-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11574,NCT00634998,Changes in aldose reductase enzyme levels,Changes in Neuropathic Pain Scale (NPS) measurement and quantitative sensory testing in the lower extremities via touch discrimination with Semmes-Weinstein monofilaments and vibratory sensation testing,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11575,NCT03619356,Change in spectral THG strength distribution,Quantify the extent of diseases in spectral THG strength distribution,,2018-02-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11576,NCT05170880,HbA1c levels,,,2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
11577,NCT04345016,rate of diabetic foot ulcer recurrence in after phase of trial,rate of lower extremity amputations in after phase of trial,,2017-04-13,COMPLETED,INTERVENTIONAL,['NA']
11578,NCT01326442,body weight,Glucose homeostasis,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11579,NCT01865331,Frequency of adverse events (AEs),Area under the glucose infusion rate curve,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11580,NCT03698396,Incidence of procedure related adverse events,Insulin independence achieved,,2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11581,NCT02074384,Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports,,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
11582,NCT01978886,prevalence of known and unknown diabetes diabetes,diabetes influence on the prognosis of frozen shoulder,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
11583,NCT03878290,Resilience,Inflammatory burden,,2017-08-03,COMPLETED,INTERVENTIONAL,['NA']
11584,NCT05798442,Reduced BMI and visceral obesity,Reduced alcohol consumption and tobacco smoking,,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11585,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study),Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study),,2013-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11586,NCT02160639,"Change from baseline fasting glucose at 3, 9, 15, and 27 months","Change from baseline food security at 3, 9, 15, and 27 months",,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
11587,NCT01627340,Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies,Number of Subjects Reporting Any Serious Adverse Events (SAEs),,2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE4']
11588,NCT02614768,Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15%,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11589,NCT01630850,HbAlc <7.0% and an absence of severe hypoglycemic events,,,2012-05,RECRUITING,INTERVENTIONAL,['NA']
11590,NCT00476437,Incidence of hypoglycaemic episodes,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11591,NCT00814294,The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.,"To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels",,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11592,NCT01288729,Length of Wear of Infusion Site,,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11593,NCT02932436,difference in E/E' ratio between 12 weeks after baseline and at baseline,difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with HbA1c 6.5%-6.9%,association analysis for selected SNPs,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11594,NCT02217943,Composite Measure of Glycemic Control - Recurrence,Assess the changes in SF-36 Health Survey,,2014-07-01,COMPLETED,INTERVENTIONAL,['NA']
11595,NCT05549583,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",,2018-04-15,COMPLETED,INTERVENTIONAL,['PHASE1']
11596,NCT00568620,Insulin sensitivity,Incretin effect,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
11597,NCT05325710,FINDRISC score,,,2022-03-20,RECRUITING,INTERVENTIONAL,['NA']
11598,NCT00638560,PGC-1alpha mRNA expression in skeletal muscle PPARgamma mRNA expression in skeletal muscle Serum malondialdehyde concentration,body weight glucose infusion rate during the steady state of an euglycemic-hyperinsulinemic clamp VO2max,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11599,NCT00660075,"Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11600,NCT04365517,Biochemical parameter of acute lung disease,Cytokine-inflammatory profile,,2021-12-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
11601,NCT02757183,Usage and Adoption of the smart phone based mobile health application,Adherence to Prescribed Medication,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
11602,NCT03106727,Antenatal Care,CHW Retention,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
11603,NCT02502929,Biological risk for type 2 diabetes,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
11604,NCT01047813,Blood glucose levels,Stress levels,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
11605,NCT05414396,Changes in biomarkers,,,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11606,NCT04221399,Concentration of serum glucose,,,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
11607,NCT03626324,Successful Home-use Performance,,,2018-07-25,COMPLETED,INTERVENTIONAL,['NA']
11608,NCT02834663,Central Macular Thickness(CMT),Safety Parameters,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11609,NCT01862237,Left Ventricular Mass measured by echocardiography,Magnetic Resonance Imaging (MRI) parameters.,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
11610,NCT01869101,Diabetes prevention treatment decisions by physician,Subject initiation and persistence with diabetes prevention interventions,BMI,2013-06,UNKNOWN,OBSERVATIONAL,['NA']
11611,NCT01273311,,,,2010-12-22,COMPLETED,OBSERVATIONAL,['NA']
11612,NCT03534544,Youth and parent preferences for automated insulin delivery systems,Quality of life,,2018-08-23,COMPLETED,OBSERVATIONAL,['NA']
11613,NCT03229850,Insulin Levels,,,2021-02-01,SUSPENDED,INTERVENTIONAL,['NA']
11614,NCT04543422,Toronto Clinical Scoring System,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
11615,NCT01923597,Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.,Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.,Effect of Green Tea (epigallocatechin gallate) in the glomerular filtration rate in patients with diabetic nephropathy.,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11616,NCT02422043,self-efficacy (Self-efficacy of Diabetes Management),socio-cognitive profile,,2015-01-28,COMPLETED,INTERVENTIONAL,['NA']
11617,NCT00564018,C-peptide Area Under the Curve,Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
11618,NCT00323349,Scores on motivation to change behavior scale after the intervention,Scores on scales of perceived barriers to healthy lifestyle choices,,2003-04,COMPLETED,INTERVENTIONAL,['NA']
11619,NCT02374788,HbA1c (mmol/mol),Change in Smoking and snuffing habits,Hospital Anxiety and Depression Scale (HADS),2013-11,COMPLETED,INTERVENTIONAL,['NA']
11620,NCT03105219,Urinary albumin excretion,Retinol binding protein,,2017-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
11621,NCT02165579,"(1.) wound healing,",(5.) recurrent ulcers.,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
11622,NCT01515592,Antibody against liraglutide,24-hour profiles of serum insulin,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11623,NCT02179788,Peak Change in Milk Output,,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11624,NCT06184373,Comparative experience of OGTT and CGM,Medical care,Infant outcomes,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11625,NCT05719155,AUClast,,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
11626,NCT05414149,CRT,postoperative fibrovascular proliferation progression,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
11627,NCT04700254,DASS (Anxiety),Eating Attitudes Test (EAT-26),,2020-12-28,COMPLETED,OBSERVATIONAL,['NA']
11628,NCT00000160,,,,1972-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11629,NCT00493051,Effect of GAM501 on the incidence of complete ulcer closure,Safety and tolerance,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11630,NCT01470807,estimation of the failure rates of system components,percent time of active CTR,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
11631,NCT03398590,Acceptability,Calorie intake,,2017-04-12,COMPLETED,INTERVENTIONAL,['NA']
11632,NCT05131451,Number of Participants Who Get Screened With a Diabetic Eye Exam,Follow-up Rates With an Eye Care Provider,,2021-11-24,COMPLETED,INTERVENTIONAL,['NA']
11633,NCT01056497,insulin secretion and insulin sensitivity To determine whether ALA ameliorates or prevents impairment of insulin secretion and insulin sensi,To determine the role of oxidative stress and inflammation in the pathogenesis of lipotoxicity,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11634,NCT02631928,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11635,NCT01393860,Measure: Change in blood pressure,Measure: Change in potassium levels,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
11636,NCT02771093,Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values,Number of Participants Reporting One or More Treatment-emergent Adverse Events,,2016-09-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11637,NCT00135083,"To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.",,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11638,NCT00682149,Amelioration of antioxidative capacity in diabetic patients by polyphenol containig antioxidants,treatment of type 2 diabetes by polyphenol containing antioxidants,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
11639,NCT02552277,"Percent change in the epidermal nerve fiber density (ENFD) at 6 months, compared to baseline",Adverse Events (AEs),,2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE2']
11640,NCT03474939,Change in copeptin concentration,,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11641,NCT01997411,Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes,Time to Achieving ≥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes,Percentage of Participants With >= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11642,NCT01218061,The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population,"Relation between ""working hours and conditions"" and metabolic disease",,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
11643,NCT04073914,Change in Parent Stress using the Perceived Stress Scale (PSS),,,2017-06-29,COMPLETED,INTERVENTIONAL,['NA']
11644,NCT02048839,Type 2 Diabetes,Metabolic syndrome and cardiovascular morbidity,Obesity,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11645,NCT01946347,Changes of endothelial function (measured by EndoPat),Insulin sensitivity measured as glucose disposal during clamp,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
11646,NCT02084251,Safety/Adverse Event Outcome Measure,,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11647,NCT00869414,Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of > 180 mg/dL.,,,2009-07,TERMINATED,INTERVENTIONAL,['NA']
11648,NCT01305551,"Evidence of BE on single-dose pharmacokinetic parameters half-life (T-HALF) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.","Active metabolite of Saxagliptin, 5-Hydroxy Saxagliptin, from 5 mg Saxagliptin/500 mg Metformin XR FDC tablet & from 5 mg Onglyza administered together with 500 mg Glifage® XR in single-dose fed & fasted state pharmacokinetics in healthy subjects",,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11649,NCT00612040,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11650,NCT00283751,HbA1c,Change in body weight,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11651,NCT02779816,Visual analog scale for ease of use,,,2017-05-01,TERMINATED,INTERVENTIONAL,['NA']
11652,NCT01045590,Change from baseline in the ratio (IAAT:SAT) between the intra-abdominal adipose tissue area (IAAT) and abdominal subcutaneous adipose tissue area [SAT] after 12 months treatment with oral glibenclamide plus rosiglitazone compared to oral glibenclamide p,Comparisons will be made between glibenclamide plus rosiglitazone and glibenclamide plus placebo treatment groups on Change from baseline after 6 and 12 months treatment with respect the following,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11653,NCT03785301,HbA1c,FGM accuracy,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA']
11654,NCT04073576,Performance of the AHCL system,Safety of the AHCL system,,2019-05-20,UNKNOWN,INTERVENTIONAL,['NA']
11655,NCT04326569,Copeptin dosage,,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
11656,NCT00931125,Efficacy of preoperative intravitreal ranibizumab,Retinal circulation integrity.,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
11657,NCT03340831,Change in hypoglycemic events,Change in Hypoglycemia Confidence PRO scores,,2017-10-20,UNKNOWN,OBSERVATIONAL,['NA']
11658,NCT04261738,Hba1c,Glucagon,,2022-09-02,RECRUITING,INTERVENTIONAL,['NA']
11659,NCT00654745,Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment,Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11660,NCT02297399,Tolerability of the bowel preparation (analogue visual scale),Adverse events,,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11661,NCT03099837,Influence of prenatal and early postnatal factors on child health,,,2013-01-10,UNKNOWN,OBSERVATIONAL,['NA']
11662,NCT02206568,Pharmacokinetics of URAL,Number of subjects with adverse events,,2014-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11663,NCT02355158,Summary of Neuropathic Pain Symptom Inventory (NPSI),,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11664,NCT00842075,HbA1c Value After 28 Days,Weight Change After 28 Days Intervention Period,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
11665,NCT01497574,Area under the insulin concentration curve (AUC),Adverse events,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11666,NCT03441750,Rate of newly diagnosed diabetes,,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE4']
11667,NCT02175732,HbA1c,Depression,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11668,NCT04090580,Impact of dapagliflozin in glycemic variability,Impact of dapagliflozin in waist circumference,,2019-08-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
11669,NCT00982293,The primary outcome measure is the improvement in Subject's hemoglobin A1c level after 13 weeks of treatment compared to baseline.,,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
11670,NCT01014832,Frequency of hypoglycemia,,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
11671,NCT00085800,,,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
11672,NCT00351585,Durability of this effect after a 2-week washout,Chance from baseline in glucagon secretion at 12 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11673,NCT02135068,Nadir blood glucose levels during exercise,Mean daytime and nighttime glucose values,,2015-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11674,NCT00985361,Hemoglobin A1c,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
11675,NCT01356953,Blood Pressure - Ambulatory blood pressure monitoring (ABPM),,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
11676,NCT00790660,Evaluation of safety through clinical safety labs and adverse events,Evaluation of routine PK and PD parameters,,2008-10-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11677,NCT05557227,"Time to hypoglycemia Secondary endpoints: Blood glucose variability, volume of intravenous glucose needed to maintain glucose above 5 mmol/l, respiratory exchange ratio.",Time in Range,,2022-12-15,RECRUITING,INTERVENTIONAL,['NA']
11678,NCT03588234,Food literacy level,Fast food consumption,,2018-06-28,COMPLETED,OBSERVATIONAL,['NA']
11679,NCT05006508,Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up,Change of Patient Health Questionnaire 9-item scale,,2021-08-16,RECRUITING,INTERVENTIONAL,['NA']
11680,NCT06329882,Change in glycemic profile,,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11681,NCT00189774,,,,na,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11682,NCT05445284,Retention feasibility,Diabetes-related emergency department visits,,2023-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11683,NCT02423850,Wound healing change quantified using digital imaging method,Wound duration is compared to outcome of the wound,Quality of life (Questionaires) using 36-Item Short Form Survey (SF-36) is compared to outcome of the wound,2015-08,COMPLETED,OBSERVATIONAL,['NA']
11684,NCT01755468,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,insulin sensitivity,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11685,NCT02102737,Correlation between measure of insulin resistance measurement by scintigraphy and hyperinsulinemic euglycemic clamp,strain by speckle tracking echocardiography,,2014-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
11686,NCT00388050,"Treatment Action, adherence",Acceptability,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
11687,NCT01892124,Change in Body Mass Index,Changes in Blood Pressure,Changes in Food Habits,2013-11,COMPLETED,INTERVENTIONAL,['NA']
11688,NCT03106480,Prevalence of hypertension,Prevalence of sub-clinical atherosclerosis,,2016-10-06,UNKNOWN,OBSERVATIONAL,['NA']
11689,NCT01855399,Percent Glycosylated Hemoglobin,,,2014-09-09,COMPLETED,INTERVENTIONAL,['NA']
11690,NCT01369082,Duration of sustained islet allograft function,Donor-specific alloantibodies,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
11691,NCT00240383,"To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2","To assess, after 12 and 24 weeks of oral administration of double-blind therapy, the percent change from baseline in fasting lipids (total cholesterol,low density lipoprotein cholesterol,HDL-C, TG, non-HDL chol",,2002-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11692,NCT02988011,Gene expression in adipose tissue,Epigenetic changes assessed as DNA methylation,,2016-02-28,UNKNOWN,INTERVENTIONAL,['NA']
11693,NCT04016662,CGM Measured Time <70 mg/dL,Hypoglycemia Unawareness,Patient Reported Questionnaires,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
11694,NCT00862849,Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]),Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11695,NCT01649167,,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
11696,NCT02622113,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Percentage Change in Body Weight,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11697,NCT01318564,Patients' Adherence to Unit Dose Packaging Devices,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
11698,NCT00213213,"- Infant pain score during the newborn screening test, assessed by the Premature Infant Pain Profile (PIPP), or individual parameters of PIPP (facial grimace, heart rate, oxygen saturation)",- Serum Glucose concentrations in infants of diabetic mothers,,2003-07,UNKNOWN,INTERVENTIONAL,['NA']
11699,NCT04025281,Endothelial Function (EF) Assessment,Office Blood Pressure,,2019-07-09,COMPLETED,INTERVENTIONAL,['NA']
11700,NCT04161859,Prevalence of the use of nutraceutical in clinical practice,,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
11701,NCT02695121,Incidence of bladder cancer,Incidence of compsite cancer outcomes,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
11702,NCT02834923,Sugar-sweetened beverages,Weight,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
11703,NCT05264727,Change in Glucagon Suppression (G50) caused by amino acids vs. saline,glucagon suppression (G50) is greater in obese compared to lean people without T2DM,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE4']
11704,NCT04881890,Adherence with food tracking,Change in body weight per participant over the study period,Change in physical symptoms,2020-10-05,COMPLETED,INTERVENTIONAL,['NA']
11705,NCT02506296,Difference in response to a standard DPPIV therapy,differences in time spent in hypoglycaemia,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
11706,NCT01146678,Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax),Time to GIRmax (GIR-Tmax),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11707,NCT01408628,Frequency of Hypoglycemia,Severity of Self-reported Hypoglycemia,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
11708,NCT01784211,Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability,Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11709,NCT02419859,Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood),Hypoglycemic events,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11710,NCT01019486,Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.,Myocardial Perfusion Index,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11711,NCT03697109,"In all patients, assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.",In patients with uncontrolled hypertension the mean change in SBP or DBP from Baseline to visit OL22/ET,,2018-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11712,NCT03077997,Diabetes Distress (As measured by the Diabetes Distress Scale),EuroQol 5D5L,,2017-03-15,TERMINATED,INTERVENTIONAL,['NA']
11713,NCT00012649,,,,na,COMPLETED,OBSERVATIONAL,['NA']
11714,NCT06075121,Blood sugar,,,2023-06-12,RECRUITING,INTERVENTIONAL,['NA']
11715,NCT06150508,Lipid profile,Lifestyle questionnaire,Satisfaction rate,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11716,NCT01623648,Plasma glucose,Change in body weight,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
11717,NCT02790892,Decrease diabetes related distress,Increase emotional,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11718,NCT05275803,Microorganism,IL-1β、IL-6、TNF-α,,2023-06-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11719,NCT00063128,test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c,assess the impact of practice inhalations on inspiratory flow parameters (peak inspiratory flow rate [IFR] and total inspired volume [TIV]) achieved by patients using the insulin inhaler following training with the DFU,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11720,NCT04871958,Blood glucose Time-In-Range (TIR) during hospital stay,Accesses to the isolation room,,2021-03-19,TERMINATED,INTERVENTIONAL,['NA']
11721,NCT02871089,Area under the meal stimulated C-peptide curve (AUC) during a mixed meal tolerance test (MMTT),Lipid profile,Qualitative Human Factor Assessment,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11722,NCT02666430,Change in Hemoglobin A1c (HbA1c) From Baseline,Change From Baseline in Cross-Reactive Insulin Antibody - Lantus Assay,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11723,NCT00721019,Total body insulin sensitivity,Glycerol turnover and free fatty acid concentrations,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
11724,NCT05298163,Albuminuria,Calcium level,,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
11725,NCT01019642,"Insulin resistance, measured by HOMA-IR index",Serum 25-OH-vitamin D3 levels,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11726,NCT05180604,The Patient Health Engagement score after intervention at 6 months,"The change Trajectory of Cholesterol level from baseline to after the intervention at 3, 6 and 12 months",,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
11727,NCT00099320,Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose,Changes in lipids between Baseline and Week 16,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11728,NCT02027740,Change in LDL-c,HbA1C,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11729,NCT05969106,Incremental Cost Efficiency Rate (ICER),,Glucose control at start of the study,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
11730,NCT00981448,Change in acute insulin response from IVGTT.,change in urinary zinc,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11731,NCT05846191,Mean different in concentration of serum pentraxin-3 and high sensitive CRP levels in study groups.,,,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11732,NCT02914821,Sugar-Sweetened Beverages Sold by Universal Product Code (UPC),Changes in types of beverages purchased,,2016-09-01,TERMINATED,INTERVENTIONAL,['NA']
11733,NCT00980356,To assess whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed NODAT as judged in OGTT 3 months after treatment start compared to placebo.,To assess differences in the change in HbA1c and fasting plasma glucose after 3 months after treatment start and to assess the safety and efficacy of Vildagliptin in renal transplanted patients.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11734,NCT01121289,Area under the serum NN1218 concentration-time curve,Area under the serum NN1218 concentration-time curve,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
11735,NCT04226846,Comparison between Bios device readings and glucose values,,,2019-12-09,UNKNOWN,OBSERVATIONAL,['NA']
11736,NCT01730885,"Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal",,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11737,NCT00389415,Adverse events profile after 52 weeks of treatment,Change from baseline to endpoint in body weight at 52 weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11738,NCT02590822,Increase in circumferential PEDSR rate as measured by CMR at 12 weeks.,Exercise Questionnaire,,2015-10-02,RECRUITING,INTERVENTIONAL,['NA']
11739,NCT00380913,The Average Pain Score at target site.,Safety will be assessed through the collection of AEs and vital signs.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11740,NCT00299871,HbA1c levels at baseline and endpoint (at 13 weeks).,"Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon.",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11741,NCT03257228,Insulin like growth factors in patients with OLP and diabetes mellitus,,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA']
11742,NCT05420714,Average change in glycemic control 3 months after Pro-CGM use,Percentage of positive patient response to the Pro-CGM Questionnaire,,2022-08,WITHDRAWN,INTERVENTIONAL,['NA']
11743,NCT03665350,Change in blood glucose variability,Changes in Hemoglobin A1c (HbA1c).,,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11744,NCT04331444,"Difference between change in TIR (3.9-10 mmol/l) in percent, assessed via blinded CGM device, between CGM group (A) and SMBG group (C)",Difference between number of participants using CGM vs. not using CGM increasing 5 % or more in TIR,Evaluating which blood glucose measured by SMBG best reflect TIR,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
11745,NCT03532620,Change from baseline in hemoglobin A1c levels,Changes from baseline in carotid intima-media thickness,Incidence of adverse events (AEs),2018-08-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11746,NCT01515059,Glycaemic shift,Change in palatability via VAS,,2012-09,TERMINATED,OBSERVATIONAL,['NA']
11747,NCT02220907,Number of Participants With Adverse Events,Percentage Change in Body Weight From Baseline,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11748,NCT06180616,Body weight,FIB-4,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11749,NCT04515745,Ever applied for public disability program benefits (Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI)),Application for Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI) benefits.,Ever participated in labor force conditional on enrollment in disability programs.,2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
11750,NCT03146156,Neonatal adiposity comparison between intervention and usual care group,Maternal metabolic status,,2017-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11751,NCT01104168,prevalence of diabetes,evaluate the impact of quality of care and glycemic control on clinical outcome in elderly subjects,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
11752,NCT05812547,To evaluate the average change in blood glucose levels with the use the Lumen device,To evaluate the change in need for neonatal intensive care unit (NICU) admission,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11753,NCT05770076,Changes in fasting plasma glucose (FPG) level,body mass index (BMI),,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
11754,NCT03784612,Change in dietary intake,Blood pressure,Change in perceived social support from family and friends for healthy eating habits,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
11755,NCT00411554,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2 Hour Postprandial Glucose at Week 12,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11756,NCT04068285,walking speed,,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
11757,NCT05920434,Pain severity,Vibration sense,The quality of life,2020-07-19,COMPLETED,INTERVENTIONAL,['NA']
11758,NCT00361023,,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
11759,NCT05525572,Changes in Endothelial Progenitor Cell Colony Forming Units (EPC-CFUs),Incidence of Serious Adverse Events (SAEs),,2024-06-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11760,NCT04210609,Wound closure rate at 20 weeks,"Time to 50%, 75%, 100% wound closure",,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
11761,NCT02938806,Analysis of gut microbial composition and diversity by 16S rRNA sequencing,Analysis of urine metabolite concentrations measured by mass spectrometry,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
11762,NCT01601990,Change of HbAlc,HbA1c Responder Rate,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11763,NCT03196362,Remission rate,Adverse events,,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11764,NCT04277117,Change in Hemoglobin A1C (HbA1c),Medication underuse due to cost (2 items),,2022-12-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11765,NCT01973231,Change in Glycosylated Haemoglobin (HbA1c) From Baseline,Number of Treatment Emergent Adverse Events (TEAEs),,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11766,NCT05110703,Examination of the effect of daily use of a prebiotic fiber meal replacement (PFMR) shake on quality of life [Time Frame: Baseline to 12 weeks],Changes from baseline on short-chain fatty acid synthesis from baseline after daily use of PFMR shakes. [Time Frame: Baseline to 12 weeks],,2021-10-11,COMPLETED,INTERVENTIONAL,['NA']
11767,NCT00790439,Level of Stimulated C-peptide at 90-minutes in Response to a Mixed-Meal Tolerance Test (MMTT),Incidence of Worsening Retinopathy,,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11768,NCT01690481,MRI brain volumes,Neuropsychological scores,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
11769,NCT04450394,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2020-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11770,NCT00742976,change in weight; change in extracellular volume,"sodium excretion in urine, 24 hour blood pressure, body composition change,urine osmolality, urine albumin excretion, GFR, HbA1c, Blood lipid profile, NT-proBNP, plasma Albumin, Plasma metanephrines, aldosterone, active renin, angiotensin II",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11771,NCT02915263,Change in Neuropathic Pain Severity as Measured by the Pain Visual Analogue Scores (VAS).,Change in Autonomic Neuropathy as Measured by Standardized Autonomic Nervous System Testing.,,2017-09-11,TERMINATED,INTERVENTIONAL,['PHASE2']
11772,NCT05252793,Healthy Lifestyle Behaviors Scale II Score Change,Self-Efficacy Questionnaire,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
11773,NCT00699023,Incremental AUC after a fat-rich meal of cholesterol concentration in chylomicron and VLDL fractions,Concentration and Composition of different lipoprotein subclasses in the fasting condition.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11774,NCT03946631,Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.,,,2019-08-20,TERMINATED,OBSERVATIONAL,['NA']
11775,NCT04962048,Change of toleration / wellbeeing due to intervention of PSNP with Numeric Rating Scale,Change of microcirculation with thermal imaging (TH),,2021-05-28,TERMINATED,INTERVENTIONAL,['NA']
11776,NCT02723019,Number of Patients With at Least 1 Hospital Readmission Within 180 Days After Enrollment,Number of Outpatient Visits Over the Past 6 Months - Patient-reported,,2016-07-14,COMPLETED,INTERVENTIONAL,['NA']
11777,NCT02280863,"Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour, and no Ketonemia, Seizures, or Loss of Consciousness","Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Integrated System Interface and Adolescent Cohort",,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11778,NCT02905487,Blood levels of C- Reactive Protein in mother and her child,Blood level of C-peptide in mother,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
11779,NCT01832935,Number Of Hypoglycemic events,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11780,NCT00888719,Change in HbA1c before and after treatment,"Triglyceride, LDL-cholesterol and HDL-cholesterol change",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11781,NCT00374907,Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12,Insulin Secretion Rate AUC During IV Hyperglycemic Clamp - Percent Change From Baseline at Week 12,Marked Laboratory Abnormalities - During ST + LT Treatment Period,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11782,NCT06227247,Receipt of intervention (Exercise Session Completion),,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
11783,NCT01522807,The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Elimination of half-life (t ½ ) as data permit.,Changes in plasma glucose and insulin due to single doses of three formulations of PF-05190457 will be estimated.,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11784,NCT01156779,Assessment of safety,Pharmacokinetics and Pharmacodynamics,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11785,NCT03370484,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11786,NCT05193578,HbA1c (mmol/mol),Absolute change in systolic and diastolic blood pressure (mmHg),,2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2']
11787,NCT05998837,Biopsy changes in the expression and location of senescence markers by immunohistochemistry,Outcomes of blood presssure control,,2021-04-13,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11788,NCT01682954,Body Weight,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
11789,NCT01342939,Incretin effect,Plasma glucagon response,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
11790,NCT05253521,The change in the frequency / absolute number of circulating ALDHhiSSChi granulocyte precursor cells between individuals of South Asian origins and White individuals of European origin,The change in the frequency / absolute number of circulating ALDHhiSSClo cells with primitive provascular progenitor cell phenotype between individuals of South Asian origins and White individuals of European origin,Changes in the concentration of serum inflammatory markers individuals of South Asian origins and White individuals of European origins,2022-01-08,COMPLETED,OBSERVATIONAL,['NA']
11791,NCT03183804,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,,2015-12-29,COMPLETED,OBSERVATIONAL,['NA']
11792,NCT01654120,Change from baseline in HbA1c at six months,GlycoMark,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11793,NCT00220337,"Number of Subjects With Urine Protein Status 'Positive +++' at Baseline, Categorized by Urine Protein Status at Last Visit",Change in Quality of Life From Visit 2 (Baseline) to Termination Visit,,2004-12-21,COMPLETED,INTERVENTIONAL,['PHASE3']
11794,NCT03178591,The average of systolic blood pressure at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group.,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11795,NCT04183868,Change of myocardial metabolic rate of glucose,Change of lipid profile,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11796,NCT03531944,Change in HbA1c level,Cost effectiveness analysis,,2018-06-06,COMPLETED,INTERVENTIONAL,['NA']
11797,NCT00687960,Post-Prandial Metabolism,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
11798,NCT06083116,"Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max",Adverse events,,2019-08-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11799,NCT03616275,Changes from Baseline Autonomic function (Heart rate variability) at 3 and 6 months,Changes from Baseline salivary cortisol at 3 and 6 months,,2017-10-17,COMPLETED,INTERVENTIONAL,['NA']
11800,NCT02881164,Satiety,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11801,NCT05766215,Body Mass Index,Adherence to diabetes treatment,Demographical information,2023-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11802,NCT00160056,,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
11803,NCT05319496,Change in HbA1c,Hospital admissions,,2022-10-05,COMPLETED,INTERVENTIONAL,['NA']
11804,NCT01410097,Short Physical Performance Battery (SPPB) Score,Modified Mini-Mental Status Exam (3MS),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11805,NCT01464073,body fat mass reduction,biological parameter,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
11806,NCT03111433,change in soluble interacellular adhesion molecule level,,,2017-03-19,COMPLETED,INTERVENTIONAL,['PHASE2']
11807,NCT01122108,"Patient Acceptability of Colesevelam HCl Powder for Oral Suspension vs. Generic Cholestyramine Via the Bile Acid Sequestrant Acceptability (BASA) Scale, Based Upon an Anticipated Equivalent Cholesterol Lowering Doses of Each Comparator Drug.",,Weighted vs. Unweighted Composite BASA Scale Scores,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11808,NCT03838380,hemoglobin A1c levels,Mode of delivery,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
11809,NCT02343146,Glycemic Control/HbA1c,Child eating as measured by Remote Food Photography by the parent,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11810,NCT05872620,Mean Percent Change from Baseline in Body Weight,Mean Change from Baseline in Short Form 36 Version 2 Health Survey Acute Form (SF-36v2) Domain Scores,,2023-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11811,NCT03646812,Insulin,,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA']
11812,NCT01175473,Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28,Percentages of Patients by Ranges of Oxyntomodulin Levels,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11813,NCT03470415,epicardial fat thickness measurement,Electrocardiogram,,2018-05,UNKNOWN,OBSERVATIONAL,['NA']
11814,NCT01231178,Body weight,Body composition,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
11815,NCT03073577,Serious adverse event morbidity,Beta-2 score,,2017-02-17,RECRUITING,INTERVENTIONAL,['PHASE1']
11816,NCT01841229,Glycated hemoglobin (HbA1c),Homeostasis model assessment of insulin resistance (HOMA-IR),,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
11817,NCT00297063,HbA1c change from baseline at Week 28.,"Efficacy variables (changes from baseline in FPG, fasting insulin, HOMA-IR and HOMA-beta) at stipulated date in each treatment group.",,2006-01-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11818,NCT03909802,Wound size,,,2019-07-06,COMPLETED,INTERVENTIONAL,['NA']
11819,NCT05994651,The effect of using the tidal model on the psychological well-being of individuals with diabetes will be evaluated.,,,2023-07-10,COMPLETED,INTERVENTIONAL,['NA']
11820,NCT02391558,"Comparison between examination techniques on the detection of morphological changes in the retina (such as vessels morphology, vascular ischemia, retinal neovascularization, choroidal neovascularization, and other vascular abnormalities).",,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
11821,NCT03746093,Changes in HbA1c levels from baseline to visit 2 and 3,Changes in fasting serum triglycerides from baseline to visit 2 and 3,,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA']
11822,NCT04432025,Proportion of patients reaching end point for glycemic control,Change in quality of life,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
11823,NCT03888053,Presence of anti-BB-101 antibodies,To evaluate plasma concentration of BB-101,,2018-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11824,NCT03182842,Time within 3.9 and 10 mmol/l,,,2017-06-17,COMPLETED,INTERVENTIONAL,['NA']
11825,NCT01447940,HbA1c measured at 12 months in Meos ePoral group versus conventional care group. Non-inferiority level is defined at a 0.15% threshold for an expected HbA1c of 8.5% at 12 months,"Qualitative analysis by semi-structured interviews, then quantitative survey by questionnaire",,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11826,NCT05845190,homocystiene,cholestrol,,2022-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11827,NCT01756716,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11828,NCT03617146,Diabetes distress score,"Self-care behaviors (medication adherence, dietary practices, and physical activity behaviors)",,2018-06-15,TERMINATED,INTERVENTIONAL,['NA']
11829,NCT02626936,Percentage of time below 4.0 mmol/L,Total glucagon delivery,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11830,NCT01026103,Proportion of Patients With an Uneventful Creation of a Functional Staple Line,Incidence of Serosal Tearing,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11831,NCT00219089,Change from baseline in mean sitting diastolic blood pressure after 8 weeks,Diastolic blood pressure less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11832,NCT05197829,Problem Areas in Diabetes,Number of Sensor Checks per Day,,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11833,NCT05592860,HbA1c,Change in blood pressure,,2021-07-10,COMPLETED,INTERVENTIONAL,['NA']
11834,NCT02451722,Reduction of Peak Pressure,Comfort of wear,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
11835,NCT00762242,change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements,,,2007-05,TERMINATED,OBSERVATIONAL,['NA']
11836,NCT03842475,Diabetes remission (complete),Change in ectopic fat,Changes in gut microbiome,2018-10-01,RECRUITING,OBSERVATIONAL,['NA']
11837,NCT00394407,blood glucose control,inflammatory markers,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11838,NCT04717050,Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -metabolic syndrome (MSY),Metabolic Dysregulation (MetD) Status During 4 month follow up period - metabolic syndrome (MSY),,2021-08-12,RECRUITING,INTERVENTIONAL,['NA']
11839,NCT04150107,Average Exogenous Total Insulin Compared to Baseline,Daytime Low Blood Glucose Index (LBGI) Compared to Baseline,,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
11840,NCT05342012,Pixel wise quantification of fat fraction will be performed from fat and water maps.,Biomarkers - cGMP,,2022-06-30,COMPLETED,INTERVENTIONAL,['NA']
11841,NCT02028078,Tracer to Tracee Ratio (the absolute relative difference ARDi ),Tracer to tracee Ratio,Time to reach each hypoglycaemic level,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11842,NCT00614939,Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF),Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Moderate Renal Impairment Subgroup,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11843,NCT03541096,Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in glycemic control after winter swimming,,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA']
11844,NCT02411006,Medication refills,LDL cholesterol,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11845,NCT01551446,Change in renal perfusion,Change in total body water,,2012-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11846,NCT04123587,the list of previously found candidate variants which are observed in the slufonylurea-dependent patients but not in the non-dependent patients,,,2019-09-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11847,NCT02630706,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation),Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation),,2015-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
11848,NCT03037190,Preservation of beta cells function,Prevention of Celiac DIsease,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
11849,NCT02211742,postprandial glucose homeostasis,,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11850,NCT06311019,Change in Haemoglobin A1c,Fraction of patients with increased number of bolus insulin per day,Diabetes Treatment Satisfaction Questionnaire (DTSQ),2024-02-27,RECRUITING,INTERVENTIONAL,['NA']
11851,NCT06235086,Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb).,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11852,NCT04763746,"Train Lifelight algorithms on a more diverse population, including patients with Fitzpatrick scale 1, 4, 5 and 6 skin tones.",,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
11853,NCT05885828,Blood glucose profile,Changes in lipid metabolism,,2023-07-17,RECRUITING,INTERVENTIONAL,['NA']
11854,NCT03624023,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change of Wound Volume for Individual Subject Measured by 3D Camera and Analysis Software up to 12 Weeks.,,2019-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11855,NCT02888951,Volume of Gastric Contents,"Episodes of intra-operative regurgitation, vomiting or aspiration",,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
11856,NCT04419337,HbA1C,insulin resistance,,2019-09-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11857,NCT02210871,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs),,2014-08-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11858,NCT02791204,Assessment of lower extremity skeletal muscle perfusion in healthy control subjects compared to patients with peripheral arterial disease and diabetes using quantitative SPECT/CT imaging.,,,2016-05,RECRUITING,OBSERVATIONAL,['NA']
11859,NCT04298424,HbA1C,Self-Efficacy Score,,2020-02-14,UNKNOWN,INTERVENTIONAL,['NA']
11860,NCT01369277,Renal clearance (CLr),,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11861,NCT06051058,To determine the effect of the Care Transitions App on post-discharge adverse events,To determine the effect of the Care Transitions App on the 30-day readmission rate,,2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11862,NCT00950599,Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort,"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 & 100 mg Cohort",,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11863,NCT05773183,To compare differences in steroid metabolomics in men with prostate cancer pre- and post-androgen deprivation therapy (ADT),To compare differences in metabolic phenotype in (i) hypogonadal men compared to healthy men (ii) hypogonadal men pre and post testosterone replacement therapy (iii) men with prostate cancer post initiation of Androgen Deprivation Therapy,,2023-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11864,NCT04018326,Final UCVA,,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA']
11865,NCT00810589,"Duration of action, time from onset of action until end of action","GIRmax, maximum glucose infusion AUCGIR,0-32h, AUCGIR,0-12h, AUCGIR,12-32h, tinf=0, Cmax,ins, tmax,ins, AUCins,0-24h AUCins,0-∞ AUCins,0-12h AUCins,12-24h",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11866,NCT00814372,Change in HbA1c from baseline and compared to placebo,Change in fasting plasma glucose (FPG) from baseline and vs. placebo,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2']
11867,NCT01453842,Plasma GLP-1,Plasma paracetamol,,2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11868,NCT00654056,Insulin sensitivity,Changes in insulin signaling proteins?,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
11869,NCT00680849,"Food Frequency Questionnaire for Fruits, Vegetables and percent calories from fat (FFQ) by Kristal and colleagues","Lipids, weight loss",,2003-12,COMPLETED,OBSERVATIONAL,['NA']
11870,NCT03331614,Reduction in Subjective Pain,Quality of Life,,2017-10-15,UNKNOWN,INTERVENTIONAL,['NA']
11871,NCT06187285,Mean blood glucose concentration,Glycated hemoglobin,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
11872,NCT00488033,"Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina",Number of Participants With Limb Amputation or Peripheral Vascular Revascularization Procedure,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
11873,NCT01508923,24-hour glucose profiles after three fixed meals,Adverse events,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11874,NCT02284893,Mean Change in HbA1c,Mean Change in Fasting Plasma Glucose (FPG),,2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11875,NCT01147627,the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks,Safety and Tolerability in Different Groups,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
11876,NCT04745572,Changes in QUICKI index,Diet Intake and Physical Activity Monitoring,,2021-05-14,COMPLETED,INTERVENTIONAL,['NA']
11877,NCT04957914,Incidence of Documented Hypoglycemia,,,2021-07-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11878,NCT05243589,"WHO Quality of Life Scale (WHOQOL BREF)( assessing change in quality of life at baseline, 4th and 6th week of intervention.",,,2021-02-26,COMPLETED,INTERVENTIONAL,['NA']
11879,NCT01481779,Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11880,NCT03083600,Plasma Glycated Haemoglobin (HbA1c) (mmol/mol),Blood pressure (mmHg),,2017-05-22,TERMINATED,INTERVENTIONAL,['NA']
11881,NCT01338922,Diabetes burden (main carer),Diabetes treatment satisfaction,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11882,NCT00462371,quality of life,impact of disease,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11883,NCT01847937,Increase in magnetic resonance signal intensity of segmented nerves,Correlation of magnetic resoance signal intensity value and nerve conduction thresholds,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
11884,NCT01871415,Change in HbA1c,Safety: Incidence of adverse events,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11885,NCT05857319,Effectiveness of the national RNPC weight reduction program on the change of treatments (drug or instrumental treatments) or in the comorbidities of overweight/obesity.,Dropout rate,,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11886,NCT05046483,Change of cardiac function,"Incidence of further cardiovascular diseases (CVD) and STEMI-related complications, new onset of prediabetes and diabetes mellitus and associated comorbidities",,2018-12-30,RECRUITING,OBSERVATIONAL,['NA']
11887,NCT02508779,"Reduced consequences of extreme BG (e.g., diabetic ketoacidosis, SH)",Improved internal locus of control (as confirmed by the Perceived Competence for Diabetes Scale and the Treatment Self-Regulation Questionnaire),,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11888,NCT00418288,The acute effect of GLP-1 on glucose uptake in the heart,The acute effect of GLP-1 on lumped constant in the brain,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
11889,NCT03120871,Insulin sensitivity (Si),Urinary follicle stimulating hormone (FSH),,2017-05-12,COMPLETED,OBSERVATIONAL,['NA']
11890,NCT01011062,insulin sensitivity measured as glucose disposal during clamp,plasma adipokines and their expressions in SAT,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
11891,NCT01105884,complete healing of the wound,,,2009-10,WITHDRAWN,INTERVENTIONAL,['NA']
11892,NCT00543556,,,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2']
11893,NCT01474161,"Safety parameters (Study Parts II, III and IV)","Pharmacokinetics parameters (Study Parts II, III and IV)",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11894,NCT04843527,Impact on time above 180 mg/dL,,,2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11895,NCT00622960,body weight,"glycemic control (glucose, insulin, and HbA1c)",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
11896,NCT04371497,differential HbA1c before and after insulin switch,Continuous Glucose Monitoring before and after insulin switch,,2011-06-01,COMPLETED,OBSERVATIONAL,['NA']
11897,NCT02378675,Difference of adipocytokines between women with GDM and women with normal glucose tolerance.,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
11898,NCT01131182,Proportion of Participants With at Least One Symptomatic Hypoglycemic Event,Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event,,2010-06-13,COMPLETED,INTERVENTIONAL,['PHASE4']
11899,NCT01724814,Incidence and severity of treatment emergent adverse events,Peak Plasma Concentration(Cmax) of HM12460A following a single dose in Parts 1-3,,2012-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
11900,NCT01086293,Number of participants hospitalized with a diagnosis of acute liver failure,Hospitalizations with acute liver injury,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
11901,NCT03636867,Incidence of amputation,Incidence of revascularization of peripheral arteries,Incidence of major cardio and cerebrovascular adverse events (MACCE),2018-08-07,COMPLETED,OBSERVATIONAL,['NA']
11902,NCT06257082,Change in Eye Health Literacy as measured by Compliance with Annual Diabetic Eye Exams Survey (CADEES),Change in Trust in Healthcare as measured by Trust in the Health Care Team (T-HCT) scale score,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11903,NCT02196571,"Number of pregnant women with complications during pregnancy, labour and delivery",Weight gain in pregnancy,Physical Activity in Pregnancy,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11904,NCT01001962,New onset of hypertension,Mortality cardiovascular,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11905,NCT06053047,Relative risk reduction in the incidence of new Diabetic Foot Ulcers (DFUs),Relative risk reduction in resource utilization,Healthcare Provider acceptance of Bluedrop Monitoring System (BMS),2024-01-22,RECRUITING,INTERVENTIONAL,['NA']
11906,NCT05413239,Time in Range (TIR),Attitudes toward diabetes device use,Diabetes incorporation/identity,2022-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11907,NCT02244164,Volumetric measurement of the pancreas,Quantitative response to secretin,Lipasemia,2014-10,TERMINATED,INTERVENTIONAL,['NA']
11908,NCT01506310,Serum fasting glucose values.,The mean birth-weight of newborns,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11909,NCT00423059,Factor VIII,complication rate,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
11910,NCT04221152,"Adverse events, Adverse drug reactions, and Presence/absence of the use of rescue treatment drugs",Postprandial glucose for 2 hours over time,,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11911,NCT01781975,Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit,Number of Adverse Events,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11912,NCT00612599,Area under the serum glucose concentration profile during 24 hours,Hypoglycaemic episodes,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11913,NCT01105455,Serum glucose concentration 1hr after glucose challenge test,Acceptability of study foods,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
11914,NCT05917808,Change in 2 hour glucose in OGTT,Change in homeostasis model assessment (HOMA) Index between 1st and second OGTT,,2023-05-29,RECRUITING,INTERVENTIONAL,['NA']
11915,NCT02667652,body mass idex,blood fat,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
11916,NCT04838600,"Incidence of clean wound bed at End of Treatment, as assessed by investigator","Relative change in devitalized tissue and wound size at End of Treatment, compared to Baseline, assessed by planimetry",,2021-06-07,TERMINATED,OBSERVATIONAL,['NA']
11917,NCT00870402,Reduction of albuminuria,Reduction of diastolic disfunction,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
11918,NCT04805996,HbA1c,Diabetes complications follow up,,2021-03-23,COMPLETED,INTERVENTIONAL,['NA']
11919,NCT00500097,"Sensitivity, specificity, kappa coefficient",,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
11920,NCT03637075,Effects of nasal insulin vs. placebo on the insulin sensitivity of the human brain as well as effects on regional availability of dopamine receptors.,Effects of nasal insulin vs. placebo on changes in autonomic nervous system,,2017-02-20,RECRUITING,INTERVENTIONAL,['NA']
11921,NCT03412253,Cure of type II DM.,,,2013-11-01,SUSPENDED,INTERVENTIONAL,['NA']
11922,NCT02614625,Sensitivity as the proportion of anatomical structures that are detectable with the two instruments,Corneal sublayer thickness and retinal sublayer thickness obtained with the two study instruments,,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
11923,NCT03997032,Plasma homocysteine level,Retinal vessel diameters,Intraocular pressure,2017-07-31,COMPLETED,INTERVENTIONAL,['NA']
11924,NCT02386943,β-cell function (measurement of insulin and c-peptide during the clamp study),Incretin effect (measurement of active GLP-1 during the clamp study),,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
11925,NCT01221207,Number of Participants Who Achieve Full Wound Healing.,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
11926,NCT02091193,Change in Endothelial Function with Krill Oil Supplementation as Compared with Baseline and Placebo,"Change in Lipid Profile (HDL, LDL, Total Cholesterol), Glucose, Hemoglobin A1C with Krill Oil Supplementation Compared with Baseline and Placebo","Effects of Longer Term Krill Oil Supplementation compared to Baseline on Endothelial function, lipid profile, Hemoglobin A1C, glucose, c-peptide and total antioxidant capacity.",2012-03,COMPLETED,OBSERVATIONAL,['NA']
11927,NCT00801450,central subfield macular thickness,Intraocular pressure,,2007-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11928,NCT04126603,Gene Expression of CD34+ Endothelial Progenitor Cell number,Biochemistry: LDL over HDl Ratio,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11929,NCT00295256,"Outcomes measures are mean fasting glucose levels, mean systolic pressure and mean diastolic pressure",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
11930,NCT03285750,GPR120 expression in adipose tissue,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
11931,NCT03078101,The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone,Mean changes in salt sensitivity after 3 months of empagliflozin treatment,Number of hospitalizations during the study.,2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE2']
11932,NCT02414217,Change in Objective Diabetes Numeracy from Baseline to ≈6 weeks,Change in Glycemic Control from Baseline to ≈3 months,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11933,NCT05724134,Serum C-peptide (relative/change) (units: fold difference and/or ∆ µIU/mL relative to previous time points),Plasma glucose kinetics: endogenous glucose production (units: mg/kg/min),Serum or plasma growth hormone (relative/change) (units: fold difference and/or ∆ng/mL relative to previous time points),2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1']
11934,NCT00875108,The frequency of occurrence of hypoglycemia measured quarterly over one year.,"Changes in total daily:Prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1C measured quarterly and over one year.",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11935,NCT02660593,Blood Sugar level,,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
11936,NCT02548585,Change From Baseline in Body Weight to the EOT (Cohort 4),"Percent Change From Baseline in Incretin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)",,2015-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11937,NCT02589028,Area under the curve (AUC) of plasma glucose level after breakfast,Area under the curve of plasma glucagon level after breakfast,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
11938,NCT02828995,Diabetes Medication Adherence,Diabetes Patient Weight (in Pounds),,2016-07-08,COMPLETED,OBSERVATIONAL,['NA']
11939,NCT05648721,Patient compliance,Patients' satisfaction from the monitoring protocol,,2023-05-18,RECRUITING,INTERVENTIONAL,['NA']
11940,NCT01469143,Area under the serum insulin aspart concentration-time curve,Time to maximum observed serum insulin aspart concentration,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11941,NCT04601311,diabetes distress,diabetes distress,Proportion of participants with one or more serious adverse events in the intervention period,2020-11-11,UNKNOWN,INTERVENTIONAL,['NA']
11942,NCT03041844,Change in wound size,Microcirculatory blood flow index change,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
11943,NCT00237952,"The primary end point is an increase in serum creatinine to 1.5 times the base-line value, measured on two occasions one month apart, or the need for hemodialysis during the longitudinal observation period.",A secondary end point is a temporal change in the creatinine clearance or glomerular filtration rate during the follow-up period.,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
11944,NCT05380817,Percentage of underrepresented minority participants enrolled,Number of patient reported device related issues,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11945,NCT00147342,,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
11946,NCT01615978,Adverse events,24-hour profiles of plasma glucose,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11947,NCT03154060,Mean Absolute Relative Difference,Precision Absolute Relative Deviation,,2017-05-19,COMPLETED,INTERVENTIONAL,['NA']
11948,NCT02337218,Gait Test (LegSys System),,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11949,NCT00571818,Evaluate insulin sensitivity/glucose effectiveness,,,2000-11-01,COMPLETED,INTERVENTIONAL,['NA']
11950,NCT02989740,The per patient incidence of the target lesion(s) related composite MACE,"The incidence of MACE (Cardiac death, MI, any clinically driven-revascularization or hospitalization due to unstable or progressive angina)",,2015-03-26,COMPLETED,OBSERVATIONAL,['NA']
11951,NCT03625856,HbA1c changes,Depression score changes,,2018-11-30,COMPLETED,INTERVENTIONAL,['NA']
11952,NCT00679939,Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days,Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76,Percent Change in Free Estradiol From Week 52 to Week 76,2008-04-21,COMPLETED,INTERVENTIONAL,['PHASE4']
11953,NCT01580852,Glucose Levels,HbA1c levels,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
11954,NCT01483560,Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT),Change in Endothelial Function,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11955,NCT02080741,Telomere length,Level of expression of candidate genes,Analysis of the specific psychological interview EMIC,2014-09-23,TERMINATED,INTERVENTIONAL,['NA']
11956,NCT04581447,Proportion of patients with partial or complete T2D remission criteria,Level of glicentin,,2021-01-07,RECRUITING,INTERVENTIONAL,['PHASE3']
11957,NCT04722354,Insulin sensitivity,,,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
11958,NCT02352974,Number of Subjects With Injection Site Reactions Month 32,"Mean IDAA1c Values, Month 43",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11959,NCT05066893,Change in HbA1c,,,2020-11-05,RECRUITING,INTERVENTIONAL,['NA']
11960,NCT06243536,Eating Attitude Test (EAT-26) questionnaire score,"Concentration of incretin hormones (GLP-1, GIP)",,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
11961,NCT02371239,Mean 24 hour glucose concentration,Homeostatic model assessment 2 (HOMA2),,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11962,NCT05662657,To evaluate the prevalence of post-traumatic stress disorder (PTSD) in adult with Type 1 Diabetes,To evaluate whether there is a correlation between PTSD and the patient participation to a therapeutic education program,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
11963,NCT02968628,Lower Margin Amplitude on aEEG,Bandwidth on aEEG,,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
11964,NCT03521362,Change from Baseline HbA1c at 6 months and 12 months,"Unified theory of acceptance and use of technology (UTAUT) Vantakesh, Morris, et al., 2003",,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
11965,NCT06305143,improvement of visual acuity,,,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE4']
11966,NCT00856882,,,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
11967,NCT02304627,Area under the serum insulin 338 concentration-time curve,Maximum observed plasma capric acid concentration,,2014-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
11968,NCT05649553,Change in HbA1c,Changes in quality of life,,2022-09-15,COMPLETED,INTERVENTIONAL,['NA']
11969,NCT04369313,Number of infants with neonatal hyperbilirubinemia,neonatal initial blood glucose levels,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
11970,NCT05596773,Occurrence of clinically relevant events (number),,Adherence to clinical algorithms provided via the eHealth application,2023-02-22,RECRUITING,OBSERVATIONAL,['NA']
11971,NCT06032221,Device Feasibility - Patient feedback on device use,,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA']
11972,NCT03938233,Total cardiovascular risk,Body mass index (BMI),Smoking,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
11973,NCT00432679,Change From Baseline in Glycosylated Hemoglobin (HbA1c) After 16 Weeks of Treatment in Rosiglitazone Group and Placebo Group,Percentage of Participants With Changes in HbA1c and FPG Meeting Specified Criteria After 16 Weeks of Treatment,,2006-05-24,COMPLETED,INTERVENTIONAL,['PHASE3']
11974,NCT02440217,Myocardial metabolic responses to stress in humans,,,2015-05,UNKNOWN,OBSERVATIONAL,['NA']
11975,NCT03495765,The primary endpoint for the study will be the mean change in best-corrected visual acuity (BCVA) from baseline to the mean level at Month 12.,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11976,NCT01255085,Energy Intake,Subjective Appetite,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
11977,NCT00024583,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
11978,NCT01220336,"Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL","Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL",,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11979,NCT03406663,Proportion of patients achieving fasting SMPG ≤ 5.6 mmol/L without hypoglycemia at 12 weeks,Health care professionals' satisfaction to the insulin titration methods (evaluated by prespecirfied questionnaire: health care provider treatment satisfaction questionnaire),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11980,NCT00377442,AUC0-6h of plasma glucose from pre-dose to 6h post-dose.,"AEs, laboratory parameters.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11981,NCT02076555,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
11982,NCT01135914,Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12,Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11983,NCT01441323,insulin sensitivity,adiposity,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
11984,NCT02840630,Change in Glycated Hemoglobin (HbA1c),Change in Vitamin D,,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11985,NCT01276743,• Difference of distribution of PTPN22 C1858T alleles between patients and controls of Greek origin,• The association between the PTPN22 C1858T polymorphism among patients and presence of autoantibodies,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
11986,NCT01754259,Change in Post-exercise Coronary Vasodilator Reserve,Change in LV Diastolic Function,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11987,NCT01595789,LVEF,Diastolic heart function (E/E*),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11988,NCT04261933,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2020-02-13,COMPLETED,OBSERVATIONAL,['NA']
11989,NCT01280409,Weight Change,Satisfaction With Medication as Assessed by a 5-point Likert Scale,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11990,NCT05485961,Time to first occurrence of CV death or MI (Phase 3),Total number of hospitalizations (Phase 3),,2022-10-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11991,NCT01348672,"Topographic distribution of retinal / ON oxygen saturation disturbance, vascular dysfunction and change in morphometric parameters",,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
11992,NCT00315133,C-peptide levels,Quality of Life,,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11993,NCT04314622,Immunogenicity Tests,PK: Tmax of Supaglutide,,2020-04-14,COMPLETED,INTERVENTIONAL,['PHASE2']
11994,NCT03338153,Major adverse cardiac event,target lesion revascularization,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
11995,NCT03168295,Change in Endogenous Glucose Production (EGP),Change in Fasting Plasma Insulin,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11996,NCT01535612,"Patients ability to successfully assemble, fill, prime, apply and use the PaQ™ device",Dermal Irritation,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
11997,NCT06068686,NT-proBNP Concentration (pg/ml),Fasting blood glucose (mg/dl),,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
11998,NCT06203275,Change in HOMA-IR .,The secondary outcome is the change in expression of GRK2,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11999,NCT00366379,Percentage of patients at each dose who achieve FPG <100mg/dL.,"AEs, laboratory parameters.",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12000,NCT05359432,Serum triglycerides,,,2020-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12001,NCT00822367,"To determine the nutritional supplements glycemic response in patients with DM, defined as the maximum glucose excursion, area under the curve, and 2 and 3 hour BG levels fol",,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
12002,NCT00630825,Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC),,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12003,NCT00737880,Pancreas graft survival,Exogenous insulin requirement,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12004,NCT00402909,Change from baseline in hemoglobin (Hb)_A1c,Proportion of patients achieving reduction in HbA1c of 0.5%,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12005,NCT04909983,Response rate of active treatment versus standard of care,Time to resolution of Irritative contact dermatitis,,2021-05-19,TERMINATED,INTERVENTIONAL,['NA']
12006,NCT01056367,Pulse wave velocity,Pulse wave analysis,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
12007,NCT01163721,Change From Baseline in Fasting Serum Glucose at Week 12,,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12008,NCT05958706,Substrate-specific JVO2 of ventricular myocardial mitochondrial oxidative capacity,Longitudinal Substrate-specific JVO2,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
12009,NCT01533688,Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy.,Measure of Patients Who Develop (Tolerance)Side Effects of Taking Bowel Preparations.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
12010,NCT00699413,Body Mass Index,Hunger,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4']
12011,NCT02328040,"Blood Glucose Measures in Subjects Treated With Sitagliptin, Compared to the Placebo","Measure of Glucagon Concentration in Subjects Treated With Sitagliptin, Compared to Placebo",,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12012,NCT04065724,Ulcer area,Participant satisfaction measured by Numeric Rating Scale(NRS),,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12013,NCT00968812,Change in HbA1c From Baseline to Week 52,Change in HbA1c From Baseline to Week 104,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12014,NCT03478202,Change from baseline in weight,Change from baseline in fasting Insulin level,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
12015,NCT02846571,HbA1C ≤ 7% or a ≥ 2.5 decrease from baseline (before transplant),,,2019-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12016,NCT00411892,HbA1c change from baseline,Change in body weight,,2006-11-29,TERMINATED,INTERVENTIONAL,['PHASE3']
12017,NCT01970566,"Compare the rate of change in fat mass in intense exercise/moderate diet restriction, topiramate-phentermine and cognitive behavior therapy","Compare the change in quality-of-life in response to intense exercise/moderate diet restriction, topiramate-phentermine and cognitive behavioral therapy",,2013-11,WITHDRAWN,INTERVENTIONAL,['NA']
12018,NCT02095418,To evaluate incidence of NODAT in patients of two arms,"To evaluate patient overall survial, OS",,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
12019,NCT02417012,Change in Hba1c,Change in glucose lowering medication,Change in low grade inflammation,2015-04,COMPLETED,INTERVENTIONAL,['NA']
12020,NCT01519505,Incident cases of type 2 diabetes,Cost-effectiveness,,2005-03,UNKNOWN,INTERVENTIONAL,['NA']
12021,NCT06147310,Ridge horizontal width,Inflammatory proliferative remodelling,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12022,NCT01049633,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
12023,NCT04077216,trans-meal blood glucose,,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
12024,NCT02375737,Adherence to the program's intervention,Clinical effectiveness/impact on cholesterol,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12025,NCT02294526,Change from baseline in fasting insulin at 6 months,Change from baseline in blood pressure at 6 months,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12026,NCT06326047,Change in Glycated haemoglobin (HbA1c),Number of adverse events,,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12027,NCT03133819,Peripheral arterial occlusive disease,"Major cardiac events ( myocardial infarction, strokes and cardiac related death)",,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12028,NCT04610749,Retinal metabolism,Depressive symptoms,,2020-11-25,COMPLETED,OBSERVATIONAL,['NA']
12029,NCT01548235,Incidence of SADR (serious adverse drug reactions) including major hypoglycaemia,"Overall, daytime and nocturnal frequency of hypoglycaemic events",,2006-02,COMPLETED,OBSERVATIONAL,['NA']
12030,NCT03152552,Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12,Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36,,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE2']
12031,NCT04947163,Audit of Diabetes Dependent Quality of Life:,30sec sit-to-stand (30secSTS),,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
12032,NCT04295005,Indirect healthcare cost,,,2020-11-16,COMPLETED,OBSERVATIONAL,['NA']
12033,NCT01661192,Safety and tolerability of the AAT in terms of laboratory values,Daily insulin dose adjusted to body weight,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12034,NCT01640210,weight of the insulin pump (JewelPUMP and usual pump),acceptability,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12035,NCT00907608,Death,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",,2007-12,TERMINATED,INTERVENTIONAL,['NA']
12036,NCT01156116,Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2,Change From Baseline in 24-hr Diastolic Blood Pressure (mmHg) at Week 2,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12037,NCT03731533,Weight,Minutes per day of exercise,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
12038,NCT05270148,Body composition: Fatmass and Fat-free mass.,Self-reported quality of life,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
12039,NCT05875259,"Cmax,ss",,,2023-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
12040,NCT01980017,Percentage of Participants Who Self Report of Not Smoking (Even a Puff) in the Last 7 Days + CO <10ppm,Cost-effectiveness of Smoking Cessation Interventions.,Implementation Costs - Clinic,2013-07,COMPLETED,INTERVENTIONAL,['NA']
12041,NCT03223129,Glucose kinetics,Metabolomics,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
12042,NCT05403502,Adverse drug reactions,CGM hypoglycemia outcomes: Rate of hypoglycemia events,Patient Reported Outcomes: ITSQ,2022-08-31,COMPLETED,INTERVENTIONAL,['NA']
12043,NCT05816577,Bristol Stool Chart,Microbiome composition,Fasting blood short chain fatty acids,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
12044,NCT00005462,,,,1991-09,COMPLETED,OBSERVATIONAL,['NA']
12045,NCT03029546,Concentration of advanced glycation end products in maternal serum following the glucose load,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12046,NCT01545401,Change in the proportion of patients achieving glycaemic and BP control,Other secondary outcome measures,,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12047,NCT04902326,Change in hemoglobin A1C from baseline to 12 months,Proportion of days covered by Metformin,,2021-09-16,COMPLETED,INTERVENTIONAL,['NA']
12048,NCT01972893,To evaluate Safety and tolerability of ZYD1,Pharmacokinetics (PK) and Pharmacodynamic (PD) effect after single and multiple subcutaneous dose administrations in healthy adult male volunteers Gender effect study.,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12049,NCT01334125,Baseline Adjusted Hemoglobin A1c Over Time,"Number of Participants With Minor, Major, and Nocturnal Hypoglycemia",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12050,NCT01455896,"time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),",,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12051,NCT00270855,Glucose Effectiveness (Sg) Between Groups,Ratio of Total Cholesterol to High Density Lipoprotein Cholesterol (TC:HDL) Between Groups,Resting Metabolic Rate Between Groups,2008-05,COMPLETED,INTERVENTIONAL,['NA']
12052,NCT02812303,Difference in differences in Blood pressure (BP) goal achievement over the follow-up period comparing PHC and non-PHC practices,Difference in differences in proportion of patients completing colorectal cancer screening over the follow-up period comparing PHC and non-PHC practices,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
12053,NCT01069965,Change from Baseline in Glycosylated Hemoglobin at Week 13,Cardiovascular and metabolic biomarkers at Baseline and 13 weeks,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2']
12054,NCT03465878,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part,Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part,,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
12055,NCT01571661,urine glucose concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge.,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12056,NCT02429258,Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System,Change in Static Insulin Secretion Rate (10^-9 Min^-1) From Baseline to Week 4 - ITT Population,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12057,NCT00909597,Absolute change from baseline in HbA1c,Adverse events; laboratory parameters; cardiovascular events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12058,NCT05553509,Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity,Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
12059,NCT02763150,Incidence of Gestational Diabetes Mellitus,Minutes per week of moderate physical activity,,2017-12-15,COMPLETED,INTERVENTIONAL,['NA']
12060,NCT02974244,Changes from baseline in weight (kg),Frequency of diarrhea and constipation,,2014-10-28,COMPLETED,OBSERVATIONAL,['NA']
12061,NCT03329118,The number of volunteers with adverse events as a measure of safety and tolerability.,,,2017-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
12062,NCT01824277,Change in A1C over the study period.,Changes in the patient perioperative outcomes,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
12063,NCT03467932,Change From Baseline of HbA1C (Glycated Hemoglobin),Change Over Time in Hb1Ac,,2018-05-29,COMPLETED,INTERVENTIONAL,['PHASE2']
12064,NCT03203694,Plasma insulin,,,2017-12-04,COMPLETED,INTERVENTIONAL,['NA']
12065,NCT04226105,Immunogenicity,Achievement of Glycated Hemoglobin < 7%,,2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE3']
12066,NCT02333734,Oral Glucose tolerance test (OGTT),Physical fitness,blood flow,2014-07,COMPLETED,INTERVENTIONAL,['NA']
12067,NCT01453049,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Electrocardiogram (ECG) Data at Week 24/EW,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE3']
12068,NCT02914496,HbA1c,The Summary of Self-Care Activities,,2016-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12069,NCT01657227,Change in Glycosylated hemoglobin (HbA1c),Change in Morisky Compliance Scale,Resource utilization and costs,2013-01,COMPLETED,INTERVENTIONAL,['NA']
12070,NCT01473654,Physical Activity,hemoglobin a1c,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12071,NCT04162067,HbA1c,Clinical outcomes stratified by age group,"HbA1c in the subgroup of patients using CSII therapy, stratified by patients considered ""atypical"" for pumping by Canadian regulatory authorities",2020-01-06,COMPLETED,OBSERVATIONAL,['NA']
12072,NCT05215730,Change in wound size,Physiological parameter - Average time to wound closure,,2021-07-07,COMPLETED,INTERVENTIONAL,['NA']
12073,NCT03330301,Bone facture,Mental diseases,Congenital disorders,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
12074,NCT05741489,Nocturnal Hypoglycemia Event Rate,Comorbidities,,2022-08-10,COMPLETED,INTERVENTIONAL,['NA']
12075,NCT03222726,kidney endpoint,Retinal progression,,2021-04-06,UNKNOWN,INTERVENTIONAL,['NA']
12076,NCT00795275,Change in Insulin Secretion,"Baseline and Change in Hormones, Substrates and Insulin Action: Glycerol",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
12077,NCT01627210,Evaluate the Dexcom G4 system utility and usability during home use.,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
12078,NCT00493012,Change in Body Weight From Baseline to 12 Months,Change in Hb A1c From Baseline to 12 Months,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
12079,NCT01292993,Plasma concentration of LX4211 and metformin after concurrent single-dose administration,Glucose-dependent insulinotropic peptide,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12080,NCT02941367,Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L),"Percentage of patients with HbA1c <7%, no weight gain and no documented symptomatic hypoglycemia (plasma glucose ≤70 mg/dL; 3.9 mmol/L)",,2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12081,NCT03483467,The primary outcome is wound healing (defined as full epithelialisation without drainage maintained for 2 weeks) within 12 weeks of starting study treatment.,Effectiveness of participant blind,,2018-03-11,COMPLETED,INTERVENTIONAL,['NA']
12082,NCT00960076,Change in HbA1c Level From Baseline to Week 18 (LOCF),Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1),,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
12083,NCT03361878,Metformin AUC,Lactate,,2014-05-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12084,NCT01490099,"Cmax, maximum serum insulin detemir concentration",Adverse events,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12085,NCT01590771,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone,,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12086,NCT04769375,Evaluation of pelvic girdle questionnaire,,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
12087,NCT03215173,Change in postpartum weight retention,Change in Readiness to Change,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
12088,NCT01829555,change from baseline in number of self-monitoring of blood glucose tests conducted,change from baseline in hemoglobin A1c levels,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12089,NCT00275223,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
12090,NCT05958368,Fasting Blood Glucose,Glycated Albumin,Insulin,2023-10-10,RECRUITING,INTERVENTIONAL,['NA']
12091,NCT03851549,System Use Evaluation,,,2019-03-12,UNKNOWN,INTERVENTIONAL,['NA']
12092,NCT02125682,effect on HDL function,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12093,NCT04108884,Prevalence of Atrial Fibrillation,Compliance of patients using the app,,2019-10-22,RECRUITING,INTERVENTIONAL,['NA']
12094,NCT04115657,Postprandial insulin,Appetite control,,2019-05-02,COMPLETED,INTERVENTIONAL,['NA']
12095,NCT04623320,Correlation of the 13C breath test with the golden standard,,,2020-10-27,UNKNOWN,OBSERVATIONAL,['NA']
12096,NCT02295696,HbA1c,Self-management,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
12097,NCT01414660,interleukin 7,metabolic parameters,,2010-06-09,COMPLETED,OBSERVATIONAL,['NA']
12098,NCT00412165,"To evaluate the effect, at 12 months, of the 3 intensities of the PACEi-DP intervention on Body Mass Index (BMI) among male & female adolescents.",behavioral measures of diet and physical activity.,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
12099,NCT00985179,health behavior (physical activity & fruits and vegetables),perceived occupational efficiency,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12100,NCT05203640,Blood glucose,carbohydrate supplementation,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
12101,NCT04791618,Life Simple 7(LS7 the metrics for defining ideal cardiovascular health) score at 6-month follow-up,Change in Tobacco Use,Change in Carotid Intima Media Thickness (CIMT),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
12102,NCT03239119,Change in HbA1c from Baseline to Week 30,Change in 7-SMBG from Baseline to Week 16，Week 24 and Week 30,,2017-11-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
12103,NCT01427660,Changes in decisional conflict,Medication adherence and intensification,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
12104,NCT04647175,Blood glucose total area under the curve (tAUC),Microbiomics,,2020-11-23,UNKNOWN,INTERVENTIONAL,['NA']
12105,NCT04911582,Area under the curve for glucose,Area under the curve for GIP (Glucose-dependent insulinotropic polypeptide),,2021-05-25,COMPLETED,INTERVENTIONAL,['NA']
12106,NCT00950534,The percentage of patients achieving glycosylated haemoglobin (HbA1c) levels < or = 7.0%,Mean change in body weight,,2009-07,TERMINATED,INTERVENTIONAL,['PHASE4']
12107,NCT04187521,Peak blood glucose following test meal (CGM),Total caloric intake on the days of test meals,,2020-02-10,RECRUITING,INTERVENTIONAL,['NA']
12108,NCT06211270,Integration,Body Mass Index,,2023-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12109,NCT00949286,Death from any cause,Myocardial infarction (non-fatal and fatal),,2010-01,COMPLETED,OBSERVATIONAL,['NA']
12110,NCT00332826,The primary safety outcome will be measurements of post bronchodilator FEV1 throughout the treatment period,,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12111,NCT03610984,Effects of structured education on β-cell endocrine function progression of T1D patients.,Effects of structured education on metabolic control.,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
12112,NCT04722289,"Change from baseline, use of healthcare services (diabetes controls at the ophthalmologist )",,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
12113,NCT00878293,Average daily pain intensity,"Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12114,NCT00134160,All cause mortality,Serious adverse events other than primary outcome events,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12115,NCT04126551,Mitochondrial DNA methylation,Mitochondrial Function,,2019-07-23,RECRUITING,OBSERVATIONAL,['NA']
12116,NCT05319301,Change in oxytocin concentration,Alexithymia assessment,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
12117,NCT00885378,Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12,Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12,Participants Experiencing Changes From Baseline in Urinalysis Parameters That Met the Marked Abnormality Criteria,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12118,NCT04183543,Change in baseline fasting blood glucose level at 17 weeks.,Change in baseline blood pressure at 17 weeks.,,2020-01-30,UNKNOWN,INTERVENTIONAL,['NA']
12119,NCT02394886,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Wound size and depth measurement,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12120,NCT03851432,Change in Hemoglobin A1c (HbA1c) From Baseline to Week 24 (Core period),Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),,2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
12121,NCT04097691,Injection of subcutaneous glucose 10% in small shots is effective in improving neuropathic signs using the Michigan Neuropathy Screening Instrument (MNSI),,,2019-07-14,COMPLETED,OBSERVATIONAL,['NA']
12122,NCT04991350,Change in vascular density of the deep retinal capillary plexus,Change of severity of diabetic retinopathy,,2021-11-26,TERMINATED,INTERVENTIONAL,['PHASE4']
12123,NCT06326034,Quality of Life Assessment tool,,,2022-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12124,NCT00491322,Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
12125,NCT05460884,Changes in maximal incremental plasma glucose level (iCmax) between baseline and endpoint within intervention groups vs. control.,Changes in plasma insulin levels between baseline and endpoint within the intervention group vs. control,,2020-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12126,NCT01638585,Duration of survival without major amputation in urokinase group compared to group with standard therapy,new lesions on the contralateral leg,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12127,NCT01376557,Change From Baseline in HbA1c to Week 12,Change From Baseline in Triglycerides at Week 12,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12128,NCT00709917,HbA1C,FBG,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
12129,NCT05524909,"Changes in Moderate to Vigorous Physical Activity Minutes between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up","Changes in five activity indicators (steps, 'sedentary minutes', 'lightly active minutes', calories burn, and sleep time)",,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12130,NCT00320879,urinary albumin excretion rate,genotypes with possible implications for the risk of cardiovascular disease,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12131,NCT00965315,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
12132,NCT03146975,"Changes in beta defensins 1, 2 and 3",Changes in percentage of diseased sites,,2014-03-02,COMPLETED,INTERVENTIONAL,['NA']
12133,NCT00840164,,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
12134,NCT01295229,Feasibility,Efficacy and Mechanisms,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
12135,NCT06181721,Percentage of time in hyperglycemic range (defined as > 13.9 mmol/L (>250 mg/dL)),Average number of hypoglycemic treatments when CGM is less than 3.9mmol/L,,2023-09-05,COMPLETED,INTERVENTIONAL,['NA']
12136,NCT04164641,Number of re-ulceration occurrences,Percentage of patients who do not experience re-ulceration after custom orthosis,,2019-12-09,RECRUITING,INTERVENTIONAL,['NA']
12137,NCT02026310,"24 weeks after treatment, HbA1c values' change compared with baseline",hypoglycemia events,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12138,NCT01681290,Bilateral change in sensory nerve conduction velocity,Quality of life questionnaire,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12139,NCT01773668,Performance data,Physical duration,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12140,NCT01291875,Changes in HbA1c and serum inflammatory markers of inflammation after periodontal intervention,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
12141,NCT06332690,Modification of inflammatory biomarkers on OCT and perfusion density parameters on OCT-A at 4 months after surgery (Change measure),"Initial clinical characteristics in patients with a gain in BCVA (Best Corrected Visual Acuity) of ≥ 5, ≥ 10, and ≥ 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters.",,2023-10-17,RECRUITING,OBSERVATIONAL,['NA']
12142,NCT00647595,Central adiposity,neonatal adiposity,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12143,NCT00324675,Proteinuria,HbA1c,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
12144,NCT05699408,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),,2023-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12145,NCT03953092,Adverse events will be evaluated,maximum plasma concentration (Cmax),,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12146,NCT02836015,Hemoglobin A1c,BMI,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA']
12147,NCT02797392,Change in proportion of citizens at increased risk of lifestyle related disease from baseline to the 12 weeks follow up,GP reported Personal belief,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
12148,NCT00570310,Daily Evening Patient Reported Pain Intensity Scores,'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12149,NCT00497133,,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
12150,NCT02006342,Time to Anion Gap Closure,Number of Participants Who Developed Hypoglycemia,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12151,NCT00938158,"The primary objective is to characterize the PK of albiglutide in subjects with type 2 diabetes and varying degrees of renal impairment, including subjects requiring hemodialysis, and in age, gender and BMI-matched subjects.","To assess the safety and tolerability of a single dose of albiglutide in subjects with varying degrees of renal impairment and in age, gender and BMI-matched subjects with normal renal function",,2009-08-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12152,NCT03606694,First phase of insulin secretion,Blood pressure,,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12153,NCT00325910,Combined endpoint of all cause mortality and all cause hospitalization at 6 months,Development of Lactic Acidosis,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE3']
12154,NCT03130101,Time in interstitial glucose target range (CGM analysis),,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
12155,NCT03232333,Percentage of Participants,,Short Form - 36: Bodily Pain,2017-07-21,COMPLETED,OBSERVATIONAL,['NA']
12156,NCT00263276,Mean change from baseline in HbA1c compared to placebo.,"Mean change from baseline in fasting plasma glucose, evaluate proportion of subjects who achieve a therapeutic response (HbA1c <7%); change from baseline in urinary glucose excretion",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12157,NCT02727231,Time spent in the target glucose range (3.9 to 10.0 mmol/l) based on subcutaneous glucose monitoring,Utility Evaluation,Accuracy of CGM,2016-03,COMPLETED,INTERVENTIONAL,['NA']
12158,NCT03579615,Time spent in the target glucose range,AUC of glucose below 3.0mmol/l (54mg/dl),,2020-12-23,COMPLETED,INTERVENTIONAL,['NA']
12159,NCT01617603,Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake,Oxidative Stress After 12 Weeks of Product Intake,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12160,NCT03546972,Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by completion rates,Changes in proposed behavioral mediators through survey,,2017-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12161,NCT00605774,catecholamine levels,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
12162,NCT05421845,incidence of gestational diabetes mellitus,maternal physical activity information,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12163,NCT02411253,"AUC (T0-T120) of serum C-peptide, determined after a mixed meal tolerance test at month 12, compared to baseline.",Adverse event.,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12164,NCT04362241,To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure.,Rescue Therapy,,2020-08-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
12165,NCT01881724,Change in HbA1c from baseline,sleep duration,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
12166,NCT05347836,To compare the levels of monocyte soluble activation markers among children with T1DM and healthy controls,,,2022-07-01,UNKNOWN,OBSERVATIONAL,['NA']
12167,NCT06273059,The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.,To describe genetic variation in young-onset DM with diabetic complications in various systems:,,2022-09-12,RECRUITING,OBSERVATIONAL,['NA']
12168,NCT05717608,fructose on glucose metabolism,changes in (postprandial )plasma metabolites,,2023-02-05,RECRUITING,INTERVENTIONAL,['NA']
12169,NCT02925676,Number of adverse events,User experience in an everyday context based on interview,,2016-10-05,TERMINATED,INTERVENTIONAL,['NA']
12170,NCT01196104,Change in HbA1c (%) From Baseline to Week 16,Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3']
12171,NCT02964585,Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation),eGFR,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12172,NCT03895515,Change in percentage of time spent in glycaemic target range (TIR),Change in Glycated Haemoglobin A1c (HbA1c),,2020-01-03,COMPLETED,OBSERVATIONAL,['NA']
12173,NCT04630925,"Glucose time in range (3,9-10 mmol/l) (% pr day)",Time with active isCGM,,2021-01-04,TERMINATED,INTERVENTIONAL,['NA']
12174,NCT00891124,"Proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline",The treatment goal of risk factors is based on ADA guideline.,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
12175,NCT02931292,Percent excess body mass index loss (%EBMIL),percent of complications,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
12176,NCT03415074,CKD progression,Occurence of the adverse events,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
12177,NCT00853151,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint,Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12178,NCT04431141,"AUCτ,ss of teneligliptin and empagliflozin",t1/2β of teneligliptin and empagliflozin,,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
12179,NCT00099333,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12180,NCT06080425,body weight measured at the five post-baseline follow-up points,Diabetes Distress,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12181,NCT00036504,,,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12182,NCT02954822,"AUCτ,ss for Evogliptin and Glimepiride",,,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
12183,NCT03294265,Glycated hemoglobin,Foot care,,2016-08-01,UNKNOWN,INTERVENTIONAL,['NA']
12184,NCT00971048,Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.,Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12185,NCT03604198,Long-term safety of relacorilant,,Long-term benefit of relacorilant,2018-05-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
12186,NCT04132531,Change in the frequency of circulating cells with aldehyde dehydrogenase activity.,Change in the frequency of circulating cells with aldehyde dehydrogenase activity and cell surface marker expression.,Changes in the concentration of oxidative stress and inflammatory markers,2018-05-01,COMPLETED,OBSERVATIONAL,['NA']
12187,NCT05645068,coefficient of variation of the superficial retinal capillary plexus,,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
12188,NCT03143764,examine cycling distance,examine changes in cardiorespiratory fitness,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
12189,NCT04721158,More Frequent Glycemic Control Monitoring,,,2021-01-17,COMPLETED,INTERVENTIONAL,['NA']
12190,NCT02109315,Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.,Oxidative stress markers,,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12191,NCT02620878,Percentage of Time Spent in Target Range (70-180 mg/dl or 3.9-10.0 mmol/L),Percentage of Time Artificial Pancreas is Active,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12192,NCT02349516,To explore the effect of Squalamine Lactate eye drops on Best Corrected Visual Acuity in subjects with diabetic macular edema,"To assess the safety and tolerability of Squalamine Eye Drops, measured by ophthalmic examination, the recording and evaluation of clinical AEs",,2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12193,NCT03333772,Acceptability,Change from baseline in Glycated hemoglobin (HbA1C) at post-intervention,,2017-11-15,COMPLETED,INTERVENTIONAL,['NA']
12194,NCT00627744,Improvement in beta-cell function measured by means of the insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT),Improvement in incretin-independent beta-cell function measured as the Acute Insulin Response (ΔAIRG) during an intravenous glucose tolerance test.,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12195,NCT02983214,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are palpitations, tachycardia, headache, diarrhea, urticaria, neoplasms, blood disorders, drug interruption.",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12196,NCT02927561,To compare the sensitivity and specificity of automated grading system versus human grading in detecting diabetic retinopathy,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
12197,NCT06221241,Change of the Average Daily Pain Score (ADPS) from baseline to Week 12. [ADPS is the weekly average pain score based on the 11-point numeric rating scale (NRS)],Adverse Events,,2024-03-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12198,NCT05314140,Proportions of diabetic patients with high coronary artery calcium score,Description of adverse events regarding to the coronary artery calcium score,,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12199,NCT01073826,Glucagon like peptide- 1 (GLP-1),,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
12200,NCT00887302,Metabolics of RYGB with Gastrostomy - Glucose,,,2009-03-25,COMPLETED,OBSERVATIONAL,['NA']
12201,NCT02064335,Physical fitness,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12202,NCT01465620,Change from Baseline in NTSS6 score at 3 months,change from baseline of thermal and vibration thresholds,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12203,NCT01238406,Sleep efficacy,Total wake up time per night,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
12204,NCT01680653,Duration of Nocturnal Hypoglycemia,Duration of Glucose Readings <70 mg/dl,Prolonged Episodes of Hypoglycemic Events,2012-05,COMPLETED,INTERVENTIONAL,['NA']
12205,NCT01251497,,,,2009-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12206,NCT03628963,Patient Activation,Acceptability,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
12207,NCT04835636,HbA1c,Weight change,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
12208,NCT03172598,Efficacy as measured by reduction in pain using a numerical rating scale.,Plasma concentration of MT-8554,,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE2']
12209,NCT01278485,Number of Participants With Hemoglobin A1c <7.0% at the Time of Enrollment,Number of Participants Reporting Body Weight Fears in the 12 Months Prior to Enrollment,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
12210,NCT01480934,Development of Posterior capsule opacification.,"duration of diabetes, stage of diabetic retinopathy",,2005-06,COMPLETED,OBSERVATIONAL,['NA']
12211,NCT04395378,Glucose concentration (mmol/L),Plasma albumin concentration (g/dL),Glucose concentration from the pilots log books for the previous 6 months,2019-12-05,SUSPENDED,OBSERVATIONAL,['NA']
12212,NCT03713502,Prevalence of pre-diabetes,,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
12213,NCT00378508,C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at Baseline,Baseline Hemoglobin A1c,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12214,NCT03363386,Change in fasting blood glucose level,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
12215,NCT00600483,Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90,Rehospitalization for Sternal Wound Infection,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12216,NCT06173765,Change in primary clinical marker of inflammation IL-6,Change in fasting Lipids,,2022-08-31,RECRUITING,INTERVENTIONAL,['NA']
12217,NCT00347542,Oral Glucose Insulin Sensitivity (OGIS),Blood Pressure,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
12218,NCT04723628,Glycemic Control,Perceived Diabetes Self-Management Scale (PDSMS),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
12219,NCT02862860,Amplitude of glycemic variations,,,2012-05-29,COMPLETED,INTERVENTIONAL,['NA']
12220,NCT00110370,(A1C less than 7%) with once-daily insulin glargine in combination with OADs.,"body weight, SAE's and study drug related AEs.",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12221,NCT01441232,Change from baseline in gut hormones,Change from baseline in urinary glucose excretion,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12222,NCT05482321,Primary outcome 4,Secondary outcome 6,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
12223,NCT01940614,Overall diagnostic accuracy,Predictive value of absent bright spot in posterior pituitary enlargement,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
12224,NCT05851651,Infant Feeding pattern,Women's prevalence of Impaired Glucose Tolerance,"Women's experience, perception, and attitude for AME practices",2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
12225,NCT01275131,"Early Exposure to Insulin (%AUC[0-60]), Stage 3","Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12226,NCT04702048,Mean change in photoreceptor cell spacing,Proportion of participants who receive intravitreal aflibercept,,2021-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12227,NCT02292433,Accumulation Ratio (Rac) on Day 7 for PF-04937319,Change From Baseline in Pre-Meal C-Peptide at Day 7,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12228,NCT01990300,Changes From Baseline in Glycosylated Hemoglobin (HbA1c),Changes From Baseline in Fasting Blood Glucose (FBG),,2011-11-28,COMPLETED,OBSERVATIONAL,['NA']
12229,NCT02076945,Duration of analgesia,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12230,NCT04172077,"Examine the effects of patients' attachment styles (secure, mixed and fearful) on their type one diabetes management represented by A1C level",b)Compare diabetes management self-efficacy and attachment style in parents,,2019-09-18,COMPLETED,OBSERVATIONAL,['NA']
12231,NCT04339296,Self-reported Medication Adherence,,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
12232,NCT04709419,Change in Tissue Oxygenation,Number of Participants with Complete Wound Closure,Number of Patients with Maintained Wound Closure,2022-10-27,TERMINATED,INTERVENTIONAL,['NA']
12233,NCT02967237,Mean change from baseline in HbA1c,Number of adverse events,,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12234,NCT00665808,treatment satisfaction (DTSQs and DTSQc),Pregnancy,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
12235,NCT03012113,The effect of Mirabegron treatment on BAT activity measured by MRI in South Asians compared with white Caucasians.,The effect of Mirabegron treatment on sympathetic output in South Asian and white Caucasian individuals.,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
12236,NCT00420511,Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR,Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12237,NCT01226537,Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test,,,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12238,NCT05227677,The achievement rate of HbA1c (≤7%),The extent of change of HbA1c,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
12239,NCT01262586,Change in Glycemic profiles between vildagliptin and glimepiride,Glucose Fluctuation before and during treatment,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12240,NCT02526524,Change in HbA1c (%) at 16 Weeks,,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12241,NCT05826054,Maximum tolerated dose (MTD),,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
12242,NCT04917926,Glycaemic control,Level of physical activity,Frequency of health service utilisation,2021-06-21,RECRUITING,INTERVENTIONAL,['NA']
12243,NCT00334503,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
12244,NCT06010992,Glycemic control,Serum levels of asprosin,,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
12245,NCT00822211,Change from baseline in HbA1c after 24 weeks,Change from baseline in fasting plasma glucose at 24 weeks,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12246,NCT02145988,Resting ankle-brachial index (ABI),Adverse events,,2015-06-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12247,NCT00975052,Weighted average active GLP-1 (glucagonlike peptide-1) concentrations,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12248,NCT00954694,"The primary endpoint of the study is the qualitative measurement, by use of a questionnaire, of attitude and interest toward exercise in participants by assessing if they choose to seek and perform other modes of exercise.","Secondary endpoints are the quantitative measurement of the change in weight, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C levels.",,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
12249,NCT01182948,Change in haemoglobin A1c (HbA1c) levels,"Changes in expression in the muscle of some genes involved in ATP production, mitochondrial biogenesis and substrate utilization",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12250,NCT06225154,Serum and saliva IL-1β levels (pg/ml),HbA1c ( %),Clinical Attachment Level (mm),2015-02,COMPLETED,INTERVENTIONAL,['NA']
12251,NCT05666791,Self-efficacy,,,2022-12-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12252,NCT00997152,Change in Fasting Plasma Glucose (FPG) levels,"Safety (biochemistry, hematology, urinalysis and adrenal-related markers) and tolerability (adverse events)",,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12253,NCT01337947,arterial vascular stiffness,nitric oxide dependent vasodilation,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12254,NCT03210896,"Chemical components in breath will be captured into absorbent tubes followed by GCMS analysis, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration.",Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition.,,2017-07-10,COMPLETED,INTERVENTIONAL,['NA']
12255,NCT04281186,Retinal sensitivity,Diabetes Specific Dementia Risk Score.,,2020-11-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12256,NCT00979719,physical activity,"social-cognitive predictors of behavior (self-efficacy, action control etc.)",,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12257,NCT02622295,Post-training Bone Turnover: Osteocalcin,Post-training Subject-report Measures: EQ-5D,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
12258,NCT02730754,Depressive symptoms measured with Patient Health Questionnaire-9,Diabetes distress measured with Problem Areas in Diabetes Scale (PAID-5),Health care utilisation/hospitalisation,2016-04,COMPLETED,OBSERVATIONAL,['NA']
12259,NCT01586065,Number of High Glucose Correction Doses Administered.,Pre- and Post-meal (2-3 Hour) Glucose Levels,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
12260,NCT00447629,Safety,Pharmacokinetics,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12261,NCT02924311,Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients,Number of participants with ocular and non-ocular safety events,Number of patients with prior intraocular steroids (DME Monitoring),2016-09-21,COMPLETED,OBSERVATIONAL,['NA']
12262,NCT04345497,HbA1c Level,Hyperglycemic Episodes,,2020-08-26,COMPLETED,INTERVENTIONAL,['NA']
12263,NCT02936115,Proportion of Patients that achieve a 50% or greater reduction in wound size by 8 weeks,Number of patients with worsening of index wound defined by ≥ 50% increase in wound size,,2016-07,TERMINATED,INTERVENTIONAL,['PHASE4']
12264,NCT03670043,Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire,,,2019-03-19,COMPLETED,INTERVENTIONAL,['PHASE4']
12265,NCT00674050,PK parameters of serum insulin,,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12266,NCT05463289,Proportion screened for diabetic retinopathy,Diagnostic Accuracy,,2022-07-11,RECRUITING,INTERVENTIONAL,['NA']
12267,NCT02386930,HbA1c%,physical exercise in minutes per day,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
12268,NCT02230631,The percentage of patients experiencing at least 1 hypoglycaemic event,Difference in the reported incidence rates of hypoglycaemia,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
12269,NCT04953442,Percentage of participants that are satisfied with participation in the study,Average of minutes of sleep per night,Autonomous motivation for physical activity as assessed using Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2),2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
12270,NCT02459899,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline to Week 12 in Fasting Plasma Glucose,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12271,NCT05780151,Query rate,,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE4']
12272,NCT01945242,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
12273,NCT04017221,Incidence rate of lower extremity amputation,Incidence rate of Fournier's gangrene,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
12274,NCT02999386,All cause Mortality,Hospital length of stay,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
12275,NCT00270439,Insulin sensitivity as measured by the minimal model and HOMA score,Decreased use of oral hypoglycemics,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12276,NCT02934425,Net incremental area under the curve (AUC) appetite VAS ratings,Composite daily hunger and fullness VAS ratings,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
12277,NCT02663713,platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover).,"• VerifyNow P2Y12 assay % inhibition, using the TRAP-induced (BASE channel) response at the end of the 2 study periods",,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12278,NCT00107107,To examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight,To examine the effects of long term pramlintide treatment on HbA1c in subjects with type 1 diabetes completing protocol 137-150.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12279,NCT01161862,Mean Plasma Blood Glucose Achieved by the Bionic Pancreas (mg/dl),Nadir Blood Glucose in Each Arm,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
12280,NCT04550403,prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients,number of days of hospitalization in patients with and without diabetes,,2020-07-30,COMPLETED,OBSERVATIONAL,['NA']
12281,NCT04744636,Guanylate triphosphate cyclohydrolase (GTP-CH) investigations,Blood pressure supine,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12282,NCT00476788,Mean Glycated Hemoglobin (A1c),Number of Reported Adverse Events,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
12283,NCT00021879,,,,2001-03,COMPLETED,OBSERVATIONAL,['NA']
12284,NCT00201110,A1C,Lipid panel,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
12285,NCT05113693,"Cmax of CKD-501, D759, H053",,,2021-11-25,COMPLETED,INTERVENTIONAL,['PHASE1']
12286,NCT00004647,,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12287,NCT02737891,Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate,Change From Baseline to End of Treatment in Body Weight,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12288,NCT05870202,Acceptability,Change in HbA1c,,2023-03-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12289,NCT01545388,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG),,2012-02-23,COMPLETED,INTERVENTIONAL,['PHASE3']
12290,NCT01730196,Weight change,hemoglobin A1C,waist circumference,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12291,NCT00407680,HbA1c,Serum angiotensinogen,,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
12292,NCT02123251,Changes in HDL From Baseline to the End of Intervention (December 2015),Change From Baseline to End of Intervention (December 2015) in Physical Component Summary Measure of the Short Form (SF-36v2) Health Survey,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
12293,NCT01435980,Clinical events,Blood testing,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12294,NCT02659007,change in 10 meter walk,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12295,NCT03544242,96 Hours Post Operative Blood Samples Serum Glucose Levels,,,2017-05-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12296,NCT00145353,Meal-regulated insulin time two peaks after the two intervention periods,,,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12297,NCT02806349,HbA1c,fasting insulin,ALT,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12298,NCT01102530,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
12299,NCT00477022,"Foot ulcer surface area was estimated stereologically, based on Cavalieri's principle before and after intervention, at pre treatment and post treatment",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
12300,NCT01206712,Investigation of ß-cell function via comparison of AUC0-300 minutes of intact Proinsulin in T2DM patients treated with LANTUS + Metformin (MET) vs. T2DM patients treated with Sulfonylurea (SU) + Metformin,"Investigation of insulin, intact proinsulin, glucose and PAI-1 levels over a 5 h period after uptake of a standardized meal comparing four different population groups",,2009-11,COMPLETED,OBSERVATIONAL,['NA']
12301,NCT01272193,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12302,NCT06277362,Safety Composite,Rutherford class,,2020-01-31,RECRUITING,OBSERVATIONAL,['NA']
12303,NCT05115175,Feasibility of the Scaled Mindfulness-Based Intervention as Assessed by Participant Feedback,,,2019-07-14,COMPLETED,INTERVENTIONAL,['NA']
12304,NCT05013346,Islet auto-antibody titre and positivity proportions,Type 1 diabetes genetic risk score,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
12305,NCT00607945,Difference in change in body weight of the intervention groups,Nutrition knowledge,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12306,NCT00472342,Improvements of adipokine levels,Prevention of diabetes,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
12307,NCT04222660,Change in cornea nerve density,Determination of tibial nerve conduction velocity,,2021-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12308,NCT05643144,Level of Situation Awareness (Aim 2),Glucose variability (Aim 1),,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
12309,NCT06227520,Wound Healing,Ulcer Reoccurrence,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12310,NCT06325111,Identification of oral microbiome characteristics associated to T1D glycaemic control,,,2023-05-29,RECRUITING,OBSERVATIONAL,['NA']
12311,NCT02726425,Change in disease control (HbA1c),Health Service Utilization,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12312,NCT01334203,The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit.,Change from baseline in exercise treadmill duration in the trough ETT at week 12,,2011-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12313,NCT06218342,Liver stiffness measurement (LSM),Body weight,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12314,NCT05147818,Identify risk factors for Acute kidney injury in diabetic patients,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
12315,NCT03452657,Proportion of eyes with a ≥ 2-step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) score,Proportion of eyes that meet the protocol-defined failure criteria,,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
12316,NCT02313090,HbA1c,low density lipoprotein cholesterol,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12317,NCT00683878,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) Among Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12318,NCT03664414,Change in the glomerular filtration rate,Change in health-related quality of life,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12319,NCT06140303,Incidence of index ulcers closed,Time to closure,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
12320,NCT04547348,Time until remission,Incidence of Adverse Events and Serious Adverse Events,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
12321,NCT01084928,body weight,Percent of Total Calories from Fat,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
12322,NCT00552942,diabetic indices,"interleukin and cytokine levels, weight loss",,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
12323,NCT02744976,Percentage plaque volume change over 24 months,Plaque volume change in metformin vs non-metformin treated patients over 24 months,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12324,NCT05677334,Time percentage (% TIR) in the range of 3.9~10.0 mmol/L blood glucose,time above range (TAR),,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12325,NCT00837941,analgesic efficacy measured by patients self reported pain level after single dose administration,The onset of analgesic efficacy following single dose of pregabalin and duloxetine hydrochloride versus placebo,,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12326,NCT02928250,effect on on urinary albumin excretion (UAE),"total antioxidant capacity (TAC), malondialdhyde (MDA).",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
12327,NCT06115265,Weight in kg,CAC scores,,2023-09-05,RECRUITING,INTERVENTIONAL,['NA']
12328,NCT01307514,,,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
12329,NCT03987412,The risk of gestational diabetes mellitus (GDM),Satisfaction of prenatal medical care; questionnaires,,2019-08-16,UNKNOWN,INTERVENTIONAL,['NA']
12330,NCT06136013,"Changes in 24-hour area under cover (AUC) glucose from baseline to 1, 2, and 3 months",Quantify the differences in the number of responders and low-responders for glycemic control and other health-related outcomes for individuals with T2DM and age-matched overweight/obese older adults.,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12331,NCT01492205,Overall acceptance of the NovoLet® system among healthcare professionals (nurses and doctors),Incidence of adverse drug reactions,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
12332,NCT02755831,Number of Participants With Adverse Pregnancy Outcomes,Hospital Costs at Time of Delivery,,2017-02-20,COMPLETED,INTERVENTIONAL,['NA']
12333,NCT04027712,b amyloid predicts cardiovascular mortality in diabetic with coronary artery,,,2014-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12334,NCT00150410,Glycosylated hemoglobin,insufficient clinical response.,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12335,NCT01370681,Geometric mean AUCt,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12336,NCT02087215,number of the participants with complete epithelization of diabetic foot ulcer,number of participants in whom local infective complications develop in diabetic foot ulcer patients,improvement of inflammatory parameters in diabetic foot ulcers,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
12337,NCT06040463,Change in A1c,CHW Support Adherence,,2023-10-23,RECRUITING,INTERVENTIONAL,['NA']
12338,NCT02645799,%NIH volume,Definite or probable ARC defined stent thrombosis,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12339,NCT01330563,CKD-501 AUC,CKD-501 Tmax,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12340,NCT04041167,Number of participants with functional independence,Number of participants with recurrence,,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12341,NCT03738449,Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration,Apparent volume of distribution of Metformin,,2019-01-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12342,NCT01247753,Change in body weight,Change in physical activity,,2011-03-01,COMPLETED,INTERVENTIONAL,['NA']
12343,NCT03217591,Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12,,,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12344,NCT02601482,Glycemic control,HOMA-2 insulin resistance index,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
12345,NCT00438503,"Effect og glucose in dialysis water on blood pressure, plasma glucose and hormones in plasma",Relationship between changes in blood pressure and and changes in hormones,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12346,NCT06323174,Change in glycated haemoglobin (HbA1c),"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
12347,NCT00286455,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Glucagon (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12348,NCT01107314,,,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
12349,NCT00432835,Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis,,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
12350,NCT04869098,Glycaemic response,respiratory quotient,,2021-04-27,RECRUITING,INTERVENTIONAL,['NA']
12351,NCT01499082,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,Change in HbA1c From Month 6 to Month 9,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12352,NCT03203278,Glycaemic control,Glycaemic control,,2017-11-06,COMPLETED,INTERVENTIONAL,['NA']
12353,NCT05967923,Range of motion of the shoulder,Shoulder and hand disability,,2023-07-05,RECRUITING,INTERVENTIONAL,['NA']
12354,NCT00577824,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24,"Change in 1,5-anhydroglucitol",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12355,NCT00789945,To determine the changes in A1C.,To determine changes in postprandial glucose excursion during the meal's 5 hour postprandial period.,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
12356,NCT05461274,Rate of patients who remain in diabetic neuropathy clinical trial to trial completion,,,2024-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12357,NCT02604875,measurement of copeptin values in mmol/l within 24 hours to assess the amount of release in a day curve.,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12358,NCT01164501,HbA1c Change From Baseline in Patients With Moderate Renal Impairment,,Hypoglycaemic Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12359,NCT04739124,"Correlation between appropriation factors, intention to use, Freestyle Libre use and glycemic control",,,2021-06-10,COMPLETED,OBSERVATIONAL,['NA']
12360,NCT01999322,Number of Microscopically Confirmed Episodes of Infusion Set Occlusions,Number of Premature Infusion Set Changes,,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3']
12361,NCT00174668,Total daily insulin dose,Physical examination,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12362,NCT00704795,"Glucagon responses (as assessed by area under curve (AUC)) during 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion, respectively.",GI-mediated glucose tolerance as assessed by the amount of glucose ingested as compared to the amount of glucose needed to mimic the OGTT curve during the iv glucose infusion.,,2008-06,UNKNOWN,OBSERVATIONAL,['NA']
12363,NCT05211375,Complete remission rate of type 2 diabetes,Late complication rate,,2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE3']
12364,NCT02442544,Glycemic control (serum hemoglobin A1c),Glycemic control (as measured by serum hemoglobin A1c),Change in gut permeability (quantification of specific sugars in urine),2015-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12365,NCT05530369,Neuropathy,Mean glucose (mg/dl),,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
12366,NCT03650023,Glucose levels,The areas under the curve (AUC) of glucose,,2018-05-09,COMPLETED,INTERVENTIONAL,['NA']
12367,NCT01891955,Fasting glucagon,Fasting HbA1c,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
12368,NCT02548767,Change of de novo lipogenesis: palmitate tracer-to-tracee ratios by gas chromatography-mass spectrometry.,Change of Very low density lipoprotein (VLDL)-triglyceride (TG) kinetics,Change of blood levels of uric acid,2016-02,COMPLETED,INTERVENTIONAL,['NA']
12369,NCT00530881,postprandial blood glucose,"fasting blood glucose, HbA1c, safety",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12370,NCT04602039,This project aimed to examine changes in insulin resistance in participants using dairy colostrum as a food supplement,This project aimed to examine changes in inflammatory markers in participants using dairy colostrum as a food supplement,,2016-07-21,COMPLETED,INTERVENTIONAL,['NA']
12371,NCT01116180,Cognitive function and brain cortical activity assessed by EEG,Cardiac conduction evaluated by a three channel digital Holter Monitor.,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
12372,NCT02595606,ocular surface disease index,corneal fluorescein staining assessment,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12373,NCT02397265,Percentage of Time in Target Range Over 24 Hour,,,2014-12-03,COMPLETED,INTERVENTIONAL,['NA']
12374,NCT06333080,Time-in-Range (TIR),Treatment-Related Impact Measure for Diabetes (TRIM-D),,2024-05-01,RECRUITING,OBSERVATIONAL,['NA']
12375,NCT02100488,Intra-subject postprandial glycemic variability,CV_AUC-PG_3-8h,Time into range,2014-03,COMPLETED,INTERVENTIONAL,['NA']
12376,NCT00553488,"Area Under Curve (AUC) of the blood glucose (BG) profile after the meal, with and without baseline correction.",Time to BGmax (tBGmax),,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12377,NCT00138554,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12378,NCT02210000,Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week 12,Trough Plasma Concentration of Camicinal on Day 28 and Day 84,,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2']
12379,NCT05145140,Diabetic Foot Ulcer relapse rate,C-reactive protein(CRP),,2022-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
12380,NCT05461716,Detection of hypoglycaemic events,Registry of hypoglycaemia events in patients with T2DM treated with insulin and insulin secretagogues,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
12381,NCT03624803,"To describe baseline characteristics of patients starting Dapagliflozin together with other anti-diabetic medications , alone or in combination. And to describe if Dapagliflozin was given as 2nd line , 3rd line or later in combination therapy.",To record the change in blood pressure (mmHg) from baseline.,,2019-03-09,COMPLETED,OBSERVATIONAL,['NA']
12382,NCT06332378,Hemoglobin A1C,,,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12383,NCT05241522,Standard uptake value in the kidney,,,2021-08-06,RECRUITING,INTERVENTIONAL,['PHASE1']
12384,NCT03784443,Number of Lucentis Injections received in the study eye,Number of focal laser treatments,,2019-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12385,NCT05553093,Brain function,"Inflammation factors, including adiponectin,leptin,IL-1,IL-6,IL-18,TNF-α,ghrelin,asprosin.",,2022-03-15,RECRUITING,INTERVENTIONAL,['PHASE4']
12386,NCT05320276,Frequency of patients with chronic diseases seen in the emergency department who have not been offered an educational program,Identification of reasons for refusal to participate,,2022-02-28,COMPLETED,OBSERVATIONAL,['NA']
12387,NCT03061981,"[Safety and Tolerability] 12-lead ECGs, Vital signs. Physical examinations, Clinical laboratory testing and Adverse event assessments",Renal clearance (CLR),Key metabolites of DA-1241 in Cohort 6,2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
12388,NCT02233491,Glucose metabolism,Hospitalization,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
12389,NCT05495451,Feasibility of an intensive multidisciplinary program based on lifestyle changes in patients diagnosed with type 2 diabetes.,"Evolution of the HOMA-IR between the start of the program, the middle of the intervention (3 months) and the end of the intervention (6 months).",,2022-01-21,COMPLETED,INTERVENTIONAL,['NA']
12390,NCT01530178,Better Targeted Blood Glucose Levels,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12391,NCT04607096,Change in first phase insulin secretion.,Change in subcutaneous adipose tissue.,Change in insuin clearance.,2021-04-08,UNKNOWN,INTERVENTIONAL,['NA']
12392,NCT01724060,Change in Energy Intake From Baseline,Change in Macronutrient Composition From Baseline,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
12393,NCT03877068,Number of Clinically Significant Hypoglycemia Events While Hospitalized,Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) After Discharge,,2019-06-26,COMPLETED,INTERVENTIONAL,['NA']
12394,NCT02822534,The steady-state urine concentration (Css) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
12395,NCT01822925,Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS),Average Weekly Rescue Medication Use,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12396,NCT02942056,Type 2 DM control,obesity,,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12397,NCT03153007,"Assessment of signs and symptoms, impacts on functioning and HRQoL among subjects with DFU",,,2017-08-11,COMPLETED,OBSERVATIONAL,['NA']
12398,NCT03443713,Percent of Time With Sensed Glucose Less Than 70 mg/dl,Mean Sensed Glucose,,2018-07-18,COMPLETED,INTERVENTIONAL,['NA']
12399,NCT06234787,To determine the cumulative incidence or risk of potential hypoglycemia during ICU admission,"To describe the theoretical cumulative incidence of potential hypoglycemia with alternative thresholds of 70, 75, 85, or 90 mg/dL",,2023-11-30,RECRUITING,OBSERVATIONAL,['NA']
12400,NCT06321302,Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52,Occurrence of ocular AEs of special interest in the study eye between baseline and EOS,,2024-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12401,NCT00086515,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24,,2004-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
12402,NCT02995863,Presence of diabetic foot ulcer,Toe - Brachial Index (TBI),,2016-12-10,COMPLETED,INTERVENTIONAL,['NA']
12403,NCT02463682,"Safety and efficacy of the system, as assessed by the composite outcome of time in range for glucose levels of 70-180 mg/dL and time < 70 mg/dL.",Failure analysis of the devices/connectivity issues that may occur.,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
12404,NCT00740012,Glucose (continuous glucose monitoring),"Hormones (norepinephrine, cortisol, glucagon, growth hormone, prolactin), Pulse, Blood glucose",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
12405,NCT03452605,BOLD fmri response,,,2015-11-20,COMPLETED,INTERVENTIONAL,['NA']
12406,NCT02235298,Epicardial Fat Thickness,Left Ventricular Mass (LVM),,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12407,NCT01871558,Percentage of Patients Who Reported at Least One Symptomatic Hypoglycemic Event During the 24 Week Randomized Period in Both Treatment Arms,Percent of Participants That Reach Therapeutic Goal (HbA1c ≤ 7%) at Week 24 Without Any Hypoglycaemic Episode (Symptomatic or Not) and Without Any Weight Gain (Variation ≥3% Compared to Baseline),,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12408,NCT02372955,arterial stiffness,composite intravascular volume status,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12409,NCT04068805,Change in self-reported HbA1C level,Change in positive affect [Patient-Reported Outcomes Measurement Information Systems - Positive Affect Subscale(PROMIS)],,2020-08-31,TERMINATED,INTERVENTIONAL,['NA']
12410,NCT02545842,Percentage of patients with HbA1c <7% achievement,Percentage of patients experienced hypoglycemic events,,2015-09-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12411,NCT05076656,Changes in HOMA-IR,Changes in glucose metabolism,,2019-06-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12412,NCT01430221,Severity of depressive symptoms,Changes in inflammation,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
12413,NCT02066155,Hemoglobin A1C,BMI,Diabetes-related distress,2013-01,COMPLETED,INTERVENTIONAL,['NA']
12414,NCT06202742,Subjective Sleep Quality,Objective sleep parameters,,2024-03-08,RECRUITING,INTERVENTIONAL,['NA']
12415,NCT01268995,90 days OGTT,Hypoglycemia,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12416,NCT05717933,thyroid abnormalities among children and adolescents with type 1 diabetes mellitus when its first detected and its relationship with disease-related variables.,,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12417,NCT05885659,Variability of glycemic levels,Anthropometric data,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12418,NCT04166032,Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device,,,2019-11-06,COMPLETED,INTERVENTIONAL,['NA']
12419,NCT00757601,Number of Participants Who Discontinued Treatment Due to an AE,Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12420,NCT03156179,fractional calcium absorption,Estimated calcium retention,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
12421,NCT03974464,Show that the negativity of S-100b protein and copeptin eliminates stroke in the face of vertigo,,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
12422,NCT02733315,Weekly self-monitoring of blood glucose times as determined by medical chart review,fasting plasma glucose as determined by medical chart review,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12423,NCT02027571,The primary outcome measure is restoration of normal glucose regulation,Glucose normalization,Incident prediabetes in observational cohort,2013-10,COMPLETED,INTERVENTIONAL,['NA']
12424,NCT06185192,Fasting Insulin levels,"Species prevalence in stool, blood, and saliva",,2023-12-13,RECRUITING,INTERVENTIONAL,['NA']
12425,NCT01326117,improvement in Gastric Emptying Study residual tracer amount,,,2011-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12426,NCT02156037,HbA1c,Depression,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
12427,NCT02497313,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve,Appetite as assessed by Visual analog scale score,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12428,NCT00263835,Change in hemoglobin A1c.,"Change in blood pressure, cholesterol, and weight.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12429,NCT01707160,Area under the Curve,Adverse events,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12430,NCT03269058,Change from baseline the Fractional Catabolic Rate of HDL 'Apo A1,,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
12431,NCT05994586,Discomfort related to metformin side effects,HbA1c level,,2023-05-25,RECRUITING,INTERVENTIONAL,['NA']
12432,NCT05700877,Rates of a composite cardiovascular endpoint,Cost-effectiveness,Cardiovascular risk markers 4,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4']
12433,NCT03547440,Metabolic control,Akkermansia muciniphila quantification in stool,Metabolic control 2,2015-03-18,UNKNOWN,OBSERVATIONAL,['NA']
12434,NCT00985881,Gait variability,,,2007-04-01,COMPLETED,INTERVENTIONAL,['NA']
12435,NCT04880850,Change in Glycated haemoglobin (HbA1c),Change in body weight,,2021-05-14,COMPLETED,INTERVENTIONAL,['PHASE3']
12436,NCT02148978,glucose tolerance after treatment with Saxagliptin,,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
12437,NCT04981067,Median effective anesthetic concentration 90 (MEAC 90),Any adverse events,,2021-08-24,RECRUITING,INTERVENTIONAL,['NA']
12438,NCT04637841,Evaluation of relaxation time,Evaluation of skin temperature,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
12439,NCT00672919,Change from Baseline in Triglyceride Levels,Change from Baseline in C-reactive Protein,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12440,NCT01347814,Gastric emptying half time,Appetite sensations,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
12441,NCT04645732,"EQ-5D-5L, the descriptive index",Mortality,Vigorous Intermittent Lifestyle Physical Activity (VILPA): Time spent on VILPA intensity activities,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12442,NCT04463082,Change in collapsibility index pre- and post-hydration,Correlation to body surface area,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
12443,NCT03554486,Percentage of Time in Range: Sensor Glucose Readings <70 mg/dl,Mean Sensor Glucose in mg/dl,,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12444,NCT05047237,Point estimates of Feasibility Measures: Time,Implementation Metric- Value,,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12445,NCT01316016,,,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12446,NCT00822471,"Improvement in the percent of subjects correctly identifying guideline-recommended treatment targets for the ""ABC's of Diabetes"", where A = A1C < 7%; B = BP <130/80mmHg and; and C = LDL-C < 100mg/dl.",Decrease the percentage of participants with self-reported ED visits and hospitalizations for severe hypoglycemia and hyperglycemia.,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
12447,NCT00737022,Macular appearance,Post-operation best-corrected visual acuity,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
12448,NCT04604223,Difference in the incidence at 4 weeks of a composite outcome comprised of:,Incidence at 4 weeks of a composite of extrapulmonary disease comprised of :,,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
12449,NCT00621140,HbA1c Change From Baseline at Week 24,Adjusted Means for 2h Post Prandial Blood Glucose (PPG) Change From Baseline at Week 24,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12450,NCT00437970,Medication side effects,Endothelial dysfunction.,,2008-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12451,NCT06057805,CGM metric of mean glucose compared to OGTT result,CGM variability measure MAGE will be compared to fructosamine test,Tolerability to dexcom adhesive,2024-02-06,RECRUITING,INTERVENTIONAL,['NA']
12452,NCT02641743,plasma glucose concentration,plasma free fatty acid concentration,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12453,NCT05951569,Measure of Loop Safety by Self-Report of Hospitalization Events,,HbA1c,2023-06-20,COMPLETED,OBSERVATIONAL,['NA']
12454,NCT00032487,Primary Major Macrovascular Events,Secondary Endpoint,,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12455,NCT03369834,strength capacities,blood flow,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
12456,NCT00271284,Efficacy data : fasting blood glucose concentration,Tolerance data : undesirable events including episodes of hypoglycaemia,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12457,NCT05521893,Average postprandial glucose concentration,Incidence of caesarean section,,2020-03-12,COMPLETED,INTERVENTIONAL,['NA']
12458,NCT00946257,Safety and tolerability after a single dose of otelixizumab in T1DM patients,,,2009-07-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12459,NCT03961516,Pancreatic Fat and Glycemic measures,Pancreatic Fat by Modulator Status,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
12460,NCT06296485,Hypoglycemia aggregate outcome,Hypoglycemia Distress,Caregiver Action,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12461,NCT06006312,the prevalence of pancreatic exocrine insufficiency,Insulin level,,2023-08,RECRUITING,OBSERVATIONAL,['NA']
12462,NCT04442451,Capillary density,,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12463,NCT05072990,"Changes from Baseline Body Mass Index at 3 months, 6 months",Changes from Diastolic Blood Pressure at 6 months,,2021-10-27,COMPLETED,OBSERVATIONAL,['NA']
12464,NCT02811289,whole body organ glucose partitioning,Electrocardiogram,,2016-08-05,COMPLETED,INTERVENTIONAL,['NA']
12465,NCT03769675,Positive Pain,Extensor Digitorum Brevis Muscle Nerve Conduction,,2018-11-20,COMPLETED,INTERVENTIONAL,['NA']
12466,NCT01726114,Performance of the test device in comparison to the reference device,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
12467,NCT05749029,Change in Diabetes Distress Scale (DDS) scores from baseline (week 0) to post-intervention (week 4).,Change in Compassionate Engagement and Action Scale (CEAS) scores at baseline (week 0) to follow-up (week 8).,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
12468,NCT01180972,"Assess the built environment for energy requirements of movement, nutrition options, suitability for outdoor physical activity, and for children's actual physical activity and energy expenditure within those environments.",Assess the impact of children's social environment on movement and nutrition choices within the built environment.,"Conduct a quantitative assessment of children's fitness, obesity, and indicators of metabolic health.",2010-08,COMPLETED,OBSERVATIONAL,['NA']
12469,NCT04219085,Composite Primary Outcome,hypertensive disorders of pregnancy.,,2020-09-01,RECRUITING,INTERVENTIONAL,['NA']
12470,NCT00543595,,,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12471,NCT00770640,Change of total daily Insulin Dose.,Change from Baseline in intact Parathyroid Hormone.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12472,NCT02231736,The quality of HbA1c influences micronuclei formation in binucleated cells,Type 2 diabetes duration of the subjects influences chromosomal damage,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
12473,NCT00744458,Percentage of patients with regular follow-up one year after the treatment was started,Treatment response of patients with arterial hypertension (blood pressure),,2008-08,COMPLETED,INTERVENTIONAL,['NA']
12474,NCT02655757,Changes in late lumen loss of target lesion,Incidence rate of MACE,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12475,NCT05689372,Number (incidence) of adverse events (AEs),Dose of Ozempic,,2024-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12476,NCT00770939,Percentage of patients with a 50% reduction of wound area after 4 and 8 weeks,Granulation rate,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12477,NCT06296836,Mean glucose levels,Mortality,Mean glucose levels while receiving metformin in the continuation arm and while not receiving metformin in the discontinuation arm,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12478,NCT02380339,Reduction of fear of hypoglycemia in type 1 diabetic patients as measured by reduction of 2 point on the HFS-W). pre-treatment and after two months post completion of treatment.,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
12479,NCT05830994,Changes in gastric emptying,Incidence of Treatment-Emergent Adverse Events rated by the ASGE lexicon for adverse events,,2023-04-12,RECRUITING,INTERVENTIONAL,['NA']
12480,NCT01578460,Offspring Birth Weight,Shoulder Dystocia (neonatal),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
12481,NCT00837512,Onset Time (Tmax),,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12482,NCT04825366,Change in the Gold score,Number of severe hypoglycemia,,2021-08-03,RECRUITING,INTERVENTIONAL,['NA']
12483,NCT05326204,Fetal weight,perinatal complications,,2021-12-30,RECRUITING,OBSERVATIONAL,['NA']
12484,NCT01472640,"Change in Left ventricular function from visit 1 to week 24, measured by Ecco",left ventricular diastolic function,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12485,NCT03218735,Number of children with birthweight above 4500 grams,Number of children admitted to NICU,,2017-07-12,WITHDRAWN,INTERVENTIONAL,['NA']
12486,NCT01068717,"Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States","Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12487,NCT02709577,Change in HbA1c Values From Baseline Measurement,Absolute Weight Change,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12488,NCT01384058,"Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs",Change of the concentrations of triglycerides,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12489,NCT05577104,the time to STSG surgery,the wound neutrophil extracellular traps (NETs) formation,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
12490,NCT02865525,Number of events 'hospitalization and death' for 2 patient groups defined through the questionnaire QUILAM score,Number of events 'hospitalization and death' for 2 patient groups separate with different cut off,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
12491,NCT05893576,Calculate the ratio of bioavailability between the new formulation and original formulation of HRS9531 according to the equation F (relative bioavailability) =AUCT·DR/AUCR·DT×100%,Incidence and severity of adverse events,,2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1']
12492,NCT01930110,The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).,The amount of dextrose infused,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12493,NCT03430310,Pancreas lipid,Insulin secretion,,2018-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12494,NCT01526980,Glucose average in 24-hour blood glucose profiles,Adverse events,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12495,NCT00959101,AUC0-t and Cmax (after repaglinide 2.0 mg and metformin 500 mg as co-administered tablets and combination tablet dosing under fed state),Repaglinide AUC(0-24 & 0-∞) and Cmax after combination tablet (repaglinide 1.0 mg/metformin 500 mg) during fed state,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12496,NCT05632601,Satisfaction Questionnaire,,,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
12497,NCT04758858,Percentage of time-in-target (range of 4-10 mmol/L),Self-reported symptoms,,2021-03,WITHDRAWN,INTERVENTIONAL,['NA']
12498,NCT01868191,Change from baseline in intraepidermal nerve fiber density,Change in neuropathic deficits,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
12499,NCT03529123,Change in HbA1c,Change in SMPG profiles,,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
12500,NCT03166852,Frequency of training,Interview,,2016-04-27,COMPLETED,INTERVENTIONAL,['NA']
12501,NCT00246987,Change in HbA1c from baseline to Week 24,Changes achieved from baseline in FPG after 24 weeks. Changes achieved from baseline in 3 hour post-prandial AUC for glucose and insulin levels after 24 weeks vs. placebo.,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12502,NCT02719132,Composite endpoint including quality of life score,Proportion of patients,laboratory values changes,2016-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12503,NCT02748239,A1c values,Depression,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12504,NCT05198765,Change in weight trajectory during 18-month post-intervention follow-up period,Intentions to engage in weight loss,,2023-04-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12505,NCT00848757,Change in Blood Pressure,Physical Activity Levels (Self-reported),,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12506,NCT02903199,Postprandial capillary glucose,24 h Interstitial Glucose,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
12507,NCT02821052,Incidence of AEs (adverse event),Change in Glycosylated haemoglobin A1c (HbA1c),,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
12508,NCT00420095,Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint,Hypoglycemia Rate Per Participant Per 30 Days,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12509,NCT03916640,AUCIns 0-8h,Safety and tolerability (Adverse Events recording),,2019-01-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12510,NCT04511325,The effects of daily white potato versus white rice consumption for 12 weeks (each intervention for 12 weeks with a 2-week washout period) on pulse wave velocity (PWV) in individuals with type 2 diabetes mellitus.,The effects of daily white potato versus white rice consumption for 12 weeks (each intervention for 12 weeks with a 2-week washout period) on waist-to-hip ratio in individuals with type 2 diabetes mellitus.,,2019-04-27,COMPLETED,INTERVENTIONAL,['NA']
12511,NCT05743907,HbA1c(%),,,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE4']
12512,NCT02844803,Change of serum glucose level after 8 weeks from baseline,,,2016-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12513,NCT04599738,Change in insulin response from baseline for 180 minutes,Satiety by visual analogue scale for 4 hours,,2017-03-06,COMPLETED,INTERVENTIONAL,['NA']
12514,NCT05884957,ِAssessments of endothelial nitric oxide synthase In diabetes mellitus,Tadalafil 5milligram (tablets) therapy in diabetic patients,,2023-06-01,COMPLETED,INTERVENTIONAL,['NA']
12515,NCT05380232,All-cause mortality,Major adverse cardiovascular events (MACE),,2006-03,COMPLETED,OBSERVATIONAL,['NA']
12516,NCT01695278,Change in hemoglobin A1c,Task related self-efficacy for initiating and maintaining diabetes self-management,Diabetes self-management behaviors,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12517,NCT06278181,asymptomatic malaria,symptomatic malaria,strongyloides infection,2023-09-21,RECRUITING,OBSERVATIONAL,['NA']
12518,NCT03851627,Liver fat,diabetes management satisfaction questionnaire,amount of pancreatic fat,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE4']
12519,NCT00959348,To investigate the ICS effect on the risk of DM/IGT/insulin resistance,To study the dose response relationship and effect modifying factors if risk is present,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
12520,NCT00562029,Measure: Resolution of Type 2 Diabetes Mellitus,Measure: Safety and efficacy of duodenal-jejunal bypass,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
12521,NCT04392557,side effects,lipid metabolism/atheroscelorisis,,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12522,NCT00191464,HbA1C,Apolipoproteins [substudy],,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12523,NCT01304537,Safety and Tolerability,Efficacy,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12524,NCT03504059,Changes in the composite ICH score of adolescents from baseline to year 2 and 4,Changes in the composite ICH score of adolescents from baseline to adulthood,,2017-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12525,NCT04786418,"Changes in liver fat >5 percent, determined by MRI, from baseline to after 12 months of intervention.","Multi organs pancreas, spleen and kidney fat content",,2021-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12526,NCT01292590,Change in insulin requirements,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
12527,NCT04764279,Partial Remission of Diabetes,Reduction in Visceral Adiposity,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
12528,NCT04020068,Improvement of patient care,,,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA']
12529,NCT04069611,Probing Pocket Depth (PPD),Patient Satisfaction,,2020-01-30,RECRUITING,INTERVENTIONAL,['NA']
12530,NCT04726163,Percentage of time spent in the range 70-180 mg / dl (TIR),Time spent bellow glycaemia < 70mg/dl,,2021-01-29,TERMINATED,INTERVENTIONAL,['NA']
12531,NCT04466007,Complication rate after treatment administration,% amputations,VascuQol-6 questionnaire,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12532,NCT05097534,Change from baseline HbA1c,Change from baseline medication Adherence,,2021-12-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12533,NCT00662519,Number of participants with adverse events,Increase T regulatory cells (Treg) from the bone marrow,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12534,NCT02053077,"Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week",Usability: Coverage of the GlucoTab,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
12535,NCT02737657,Percentage of Participants With at Least one Episode of Hypoglycaemia,Relationship of Volume Depletion Events With Number of Fasting Days,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
12536,NCT05140564,HbA1c,,,2022-01-18,COMPLETED,INTERVENTIONAL,['NA']
12537,NCT05470842,"Proportion of participants with captured hypoglycaemia; within that group, the time spent in the hypoglycaemic range","Emergency department re-attendances and/or hospital re-admissions for falls, fractures, heart attacks, ischaemic strokes and death within 30 days",,2023-06-06,COMPLETED,INTERVENTIONAL,['NA']
12538,NCT01288326,Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1%,Frequency of hypoglycaemic episodes (frequency of episodes with low blood sugar),,2011-02,COMPLETED,OBSERVATIONAL,['NA']
12539,NCT04632862,HbA1c level at Week 24 after administration of the IP,"HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",,2020-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12540,NCT04160078,Number of Participants With PSS Score Indicating High Stress,Blood Pressure,,2019-12-18,COMPLETED,INTERVENTIONAL,['NA']
12541,NCT05415878,Offloading adherence,Cumulative plantar tissue stress,Correlates of joint pain,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12542,NCT01270191,The time of monotherapy failure and monotherapy failure rate,"Comparison of A1C change, the proportion of subjects who reached the treatment target",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12543,NCT04864483,Incidence of early day hypoglycemia,Patient satisfaction and preference,,2021-03-21,COMPLETED,INTERVENTIONAL,['NA']
12544,NCT05005741,haemoglobin A1c(HbA1c),Homeostasis model assessment for β cell(HOMA-β),,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12545,NCT05359796,the development or progression of diabetic retinopathy,the changes of carotid intima-media thickness(IMT),,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
12546,NCT05388721,Environmental contaminants 2,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
12547,NCT00446251,The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion.,The Number of Subjects With a Negative Crossmatch at the Time of Transplant.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12548,NCT03327896,Provider Ranking as Assessed by Health Care Quality Metrics,Colorectal Cancer Screening (Patient level),,2017-01-15,UNKNOWN,OBSERVATIONAL,['NA']
12549,NCT03137966,Healing,Improvement of ulcer,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12550,NCT03966911,Percentage of Readings Within 20% Agreement,,,2019-06-14,COMPLETED,INTERVENTIONAL,['NA']
12551,NCT00486187,Change in adiponectin level in the rosiglitazone vs. metformin/sulfonylurea arms,"Secondary end-points include changes in leptin, resistin, hs-CRP, IL-6, MMP-9, ICAM-1, insulin sensitivity (as estimated by the HOMA technique), HbA1c, and lipid levels in the rosiglitazone vs. metformin/sulfonylurea arms",,2006-04,COMPLETED,INTERVENTIONAL,['NA']
12552,NCT01469481,radioactivity t1/2,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12553,NCT02232971,Maximum plasma glucose response,Duration of hyperglycemic effect of glucagon,Plasma triglycerides,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12554,NCT04143945,Intensity of Injection Site Pain,,,2019-10-28,COMPLETED,INTERVENTIONAL,['PHASE2']
12555,NCT04450810,Clinical attachment level,,,2014-06-01,COMPLETED,OBSERVATIONAL,['NA']
12556,NCT03938441,Number of hypoglycemic events,,,2019-07-31,TERMINATED,INTERVENTIONAL,['NA']
12557,NCT06305377,Glucometric data,,,2024-03-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12558,NCT03455101,Glycemia control status of Turkish adult patients with diabetes mellitus,Weight control status of Turkish adult patients with diabetes mellitus.,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
12559,NCT00929201,Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin,Peak Plasma Concentration (Cmax) of Metformin,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12560,NCT03543644,75g OGTT derived plasma glucose iAUC,75g OGTT derived Matsuda whole body insulin sensitivity index [Matsuda ISI OGTT],Urinary and blood proteomic panel,2018-05-31,COMPLETED,INTERVENTIONAL,['NA']
12561,NCT01618162,Change in Glycosylated Haemoglobin (HbA1c),Number of Adverse Events (AEs),,2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
12562,NCT03701087,incidence of gestational diabetes recurrence,,,2018-08-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12563,NCT02782195,To measure the rate of glucose absorption after a standard evening meal,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
12564,NCT03293082,Glucose variability,HbA1c,,2017-09-30,COMPLETED,OBSERVATIONAL,['NA']
12565,NCT04972539,Cmax,,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12566,NCT05816759,AUCt of CKD-383,,,2023-05-26,COMPLETED,INTERVENTIONAL,['PHASE1']
12567,NCT01017302,Safety and Tolerability of various doses of RO5095932,"Pharmacodynamics: glucose, insulin, C-peptide",,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12568,NCT03666546,Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)],"Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min))",Blood glucose concentration at 240 minutes - only when blood glucose is >10 mmol/L (>180 mg/dL) at 180 minutes,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4']
12569,NCT00160927,,,,2003-01,UNKNOWN,OBSERVATIONAL,['NA']
12570,NCT02702375,Gout,,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
12571,NCT05544214,"Cmax of CKD-371, D745+D759",,,2022-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
12572,NCT02088658,Hemoglobin A1c,Resource Utilization & Cost,,2013-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12573,NCT01357889,Maximum Observed Plasma Concentration (Cmax) of Albiglutide in the BE Phase,Number of Participants With a Change From Baseline of Clinical Concern in Electrocardiogram (ECG) Values by Any On-therapy Visit,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12574,NCT05988346,normalization of LV diastolic dysfunction,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
12575,NCT00338923,Safety,Time to Heal & Rate of Healing,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12576,NCT02608177,Glucose Time in Range,Biomarkers of Albuminuria,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
12577,NCT02097069,Insulin resistance level evaluated by homeostasis model assessment of insulin resistance (HOMA-IR),insulin therapy requirements,,2014-04,UNKNOWN,INTERVENTIONAL,['NA']
12578,NCT01805414,Relative change in Blood sugar,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
12579,NCT02982408,Adipose tissue expandability,Epigenetics,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
12580,NCT02926937,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo),Change From Baseline in HbA1c at Week 26 (Sotagliflozin 200 mg Versus Placebo),Percentage of Participants With Hypoglycemic Events (Sotagliflozin 200 mg Versus Placebo),2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12581,NCT06238778,hypoglycemia percentage of time,blood chemistry values,,2024-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
12582,NCT03703440,Hemaglobin A1c (HbA1c),Cost effectiveness (self-efficacy),,2019-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12583,NCT05560256,Building Capacity in Human-Centered Design: Developing a Diabetes mHealth Application for and with Kenyan Adolescents,,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
12584,NCT02778269,Number of power-line interference on the ECG,"Number of congruences concerning identified arrhythmias of this validation study and the previous study ""Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease"".",,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12585,NCT06150495,"Retinal vessel density (VD, %)",,,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12586,NCT00361868,HbA1c/TG,Lipid and glycemic parameters.,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12587,NCT03906201,Changes in glycosylated hemoglobin (A1C) after 90 days of intervention with betaecdysterone and placebo,Blood pressure,,2019-02-06,UNKNOWN,INTERVENTIONAL,['NA']
12588,NCT05097339,Change in ketone concentration during and after morning Aerobic and Symptom Limited Maximal Exercise Test,,,2019-05-10,COMPLETED,OBSERVATIONAL,['NA']
12589,NCT02592421,Change in Endogenous Glucose Production (EGP),Change in Glucagon During EGP Measurement,,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
12590,NCT00813020,"AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration",Cmax of the plasma NN9535 curve,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12591,NCT05626842,Primary study objective- HbA1c,Secondary study objective- participant experience,,2021-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12592,NCT03574558,Number of hypoglycemic below 54 mg/dl,,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
12593,NCT02390973,Type 2 diabetes remission rate,Dislipidemia remission,Long-term complications,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
12594,NCT04022499,Weight loss,Attendance,,2019-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12595,NCT01379690,Hip Fracture,,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12596,NCT00761540,AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing.,Hypoglycaemic events,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12597,NCT02299960,Test-retest-reliability EndoPAT,Clinical feasibility of circulating endothelial cells and EndoPAT,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
12598,NCT05421390,Change in whole-body insulin sensitivity,Change in C-reactive protein,Change in subcutaneous adipose tissue gene expression signature,2022-06-10,RECRUITING,INTERVENTIONAL,['NA']
12599,NCT02341664,"Lipid-lowering therapy use among a contemporary, nationally representative, community-based sample of adult patients receiving primary and subspecialty care in the US.",,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
12600,NCT03708887,Change in blood lipids from baseline,Change in gut microbiota from baseline,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12601,NCT01572610,Adverse Event collection and assessment,,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
12602,NCT06229379,Students' scores in the medical history acquisition exam,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12603,NCT02957721,Change in A1C,Blood Pressure (BP),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
12604,NCT00644748,Change from baseline Mean Pain Score,Global Change Impression from the Physician's Point of View,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12605,NCT05794009,Glycated Hemoglobin (HbA1C),Depression,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
12606,NCT04691973,Change of long-term blood glucose concentration measured as glycated hemoglobin at one year,Insulin secretion,"Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.",2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12607,NCT02423993,HbA1c,Quality of Life (SF36 Questionnaire),,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12608,NCT05360147,Changes in cognitive function from baseline to 12 weeks,Changes of metabolic parameters from baseline to 12 weeks,,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
12609,NCT01208012,The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells,Safety evaluation,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12610,NCT01875224,Decreased insulin resistance,,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
12611,NCT01398670,Change in HbA1c,Correlation of the immunogenicity with hypoglycemia,,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12612,NCT04946188,Validation of predictive model for determining blood glucose levels,,,2020-07-21,COMPLETED,INTERVENTIONAL,['NA']
12613,NCT04127383,Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care,Productivity losses,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
12614,NCT04858386,Excessive Fetal Growth,Adverse Pregnancy Outcomes,,2017-11-01,TERMINATED,OBSERVATIONAL,['NA']
12615,NCT04456192,C-reactive protein concentration (CRP) [mg/l],"Resting SBP [mmHg], Resting DBP [mmHg], Exercise SBP [mmHg], Exercise DBP [mmHg]",,2013-01-01,COMPLETED,INTERVENTIONAL,['NA']
12616,NCT01798706,Absolute Change in HbA1c From Baseline to Week 24,Percentage of Participants With Gastrointestinal Disorders,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12617,NCT05819749,Acceptability of intervention,Diabetes medication adherence,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
12618,NCT03845465,Glycemic Control (HbA1c),Diabetes-Related Quality of Life,,2019-12-17,COMPLETED,INTERVENTIONAL,['NA']
12619,NCT03316690,Change in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Training rate of perceived exertion,,2017-10-20,COMPLETED,INTERVENTIONAL,['NA']
12620,NCT03547427,Relative glucagon counterregulation (GCR) response,Rate of gastric emptying,,2018-05-20,TERMINATED,INTERVENTIONAL,['NA']
12621,NCT05658770,MAGE,quality of life (self-reported questionnaire),,2023-09-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12622,NCT02024971,Number of Participants With Adverse Drug Reactions,Change From Baseline in Fasting Insulin,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
12623,NCT00719251,Quality of life with the EQ-5D.,"Sociodemographic data like gender and age, were recorded. Additionally clinical history, deformities, alcohol dependence or smoking history, previous and present pharmacologic treatment and corticosteroids were included.",,2004-03,COMPLETED,INTERVENTIONAL,['NA']
12624,NCT01033500,Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year.,,,2010-07,WITHDRAWN,INTERVENTIONAL,['NA']
12625,NCT02254291,Number of Treatment Emergent Adverse Events (TEAEs),Change in Glycosylated Haemoglobin A1c (HbA1c),,2014-10-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12626,NCT04148482,Hunger perception before and after test meals consumption using visual analogue scales,Appetite satiety hormones levels by immunoassay kits,,2021-06-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12627,NCT05262595,"AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)","GIRmax,basal-corrected: Maximum observed basal-corrected GIR",,2022-03-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12628,NCT06243172,"Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU))","Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU))",Cardiovascular autonomic neuropathy,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12629,NCT00940251,antidiabetic activity,"Improvement in metabolic, insulin level, HbA1c,kidney and lipid profile",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12630,NCT02545140,Chronic disease risk factor - Body mass index (BMI),Chronic disease risk factor - total cholesterol,Risk tool refinement,2015-10,COMPLETED,OBSERVATIONAL,['NA']
12631,NCT02215200,Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12632,NCT01681550,Death,Macrovasular complications,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
12633,NCT02682056,Glucose Level,Pain Level Assessed by Pain Visual Analog Scale (VAS),,2017-12-21,COMPLETED,INTERVENTIONAL,['NA']
12634,NCT00235469,"To investigate the efficacy of 200, 400, and 600 mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12635,NCT03020069,Change in Score of Diabetes Empowerment Scale Short Form (DES-SF) From Baseline to 3 Months,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
12636,NCT01944449,Fasting circulating levels of HbA1c,Body Weight,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
12637,NCT00130845,time to progression of diabetic retinopathy,time to moderate vision loss,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12638,NCT01758757,Incidence of retinal breaks,Incidence of neovascular glaucoma,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12639,NCT00297401,Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin.,Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12640,NCT00324363,To test the hypothesis that exenatide (before morning and evening meals) produces a greater decrease in HbA1c than placebo in patients with type 2 diabetes and inadequate glycemic control taking metformin alone or metformin and sulfonylureas.,To compare exenatide and placebo groups with respect to: *safety and tolerability; *proportion of patients achieving HbA1c<=7%; *body weight; *incidence and rate of hypoglycemic events; *glucose measurements,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12641,NCT02969954,Self-efficacy for diabetes management,,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
12642,NCT04769687,inflammation,fragility,,2020-11-21,RECRUITING,INTERVENTIONAL,['PHASE2']
12643,NCT00924599,Gestational diabetes not present in pregnancy,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
12644,NCT00751114,HbA1c: Change From Baseline to Study Endpoint,Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12645,NCT00696605,,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
12646,NCT05029271,Endpoints are exploratory and descriptive related to time in glycemic range.,,,2023-04-17,COMPLETED,INTERVENTIONAL,['NA']
12647,NCT00935064,Expiration/Inspiration Ratio Before and After Treatment,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
12648,NCT05906199,Changes in carotid IMT,,,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE4']
12649,NCT04315688,Change in laboratory measured HbA1c (mmol/mol),"Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable (according to pre-specified response options)",,2020-03-30,COMPLETED,OBSERVATIONAL,['NA']
12650,NCT02713321,Diabetes-related preventable hospitalizations,Number of months of Medicaid coverage,,2017-01-24,COMPLETED,OBSERVATIONAL,['NA']
12651,NCT05893784,Fatigue Severity Scale,,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA']
12652,NCT01436916,Change in insulin sensitivity using OGIS (oral glucose insulin sensitivity index),Change in fasting and post prandial blood glucose,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12653,NCT03430856,Change From Baseline in HbA1c at 24 Weeks (Part 1),CGM,Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24,2017-12-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12654,NCT05350553,Methylglyoxal Evaluation,Neuropathy Status using the Michigan Neuropathy Screening Index,,2022-05-02,UNKNOWN,OBSERVATIONAL,['NA']
12655,NCT02923960,Plasma Glucose Concentration,Serum Insulin Concentration,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
12656,NCT06062576,2-week reduction rate of wound area,,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12657,NCT00328965,To investigate the clinical effectiveness of lacidipine on elevated systolic blood pressure (SBP) in Korean patients aged 35 to 75 years.,To investigate the clinical effectiveness of lacidipine on elevated diastolic blood pressure and endothelial function by flow-medicated vasodilation and measurement of markers of inflammation in Korean patients aged 35 to 75 years with type 2 diabetes.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12658,NCT00228579,Visceral adipose tissue volume,Insulin sensitivity,,2003-06,COMPLETED,OBSERVATIONAL,['NA']
12659,NCT04161976,PK: Maximum Observed Insulin Lispro Concentration (Cmax),Duration Until Catheter Failure,,2019-12-27,COMPLETED,INTERVENTIONAL,['PHASE1']
12660,NCT05011292,Percentage of parents who report that they do not give their young children fruit juice,Percentage of parents who viewed an intervention video report that they enjoyed it or learned something from it,,2021-08-10,COMPLETED,INTERVENTIONAL,['NA']
12661,NCT06289920,Cmax,,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1']
12662,NCT00546741,To determine the effect of metformin on the exposure of dapagliflozin and the effect of dapagliflozin on the exposure of metformin in healthy subjects after a single dose of each treatment,To assess the safety and tolerability of dapagliflozin when administered alone or with metformin after a single dose of each treatment,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12663,NCT04115579,Postprandial glucose,Postprandial insulin,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
12664,NCT03003793,Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12665,NCT04336176,Pressure Time Integral,Modified Monitoring Orthopaedic Shoes questionnaire,,2018-03-22,COMPLETED,INTERVENTIONAL,['NA']
12666,NCT04965935,Systolic blood pressure,Adverse Events (AEs),,2021-07-15,RECRUITING,INTERVENTIONAL,['PHASE3']
12667,NCT06296992,Retention for follow-up measurements,Quality of Life (PedsQL 4.0),Motivation for Physical Activity (EMI-2),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12668,NCT06071559,"Blood tests for extracellular vesicles comparing two years after surgery with baseline (below referred to as ""changes in"").",,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
12669,NCT05488210,Muscle mass (%),Sensory perception,,2022-07-01,UNKNOWN,OBSERVATIONAL,['NA']
12670,NCT00403026,"Electrophysiological changes (ERG, VEP)","Ocular side effects (infection, RD, IOP rise, cataract)",,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
12671,NCT02330549,Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR ) Index,Number of Participants With Abnormal Physical Examination Findings,,2015-07-17,COMPLETED,INTERVENTIONAL,['PHASE2']
12672,NCT02040441,Albuminuria,Slope of estimated GFR,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12673,NCT05708820,HbA1c,Awareness of hypoglycemia,,2022-12-14,RECRUITING,INTERVENTIONAL,['NA']
12674,NCT02707406,Incidence of adverse events collected throughout the trial compared between the two groups,Difference in score of quality of life assessment determined by Cardiff Wound Impact Schedule (CWIS),,2016-02,COMPLETED,INTERVENTIONAL,['NA']
12675,NCT06315361,Prevalence of significant fibrosis by non invasive tests,Identification of MACE,,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12676,NCT02156843,Time to composite endpoint of >=50% SCr increase from baseline or ESRD,Time to the composite endpoint >=100% SCr increase or ESRD,Change in SCr,2014-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12677,NCT01117103,Proportion of subjects who discontinue Glucophage XR treatment prematurely (< 12 weeks) due to side effects,Change in glycosylated haemoglobin (HbA1c) levels from baseline after 12 weeks,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
12678,NCT06260722,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE3']
12679,NCT05273840,the proportions of participants regressing back to normal glucose level,body weight,changes in triglyceride level (blood lipids),2021-06-11,RECRUITING,INTERVENTIONAL,['NA']
12680,NCT00655200,Safety profile of Insulin Detemir among Filipino patients,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
12681,NCT01481623,"Identification and genetic, clinical and metabolic characterization of monogenic diabetes forms",Clinical and biological characterization of total or partial deficiency of the genes responsible for monogenic diabetes,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
12682,NCT01136902,Vessel caliber,Blood glucose level,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
12683,NCT02605148,Change in glucose metabolism,Incidence of Treatment-Emergent Adverse Events,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
12684,NCT03410537,Ankle-brachial index,Fasting serum insulin,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
12685,NCT01647308,Total apoC-III,Insulin Sensitivity,,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12686,NCT03576300,Tear cytokines levels,Clinical correlations of the tear cytokines,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA']
12687,NCT03909451,Adverse events (AEs),Assessment of PD parameter: urinary glucose excretion (UGE),,2019-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
12688,NCT00384085,Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis),Adjusted Hypoglycemic Event Rates (Event/Patient-year),,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12689,NCT04529590,Rate of cardiovascular death,Rate of all-cause death,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
12690,NCT01885234,glycated hemoglobin,HOMA,First ventilatory threshold,2011-12,COMPLETED,INTERVENTIONAL,['NA']
12691,NCT02668601,hypothalamic CBF,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
12692,NCT06061237,Functional reach test,Muscle mass,,2022-09-19,COMPLETED,INTERVENTIONAL,['NA']
12693,NCT02175784,Change in HbA1C from baseline,"Safety assessed by the adverse events, vital signs. and laboratory tests",,2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE4']
12694,NCT02284269,Incidence of adverse events,The change from baseline in Fasting Plasma Glucose,,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
12695,NCT01988246,Number of Participants With Ocular and Non-Ocular Adverse Events,Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score,Change From Baseline in Retinal Thickness,2013-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12696,NCT00605592,A decrease in the average daily insulin requirement post-islet cell transplantation.,,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
12697,NCT04992325,"The measurements of corneal features in patients with type 2 diabetes mellitus, using anterior segment-optical coherence tomography",,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
12698,NCT02428998,All adverse events occurring up to 24 weeks time after taking the Investigational product,Baseline by 24 weeks after the change in quality of life measures ingestion of Investigational product,variation of biological age,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12699,NCT04945109,Changes in glycemic control,questionnaire 4,,2021-10-19,COMPLETED,INTERVENTIONAL,['NA']
12700,NCT01809184,Number of adverse events (AEs),Area under the glucose infusion rate (GIR)-time curve,,2013-03-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12701,NCT01875783,Rates of Retina Care Referral for Patients With Diabetic Macular Edema,Rates of Retinal Treatment Over 1 Year for Patients With DME,,2014-03-17,COMPLETED,INTERVENTIONAL,['NA']
12702,NCT01028404,Number and severity of adverse events for trial part 2,Area under the glucose infusion rate-time curve after a single dose,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12703,NCT03592667,Ambulatory arterial stiffness index,Glomerular filtration rate,,2019-02-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
12704,NCT01274663,Single dose pharmacokinetics of PF-05175157,Exploratory pharmacodynamic biomarkers,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12705,NCT02960295,Compliance With Requirements for Frequency of Glucose Measures,Glucose Concentrations,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12706,NCT04121572,To utilize capnography as a noninvasive tool for the detection and monitoring of DKA,To find the ability of EtCO2 in ruling in or out DKA,To evaluate the different severity grades of DKA using EtCO2 Monitoring,2019-10-10,RECRUITING,OBSERVATIONAL,['NA']
12707,NCT01399892,incidence of hypoglycemia after fiber supplementation,,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
12708,NCT02172313,Area under the semaglutide plasma concentration time curve,Area under the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) plasma concentration time curve,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12709,NCT02356835,Percent change in total wound size,Wound pain,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
12710,NCT02000817,Number of Participants With Abnormal Vital Sign Results,Number of Participants With Anti-drug Antibody Binding,,2014-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12711,NCT00012662,,,,na,COMPLETED,INTERVENTIONAL,['NA']
12712,NCT00734669,Number of hypoglycemic events,"Secretion of hormones increasing blood glucose, effect of exercise on hypoglycemic events, postprandial glucose excursions, heart rate and forearm blood flow at hypoglycemia",,2008-07,COMPLETED,OBSERVATIONAL,['NA']
12713,NCT00341614,Total kcal and fat kcal at 3 months,Bone-mineral density at 3 months,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12714,NCT03760640,Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) (24-Hour),Total Daily Insulin Dose,,2019-02-18,COMPLETED,INTERVENTIONAL,['PHASE2']
12715,NCT00336310,Change of postprandial plasma glucose (PPG) at 12 weeks,change of liver and renal function test,,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
12716,NCT01935765,Compare the prevalence of sleep apnea syndrome by polysomnography between type 1 diabetic patients and healthy volunteers,Precise clinical symptoms in DT1 patients with Sleep apnea syndrome,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
12717,NCT02816710,Intraoperative Bleeding,Need for Reoperation,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12718,NCT04146740,Blood glucose level,Edinburgh Post Natal Depression scale (Punjabi version),,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
12719,NCT00380822,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
12720,NCT05760677,The recovery of menstrual cycle,The changes in body weight,,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1']
12721,NCT02139878,Blood Pressure,Glucose,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
12722,NCT03789526,changes in ultrasound images of the Tenoasynovitis.,,,2018-12-11,COMPLETED,INTERVENTIONAL,['NA']
12723,NCT02138331,Total daily insulin dose,Pancreatic β-cell Mass,Hemoglobin A1c,2014-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12724,NCT03420781,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results,,2018-01-24,TERMINATED,INTERVENTIONAL,['PHASE3']
12725,NCT02189005,Safety of Dietary Supplement PreCrea 600 mg twice-daily,Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Fasting Plasma Glucose (FPG),Safety of Dietary Supplement PreCrea 600 mg twice-daily with Liver Function,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12726,NCT00706017,Incidence of SADR (serious adverse drug reactions ) incl major hypo (hypoglycaemic events),Weight,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
12727,NCT00273572,Parameters of the metabolic syndrome,Attainment of weight reduction and physical activity targets,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
12728,NCT02897349,Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Percentage of Participants With Any Severe Hypoglycaemic AE,,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE3']
12729,NCT01242215,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
12730,NCT02650830,bile acid profile,,,2015-09-12,COMPLETED,OBSERVATIONAL,['NA']
12731,NCT05571865,Primary Outcome Measure-II,Secondary Outcome Measure-I,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12732,NCT00313937,Difference of change of blood glucose between patients on Insulin glargine and NPH insulin.,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12733,NCT05494775,Visual acuity,Central subfield thickness,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
12734,NCT00086450,"5-year Composite Endpoint of All-cause Mortality, Non-fatal Myocardial Infarction, and Stroke",Rates of Individual MACCE Endpoints,,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
12735,NCT03021746,Change in A1C Blood Glucose level,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
12736,NCT00472875,Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia,Improvement in counter regulatory hormone response to hypoglycaemia,,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
12737,NCT00877526,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
12738,NCT00962026,Incidence and severity of infection in study participants,"Changes in participants' HbA1c levels, insulin doses, and beta cell preservation",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12739,NCT03462940,Change in vascular function,Change in lipid levels,,2018-04-02,TERMINATED,INTERVENTIONAL,['NA']
12740,NCT04957589,Muscle Protein Breakdown (MPB) (3MH),Skeletal Muscle & Creatine Pool Assessment (D3-C),,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
12741,NCT00865397,Change in HbA1c,Change in waist and hip circumference,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12742,NCT04419948,Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Triglycerides,Incremental Area Under the Plasma Concentration Versus Time Curve (AUC) of Protein Carbonyls,,2019-05-16,UNKNOWN,INTERVENTIONAL,['NA']
12743,NCT01474473,Kinetics of Evolution of wound size within 60 days,Pain experienced during time,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
12744,NCT01415726,Inflammation control,Metabolic control,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12745,NCT00820313,Biomarkers of Cardiovascular Disease,Dietary Intake,,2006-10,UNKNOWN,INTERVENTIONAL,['NA']
12746,NCT05937737,Total Reactive Antioxidant Potential (TRAP),,,2020-04-20,COMPLETED,INTERVENTIONAL,['NA']
12747,NCT00283777,"Insulin Senstivity, glycated hemoglobin","weight, body composition",,1998-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12748,NCT02699541,"Participants' diabetes self-Management activities: diet habits, physical activity and medications Management",Diabetes Self-Management Self-Efficacy.,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
12749,NCT02061579,Changes in Self-Reported Physical Activity Level Across Study Visits,Changes in Patient Satisfaction During Intervention Period,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
12750,NCT01571310,Postprandial Glucose Response,Postprandial Free Fatty Acids Response,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
12751,NCT03644134,Change in HbA1c,,,2013-09-26,COMPLETED,INTERVENTIONAL,['NA']
12752,NCT05754281,Mean absolute relative difference (MARD),,,2023-02-03,RECRUITING,OBSERVATIONAL,['NA']
12753,NCT00135109,"To investigate the efficacy of 200, 400, and 600mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, and quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12754,NCT02694172,Fecal microbiota profile,Plasma HDL cholesterol,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12755,NCT00836940,Change from baseline in HbA1c compared with placebo at the end of 12 week treatment period,Waist circumference,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
12756,NCT04994288,HbA1c,salvage treatment,,2021-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12757,NCT02167620,"Improvement in HbA1C derived from Oral glucose tolerance test (Matsuda, index of insulin sensitivity; area under glucose curve; insulin secretion sensitivity index-2 (ISSI-2))",Improvements in hippocampal volume,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12758,NCT04271228,HbA1c,Total daily consumed carbohydrates,"Time required to review insulin pump and sensor data, make and send recommendations or length of visit",2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
12759,NCT00866658,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12760,NCT01050465,seeking information using MedlinePlus,,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
12761,NCT02870816,The number of participants out of 60 with complete healing of their diabetic foot ulcers as measured by complete epithialization of the foot wound comparing the two active treatment groups,Cost effectiveness of each treatment modality.,,2016-08-31,COMPLETED,INTERVENTIONAL,['NA']
12762,NCT02231021,Change in glycohemoglobin(HbA1c) from baseline,The number of subject with any change of findings in electrocardiogram from baseline,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12763,NCT04049500,Usability will be assessed using a 5-point Likert scale,,,2021-09,WITHDRAWN,OBSERVATIONAL,['NA']
12764,NCT04970108,Systolic blood pressure (SBP),Adverse events,,2023-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12765,NCT00005485,Cardiovascular Disease,Mortality,,2000-09-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12766,NCT01022112,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),Safety and Tolerability,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12767,NCT04488848,Interleukin-6,,,2019-04-11,UNKNOWN,INTERVENTIONAL,['NA']
12768,NCT01242059,Energy Intake,Subjective Appetite,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12769,NCT02680054,Time of Peak Glucose Level Following Test Meal,Number of Participants With Hypoglycaemia Events Following the Insulin Dosing,Acceptability of Giving Insulin at Different Times Related to Test Meal,2016-02,TERMINATED,INTERVENTIONAL,['PHASE4']
12770,NCT00302055,Weight Loss,Rate of Community Program Participation,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
12771,NCT03918525,Type 2 diabetes,Dyslipidemia,,2017-02-20,COMPLETED,OBSERVATIONAL,['NA']
12772,NCT03323788,Response of muscle mRNA to acute exercise,,,2016-11,UNKNOWN,OBSERVATIONAL,['NA']
12773,NCT01951768,Clinical Cure,Pathogen Eradication,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12774,NCT00954109,Blood Flow in Response to Oral Glucose Tolerance Tests,,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
12775,NCT00358124,"Other efficacy variables were the change from baseline in FPG, serum lipids and weight.",Health-related quality of life was compared between the baseline visit and the follow-up assessments,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12776,NCT00190320,reduction of neonatal traumatism risk,reduction of maternal morbidity and caesarean,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12777,NCT01204775,Mean Change in HbA1c From Baseline to Week 16,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12778,NCT00989924,The smooth index of corrected QT interval (SIQTC) measured by MCG,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
12779,NCT06143423,Severity of serious adverse events (SAEs),Anti-Drug Antibody (ADA),,2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE1']
12780,NCT00119054,Blood Pressure and Hemaglobin A1c,Knowledge Compliance Self-efficacy Quality of life Satisfaction with care,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
12781,NCT02439177,User Performance of blood glucose monitoring system indicated by patient,,,2015-05,TERMINATED,INTERVENTIONAL,['NA']
12782,NCT02559180,Mean Absolute Change on Central Foveal Thickness,Mean Change on Visual Acuity Score,Number of Participants That Gained or Lost Letters of Visual Acuity.,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12783,NCT06117098,Change and ceiling and floor effect in outcomes,Antropometric measures,,2023-05-02,RECRUITING,INTERVENTIONAL,['NA']
12784,NCT06079450,Hypoglycemic Confidence Scale,hospitalization rate,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA']
12785,NCT02090673,The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus,Change from baseline to endpoint in subjective measures include improvement of main indication,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12786,NCT01726075,"Changes in the Implicit Time assessed by mfERG (IT-mfERG) at month 6, 12, 18 and 24",DR severity assessed by ETDRS scale CFP - 30º/35º-7 fields at month 24,"ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 24",2013-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12787,NCT00944697,Short Form McGill Pain Score.,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12788,NCT06278571,Number of participants with body mass index profile in control target,The proportion of patients with adequate knowledge of diabetes,,2023-01-30,RECRUITING,INTERVENTIONAL,['NA']
12789,NCT04976283,Change in radiologic liver parameters,Change in Lipid profile,Change in Systolic and Diastolic blood pressure,2021-09-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
12790,NCT01369602,Amount of drug excreted (Ae),,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12791,NCT01299012,Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
12792,NCT02291666,Metabolic ratio,Renal clearance,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12793,NCT01876485,Change in Diabetes Specific Quality of Life,,,2015-07-13,COMPLETED,INTERVENTIONAL,['NA']
12794,NCT05299918,Cardiac Autonomic Neuropathy assesed by Othostatic BP change,,,2014-07-15,COMPLETED,OBSERVATIONAL,['NA']
12795,NCT00004984,Rate of Type 1 Diabetes Per Year,,,1994-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12796,NCT04711980,Changes in total score on the Michigan Diabetic Neuropathy Score (MDNS) of Scale,Changes in total score on the Clinical Symptoms Score of Scale,,2021-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12797,NCT01870557,Bone Mineral Density (t-score),Lifestyle and Medical history,urine creatinine albumin ratio,2013-03,COMPLETED,OBSERVATIONAL,['NA']
12798,NCT00123604,Flow Mediated Dilation,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12799,NCT05932251,glucose-disposition-index,Neonatal body length,,2023-06-19,RECRUITING,OBSERVATIONAL,['NA']
12800,NCT02189694,Percentage of time of glucose levels spent below 4.0 mmol/L.,Hypoglycemic risk assessed by the number of patients experiencing at least one hypoglycemic event (> 15 minutes) below 3.1 mmol/L,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12801,NCT00982254,Glucose Infusion Rate (GIR),Adverse Events,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12802,NCT05333835,Mean Change From Baseline in HbA1c at Week 26,Number of Hypoglycaemic Episodes at Week 26,,2022-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
12803,NCT02091362,Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure,Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12804,NCT04629586,Gather longitudinal data from individuals living with type 1 diabetes.,,,2018-12-13,RECRUITING,OBSERVATIONAL,['NA']
12805,NCT06196996,insulin,Dose of exogenous insulin,,2021-09-14,RECRUITING,INTERVENTIONAL,['NA']
12806,NCT01792518,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12807,NCT03503370,Time to new foot complication among all randomized participants,Susceptibility to chlorhexidine among bacterial pathogens on the feet,Time to new foot complication among participants with a healed foot complication at randomization.,2019-01-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12808,NCT05797935,To assess and estimate the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks,To estimate the correlation between two advanced MR techniques commonly used for quantification of pancreatic fat(PDFF and MR Spectroscopy),,2021-08-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12809,NCT00208598,,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
12810,NCT00184639,Fasting plasma glucose,Hypoglycaemia,,2004-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
12811,NCT02612402,increase in daily physical activity,glycemic control,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
12812,NCT03321032,Target lesion failure at 2-years follow-up,Non-target lesion revascularization,,2017-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
12813,NCT00994357,Prevalence of LGA in children of diabetic women.,The occurrence of low grade inflammation and endothelial dysfunction in pregnant women with diabetes.,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12814,NCT02443922,Beta Cell Function as measured by the arginine stimulation test in response to two therapies for type 2 diabetes mellitus,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
12815,NCT05214235,Visual Analogue Scale (VAS) at 1 Year after Surgery,Number of Participants with Spinal Fusion at 1 Year after Surgery,,2022-02-07,RECRUITING,OBSERVATIONAL,['NA']
12816,NCT04096794,changes in serum hemoglobin A1c level,Adverse effects,,2016-09,RECRUITING,OBSERVATIONAL,['NA']
12817,NCT00464880,To investigate whether renin-inhibition using aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist irbesartan 300 mg with an equivalent potential for reno-protection,"To investigate whether aliskiren, irbesartan or the combination reduce biomarkers of inflammation and cardiovascular risk",,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12818,NCT02426541,Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake,Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8,,2015-03-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12819,NCT04617795,Hypoglycemia,Change in Hemoglobin A1c (HbA1c),,2020-11-23,COMPLETED,INTERVENTIONAL,['NA']
12820,NCT00818779,Plasminogen Activator Inhibitor 1,Serum Level of Nitric Oxide,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12821,NCT05174806,Proportion of patients with adverse events,Proportion of subjects undergoing lower-extremity amputation,,2022-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12822,NCT06118008,Temperature,Pharmacodynamics (PD): HbA1c,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2']
12823,NCT00826007,Hypoglycemia Incidence,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
12824,NCT00024921,,,,na,COMPLETED,OBSERVATIONAL,['NA']
12825,NCT00395031,"Reduced Glucose, Cholesterol and Lipid Levels",Improvement in quality of life & Positive and Negative Symptoms,,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12826,NCT03228602,Latency of the gustatory evoked potential,,,2016-07-11,TERMINATED,INTERVENTIONAL,['NA']
12827,NCT04217902,Description of individual experiences of patients and health care professionals in diabetes care.,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
12828,NCT02005432,fluorescein angiography leakage area,,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12829,NCT00138580,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12830,NCT01783717,Insulin sensitivity.,waistline/hipline ratio,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
12831,NCT02419898,Recruitment feasibility,Acceptability of the data collection procedures to participants.,,2013-04,UNKNOWN,OBSERVATIONAL,['NA']
12832,NCT02278926,Glucose control,Glucose control,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
12833,NCT03531294,Incidence of Adverse Events for diabetic retinopathy subjects who receive intravitreal Aflibercept,Cytokine Levels,,2018-05-23,COMPLETED,INTERVENTIONAL,['PHASE2']
12834,NCT02606357,Change from baseline in HbA1c,- Time to reach control,,2015-11-22,COMPLETED,INTERVENTIONAL,['PHASE4']
12835,NCT02009410,Recovery rate of 13CO2 (carbon dioxide with stable isotope of carbon),Change in clinical global impression of disease symptoms,routine safety laboratory,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12836,NCT00178633,Change in Weight,Change in Left Ventricular Mass,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
12837,NCT05047471,risk factors of albuminuria: Increase in Low density lipoprotein cholesterol (LDL-C),OR of the incidence of the adverse events,MD the Percentage change from baseline of other laboratory test parameters of interest,2021-12-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12838,NCT01284465,HbA1c,Risk factors for co-morbidity and daily self-management behaviors,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
12839,NCT05670769,Diabetes Self-Care Activities Questionnaire,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12840,NCT04711382,Time in Range,Coefficient of variation,,2018-01-29,COMPLETED,OBSERVATIONAL,['NA']
12841,NCT03227094,Predictive value (positive and negative),Cost evaluation of methods,,2017-11-13,COMPLETED,INTERVENTIONAL,['NA']
12842,NCT00482768,glycosylated hemoglobin,Change in risk of coronary heart disease,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
12843,NCT04587297,number of meals,,,2020-12-08,COMPLETED,OBSERVATIONAL,['NA']
12844,NCT04344210,Variation in HbA1c levels,Comparison of sleep pattern changes between groups,,2020-04-17,COMPLETED,INTERVENTIONAL,['NA']
12845,NCT06115304,Appetite regulating hormones measured by specific immunoassays,,Peptidomicsmeasured in blood and cerebrospinalfluid using mass spectrometry,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
12846,NCT02973100,Change From Baseline in Hemoglobin A1c (HbA1c),"Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide",,2016-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12847,NCT05500352,"Change in the global work during hypoglycemia in individuals with type 1 diabetes, type 2 diabetes, and without diabetes, respectively.","Change in mechanical dyssynchrony during hyperglycemia in individuals with type 1 diabetes, type 2 diabetes and without diabetes, respectively.",,2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12848,NCT04141111,Glycemic control,Therapeutic changes,,2015-03-22,COMPLETED,INTERVENTIONAL,['NA']
12849,NCT05147259,Onset of appearance,Assessment of development of Anti-drug Antibodies (ADAs),,2021-11-29,UNKNOWN,INTERVENTIONAL,['PHASE1']
12850,NCT01073566,Mean Daily Blood Glucose,Self-reported Hypoglycemic Episodes,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12851,NCT03754465,Proportions of subjects who achieved complete wound closure,Durability of complete wound closure,,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12852,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,Blood sample calprotectin,,2019-05-02,RECRUITING,INTERVENTIONAL,['NA']
12853,NCT02548494,Blood glucose,Urinalysis for levels of ketones & glucosuria,Hypoglycemic events,2015-11,TERMINATED,INTERVENTIONAL,['NA']
12854,NCT02036138,To assess the efficacy of intensive medical therapy alone versus medical therapy combines with LRYGB or LSG in controlling type 2 DM in non-morbid obese patients (BMI 30-34.9),To assess the safety of intensive medical therapy alone versus medical therapy combines with LRYGB or LSG in diabetic non-morbid obese patients (BMI 30-34.9).,,2015-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12855,NCT00808860,HbA1C (glycosylated hemoglobin),"body weight (BMI, hip-weight ratio)",,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12856,NCT02981121,Cumulative incidence of Diabetes Mellitus after randomization,Change on HOMA2%B,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12857,NCT05848180,The Falls Efficacy Scale International (FES-I),,,2023-05-05,COMPLETED,INTERVENTIONAL,['NA']
12858,NCT02482675,Vascular Endothelial Function,Arachidonic Acid,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
12859,NCT01477567,Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs,Number of Participants Forming Antibody to LY3009385,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12860,NCT05624034,EGG findings,Factors affecting the condition,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
12861,NCT01707147,Percentage of Patients With Incidence of Adverse Events Who Had Taken at Least One Dose of Trajenta,Change From Baseline After 24 Weeks in Fasting Plasma Glucose (FPG),,2012-11-16,COMPLETED,OBSERVATIONAL,['NA']
12862,NCT04981847,Hemoglobin A1c,Blood pressure,,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12863,NCT02718326,Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline,Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52,,2016-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
12864,NCT05219994,Insulin change in response to OGTT,,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
12865,NCT06124443,Assesment of prevalence of congenital heart defects among infants of diabetic mother compared to that in infants of non-diabetic mothers.,,,2024-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12866,NCT00846898,HbA1c,"Plasma glucose concentration Plasma lipid profiles (HDL, LDL, Triglycerides and total cholesterol) systolic and diastolic blood pressures. Body Mass Index. Waist circumference. Total calorie intake.",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12867,NCT00845858,The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.,,The Pre-specified Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score by Gender.,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12868,NCT06049550,renal failure,,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12869,NCT01064414,Change in HbA1c From Baseline to Week 26,Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12870,NCT05435157,Residual gastric volume,Antral cross-sectional area,,2022-03-09,RECRUITING,OBSERVATIONAL,['NA']
12871,NCT02688933,Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM,Coefficient of Variation (CV%) in Mean CGM Glucose,Change From Baseline in Daily Insulin Dose at Week 16,2016-05-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12872,NCT06094231,Changes in HbA1c,Time in range,,2023-09-25,RECRUITING,INTERVENTIONAL,['NA']
12873,NCT06228911,low blood glucose,,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
12874,NCT02135328,"Acceptability and effectiveness of radio stories, a health communication intervention that addresses family eating behaviors and physical activity among immigrant Somali, Latino, and Hmong families",,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
12875,NCT04094649,"Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia",Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.,,2019-08-01,SUSPENDED,INTERVENTIONAL,['NA']
12876,NCT01565824,Well-Being Questionnaire (W-BQ12),,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12877,NCT02547935,Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24,Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24,,2015-09-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12878,NCT03849755,Change in the percentage of time in glucose target range (glucose levels 3.9-10 mmol/l or 70 - 180 mg/dl),Evaluation of usability of PEPPER system by conducting the usability test,,2018-11-15,COMPLETED,INTERVENTIONAL,['NA']
12879,NCT01173094,Occlusion of the below-knee artery or bypass,Restenosis measured by Duplex Ultrasound or CTA,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
12880,NCT04936633,Changes in glycemic control measured by HbA1c,Changes in anxiety assessed by questionnaires,,2021-06-30,COMPLETED,INTERVENTIONAL,['NA']
12881,NCT06245369,Change in Healthy Eating Index,Change in Body weight,,2024-04-01,RECRUITING,INTERVENTIONAL,['NA']
12882,NCT02113332,Change in HbA1c from baseline to week 24.,Change in blood lipid levels from baseline to week 24,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12883,NCT02921906,Insulin levels,Paracetamol levels,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12884,NCT04256304,The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus,,Health Literacy Scale for Turkish Diabetic Patients,2018-12-28,COMPLETED,INTERVENTIONAL,['NA']
12885,NCT02710370,Change from baseline (time of operation) in metabolite profile.,Generation of intestinal organoids from Roux limb biopsies.,,2016-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12886,NCT00004407,,,,1998-02,TERMINATED,INTERVENTIONAL,['NA']
12887,NCT05695417,Safety and Tolerability,Diabetic Retinopathy Severity Scale (DRSS) changes,,2023-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12888,NCT01812291,Depressive Mood - Hamilton Rating Scale for Depression (HAMD),Diabetes Self-Care Behavior - The Diabetes Self-Management Questionnaire (DSMQ),Major Depressive Disorder,2012-02,COMPLETED,INTERVENTIONAL,['NA']
12889,NCT03389490,Glycemic variability,Heart rate variability,,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12890,NCT06021691,delayed language development in children,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
12891,NCT04463160,"The impact of the ""Say No to Diabetes"" intervention on the incidence of type 2 diabetes",HbA1c assay for the diagnosis of glucose intolerance and prediabetes compared to HGPO,,2019-07-18,RECRUITING,INTERVENTIONAL,['NA']
12892,NCT04436666,pain relief,,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
12893,NCT02093234,Change From Baseline in the Unmet Behaviors/Goals That Were Not Achieved at Year 1,Change in Medication Adherence,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
12894,NCT02079415,Congenital malformations,Length of hospital stay,Admission to neonatal intensive care unit,2011-01,COMPLETED,OBSERVATIONAL,['NA']
12895,NCT06292871,Satisfaction levels,Proportion of participants with optimal blood glucose control,Proportion of participants delivering healthy live birth,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12896,NCT04499846,Compliance rate to the statin treatment,Compliance rate to the statin treatment according to treatment duration.,,2020-06-11,COMPLETED,OBSERVATIONAL,['NA']
12897,NCT02908152,Hepatic steatosis,AST,,2017-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12898,NCT03351530,"The change of hs-CRP between diabetes mellitus patients, periodontal disease patients and healthy people after receiving periodontal therapy and using mouthwash",,,2017-05-18,UNKNOWN,OBSERVATIONAL,['NA']
12899,NCT01022645,Glucose tolerance at 12 months postpartum.,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
12900,NCT01316783,Metabolic disorders,,,2011-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12901,NCT00567905,Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the major outcome measurement.,"HbA1C, blood sugar, creatinine, aminotransferases aspartate, aminotransferases alanine, uric acid, and plasma lipoproteins (triglyceride, cholesterol, cholesterol-HDL (HDL) and cholesterol-LDL (LDL)) cholesterol; BMI,WC---.",,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12902,NCT00646438,The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.,Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
12903,NCT02009813,Insulin sensitivity,Hypoxia and inflammatory markers,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
12904,NCT04055090,Long-term Safety for Engensis Versus Placebo,Subgroup Analysis of the Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo for Subjects Without Gabapentin and/or Pregabalin Use at Baseline,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12905,NCT00841048,"Safety and Tolerability (Adverse events, vital signs, ECGs, physical examination, laboratory variables",Pharmacodynamic measurements allowing to assess AZD4017 effect in different tissues,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12906,NCT02636192,Number of Participants with a recorded diagnosis of Diabetic Ketoacidosis (DKA),,,2015-07-31,COMPLETED,OBSERVATIONAL,['NA']
12907,NCT00631007,Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12908,NCT05294458,"Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted state",Evaluate immunogenicity for cotadutide administered as low and high concentration SC formulations and an IV formulation,Temperature needed at the injection site to homogenize at the point of injection,2022-03-28,COMPLETED,INTERVENTIONAL,['PHASE1']
12909,NCT05609175,Area under the receiver operator characteristics curve (AUROC) in detecting nocturnal level 1 hypoglycemia based on motion data obtained by radar signals,"AUROC in classifying motion patterns according to thermal camera measurements based on motion data, physiological data, and Artificial Intelligence",,2023-02-14,RECRUITING,OBSERVATIONAL,['NA']
12910,NCT00460941,Percentage of patients withdrawn because of gastrointestinal effects,"Mean changes in 24h blood glucose Area Under the Curve (AUC), Fasting Plasma Glucose (FPG), fructosamine, Hemoglobin A1c (HbA1c), body weight, Adverse Events (AEs), laboratory parameters.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12911,NCT01323114,Hemoglobin A1C,,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
12912,NCT03786718,User Experience - Qualitative,Change in Patient Activation,,2018-12-27,COMPLETED,INTERVENTIONAL,['NA']
12913,NCT00691249,Post-Prandial metabolism,Satiety,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
12914,NCT04174508,Average annual number of new cases of diabetes according to World Health Organization (WHO) criteria,,,2020-03-24,RECRUITING,OBSERVATIONAL,['NA']
12915,NCT02622282,Change in Physical Activity,Change in Quality of Life,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
12916,NCT02151461,Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr,Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12917,NCT04871438,HbA1c,Glucose Monitoring Satisfaction Score (GMSS),Exercise duration,2021-11-10,RECRUITING,INTERVENTIONAL,['NA']
12918,NCT00711503,Δ 2-h AUC C-peptide response,"Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP",,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12919,NCT00948493,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
12920,NCT05352230,Compliance,Time in Range (TIR) of 70 to 180 mg/dL,,2023-04-15,RECRUITING,INTERVENTIONAL,['PHASE1']
12921,NCT03278704,Change in fibre-type specific satellite cell content,Change in glycaemic control,,2017-12-06,TERMINATED,INTERVENTIONAL,['NA']
12922,NCT03739099,Percent of time spent in the 70-180 mg/dl glucose range assessed on daily CGM data,Score of the Artificial Pancreas Acceptance Questionnaire,,2018-11-05,UNKNOWN,INTERVENTIONAL,['NA']
12923,NCT04921306,insulin-stimulated fluorodeoxyglucose (18F-FDG) uptake in quadriceps muscle.,insulin-stimulated 18F-FDG uptake in BAT,skeletal muscle GLUT4 translocation,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12924,NCT05598203,Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months,Change in baseline blood pressure at 12 months,Change in baseline adherence to recommendations at 12 months,2022-09-06,RECRUITING,INTERVENTIONAL,['NA']
12925,NCT00614120,Change in Glycosylated Haemoglobin A1c (HbA1c),Hypoglycaemic Episodes,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12926,NCT00221234,Physical Activity Behaviour,"HbA1c, CRP, lipid concentrations, fasting blood glucose, insulin, health related quality of life, psychosocial predictors of physical activity.",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12927,NCT00286442,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12928,NCT00106561,percent reduction in 24 hour urine protein excretion,,,2002-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12929,NCT01539811,Wound Healing,,,2012-02,TERMINATED,INTERVENTIONAL,['NA']
12930,NCT03912766,change of serum sodium after surgery,,,2016-02-01,COMPLETED,OBSERVATIONAL,['NA']
12931,NCT04129528,Stimulated C-peptide AUC by mixed meal tolerance test (MMTT).,Stimulated C-peptide AUC by MMTT.,,2019-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12932,NCT00799448,HbA1c,Adverse events,,2003-09-16,TERMINATED,INTERVENTIONAL,['PHASE4']
12933,NCT03243383,Incidence of initial hospital readmission,Change in A1c level,,2017-09-07,COMPLETED,INTERVENTIONAL,['NA']
12934,NCT01717937,Measurement of to be determined physical characteristics of retinovascular structures seen on phase variance optical coherence tomography (PV-OCT) and fluorescein angiography(FA).,Changes over time in the to be determined measured physical characteristics of retinovascular structures seen on PV-OCT and FA.,,2013-02,TERMINATED,OBSERVATIONAL,['NA']
12935,NCT05083559,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units),,2021-12-08,COMPLETED,INTERVENTIONAL,['NA']
12936,NCT05579314,"Mean change from baseline in clinical laboratory values, vital signs, clinical findings from physical exam and ECG abnormalities",,,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE1']
12937,NCT03650127,Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis,,,2018-02-02,UNKNOWN,OBSERVATIONAL,['NA']
12938,NCT00976729,"Safety and tolerability of NOX-E36 by means of adverse events, vital signs, laboratory parameters, 12-lead ECG and immunogenicity assessment",Pharmacodynamic profile,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12939,NCT03492580,Number of Participants with Below Knee Lower Extremity Amputation Events,,,2018-02-22,COMPLETED,OBSERVATIONAL,['NA']
12940,NCT04988581,Phase 2,The secondary outcomes,,2021-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12941,NCT04053959,Proportion of time in target range,Total insulin dose,,2019-09-27,COMPLETED,INTERVENTIONAL,['PHASE4']
12942,NCT02036372,Median glucose,Glucose,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12943,NCT00813228,Changes in plasma TGF-Beta 1 levels.,"Changes in plasma or stimulated PBMC cytokines levels, changes in stimulated PBMC proliferation, changes in peripheral blood gene expression and changes in immune phenotyping.",,2009-01-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12944,NCT02424500,Reduction in HbA1C,Comparison Percent Reduction HbA1c w/out Hypoglycemia,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12945,NCT03259789,Change From Baseline in HbA1c at Week 24 for High Glycemic Group,Change in HbA1c Over Time Among Subjects Who Have Baseline HbA1c of > 10.5% and ≤ 12.0%,,2017-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
12946,NCT03124043,Change in HbA1c,Change in Treatment Satisfaction,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
12947,NCT03717688,GLP-1,Glucagon,GIP,2018-05-17,COMPLETED,INTERVENTIONAL,['PHASE4']
12948,NCT01400971,Number of Participants With Insulin-Related Treatment Change From Initial Insulin Therapy,Number of Participants Who Achieved Their Personalized HbA1c Target by the End of the Study,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
12949,NCT01382498,high sensitivity CRP and Endothelin-1 serum levels,,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12950,NCT00446992,LDL,,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12951,NCT04598893,"Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies",HbA1c,,2020-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12952,NCT00005489,,,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
12953,NCT02004327,Maximum Concentration of DW1029M in plasma,Apparent volume of distribution of DW1029M in Plasma,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12954,NCT02597400,The primary pharmacokinetics parameters of Cmax To assess the potential pharmacokinetic interaction between HMS5552 and metformin in subjects with T2DM,"Pharmacodynamic responses (serum levels) of glucose, insulin and C-peptide will be evaluated.",,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12955,NCT04656106,Change in HbA1c (Glycosylated Hemoglobin),Change in body weight,,2021-04-27,COMPLETED,OBSERVATIONAL,['NA']
12956,NCT05717127,Pancreatic beta-cell function,Fasting glucose,Satiety,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
12957,NCT04789798,BMI,The number of patients who added insulin to their oral antidiabetic medication or switched to oral antidiabetic medication by discontinuing insulin,Urine microalbuminurea,2013-10-21,COMPLETED,INTERVENTIONAL,['NA']
12958,NCT05483803,Sub-study 2: Changes on caregiver's positive mood,Behavioral outcome: Usability,,2022-10-01,COMPLETED,INTERVENTIONAL,['NA']
12959,NCT02505451,Regional longitudinal strain,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12960,NCT06325917,glycemic control,diabetes self management behaviors,,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12961,NCT03281486,Relief from drymouth using VAS scoring,,,2018-01-28,COMPLETED,INTERVENTIONAL,['NA']
12962,NCT05605821,Evaluation of the association between diabetic disease control and the degree of hepatic fibrosis,Percentage of patients at risk of severe fibrosis in a population of type 2 diabetics followed in a tertiary diabetes service.,,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12963,NCT05280184,Change in daily insulin Bolus score,,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
12964,NCT04707508,Serum glycosylated hemoglobin A1c,Blood pressure,,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12965,NCT05208164,Sleep Impairment,Inflammatory Markers,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
12966,NCT04943614,Functional reach test,,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
12967,NCT00848822,This study could help find if there are particular times of day or times during sleep that change glucose the most.,This study may help make recommendations about the best time to test glucose values and better help children with Type 1 Diabetes Mellitus control their glucose levels.,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12968,NCT01937845,Weight loss of 7% body weight,,,2006-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12969,NCT01554358,cardimetablic risk,approximately 40 SNPs,,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
12970,NCT02789319,Analytical accuracy and clinical performance criteria,Device issues,Results,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12971,NCT03377127,Hemoglobin A1c at 12 Months,No-show,,2018-02-19,COMPLETED,INTERVENTIONAL,['NA']
12972,NCT03660345,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12973,NCT02284009,Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52,Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka],,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12974,NCT01582230,"Change from baseline in glycosylated hemoglobin (HbA1c) at study endpoint, assessed in Chinese study population",Percentage of patients meeting responder criteria after 24 weeks treatment on Chinese population,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12975,NCT05650229,Change in 30 Second Site-to-Stand Test.,Change from baseline in Glycated haemoglobin (HbA1c) for subjects with diabetes,,2022-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12976,NCT00143949,"To obtain two percutaneous renal biopsies from each patient, five years apart.",To evaluate retinal lesions in RASS cohort to determine relationship to the histologic changes of DN and the effects of RAS inhibition and/or systemic blood pressure.,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12977,NCT03135327,Tear film thickness,Conjunctival blood flow velocity by functional slit-lamp (FSLB),,2007-01-01,RECRUITING,INTERVENTIONAL,['NA']
12978,NCT01921491,Proportion of ulcers achieving 100% epithelialization in the dHACM group vs other commercially available product and control.,Cost effectiveness of each treatment modality.,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
12979,NCT03973515,Area under the plasma concentration versus time curve (AUC),The change for plasma insulin,,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1']
12980,NCT01303302,Comparison of the differences in HbA1c levels,Improvement in weigth and metabolic parameters,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
12981,NCT01616784,The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol).,Quality of adjusted life years,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12982,NCT03485586,the visual quality of the eye after surgery,,,2018-04-03,UNKNOWN,OBSERVATIONAL,['NA']
12983,NCT02366377,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
12984,NCT02021695,DNA methylation and gene expression in blood monocytes and lymphocytes,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
12985,NCT02039258,Plasma concentration of metformin following the single dose of CANA/MET XR FDC after fed and fasted conditions,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12986,NCT05703880,Descriptive summary of comedications of patients who initiate finerenone and have CKD and T2D in the US.,Incidence rate of proliferative diabetic retinopathy in patients who initiate finerenone with prior non-proliferative diabetic retinopathy,,2023-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12987,NCT02845219,Area under the levonorgestrel plasma concentration-time curve during a dosing interval (0-24 hours) at steady state,Maximum observed levonorgestrel plasma concentration during a dosing interval 0-24 hours) at steady state,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12988,NCT00243984,"BMI on days 1, 84, 168, and 175.","C reactive protein on days 1, 84, and 168.",,2005-03,SUSPENDED,INTERVENTIONAL,['PHASE3']
12989,NCT00232375,The primary endpoint was insulin-dependency (IDDM: integrated C-peptide values [sigma C-peptide] <4 ng/ml).,,,1996-01,COMPLETED,INTERVENTIONAL,['NA']
12990,NCT04092738,Change in Waist circumference,Change in subjective occupational physical activity,"Sociodemographic variables (age, gender, socio economic status)",2019-03-04,UNKNOWN,INTERVENTIONAL,['NA']
12991,NCT02372630,JNK-1 Protein in MNC,Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp,,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12992,NCT03326206,Change in hemoglobin A1c,Change in counseling / behavioral services,Change in self-report coping,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
12993,NCT00813657,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12994,NCT01588093,Difference in MD (microdialysate) IGF-1 over time (expressed as AUC or peak microdialysate IGF-I) between saline and IGF-I injection.,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
12995,NCT00157638,"Symptom improvement (constipation, pain)",Health services utilization,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12996,NCT02025907,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Systolic Blood Pressure (SBP) at Week 26,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12997,NCT05902468,Glycemic control,Serum asprosin,,2023-06-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12998,NCT05022316,diabetes control,completion of medication adherence documentation,,2022-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12999,NCT02443415,Acute change in brain morphology,Change in neurocognitive assessment,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
13000,NCT03448029,Outcome Quality after Revascularization: Re-Intervention,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
13001,NCT00460304,The mean ICR from Vist 3a-e and 4a-e will be compared. Percentage reduction of ICR will be calculated. From these the mean ICR will be calculated.,The mean post-meal glucose from the four hour period after beginning a meal will be averaged for each bolus wave form. Then the three wave form mean glucose results will be compared.,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
13002,NCT03839667,change in HbA1C level (%),cardiovascular risk,,2019-01-07,COMPLETED,INTERVENTIONAL,['NA']
13003,NCT05301855,The fifth part of the questionnaire is the Beliefs about medicine which is assessed using the Arabic version of the Beliefs about Medicines Questionnaire Specific (BMQ-Specific).,,,2022-03,RECRUITING,OBSERVATIONAL,['NA']
13004,NCT02540642,To compare the change in HbA1c levels (%) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,To compare the change in serum homocysteine level (micromol/L) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13005,NCT04520971,time in range,number with composite neonatal outcome,,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
13006,NCT00552409,Change in Urine Albumin Excretion,,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13007,NCT00471549,Relative reduction in circulating osteoprotegerin levels,Relative reduction in adhesion molecules (ICAM and VCAM),,1991-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13008,NCT00854347,Prevalence of diabetes and prediabetes.,Evaluate insulin needs capacity to predict subsequent diagnosis of diabetes and prediabetes,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
13009,NCT05339841,Long-term CV clinical outcome at 7 years follow-up,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - history of vaccination (questionnaire),Ancillary study of UO-14 (IRCCS San Raffaele Roma): mean corpuscular hemoglobin (MCH) in the CV-PREVITAL Exercise sub-study cohort,2022-06-10,RECRUITING,INTERVENTIONAL,['NA']
13010,NCT00399620,,,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
13011,NCT05179798,Percentage of postprandial capillary glucose values above target (>7.0 mmol/L),Patient satisfaction evaluated through a questionnaire,,2022-01-12,RECRUITING,INTERVENTIONAL,['NA']
13012,NCT03596450,Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No),Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence For The Two Years of The Study,,2018-07-13,COMPLETED,INTERVENTIONAL,['PHASE4']
13013,NCT00708981,Delay in development in end-stage renal failure in subjects with Advanced Diabetic Nephropathy (CKD stages 3 and 4),,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
13014,NCT00099918,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13015,NCT00392678,Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1,"Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index",,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13016,NCT03177096,Evolution of Peds QL questionnaire results,Evolution of WHO-5 and felt questionnaire,,2016-09-20,COMPLETED,INTERVENTIONAL,['NA']
13017,NCT02284230,Plasma glucose during oral glucose tolerance test at week 26,Plasma liraglutide,,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13018,NCT03516474,Lower rates of DFU recurrence in patients monitored using mHealth,,,2018-05-15,UNKNOWN,OBSERVATIONAL,['NA']
13019,NCT04687215,Vascular improvement on lower extremities with the Doppler Flowmetry,Vascular improvement on lower extremities by performing the flow mediated arterial dilation test,,2022-01-27,RECRUITING,OBSERVATIONAL,['NA']
13020,NCT03889522,Examine the relationship between artificial sweeteners and hemoglobin A1c,,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
13021,NCT04205617,Change in Hemoglobin A1c,Change in diastolic blood pressure,,2019-12-14,COMPLETED,INTERVENTIONAL,['NA']
13022,NCT00094796,Peak VO(2) after 3 months of rosiglitazone therapy compared with baseline VO(2) max.,,,2004-10-20,COMPLETED,INTERVENTIONAL,['PHASE2']
13023,NCT00278057,,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13024,NCT03654651,Fasting Plasma Glucose,Microbiota Alpha-diversity,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13025,NCT01932671,Combined endpoint of cardiovascular events,All cause mortality,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
13026,NCT04416737,Glucagon response to induced hypoglycemia,Glucose Values,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
13027,NCT01109927,Glucagon stimulated C-peptide,,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13028,NCT05073692,Incidence of 3-point Major Adverse Cardiovascular Events (MACE),,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
13029,NCT02621736,Change of copeptin at baseline and after 28 days during routine desmopressin therapy,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
13030,NCT01459120,Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care,Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
13031,NCT02846831,Percentage of time of glucose levels spent between 3.9 and 10 mmol/L.,Number of patients calling for technical issues related to the closed-loop system,,2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2']
13032,NCT04211220,Percentage of time spent in 70-180mg/dl (time in range) in the last month of each period of the study (without and then with IRTA©),Type of advice given by the IRTA system that is more often asked,,2020-01-09,COMPLETED,INTERVENTIONAL,['NA']
13033,NCT03336411,"Body weight, percent change",Weight regain,Self-efficacy,2017-12-12,COMPLETED,INTERVENTIONAL,['NA']
13034,NCT00138619,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 24 weeks and 104 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13035,NCT01014949,Coronary Flow Reserve and Index of Microvascular Resistance values,,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13036,NCT00978263,Change From Baseline in Glycosylated Hemoglobin at month 6,Change From Baseline in Body Weight (month 12),,2009-02,COMPLETED,INTERVENTIONAL,['NA']
13037,NCT00360334,Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg),Severe Hypoglycemic Rate Per 30 Days,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13038,NCT06120322,"To identify the factors contributing to chronic inflammation within the intestine and in peripheral organs, in particular focusing on biopsies markers","Taking advantage of the measurements collected in Outcome 1, the investigators will use a machine learning-based multi-omics approach to easily recognize patient differences, stratification and characterization",,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13039,NCT03345667,Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema,Frame between the injections,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
13040,NCT05974020,Plantar Pressure Distribution,Foot Posture,,2023-08-04,COMPLETED,INTERVENTIONAL,['NA']
13041,NCT06103799,Peri-implant bone resorption,Patient satisfaction,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
13042,NCT05120544,Change in HbA1c,Change in hypertension knowledge,,2022-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13043,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,,2017-01-19,UNKNOWN,OBSERVATIONAL,['NA']
13044,NCT02074423,"Blood glucose incremental Area Under the Curve between 0 and 120 minutes after consumption of a standard meal, compared between MealShape and the placebo",Insulin incremental Area under the Curve between 0 and 60 minutes compared between MealShape and Placebo after consumption of a standard meal,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13045,NCT01743781,The acceptance rate of comprehensive eye examination in both groups,knowledges of eye disease and attitude of eye examination,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
13046,NCT02580266,Cellular phenotype,,,2015-09,WITHDRAWN,OBSERVATIONAL,['NA']
13047,NCT03423862,Predicting the honeymoon period,Establishing the relationship between baseline inflammation and other measures,,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
13048,NCT01017965,HbA1c in %,Quality of life assessed through questionnaire,,2009-11,TERMINATED,OBSERVATIONAL,['NA']
13049,NCT02872974,Carotid intima-media thickness,Cardiovascular risk factors,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
13050,NCT02173834,Difference in sympathetic stimulation to BAT between lean and obese individuals,Difference in correlation between sympathetic stimulation of BAT as assessed with 123I-MIBG SPECT scans and metabolic BAT activity as assessed with 18F-Fluorodeoxyglucose(FDG)- positron emission tomography(PET)-CT scan in lean and obese individuals,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13051,NCT01557907,Insulin levels,Number of participants with adverse events,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13052,NCT02024542,Tensile Strength of White Adipose Tissue,,,2011-02,RECRUITING,OBSERVATIONAL,['NA']
13053,NCT03918148,Urinary albumin to creatinine ratio excretion,estimated Glomerular filtration rate (eGFR),Lipid profile,2018-01-15,RECRUITING,OBSERVATIONAL,['NA']
13054,NCT02359461,Changes from Baseline in endothelial function of the large vessels by FMD (Flow Mediated Dilatation),Assessment of microalbuminuria levels of 24 hours,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
13055,NCT01497938,The Event Area Under the Curve (AUC) Was Used to Demonstrate the Reduction of Nocturnal Hypoglycemia With the Low Glucose Suspend (LGS) Feature (LGS ON),,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13056,NCT00724087,Total energy expenditure,Glycerol turnover and free fatty acid concentration,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13057,NCT02011529,Hemoglobin A1c,LDL cholesterol,Brief Psychiatric Rating Scale (BPRS),2013-11,COMPLETED,INTERVENTIONAL,['NA']
13058,NCT00328627,Change From Baseline to Week 26 in HbA1c,Change From Baseline to Week 26 in Mean HDL Particle Size,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13059,NCT01471808,the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients,the effects of different interventions on the remission rate in newly-diagnosed type 2 diabetic patients,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13060,NCT00660374,HbA1c,HbA1c,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13061,NCT02004561,Change in Glucose Tolerance,Changes in nutritional health,Fat distribution,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13062,NCT01206322,Perfusion Outcome: Right Insular Cortex Perfusion (ml/100g/Min/mmHg),,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13063,NCT02290860,abnormal glucose tolerance,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
13064,NCT05785832,HbA1c,Coefficient of variation,Other device malfunctions/device issues,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
13065,NCT00516620,Body Weight,"Biomarkers of diet and obesity-related chronic diseases (serum lipids, homocysteine and C-reactive protein) and genotypes",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13066,NCT04497792,HbA1C level,,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13067,NCT03890003,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-03-28,COMPLETED,INTERVENTIONAL,['NA']
13068,NCT03536377,change in Hba1C,change in blood pressure medication,,2019-02-11,UNKNOWN,INTERVENTIONAL,['NA']
13069,NCT00737152,To determine cardiovascular side effects such as coronary artery disease (CAD) and congestive heart failure (CHF) in patients treated with RAS 130 along with diet and exercise.,To determine the effect of RAS 130 on reduction of blood glucose level with or without diet and exercise,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
13070,NCT05631561,The changes of Hba1c from baseline at 6 months post procedure,Quality of life assessment (EQ-5D-5L) at pre-procedure and 6 months post procedure,,2022-12-27,RECRUITING,INTERVENTIONAL,['NA']
13071,NCT03096002,independent bouts of physical activity,independent bouts of physical activity,dietary adherence,2017-06-12,UNKNOWN,OBSERVATIONAL,['NA']
13072,NCT00246623,Proportion of patients with type 2 diabetes (A1C 7.5-10% on >= 2 oral agents) in each study arm (Exubera dosage adjusted 'once weekly' or 'twice weekly') that attain an A1C of <=7% with forced dose titration of Exubera at 6 months.,"Secondary endpoints include change in A1C, fasting and 2 hr PP glucose, 24-hr mean glucose measured by continuous glucose monitoring, weight, lipids, and markers of oxidative stress. Hypoglycemia will also be assessed.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13073,NCT02221284,Percentage of Participants Who Had One or More Adverse Reactions,Change From Baseline in Laboratory Test Values (Homeostasis Model Assessment of Beta-cell Function [HOMA-β]),,2014-06-30,COMPLETED,OBSERVATIONAL,['NA']
13074,NCT00575783,,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
13075,NCT03378895,Individualized Prevention Program participation rate,Variation of the risk score in at least one of the three behavioral domains; The risk score will be calculated from the results reported on a self-administered questionnaire,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
13076,NCT03503942,Diabetes incidence,Metformin adherence,,2017-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13077,NCT04283994,EHR documentation of Goals of Care discussions,Goal concordance,Key Implementation Factors,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13078,NCT04575181,Change in flow mediated dilation,"Number of clinically significant hypoglycaemic episodes s (level 2) ((below 3.0 mmol/L (54 mg/dL), confirmed by BG meter)",,2020-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
13079,NCT02248857,Prescription Understanding,Medication Adherence: Pharmacy Records,Changes in Low-density Lipoprotein Cholesterol (LDL),2014-12,COMPLETED,INTERVENTIONAL,['NA']
13080,NCT01722682,Insulin secretion under stimulation,Islet function,,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13081,NCT00638131,change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF,change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE3']
13082,NCT01041365,Insulin Sensitivity,Vascular Function,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
13083,NCT00065676,Does quercetin effect glucose absorption,,,2010-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13084,NCT03940937,Oxygen consumption (VO2; mL/kg/min),,,2019-05,UNKNOWN,OBSERVATIONAL,['NA']
13085,NCT01928550,Total retinal blood flow & visual acuity,"Macular ischemic areas and microaneurysms, as identified by FA vs. OCT",,2013-08,COMPLETED,OBSERVATIONAL,['NA']
13086,NCT01855282,Change in BMI,Change in Waist Circumference,Change in fasting blood glucose,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13087,NCT03209089,clinical characteristics of T2DM patients managed by GPs,,,2017-08-07,COMPLETED,OBSERVATIONAL,['NA']
13088,NCT05168488,Capillary glucose (change during exercise),percent time in hypoglycemia,,2021-11-16,COMPLETED,INTERVENTIONAL,['NA']
13089,NCT02244385,Blood Pressure,Uteroplacental assessment,Urinary podocyte markers,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13090,NCT01901952,Hemoglobin A1c,Medications,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
13091,NCT00333554,"At least a 20% reduction in the level of the major inflammatory cytokine, IL1-beta, achieved in the plasma of the treatment group",95% of families will continue to attend follow-up visits,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
13092,NCT00688363,Haemoglobin A1c after one year,the number of serious hypoglycaemic episodes (hypoglycaemic episodes when the patient needs help from other people),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13093,NCT04082351,HbA1c,,,2016-07-03,COMPLETED,INTERVENTIONAL,['NA']
13094,NCT05237895,Detection of diagnostic value of serum endocan levels in patient with gestational diabetes,,,2022-03-03,COMPLETED,INTERVENTIONAL,['NA']
13095,NCT02032108,between groups difference in glycated haemoglobin (HbA1c),endpoint versus baseline differences in glycated hemoglobin,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13096,NCT01129297,Study the influence of phenotypic characteristics on gene expression of tissues involved in glucose metabolism,Genotype-Phenotype correlation,,2006-06-13,RECRUITING,OBSERVATIONAL,['NA']
13097,NCT02288351,Elevated Glut-1 gene and protein expression levels,Glut-1 level change in fasting glucose,,2014-11,WITHDRAWN,INTERVENTIONAL,['NA']
13098,NCT03397225,Hemoglobin A1c,,,2013-11-15,COMPLETED,INTERVENTIONAL,['NA']
13099,NCT03768245,Mean Change From Baseline In Power At 12 Weeks,,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
13100,NCT02474147,Functional brain imaging of reward circuitry,Serum concentrations of oxidative stress markers,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
13101,NCT05007990,Natural History,,,2022-09-08,RECRUITING,OBSERVATIONAL,['NA']
13102,NCT02317796,Change in PPG AUC0-3h in a MMTT between Days 1 and 29.,Differences between placebo and MLR-1023 dose groups in PPG AUC0-3h Days 1 and 29.,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13103,NCT00971139,Impacts of the OPPC service on organizational processes/organizational change such as care processes,"Characteristics of high/low volume users, patient-caregiver communication and use patterns",,2009-11,COMPLETED,INTERVENTIONAL,['NA']
13104,NCT02302716,Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c),Percentage of Participants With Hypoglycemic Events,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13105,NCT04216485,Gestational weight gain,Incidence of Gestational Diabetes Mellitus,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13106,NCT02130401,Measurement of glycosylated hemoglobin (A1c),Feasibility and acceptability of the device as an intervention for the diabetes population,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
13107,NCT01455857,Change in HbA1c,,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13108,NCT04116203,Plasma Triglycerides and apoB-lipoprotein remnants in non-fasting and fasted state,"Plasma hormones, testosterone, SHBG, Estrogen",,2016-06-30,SUSPENDED,INTERVENTIONAL,['PHASE1']
13109,NCT03120299,Change in blood metabolomics profile of lipid species from baseline,Pharmacogenomics analysis,,2017-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13110,NCT05570357,HbA1C,Lipid profile,,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13111,NCT02728453,change in left ventricular mass,change in body fat mass,number of participants with lower urinary tract infections or genital fungal infections,2016-04-27,TERMINATED,INTERVENTIONAL,['PHASE4']
13112,NCT04635670,Change in albuminuria based on urinary albumin-creatinine ratio (UACR),Change in autonomous neuropathy evaluated by VagusTM,Change in Gut microbiome characterization assessed by 16S RNA sequencing,2020-06-29,COMPLETED,INTERVENTIONAL,['NA']
13113,NCT02641522,Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12,,Adverse Event Monitoring,2016-03-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13114,NCT00172757,,,,2002-01,UNKNOWN,OBSERVATIONAL,['NA']
13115,NCT02843503,Mean Absolute Relative Difference (MARD),Glucose content (mg/dL) of capillary reference samples.,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
13116,NCT00467168,Lipids including triglyceride and cholesterol in four subfractions of ppTRLs.,Lipids lipoproteins in the postprandial plasma,,1998-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13117,NCT05663736,HbA1c,CK-MB,,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13118,NCT03285308,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,2017-09-29,TERMINATED,INTERVENTIONAL,['PHASE3']
13119,NCT03800680,Change in HbA1c levels at Month 12,Incremental cost-effectiveness ratios based on QALY at Month 12,,2019-10-19,COMPLETED,INTERVENTIONAL,['NA']
13120,NCT04568382,Pilot acceptability),Anxiety Symptoms,,2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
13121,NCT02043054,Change in peak early diastolic strain rate measured by cardiac MRI,Composite 7 point glucose profile,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13122,NCT01106573,,,,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
13123,NCT04445714,To assess the safety of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,To assess the efficacy of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,,2021-04-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13124,NCT00861445,The primary objective of this trial is to evaluate the efficacy of SPM 927 in reducing pain in subjects with diabetic distal sensory polyneuropathy,Examine the pharmacokinetics of SPM927 (assessment at all site visits during entire trial participation),,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13125,NCT00715780,Incidence of major hypoglycaemic episodes,Percentage of patients reaching the target of HbA1c less than 6.5%,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
13126,NCT02168348,Percentage of healed lesions,Number of malnourished patients according to HAS 2003 and 2007 criteria,Number of malnourished patients at 12 and 24 weeks,2013-11-26,COMPLETED,OBSERVATIONAL,['NA']
13127,NCT04977908,Time in target glucose range,"Total, basal, and bolus insulin dose",Human Factor assessment,2021-08-31,COMPLETED,INTERVENTIONAL,['NA']
13128,NCT03152994,fasting blood glucose(FBG),Exercise capacity (composite outcome measure),Symptom Evaluation(composite outcome measure),2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
13129,NCT01843114,Total retinal blood flow,Retinal blood velocities,,2015-01-12,COMPLETED,INTERVENTIONAL,['NA']
13130,NCT00816218,Vascular Endothelial Function,Insulin Resistance,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13131,NCT01879579,Percentage of Subjects Who Reach Optimal Long-acting Insulin Dose,Incidence of Hypoglycemia,Qualitative Patient Satisfaction Interview,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13132,NCT02015988,Percentage change from baseline in triglycerides (TG) at week 12,Percentage changes from baseline in uric acid at week 52,Number of adverse events (AE) caused discontinuations of investigational products,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13133,NCT01334606,Glycemic Control as Measured by Percent (%) Absolute Change in Fructosamine,,,2011-03,TERMINATED,INTERVENTIONAL,['NA']
13134,NCT03653091,Change in Hemoglobin A1c (HbA1c),,,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
13135,NCT01071967,All-cause mortality,Weight control,,2002-04,UNKNOWN,INTERVENTIONAL,['NA']
13136,NCT00574665,Endothelial function and fibrinolytic balance,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13137,NCT03050229,Reduction of nocturnal blood pressure measured by ABPM,The correlation between blood pressure and body weight,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13138,NCT03057470,Reduction In Plasma Glucose (YSI),"Investigate Glycemic Response of a 0%, 50%, 100% and 150% Bolus Insulin Correction of Post-exercise Hyperglycemia Compared to no Bolus Insulin Correction",,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
13139,NCT02858648,Change in Glycemic control as assessed by HbA1c levels,Change in Self-efficacy for diabetes as assessed by the Self-efficacy for diabetes measure,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13140,NCT01310556,Frequency of unknown glucose metabolism disorders in patients with coronary artery disease,Fasting and 120 minute glucose levels have relation with vessels' stenosis.,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13141,NCT01062763,Change of Diastolic Blood Pressure,Adverse Effects,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13142,NCT01476501,Change in serum vitamin D from baseline to 3 and 6 months,Change in bone health from baseline to 3 and 6 months,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13143,NCT03542084,Glycemic Control,A1c testing frequency,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
13144,NCT00490165,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
13145,NCT03860558,Spermatozoa concentration,RNA Sequencing,,2018-05-01,RECRUITING,INTERVENTIONAL,['NA']
13146,NCT00668239,diffuse macular oedema,morphofunctional assessment of retina,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
13147,NCT02500979,Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM),Pharmacokinetics of Insulin as Demonstrated by the Time to the Maximum Plasma Insulin Concentration,,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
13148,NCT04285554,Rate of Serious Adverse Device Effects,Adverse Event rate 365 days,,2020-07-28,COMPLETED,INTERVENTIONAL,['NA']
13149,NCT01424319,The change from baseline to each post-baseline visit in log-transformed UACR (urinary albumin to creatinine ratio),The proportion of subjects who achieve various percent of reduction in UACR (Urinary Albumin to Creatinine Ratio) from baseline to final,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13150,NCT05138432,Change in Hemoglobin A1c,Change in HDL cholesterol,,2021-11-29,RECRUITING,INTERVENTIONAL,['NA']
13151,NCT03877523,Change in macrophages activation after 30-days Cocarnit administration,,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA']
13152,NCT02315235,Changes in pain for a week after the procedure,The evaluation of changes in the specific neuro-sensory system,The secondary effect of the procedure for the peripheral nerves and blood vessels,2014-05,WITHDRAWN,INTERVENTIONAL,['NA']
13153,NCT04927377,Glycemic Management,Health Technology Usability,,2022-10-31,RECRUITING,INTERVENTIONAL,['NA']
13154,NCT00792935,Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic),,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13155,NCT04603937,Non-inferiority of KSI-301 to Aflibercept measured by changes in BCVA.,Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.,,2020-09-30,TERMINATED,INTERVENTIONAL,['PHASE3']
13156,NCT02606838,Number of Subjects With Numeric Meter Results When Users Obtain Fingerstick Capillary Blood Using the Styx Lancing Device ( 28 Gauge Lancets),Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding the Styx Lancing Device,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
13157,NCT02140645,Binary EMR Characteristic: Pancreatitis,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
13158,NCT01588795,proteinuria/creatininuria ratio,Evaluate the outcome of specific kidney injury markers,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13159,NCT01065155,"Cardiovascular target organ damage (renal, cardiac and vascular) and new cardiovascular events",,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
13160,NCT02384356,"Health Status using general health-related quality of life, perceived health, and PHQ8","Demographics, use of formal care and access, substance use, NCD diagnoses, self-care behavior, knowledge/perceptions, and anthropometric measures",,2014-06,COMPLETED,OBSERVATIONAL,['NA']
13161,NCT01906333,Change in IntraMyoCellularLipid (IMCL)content,Change in substrate metabolism,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
13162,NCT03665090,Prevalence and incidence rate of diabetic eye disease,Visual impairment,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13163,NCT05003154,Concentration of glycosylated hemoglobin A1c,Proportion of patients with abnormal resulets of postnatal oral glucose tolerance test,,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13164,NCT04278664,"HbA1c, maternal glycemic control",,,2015-07,TERMINATED,OBSERVATIONAL,['NA']
13165,NCT01213277,Primary endpoint is to see whether they are fast glycators,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-10,SUSPENDED,INTERVENTIONAL,['NA']
13166,NCT05574699,Change in the number of social needs identified during the visit,Change in the number of hospitalization events and emergency department (ED) visits between intervention and control arms,,2023-04-30,RECRUITING,INTERVENTIONAL,['NA']
13167,NCT01185743,gene expression profiling,,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13168,NCT03063138,Wound volume,,,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
13169,NCT02514850,Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg),Local tolerability,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13170,NCT00341406,adipose cell size distribution,,,2003-09-04,COMPLETED,OBSERVATIONAL,['NA']
13171,NCT00250731,diabetes regimen adherence,diabetes self-efficacy,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13172,NCT00818571,Measure: pharmacokinetics of vildagliptin and its metabolites,"Measure: safety assessments will include vital signs, electrocardiograms and adverse events",,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13173,NCT02399423,Change in adipose cell function after gaining 7% body weight and after losing 7% body weight,Change in cognition after gaining 7% body weight and after losing 7% of body weight,,2015-03-11,COMPLETED,INTERVENTIONAL,['NA']
13174,NCT01982019,Serum 26RFa levels,score of satiety,,2014-02-04,UNKNOWN,INTERVENTIONAL,['NA']
13175,NCT04515576,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD):Change from baseline to Day 29 in Fasting Glucose (FG),,2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE1']
13176,NCT05083767,Fasting Blood Sugar,,,2019-04-03,COMPLETED,INTERVENTIONAL,['NA']
13177,NCT01963559,Cutaneous blood flow,Effect of neuropathy on PIV impairment,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
13178,NCT00050479,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13179,NCT02598544,Adipose tissue inflammation,Concomitant medication,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
13180,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",,,2010-07,RECRUITING,OBSERVATIONAL,['NA']
13181,NCT00005137,,,,1992-07,COMPLETED,INTERVENTIONAL,['NA']
13182,NCT03545178,Hypoglycemia prediction (for Substudy B),Change of mean amplitude of glucose excursion (MAGE) day 0-3 compared to day 4-28 and day 0-7 compared to day 8-28 prior to consultation (for Substudy A),Change of mean of daily differences (MODD) day 0-3 compared to day 4-28 and day 0-7 compared to day 8-28 prior to consultation (for Substudy A),2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
13183,NCT04167553,adverse events (AEs):,,,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13184,NCT04897945,Weight change,Health-related quality of life,,2021-10-12,RECRUITING,INTERVENTIONAL,['NA']
13185,NCT05015283,"One year after operation, the complete remission rate of type 2 diabetes mellitus [HbA1c < 6%, fasting plasma glucose < 5.6 mmol/L, no need to use any hypoglycemic drugs]",Dumping syndrome and hypoglycemia symptoms,,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
13186,NCT03216226,Percentage of Patients With ADA,Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment,,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE3']
13187,NCT02675608,Change in HAI titer from day 0 to day 30 (+/- 4 days),Inflammatory Soluble Factor and Cellular Analysis additional measurements,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
13188,NCT03277742,Blood glucose control,,,2017-09-20,WITHDRAWN,INTERVENTIONAL,['NA']
13189,NCT05553912,HbA1c at Month 6,Quality of communication assessed using 3 questions from the CAHPS Clinician and Group survey,Clinician satisfaction survey,2022-11-02,RECRUITING,INTERVENTIONAL,['NA']
13190,NCT00110851,Effect on HbA1c levels,Effect on lipid levels,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13191,NCT01659697,occurence of diabetes,change in Body Mass index and Physical activity,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
13192,NCT05950516,Change in HbA1c,Percentage of Participants That Achieved Body Weight Loss ≥5%,,2023-07-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13193,NCT03156985,Incidence of adverse events,,The incidence of interested adverse events,2017-08-16,COMPLETED,OBSERVATIONAL,['NA']
13194,NCT02167061,Maximum of concentration (Cmax) of Evogliptin and Metformin,Time prior to the first measurable concentration (tlag) of Metformin (only in Part 2 trial),,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13195,NCT03554200,effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure,Effect of Empagliflozin 10 mg daily on Left ventricular diastolic function,,2018-06-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13196,NCT01123980,Change in Glycosylated Haemoglobin (HbA1c),Number of Hypoglycaemic Episodes,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13197,NCT00677599,"Change in cardiovascular disease risk indictaors - including carotid intima-media thickness (CIMT), total plaque volume (TPV) (at the carotid bifurcation), pulse wave velocity (PWV) and biomarkers of risk in blood samples .",,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
13198,NCT01236404,Safety/Tolerability,Pharmacodynamic Response,,2010-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13199,NCT01145092,Insulin Sensitivity,skeletal muscle lipid content,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
13200,NCT05495386,To collect continuous glucose monitoring (CGM) data to develop a hypoglycaemia notification algorithm.,To evaluate the surgeon satisfaction of H02 in participants with type 1 diabetes.,,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
13201,NCT00289237,Incidence of CHD and other lifestyle related diseases after ten years,"Changes in lifestyle and biological markers after one, three and five years",,1999-03,COMPLETED,INTERVENTIONAL,['NA']
13202,NCT02456064,HbA1c,,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
13203,NCT04723160,consistent rate of diagnoses,full coincidence rate of software's diagnoses,,2020-08-10,COMPLETED,OBSERVATIONAL,['NA']
13204,NCT04496401,To characterise the bioavailability of Envarsus® and compare it to the bioavailability of tacrolimus,Assessment of biological and clinical tolerance/ safety: Incidence of serious adverse events,,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
13205,NCT05706506,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Weight,,2023-03-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13206,NCT00005539,,,,1999-02,COMPLETED,OBSERVATIONAL,['NA']
13207,NCT01955694,The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10,Change in serum potassium,,2013-11-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13208,NCT00079638,Mean percent change in LDL-C from Baseline to Week 12,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13209,NCT01280929,Regression of neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment relative to the three treatment arms.,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13210,NCT02040246,HbA1c change from baseline,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13211,NCT00397553,HbA1c,Post-prandial glycemia (2 hour after breakfast),,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13212,NCT05917093,Change in Blood Glucose,Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,Patient's Perceived Involvement in Care Scale (PICS),2024-03,RECRUITING,INTERVENTIONAL,['NA']
13213,NCT05218304,"To know the prevalence of the main risk factors chronic diseases (obesity, diabetes, high blood pressure, high cholesterol and kidney failure) in the adult population of New Caledonia aged 18 to 64 using the WHO STEPS survey method.",Seroprevalence of infectious diseases,,2021-07-26,SUSPENDED,INTERVENTIONAL,['NA']
13214,NCT01176097,To investigate the safety and tolerability of AZD5658 following oral administration of single ascending doses and to estimate the maximum tolerated dose (MTD).,Effect of fasting on the pharmacokinetics and explore the pharmacodynamics of AZD5658.,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13215,NCT03947333,Change in Patient Activation at 3 Months,System Usage Data for My Diabetes Care - Utilization of Embedded Features and Functionality (Intervention Group Only),,2020-03-09,COMPLETED,INTERVENTIONAL,['NA']
13216,NCT01553526,Target Lesion Failure (TLF),Clinical Procedural Success,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
13217,NCT05919706,SF-36,,,2022-10-06,COMPLETED,INTERVENTIONAL,['NA']
13218,NCT01298726,GLYCATED HEMOGLOBIN (A1C) LEVELS,DIASTOLIC BLOOD PRESSURE LEVELS,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
13219,NCT03170518,Percentage of Participants with Adverse Events as a Measure of Safety and Tolerability,Percent Change in Body Weight From Baseline at Week 26 and Week 52,Change in Urinary Albumin/Creatinine Ratio (ACR) From Baseline at Week 26 and Week 52,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE3']
13220,NCT01844050,Change from Baseline Total score of diabetes symptoms at 4 weeks,Change from Baseline blood glucose at 2 hours after meal at 4 weeks,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
13221,NCT00390728,"Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.",Proportion of patients reaching HbA1c target as per participation with the Prescription Plan,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13222,NCT01422668,Glycemic Index of Khalas dates with and without coffee,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13223,NCT02770235,erectile dysfunction and AGE levels,,,2014-03-17,COMPLETED,INTERVENTIONAL,['NA']
13224,NCT02904512,Number of Participants With Hypoglycemic Events (< 70mg/dL),,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13225,NCT02984605,glycated hemoglobin,,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
13226,NCT04569214,Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13227,NCT05014204,Primary Safety Endpoint,Changes in glucose-lowering medication usage,Procedural Time,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13228,NCT01361971,Insulin sensitivity,Hypoxia and inflammatory markers,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
13229,NCT00057499,"Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests",T cells' secretion of IL-4 and Interferon (IFN)-gamma,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13230,NCT04443153,Glycemic Outcomes,High Blood Glucose Index,,2020-09-04,RECRUITING,INTERVENTIONAL,['NA']
13231,NCT02956044,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion up to 0-72 hr,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13232,NCT02735369,The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.,Number of patients requiring pars plana vitrectomy surgery due to traction retinal detachment at the end of the study.,Evaluation of systemic exposure as measured by bioanalytic methods.,2014-12,TERMINATED,INTERVENTIONAL,['PHASE2']
13233,NCT02931630,Postprandial triglyceride response,Microbiota,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
13234,NCT04141423,Anti-insulin Tregopil antibodies,PD Endpoints - CGM profile,,2019-10-28,TERMINATED,INTERVENTIONAL,['PHASE1']
13235,NCT01719029,Glucose area-under-the-curve,Infant Adiposity,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
13236,NCT01223612,Functional and anatomical change in the retina,OCT macular thickness,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13237,NCT06074913,Temperature of the back of the hand,2-hour postprandial blood glucose (2hPG),,2023-07-07,RECRUITING,INTERVENTIONAL,['NA']
13238,NCT02857764,Incidence of Below-Knee Lower Extremity Amputation in Canagliflozin New Users Versus non-SGLT2i Aha New Users,,,2016-02-15,COMPLETED,OBSERVATIONAL,['NA']
13239,NCT02363803,Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS),Change in Spontaneous Pain Intensity as a Function of Baseline HPT,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
13240,NCT00090519,Occurrence of Sustained Moderate Visual Loss (SMVL) in a Diabetic Retinopathy (DR) Study Eye,Number of Participants With Adverse Events,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13241,NCT00362193,Glycemic relapse: increase in HbA1c by 1% over baseline and >8%,Fasting Lipid Panel,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13242,NCT04914559,Area under the blood glucose curve,Insulinogenic index,,2021-05-17,COMPLETED,INTERVENTIONAL,['NA']
13243,NCT04767789,Glycated Hemoglobin A1c (HbA1c),Gastrointestinal Symptoms,Fecal calprotectin,2021-05-12,COMPLETED,INTERVENTIONAL,['NA']
13244,NCT01992588,CSII bolus related baseline corrected area under the serum insulin aspart concentration-time curve,CSII bolus related baseline corrected area under the glucose infusion rate curve,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13245,NCT04645875,Glycaemia,,,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA']
13246,NCT04189848,Intensity of Injection Site Pain,,,2019-12-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13247,NCT01130207,Changes in microflora after bariatric surgery,,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
13248,NCT00805506,To collect sufficient glucose data by means of continuous glucose monitoring for the purpose of detecting clinically relevant alterations in blood glucose throughout a typical or modal day.,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
13249,NCT00231647,Percent change in body weight from baseline to Week 16.,"Changes in body weight, body mass index,anthropometric measurements (waste and hip circumference and their ratio),fasting blood glucose and lipid profile from baseline to Week 16; safety evaluations including incidence of adverse events during the study.",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13250,NCT01154478,incremental AUC after a test meal of triglycerides concentration in chylomicrons and VLDL fraction,endothelial function,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
13251,NCT05037045,Change from baseline serum lipids at 6 month,incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,,2019-01-10,RECRUITING,INTERVENTIONAL,['NA']
13252,NCT02330042,Number of participants with measureable macular edema by OCT imaging,,,2014-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13253,NCT01202474,Percentage of patients achieving HbA1c level < 8% (in patients 6-12 year-old) and HbA1c level < 7.5 % (in patients 13-17 year-old),Change in daily dose of glargine and glulisine,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13254,NCT05847907,Complications,Implant stability quotient (ISQ),,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13255,NCT04288362,Change in HbA1c levels,"Change in healthcare cost in terms of total healthcare cost of polyclinic, emergency department, hospital admissions and specialist outpatient clinic visits",Change in Diabetes Retinal Photography rates,2019-03-25,COMPLETED,INTERVENTIONAL,['NA']
13256,NCT03718832,HbA1c,Healthy behaviors observed in paid claims HEDIS measures,Heterogeneity: HbA1c by causal tree,2019-04-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13257,NCT01346254,Oral glucose tolerance test (OGTT),Lipid profiles,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13258,NCT01563419,the time spent to complete dialing up insulin pens,the recommendation for the use of a magnifier,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
13259,NCT03864510,Genetic factors associated with advanced liver disease (fibrosis >2),Number of patients that develop symptoms of end-stage liver disease,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
13260,NCT04772729,Glycaemia difference in time in range (TIR) 70-180mg/dl,Difference in the basal rate of insulin,,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13261,NCT05789810,Fear Severity,,,2022-09-10,COMPLETED,INTERVENTIONAL,['NA']
13262,NCT02682901,Change in Hands ESC From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo,,,2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13263,NCT04457752,Complete Wound Closure,Changes in bacterial Load,,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13264,NCT01053234,Prothrombin fragment 1+2,C-reactive protein,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
13265,NCT05986097,HbA1c change,Change in insulin resistance,,2023-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13266,NCT05214547,Change from 4 weeks Shoulder Pain at 6 weeks,Change from 4 weeks Shoulder Function at 6 weeks,Change from baseline Shoulder Muscle Tone at 6 weeks,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13267,NCT00836225,To evaluate the safety and tolerability of single and multiple doses of ISIS-SGLT2Rx administered subcutaneously,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13268,NCT01195454,The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36),"Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax)",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13269,NCT02565862,Area Under the Curve (AUC),adverse events,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13270,NCT01881347,Change from baseline in Brachial artery flow mediated dilation,Change from Baseline in Reactive hyperemia,Change from Baseline in Endothelial cell protein expression,2013-01-01,COMPLETED,INTERVENTIONAL,['NA']
13271,NCT01610674,Barrier analysis,feasibility study,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13272,NCT02012166,Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 2,Number of Participants Who Discontinued Study Treatment Due To AEs,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13273,NCT04599075,Neonatal Hypoglycemia,Umbilical Cord Blood Level of Insulin,,2021-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13274,NCT05054283,Prolonged Length of hospital,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13275,NCT01021930,Comparison of the surface coverage between DM and Non-DM at 6 months after Cypher and YINYI stent implantation using OCT.,MACE,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13276,NCT01572415,Comparison of SCOUT DS to Random Capillary Glucose,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
13277,NCT00863967,Cardiovascular events,Disease activity score,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
13278,NCT03434860,HOMA-IR,cytokines levels,,2016-01-15,COMPLETED,INTERVENTIONAL,['NA']
13279,NCT02880267,"Proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a proportion of blood glucose values, compared between CGM and a lab glucose analyzer matched to an accuracy measurement of %20/20 mg/dL",,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
13280,NCT01269008,Better meal and post meal sugars on the closed loop device using the study medications.,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13281,NCT01583790,Weightloss of patients,Improvement of co-morbidities after surgery,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
13282,NCT04805541,Number of subject eyes whose EyeCheckup results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
13283,NCT00146484,* Hemoglobin A1c over the first 24 months of diabetes,* Family Functioning (Family Environment Scale)over the first 24 months of diabetes,,1996-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13284,NCT03631134,Changes of glycemic variation,Change of insulin dose,,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
13285,NCT05526430,Dose Limiting Toxicity (DLT),Visual Analog Scale (VAS),,2022-09-13,COMPLETED,INTERVENTIONAL,['PHASE1']
13286,NCT01272232,Proportion of Subjects Losing More Than 10% of Baseline Body Weight,Incidence of Hypoglycaemic Episodes,,2011-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13287,NCT06137963,Change in percent of body weight before and after a 6 month intervention period.,Postoperative length of stay,,2024-01-24,WITHDRAWN,INTERVENTIONAL,['NA']
13288,NCT00677937,Reduction in incidence of diabetes at 3 years,"change in hba1c, fasting and post glucose levels, cardiovascular risk (framingham), presence of MetS (NCEP ATP III)",,2009-05,COMPLETED,INTERVENTIONAL,['NA']
13289,NCT01209312,Blood glucose area under the curve,,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
13290,NCT04595968,Frequency of all device related Serious Adverse Events,Frequency of hypoglycemic episodes,,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13291,NCT03315143,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)","Total Number of Occurrences of CV Death, Non-fatal Myocardial Infarction and Non-fatal Stroke",,2017-12-19,TERMINATED,INTERVENTIONAL,['PHASE3']
13292,NCT02258373,"Percentage of Time in Range of 70 to 180 mg/dl, Measured With CGM",Number of Participants With >=1 Serious Adverse Event Other Than SH,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
13293,NCT04801121,Placental pathology,,,2020-11-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13294,NCT01301092,Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV),)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC),,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13295,NCT04796649,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2022-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13296,NCT00841503,determine glucose-lowering potential of the buckwheat bioactive compound during acute phase testing in volunteers with Type 2 diabetes,determine bioavailability of buckwheat bioactive compounds,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
13297,NCT05536232,Peptide C evolution,Circulating rate of cytokines,,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
13298,NCT01243138,"Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension","Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13299,NCT04765254,Investigation of bad prognosis cause for covid-19 diabetic patients,,,2021-02-20,UNKNOWN,OBSERVATIONAL,['NA']
13300,NCT03447301,HbA1c (glycated hemoglobin),Weight,,2018-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13301,NCT02533648,muscle oxidative stress in diabetic patients,Tolerance of the treatment measured by any adverse events during treatment and between each visit.,,2011-09-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13302,NCT05190744,Change in urine osmolality,Change in urine output,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13303,NCT00511602,HbA1c change from baseline (week 2) to end of treatment (week 12),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13304,NCT00486109,Glycosylated albumin levels,"Participants' satisfaction evaluated with standard quality of life questionnaires and adverse events related to the study device including incidents of erythema > 2cm diameter, incidence of induration > 1cm dimater and incidence of suppuration.",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13305,NCT01393275,alteration of HbA1c-level (haemoglobin A1c),follow up of all parameters mentioned above,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
13306,NCT02857491,perioperative hemorrhage of the surgical eye,best-corrected visual acuity,grade of surgical difficulty,2014-07,COMPLETED,INTERVENTIONAL,['NA']
13307,NCT03063580,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion),,2017-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
13308,NCT00924534,Change from baseline in Creatinine kinase level to Day 35,Change from baseline in High density lipoprotein cholesterol level to Day 28,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13309,NCT04814849,number of participants reporting financial burden,number of participants reporting emotional and/or psychosocial burden,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
13310,NCT05480228,The frequency (i.e. number of participants) with treatment emergent adverse events (TEAEs) reported in the time period defined by first administration of IP until 7 days after the last dose of IP.,Occurrence of 50% reduction of WAP from Baseline to Week 13.,To assess the effect of NRD135S.E1 in comparison to placebo with respect to the actigraphy step count.,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
13311,NCT01196325,Quantitative inner retinal blood flow,Mean angle opening distance and trabecular-iris spur area,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
13312,NCT03406975,Percentage of Excess Weight Loss (EWL),Change in Eating Behaviors,,2017-12-20,COMPLETED,INTERVENTIONAL,['NA']
13313,NCT02285218,new hepatokines,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
13314,NCT06011798,Mean change from baseline in BCVA by ETDRS letter,Assess safety outcome - TEAE,,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
13315,NCT03451630,Change in Hospital Readmission Rate,Gaps in care,,2018-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13316,NCT01749176,HbA1c,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
13317,NCT01069393,Improvement in HbA1c (glycosylated haemoglobin),Qualitative evaluation via in-depth interviews to assess patients' experiences of the intervention,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
13318,NCT03258268,HbA1c,Hypoglycemia,,2017-08-07,COMPLETED,INTERVENTIONAL,['NA']
13319,NCT02727790,"Number of participants with hypoglycemia, and/ or adverse events that are related to treatment",Changes in mean interstitial glucose levels measured by CGM,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
13320,NCT02052817,Change from baseline measured wound area,,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
13321,NCT00885638,Glucagon-like Peptide-1 Secretion After Meal Ingestion,Insulin Secretion After Ingestion of Meal,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13322,NCT06265935,SF-36 Quality of Life Scale:,Visual Similarity Scale for Fatigue,,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13323,NCT06327737,Prediction of cerebral edema with Integrated Pulmonary Index,,,2020-12-15,COMPLETED,OBSERVATIONAL,['NA']
13324,NCT05108987,Body Weight,Flow-mediated dilation,,2021-09-25,RECRUITING,INTERVENTIONAL,['NA']
13325,NCT00005347,,,,1992-02,COMPLETED,OBSERVATIONAL,['NA']
13326,NCT03233178,"Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control",Change in triglycerides from baseline to follow-up,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
13327,NCT00753181,Average daily blood glucose level,"Percentage of time in specified glucose ranges; Glycemic excursions; Change in plasma glucose, insulin, free fatty acids, triglycerides, 1,5-anhydroglucitol, and fructosamine; Dietary intake variables",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13328,NCT01198730,Diabetes,Mortality,,2009-04,RECRUITING,OBSERVATIONAL,['NA']
13329,NCT02803892,Change from Baseline C-peptide after the MMTT,Adverse Events (AEs) and Serious Adverse Events (SAEs),,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13330,NCT03113916,Waist Circumference in Centimeters,Number of Vegetable Servings Per Day (Transformed Using the Natural Log),Recruit Participants for Sustainability Phase,2014-06-23,COMPLETED,INTERVENTIONAL,['NA']
13331,NCT00315991,Accuracy of blood glucose level estimation,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
13332,NCT02171130,Percentage of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events (AEs) Reported Through the Nasal Score Questionnaire,Number of Participants With Treatment-Emergent Glucagon Anti-Drug Antibodies (ADA),2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13333,NCT01358994,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13334,NCT02627027,Cmax of Lobeglitazone Metformin,Vd/F of Metformin,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13335,NCT01114750,Pharmacokinetic variable: insulin,,,2010-04,SUSPENDED,INTERVENTIONAL,['PHASE1']
13336,NCT01785667,Incidence of diabetic retinopathy and proliferative diabetic retinopathy,Vessel diameters as a predictor of diabetic retinopathy and proliferative diabetic retinopathy,Fractal dimensions as a predictor of diabetic retinopathy and proliferative diabetic retinopathy,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13337,NCT05892848,"level of serum ostecalcin, sclerostin in patients with type 1 diabetes ann d their age and sex matched control",,,2023-06-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13338,NCT00330473,To assess blood sugar control as measured by HbA1c,To assess patient-reported outcomes based on the DTSQ Questionnaire,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13339,NCT01791465,Serum Interleukin 6 (IL-6) at Levels at Baseline and 16 Weeks,Waist to Hip Ratio at Baseline and 16 Weeks,"Peripheral Endothelial Tonography, as Measured by the Non-invasive EndoPAT System Using the LnRHI (Natural Log of Reactive Hyperemia Index), at Baseline and 16 Weeks",2013-03,TERMINATED,INTERVENTIONAL,['PHASE4']
13340,NCT02314637,Number of Participants With Adverse Events,Change From Baseline in Fasting Plasma Glucose at Week 52,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13341,NCT04917965,Coagulation Index,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
13342,NCT01739712,Academic performance,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
13343,NCT03680794,sCD160 concentration in the aqueous humor,Stromal cell-derived factor 1 (SDF-1),,2018-06-27,RECRUITING,INTERVENTIONAL,['NA']
13344,NCT05502016,"Glycemic control, measured by change in mean HbA1c (%) from baseline",,,2023-06-30,RECRUITING,INTERVENTIONAL,['NA']
13345,NCT00318032,"To contribute to the ADDITION-Europe study, to assess screening and intensive treatment on 5 year cardiovascular outcomes",To assess the economic and psychological cost of screening,,2004-08,UNKNOWN,INTERVENTIONAL,['NA']
13346,NCT05541120,Percentage of participants in each group who have HbA1c < 7%,Mean change in PAM-13 at 9 months,,2022-10-18,WITHDRAWN,INTERVENTIONAL,['NA']
13347,NCT05096078,Blood count test 8,WMS Number Range Test,,2020-10-16,UNKNOWN,INTERVENTIONAL,['NA']
13348,NCT04948112,Average percent time in glucose range,Neonatal hypoglycemia,Perceived benefit questionnaire (GMS),2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13349,NCT02120976,Plasma glucose,,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE1']
13350,NCT05634174,Free Fatty Acid measured Catecholamine Sensitivity,IL-6 Adipokine Gene Expression,ADRB3 Signaling Pathway,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
13351,NCT03945656,Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulin,"Clinically significant hypoglycaemia (Triple dose) - Clinically significant hypoglycaemia [PG less than 3.0 mmol/L (54 mg/dL)], after 3 times the individualised optimal basal dose of insulin",,2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13352,NCT04176120,Complete wound healing,Patient-reported mobility,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13353,NCT00815932,Changes in the Latency of P300,Changes in Pain Thresholds for Tactile and Thermal Stimuli will be calculated as the difference between ratings obtained form pain threshold measurements before- and after tDCS,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
13354,NCT00690287,Pharmacodynamic variables,Pharmacokinetic variables,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13355,NCT00099853,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13356,NCT04200625,Epicardial Fat thickness,,,2019-09-24,COMPLETED,OBSERVATIONAL,['NA']
13357,NCT03200535,Enrollment in Diabetes Prevention or Weight Management Class (Online),Enrollment in Diabetes Prevention or Weight Management Class (in Person),,2017-06-26,COMPLETED,INTERVENTIONAL,['NA']
13358,NCT05029076,"Adverse Event, Serious Adverse Event and Drug Combination",The Number of participants with abnormal laboratory examinations,,2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
13359,NCT01162772,catecholamine,Homeostasis model assessment-estimated insulin resistance,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
13360,NCT04395521,The efficacy of the study intervention on participants' foot self-care adherence.,The efficacy of the study intervention on participants' quality of life.,,2021-02-16,COMPLETED,INTERVENTIONAL,['NA']
13361,NCT01550328,Determine Device Bias,,,2012-04,TERMINATED,OBSERVATIONAL,['NA']
13362,NCT03696797,Change in FSIGTT DI (Frequently sampled intravenous glucose tolerance test),Number of participants that converted from pre-diabetes to normal glucose tolerance,,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13363,NCT05491746,Visual acuity at distance,Contrast sensitivity,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
13364,NCT00476658,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
13365,NCT05571436,Diabetes self-management behavior,Self-efficacy related to diabetes self-management,,2022-10-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13366,NCT01169779,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13367,NCT03305939,"Proportion of women with a change of glycaemic category, at or prior to final visit",Change in dietary habits as assessed by Intake 24 (a 24-hour recall questionnaire),,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13368,NCT06114134,Hemoglobin A1C (HbA1C),Antropometric Indices,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13369,NCT00220831,A combination of CVD mortality non fatal MI and Stoke at a 4 year follow up.,"etc…), all cause mortality, heart failure, at a 4 year follow up.",,2005-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13370,NCT00065130,Postprandial glycemic control,Adverse events,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13371,NCT01437072,HbA1c (Glycosylated Haemoglobin) level,The presence of retinopathy,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
13372,NCT02756442,Respiratory Disturbance Index,Air flow debit associated to micro awaking during sleep,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
13373,NCT04656093,Beliefs about Medicines Questionnaire (BMQ scores),Illness Perceptions Questionnaire (IPQ scores),,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
13374,NCT02092870,Percent change in wound size from baseline at 12 weeks,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13375,NCT00288392,- Time to healing,Safety,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13376,NCT05417646,Urinary glucose excretion,Renal threshold of glucose excretion,,2022-06-22,COMPLETED,INTERVENTIONAL,['NA']
13377,NCT01320345,Occurrence of clinical significant retinopathy progression.,Frequency of foot ulcer and non-traumatic amputation.,Quality of Life questionnaire,2016-11-03,RECRUITING,INTERVENTIONAL,['PHASE3']
13378,NCT02826655,Peripheral Retina Structure Differences between Healthy Controls and participants with diabetic retinopathy.,,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
13379,NCT03749642,Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).,Frequency of adverse events,,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2']
13380,NCT04254016,Variation of mitral E' velocity,Variation of lipid profile.,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13381,NCT04238702,Effective Renal Plasma Flow (ERPF),Vascular function,,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13382,NCT01175408,The primary endpoint is the A1c level or the change in A1c level,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
13383,NCT04834648,Primary Outcome,,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
13384,NCT06013826,Fear,,,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
13385,NCT05854862,TIR,Incidence of hypoglycemia,,2013-08-01,RECRUITING,OBSERVATIONAL,['NA']
13386,NCT00279266,Daily pain evaluations on a visual analog pain scale,Changes in sleep disturbance in secondary to pain as rated by a visual analog scale,,2006-01,WITHDRAWN,INTERVENTIONAL,['NA']
13387,NCT02405949,"Predictive value of the genetic test in identifying individuals who will have a good response to bariatric surgery, in terms of type 2 diabetes remission after the surgery.",,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
13388,NCT06098040,time in range,PAT plasma antioxidant capacity,,2023-09-22,RECRUITING,INTERVENTIONAL,['NA']
13389,NCT01524159,fibrinogen,Creatinine,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
13390,NCT01584232,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Percentage of Participants With Hypoglycemic Episodes,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13391,NCT05161741,Change from baseline in fasting plasma glucose to the last- observation on treatment,,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13392,NCT01970163,Effect of DermACELL on the proportion of chronic wounds of the lower extremity that have healed.,Proportion of wounds closed at 12 weeks and weekly thereafter for up to 24 weeks,"Incidence of treatment-emergent adverse events (AE), changes in vital signs, ankle-brachial index (ABI) and physical examination findings.",2013-10,COMPLETED,INTERVENTIONAL,['NA']
13393,NCT03369626,Level of engagement with the assigned mobile app,Change in self-reported diabetes medication type or dose,,2017-07-26,COMPLETED,INTERVENTIONAL,['NA']
13394,NCT05314855,Amplitude of SCN activity rhythm (peak-trough change in SCN activity),,,2023-01-04,RECRUITING,OBSERVATIONAL,['NA']
13395,NCT03171623,Safety and tolerability of single dose of SY-004,C-peptide secretion following single dose of SY-004,,2017-04-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13396,NCT02247635,"Reduction in the prevalence of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia)",Reduction of hypercholesterolemia,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
13397,NCT00368134,Change in HbA1c after 12 weeks,Safety Profile after 12 weeks treatment,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13398,NCT04081792,Number of Participants with a clinical and microbiological remission of treated infection at 2 months,Statistical evaluation of risk factors for failure of remission,,2019-09-04,RECRUITING,INTERVENTIONAL,['NA']
13399,NCT03844789,Continuous Glucose Monitor (CGM)-Measured Percent Time in Range 70-180mg/dL Over 16 Week Trial Period,Continuous Glucose Monitor (CGM)-Measured Glucose Variability Percentage Measured With the Coefficient of Variation (CV) Over 12 Week Trial Extension Period,Body Mass Index (BMI) at Conclusion of 12 Week Trial Extension Period,2019-06-06,COMPLETED,INTERVENTIONAL,['NA']
13400,NCT00554450,Iohexol PK blood & urine samples for GFR assessment,"The following urine/serum safety parameters will be assessed: sodium, potassium, magnesium, phosphorus, calcium, and total protein (urine only)",,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13401,NCT00704132,Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6,,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
13402,NCT05301478,Plantar pressure,,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
13403,NCT03176524,Assessments of local tolerability at injection site,Time to plasma glucose increase of ≥20 mg/dL from baseline,,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13404,NCT01310491,HbA1c change over time (participants with T2DM only),Satisfaction and usability of the technology and equipments.,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
13405,NCT02926950,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,Percentage of Participants With Hypoglycemic Events,2016-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13406,NCT04227769,Change in insulin concentration in blood during the cephalic phase of insulin secretion in obese patients with type 2 diabetes,Change in autonomic function,,2020-01-13,RECRUITING,INTERVENTIONAL,['PHASE2']
13407,NCT04173117,Recruitment and retention rates,The number of participants who experience any Major Adverse Cardiovascular Events (MACE),,2020-02-28,TERMINATED,INTERVENTIONAL,['NA']
13408,NCT02695095,incidence of acute liver injury,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
13409,NCT00174681,Percentage of subjects achieving HbA1c < 7% at the end of the study.,,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13410,NCT01982630,Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2,Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Non-Diabetic Overweight/Obese Participants in Part 2,,2013-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13411,NCT03771261,Change from Baseline Body weight at 4 months,Change from Baseline Insulin Sensitivity at 4 months,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
13412,NCT03252132,Muscle strength (isokinetic strength),,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
13413,NCT01688778,Changes in HbA1c,Use of medication,Number of visits at GP,2012-06,COMPLETED,INTERVENTIONAL,['NA']
13414,NCT02487888,Glucose levels for patients being treated for T2DM,Urine drug screen results,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
13415,NCT01432275,Overall User Preference for the FreeStyle InsuLinx System Compared to Current Method.,Preference Questionnaire (Insulin Calculator Not Activated),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
13416,NCT02330406,Change in glycated hemoglobin,Change in fatty acid fraction,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13417,NCT03111238,Complete relief of ischemic rest pain without developing ischemic lesions on the index leg.,,,2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE3']
13418,NCT00512707,Change From Baseline in Erectile Function Domain Score of the International Index of Erectile Function (IIEF),Change From Baseline in Positive Affects Ratio (PAR) of Derogatis Affects Balance Scale (DABS),Change From Baseline in Sex Hormone Binding Globulin (SHBG),2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13419,NCT04424888,2-hour Interstitial Glucose Area Under the Curve (AUC),CGM-Smartphone Usability Feedback,,2018-03-15,COMPLETED,INTERVENTIONAL,['NA']
13420,NCT03207841,"Change in HDL, LDL, total cholesterol and triglycerides",Change in Spinal Cord Injury-Quality of Life (SCI-QOL) Score,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
13421,NCT02854696,Incremental cost- utility ratio at 1 year,Assessment of total cost of islet cell transplantation,,2016-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13422,NCT05165615,Percentage of time in target ranges,The 5-item World Health Organization well-being index (WHO-5 index),,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
13423,NCT02204657,Glycemic Control by Measurement of HbA1c,Hypoglycemia,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
13424,NCT02365363,Exercise intensity,Substrate Oxidation,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13425,NCT02076347,Percentage of patients in each arm who obtain monitoring of vitamin B12 as recommended,Percentage of patients with newly identified vitamin B12 deficiency who have prior evidence of neuropathy upon chart review,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
13426,NCT01076218,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13427,NCT04455880,Prediction and differentiation of GDM and prognosis with Shear wave elastography velocity cut-offs,,,2019-05-15,COMPLETED,INTERVENTIONAL,['NA']
13428,NCT02623452,(Part B) PK: AUC of Insulin Lispro,(Part B) PD: AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13429,NCT00435240,"waist circumference at baseline, 3 months and 6 months","C-reactive protein at baseline, 3 months and 6 months",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13430,NCT01928381,"Brief Pain Index - Item 5, Average Daily Pain Score (Range 0-10) Higher Values Indicate Worse Pain",,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13431,NCT00964418,Area under the glucose infusion rate curve during one dosing interval at steady state (for NN1250),Area under the NN1250 concentration-time curve during one dosing interval at steady state,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13432,NCT00642278,Change in HbA1c From Baseline to Week 12,Percent Change in Body Weight From Baseline to Week 12,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13433,NCT03982693,Prevention of major cardiovascular endpoints,Changes in PAD Quality of Life,,2019-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
13434,NCT00024518,C-Peptide Level,Hemoglobin A1C,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13435,NCT03557892,HbA1c,Local Reactions,,2018-04-01,COMPLETED,INTERVENTIONAL,['NA']
13436,NCT01316861,Glycosylated hemoglobin (HbA1c),Safety will be evaluated by the Adverse events occurence,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13437,NCT00947024,Bioequivalence based on AUC and Cmax,,,1993-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13438,NCT03732690,Post meal tolerance test glycemic excursion (area under the curve),Adipose tissue gene expression modifications,,2018-12-05,COMPLETED,INTERVENTIONAL,['NA']
13439,NCT02599805,Comparative change in ulcer surface area,,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
13440,NCT00097955,Change from baseline in urinary albumin creatinine ratio after 24 weeks,Change from baseline in urinary albumin excretion rate after 24 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13441,NCT01497912,Fibrin network permeability,skin microvascular reactivity,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13442,NCT00495235,Prevalence Rate of Insulin Resistance,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
13443,NCT01475422,HbA1c,Diabetes Attitude Questionnaire - ATT-19,,2011-09,UNKNOWN,INTERVENTIONAL,['NA']
13444,NCT01136798,Total Amount of Slow Wave Activity,Mean 24-h Blood Glucose Levels,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
13445,NCT02114008,Residual gastric volume (RGV) in morbidly obese diabetics. A comparison of 3 hour versus 8 hour fasting,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
13446,NCT01373489,Hemoglobin A1c (HbA1c) at 6 Months Post Randomization,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
13447,NCT04364685,HbA1c,Quality of life-39,,2017-01-25,COMPLETED,INTERVENTIONAL,['NA']
13448,NCT02834858,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
13449,NCT00458081,Relative change in the microalbuminuria level.,Safety (including neuropsychiatric events) and Laboratory assessments.,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
13450,NCT02354027,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability.,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13451,NCT05188014,Blood glucose,percent of time in hyperglycemia,Carbohydrate supplementation,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
13452,NCT02278068,Primary Safety Outcome as assessed by Incidence of serious adverse device effects,Adverse Event Rate,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
13453,NCT01513746,Blood Glucose Values,Ecological Momentary Assessment of Emotional and Behavioral Outcomes,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
13454,NCT00286962,incidence of hypoglycemia; data taken from patient diaries during either study arm.,"daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13455,NCT02426138,Healthy Eating Index 2010 Score,Diabetes Distress Scale,Total Cholesterol,2015-04-01,COMPLETED,INTERVENTIONAL,['NA']
13456,NCT00233649,,,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
13457,NCT03607617,SDH data adoption,DM Key tests,,2018-09-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13458,NCT05391854,Glycated haemoglobin (HbA1c),SF-12 (Short-fom 12),,2022-06-21,COMPLETED,INTERVENTIONAL,['NA']
13459,NCT03941132,"Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome.",Glycaemic variability in continuous glucose monitoring and hypoglycaemia rates.,,2021-01-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13460,NCT00850135,Correlation Between Glucose AUC and Birth Weight.,"Pregnancy and Delivery Characteristics for Participants With AUC-130 <= 22,000 and AUC-130 > 22,000",,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13461,NCT01053026,1. Vascular function testing,"Circulating biomarkers including hs-CRP, adiponectin, myostatin, MMP, etc",,2009-12,COMPLETED,OBSERVATIONAL,['NA']
13462,NCT01160887,glucose,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
13463,NCT00569400,Change of human insulin antibodies,Frequency of adverse events,,2003-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13464,NCT02525263,"Serial Estimation of Glomerular Filtration Rate (GFR) Through 6 Months Following the Final Cell Implantation, as Measured by Serial Serum Creatinine.",Renal-specific Laboratory Assessments Through 12 Months Following the Last NKA Implantation Under This Protocol.,Evaluation of Renal Structure Over Time as Measured by Imaging Modalities.,2016-07,TERMINATED,INTERVENTIONAL,['PHASE2']
13465,NCT01545492,difference in 'change in z score for weight' at 12 m(+/- 2m),differences in DNA methylation,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
13466,NCT05482958,Glycemic control amongst people with established T2DM.,Change in glycemic control.,,2022-07-29,RECRUITING,OBSERVATIONAL,['NA']
13467,NCT04317404,Post-injection glucose levels,KOOS Knee survey,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
13468,NCT02343471,Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in healthy subjects and subjects with type 2 diabetes measured as incremental Area Under the Curve (iAUC -15 - 360 min).,Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min).,Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -15 - 360 min),2015-03,COMPLETED,INTERVENTIONAL,['NA']
13469,NCT02489773,Compare the Pearson Correlation of Glycated Albumin (GA) and Fructosamine Within All Subjects With the Performance Goal of 0.8,"Kendall Correlation Analysis of Changes in GA, HbA1c, and 7-day Interval MBG in the First 3 Months in Group 1",,2015-06,COMPLETED,OBSERVATIONAL,['NA']
13470,NCT06143449,Provide data on disease management.,,,2015-10-01,RECRUITING,OBSERVATIONAL,['NA']
13471,NCT04601519,Objective sleep fragmentation,Sleep fragmentation by subgroups,,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA']
13472,NCT04554810,Knowledge about chronic medications scores,,,2015-05-10,COMPLETED,INTERVENTIONAL,['NA']
13473,NCT05654727,BDNF,,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
13474,NCT02813759,Satiety,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
13475,NCT06143267,Total glucagon response,Food intake,,2022-12-06,RECRUITING,INTERVENTIONAL,['NA']
13476,NCT00767260,area under the curve of c-peptide,area under the curve of serum insulin,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13477,NCT03774186,Fear of Hypoglycemia Score,Fetal Outcomes: Number of Participants With Neonatal Hypoglycemia Infants,,2019-03-21,COMPLETED,INTERVENTIONAL,['NA']
13478,NCT04051866,Glycated Hemoglobin A (HbA1c),Gingival Probing bleeding,,2022-12-02,WITHDRAWN,INTERVENTIONAL,['NA']
13479,NCT00978627,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13480,NCT00325559,Paired difference in the time to complete a time trial corresponding to 5 km cycling between euglycaemia and hyperglycaemia,Pretest diary data,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
13481,NCT05027334,Fasting blood glucose (FBG),Weight,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
13482,NCT01671735,weight loss,,,2012-09,WITHDRAWN,INTERVENTIONAL,['NA']
13483,NCT01547897,Effect of NOX-E36 on albuminuria as measured by ACR (albumin to creatinine ratio; mg/g),Effect of NOX-E36 on eGFR,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13484,NCT05136287,Weight loss,Number of participants experiencing adverse events,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
13485,NCT00205738,Effects of olanzapine/risperidone/haloperidol on glucose regulation.,Explore Treatment-related effects on glucose effectiveness.,,2000-07,COMPLETED,INTERVENTIONAL,['NA']
13486,NCT01529216,HbA1c,HbA1c,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
13487,NCT00873223,Insulin detemir pharmacokinetics with and without liraglutide administration,Pharmacokinetics of liraglutide with and without insulin detemir,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13488,NCT04013581,Change of HbA1c,Change of liver enzymes,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13489,NCT01363336,General evaluation of patient concerning efficacy of AdalatCR treatment in real practice,Overall evaluation,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
13490,NCT04040595,Mean adipocyte size (µm2) assessed using Image J software.,"Adipose tissue expression of genes that are determinants of adipose inflammation (IL-1beta, IL-6, and 8, TNFalpha, MCP-1/CCL2).",,2019-03-07,COMPLETED,INTERVENTIONAL,['NA']
13491,NCT02449330,Change of the ratio of peak velocity of early transmitral diastolic filling by echocardiography (E) to early diastolic mitral annular velocity by tissue Doppler echocardiography (E/e'),Change of plasma levels of NT-proBNP,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
13492,NCT02417090,Metabolic late effects,,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
13493,NCT01929018,Timed Up-and-Go Test,World Health Organization Disability Assessment Scale,,2013-10-09,COMPLETED,INTERVENTIONAL,['NA']
13494,NCT01762046,Metformin response,Vitamin D,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
13495,NCT03483129,Percentage of eligible patients recruited into the study assessed by study attendance and surgery patient records,Change in the urinary concentration of metabolites of high health importance assessed by FIE-MS,,2018-04-25,COMPLETED,INTERVENTIONAL,['NA']
13496,NCT06024590,The primary endpoint is the percentage of index ulcers healed at 12 weeks,Wound complication rate,,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE4']
13497,NCT02158442,"Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With Diabetes, and Significant Wound Infection of the Lower Limb.",,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13498,NCT00705952,"Whether weight loss achieved through a programme of intensive lifestyle management can result in enhanced production of Glucagon-Like Peptide-1 together with improvements in glycaemic control, in patients with new onset type 2 diabetes.","To examine the changes in hormonal regulators of energy homeostasis (leptin, adiponectin, ghrelin) and cardiovascular risk factors occurring with this intervention.",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
13499,NCT03162926,Incidence of all adverse events reported for subjects,,,2017-07-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13500,NCT05785780,Up-to-date CRC screening,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes,Implementation Fidelity,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
13501,NCT04439474,HBA1C,,,2018-10-10,COMPLETED,INTERVENTIONAL,['NA']
13502,NCT00214253,post-transplant islet function,Suitability of cadaver donor pancreases for islet transplantation,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13503,NCT00159679,Nerve conduction measurements; Pain scores from patient diaries,Proportion of patients with at least a 50% reduction in pain scores; Short-Form McGill Pain Questionnaire; Sleep interference scores from patient diaries; Clinical Global Impression of Change; Patient Global Impression of Change,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13504,NCT05174390,Number of participants with the diagnosis of atrial fibrillation,Patient-reported symptoms (descriptive category variables) of atrial fibrillation using a questionnaire in a digital application,,2021-09-20,UNKNOWN,OBSERVATIONAL,['NA']
13505,NCT05980754,biochemical parameters including level of insulin,pancreatic fat content,,2024-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13506,NCT04407650,Glycaemic control,Biomedical neonatal outcomes,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13507,NCT03685773,Endogenous glucose production (EGP),Change in Arterial Spin Labeling (ASL) signal,,2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13508,NCT00660790,Change of Intima Media Thickness (IMT),,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13509,NCT01108263,Overall Decrease in Wound Size,Decreased Peak Plantar Pressures in Both the Static and Dynamic Phases of Gait as Compared to Pre-operative Pressure Values.,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE4']
13510,NCT02772497,Proportion of visual acuity improvement using Snellen chart or equivalent,Number of eyes with retinal toxicity after ziv aflibercept treatment,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13511,NCT04336969,Change in rise of HbA1c,Change in education exposure to safe exercise strategies,"T1D Patients receiving 4T education and care monitored on a step-down cadence in study 2, will achieve an HBA1c non-inferior to weekly review",2020-06-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
13512,NCT03378024,The correlation of changes of albuminuria and the outcome of PAD,,,2016-12-01,UNKNOWN,OBSERVATIONAL,['NA']
13513,NCT00605280,Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year,Number of Participants Requiring Focal or Grid Laser Treatment During Year 2,,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13514,NCT05188586,Specificity,Stage Shift,,2022-12-06,RECRUITING,INTERVENTIONAL,['NA']
13515,NCT03962010,Change in HbA1c,,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13516,NCT00850161,The primary endpoint is to determine whether intranasal administration of Nasulin™ will stimulate glucose disposal and suppress endogenous glucose production.,,,2009-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13517,NCT03444467,Number of treatment emergent adverse events (TEAEs),Change from baseline in Activated Partial Thromboplastin time (APTT),,2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13518,NCT05039307,Change from baseline in the adherence to a healthy lifestyle score at 12 months,Change from baseline in systolic and diastolic blood pressure at 12 months,,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13519,NCT01029392,Change in Hemoglobin A1c,Change in Insulin Requirements,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13520,NCT00179400,Whole body in vivo glucose turnover,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13521,NCT04547439,Melatonin and Cortisol Rhythm,,,2021-02-03,RECRUITING,INTERVENTIONAL,['PHASE2']
13522,NCT05443204,MFG discharge - hypoglycaemic events,Postprandial glucose intersticial monitoringdiabetes specific supplement,,2022-07-07,RECRUITING,INTERVENTIONAL,['NA']
13523,NCT03084900,HbA1c value,DKA,,2017-07-27,COMPLETED,INTERVENTIONAL,['NA']
13524,NCT00000539,,,,1992-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13525,NCT03258840,HbA1c,Serum Lpa,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13526,NCT03133156,Changes in human adipose tissue characteristics following exercise training.,,,2017-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13527,NCT04182451,Efficacy of Meso Wound Matrix,Health Economics,,2019-12-05,COMPLETED,INTERVENTIONAL,['NA']
13528,NCT03383627,Mean HbA1c,Determination of Serum Fructosamine,,2017-11-30,COMPLETED,INTERVENTIONAL,['NA']
13529,NCT01729299,post-prandial insulin secretion,gastric emptying,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
13530,NCT01890226,Change in Composite Quality Score,Change in Health-related Quality of Life,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
13531,NCT03513055,the relationship between SDBG and injection score,the relation between insulin antibodies and glucose excursions,,2018-05-07,UNKNOWN,INTERVENTIONAL,['NA']
13532,NCT05950477,"In 100 subjects with type 1 diabetes it will be evaluated the relationship between time in range, assessed though continuous glucose monitoring, and the score of the depression questionnaire CES-D",,,2023-06-12,RECRUITING,OBSERVATIONAL,['NA']
13533,NCT01514292,CGM Relative Differences to Laboratory Reference,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
13534,NCT01079234,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13535,NCT01590797,Number of Participants Discontinuing Study Medication Due to an AE,Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin,,2012-07-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13536,NCT05759897,Mean Change From Baseline in HbA1c at Week 16,"A summary of adverse events, including serious adverse events (SAEs), and Hypoglycemic Event[",,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13537,NCT00693537,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
13538,NCT02321878,Number of AEs (adverse events),Change in HbA1c (glycosylated haemoglobin),,2014-12-15,COMPLETED,OBSERVATIONAL,['NA']
13539,NCT05541484,Ketone levels measured in blood and breath in persons with T1D in persons with T1D,Ketone levels in persons with T1D during usual care versus usual care plus SGLT2i treatment,Ketone levels in persons with T1D undergoing insulin withdrawal,2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE4']
13540,NCT01765517,effects of probiotics on endotoxin levels in patients with T2DM,effects of probiotics on gut microflora,Effects of probiotics on insulin resistance,2013-10,COMPLETED,INTERVENTIONAL,['NA']
13541,NCT01221194,Number of Participants Who Developed Foot Ulcer During Study Time Frame,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13542,NCT00288132,Hemoglobin A1c,Waist Circumference,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
13543,NCT01383772,Risk of failing visual field criteria to hold a driving licence.,Visual field assessment prior to planned pan retinal photocoagulation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
13544,NCT04318184,"""Change"" is being assessed for Triglyceride","""Change"" is being assessed for BMI",,2018-01-02,COMPLETED,INTERVENTIONAL,['NA']
13545,NCT00268541,Adipose tissue gene expression at 8 weeks,Body composition/adiposity at 8 weeks,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
13546,NCT05525884,Diagnosis of significant hepatic fibrosis,High HOMA-IR,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
13547,NCT00742521,catecholamine measures,,,2001-03,COMPLETED,INTERVENTIONAL,['NA']
13548,NCT01500590,change of estimated GFR calculated by MDRD equation and onset of microalbuminuria,,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13549,NCT03975309,Montreal Cognitive Assessments (MoCA),Number Span Test (Forward/Backward),,2019-09-09,COMPLETED,OBSERVATIONAL,['NA']
13550,NCT03312582,Peri-implant prpbing depth,,,2015-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13551,NCT05705271,Number of participants with hyperkalemia events,Change in urine albumin-to-creatinine ratio (UACR) from baseline to 4 months,,2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE4']
13552,NCT05095922,Blood pressure,,,2023-03-28,RECRUITING,INTERVENTIONAL,['PHASE4']
13553,NCT03797885,"Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis",Type of pharmacological treatment,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
13554,NCT00518167,Diabetes incidence,CVD incidence,,1993-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13555,NCT02816073,Regression of neovascularization,Retreatment rate,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
13556,NCT01565317,Change in Sural nerve conduction velocity,Change in Sural Nerve Amplitude potential,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
13557,NCT03634098,"To study in type 2 diabetic participants with liver biopsy, the performance of a composite biomarker (3rd generation test) for the diagnosis of NASH",Constitution of a bio-collection,,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
13558,NCT00237094,,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
13559,NCT00633763,Difference in fallypride binding in the pancreas of long-standing T1DM patients versus healthy controls,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
13560,NCT00839865,The primary objective is to determine the effect of this ointment on the incidence of complete wound closure.,"Secondary objectives include: evaluating the acceleration of ulcer closure or facilitation of surgical closure, reduction of ulcer surface area over time, reduction in complications, the quality of life and it's safety.",,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
13561,NCT00005146,,,,1979-05,COMPLETED,OBSERVATIONAL,['NA']
13562,NCT01572649,GLU-AUC 0:30-4:30h: area under the plasma glucose concentration time profile from time of the standardized breakfast start (30 min after IMP injection and pre-meal plasma glucose) until 4 hours later subtracting the pre-meal value,"Area under the concentration time profile from time of standardized breakfast start (30 min after IMP injection) until 4 hours later for insulin, C-peptide and glucagon",,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13563,NCT00431977,Cardiac death,All-caused death,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
13564,NCT03536364,Effect of food order on postprandial glucose excursions as measured by incremental area under the curve (iAUC) for glucose ((mg/dl)*180) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,Effect of food order on satiety as measured by a visual analog scale (cm) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
13565,NCT03130426,The first occurrence of diabetes relapse,Glycated hemoglobin (HbA1C),,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
13566,NCT03815955,Positive and Negative Affect,,,2019-03-14,COMPLETED,INTERVENTIONAL,['NA']
13567,NCT04678557,Cohort 2: The Change in AUC (Area Under Curve) From Baseline to Week 26 in C-peptide During 4-hour MMTT,,,2019-06-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13568,NCT01020955,Insulin sensitivity,body composition,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13569,NCT03400618,The difference in mean glucose level,Hypoglycemia confidence score,Ketoacidosis,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
13570,NCT05487534,Glucose variability and insulin resistance (CGMS - 10 days),Attentional Cueing Procedure,,2023-04-26,RECRUITING,OBSERVATIONAL,['NA']
13571,NCT01125553,Maximum observed serum insulin aspart concentration,Time to maximum observed serum insulin aspart concentration,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13572,NCT02362737,Change help-seeking behaviors (Medication adherence and doctor/ER visits).,Change HbA1c.,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
13573,NCT00241085,Change from baseline in urinary protein excretion after 30 weeks,"Change from baseline in circulating markers of blood vessel inflammation, insulin resistance, serum creatinine, diabetic control, and proportion of patients who return to normalization of protein excretion after 30 weeks",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13574,NCT05597202,Difference in coronary 68Ga-Dotatate uptake after treatment.,Difference in bone marrow aspirates after treatment.,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13575,NCT01886989,Blood pressure (mm Hg),Inflammation,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
13576,NCT05756829,Change from Baseline HbA1c at 6 months,,,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
13577,NCT01965496,To assess HbA1C levels after 14 weeks continuous treatment,To assess Fasting blood glucose levels,To assess the body weights after the treatment,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13578,NCT04413578,HbA1c Range,Healthcare Cost,,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13579,NCT03782649,Generation and validation of prediction models - Consensus Error Grid,Safety evaluation: paucity of adverse events,,2018-11-29,COMPLETED,INTERVENTIONAL,['NA']
13580,NCT05536804,Change from Baseline in Kidney Oxygenation in Participants With or Without T2D,Percent Change from Baseline in Urine Albumin-to-Creatine Ratio (UACR),,2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE2']
13581,NCT03015220,Number of Treatment-emergent Adverse Events (TEAEs),Diabetes Therapy-Related Quality of Life (DTR-QoL): Total Score and Scores for the 4 Domains,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13582,NCT05073302,Rate of inflammation in the DL implant site,Cellular composition demonstrated by immunohistochemistry,,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE1']
13583,NCT06241664,Sensitivity and Specificity,,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
13584,NCT02963766,Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26,PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss],,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3']
13585,NCT02036515,Percentage of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in EQ-5D-3L Score at Week 52,,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13586,NCT02470806,Percentage Change in Ulcer Area From Baseline to the End of the Treatment Period,Percentage Change in Target Ulcer Depth and Volume Following Treatment With Either PICO or tNPWT From Baseline Over the 12-week Treatment Period,,2015-07-02,COMPLETED,INTERVENTIONAL,['NA']
13587,NCT04866667,New-onset cardiovascular events,Microvascular complications,,2021-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13588,NCT01845831,Change in HbA1C,Hospital Mortality Rate,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13589,NCT05498688,Plasma fatty acid composition,Subjective appetite,,2022-08-25,RECRUITING,INTERVENTIONAL,['NA']
13590,NCT04977583,Connection to New Resources,Hemoglobin A1c (HbA1c),,2022-05-02,COMPLETED,INTERVENTIONAL,['NA']
13591,NCT02118714,Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26,Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B,,2015-04-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13592,NCT05990530,Residual β-Cell function (RBCF),Quality of life score,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
13593,NCT04143737,Change in average daily steps- measured by Pedometer,Change in Leadership self-efficacy scale,,2016-03-07,COMPLETED,INTERVENTIONAL,['NA']
13594,NCT03101865,Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl),AUC of glucose below 3.5mmol/l (63mg/dl),Percentage of time of CGM availability,2017-08-08,COMPLETED,INTERVENTIONAL,['NA']
13595,NCT01511692,The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10,Adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13596,NCT04090008,Percent reduction in the ulcer size,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13597,NCT02072902,Hazard ratios for all-site and site specific cancer,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
13598,NCT01193387,Maximum observed Insulin Degludec concentration,Area under the Insulin Degludec concentration-time curve,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13599,NCT06111508,Change in Time in Range,Frequency of Dose Changes,,2023-11-29,RECRUITING,INTERVENTIONAL,['NA']
13600,NCT02377362,Number of Participants With One or More Treatment Emergent Adverse Events (Parts B),Change From Baseline in Hip Circumference (Part B),,2015-03,TERMINATED,INTERVENTIONAL,['PHASE1']
13601,NCT00171561,Blood measures of hypertension after 24 weeks,Change in serum markers of endothelial function and oxidative stress after 24 weeks,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13602,NCT01246687,Change from Baseline in Dietary KAB Score at 12 months,Change from Baseline in blood biomarkers at 12 months,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
13603,NCT03364868,The development of diabetes,Abnormal glucose tolerance (AGT) defined by dysglycemia or diabetes.,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13604,NCT02206152,Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions,,,2015-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13605,NCT03235908,Copeptin level,operational function (functioning) after 12 months compared to baseline assessed by questionnaire,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
13606,NCT05411965,Pharmacokinetic variables - Cmax,Pharmacokinetic variables - t1/2 of Pioglitazone M-IV,,2022-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
13607,NCT04501107,AUCLIS.0-1h,AUCGIR.4-8h,,2020-08-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13608,NCT02986256,Number of hospitalization days related to diabetic foot ulcers after one year of follow-up,Patient satisfaction score,,2017-01-04,COMPLETED,INTERVENTIONAL,['NA']
13609,NCT03416855,Percentage of patients with AEs at week 26,Changes from baseline in PPBG/PPPG after 26 weeks treatment,,2018-01-31,COMPLETED,OBSERVATIONAL,['NA']
13610,NCT05319275,mTCNS total score change from baseline at week 24,Changes in Nerve Conduction Amplitude from baseline at week 24,,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE3']
13611,NCT01792635,Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B,Ra in Part B in PF-05175157 200 mg BID Group,,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2']
13612,NCT03036774,Number of patients with full stomach,Intraoperative hypoxemia,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
13613,NCT02665455,Point Accuracy Determined as % Within Consensus Error Grid Zone A,,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
13614,NCT04917692,Number of episodes of diabetic ketoacidosis per patient,Number of episodes of hypoglycemia per patient,,2021-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13615,NCT01464320,Change in glomerular filtration rate,Change in urinary albumin excretion,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13616,NCT01580813,Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak VO2,Triglycerides,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
13617,NCT03476876,Wound Saturation of Oxygen at 16 Weeks,Number of Participants With Wound Complications at 16 Weeks,,2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13618,NCT03360604,Change in cognitive performance on a Letter Memory Task,Fullness,,2018-04-04,COMPLETED,INTERVENTIONAL,['NA']
13619,NCT01167959,Changes in gut hormones,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13620,NCT00547027,weekly physical activity,physical activity stage of change,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13621,NCT04359771,Change in the Best Corrected Visual Acuity (BCVA),,,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE4']
13622,NCT02353273,"Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below. (AUC0-∞, AUC0-t, Cmax)(Cmax,ss, AUC0-τ)","Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below, if appropriate. (Tmax,ss)",,2015-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
13623,NCT00954577,"Reduction in diabetes risk factors including insulin secretory capacity, insulin sensitivity, body fat content, dyslipidemia, and circulating concentrations of pro-inflammatory cytokines.",Improvement in self-esteem and in health-related behaviors.,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
13624,NCT05680129,Change from baseline in HbA1c,Pharmacokinetics: plasma trough level of XW003,,2023-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13625,NCT02935868,"Salivary peroxidase - collection of stimulated saliva in 10 minutes, measurement by a spectrophotometer.","Plaque index - measured by visual observation and classification in scores (1 for presence, 0 for absence)",,2013-11,COMPLETED,OBSERVATIONAL,['NA']
13626,NCT02700477,Post prandial blood sugar levels,Glycosylated haemoglobin (HbA1C)(%),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13627,NCT02052037,Glycemic Index,Physical Activity,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
13628,NCT00957957,Change from baseline in PYY (Peptide YY) measured by ELISA 4 weeks after RYGBP,Change from baseline in PYY measured by dMS 4 weeks after RYGBP,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
13629,NCT03076424,Intestinal Microbiome Composition,Hemoglobin A1-c,,2017-03-08,COMPLETED,OBSERVATIONAL,['NA']
13630,NCT02382536,In-line fluid pressure,Leakage,Number of subjects with adverse events,2014-08,COMPLETED,OBSERVATIONAL,['NA']
13631,NCT04023344,Antibody Response,Treatment Satisfaction,,2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE3']
13632,NCT02917057,Changes from baseline in weight (kg),Frequency of Vomiting,,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
13633,NCT05369585,Evolution of energy metabolism (energy expenditure),"Evolution of metabolomics (amino acids, fatty acids and acylcarnitine species)",,2022-04-25,COMPLETED,INTERVENTIONAL,['NA']
13634,NCT06228313,VivaChek Ino glucose concentration,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
13635,NCT03737942,neuromuscular monitoring,,,2018-11-15,UNKNOWN,OBSERVATIONAL,['NA']
13636,NCT02011100,chronic systemic inflammation,level of glucose intolerance,muscle carnosine content,2013-12,COMPLETED,INTERVENTIONAL,['NA']
13637,NCT02616666,Proportion of patients achieving clinical success as measured by a 4-item composite endpoint.,"To assess differences between dapagliflozin and SOC in the healthcare resource utilization up to 52 weeks following randomization and separately, up to 104 weeks following randomization",,2016-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
13638,NCT01318070,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13639,NCT00164658,Change in stage of adoption of health behaviors and referral for additional screening and follow up for high risk participants at 6 month post evaluation,Primary care physicians' provision of preventive services in response to family medical history.,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13640,NCT01067092,% of persons with blood pressure less than 130/80,Summary of Diabetes Self-Care Activities,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
13641,NCT03058029,Percent change in body weight,Change in HbA1c,Proportion of subjects with weight loss ≥7.5%,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA']
13642,NCT01053936,To assess a trend in mean change from baseline to Day 29 in eGFR (as estimated by the 4-component MDRD formula) with increasing doses of bardoxolone methyl (amorphous dispersion) in patients with Type 2 diabetes and CKD (eGFR 15-45 mL/min/1.73m2).,To assess a trend in mean change from baseline to Day 85 in eGFR (as estimated by the 4-component MDRD formula with increasing doses of bardoxolone methyl (amorphous dispersion) in patients with Type 2 diabetes and CKD (eGFR 15-45 mL/min/1.73m2),,2010-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
13643,NCT02025751,"Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure",,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13644,NCT02370719,Change in HbA1c from baseline to 12 months,Summary of Diabetes Self-Care Activities,,2015-06-28,TERMINATED,INTERVENTIONAL,['NA']
13645,NCT01475201,change in arterial stiffness,change in diastolic blood pressure,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
13646,NCT05679037,The change in carotid artery intima-media thickness (CIMT),Fast blood glucose measuremt,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13647,NCT01171456,Effect of metformin versus placebo on the development of GDM,Effects on maternal and fetal pregnancy outcomes of pre-conception metabolic intervention with metformin.,,2010-04,WITHDRAWN,INTERVENTIONAL,['NA']
13648,NCT05476627,Number of Participants with all cause death,Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE),,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
13649,NCT01911663,change from baseline in glucose,change from baseline in C-peptide,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13650,NCT00355849,"To compare in patients who at study entry have type 2 diabetes not optimally controlled by one or more oral antihyperglycemic medications plus once daily insulin glargine, a regimen that may include mealtime AIR Insulin.",To assess rate and incidence of hypoglycemia,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13651,NCT00935532,Change in HbA1c From Baseline to Endpoint (Week 26),Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13652,NCT00398060,Weight,"Blood pressure (diastolic, systolic)",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13653,NCT04922294,Implementation preferences,,,2020-07-20,COMPLETED,OBSERVATIONAL,['NA']
13654,NCT03339453,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia,PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon,,2017-11-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13655,NCT01956773,Number of Participants With Uptake of Genetic Counseling for Those at Risk of Hereditary Conditions at 1 Year,Number of Providers Who Were Successfully Using MeTree in Their Clinical Work Flow,,2014-04-11,COMPLETED,INTERVENTIONAL,['NA']
13656,NCT02687893,Mean duration of time with sensed glucose less than 70 mg/dl post-exercise,Mean duration of time with capillary blood glucose > 180 mg/dl,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
13657,NCT03761719,Neurocognitive test domain scores,,,2018-07-30,COMPLETED,OBSERVATIONAL,['NA']
13658,NCT04984044,Change from baseline Michigan Neuropathy Screening Instrument (MNSI) scores at 8 weeks.,Change from baseline Serum 25(OH) D level at 8 weeks.,,2020-11-07,COMPLETED,INTERVENTIONAL,['NA']
13659,NCT01618045,Monocyte Function,Lipid Profile,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
13660,NCT04266054,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,triglycerides will be measured from the same blood sample used to derive the outcome measure.,,2019-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13661,NCT02181621,Within-patient Change From Baseline in Log^10 Biofilm-protected Bacteria Count (Colony Forming Units [Cfu]/Gram[g]),Presence of Biofilm by Clinical Judgment Versus Presence of Biofilm by Laboratory Test,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13662,NCT00179374,Metabolic control (measured by HbA1c),Cost evaluations,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
13663,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
13664,NCT03164187,Percentage of patients achieving HbA1c level ≤ 7 %,Mean daily dosage of Diabeton MR,,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
13665,NCT01912092,"Clinical signs of local infection (Presence of erythema, pain, tenderness, warmth or induration)",Wound surface area,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
13666,NCT05477368,To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study,Self-reported blood pressure (systolic and diastolic),Viability of methods,2022-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13667,NCT01507389,Area under the Curve (0-infinity),Adverse events,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13668,NCT05393284,Improvement in Diabetic Retinopathy Severity Scale (DRSS) score,Safety and tolerability,,2022-08-16,RECRUITING,INTERVENTIONAL,['PHASE2']
13669,NCT00513201,Glycemic control in lyspro vs regular insulin in cirrhotic patients,Tolerance to treatment and reduced postprandial hypoglycemia episodes,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
13670,NCT01107717,Difference in HbA1c level,hypoglycemic events,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13671,NCT00270842,Gait and Balance Measures,Fall Self Efficacy,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
13672,NCT04731142,Number of Participants With Hospital Admissions,Change in Systolic Blood Pressure,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
13673,NCT01497535,Maximum glucose infusion rate (GIRmax),Adverse events,,2004-05-27,COMPLETED,INTERVENTIONAL,['PHASE1']
13674,NCT02783677,Digital infrared thermal imaging (DITI),,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
13675,NCT04051294,Insulin level,Blood pressure,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
13676,NCT05026723,Bodyweight at Month 6,Diabetes Distress Score as assessed by PAID-11 at Month 18,C-Reactive Protein (CRP) at Month 6,2021-10-04,RECRUITING,INTERVENTIONAL,['NA']
13677,NCT02935855,Efficacy on coagulation parameters,Safety and tolerability parameters,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13678,NCT06091501,The between group differences for change in Perceived competence in Diabetes (PCS-5),The between group differences for change in physical activity,,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13679,NCT04746599,Pain reduction,Limb salvage,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
13680,NCT01778738,Beta-cell function,Vitamin and mineral deficiencies,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13681,NCT00668850,"To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy","To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System",,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
13682,NCT01907958,Stabilisation or improvement of urine albumin excretion status by at least one stage,Microalbuminuria (or further stages of CKD) after 12 months,"Demographics, medical history and medication Diabetes and hypertension status Blood pressure measurements",2013-04,UNKNOWN,OBSERVATIONAL,['NA']
13683,NCT03844217,"Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weight",Change in Follicle-stimulating hormone value(FSH) (IU/mL),,2019-03-07,COMPLETED,INTERVENTIONAL,['NA']
13684,NCT02762578,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Device Specific Questionnaires II (Would You Recommend the Pen?),,2016-05-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13685,NCT04789148,Dot-probe task - anxious behavior between low dose oxytocin and placebo,Socioemotional functioning - Emotion recognition task between all three interventions,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
13686,NCT03912363,Neonatal blood glucose value,Incidence of composite neonatal outcome,,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
13687,NCT04627636,- Visual analogue scale for pain (VAS-P) for pain assessment,,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
13688,NCT01301339,Do Air Force personnel who fail the Air Force physical fitness test have a higher incidence of pre-diabetes than those who pass the test?,"And for those who fail, do they have higher cardiovascular risks as correlated with fasting lipid panel.",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13689,NCT00144937,Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months),All the above-mentioned primary and secondary outcomes will be evaluated at 12 months,,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
13690,NCT03528174,Mean Absolute Relative Difference of Sensed Glucose Values,Mean Draize Scale for Erythema for the Right Sensing Cannula at End of Study for All Subjects,,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
13691,NCT03724981,Participant Preference Between 2 Injection Devices Based on Global Preference Item,Participant Preference Between 2 Injection Devices Based on Ease of Use,,2018-10-18,COMPLETED,INTERVENTIONAL,['PHASE4']
13692,NCT03482596,Glucose incremental Area Under the Curve (iAUC),Intervention perception,,2018-02-21,COMPLETED,INTERVENTIONAL,['NA']
13693,NCT05765097,TIR,mean BG,,2022-09-28,COMPLETED,INTERVENTIONAL,['NA']
13694,NCT02062034,Oxidative Stress markers,Progression and regression of non-proliferative diabetic retinopathy,Security profile,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13695,NCT01614496,Time spent with glucose in the target range,,,na,COMPLETED,INTERVENTIONAL,['NA']
13696,NCT03166124,Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) for Each Treatment Arm,Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
13697,NCT00501397,"urine collections for volume, glucose, & creatinine at Day 1 Session 1, Days 5 & 6 Session 3.","Vitals: Screening,Days -1 & 1 Session 1,Days 1-4 Session 2,Days 5-6 Session 3,followup",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13698,NCT00403195,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
13699,NCT03240874,Number of Participants Who Used the SweetMama Application,Difference in Hemoglobin A1c From Enrollment to Delivery,Clinical Outcomes of Pregnancy - Number of Babies With Neonatal Intensive Care Unit Admission,2017-08-02,COMPLETED,INTERVENTIONAL,['NA']
13700,NCT01234727,,,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
13701,NCT05104333,Neutralizing antibody level,Adverse events following vaccination,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13702,NCT03931759,The measurement of heart rate variability in laparoscopic surgeries,,,2019-06,UNKNOWN,INTERVENTIONAL,['NA']
13703,NCT05414968,Change from Baseline Pain Assessment,,,2023-03-22,RECRUITING,INTERVENTIONAL,['NA']
13704,NCT01845324,width of fetal interventricula heart septum,glucose control in patients with normal and abnormal interventricular septal width,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
13705,NCT04653207,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
13706,NCT02132442,Change in hepatic triglyceride content (HTGC),Hemoglobin A1c,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13707,NCT00940082,"the gender, height, weight, blood pressure, course of the disease of each patient was recorded","Left ventricular mass index (LVMI), relative wall thickness (RWT) were calculated and High-sensitive C-reactive protein (HsCRP), homocysteine and TNF-α were detected",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
13708,NCT05977205,Glycemic control,Fear of COVID-19 infection,,2020-05-02,COMPLETED,OBSERVATIONAL,['NA']
13709,NCT00674466,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13710,NCT01030471,Diabetes-Related Family Conflict Scale (DFCS)-Measure of family conflict around diabetes-specific tasks,Hemoglobin A1c value,,2009-09,WITHDRAWN,INTERVENTIONAL,['NA']
13711,NCT05390307,Weight,Weight change,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
13712,NCT05430204,Number of fetal or neonatal deaths,Number of participants who formula fed their babies,,2023-03-07,RECRUITING,INTERVENTIONAL,['NA']
13713,NCT01563120,glycemic control,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13714,NCT01529385,Microcirculation for Dorsum of Foot,Physical Activity Level,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
13715,NCT01758471,euglycemia,,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
13716,NCT03367390,Number of Participants Who Show a Resumption of Auto Mode Following Restored Continuous Glucose Monitoring (CGM) Connectivity,,,2017-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13717,NCT06066801,the remission of DFO,Incremental cost effectiveness ratio,,2024-03-14,RECRUITING,INTERVENTIONAL,['NA']
13718,NCT02473809,Change in collagen I cross-linked C-terminal telopeptide measured in serum,Change in procollagen type I N-terminal propeptide measured in serum,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13719,NCT05492448,Changes in ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).,Changes in scores of modified Bristol stool form scale.,,2022-09-19,RECRUITING,INTERVENTIONAL,['NA']
13720,NCT05730634,DOTATATE coronary arteries,Change in splenic/bone marrow DOTATATE signal,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
13721,NCT03523143,TESGO composite outcome,The growth and development of the offspring,,2018-06-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13722,NCT00264914,"Safety : Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry",Serum sodium,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13723,NCT01876849,"Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.",,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13724,NCT00985257,Percent of Blood Glucose (BG) Results Within +/-15mg/dL or +/-20% of Laboratory Glucose Method,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
13725,NCT04335656,Change in composite inflammatory index after probiotic supplementation,scRNA-seq analyses of peripheral blood mononuclear cells,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13726,NCT00687479,Insulin action measures,infant gestational age,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13727,NCT00805922,Mean blood glucose parameters of diabetic patients,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2008-12,COMPLETED,OBSERVATIONAL,['NA']
13728,NCT05168306,Difference in bodyweight from the control arm at 6 months,,,2021-12-05,TERMINATED,INTERVENTIONAL,['NA']
13729,NCT04387045,Salivary Tumor Necrosis Factor alpha,Depression,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
13730,NCT01143948,optimal glycemic control in inpatient cirrhotics,Incidence of hypoglycemic episodes,,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13731,NCT03958539,The incidence of new ulcer in patients with high-risk diabetic feet is our primary outcome measure,Need for debridement of callus,,2019-08-05,UNKNOWN,INTERVENTIONAL,['NA']
13732,NCT05719961,Time to maximum concentration （Part II）,Incidence and severity of adverse events (AEs)（Part II）,,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE1']
13733,NCT01090752,Effects of Pioglitazone on 24h Blood Pressure Control,Effects of Pioglitazone on Salt Sensitivity,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13734,NCT00599040,Insulin Sensitivity,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13735,NCT00799695,"a change in the proportion of diabetic patients who acted as a result of the phone contact, and obtained a retina eye exam.",,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
13736,NCT01106625,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13737,NCT05244200,Fasting plasma glucose (FPG),Body Weight.,,2022-01-20,UNKNOWN,INTERVENTIONAL,['NA']
13738,NCT04424290,Multiple dosing (MD) part: Number of patients with drug related adverse events (AEs) from drug administration till end of study (EOS),MD part: Number of patients with ocular AEs at EOS,,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13739,NCT01511185,AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13740,NCT00005374,,,,1994-01,COMPLETED,OBSERVATIONAL,['NA']
13741,NCT04830462,OGTT (oral glucose tolerance test),Changes in body composition,,2021-04-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13742,NCT05712720,Change in Central Subfield Thickness,Repeat-dose AUC of RZ402,,2023-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13743,NCT02447185,intraoperative bleeding,the change of inflammatory factors in vitreous body,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
13744,NCT01396772,Average number of vegetable and fruit servings consumed per day,average number of physical activity minutes per day,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
13745,NCT02630524,Adherence to prescribed macronutrient composition as measured by multiple pass 24 hour dietary recall,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
13746,NCT02914730,Number of Missed Insulin Doses,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
13747,NCT03554590,glycemic control,glucose variability: incidence of hypoglycaemia,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
13748,NCT03284216,Exercise-induced change in blood glucose control.,Hyperglycemia-induced change in cognitive function.,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13749,NCT02040012,"To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus.",To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses,To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
13750,NCT04374864,Area under the curve,,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13751,NCT03194009,Physical Activity,Cost-utility of Metformin. Measured using cost per QALYS,,2017-08-10,UNKNOWN,INTERVENTIONAL,['NA']
13752,NCT02830113,Insulin sensitivity,Inflammation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
13753,NCT06019624,Change in Food Security,Change in Emergency Room Utilization,,2023-09-13,RECRUITING,INTERVENTIONAL,['NA']
13754,NCT01322256,The difference between AUCs for PET/CT scan and scintigraphy,,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
13755,NCT00194805,glycosylated hemoglobin (A1C) levels.,"Study participants who receive the web-based telehealth intervention will have fewer depression symptoms and higher quality of life, social support, at the 12 month (long-term) follow-up than participants in the control group.",,2003-09,COMPLETED,INTERVENTIONAL,['NA']
13756,NCT05261841,Change from Baseline HbA1c at 6 and 12 months,,,2021-06-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13757,NCT04862858,"Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, excluding combination products, based on administrative claims data","Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, including combination products, based on administrative claims data",,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13758,NCT00400491,glycated hemoglobin,insulin sensitivity,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13759,NCT06010433,Primary Outcomes,Secondary Outcome,,2023-09-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13760,NCT04511312,Days at Home at 30 Days after surgery (DAH-30),Quality of Recovery QoR-15 measuring quality of recovery on Day 1 only,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
13761,NCT03188757,prolonged reaction time,,,2017-07-13,COMPLETED,INTERVENTIONAL,['NA']
13762,NCT03340311,Glucose log completeness,Patient satisfaction,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
13763,NCT06124560,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2022-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
13764,NCT05949320,Eating Behaviour Questionnaire from the EatSmart Restaurant Star+ Campaign,,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
13765,NCT00756041,Weight.,"Change from Baseline in quality of life index as assessed by the Short-Form, 36-Item Health Survey.",,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2']
13766,NCT01865305,Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes),Area under the serum insulin degludec concentration curve,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13767,NCT02407899,Absolute changes from baseline in Fasting C-peptide levels at week 104.,"Absolute changes of body weight and BMI level from baseline and at week 26, 52, 78 and 104.",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13768,NCT01916096,Blood Volume Measurements,,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
13769,NCT04270604,"Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information.",,,2012-02-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13770,NCT01788033,C-peptide level,Number of Adverse Events,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13771,NCT03022344,Progression of contrast enhanced cardiac CT in relation to baseline and follow-up cardiovascular risk factors and biomarkers.,Blood pressure (mmHg),,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
13772,NCT00260130,"satiation and satiety on liquid verses solid foods with concurrent measurements of appetite, dietary intake, energy expenditure and body weight/composition.",cephalic phase testing at week 8,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
13773,NCT01691755,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13774,NCT01606007,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Adjusted Mean Change From Baseline in Body Weight at Week 24,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13775,NCT01297049,Blood glucose control with changes in Glycated hemoglobin (HbA1c) values,Audit of Diabetes Dependence Quality of Life (ADDQoL-19),,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13776,NCT05996601,Medication adherence of participants using a 4-item medication adherence scale,,,2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13777,NCT03997526,Complete healing,Minor amputation - contralateral limb,,2020-07-15,TERMINATED,OBSERVATIONAL,['NA']
13778,NCT00564070,Depression on the CGI at Acute Outcome,Glucose Control,Glucose Control Over Follow up,2007-06,COMPLETED,INTERVENTIONAL,['NA']
13779,NCT06033872,a. To compare the first incidence rate of hypoglycemia or severe hypoglycemia between intervention and control groups in Ramadan,"Healthcare utilizations costs - Medical services, drugs and devices utilized, outpatient and inpatient visits, cost of intervention sessions, telemonitoring and equipment, indirect costs related to health care utilisation, and caregiver costs.",,2021-01-25,COMPLETED,INTERVENTIONAL,['NA']
13780,NCT03553524,Compare the efficacy of the morning and afternoon HIIT in lowering blood glucose values in participants with type 2 diabetes.,Respiratory exchange ratio (RER),,2021-10-30,WITHDRAWN,INTERVENTIONAL,['NA']
13781,NCT01693510,Gestational weight gain within IOM guidelines,Bone outcomes,,2012-11-12,COMPLETED,INTERVENTIONAL,['NA']
13782,NCT02658591,Change in gut hormone levels measured in the blood,Ad libitum food (pizza meal) intake as measured by the amount of pizza (in grams) consumed during the 20 minute period,,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13783,NCT01803711,Hospital Anxiety and Depression Scale,Leeds Sleep Evaluation Questionnaire (LSEQ),,2013-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13784,NCT00426920,AUC,AUC,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
13785,NCT01521624,Serum concentrations of various markers of oxidative stress,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13786,NCT01143714,Change in Wound Area,Number of Sharp Debridements Performed During the 4-week Treatment Phase and the 8-week Follow-up Period (12 Weeks Total),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13787,NCT05874323,correlation of RAGE gene polymorphism rs1800625 with the incidence of type I diabetes,"the relation between MiRNA-34, MiRNA-146, to TID severity and activity.",,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
13788,NCT02131961,Proportion of contact cast systems intact by day 14,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13789,NCT01270633,Percent of study ulcers healed,Cost of Treatment,,2010-12,TERMINATED,INTERVENTIONAL,['NA']
13790,NCT04972890,Changes in microRNA 126 expression after stem cells injection,Number of participants with side effects after intracavernosal injection,,2020-10-27,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13791,NCT02036528,Complete wound clearing of infection,DFU Area % Change,,2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13792,NCT05628168,Effect of Neurodynamic Mobilization Techniques in Patients With Diabetic Neuropathy,,,2021-12-05,COMPLETED,INTERVENTIONAL,['NA']
13793,NCT02194608,Change from baseline in body mass index,Number of severe/symptomatic hypoglycemic episodes,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
13794,NCT01914146,1. Presence or absence of orthostatic hypotension,3. The nadir of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during tilt table test.,,2015-04,WITHDRAWN,INTERVENTIONAL,['NA']
13795,NCT00497198,Change From Baseline in Hemoglobin A1c(HbA1c) at Week 12,Change From Baseline in Low Density Lipoprotein Cholesterol(LDL-c) at Week 12,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13796,NCT03154398,the percentage of patients progress to advanced diabetic nephropathy,,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
13797,NCT05086445,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,,2021-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13798,NCT01625507,Change in Nutrient Intake,Change in Waist Circumference,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13799,NCT04641650,Difference between estimated Hba1c (or Glucose Management Index (GMI)) with FreeStyle Libre Pro sensor and laboratory Hba1c,Glucose total coefficient of variation (CV),,2021-07-21,UNKNOWN,OBSERVATIONAL,['NA']
13800,NCT04716244,Identification of four consistent themes on thematic qualitative analysis,,,2021-01-20,RECRUITING,OBSERVATIONAL,['NA']
13801,NCT05766449,"Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure","Incidence of cirrhosis, cancer and liver failure in patients with chronic hepatitis B and non-alcoholic fatty liver disease",,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
13802,NCT01159600,HbA1c Change From Baseline,Mean Daily Plasma Glucose (MDG) Change From Baseline,Confirmed Hypoglycaemic Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13803,NCT02371759,Electrocardiogram at 20 Minutes,Local Postoperative Complications,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13804,NCT03175315,Changes in Glycemic Control Measured by A1c,Depressive symptoms,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
13805,NCT01755442,Mean 24-hour systolic blood pressure,Safety end points will include ECGs.,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE1']
13806,NCT04624672,RATE OF PARTIAL REMISSION OF DIABETES,RATE OF COMPLETE REMISSION OF DIABETES,,2021-08-25,TERMINATED,INTERVENTIONAL,['PHASE4']
13807,NCT02511067,Anatomic Retinal Changes,Rescue Therapy,,2016-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13808,NCT01933672,Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14,Plasma PF-04937319 Time for Cmax (Tmax) on Day 14,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13809,NCT02720393,Change in hemoglobin A1c,Change in insulin signaling pathway,Change in fecal calprotectin,2016-02,COMPLETED,INTERVENTIONAL,['NA']
13810,NCT02612493,Insulin dosage,Change in lipids,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13811,NCT00330265,Percent of subjects achieving complete or (100%) study wound closure by week 12 after initial treatment,,,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13812,NCT03157414,Weighted mean glucose,Renal function,Urinary glucose excretion,2016-11-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13813,NCT00972322,Number of Participants Discontinuing Study Drug Due to an AE,,,2009-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
13814,NCT01869348,Change in Physical Activity From Baseline to 12 Weeks,Change in Weight From Baseline to 12 Weeks,Acceptability,2014-06,COMPLETED,INTERVENTIONAL,['NA']
13815,NCT03671161,Number of ketoacidosis episodes,Any changes in Weight,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
13816,NCT03042039,Total number of hospital admissions per participant measured at end of study (at approx 12 months),Change in Disease specific health status measurement (6) as measured with BMI of all patients with chronic heart failure between start and end of study (12 months),,2015-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13817,NCT01152372,"Glucose (labeled and unlabeled), insulin and c-peptide will be measured to calculate insulin sensitivity, endogenous glucose production and insulin secretion",Characterize the patterns of intermediate metabolites in healthy subjects and subjects with type 2 diabetes mellitus,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13818,NCT00467246,Reduction of recurrence of ketoacidosis and hyperglycaemia.,To investigate time to treatment in patients presenting with a hyperglycaemic emergency,,na,WITHDRAWN,INTERVENTIONAL,['NA']
13819,NCT00627146,"The difference in change in daily insulin need between baseline and month 48, between placebo and ChAgly CD3 treated patients",,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13820,NCT03835195,Differences in HbA1C value after the intervention,Difference in the body mass index after the intervention,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
13821,NCT02345239,Mean post-prandial glucose excursion,Postprandial glucose excursion,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
13822,NCT03936010,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
13823,NCT01513798,Fat mass,Substrate utilization during submaximal exercise,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
13824,NCT05488197,Uterine artery Doppler ultrasonography in gestational diabetes mellitus,Prediction of GDM with uterine artery pulsatility index cut-offs,,2021-06-10,COMPLETED,OBSERVATIONAL,['NA']
13825,NCT03424044,Percent of Time With Sensed Glucose < 70 mg/dl,Mean Amount of Glucagon Delivered in One Day,,2018-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
13826,NCT02151695,Percentage of patients with regression of retinal neovascularization between baseline and 12th month.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13827,NCT03423108,HbA1c,Lower body maximal muscle strength,,2018-09-10,UNKNOWN,INTERVENTIONAL,['NA']
13828,NCT03665870,Fear of Hypoglycemia,Knowledge of Diabetes,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
13829,NCT00787475,HgA1C level,Measurement of systolic blood pressure,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
13830,NCT01340911,Number of participants with adverse events and incidence of adverse events will be used as a measure of safety and tolerability of multiple doses of SRT3025 in healthy male subjects.,Plasma levels of SRT3025 may be compared to the number and types of adverse events experienced by subjects receiving multiple doses of SRT3025 to assess any relationship between plasma SRT3025 levels and adverse events.,,2011-06-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13831,NCT05204706,Number of women withdrawn or loss to follow up,Number of women randomised,Length of stay at the hospital ward,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
13832,NCT04474795,Staff - Self-efficacy to Provide Diabetes Education Questionnaire (Newly Developed),Staff - Intention to Recommend Diabetes Prevention Activities Questionnaire (Newly Developed),Staff-Provider Teaching Motivation Questionnaire Intrinsic Motivation Subscale,2020-06-18,COMPLETED,INTERVENTIONAL,['NA']
13833,NCT00005399,Incident coronary heart disease and stroke events,all-cause and cause-specific mortality,,1996-08,COMPLETED,OBSERVATIONAL,['NA']
13834,NCT00563043,changes in ERG implicit time,,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13835,NCT01364675,Cardiovascular Events,Incidence of Individual Cardiovascular Disease,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
13836,NCT00682448,Weight Gain,Hemoglobin A1C,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13837,NCT00615121,Discover novel gene expression pattern in peripheral arterial disease,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
13838,NCT05226897,HbA1c,C-peptide,,2021-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13839,NCT03438617,Change from Baseline HbA1c at 12 and 18 months,Change from Baseline Depression at 12 and 18 months,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
13840,NCT04452331,Contextualization of Care,hospital admission rate,,2021-10-05,RECRUITING,INTERVENTIONAL,['NA']
13841,NCT03182712,Changes on hs-CRP (High-sensitivity C reactive protein),Changes on Total Antioxidant activity,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
13842,NCT02557022,Body weight analysis,,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
13843,NCT00614341,Pain reduction in diabetic patients with chronic diabetic neuropathy,Improvement in sensation and overall foot condition,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13844,NCT06240910,Berge balance scale,Functional reach test,Michigan neuropathy screening instrument questionnaire,2023-07-17,RECRUITING,INTERVENTIONAL,['NA']
13845,NCT03059069,changes in Hamilton Depression Rating Scale (HDRS),changes in Mini-mental state examination (MMSE) score,,2016-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13846,NCT01157611,change of the blood glucose,satisfaction score,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
13847,NCT00982228,Extension Trial (Primary Endpoint): Cross-reacting Antibodies to Human Insulin,Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52,,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13848,NCT00993018,Average pain intensity,Number of patients with adverse events,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13849,NCT03403283,Increase in acid sphingomyelinase (ASM) expression and activity in bone marrow-derived endothelial progenitor cells (EPCs),,,2014-01,RECRUITING,OBSERVATIONAL,['NA']
13850,NCT00574808,Quality of care process index = ∑ of recommended services received by patient/ ∑ of the recommended services for which the patient was eligible,Quality of care outcome index = ∑ of recommended targets reached / ∑ of the number of targets for which the patient is eligible based on the number of conditions suffered by the patient,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13851,NCT00792662,Hemoglobin A1C as a Marker for Glycemic Control,Instrumental Activities of Daily Living (IADL) Scale,,2008-11-18,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13852,NCT05095038,Fasting blood glucose,Change in subjective assessment of investigational product,,2022-02-10,TERMINATED,INTERVENTIONAL,['NA']
13853,NCT05912647,Change in mean hemoglobin A1c score,Mean scores on the Adherence to Refills and Medications Scale for Diabetes,,2024-02-03,RECRUITING,INTERVENTIONAL,['NA']
13854,NCT06060483,major adverse cardiovascular events,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13855,NCT00965549,Glycosylated Haemoglobin (HbA1c),"Hypoglycaemia (total, severe and nocturnal)",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13856,NCT00381186,insulin resistance,exercise change,,1999-02,COMPLETED,INTERVENTIONAL,['NA']
13857,NCT03202563,Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12,Changes from baseline Nitrotyrosine at week 12,Changes of baseline Body weight at week 13,2017-08-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13858,NCT05526131,val66met polymorphism of BDNF gene,,,2021-02-17,COMPLETED,INTERVENTIONAL,['NA']
13859,NCT03782805,Change from Baseline TNF-alpha at 6 months,Change from Baseline Parathyroid hormone (PTH) at 6 months,,2018-05-09,COMPLETED,INTERVENTIONAL,['NA']
13860,NCT04550806,Area under the curve of GA combined with body composition for GDM diagnosis,GDM prediction model establishment,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13861,NCT02322554,Healing,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
13862,NCT00099957,Postprandial serum total triglycerides at 4 weeks,Postprandial apo B-48 and apo B-100 in the two lipoprotein fractions - chylomicrons and VLDL1+VLDL2+IDL (VLDL/IDL) at 4 weeks,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13863,NCT00849849,Determine best way to assess glucose disorder prevalence in women with prior GDM,"Investigate if cardiometabolic markers-lipid profile and blood pressure anthropometric markers such as BMI [BMI, absolute body weight]; visceral adiposity as assessed by abdominal girth are associated with an increased diabetes risk",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13864,NCT05727579,To investigate the modifying effect of sodium intake on Ertugliflozin on blood pressure,To investigate the effect of Ertugliflozin on the hypertensive effects of high dietary sodium intake,Biomarkers,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
13865,NCT04258904,Incidence of dermatological complications,Trans Epidermal Water Loss (TEWL):,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
13866,NCT02478554,Detection of fetal growth abnormalities,,,2015-08,WITHDRAWN,INTERVENTIONAL,['NA']
13867,NCT05539066,Compliance rate of BMI (Body Mass Index),Incidence of hypoglycemia,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13868,NCT05132725,TTG-IgA,BMI,,2021-11-15,UNKNOWN,INTERVENTIONAL,['NA']
13869,NCT00000151,,,,1979-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13870,NCT04192422,Neonatal sensor glucose time in target,,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
13871,NCT03025607,Change in Autonomous Motivation to Prevent T2DM,Change in psychosocial measures,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
13872,NCT01349855,"Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory",Pharmacokinetic parameter : AUC,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13873,NCT02180555,Glucose metabolism disturbance,Patient characteristics predicting adverse outcome,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
13874,NCT01947036,Identify shared defects in T and B cell function by disease classification,,,2014-01,TERMINATED,OBSERVATIONAL,['NA']
13875,NCT01768208,The primary objective of the study is to evaluate the changes in the metabolomic parameters before and after Saxagliptin treatment in type 2 diabetic patients.,,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13876,NCT02019186,endothelial function,Endothelial progenitor cells,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13877,NCT00406458,"Visual analog scale for pain intensity (VASPI), Nerve Conduction Velocity (NCV), Total Neuropathy Score (TNS), Epidermal Nerve Fiber Density (ENFD) & Epidermal Nerve Fiber Density Regeneration (ENFDR)",Safety,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13878,NCT00328536,"Postprandial (2, 4 and 6 hours) flow-mediated vasodilation after a 6-week treatment with Omacor",Baseline flow-mediated vasodilation after a 6-week treatment with Omacor,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13879,NCT02131675,C-peptide level,Duration of diabetes,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
13880,NCT03908125,Time in Range,,,2019-03-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13881,NCT00886392,"Thickening measured by optical coherence tomography in 3 zones: central subfield (when field 1 was thickened), inner ring (when any of fields 2, 3, 4 or 5 was thickened), and inner ring or outer ring (when any of fields 6, 7, 8, or 9 was thickened)","Severity level: adaptation of International clinical diabetic macular edema severity scale to fields of the OCT; mild if thickening exclusively involved outer-ring, moderate if was in inner-ring without involvement field 1, and severe if was in field 1",,2006-06,COMPLETED,OBSERVATIONAL,['NA']
13882,NCT01813929,Flow-mediated Brachial Artery Dilation,Cardiac Function,Mitochondrial Oxidant Generation,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13883,NCT00965510,"Scores on PHQ9, PAM and health indicators",Satisfaction with care coordination model.,,2009-09,TERMINATED,INTERVENTIONAL,['NA']
13884,NCT00961207,Reduction in albuminuria/proteinuria,"Safety of Triple RAAS inhibition with ACE-I, ARB and DRI",,2009-08,TERMINATED,INTERVENTIONAL,['PHASE4']
13885,NCT03504566,Strongest albuminuria-lowering effect.,Effect on glycocalyx.,,2017-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13886,NCT06097351,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13887,NCT06089655,The change of blood glucose level from diet consulting,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
13888,NCT00316758,"AEs, laboratory parameters, ECG.","Mean change from original baseline in HbA1c, FPG, lipid profile.",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13889,NCT01153048,"compare the improvement of HbA1c 1 year after an intervention led by peer educators, versus a conventional care in health centre","Study the evolution of bio clinical parameters: fasting glucose, weight, BMI, blood pressure, waist size",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13890,NCT04184440,changes of OGTT,changes of short chain fatty acids,,2020-03,UNKNOWN,INTERVENTIONAL,['NA']
13891,NCT04712266,hyperglycemic excursions,,,2020-09-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13892,NCT02488733,Rate of patients achieving diabetes resolution,"Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy",,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13893,NCT00383110,Health Care System Distrust Scale,LDL-cholesterol,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
13894,NCT01889355,Enhanced Meter Feature Usability,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
13895,NCT00011141,,,,na,COMPLETED,INTERVENTIONAL,['NA']
13896,NCT01120912,Adverse events occurrence,Evaluate the glucose lowering effect of Oshadi Oral Insulin,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13897,NCT00271739,Serum Lipids Levels; Low-density Lipoprotein (LDL)-Cholesterol,,,2000-12,COMPLETED,INTERVENTIONAL,['NA']
13898,NCT01959529,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",Change in Glycosylated Haemoglobin (HbA1c),,2013-10-29,COMPLETED,INTERVENTIONAL,['PHASE3']
13899,NCT03998267,Difference in mean HbA1c,Lipids,Exploratory outcome,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA']
13900,NCT04074668,Mitochondrial Function,Kidney Injury Biomarkers,Epigenetic profiling,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
13901,NCT03784027,Time in target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl),Percentage of time of CGM availability,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
13902,NCT02463084,Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42),Change in brain perfusion,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13903,NCT00568984,HbA1c,Adverse events,,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE4']
13904,NCT00122447,AIM 1: Change in Flow Mediated Dilation (FMD) (%),AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level,AIM 2: Difference in FMD (Measure of Endothelial Function),2005-05,COMPLETED,INTERVENTIONAL,['NA']
13905,NCT01432509,Type 2 Diabetes occurrence,Others cardiovascular risk factors,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
13906,NCT06241976,Postprandial glycaemic response,Knowledge and perception of vitamin D,C-reactive protein (CRP),2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
13907,NCT04674254,Change in vascular density of the retinal capillary plexuses,Change in orbital blood flow,,2021-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
13908,NCT00444392,Brachial artery flow mediated dilation,Inflammatory Markers,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13909,NCT02919345,Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion),Change in body composition (% of fat mass and % free fat mass),Change in Waist Circumference,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13910,NCT01737957,Macular thickness change,Adverse events,"Regression of neovessels, change over time",2012-11,UNKNOWN,INTERVENTIONAL,['NA']
13911,NCT04377399,Microcirculation,Neuropathic symptom score,,2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13912,NCT00718614,choroidal blood flow,heart rate variability,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
13913,NCT00817622,Changes in leptin and adiponectin after 12 Weeks,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13914,NCT01959334,Number of Participants With At Least One Adverse Event,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13915,NCT03228004,Frequency of data upload,,,2017-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
13916,NCT05305352,Asses change in NFk,,,2024-01,SUSPENDED,INTERVENTIONAL,['NA']
13917,NCT03935191,Dexcom G6 CGM Accuracy,Dexcom G6 CGM Safety,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
13918,NCT04503174,Percent of Boluses Using the Auto Population Feature Resulting in Fewer Readings Less Than 70 mg/dL Than Those Not Using the Feature,"Diabetes Impact and Satisfaction Scale (DIDS), Impact Score",,2020-08-04,COMPLETED,OBSERVATIONAL,['NA']
13919,NCT00339482,To investigate the determinants of type 2 diabetes and its complications.,,,1976-09-03,COMPLETED,OBSERVATIONAL,['NA']
13920,NCT04352738,Intrahepatic free glucose concentration,First-pass hepatic extraction of glucose,Changes in intrahepatocellular lipid (IHCL),2021-04-15,COMPLETED,OBSERVATIONAL,['NA']
13921,NCT02591849,Concentration of glucagon during fasting glycemia and during hyperglycemic conditions measured in picomoles per liter,Insulin sensitivity index,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
13922,NCT06054659,Time to DFU healing,Relationship of glycemic variability and the likelihood of healing,,2024-02-20,RECRUITING,INTERVENTIONAL,['NA']
13923,NCT01231984,Glycemic Control as Measured by HbA1c (4 mm vs. 12.7 mm),"Number of Serious, Unexplained Hyperglycemic Events, Reported as Number of Events by Needle.",,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13924,NCT02864654,Serious adverse reactions,Quality of life monitoring - 2,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13925,NCT02909829,AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions for the lunch meal.,1. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal,,2017-10-31,COMPLETED,INTERVENTIONAL,['NA']
13926,NCT00402727,Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population,Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13927,NCT03328975,Can diabetic patients maintain their blood glucose in a normal range after receiving a corticosteroid injection?,,,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
13928,NCT00001310,,,,1992-03-05,TERMINATED,OBSERVATIONAL,['NA']
13929,NCT02577120,Ceramiseal and EpiCeram restore barrier function to wounds in patients,,,2019-01-09,RECRUITING,INTERVENTIONAL,['PHASE4']
13930,NCT03591354,Time in Target Range,BMI,Any Adverse Event Rate Per 100 Person-years From Months 4-12,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
13931,NCT03450863,Change in Glycated Haemoglobin (HbA1c),Change in fasting plasma glucose (FPG),,2018-03-22,COMPLETED,OBSERVATIONAL,['NA']
13932,NCT02070926,Time to major adverse events,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13933,NCT01478763,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13934,NCT02605772,redunction of Hemoglobin A1c (HbA1c) Levels (%) in two groups respectively after three months intervention,Difference of Homeostasis model assessment of insulin resistance (HOMA-IR) and Homeostasis model assessment beta cell function index (HOMA-β) between two groups after three months intervention,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
13935,NCT03091673,Change in Plasma Glucose,Plasma Glucagon Tmax,,2017-03-27,COMPLETED,INTERVENTIONAL,['PHASE3']
13936,NCT02494375,Association between HbA1c and sleep characteristics,Body composition (BMI fat and lean mass percentage),,2015-06-28,UNKNOWN,INTERVENTIONAL,['NA']
13937,NCT04268212,incremental area under the curve,,,2016-04-15,COMPLETED,INTERVENTIONAL,['NA']
13938,NCT00853424,"Composite outcome consisting of progression of DR, development of significant ME, or moderate visual loss in patients who have significant ME at randomization.",,,2009-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
13939,NCT04612257,Time in range,Total insulin delivery,,2019-06-18,TERMINATED,INTERVENTIONAL,['NA']
13940,NCT05074342,The provision of a DRS status list to primary health care settings will increase the rate of annual DR screening in patients with type 1 or type 2 diabetes who have attended the centres.,,,2022-02-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13941,NCT02004964,eligibility for islet transplantation,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
13942,NCT05238987,Change in insulinogenic index,Change in insulin clearance rate,,2020-10-10,COMPLETED,INTERVENTIONAL,['NA']
13943,NCT05729334,Repeatability of Clinicgram Euclides in the automatic calculation of skin lesion areas between two measurements performed by the same investigator.,Usability of the investigational software Clinicgram Euclides.,,2022-11-28,COMPLETED,INTERVENTIONAL,['NA']
13944,NCT05402579,Identification of genomic variants associated with an increased risk of SGLT2 inhibitor-associated DKA,,,2022-07-29,RECRUITING,OBSERVATIONAL,['NA']
13945,NCT06224790,15% improvement in eGFR,Safety - Adverse Effects of Drugs,,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE4']
13946,NCT00264940,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
13947,NCT05348863,HbA1c,Physical activity using accelerometry,,2022-10-28,RECRUITING,INTERVENTIONAL,['NA']
13948,NCT04729296,The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized,,,2021-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13949,NCT00428571,Diabetic control as assessed by HbA1c,Utilization of resources and productivity losses,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
13950,NCT05933460,Diastolic Blood pressure,Continuous glucose monitoring statistic data,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
13951,NCT06092827,Satisfaction towards physical activity intervention,Questionnaire on motivation to practice physical activity,Hemoglobin (safety parameter),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13952,NCT05003908,Safety (adverse events),Efficacy: Insulin dose reduction,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
13953,NCT05613985,To assess the ulcer after 2 weeks of study treatment by evaluation of the following primary endpoint:,The key secondary objective is to evaluate the ulcer after 4 weeks of study treatment by evaluation of the following endpoint:,,2021-09-14,RECRUITING,INTERVENTIONAL,['NA']
13954,NCT00284609,Change in HgbA1c (Glycemic control),Body mass index,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
13955,NCT02956577,Changes in Global Longitudinal Strain (GLS) stratified by Coronary Artery Calcium Score (CAC) in patients with diabetes during one year of follow-up,Changes in GLS in patients with long-term diabetes and no macrovascular disease,LA function stratified by micro- and macrovascular status,2016-03-16,COMPLETED,OBSERVATIONAL,['NA']
13956,NCT00496457,Effect of TRO19622 versus Placebo on the mean 24h neuropathic pain score on the Likert numerical rating scale.,Adverse events,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13957,NCT02218931,"Composite fetal outcomes: stillbirth, small for gestational age or admission to neonatal intensive care unit",Development of a cohort for medium and long term follow up of mothers and babies after birth through applications to other grant giving bodies.,,2014-09-12,COMPLETED,INTERVENTIONAL,['NA']
13958,NCT03333642,Remission of type 2 Diabetes at 24 months,Control of type 2 diabetes,Measurement of surgical adverse events,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA']
13959,NCT04743479,Hazard ratio (HR),Diagnostic yield,,2020-12-01,RECRUITING,OBSERVATIONAL,['NA']
13960,NCT01879228,Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13961,NCT00960674,HbA1c,Quality of life by SF-36,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13962,NCT01013766,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F",Relationship between pharmacokinetic and pharmacodynamic parameters,,2009-08-13,COMPLETED,INTERVENTIONAL,['PHASE1']
13963,NCT02378909,Improvement in ulcer size at monthly intervals up to 12 months follow up.,Proportion of wounds healed at monthly intervals up to 12 months followup,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
13964,NCT05146401,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
13965,NCT05937321,Time in Range,Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes,World Health Organisation-Five Well-Being Index,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
13966,NCT05698875,Mean glucose (mmol/l),"Range times (Time in range, time above range, time below range)",,2023-02-14,COMPLETED,INTERVENTIONAL,['NA']
13967,NCT05329610,Adherence to the intervention,Blinding to the intervention,Fractional shortening (%),2022-04-05,COMPLETED,INTERVENTIONAL,['NA']
13968,NCT02068300,"The correlation between 1,5-anhydro-D-glucitol and Modified Hypoglycemic score","The relation between glycemic variability indices such as MAGE of continuous glucose monitoring system and 1,5-AG in insulin using patients.","The plasma 1,5-anhydro-D-glucitol level may be a useful marker of daily glucose excursion in diabetes patients",2013-10,COMPLETED,OBSERVATIONAL,['NA']
13969,NCT03837119,urinary tract infection,,,2018-04-04,COMPLETED,OBSERVATIONAL,['NA']
13970,NCT02588898,Polyneuropathy grade estimated using a score including a combination of data from questionnaire and electrophysiology investigations,Plasma cobalamin levels,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
13971,NCT03386864,mitochondrial oxygen flux,,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
13972,NCT01242202,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3']
13973,NCT04485845,estimation of metabolic syndrome deterioration,reduce nephropathic impairement,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13974,NCT02153190,Percent time spent in target range (3.9-10.0 mmol/L or 70-180 mg/dL) during each study period,Low Blood Glucose Index (LBGI),,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13975,NCT01917227,HbA1c,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
13976,NCT04759144,Time in target (3.9 to 10.0mmol/L) (70 to 180 mg/dL),Human factors assessment,,2021-03-12,COMPLETED,INTERVENTIONAL,['NA']
13977,NCT00499954,,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
13978,NCT01876914,Total retinal blood flow & visual acuity,The degree of parafoveal ischemia as identified by OCT and visual acuity,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
13979,NCT01979081,Physical Functioning Inventory,Patient Specific Functional Scale (PSFS),Brief Pain Inventory,2013-01,COMPLETED,OBSERVATIONAL,['NA']
13980,NCT04101045,Fractional hepatic DNL,,,2019-11-21,TERMINATED,INTERVENTIONAL,['NA']
13981,NCT01727817,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13982,NCT04495231,Presence of metabolic syndrome,"Cardiovascular risk as estimated by Progetto Cuore Score (english translation: ""Heart Project Score"")",,2007-09-01,COMPLETED,OBSERVATIONAL,['NA']
13983,NCT06323161,Change in Glycated Haemoglobin (HbA1c),Number of Clinically Significant Hypoglycaemic Episodes (level 3),,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE3']
13984,NCT00552227,The primary efficacy measure is the ratio of urinary isoprostane to creatinine as measured by gas chromatography/mass spectrometry (GC/MS) in the two consecutive 12-hour urine samples obtained prior to both Visit 2 (baseline) and Visit 3 (endpoint).,The ratio of urinary albumin to creatinine,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13985,NCT01919684,Safety and tolerability of single oral doses of LGD-6972 in healthy subjects and in subjects with T2DM.,The effect of food on the bioavailability and PK profile of LGD-6972 and its potential metabolites after a single oral 40 mg dose in healthy subjects.,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13986,NCT05843175,Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition,Placenta efficiency,Sleep quality (questionnaire),2023-06-22,RECRUITING,INTERVENTIONAL,['NA']
13987,NCT02656069,Hypoglycemia Rescue: Alternate Glucose Response Definition,Global Assessment of Hypoglycemia,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
13988,NCT02318797,Change in Health Status ( SF-12v2™): Mental Health Sub-scale,Change in Lab Monitoring - EKG,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
13989,NCT02510885,Number of Participants With Image Quality Sensitive Enough to Identify Specific New Vessel Morphology,,,2015-07,TERMINATED,INTERVENTIONAL,['NA']
13990,NCT02137070,Change in BOLD fMRI signal,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
13991,NCT01234649,Insulin Secretion-Sensitivity Index (IS-SI),Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio,,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13992,NCT00701051,Skeletal Muscle Capillarization (Pre/Post Intervention),Body Composition (%Fat),,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13993,NCT03835208,mean amplitude of glucose excursions (MAGE),C-peptide,3-hydroxy-butyrate,2019-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13994,NCT04233658,Change of HbA1c-level from baseline to week 12,,,2020-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
13995,NCT00698698,,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
13996,NCT03018665,Time of Maintaining Diabetes Remission,The Incidence of Diabetic Nephropathy,,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
13997,NCT01371955,comparison of prevalence of homozygous polymorphism between the DN-group and the non-DN group,delay between diabetes diagnosis and ND onset by genetic polymorphism,HbA1c,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13998,NCT00732407,arterial stiffness and platelet function,"oxidative stress parameters (oxidized LDL and Isoprostanes), markers of inflammatory status (highly sensitive CRP test) and 24 hours blood pressure monitoring",,2008-09,UNKNOWN,INTERVENTIONAL,['NA']
13999,NCT04012775,Antibody Response,Change in total basal insulin dose (U) from baseline,,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE3']
14000,NCT03094910,Heart rate variability (HRV),,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
14001,NCT06067178,Change in systolic blood pressure (mmHg),,Costs per attained blood pressure target among individuals in the health dialogue group vs. the opportunistic screening group,2023-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14002,NCT03585738,Weight gain in pregnancy,,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14003,NCT03849495,Cmax of Empagliflozin,Vd/F of Empagliflozin,,2019-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
14004,NCT02118376,Dual energy X-ray absorptiometry,lab testing,lab testing,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
14005,NCT04682977,Executive functioning using the Executive Function Performance Test,Participation in life activities and roles using the Late Life Functioning and Disability Index,,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA']
14006,NCT00282360,silent ischemia,symptomatic myocardial ischemia,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14007,NCT02539355,Change in adipose tissue macrophage cell surface expression of metabolic activation marker ABCA1 as measured by relative mean fluorescence intensity (rMFI),Change in fasting plasma total adiponectin assessed by ELISA,Changes in gut microbiota assessed by stool sample analysis,2015-08,COMPLETED,INTERVENTIONAL,['NA']
14008,NCT04988321,Change in bodily and emotional perception of pain (BEEP) score,Change in corticospinal excitability (CE),,2021-09-03,COMPLETED,INTERVENTIONAL,['NA']
14009,NCT03362112,Lipoprotein-associated Phospholipase A2,C Peptide,,2015-01-30,COMPLETED,OBSERVATIONAL,['NA']
14010,NCT03936660,Implementing a clinic-level multifaceted intervention,Measurement of average time from baseline to patient event.,,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14011,NCT04588896,1-hour glucose from OGTT,Socio-cognitive measures,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
14012,NCT00952445,,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14013,NCT03910361,Changes from baseline intrahepatic fat (%),,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14014,NCT03738852,Brain glucose levels,,,2018-11-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14015,NCT01527981,Changes in depression severity,Changes in glucose levels,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14016,NCT00311064,too large infants (> 2 standard deviation [SD]),induction of labour,,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14017,NCT01671969,Urinary albumin excretion,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
14018,NCT03555591,Number of Participants Who Had One or More Adverse Drug Reactions,Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.0 Percent),,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
14019,NCT00675857,Change from baseline to Week 26 in HbA1c levels,Change in fasting serum glucose levels,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14020,NCT04735835,Glucose and HbA1c,Covid-19 symptom assessment,Hip Circumference (in sub-cohort),2020-07-20,RECRUITING,INTERVENTIONAL,['NA']
14021,NCT01779141,Percent of Sensor Glucose Values in 70-140 mg/dL,Unhealthy Babies,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
14022,NCT04654390,Change from Visit 2(Randomization) in HbA1c level at Week 24 after administation of the IP,"Proportions of subjects who achieved HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",,2020-12-30,COMPLETED,INTERVENTIONAL,['PHASE3']
14023,NCT04231838,Change in Metabolic Syndrome Prevalence,Change in Waist Circumference,,2021-09-27,RECRUITING,INTERVENTIONAL,['NA']
14024,NCT02122874,Serum glucose levels (mg/dl),Homeostasis model assessment (HOMA),,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14025,NCT03766750,Reduction of glycated hemoglobin levels measured between the first visit and the last visit.,Incidence and severity of adverse events recorded during the study.,,2021-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
14026,NCT05248334,Visual acuity,The number of pars plana vitrectomy,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE1']
14027,NCT04349696,Blood glucose concentration change from baseline at 2 hours after drug administration,,,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14028,NCT03787563,Number of Subject with adverse events,Flash Glucose Measurements,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
14029,NCT00299169,mean LDL levels,the proportions of participants taking statins at the end of the trial,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4']
14030,NCT03074214,Major adverse cardiovascular events (MACE),myocardial infarct size,,2017-03-06,UNKNOWN,OBSERVATIONAL,['NA']
14031,NCT02039141,"Change in Quality of Life Measured at Baseline, 3-months, 6-months, and 12-months",Change in Social support from family and friends on healthy eating and exercise.,Initial incremental cost effectiveness of intervention vs. standard care,2012-04,COMPLETED,INTERVENTIONAL,['NA']
14032,NCT03102801,"Measurement of endothelial microparticles (composite number of CD105, CD106, CD142, CD54, CD62 & CD31) following hypoglycemic event",,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
14033,NCT00707629,Ease of Injections versus Insulin pump Therapy,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
14034,NCT04634838,Percent reduction of wound size,Number of infectious episodes,,2021-02-02,TERMINATED,INTERVENTIONAL,['NA']
14035,NCT02379468,Time to complete wound healing within 12 weeks before the end of treatment duration.,To identify adverse events associated with the application of Pedyphar® ointment.,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14036,NCT05576116,Patients achieving normoglycemia,Proportion of participants with morbid obesity post PAK,,2022-09-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14037,NCT03501511,Hypoglycemia,Number of successful fasting days,,2018-04-07,COMPLETED,INTERVENTIONAL,['NA']
14038,NCT00536744,The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.,"Time to Wound Closure, Wound Closure Area and Volume Between Active and Control 12 Weeks Post Initial Application, Subject Pain Assessment Between Active and Control 24 Weeks Post Initial Application",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14039,NCT01796834,HbA1C Blood Test,Blood Pressure,patient evaluation of MBSR intervention,2012-08,COMPLETED,INTERVENTIONAL,['NA']
14040,NCT01941329,Regression of neovascularization,Adverse events related to the treatments,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14041,NCT00252720,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
14042,NCT01597882,Grip strength,Sickness behaviour scale,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
14043,NCT03457012,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-03-29,COMPLETED,OBSERVATIONAL,['NA']
14044,NCT00398944,Patients who underwent the recommended procedures during the last 12 months,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
14045,NCT03745885,Pharmacokinetic: t½ of Supaglutide,,,2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14046,NCT03399357,Humoral immune response measure,,,2017-05-31,UNKNOWN,OBSERVATIONAL,['NA']
14047,NCT00235443,Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.,Change From Baseline in Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS),,2004-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14048,NCT03202732,HbA1c,Mortality,,2017-10-09,COMPLETED,INTERVENTIONAL,['NA']
14049,NCT01796366,Number of treatment emergent adverse events,Area under the glucose infusion rate-time curve,,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14050,NCT01515228,In-segment late luminal loss,Stent thrombosis (by ARC definition),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14051,NCT01708083,Difference in polymorphids and/or mRNA expression in different types of fat tissue in patients with normal weight or obesity with or without diabetes type 2,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
14052,NCT03871621,Left ventricular mass index,Plasma biomarker: fatty acid binding protein 4 (FABP-4),,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14053,NCT00970294,"Recruitment, Retention, Adherence",Glycemic Control,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
14054,NCT00027287,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14055,NCT00824330,Arterial baroreflex sensitivity,Increase in Gosling's pulsatility index,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
14056,NCT01668485,Whole body glucose counterregulation,Gluconeogenesis from lactate,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14057,NCT03642184,eGFR,Adverse events,,2018-07-14,TERMINATED,INTERVENTIONAL,['PHASE4']
14058,NCT02486237,Number of patients with microvascular and cardiovascular complications,Number of patients with microvascular and cardiovascular complications stratified by diabetes pharmacologic treatment,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
14059,NCT01976858,To determine serum concentrations of PEX168,To determin HbA1c levels of PEX168,To assess number of participants with Adverse Events as a Measure of Safety and To assess number of participants with Adverse Events as a Measure of Safety and Tolerability,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14060,NCT05662267,"Graft failure defined by death-uncensored graft survival, i.e. the return to dialysis or death",Death-censored graft survival,,2020-03-10,RECRUITING,OBSERVATIONAL,['NA']
14061,NCT00147745,Acute Effect of a Single Dose of Colesevelam on Oral Glucose Absorption From Baseline to First Dose,Change in Hemoglobin A1C Due to Effect of Colesevelam From Baseline to 12 Weeks,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14062,NCT05540197,Early islet graft function,Insulin concentration,,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14063,NCT04429503,Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48,Safety Assessed by Serious Adverse Events (SAEs) Through Week 156,,2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14064,NCT05759884,central macular thickness (CMT),nonperfusion (NP),,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
14065,NCT04429958,BMI in offspring,Adiposity offsping skin folds,,2021-01-25,COMPLETED,OBSERVATIONAL,['NA']
14066,NCT05270343,Residual β-Cell function (RBCF),Daily Insulin Dosage,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14067,NCT05944731,Impact of continuous and intermittent CGM used on blood glucose levels in comparison to standard of care in people living with type 1 diabetes,Cost of continuous and intermittent CGM from a user and provider perspective,,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14068,NCT02226822,Classes of diabetic medications at baseline and changes up to 3 years,Treatment choice,,2014-09-20,COMPLETED,OBSERVATIONAL,['NA']
14069,NCT03983733,Hunger and appetite assessment,Covid-19 symptom assessment,Gut microbiome species richness,2019-06-10,COMPLETED,INTERVENTIONAL,['NA']
14070,NCT03260452,Number of pro-inflammatory macrophages derived from human adipose tissue in mice transplanted with adipose tissue-hematopoietic stem cells .,Comparison of the metabolic profile of the transplanted mice evaluated by the grafted mice's oral glucose tolerance test.,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
14071,NCT03811132,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),Fear of diabetes complications,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
14072,NCT06005987,Compliance,Percentage of in-range blood glucose levels,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14073,NCT01211197,Metformin: Maximum Measured Concentration (Cmax),"Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.",,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14074,NCT02610179,The serum glucose levels will be measured in response to oral glucose challenge and compared between Twizzlers and glucola beverage.,Cost-effectiveness,,2015-04,RECRUITING,INTERVENTIONAL,['NA']
14075,NCT02344732,Mean corneal epithelial wound healing time (in days),Duration of diabetes mellitus (measured in years) and its influence on wound healing time,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
14076,NCT04403789,Change from Baseline Fasting Plasma Glucose (mmol/L) at 12 Weeks,Change from Baseline Physical Activity (AX3 Device) at 12 Weeks and 16 weeks,,2021-03-28,COMPLETED,INTERVENTIONAL,['NA']
14077,NCT01242228,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3']
14078,NCT00979823,Number of risky prescribing events,"Secondary analyses will evaluate the actual use of the tool by residents, direct costs of the program, and resident satisfaction.",,2010-09,COMPLETED,INTERVENTIONAL,['NA']
14079,NCT00017953,First Occurrence of a Severe Cardiovascular Event,First Occurrence of Major Clinical Events,,2001-06,COMPLETED,INTERVENTIONAL,['NA']
14080,NCT01540396,Diagnosis of gestational diabetes,Maternal birth trauma,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
14081,NCT04807452,Toronto Clinical Neuropathy Scoring System,,Berg Balance Scale,2020-03-30,COMPLETED,INTERVENTIONAL,['NA']
14082,NCT01541735,Total Insulin Secretion,Glycated Hemoglobin A1C,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14083,NCT02763007,Proportion of subjects achieving HbA1c <7% after 36 month treatment,change of HOMA-beta(homeostasis model assessment of beta cell) from baseline to 36 month,,2016-05-18,TERMINATED,INTERVENTIONAL,['PHASE4']
14084,NCT04469855,Number of adverse events (AEs),Change in patient-reported outcomes (PROs) using the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire - satisfaction with treatment,,2020-07-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14085,NCT04065581,AUC (plasma metformin),Frequency of TEAE (treatment-emergent adverse event）,,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
14086,NCT03990844,Change in insulin response,Change in satiety rating,,2019-01-12,COMPLETED,INTERVENTIONAL,['NA']
14087,NCT02738671,Functional MRI of the brain tracking testing.,Change from baseline Functional magnetic resonance imagine,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14088,NCT03917238,Pancreatic uptake of gallium-68-NODAGA-exendin-4,,,2019-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14089,NCT04082091,Early Impact Measure of Intervention for Detection,Change in Physiological Characteristics of Intervention Participants - Physical Activity,,2019-09,UNKNOWN,OBSERVATIONAL,['NA']
14090,NCT05603130,Effectiveness of patients with COVID-19 who have developed de novo diabetes.,Demographic characteristics of diabetic patients,,2022-03-23,COMPLETED,OBSERVATIONAL,['NA']
14091,NCT00900146,Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd) Over 4 Months (Period III),Percentage Change From Baseline in Fasting Lipids Profile at Month 4 (Period II),,2009-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14092,NCT00698789,"Safety and tolerability as determined by monitoring of AEs, vital signs, ECGs, physical examinations, and clinical laboratory blood and urine parameters.",Change from Baseline in fasting plasma glucose and population pharmacokinetics of INCB019602 in type 2 diabetic patients.,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
14093,NCT04196231,Proportions of patients with significant HbA1c change,Diabetes treatment satisfaction,,2019-11-27,COMPLETED,INTERVENTIONAL,['PHASE4']
14094,NCT05189015,angiotensin(1-7),LDL,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14095,NCT00331851,HbA1c,Glycaemic control,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14096,NCT01375660,Oral Glucose Insulin Sensitivity (OGIS),Incident Diabetes,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
14097,NCT06115213,Emergency room visits,New diagnosis of peripheral artery disease,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
14098,NCT00476281,nutritional and respiratory parameters,abnormal glucose tolerance,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
14099,NCT03830281,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 16,Percentage of Participants With at Least 1 Event of Unexplained Hyperglycemia >300 mg/dL Confirmed by SMBG That Leads to an Unplanned Infusion Set Change,,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE3']
14100,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
14101,NCT00887094,Reduction of the prevalence of hyperglycemic peaks during a 24-h period after a bout of aerobic or aerobic/resistance exercise in type 2 diabetes patients on metformin/diet therapy.,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
14102,NCT03851055,Fasting blood glucose mg/dl,fructosamine mg/dl,,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14103,NCT02089477,The primary outcome is amount of time duing interval walking (in minuts) with InterWalk per week after 3 month,VO2-peek test in the InterWalk Application,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
14104,NCT03561571,after breakfast thromboxane B2 concentration,post prandial lipidomic composition of triglyceride rich lipoproteins,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
14105,NCT01182935,Number of subjects with type 2 diabetes diagnosed with oral glucose tolerance test (OGTT),The relation between serum 25(OH)D levels and blood glucose levels at OGTT,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
14106,NCT00591903,,,,2007-12-14,COMPLETED,OBSERVATIONAL,['NA']
14107,NCT06212778,Fatigue,,,2023-09-26,RECRUITING,OBSERVATIONAL,['NA']
14108,NCT05404789,Time of data entry completion during Emergency Scenario,,,2021-09-27,COMPLETED,INTERVENTIONAL,['NA']
14109,NCT02152384,"Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro",Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14110,NCT00887874,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
14111,NCT04883372,glycated hemoglobin,Time spent below target (TBR),,2021-05-22,COMPLETED,OBSERVATIONAL,['NA']
14112,NCT05129345,Aim 3: Number of strategies modified in the self-management support and education,,,2022-06-07,RECRUITING,OBSERVATIONAL,['NA']
14113,NCT03273738,metabolic changes in type 2 diabetes,,,2018-10-02,UNKNOWN,OBSERVATIONAL,['NA']
14114,NCT06058338,Hemoglobin A1c,Program satisfaction,Program feasibility,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14115,NCT05228860,HgbA1c,Food Assistance Programs,,2023-09-18,RECRUITING,INTERVENTIONAL,['NA']
14116,NCT00937222,The primary outcome measure is HDL-C,"Serum lipids, glucose, HbA1c, anthropometrics and blood pressure",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
14117,NCT02684331,On CMR; passive atrial emptying fraction (%) as a measure for cardiac diastolic function,Echocardiography,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14118,NCT05364723,distribution of diabetic retinopathy in eastern morocco,,,2022-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14119,NCT00456105,Glycemic control,Readmission,,2006-07,TERMINATED,INTERVENTIONAL,['NA']
14120,NCT05220917,Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF),Coronary revascularization,Switching patterns,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14121,NCT06147752,Change of homeostasis model assessment-insulin resistance（HOMA-IR）,Change of hepatic steatosis value,,2023-03-28,RECRUITING,INTERVENTIONAL,['NA']
14122,NCT00797771,"User satisfaction regarding the ""Adi"" pump functioning will be evaluated by questionnaire. The questionnaire will be administrated during the last study visit",Number of severe hypoglycemic events,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
14123,NCT00534547,Treatment success based on patients' glycemic control,"Physiologic Measurements, Comorbidity improvement, Improvement in QOL",,na,WITHDRAWN,INTERVENTIONAL,['NA']
14124,NCT03503747,Quantification of the number of participants with high-risk genetic markers for the development of type 1 diabetes.,,,2018-04-25,COMPLETED,OBSERVATIONAL,['NA']
14125,NCT00410722,Fasting insulin,Cancer cell proliferation,,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
14126,NCT02154126,Accuracy (mean absolute relative difference) compared to be reference device should be less than 20%,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
14127,NCT00501020,The primary efficacy variable was HbA1c change from baseline (visit 3) after 24 weeks of treatment with either RSG+MET combination therapy or Metformin monotherapy.,"Secondary efficacy variables included: the change from baseline (visit 3) at week 24 (visit) in FPG, immunoreactive insulin, HbA1c and FPG responders, Questionnaire-Tolerability of GI side-effects, and Questionnaire - Quality of Life.",,2001-06-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14128,NCT02923063,Quadriceps muscle work efficiency,Perceived Stress (NIH),Walking economy during 6 minute walk,2020-01-16,RECRUITING,INTERVENTIONAL,['PHASE2']
14129,NCT00336674,Diagnosis of Diabetes AT 5 years according to American Diabetes Association / World Health Organization (ADA/WHO) criteria.,Immune function,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14130,NCT03341429,%WL,HRQoL,,2018-08-22,COMPLETED,INTERVENTIONAL,['PHASE4']
14131,NCT01942694,Time to Development of Diabetes,Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration.,Quality of Life and Mood Scores in Pre-diabetes Population Using a Validated Instrument (PROMIS-29 Profile v2.0 and a General Question on Perception of Overall Health From the PROMIS Scale 1.2).,2013-10,COMPLETED,INTERVENTIONAL,['NA']
14132,NCT05638880,Reduction of albuminuria,,,2022-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
14133,NCT06248190,Improved control of at least one condition that was not optimally controlled at baseline,Heathcare utilisation and cost,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
14134,NCT01252082,Metabolic control,periodontal improvement after scaling and rootplaning,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14135,NCT05099887,Percent of Wound closure,,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
14136,NCT00413335,Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF),Mean Percent Change From Baseline in Adiponectin,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
14137,NCT00593255,2-hours postprandial plasma glucose (PPPG),Hypoglycaemic episodes,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14138,NCT02064023,Composite obstetrical/perinatal endpoint consisting of specific elements (see description),Mean maternal HbA1c during pregnancy,Number of episodes of severe hypoglycemia,2014-04,TERMINATED,INTERVENTIONAL,['NA']
14139,NCT02348190,protein kinase C enzyme activity in tissue samples,protein kinase C enzyme activity in T cells,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
14140,NCT00536796,Cholesterol levels,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
14141,NCT06160934,Client Satisfaction Questionnaire,Time in Range,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14142,NCT05974566,Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),Change in renal function level,,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14143,NCT03332927,Insulin sensitivity index (IV-SI) from short (40 min) IVGTT.,Vertical Auto-Profile (VAP) analysis of cholesterol carried by lipoproteins and lipoprotein subfractions.,,2017-10-25,COMPLETED,INTERVENTIONAL,['NA']
14144,NCT06086067,Time spent at each glucose range,Progesterone,,2023-09-15,COMPLETED,INTERVENTIONAL,['NA']
14145,NCT03608358,Mean change from baseline in HbA1c at Week 24,Percent of subjects achieving a therapeutic glycaemic response of HbA1c <7.0% at Week 24,,2019-02-27,TERMINATED,INTERVENTIONAL,['PHASE3']
14146,NCT06208189,Prevalence of hypoglycemia,Session rating of perceived exertion,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14147,NCT01407003,"Safety and tolerability of single and multiple dose(s) of LIK066: number of patients with adverse events and changes from baseline in vital signs, ECG and clinical labs (blood chemistry, hematology and urinalysis).",Change in fasting and post-challenge plasma glucose after a single dose and 2 weeks of treatment,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14148,NCT02742987,Flow-mediated Dilation of the Brachial Artery,Number of Patients With Platelet Reactivity >256 P2Y12 Reaction Units,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14149,NCT03032991,Electroencephalography (EEG),Metabolomic,Physical Activity,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14150,NCT03958760,Triglyceride (TG) (mmol/L),The proportion of re-hospitalization,,2021-02-28,COMPLETED,OBSERVATIONAL,['NA']
14151,NCT02088268,effect of PRP on diabete wound closure,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14152,NCT02596932,Mean neonatal blood glucose levels,Maternal hypoglycemia,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14153,NCT02817360,Number of patients with an unplanned cardiac hospitalization or death due to a cardiac event,,Change of kidney function,2016-02,RECRUITING,INTERVENTIONAL,['PHASE4']
14154,NCT01178957,Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
14155,NCT01652911,To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.,To obtain preliminary data on the efficacy of the Cell Pouch™.,,2012-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14156,NCT02201004,Change in HbA1c from baseline,Number of subjects with adverse events,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14157,NCT00545584,Hemoglobin A1c Measurement,Fasting Plasma Glucose (FPG) Measurement,,2007-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14158,NCT02131766,USS Virginia Time Within Target,Morning Glucose Levels,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
14159,NCT04057417,Major adverse cardiovascular events,Cardiovascular disease-related risk factors,Trail counts,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA']
14160,NCT03748251,Continuous glucose sensor data,Content of carbohydrates,Content of amino acids,2018-02-14,COMPLETED,INTERVENTIONAL,['NA']
14161,NCT04038125,Evaluate re perfusion following Ozurdex use.,,,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
14162,NCT02337972,Change of conjunctival flora and bacterial resistance,,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
14163,NCT04201496,CGM-measured time in the target range 70-180mg/dl (TIR) during the day,Number of hyperglycemic episodes as defined by contiguous CGM above 300 mg/dL,,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1']
14164,NCT04973111,Change in insulin secretion rate and ambient glucose levels,Change in blood glucose levels at each level of glucose infusion,,2021-07-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14165,NCT00672386,Mean change in HbA1c from baseline to week 12,Changes in insulin sensitivity and beta cell function (homeostatic model assessment 2 - HOMA-2 and MMTT); Changes in GLP-1 (glucagon-like peptide 1) and PYY (peptide tyrosine tyrozine) levels in the MMTT; Changes in insulin and glucagon,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14166,NCT01686932,Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2,Number of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14167,NCT06161844,Change from baseline to week 32 in glycosylated haemoglobin (HbA1c),Incidence and severity of adverse events,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14168,NCT03065140,Non-invasive 1H Magnetic Resonance Spectroscopy of vastus lateralis,Saturated and unsaturated lipid pool turnover examined by stable isotopes,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
14169,NCT02726256,"HOMA-IR, HOMA-β",,,2007-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14170,NCT00961324,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the NN1250 concentration-time curve during one dosing interval at steady state,,2009-07-27,COMPLETED,INTERVENTIONAL,['PHASE1']
14171,NCT02328911,Change in self-reported pain.,Change in quality of life.,,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14172,NCT02225691,Baseline change in HbA1c at month 3 and 6 between paired testing and control arms for each of the 3 patient segments.,Proportion of patients who achieve good glycemic control (HbA1c≤7%),Baseline change in self-care scores (based on Diabetes Self-Efficacy Scale Questionnaire),2014-12,UNKNOWN,INTERVENTIONAL,['NA']
14173,NCT03952819,change from levels of serum sclerostin of control group,,,2017-09-14,COMPLETED,OBSERVATIONAL,['NA']
14174,NCT05956743,Pittsburgh Sleep Quality Index,,,2023-06-01,COMPLETED,INTERVENTIONAL,['NA']
14175,NCT05143411,Change in glucose levels,Change in glycemic variability,,2021-10-08,COMPLETED,INTERVENTIONAL,['NA']
14176,NCT04905589,Diurnal glucose Incremental area under curve (iAUC) concentrations,Peptide tyrosine tyrosine (PYY) Incremental area under curve (iAUC),,2021-04-30,COMPLETED,INTERVENTIONAL,['NA']
14177,NCT01031680,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14178,NCT01655810,Change from baseline in carotid intima-medial thickness,Urinary Calcium,,2012-08-13,COMPLETED,INTERVENTIONAL,['NA']
14179,NCT02009488,"Change from baseline in beta-cell glucose sensitivity, determined as a slope of ISR vs. plasma glucose concentration during MMTT","Change from baseline in renal threshold for glucose (RTG), estimated using an MMTT-based method",,2014-09-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14180,NCT03533738,Insulin response,,,2017-10-12,COMPLETED,INTERVENTIONAL,['NA']
14181,NCT06025292,Whole Body Protein Balance,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14182,NCT00044447,Change in HbA1C from baseline to Week 26.,Incidence of hypoglycemia.,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14183,NCT05343962,PROMIS Scale v1.2 - Global Health9. Spanish version,PROMIS-10_Q01. Spanish version.,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA']
14184,NCT04007926,Whole-body Insulin sensitivity,Waist circumference,,2021-08,SUSPENDED,INTERVENTIONAL,['NA']
14185,NCT00845130,Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
14186,NCT01918488,24-hour urinary sodium excretion induced by amiloride,Office blood pressure measurements,,2013-10,UNKNOWN,INTERVENTIONAL,['NA']
14187,NCT03272854,Graft Failure,Non-Cardiovascular Mortality,Venous Thrombosis,2001-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14188,NCT05219409,Rate of new diagnoses of Type 1 Diabetes Mellitus per year,Number of participants with adverse effects on Sitagliptin,Monitor Stage 2 patients with a CGM system (continuous blood glucose detection),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14189,NCT03196154,HbA1C,Cardiovascular risk estimation,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
14190,NCT02109094,Plasma Leptin Level,,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
14191,NCT05285085,Statin use on primary prevention,High dose statin use on patients with unknown diagnosis,,2021-11-19,COMPLETED,OBSERVATIONAL,['NA']
14192,NCT03136471,Glycemic Control (HbA1c) for Telehealth visits for COVID-19 patients,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
14193,NCT05298111,Changes in fasting and postprandial blood glucose,Changes in food intake,Habitual physical activity,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
14194,NCT00706420,Percent of subjects who have achieved insulin independence post transplant.,HgAlc</= 6.5%,,2004-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14195,NCT06292026,time to wound closure,,,2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14196,NCT01791114,Insulin Sensitivity,Metabolic profile,Thermoregulation,2012-01,COMPLETED,INTERVENTIONAL,['NA']
14197,NCT03434119,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,"Percentage of Participants With Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Hypoglycemia) During the On-Treatment Period",,2018-02-20,TERMINATED,INTERVENTIONAL,['PHASE3']
14198,NCT04424706,total MMP-9 levels,,,2020-06-30,UNKNOWN,OBSERVATIONAL,['NA']
14199,NCT01363141,Change in Blood Glucose and Insulin levels in 1 year as compared to baseline,Change in markers of cardiovascular disease in 1 year as compared to baseline,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
14200,NCT05337306,Health Literacy Questionnaire Subscale 2: having sufficient information to manage my health,Perceived Diabetes Self-Management Scale score,,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14201,NCT01059669,Peak enzyme Concentration IE,peak amylase,Rosemont score US,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
14202,NCT04851223,Changes in BCAA and its derivatives,,,2021-03-22,RECRUITING,OBSERVATIONAL,['NA']
14203,NCT00541515,Blood glucose levels,,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
14204,NCT05685810,Kidney disease,Insulin resistance,,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14205,NCT05016375,Explore bathing and spa behaviour by applying the social-ecological model to interpretivist thematic analysis.,Explore how passive heating might impact physical activity by applying the social-ecological model to interpretivist thematic analysis.,,2022-06-28,COMPLETED,OBSERVATIONAL,['NA']
14206,NCT01622777,Nerve growth factor,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14207,NCT06264258,Change in glucose average and variability,Change in game play patterns over time,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
14208,NCT04945551,Gene expression will be quantitatively determined at cellular resolution using single nuclei sequencing,Cardiorespiratory fitness,,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA']
14209,NCT05286450,Distribution of Participants Responses as Regards DSMQ Health Care Use Domain,,,2022-03-15,COMPLETED,OBSERVATIONAL,['NA']
14210,NCT01341899,Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation,mortality and dysfunction of other endocrine glands,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14211,NCT05197920,diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP),Fecal Elastase,,2022-01-14,RECRUITING,OBSERVATIONAL,['NA']
14212,NCT05188703,Number of participants who completed a follow-up eye exam 12+ months after baseline eye exam,,,2022-07-25,RECRUITING,INTERVENTIONAL,['NA']
14213,NCT06020235,Efficacy,Pharmacokinetics,Wound healing,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14214,NCT00794430,Investigate the safety and tolerability of V3381 in patients with diabetic neuropathic pain at doses of up to 400 mg bid,Determine the efficacy of V3381 in the treatment of diabetic peripheral neuropathic pain at does of up to 400 mg bid,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14215,NCT03967639,Smoking habits of patients undergoing cardiac surgery,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14216,NCT02964104,Number of treatment emergent adverse events (TEAE),"AUCGIR,0-24h,SS, area under the glucose infusion rate-time curve at steady state",,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14217,NCT05769127,Change in body weight for DPP participants,change in liver elastography in DPP participants,,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
14218,NCT03960333,circulating CD4+T cells in Type 2 Diabetic pre/post Metformin,,,2019-04-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14219,NCT06180837,Insulin Sensitivity,Cardiac Event Risk Test 1 (CERT 1),,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14220,NCT04507867,Overall Mortality at Day 40,Number of Participants With Distension on Day 3,Number of Deceased Participants Stratified by Urea Level,2020-09-07,COMPLETED,INTERVENTIONAL,['NA']
14221,NCT00897169,"Beta-cell function index estimated by a model-based analysis fit to the complete OGTT C-peptide and glucose profiles (12 time points), and including diabetes progression (as assessed by the glucose concentration 2 hours after an oral glucose load)",Evaluation of comparability of OGTT and clamp data based on modelling data of insulin sensitivity from steady-state clamp insulin and glucose concentrations and OGTT insulin and glucose profiles (12 time points),,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14222,NCT02313220,Body weight (kg),Body weight (%),"Adverse events /serious adverse events, vital signs and collection of clinical chemistry/haematology parameters.",2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14223,NCT01474018,Change in A1c,Total Daily Insulin Dose,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14224,NCT02041234,number of subjects achieving LDL level of <100mg/dl without lipid lowering medication,Weight loss,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14225,NCT01602003,Change of HbAlc,HbA1c Responder Rate,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14226,NCT02505321,Level of Circulatory Lipids following Triglyceride stimulation test (OTTT) (mmol/L),Incremental Area under the Curve NEFA levels (µmol/L),,2015-05-29,COMPLETED,INTERVENTIONAL,['NA']
14227,NCT04645641,System Performance,System Related Adverse Device Effects,,2020-10-12,UNKNOWN,INTERVENTIONAL,['NA']
14228,NCT03809858,Number of missed meal boluses,Diabetes Distress Scale (DDS) Scores,,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
14229,NCT04161430,Change from baseline in HbA1c (%) compared to placebo comparator at week 24,"Change from baseline in fasting plasma glucose/2-hour postprandial plasma glucose/body weight at week 12,week 24",,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14230,NCT01831921,Hemoglobin A1c,Triglycerides,Homeostasis Model of Insulin Resistance (HOMA IR),2014-01,COMPLETED,INTERVENTIONAL,['NA']
14231,NCT02158741,Summary of Diabetes Self-Care Activities,SF12v2,Health Assessment forms,2014-09,COMPLETED,INTERVENTIONAL,['NA']
14232,NCT04088201,Interstitial fluid glucose readings,Acceptablility of sensor,,2019-09-26,UNKNOWN,INTERVENTIONAL,['NA']
14233,NCT00324207,,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
14234,NCT00363233,Total cholesterol at 3 months,LDL and triglycerides at 3 months; Blood glucose and HbA1C at 3 months,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14235,NCT02490969,All-cause mortality,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
14236,NCT02647515,intraocular pressure,,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14237,NCT02691234,"To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.",,,2016-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14238,NCT02034513,Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,FPG (Fasting Plasma Glucose),,2014-01-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14239,NCT01836172,Flow-mediated dilation (FMD),Systolic and Diastolic Blood Pressure,"Serum Lipids (LDL, HDL and TG)",2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
14240,NCT03042325,Percentage of Participants with Glycosylated Hemoglobin < 7.0%,,,2017-07-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14241,NCT02432859,"The wound fluid level of VEGF, VEGFR-2, HIF-1α and NO (pg/ml)",Wound surface area(cm2),,2013-11,COMPLETED,INTERVENTIONAL,['NA']
14242,NCT01076608,,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
14243,NCT05188027,Blood glucose,carbohydrate supplementation,,2021-11-16,RECRUITING,INTERVENTIONAL,['NA']
14244,NCT00989339,endothelial function,carbohydrate metabolism,,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14245,NCT02578563,Change from baseline in the HbA1c level after 1 year,Change from baseline in Waist circumference at 12 months,,2016-02-12,COMPLETED,OBSERVATIONAL,['NA']
14246,NCT02196272,Medication adherence,Contacts with health services,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
14247,NCT06028399,Quality of life for disease-specific patient reported outcomes,,,2023-07-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14248,NCT03365180,Accuracy of estimate 2,Time spent in normoglycemia,,2018-01-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14249,NCT01040819,Plasma 15-epi-lipoxin A4,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14250,NCT02324036,Attainment of concrete behavioral goal (assessed in a two-week follow-up phone call to the patient),"Improvement in ""red flag"" outcome (assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome)",,2014-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14251,NCT05222815,Change in Diabetes Distress,,,2022-08-29,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14252,NCT04372810,Tibiotarsal joint range of motion,Static balance,,2017-08-09,COMPLETED,INTERVENTIONAL,['NA']
14253,NCT02637037,Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State,Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F],,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14254,NCT02307968,leaking,,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
14255,NCT01772173,Area under the Curve of algorithm,,,2013-02-01,COMPLETED,OBSERVATIONAL,['NA']
14256,NCT05181449,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than 6.5 and are not on any glucose lowering medications (excluding Metformin up to 2000 mg/day) at 12 months (360 days).,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than at 6.5 and are not on any glucose lowering medications at 12 months (360 days).,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14257,NCT02011620,Improvement in endothelial function as measured by laser doppler imaging.,Improvement in bone metabolism,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14258,NCT00005248,,,,1989-08,COMPLETED,OBSERVATIONAL,['NA']
14259,NCT05787457,Metabolic phenotype of type 2 diabetes mellitus across groups,Genetic Differences,,2014-07-31,TERMINATED,OBSERVATIONAL,['NA']
14260,NCT02539160,Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %),Platelet Reactivity Measured by VerifyNow P2Y12,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14261,NCT01124656,Incidence of Adverse Events.,Change from Baseline for Glycosylated Hemoglobin.,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
14262,NCT01345227,Adverse events related to the procedure of intra bone marrow islet infusion,Beta-cell function,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
14263,NCT03842267,Changes from baseline HbA1c at week 24,,,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE3']
14264,NCT03018444,Postprandial GLP-1 secretion,Resting Energy Expenditure,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
14265,NCT06071325,Types and Amount of Diabetes Waste,,,2023-09-19,RECRUITING,OBSERVATIONAL,['NA']
14266,NCT05376969,"Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP","Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP",,2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14267,NCT01514487,"Cmax, maximum concentration",Adverse events,,2005-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
14268,NCT00428727,Ulcer reduction percentage,Presence of adverse events related to the application of the patches,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14269,NCT00515723,Clamp Derived Insulin Sensitivity (mg/kg/Min),,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
14270,NCT02008435,Percent body weight loss,Exercise stress test (EST),Habit formation indices of fat grams and calorie tracking,2013-04,COMPLETED,INTERVENTIONAL,['NA']
14271,NCT04181853,genetic molecules,,,2020-02-05,COMPLETED,INTERVENTIONAL,['NA']
14272,NCT04938388,HbA1c < 7.0%,Number of participants with treatment-related adverse events assessed by research physician classified according to Good Clinical Practice guidelines,,2022-01-29,TERMINATED,INTERVENTIONAL,['PHASE4']
14273,NCT02308293,"Plasma level of adrenaline in response to hypoglycemia (Adrenaline, measured in arterial plasma)",Brain lactate accumulation measured with 1H-MRS,"Plasma insulin concentration (Insulin levels, measured in arterial plasma)",2015-01,COMPLETED,INTERVENTIONAL,['NA']
14274,NCT02965443,Percentage of subjects achieving a HbA1c ≤ 7.5% and having a reversal from a BBIT to a BOT regimen,changes in fear of hypoglycemia between groups,changes in clinical chemistry/haematology parameters between groups,2018-02-02,TERMINATED,INTERVENTIONAL,['PHASE4']
14275,NCT01590433,Change in Body Weight,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14276,NCT04349670,Complications,Correlation of symptoms,,2020-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14277,NCT04131608,Iron deficiency detected by Hemoglobin level in g/dl HBA1C level in diabetic patients,,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14278,NCT03502083,Forearm bloodflow ratio with GLP-1,,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA']
14279,NCT00265746,Incidence of type 2 diabetes mellitus.,Incidence of IGT,,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14280,NCT01719640,microvascular complications,The incidence and severity of adverse events related to the stem cell infusion procedure,,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14281,NCT03296436,complete ulcer closure,recurrent ulcer-related complications,,2020-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
14282,NCT04426422,gut micribiota,glycemic control,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14283,NCT00173628,,,,1990-01,UNKNOWN,OBSERVATIONAL,['NA']
14284,NCT05426525,Insulin-stimulated glucose disposal,Skeletal muscle energetic stress,,2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE4']
14285,NCT04813133,Serum High Density Lipoproteins (HDL),,,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA']
14286,NCT00952991,Gastrointestinal Symptoms,Glucagon Secretion,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14287,NCT00872456,"Composite of major CVD events (non fatal MI, Stroke and CVD death)",Revascularization procedures,,2005-03,COMPLETED,OBSERVATIONAL,['NA']
14288,NCT02038517,Relationship of insulin secretion and sensitivity with the development of abnormalities of glucose metabolism after OLT,Relationship of insulin secretion and sensitivity with the development of the metabolic syndrome after OLT,Morbidity and mortality after OLT,2013-06,RECRUITING,OBSERVATIONAL,['NA']
14289,NCT03820349,MRI outcome,Cognitive function,,2018-05-07,COMPLETED,OBSERVATIONAL,['NA']
14290,NCT01079325,To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy (DN) on sural Nerve Conduction Velocity (NCV) at six-months,To evaluate the safety of SB-509 in subjects with moderately severe diabetic neuropathy,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14291,NCT02673866,Change in weekly Average Daily Pain Score (ADPS),Rescue medication usage,,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14292,NCT04583839,Postpartum weight retention,Diabetes risk perception,Participant adherence with navigation,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14293,NCT03361631,To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.,Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved,,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
14294,NCT02002611,Assess Cmax of R-warfarin,Assess Vd/F of R-warfarin,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14295,NCT04942119,Lifestyle adherence,Side effects or complications,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14296,NCT02791035,Correlation between change of HbA1c and urinary glucose excretion,Percentage of subjects achieving the target HbA1c(<6.5%),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14297,NCT04630795,Plantar skin perfusion before and after use.,Plantar Pressure during walking,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14298,NCT03439072,Number of Subjects With a Positive Glucose Response,Glucagon Preparation and Administration Time,,2018-01-23,COMPLETED,INTERVENTIONAL,['PHASE3']
14299,NCT01018173,Time to cardiovascular composite primary endpoints,"Metabolic and renal function parameters: HbA1c, fasting plasma glucose, body weight, lipid profile, albumin/creatinine ratio (ACR), albuminuria, glomerular filtration rate (GFR)",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14300,NCT03912623,HbA1c evolution,Subgroup analysis,,2019-09-13,UNKNOWN,INTERVENTIONAL,['NA']
14301,NCT01454973,,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
14302,NCT00924053,Vz/F,,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14303,NCT00879125,glycemic control,Correction of lipid profiles,,1999-11,COMPLETED,OBSERVATIONAL,['NA']
14304,NCT06327503,opiorphin levels in saliva,unstimulated saliva flow,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14305,NCT03104738,"Pre-operative Fasting Blood Glucose, as Measured by Standardized Point of Care Capillary Blood Glucose (CBG) Device in the Pre-op Holding Area.",Mean 24-hour Glucose Postoperatively,,2013-11-20,COMPLETED,INTERVENTIONAL,['NA']
14306,NCT02043886,Catecholamines,,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14307,NCT03912961,Number of subjects where the image readout by retina specialists match the readouts by EyeStar AI system for identifying diabetic eye disease,Number of subjects with ocular diseases other than diabetic retinopathy between the readout by the EyeStar AI system and those by the retina specialists,,2019-01-21,COMPLETED,OBSERVATIONAL,['NA']
14308,NCT03671915,"The time spent of the glucose level drop in below 70 mg/dl over the 72-h, as recorded by continuous subcutaneous glucose monitoring (CGM).","Subject's perception in terms of life-style change, satisfaction and diabetes management",,2019-05-06,COMPLETED,INTERVENTIONAL,['NA']
14309,NCT06251635,Resting State Functional Connectivity (assessed through Functional MRI),Processing Speed,,2024-02-28,RECRUITING,INTERVENTIONAL,['NA']
14310,NCT00138515,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14311,NCT03981328,LGA newborns,Health-related quality of life,,2020-08-26,RECRUITING,INTERVENTIONAL,['NA']
14312,NCT01715428,carotid intima-media thickness,changes in atherogenic lipoproteins,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
14313,NCT02715193,"Changes from baseline in 24-hour insulin requirements on Day 1 relative to the two 24 hour periods post-treatment on Days 3 and 4, between the REMD-477 and placebo treated subjects, needed to maintain targeted glycemic control.",Changes from baseline over time of lipase,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14314,NCT05100576,Change of HbA1c level,Difference in the decisions between the two type of visits,,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA']
14315,NCT03829891,Changes of blood sugar variation .,Inflammatory factors (hs-CRP) change,Safety Outcome Measure: Serious adverse event,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
14316,NCT06192693,Hba1c change from baseline to 6 months post randomization,Evaluate quality of life,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14317,NCT03713268,Estimate of subretinal fluid volume before and after surgery for retinal detachment based on surgical view versus based on OCT output,,,2018-09-30,RECRUITING,OBSERVATIONAL,['NA']
14318,NCT04903743,duration of postoperative analgesia,,,2021-01-10,UNKNOWN,INTERVENTIONAL,['NA']
14319,NCT00128154,Increase in insulin sensitivity,weight and/or body composition,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
14320,NCT00707590,"AEs, vital signs, ECG and clinical laboratory test results",DPP-4 inhibition and incretin response,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE1']
14321,NCT00605839,Quality of Parent-child Relationship,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14322,NCT06072573,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11 and ≤14",Number and severity of adverse events (AE),2023-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
14323,NCT01377961,A1C,"For Arm 1 :AUCglucose,Plasma Lipids concentrations,BMI,Plasma lycopene and isoflavones concentration,EPCs count and function,Chlamydia Trachomatis titers in serum",,2010-09,WITHDRAWN,INTERVENTIONAL,['NA']
14324,NCT02219646,Endothelin-1,Flow Mediated Dilation,carotid Intima Media Thickness,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14325,NCT01572740,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16,Number of Confirmed Hypoglycaemic Episodes,,2012-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14326,NCT04742751,Drug adherence/Pill Counts,Glycemic Control,,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2']
14327,NCT00829296,Change in Central Systolic Blood Pressure (SBP),Change in Pulse Pressure Amplification,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14328,NCT03989063,Change in balance performance,Change in patient's self-reported outcomes,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
14329,NCT05569525,Glycated hemoglobin (HbA1c),Glucose coefficient of variability (CV),,2022-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14330,NCT02854423,major cardiac adverse events,Rate of target-vessel revascularization (TVR) in all participants,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
14331,NCT01212198,Incidence of diabetes in patients with high risk for diabetes and gestational diabetes in Koreans,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA']
14332,NCT03963219,"% Time blood glucose in target, day time assess by device",,,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA']
14333,NCT02404870,AUC of FGF23,"1, 25 vitamin D",,2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
14334,NCT02328521,Neointimal area,number of major adverse cardiovascular events,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
14335,NCT01506869,number of participants who develop cancer during follow-up,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA']
14336,NCT04937296,HBA1c (Glycated hemoglobin),Triglyceride-glucose index,,2022-01-12,COMPLETED,INTERVENTIONAL,['NA']
14337,NCT06239129,Effect of medications or conditions on kidney function decline,Adverse health events associated to laboratory abnormalities,,2006-01-01,COMPLETED,OBSERVATIONAL,['NA']
14338,NCT02526810,mean amplitude of glycemic excursions( MAGE),the level of blood 8-hydroxy-2-deoxyguanosine(8-OHdG),the incidence of severe hypoglycemia,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
14339,NCT05974592,Foot Care Behavior Scale (USAS),Diabetic Foot Evaluation Form (DADF),,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
14340,NCT04689984,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14341,NCT04620668,Changes in stress as measured by the Perceived Stress Scale (PSS-10),Changes in life satisfaction as measured by the Satisfaction with Life Scale,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
14342,NCT04874012,HbA1c,Body mass index (BMI),,2021-06-12,RECRUITING,INTERVENTIONAL,['PHASE2']
14343,NCT02816762,Change form baseline in albuminuria levels,To identify the CPAP-responder subgroup of OSA patients with diabetic nephropathy,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14344,NCT01198678,Evaluate capability to follow glucose concentration changes over 15 consecutive days,,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14345,NCT03613805,device accuracy,changes in fear of hypoglycaemia,,2018-03-14,COMPLETED,INTERVENTIONAL,['NA']
14346,NCT03937050,Mean fasting blood sugar (women with GDM),Adverse perinatal outcomes (composite measure),,2021-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14347,NCT03324737,Weight at 4 months post-delivery,Breastfeeding Status,,2017-11-16,COMPLETED,INTERVENTIONAL,['NA']
14348,NCT01742624,"Incidence of efficacy failure (treated-BCAR, biopsy-confirmed acute rejection, graft loss rate, death, or follow-up failure)","Safety assessed by the incidence of adverse events, physical exam, and labo-tests",,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
14349,NCT05116410,"Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug",Weight change,,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14350,NCT02003274,1. Composite plasma glucose and hormone responses to a mixed meal; 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,,2013-10,UNKNOWN,INTERVENTIONAL,['NA']
14351,NCT02710799,Number of consultations authorized,Usage of TelessaúdeRS teleconsultations,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
14352,NCT05013294,Glycated hemoglobin,Waist-hip ratio,,2021-08-23,COMPLETED,INTERVENTIONAL,['NA']
14353,NCT03399565,HDL-C,,,2016-01-18,UNKNOWN,OBSERVATIONAL,['NA']
14354,NCT06013865,Discontinuation of Empagliflozin,Blood Pressure,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
14355,NCT05583877,Process Evaluation,Change in HbA1c Percentage,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14356,NCT01076647,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14357,NCT01315808,Study the rate of change of HbA1c in normal population with known risk factors of diabetes,Diabetes prediction model based on the rate of change in HbA1c,,2011-03,TERMINATED,OBSERVATIONAL,['NA']
14358,NCT00272012,Change in HbA1c.,Adverse events.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
14359,NCT02848261,Pediatric Quality of Life Inventory,General and diabetes-specific technology use,,2016-08-15,COMPLETED,INTERVENTIONAL,['NA']
14360,NCT05714852,Change in blood glucose,Change in waist circumference,,2023-02-15,RECRUITING,INTERVENTIONAL,['NA']
14361,NCT00608816,catecholamine levels,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
14362,NCT05452551,Logarithmic decrement,,,2021-07-06,COMPLETED,OBSERVATIONAL,['NA']
14363,NCT00013286,,,,1999-10,COMPLETED,OBSERVATIONAL,['NA']
14364,NCT01606371,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Glucose excursion after meals,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14365,NCT02352298,Dario Blood Glucose Monitoring System Accuracy at High Altitude (ISO 15197:2003),,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
14366,NCT01913145,Usability and HbA1c Method Comparison Study Using Lay-Person Micro-Blood Specimens,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14367,NCT01980459,The magnesium cellular levels will provide a stronger correlation with antiinflammatory indicators compared to the circulating serum levels of magnesium.,Magnesium supplementation will lower parameters of inflammation in hypomagnesemic diabetic patients.,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14368,NCT03227484,effect of treatment with 25 mg empagliflozin daily versus placebo on regional brain insulin sensitivity,effect of treatment with empagliflozin versus placebo on energy expenditure,,2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14369,NCT05262946,Cumulative Somatosensory Impairment Index,Validated Spanish version of Short-Form Late-Life Function and Disability Instrument,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
14370,NCT05155410,Glucose Control: Change in Fructosamine,Waist circumference,Cravings,2022-02-15,COMPLETED,INTERVENTIONAL,['NA']
14371,NCT01774474,Change in central subfield mean macular thickness as a measurement of efficacy,No. of subjects developing clinically significant macular edema as a measurement of efficacy,Change in central subfield mean macular thickness as a measurement of efficacy,2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14372,NCT03605810,Performance of classification to predict eGFR,,,2018-07-15,COMPLETED,OBSERVATIONAL,['NA']
14373,NCT01224366,HbA1c reduction,Incidence of hypoglycemia and severe hypoglycemia (overall and subpopulations),,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
14374,NCT01177384,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2011-01-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14375,NCT05670548,Serum metabolomics,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
14376,NCT04055064,Change in dietary intake of nutrients,Change in Ankle Brachial Index(ABI),,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
14377,NCT03725709,Exam metabolic profiles of CSF and plasma in diabetes. (Metabolites analysis of CSF and plasma),,,2016-08-01,COMPLETED,OBSERVATIONAL,['NA']
14378,NCT00569556,"Combined outcome of BP<130/80 mmHG, HgbA1C<8%, and LDL<100mg/dl at 1 year; the primary analysis will compare the intervention to usual care with respect to the percentage of diabetic individuals achieving all three therapeutic goals",Safety of the intervention (occurence of adverse events over the course of the trial),,2006-09,COMPLETED,INTERVENTIONAL,['NA']
14379,NCT01720290,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of hypoglycemic episodes,,2002-07-25,COMPLETED,INTERVENTIONAL,['PHASE4']
14380,NCT03912012,"Glomerular hyper filtration (Glomerular filtration > 135 mL/min/1,73 m2)",trabecular microarchitecture,,2019-07-09,COMPLETED,INTERVENTIONAL,['NA']
14381,NCT02542735,Metabolic syndrome incidence,Risk of metabolic syndrome according to each of the measured SNP,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
14382,NCT00813280,glucose levels,type of insulin treatment,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
14383,NCT04481997,Reasons for prolonging DAPT over 1 year,Diabetes control (HbA1c values),,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA']
14384,NCT05128097,Retrospective study of the management of the main geriatric risks in the University HÔptaux de Strasbourg,,,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA']
14385,NCT03998475,Program acceptability - provider,Change in transition readiness,Change in problem solving,2019-07-11,COMPLETED,INTERVENTIONAL,['NA']
14386,NCT01756274,Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value,Percent of BG Results (Per Population) Within +/-15 mg/dL (<100 mg/dL)and Within +/-15% (>=100 mg/dL) of the Reference Instrument BG Value,"Number of Blood Samples From Babies in the Neonatal Intensive Care Unit (NICU) That Produced Meter Results Beyond What Random Chance Would Predict (i.e., Outside 95% Limits for Studentized Residuals)",2012-12,COMPLETED,INTERVENTIONAL,['NA']
14387,NCT05224986,Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose,"Endothelial cell oxidative stress (sub-set, n≤10)",,2022-01-19,RECRUITING,INTERVENTIONAL,['NA']
14388,NCT05908812,Differences in glycated hemoglobin and/or insulin resistance in diabetic patients with non-sarcopenic obesity vs patients with sarcopenic obesity,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
14389,NCT02317484,HbA1c change level,Body composition and visceral fat change levels,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
14390,NCT00607906,vital signs assessments:,Correlation between drug concentrations & blood sugar levels:,,2007-11-16,COMPLETED,INTERVENTIONAL,['PHASE1']
14391,NCT01920256,Change in baseline A1C (glycated hemoglobin) at 12 months,Change in baseline insulin satisfaction at 12 months,Cost,2013-08,COMPLETED,INTERVENTIONAL,['NA']
14392,NCT02910518,Assessment of PK parameter: area under the concentration time curve,Number of patients with treatment emergent adverse events,,2017-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14393,NCT02025296,proportion of patients achieving the target of HbA1c <7% without hypoglycemia,Lifestyle,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
14394,NCT01699932,Change in HbA1c,Hypoglycemia,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
14395,NCT01396187,Number of Participants With Blood Glucose Abnormalities,Average Plasma Concentration (Cav) of PF-05231023 at Steady State,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14396,NCT02540486,Percentage of subjects reaching fasting plasma glucose (FPG) target,Serious adverse events,List of concomitant medications initiated after randomization,2013-12,COMPLETED,INTERVENTIONAL,['NA']
14397,NCT03696368,GDM Diagnosis,,,2019-01-04,RECRUITING,OBSERVATIONAL,['NA']
14398,NCT02170870,Mean Intestinal Chemosensitivity to Lipids Perfusion,Rate of Gastric Emptying (GE t 1/2) in Patients With Diabetes Mellitus (DM) or Non-ulcer Dyspepsia (NUD) Compared to Placebo,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14399,NCT01605149,,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
14400,NCT00690456,Change from baseline in HbA1c,Percent change from baseline in HDL-C and Triglycerides,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3']
14401,NCT02178176,Adherence to oral hypoglycemic agents: Medication Event Monitoring System,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
14402,NCT01906099,Fasting blood glucose (mg/dl),Triglyceride (mg/dl),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14403,NCT01354990,Number of Participants With Concomitant Conditions,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
14404,NCT02796079,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14405,NCT05731544,Change in HbA1c,To assess the effect on HbA1c,,2022-08-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14406,NCT05662475,Sirtuin 1 concentration in GCF,,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
14407,NCT01006018,Insulin Secretion,,,2011-07,TERMINATED,INTERVENTIONAL,['NA']
14408,NCT03329261,Major Cardiovascular Events (MACE),Incidence of Adverse Events,,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14409,NCT06195488,determine stomach fullness,Incidence of risk factors,,2022-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14410,NCT02673762,A multi marker test score based on a pre-specified model is measured in each patient. The test score is on a scale of 0 to 1.0 and relates to the probability of disease.,Housekeeping gene Ct values on PCR analysis will be measured in individual patients,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14411,NCT05165758,Compare the levels of quality of life in diabetic subjects with and without foot ulcer,"Compare the quality of life levels according to the type of antidiabetic treatment, in diabetic subjects with and without foot ulcer",,2022-01-21,COMPLETED,OBSERVATIONAL,['NA']
14412,NCT06263348,Incidences of ADRs and SAEs,Response rate,,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE4']
14413,NCT00609154,Insulin Biosynthesis Rate,,,2010-08-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14414,NCT05899166,Decline in Beta-cell Function,"Qualitative patient perspectives, interview - child",Study termination for dyslipidemia,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14415,NCT00817271,P-Glucose levels,"Pharmacodynamics (P-Glucose, S-Insulin and S-C-peptide)",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
14416,NCT03409523,Compliance with Choosing Wisely guidelines measured by number of reductions of medications,Usability measured by module user testing with direct observation and semi structured interviews,,2018-01-08,COMPLETED,OBSERVATIONAL,['NA']
14417,NCT02471963,Effect of empagliflozin after 6 weeks of treatment on macrocirculation,Biomarkers,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14418,NCT04289727,Change in bone mineral density by Dual X-ray Absorptometry (DXA),,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
14419,NCT00490178,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14420,NCT00805974,Ambulatory blood pressure monitoring on 24 hours,Glycemic measurements on 24h (D0-D1).,,2005-10,TERMINATED,INTERVENTIONAL,['NA']
14421,NCT01869608,Diagnosis of abnormal glucose tolerance,Patient's satisfaction,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
14422,NCT01241864,HbAlc <6.5% and an absence of severe hypoglycemic events,HbAlc < 6.5% and an absence of severe hypoglycemic events measured after last transplant,,2010-12,RECRUITING,INTERVENTIONAL,['PHASE2']
14423,NCT02274844,Change in Low-Density Lipoprotein (LDL) Cholesterol,Change in Diabetes Medication Counts,Change in Medication Beliefs- Concerns (Concerns About the Negative Effects of Medications),2016-04,COMPLETED,INTERVENTIONAL,['NA']
14424,NCT04593992,Neuropathy symptom score,,,2020-10-20,COMPLETED,INTERVENTIONAL,['NA']
14425,NCT06305416,Changes in Central Subfield Thickness (CST) from Baseline,Evaluation and comparison of safety between reference vs. test drug.,,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE3']
14426,NCT05071235,Quality of life (QoL) follow up,Change in visual analogue scale (VAS),,2019-08-27,COMPLETED,INTERVENTIONAL,['NA']
14427,NCT04074148,glycated haemoglobin (HbA1c) percent,,,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
14428,NCT05107388,Incidence rate of hyperglycemia,,,2021-12,UNKNOWN,INTERVENTIONAL,['NA']
14429,NCT04847414,change in BMI,HOMA-IR,,2021-04-10,UNKNOWN,OBSERVATIONAL,['NA']
14430,NCT05202067,Medication adherence,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
14431,NCT02001337,To create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and identify pancreatic cancer in this cohort.,,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
14432,NCT05944640,TIR,Mean sensor glucose concentration,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
14433,NCT00005669,Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS).,Change in Body Fat by Bod Pod,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14434,NCT03062774,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Determine PB-119 blood concentration,,2014-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14435,NCT04182503,Incidence of gestational hypertension,,,2019-08-12,UNKNOWN,OBSERVATIONAL,['NA']
14436,NCT02785198,Wound healing change quantified by digital photo planimetry,"The biochemical changes during wound healing, is assessed by biochemical markers in peripheral venous blood samples.",,2016-04,TERMINATED,INTERVENTIONAL,['NA']
14437,NCT02803918,Number of patients with anti-lixisenatide antibodies,Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours,,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14438,NCT05887817,Change in CAVI,Change in urinary L-FABP,,2023-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
14439,NCT03291171,Change in self-reported sedentary behaviour,change in coping planning,,2017-10-15,COMPLETED,INTERVENTIONAL,['NA']
14440,NCT01398267,"Glomerular filtration rate (mGFR), measured as iohexol clearance",High density lipoprotein-cholesterol (HDL-C) blood levels,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14441,NCT01765270,Troponin I (TnI) Area Under the Curve (AUC),Need for Antiarrhythmic Therapy,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE4']
14442,NCT02563834,Myocardial Fatty Acid Uptake Rate,Myocardial Perfusion Rate,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
14443,NCT01061216,Insulin measurements will be used to compute PK model parameters: absorption rate(s) and elimination rate using an appropriate transport model.,Feasibility of RCS for longer-term ID infusion,,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14444,NCT02138188,"Change from baseline glycosylated haemoglobin (HbA1c) at 6th, 12th and 24th months after transition to CSII.",Measures of Coping Strategies at Baseline,,2013-09,UNKNOWN,OBSERVATIONAL,['NA']
14445,NCT00651196,histomorphometry measurements,Bone mineral density,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
14446,NCT05689099,"Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of subcutaneous semaglutide 0.5 mg administration",,,2023-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14447,NCT06014684,Peripheral Insulin sensitivity,24h substrate metabolism,Blood glucose levels measured continuously over 7 days.,2023-07-13,RECRUITING,INTERVENTIONAL,['NA']
14448,NCT02128854,Diet Score on the Rapid Eating and Activity Assessment for Participants,Quality of Life Using the Medical Outcomes Study Short Form,,2014-08-14,COMPLETED,INTERVENTIONAL,['NA']
14449,NCT00832624,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18,,,2008-11-26,TERMINATED,INTERVENTIONAL,['PHASE4']
14450,NCT00729040,Total steps,content of posts (qualitative),,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14451,NCT05551988,Predictors of amputation in diabetic foot ulcer patient,Antibiotic resistance level,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
14452,NCT00663949,decreasing urinary protein,,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14453,NCT02172092,Extracellular volume,Distribution of strong and weak acids,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
14454,NCT05435196,The glycosylated hemoglobin A1c,The Visual Analog Scale,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
14455,NCT01702311,Mean Fasting Blood Glucose,Number of Subjects With BG > 300 mg/dL,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14456,NCT00123227,Plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR),Change in plaque gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation,,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
14457,NCT00738023,Changes in Systolic Blood Pressure During Initial Intralipid Infusion,Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14458,NCT02496156,Continuous Glucose Monitor Use Profile or Insulin Pump Use Profile,SURE Test,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
14459,NCT02358109,The Incremental Cost Effectiveness Ratio (ICER),Quality Adjusted Life Years (QALYs),Hemogram profile,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14460,NCT00819884,"24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose)",Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14461,NCT03022058,Presence of significant qEEG hypoglycaemia indicators when comparing normo- and hypoglycaemic EEG as measured by the EarEEG systems for subjects where hypoglycaemia-induced changes have been observed in the scalp EEG (visit 4),,,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
14462,NCT03285594,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Percentage of Participants With Adverse Events (AEs),Percentage of Participants With Hypoglycemic Events,2017-09-15,COMPLETED,INTERVENTIONAL,['PHASE3']
14463,NCT02413086,Grades of wound healing,SF-36,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
14464,NCT00455988,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
14465,NCT01858233,The IBEP Study,The IBEP Study,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
14466,NCT02084498,Change in HbA1c,Frequency of serious hypoglycemic events,Treatment Satisfaction,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14467,NCT00295659,,,,2001-01,COMPLETED,OBSERVATIONAL,['NA']
14468,NCT00138671,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco),Severe Hypoglcyemic Event Rates,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3']
14469,NCT05461495,BMI,,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
14470,NCT00501462,drug & metabolite plasma levels,"Safety and tolerability parameters, including AEs and clinically relevant changes in vital signs (heart rate and blood pressure), ECGs, urine electrolytes, and clinical laboratory assessments (clinical chemistry, hematology, and urinalysis).",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14471,NCT00461006,Relative change from baseline in glomerular filtration rate,"Adverse events (AEs), laboratory parameters.",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14472,NCT04636307,Presence of ischemia,,,2021-09-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14473,NCT03317028,The HbA1c treatment effect among CS02 groups and the Placebo group,,,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14474,NCT01153100,Reduction in rebound hyperglycemia (blood glucose levels over 180 mg/dl),Reduction in time to get back to control of glycemia (140-180 mg/dl) if rebound hyperglycemia occurs,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14475,NCT00433758,Clarke Error Grid,,,2006-12,UNKNOWN,INTERVENTIONAL,['NA']
14476,NCT03025399,"the changes of degree of retinal microvascular lesions before and after treatment (no, mild non proliferative phase, moderate non proliferative phase, severe non proliferative phase, proliferative phase)",Change of Vision (analysis of visual acuity before and after medication using EDTRS international visual acuity chart),,2017-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14477,NCT00359112,Change in HbA1c level from baseline following 52 weeks of treatment.,Diabetes treatment satisfaction.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14478,NCT04341571,First phase of insuline secretion,Incidence of treatment-Emergent Adverse Events,,2019-10-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14479,NCT05970237,Target blood glucose achievement rate,,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA']
14480,NCT03172260,HbA1c,Kidney function,,2017-02-08,COMPLETED,OBSERVATIONAL,['NA']
14481,NCT01866462,Metformin Tolerance,Weight Loss,,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14482,NCT00811889,To determine the safety and tolerability of bardoxolone methyl when administered for 12 months (52 weeks)following randomization to type 2 diabetic patients with CKD (eGFR 20 - 45 mL/min/1.73m2).,To determine the change in eGFR from baseline in patients with type 2 diabetes and CKD (baseline eGFR = 20 - 45 mL/min/1.73m2) after receiving bardoxolone methyl for 12 months (52 weeks) following randomization.,,2009-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
14483,NCT02409511,Complementary markers for improving the performance of MA,To test whether the enhancement of this specific marker of kidney injury is able to identify those patients in which MA really means diabetic nephropathy.,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14484,NCT04838561,"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire Post Intervention (Youth and Parent Versions)",Estimated HbA1c (%),"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire (Baseline and Post Intervention)",2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
14485,NCT05228067,Change in dopamine-dependent cognitive function,Food choice,,2021-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14486,NCT03195257,C-terminal telopeptide of type I collagen (CTX).,N-terminal propeptide of type 1 procollagen (P1NP).,,2012-11-17,COMPLETED,INTERVENTIONAL,['NA']
14487,NCT03326232,Mean blood glucose (mg/dL),Respiratory distress syndrome,,2017-11-13,UNKNOWN,INTERVENTIONAL,['NA']
14488,NCT06304844,Determine the number of participant with eGFR<60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD,,,2024-04-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14489,NCT00543517,,,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3']
14490,NCT01328717,Percent of Fingerstick Blood Glucose (BG) Results Within +/-20%(>=75 mg/dL) and Within +/- 15mg/dL (<75 mg/dL) of Laboratory Glucose Method,Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Evaluation),,2010-12,COMPLETED,INTERVENTIONAL,['NA']
14491,NCT02312050,The change in eGFR from Screening to measurements taken at Week 26,Incidence of major cardiac events,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14492,NCT01691846,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14493,NCT02867436,Change in C-peptide area under the curve measured by mixed-meal tolerance test (MMTT) between group on GFD and standard gluten-containing diet.,Differences in fecal microbiome between children on normal diet and children on gluten-free diet over the first year of diabetes duration;,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
14494,NCT03437525,Change from Baseline HbA1c at 6 and 12 months,Change from Baseline Insulin Attitudes at 6 and 12 months,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
14495,NCT00489645,• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.,"• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
14496,NCT01158040,Neonatal hypoglycemia (neonatal capillary blood glucose lowers then 40 mg/dL),Mean maternal blood glucose during labor,,2010-08,UNKNOWN,OBSERVATIONAL,['NA']
14497,NCT01285076,Number of Participants With Hypoglycemic Episodes,Self-reported Barrier Questionnaire,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
14498,NCT04595474,Proportion of subjects with advanced fibrosis,Lipid profile,,2021-01-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14499,NCT00813475,All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital,Total # of in-hospital days during 1 year follow-up.The rate of any major clinical events during 1 year follow-up. Hypoglycemic events during index hospital stay,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
14500,NCT01606085,Diabetes health related quality of life measures,Diabetes (DM) self efficacy,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
14501,NCT00419302,Glycemic response to a meal challenge,Safety variables,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14502,NCT00562133,the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin,"postprandial time course of blood glucose, insulin, intact proinsulin, ADMA, MMP-9, FFA, ox-LDL, per ox Status, IL-18, postprandial time course of microvascular blood circulation measured with laserdopplerflux at 37 °C and 44 C",,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14503,NCT01275794,To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy,To compare the results of OAD monotherapy in different groups of patients,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
14504,NCT00477581,Effect of Exenatide on postprandial glucose,"Assessment of effect of exenatide to the effect of sitagliptin the acetaminophen absorption test, and 6-point self-monitored blood glucose (SMBG) profiles",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14505,NCT00360893,,,,1994-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14506,NCT06330727,Fasting triglycerides (mmol/L),Standard deviation of heart rate variability (SDNN),,2024-02-05,RECRUITING,INTERVENTIONAL,['NA']
14507,NCT01411930,Insulin sensitivity,Hepatic glucose production,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14508,NCT02859779,Needs and expectations of adolescents with type 1 diabetes for skills to be developed during the educational sessions,Needs and expectations of parents of adolescents with type 1 diabetes for skills to be developed during the educational sessions,,2017-02-04,COMPLETED,INTERVENTIONAL,['NA']
14509,NCT00118950,HaemoglobinA1c,"Adverse events and safety variables (e.g. hypoglycaemia, haemoglobin, white blood cell count, cobalamine and folate).",,2001-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14510,NCT03179423,Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE),,,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2']
14511,NCT02059538,Look for differences in gut microbiota signatures using metagenomic approach in the 8 different groups,Establish differences in fecal metabolomic signatures using 1H nuclear magnetic resonance (NMR) spectroscopy and Ultra-high Performance Liquid Chromatography Mass Spectrometry ((UPLC-MS) on fecal samples) in the 8 different groups (cf above mentioned),Look for statistical association between gut derived signatures and lifestyle factors such as environment and diet (using data obtained from environment questionnaires and the results of both FFQ and Three day 24h diet recall),2013-06,UNKNOWN,INTERVENTIONAL,['NA']
14512,NCT00330200,Evaluate the effects on hemoglobin A1c (HbA1c),Assess the effects of ISIS 113715 on insulin suppression of local rates of lipolysis (microdialysis),,2005-11-01,TERMINATED,INTERVENTIONAL,['PHASE2']
14513,NCT05218915,Glycemic variability,Diabetes Treatment Satisfaction,,2022-01-28,RECRUITING,INTERVENTIONAL,['PHASE4']
14514,NCT00938119,"MACE (clinically driven TLR, cardiac death, MI, ST) at 12 months","ARC (probable + definite) ST at 1-day, and 1 and 12 months",,2009-08,TERMINATED,OBSERVATIONAL,['NA']
14515,NCT00700960,HbA1c,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
14516,NCT02823808,Cumulative treatment failure (HbA1c≥7.0%) rate for glycemic control,Change in glucagon,,2017-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
14517,NCT01380873,△Cmax of plasma glucose,,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14518,NCT01345435,Changes in Hemoglobin A1c,Medication compliance,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14519,NCT02846779,Insulin Persistence,Number of Hospitalizations,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
14520,NCT02906917,Change in HbA1c (%) - Week 26,Incidence of TEAEs,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
14521,NCT01685879,Blood Glucose response,Appetite Response,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14522,NCT00273104,Improvement of co-morbidities,Safety issues,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
14523,NCT05769439,evidence-based DhMRs concerning incident obesity,,,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14524,NCT00832741,blood glucose,gastric emptying,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
14525,NCT03196336,hospitalization,"severe evolving complication (ischemic or proliferative retinopathy, severe renal insufficiency, severe hypoglycemia, coronaropathy or evolving foot lesion)",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14526,NCT01438814,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment,Change From Baseline in HbA1c Over Time,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14527,NCT00674596,,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14528,NCT04662866,Endogenous glucose production during fasting,,Intraabdominal fat,2021-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14529,NCT02324309,Post-breakfast glucose exposure (AUC),Injection site toleration (VAS and severity scales),,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14530,NCT04529824,Diabetes Status,Fitbit-derived sedentary time,Healthcare medical costs,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
14531,NCT04678895,Change in Numeric Rating Scale for Pain,Ratio of Pre-treatment Expectations Compared to Change in Numeric Rating Scale,,2020-12-22,RECRUITING,INTERVENTIONAL,['PHASE2']
14532,NCT01552213,Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation.,Number of Participants With Intrauterine Fetal Demise,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
14533,NCT00941161,"fasting glucose, HbA1c","total cholesterol, C-LDL, C-HDL, triglycerides, VLDL, insulin",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14534,NCT00946517,Parenting styles,Adherence to therapy,,2009-07,TERMINATED,OBSERVATIONAL,['NA']
14535,NCT01040104,Time to wound healing / Scar maturation,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
14536,NCT01452451,Number of subjects with adverse events as a measure of safety and tolerability,The pharmacodynamics in repeat-dose,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14537,NCT01620489,Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin),Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula),,2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE3']
14538,NCT00399711,HbA1c,Percentage of subjects achieving sudden levels of HbA1c,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14539,NCT00534183,Study of metabolic profile,Study of obesity and diabetes,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
14540,NCT05031572,To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin after crossing arm),variability on biliary acids (BA) after weight loss,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
14541,NCT02583061,Glucose tolerance status,,,2003-09,RECRUITING,OBSERVATIONAL,['NA']
14542,NCT02863887,Percent weight loss,Change in Pulse,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
14543,NCT04551625,"High amplitude, antegrade contractions assessed with HRCM",Distance of capsule movement.,,2020-10-15,UNKNOWN,OBSERVATIONAL,['NA']
14544,NCT00770367,Asymmetric Dimethylarginine (ADMA) Level,NOx f2-isoprostanes,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14545,NCT00372060,Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 12,Change From Baseline in Fasting Plasma Glucose at Week 12,Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 52,2006-08-21,COMPLETED,INTERVENTIONAL,['PHASE3']
14546,NCT01638780,"insulin sensitivity (overall, muscle- and liver specific)",heart function,,2012-05,UNKNOWN,INTERVENTIONAL,['NA']
14547,NCT00065650,HbA1C,Lipids,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14548,NCT03217175,Number of Subjects With Plasma Glucose < 60 mg/dl,Time From Exercise Start to Plasma Glucose < 60 mg/dl,,2017-08-18,TERMINATED,INTERVENTIONAL,['NA']
14549,NCT03601494,visual analog scale of pain,Nerve conduction velocity,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
14550,NCT03794960,Treatment Effect,Immunologic,,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14551,NCT05176847,Change in body weight,Change in minutes a week of moderate to vigorous physical activity (MVPA),,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14552,NCT00590876,fMRI,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
14553,NCT05570435,3h-iAUC of PPGR,iCmax of PPIR,additional endpoints slopes derived from PPGR,2022-11-16,COMPLETED,INTERVENTIONAL,['NA']
14554,NCT01377688,Blood pressure and /or Estimated Glomerular Filtration Rate (eGFR),,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
14555,NCT00678080,The Number of Participants Who Achieved a Hemoglobin A1C <7%,Number of Participants With Newborns Who Needed Neonatal Dextrose,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
14556,NCT01862120,Treg response following the induction cure period,Treg response during the maintenance period compare to the baseline,,2013-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
14557,NCT03949504,Concentration of glucose in plasma,,,2019-01-09,COMPLETED,OBSERVATIONAL,['NA']
14558,NCT02147496,Food intake,Appetite hormones,Subjective Appetite,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14559,NCT01127269,Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no severe documented nocturnal hypoglycemia episode.,Hypoglycemic episodes,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14560,NCT03865342,Change in weight,Change in hemoglobin A1c,Change in quality of life,2016-09,COMPLETED,INTERVENTIONAL,['NA']
14561,NCT00665106,Ocular safety,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14562,NCT01363284,Prediction of duloxetine pain relief efficacy by pre-treatment extent of the CPM response,Treatment-related increase in CPM response,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
14563,NCT06037512,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-04-13,COMPLETED,INTERVENTIONAL,['NA']
14564,NCT01964976,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
14565,NCT00302224,"To evaluate the safety and tolerability of 14 daily doses; To determine the pharmacokinetic (PK) profile in plasma of DIO-902 after a single dose, and after fourteen daily doses; To evaluate the pharmacodynamic effects of fourteen daily doses","To explore the impact of treatment with the enantiomer of ketoconazole on markers of inflammation and coagulation as well as on lipomic profiles, pre- and post-treatment",,2005-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14566,NCT03791567,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
14567,NCT01136512,Vitamin B12 level,methylmalonic acid,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
14568,NCT00035542,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14569,NCT00744965,Mean Fetal Weight at Birth,Need for Insulin Therapy,,2008-09-16,COMPLETED,INTERVENTIONAL,['PHASE4']
14570,NCT02750410,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Total Insulin Dose,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14571,NCT00605020,HbA1c,Change in weight,,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14572,NCT05809817,Metabolic control,,,2023-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14573,NCT01425645,Proportion of study subjects achieving a 7% weight loss,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
14574,NCT03073070,Measurement of RBC survival in diabetic children using biotin-labeled RBCs,,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14575,NCT03653533,Occurrence of hypoglycemia between a phase with no SmartGuard® function and a phase with SmartGuard® function,,,2019-01-07,TERMINATED,INTERVENTIONAL,['NA']
14576,NCT03919617,Rate of Resting Energy Expenditure (REE),,,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14577,NCT01353495,Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
14578,NCT01579292,Body mass index,Fasting plasma glucose,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14579,NCT03188094,probability of eligible patients at a practice site to lose 5% or more of their body weight six months following the index office visit.,improved blood pressure following the index office visit,,2018-12-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14580,NCT03208010,Change from baseline in body mass index (BMI) at 36 months,Text Messages Intervention - Follow-up Phone Call Interview,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
14581,NCT00457470,Change of retinal thickness at Day 15 or Day 25 depending on dosing regimen,; Proportion of eyes experiencing an improvement in the degree of retinopathy at Day 28,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14582,NCT01434030,Desire to Receive Advice From Personal Glucose Advisory System (PGASystem),Willingness to Follow PGASystem Advice,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
14583,NCT01917656,Change in Fructosamine From Start of Ramadan to End of Ramadan,"Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.",,2014-01-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14584,NCT02421510,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14585,NCT02642159,Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum,Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis,,2016-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
14586,NCT04265469,Foot Self-care Behavior,,,2016-02-10,COMPLETED,INTERVENTIONAL,['NA']
14587,NCT00208637,Dietary intake as measured by 3-day weight diet records,All measures to be compared at end of study (6 months),,2002-08,COMPLETED,INTERVENTIONAL,['NA']
14588,NCT02773368,Change in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D),,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
14589,NCT00501930,"Clinical laboratory tests, ECGs, adverse events",clinical lab tests,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14590,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions",Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14591,NCT02023918,Insulin Sensitivity,Lipolysis,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14592,NCT05915949,HbA1c,Fib-4,Adverse events,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14593,NCT00900887,"ocular topic antiinflammatory therapy (ketorolac, nepafenac or placebo) applied 3 times a day in the treated eye for a week after selective photocoagulation",visual capacity under subjective refractive correction measured in decimal equivalent,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14594,NCT02503527,Blood glucose variability (within patient standard deviation of blood glucose values per day),"Gastro-intestinal intolerance (AEs, complications)",,2015-08,TERMINATED,INTERVENTIONAL,['NA']
14595,NCT01106690,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14596,NCT01843387,The primary objective of the study is to assess the safety and tolerability of MPC therapy,Exploratory assessment of the efficacy of MPC therapy,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14597,NCT04569396,Fatty Liver Index,,,2016-01-12,COMPLETED,OBSERVATIONAL,['NA']
14598,NCT04448496,Mean change of best corrected visual acuity,Changes of total area (mm^2)of nonperfusion within the ETDRS grid using fluorescein angiography and optical coherence tomography angiography,,2020-06-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
14599,NCT04226820,exercise test wilt hand held dynamometer,Blood pressure analysis,,2020-02-01,RECRUITING,INTERVENTIONAL,['NA']
14600,NCT00803296,Incretin effect,Insulin resistance,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
14601,NCT05473494,Diabetic Foot Care Self-Efficacy Scale,Foot Care Behavıor Scale,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
14602,NCT05454176,Cost analysis of CGM,,,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE4']
14603,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",Remission rates of co-morbidities,,2015-09-01,COMPLETED,INTERVENTIONAL,['NA']
14604,NCT01542424,HbA1c (glycosylated haemoglobin),Incidence of adverse events,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14605,NCT01023919,To investigate the difference of surface coverage pattern between diabetic patients and non-diabetic patients after DES (Cypher stent or YINYI stent)implantation,To investigate the differences of surface coverage pattern，malapposition and the incidence of thrombosis between Cypher stent and YINYI in non-diabetic patients,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14606,NCT05124808,Number of participants with composite neonatal morbidity,Infant adiposity,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
14607,NCT03339336,Change from Randomization in Weekly Mean ADP Score,Maximum Observed Concentration (Cmax) at Steady State,,2018-05-31,TERMINATED,INTERVENTIONAL,['PHASE2']
14608,NCT04674332,time needed to achieve glycemic control,,,2019-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14609,NCT05594446,Collection of anthropometric measurements of the foot : European shoe size,,,2022-09-09,COMPLETED,OBSERVATIONAL,['NA']
14610,NCT05069545,Change in time in range (3.9-10 mmol/L),DHSS-HCP(Health Care Professional),,2021-10-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14611,NCT02245659,Average nightly hours of CPAP use,Maternal glucose levels,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14612,NCT03972904,Insulin resistance index changes,Glycated albumin changes,BMI changes,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA']
14613,NCT05439928,Time to Resolution of Metabolic Acidosis,Cost savings,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14614,NCT04243200,Repeat ambulance calls and attendances for hypoglycaemia within 14 days.,"To assess whether the ""Hypos can strike twice"" intervention can reduce repeat ambulance calls and attendance for hypoglycaemia within 30 and 90 days.",,2020-09-14,COMPLETED,OBSERVATIONAL,['NA']
14615,NCT01570660,whole body insulin sensitivity,intrahepatocellular lipid content,,2002-02,COMPLETED,INTERVENTIONAL,['NA']
14616,NCT04017832,Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%),Number of Participants With Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes During Exposure to Trial Product,,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE3']
14617,NCT00276250,The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation,"Number of Subjects With Normal Renal Function, as Measured by Serum Creatinine Levels",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14618,NCT01986231,Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration,Assess Difference in Hepatic Glycogen Measured in the Fed State Before vs. After Repeated Glucagon Administration,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14619,NCT05542420,The proportion of patients prescribed cardiovascular disease (CVD) medications,,,2022-10-19,COMPLETED,OBSERVATIONAL,['NA']
14620,NCT05831384,Overall diabetes distress score,"The The patient's glycated haemoglobin (Hba1c) result, expressed as a %, taken during the standard check-up on the day of admission to hospital result (Hba1c)",,2023-05-11,COMPLETED,OBSERVATIONAL,['NA']
14621,NCT04026165,eGFRcr Slope,eGFRcys Slope,,2019-07-24,COMPLETED,INTERVENTIONAL,['PHASE2']
14622,NCT04238208,Outcome 2 Patient Global Impression of Change score,,,2019-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14623,NCT05641753,Change in Light Transmission Aggregation (LTA) from Baseline,Percent Change in CD8 Cell Population from Baseline,,2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE4']
14624,NCT06273657,HbA1c,Diabetes Treatment Satisfaction,,2024-02-07,RECRUITING,INTERVENTIONAL,['NA']
14625,NCT04467255,Six-minute walk test,Surface multichannel electromyographic variables.,,2018-05-03,RECRUITING,INTERVENTIONAL,['NA']
14626,NCT01603329,Medication Adherence,Demographic Controls for Patients,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
14627,NCT00194506,Hemoglobin A1c,Utilization,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
14628,NCT05659043,Qualitative and Quantitative Mapping ApoA-I Glycation Modification Profiles,Individual ApoA-I Glycation Profiles Variability and Cardiovascular Events,,2017-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14629,NCT01858896,Change in Flow mediated dilation (FMD),,,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14630,NCT01220349,Measurement of the alteration of left ventricular myocardial strain (≤ 18% in absolute value) by echocardiography and the relationship to micro-angiopathy.,"Analyses of this association (alteration of myocardial strain and micro-angiopathy) in relation with the duration of diabetes, and other co-factors such as dyslipidemia, unstable diabetes, and coexisting macro-angiopathy.",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14631,NCT02685384,Change of health insurance status,Change of Medicaid expenditures,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
14632,NCT02958995,Hazard Ratio for Risk of 10 Common Cancers Associated With Diabetes,,,1997-01-01,COMPLETED,OBSERVATIONAL,['NA']
14633,NCT03041571,Patient provider orientation scale score (PPOS),Medical honors students focus group,,2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA']
14634,NCT01005264,Decrease in ulcer size,Complete healing rate at the end of the study,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14635,NCT03322631,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14636,NCT05696015,"Change from baseline discharge telehealth orientation and application of the Diabetes Self-Care Activity Questionnaire (QAD) at within 72 hours after discharge, 10 days after and within 30 days after discharge",,,2023-03-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14637,NCT02538120,Neurovascular microcirculatory response,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14638,NCT03376607,Change in HbA1c,Alcohol intake per week,The differences the HBCPs note from patient to patient,2019-01-11,UNKNOWN,INTERVENTIONAL,['NA']
14639,NCT06059287,Extra-cellular volume fraction,Native T2 mapping,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14640,NCT04523363,Birth Weight,Placental Pathology,,2025-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
14641,NCT02050191,attitudes and perceptions re: feasibility of web portal,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
14642,NCT01468987,Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA) at 26 Weeks,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14643,NCT04242758,Urinary Phthalates concentration,Albumin excretion,,2019-06-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
14644,NCT05128747,Evaluate the effectiveness of one of the most common dietary approches;DASH diet in controlling lipid profile in diabetic patients.,,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
14645,NCT00627783,"Death from all causes, non-fatal myocardial infarction, non-fatal stroke, or heart failure requiring hospitalization or emergency service intervention, measured after a minimum follow-up of 2 years",Unstable angina requiring hospitalization Coronary events Coronary revascularization,,2000-12,TERMINATED,INTERVENTIONAL,['NA']
14646,NCT00262977,Patient reported aspirin use daily or every other day.,,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
14647,NCT00811044,Genes affecting the development of Type 2 diabetes will be identified,Any differences between genetic groups in the metabolism of glucose/sugar will be studied to the extent that the data allow,,2000-10,WITHDRAWN,OBSERVATIONAL,['NA']
14648,NCT06243939,Quality of Life Scale,,,2023-06-06,RECRUITING,INTERVENTIONAL,['NA']
14649,NCT03971838,Enrollment and participation rates in a diabetes prevention intervention,BMI,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
14650,NCT02251067,Change from baseline in albuminuria,Change from baseline in eGFR,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14651,NCT01215994,,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
14652,NCT00775840,The change from Baseline in N-terminal pro-B-type Natriuretic Peptide biomarker.,"Progression of preserved (Left Ventricular Ejection Fraction greater than or equal to 45%) to impaired systolic dysfunction (Left Ventricular Ejection Fraction less than 45%), based on echocardiographic results.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14653,NCT01884792,Blood sugar area under the curve,Accelerometer counts,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
14654,NCT02051842,Oxidative stress,,Oxidative stress,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14655,NCT03444584,Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT,Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within Clinically Significant Hypoglycemic Range to the End of Each Dosing as Measured by CGM,,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14656,NCT01270789,Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2),Glycemic Control,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14657,NCT05601349,Rate of patients who received comprehensive Rehabilitation,,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
14658,NCT05335889,Proportion of participants who are fully compliant with eButton use,,,2022-07-18,COMPLETED,OBSERVATIONAL,['NA']
14659,NCT00617916,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14660,NCT01812590,Pancreatic endocrine function,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
14661,NCT01131091,The primary objective is to determine the effect of renal insufficiency on the pharmacokinetics of a single 400 mg dose of SK 0403.,The secondary objective is to determine the safety and tolerability of a single 400 mg dose of SK 0403 in subjects with renal insufficiency.,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14662,NCT04616027,Fraction of unbound drug in plasma [fu],Incidence of treatment emergent Electrocardiogram [ECG] abnormalities,,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
14663,NCT02908087,Serum C-peptide AUC,Insulin dose,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14664,NCT05166525,90-day hospitalization for any cause,"90-day composite of hospitalization for any cause, emergency department visit for any cause or all-cause death",,2020-04-27,COMPLETED,INTERVENTIONAL,['NA']
14665,NCT01087541,Glycosylated Haemoglobin A1c at 6 Months,Systolic and Diastolic Blood Pressure,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14666,NCT05037695,NGAL values in pre-specified periods,Death,,2021-07-21,UNKNOWN,INTERVENTIONAL,['PHASE4']
14667,NCT00058968,Reduction in average pain severity as measured by an 11-point Likert scale.,Dynamic Allodynia measure to elicit the pain severity to a normally non-painful stimulus.,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14668,NCT01401127,Glucose excursion,Comparison between the two groups of levels of cortisol,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
14669,NCT01512940,Percent excess weight loss,Resolution of comorbidities,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
14670,NCT05588583,Wound progress of the total effect of treatment using Mepilex Up,Evaluation of all reported adverse events and device deficiencies,,2022-10-31,RECRUITING,INTERVENTIONAL,['NA']
14671,NCT01326299,Positive AUC from 0 to 240 minutes for plasma glucose.,Plasma glucose concentrations,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14672,NCT01233622,HbA1c Reduction,Responder Rate,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14673,NCT04132089,20 participants baseline diabetes self-management score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.,Participants who receive a Spark trigger message will login and use capABILITY quicker (time measured in seconds) than those participants who receive Facilitator trigger message.,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14674,NCT01674348,Change in HbA1c from baseline,Number of subjects with adverse events,"Pharmacokinetic profile (Cmax, Tmax and AUC)",2011-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14675,NCT02215642,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14676,NCT00143013,,,,2004-10,UNKNOWN,OBSERVATIONAL,['NA']
14677,NCT00175721,Health care utilization and patient/provider satisfaction (5 years),Patient outcomes (5 years),,2005-12,COMPLETED,INTERVENTIONAL,['NA']
14678,NCT03832725,Remission of Type 2 Diabetes,Metabolom Markers,,2018-03-01,RECRUITING,INTERVENTIONAL,['NA']
14679,NCT02229175,Retinal thickness,Number of injections of bevacizumab needed,,2021-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14680,NCT02547311,Cost effectiveness,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14681,NCT02862067,SGLT2 inhibition effects on cardiorespiratory fitness (CRF).,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
14682,NCT00221208,Muscular strength,"Fasting blood glucose, insulin, lipid concentrations, C-reactive protein, body composition (DEXA), exercise adherence, behaviour change, psychosocial predictors of resistance training, quality of life.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14683,NCT00529165,HbA1c,Quality of Life,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
14684,NCT01560676,BMI,Physical activity,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14685,NCT01970319,Left ventricle mass,RAAS activity,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
14686,NCT05593653,Insomnia Severity Index Score,Fasting Plasma Glucose,,2023-01-06,RECRUITING,INTERVENTIONAL,['PHASE4']
14687,NCT00895440,Identify patients with peripheral neuropathy with the Neuropad indicator test,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
14688,NCT03490773,Difference in immune function in Cpeptide negative and positive,Difference in HLA type in Cpeptide negative and positive groups,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA']
14689,NCT03772067,Clock genes mRNA expression,Body Weight,,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA']
14690,NCT02365233,Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit,,,2013-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
14691,NCT01464346,"Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites","Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With 3-4 Calibrations Per Day, Combined Abdomen and Buttock Insertion","Mean Absolute Relative Difference (MARD) Between Sensor and YSI for Buttock Insertion Site, With Calibration Every 12 Hours",2011-11,COMPLETED,INTERVENTIONAL,['NA']
14692,NCT01458158,Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease,Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease,,2011-10,UNKNOWN,OBSERVATIONAL,['NA']
14693,NCT01199848,Postprandial Insulin Levels for 6 Hours,Strawberry Dose-response Effect on Postprandial Oxidative Stress (Ox-LDL) in Insulin-resistant Men and Women in an Acute Postprandial Paradigm,,2010-09-15,COMPLETED,INTERVENTIONAL,['NA']
14694,NCT00500955,The primary efficacy endpoint was percent change from baseline in ACR after 32 weeks of treatment.,"Secondary efficacy endpoints included change from baseline (visit 3) at week 32 (visit 7) in the following: serum TGF, creatinine clearance (calculated), PAI-1, CRP, IL-6, vWF, sVCAM, fibrinogen, TNF alpha, ET-1, heart rate and blood pressure",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14695,NCT02191644,Lp-PLA2 Activity in PBMC,PBMC metabolites,LDL particle size,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14696,NCT01887067,Change in office systolic & diastolic blood pressure from baseline to 6 months,Change in glucose metabolism,,2013-06,TERMINATED,INTERVENTIONAL,['NA']
14697,NCT01601704,Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE),Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal),,2012-06,TERMINATED,INTERVENTIONAL,['PHASE3']
14698,NCT00760448,"Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise",,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14699,NCT02653209,On treatment HbA1c in patients with an eGFR <90 mls/min/1.73m2 compared to patients with an eGFR >90 mls/min/1.73m2.,HbA1c on therapy against predefined test of gender heterogeneity,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14700,NCT03883503,Difference in copeptin levels between the interventions,Difference in Response to lottery Experiment before and after the intervention,,2019-02-25,COMPLETED,INTERVENTIONAL,['NA']
14701,NCT05221580,Change in Glycosylated Haemoglobin (HbA1c),Treatment satisfaction questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQ)),,2022-03-18,COMPLETED,OBSERVATIONAL,['NA']
14702,NCT02786953,Sleep Duration: 3 Months,Adherence (Self Care Inventory) Teen,,2017-10-19,COMPLETED,INTERVENTIONAL,['NA']
14703,NCT00698269,Change in HbA1c,Number of adverse drug reactions (ADR),,2008-02,COMPLETED,OBSERVATIONAL,['NA']
14704,NCT02577874,Blood sugar response measured by 7 finger prick blood samples,,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
14705,NCT00858676,"sudden cardiac death, fatal or non-fatal myocardial infarction, coronary revascularization, admission due to heart failure, fatal or non-fatal stroke",,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
14706,NCT06295289,TIR,MBG,postoperative infection,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
14707,NCT00529594,The group taking the etoricoxib feel less pain then the group taking placebo,,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
14708,NCT01611363,"Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM","Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia",,2011-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
14709,NCT01729546,Evaluation of System Accuracy according to ISO 15197,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
14710,NCT01197963,Serial Postoperative HgA1c levels,Serial Postoperative Lipid Profiles levels,,2010-09,TERMINATED,INTERVENTIONAL,['NA']
14711,NCT05387434,Change in Body Weight From 0-6 Months,Average Program Attendance,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA']
14712,NCT03840161,CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment.,Treatment satisfaction questionnaire,,2018-07-16,COMPLETED,OBSERVATIONAL,['NA']
14713,NCT01726816,A/C ratio,P/C ratio,c-peptide,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14714,NCT04339283,Change form Baseline Pulse on the 28th day,Change from Baseline Body Mass Index on the 28th day,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
14715,NCT02790931,Fast gait speed,EQ-5D score of the quality of life,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14716,NCT06182891,Evaluation of the biomarkers of the epithelial-mesenchymal transition process,Evaluation of adverse event,,2021-10-30,COMPLETED,INTERVENTIONAL,['NA']
14717,NCT04984421,Change in fidelity (R) assessed by questionnaire to parents,Change in parents' risk of type 2 diabetes assessed by FINDRISC questionnaire,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14718,NCT00132132,Percentage of Participants With BMI Reduction,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
14719,NCT02887625,HbA1c,change in body weight,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
14720,NCT02018497,"Relationship between blood pressure group, adaptability group and comorbidities","Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)",Description of the blood pressure hemodynamic profile at a medical office and their prognostic implications.,1995-01,RECRUITING,OBSERVATIONAL,['NA']
14721,NCT00786890,"Cardiovascular risk factors: anthroprometric parameters, blood pressure and lipid profiles",,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
14722,NCT04750837,size of the ulcer reduce to zero cm,,,2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2']
14723,NCT02743598,Neurocognitive performance- change in domain averages on a standard neuropsychological profile,Change from baseline serum LDL,,2016-09,TERMINATED,INTERVENTIONAL,['PHASE4']
14724,NCT00946504,Bioequivalence based on AUC and Cmax,,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14725,NCT02325531,"Rate Ratio of the Percent of the Clinics' Patients ""Indicated"" for ACE/ARB With Guideline-appropriate Prescription for ACE/ARBs",Rate Ratio of the Change in the Percent of the Clinic's 'Indicated' Patients With Correct Intensity Statin Prescribing,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
14726,NCT04070963,Diabetes incidence,Association of HbA1C levels with post operative complications,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
14727,NCT01681160,change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 3days and change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 6 days,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
14728,NCT01571297,Effect of RM-131 on gastric emptying time,Safety and tolerability of RM-131,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14729,NCT01076829,The protocol is designed to study the effect of spice on MDA production in hamburg meat,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
14730,NCT00718198,Mean Inpatient Glucose,Percent of patient-days with severe hypoglycemia,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14731,NCT00553787,Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF,,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14732,NCT00541606,"Primary outcomes included the achievement of targets for A1c (< or = 7%), LDL cholesterol (< or = 100 mg/dL) and blood pressure (< or = 130/80), changes in quality of life as measured by the SF-36 Health Survey, and patient satisfaction.",Secondary outcomes included diabetes-related hospitalizations and acute care visits during the study period for both the intervention and control groups.,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
14733,NCT03447340,Healthy food intake,Diastolic Blood pressure,,2016-11-09,COMPLETED,INTERVENTIONAL,['NA']
14734,NCT01891786,Coronary heart disease 10 year risk,Impact of receiving genetic results,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
14735,NCT03513874,Change in C-peptide,Adverse effects,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14736,NCT03380338,Change in capillary recruitment,Changes in continous cardiovascular monitoring,,2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
14737,NCT04678661,Change From Baseline in Glycemic Control at 3 Months,Number of Participants Who Experienced Severe Hypoglycemic Events.,Type of Escalation of Care,2021-02-15,TERMINATED,INTERVENTIONAL,['NA']
14738,NCT05378295,Peripheral insulin sensitivity,body weight,,2021-11-05,RECRUITING,INTERVENTIONAL,['NA']
14739,NCT05566197,Body Fat Percentage,,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
14740,NCT05545657,Baseline brain functional MRI scan,Longitudinal changes of brain functional MRI scan,,2022-10-18,RECRUITING,OBSERVATIONAL,['NA']
14741,NCT00110435,Percent reduction in LDL-C from baseline after 6 weeks of treatment,Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14742,NCT05156021,Changes in Intraocular Pressure from baseline to 12 months after surgery,Changes in Ocular and Systemic Adverse Events from baseline to 12 months after surgery,,2021-12-12,COMPLETED,INTERVENTIONAL,['NA']
14743,NCT05730582,Cost effectiveness as measured by cost per case found,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14744,NCT02053584,BGMS Accuracy Assessment When Used by Layperson,Evaluation of the Ease of Use of the Dario BGMS by the Lay-person,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14745,NCT02169999,Patients' change in knowledge about diabetes and its treatments,Patients' Change in Decisional Conflict Scores,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
14746,NCT03722199,FMD -Flow mediated dilatation test,blood pressure analysis,exercise test with hand held dynamometer,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
14747,NCT03298009,Change to be observed with canagliflozin on whole-body partitioning.,plasma NEFA turnover,body composition,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
14748,NCT03406910,Risk for Type 2 Diabetes (T2D) in subjects who consume different frequencies/amounts of eggs and meat.,,,2015-02-13,COMPLETED,OBSERVATIONAL,['NA']
14749,NCT03499223,Change from baseline in BCVA,Withdrawal from repeat study treatment and reason for withdrawal,,2018-04-20,COMPLETED,INTERVENTIONAL,['PHASE2']
14750,NCT04810780,Primery Effectivness Endpoint,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
14751,NCT06185465,Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 7th day of treatment in Group A and Group B,Detection rate of bacteria/drug-resistant bacteria on the wound and their correlation with the detection rate of bacterial biofilm,,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
14752,NCT02234947,Ultrasound of Pancreatic volume,Blood Test will be done for pancreatic function and diabetes markers,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
14753,NCT03231839,change in glucose metabolism,body composition,,2009-02-01,COMPLETED,INTERVENTIONAL,['NA']
14754,NCT02960659,Change in Absolute Gluconeogenesis From Baseline to 12 Weeks,Change in Palmitate Turnover From Baseline to 12 Weeks,,2017-05-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14755,NCT04150926,Insulin concentration,,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA']
14756,NCT03084822,Physical activity self-efficacy (using Self-Efficacy and Exercise Habits Survey),Cardiovascular health knowledge,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
14757,NCT00252733,Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14758,NCT03943940,Adverse events,Insulin dose and drug dosage,,2019-04-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14759,NCT04572165,Occurrence of first time malignant neoplasm of pancreas,,,2021-01-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14760,NCT03824002,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change from Baseline Pulse Wave Velocity at 3 and 9 months,,2017-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14761,NCT03862963,Usage of diabetes medications,Waist circumference,,2006-06-01,COMPLETED,INTERVENTIONAL,['NA']
14762,NCT00172796,,,,2005-04,UNKNOWN,OBSERVATIONAL,['NA']
14763,NCT03188484,Atrial fibrillation (AF) diagnosis,,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
14764,NCT05620225,Comparison of therapy-related AEs between the 2 Study arms,Neurological Exam - percentage of treatment arm with a change in neurological status,,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14765,NCT05191160,Liver fat,Glucose tolerance - 2-hour plasma glucose (2h-PG),Adherence biomarkers - Objective biomarkers of SSBs (urinary fructose),2021-11-02,RECRUITING,INTERVENTIONAL,['NA']
14766,NCT00272831,Fatal or severe bleeding,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14767,NCT05930210,The ulcer complete closure rate,The proportion of subjects with complete ulcer closure,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3']
14768,NCT02096705,Adjusted Mean Change in HbA1c From Baseline to Week 24,Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24,,2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE3']
14769,NCT02880592,Time to initial closure of diabetic foot ulcer,Incidence of adverse events,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14770,NCT03316508,Change of Copeptin concentrations,Complexity of procedures,,2017-06-14,COMPLETED,OBSERVATIONAL,['NA']
14771,NCT03973931,Medication adherence,Healthcare utilization costs (Costs),,2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14772,NCT02716610,Maximum glucose infusion rate (GIRmax),Bioavailability,,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14773,NCT05973799,Glucose infusion rate,Peripheral glucose uptake,Growth Hormone,2019-10-10,RECRUITING,INTERVENTIONAL,['NA']
14774,NCT01396941,Insulin sensitivity,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
14775,NCT04823208,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
14776,NCT00828425,evolution of diabetic retinopathy,concomitant medication,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
14777,NCT02139254,Number of women with gestational diabetes,Delivery Mode,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
14778,NCT06318442,Difference in Glucose tolerance,Difference in insulin sensitivity,Tissue specific changes in AMPK determined from adipose and muscle biopsies,2024-04-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14779,NCT05256706,Changes in prescriptions of participants with type 2 diabetes (T2D) in concordance with SSCVD results over a 6-month period,Change in medication possession ratio,,2022-02-03,COMPLETED,INTERVENTIONAL,['NA']
14780,NCT00489190,Dynamics compared with the initial level of glycemia and insulin dosages.,"Evaluation of frequency of glycemia episodes. Also undesirable events, Influence on indexes of general clinical analysis of blood and biochemical analysis of blood.",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14781,NCT05228561,The effect of mobile application supported diabetes education on blood sugar,,,2022-03-15,UNKNOWN,INTERVENTIONAL,['NA']
14782,NCT00312780,Reduction in albumin excretion relative to creatinine,Pharmacokinetics and renal elimination,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14783,NCT00071526,"Plasma, neutrophil and RBC Vitamin C concentrates",Determine the renal threshold and relative bioavailability for vitamin C,,2006-04-11,RECRUITING,OBSERVATIONAL,['NA']
14784,NCT02345057,Change from baseline in urinary albumin to creatine ratio (UACR),Change in serum potassium,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14785,NCT00853619,Compliance with guideline,Patient outcomes,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
14786,NCT00351767,Skin re-epithelialization without drainage or dressing requirements,Number of debridements performed,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14787,NCT01503008,Self-efficacy,Device-related and -unrelated adverse events,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
14788,NCT01731808,feasibility of an intensive nurse led education program,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
14789,NCT00850239,"Primary objective is to demonstrate the efficacy of dutogliptin, as evidenced by placebo-corrected changes in HbA1c relative to baseline.",• Demonstrate changes in fasting plasma glucose,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3']
14790,NCT05083013,Need for ventilatory support,Incidence of other complications,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
14791,NCT00301249,,,,1999-10,COMPLETED,OBSERVATIONAL,['NA']
14792,NCT01101867,Mean Glucose,"1,5-anhydroglucitol Change",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14793,NCT04067999,Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol),Patient completed the study under treatment with semaglutide (yes/no),,2019-08-05,COMPLETED,OBSERVATIONAL,['NA']
14794,NCT02633722,Postprandial glucose response to meal test,Glycaemic response over 1 week by continuous glucose monitoring,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
14795,NCT02361931,Number of participants with the reduction of wound area by 75%$ or more,Recurrence of closed wounds,,2016-03-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14796,NCT02280486,Proportion of subjects achieving glycemic response defined as Glycosylated hemoglobin (HbA1c) < 7.0%,"Safety and tolerability of saxagliptin vs. glimepiride measured by adverse events, serious adverse events (SAEs); laboratory assessments (biochemistry, lipids, blood and urine routine tests",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14797,NCT03813927,Wound healing,Vitamin D blod level status,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
14798,NCT05063253,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14799,NCT01640873,Fasting Plasma Glucose (FPG),Change From Baseline at 2 Hours Oral Glucose Tolerance Test,,2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
14800,NCT04689685,Accuracy of the RADAR model: Diagnostic accuracy of wearable based physiological data in detecting dysglycemia (glucose > 13.9mmol/L and glucose < 3.9 mmol/L) quantified as the area under the receiver operator characteristics curve (AUC-ROC),24. Analysis of user requirements for smartwatch based dysglycemia warning systems,,2021-02-19,COMPLETED,OBSERVATIONAL,['NA']
14801,NCT01194882,Change in glycosylated hemoglobin (HbA1c),Antibody assessments (anti-Insulin antibodies),,2010-11-16,COMPLETED,INTERVENTIONAL,['PHASE3']
14802,NCT02737527,Difference in Procedure time (I1),A 5-pointed Likert satisfaction scale related to the procedure,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
14803,NCT04657783,Major adverse cardiovascular events (MACE),All cause mortality,,2020-06-10,RECRUITING,OBSERVATIONAL,['NA']
14804,NCT06268145,ECC5004 PK parameters: tmax,ECC5004 PK parameters: AUC(extr),,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE1']
14805,NCT01755351,The influence of diabetes distress on treatment sdherence,,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
14806,NCT01174303,Area under the Glucose Infusion Rate curve (only for NN5401),Area under the glucose infusion rate curve (only for biphasic insulin aspart 30),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14807,NCT00381992,"The prevalence of hepatitis B, hepatitis C, hypertension, hyperlipidemia, diabetes and obesity, HIV, N. gonorrhoeae, and C. trachomatis",,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
14808,NCT05440591,Carotid Femoral Pulse Wave Velocity,Advanced glycation end products,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14809,NCT01316341,Fasting Plasma Glucose (FPG) Change From Baseline,"Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14810,NCT00612625,insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min,The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
14811,NCT04689958,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14812,NCT02402933,Number of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events Through the Nasal Score Questionnaire,Change in Blood Glucose Level Over Time,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14813,NCT05272059,Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs),Time to Reach Maximum Blood Concentrations (Tmax) of MHS552,,2023-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14814,NCT00718874,decreased insulin secretion,decreased markers of inflammation; decreased estradiol concentration,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
14815,NCT00472953,To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections,Preprandial Insulin Doses,,2007-05-15,TERMINATED,INTERVENTIONAL,['PHASE3']
14816,NCT03658512,Glycemic control (HbA1C),,Nasal and skin swab,2018-08-13,RECRUITING,OBSERVATIONAL,['NA']
14817,NCT00922649,Number of daily basal rates at Week 16,Change from baseline to week 16 in Patient Reported Outcomes (PROs),,2008-02-01,COMPLETED,INTERVENTIONAL,['NA']
14818,NCT04332302,Genotyping of HLA (rs2854275),Change from Baseline Balance at 12 weeks,,2020-01-15,UNKNOWN,INTERVENTIONAL,['NA']
14819,NCT00332085,Hemoglobin A1c,Oral Glucose Tolerance Test,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1']
14820,NCT00042458,- To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.,- To examine the pattern of daily insulin use over the course of the study.,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14821,NCT05691738,Falling Risk,Diaposan (Vibration) Evaluation,,2022-10-03,COMPLETED,INTERVENTIONAL,['NA']
14822,NCT00454233,"Safety and tolerability (adverse events; biochemical, hematological and urine analysis tests; vital signs, 12-lead ECG, physical examination)","Efficacy and pharmacodynamics (change in HbA1c and fasting plasma glucose; change in urinary glucose excretion; plasma levels of YM543; C-peptide, insulin, fructosamine, non-esterified fatty acids, triglyceride, cholesterol-panel)",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14823,NCT04902638,Hyperglycaemia time,,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA']
14824,NCT02694796,Achievement of Physical activity recommendations,Captured physical activity,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
14825,NCT03784703,leptin (ng/mL),Triglycerides,,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14826,NCT03593135,HbA1c (Glycosylated Hemoglobin),fasting lipid profile,,2017-07-15,COMPLETED,INTERVENTIONAL,['NA']
14827,NCT03769870,"AUCτ,ss(Area under the concentration-time curve at steady state)",,,2019-01-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14828,NCT06065098,Fidelity summary score,Sustainability (Participants),Difference in quality of life (QoL),2023-11-18,RECRUITING,INTERVENTIONAL,['NA']
14829,NCT02429024,A1c change from baseline in subjects using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system compared to subjects using only the OneTouch Verio® Flex (without Bluetooth) for 24 weeks.,OneTouch Reveal Mobile APP interaction and usage via APP analytics over 24wks.,Healthcare efficiency survey by the HCP,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14830,NCT00005380,,,,1993-09,COMPLETED,OBSERVATIONAL,['NA']
14831,NCT02189395,difference in glycemic control between treatment groups as measured by the mean daily blood glucose,number of hypoglycemic events,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
14832,NCT01736930,Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 3,Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 3,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14833,NCT01076478,To determine the relationship of peripheral neuropathy with peripheral vascular disease using the WIQ and the ABI from baseline to W12.,To assess the safety of Cilostazol therapy.,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14834,NCT05791188,Serum chloride,,,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14835,NCT05644730,Primary Efficacy Outcome,Percent Time in the Desired Control Range,Glucose readings from CGM's versus from blood,2022-11-08,RECRUITING,INTERVENTIONAL,['NA']
14836,NCT02099409,Time spent in normal glucose range ( mg/dl),time spent in high glucose range (>180mg/dl),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14837,NCT02347709,Measure the degree of loss of epidermal nerve fibers near a lower extremity diabetic wound using Intra-epidermal Nerve Fiber Density analysis.,,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA']
14838,NCT01648296,The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With [11C]Palmitate and Calculation of Human Dosimetry.,To Determine Human Dosimetry Based on the Human Biodistribution of [18F](+/-)NOS in Both Normal Healthy Volunteers and Dilated Non-ischemic Cardiomyopathy Patients.,,2012-09-13,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14839,NCT05309850,Incidence of type 2 diabetes,,,2022-04-05,RECRUITING,INTERVENTIONAL,['NA']
14840,NCT03370497,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
14841,NCT02869659,Chang in Epigengene score (and related individual transcriptional and methylation measures),change in homeostatic model assessment (HOMA) estimates of insulin resistance,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
14842,NCT04279587,Change in Hemoglobin A1c,Change in Behavioral Pediatrics Feeding Assessment,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14843,NCT00278980,Change in sensory nerve conduction velocity from baseline to 6 mo of treatment,- Safety and tolerability of C-peptide,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14844,NCT05760456,Change from Baseline at Week 12 in Hemoglobin A1c (HbA1c),Safety assessments,,2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14845,NCT03479866,Hunger and appetite assessment,,Carotid plaque,2018-06-04,UNKNOWN,INTERVENTIONAL,['NA']
14846,NCT03864562,Gastric emptying rate,Recruitment rate,,2019-03-01,COMPLETED,OBSERVATIONAL,['NA']
14847,NCT04200313,HbA1c,Other Secondary Efficacy Endpoint: Mean Participant-reported Grams of Carbohydrate Taken Specifically to Prevent or Treat Hypoglycemic Events Per 24 Hours,Safety Outcome Measure: Worsening of HbA1c by >0.5%,2020-03-31,COMPLETED,INTERVENTIONAL,['NA']
14848,NCT00123136,improve quality of life,"serial changes in EDX, QST, autonomic functions, biopsy",,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
14849,NCT04243174,"Feasibility of mobile phone text messaging intervention for people with T2DM: Number of Participants recruited, completed the study, dropped out",Self-report questionnaire (International Physical Activity Questionnaire - IPAQ),,2020-01-23,COMPLETED,INTERVENTIONAL,['NA']
14850,NCT00915200,Urinary Albumin excretion,tolerance and safety,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14851,NCT04619303,Difference in best corrected visual acuity change between treatment arms,Adverse Events,,2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14852,NCT00676819,Glucose infusion rate,"Cmax,ins: the maximal serum insulin (or serum insulin aspart) concentration",,2002-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14853,NCT03182972,Medication reconciliation: Percentage unreconciled medications,,,2016-08-02,COMPLETED,INTERVENTIONAL,['NA']
14854,NCT02409238,Primary cognitive endpoint (Neuropsychological Performance),Secondary adherence endpoints Fasting Lipids,,2015-03-11,TERMINATED,INTERVENTIONAL,['PHASE4']
14855,NCT03131687,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response,Pharmacokinetics (PK): Model Predicted Concentration at Steady State (Css) of Tirzepatide,,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE2']
14856,NCT05628090,Proportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 6th month,Proportion of patients on Toujeo® who switched to other therapy at the end of 6th month,,2022-11-30,COMPLETED,OBSERVATIONAL,['NA']
14857,NCT02996539,Association between HRV and renal function (eGFR and UACR),Clinical characteristics of patients,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
14858,NCT00129259,Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT),Change in Average Total Insulin Dose Per Body Weight,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14859,NCT01150955,Metabolic parameters,Pathways of substrate metabolism.,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
14860,NCT03816280,Central venous oxygen saturation,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14861,NCT04420845,Change in mean HbA1c (NGSP%) from baseline to 12 weeks post-intervention,Change in diabetes-related quality of life from baseline to 12 weeks post-intervention,,2022-03-25,WITHDRAWN,INTERVENTIONAL,['NA']
14862,NCT02451436,Sleep Duration,hs-CRP,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14863,NCT00734591,Rate of Primary Lung Cancer Mortality,Rate of Primary Lung Cancer Diagnosis,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
14864,NCT04134143,Number of participants with adverse events through study completion,,,2019-11-07,TERMINATED,INTERVENTIONAL,['PHASE1']
14865,NCT03046927,Residual beta-cell function (RBCF),Duration of Partial Clinical Remission (PCR),,2017-10-19,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14866,NCT00085969,Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28,Change in postprandial blood glucose concentrations from Baseline to Day 28,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14867,NCT01060241,The primary endpoint is the A1c level or the change in A1c level,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",,2010-02,SUSPENDED,INTERVENTIONAL,['NA']
14868,NCT00847327,Glycemic variability,Hemoglobin A1C,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
14869,NCT02299050,Glucose Metabolism During Mixed Meal Tolerance Test,Arterial Stiffness (AS),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14870,NCT05344859,Change in Hemoglobin A1C level between screening and 6 months,,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
14871,NCT06242548,Ketonemia variation among groups over time during mountains outings,weight measurements for each of the 4 mountains outings,,2023-06-02,COMPLETED,INTERVENTIONAL,['NA']
14872,NCT00827853,Rate of binary restenosis as determined by duplex ultrasound.,Resting ankle-brachial index,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
14873,NCT03061214,Change in HbA1c,Occurence of Cross Reacting Antibodies With in Vitro Neutralising Effect to Endogenous GLP-1 (Yes/no),,2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE3']
14874,NCT03281083,Liver fat content,Abdominal fat,,2014-03-28,TERMINATED,INTERVENTIONAL,['PHASE2']
14875,NCT01081834,Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy),Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14876,NCT01135927,Area under the NN1250 GIR (glucose infusion rate) curve,Area under the serum insulin detemir concentration-time curve,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14877,NCT04074954,Amount of activity conducted by the patient after receiving surgery,,,2023-03-23,WITHDRAWN,OBSERVATIONAL,['NA']
14878,NCT02643771,Percentage of bleeding on probing,Clinical attachment level (mm),,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14879,NCT01221467,Primary Efficacy Outcome,Secondary outcomes,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14880,NCT00434954,Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode),Patient Reported Outcomes: Quality of Life (SF-12),,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14881,NCT03447080,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,,2017-06-02,COMPLETED,INTERVENTIONAL,['NA']
14882,NCT04564391,change of fasting insulin sensitivity in mixed-meal test,change of urea concentration in serum(mmol/l),change in uric Acid concentration in Serum (µmol/l),2020-09-21,RECRUITING,INTERVENTIONAL,['NA']
14883,NCT03273881,Neonatal hypoglycemia,NICU admission,,2017-10-31,RECRUITING,INTERVENTIONAL,['NA']
14884,NCT01386801,,,,2009-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14885,NCT05683990,"Number of Clinically Significant Abnormal Results From Laboratory measurements, including hematology, clinical chemistry, metabolic status parameters (fasting C-peptide, HbA1c, fasting glucose) and urine analysis",Variables that indicate effects on the immune system,,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE2']
14886,NCT02089438,Postprandial glucose,Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14887,NCT04628481,Change from baseline in HbA1c,Estimated Glucose Disposal Rate (eGDR),,2020-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14888,NCT04929379,Baseline-adjusted levels of serum biomarkers of increased ESKD risk at the end of the drug wash-out period,Levels of serum biomarkers of increased ESKD risk at the end of treatment,,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2']
14889,NCT02544568,Maximum plasma concentration [Cmax] of glucose and triglycerides,Maximum plasma concentration [Cmax] of glucagon,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
14890,NCT02334137,Change from Baseline in Patient Knowledge about Diabetes at 3 months (via multiple-choice surveys),Change from Baseline in Patient Knowledge about Diabetes Immediately after using Educational Services (via multiple-choice surveys),,2014-11,COMPLETED,OBSERVATIONAL,['NA']
14891,NCT01707784,Markers of stress,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
14892,NCT03343730,Rate of Diabetic Retinopathy Detection,,,2018-02-27,UNKNOWN,INTERVENTIONAL,['NA']
14893,NCT00312104,HbA1c,Hypoglycaemia,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14894,NCT00501072,Clinical effectiveness: percentage of time spent in euglycaemia,"Incidence of hypoglycaemia; Number of SMBG performed, Number of adjustments of insulin therapy, Patient satisfaction, agreement of paired SMBG and RT-CGMS measurements.",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
14895,NCT03135535,Change in Skin Perfusion From Baseline to 4 Weeks,Change in Stride Velocity From Baseline to 4-week,,2017-05-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14896,NCT01054118,GLP-1 levels after a standard meal,Assess incremental glucose changes after a meal tolerance test (MTT),,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14897,NCT01112709,Muscular Strength,Body Composition,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14898,NCT02476760,Hospitalization for acute pancreatitis,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
14899,NCT05505773,To evaluate the systemic metabolic rate of diabetic patients before and after bariatric gastric bypass surgery using the Breezing® device.,,,2017-01-06,COMPLETED,OBSERVATIONAL,['NA']
14900,NCT05237128,Change in HbA1c,Change in HbA1c,,2022-03-22,RECRUITING,INTERVENTIONAL,['NA']
14901,NCT03835312,Concentration of serum C-peptide,Occurrence of graft versus host disease,,2019-02-20,RECRUITING,INTERVENTIONAL,['NA']
14902,NCT03609294,AUClast,,,2018-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
14903,NCT02034045,Hospital admissions per patient,Cost Effectiveness,Trial Fidelity and Safety,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14904,NCT01841697,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment,,2013-06-13,COMPLETED,INTERVENTIONAL,['PHASE3']
14905,NCT01782261,Increase of regulatory FOXP3+ T cells,Immunophenotyping,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14906,NCT01680978,Cardiac energetics: Change in PCr/ATP ratio using phosphorus magnetic resonance spectroscopy (MRS),Change in cardiac/hepatic triglyceride content assessed my MRS,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14907,NCT06147583,Sensitivity,False positive per day,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14908,NCT02930044,Duration of intravenous insulin infusion,Incidence of low serum glucose (hypoglycemia) within 24 hours,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
14909,NCT01277432,Depression and psychological well-being,Quality of life,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
14910,NCT03709108,Safety and feasibility of the SI-informed bolus calculator: Low Blood Glucose Index,,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
14911,NCT00857558,changes in HbA1C from baseline,adverse event,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14912,NCT00599885,Comparison of telmisartan and valsartan on neointima volume with IVUS at 8 months after zotarolimus-eluting stent implantation.,"Comparison of telmisartan and valsartan on the levels of RBP-4 and inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14913,NCT00781534,,,,2003-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14914,NCT01578382,Martorell HYTILU and calciphylaxis show both decreased tissue protection mechanisms against tissue calcification,Martorell hypertensive ischemic leg ulcer and calciphylaxis are both characterized by non-infectious inflammation,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
14915,NCT03997396,Changes in Gesell developmental scale test results within 6 months of age,Changes in percentage of RBC width distribution(RDW%),,2019-06-01,RECRUITING,OBSERVATIONAL,['NA']
14916,NCT05773677,incidence of maternal obstetric complications:,differences in early or late enrollment of patients,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
14917,NCT01468675,Number of Subjects Who Discussed Disease Risk With Primary Care Provider,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
14918,NCT01517490,"Changes in visual acuity, diabetic retinopathy grading and OCT",,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
14919,NCT03449251,Sub-study 5: Change in hand vein diameter after relaxin infusion in healthy participants,Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (TNF alpha),,2018-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14920,NCT04745780,Glycated hemoglobin,Hypoglycemic events,,2021-02-10,COMPLETED,INTERVENTIONAL,['NA']
14921,NCT05543850,Time in range,Satisfaction,Glucagon dose,2022-10-28,COMPLETED,INTERVENTIONAL,['NA']
14922,NCT04079881,AUC Postprandial Glucagon,AUC Postprandial Glucose,,2020-02-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14923,NCT01048268,The difference in glucagon secretion quantified as the difference in plasma glucagon concentration and incremental baseline-subtracted area under the curve (AUC) for plasma glucagon,The difference between the amount of infused glucose and the insulin responses,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14924,NCT06310356,a composite of pregnancy outcomes,day glucose time in range >180mg/dl,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14925,NCT02435862,Observation of pharmacologic induction of PVD.,The secondary endpoints of this study is the observation of a complete stage 4 PVD to the equator including vitreopapillary release as seen by B-scan ultrasound and confirmed by OCT where possible by study day 90 as determined by the reading center.,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14926,NCT01469104,Change in plasma glucose concentration,Change in serum insulin concentrations,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
14927,NCT01425359,Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment,Patient's Global Impression of Change (PGIC) Scale Score,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14928,NCT00072891,,,,na,COMPLETED,INTERVENTIONAL,['NA']
14929,NCT06137586,Total glucagon response,Difference in heart rate,,2022-08-10,RECRUITING,INTERVENTIONAL,['NA']
14930,NCT00819091,Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18,Change From Baseline in Fasting Plasma Glucose at Week 12,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14931,NCT06237322,Blood Glucose Measurement taken with alternate PPG software device,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14932,NCT00997178,Change in Glycosylated Hemoglobin (HbA1c),Need for Diabetes Rescue Therapy,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14933,NCT01912170,Fasting insulin,"birth weight, length of children","blood lipids, inflammatory markers",2013-08,UNKNOWN,INTERVENTIONAL,['NA']
14934,NCT05946785,microvascular insulin-mediated dilation,endothelial cell insulin-stimulated eNOS phosphorylation,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14935,NCT00013975,,,,2001-03,COMPLETED,OBSERVATIONAL,['NA']
14936,NCT03297762,CGM use,Hgb A1c,,2018-05-07,TERMINATED,INTERVENTIONAL,['NA']
14937,NCT01542242,Hemoglobin A1C,Total Body Adipose Tissue Distribution (whole body Computed Tomography),,2012-02,TERMINATED,INTERVENTIONAL,['PHASE4']
14938,NCT03276312,Healing time,Quality of Life using the Short Form 36 (SF-36) questionnaire,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
14939,NCT00105755,Reduce the risk for lower extremity ulceration and amputation in veterans at high risk for these complications.; Incidence of diabetic foot ulcers over 18 months. Incidence of foot infections over 18 months. Incidence of Charcot fractures.,Improve quality of life. Health Related Quality of Life (change over 18 months),,2003-01,COMPLETED,INTERVENTIONAL,['NA']
14940,NCT02440061,β-cell function (DI-meal),,,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14941,NCT03629704,28 day prognosis,Incidence of hypoglycemia,,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA']
14942,NCT02159638,Difference between the two CGM systems compared to capillary glucose value,Evaluation of two CGM systems from questionnaire,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
14943,NCT05145673,Variation of blood glucose maximum concentration,Antioxidant activity,,2016-01-19,COMPLETED,INTERVENTIONAL,['NA']
14944,NCT00313313,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14945,NCT01599442,duration of survival without major amputation,total mortality,,2010-06,TERMINATED,OBSERVATIONAL,['NA']
14946,NCT02561130,Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group,Number of Participants With Severe Hypoglycemic Episodes,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14947,NCT05133973,Incidence and severity of device related adverse events (ADE),User satisfaction questionnaire score,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
14948,NCT04554199,Cognitive function assessment in controlled type 2 diabetic patients wearing RPD.,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
14949,NCT01495052,changes from baseline in insulin resistance Hematology index detection Hematology index detection Hematology index detection Hematology index detection Hematology index detection,changes from baseline in WHR,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
14950,NCT04787952,The potential associations between BAT activity and transcriptome profile,The potential associations between BAT activity and fT4 concentrations,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
14951,NCT05566717,Primary Endpoint,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
14952,NCT04521049,to classify renal responders to saxagliptin using tubular markers,,,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14953,NCT01786408,Non-Inferiority of Analyte Levels,,,2013-03,WITHDRAWN,INTERVENTIONAL,['NA']
14954,NCT06079463,Beck Anxiety Scale,World Health Organization Quality of Life Scale,,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14955,NCT04999722,Change from Baseline Glycated hemoglobin at 12 months,Change from Baseline Diabetic nephropathy at 12 months,,2021-08-25,UNKNOWN,INTERVENTIONAL,['NA']
14956,NCT05737576,Area under the concentration-time curve (AUC0-0.5h),Incidence and severity of adverse events (AEs),,2023-03-20,COMPLETED,INTERVENTIONAL,['PHASE1']
14957,NCT02696252,"proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL",,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14958,NCT05816057,The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment.,Change From Baseline to Week 32 in Fasting Blood Lipids: Total Cholesterol、Low-density Lipoprotein (LDL) Cholesterol、 High-density Lipoprotein (HDL) Cholesterol 、Triglycerides (Ratio to Baseline).,,2022-07-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14959,NCT01710540,"Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2",Safety profile,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14960,NCT04201600,Aggregate Language Score,Instrumental Activities of Daily Living (IADL) total score,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
14961,NCT04233229,Time in range (TIR),Body Weight,,2019-12-30,COMPLETED,INTERVENTIONAL,['NA']
14962,NCT02893306,Changes in insulin pancreatic reserve,Changes in insulin requirement,Number of patients with grade 3 through grade 5 adverse events (CTCAE v3.0),2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14963,NCT00838825,resource utilization,metabolic outcome,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14964,NCT03648424,Composite Cardiovascular (CV) Outcome,,,2011-05-01,COMPLETED,OBSERVATIONAL,['NA']
14965,NCT01047982,difference in HOMA values,"incidence of pregnancy complications: hypertension, preterm delivery. macrosomia, shoulder dystocia, etc.",,2010-03,COMPLETED,INTERVENTIONAL,['NA']
14966,NCT01745900,Continuing validation of near infrared spectroscopy-based glucose meter algorithm,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
14967,NCT05512871,Mobile health application feasibility,Change in intake of meals,,2022-09-19,COMPLETED,INTERVENTIONAL,['NA']
14968,NCT03958838,Change from Baseline HbA1c and at 12 months,Change in Peer Support Engagement and Health Care Utilization and 12 months,,2019-05-25,COMPLETED,INTERVENTIONAL,['NA']
14969,NCT02970344,Change in psychological distress,Assessing change in Physical Activity,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
14970,NCT01235260,The number and rate of deaths from cancer in patients who have used becaplermin and patients who have not used not used becaplermin.,The number of becaplermin doses associated with risk of incident cancer and/or cancer death.,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
14971,NCT00608439,Total Symptom Score,Quantitative Sensory Test,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14972,NCT05921019,the Brief Pain Inventory-Short Form,Nerve conduction velocity (NCV),,2022-08-31,RECRUITING,INTERVENTIONAL,['NA']
14973,NCT01501032,Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14974,NCT03495102,Change in Hemoglobin A1c (HbA1c) From Baseline,Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State,,2018-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14975,NCT02274740,Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min),Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction,,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14976,NCT01358435,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14977,NCT05545800,Amplitude of glycemic excursions,Percentage of adverse events,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
14978,NCT03018028,Change in HbA1c (Week 26),Change From Baseline in DTR-QOL: Sub-domains,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14979,NCT04502212,Change From Baseline in Rate of Glucose Disappearance (Rd),Incidence of Adverse Device Effects (ADEs) With a Severity Score of 5: Treatment Emergent Adverse Events (TEAEs) by System Organ Class and Preferred Term,Change From Baseline in Inflammatory Biomarkers: Interleukin-6,2020-07-30,COMPLETED,INTERVENTIONAL,['NA']
14980,NCT04942756,Evaluate CGM by using FSL2 in preventing severe hyperglycemia peaks,,,2021-06-30,UNKNOWN,INTERVENTIONAL,['NA']
14981,NCT05883072,Internet Speed,Analyzing Chat response generated by AI Chatbot,,2023-01-05,RECRUITING,OBSERVATIONAL,['NA']
14982,NCT05571878,"The change in brain imaging outcomes, measuring brain insulin resistance, following intranasal insulin or placebo challenges, compared between the participants with depression and healthy controls.",Correlation between brain insulin resistance with cognitive functioning at baseline and 6-month study follow up,"Correlation between brain insulin resistance, and hepatic and visceral adiposity",2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14983,NCT02750774,Gestational Diabetes Mellitus (GDM) occurrence,Neonatal Intensive Care Unit (NICU) admission,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
14984,NCT00817778,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14985,NCT02669524,Difference in postprandial glucose excursions,Fibroblast growth factor-21,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14986,NCT02875704,"Aqueous levels of oxidized adducts on protein (i.e. oxidative biomarker) in patients with stargardt disease, AMD, DR and controls",,,2017-01-03,TERMINATED,OBSERVATIONAL,['NA']
14987,NCT05667051,Percentage of bleeding on probing sites (BOP%),,,2022-04-05,COMPLETED,OBSERVATIONAL,['NA']
14988,NCT03782129,Mortality rate 5 years after DFU diagnosis,Risks factors correlated to mortality rate among DFU patients diagnosed in 2010,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
14989,NCT01594801,Safety,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14990,NCT02768935,level of expression markers,,,2017-10-30,COMPLETED,INTERVENTIONAL,['NA']
14991,NCT05039970,Number of Sessions Attended,Participants' game rating/Net Promoter Score or questionnaire.,Fitness tracker integration with the game.,2021-09-07,COMPLETED,INTERVENTIONAL,['NA']
14992,NCT05424965,Activity of Wnt signaling pathway in placental tissue,,,2018-03-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14993,NCT01493258,Change in CERSG Knowledge Score from baseline to 24-hr and to 6-month follow up,CERSG Acceptance,,2010-08,WITHDRAWN,INTERVENTIONAL,['NA']
14994,NCT05386849,Primary Efficacy Outcome,Time in desired control range,Glucose readings from CGM's versus from blood,2022-05-09,COMPLETED,INTERVENTIONAL,['NA']
14995,NCT04868851,Drop out,Parent survey on intervention acceptability (Here for Health),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14996,NCT02744300,Weight loss,Number of participants with either: a HbA1c value greater than or equal to 5.7; or a 2 hour value on a 75 g oral glucose tolerance test of greater than or equal to 140,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
14997,NCT02682342,change in mitochondrial network complexity of endothelial cells as measured by mitochondrial network fragment ratio,,,2016-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14998,NCT00722917,Change from Baseline in Glycosylated Hemoglobin,Plasma concentrations of TAK-379 and its metabolite M-I via a sparse sampling population approach.,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2']
14999,NCT00779363,Device Functionality Evaluation,Percentage of body weight loss,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
15000,NCT04427189,Change of HbA1c level,DKA rate,,2008-04,RECRUITING,OBSERVATIONAL,['NA']
15001,NCT01468519,Change in total International Index of Erectile Function (IIEF) score from baseline to six months,Global assessment question on erectile function,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15002,NCT01257334,the change from baseline in HbA1c,,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
15003,NCT05431296,Primary outcome: Percent time spent in glucose target range (3.9-10mmol/L),Audit of Diabetes Dependent Quality of Life questionnaire domain.,"Changes in care, measured by changes in diabetes medication usage.",2023-02-07,RECRUITING,INTERVENTIONAL,['NA']
15004,NCT04098562,Changes of Inflammation Marker at 3 Week,,,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15005,NCT00970723,"The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye.",Comparison of blood pressure in each group at one year,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
15006,NCT04698122,Biological samples collection for establishment of the first National Microbiome Biobank,,,2021-05-27,COMPLETED,OBSERVATIONAL,['NA']
15007,NCT02462369,microalbuminuria improvement in T2DM treated with saxagliptin,incidence of hypoglycaemia of saxagliptin or glimepiride,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
15008,NCT05145439,Transcutaneous Oxygen Pressure (TcPO2),Ankle Brachial Index (ABI),,2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15009,NCT02524938,Change in estimated glomerular filtration rate (eGFR),Change in 8hydroxy 2'deoxyguanoside (8OhdG),,2016-06-01,TERMINATED,INTERVENTIONAL,['NA']
15010,NCT02026024,mean amplitude of glycaemic excursions (MAGE),,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
15011,NCT05407454,The Diabetes Quality of Life - Brief Clinical Inventory,,,2022-06-07,COMPLETED,OBSERVATIONAL,['NA']
15012,NCT03528811,"Coincidence rate of ""5 points test of Tongji university""",,,2016-08-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
15013,NCT02596204,Change in Hemoglobin A1c,Change in Hemoglobin A1c,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
15014,NCT03406000,Mean change in HbA1c,Number of hypoglycemic events per patient-year,,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE4']
15015,NCT01155050,Change in Waist Circumference,Change in Fasting Plasma Glucose,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
15016,NCT01607190,CSME needing treatment either photocoagulation or ITV.,"Microaneurysm(MA) activity (number of MA, MA formation and MA disappearance rates and MA turnover)",,2012-11,COMPLETED,OBSERVATIONAL,['NA']
15017,NCT03760965,Change in hemoglobin A1c (HbA1c),Adverse events,,2018-11-27,TERMINATED,INTERVENTIONAL,['PHASE3']
15018,NCT00552994,In stent neointimal hyperplasia,Peri-stent remodeling - Edge response to Cypher Select plus and Xience V stent - Malapposition - Angiographic late lumen loss,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
15019,NCT02106364,Change from Baseline in Hemoglobin A1c (HbA1c) at 26 Week Endpoint,Change from Baseline in Lipid Profile,,2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15020,NCT05347420,The quantitative Neuropad test,The visual Neuropad test,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
15021,NCT03444142,Blood pressure,Waist Circumference,,2017-11-17,UNKNOWN,INTERVENTIONAL,['PHASE4']
15022,NCT01467414,Area under the glucose infusion rate curve during one dosing interval at steady state,Maximum observed serum insulin degludec concentration at steady state,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15023,NCT00502008,"Fasting and Post Prandial Blood Glucose, Glycosylated Hemoglobin",Serum Lipid levels,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
15024,NCT03102424,Change in HbA1c values to evaluate of the effect of DW1330,Change from baseline in OAD drugs description,Change from baseline of inflammatory biomarkers,2017-04-10,COMPLETED,INTERVENTIONAL,['NA']
15025,NCT03922932,Structural OCT Retinal Thickening Area,,,2017-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15026,NCT00226902,Change in pulse wave velocity at the three different haemoglobin levels,,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
15027,NCT01006590,Absolute Change From Baseline in HbA1c at Week 24,Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15028,NCT01375803,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
15029,NCT02617654,"The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production",Change in QoL between after and prior to treatment with liraglutide,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15030,NCT01065766,"Percentage of Participants With an Overall Efficacy Evaluation by the Investigator of Improved, Stable, or Worse at Week 24",,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
15031,NCT03208686,Blood glucose levels,,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
15032,NCT04914819,Number of Participants Losing 5 Percent or More of Weight From Baseline to 16-week Follow-up,Intervention Arm: Number of Weeks With Daily Data Reporting for at Least 5 of 7 Days,,2021-06-18,COMPLETED,INTERVENTIONAL,['NA']
15033,NCT03737188,Analysis of system accuracy based on ISO 15197,,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
15034,NCT00237549,"Amputations, non traumatic","Neuropathy, periphery and autonomy",,2001-01,COMPLETED,INTERVENTIONAL,['NA']
15035,NCT00118937,HbA1c - difference between final visit and baseline.,Extra blood- and urine-samples will be stored at -80 degrees Celsius for potential extra analyses after closure of the study. DNA will be stored for later pharmaco-genetic analysis.,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15036,NCT05231642,Glucose AUC,PAI-1,,2021-11-30,COMPLETED,INTERVENTIONAL,['NA']
15037,NCT00372957,Glucose Weighted Mean AUCs at Baseline (Day -1) and Day 7,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2006-03-22,COMPLETED,INTERVENTIONAL,['PHASE2']
15038,NCT03785886,Change from Baseline Fasting Blood Glucose at 3 months,Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion,,2019-03,UNKNOWN,INTERVENTIONAL,['NA']
15039,NCT05394519,Achievement of greater than or equal to (≥) 5% weight reduction,"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2023-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15040,NCT01739283,plasma glucagon area under curve values,"plasma gut hormones and nutrients (absolute, incremental and area under curve values)",glucose (g/kg body weight) needed to be infuse to keep clamp,2012-07,COMPLETED,INTERVENTIONAL,['NA']
15041,NCT00987662,Reduction of 24h BP and arterial stiffness in obese hypertensives,Drug specific effect on reduction in central fat deposition and the leptin to adiponectin ratio,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15042,NCT03338517,Ulcer surface area,,,2016-08-04,COMPLETED,INTERVENTIONAL,['NA']
15043,NCT02413385,Average steps per day,Body mass index,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
15044,NCT05333185,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
15045,NCT05601583,Total Scan Time,,,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
15046,NCT03273140,Better Sense of Coherence,Better Quality of life,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
15047,NCT02127762,"Change from baseline in pain-related disability, as measured by the Brief Pain Inventory. Pain interference scale at 3-month post-intervention.","Change from baseline in glycemic control, as measured by blood levels of Hemoglobin A1c.",,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15048,NCT00970593,Change From Baseline in Predose Fasting Glucose Levels at Day 15,,Plasma Concentration Versus Time Summary of Multiple Dose of OAP-189,2009-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15049,NCT03590223,occurence of Major adverse cardiac events,mortality,,2017-12-29,COMPLETED,OBSERVATIONAL,['NA']
15050,NCT01024218,Device preference,Comparison of the frequency of adverse events (needle stick injuries),,2004-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15051,NCT00658099,Change in weight,"The satisfaction of physicians who treat the subjects with either insulin detemir or NPH insulin by using 4 questions, which are included in CRF, at the final visit.",,2007-11,COMPLETED,OBSERVATIONAL,['NA']
15052,NCT02723968,Measurement of the sensitivity and the specificity of HOMA-%IR (homeostasis model assessment index of insulin resistance) for the diagnosis of diabetes mellitus in comparison to a continuous glucose monitoring system.,Correlation between IGTT and HbA1C dosage (glycated haemoglobin A1C).,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
15053,NCT00143104,"To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15054,NCT02861261,HbA1c,"Inflammation markers (hs-CRP, TNF-alfa, IL-6, and IL-8 etc. in ng/ml)",,2016-08-18,UNKNOWN,INTERVENTIONAL,['PHASE3']
15055,NCT03904485,Assessment of myocardial injury,,,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA']
15056,NCT02076542,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in self-care behaviors at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
15057,NCT06124586,effect of an immediate (within first 48h) PTA intervention on microbiome composition,Effect of the immediate PTA intervention on related complications,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
15058,NCT00537264,Health-related quality of life outcomes,,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15059,NCT01933529,Insulin secretion,Inflammation,Clinical chemistry parameter,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15060,NCT05529589,Change of visual acuity,B-mode ultrasound imaging,,2023-02-10,RECRUITING,OBSERVATIONAL,['NA']
15061,NCT00793390,breast cancer,,,2008-11-17,COMPLETED,OBSERVATIONAL,['NA']
15062,NCT05413330,Change in diabetic retinopathy grade as a measurement of efficacy,No. of subjects with Adverse Events as a measurement of safety,,2020-09-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15063,NCT04222348,Baby wellness,LBP profile and oxidativge stress as well as in lipid profile,,2016-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
15064,NCT00422253,,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
15065,NCT05596747,Incidence and Severity of Hypoglycemia,PD: Change from Baseline in 7-Point Glucose,,2022-11-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15066,NCT00985114,Percent (%) of Subjects Who Achieve a ≥ 0.5% Reduction in HbA1C at 24 Weeks or Last Visit From Baseline.,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
15067,NCT06256419,Genotype identification in patients with T2DM,Incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
15068,NCT02039245,Plasma concentration of metformin following the dose of 2 CANA/MET XR FDC tablets,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15069,NCT04592107,progression of chronic kidney disease,,,2017-12-12,COMPLETED,OBSERVATIONAL,['NA']
15070,NCT00357955,"Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg",,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
15071,NCT06088615,Accuracy of non-invasive glucose measurement in comparison to invasive glucose measurement,,,2023-11-08,RECRUITING,OBSERVATIONAL,['NA']
15072,NCT06077708,Periodontal Clinical Parameters,Biochemical Data,,2022-08-23,COMPLETED,INTERVENTIONAL,['NA']
15073,NCT03198832,Probing depth change,Clinical Attachment Level,,2016-05-02,COMPLETED,INTERVENTIONAL,['NA']
15074,NCT00327574,the three intervention arms,Cost outcomes: the total cost per intervention and cost per subjects,,2004-06,UNKNOWN,INTERVENTIONAL,['NA']
15075,NCT01206582,Gastric Emptying Half-time,Leukocyte and Platelet Counts,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15076,NCT03528226,Change in percent flow-mediated dilation (FMD) values,Body composition (DEXA),,2019-11-12,RECRUITING,INTERVENTIONAL,['NA']
15077,NCT00821899,"Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.","Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
15078,NCT05135130,"Frequency of wound infection, gangrene, and amputation",,,2021-10-04,UNKNOWN,OBSERVATIONAL,['NA']
15079,NCT04835493,HbA1c,Telehealth Acceptability,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
15080,NCT03355040,number of Neonatal death,Number of Anal sphincter tear for the patient,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
15081,NCT00658021,Number of Participants With Post-Treatment Adverse Events of Special Interest (AESI) During Safety Follow-up Period,Percentage of Participants Discontinuing the Study Due to Failure to Maintain Glycemic Control Through Week 28,,2008-05-30,COMPLETED,INTERVENTIONAL,['PHASE3']
15082,NCT01206101,Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant,Glucose Level Variability And Hypoglycaemia Duration Derived From The Continuous Glucose Monitoring System (CGMS),,2012-03-21,TERMINATED,INTERVENTIONAL,['PHASE2']
15083,NCT01241695,postprandial blood glucose (iAUC) (0-240 min),daily compliance,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
15084,NCT01548729,Metabolic efficiency at 1 year,Adverse events,,2012-02-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15085,NCT03048747,Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration,Change in Serum Sodium Concentration,,2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15086,NCT00725036,Long term pulmonary safety profiles,Treatment satisfaction,,2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15087,NCT02394314,Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382,Proportion of subjects with ADA to MEDI0382,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15088,NCT06284681,Response to weight-neutral health coaching measurement,Change in Metabolic Syndrome Severity Score,Change in Metabolic Syndrome Severity Score,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15089,NCT00287066,18F-labeled glucose uptake in muscle,Glucose turnover overnight Insulin pharmacokinetics,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
15090,NCT05433415,Change from Block Kids 2004 Food Frequency Questionnaire (BKFFQ) at 12 and 24 weeks,Change fron Quality of Mother Interaction at 12 and 24 weeks,Change from Weight Efficacy Lifestyle Questionnaire at 12 and 24 weeks,2023-03-06,RECRUITING,INTERVENTIONAL,['NA']
15091,NCT03770767,Birth weight standard deviation score,"Neonatal morbidity (neonatal hypoglycaemia, jaundice, respiratory distress and duration of stay in neonatal intensive care unit) and infant morbidity evaluated as hospitalization during the first 3 months of life (after discharge in the neonatal period)",,2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15092,NCT02629952,Improvement in Glucose Tolerance after 4 weeks of drinking blueberry tea.,Improvement in large artery stiffness after 4 weeks of drinking blueberry tea.,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
15093,NCT03807440,Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist,Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication,,2019-08-26,COMPLETED,OBSERVATIONAL,['NA']
15094,NCT02882945,Test of allelic frequencies,Evaluation of serum CRP(C-reactive protein) levels,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
15095,NCT00184613,Variation in morning FPG,Variation of pre-dinner plasma glucose collected in hospital on the last 3 days,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15096,NCT03819634,Time to Infusion Set Failure,,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA']
15097,NCT04905628,Dexcom Continuous Glucose Monitoring (CGM) System Performance,System Related Adverse Device Effects,,2021-07-08,UNKNOWN,OBSERVATIONAL,['NA']
15098,NCT03923205,AUC for postprandial glucose,Urine glucose concentration,,2019-03-07,UNKNOWN,INTERVENTIONAL,['NA']
15099,NCT02770885,Fluid intake in ml,Thirst perception,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15100,NCT01724515,Mitochondrial Respiration,Phosphorylation of proteins,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15101,NCT03330756,glycaemic control,Cardiac / ventricular hypertrophy,,2017-10-23,UNKNOWN,INTERVENTIONAL,['NA']
15102,NCT01787903,Time spent in the euglycemic range,Changes in hypoglycemia awareness score,RT-CGM satisfaction,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15103,NCT03250533,Rate of ulcer healing - Digital photography,Bioimpedance,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15104,NCT00966407,"Genotype for specific genes related to obesity, metabolic syndrome, and/or type 2 diabetes; Fasting serum biomarkers; Hand grip strength, muscle strength of upper and lower extremities; Fitness measurements; Body composition measures",Perception of physical fitness; Relationship between physiological measures and genotype variation,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
15105,NCT01774981,Part A and Part B: Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs,Part B: Change From Baseline in Albuminuria Over Time,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15106,NCT02538848,"Incidence, severity and causality of adverse events",,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15107,NCT02453555,Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline),Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo),,2015-05-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15108,NCT00032864,,,,1997-01,COMPLETED,OBSERVATIONAL,['NA']
15109,NCT02667964,FGF-21 change after physical activity,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
15110,NCT01463904,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
15111,NCT01530789,Percentage of patient using the system,satisfaction level of the telemedecin nurse,,2011-05,TERMINATED,OBSERVATIONAL,['NA']
15112,NCT03112538,between group difference of HbA1c changes from baseline to 6 months,Treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire DTSQs,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15113,NCT02687776,myocardial injury in non-cardiac surgery (MINS),composite events composed of all-cause mortality and/or major adverse cardiac and cerebrovascular events (MACCE),,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
15114,NCT02230501,HbA1c,antidiabetic medication,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15115,NCT01223547,Change in HbA1c,Weight,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
15116,NCT02163278,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Pharmacodynamic parameters,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15117,NCT01623882,Percentage of wounds closed,,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA']
15118,NCT01426737,Mean amplitude of glycemic excursion as described by Service et al. (1970) calculated from the glucose excursions of the CGMS profiles using MiniMedSolution Software (MedtronicMiniMed).,,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15119,NCT00532935,Change From Baseline in A1C at Week 32,Percent of Participants With A1C <7.0% at Week 32,,2008-01-26,COMPLETED,INTERVENTIONAL,['PHASE3']
15120,NCT05258292,Mean glucose levels during the late luteal phase,Total insulin delivery,,2022-05-02,RECRUITING,OBSERVATIONAL,['NA']
15121,NCT00723853,"Biochemical markers (glucose tolerance, lipid panel, insulin, hemoglobin A-1-C)","Cost Assessment (costs incurred to attend meetings, eat healthier, exercise more)",,2008-04,COMPLETED,INTERVENTIONAL,['NA']
15122,NCT00858351,Subjective Pain,Temperature,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15123,NCT01775878,glycosylated hemoglobin,blood pressure,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
15124,NCT00022750,,,,2000-10,COMPLETED,INTERVENTIONAL,['NA']
15125,NCT05580705,Patient Satisfaction Level,,,2022-09-22,COMPLETED,INTERVENTIONAL,['NA']
15126,NCT02097316,"Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4",Time spent in the strict glycemic area 80-140 mg / dl,Time spent above 180mg/dl;,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15127,NCT01474889,Endogenous Glucose Production,Autonomic Symptom Response to Hypoglycemia,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
15128,NCT04088981,Rate of glycemic control,Body weight,Endothelial function,2024-07,SUSPENDED,INTERVENTIONAL,['NA']
15129,NCT01602913,"Incidence of T2DM defined as having at least 2 diagnostic codes indicating T2DM after the index date, or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date",,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
15130,NCT02382757,Long-term complications,Percentage of children lost to follow-up,,2011-09,TERMINATED,OBSERVATIONAL,['NA']
15131,NCT03786406,Diagnosed with carotid artery disease,High risk of CVD (above 20% over 10 years) according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),,2018-12-03,COMPLETED,OBSERVATIONAL,['NA']
15132,NCT00139516,,,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
15133,NCT04216303,cause specific mortality from infection/sepsis,,,2019-09-12,WITHDRAWN,OBSERVATIONAL,['NA']
15134,NCT00297635,Magnitude of glucose excursions and fluctuations as indicated by the standard deviation between glucose tests to indicate relative glucose control and the mean daily glucose value over the 3 month period following the initiation of pump therapy,Whether use of the technology results in perceived improvement in the quality of care and improved satisfaction for all involved,,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15135,NCT01936935,Matsuda Insulin Sensitivity Index (MISI),Plasma high-sensitivity C-reactive protein (hs-CRP),Mean peak postprandial glucose,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15136,NCT00457093,"In the time period 2400 to 0600 hours (the Basal Period) when post-meal food is least likely to affect the glucose level, detect the mean percentage pf time the glucose level is between 70-119 mg/dL","Establish the mean percentage of time spent in the glucose ranges of 40-70 mg/dL, 120-179 mg/dL, 180-240 mg/dL and >240 mg/dL in the Basal Period and for the entire day, and the average glucose for the entire 24 hour period.",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
15137,NCT04982705,Percentage of subejcts with clinically significant change from baseline in safety laboratory test results,Apparent volume of distribution following oral administration (Vd/F),HbA1c level,2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE1']
15138,NCT03258918,Percentage of participants who achieve weight loss goal,Study attrition,Change in physical symptoms,2017-09-11,COMPLETED,INTERVENTIONAL,['NA']
15139,NCT00960661,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30,Minor Hypoglycemia Rate Per Year,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15140,NCT00276406,Ascending Colon Emptying Half-time (AC t1/2) Measured in Hours,QTc Interval Before and After Treatment,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15141,NCT01221090,HbA1c,Quality of Life (QOL),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15142,NCT02410499,Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Day 85,Change from Baseline in Urinary Protein:Creatinine Ratio (UPCR) Over Time,,2015-05-20,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15143,NCT03258853,Percentage of Time in Glucose Target Range (70-180 mg/dl) as Determined by Continuous Glucose Monitor (CGM) on Days 3-14,Number of Subjects With Time in Range (70-180 mg/dl) of 70% or Greater,,2021-08-26,COMPLETED,INTERVENTIONAL,['NA']
15144,NCT00139763,Will availability of inhaled insulin result in more type 2 diabetes patients choosing a treatment that involves insulin (if now on >2 OAs) or a more intensive insulin regimen (if now on OAs + glargine) compared to only standard therapies available,Determine both patient and MD reasons for treatment choices made. Determine if treatment choice is influenced by physician specialty or patient ethnicity. Determine how cost impacts patient treatment choice.,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15145,NCT01536236,Visual Analog Scale (VAS),Short Form 36 (SF-36) Quality of Life Questionnaire,,2011-10,WITHDRAWN,INTERVENTIONAL,['NA']
15146,NCT01480843,"Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months",,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15147,NCT05096325,Difference in the number of occlusion alarms generated by the new software algorithm compared to the currently implemented occlusion detection system.,Qualitative assessement of the state of the adhesive tapes after study completion,,2022-01-03,COMPLETED,OBSERVATIONAL,['NA']
15148,NCT01751321,glucose variability,,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
15149,NCT00348972,Safety / tolerability: hypoglycemia,Fasting supine levels of counterregulatory hormones,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15150,NCT04591457,Anti-insulin antibodies (AIAs),Adverse events,,2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15151,NCT03590561,Change in brain metabolites,Change in insulin secretion,,2018-06-13,COMPLETED,INTERVENTIONAL,['NA']
15152,NCT03164200,"Respiratory quotient (RQ, a measure of substrate oxidation)",,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA']
15153,NCT03734887,Change of Medication Adherence Rate,Program Acceptability assessed by a random sub-sample of interviews,,2019-10-31,TERMINATED,INTERVENTIONAL,['NA']
15154,NCT01516320,Difference in insulin secretion between groups.,Difference in Body composition between groups,,2009-05-13,COMPLETED,INTERVENTIONAL,['NA']
15155,NCT01319656,Evaluation of effects,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15156,NCT06119204,Weight loss,EuroQol 5 Dimension 5 Level (EQ-5D),,2024-01-26,RECRUITING,INTERVENTIONAL,['NA']
15157,NCT01582139,Hypoglycemic Events,Time in Range,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15158,NCT03987191,Time Spent With CGM Glucose Levels >180mg/dl Between Two Groups,Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups,,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15159,NCT04881019,Gylcemic response profiles,,,2021-06-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15160,NCT05641337,Compound adverse events,Incidence rate of complications of liver cirrhosis within six months,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
15161,NCT03980574,Hospital Readmission Rates,,Serological Assessment,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
15162,NCT01288144,Rate of screening,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
15163,NCT01938365,Deterioration of pancreatic islet function,"Insulin dosage, HbA1c levels and evaluation of chronic complications",,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
15164,NCT03063515,First phase insulin response to IV glucose infusion,Glucose excursion after IV glucose infusion,,2017-04-19,COMPLETED,INTERVENTIONAL,['PHASE1']
15165,NCT01706289,,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
15166,NCT05396898,Difference in insulin secretion,Drug concentration/dose ratio,,2020-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15167,NCT00458497,Oxygenation levels of blood in the feet will be compared between Holofiber and placebo socks at several time points using standard nonparametric t-test statistics.,,,2007-04,TERMINATED,INTERVENTIONAL,['NA']
15168,NCT02081573,Acceptability Questionnaire.,Body Mass Index,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15169,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,Provider-reported care coordination,PCP-reported care coordination,2021-06-14,RECRUITING,INTERVENTIONAL,['NA']
15170,NCT03294044,Success in clinical outcomes of primary disease Diabetes from baseline to 3 months,Quality of life (Euro-QoL),,2017-10-27,COMPLETED,INTERVENTIONAL,['NA']
15171,NCT00726440,Comparison of HbA1c mean between the 3 groups,comparison of the sensors consumption in group 1 and 2 and the evolution in time of this consumption,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
15172,NCT03512119,"Measure of 2 hours plasma glucose value (mmol/l) of OGTT, change from baseline at one year of Lumacaftor-Ivacaftor treatment",Number of cures of antibiotics IV and per os /year and interval between 2 cures (week),,2016-02-11,COMPLETED,OBSERVATIONAL,['NA']
15173,NCT03028506,large for gestational age infants,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
15174,NCT03466866,number of incident diabetes-related ED visits and/or hospitalizations,Diabetes self-care behaviors,,2018-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15175,NCT01026675,oral glucose challenge test plasma glucose value,oral glucose challenge test plasma glucose cut-off value,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
15176,NCT01055626,Differences in body fat,Differences in cardiovascular risk factors,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
15177,NCT03191396,Change in HbA1c,Change in Pulse Rate,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
15178,NCT00340132,24-hour metabolic rate,,,1983-01-01,COMPLETED,OBSERVATIONAL,['NA']
15179,NCT06013228,Fatigue,,,2023-08-30,RECRUITING,OBSERVATIONAL,['NA']
15180,NCT01188863,Half-life of the drug in plasma,Glucagon-like Peptide 1,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
15181,NCT03504046,Percent time in glucose range 70-180 mg/dL,Connectivity Analysis (Number of Connection Errors Between devices),,2018-02-28,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15182,NCT04623567,Change from Baseline Triglyceride at 12 weeks,Change from Baseline TCM Symptom Score at 12 weeks,Compositional and Functional Changes from Baseline Metabolites in blood and feces at 12 weeks,2021-12-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15183,NCT04078516,"Diagnostic value of CCM, PTT, AF and MRI",Validation of PainDETECT in diabetes,Exploratory measures,2019-08-12,COMPLETED,OBSERVATIONAL,['NA']
15184,NCT05418946,Variation in glycated hemoglobin (HbA1c) values (% -point) from baseline to 4 months from enrollment,Evaluation of albuminuria (mg/g creatinine),,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15185,NCT01283308,Diabetes Incidence,Program Acceptability,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
15186,NCT03629912,Timed Up and Go (TUG) Test: Change in Dynamic Balance,Diastolic Blood Pressure,,2018-08-13,COMPLETED,INTERVENTIONAL,['NA']
15187,NCT00430742,"Body weight at 36 weeks, HbA1c at 36 weeks","Body weight at 24 and 52 weeks, HbA1c at 24 and 52 weeks",,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15188,NCT02531035,Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization,Percent Change From Baseline in Mean Daily Bolus Insulin Dose,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15189,NCT00492700,improvement in steatosis,improvement in transaminase levels; improvement/less worsening in necrosis and inflammatory activity and /or fibrosis,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15190,NCT03827902,Change in HbA1c,Cost of glycemic management during study,Frequency of hypoglycemic events,2019-07-09,WITHDRAWN,OBSERVATIONAL,['NA']
15191,NCT00491400,Brachial Artery Flow-mediated Dilation,Serum Lipids,,2005-09,TERMINATED,INTERVENTIONAL,['NA']
15192,NCT01840189,nocturnal hypoglycemic events,o Subjective health status,,2013-04-24,TERMINATED,INTERVENTIONAL,['PHASE2']
15193,NCT01594762,Number of Participants With Clinical Response,Number of Participants With Treatment-Emergent Adverse Events (TEAE),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15194,NCT01232179,no leakage in widefield fluorescin angiography,,,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15195,NCT03367351,Adherence to CGM,CGM Self-Efficacy,,2018-03-09,COMPLETED,INTERVENTIONAL,['NA']
15196,NCT01887691,change in continuous glucose profile,change in Sleep effectiveness biomarkers,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15197,NCT05260879,Adoption of the recommended diet and exercise behavior,Reduction in number of participants with hyperglycemia,,2021-11-26,COMPLETED,INTERVENTIONAL,['NA']
15198,NCT04196348,Change in GIP dynamic profile,,,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15199,NCT05515939,Change in Hemoglobin A1c (HbA1c),Clinical Evaluation of Treatment,,2022-09-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
15200,NCT00539448,Evaluating the Glycemic control of the regimen : Change in A1C levels,Average daily dose : - For both insulin Glulisine & insulin Glargine. - FBG and PPBG if possible ?,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15201,NCT01662921,show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus,Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms,Compare incidence of primary cesarean section,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15202,NCT02527265,Insulin Maximum Observed Concentration (Cmax),Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2),,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
15203,NCT02664064,% Weight Loss,HbA1c,Program engagement,2016-01,COMPLETED,INTERVENTIONAL,['NA']
15204,NCT06213337,Development of foot care self-efficacy in diabetic patients,,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15205,NCT05277805,Relational empowerment,,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15206,NCT04183413,Systolic blood pressure among adults with hypertension,"21. Knowledge on diabetes and hypertension among adults with diabetes, prediabetes, or hypertension",,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
15207,NCT01338376,HbA1c,The incidence of Hypoglycemia,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
15208,NCT05970601,Effect of a single oral high-sodium chloride load or a partial substitution by potassium chloride on hypoxia-induced dilatation of brachial artery.,Effect of a single oral high-sodium chloride load or a partial substitution by potassium on systemic inflammation markers.,Effect of a single oral high-sodium chloride load or a partial substitution by potassium on metabolomics in stool.,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15209,NCT02198989,HbA1c,Insulin resistance measured as HOMA-IR,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15210,NCT04990427,Serious Adverse Events,UACR & UPCR,,2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15211,NCT03711383,Plasma acetate concentrations (microM),"Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)",,2018-02-20,COMPLETED,INTERVENTIONAL,['NA']
15212,NCT04041375,Change in Diabetes Distress Screening Scale (DDS17),Change in Use of community resources,Change in Use of VHA resources,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
15213,NCT00162240,compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + metformin vs placebo + metformin,"change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15214,NCT02328118,"composite outcome including amotio retinae,vitreous hemorrhage within 12 months after vitrectomy",the change of inflammatory factors in vitreous body,,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15215,NCT05338463,Incidence of treatment-related Adverse Events associated with Fespixon cream,Time to complete ulcer healing,,2021-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15216,NCT05426018,Changes of HbA1c compared with baseline at 12 weeks,Blood drug concentration level,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15217,NCT00659165,Calories Consumed After Fast.,,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
15218,NCT03292315,Homeostatic Model Assessment of Beta-Cell Function (HOMA-B),Glycated Hemoglobin (HbA1C),,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15219,NCT02061969,Mean Fasting Blood Glucose Level,Mortality,,2014-04-25,COMPLETED,INTERVENTIONAL,['PHASE4']
15220,NCT05510583,"Assessment of the non-inferiority of the occurrence of maternal, fetal, and neonatal complications for patients of both groups",Comparison of the rate of patients put on insulin in both groups,,2022-08-02,COMPLETED,OBSERVATIONAL,['NA']
15221,NCT02772887,Blood pressure,Placental growth factor (PlGF),,2016-08,TERMINATED,INTERVENTIONAL,['NA']
15222,NCT00401453,daily insulin requirements and glycemic control,"c-reactive protein, prostaglandin F2 alpha, cholesterol, HDL and LDL.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15223,NCT04811183,Evolution in the adherence,,,2021-06-04,UNKNOWN,OBSERVATIONAL,['NA']
15224,NCT05519501,Percent of subjects with study wound deemed closed at 12 weeks,,,2021-10-10,RECRUITING,INTERVENTIONAL,['NA']
15225,NCT02384889,Number of Participants with Dose Limiting Toxicities,,Changes in Serum Markers of Beta Cell Stress,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15226,NCT00592969,HbA1c,Adverse events,,2003-12-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15227,NCT02497170,Hemoglobin A1c,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
15228,NCT06125561,oral health-related quality of life,Clinical attachment loss,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
15229,NCT00105404,,,,2005-03-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15230,NCT04723134,Number of Wounds with Complete Healing,,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15231,NCT05360056,Change in DTSQc scores,,,2022-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15232,NCT05400525,Changes in immune response,Dietary Habits,,2022-06-15,COMPLETED,INTERVENTIONAL,['NA']
15233,NCT01167231,"Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressure","Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profile",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
15234,NCT05916729,Presence of Candida albicans after therapy at fourth reexamination,,,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15235,NCT05427682,Plasma concentrations of rongliflozin,Incidence of Adverse Events [safety],,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
15236,NCT03964428,hepicidin concentration,,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
15237,NCT03348280,Renin production by monocytes,Renin production by monocyte media,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
15238,NCT03360058,"Measure the effectiveness of an online training programme, practice implementation toolkit and face to face training for primary care staff",Training uptake,,2017-10-07,COMPLETED,INTERVENTIONAL,['NA']
15239,NCT03916601,(Cohort 2) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax),Assessment of PD parameter: Time to GIRmax (GIR-tmax),,2017-12-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15240,NCT03656744,Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF,Number of Participants Reporting an Adverse Events From Baseline Through Week 18,,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15241,NCT05933018,to evaluate presence of fatty liver in type 1 diabetes,presence of metabolic syndrome in type 1 Diabetes Mellitus,,2023-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15242,NCT02583438,gut microbiota,The change of inflammatory markers,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
15243,NCT00813215,Incremental AUC og the triglyceride response,Gene expression of genes involved in lipid metabolism and inflammation,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
15244,NCT02225457,Change from baseline in insulin sensitivity,Change from baseline in muscle and adipose tissue gene expression,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
15245,NCT01461577,Efficacy assessment of insulin glargine measured by changes of HbA1c levels from baseline,Number of patients with treatment-emergent adverse events,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
15246,NCT05801627,HbA1c change from baseline at week 24,eatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,,2020-05-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15247,NCT03925909,Rate of change in microbiome,Rate of change in plasma glucose concentration,,2019-05-01,TERMINATED,INTERVENTIONAL,['NA']
15248,NCT05305794,Percentage of time spent within glycemic target range (0.70-1.80 g/l),,,2022-07-12,RECRUITING,INTERVENTIONAL,['PHASE3']
15249,NCT05501093,Bacterial composition,Gingival inflammation,,2019-03-11,RECRUITING,OBSERVATIONAL,['NA']
15250,NCT01272219,Proportion of Subjects With Onset of Type 2 Diabetes,Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes),,2011-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15251,NCT06316544,admission to ICU,,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
15252,NCT03830840,"Success (evaluated by Yes/No format) recruiting and establishing an observational cohort of 1,000 Latino families with at least one family member living with type 2 diabetes by deploying the methods proven feasible by Mil Familias Operational Pilot.",National survey of children's health (NSCH) for all children and youth,Physical activity measured by two wearable physical activity monitors for 1 week,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
15253,NCT01353937,Quality of Life,cEPCs by FACS analysis,,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
15254,NCT03195153,"Assessment of platelet reaction units Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] After 30 days of treatment with each drug",,,2017-03-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
15255,NCT00005754,Progression of coronary artery calcification,,,1999-09,COMPLETED,OBSERVATIONAL,['NA']
15256,NCT03644238,Blood glucose,,,2017-08-21,COMPLETED,INTERVENTIONAL,['NA']
15257,NCT01002209,Time to complete healing of operative wounds,"HBO complications (confinement anxiety, barotrauma, oxygen convulsions)",,2019-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15258,NCT02022254,Area under the R-warfarin plasma concentration-time curve,Incremental area under the INR (international normalised ratio) -curve,,2013-12-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15259,NCT00322478,Patient Satisfaction,Standard Deviation of A1c and SMBG,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15260,NCT01485913,"Compare the intermediate evolution of the HbA1c (3, 6 and 12 months)","Compare the evolution of the bio-clinical parameters at 3.6, and 12 months: weight, BMI, blood pressure, waist measurement",,2011-07-01,COMPLETED,INTERVENTIONAL,['NA']
15261,NCT05831059,Numeric Rating Scale,,,2022-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15262,NCT01235026,Plasmatic Interleukin-6 (IL-6),Plasmatic usCRP,,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
15263,NCT05274009,Core temperature (AUC),Change in plasma volume,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15264,NCT03766256,Choice of evidence-based diabetes prevention (lifestyle change or metformin),Decisional conflict,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
15265,NCT04280315,TEWL,Sebum content in skin,,2020-02-18,COMPLETED,OBSERVATIONAL,['NA']
15266,NCT03817463,"Number of participants with myocardial infraction (MI), stroke, all cause mortality",Cost of care,,2019-04-15,COMPLETED,OBSERVATIONAL,['NA']
15267,NCT00597545,Number of Participants With Improved Neuropsychometric Changes,,,2007-03,TERMINATED,INTERVENTIONAL,['NA']
15268,NCT02992431,15D,visits to physician,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
15269,NCT04577274,Change from baseline Insulin at 240 minutes,Creatinine concentration analysis,,2020-11-04,COMPLETED,INTERVENTIONAL,['NA']
15270,NCT06060392,Change in liver fat content,Change in LDL-cholesterol,,2023-10-30,RECRUITING,INTERVENTIONAL,['NA']
15271,NCT05429229,Change from baseline in lipoperoxides levels in tear film at 30 days.,Change from baseline in tear secretion in mm with Schirmer I test at 30 days.,Change from baseline severity of dry eye symptoms according the punctuation in Ocular Surface Disease Index (OSDI) at 30 days,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15272,NCT01349374,"Nothing will be measured, the aim of the study is the obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines.",,,2011-01,TERMINATED,INTERVENTIONAL,['NA']
15273,NCT02325193,"average AUC/day in hypoglycaemic range < 70mg/dl (3,9mmo/l)",Number of PLGM activities,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
15274,NCT01382264,Improved glycemic control as determined by A1C in a population of patients with inadequately controlled type 2 diabetes mellitus.,Satisfaction with treatment and quality of life.,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
15275,NCT02284425,Incidence and severity of treatment emergent adverse events (TEAEs),Concentration of REGN1193 in serum over time,,2014-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15276,NCT00729898,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
15277,NCT01177709,Weight (wt) in Pounds (Lbs)..,Insulin Level,,2008-05,TERMINATED,INTERVENTIONAL,['NA']
15278,NCT06176495,Percentage change in glycemic control determined by HbA1C (in percent) in participants with diabetes pre and post intervention.,Assessment of Changes in Anxiety Screening score (in percentage pre and post intervention),,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15279,NCT05852626,Number of patients who achieved individualized target HbA1c,Foot evaluation,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15280,NCT03179332,AUCGIR(0-60min),Clinical safety laboratory,,2017-06-20,COMPLETED,INTERVENTIONAL,['PHASE1']
15281,NCT01861860,The incidence of MACE composite criteria among patients who received a TAXUS long stent deployed using IVUS according to the OPERA criteria according to the LPPR during a 12 months period after inclusion in the trial.,Medico-economics data at 12 months including,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
15282,NCT03390322,Incidence of procedure related SAEs.,Change to HbA1c levels,,2017-07-28,RECRUITING,INTERVENTIONAL,['NA']
15283,NCT04469270,Efficacy of Engensis compared to Placebo on painful DPN in the feet and lower legs comparing the Average Daily Pain Score from the Day 0 Visit to the Day 180 Visit on the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy,To evaluate the possibility of humoral responses to Engensis,"To determine whether IM administration of Engensis has the potential for improving quality of life, sensation, proprioception, and deep tendon reflexes by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline",2020-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15284,NCT05254002,"Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to finerenone alone",Total number of urosepsis and pyelonephritis events,,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE2']
15285,NCT02947503,Development of T2D and obesity during Phase C,Secondary outcome measures phase C,,2019-11-26,RECRUITING,INTERVENTIONAL,['PHASE3']
15286,NCT01469559,Hypoglycemia monitoring,Short Form-36 (SF-36) Quality of life scale,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15287,NCT05502562,Change in Glycated haemoglobin A1c (HbA1c),HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 3%,,2023-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15288,NCT00843609,"Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia).",Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire);,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
15289,NCT01609881,"Vitreous and anterior chamber levels of prostaglandins, other cytokines, and Acuvail",Secondary Outcome,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
15290,NCT05241262,Maximum tolerated dose (MTD) of NAC,Change in Brain glutathione (GSH) level,,2023-04,RECRUITING,INTERVENTIONAL,['PHASE1']
15291,NCT00608179,catecholamines,,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
15292,NCT01434862,Percent of Blood glucose tests within target range of 70 to 180 mg/dl,Percent of Continuous Glucose Monitoring (CGM) System estimated blood glucose within target range of 70 to 180 mg/dl,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
15293,NCT04094194,LDL-cholesterol (randomized and non-randomized controlled trials),Incident Stroke (Prospective Cohort Studies),,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
15294,NCT02939768,Mitochondrial superoxide dismutase (MnSOD) activity,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
15295,NCT02074540,Insulin adherence,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
15296,NCT05134987,"AUCPG,0.5-2h Area under the plasma glucose-time curve at steady concentrations",Number of adverse events,,2021-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15297,NCT03118336,epicardial adipose tissue volume,myocardial PCr/ATP ratio,,2017-06-16,COMPLETED,INTERVENTIONAL,['PHASE3']
15298,NCT03080337,Compliance with glucose testing over time,Cost-effectiveness (dollars per hour),,2017-03-17,TERMINATED,INTERVENTIONAL,['NA']
15299,NCT00321256,and 12 months following transplantation.,Morbidity and quality of life will also be assessed.,,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15300,NCT04991168,Number of missing and decayed teeth on the oral examination and clinical signs in diabetology.,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
15301,NCT00142974,Reduction in weekly mean of a daily composite diabetic gastropathy dyspeptic symptom severity score throughout 6 weeks of treatment.,"Weekly mean severity of individual dyspeptic symptoms (nausea, vomiting, retching, epigastric/stomach, discomfort/pain, postprandial fullness, bloating, early satiety).",,2004-05,TERMINATED,INTERVENTIONAL,['PHASE2']
15302,NCT01508806,Area under the Curve (AUC),Adverse events,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15303,NCT02218138,Homeostasis model assessment of insulin resistance,Center for Epidemiological Studies-Depression Scale,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15304,NCT03520153,Hepatic glucose fluxes (gluconeogenesis and glycogenolysis),Tumor necrosis factor alpha (TNF-alpha),Maturity-Onset Diabetes of Young (MODY) genetic testing,2018-08-07,WITHDRAWN,OBSERVATIONAL,['NA']
15305,NCT01704261,Percentage of Participants Who Discontinued From the Study Due to an AE,Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24,,2012-10-18,COMPLETED,INTERVENTIONAL,['PHASE3']
15306,NCT05892341,Effectiveness of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® on wound management,Safety assesment,Quality of Life assesment,2022-12-05,COMPLETED,INTERVENTIONAL,['NA']
15307,NCT02999867,response to the dietary intervention by the change from baseline in insulin resistance at 30-day,response to the dietary intervention by the change from baseline in iron absorption at 30-day,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
15308,NCT03758144,change in glycemic control,Gastrointestinal symptom questionnaire,change in weight,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
15309,NCT06293417,major adverse cardiovascular events and diabetic microvascular events for 48 months,change in TC/HDL-C ratio at 48month from baseline,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15310,NCT00707954,"Safety: Adverse Events, Adverse Drug Reactions",Pharmacodynamics- 1)Urinary Glucose Excretion; 2)Plasma Glucose Concentration; 3)Insulin Concentration in Serum; 4)Insulinogenic Index;and 5)Hemoglobin A1c and Glycoalbumin,,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15311,NCT00474838,Change of pancreatic beta cell function,Time to reach target goal of blood glucose level,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15312,NCT02910089,Glycosylated Hemoglobin (HbA1c):,Patients Achieving HbA1c,,2016-10-20,COMPLETED,INTERVENTIONAL,['PHASE4']
15313,NCT04971889,Change from Baseline HbA1c,Change from baseline Systolic Blood Pressure,Change from baseline Situational Obstacles to Dietary Adherence Questionnaire,2021-08-03,RECRUITING,INTERVENTIONAL,['NA']
15314,NCT01947556,T-BG≥10,T-INSAUC50%,time exogenous glucose requirement,2014-03,COMPLETED,INTERVENTIONAL,['NA']
15315,NCT01148862,The Primary Treatment Comparison is the Evaluation of the Severity (Milligrams Per Deciliter) of Induced Hypoglycemia.,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
15316,NCT00737763,The primary endpoint for this study will be the difference from baseline in the body's ability to respond to a Mixed Meal Tolerance Test at 12 months after enrollment.,,,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15317,NCT02169050,Oral Glucose Insulin Sensitivity (OGIS),Inflammatory markers in plasma,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
15318,NCT00198146,"Area under the curve, Glucagon Stimulation Testing for c-peptide measurements at 0, +6min and +10min intervals over 2 years",Insulin requirements (units/kg/day),,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15319,NCT01037647,VLDL-TG production and clearance rates,VLDL-TG subcutaneous adipose tissue storage,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
15320,NCT04841291,The number of participants who believed in the practicality of the virtual simulation-based foot care education.,The participants' level of foot self-care efficacy to perform recommended diabetic foot self-care activities.,,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
15321,NCT04334109,"Change in mean HbA1c (NGSP%) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention","Change in diabetes-related quality of life from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention",,2021-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15322,NCT02750501,Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA),Plasma Composition (%) Ratio of n6/n3 Fatty Acids.,GI Symptoms,2016-07-20,COMPLETED,INTERVENTIONAL,['NA']
15323,NCT01531114,the superiority antiplatelet effect in terms of PR level of loading dose (LD) of Prasugrel (60 mg) versus LD of Ticagrelor (180 mg) in diabetic patients with STEMI undergoing primary PCI at 2 hours post drug administration.,PR level measured at 6 and 12 hours post study drugs administration.,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15324,NCT04715776,"From baseline to 3 months after using dietary supplements (compare yourself with yourself), follow up for a total of 12 months",,,2018-12-10,UNKNOWN,INTERVENTIONAL,['NA']
15325,NCT01260337,Change in weight at 3 and 6 months,Change in HbA1C at 3 and 6 months,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
15326,NCT04982575,Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide),"Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)",,2021-08-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15327,NCT04743778,Regimen Adherence,Diabetes Quality of Life,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
15328,NCT03878459,Decrease in HbA1c,insulin dose,,2019-08-08,RECRUITING,INTERVENTIONAL,['PHASE4']
15329,NCT06104969,Standard of Care Adherence,Change from baseline to later of Week 52 or Confirmation Visit in PROMIS Sleep Disturbance,,2023-06-15,RECRUITING,OBSERVATIONAL,['NA']
15330,NCT03673904,statistical significant elevation of high sensitive CRP in diabetics and prediabetes,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15331,NCT04387058,the cumulative incidence,,,2019-06-16,UNKNOWN,INTERVENTIONAL,['NA']
15332,NCT03702374,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,Diabetic retinopathy severity progress at the end of intervention from baseline,,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
15333,NCT01472159,"Change in glycemic control, assessed by hemoglobin A1c","Change in psychosocial factors (e.g., self-efficacy, fear of hypoglycemia, quality of life, diabetes-specific family conflict, diabetes responsibility sharing, diabetes-specific burden, anxiety, depressive symptoms)",,2011-10,COMPLETED,INTERVENTIONAL,['NA']
15334,NCT02681588,birthweight,,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
15335,NCT02741674,Reoperation/Rehospitalization Rate,Composite Adverse Event,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
15336,NCT03881540,Change in Glycated haemoglobin (A1C),Change in exercise minutes,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
15337,NCT05471986,Sensitivity and Specificity of EyeCheckup to detect vision-threatening diabetic retinopathy,Negative Predictive Value,,2024-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15338,NCT02268929,The mean HbA1c change by Generalized Estimating Equations (GEE) methods,Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods,,2014-10-14,COMPLETED,INTERVENTIONAL,['NA']
15339,NCT04753294,Change in wound progress,Wear time,,2021-06-14,COMPLETED,INTERVENTIONAL,['NA']
15340,NCT06245980,Heart failure readmission,cardiovascular death,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
15341,NCT02477969,HbA1c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-02-27,UNKNOWN,INTERVENTIONAL,['PHASE3']
15342,NCT03350984,Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.,Number of Participants With Sustained Glycemic Control During Hospital Stay,,2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15343,NCT02482584,Change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-PWV) from start to end of 12 weeks intervention,Change from start to end of 13 weeks intervention in insulin sensitivity measured by hyperinsulinemic euglycemic clamp,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
15344,NCT04682795,Time In Range,Insulin dose,Insulin treatment compliance,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15345,NCT05674799,BMI in early pregnancy,Glycemia in early pregnancy,Rate of neonatal hypoglycemia requiring treatment,2023-04-08,RECRUITING,INTERVENTIONAL,['NA']
15346,NCT05525364,Variables of interests - Blood glucose and hyperglycemia data,,,2019-06-20,COMPLETED,OBSERVATIONAL,['NA']
15347,NCT05186519,All non-traumatic amputate events,Length of stay in hospital,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
15348,NCT00393770,Insulin sensitivity,Lipid profile.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15349,NCT06264427,Number of participants with obstructive sleep apnea,CPAP treatment effect on daytime sleepiness measured with the functional outcome of sleep questionnaire (FOSQ-10).,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
15350,NCT00673296,Interval between the treatment and clearing of premacular hemorrhage,"Snellen best-corrected visual acuity measurements, intraocular pressure, slit-lamp examination and non-contact lens biomicroscopic examination.",,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
15351,NCT01838083,Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6,"Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15352,NCT03022721,Development of diabetic complications,,,2016-09,RECRUITING,OBSERVATIONAL,['NA']
15353,NCT00948584,The primary objective was to compare the mean changes of A1C from baseline to end point between two groups.,Secondary objectives included the proportion of patients to achieve A1C level below 7.0%; incidence of hypoglycemic episodes; change in body weight; and insulin dose.,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15354,NCT02162407,Steady state glucose infusion rate (GIR) / interstitial insulin steady state concentration,Insulin concentration profiles,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15355,NCT00440440,Mean absolute change in visceral adipose tissue mass in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy.,Mean absolute change in spine BMC and lumbar spine (L1-L4) BMD,,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15356,NCT05689658,Minutes of Moderate Physical activity,Glycemia,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
15357,NCT02811055,Difference from baseline in Plasma aldosterone concentration,Difference from baseline in HOMA index,,2017-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
15358,NCT05147194,Ratio of UACR levels at 6 months to baseline UACR,Ratio of UACR levels at 1 months to baseline UACR,,2022-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
15359,NCT00824395,,,,2006-01,WITHDRAWN,OBSERVATIONAL,['NA']
15360,NCT01096940,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of simvastatin (including simvastatin acid) and vice versa by assessment of AUC(0-24) and Cmax.,"To evaluate the safety and tolerability of AZD1656 alone and in combination with simvastatin by assessments of adverse events, laboratory variables, electrocardiogram, blood pressure, pulse, results of physical examination, and weight.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15361,NCT06061861,6-month change in glycosylated hemoglobin level,Change in self-reported readiness to change,,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
15362,NCT01905020,Percentage of time in target range,Number of hypoglycemic events requiring treatment,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15363,NCT03222284,Device usability as assessed by the System Usability Scale (SUS),,,2017-07-17,UNKNOWN,INTERVENTIONAL,['NA']
15364,NCT03980353,Identification of community integration obstacles for children with type 1 diabetes,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
15365,NCT00878605,Hemoglobin A1C,,,2010-04-01,TERMINATED,INTERVENTIONAL,['PHASE2']
15366,NCT01722266,Change in Mean Weekly Glucose Concentrations,Change in Glucagon Concentrations,,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15367,NCT00812032,An exploratory study with three co-primary response variables which are directly related to platelet COX-1 inhibition: arachidonic acid-induced platelet aggregation in whole blood and PRP and in the Cone-and-Plate(let) Assay (CPA),"Indirectly COX-related platelet aggregation induced by collagen or ADP, and thromboxane metabolite excretion.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15368,NCT03368209,Calibration models for device predictive purposes,,,2015-12-04,TERMINATED,INTERVENTIONAL,['NA']
15369,NCT05894746,Amino acid metabolism,Fibrinogen,multiomics explorative analyses,2023-05-04,RECRUITING,INTERVENTIONAL,['NA']
15370,NCT00570154,,,,2007-11-27,COMPLETED,OBSERVATIONAL,['NA']
15371,NCT00358254,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
15372,NCT05308836,Safety measure,Insulin dose,,2021-10-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
15373,NCT01892319,"Proportion of pregnancies (Levemir® treatment), compared to pregnancies (other basal insulin treatment regimens), resulting in none of the following events: Major congenital malformations, Perinatal death, Neonatal death",Proportion with changes (progression/regression) of major congenital malformations,,2013-09-30,COMPLETED,OBSERVATIONAL,['NA']
15374,NCT02220036,Serum creatinine,high sensitive C-Reactive Protein,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
15375,NCT04707157,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),,2021-05-06,TERMINATED,INTERVENTIONAL,['PHASE2']
15376,NCT04625088,Time course change in plasma HISS levels,Time course change in Meal Induced Glycemia (MIG) scores (Molar Units),,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
15377,NCT04430946,Gut peptide hormone responses,Meal induced thermogenesis,,2020-08-25,RECRUITING,INTERVENTIONAL,['NA']
15378,NCT01223131,Absolute change of glycosylated hemoglobin (HbA1c),Anti-glargine and anti-human insulin antibody assessment,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15379,NCT01545570,"pharmacokinetic parameters of GSK2374697, after ascending single or titrated multiple subcutaneous doses, in healthy subjects",dose proportionality of GSK2374697,,2011-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15380,NCT02498119,"Composite measure of patient physical observations to include weight, height and BMI",The effect of LTB4 and LTC4 of eicosanoids,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
15381,NCT05612698,fasting plasma glucose,body composition (measured by bioimpedance),,2023-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15382,NCT05409924,Safety analyses after multiple doses of ATR-258,PK analyses will be performed after PK of ATR-258 multiple dose,,2022-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15383,NCT01165684,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32,Hypoglycaemic Episodes (Rate of All Treatment Emergent Hypoglycaemia Episodes),,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15384,NCT01890993,Change in HbA1c (glycosylated haemoglobin),Change in systolic blood pressure,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
15385,NCT04259801,Number of treatment emergent adverse events (TEAE) in Part 2,The maximum concentration of semaglutide after administration of the 12th dose of semaglutide,,2020-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15386,NCT05430061,Gastric half emptying time,Height and Weight,,2017-07-27,COMPLETED,INTERVENTIONAL,['NA']
15387,NCT02303730,Change in liver fat content（%） measured by MRS,"Change in body weight,waist circumference and hip circumference",Incidence of adverse events（AEs）and Severe adverse events(SAEs),2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15388,NCT00422955,Change in transcapillary escape rate of L125 albumin following 16 weeks treatment,"Change in plasma volume, pedal oedema, extracellular fluid volume following 16 weeks treatment.",,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15389,NCT04218734,Change in HbA1c (%) from baseline to week 24,Change in body weight from baseline to week 12 and week 24,,2020-01-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15390,NCT00431717,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15391,NCT01478399,Pharmacokinetics,Safety/Tolerability,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15392,NCT02002130,Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by quantitative C-peptide secretion,Compare the effect of oral GABA or oral GABA/GAD administration on diabetes related autoantibodies,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15393,NCT01482481,HbA1c level,Body Mass Index (BMI),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
15394,NCT01901913,Area under the curve above 180 mg/dl (10 mmol/l),"Percentage of time spent above 180, 250, (10, 13.9 mmol/l)",,2013-10,COMPLETED,INTERVENTIONAL,['NA']
15395,NCT01626586,Diabetes-related Outcomes,Diabetes-related medical outcome data,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15396,NCT00918879,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c < 7.0% at Week 24,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15397,NCT03341117,"Modification in the antioxidant enzymatic system activity (total antioxidant capacity, catalase, glutathione peroxidase , superoxide dismutase) in patients with type 2 diabetes after the administration of acetylsalicylic acid",Modification in fasting glucose in patients with type 2 diabetes after the administration of Acetylsalicylic acid,,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15398,NCT06038968,assess functional outcomes by multifocal electroretinogram,visual acuity,,2022-09-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15399,NCT00451620,The objective of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and postprandial glucose levels in elderly people with type 2 diabetes who are diet controlled.,,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15400,NCT02752828,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
15401,NCT04080596,AUClast,,,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15402,NCT05153564,"Area under the levonorgestrel plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,LN,SS)","Maximum observed paracetamol concentration following a standardised meal (Cmax,para)",,2021-12-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15403,NCT04196140,Time in range 70-180 mg/dL,Body Mass Index (BMI) (kg/m2),Coefficient of variation,2019-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15404,NCT01871324,the efficacy will be evaluated using Diabetes Quality of Life questionnaire before and after the program.,the efficacy will be evaluated using behavioral changes related to diabetes questionnaire before and after the program.,"the efficacy will be evaluated using HbA1c values, glucose levels before and after the program",2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
15405,NCT03025919,area under the ROC curve,sensitivity and specificity of screening,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
15406,NCT02147041,composite of anthropometric measures,Quality of life evaluation,,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15407,NCT03530176,18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes,,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
15408,NCT00425919,Fasting Plasma Glucose,"Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.",,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
15409,NCT01174901,"Differentiation between serious secondary non-traumatic headache as opposed to benign, self-limiting non-traumatic headache by copeptin level measurement",Comparison of copeptin with other potential biomarkers in non-traumatic headache,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
15410,NCT05081440,primary outcome,secondary outcome,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
15411,NCT04058951,Urine albumin creatinine ratio (UACR),,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
15412,NCT00909051,"Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)",,,2009-03-24,COMPLETED,OBSERVATIONAL,['NA']
15413,NCT04461236,Change in whole-body protein metabolism in type 2 diabetic obese subjects,Changes in quality of life as measured by Short Form (36) Health Survey (SF36) in type 2 diabetics obese subjects,Group differences in Bi-manual Coordination Task between type 2 diabetics and non-diabetic subjects,2019-05-30,UNKNOWN,INTERVENTIONAL,['NA']
15414,NCT03648307,Glucose tolerance,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
15415,NCT00738907,Pancreatic tracer binding as standardized uptake value (SUV) or binding potential (BPnd),,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15416,NCT04627272,Specificity,,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
15417,NCT00770653,The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.,Change From Baseline in Erythrocyte Deformability (60.00).,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15418,NCT04741685,TIR,Hypoglycemia perception 2,,2021-02-15,COMPLETED,OBSERVATIONAL,['NA']
15419,NCT00090506,,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15420,NCT04873232,To evaluate the efficacy of IM administration of Engensis on pain in Participants with painful DPN in the feet and lower legs as compared to Placebo,To evaluate the safety of IM administration of Engensis in Participants with painful DPN in the feet and lower legs,,2021-05-17,RECRUITING,INTERVENTIONAL,['PHASE3']
15421,NCT02625649,Number of patients with HbA1c<48 mmol/mol.,Number of patients with two-step change from preoperative level on the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) scale,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
15422,NCT01792323,tmax(GIR); time to maximum glucose infusion rate,"GIRmax, maximum glucose infusion rate","tmax(ins), time to maximum observed plasma insulin lispro concentration",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15423,NCT02204384,Area Under the Curve (AUC 0-180min) for glycemic and insulinemic responses,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
15424,NCT01470937,Progression of fasting glucose >140 mg/dL,,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15425,NCT02575599,The Patient Activation Measure (PAM),Glycosylated haemoglobin (HbA1c),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15426,NCT05659368,changing in insulin production,change in HbA1c,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15427,NCT05173025,Angiotensin(1-7),HbA1c,,2018-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15428,NCT00803920,Characterize glucose control using periodic CGM in subjects participating in protocol 2993LAR-105 at the International Diabetes Center study site.,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
15429,NCT01707979,near infrared spectroscopy,,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
15430,NCT05541237,remission rate,blood lipid profile,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA']
15431,NCT05669599,Percent Change From Baseline to Week 52 in Body Weight,Percent Change From Baseline in Free Fatty Acids (FFA),,2023-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15432,NCT00813085,Comparison of change in diabetes quality of care between intervention and usual care group.,"Change in diabetes risk factor variables, satisfaction with care and technology, quality of life and health care utilization, health data privacy issues.",,2002-04,COMPLETED,INTERVENTIONAL,['NA']
15433,NCT00540462,"Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT.","Comparing the DM controls between Medical and Surgical treatment In surgery groups, compare the bypass surgery and sleeve gastrectomy",,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
15434,NCT05322122,Feasibility and performance measured by anastomosis success,Quality of life improvement,,2021-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15435,NCT02249871,Area under the semaglutide plasma concentration time curve,Number of hypoglycaemic episodes,,2014-09-24,COMPLETED,INTERVENTIONAL,['PHASE1']
15436,NCT04592601,Weight Loss,Adverse Events,,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA']
15437,NCT00282945,"This study will examine whether biomarkers of B-cell function measured early in the study (1, 3, and/or 6 months) will predict long-term changes in B-cell function (as represented by HOMA-B).",,,2006-01,TERMINATED,INTERVENTIONAL,['NA']
15438,NCT05054361,blood MAIT cells frequency,16 S sequencing in the Subjects stools,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
15439,NCT01624259,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),Percent Change From Baseline in Lipid Parameters at 26 Weeks,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15440,NCT04612933,Change from baseline of Time in Range (TiR),Change from baseline of time spent below target glucose range (TbR) level 2,Semi-structured interviews,2021-06-28,RECRUITING,INTERVENTIONAL,['NA']
15441,NCT03367455,Associations of serum potassium and KCNJ11 variants with incident diabetes as represented by odds ratio,,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
15442,NCT05899439,Genetic risk of type 1 diabetes,,,2005-01-01,RECRUITING,OBSERVATIONAL,['NA']
15443,NCT02488785,Hemoglobin A1c,,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
15444,NCT03168867,Glycemic Control,Household Chaos (Self-reported),,2017-09-25,COMPLETED,INTERVENTIONAL,['NA']
15445,NCT04611737,height,Depression Anxiety Stress Scales,,2020-11-03,COMPLETED,INTERVENTIONAL,['NA']
15446,NCT02390245,Diagnostic Image Confirmation by Ophthalmologist,Adherence to Follow-up Ophthalmic Care.,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
15447,NCT01871870,Verification of the Automation and Telemetry Components,Deviation From Target Blood Glucose,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15448,NCT00989378,Amount of Slow Wave Activity determines insulin sensitivity.,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
15449,NCT05464407,Foot ulcer healing,Number of new foot ulcers,,2022-02-24,TERMINATED,INTERVENTIONAL,['NA']
15450,NCT03169959,Maximum observed plasma concentration (Cmax),Laboratory assessments of urinalysis,,2017-05-29,COMPLETED,INTERVENTIONAL,['PHASE1']
15451,NCT05819151,Tongue image features,Symptom patterns,,2022-10-12,RECRUITING,OBSERVATIONAL,['NA']
15452,NCT05579561,Change from baseline of triglycerides,Change in the microbiome,,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15453,NCT03973762,Se and Sp under investigation target 3,Se and Sp under investigation target 1/2/4/5,,2019-05-31,COMPLETED,INTERVENTIONAL,['NA']
15454,NCT03584217,Glomerular filtration rate (GFR),Renal perfusion,Epigenetic profiling,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15455,NCT02632292,In-stent late lumen loss,Anginal status assessed by the Seattle Angina Questionnaire,,2016-01,TERMINATED,INTERVENTIONAL,['NA']
15456,NCT05563090,Tongue imaging device,Health Evaluation - Existing symptoms,,2022-09-17,RECRUITING,OBSERVATIONAL,['NA']
15457,NCT01029639,"Questionnaires completed by subjects at baseline quarterly to assess ability to sense low blood sugar. Tracking incidences requiring outside assistance including paramedics, ER visits and hospitalizations due to low blood sugar incidences.",,,2007-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15458,NCT02846545,Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52,Titers of Antibodies to Golimumab,,2016-08-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15459,NCT04891159,"Adoption of a shared decision making measured by the total score obtained on the 9 items of the shared decision making questionnaire (SDM-Q-9), translated into French.",,,2021-09,UNKNOWN,OBSERVATIONAL,['NA']
15460,NCT03421119,HbA1c,Liver enzymes,,2019-06-20,UNKNOWN,INTERVENTIONAL,['PHASE3']
15461,NCT04504045,Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12.,Change from Baseline in High Sensitivity C-Reactive Protein at Week 12.,,2020-09-01,TERMINATED,INTERVENTIONAL,['PHASE1']
15462,NCT02890745,"Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)","Plasma levels of iron, ferritin, transferrin and transferrin saturation",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15463,NCT05709444,"To determine the incidence of overall adverse events, related adverse events, a composite of adverse events of special interest, serious adverse events, and the incidence of BMT discontinuation.",To measure the efficacy of SQ BMT in combination with RAAS inhibition therapy to achieve a <1.0 ml/min/year drop in eGFR after six months,,2022-12-26,RECRUITING,INTERVENTIONAL,['PHASE2']
15464,NCT03108521,Glycosylated Hemoglobin A1c (HbA1c),Change in C-peptide,,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE4']
15465,NCT02898467,Neutrophile activation assessed by free DNA levels in atherothrombotic plaques,Atherothrombosis characterization assessed by histological analysis,Banking of biological samples,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
15466,NCT00655863,Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.,Change From Baseline in Endothelial Function Through Pulse Wave Tonometry,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15467,NCT02161588,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs) recorded,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15468,NCT05624775,Change in cooking self-efficacy by the Nourishing the Community Through Culinary Medicine survey (NCCM),Change in Triglyceride,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
15469,NCT05716724,Change in glycated haemoglobin (HbA1c),Timing of intake of oral semaglutide as reported in patient diary,,2023-01-25,COMPLETED,OBSERVATIONAL,['NA']
15470,NCT00790530,Completion of dilated eye examination,Completion of microalbumin testing,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
15471,NCT02563015,Lean mass,25(OH)D,,2016-03-07,TERMINATED,INTERVENTIONAL,['NA']
15472,NCT01378117,Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy,Percent of Blood Glucose Readings Within Target Range Between 70 and 140 mg/dL Among the Three Groups After 24 Hrs of Randomized Treatment,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15473,NCT02496000,Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.,The Effect of ORMD-0801 on the Percent Change in HbA1c,,2015-07-27,COMPLETED,INTERVENTIONAL,['PHASE2']
15474,NCT02216955,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
15475,NCT00847899,Glucose dynamics and insulin sensitivity,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15476,NCT05629117,Changes in Blood Pressure Level including Systolic blood pressure (SBP) and Diastolic blood pressure (DBP),Changes in Quality of Life,,2022-12-26,COMPLETED,INTERVENTIONAL,['NA']
15477,NCT01144091,The purpose of the study is to examine the potential renal protective effect of pentoxyphylline in high-risk patients undergoing angiography,The purpose of the study is to examine the potential renal protective effect of pentoxyphylline in patients with elevated base line creatinin level > 2 undergoing angiography,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
15478,NCT04757233,Change in score on Summary of Diabetes Self-Care Activities Questionnaire (SDSCA),,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
15479,NCT02432924,Change in physical activity level (PAL),QIntervention: Change in cardiovascular disease and type 2 diabetes risk,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
15480,NCT01593774,Change from baseline in weight at week eight,Changes from baseline in HOMA-IR values at week 8,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15481,NCT00659295,"Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events",,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
15482,NCT05666479,Accuracy of Real-Time Continuous Glucose Monitoring,Assess Irreversible Damage/Interference of Real-Time Continuous Glucose Monitoring Devices Caused by Electrocautery,,2022-09-09,RECRUITING,OBSERVATIONAL,['NA']
15483,NCT00517283,To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15484,NCT03095846,5. Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in resting energy expenditure after cooling versus no cooling,,2017-04-02,COMPLETED,INTERVENTIONAL,['NA']
15485,NCT02619487,glycemic control assessed by HbA1C level.,number of hospitalizations related to T1D,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
15486,NCT03577184,Change from baseline in Random blood sugar (RBS) and fasting blood sugar (FBS) levels at week 12 in participants receiving Vildagliptin combination with Metformin,Number of participants who experienced an Adverse Event,,2018-07,WITHDRAWN,OBSERVATIONAL,['NA']
15487,NCT00889226,Proportion of Patients Achieving LDL- C<100mg/dL,The Change of LDL-C,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15488,NCT01009021,Pain recorded using a Visual Analog Scale,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
15489,NCT00945659,Glycated Hemoglobin (HbA1c),Hypoglycemia Fear Survey-Parent,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
15490,NCT05965973,"Change in the expression of key genes in hepatic fibrogenesis including transforming growth factor beta 1, a-smooth muscle actin, type-1 collagen, connective tissue growth factor",Identify bacteria strains involved in the control of blood glucose such as C elegans.,,2023-06-09,RECRUITING,INTERVENTIONAL,['NA']
15491,NCT01207349,%HbA1c,anthropometry,,2002-08,COMPLETED,OBSERVATIONAL,['NA']
15492,NCT06145542,Continuous glucose monitoring at follow-up,Ambulatory Blood Pressure at follow-up,,2023-12-11,RECRUITING,INTERVENTIONAL,['NA']
15493,NCT00097877,HbA1c,other glycemic variables,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15494,NCT05691712,Mean Change from Baseline in HbA1c (Tirzepatide 10 or 15 milligram [mg]),"Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)",,2023-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15495,NCT03474731,Hemoglobin A1c,Total cholesterol,,2018-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15496,NCT02077179,Metabolic Syndrome Z Score,Adherence to the HIP Program; Percent of Dietary Logs Completed,,2014-09,TERMINATED,INTERVENTIONAL,['NA']
15497,NCT02601989,insulin sensitivity,"Endothelial function in peripheral arteries measured with EndoPAT, measured as difference in reactive hyperemia",,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15498,NCT02564926,Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan,Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52,,2016-01-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15499,NCT04163055,The rate of CWH of DFUs will be estimated as a proportion and compared between the two groups using a chi square test. The superiority of AF-guided intervention (Arm 2) will be established if the null hypothesis is rejected.,Quality of Life improvement due to the device as assessed Diabetic Foot Ulcer Scale,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15500,NCT03660683,CD 34+ Cell Migratory Function,Arterial Stiffness - Augmentation Pressure,Serum Glucose,2018-10-22,TERMINATED,INTERVENTIONAL,['PHASE4']
15501,NCT03506230,Differences in HbA1c after six months,Whether or not HbA1c test was performed at 3 months,Differences in the number of GP visits,2018-11-25,UNKNOWN,INTERVENTIONAL,['NA']
15502,NCT05962372,Cardiometabolic Improvement Score (CIS),Change in levels of metabolic risk factors,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15503,NCT03261895,Self-management,,,2017-05-04,COMPLETED,INTERVENTIONAL,['NA']
15504,NCT04090307,Effects of TLC group prenatal care on infant skinfold thickness,Determine the effect of TLC on psychosocial stress and depression using the Munich Chronotype Questionnaire (MCTQ),,2019-11-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15505,NCT00589134,osmotic regulation of AVP,temperature responses,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
15506,NCT04920253,Wound Closure,Healed Proportion,AWC Failure,2021-11-29,RECRUITING,INTERVENTIONAL,['NA']
15507,NCT02031081,Change In Cumulative Meal-related Symptoms,Gastric Emptying Rate,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15508,NCT01373476,Ocular fundus,Optic coherence tomography (OCT),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15509,NCT03774095,Gastrointestinal tolerability,,,2018-06-11,UNKNOWN,INTERVENTIONAL,['NA']
15510,NCT00476151,Placebo vs. Active Comparison of the Change From Average Pain at Baseline to Average Pain at 4 Weeks.,,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15511,NCT03449654,Change in vascular inflammation,Carotid intima media thickness,Autonomic nervous system function,2017-10-26,COMPLETED,INTERVENTIONAL,['PHASE4']
15512,NCT03034226,Insulin sensitivity,Symptoms during hypoglycemia,,2017-02-23,COMPLETED,INTERVENTIONAL,['NA']
15513,NCT04701424,Time in the target glucose range (3.9 to 10.0 mmol/l),Total insulin dose,Percentage of time of CGM availability,2020-12-16,COMPLETED,INTERVENTIONAL,['NA']
15514,NCT02183324,"Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, and urinalysis)",DPP-IV activity at different time points,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15515,NCT03760068,Treatment Emergent Antibody Response (TEAR),Change in 7-point Self-monitored Blood Glucose (SMBG) Profile From Baseline,,2018-11-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15516,NCT03520972,Change of glycosylated hemoglobin(HbA1c),Self-monitoring of blood glucose (SMBG),Blood lipid,2018-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15517,NCT02350374,"The individual variation of CHO amount at each main meal : Breakfast, Lunch, Snacks, Dinner",,,2014-11-17,COMPLETED,INTERVENTIONAL,['NA']
15518,NCT05569772,type 2 diabetes,diabetes remission,,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3']
15519,NCT01357109,Peripheral endothelial function,Myocardial perfusion,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15520,NCT00377676,Subjects Experiencing Serious Adverse Events,Change in HbA1c From Baseline to Week 24 for Subjects With a Baseline HbA1c of ≥ 7.5% Who Were Taking at Least One Oral Hypoglycemia Agent (OHA) at Baseline.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15521,NCT02779452,Change in neurodevelopment,Change in DHA level in cord blood,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
15522,NCT02138097,Subsequent Insulin Initiation for MarketScan Patients,Persistence at 12 Months for MarketScan Patients,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
15523,NCT05110404,fasting lipid profile,,,2021-12-25,COMPLETED,INTERVENTIONAL,['NA']
15524,NCT01939522,Pneumococcal serotype-specific (SpVS) antibody concentrations at 3 months following a single dose of 13-valent pneumococcal conjugate vaccine (PCV13),Blood glucose control in the week preceding and the week following immunisation with PCV13,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15525,NCT00511875,Change in Early Treatment Diabetic Retinopathy Study (ETDRS),Change in Arteriovenous Ratio Diameter,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15526,NCT04820270,Immunization,PRA level,,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA']
15527,NCT04924686,NOD2 ligands in fecal and plasma,,,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA']
15528,NCT05739214,percent of wound size measurement methods,percent of wounds complete closure,,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
15529,NCT00001723,Change in BMI Standard Deviation Score,Effect of Race on Change in Weight (kg),,1998-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15530,NCT05282641,Chronic glucose metabolism,Cerebral blood flow (CBF),Exploratory objective micro-albuminuria and kidney function,2021-05-26,COMPLETED,INTERVENTIONAL,['NA']
15531,NCT05291026,Primary outcome measure,Secondary outcome measure II,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
15532,NCT06098729,Accuracy,Interview themes,,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
15533,NCT01715090,Mean change in HbA1c,Detection of important factors for patient compliance to internet-based self-care interventions,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
15534,NCT05094986,Rate of use of services,Outliers registries,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
15535,NCT01603121,Safety and Tolerability of Study Drug,Evaluation of Early Efficacy of Study Drug,,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15536,NCT02675335,mean ulcer size after a treatment period of 12 weeks,,,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15537,NCT05466643,Changes from Baseline HbA1c,,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
15538,NCT05429359,CGM outcomes during and after morning exercise,Change in growth hormone concentration in venous blood during and after morning exercise test,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15539,NCT01703221,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline for Fasting Plasma Glucose (FPG) at Week 24,,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3']
15540,NCT05763303,assessment of change in measurements of glycated hemoglobin (HbA1c),assessment of change in measurement of body mass index (BMI),,2023-10-25,RECRUITING,INTERVENTIONAL,['NA']
15541,NCT02882737,"The primary endpoint is peak plasma glucose achieved within 2 hours after the 200 μg subcutaneous glucagon injection. In the primary analysis, the investigators will compare the peak plasma glucose after exercise and after resting.",The fused data from the two sensors.,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
15542,NCT00775216,The primary outcome will be assessed by the short version of the International Physical Activity Questionnaire and the 6-minute Walk Test.,"Questions regarding readiness to change, self-efficacy, knowledge of and access to physical activity centers, basic demographics, height/weight, and blood pressure will be assessed.",,2008-10,TERMINATED,INTERVENTIONAL,['NA']
15543,NCT02015780,Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Change from Baseline in Total Daily Dose of Insulin at Week 52,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15544,NCT00608387,Glycosylated hemoglobin (HbgA1c),Overall cost-effectiveness,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
15545,NCT01492218,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score,Technical complaints of NovoLet® device,,2004-03-15,COMPLETED,OBSERVATIONAL,['NA']
15546,NCT04731272,Early-phase insulin secretion,Glucose tolerance,,2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
15547,NCT02273258,Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12),"Number of patients with AEs, SAEs, laboratory, vital signs and electrocardiographic abnormalities , injections site reaction assessment (ISR), and if any, hypoglycemia",,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15548,NCT01512849,Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284,Clinical Laboratory Tests,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15549,NCT05756361,Change in Weight for parent and child,"In parents, change in medication dosing",,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
15550,NCT02229383,Change in HbA1c From Baseline to Week 28,Change in Seated Systolic Blood Pressure From Baseline to Week 28,,2014-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15551,NCT01524874,Change in mean serum 25-hydroxycholecalciferol concentration,Change in mean cardiometabolic risk factors,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
15552,NCT01679210,Dietary Intake,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15553,NCT01485614,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin),Participants With Worsening in Dental Status at Week 54,,2012-02-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15554,NCT03380325,Capillary recruitment,Continous cardiovascular monitoring,,2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
15555,NCT00986349,Change in Anti-diabetes Medications,Total Weight Change (kg) at Week 52 Compared to Baseline Weight,Fasting Plasma Glucose Over Time for All Subjects,2010-06,COMPLETED,INTERVENTIONAL,['NA']
15556,NCT02600845,Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24,Percentage of Blood Glucose Tagged Data,,2015-12-30,COMPLETED,INTERVENTIONAL,['NA']
15557,NCT03994289,Postprandial glucose AUC,,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
15558,NCT01368328,Insulin Sensitivity as assessed with homeostatic model assessment (HOMA),urea and creatinine,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
15559,NCT04324229,Incidence of type 2 diabetes,,,2020-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15560,NCT01850134,Hunger,Prospective Consumption,,2013-06,WITHDRAWN,INTERVENTIONAL,['NA']
15561,NCT01854463,glycemic control,arterial stiffenss,non-alcoholic fatty liver diseases and bone turnover marker,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15562,NCT00725257,Hemoglobin A1c,Time to introduction of an oral hypoglycemic agent,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
15563,NCT05170984,Rate of wound closure,Changes in the Pain Visual Analogic Scale,,2022-02-10,RECRUITING,INTERVENTIONAL,['NA']
15564,NCT00573781,"Changes in glucose metabolism, changes in transcriptomic and metabolomic profiles",Interaction between the diet and genetic factors within treatment groups,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
15565,NCT01883258,Change in vascular endothelial function,Change in maximal oxygen consumption,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
15566,NCT02723110,Calculated Incretin Effect,PAM enzyme activity assay,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
15567,NCT05166382,Prescription rates of cardioprotective medications in the informed group vs uniformed group at Month 6,Standard of care risk assessment: Atherosclerotic Cardiovascular Disease risk calculator (ASCVD) at 6 months,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15568,NCT00006438,,,,1997-01,COMPLETED,INTERVENTIONAL,['NA']
15569,NCT00288236,Absolute change in HbA1C from baseline to Week 48,"Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events).",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15570,NCT00147758,To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride as add-on therapy,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15571,NCT00097786,Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15572,NCT00707447,Waist Circumference,Emotional Well-being/ Depression (CES-D),,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15573,NCT00603291,Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52,Percent Change in Body Weight From Baseline to Week 52,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15574,NCT01103622,"evaluate the pharmacokinetics of digoxin after a single dose when administered alone and in combination with AZD1656 at steady state, by assessment of AUC and Cmax of digoxin",describe the pharmacokinetics of digoxin when administered alone or in combination with AZD1656 by assessment of tmax and t1/2.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15575,NCT01574820,"major cardiovascular events, including myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD",Biomarkers measurements,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15576,NCT00592670,Catecholamine measures,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
15577,NCT03267264,Overall User Preference -Combined Groups,User Experience - Each Individual Study Group,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
15578,NCT02863328,Change in HbA1c,Change in CoEQ: Scores From the 4 Domains and the 19 Items,,2016-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15579,NCT00291772,Area under the curve for glucose,glucagon and gastric emptying,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15580,NCT03439345,Progression to referable diabetic retinopathy/maculopathy,Cost-effectiveness (incremental cost per QALY gained),Minor and major non-traumatic lower limb amputation (minor [defined as distal to the ankle] or major [defined as through or proximal to the ankle]),2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4']
15581,NCT03593694,Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months,,,2017-11-06,TERMINATED,INTERVENTIONAL,['NA']
15582,NCT05589467,height in centimeters,,,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15583,NCT06010004,Number of Participants with Treatment Emergent Adverse Events (TEAEs),Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG),,2023-09-28,RECRUITING,INTERVENTIONAL,['PHASE3']
15584,NCT02143765,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Diabetes Treatment Satisfaction,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15585,NCT02722239,Adverse Events,,,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15586,NCT02092051,Difference in HbA1c between week 26 and week 69,Difference in the mean number of severe hypoglycaemic events between weeks 1-26 and weeks 43-69 defined as unconsciousness due to hypoglycaemia or need of assistance from another person to resolve the hypoglycaemia,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15587,NCT03490747,Change in cardiorespiratory fitness,Change in patient health care utilisation costs,Exercise referral practitioner (ERP) interviews (intervention group only),2018-03-12,COMPLETED,INTERVENTIONAL,['NA']
15588,NCT03211832,Partnerships to Support EBDM,Inter-agency Connectedness,,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
15589,NCT02906319,HbA1c levels,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
15590,NCT00607867,Change in Overnight Fasting Glucose Concentration at 5 Weeks From Baseline,Change in Fasting Triglycerides at 5 Weeks From Baseline,,2008-04,TERMINATED,INTERVENTIONAL,['NA']
15591,NCT00655044,HbA1C,Safety,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
15592,NCT06285487,Changes in Glycemic Control,,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15593,NCT02184455,Percentage of Wound Area Reduction Compared to Baseline,Percent Change in Wound Area From Baseline,,2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15594,NCT01867216,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve (AUEC₀-₁₂) During Mixed Meal Tolerance Test at Day 28,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15595,NCT05979987,Opening link within SMS Text message,Completion rate of one screening/test,,2023-07-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15596,NCT01247896,"The single dose PK of PF-05190457 will be described by estimating parameters of AUC(0-infinity), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit","Gastric half-emptying time (GET½), the duration of the lag phase (Tlag), gastric emptying coefficient (GEC)",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15597,NCT03681249,24H urine total protein,,,2018-11-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15598,NCT05921461,PedCheck parameters that demonstrate correlation between HOVR and Ankle Brachial Index (ABI) and Toe Brachial Index (TBI).,Evaluation of usability based on collected data using standard pain scoring questionnaires.,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
15599,NCT01559181,Pubertal development,PCOS,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
15600,NCT03520855,Diapason questionnaire (Aide aux Jeunes Diabètes),Evaluation of well-being with DQOLY,,2019-04-03,RECRUITING,INTERVENTIONAL,['NA']
15601,NCT03202277,Fasting glucose,Dietary quality measured by the NCI dietary factor screener,,2017-09-17,COMPLETED,INTERVENTIONAL,['NA']
15602,NCT04503551,Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52,Reported incidence of device deficiencies,,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15603,NCT01390610,Derive optimum Self Monitored Blood Glucose (SMBG) testing patterns from CGM data. CGM data will be graphically and statistically represented by an Ambulatory Glucose Profile (AGP).,,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
15604,NCT05660941,Time in range,Time above and below significant sensor glucose levels,,2023-07-21,RECRUITING,INTERVENTIONAL,['NA']
15605,NCT01177163,The number of patients with symptomatic hypoglycemia and severe hypoglycemia,Change in urine glucose excretion (pharmacodynamics parameter),,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15606,NCT05127538,Dynamic Balance,,,2021-12-10,COMPLETED,INTERVENTIONAL,['NA']
15607,NCT01996228,Autoimmune control,Metabolic control,,2013-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15608,NCT01467674,HbA1c,Clinical Periodontal Status,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
15609,NCT03926806,Glycemic control,Change of GLP-1 response,,2016-11-25,COMPLETED,INTERVENTIONAL,['NA']
15610,NCT02806960,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1']
15611,NCT01831752,blood glucose correlation coefficient,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
15612,NCT06082063,MACE + HHF,"Diabetic ketoacidosis, safety",Long term risk of DKA,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15613,NCT05221359,Safety: Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the whole duration of the study (extension phase included),Quality of Life: Overall score and subscores of the Diabetes Quality of Life (DQOL) questionnaire,,2022-05-05,RECRUITING,INTERVENTIONAL,['NA']
15614,NCT00727779,euglycemic clamp steady state glucose infusion rate (clamp GIR),GLUT4 content of muscle,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15615,NCT01677546,HbA1c (Glycated hemoglobin),Frequency of bolus calculator using,Body mass index- standard deviation (BMI- sds),2011-01,COMPLETED,INTERVENTIONAL,['NA']
15616,NCT05132335,To evaluate the repeatability of the ratio of subcutaneous adipose tissue (SAT) to skeletal muscle fatty acid uptake rates,,,2021-03-29,COMPLETED,INTERVENTIONAL,['NA']
15617,NCT00035984,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15618,NCT04714762,Change in fasting glucose,Costs,,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15619,NCT02500485,The number of volunteers with adverse events as a measure of safety and tolerability.,,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
15620,NCT05915975,Change in Glycemic Control,Change in Diabetes Self-Management,,2023-11-07,RECRUITING,INTERVENTIONAL,['NA']
15621,NCT06246851,Intradermal (in type 2 diabetics) vs intradermal (in non-type 2 diabetics),Intradermal or aerosol BCG re-vaccination safety in healthy volunteers,Examination of immunological and microbiological markers,2024-02,RECRUITING,INTERVENTIONAL,['NA']
15622,NCT03311724,Change From Baseline in Haemoglobin A1c (HbA1c),Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide,,2017-10-19,COMPLETED,INTERVENTIONAL,['PHASE2']
15623,NCT06005519,change in body fat percentage in long time period,,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA']
15624,NCT03362528,Generation and validation of predictive algorithms for determining blood glucose levels,,,2017-09-25,COMPLETED,INTERVENTIONAL,['NA']
15625,NCT01137474,Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12,Adjusted Mean Change From Baseline in Serum Uric Acid Levels at Week 12,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15626,NCT03734718,Blood glucose,Number of symptomatic hypoglycemic events,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
15627,NCT02502253,"Evaluate BDPP effect on cognition with measures of memory, executive function, and attention measures (composite)",,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15628,NCT01396330,Mean and maximum change from baseline in glucose level (mmol/l),,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
15629,NCT05936203,Insulin doses delivered,,,2023-01-11,COMPLETED,INTERVENTIONAL,['NA']
15630,NCT05140694,Changes of CAP score,Changes of inflammation biomarker,Changes of gut microbiota,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
15631,NCT00409461,,,,na,TERMINATED,INTERVENTIONAL,['NA']
15632,NCT03468283,hemoglobin A1c levels,the Problem Areas in Diabetes,,2012-08-07,COMPLETED,INTERVENTIONAL,['NA']
15633,NCT00675311,"The primary study measures for this study include glycemic control and LDL levels, satisfaction with diabetes care, and adherence to diabetes medications and self-monitoring recommendations",Secondary measures include diabetes-related health-care utilization and physiologic data.,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
15634,NCT00774904,"GFR, HbA1c and the adiponectin concentration",,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
15635,NCT03539133,Rehospitalization due to heart failure,Restenosis rate,,2017-10-18,RECRUITING,OBSERVATIONAL,['NA']
15636,NCT05104437,Neutralizing antibody level,Adverse events following vaccination,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
15637,NCT00676741,Metabolic control measured as HbA1c,Number of adverse drug reactions (ADR),,2008-02,COMPLETED,OBSERVATIONAL,['NA']
15638,NCT06288412,"Time below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe)","Number of hypoglycaemic episodes for 18 hours in reference week (26 to 44 hours after dosing) (Hypo18h,ref)",,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE1']
15639,NCT05309057,Body weight,Markers of inflammation - CRP,,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA']
15640,NCT00332488,Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue,Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment),,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15641,NCT02298192,Change From Baseline in HbA1c,Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes,,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3']
15642,NCT04833413,Change in HbA1c,Impact on body weight,,2021-04-15,RECRUITING,OBSERVATIONAL,['NA']
15643,NCT05093569,to determine the accuracy of K'Watch Release 0.x CGM system glucose readings at day 1 as compared to standard references.,Safety of the K'Watch system characterizing device-related pain intensity (Visual Analogue Scale scores from 0-10) recorded during the study.,,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA']
15644,NCT00362765,Endogenous Glucose Production (EGP) and Glucose Disposal Rate (GDR) by two-step hyperinsulinemic euglycemic clamp (HEC),"Gluconeogenesis, Glycogenolysis, Skeletal muscle and liver fat content, Abdominal fat content, Body energy expenditure and respiratory quotient, Lipids and glycemic parameters",,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15645,NCT04791826,Frequency of prescription of SGLT-2i medication at outpatient clinic visits,Adherence of prescription of SGLT-2i medication at outpatient clinic visit,Frequency of incident HF,2021-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15646,NCT00869076,Hgb A1c change,Percent of patients with a 1 point decrease in A1c by ethnicity,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15647,NCT06018844,Moderate to Vigorous Physical Activity (MVPA) levels,Change in participant HbA1c,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15648,NCT04531462,Change in HbA1c From Baseline After 52 Weeks of Treatment,Change of Time in the 5-time Chair Stand Test From Baseline to Week 52,,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15649,NCT04076800,Insulin daily doses,HbA1c,,2019-08-01,RECRUITING,INTERVENTIONAL,['NA']
15650,NCT01761318,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Myocardial T1 - mapping,Hypoglycaemic episodes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
15651,NCT05261776,Blood glucose level,,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
15652,NCT02501746,Change in Systolic Blood Pressure,Change in cardiovascular disease (CVD) risk Score,,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
15653,NCT01276106,Change in HbA1c From Baseline,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15654,NCT01786707,Number of Participants With a Reduction of HbA1c of >0.5%,The Number of Subjects With a Reduction of >1% in HbA1c,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15655,NCT03658980,Number of Participants Who Had Successful Referrals,Increase in Knowledge About Diabetic Retinopathy,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
15656,NCT01309698,Pharmacokinetics of vildagliptin,"Pharmacodynamic parameters (dipeptidyl peptidase IV (DPP-4) activity, glucagon-like peptide-1(GLP-1), glucose, insulin, glucagon)",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15657,NCT06200519,Persistence of diastolic function changes into infancy,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15658,NCT03766308,HbA1c,Change in Waist circumference,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
15659,NCT03150199,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,Change in Hemoglobin A1c,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
15660,NCT04667143,Mean change from baseline in HbA1c at Week 24,,,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
15661,NCT03659383,Rate of reaching target of glucose,Time of reaching target of glucose,,2018-09-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
15662,NCT00933062,To assess the plasma pharmacokinetic profile of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.,To assess the safety and tolerability of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.,,2009-03-23,COMPLETED,INTERVENTIONAL,['PHASE1']
15663,NCT00138606,Change from baseline in HbA1c at 52 weeks,Change from baseline in mean daily number of insulin injections at 52 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15664,NCT02693964,Difference in carotid intima media thickness between postmenopausal women with type 1 diabetes and controls,Correlation between biomarkers with cardiovascular risk measures (carotid intima media thickness),,2016-03,COMPLETED,OBSERVATIONAL,['NA']
15665,NCT00130208,Number of Subjects With Greater Than 50% Reduction in Microalbuminuria,Change in Serum Albumin From Baseline to End of 26 Weeks,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
15666,NCT01864174,"Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation",Percent of Participants With HbA1c < 7%,,2013-06-20,COMPLETED,INTERVENTIONAL,['PHASE4']
15667,NCT05630417,Blood Parameters Follow-up Form,Blood Parameters Follow-up Form,,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
15668,NCT00879970,Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D,"Mean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)",,2009-05,TERMINATED,INTERVENTIONAL,['PHASE4']
15669,NCT01515202,"Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests","Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione)",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15670,NCT00715624,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15671,NCT05163002,Differences between baseline A1c (%) and 90 days after the last educational session.,Difference in mean glycaemia (mg /dL) between baseline and 90 days following the last educational session,,2021-05-10,UNKNOWN,INTERVENTIONAL,['NA']
15672,NCT04412200,Cytokine secretion,AUC of stimulated C peptide,,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
15673,NCT03367663,Serum atherogenicity,,,2018-01-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15674,NCT03017287,Correlation between GlucoMe and HCT recommendations,Target HbA1C/glucose achievement,,2017-01,TERMINATED,INTERVENTIONAL,['NA']
15675,NCT03502174,FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects,,,2018-04-05,COMPLETED,OBSERVATIONAL,['NA']
15676,NCT00331604,Treatment difference in HbA1c,Hypoglycaemia,,2006-08-31,TERMINATED,INTERVENTIONAL,['PHASE3']
15677,NCT00759720,Change from Baseline in Glycosylated hemoglobin level.,"Low-density lipoprotein fractionation [L-DL particles (total), intermediate-density lipoprotein, large L-DL, small L-DL (total), medium-small L-DL, very-small L-DL, mean L-DL size].",,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15678,NCT03761615,Time in range glucose levels as determined by CGM,Carbohydrate consumption,Length of hospital stay,2018-11-13,COMPLETED,OBSERVATIONAL,['NA']
15679,NCT05041621,Comparison of 5 hours postprandial percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations,Mobile app usability questionnaire: score is the average of 16 items and each item scores ranges 0-6 (average of higher scores means higher usability),,2021-07-07,COMPLETED,INTERVENTIONAL,['NA']
15680,NCT02350478,Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks,Changes in Biochemical Markers (svCAM-1),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15681,NCT03928379,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline in Fasting Plasma Insulin,,2019-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
15682,NCT03958591,the proportions of treatment simplification,,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15683,NCT01882036,Measure homeostasis model assessment i.e. estimated change in insulin resistance (HOMA-IR) index,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15684,NCT02361437,Rate of healing of diabetic ulcers measured by ulcer size,lower extremity skin oxygenation measured by trancutaneous oximetry,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
15685,NCT02947555,Association of lens autofluorescence with atherosclerotic vascular events,Association of lens autofluorescence with antropoetric parameters,,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA']
15686,NCT04548232,Hepatic steatosis,Fertility,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15687,NCT04926623,HbA1c (%) changes at 24 weeks compared to baseline,,,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
15688,NCT01493895,To assess the efficacy of b-cure laser in patients with diabetes mellitus induced lower leg skin ulcers,safety,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15689,NCT01960062,Change in Hemoglobin A1c,Office visit time,,2011-10,WITHDRAWN,INTERVENTIONAL,['NA']
15690,NCT03073343,Change in alanine aminotransferase (ALT) level in all study participants,Compare changes in alanine aminotransferase (ALT) level in both cohorts,,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA']
15691,NCT01063374,plaque volume,retinal photography,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15692,NCT01709201,Percent days abstinent,Medical complications,Medical complications 90 days post baseline,2013-07,WITHDRAWN,INTERVENTIONAL,['NA']
15693,NCT02247271,Patient Activation Measure (PAM),Self-reported healthcare utilization,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
15694,NCT00279240,Reduction in conversion of IGT to diabetes,Benefits of the drug on anthropometric variables and biochemical parameters,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15695,NCT00435981,To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase).,To evaluate the safety of Diamyd® 20ug.,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15696,NCT03932721,Difference in the percentage change in flow mediated dilation (FMD),Difference in the percentage change in FMD reserve,Difference in Plasma C-Reactive Protein Change in mg/dL from randomization to 16 weeks of treatment.,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15697,NCT00974272,Triglyceride concentration in serum,"serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15698,NCT01818674,Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.,Relative changes in blood pressure between individual trial arms,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
15699,NCT05148897,Evaluate general knowledge of women about different aspects of Gestational Diabetes: Questionnaire,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
15700,NCT03185689,Proportion of T2D patients with controlled BGL as measured by a change in HbA1c,Proportion of T2D patients with a recommended level of diabetes self-care behavior as measured by summary of diabetes self-care activities (SDSCA) questionnaire,Change in the level of depressive symptoms as measured by patient health questionnaire depression scale (PHQ-9),2016-04-04,COMPLETED,INTERVENTIONAL,['NA']
15701,NCT03591939,rate of patients with positive T-regulatory cells in blood,,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
15702,NCT05540132,Time to completion of distance bike challenge,Glycemic variability in the 12 hours following the exercise test,,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15703,NCT02804698,Framingham cardiovascular disease risk,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
15704,NCT02455011,"Number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs","Geometric mean ratio to baseline over time of AST, ALT, ALP and total bilirubin.",,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15705,NCT03478306,"Progression of diabetic retinopathy, oscillary potential",Retinal structure,,2018-03-27,COMPLETED,INTERVENTIONAL,['PHASE3']
15706,NCT03602950,changes in wound healing,morbidly wound healing,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15707,NCT06291766,Adverse Pregnancy Outcome,Week of delivery,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
15708,NCT05396378,Increase of blood glucose following the oral glucose dose,Maternal subjective well being after oral glucose dose during the preoperative fasting period,,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15709,NCT00891995,C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.,BMI Percentile,,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15710,NCT01978704,mean plasma glucose concentrations,postprandial plasma glucose concentrations,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15711,NCT02951260,Overall aerobic work performed during an exercise bout with self-selected intensity,Physical fitness (VO2max),Oxidative phosphorylation in skeletal muscle fibers,2016-10,COMPLETED,INTERVENTIONAL,['NA']
15712,NCT02917226,fasting blood glucose,,,na,UNKNOWN,INTERVENTIONAL,['NA']
15713,NCT01154413,Reduction in hypo/hyperglycemia episodes,"Lower mean glycemia, reduced time of stay in hospital",,2007-12,COMPLETED,INTERVENTIONAL,['NA']
15714,NCT01135394,Change in Insulin Resistance,Number of Genes Determined to be Correlated With Change in Insulin Sensitivity,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
15715,NCT00321321,Insulin Secretion,,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15716,NCT00191178,Instruments used/tests performed:hand held computers to rate a series of 13 symptoms;hand held computers to administer a series of cognitive-motor performance tests;blood glucose testing,"blood glucose rate of change;eight-point self-monitored blood glucose profile;episodes of hypoglycemia, including episodes of severe hypoglycemia",,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15717,NCT01780051,AUCt and Cmax of repaglinide and metformin,"AUC∞, Tmax, t1/2, CL/F and Vd/F of repaglinide and metformin",,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15718,NCT05802121,Side effects and tolerability,Bone health: Vitamin K2,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15719,NCT02998008,echocardiography,,,2017-01-02,TERMINATED,INTERVENTIONAL,['NA']
15720,NCT06318611,Chronotype,Glycemic control,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
15721,NCT05935839,Visualization of tissue changes in diabetic patients using MSOT.,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15722,NCT01899274,Changes in Hemoglobin A1C levels,bant Component Usage,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
15723,NCT01830569,Pre- to post-implementation change in HbA1c.,Pre- to post-implementation change in a composite process score.,Actual use of the EBMeDS system,2017-03-29,COMPLETED,INTERVENTIONAL,['NA']
15724,NCT02430870,Percentage of Participants Who Have Severe Hypoglycemia at Least Once Post-dose During Dosing For Part 2,AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 Over the Dosing Interval for TAK-648 for Part 2,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15725,NCT04585581,Plasma glucose concentration,Infant bone mass,Infant bone mass,2020-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15726,NCT03662984,Myocardial insulin sensitivity,Cholesterol profile,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15727,NCT02115932,Change in EQ5D HUI from baseline at 2 and 6 months,Cost-utility of intervention measured by cost per Quality-Adjusted Life Year (QALY) gained,Change in gait from baseline at 2 and 6 months,2014-07-30,COMPLETED,INTERVENTIONAL,['NA']
15728,NCT05181631,Echographic cardiomyopathy,,,2022-01-15,UNKNOWN,INTERVENTIONAL,['NA']
15729,NCT01285518,Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry,Volume of Distribution at Steady State (Vss) of PF-05231023,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15730,NCT00639964,fetal weight corrected by gestational age,erythrocytary and plasmatic fatty acid distribution,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15731,NCT01030796,Caffeine abstinence,HbA1c,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15732,NCT00343343,Deposition of sterile air depositions.,Amount of backflow,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15733,NCT00315952,"To perform positron emission tomography (PET) imaging of [18F]-fluoro-deoxy-glucose (FDG) uptake by muscle, following administration of a single dose of inhaled compared to infused insulin in volunteers with type 1 diabetes",To determine overnight rates of glucose production and plasma glucose after a single pre-dinner dose of inhaled compared to IV infused insulin in volunteers with type 1 diabetes,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15734,NCT00848705,Self-management behaviors,Self-management Problem solving,,2007-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15735,NCT04698720,Immune cells,Representations regarding the DFU,Heart rate,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15736,NCT02749435,Mean Change from baseline to Month 6 in HbA1c,Proportion of patients in both cohorts who intensify antihyperglycaemic treatment from Visit 1,Change from baseline to Month 6 in Morisky 8-item scale (adherence),2016-05-03,TERMINATED,OBSERVATIONAL,['NA']
15737,NCT01486888,Maximum serum insulin concentration (Cmax),Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15738,NCT02675855,Complete closure of index wound,Number of patients with worsening of wound by ≥50% increase in size,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15739,NCT01327404,,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
15740,NCT01820715,Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event,overnight pain score,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15741,NCT05483777,Wound Observation and Evaluation Form,,,2023-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15742,NCT03512665,Homeostasis Model Assessment - Insulin Resistance (HOMA-IR),Change in plasma FGF-21,,2018-04-07,COMPLETED,INTERVENTIONAL,['NA']
15743,NCT04001283,Metabolic protein expression in cardiac biopsies and vascular offcuts,,,2013-01-21,UNKNOWN,INTERVENTIONAL,['PHASE2']
15744,NCT01976923,Visual acuity change,Proportion of eyes gaining at least 15 letters of BCVA,Molecules in the vitreous humor and epiretinal membranes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15745,NCT05841225,diet adherence,,,2023-06-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15746,NCT06333977,"Incidence, severity of adverse events",Renal Clearance (CLR) in urine,HbA1c,2022-03-25,COMPLETED,INTERVENTIONAL,['PHASE1']
15747,NCT02079805,Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12),Number of Participants With Treatment-Emergent Adverse Events,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15748,NCT03766854,"AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state","GIRmax,0-24h,SS - Maximum observed glucose infusion rate at steady state",,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15749,NCT02842554,Pain Assessment Training,Predicted Response to Training,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15750,NCT02344082,Change in hemoglobin A1c,Telemedicine Adherence (Percent of telephone encounters completed in intervention arm),,2015-01,COMPLETED,INTERVENTIONAL,['NA']
15751,NCT04829903,Adverse effects,,,2020-01-02,COMPLETED,INTERVENTIONAL,['NA']
15752,NCT01973400,"Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes type 1 and 2 neuropathy.",Neuropathy Impairment Score (NIS) of patients with diabetes type 1 and 2 neuropathy,"Mini Mental State Examination (MMSE) score, Montreal Cognitive Assessment (MoCA) test.",2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15753,NCT03489083,Heat Shock Response Change.,Visceral Adipose Tissue Change.,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
15754,NCT04647617,5-time chair stand test,WHOQOL-BREF World Health Organization Quality of Life Taiwan version,,2020-08-24,COMPLETED,INTERVENTIONAL,['NA']
15755,NCT04537637,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-08-28,COMPLETED,OBSERVATIONAL,['NA']
15756,NCT03549845,Healthcare Utilization Composite - Change in CVD-related emergency department visits and hospitalizations,Participant experience of the CHAP intervention,Cardiovascular Risk - Change in diabetes risk score,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
15757,NCT00754624,Annual Rate of Change in FEV1 From Baseline to End of Study,High Resolution Computerized Tomography Scans of the Chest,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15758,NCT02617693,Difference in waist circumference,"Change in stress levels, as measured by the Depression Anxiety and Stress Scale 21-items (DASS-21) used in National Health Surveys in Malaysia",,2015-11-23,COMPLETED,INTERVENTIONAL,['PHASE4']
15759,NCT00289705,BMI development,"Medical risk factors, incidence of diseases (such as diabetes, hypertension etc), quality of life, socioeconomic development, eating pattern.",,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
15760,NCT01096277,Endothelial function,Effect on EPCs,,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
15761,NCT01490112,Change in weight,Adverse events: Serious and non-serious,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
15762,NCT04593173,Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
15763,NCT00333723,Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy in reducing glycosylated hemoglobin (HbA1c).,"Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy upon FPG, c-peptide, HOMA and responder rates.",,2000-07-28,COMPLETED,INTERVENTIONAL,['PHASE4']
15764,NCT01770639,Treatment failure within the first year after surgery,Foot angles,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
15765,NCT04141761,Effect of Multistrain Probiotic on Immune System Inflammation as measured by plasma transcription analysis,System-wide Effects as measured by systemic microbial antigen (a marker of intestinal permeability) as measured by plasma analysis,,2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15766,NCT03283774,Cost analysis,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
15767,NCT04215328,Weight change between groups,Changes in gut hormone levels,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
15768,NCT06086912,"After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax)",Immunogenicity indicators: anti-INS068 antibodies,,2023-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15769,NCT03088566,Patients reported experience measure (PREM),Patients reported outcome measure (PROM),,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
15770,NCT01556984,The changes of endothelial function,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
15771,NCT02377388,changes on platelet aggregability.,platelet aggregability differences by two point-of-care methods.,"measure of safety, Number of participants with adverse effects by analysis on changes of serum level",2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15772,NCT03249077,Weight,HbA1c (24-month for digital DPP),Motivation for continuing,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
15773,NCT02084654,First-phase insulin response,glucose lowering effect,insulin-mediated glucose uptake (insulin sensitivity),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15774,NCT01037582,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9924 compared to i.v. and s.c. administration of the same compound,,2009-12-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15775,NCT01183715,Single dose pharmacokinetics of PF-05161704 and its metabolite PF-05200145,Preliminary pharmacodynamics of PF-05161704,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15776,NCT01304836,Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantation,Change from Baseline in HbA1C levels,,2011-01-22,COMPLETED,INTERVENTIONAL,['PHASE4']
15777,NCT03740074,App utility,Personal Activity Intelligence (PAI) Score,,2018-10-02,COMPLETED,INTERVENTIONAL,['NA']
15778,NCT04057261,Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months,Differences in circulation inflammatory cell composition by flow cytometry analyses (FACS) between Liraglutide treatment group and placebo group,,2020-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15779,NCT01191866,,,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
15780,NCT04029402,Renal function change,,,2019-07-01,RECRUITING,OBSERVATIONAL,['NA']
15781,NCT01839344,Glucose tolerance following a maltose tolerance test,Area under the Glucose Curve (AUC),Reactive Hyperemia Index (RHI),2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15782,NCT03318601,Correlation between copetine and other biomarkers,Copetine concentrations,,2016-05-09,UNKNOWN,INTERVENTIONAL,['NA']
15783,NCT00560417,Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]),Total Daily Insulin Dose at Endpoint (LOCF),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15784,NCT00642174,Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay,Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15785,NCT04186195,Children's type 1 diabetes glycemic control,Parent's type 1 diabetes glycemic status,,2020-11-03,COMPLETED,OBSERVATIONAL,['NA']
15786,NCT03064347,Difference in AUC of GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,Difference in Peak GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,,2017-02-22,COMPLETED,INTERVENTIONAL,['NA']
15787,NCT03961854,Adverse Event and/or Serious Adverse Event,,,2019-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
15788,NCT02065310,Percentage of quality controls that fall within 15% of the nominal value for a analytical run of the CEdG assay.,Correlation of Hemoglobin A1c and CEdG levels,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
15789,NCT03774511,Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),Visceral adipose fat,,2017-07-09,COMPLETED,INTERVENTIONAL,['NA']
15790,NCT00823849,"Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.",,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15791,NCT05887999,Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia,Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,,2023-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15792,NCT03817749,Glucose control,Change from baseline caspase-1 activation at 14 days,,2019-02-06,COMPLETED,INTERVENTIONAL,['NA']
15793,NCT03977727,1-Hour Change in Postprandial Plasma Glucose (PPG),Pump Occlusions,,2019-06-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15794,NCT03077360,Percent Change in Body Weight Compared to Baseline Measurement,,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
15795,NCT06336486,Visual Analog Scale(VAS),36-Item Short Form Health Survey(SF-36),,2018-12-04,COMPLETED,INTERVENTIONAL,['NA']
15796,NCT06146322,Food intake,,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
15797,NCT05292833,The percentage of patients adhering to the Mediterranean Diet,Describe the difficulties/barriers to the initiation of the Mediterranean Diet,,2023-07-06,RECRUITING,OBSERVATIONAL,['NA']
15798,NCT01617434,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26,Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15799,NCT01935167,log ACR,Cystatin C,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15800,NCT00627484,Change in Insulin Sensitivity,Change in Resting Energy Expenditure,,2005-03-01,COMPLETED,OBSERVATIONAL,['NA']
15801,NCT03254524,Emergency Deparrtment (ED) visit by a patient,Hospital Selection,,2014-08-20,COMPLETED,OBSERVATIONAL,['NA']
15802,NCT05434559,Time in range,Body mass index,Glycemic consensus targets,2022-02-20,COMPLETED,OBSERVATIONAL,['NA']
15803,NCT02634333,Change in Visual Acuity From Baseline,Development of PDR and/or DME (Whichever Came First),,2016-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15804,NCT01588418,Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism,Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15805,NCT02028195,Functional capacity,,Health economy assessment,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
15806,NCT03865381,Mean Change in Hemoglobin A1c,Mean Change in A1c,,2019-02-08,COMPLETED,INTERVENTIONAL,['NA']
15807,NCT00683735,To assess the effect of co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load),To assess the effect of sitagliptin compared with placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load),,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15808,NCT02226640,Perform 'deep' clinical and molecular phenotyping of 360 adults- Diabetic and Non-Diabetic,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
15809,NCT06064669,healthy live birth,Cumulative live birth,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15810,NCT03607435,Calibration of the KBS-1 Test Article using the POC Control data for comparison.,Calibration of the RBA-1 Test Article using the hospital lab test Control data and POC blood glucose monitor Control data for comparison.,,2018-08-02,UNKNOWN,INTERVENTIONAL,['NA']
15811,NCT04428645,Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl,Change in Coefficient of Variation of Sensor Glucose Based on the Dexcom G6 CGM Data.,,2020-07-21,COMPLETED,INTERVENTIONAL,['NA']
15812,NCT01088451,Differences in mean blood glucose concentrations and the pattern of fluctuation on control and study days; and changes in the glycated hemoglobin A1c after the study period. Occurrence of side effects especially hypoglycemic episodes.,"The difference in postprandial areas under the curve when comparing conventional therapy and experimental combined prandial insulin therapy in the 5 to 6 hours following meal ingestion, taking into account the glycemic index profile of the meal.",,2009-12,UNKNOWN,INTERVENTIONAL,['NA']
15813,NCT04105608,Changes in serum GLP-1 concentration,Hunger-satiety scores (millimeters),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
15814,NCT03987438,The risk of diabetes mellitus (DM) in patients with impaired glucose tolerance,Changes in glycosylated hemoglobin levels.,,2019-08-03,UNKNOWN,INTERVENTIONAL,['NA']
15815,NCT03033849,Acceptance criteria defined by ISO 15197:2013 (E) will be applied,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
15816,NCT00893425,Flow mediated dilatation,ADMA CD95,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15817,NCT03602638,coronary calcification score,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15818,NCT00767884,Changes in optic nerve head topography before and after panretinal photocoagulation,,,2008-10-29,TERMINATED,OBSERVATIONAL,['NA']
15819,NCT02123563,plaque and gingival indices,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15820,NCT05622630,Vibration sensation test,,,2019-08-13,COMPLETED,INTERVENTIONAL,['NA']
15821,NCT03487029,muscle oxigeneration,Physical activity level,,2018-03-02,COMPLETED,INTERVENTIONAL,['NA']
15822,NCT01429818,%ΔMBF,Adverse effects,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15823,NCT03910205,Interleukin-18 level,Tnf-alpha level,,2019-04-08,COMPLETED,OBSERVATIONAL,['NA']
15824,NCT04499820,density of the deep capillary plexus in optical coherence tomography angiography (OCTA),Diet questionnaire,,2020-06-26,RECRUITING,INTERVENTIONAL,['NA']
15825,NCT03699189,HbA1c,The quality of life,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15826,NCT05373199,AUCGIR 6-24h,Local tolerability,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15827,NCT00645424,Percentage of subjects with low-density lipoprotein cholesterol (LDL-C) levels of <100 mg/dL (LDL-C responders) at Week 12,"Percentage of subjects with total cholesterol (TC) levels of <160 mg/dL (TC responders) at Weeks 4, 8, and 12",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15828,NCT03594344,Intact skin with no abnormal openings at the site of primary amputation,The Foot and Ankle Ability Measure (FAAM),,2018-07-04,RECRUITING,INTERVENTIONAL,['NA']
15829,NCT05348499,Diabetes Distress Score-T1 score in people with type 1 diabetes,Thematic analysis of semi-structured interviews to explore the impact of HCL systems on different aspects of life and daily functioning of people with type 1 diabetes and their partners.,,2021-11-14,RECRUITING,OBSERVATIONAL,['NA']
15830,NCT00184600,HbA1c (Glycosylated Haemoglobin) at Month 36,Number of Participants Having an 'Other' Adverse Event,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15831,NCT05317455,PDH flux in the frontal lobe,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15832,NCT00006165,,,,na,COMPLETED,INTERVENTIONAL,['NA']
15833,NCT01377155,Days to reach the titration target,The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
15834,NCT05517863,percent of wounds complete closure,percent of days needed for surface area reduction,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
15835,NCT04795531,Change in HbA1c (glycated haemoglobin),Mean weekly insulin dose,,2021-03-24,COMPLETED,INTERVENTIONAL,['PHASE3']
15836,NCT00148304,diabetes self-care/attitudes,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
15837,NCT01616433,Glucose,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15838,NCT06192121,Diabetes Self-Care Activities,,,2023-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15839,NCT00857870,Area under the curve (AUC) after a testmeal measured CGM.,"HbA1C, glycemic variability, glycemic load, insulin secretion after testmeal, free fatty acids, biomarkers of low grade inflammation, endothelial dysfunction.",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15840,NCT05782881,"Composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome)",Blood pressure( both diastolic and systolic will be measured),,2023-01-15,RECRUITING,INTERVENTIONAL,['NA']
15841,NCT04878393,Number of adverse event (AEs),Number of serious adverse reactions (SARs),,2021-04-30,COMPLETED,OBSERVATIONAL,['NA']
15842,NCT03222245,Change in quality of life,Change in HbA1c,,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
15843,NCT03398902,Change in % time glucose is ≥ 140mg/dL,,,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15844,NCT01617824,M1/M2 polarization balance,Endothelial progenitor cell levels,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
15845,NCT02397447,Insulin Sensitivity (Matsuda Index) After 90 Days,AUC-insulin After 90 Days,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15846,NCT00471926,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
15847,NCT00348725,Quotation by Visual Numeric Rating Scale before and after 4-week treatment,Assessment of safety by reporting of Adverse Events,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15848,NCT03353376,change in in Hba1c levels,change in non HDL Cholesterol,change in number in hospital admission,2010-09-13,COMPLETED,INTERVENTIONAL,['NA']
15849,NCT03591081,"The proportion of patients who self-refer for recurrence of diabetic foot-ulcer over a twelve-month period, compared with the current National diabetes foot audit average of 33.3%",Changes in cardiovascular markers,,2018-06-22,COMPLETED,INTERVENTIONAL,['NA']
15850,NCT06121856,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood,,,2023-02-07,COMPLETED,OBSERVATIONAL,['NA']
15851,NCT05365529,Glycemic regulation assessed by HbA1c,Quality of life Assessment via Short Form-36 Questionnaire (SF-36),Long term TRE adherence,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
15852,NCT03024944,Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR),,,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15853,NCT00743002,"To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg.",To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15854,NCT06160063,Evaluation of Literacy Scale for Acute Complications of Diabetesfor Children with Type 1 Diabetes (8-12 years),,,2023-01-16,COMPLETED,INTERVENTIONAL,['NA']
15855,NCT04167761,Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.,Distribution of adipose cell size in epicardial tissue.,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15856,NCT02518945,Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.,Change in Blood Ketone Bodies,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE3']
15857,NCT05773495,Change in Diabetic Screening Rate,Follow Up Rate For In-Person Eye Care Among Screen Positives,,2024-03-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15858,NCT01212913,Change in hemoglobin A1c level (HbA1c),Continuous Glucose Monitoring System (CGMS) data,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15859,NCT02144441,Trial feasibility metric: reasons for disenrollment,Hypoglycemia,,2014-06,WITHDRAWN,INTERVENTIONAL,['NA']
15860,NCT01847144,Change in fasting glucose,Additional changes in biochemical results,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15861,NCT03010475,Area under the rosuvastatin plasma concentration-time curve,Maximum observed rosuvastatin plasma concentration,,2017-01-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15862,NCT01825148,pancreatic uptake of radiolabeled Exendin,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
15863,NCT01827735,The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2.,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15864,NCT02230488,Prevent <31 day readmission,improve overall glycemic management,Patient satisfaction,2014-09,TERMINATED,INTERVENTIONAL,['NA']
15865,NCT05256615,Sleep (minutes per night),Infant Apgar Scores,,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
15866,NCT01762644,Insulin Independence and Hemoglobin A1c (A1C) < 6.5%,Average daily insulin requirement per week,,2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15867,NCT04418908,Change in quantitative immunuofluorescence of endothelial cell proteins,,,2010-11-24,COMPLETED,INTERVENTIONAL,['NA']
15868,NCT01649219,Glucose and lipid metabolism,Changes in muscle metabolism,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15869,NCT02250222,Number of participants with one or more drug related adverse events or serious adverse events,PK profile (maximum concentration (Cmax) of LGD-6972 after repeat oral doses in NHS and in subjects with T2DM,"Change from baseline in fasting plasma active and total GLP-1 measured during an OGTT on Day 14 of treatment with LGD-6972 at 0.5, 1, 1.5, 2, 3, and 4 hours post-glucose load in one dose group of subjects with T2DM",2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15870,NCT03155594,Changes in care,Accuracy of device,,2017-05-09,UNKNOWN,INTERVENTIONAL,['NA']
15871,NCT04900636,Impact on quality of life,Metabolic control,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
15872,NCT05035082,Change in Glycosylated hemoglobin A1c (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Relative treatment satisfaction total score",,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15873,NCT02464800,Visual acuity,Retinal reattachment,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
15874,NCT04466501,"Evaluate the performance agreement of the ACR |LAB compared to the comparator device, tested by professional users.",,,2019-06-30,COMPLETED,INTERVENTIONAL,['NA']
15875,NCT05216172,peripheral regulatory T cells,incidence of treatment emergent adverse events (with particular reference to episodes of infection),regulatory T cells: functional assay,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15876,NCT03914326,"Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke",Time to first occurrence of a severe hypoglycaemic episode,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15877,NCT01637727,Long term effects of gestational diabetes mellitus in a population of parous women,Long term effects of gestational diabetes mellitus in a population of parous women,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
15878,NCT00659282,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,,,2006-09-11,COMPLETED,OBSERVATIONAL,['NA']
15879,NCT00544934,glycated albumimin concentration,urine albumin,,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15880,NCT01223560,,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
15881,NCT05857085,evaluation of arterial stiffness with peak wave velocity ( PWV),evaluation of endothelial progenitor cells EPC count,changes of glycemia endpoints glucovariability/time in range,2021-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
15882,NCT01547403,Primary Endpoint for CUSTOM Trial,,,2012-08,WITHDRAWN,OBSERVATIONAL,['NA']
15883,NCT00241124,Change from baseline in systolic 24 hour blood pressure after 12 weeks,"Adverse events, serious adverse events, laboratory values, physical examinations, vital signs for up to 26 weeks",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15884,NCT02302508,"Pharmacokinetics (AUC0-t metabolites and parent drug) of clopidogrel, prasugrel and ticagrelor.",Platelet function activities,,2019-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15885,NCT01084369,Improvement in endothelial dependent and endothelial-independent vasodilatation,Markers of endothelial function,,2013-10-11,TERMINATED,INTERVENTIONAL,['PHASE4']
15886,NCT05392166,pancreatic enzymes elevation in diabetic children .,,,2022-05-13,RECRUITING,INTERVENTIONAL,['NA']
15887,NCT01333514,Probability of Hypoglycemia,Probability of Hyperglycemia,,2011-04,TERMINATED,INTERVENTIONAL,['PHASE4']
15888,NCT05540405,Glycated hemoglobin (HbA1c),Skeletal muscle mass,,2023-01-24,COMPLETED,INTERVENTIONAL,['NA']
15889,NCT04618406,Change in the number of wound complications,Number of participants requiring re-amputation,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
15890,NCT04346524,Maternal complications during pregnancy,Fetal complications during pregnancy,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
15891,NCT05613920,Changes in blood glucose levels over time,pregnancy outcomes,Apgar score of newborn,2022-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15892,NCT00892151,Number of Participants Rated Successful (<=3) at Performing Specific Tasks,Number of Participants Who Rated Clarity and Usefulness of User Instructions as >=3,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
15893,NCT03854656,Change in body weight (kg),Satisfaction with the intervention (qualitative methods),,2019-02-25,COMPLETED,INTERVENTIONAL,['NA']
15894,NCT00838344,medication adherence,medication adherence challenges,,2008-04,UNKNOWN,INTERVENTIONAL,['NA']
15895,NCT00236639,The percent change in body weight from the baseline (randomization) to Week 60 (after one year of maintenance therapy).,"Changes from either baseline to Week 60 and/or Week 112, or enrollment to Week 60 and/or Week 112 in absolute body weight, Body Mass Index (BMI), body measurements, fasting lipid profile.",,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15896,NCT05449782,Macrovascular endothelial function,Leg perfusion pressure,Photoplethysmography (PPG) blood flow,2021-05-17,COMPLETED,INTERVENTIONAL,['NA']
15897,NCT04698200,Change of systolic and diastolic blood pressure,Skin and body temperature,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
15898,NCT03610412,The effect of cinnamomum cassia on body weight,The effect of cinnamomum cassia potentiates the IGF1 insulin response on body fat%.,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15899,NCT05515744,Incidence of neonatal intensive care unit (NICU) > 1 day (24 hours) stay,Duration of maternal hospital stay,,2023-01-20,RECRUITING,INTERVENTIONAL,['NA']
15900,NCT01268488,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 15mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 15 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
15901,NCT02832739,Level of and potential changes in technology acceptance in participants,Level of and potential changes in eHealth Literacy in participants,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
15902,NCT03490136,Prevalence of type 2 diabetes,Changes in dietary habits,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
15903,NCT01510509,Major adverse cardiac events,Late luminal loss,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15904,NCT05911256,Change in participant HbA1c values,Change in Glycemic variability from baseline,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15905,NCT00564668,Safety,HbA1c,,2004-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
15906,NCT00270985,HbA1c,Il-6,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15907,NCT05372445,Gut microbiota metabolic pathways changes,Gut microbiota diversity changes,,2022-05-30,RECRUITING,INTERVENTIONAL,['NA']
15908,NCT00282451,HbA1c,Postprandial glucose concentration increments (calculated based on 7-point blood glucose profiles),,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15909,NCT03136939,the rate of positive reactivation against the IGRP epitopes,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15910,NCT01290575,"Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",AUC(0-24 h) and postprandial AUC(0-4h) for biomarkers of glucose homeostasis,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15911,NCT03085550,Degree of wound healing,Patient reported outcome measures,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
15912,NCT02073474,Incidence rates of adverse events.,Number of MS patients discontinuing medications for MS symptoms other than anti-spasticity medications.,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
15913,NCT01437592,Area under the serum insulin degludec concentration-time curve,Time to maximum observed serum insulin degludec concentration,,2011-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15914,NCT01072708,Describe the natural history of the glucose tolerance in cystic fibrosis patients and to identify the predictive factors of the reversibility or the aggravation in the disorders of the glucidic metabolism.,"Estimate the probability of arisen the complications associated to the disorders of the glucidic metabolism : - deterioration of the respiratory function, - lung exacerbations - alteration of the nutritional state",,2009-04,COMPLETED,INTERVENTIONAL,['NA']
15915,NCT00105898,Change in HbA1c at 12 months,"Change in blood pressure, lipid profile and diabetes-related stress (self-report) at 12 months; cost-effectiveness analysis of the interventions.",,2005-02,COMPLETED,INTERVENTIONAL,['NA']
15916,NCT02174562,"Percent of Participants With Improvement in Hemoglobin A1c by 0.5%""",Adherence as Measured By Percentage of Doses Taken as Prescribed,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
15917,NCT05295329,IMR improvementcompared with baseline.,,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
15918,NCT00870454,Mean of the last 7 daily average diabetic peripheral neuropathy (DPN) pain scores,The mean of the last 7 Daily Sleep Interference scores.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15919,NCT00770445,Change from Baseline in Matrix Metallo Proteinase 9.,Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 12).,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15920,NCT02387749,Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.,Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
15921,NCT04867785,Change From Baseline in Hemoglobin A1c (HbA1c),"Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943",,2021-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
15922,NCT01585818,Average mean glucose levels and variability,Glucose and Insulin Levels,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
15923,NCT00511108,Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment,Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment,,2007-07-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15924,NCT05880810,Mean daily glucose,Percentage of subjects to continue use of continuous glucose monitor,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15925,NCT03811470,All cancers,Cost-effectiveness,,2017-05-31,RECRUITING,OBSERVATIONAL,['NA']
15926,NCT01685502,Decrease rate of HbA1c,Body weight,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
15927,NCT01805245,Diabetes Distress,Mean Night Diastolic Ambulatory Blood Pressure,Mindfulness,2012-01,COMPLETED,INTERVENTIONAL,['NA']
15928,NCT03436212,Relationships between glucose levels and insulin doses,,,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA']
15929,NCT05673668,Changes of islet secretory function (HOMA-β),Change of sympathetic nervous system activity,,2022-12-27,RECRUITING,INTERVENTIONAL,['NA']
15930,NCT01508858,AUC of levonorgestrel,Adverse events,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15931,NCT06209411,Number of participants who completed OGTT during the first year postpartum,"Number of women with abnormal OGTT who get tests including hemoglobin, lipid profile, creatinine.",,2024-03-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15932,NCT00337337,"Changes in glycemic parameters including fasting plasma glucose, postprandial plasma glucose, insulin sensitivity and lipid profile",Acceptabiliy and tolerability,,2005-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15933,NCT04025801,Confocal microscopy exam of sub-basal corneal nerve fibre tortuosity (NFT) by using the CCMetrics software,,,2019-07-31,UNKNOWN,OBSERVATIONAL,['NA']
15934,NCT00263939,"Health related quality of life (HRQoL) at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention","self-care self-efficacy at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention",,2004-07,COMPLETED,INTERVENTIONAL,['NA']
15935,NCT03553680,Change in Diabetes Distress,Change in Diabetes Self-Care,,2017-10-20,COMPLETED,INTERVENTIONAL,['NA']
15936,NCT05631444,Efficacy profile: Quality of life,,,2019-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15937,NCT03733743,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in energy status of the heart between morning and evening,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
15938,NCT01727661,exercise testing with near-infrared spectroscopy,quality of life,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
15939,NCT02970656,Glycosylated Hemoglobin (HbA1c),DNA Methylation,,2017-02-08,COMPLETED,INTERVENTIONAL,['NA']
15940,NCT00598663,HbA1c at 6 Month,Diabetic Ketoacidosis Events,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15941,NCT00526552,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
15942,NCT03334318,iGFR at the end of the PERL trial,HBGI (High blood glucose index),,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
15943,NCT00668109,Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group,Safety and tolerability,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15944,NCT04190160,The Diabetes Treatment Satisfaction (DTSQ),Cognitive function (MMSE),,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
15945,NCT00931879,Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15946,NCT04779645,Change in Cardiovascular Disease (CVD) Risk Markers.,,,2021-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15947,NCT00038727,"Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)",Mortality,,2002-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15948,NCT03371940,Change in depression status - Diagnosis of Major Depressive Disorder,Cost effectiveness analyses,,2012-01-01,COMPLETED,INTERVENTIONAL,['NA']
15949,NCT02955875,Medications knowledge at 9 months,Cost-effectiveness of pharmaceutical care at 9 months,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
15950,NCT01555164,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15951,NCT02060201,Area under the concentration-time curve from time zero extrapolated to infinite time [(AUC(INF)] for Saxagliptin and Dapagliflozin,"Safety measured by the occurrence of deaths, adverse events (AEs), serious adverse events (SAEs), results of clinical laboratory tests, vital sign measurements, physical examination findings, and 12-lead electrocardiogram (ECG) results",,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15952,NCT00069602,Accuracy of the GlucoWatch G2 Biographer and CGMS sensors,,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15953,NCT01608425,Surgical procedures,Ulcer healing,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
15954,NCT03089333,Change in Systolic Blood Pressure,Change in microalbuminuria,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15955,NCT00259701,,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
15956,NCT05247437,Changes in weight from baseline (week 0) to posttreatment (week 9),Changes in the scores on the Weight loss self-efficacy scale,,2022-02-19,UNKNOWN,INTERVENTIONAL,['NA']
15957,NCT02883751,Wound closure,Cost-benefit ratio of ulcer treatment following minor amputations,,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
15958,NCT00888238,Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose,Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose,,2009-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15959,NCT03647306,MI-IS,,,2018-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15960,NCT00231660,The percent change in body weight and change in HbA1c from baseline (Week 0) to one year after maintenance therapy (Week 60).,"Changes from baseline or from enrollment to Week 60 in BMI and HRQOL measures; safety evaluations, such as adverse events and vital signs throughout study.",,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15961,NCT03091686,Participants' intentions to reduce occupational sitting time,Participants confidence to reduce occupational sitting time,,2017-08-17,COMPLETED,INTERVENTIONAL,['NA']
15962,NCT01856907,Normalization of Glucose Levels,Waist-to-Height Ratio,Liver Enzymes as Safety Measure,2013-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
15963,NCT05711108,Biochemical hypoglycemia,Symptoms of hypoglycemia reported to the staff by the resident in between or at the time of fingerstick glucose monitoring (information derived from nursing notes),,2022-01-19,RECRUITING,OBSERVATIONAL,['NA']
15964,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),Cognitive function,,2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15965,NCT00097071,HbA1c,"Measurements of glycaemic control, safety parameters including frequency of hypoglycaemia, laboratory tests, clinical evaluations and adverse events",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15966,NCT02458131,Change in BMI,"Change in knowledge, attitudes, beliefs and behaviors related to diabetes and weight loss",,2016-11-11,COMPLETED,INTERVENTIONAL,['NA']
15967,NCT01910727,Change in percent of total calories from fat from baseline through 12 months follow-up,Increased numbers of individuals having been screen for diabetes between baseline and 12 months follow-up,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
15968,NCT02744963,Appropriate medicine adherence,Healthcare costs including medication costs,Count of healthcare encounters,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
15969,NCT00269646,insulin sensitivity,Flow-mediated dilation,,2004-11,UNKNOWN,INTERVENTIONAL,['NA']
15970,NCT05132179,Time to healing,"Change of diabetic foot ulcer´s, DFU´s, depth",,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
15971,NCT01332370,medical resource utilization,,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
15972,NCT05015894,"AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose","Cmax,NNC0480-0389,SD, Maximum observed NNC0480-0389 plasma concentration after a single dose",,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15973,NCT04209075,Gastrointestinal (GI) Tolerability Score,Stool Short Chain Fatty Acids (SCFA),,2020-03-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15974,NCT05872269,Frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs),Change in BMI,,2023-07-20,RECRUITING,INTERVENTIONAL,['PHASE4']
15975,NCT00762684,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15976,NCT00700622,Change From Baseline in HbA1c to Week 16,,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3']
15977,NCT02528695,Glucose uptake in adipose tissue measured by uptake of 18F-FDG on PET images,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
15978,NCT03482869,Maximal walking distance,,,2018-03-30,UNKNOWN,INTERVENTIONAL,['NA']
15979,NCT01783275,Splanchnic glucose uptake,Endogenous glucose production,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15980,NCT03993366,Time in hyperglycemia,,Gastrointestinal symptoms,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
15981,NCT03199638,"HbA1c, Glycated Hemoglobin",Insulin Sensitivity Score (ISS),,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
15982,NCT03703869,Change in HbA1c at month 6,Body weight,,2018-03-06,COMPLETED,OBSERVATIONAL,['NA']
15983,NCT01587599,drug-drug-interactions,improved overall health status,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
15984,NCT02291874,Fasting plasma glucose,"Adverse events (AEs), vital signs, and laboratory tests",,2014-10-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15985,NCT03204799,Metagenomic profile change,blood glucose change,,2016-12-17,UNKNOWN,OBSERVATIONAL,['NA']
15986,NCT02889510,Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1),Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC),,2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15987,NCT03268941,Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values,Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1,,2017-09-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15988,NCT00703612,"Lowering of blood glucose be it fasting, random or post prandial",Lowering of glycosylated hemoglobin (HbA1C).,,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15989,NCT02856113,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in CD26 (CD8+T Cells) Surface Antigen Levels at Weeks 26 and 52,,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15990,NCT00931372,Area under the insulin secretion curve,Area under the insulin secretion curve,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15991,NCT03312179,MACE,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15992,NCT05544266,"Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods",,,2020-09-30,RECRUITING,OBSERVATIONAL,['NA']
15993,NCT05310916,"Evaluation of the study biomarkers, IL-6, and VEGF",Occurrence of adverse events,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE3']
15994,NCT05418699,HbA1c level,Coefficient of variation,,2022-09-26,RECRUITING,OBSERVATIONAL,['NA']
15995,NCT05195944,Change in HbA1c level (%),Number of treatment-emergent adverse events,Change in alanine aminotransferase (ALT) level,2022-10-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
15996,NCT02197520,Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value),Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15997,NCT01413035,To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15998,NCT01031108,To examine the effects of SRT2104 (2.0 g administered once daily for 28 days) on reversing vasomotor and fibrinolytic dysfunction in both type 2 diabetes mellitus patients and otherwise healthy smokers in a fed state.,"To explore the effects of SRT2104 on potential biomarkers of activity for glucose control (HbA1c, glycated albumin and fructosamine) and/or Sirt1 activation.",,2010-05-28,COMPLETED,INTERVENTIONAL,['PHASE1']
15999,NCT01065948,"monitor safety and performance of FAS response in two different body sites (abdomen, forearm)","assess comfort level during FAS insertion, when worn during normal activities, and during FAS removal",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
16000,NCT01614613,MAD Mean Absolute Value of the Difference Between Blood Glucose Meter (BGMS) Results and Corresponding YSI Blood Glucose (BG) Results in the Low BG Range(<70 mg/dL),Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
16001,NCT02582736,Hospitalization for a hyperglycemic emergency,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
16002,NCT05262387,Change From Baseline in Plasma Glucose (PG) From the Start to the End of Exercise for Each Treatment Arm,Change From Baseline in Postprandial Plasma Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) for Each Treatment Arm,,2022-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
16003,NCT04025762,Time spent in the target sensor glucose range,"Total, basal and bolus insulin dose",Sleep quality assessment,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
16004,NCT05691985,The association of fibrinogen to albumin ratio (FAR) with DKD type 2.,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16005,NCT04096989,Health-related quality of life of short form 36 (SF-36),Body mass index (BMI),,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
16006,NCT04279613,Adverse Events,Change in the area under the plasma C-peptide concentration-time curve,,2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
16007,NCT01987258,Glycemic control,Excess post-exercise oxygen consumption (EPOC),,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16008,NCT05714059,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),,2023-02-28,COMPLETED,INTERVENTIONAL,['NA']
16009,NCT04234373,Effect of a low-carb dietary intervention on glycemic control as defined by blood glucose level at 2h after an oral glucose tolerance test.,Effect of a low-carb dietary intervention on liver fat fraction as measured with MRI,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
16010,NCT01609582,Time to First Occurrence of Any Component of Primary Major Adverse Cardiovascular Event (MACE) Composite,Time to First Occurrence of Any Component of Secondary Major Adverse Cardiovascular Event (MACE) Composite,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE3']
16011,NCT01163591,"The optimal eZscan unit to detect the presence of diabetic nephropathy as defined by eGFR and ACR using ROC analysis, sensitivity and specificity values.","A prediction algorithm using age, sex, body mass index and eZcan score will be developed to predict eGFR as continuous and categorical variables using Cox regression analysis.",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
16012,NCT03122041,The main outcome was change in HOMA-β index (Homeostasis model assessment for beta cell function index).,The secondary outcome was change in plasma glucose level at 120 minutes (G120) after glucose load in oral glucose tolerant test (OGTT).,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
16013,NCT03119142,Adherence to the Mediterranean diet,Inflammation,,2017-05-02,COMPLETED,OBSERVATIONAL,['NA']
16014,NCT04388280,Major adverse cardiovascular events (MACE),Differences in the outcome between functional and angiographic imaging in imaging arm,,2021-01-28,UNKNOWN,INTERVENTIONAL,['NA']
16015,NCT03771066,Change in rate of glucose appearance,Change in concentration of clostridia,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
16016,NCT01121276,Area under the blood glucose concentration-time curve,Area under the blood glucose concentration-time curve,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16017,NCT00095446,Treatment satisfaction with insulin pump therapy,infusion set in-use times,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16018,NCT03922022,Rate of recruitment,EQ-5D-5L,,2019-05-21,COMPLETED,INTERVENTIONAL,['NA']
16019,NCT05247840,diagnostic accuracy of peripheral nerve conduction test 3.6,clinical symptoms of diabetic patients will be measured and compared to healthy children. 8.6,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16020,NCT03008239,Adverse Events reporting,Blood maltose concentrations,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA']
16021,NCT05392959,the longitudinal change of the Index of Microvascular Resistance (IMR).,,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE4']
16022,NCT02065349,"Change in mean of 24-hour average pain intensity, Numeric pain rating scale (NPRS)","Composite of pharmacokinetics of ASP8477 concentration: Trough concentration (Ctrough), observed maximum concentration (Cmax), Area under the curve (AUC)0-6",,2014-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
16023,NCT00660764,"Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.",Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
16024,NCT01537120,24 Hour Weighted Mean Glucose (WMG) At 2 Weeks,HbA1C At 12 Weeks,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
16025,NCT02132676,Change in Glycemic Control,Endocrinology Visits,,2016-04-25,COMPLETED,OBSERVATIONAL,['NA']
16026,NCT03740919,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values at Week 26,,2019-04-07,COMPLETED,INTERVENTIONAL,['PHASE3']
16027,NCT01493050,glucose metabolism,serum phosphate level,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16028,NCT01247558,All-Cause Health Plan Costs,Demographics of Patients Taking Metanx®,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
16029,NCT00898534,Hemoglobin A1c,Number of phone and/or email contacts between practitioner and patient,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16030,NCT00171119,Change from baseline in urine albumin excretion rate after 24 weeks,Percent of patients returning to normal urine albumin excretion rate after 24 weeks,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE4']
16031,NCT01333176,Does the HbA1c identify the same individuals as fasting and 2-hr pc glucose tests to identify diabetes and pre-diabetes in a First Nation community,"To identify the response rate of ""gold standard"" diabetes testing in a First nation community",,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
16032,NCT01812694,Gestational weight gain,Gestational Diabetes,,2013-03-28,COMPLETED,INTERVENTIONAL,['PHASE3']
16033,NCT00992797,"Insulin sensitivity measured with euglycemic, hyperinsulinemic clamp",Metabolomics analyses.,,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
16034,NCT00851903,HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period),Change in Body Weight From Baseline to Study Endpoint,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16035,NCT02242825,Change from Baseline in diastolic blood pressure (DBP),Number of patients with adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
16036,NCT06012799,Rate of NODAT,,,2021-05-15,RECRUITING,OBSERVATIONAL,['NA']
16037,NCT03555734,Cardiovascular disease (CVD),Obesity,,2017-11-21,UNKNOWN,OBSERVATIONAL,['NA']
16038,NCT01566006,proteinuria,,,2012-04,UNKNOWN,INTERVENTIONAL,['NA']
16039,NCT03783598,Canada activity performance measure (COPM),Demographic questionnaire,,2015-12-02,COMPLETED,INTERVENTIONAL,['NA']
16040,NCT05957055,The frequency of adverse events - lisdexamphetamine arm,"Percentage of trial participants achieving an improvement in ADHD symptom severity on the basis of Conners 3 ""hyperactivity/impulsivity"" scale",,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
16041,NCT00349362,The effect of 6 months of testosterone replacement on diabetes control measured by HbA1c in hypogonadal men with type 2 diabetes treated with insulin.,The effect of the CAG repeat polymorphism in exon 1 of the androgen receptor gene on the response of the study population to testosterone.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16042,NCT02429232,Change from baseline in bone turnover markers,Change from baseline in urine biomarkers,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
16043,NCT05282602,Timed Up and Go Test,,,2022-02-20,COMPLETED,INTERVENTIONAL,['NA']
16044,NCT04354090,Incidence of adverse events and serious adverse events related to JY09,Immunogenicity,,2018-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16045,NCT03448367,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,,2018-02-27,TERMINATED,OBSERVATIONAL,['NA']
16046,NCT02276196,"Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)",Blood Pressure,Arterial stiffness,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
16047,NCT05029115,recurrence rate of AF within a year in ablated participants,Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) score,,2021-10-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
16048,NCT00374270,difference in change in systolic BP between the intervention and usual care groups,proportion of patients that are prescribed an ACE inhibitor or angiotensin receptor antagonist between groups,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
16049,NCT00005124,,,,1969-07,COMPLETED,OBSERVATIONAL,['NA']
16050,NCT00699790,Change in HbA1c,"Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16051,NCT01656850,Plasma Vitamin E Level at the Baseline and at the End of 3-month Dietary Intervention,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
16052,NCT04782128,"The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52",Safety of RC28-E injection,,2021-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
16053,NCT01812811,Fraction of missed pulse wave analysis,Reproducibility of pulse wave analysis parameters,"Diurnal variation of brachial blood pressure, central blood pressure and pulse wave velocity",2012-09,COMPLETED,OBSERVATIONAL,['NA']
16054,NCT02954601,Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM),Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2']
16055,NCT02498002,ACADM Gene Expression in Subcutaneous Adipose Tissue,Post-Prandial Protein Oxidation,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
16056,NCT02506972,Incremental area under the blood glucose response curve,Time to baseline,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
16057,NCT01133600,Pharmaco-economic,Quality of Life/patient satisfaction,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE4']
16058,NCT03150654,Change macular pigment optical density from baseline at 6 months,Correlation analysis between macular pigment optical density and panretinal laser photocoagulation parameters during 6 months,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
16059,NCT04141787,Clinical cure rate of deep-seated methicillin sensitive Staphylococcal infections,Adverse event rate,Duration of therapy,2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
16060,NCT06327191,"To determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds.",,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16061,NCT05478525,Number of participants with adverse events [safety and tolerability of GLY-200],Change from baseline in 3-hours postprandial plasma insulin profile,,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16062,NCT00547183,Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary,"Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16063,NCT00537498,"Number of patients being alive, having no major amputation and healed ulceration","Each of overall survival, major amputation rate, survival free of major amputation rate, rate of ulcer healing, and safety",,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16064,NCT04240652,Diabetic macular edema,Albumin-creatinine-ratio (mg/mmol),,2018-06-05,RECRUITING,OBSERVATIONAL,['NA']
16065,NCT02519309,Change from Baseline Body Weight,Change from Baseline Body Weight,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
16066,NCT02373319,Pre-post changes in blood lipid levels,Pre-post changes in body mass index,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16067,NCT00528372,Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2,Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Findings (Last Observation Carried Forward {LOCF]),,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16068,NCT03378765,BMI,,,2018-01-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16069,NCT00403741,"Score on Treatment Self-Regulation Questionnaire(TSRQ)at Treatment Self-Regulation Questionnaire (TSRQ) at 3 months, 9 months and 15 months after assesment's day of the education period.","HbA1c et lipid profile at 3 months, 9 months and 15 months after assesment's day of the education period.",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
16070,NCT05949281,Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L),Safety-related events,Change in interleukin messenger ribonucleic acid (mRNA) expression measured by quantitative polymerase chain reaction,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2']
16071,NCT04600167,First diagnosis of TB,"Occurrence of possible, probable, or definite TB, or death",,2022-06-17,RECRUITING,INTERVENTIONAL,['PHASE3']
16072,NCT03839511,Peak Epinephrine Levels,CGM Glucose,,2018-11-28,COMPLETED,OBSERVATIONAL,['NA']
16073,NCT00185601,HbA1c,Health care utilization,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
16074,NCT00118976,albuminuria,Tertiary: differences in response to treatment in patients with different ACE/ID and other renin angiotensin system genotypes.,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
16075,NCT05237076,Chemosensitivity of carotid bodies during baseline and euglycemic clamp,HRV during baseline and euglycemic clamp,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
16076,NCT01542060,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
16077,NCT01257373,Cumulative major adverse cardiovascular events（MACE）,Stroke,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
16078,NCT04277598,Wound area reduction after 4 weeks treatment with APO-2,Evaluation of Quality of Life: questionnaire,,2020-10-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16079,NCT06003634,Number of Participants with Change in A1c,Social Network Scale,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
16080,NCT04445168,Moderate to vigorous physical activity (MVPA),Health-related quality of life,,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA']
16081,NCT03909555,Difference in the proportions of chronic complications,Difference of quality of life,New biomarkers which may indicate the occurrence of chronic complications of diabetes,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA']
16082,NCT00484068,nutritional status,,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
16083,NCT05782192,HbA1c change from baseline at week 24,Pancreatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,,2019-06-13,COMPLETED,INTERVENTIONAL,['PHASE3']
16084,NCT00237250,Change in area under the 0-2 hour prandial glucose curve at 12 weeks,Change in fasting proinsulin/insulin ratio at 12 weeks,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16085,NCT00469287,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
16086,NCT05956106,Blood pressure will be assessed before and after the trial.,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
16087,NCT04531111,Impact of COVID-19 pandemic and lockdown on glycemic control among a sample of Egyptian children and adolescents with type 1 diabetes,Impact of COVID-19 pandemic and lockdown on insulin dosage among a sample of Egyptian children and adolescents with type 1 diabetes,,2020-07-07,UNKNOWN,OBSERVATIONAL,['NA']
16088,NCT03064321,Average Glucose Control for Last 3 Months Assessed by A!C level,Sleep Quality,Insomnia Severity,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
16089,NCT04726657,Fructosamine,time below 70,,2016-01-18,COMPLETED,INTERVENTIONAL,['NA']
16090,NCT01525992,Hemoglobin A1c,Blood pressure,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
16091,NCT00198900,,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
16092,NCT02367131,Percentage of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose at the Last Observation During the Observation Period,,2015-02-24,COMPLETED,OBSERVATIONAL,['NA']
16093,NCT02547519,The activation of an antibody response against insulin.,GAD and IA-2 autoantibodies,Adverse events,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16094,NCT00609986,Acute/Active Rejection,Severe Hyperglycemia,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
16095,NCT01456650,Change in plasma fasting glucose,HbA1c levels,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
16096,NCT00123435,Weight loss,Quality of life and participant satisfaction,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
16097,NCT00554671,Hemoglobin A1c,Health-care Costs to the VHA,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
16098,NCT02747277,Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers,,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
16099,NCT03740698,% Time in Target Range Defined as 3.9-10mmol/l,,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA']
16100,NCT02162212,Arm elevation.,"Disability of the Arm, Shoulder, and Hand (DASH) questionnaire",,2014-09,COMPLETED,INTERVENTIONAL,['NA']
16101,NCT06137222,Incidence of adverse events (AEs) and serious adverse events (SAEs). Primary safety endpoint,Wound size (area in cm2) reduction from baseline/treatment initiation,,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16102,NCT05888259,pressure-time integrals,,,2021-09-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16103,NCT00509223,HbA1c Change,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
16104,NCT05141929,Change from Self Rated Abilities for Health Practices levels in pregnant women with GDM,Rate of maternal-fetal-neonatal complications in pregnant women with GDM,,2020-06-01,COMPLETED,INTERVENTIONAL,['NA']
16105,NCT02023320,Change in HbA1c from baseline,Change in serum C-peptide from baseline,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
16106,NCT02796950,Levels of GLP-1 in plasma,Insulin sensitivity by measuring blood glucose after an OGTT,"Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma",2016-06,COMPLETED,INTERVENTIONAL,['NA']
16107,NCT00992537,Area under the glucose infusion rate curve,Maximum observed insulin aspart concentration,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16108,NCT03363594,To evaluate total body fat content across various BMI categories in the study population,To correlate HbA1C level with various BMI categories,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA']
16109,NCT00381342,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24,"Changes in fasting and 30, 60, 120 and 180-minute glucose measurements",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16110,NCT05680207,improvement in The Diabetes Empowerment Scale scores,improvement in triglyceride,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
16111,NCT00992043,glycated hemoglobin,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16112,NCT05375656,Glycemic variability during Inuit diet,Glycemic variability during habitual diet,Fecal proteomics.,2022-01-08,COMPLETED,INTERVENTIONAL,['NA']
16113,NCT04432090,Incremental AUC for glucagon during hypoglycemia (above baseline levels during euglycemia),,,2021-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
16114,NCT02643251,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
16115,NCT00068094,,,,2005-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16116,NCT05322551,Changes in lipid related biochemical parameters,Dietary Intake changes,,2022-06-24,RECRUITING,OBSERVATIONAL,['NA']
16117,NCT05977465,Change in HbA1c %,,,2022-01-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16118,NCT05067270,"Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas",,,2021-10-22,COMPLETED,INTERVENTIONAL,['PHASE1']
16119,NCT05203575,HbA1c after Cycle 2,Sleep quality after Cycle 2,,2022-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16120,NCT04753099,parental competence with managing child's care,,,2020-10-09,COMPLETED,INTERVENTIONAL,['NA']
16121,NCT02509624,PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509,Percentage of Participants Experiencing Any Treatment-Emergent and Grade ≥ 3 Laboratory Abnormalities,,2015-08-18,COMPLETED,INTERVENTIONAL,['PHASE1']
16122,NCT00484419,Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint,Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean),,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
16123,NCT00894322,Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population,Mean Change From Baseline at Week 12 in Fasting Plasma Glucose in Participants With Diabetes (Cohort 2) for the ITT Population,,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16124,NCT05427084,TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta,Change in monocyte marker expression,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16125,NCT03766334,Average blood glucose fluctuations at endpoint and baseline,Waist circumference(endpoint)-Waist circumference(baseline),,2018-12-05,WITHDRAWN,INTERVENTIONAL,['NA']
16126,NCT02087826,Response to the Mixed Meal Tolerance Test,Response to Metformin,Response to a Mixed Meal Tolerance Test after Metformin,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16127,NCT05386927,Urine metabolomics,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
16128,NCT05597709,Analysis of risk factors for clinical outcomes in patients with T2DM,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
16129,NCT01973374,Compliance with Obstetric and Diabetes Care,Neonatal Outcomes,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
16130,NCT03048227,Time spent with glucose,Score of Quality of Life questionnaire (IDSRQ),,2017-04-21,TERMINATED,INTERVENTIONAL,['NA']
16131,NCT01726491,DNA methylation of genes in insulin resistance,mRNA expression of genes,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
16132,NCT02701569,Glycated hemoglobin,Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire,Depressive symptoms as measured by the Beck's Depression Inventory,2014-07,COMPLETED,INTERVENTIONAL,['NA']
16133,NCT05231174,AUROC of the self-evaluation tool,,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
16134,NCT04120844,Problem Areas in Diabetic (PAID) Questionnaire,Stages of Change score,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
16135,NCT00407771,"The magnitude of platelet aggregation inhibition before randomization, 10 minutes (t=0) and 8 hours (t=8) post tirofiban administration using the Ultegra RPFA assay.",Major adverse cardiac events (MACE) at 24 hours and 30 days post PCI.,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
16136,NCT01921192,homocysteine,folic acid,vitamin B12,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
16137,NCT00231023,,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16138,NCT02756117,Change in plasma 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),Change in urinary 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1']
16139,NCT01454024,Number of adverse events and technical complaints,HbA1c (haemoglobin A1c),,2011-11,COMPLETED,OBSERVATIONAL,['NA']
16140,NCT05791929,Area Under ROC curve generated by the statistical model able to discriminate between healing and not healing ulcers,The AUC of the models estimated according to different sites of ulcers.,,2023-04-13,WITHDRAWN,OBSERVATIONAL,['NA']
16141,NCT01145599,"Identify ""progressors""","Identify correlations between ""progressors"" and study outcomes.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
16142,NCT05900505,"To compare participant satisfaction with NSRCH (social navigator) vs. standard care (social worker), as measured by the Client Satisfaction Questionnaire (CSQ).","To compare change in Quality of Life (QOL) of participants (pre/post intervention) referred to NSRCH (social navigator) vs standard care (social worker), as measured by the WHOQOL-BREF.",To compare the resource cost of the social navigator compared to the social worker.,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
16143,NCT00997282,Changes in HbA1C from baseline,Changes in 3 hour PPG AUC from baseline,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16144,NCT03565809,Diabetes control,hospitalization for falls and femoral fracture,,2017-05-02,COMPLETED,OBSERVATIONAL,['NA']
16145,NCT06317584,Diabetes Empowerment scale,Albumin to Creatinine Ratio (ACR),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16146,NCT02131272,Change in HbA1c (Glycosylated Haemoglobin),Incidence of Adverse Events (AEs),,2014-06-11,TERMINATED,INTERVENTIONAL,['PHASE3']
16147,NCT02941874,Normal values of IRAP concentration will be calculated by making the average of the three dosages of IRAP measured at base line.,Temporal reproducibility of the concentration of IRAP,kinetic profile of the concentration of IRAP during OGTT,2017-04-07,COMPLETED,OBSERVATIONAL,['NA']
16148,NCT04430608,Time In Range (TIR) for blood glucose,Course of hospital stay.,,2020-05-25,UNKNOWN,INTERVENTIONAL,['NA']
16149,NCT02425410,Delay between viral events and T1D diagnosis,Age at T1D diagnosis as a quantitative trait,,2010-03,UNKNOWN,OBSERVATIONAL,['NA']
16150,NCT03661684,AUC for glucose during OGTT,AUC for Insulin during OGTT,,2016-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16151,NCT03022682,Complete recruitment of IDEO cohort participants to spur novel and creative interactions between investigators that have transformative potential in obesity research.,Adipose tissue inflammation and fibrosis,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
16152,NCT03936062,"Relative hazard of composite outcome of ACS/unstable angina, Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
16153,NCT03645382,Change from baseline fat mass at 12-week.,Change from baseline visceral/subcutaneous fat area ratio of L1 and L4 at 12-week.,Change from baseline blood pressure (BP; mmHg) at 12-week.,2017-02-21,COMPLETED,INTERVENTIONAL,['NA']
16154,NCT00933881,Improvement in heart rate control post-GDM,Improvement in SDB post-GDM,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
16155,NCT04328207,Percentage of participants that adhere to referral appointment,,,2020-11-18,RECRUITING,INTERVENTIONAL,['NA']
16156,NCT01051089,"HbA1c, serum adipokine levels",VO2max,,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
16157,NCT01353066,Measurement of the progression carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16158,NCT06003153,Insulin response to oral semaglutide treatment,Baseline incretin level,,2024-03-12,RECRUITING,INTERVENTIONAL,['PHASE4']
16159,NCT04025489,Investigation of gene polymorphism and other markers in 500 subjects,Effect of vitamin d supplementation on raging and other metabolic measures.,,2020-03-01,RECRUITING,INTERVENTIONAL,['NA']
16160,NCT04613700,Duration of ad libitum meal,Gallbladder motility,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
16161,NCT05071898,Rate of glucose disappearance,Weight loss,Glucose effectiveness (Sg),2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1']
16162,NCT02824510,Subcutaneous glucose evolution,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
16163,NCT01552005,Retention rate of Saxagliptin and to describe discontinuation rate and reasons,Saxagliptin utilization according to patient's profile and disease characteristics,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
16164,NCT05722873,Trabecular bone microarchitecture,Insulin sensitivity,,2023-10-25,RECRUITING,INTERVENTIONAL,['NA']
16165,NCT03259321,Type 2 diabetes,Fish and polyunsaturated fatty acids intake,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
16166,NCT05651724,Predictive power of non-invasive tests for detection of high-risk patients,Patient Reported Outcomes: Disease-specific health-related Quality of Life (HR-QoL),Assess if implementation of the patient care pathway as proposed in this study increases awareness and knowledge of NAFLD and NASH management among participating physicians and clinicians,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16167,NCT01507337,Area under the liraglutide plasma concentration time curve (AUC 0-t),Adverse events,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16168,NCT05802862,Change From Baseline in Hemoglobin A1c (HbA1c),Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE),,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
16169,NCT00477204,Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.,,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16170,NCT04507347,Primary composite endpoint consisting of incidence of cardiac mortality and/or number of worsening of heart failure and/or change from baseline to week 48 in functional capacity,,,2021-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16171,NCT01713764,Hemoglobin A1c,Hemoglobin A1c,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
16172,NCT02556840,Birth weight for gestational age,Anxiety score (short form of the Spielberger State - Trait Anxiety Inventory,,2016-04-25,COMPLETED,INTERVENTIONAL,['NA']
16173,NCT01525238,Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin,Number of Participants With Marked Urinalysis Abnormalities,,2012-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
16174,NCT04924504,Association between insulin sensitivity Versus structural and functional changes in the placenta,Changes from baseline in the central aortic pressure waveform,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
16175,NCT01357603,Pharmacokinetic Parameters: Maximum concentration (Cmax),Pharmacodynamic parameter: GIR max and tGIR max,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16176,NCT04643171,superoxide dismutase,lipid hydroperoxidase,,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA']
16177,NCT01014884,Determine the impact of multidisciplinary team interventions in reducing the rate of non-elective hospitalizations over a 12 month period compared to usual care,Determine the impact of multidisciplinary team interventions versus usual care on the length of stay (LOS) of each non-elective hospitalization,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
16178,NCT02562313,Pharmacokinetics: AUClis 0-30min,Local tolerability,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
16179,NCT00920764,Mean change from baseline to each post-baseline observation on UACR over the course of treatment period versus standard of care,Change from baseline to each weekly measurement in NGAL,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
16180,NCT04219462,the Five-Version of International Index of Erectile function,,,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA']
16181,NCT03928899,caesarean section rate,rate of labor pain,,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
16182,NCT05362474,Change in Albuminuria at 3 months,,,2022-07-01,TERMINATED,INTERVENTIONAL,['PHASE3']
16183,NCT01513473,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory),"Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)",,2012-01-16,COMPLETED,INTERVENTIONAL,['PHASE3']
16184,NCT02063321,Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema,Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy),,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
16185,NCT04626453,Oxyhemoglobin differences,blood glucose level in mg/dL,,2020-10-29,COMPLETED,INTERVENTIONAL,['NA']
16186,NCT00703989,prostacyclin synthase activity,,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
16187,NCT00545857,C-peptide response to a Sustacal meal,Hemoglobin A1c,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16188,NCT04902378,Glycemic control as reflected by percent glucose time-in-range,Proportion of participants who experience device-related adverse events,,2021-06-15,RECRUITING,INTERVENTIONAL,['NA']
16189,NCT04642534,Correlation of in vitro circadian parameters (amplitude and magnitude) with clinical metabolic health outcomes (body weight),"Glucose excursion (time-in-range, coefficient of variation)",Metabolomic parameters of energy metabolism,2020-02-12,COMPLETED,OBSERVATIONAL,['NA']
16190,NCT02591576,Long term excess mortality,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
16191,NCT02923089,Postprandial plasma insulin,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
16192,NCT05762783,Daytime time-in-range (TIR),,,2023-03-27,RECRUITING,OBSERVATIONAL,['NA']
16193,NCT01818557,Neonatal weight,Macrosomia,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
16194,NCT01708096,Insulin sensitivity,Weight reduction,Insulin signaling and glucose transport in skeletal muscle,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16195,NCT04758364,gait speed,,,2021-02-20,COMPLETED,OBSERVATIONAL,['NA']
16196,NCT00934414,To compare the relative bioavailability and bioeffect of TI Inhalation Powder in subjects with type 2 diabetes who smoke and who do not smoke to determine relative insulin bioavailability,,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16197,NCT02412852,Reporting of Adverse Events During 12 Week Study Period,Assessment of Blood Oxygenation. (Pulse Oximetry),,2015-04-28,COMPLETED,INTERVENTIONAL,['PHASE2']
16198,NCT01486381,"Standard safety parameters: Haematology, biochemistry and vital signs",BMI (Body Mass Index),,2002-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
16199,NCT04079413,Immunogenicity,Achievement of Glycated Hemoglobin < 7%,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16200,NCT04812392,Change in glycemic control during a reduced physical activity state,,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
16201,NCT00042471,Effect of varying needle length on bioavailability of Pramlintide,Effect of varying needle length on safety and tolerability of Pramlintide,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
16202,NCT05619198,Percentage of time spent in sensor-derived time in range (3.9-10.0 mmol/L) during and after a bout of exercise,Physical activity level assessed by Actigraph GT3x,,2022-12-19,RECRUITING,INTERVENTIONAL,['NA']
16203,NCT00593476,Changes in weight at 12 weeks.,"Changes in HbA1c, lipids, inflammatory markers (hs-CRP), fasting glucose, blood pressure, waist circumference and survey measures at 12 weeks.",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
16204,NCT06198881,Number of vaginal deliveries among the population studied,,,2023-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16205,NCT03479242,Functional skin closure in DFU in relation to biofilm infection,,,2019-01-25,TERMINATED,OBSERVATIONAL,['NA']
16206,NCT04460885,Change in HbA1c,"Time spent > 10 mmol/L (180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6",,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
16207,NCT00046501,to measure change in glycemic control as measured by hemoglobin A1c (A1c).,"Clinical values: physical examination, vital signs, change in age-adjusted body mass index (BMI)",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
16208,NCT05297110,rate of fasting glycemia level reduction,rate of adverse effects,,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16209,NCT01257464,Insulin release,Incretin Response,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2']
16210,NCT03338803,Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories,Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories,,2017-11-21,COMPLETED,OBSERVATIONAL,['NA']
16211,NCT01365507,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16212,NCT01933256,The safety and tolerability of repeat doses of HIP2B in subjects with type 2 diabetes mellitus.,Glucose-stimulated insulin secretion.,Pharmacodynamic (PD) effects of repeat doses of HIP2B on measures of glycemic control and β-cell function,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16213,NCT03781102,Change in Body Mass Index (BMI) Percentile,Change in demographic and social and environmental risk factors for T2D,,2019-07-01,SUSPENDED,INTERVENTIONAL,['NA']
16214,NCT01185496,,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
16215,NCT05290246,Change in glycemic measures- HbA1c (12w),Intervention burden (24w),,2022-05-27,RECRUITING,INTERVENTIONAL,['NA']
16216,NCT06192940,Insulin Injection,Acute Diabetes Events,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16217,NCT02420392,Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion,Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
16218,NCT00223782,Plantar Pressure,,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
16219,NCT01948986,Change From Baseline in 24 Hour Fluid Balance,Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin,,2013-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
16220,NCT01653899,To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant,2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.,,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16221,NCT00619983,Visual Analog Scale for Pain,,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4']
16222,NCT01677104,skin blood flow,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
16223,NCT03890991,Diabetes self-care activities measured using the Revised Summary of Diabetes Self-care Activities,Proportion of participants who adhere to yearly eye and foot screening,,2019-02-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16224,NCT01669473,Medication adherence,"Clinical outcomes-systolic blood pressure, HbA1, and LDL cholesterol.",,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16225,NCT04463277,Serum Lipid Profile.,,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
16226,NCT04005261,Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings,,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
16227,NCT03127852,Quality of Life as Measured by SF-36,Self-efficacy as Measured by the SEMCD6.,,2016-08-23,COMPLETED,INTERVENTIONAL,['NA']
16228,NCT04041492,Insulin,HOMA Index,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
16229,NCT01934608,Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure,"Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use.",,2013-09,COMPLETED,INTERVENTIONAL,['NA']
16230,NCT00775541,"MRI, mRS, urine and blood samples",7 day food and DHQ food questionnaire,,2007-10,TERMINATED,INTERVENTIONAL,['NA']
16231,NCT04797208,Time in range,Level 2 hypoglycaemia,Usability,2023-01-09,RECRUITING,INTERVENTIONAL,['NA']
16232,NCT05503303,"Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols",,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
16233,NCT05288452,Primary Outcome for the HIV Cohort: Change in HbA1c level between baseline and 6 months,,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
16234,NCT03027934,Aggregation Response,Reticulated Platelet Reactivity Index (PRI),,2017-08-28,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16235,NCT04322240,measurement of Compound Muscle Action Potential (CMAP) distal latency,,,2020-04-02,COMPLETED,INTERVENTIONAL,['NA']
16236,NCT05822349,change in anxiety level,,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
16237,NCT02302963,Change in Hypoglycemia During Closed Loop Control (Assessed by Low Blood Glucose Index [LBGI]),,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
16238,NCT04190277,Difference in percentage of time spent in hypoglycemia (<70mg/dL) during 12 weeks between closed-loop and open-loop,"Questionnaire of usability (for 50 subjects from Arm 1, including 15 adolescents and 35 adults)",,2020-01-07,TERMINATED,INTERVENTIONAL,['NA']
16239,NCT04878419,Recruitment Rate,Correlation of outcome expectation on degree of change in participants Time in Range after the educational intervention.,Correlation of childhood opportunity index (COI) with degree of change in participants' Time In Range after the educational intervention.,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
16240,NCT04333823,Measured Glomerular Filtration Rate (mGFR),Total Daily Insulin Dose (TDID),Exercise Session - Blood Glucose Variability,2020-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
16241,NCT01863147,Left ventricular mass and left ventricular volume,Endothelial function and augmentation index (AIx),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16242,NCT04831385,"The primary outcome measure will be changes in glycemic control, as measured by HbA1c, from baseline.",,,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16243,NCT00703027,,,,2002-10,COMPLETED,OBSERVATIONAL,['NA']
16244,NCT06224803,Concentration of HbA1c,Concentration of Blood Sugar,,2020-08-26,COMPLETED,INTERVENTIONAL,['NA']
16245,NCT00536965,HbA1c profile,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
16246,NCT04420728,Effect of Auto vs. Manual Mode of MiniMed 670G on Time in Target Range Assessed via CGM,"Assess Feasibility of Auto-mode MiniMed 670G via study recruitment, retention and completion rates.",Impact of Weaning on Total Daily Insulin Requirement Assessed by Child Food and Liquid Intake Questionnaire,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
16247,NCT01722643,HbA1c at 12 Months,Daily Frequency of Self Monitoring of Blood Glucose Checks 12 Months Following Enrollment,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
16248,NCT04080960,hemoglobin A1C,,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
16249,NCT03547960,Gestational diabetes,Insulin secretion,,2018-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16250,NCT04889859,diabetes remission rate (%),changes in gut microbiota,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
16251,NCT03817099,Rate of participants completed the study,Efficacy potential on body mass index,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
16252,NCT02913703,Effect of preprandial ghrelin on glucose tolerance,Effect of preprandial ghrelin on insulin sensitivity (as measured by Matsuda index),,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE1']
16253,NCT00318786,Hemoglobin A1C (HbA1C),"HbA1C, after 28 weeks of treatment; Plasma glucose levels",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
16254,NCT03163511,Change in C-peptide for Cohort 2 subjects,,,2017-07-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16255,NCT04776239,Post-PCI coronary artery endothelial function as assessed via FFR,Number of participants with Target Vessel Failure,,2021-08-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16256,NCT04035044,Analytical verification of Allegro - Urine Albumin comparison,,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
16257,NCT00006068,,,,na,UNKNOWN,INTERVENTIONAL,['NA']
16258,NCT01291719,glucose control in target range,hypoglycemia,,2008-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16259,NCT00780559,Change in 6-Minute-Walk Test Measured in Feet Between Baseline and 12 Months,Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh,Change in Physical Activity (PA) at 12 Months as Measured by the CHAMPS (Community Health Activities Model Program for Seniors) Activity Scale,2009-11-01,COMPLETED,INTERVENTIONAL,['NA']
16260,NCT01840982,"1. Glycemic index(GI) 2. Glucose, insulin AUC(incremental area under the curve) 3. C-peptide","Homeostatic model assessment-insulin resistance(HOMA-IR), quantitative insulin sensitivity check index(QUICKI), Insulinogenic index(IGI)",,2010-10,COMPLETED,INTERVENTIONAL,['NA']
16261,NCT01045447,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
16262,NCT02885428,diagnostic of the silent myocardial ischemia,,,2015-04-15,TERMINATED,OBSERVATIONAL,['NA']
16263,NCT01576887,Number of Adverse Events,Area under the curve,,2012-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16264,NCT04106440,Connected Health Survey,Hemoglobin A1c values,,2019-10-18,COMPLETED,INTERVENTIONAL,['NA']
16265,NCT04495972,Insulin sensitivity,Level of 2-hour blood glucose Area Under the Curve (AUC),,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
16266,NCT04838743,Change in local laboratory measured HbA1c (Glycated haemoglobin ),Change in daily dose of Xultophy®,,2021-04-23,COMPLETED,OBSERVATIONAL,['NA']
16267,NCT01667003,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
16268,NCT03196687,percentage of Frequency of asymptomatic left ventricular diastolic dysfunction in diabetes mellitus type 2,,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA']
16269,NCT02366481,Change in beta-cell function,Change in endothelial function (FMD),,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
16270,NCT03392961,Glucose concentration (Tmin) will be assessed. (Cohort 3),Number of Participants With Adverse Events as a Measure of Safety and Tolerability,,2014-03-27,COMPLETED,INTERVENTIONAL,['PHASE1']
16271,NCT06057454,Measurement of adverse events from the date of the first dose through 12 weeks of R-5280 tolerance,Measurement of clinical activity and to determine the gut microbiome profile in youth with recently diagnosed Type 1 Diabetes,,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE1']
16272,NCT03930758,Bone-specific alkaline phosphatase,Novel Pedar,,2009-10-08,COMPLETED,INTERVENTIONAL,['NA']
16273,NCT02213159,Total dose of morphine consumed in Post Anesthesia Care Unit (PACU),overall satisfaction at one month,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16274,NCT05628311,HbA1c change from baseline at week 24,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
16275,NCT06067022,Temporomandibular Dysfunction,Pain assessment,,2023-01-05,COMPLETED,OBSERVATIONAL,['NA']
16276,NCT05011032,Erythrocyte sedimentation rate (ESR),,,2021-08-12,WITHDRAWN,INTERVENTIONAL,['NA']
16277,NCT03057444,Change of short chain fatty acid concentration in the gut,Change from baseline in anthropometry at four weeks and eight weeks after consumption resistant starch type III,Change from baseline in GLP-1 (Glucagon-like peptide-1) at four weeks and eight weeks after consumption resistant starch type III,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
16278,NCT03703999,HbA1c,insulin use,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
16279,NCT04267367,Change in HbA1c level,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
16280,NCT01076634,"Area under the glucose infusion rate curve during one dosing interval at steady-date""",Area under the serum Insulin Degludec concentration-time curve,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
16281,NCT00854984,The obstacles to providing access and support to a generic online self help computerised cognitive behavioural therapy (CBT) programme for such patients.,"A change in depression (BDI-2), anxiety , social function (WASAS), quality of life (Euroqol 5D) or illness perception (IPQ-R) from participation in a self help programme.",,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
16282,NCT04623086,Mean Change in Percent Time in Range,Correction Boluses,,2020-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
16283,NCT02351466,Changes in total and regional gray and white matter volumes and white matter microstructure.,Changes in Neurocognitive metrics including IQ as well as executive and visual-spatial memory.,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
16284,NCT02192450,Symptomatic nocturnal hypoglycaemia,Quality of life incl. pre-depression scale,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
16285,NCT01430143,Change from baseline in insulin sensitivity at 12 weeks,Diameter of t-tubuli in skeletal muscle,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
16286,NCT00447382,Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies,Adverse Events,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16287,NCT02690883,the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24,Change in Blood pressure,,2016-04-08,COMPLETED,INTERVENTIONAL,['PHASE4']
16288,NCT04565418,Change in 24 rhythm in whole-body energy metabolism (fat oxidation),Change in 24h rhythm in serum cholesterol,,2021-01-26,COMPLETED,INTERVENTIONAL,['NA']
16289,NCT01273675,,,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
16290,NCT04650646,Hypoglycaemia and QTc interval prolongation,"Type 1 diabetes, healthy controls and coagulability",,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
16291,NCT00857376,This study will provide information on the effect of a dose range of ALA on oxidative stress biomarkers.,To determine whether ALA improves vascular function through its effects on oxidative stress,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16292,NCT01573897,Transcutaneous oxygen tension (PtcO2),,,2012-06-04,TERMINATED,OBSERVATIONAL,['NA']
16293,NCT01707134,Number of hypoglycaemic events,HbA1c (glycosylated haemoglobin),,1997-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16294,NCT04793165,To evaluate the effectiveness and safety of AP treatment without CHO counting in an outpatient setting.,"To determine, as a safety parameter, the percentage of time with glycemic levels less than 70 mg/dl.",,2021-03-08,COMPLETED,INTERVENTIONAL,['NA']
16295,NCT04761016,Blood pressure,Medication use,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16296,NCT01155206,Triglyceride-rich lipoprotein production rate,,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16297,NCT00894270,Assess the safety and effectiveness of 5 mm needles using either thigh or abdomen and either a pinched or unpinched skin fold.,Examine pain/discomfort of injections using the different techniques and the different injection sites.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16298,NCT02305914,Change in the Levels of fecal elastase-1,outpatient clinic and phone questionnaire,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
16299,NCT01500850,Fasting Intact Proinsulin,Hypoglycemic events.,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
16300,NCT02258932,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
16301,NCT06119737,Thyroid Stimulating Hormone,,,2021-05-02,COMPLETED,INTERVENTIONAL,['NA']
16302,NCT00915772,Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE,Change in HbA1c From Baseline Over Time,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16303,NCT00823953,serum fructosamine at end of trial phase in each of the groups,"Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase",,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16304,NCT01941290,Target Lesion Failure (TLF),Clinical Procedure Success,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
16305,NCT00799435,"Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity","Changes in Left Ventricular Diastolic Stiffness, Serum Levels of Advanced Glycation End Products, Serum Biomarkers of Collagen Synthesis, and Serum Levels of Brain Natriuretic Peptide",,2009-07,TERMINATED,INTERVENTIONAL,['PHASE4']
16306,NCT05347862,Change from Baseline Glycated Hemoglobin at 3 and 6 months,Short Form Health Survey (SF-36),Handgrip strength,2022-12-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16307,NCT00522158,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
16308,NCT02688218,Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
16309,NCT01296100,The proportion of patients who reach normal levels of all glycaemic parameters.,Difference in reduction of 10 year-estimated cardiovascular risk score of 10% between the standard therapy control group and the lifestyle intervention groups (WHO CVD prediction chart).,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
16310,NCT02358668,Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo,Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis,Changes in Complete Blood Count in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE2']
16311,NCT04558710,Coefficient of variation,Time Above Range,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
16312,NCT02821871,Cumulative percentage drainage of SP2086 in fecal,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
16313,NCT01057628,change from baseline in HbA1c,"safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-01-13,COMPLETED,INTERVENTIONAL,['PHASE3']
16314,NCT03226457,The Effect of Empagliflozin Versus Placebo on the Change in Urine Output.,"The Effect of Empagliflozin Versus Placebo on the Change to the Renal Biomarker, Cystatin C.",,2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16315,NCT00121641,A1C Changes From Baseline at Week 24 - Open Label Cohort,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort,Changes From Baseline in Heart Rate During the ST + LT Period - Open Label Cohort,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
16316,NCT04420507,the gut and oral microbiome of healthy pregnant women,The glucose level during pregnancy,,2017-05-15,COMPLETED,OBSERVATIONAL,['NA']
16317,NCT00605189,Compare Energy Charge Between Wound Treatment Therapies,,,2007-07,TERMINATED,INTERVENTIONAL,['NA']
16318,NCT06297603,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),,2024-04-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
16319,NCT00349986,HgbA1c measurement,,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4']
16320,NCT03354806,Foot tissue oxygenation on day 2,Foot tissue oxygenation in hyperaemia-induced condition on day 2,,2018-06,WITHDRAWN,INTERVENTIONAL,['NA']
16321,NCT03592784,Feasibility of the Food Order Intervention,Birthweight,,2018-06-18,TERMINATED,INTERVENTIONAL,['NA']
16322,NCT04067440,Characterization of microbiome,,,2019-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16323,NCT06208618,Diabetes management self-efficacy,Belief in a healthy lifestyle,,2024-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16324,NCT05960565,Area under the glucose curve,Pharmacokinetics of glucagon,,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2']
16325,NCT03999385,Change in diabetes self-management,Change in Eating Disorder Symptomatology,,2019-06-24,UNKNOWN,INTERVENTIONAL,['NA']
16326,NCT01459809,Change in HbA1c,Frequence and incidence of hypoglycemia,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
16327,NCT02178787,To Compare Profiles of TCD-blood Flow Velocities (TCD_BFV).,To Compare Profiles of UTlight Blood Flow (UT_BF) and Regional Oximetry (UT_Ox).,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
16328,NCT03415256,Skin blood flow,balance,,2018-11,WITHDRAWN,INTERVENTIONAL,['NA']
16329,NCT02164279,Identify predictive non-invasive urinary biomarkers,Relation of urinary markers with patient characteristics,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
16330,NCT03730662,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,,2018-11-20,COMPLETED,INTERVENTIONAL,['PHASE3']
16331,NCT04109235,Change in HbA1C,Physical Activity (minutes per week),,2020-02-13,RECRUITING,INTERVENTIONAL,['NA']
16332,NCT03239457,Proportion of patients with 100% of the lesion area covered by granulation tissue.,Adverse events,,2015-12,COMPLETED,OBSERVATIONAL,['NA']
16333,NCT04653961,Sensor glucose percentage of time in hyperglycemia above 250 mg/dl,Number of Serious Adverse Events,The amount of bolus insulin dose,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
16334,NCT00101478,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
16335,NCT01523041,Area under the insulin aspart curve in the interval from 0-24 hours,"tmin, time to minimum concentration",,1999-11-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16336,NCT04714216,Percentage of time sensor glucose is within target glucose range,Patient Survey,,2021-06-29,COMPLETED,INTERVENTIONAL,['NA']
16337,NCT04069234,Coronary Flow Velocity Reserve (CFR),Coronary flow parameter-LAD resting mean diastolic flow velocity,,2019-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16338,NCT02742701,Predictive performance of glycosuria measured on urine collected between 10 am and 16 am on the blood glucose level at 6 pm,"Type, frequency and intensity of symptoms in relation to the blood glucose level",,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
16339,NCT01083043,Serum levels of endothelial dysfunction biomarkers and glycemic variability,Metabolic parameters and glycemic variability,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
16340,NCT04073524,Level of quality of life - total score,Level of self perceived stress,,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA']
16341,NCT05890950,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,,2023-03-13,COMPLETED,INTERVENTIONAL,['PHASE1']
16342,NCT01963663,Serum concentration of YKL-40,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
16343,NCT01618214,Change From Baseline in HbA1c (Glycosylated Haemoglobin),"Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16344,NCT03319784,Change in blood glucose level,American Shoulder and Elbow Surgeon (ASES) Shoulder Score,,2018-09-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16345,NCT04269070,Change in 2-hour postprandial area-under-the-curve blood glucose at 2 weeks,Change in baseline workplace stepping time at 2 weeks,Change in central aortic diastolic and systolic blood pressure at 2 weeks,2021-03-25,COMPLETED,INTERVENTIONAL,['NA']
16346,NCT02656212,Change from baseline in major safety endpoints: Hepatic Function,Change from baseline: C-Peptide,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
16347,NCT00579371,Incidence of insulin independence with a single islet transplant,Metabolic functional assessments of the islet graft,,2004-03-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16348,NCT00891943,"Changes in weight, waist circumference and percent body fat at 12 months.","BMI, blood pressure, resting heart rate; obesity and weight related quality of life, Rosenberg measure of self-esteem changes at 12 months.",,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
16349,NCT04230382,OGTT,,S-Magnesium,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
16350,NCT01614262,change in glycosylated hemoglobin using intensive periodic CGM monitoring vs traditional monitoring,quality of life data evaluation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
16351,NCT01555008,Change from baseline in postprandial glucose,Area Under Curve (AUC),,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16352,NCT06268821,HbA1c,Frequency of hypoglycaemia events,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16353,NCT04421001,Total insulin daily dose per kg per day,"treatment satisfaction, scale up to 10, higher is better",,2020-10,UNKNOWN,INTERVENTIONAL,['NA']
16354,NCT00833846,,,,2009-01-27,COMPLETED,OBSERVATIONAL,['NA']
16355,NCT03620890,Number of Neonates With Composite Adverse Neonatal Outcome,Number of Neonates Who Had Jaundice Requiring Therapy,,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE4']
16356,NCT05864183,comparison between the measurement of HbA1c in normal non prediabetics and prediabetics at Sohag university hospital .,,,2023-04-15,RECRUITING,OBSERVATIONAL,['NA']
16357,NCT06087679,change in resting PPS,Problem Areas In Diabetes (PAID-20),Kidney function measured as creatinine,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16358,NCT03857802,Change of glycated hemoglobin levels.,Change in sleep quality: Pittsburgh Sleep Quality Index,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
16359,NCT01520831,Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes,"t½, terminal half-life",,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16360,NCT00399204,,,,2006-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16361,NCT03625752,Changes in pain as measured by the Visual Analog Scale (VAS),Adverse events,,2019-06-06,RECRUITING,INTERVENTIONAL,['NA']
16362,NCT01464437,To evaluate the dose-effect relationship of AMG 151 compared to placebo on fasting plasma glucose in subjects with type 2 diabetes treated with metformin,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16363,NCT01607294,assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes,"assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters",,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
16364,NCT00445003,Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks,Change in Optical Coherence Tomography Retinal Volume,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16365,NCT00847262,"Metabolic profiles, including lipid profile and blood glucose",Incidents of side effects between groups,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16366,NCT06096935,exom,exome variations,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16367,NCT04881110,Peripheral transcutaneous oxygen pressure,Female sexual function,,2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
16368,NCT01157923,Time spent in the normal range,Number and type of changes in any pump setting per iteration,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
16369,NCT02650050,Number of intra-vitreal anti-VEGF injections,Time to reduction of the macular thickness,,2016-01-19,TERMINATED,INTERVENTIONAL,['NA']
16370,NCT05218395,To assess the risk of Persistent organic pollutant exposure to type 2 diabetes,To assess the risk of Persistent organic pollutant exposure to thyroid cancer,,2021-12-20,RECRUITING,OBSERVATIONAL,['NA']
16371,NCT04233801,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24,Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events,,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
16372,NCT00108225,"IGF-1, GH, Body Composition",,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
16373,NCT02699307,Change in physical activity: Community Healthy Activities Model Program for Seniors (CHAMPS) survey,Change in social participation:validated questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) assessment center,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
16374,NCT04484779,Total and Domain Specific Score of the mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients,Likelihood of Site to Recommend the IIM System,,2020-07-14,COMPLETED,INTERVENTIONAL,['NA']
16375,NCT04834518,Frequency of Diabetic Ketoacidosis on the clinical presentation of Type 1 Diabetes,The rate of progression from pre-symptomatic T1D to clinical diabetes,,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
16376,NCT01606397,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Change in fasting glucagon-like peptide-1 (GLP-1) level,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16377,NCT01170039,"Efficacy, Measured by the Average Number of Spontaneous Bowel Movements (SBMs) Per Week",Change in Scores on the Patient Assessment of Constipation Quality of Life (PAC-QOL) Questionnaire,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
16378,NCT02456922,Harmony 1 Sensor accuracy,,,2018-07,WITHDRAWN,INTERVENTIONAL,['NA']
16379,NCT05144360,Systolic blood pressure (SBP),Adverse events,,2022-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16380,NCT03690778,Cmax of Metformin and rosuvastatin,,,2018-10-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16381,NCT02409017,Mean maternal glucose,,,2015-04,TERMINATED,INTERVENTIONAL,['NA']
16382,NCT01795833,Number of Participants With Progression to Type 2 Diabetes,Total Physical Activity,,2013-06-03,COMPLETED,INTERVENTIONAL,['NA']
16383,NCT02049359,Change From Baseline A1C,"Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
16384,NCT05620927,Impaired awareness of hypoglycemia (IAH) - Clarke's Questionnaire,occurrence of cognitive impairment,,2022-11-24,RECRUITING,OBSERVATIONAL,['NA']
16385,NCT04830969,Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline,Change in Distance to the Healthy Plane Based on the Subgingival Plaque Microbiome at 6 Months,,2016-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16386,NCT04181424,Glycemic control (HbA1c),Blood Pressure,,2019-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16387,NCT06197906,accuracy,,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16388,NCT03499704,Mean Change from Baseline in HbA1c at Week 26,Number of Participants who Achieved an HbA1c Goal Target of Less than (<) 6.5 Percent (%) at Week 26,,2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
16389,NCT01595750,Endotelial function,"Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA",,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
16390,NCT05607160,Proportion of participants achieving the HbA1c target value,"Absolute change in HbA1c (%), from baseline to month 3 and 6",,2022-10-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16391,NCT00994955,best-corrected visual acuity,"change of retinal thickness, presence of hard exudates and leakage in FFA, specificity and sensitivity of optoacoustic measurements",,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16392,NCT01513369,reduction in HBA1c-levels,Change in used insulin dosage during study,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
16393,NCT01168076,,,,2001-12,COMPLETED,OBSERVATIONAL,['NA']
16394,NCT00986375,physical activity fruit & vegetable consumption,intervention engagement,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16395,NCT02411578,Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment,CGM Coefficient of Variation,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16396,NCT00276939,Hemoglobin A1c,Dietary Acceptability,,2003-09,COMPLETED,INTERVENTIONAL,['NA']
16397,NCT02637622,The importance of medication cost from patient perspective,,Self-reported difficulty in understanding and answering the survey questions,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
16398,NCT03940183,HbA1c,Body Mass Index,,2019-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
16399,NCT02035371,Area under the serum insulin aspart concentration-time curve,Maximum observed serum insulin aspart concentration,,2014-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
16400,NCT05845242,"Correlation of the above features with the chance of developing ulcers (Risk 0, Risk 1, Risk 2 and Risk 3).","Assessing the practical needs for transferring measurements to a different environment (e.g., home) by interviewing the clinicians involved in the consortium.",,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16401,NCT04308291,Time in range (TIR),Glycemic parameters changes,,2021-02-15,COMPLETED,OBSERVATIONAL,['NA']
16402,NCT02846857,Percentage of time of glucose levels below 3.9 mmol/L,Percentage of time when the closed-loop was automatically switched to insulin pump therapy,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16403,NCT03437044,P2Y12 Reaction Units (PRU),Platelet Reactivity Index (PRI),,2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE4']
16404,NCT04442698,Delta Hemoglobin A1c Levels (HbA1c),,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
16405,NCT03266952,Incidence of Stroke,Scoring cognitive impairment,Incidence of diabetes,1993-01,COMPLETED,OBSERVATIONAL,['NA']
16406,NCT00771004,Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.,Time course of Adiponectin Laboratory Procedure.,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16407,NCT00502138,Fasting and postprandial pramlintide pharmacokinetics,Hemoglobin A1c,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16408,NCT03931434,Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.,Rate of change in endothelial function,,2016-02-23,COMPLETED,INTERVENTIONAL,['NA']
16409,NCT02037321,Non-alcoholic fatty liver disease (NAFLD) analysis,,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
16410,NCT03385135,Endothelium-dependent vasodilation,Major adverse cardiac events (MACE),,2017-12,UNKNOWN,INTERVENTIONAL,['NA']
16411,NCT04378114,Bias (mg/dL) Between the Guardian™ Sensor (3) Values and Yellow Springs Instrument™ (YSI™) Plasma Glucose,Percentage of Guardian™ Sensor (3) Values That Were Within 20% of YSI™ Plasma Glucose Values,,2020-05-18,COMPLETED,INTERVENTIONAL,['NA']
16412,NCT01025856,postprandial lipids metabolism,adipose tissue lipolytic activities,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
16413,NCT00634543,Change From Baseline in Pain Intensity Score at Day 43,Change From Baseline in Short Form-36 (SF-36) Score at Day 43,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
16414,NCT04062890,Blood Pressure,,,2019-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
16415,NCT00369148,glycohemoglobin,blood pressure,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16416,NCT01245166,The changes from baseline in HbA1c to the end of treatment period,"the change from baseline to the end of treatment in FBG, PBG, lipid profiles, and body weight. The safety evaluation will include: 1) Adverse events; 2) Laboratory data; 3) Physical examination; 4) Vital signs; 5) 12- lead ECG",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
16417,NCT04515758,Participant and Instructor Age,Change in Exercise-related Self-Efficacy,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
16418,NCT05887544,Concentration of Indole-3-lactic acid in blood,Concentration of 3-Phenyllactic acid in urine,Exploratory analyses,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
16419,NCT01708902,The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG,The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16420,NCT00628524,"Parameters of triglyceride tolerance and glucose tolerance in correlation to cardiovascular events, cardiovascular mortality, total mortality.","Waist-to-Hip ratio, nutrition protocol, physical activity, non-invasive endothelial function, body fat composition, other biomarkers of lipid and glucose metabolism.",,2008-02,COMPLETED,OBSERVATIONAL,['NA']
16421,NCT02779413,Number of Adverse Events (AE),Weight gain,,2016-06-02,COMPLETED,OBSERVATIONAL,['NA']
16422,NCT01498276,Intergenerational transfer of diet-related behaviors,Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors.,,2012-01-03,COMPLETED,OBSERVATIONAL,['NA']
16423,NCT05501223,Number of medications used at baseline compared to number of medications used at follow-up. Resulting in a rate of medications used at baseline compared to follow-up i.e. no. medication at follow-up/no. at baseline.,EQ5D index score. (a Euro Quality of Life 5-dimension 5-level (EQ-5D-5L) scale). The score is retrieved by using the validated EQ5D questionnaire which translates to a corresponding EQ5D index score using country specific value sets.,,2020-11-01,RECRUITING,INTERVENTIONAL,['NA']
16424,NCT04331535,Time-to-new diagnosis of common complex disease,Medication adherence,Health status and quality of life,2020-07-17,RECRUITING,INTERVENTIONAL,['NA']
16425,NCT01042977,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16426,NCT05553184,"Change in Brown Adipose Tissue thermogenesis (formoterol induced, cold-induced and effect of nicotinic acid)",Protein expression of subcutaneous abdominal white adipose tissue,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
16427,NCT04602754,Percentual reduction of LDL-c levels measured between the first visit and the last visit.,Incidence and severity of adverse events recorded during the study.,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
16428,NCT05031871,AUC0-inf：Area under the curve from time 0 to infinity；,ADA：anti-drug antibody,,2021-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
16429,NCT01217307,Improvement in Left Ventricular Ejection Fraction,"Cardiac MRI After 4 Months, Per Protocol Analysis",,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16430,NCT04470635,Vascular endothelial growth factor level,Thiol/disulphide measurement,,2020-07-25,COMPLETED,OBSERVATIONAL,['NA']
16431,NCT04495114,Preoperative glucose,,,2017-08-31,COMPLETED,INTERVENTIONAL,['NA']
16432,NCT01386541,Assessment of the safety/tolerability of multiple dosing of BYK324677 given once daily (SID) or twice daily (BID) in healthy volunteers.,Exploratory assessment of the pharmacodynamics (PD) of multiple dosing of BYK324677 (SID or BID) under steady state conditions in healthy volunteers.,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16433,NCT03968952,Number of home visits completed by Community Health Worker,Mean postpartum Diastolic Blood Pressure,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
16434,NCT02523131,Time spent in the target glucose range from 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on CGM glucose levels,Change of body weight from screening to end of study,Amount of CGM use,2016-05,COMPLETED,INTERVENTIONAL,['NA']
16435,NCT02660476,"Diabetes Complications (Nephropathy, Neuropathy, Retinopathy)",Physical activity,,2014-10,TERMINATED,OBSERVATIONAL,['NA']
16436,NCT05902650,OCTA data,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
16437,NCT04531163,Systolic blood pressure,,,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16438,NCT05165693,Glucose positive area under the curve (AUC),Insulin Concentrations,Sensory Questionnaire,2022-02-23,COMPLETED,INTERVENTIONAL,['NA']
16439,NCT03366168,"To demonstrate that in humans, epithelial stem cells isolated from the base of human taste buds can be propagated.",To investigate if differentiation capability of the stem cells changes as a factor of age.,,2017-12-18,RECRUITING,OBSERVATIONAL,['NA']
16440,NCT02823678,Percent resected volume of pancreas and diabetes development,Blood glucose control,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
16441,NCT02459535,"change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
16442,NCT04245826,Total mortality,,,2019-05-16,UNKNOWN,OBSERVATIONAL,['NA']
16443,NCT00967629,serum AGE levels,inflammatory markers,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16444,NCT04158921,The mean change in blood glucose.,The change in the number of hypoglycemic episodes.,,2019-11-07,TERMINATED,INTERVENTIONAL,['NA']
16445,NCT01361594,Hospital Mortality,Cerebrovascular Events,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16446,NCT00435786,,,,na,COMPLETED,OBSERVATIONAL,['NA']
16447,NCT01797601,Insulin effect on regional brain activity assessed by fMRI,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
16448,NCT01383304,"Combined primary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke",Single endpoints:cardiovascular death; acute myocardial infarction; ischemic stroke; stent thrombosis; all-cause death,Genotype according to pre-specified genetic single nucleotide polymorphisms (SNPs),2007-11,UNKNOWN,OBSERVATIONAL,['NA']
16449,NCT03445065,Cohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120,Change From Baseline in the Partner Diabetes Distress Scale (Partner-DDS) Questionnaire Total and Subscale Scores at Day 60 and Day 180,,2018-02-28,COMPLETED,INTERVENTIONAL,['NA']
16450,NCT00516958,"To compare the rates of clinical success (cure + improvement) of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in patients with mild diabetic foot infections in non ischemic ulcers",To compare the treatment groups with respect to microbiological outcome. Incidence of adverse events and other safety outcomes,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16451,NCT05102851,CCU admission,,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
16452,NCT05452525,AUClast,,,2022-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16453,NCT01170403,Cardiovascular event,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
16454,NCT02317211,Glycemic Control,Blood lipids,,2014-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16455,NCT05147883,Score of Quality of Life,Depression,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
16456,NCT02367066,Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide,"Apparent Oral Plasma AZD1981 at Steady-State, CL_ss/F",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16457,NCT00482729,Change From Baseline in Hemoglobin A1c (A1C) at Week 18,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18,Number of Patients With A1C < 7.0% at Week 44,2007-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
16458,NCT04234867,time to development of DKA,time to decrease of ph level,,2022-05-18,TERMINATED,INTERVENTIONAL,['PHASE1']
16459,NCT01763567,Device Performance: Accuracy of HGMS,,Functionality of HGMS: Alerts and Alarms - % of Hyper False Alert,2012-03,COMPLETED,OBSERVATIONAL,['NA']
16460,NCT01972477,Percent change in HDL-cholesterol level,Adverse event,,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16461,NCT01342874,altered OGTT,delivery and neonatal outcomes,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
16462,NCT01449747,"Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment",Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
16463,NCT01629862,Absolute Change in Brachial Artery Flow-mediated Dilation (FMD).,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
16464,NCT01941238,Incidence of hypoglycemia,Rate of acute complications,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
16465,NCT03923114,Pituitary uptake of Ga-68-NODAGA-exendin,Metabolic status (ACTH),,2019-05-23,UNKNOWN,INTERVENTIONAL,['NA']
16466,NCT04948931,Spielberger State-Trait Anxiety Scale (STAI),,,2021-07-28,COMPLETED,INTERVENTIONAL,['NA']
